FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Krause, M
   Gerchman, F
   Friedman, R
AF Krause, Mauricio
   Gerchman, Fernando
   Friedman, Rogerio
TI Coronavirus infection (SARS-CoV-2) in obesity and diabetes
   comorbidities: is heat shock response determinant for the disease
   complications?
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Article
DE SARS-CoV-2; Inflammation; Heat shock response; Metabolic diseases
ID NF-KAPPA-B; EXTRACELLULAR HSP70; PROTEINS; INFLAMMATION; MECHANISM;
   MUSCLE; PROTECTION; BGP-15; ALPHA; BLOOD
AB Chronic inflammation is involved in the pathogenesis of several metabolic diseases, such as obesity and type 2 diabetes mellitus (T2DM). With the recent worldwide outbreak of coronavirus disease (SARS-CoV-2), it has been observed that individuals with these metabolic diseases are more likely to develop complications, increasing the severity of the disease and a poorer outcome. Coronavirus infection leads to the activation of adaptive and innate immune responses, resulting in massive inflammation (to so calledcytokine storm), which in turn can lead to damage to various tissues, septic shock and multiple organ failure. Recent evidence suggests that the common link between metabolic diseases and SARS-CoV-2 is the inflammatory response (chronic/low-grade for metabolic diseases and acute/intense in coronavirus infection). However, the ability of the infected individuals to resolve the inflammation has not yet been explored. The heat shock response (HSR), an important anti-inflammatory pathway, is reduced in patients with metabolic diseases and, consequently, may impair inflammation resolution and control in patients with SARS-CoV-2, thus enabling its amplification and propagation through all tissues. Herein, we present a new hypothesis that aims to explain the increased severity of SARS-CoV-2 infection in people with metabolic diseases, and the possible benefits of HSR-inducing therapies to improve the inflammatory profile in these patients.
C1 [Krause, Mauricio] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Physiol, Lab Inflammat Metab & Exercise Res LAPIMEX, Porto Alegre, RS, Brazil.
   [Krause, Mauricio] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Physiol, Lab Cellular Physiol, Porto Alegre, RS, Brazil.
   [Gerchman, Fernando; Friedman, Rogerio] Hosp Clin Porto Alegre, Endocrine & Metab Unit, Porto Alegre, RS, Brazil.
   [Gerchman, Fernando; Friedman, Rogerio] Fac Med, Dept Internal Med, Grad Program Med Sci Endocrinol, Porto Alegre, RS, Brazil.
RP Krause, M (corresponding author), Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Physiol, Lab Inflammat Metab & Exercise Res LAPIMEX, Porto Alegre, RS, Brazil.; Krause, M (corresponding author), Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Physiol, Lab Cellular Physiol, Porto Alegre, RS, Brazil.
EM mauricio.krause@ufrgs.br
RI Gerchman, Fernando/W-2230-2019
OI Krause, Mauricio/0000-0001-9814-742X
FU FAPERGSFoundation for Research Support of the State of Rio Grande do Sul
   (FAPERGS); CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERGSFoundation for Research Support of the State
   of Rio Grande do Sul (FAPERGS) [03/2017 -PPSUS, 17/2551-0001424-3]
FX This work was supported by FAPERGS and CNPq. Mauricio Krause was the
   responsible for the grant support from FAPERGS (Edital
   FAPERGS/Decit/SCTIE/MS/CNPq/SESRS n. 03/2017 -PPSUS #17/2551-0001424-3).
CR Benfield T, 2007, DIABETOLOGIA, V50, P549, DOI 10.1007/s00125-006-0570-3
   Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583
   Borges TJ, 2013, INT J HYPERTHER, V29, P455, DOI 10.3109/02656736.2013.798037
   Bruxel MA, 2019, BIOCHIMIE, V156, P33, DOI 10.1016/j.biochi.2018.09.011
   Camporez JPG, 2013, ENDOCRINOLOGY, V154, P1021, DOI 10.1210/en.2012-1989
   Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105
   Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200
   Muller CHD, 2018, EXP GERONTOL, V111, P180, DOI 10.1016/j.exger.2018.07.014
   de Lemos Muller CH, 2019, J SCI SPORT EXER, V2, P19
   De Maio A, 2011, CELL STRESS CHAPERON, V16, P235, DOI 10.1007/s12192-010-0236-4
   de Thonel A, 2012, INT J BIOCHEM CELL B, V44, P1593, DOI 10.1016/j.biocel.2012.06.012
   Degens H, 2010, SCAND J MED SCI SPOR, V20, P28, DOI 10.1111/j.1600-0838.2009.01018.x
   Di Naso F, 2015, OBESITY, V23, P120, DOI 10.1002/oby.20919
   Englmeier L, 2020, J Biol Regul Homeost Agents, V34, P1125, DOI 10.23812/20-221-L-49
   Farinha JB, 2015, LIFE SCI, V121, P152, DOI 10.1016/j.lfs.2014.11.022
   Ferat-Osorio E, 2014, J INFLAMM-LOND, V11, DOI 10.1186/1476-9255-11-19
   Frydrych LM, 2020, J LEUKOCYTE BIOL, V104, P525
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gillum T, 2013, INT J ENDOCRINOL MET, V11, DOI 10.5812/ijem.8739
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hulina A, 2018, CELL STRESS CHAPERON, V23, P373, DOI 10.1007/s12192-017-0847-0
   Jose RJ, 2020, OBESITY, V28, P1007, DOI 10.1002/oby.22835
   Knowlton AA, 2006, CARDIOVASC RES, V69, P7, DOI 10.1016/j.cardiores.2005.10.009
   Krause M, 2015, CURR OPIN CLIN NUTR, V18, P374, DOI 10.1097/MCO.0000000000000183
   Krause M, 2015, CLIN SCI, V128, P789, DOI 10.1042/CS20140695
   Krause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/249205
   Krause M, 2012, METABOLISM, V61, P1528, DOI 10.1016/j.metabol.2012.05.003
   Literati-Nagy B, 2010, BRAIN RES BULL, V83, P340, DOI 10.1016/j.brainresbull.2010.09.005
   Literati-Nagy B, 2009, HORM METAB RES, V41, P374, DOI 10.1055/s-0028-1128142
   Madden LA, 2008, AMINO ACIDS, V34, P511, DOI 10.1007/s00726-007-0004-7
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mu P, 2011, IRISH J MED SCI, V180, P221, DOI 10.1007/s11845-010-0594-z
   Newsholme P, 2014, CURR OPIN CLIN NUTR, V17, P295, DOI 10.1097/MCO.0000000000000077
   Newsholme Philip, 2012, Clin Biochem Rev, V33, P35
   Newsholme P, 2010, CLIN SCI, V118, P341, DOI 10.1042/CS20090433
   Noble EG, 2008, APPL PHYSIOL NUTR ME, V33, P1050, DOI 10.1139/H08-069
   Qin L, 2020, J MED VIROL, V92, P2684, DOI 10.1002/jmv.26137
   Rao Kondapally Seshasai S, 2020, NEW ENGL J MED, V364, P829
   Rodrigues-Krause J, 2012, CELL STRESS CHAPERON, V17, P293, DOI 10.1007/s12192-011-0319-x
   Rogers RS, 2016, DIABETES, V65, P3341, DOI 10.2337/db16-0292
   Rossato JD, 2014, J PHYSIOL BIOCHEM, V70, P363, DOI 10.1007/s13105-013-0310-3
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200
   Singh IS, 2013, INT J HYPERTHER, V29, P423, DOI 10.3109/02656736.2013.808766
   Slight-Webb SR, 2015, J AUTOIMMUN, V57, P66, DOI 10.1016/j.jaut.2014.12.003
   Smuder AJ, 2019, J CACHEXIA SARCOPENI, V10, P767, DOI 10.1002/jcsm.12427
   Stice JP, 2011, ENDOCRINOLOGY, V152, P1589, DOI 10.1210/en.2010-0627
   Tang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069066
   Trussardi Fayh Ana Paula, 2018, Oncotarget, V9, P28784, DOI 10.18632/oncotarget.25609
   Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943
   Zbinden-Foncea H, 2020, OBESITY, V28, P1378, DOI 10.1002/oby.22849
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 57
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD JUL 16
PY 2020
VL 12
IS 1
AR 63
DI 10.1186/s13098-020-00572-w
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MP7KL
UT WOS:000552380200002
PM 32690985
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Favalli, EG
   Ingegnoli, F
   Biggioggero, M
   Caporali, R
AF Favalli, E. G.
   Ingegnoli, F.
   Biggioggero, M.
   Caporali, R.
TI Is there really room for anti-rheumatic drugs in the treatment of
   COVID-19?
SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
LA English
DT Letter
C1 [Favalli, E. G.; Ingegnoli, F.; Biggioggero, M.; Caporali, R.] ASST Gaetano Pini CTO Inst, Div Clin Rheumatol, I-20122 Milan, Italy.
   [Ingegnoli, F.] Univ Milan, Dept Clin Sci & Community Hlth, Res Ctr Adult & Pediat Rheumat Dis, Milan, Italy.
RP Favalli, EG (corresponding author), ASST Gaetano Pini CTO Inst, Div Clin Rheumatol, I-20122 Milan, Italy.
EM enniofavalli@me.com
CR Accortt NA, 2018, ARTHRIT CARE RES, V70, P679, DOI 10.1002/acr.23426
   Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Italian Ministry of Health, 2020, COVID 19 SIT IT
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-9742
EI 1502-7732
J9 SCAND J RHEUMATOL
JI Scand. J. Rheumatol.
PD SEP 2
PY 2020
VL 49
IS 5
BP 412
EP 413
DI 10.1080/03009742.2020.1765413
EA JUL 2020
PG 2
WC Rheumatology
SC Rheumatology
GA NY7BQ
UT WOS:000553352200001
PM 32720847
DA 2021-01-01
ER

PT J
AU Dodd, LE
   Follmann, D
   Wang, J
   Koenig, F
   Korn, LL
   Schoergenhofer, C
   Proschan, M
   Hunsberger, S
   Bonnett, T
   Makowski, M
   Belhadi, D
   Wang, YM
   Bin Cao
   Mentre, F
   Jaki, T
AF Dodd, Lori E.
   Follmann, Dean
   Wang, Jing
   Koenig, Franz
   Korn, Lisa L.
   Schoergenhofer, Christian
   Proschan, Michael
   Hunsberger, Sally
   Bonnett, Tyler
   Makowski, Mat
   Belhadi, Drifa
   Wang, Yeming
   Bin Cao
   Mentre, France
   Jaki, Thomas
TI Endpoints for randomized controlled clinical trials for COVID-19
   treatments
SO CLINICAL TRIALS
LA English
DT Article
DE COVID-19; censoring; clinical trials; endpoints; log-rank test; WHO
   ordinal scale; proportional odds model
ID PNEUMONIA
AB Background: Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information. COVID-19 presentation is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks to over a month and can end in death. While improvement in mortality would provide unquestionable evidence about the clinical significance of a treatment, sample sizes for a study evaluating mortality are large and may be impractical, particularly given a multitude of putative therapies to evaluate. Furthermore, patient states in between "cure" and "death" represent meaningful distinctions. Clinical severity scores have been proposed as an alternative. However, the appropriate summary measure for severity scores has been the subject of debate, particularly given the variable time course of COVID-19. Outcomes measured at fixed time points, such as a comparison of severity scores between treatment and control at day 14, may risk missing the time of clinical benefit. An endpoint such as time to improvement (or recovery) avoids the timing problem. However, some have argued that power losses will result from reducing the ordinal scale to a binary state of "recovered" versus "not recovered." Methods: We evaluate statistical power for possible trial endpoints for COVID-19 treatment trials using simulation models and data from two recent COVID-19 treatment trials. Results: Power for fixed time-point methods depends heavily on the time selected for evaluation. Time-to-event approaches have reasonable statistical power, even when compared with a fixed time-point method evaluated at the optimal time. Discussion: Time-to-event analysis methods have advantages in the COVID-19 setting, unless the optimal time for evaluating treatment effect is known in advance. Even when the optimal time is known, a time-to-event approach may increase power for interim analyses.
C1 [Dodd, Lori E.; Follmann, Dean; Proschan, Michael; Hunsberger, Sally] NIAID, Biostat Res Branch, 5601 Fishers Lane, Bethesda, MD 20892 USA.
   [Wang, Jing; Bonnett, Tyler] Frederick Natl Lab Canc Res, Clin Monitoring Res Program Directorate, Frederick, MD USA.
   [Koenig, Franz] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
   [Korn, Lisa L.] Yale Univ, Dept Med, Rheumatol Allergy & Immunol Sect, New Haven, CT 06520 USA.
   [Korn, Lisa L.] Yale Univ, Dept Immunobiol, New Haven, CT USA.
   [Schoergenhofer, Christian] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Makowski, Mat] Emmes Co LLC, Rockville, MD USA.
   [Belhadi, Drifa; Mentre, France] Univ Paris, INSERM, IAME, Paris, France.
   [Belhadi, Drifa; Mentre, France] Hop Bichat Claude Bernard, AP HP, DEBRC, Paris, France.
   [Wang, Yeming; Bin Cao] Natl Clin Res Ctr Resp Dis, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Wang, Yeming; Bin Cao] Capital Med Univ, China Japan Friendship Hosp, Dept Resp Med, Beijing, Peoples R China.
   [Jaki, Thomas] Univ Lancaster, Dept Math & Stat, Lancaster, England.
   [Jaki, Thomas] Univ Cambridge, MRC, Biostat Unit, Cambridge, England.
RP Dodd, LE (corresponding author), NIAID, Biostat Res Branch, 5601 Fishers Lane, Bethesda, MD 20892 USA.
EM doddl@mail.nih.gov
OI Follmann, Dean/0000-0003-4073-0393; Konig, Franz/0000-0002-6893-3304
FU National Cancer Institute, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [75N91019D00024, 75N91019
   F00130]; UK Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_0002/14]; National Institute for Health ResearchNational
   Institute for Health Research (NIHR) [NIHR-SRF-2015-08-001]; Austrian
   Federal Ministry of Education, Science and Research
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: J.W. and
   T.B. received funds from the National Cancer Institute, National
   Institutes of Health, under Contract No. 75N91019D00024, Task Order No.
   75N91019 F00130. The content of this publication does not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the US Government. T.J. received
   funding from the UK Medical Research Council (MC_UU_0002/14). This
   report is independent research arising in part from T.J.'s Senior
   Research Fellowship (NIHR-SRF-2015-08-001) supported by the National
   Institute for Health Research. The views expressed in this publication
   are those of the authors and not necessarily those of the NHS, the
   National Institute for Health Research, or the Department of Health and
   Social Care (DHCS). F.K. and C.S. and their Medical University Vienna
   contribution is financially supported by the Austrian Federal Ministry
   of Education, Science and Research
CR Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Comet Initiative, 2020, COR OUTC SET DEV RES
   COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   GRAUBARD BI, 1987, BIOMETRICS, V43, P471, DOI 10.2307/2531828
   Hedeker D, 2003, STAT MED, V22, P1433, DOI 10.1002/sim.1522
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Markowicz P, 2000, AM J RESP CRIT CARE, V161, P1942, DOI 10.1164/ajrccm.161.6.9909122
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Peterson RL, 2019, CONT CLIN TRIAL COMM, V15, DOI 10.1016/j.conctc.2019.100401
   Peterson RL, 2017, CLIN TRIALS, V14, P264, DOI 10.1177/1740774517697919
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Royal College of Physicians, 2017, NAT EARL WARN SCOR N
   Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536
   SELLNER J, 2020, EUR J NEUROL 0512, DOI DOI 10.1111/ene.14257.
   Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603
   Stallard N, EFFICIENT ADAP UNPUB
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   The CONSORT Group, 3B CHANG TRIAL DES
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO R&D Blueprint, 2020, WHO R D BLUEPR NOV C
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 31
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2020
VL 17
IS 5
BP 472
EP 482
AR 1740774520939938
DI 10.1177/1740774520939938
EA JUL 2020
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU8GJ
UT WOS:000549952900001
PM 32674594
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Wang, JB
   Wang, ZX
   Jing, J
   Zhao, P
   Dong, JH
   Zhou, YF
   Yang, G
   Niu, M
   Zhao, X
   Jiang, TJ
   Bi, JF
   Xu, Z
   Zhang, P
   Wu, D
   Bai, ZF
   Guo, YM
   Yu, SM
   Sun, YQ
   Zhang, ZT
   Zhan, XY
   Li, PY
   Ding, JB
   Zhao, PF
   Song, XA
   Tang, JY
   He, DC
   Chen, Z
   Qin, EQ
   Wang, RL
   Xiao, XH
AF Wang Jia-bo
   Wang Zhong-xia
   Jing Jing
   Zhao Peng
   Dong Jing-hui
   Zhou Yong-feng
   Yang Guang
   Niu Ming
   Zhao Xu
   Jiang Tian-jun
   Bi Jing-feng
   Xu Zhe
   Zhang Ping
   Wu Dan
   Bai Zhao-fang
   Guo Yu-ming
   Yu Si-miao
   Sun Yong-qiang
   Zhang Zi-teng
   Zhan Xiao-yan
   Li Peng-yan
   Ding Jin-biao
   Zhao Peng-fei
   Song Xue-ai
   Tang Jian-yuan
   He Dong-chu
   Chen Zhu
   Qin En-qiang
   Wang Rui-lin
   Xiao Xiao-he
TI Exploring an Integrative Therapy for Treating COVID-19: A Randomized
   Controlled Trial
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; acute respiratory distress syndrome; Chinese
   medicine
ID RESPIRATORY-DISTRESS-SYNDROME; PNEUMONIA; CORONAVIRUS; PROGRESS
AB Objectives: To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. Methods: A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 mu g twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group. After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed. Results: An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS ( P=0.048). Conclusions: Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.
C1 [Wang Jia-bo; Zhou Yong-feng; Niu Ming; Zhao Xu; Zhang Ping; Bai Zhao-fang; Guo Yu-ming; Zhang Zi-teng; Zhan Xiao-yan; Li Peng-yan; Xiao Xiao-he] Chinese Peoples Liberat Army Gen Hosp, China Mil Inst Chinese Med, Med Ctr 5, Beijing 100039, Peoples R China.
   [Wang Zhong-xia; Jing Jing; Yu Si-miao; Sun Yong-qiang; Song Xue-ai; Wang Rui-lin; Xiao Xiao-he] Chinese Peoples Liberat Army Gen Hosp, Integrat Med Ctr, Med Ctr 5, Beijing 100039, Peoples R China.
   [Zhao Peng; Yang Guang; Jiang Tian-jun; Xu Zhe; Wu Dan; Qin En-qiang] Chinese Peoples Liberat Army Gen Hosp, Treatment & Res Ctr Infect Dis, Med Ctr 5, Beijing 100039, Peoples R China.
   [Zhao Peng; Chen Zhu; Qin En-qiang] Natl Clin Res Ctr Infect Dis, Beijing 100039, Peoples R China.
   [Dong Jing-hui] Chinese Peoples Liberat Army Gen Hosp, Dept Radiol, Med Ctr 5, Beijing 100039, Peoples R China.
   [Bi Jing-feng; Ding Jin-biao] Chinese Peoples Liberat Army Gen Hosp, Res Ctr Clin & Translat Med, Med Ctr 5, Beijing 100039, Peoples R China.
   [Tang Jian-yuan] Chengdu Univ Tradit Chinese Med, Sichuan Evidence Based Med Ctr Tradit Chinese Med, Affliated Hosp, Chengdu 610075, Peoples R China.
   [Zhao Peng-fei] Beijing Univ Chinese Med, Coll Life Sci, Beijing 100029, Peoples R China.
   [He Dong-chu] Gen Hosp Cent Theater Command, Dept Integrated Treatment, Wuhan 430070, Peoples R China.
RP Xiao, XH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, China Mil Inst Chinese Med, Med Ctr 5, Beijing 100039, Peoples R China.; Wang, RL; Xiao, XH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Integrat Med Ctr, Med Ctr 5, Beijing 100039, Peoples R China.; Qin, EQ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Treatment & Res Ctr Infect Dis, Med Ctr 5, Beijing 100039, Peoples R China.; Qin, EQ (corresponding author), Natl Clin Res Ctr Infect Dis, Beijing 100039, Peoples R China.
EM qeq2004@sina.com; wrl7905@163.com; pharmacy302xxh@126.com
FU National Administration of Traditional Chinese Medicine Project
   [2020ZYLCYJ05-1]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81630100, 81721002,
   81930110]; China PLA Biosecurity Project [19SWAQ13]; China PLA Emergency
   Project [BWS20J006]; Beijing Administration of Traditional Chinese
   Medicine Project [YJ2020-03, SYFY202011]; China Military Institute of
   Chinese Medicine, The Fifth Medical Center of Chinese PLA General
   Hospital, Beijing, China; Integrative Medical Center, The Fifth Medical
   Center of Chinese PLA General Hospital, Beijing, China; Treatment and
   Research Center for Infectious Diseases, The Fifth Medical Center of
   Chinese PLA General Hospital, Beijing, China; National Clinical Research
   Center for Infectious Diseases, Beijing, China; Department of Radiology,
   The Fifth Medical Center of Chinese PLA General Hospital, Beijing,
   China; Research Center for Clinical and Translational Medicine, The
   Fifth Medical Center of Chinese PLA General Hospital, Beijing, China;
   Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine
   Affliated Hospital, Chengdu University of Traditional Chinese Medicine,
   Chengdu, China; College of Life Science, Beijing University of Chinese
   Medicine, Beijing, China; Department of Integrated Treatment, General
   Hospital of Central Theater Command, Wuhan, China
FX Supported by the National Administration of Traditional Chinese Medicine
   Project (No. 2020ZYLCYJ05-1), the National Natural Science Foundation of
   China (Nos. 81630100, 81721002, 81930110), China PLA Biosecurity Project
   (No. 19SWAQ13), China PLA Emergency Project (BWS20J006) and the Beijing
   Administration of Traditional Chinese Medicine Project (Nos. YJ2020-03,
   SYFY202011) 1. China Military Institute of Chinese Medicine, The Fifth
   Medical Center of Chinese PLA General Hospital, Beijing (100039), China;
   2. Integrative Medical Center, The Fifth Medical Center of Chinese PLA
   General Hospital, Beijing (100039), China; 3. Treatment and Research
   Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA
   General Hospital, Beijing (100039), China; 4. National Clinical Research
   Center for Infectious Diseases, Beijing (100039), China; 5. Department
   of Radiology, The Fifth Medical Center of Chinese PLA General Hospital,
   Beijing (100039), China; 6. Research Center for Clinical and
   Translational Medicine, The Fifth Medical Center of Chinese PLA General
   Hospital, Beijing (100039), China; 7. Sichuan Evidence-Based Medicine
   Center of Traditional Chinese Medicine Affliated Hospital, Chengdu
   University of Traditional Chinese Medicine, Chengdu (610075), China; 8.
   College of Life Science, Beijing University of Chinese Medicine, Beijing
   (100029), China; 9. Department of Integrated Treatment, General Hospital
   of Central Theater Command, Wuhan (430070), China
CR Adalja A, 2019, EXPERT REV ANTI-INFE, V17, P467, DOI 10.1080/14787210.2019.1635009
   Al-Omari A, 2019, DIAGN MICR INFEC DIS, V93, P265, DOI 10.1016/j.diagmicrobio.2018.10.011
   Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   Bauer TT, 2006, CLIN INFECT DIS, V43, P748, DOI 10.1086/506430
   Cao B., 2020, NEW ENGL J MED
   CHAN K, 1995, TRENDS PHARMACOL SCI, V16, P182, DOI 10.1016/S0165-6147(00)89019-7
   Chen YB, 2020, CHIN J INTEGR MED, V26, P857, DOI 10.1007/s11655-019-3078-7
   Cheng L, 2015, INT IMMUNOPHARMACOL, V28, P494, DOI 10.1016/j.intimp.2015.07.011
   China National Emergency Office, 2020, PREV CONTR PNEUM CAU
   Civljak R, 2020, CROAT MED J, V61, P1, DOI 10.3325/cmj.2020.61.1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kil HR, 2011, CRIT CARE, V15, DOI 10.1186/cc10082
   Labonte Patrick, 2008, Expert Rev Anti Infect Ther, V6, P581, DOI 10.1586/14787210.6.5.581
   Lee KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020388
   Li Nan, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3899, DOI 10.19540/j.cnki.cjcmm.20190524.503
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   National Health Commission of the People's Republic of China, 2020, DIR DIAGN REC TREATM
   Park SY, 2018, ENVIRON TOXICOL PHAR, V62, P1, DOI 10.1016/j.etap.2018.06.001
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC
   US Department of Health and Human Services, COMM TERM CRIT ADV E
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   World Health Organization, NAM COR DIS COVID 19
   Wuhan Municipal Health Commission, 2019, REP CLUST PNEUM UNKN
   Yang XL, 2020, ADV OPT MATER, V8, DOI 10.1002/adom.202000079
NR 31
TC 2
Z9 2
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP
PY 2020
VL 26
IS 9
BP 648
EP 655
DI 10.1007/s11655-020-3426-7
EA JUL 2020
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NF2SH
UT WOS:000549310000001
PM 32676976
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Koschmieder, S
   Jost, E
   Cornelissen, C
   Muller, T
   Schulze-Hagen, M
   Bickenbach, J
   Marx, G
   Kleines, M
   Marx, N
   Brummendorf, TH
   Dreher, M
AF Koschmieder, Steffen
   Jost, Edgar
   Cornelissen, Christian
   Mueller, Tobias
   Schulze-Hagen, Maximilian
   Bickenbach, Johannes
   Marx, Gernot
   Kleines, Michael
   Marx, Nikolaus
   Bruemmendorf, Tim H.
   Dreher, Michael
TI Favorable COVID-19 course despite significant comorbidities in a
   ruxolitinib-treated patient with primary myelofibrosis
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE COVID-19; cytokine storm; mild course; primary myelofibrosis;
   ruxolitinib
AB COVID-19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID-19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental "cytokine storm", such as Janus-activated kinase (JAK) inhibitors, are being discussed. Here, we report a compelling case of a 55-yo patient with proven COVID-19 pneumonia, who was taking the JAK1/2 inhibitor ruxolitinib in-label for co-existing primary myelofibrosis for 15 months prior to coronavirus infection. The patient had significant comorbidities, including chronic kidney disease, arterial hypertension, and obesity, and our previous cohort suggested that he was thus at high risk for acute respiratory distress syndrome (ARDS) and death from COVID-19. Since abrupt discontinuation of ruxolitinib may cause fatal cytokine storm and ARDS, ruxolitinib treatment was continued and was well tolerated, and the patient ' s condition remained stable, without the need for mechanical ventilation or vasopressors. The patient became negative for SARS-CoV-2 and was discharged home after 15 days. In conclusion, our report provides clinical evidence that ruxolitinib treatment is feasible and can be beneficial in patients with COVID-19 pneumonia, preventing cytokine storm and ARDS.
C1 [Koschmieder, Steffen; Jost, Edgar; Bruemmendorf, Tim H.] Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany.
   [Cornelissen, Christian; Mueller, Tobias; Dreher, Michael] Rhein Westfal TH Aachen, Fac Med, Dept Pneumol & Intens Care Med, Aachen, Germany.
   [Schulze-Hagen, Maximilian] Rhein Westfal TH Aachen, Dept Diagnost & Intervent Radiol, Aachen, Germany.
   [Bickenbach, Johannes; Marx, Gernot] Rhein Westfal TH Aachen, Dept Intens Care & Intermediate Care, Aachen, Germany.
   [Kleines, Michael] Rhein Westfal TH Aachen, Lab Diagnost Zentrum, Aachen, Germany.
   [Kleines, Michael] Rhein Westfal TH Aachen, Dept Med Microbiol, Aachen, Germany.
   [Marx, Nikolaus] Rhein Westfal TH Aachen, Med Clin 1, Clin Cardiol Angiol & Internal Intens Med Med, Aachen, Germany.
RP Brummendorf, TH (corresponding author), Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany.; Dreher, M (corresponding author), Rhein Westfal TH Aachen, Fac Med, Dept Pneumol & Intens Care Med, Aachen, Germany.
EM tbruemmendorf@ukaachen.de; mdreher@ukaachen.de
RI Kleines, Michael/C-8801-2009; Muller, Tobias/ABH-7263-2020
OI Muller, Tobias/0000-0002-9801-3496; Schulze-Hagen,
   Maximilian/0000-0002-9182-2688; Koschmieder, Steffen/0000-0002-1011-8171
CR Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   [Anonymous], 2020, COVID 19 EMPFEHLUNGE
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Dreher M, 2020, DTSCH ARZTEBLATT, V5, P20
   Gaspari V, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106023
   Harrison CN, 2016, LEUKEMIA, V30, P1701, DOI 10.1038/leu.2016.148
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Peterson D, 2020, J AM ACAD DERMATOL, V82, pE223, DOI 10.1016/j.jaad.2020.03.099
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tefferi A, 2011, MAYO CLIN PROC, V86, P1188, DOI 10.4065/mcp.2011.0518
   Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 12
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD NOV
PY 2020
VL 105
IS 5
BP 655
EP 658
DI 10.1111/ejh.13480
EA JUL 2020
PG 4
WC Hematology
SC Hematology
GA NW8SK
UT WOS:000549893500001
PM 32593209
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Giovanni, A
   Radulesco, T
   Bouchet, G
   Mattei, A
   Revis, J
   Bogdanski, E
   Michel, J
AF Giovanni, Antoine
   Radulesco, Thomas
   Bouchet, Gilles
   Mattei, Alexia
   Revis, Joana
   Bogdanski, Estelle
   Michel, Justin
TI Transmission of droplet-conveyed infectious agents such as SARS-CoV-2 by
   speech and vocal exercises during speech therapy: preliminary experiment
   concerning airflow velocity
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Article; Early Access
DE COVID-19; Voice; Pulmonary ventilation; Speech therapy
AB Purpose Infectious agents, such as SARS-CoV-2, can be carried by droplets expelled during breathing. The spatial dissemination of droplets varies according to their initial velocity. After a short literature review, our goal was to determine the velocity of the exhaled air during vocal exercises. Methods A propylene glycol cloud produced by 2 e-cigarettes' users allowed visualization of the exhaled air emitted during vocal exercises. Airflow velocities were measured during the first 200 ms of a long exhalation, a sustained vowel /a/ and varied vocal exercises. For the long exhalation and the sustained vowel /a/, the decrease of airflow velocity was measured until 3 s. Results were compared with a Computational Fluid Dynamics (CFD) study using boundary conditions consistent with our experimental study. Results Regarding the production of vowels, higher velocities were found in loud and whispered voices than in normal voice. Voiced consonants like // or /v/ generated higher velocities than vowels. Some voiceless consonants, e.g., /t/ generated high velocities, but long exhalation had the highest velocities. Semi-occluded vocal tract exercises generated faster airflow velocities than loud speech, with a decreased velocity during voicing. The initial velocity quickly decreased as was shown during a long exhalation or a sustained vowel /a/. Velocities were consistent with the CFD data. Conclusion Initial velocity of the exhaled air is a key factor influencing droplets trajectory. Our study revealed that vocal exercises produce a slower airflow than long exhalation. Speech therapy should, therefore, not be associated with an increased risk of contamination when implementing standard recommendations.
C1 [Giovanni, Antoine; Mattei, Alexia; Revis, Joana; Bogdanski, Estelle] Aix Marseille Univ, CNRS, LPL, Aix En Provence, France.
   [Giovanni, Antoine; Radulesco, Thomas; Mattei, Alexia; Revis, Joana; Bogdanski, Estelle; Michel, Justin] Aix Marseille Univ, La Concept Univ Hosp, ENT HNS Dept, Marseille, France.
   [Radulesco, Thomas; Bouchet, Gilles; Michel, Justin] Aix Marseille Univ, CNRS, IUSTI, Marseille, France.
   [Giovanni, Antoine] CHU Concept, Serv ORL, 147 Blvd Baille, F-13385 Marseille 5, France.
RP Giovanni, A (corresponding author), Aix Marseille Univ, CNRS, LPL, Aix En Provence, France.; Giovanni, A (corresponding author), Aix Marseille Univ, La Concept Univ Hosp, ENT HNS Dept, Marseille, France.; Giovanni, A (corresponding author), CHU Concept, Serv ORL, 147 Blvd Baille, F-13385 Marseille 5, France.
EM antoine.giovanni@ap-hm.fr
OI GIOVANNI, antoine/0000-0003-3174-3854
CR Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   Asadi S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227699
   Asadi S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38808-z
   Bertholon JF, 2013, REV MAL RESPIR, V30, P752, DOI 10.1016/j.rmr.2013.03.003
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Bourouiba L, 2014, J FLUID MECH, V745, P537, DOI 10.1017/jfm.2014.88
   Dbouk T, 2020, PHYS FLUIDS, V32, DOI 10.1063/5.0011960
   DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288
   Gupta JK, 2010, INDOOR AIR, V20, P31, DOI 10.1111/j.1600-0668.2009.00623.x
   Johnson GR, 2009, J AEROSOL MED PULM D, V22, P229, DOI 10.1089/jamp.2008.0720
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Lindsley WG, 2013, AEROSOL SCI TECH, V47, P937, DOI 10.1080/02786826.2013.803019
   Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002
   Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730
   Read R., 2020, LOS ANGELES TIMES
   SCHUTTE HK, 1983, FOLIA PHONIATR, V35, P286, DOI 10.1159/000265703
   Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117
   Thamboo A, 2020, J OTOLARYNGOL-HEAD N, V49, DOI 10.1186/s40463-020-00425-6
   Traunmuller H, 2000, J ACOUST SOC AM, V107, P3438, DOI 10.1121/1.429414
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wei JJ, 2016, AM J INFECT CONTROL, V44, pS102, DOI 10.1016/j.ajic.2016.06.003
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097
   WHO, 2020, MOD TRANSM VIR CAUS
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xie XJ, 2009, J R SOC INTERFACE, V6, pS703, DOI 10.1098/rsif.2009.0388.focus
NR 25
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
DI 10.1007/s00405-020-06200-7
EA JUL 2020
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA ML1FK
UT WOS:000549220600001
PM 32676677
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Yeo, KR
   Zhang, M
   Pan, X
   Ke, AB
   Jones, HM
   Wesche, D
   Almond, LM
AF Yeo, Karen Rowland
   Zhang, Mian
   Pan, Xian
   Ke, Alice Ban
   Jones, Hannah M.
   Wesche, David
   Almond, Lisa M.
TI Impact of Disease on Plasma and Lung Exposure of Chloroquine,
   Hydroxychloroquine and Azithromycin: Application of PBPK Modeling
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID SERUM; TISSUE; PHARMACOKINETICS; ELIMINATION; MECHANISMS; KINETICS;
   DRUGS; VITRO
AB We use a mechanistic lung model to demonstrate that accumulation of chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZ) in the lungs is sensitive to changes in lung pH, a parameter that can be affected in patients with coronavirus disease 2019 (COVID-19). A reduction in pH from 6.7 to 6 in the lungs, as observed in respiratory disease, led to 20-fold, 4.0-fold, and 2.7-fold increases in lung exposure of CQ, HCQ, and AZ, respectively. Simulations indicated that the relatively high concentrations of CQ and HCQ in lung tissue were sustained long after administration of the drugs had stopped. Patients with COVID-19 often present with kidney failure. Our simulations indicate that renal impairment (plus lung pH reduction) caused 30-fold, 8.0-fold, and 3.4-fold increases in lung exposures for CQ, HCQ, and AZ, respectively, with relatively small accompanying increases (20 to 30%) in systemic exposure. Although a number of different dosage regimens were assessed, the purpose of our study was not to provide recommendations for a dosing strategy, but to demonstrate the utility of a physiologically-based pharmacokinetic modeling approach to estimate lung concentrations. This, used in conjunction with robustin vitroand clinical data, can help in the assessment of COVID-19 therapeutics going forward.
C1 [Yeo, Karen Rowland; Zhang, Mian; Pan, Xian; Ke, Alice Ban; Jones, Hannah M.; Almond, Lisa M.] Certara UK Ltd, Simcyp Div, Sheffield, S Yorkshire, England.
   [Wesche, David] Certara Inc, Princeton, NJ USA.
RP Yeo, KR (corresponding author), Certara UK Ltd, Simcyp Div, Sheffield, S Yorkshire, England.
EM Karen.Yeo@certara.com
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
FX The authors would like to acknowledge The Bill & Melinda Gates
   Foundation for funding the development of the original chloroquine
   model. We would like to thank Dr. Ping Zhao for his review of the
   manuscript and Eleanor Savill for her assistance with manuscript
   preparation.
CR ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   ADELUSI SA, 1982, J PHARM PHARMACOL, V34, P733, DOI 10.1111/j.2042-7158.1982.tb06211.x
   Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   BOHTE R, 1995, ANTIMICROB AGENTS CH, V39, P2801, DOI 10.1128/AAC.39.12.2801
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639
   EFFROS RM, 1969, J CLIN INVEST, V48, P1983, DOI 10.1172/JCI106164
   Fan Jianghong, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa623
   FERRARI V, 1991, BIOCHEM PHARMACOL, V41, P23, DOI 10.1016/0006-2952(91)90006-Q
   Fischer H, 2006, J MEMBRANE BIOL, V211, P139, DOI 10.1007/s00232-006-0861-0
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gaohua L, 2015, CPT-PHARMACOMET SYST, V4, P605, DOI 10.1002/psp4.12034
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Hallifax D, 2007, DRUG METAB DISPOS, V35, P1325, DOI 10.1124/dmd.107.015131
   Jamei M, 2014, CLIN PHARMACOKINET, V53, P73, DOI 10.1007/s40262-013-0097-y
   Johnson TN, 2016, DRUG METAB DISPOS, V44, P1090, DOI 10.1124/dmd.115.068643
   Johnson TN, 2010, CLIN PHARMACOKINET, V49, P189, DOI 10.2165/11318160-000000000-00000
   Jones HM, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.41
   Katneni K, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2493-3
   Kiem S, 2008, ANTIMICROB AGENTS CH, V52, P24, DOI 10.1128/AAC.00133-06
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lucchi M, 2008, J ANTIMICROB CHEMOTH, V61, P884, DOI 10.1093/jac/dkn032
   MCCHESNEY EW, 1967, J PHARMACOL EXP THER, V158, P323
   Munster T, 2002, ARTHRITIS RHEUM-US, V46, P1460, DOI 10.1002/art.10307
   Nozinic D, 2010, CROAT CHEM ACTA, V83, P323
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Polak S, 2018, J PHARMACOKINET PHAR, V45, P457, DOI 10.1007/s10928-018-9580-2
   Rodgers T, 2005, J PHARM SCI-US, V94, P1259, DOI 10.1002/jps.20322
   Rowland Yeo Karen, 2011, Expert Rev Clin Pharmacol, V4, P261, DOI 10.1586/ecp.10.143
   Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846., DOI 10.1101/2020.04.03.023846]
   Viasus D, 2013, J INFECTION, V66, P415, DOI 10.1016/j.jinf.2012.12.007
   Wan J, 2006, PROTEOMICS, V6, P2886, DOI 10.1002/pmic.200500638
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wi YM, 2014, INT J CLIN PRACT, V68, P222, DOI [10.1111/ijcp.12249, 10.1111/ijcp.12368]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 37
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD NOV
PY 2020
VL 108
IS 5
BP 976
EP 984
DI 10.1002/cpt.1955
EA JUL 2020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OA1YS
UT WOS:000548707100001
PM 32531808
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lamprou, DA
AF Lamprou, Dimitrios A.
TI Emerging technologies for diagnostics and drug delivery in the fight
   against COVID-19 and other pandemics
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Article
DE 3D-printing; COVID-19; diagnostics; disease monitoring; drug delivery;
   MEMS devices; microfluidics; pandemic; personalized treatment
AB Introduction A pandemic is the worst-case scenario in the field of infectious diseases. Innovative technologies have the potential to address the challenges associated with the manufacture of personalized drug delivery systems, biosensors, and medical devices during a pandemic. 3D-Printing, microfluidics, and Microelectromechanical systems (MEMS) can provide an important part on this fight, as are cheap, easy to be operated, capable to provide rapid detection and monitoring of a disease, and deliver medicines. Areas covered This manuscript answers the question of how these emerging technologies can save lives during a pandemic by avoiding supply chain delays and also by providing rapid diagnostics, disease monitoring, or by offering personalized treatments. The manuscript covers recent approaches in the topic with a focus in manuscripts published in the last year and by emphasising recent regulatory considerations by regulatory agencies in the manufacturing of 3DP systems or other medical devices during COVID. Expert opinion New manufacturing techniques are emerging with the ability to address the challenges associated with the development of medical devices or diagnostics, during a pandemic. Are many challenges in order to achieve this and especially in short times that are required under a pandemic attack, which will also be covered in this manuscript.
C1 [Lamprou, Dimitrios A.] Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland.
RP Lamprou, DA (corresponding author), Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland.
EM d.lamprou@qub.ac.uk
RI Lamprou, Dimitrios/ABB-6826-2020
OI Lamprou, Dimitrios/0000-0002-8740-1661
FU Queen's University Belfast (QUB)
FX The author would like to thank the research group alumni and current
   members; Erasmus+ students, research visitors, PhD students, and
   postdoctoral researchers. The author thanks also Queen's University
   Belfast (QUB) and all the funders that have supported the lab research
   during all these years.
CR Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Economidou SN, 2019, MAT SCI ENG C-MATER, V102, P743, DOI 10.1016/j.msec.2019.04.063
   Garzotto F, 2020, EXPERT REV MED DEVIC, V17, P483, DOI 10.1080/17434440.2020.1772757
   Jiao ZQ, 2019, ANAL METHODS-UK, V11, P3286, DOI 10.1039/c9ay01108k
   Kitson PJ, 2018, SCIENCE, V359, P314, DOI 10.1126/science.aao3466
   Lamprou DA, 2019, EXPERT OPIN DRUG DEL, DOI 10.1080/17425247.2019.1689956
   Larraneta E, 2020, 3D PRINT ADDIT MANUF, V7, P100, DOI 10.1089/3dp.2020.0106
   Lee DS, 2019, 2019 20TH INTERNATIONAL CONFERENCE ON SOLID-STATE SENSORS, ACTUATORS AND MICROSYSTEMS & EUROSENSORS XXXIII (TRANSDUCERS & EUROSENSORS XXXIII), P1063, DOI 10.1109/TRANSDUCERS.2019.8808729
   Lee HJ, 2018, ADV DRUG DELIVER REV, V128, P132, DOI 10.1016/j.addr.2017.11.003
   Leong HS, 2019, NAT NANOTECHNOL, V14, P629, DOI 10.1038/s41565-019-0496-9
   Li DS, 2020, KOREAN J RADIOL, V21, P505, DOI 10.3348/kjr.2020.0146
   Li Y, 2019, MICROSYST NANOENG, V5, DOI 10.1038/s41378-019-0077-y
   Luzuriaga MA, 2018, LAB CHIP, V18, P1223, DOI 10.1039/c8lc00098k
   Ma YD, 2019, SENSOR ACTUAT B-CHEM, V296, DOI 10.1016/j.snb.2019.126647
   Mathew E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030266
   Paull B, 2019, 3D PRINTING CHEM SCI, P1
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2
   Shrestha J, 2020, ORGANS ON A CHIP, V1, P100001
   Simpson C, 2018, CURR CLIN MICROBIOL, V5, P245, DOI 10.1007/s40588-018-0105-y
   Nguyen T, 2018, MICROMACHINES-BASEL, V9, DOI 10.3390/mi9080403
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Worldometer, 2020, COVID 19 COR PAND ST
   Yen YK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60057-8
   Zhang P, 2019, MICROSYST TECHNOL, V15, P1073
   Zuniga JM, 2020, EXPERT REV MED DEVIC, V17, P477, DOI 10.1080/17434440.2020.1756771
NR 28
TC 2
Z9 2
U1 6
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD OCT 2
PY 2020
VL 17
IS 10
BP 1007
EP 1012
DI 10.1080/17434440.2020.1792287
EA JUL 2020
PG 6
WC Engineering, Biomedical
SC Engineering
GA OZ8JZ
UT WOS:000549021000001
PM 32674622
OA Bronze
DA 2021-01-01
ER

PT J
AU Deruelle, E
   Salem, OB
   Hieng, SS
   Pichereau, C
   Outin, H
   Jamme, M
AF Deruelle, Emilie
   Salem, Omar Ben Hadj
   Hieng, Sonnthida Sep
   Pichereau, Claire
   Outin, Herve
   Jamme, Matthieu
TI Immune thrombocytopenia in a patient with COVID-19
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
AB This case report describes immune thrombocytopenic purpura in a 41-year-old man hospitalized in the intensive-care unit for COVID-19, 13 days after the onset of COVID-19 symptoms with respiratory failure at admission. Acute respiratory distress syndrome was treated with, among other drugs, low-molecular-weight heparin. On day 8, his platelet count began descending rapidly. On day 10, heparin treatment was replaced by danaparoid sodium, but by day 13, the continued low platelet count made a diagnosis of heparin-induced thrombocytopenia unlikely. Normocytic nonregenerative anemia gradually developed. On day 13, a bone marrow aspiration showed numerous megakaryocytes and a few signs of hemophagocytosis. Corticosteroids were introduced on day 14, and platelets began rising after 3 days and then fell again on day 19. Intravenous immunoglobulin (IV Ig) was then administered. Two days later, the platelet count returned to normal. The immune cause was confirmed by ruling out the differential diagnoses and the excellent and rapid response to intravenous immunoglobulins. Finally, the patient's respiratory state improved. He was discharged to a respiratory rehabilitation unit on day 38. Our case suggests that an immunological cause should be considered in patients with thrombocytopenia during COVID-19.
C1 [Deruelle, Emilie; Salem, Omar Ben Hadj; Pichereau, Claire; Outin, Herve; Jamme, Matthieu] Poissy St Germain Hosp, Intens Care Unit, 9-10 Rue Champ Gaillard, F-78300 Poissy, France.
   [Hieng, Sonnthida Sep] Poissy St Germain Hosp, Lab Hematol, 9-10 Rue Champ Gaillard, F-78300 Poissy, France.
   [Jamme, Matthieu] UVSQ, INSERM U1018, CESP, Team EpReC Renal & Cardiovasc Epidemiol 5, Villejuif, France.
RP Jamme, M (corresponding author), Poissy St Germain Hosp, Intens Care Unit, 9-10 Rue Champ Gaillard, F-78300 Poissy, France.; Jamme, M (corresponding author), UVSQ, INSERM U1018, CESP, Team EpReC Renal & Cardiovasc Epidemiol 5, Villejuif, France.
EM Matthieu.Jamme@ght-yvelinesnord.fr
CR Ahmed MZ, 2020, BRIT J HAEMATOL, V189, P1057, DOI 10.1111/bjh.16769
   Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Franchini M, 2017, EXPERT REV HEMATOL, V10, P99, DOI 10.1080/17474086.2017.1271319
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hu ZL, 2020, ANN HEMATOL, DOI 10.1007/s00277-020-04070-x
   Humbert S, 2020, MED MALADIES INFECT, V50, P459, DOI 10.1016/j.medmal.2020.05.003
   Jiang SQ, 2020, BRIT J HAEMATOL, V190, pE29, DOI 10.1111/bjh.16817
   Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706
   Li M, 2020, BRIT J HAEMATOL, V190, pE59, DOI 10.1111/bjh.16846
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu YN, 2020, PATTERN ANAL APPL, V23, P1551, DOI 10.1007/s10044-020-00877-6
   Lorenzo-Villalba Noel, 2020, Eur J Case Rep Intern Med, V7, P001702, DOI 10.12890/2020_001702
   Merli M, 2020, ANN HEMATOL, V99, P1951, DOI 10.1007/s00277-020-04130-2
   Murt A, 2020, J MED VIROL, DOI 10.1002/jmv.26138
   Neunert C, 2019, BLOOD ADV, V3, P3829, DOI 10.1182/bloodadvances.2019000966
   Patel PA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1437
   Pavord S, 2020, BRIT J HAEMATOL, V189, P1038, DOI 10.1111/bjh.16775
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Sadr S, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00820
   Tang MW, 2020, AM J HEMATOL, V95, pE191, DOI 10.1002/ajh.25877
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tsao HS, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1419
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
   Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170
   Yang M, 2004, INT J MOL MED, V14, P311
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Zhang YJ, 2020, THROMB RES, V193, P110, DOI 10.1016/j.thromres.2020.06.008
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 28
TC 1
Z9 1
U1 2
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD DEC
PY 2020
VL 112
IS 6
BP 883
EP 888
DI 10.1007/s12185-020-02943-5
EA JUL 2020
PG 6
WC Hematology
SC Hematology
GA OQ3VM
UT WOS:000549246300001
PM 32677007
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Celik, I
   Onay-Besikci, A
   Ayhan-Kilcigil, G
AF Celik, Ismail
   Onay-Besikci, Arzu
   Ayhan-Kilcigil, Gulgun
TI Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2:
   a molecular docking study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Hydroxychloroquine; chloroquine; SARS-CoV-2; ACE2; molecular docking
ID CHLOROQUINE; INHIBITION
AB We aimed to analyze the interactions of both hydroxychloroquine and chloroquine with SARS-CoV-2 and identify their possible role for the prevention/treatment of COVID-19 by molecular docking studies. Protein crystal structures of SARS-CoV-2 and ACE2, the compounds hydroxychloroquine and chloroquine, and other ligand structures were minimized by OPLS3 force field. Glide Standard Precision and Extra Precision docking are performed and MM-GBSA values are calculated. Molecular docking studies showed that hydroxychloroquine and chloroquine do not interact with SARS-CoV-2 proteins, but bind to the amino acids ASP350, ASP382, ALA348, PHE40 and PHE390 on the ACE2 allosteric site rather than the ACE2 active site. Our results showed that neither hydroxychloroquine and chloroquine bind to the active site of ACE2. However, both molecules prevent the binding of SARS-CoV-2 spike protein to ACE2 by interacting with the allosteric site. This result can help ACE2 inhibitor drug development studies to prevent viruses entering the cell by attaching spike protein to ACE2. Communicated by Ramaswamy H. Sarma
C1 [Celik, Ismail; Ayhan-Kilcigil, Gulgun] Ankara Univ, Fac Pharm, Dept Pharmaceut Chem, Ankara, Turkey.
   [Celik, Ismail] Erciyes Univ, Fac Pharm, Dept Pharmaceut Chem, Kayseri, Turkey.
   [Onay-Besikci, Arzu] Ankara Univ, Fac Pharm, Dept Pharmacol, Ankara, Turkey.
RP Celik, I (corresponding author), Erciyes Univ, Fac Pharm, Dept Pharmaceut Chem, TR-38280 Talas Kayseri, Turkey.
EM ismailcelik@erciyes.edu.tr
RI celik, ismail/AAX-3221-2020
OI celik, ismail/0000-0002-8146-1663
CR BYRD TF, 1991, J CLIN INVEST, V88, P351, DOI 10.1172/JCI115301
   Chong CR, 2003, BIOCHEM PHARMACOL, V66, P2201, DOI 10.1016/j.bcp.2003.08.009
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Furst D. E., 2009, BASIC CLIN PHARM, V11, P621
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   GonzalezDunia D, 1998, J VIROL, V72, P783, DOI 10.1128/JVI.72.1.783-788.1998
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Radcliffe S., 2020, TRUMP IS TAKING HYDR
   Rosenthal P. J., 2009, BASIC CLIN PHARM, P899
   Satarker S., 2020, STRUCTURAL PROTEINS
   Schrodinger LLC, 2018, SCHRODINGER RELEASE
   Tatiana Arias C., 2020, SALVADORAN LEADER SA
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Valsler Ben., 2020, POPCAST CHLOROQUINE
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   World Health Organization, 2020, CORONAVIRUS DIS COVI
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 28
TC 1
Z9 1
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792993
EA JUL 2020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK8KZ
UT WOS:000549032100001
PM 32677545
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Koulgi, S
   Jani, V
   Uppuladinne, M
   Sonavane, U
   Nath, AK
   Darbari, H
   Joshi, R
AF Koulgi, Shruti
   Jani, Vinod
   Uppuladinne, Mallikarjunachari
   Sonavane, Uddhavesh
   Nath, Asheet Kumar
   Darbari, Hemant
   Joshi, Rajendra
TI Drug repurposing studies targeting SARS-CoV-2: an ensemble docking
   approach on drug target 3C-like protease (3CL(pro))
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; main protease; repurposing; cryptic pockets;
   3CL(pro)
ID COVID-19; FEATURES; MODELS
AB The COVID-19 pandemic has been responsible for several deaths worldwide. The causative agent behind this disease is the Severe Acute Respiratory Syndrome - novel Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the category of RNA viruses. The main protease, responsible for the cleavage of the viral polyprotein is considered as one of the hot targets for treating COVID-19. Earlier reports suggest the use of HIV anti-viral drugs for targeting the main protease of SARS-CoV, which caused SARS in the year 2002-2003. Hence, drug repurposing approach may prove to be useful in targeting the main protease of SARS-CoV-2. The high-resolution crystal structure of the main protease of SARS-CoV-2 (PDB ID: 6LU7) was used as the target. The Food and Drug Administration approved and SWEETLEAD database of drug molecules were screened. The apo form of the main protease was simulated for a cumulative of 150 ns and 10 mu s open-source simulation data was used, to obtain conformations for ensemble docking. The representative structures for docking were selected using RMSD-based clustering and Markov State Modeling analysis. This ensemble docking approach for the main protease helped in exploring the conformational variation in the drug-binding site of the main protease leading to the efficient binding of more relevant drug molecules. The drugs obtained as top hits from the ensemble docking possessed anti-bacterial and anti-viral properties. Thisin silicoensemble docking approach would support the identification of potential candidates for repurposing against COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Koulgi, Shruti; Jani, Vinod; Uppuladinne, Mallikarjunachari; Sonavane, Uddhavesh; Nath, Asheet Kumar; Darbari, Hemant; Joshi, Rajendra] Ctr Dev Adv Comp, High Performance Comp Med & Bioinformat Applicat, Pune, Maharashtra, India.
RP Joshi, R (corresponding author), Ctr Dev Adv Comp, Pune, Maharashtra, India.
EM rajendra@cdac.in
FU National Supercomputing Mission (NSM), Ministry of Electronics and
   Information Technology (MeitY), Government of India
FX The authors would like to acknowledge the National Supercomputing
   Mission (NSM), Ministry of Electronics and Information Technology
   (MeitY), Government of India for funding this work.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Ahmad S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775129
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Allen WJ, 2015, J COMPUT CHEM, V36, P1132, DOI 10.1002/jcc.23905
   Amin M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1775703
   ANDERSEN KG, 2020, NAT MED 0317, DOI DOI HTTPS://DOI.ORG/10.1038/S41591-020-0820-9
   ANWAR F, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775123
   ARYA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1773929
   Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839
   BABADAEI MMN, 2020, J BIOMOL STRUCT 0529, DOI DOI https://doi.org/10.1080/07391102.2020.1767211
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   BASIT A, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768150
   BAUER DC, 2020, TRANSBOUND EMER 0525, DOI DOI https://doi.org/10.1111/tbed.13588
   BEURA S, 2020, J BIOMOL STRUCT 0604, DOI DOI https://doi.org/10.1080/07391102.2020.1772111
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Borkotoky S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1774419
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Case D.A., 2016, AMBER 2016
   Center for Drug Evaluation and Research (U.S.), 2004, DRUGS FDA
   CHANDRA A, 2020, J BIOMOL STRUCT 0608, DOI DOI https://doi.org/10.1080/07391102.2020.1775127
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cherian Sarah S, 2020, Indian J Med Res, V151, P160, DOI 10.4103/ijmr.IJMR_585_20
   Chodera JD, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2714538
   Chodera JD, 2014, CURR OPIN STRUC BIOL, V25, P135, DOI 10.1016/j.sbi.2014.04.002
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   DEOLIVEIRA OV, 2020, J BIOMOL STRUCT 0601, DOI DOI https://doi.org/10.1080/07391102.2020.1772885
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Ester M., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Fearon D., 2020, PANDDA ANAL GROUP DE
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gupta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776157
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   HENDAUS MA, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1767691
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jani V, 2019, RSC ADV, V9, P14567, DOI 10.1039/c9ra01507h
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   KHAN MT, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1769733
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   KUMAR A, 2020, J BIOMOL STRUCT 0602, DOI DOI https://doi.org/10.1080/07391102.2020.1772112
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   KUMAR V, 2020, J BIOMOL STRUCT 0609, DOI DOI https://doi.org/10.1080/07391102.2020.1775704
   KUMAR V, 2020, J BIOMOL STRUCT 0530, DOI DOI https://doi.org/10.1080/07391102.2020.1772108
   Kuzmanic A, 2020, ACCOUNTS CHEM RES, V53, P654, DOI 10.1021/acs.accounts.9b00613
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu S, 2020, BIOINFORMATICS, V36, P3295, DOI 10.1093/bioinformatics/btaa224
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   MAHANTA S, 2020, J BIOMOL STRUCT 0522, DOI DOI https://doi.org/10.1080/07391102.2020.1768902
   MITTAL L, 2020, J BIOMOL STRUCT 0519, DOI DOI https://doi.org/10.1080/07391102.2020.1768151
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   NADEEM MS, 2020, PATHOGENS, V9, DOI DOI https://doi.org/10.3390/pathogens9040307
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PHADKE M, 2020, DRUG DEVELOP RE 0329, DOI DOI https://doi.org/10.1002/ddr.21666
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Prinz JH, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3565032
   QUIMQUE MTJ, 2020, J BIOMOL STRUCT 0613, DOI DOI https://doi.org/10.1080/07391102.2020.1776639
   ROSA SGV, 2020, REV PANAM SALUD PUBL, V44, DOI DOI https://doi.org/10.26633/RPSP.2020.40
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Scherer MK, 2015, J CHEM THEORY COMPUT, V11, P5525, DOI 10.1021/acs.jctc.5b00743
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Sirur A, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4941579
   SK MF, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1768149
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   TU YF, 2020, INT J MOL SCI, V21, DOI DOI https://doi.org/10.3390/ijms
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Vangone A, 2019, BIOINFORMATICS, V35, P1585, DOI 10.1093/bioinformatics/bty816
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Xu D, 2005, EUR J CLIN MICROBIOL, V24, P165, DOI 10.1007/s10096-005-1299-5
   Yadav Pragya D, 2020, Indian J Med Res, V151, P200, DOI 10.4103/ijmr.IJMR_663_20
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 102
TC 2
Z9 2
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792344
EA JUL 2020
PG 21
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK8HM
UT WOS:000549023000001
PM 32679006
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rane, JS
   Pandey, P
   Chatterjee, A
   Khan, R
   Kumar, A
   Prakash, A
   Ray, S
AF Rane, Jitendra Subhash
   Pandey, Preeti
   Chatterjee, Aroni
   Khan, Rajni
   Kumar, Abhijeet
   Prakash, Amresh
   Ray, Shashikant
TI Targeting virus-host interaction by novel pyrimidine derivative: anin
   silicoapproach towards discovery of potential drug against COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE hACE2; receptor; coronavirus; pyrimidine derivatives; binding site
ID IN-SILICO; BINDING; PROTEIN; INHIBITORS; LOMEFLOXACIN; MECHANISMS;
   PARAMETERS; DOCKING; SURFACE; ION
AB The entire human population over the globe is currently facing appalling conditions due to the spread of infection from coronavirus disease-2019 (COVID-19). The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present on the surface of the virion mediates the virus entry into the host cells and therefore is targeted by several scientific groups as a novel drug target site. The spike glycoprotein binds to the human angiotensin-converting enzyme-2 (hACE2) cell surface receptor abundantly expressed in lung tissues, and this binding phenomenon is a primary determinant of cell tropism and pathogenesis. The binding and internalization of the virus is the primary and most crucial step in the process of infection, and therefore the molecules targeting the inhibition of this process certainly hold a significant therapeutic value. Thus, we systematically applied the computational techniques to identify the plausible inhibitor from a chosen set of well characterized diaryl pyrimidine analogues which may disrupt interfacial interaction of spike glycoprotein (S) at the surface of hACE2. Using molecular docking, molecular dynamics (MD) simulation and binding free energy calculation, we have identified AP-NP (2-(2-amino-5-(naphthalen-2-yl)pyrimidin-4-yl)phenol), AP-3-OMe-Ph (2-(2-amino-5-(3-methoxyphenyl)pyrimidin-4-yl)phenol) and AP-4-Me-Ph (2-(2-amino-5-(p-tolyl) pyrimidin-4-yl)phenol) from a group of diaryl pyrimidine derivatives which appears to bind at the interface of the hACE2-S complex with low binding free energy. Thus, pyrimidine derivative AP-NP may be explored as an effective inhibitor for hACE2-S complex. Furthermore,in vitroandin vivostudies will strengthen the use of these inhibitors as suitable drug candidates against SARS-COV-2. Communicated by Ramaswamy H. Sarma
C1 [Rane, Jitendra Subhash] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India.
   [Pandey, Preeti] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
   [Chatterjee, Aroni] ICMR, NICED, Virus Res Lab, Kolkata, India.
   [Khan, Rajni] Motihari Coll Engn, Motihari, India.
   [Kumar, Abhijeet] Mahatma Gandhi Cent Univ, Dept Chem, Motihari 845401, India.
   [Prakash, Amresh] Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.
   [Ray, Shashikant] Mahatma Gandhi Cent Univ, Dept Biotechnol, Motihari 845401R, India.
RP Kumar, A (corresponding author), Mahatma Gandhi Cent Univ, Dept Chem, Motihari 845401, India.; Prakash, A (corresponding author), Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.; Ray, S (corresponding author), Mahatma Gandhi Cent Univ, Dept Biotechnol, Motihari 845401R, India.
EM abhijeetkumar@mgcub.ac.in; amreshprakash@jnu.ac.in;
   shashikantray@mgcub.ac.in
OI KUMAR, ABHIJEET/0000-0003-3617-0741; Prakash, Amresh/0000-0002-4821-1654
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Abu-Hashem AA, 2011, J CHIN CHEM SOC-TAIP, V58, P41, DOI 10.1002/jccs.201190056
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Amir M., 2007, Indian Journal of Pharmaceutical Sciences, V69, P337
   Balzarini J, 2002, J ANTIMICROB CHEMOTH, V50, P5, DOI 10.1093/jac/dkf037
   Batt SM, 2012, P NATL ACAD SCI USA, V109, P11354, DOI 10.1073/pnas.1205735109
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DeLano W.L., 2002, PYMOL
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   ELFIKY AA, 2020, J BIOMOL STRUCT 0424, DOI DOI https://doi.org/10.1080/07391102.2020.1758789
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Gombar VK, 2003, CURR TOP MED CHEM, V3, P1205, DOI 10.2174/1568026033452014
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   JAYARAM B, 2012, BMC BIOINFORMATI S17, V13, DOI DOI https://doi.org/10.1186/1471-2105-13-S17-S7
   Jitendra Subhash R., 2020, TARGETING SARS COV 2, DOI [https://doi.org/10.26434/chemrxiv.12094203.v1, DOI 10.26434/CHEMRXIV.12094203.V1]
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Joung IS, 2008, J PHYS CHEM B, V112, P9020, DOI 10.1021/jp8001614
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   KUMAR A, 2018, J CHEM SCI, V130, DOI DOI https://doi.org/10.1007/s12039-018-1565-6
   KUMAR N, 2019, J BIOMOL STRUCT 0824, V38, DOI DOI https://doi.org/10.1080/07391102.2019.1657499
   Kumar V, 2018, BIOCHEM J, V475, P1701, DOI 10.1042/BCJ20180085
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mishra CB, 2018, EUR J MED CHEM, V151, P520, DOI 10.1016/j.ejmech.2018.04.007
   Mokaberi P, 2019, NEW J CHEM, V43, P8132, DOI 10.1039/c9nj01048c
   MONGRE RK, 2019, CANCERS, V11, DOI DOI https://doi.org/10.3390/cancers11091245
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pandey P, 2018, CHEM PHYS LETT, V695, P69, DOI 10.1016/j.cplett.2018.01.059
   Pandey P, 2017, BIOINFORMATION, V13, P144, DOI 10.6026/97320630013144
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Prakash A, 2018, J BIOMOL STRUCT DYN, V36, P2391, DOI 10.1080/07391102.2017.1355847
   Prakash A, 2012, AMINO ACIDS, V43, P1451, DOI 10.1007/s00726-012-1218-x
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shakibapour N, 2019, J BIOMOL STRUCT DYN, V37, P359, DOI 10.1080/07391102.2018.1427629
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   SHARIFIRAD A, 2020, J BIOMOL STRUCT 0211, DOI DOI https://doi.org/10.1080/07391102.2020.1724568
   Sharma V, 2014, INT J MED CHEM, V2014, DOI 10.1155/2014/202784
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   SINGH R, 2019, J BIOMOL STRUCT 1127, DOI DOI https://doi.org/10.1080/07391102.2019.1695669
   Sohrabi T, 2018, J MOL LIQ, V256, P127, DOI 10.1016/j.molliq.2018.02.031
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VEGA S, 1990, J HETEROCYCLIC CHEM, V27, P269, DOI 10.1002/jhet.5570270229
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CH, 2016, J COMPUT CHEM, V37, P2436, DOI 10.1002/jcc.24467
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI 10.1080/10409230802058320 
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xie FC, 2011, J MED CHEM, V54, P3200, DOI 10.1021/jm101388d
   Xu J, 2002, MOLECULES, V7, P566, DOI 10.3390/70800566
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 66
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1794969
EA JUL 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MM4EO
UT WOS:000550112100001
PM 32684109
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Esposito, G
   Pesce, M
   Seguella, L
   Sanseverino, W
   Lu, J
   Corpetti, C
   Sarnelli, G
AF Esposito, Giuseppe
   Pesce, Marcella
   Seguella, Luisa
   Sanseverino, Walter
   Lu, Jie
   Corpetti, Chiara
   Sarnelli, Giovanni
TI The potential of cannabidiol in theCOVID-19pandemic
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID INFLAMMATION
AB Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons:- (a) High-cannabidiolCannabis sativaextracts are able to down-regulate the expression of the two key receptors for SARS-CoV2 in several models of human epithelia, (b) cannabidiol exerts a wide range of immunomodulatory and anti-inflammatory effects and it can mitigate the uncontrolled cytokine production responsible for acute lung injury, (c) being a PPAR gamma agonist, it can display a direct antiviral activity and (d) PPAR gamma agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies to test cannabidiol as a support drug against the COVID-19 pandemic.
C1 [Esposito, Giuseppe; Seguella, Luisa; Corpetti, Chiara] Sapienza Univ Rome, Dept Physiol & Pharmacol V Erspamer, Rome, Italy.
   [Pesce, Marcella; Sarnelli, Giovanni] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
   [Sanseverino, Walter] Sequentia Biotech SL, Barcelona, Spain.
   [Lu, Jie] China Med Univ, Coll Basic Med Sci, Dept Human Anat, Shenyang, Peoples R China.
RP Sarnelli, G (corresponding author), Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
EM sarnelli@unina.it
RI Pesce, Marcella/ABD-6001-2020
OI Pesce, Marcella/0000-0001-5996-4259; Lu, Jie/0000-0001-6843-9720;
   Esposito, Giuseppe/0000-0001-8080-8218; Sarnelli,
   Giovanni/0000-0002-1467-1134; Sanseverino, Walter/0000-0003-3324-5912
CR Barichello T, 2012, EUR J PHARMACOL, V697, P158, DOI 10.1016/j.ejphar.2012.09.053
   Bassaganya-Riera J, 2010, VIRAL IMMUNOL, V23, P343, DOI 10.1089/vim.2010.0016
   Carboni E, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109776
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Costiniuk CT, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024793
   Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223430
   Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034
   Lowe HIC, 2017, PHARMACOGN RES, V9, P116, DOI 10.4103/0974-8490.199780
   Milam JE, 2008, AM J PHYSIOL-LUNG C, V294, pL891, DOI 10.1152/ajplung.00333.2007
   Millar SA, 2019, BRIT J CLIN PHARMACO, V85, P1888, DOI 10.1111/bcp.14038
   Ng FH, 2020, HONG KONG MED J, V26, DOI 10.12809/hkmj208490
   O'Sullivan SE, 2010, IMMUNOBIOLOGY, V215, P611, DOI 10.1016/j.imbio.2009.09.007
   Reznik SE, 2016, INT J INFECT DIS, V52, P74, DOI 10.1016/j.ijid.2016.09.020
   Ribeiro A, 2015, IMMUNOPHARM IMMUNOT, V37, P35, DOI 10.3109/08923973.2014.976794
   Ribeiro A, 2012, EUR J PHARMACOL, V678, P78, DOI 10.1016/j.ejphar.2011.12.043
   Vuolo F, 2019, EUR J PHARMACOL, V843, P251, DOI 10.1016/j.ejphar.2018.11.029
   Wang B., 2020, SEARCH PREVENTATIVE, DOI [10.20944/preprints202004.0315.v1, DOI 10.20944/PREPRINTS202004.0315.V1]
NR 19
TC 5
Z9 5
U1 13
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2020
VL 177
IS 21
BP 4967
EP 4970
DI 10.1111/bph.15157
EA JUL 2020
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC7OD
UT WOS:000548683700001
PM 32519753
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ruggeri, RM
   Campenni, A
   Siracusa, M
   Frazzetto, G
   Gullo, D
AF Ruggeri, Rosaria Maddalena
   Campenni, Alfredo
   Siracusa, Massimiliano
   Frazzetto, Giuseppe
   Gullo, Damiano
TI Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine
   complication linked to the COVID-19 pandemic
SO HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
LA English
DT Letter; Early Access
DE COVID-19; SARS-COV-2; Subacute thyroiditis; Viral thyroiditis
AB Purpose Subacute thyroiditis (SAT) is an inflammatory thyroid disorder of viral origin, generally preceded by an upper respiratory tract infection. Since the disorder is self-limiting, it is frequently underdiagnosed. However, the disease should not be overlooked since the associated thyrotoxicosis may worsen the clinical course of concomitant disorders (e.g., respiratory distress) and long-term sequelae, such as autoimmune hypothyroidism, have been reported. Methods Here we describe a woman who developed SAT with thyrotoxicosis after SARS-COV-2 infection. Coronavirus disease (COVID-19) symptoms were mild and the patient was managed with no specific treatment and recovered rapidly. Results Six weeks after the onset of the upper respiratory tract infection, the patient developed pain and tenderness in the anterior cervical region, fatigue, tremors, and palpitations. Physical examination revealed mild tremors of the extremities, a diffuse and painful goiter, and enlarged and tender cervical and submandibular lymph nodes. At biochemical evaluation, TSH was suppressed, FT3 and FT4 were high, and serum thyroglobulin was markedly increased (188 pg/mL; n.v. 0-40). Thyroid scintigraphy showed markedly reduced Tc-99m-perthecnetate uptake in the gland. All findings were consistent with SAT, and treatment with oral prednisone (25 mg/day as the starting dose, gradually tapered) was started. Under the corticosteroid therapy, there was progressive resolution of symptoms and signs, and, within 4 weeks, all thyroid functional tests and inflammatory indexes normalized. Conclusion Clinicians should be aware of thyroid manifestations potentially associated with COVID-19.
C1 [Ruggeri, Rosaria Maddalena] Univ Messina, Gaetano Martino Univ Hosp, Dept Clin & Expt Med, Unit Endocrinol, I-98125 Messina, Italy.
   [Campenni, Alfredo; Siracusa, Massimiliano] Univ Messina, Dept Biomed Sci & Morphol & Funct Images, Unit Nucl Med, Messina, Italy.
   [Frazzetto, Giuseppe; Gullo, Damiano] Univ Catania, Sch Med, Garibaldi Nesima Hosp, Endocrine Unit,Dept Clin & Mol Biomed, Catania, Italy.
RP Ruggeri, RM (corresponding author), Univ Messina, Gaetano Martino Univ Hosp, Dept Clin & Expt Med, Unit Endocrinol, I-98125 Messina, Italy.
EM rmruggeri@unime.it
CR Desailloud R, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-5
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Ippolito S, 2020, J ENDOCRINOL INVEST, V43, P1171, DOI 10.1007/s40618-020-01312-7
NR 3
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1109-3099
EI 2520-8721
J9 HORM-INT J ENDOCRINO
JI Horm.-Int. J. Endocrinol. Metab.
DI 10.1007/s42000-020-00230-w
EA JUL 2020
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA ML2CA
UT WOS:000549279400001
PM 32676935
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Thomson, DJ
   Palma, D
   Guckenberger, M
   Balermpas, P
   Beitler, JJ
   Blanchard, P
   Brizel, D
   Budach, W
   Caudell, J
   Corry, J
   Corvo, R
   Evans, M
   Garden, AS
   Giralt, J
   Gregoire, V
   Harari, PM
   Harrington, K
   Hitchcock, YJ
   Johansen, J
   Kaanders, J
   Koyfman, S
   Langendijk, JA
   Le, QT
   Lee, N
   Margalit, D
   Mierzwa, M
   Porceddu, S
   Soong, YL
   Sun, Y
   Thariat, J
   Waldron, J
   Yom, SS
AF Thomson, David J.
   Palma, David
   Guckenberger, Matthias
   Balermpas, Panagiotis
   Beitler, Jonathan J.
   Blanchard, Pierre
   Brizel, David
   Budach, Wilfred
   Caudell, Jimmy
   Corry, June
   Corvo, Renzo
   Evans, Mererid
   Garden, Adam S.
   Giralt, Jordi
   Gregoire, Vincent
   Harari, Paul M.
   Harrington, Kevin
   Hitchcock, Ying J.
   Johansen, Jorgen
   Kaanders, Johannes
   Koyfman, Shlomo
   Langendijk, J. A.
   Le, Quynh-Thu
   Lee, Nancy
   Margalit, Danielle
   Mierzwa, Michelle
   Porceddu, Sandro
   Soong, Yoke Lim
   Sun, Ying
   Thariat, Juliette
   Waldron, John
   Yom, Sue S.
TI Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation
   Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; RADIOTHERAPY
AB Purpose: Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff.
   Methods and Materials: A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (>= 80%) and agreement (>= 66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases.
   Results: In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care.
   Conclusions: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit. (C) 2020 The Authors. Published by Elsevier Inc.
C1 [Thomson, David J.] Christie NHS Fdn Trust, Dept Clin Oncol, Manchester, Lancs, England.
   [Thomson, David J.] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Palma, David] Western Univ, Div Radiat Oncol, London, ON, Canada.
   [Guckenberger, Matthias; Balermpas, Panagiotis] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland.
   [Beitler, Jonathan J.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Blanchard, Pierre] Gustave Roussy Canc Ctr, Dept Radiat Oncol, Villejuif, France.
   [Brizel, David] Duke Canc Inst, Dept Radiat Oncol, Durham, NC USA.
   [Budach, Wilfred] Univ Hosp Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany.
   [Caudell, Jimmy] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA.
   [Corry, June] St Vincents Hosp, Dept Radiat Oncol Genesiscare, Melbourne, Vic, Australia.
   [Corvo, Renzo] Osped Policlin San Martino, Dept Radiat Oncol, Genoa, Italy.
   [Corvo, Renzo] Univ Genoa, Genoa, Italy.
   [Evans, Mererid] Velindre Univ NHS Trust, Dept Clin Oncol, Cardiff, S Glam, Wales.
   [Garden, Adam S.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Giralt, Jordi] Hosp Univ Vall dHebron, Dept Radiat Oncol, Barcelona, Spain.
   [Gregoire, Vincent] Ctr Leon Berard, Dept Radiat Oncol, Lyon, France.
   [Harari, Paul M.] Univ Wisconsin, Dept Human Oncol, Madison, WI USA.
   [Harrington, Kevin] Inst Canc Res, Div Radiotherapy & Imaging, London, England.
   [Hitchcock, Ying J.] Univ Utah, Dept Radiat Oncol, Huntsman Canc Hosp, Salt Lake City, UT USA.
   [Johansen, Jorgen] Odense Univ Hosp, Dept Oncol, Odense, Denmark.
   [Kaanders, Johannes] Radboudumc, Dept Radiat Oncol, Nijmegen, Netherlands.
   [Koyfman, Shlomo] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
   [Langendijk, J. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands.
   [Le, Quynh-Thu] Stanford Univ, Dept Radiat Oncol, Palo Alto, CA 94304 USA.
   [Lee, Nancy] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Margalit, Danielle] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
   [Mierzwa, Michelle] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
   [Porceddu, Sandro] Univ Queensland, Princess Alexandra Hosp, Dept Radiat Oncol, Brisbane, Qld, Australia.
   [Soong, Yoke Lim] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore.
   [Sun, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Thariat, Juliette] Univ Normandy, Ctr Francois Baclesse, Dept Radiat Oncol, Caen, France.
   [Waldron, John] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada.
   [Yom, Sue S.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
RP Yom, SS (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
EM sue.yom@ucsf.edu
RI Guckenberger, Matthias/AAX-4994-2020; Johansen, Jorgen/I-6816-2013
OI Guckenberger, Matthias/0000-0002-7146-9071; Johansen,
   Jorgen/0000-0003-3911-3929; Garden, Adam/0000-0001-7926-2641; Balermpas,
   Panagiotis/0000-0001-5261-6446; Brizel, David/0000-0001-9828-4790;
   Langendijk, Johannes A./0000-0003-1083-372X
CR Agger A, 2009, HEAD NECK-J SCI SPEC, V31, P1593, DOI 10.1002/hed.21132
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Benghiat H, 2014, CANC CLIN ONCOL, V3
   Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1
   Cheah NLC, 2009, CLIN ONCOL-UK, V21, P494, DOI 10.1016/j.clon.2009.02.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chera BS, 2010, INT J RADIAT ONCOL, V78, P461, DOI 10.1016/j.ijrobp.2009.08.066
   Ermis E, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0505-6
   Fitch K, 2003, RAND UCLA APPROPRIAT
   Gowda RV, 2003, RADIOTHER ONCOL, V68, P105, DOI 10.1016/S0167-8140(03)00059-8
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Jacinto AA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4893-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Meade S, 2017, CLIN ONCOL-UK, V30, P366
   Mehanna H, 2016, NEW ENGL J MED, V374, P1444, DOI 10.1056/NEJMoa1514493
   Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014
   Stavas MJ, 2014, J THROID RES, V2014, DOI 10.1155/2014/764281
   Thomson DJ, 2015, ACTA ONCOL, V54, P88, DOI 10.3109/0284186X.2014.958528
   Tobias JS, 2010, LANCET ONCOL, V11, P66, DOI 10.1016/S1470-2045(09)70306-7
   World Health Organization, COR DIS 2019 COVID 1
   2020, MMWR MORBID MORTAL W, V69, P343
NR 21
TC 48
Z9 48
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 15
PY 2020
VL 107
IS 4
BP 618
EP 627
DI 10.1016/j.ijrobp.2020.04.016
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MD7XD
UT WOS:000544182500004
PM 32302681
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gupta, T
   Agarwal, JP
   Bentzen, SM
AF Gupta, Tejpal
   Agarwal, Jai Prakash
   Bentzen, Soren M.
TI Head and Neck Cancer Radiation Therapy During COVID-19
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Letter
ID HYPOFRACTIONATED ACCELERATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA
C1 [Gupta, Tejpal; Agarwal, Jai Prakash] HBNI, Tata Mem Ctr, Dept Radiat Oncol, Mumbai, Maharashtra, India.
   [Bentzen, Soren M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth & Radiat Oncol, Baltimore, MD 21201 USA.
RP Gupta, T (corresponding author), HBNI, Tata Mem Ctr, Dept Radiat Oncol, Mumbai, Maharashtra, India.
CR Bauml JM, 2019, JNCI-J NATL CANCER I, V111, P490, DOI 10.1093/jnci/djy133
   Benghiat H, 2014, CANC CLIN ONCOL, V3, P2
   Chan AK, 2011, CLIN ONCOL-UK, V23, P34, DOI 10.1016/j.clon.2010.07.015
   Covelas A. D., 2018, J NATL COMPR CANC NE, V16, P479, DOI [10.6004/jnccn.2018.0026, DOI 10.6004/JNCCN.2018.0026]
   Gupta B, 2016, ONCOLOGY-BASEL, V91, P13, DOI 10.1159/000446117
   Roques T, HEAD NECK CANC COVID
   Royal College of Radiologists, HEAD NECK CANC RAD D
   Sanghera P, 2007, INT J RADIAT ONCOL, V67, P1342, DOI 10.1016/j.ijrobp.2006.11.015
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 15
PY 2020
VL 107
IS 4
BP 853
EP 854
DI 10.1016/j.ijrobp.2020.04.031
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MD7XD
UT WOS:000544182500029
PM 32589991
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Thomson, DJ
   Yom, SS
AF Thomson, David J.
   Yom, Sue S.
TI Head and Neck Cancer Radiation Therapy During COVID-19 Reply
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Letter
C1 [Thomson, David J.] Christie NHS Fdn Trust, Dept Clin Oncol, Manchester, Lancs, England.
   [Thomson, David J.] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Yom, Sue S.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
RP Thomson, DJ (corresponding author), Christie NHS Fdn Trust, Dept Clin Oncol, Manchester, Lancs, England.; Thomson, DJ (corresponding author), Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
CR Gupta T, 2020, INT J RADIAT ONCOL, DOI DOI 10.1016/J.IJR0BP.2020.04.031
   The Royal College of Radiologists, HEAD NECK CANC COVID
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   U.S. National Library of Medicine, 2020, RES SPAR CUR RAD LOC
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 15
PY 2020
VL 107
IS 4
BP 854
EP 854
DI 10.1016/j.ijrobp.2020.04.032
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MD7XD
UT WOS:000544182500030
PM 32589992
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Guckenberger, M
   Belka, C
   Bezjak, A
   Bradley, J
   Daly, ME
   DeRuysscher, D
   Dziadziuszko, R
   Faivre-Finn, C
   Flentje, M
   Gore, E
   Higgins, KA
   Iyengar, P
   Kavanagh, BD
   Kumar, S
   Le Pechoux, C
   Lievens, Y
   Lindberg, K
   McDonald, F
   Ramella, S
   Rengan, R
   Ricardi, U
   Rimner, A
   Rodrigues, GB
   Schild, SE
   Senan, S
   Simone, CB
   Slotman, B
   Stuschke, M
   Videtic, G
   Widder, J
   Yom, SS
   Palma, D
AF Guckenberger, Matthias
   Belka, Claus
   Bezjak, Andrea
   Bradley, Jeffrey
   Daly, Megan E.
   DeRuysscher, Dirk
   Dziadziuszko, Rafal
   Faivre-Finn, Corinne
   Flentje, Michael
   Gore, Elizabeth
   Higgins, Kristin A.
   Iyengar, Puneeth
   Kavanagh, Brian D.
   Kumar, Sameera
   Le Pechoux, Cecile
   Lievens, Yolande
   Lindberg, Karin
   McDonald, Fiona
   Ramella, Sara
   Rengan, Ramesh
   Ricardi, Umberto
   Rimner, Andreas
   Rodrigues, George B.
   Schild, Steven E.
   Senan, Suresh
   Simone, Charles B., II
   Slotman, Ben J.
   Stuschke, Martin
   Videtic, Greg
   Widder, Joachim
   Yom, Sue S.
   Palma, David
TI Practice Recommendations for Lung Cancer Radiotherapy During the
   COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID RADIATION-THERAPY; RANDOMIZED-TRIAL; SINGLE; NSCLC
AB Background: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic.
   Methods: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC.
   Results: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided.
   Conclusion: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Guckenberger, Matthias] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland.
   [Belka, Claus] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, LMU Klinikum, Munich, Germany.
   [Bezjak, Andrea] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
   [Bradley, Jeffrey] Emory Univ, Dept Radiat Oncol, Princess Margaret Canc Ctr, Atlanta, GA 30322 USA.
   [Daly, Megan E.] Univ Calif Davis, Comprehens Canc Ctr, Dept Radiat Oncol, Sacramento, CA 95817 USA.
   [DeRuysscher, Dirk] Maastricht Univ, GROW Res Inst, Dept Radiat Oncol, Med Ctr,Maastro Clin, Maastricht, Netherlands.
   [Dziadziuszko, Rafal] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland.
   [Faivre-Finn, Corinne] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Faivre-Finn, Corinne] Christie NHS Fdn Trust, Manchester, Lancs, England.
   [Flentje, Michael] JMU Wurzburg, Dept Radiat Oncol, Univ Hosp Wurzburg, Wurzburg, Germany.
   [Gore, Elizabeth] Med Coll Wisconsin & Zablocki VAMC, Dept Radiat Oncol, Milwaukee, WI USA.
   [Higgins, Kristin A.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Iyengar, Puneeth] UT Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX USA.
   [Kavanagh, Brian D.] Univ Colorado, Dept Radiat Oncol, Aurora, CO USA.
   [Kumar, Sameera] Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Le Pechoux, Cecile] Dept Radiat Oncol, Gustave Roussy Canc Campus, Villejuif, France.
   [Lievens, Yolande] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium.
   [Lievens, Yolande] Univ Ghent, Ghent, Belgium.
   [Lindberg, Karin] Karolinska Univ Hosp, Dept Head Neck Lung & Skin Canc, Theme Canc, Stockholm, Sweden.
   [McDonald, Fiona] Royal Marsden Hosp, London, England.
   [Ramella, Sara] Campus Biomed Univ Rome, Radiat Oncol, Rome, Italy.
   [Rengan, Ramesh] Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA USA.
   [Ricardi, Umberto] Univ Turin, Dept Oncol, Turin, Italy.
   [Rimner, Andreas] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Rodrigues, George B.; Palma, David] Western Univ, Div Radiat Oncol, London, ON, Canada.
   [Schild, Steven E.] Mayo Clin, Dept Radiat Oncol, Phoenix, AZ USA.
   [Senan, Suresh; Slotman, Ben J.] Amsterdam UMC, Dept Radiat Oncol, Amsterdam, Netherlands.
   [Simone, Charles B., II] New York Proton Ctr, Dept Radiat Oncol, New York, NY USA.
   [Simone, Charles B., II] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Stuschke, Martin] Univ Duisburg Essen, Dept Radiotherapy, Duisburg, Germany.
   [Videtic, Greg] Case Western Univ, Dept Radiat Oncol, Cleveland Clin, Lerner Coll Med, Cleveland, OH USA.
   [Widder, Joachim] Med Univ Vienna, Comprehens Canc Ctr, Dept Radiat Oncol, Vienna, Austria.
   [Yom, Sue S.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
RP Guckenberger, M (corresponding author), Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland.
EM Matthias.Guckenberger@usz.ch
RI Guckenberger, Matthias/AAX-4994-2020
OI Guckenberger, Matthias/0000-0002-7146-9071; Senan,
   Suresh/0000-0003-3995-2204; Faivre-Finn, Corinne/0000-0001-5617-9781
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Belderbos J, 2007, EUR J CANCER, V43, P114, DOI 10.1016/j.ejca.2006.09.005
   Bezjak A, 2002, INT J RADIAT ONCOL, V54, P719, DOI 10.1016/S0360-3016(02)02989-9
   BLEEHEN NM, 1992, BRIT J CANCER, V65, P934, DOI 10.1038/bjc.1992.196
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Christian MD, 2019, CRIT CARE CLIN, V35, P575, DOI 10.1016/j.ccc.2019.06.009
   Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Ferguson NM, 2020, IMPACT NONPHARMACEUT, P20, DOI [10.25561/77482, DOI 10.25561/77482]
   Filippi AR, 2020, INT J RAD ONCOL BIOL
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hsu C-C, DELPHI TECHNIQUE MAK, V12
   Iyengar P, 2016, INT J RADIAT ONCOL, V96, pE451, DOI 10.1016/j.ijrobp.2016.06.1763
   JING CJ, 2020, ZHONGHUA ZHONG LIU Z, V42, DOI DOI 10.1007/S11738-020-03039-7
   Kotter T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-21
   Krengli M, 2020, ADV RAD ONCOL
   Maguire J, 2014, EUR J CANCER, V50, P2939, DOI 10.1016/j.ejca.2014.07.009
   Medical Research Council Lung Cancer Working Party, 1996, CLIN ONCOL, V8, P167
   Osti MF, 2013, INT J RADIAT ONCOL, V85, pE157, DOI 10.1016/j.ijrobp.2012.10.012
   Persad G, 2020, NEW ENGL J MED, V382
   Rosenbaum L., 2020, N ENGL J MED
   Stroud C, 2010, CRISIS STANDARDS CAR
   Videtic GM, 2019, INT J RADIAT ONCOL, V103, P1077, DOI 10.1016/j.ijrobp.2018.11.051
   Westover KD, 2015, INT J RADIAT ONCOL, V93, P72, DOI 10.1016/j.ijrobp.2015.05.004
   Xia Y, 2020, LANCET ONCOL
   Yang T, 2020, J MT SCI-ENGL, V17, P2108, DOI 10.1007/s11629-019-5772-5
   Zhou F., 2020, LANCET
NR 26
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 15
PY 2020
VL 107
IS 4
BP 631
EP 640
DI 10.1016/j.ijrobp.2020.05.012
PG 10
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MD7XD
UT WOS:000544182500006
PM 32589990
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zost, SJ
   Gilchuk, P
   Case, JB
   Binshtein, E
   Chen, RTE
   Nkolola, JP
   Schafer, A
   Reidy, JX
   Trivette, A
   Nargi, RS
   Sutton, RE
   Suryadevara, N
   Martinez, DR
   Williamson, LE
   Chen, EEC
   Jones, T
   Day, S
   Myers, L
   Hassan, AO
   Kafai, NM
   Winkler, ES
   Fox, JM
   Shrihari, S
   Mueller, BK
   Meiler, J
   Chandrashekar, A
   Mercado, NB
   Steinhardt, JJ
   Ren, KS
   Loo, YM
   Kallewaard, NL
   McCune, BT
   Keeler, SP
   Holtzman, MJ
   Barouch, DH
   Gralinski, LE
   Baric, RS
   Thackray, LB
   Diamond, MS
   Carnahan, RH
   Crowe, JE
AF Zost, Seth J.
   Gilchuk, Pavlo
   Case, James Brett
   Binshtein, Elad
   Chen, Rita E.
   Nkolola, Joseph P.
   Schafer, Alexandra
   Reidy, Joseph X.
   Trivette, Andrew
   Nargi, Rachel S.
   Sutton, Rachel E.
   Suryadevara, Naveenchandra
   Martinez, David R.
   Williamson, Lauren E.
   Chen, Elaine C.
   Jones, Taylor
   Day, Samuel
   Myers, Luke
   Hassan, Ahmed O.
   Kafai, Natasha M.
   Winkler, Emma S.
   Fox, Julie M.
   Shrihari, Swathi
   Mueller, Benjamin K.
   Meiler, Jens
   Chandrashekar, Abishek
   Mercado, Noe B.
   Steinhardt, James J.
   Ren, Kuishu
   Loo, Yueh-Ming
   Kallewaard, Nicole L.
   McCune, Broc T.
   Keeler, Shamus P.
   Holtzman, Michael J.
   Barouch, Dan H.
   Gralinski, Lisa E.
   Baric, Ralph S.
   Thackray, Larissa B.
   Diamond, Michael S.
   Carnahan, Robert H.
   Crowe, James E., Jr.
TI Potently neutralizing and protective human antibodies against SARS-CoV-2
SO NATURE
LA English
DT Article; Early Access
ID HUMAN MONOCLONAL-ANTIBODY; RESPIRATORY SYNDROME CORONAVIRUS; CRYO-EM
   STRUCTURE; SARS CORONAVIRUS; MERS-COV; STRUCTURAL DEFINITION; RECEPTOR;
   SPIKE; EPITOPE
AB An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.
   The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health(1)and the medical countermeasures available so far are limited(2,3). Moreover, we currently lack a thorough understanding of the mechanisms of humoral immunity to SARS-CoV-2(4). Here we analyse a large panel of human monoclonal antibodies that target the spike (S) glycoprotein(5), and identify several that exhibit potent neutralizing activity and fully block the receptor-binding domain of the S protein (S-RBD) from interacting with human angiotensin-converting enzyme 2 (ACE2). Using competition-binding, structural and functional studies, we show that the monoclonal antibodies can be clustered into classes that recognize distinct epitopes on the S-RBD, as well as distinct conformational states of the S trimer. Two potently neutralizing monoclonal antibodies, COV2-2196 and COV2-2130, which recognize non-overlapping sites, bound simultaneously to the S protein and neutralized wild-type SARS-CoV-2 virus in a synergistic manner. In two mouse models of SARS-CoV-2 infection, passive transfer of COV2-2196, COV2-2130 or a combination of both of these antibodies protected mice from weight loss and reduced the viral burden and levels of inflammation in the lungs. In addition, passive transfer of either of two of the most potent ACE2-blocking monoclonal antibodies (COV2-2196 or COV2-2381) as monotherapy protected rhesus macaques from SARS-CoV-2 infection. These results identify protective epitopes on the S(RBD)and provide a structure-based framework for rational vaccine design and the selection of robust immunotherapeutic agents.
C1 [Zost, Seth J.; Gilchuk, Pavlo; Binshtein, Elad; Reidy, Joseph X.; Trivette, Andrew; Nargi, Rachel S.; Sutton, Rachel E.; Suryadevara, Naveenchandra; Jones, Taylor; Day, Samuel; Myers, Luke; Carnahan, Robert H.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA.
   [Case, James Brett; Chen, Rita E.; Hassan, Ahmed O.; Kafai, Natasha M.; Winkler, Emma S.; Fox, Julie M.; Shrihari, Swathi; McCune, Broc T.; Keeler, Shamus P.; Holtzman, Michael J.; Thackray, Larissa B.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Chen, Rita E.; Kafai, Natasha M.; Winkler, Emma S.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Nkolola, Joseph P.; Chandrashekar, Abishek; Mercado, Noe B.; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
   [Schafer, Alexandra; Martinez, David R.; Gralinski, Lisa E.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Williamson, Lauren E.; Chen, Elaine C.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
   [Mueller, Benjamin K.; Meiler, Jens] Vanderbilt Univ, Dept Chem, Nashville, TN USA.
   [Meiler, Jens] Univ Leipzig, Inst Drug Discovery, Sch Med, Leipzig, Germany.
   [Steinhardt, James J.] AstraZeneca, BioPharmaceut R&D, Antibody Discovery & Prot Engn, Gaithersburg, MD USA.
   [Ren, Kuishu; Loo, Yueh-Ming; Kallewaard, Nicole L.] AstraZeneca, BioPharmaceut R&D, Microbial Sci, Gaithersburg, MD USA.
   [Keeler, Shamus P.; Holtzman, Michael J.] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO USA.
   [Carnahan, Robert H.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
RP Carnahan, RH; Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA.; Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Carnahan, RH; Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
EM Robert.carnahan@vumc.org; james.crowe@vumc.org
RI Chandrashekar, Abishek/P-2610-2019; Mercado, Noe/ABE-8247-2020; Keeler,
   Shamus/ABC-1774-2020
OI Chandrashekar, Abishek/0000-0001-7821-5552; Mercado,
   Noe/0000-0001-7769-7326; Keeler, Shamus/0000-0002-1301-0852; Case,
   James/0000-0001-7331-5511; Binshtein, Elad/0000-0003-2745-104X; Cuasquen
   Mera, Anguie Maritza/0000-0001-9124-4040; Zost, Seth/0000-0001-6712-5076
FU Defense Advanced Research Projects Agency (DARPA)United States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR0011-18-2-0001, HR00 11-18-3-0001]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [T32
   AI138932, 75N93019C00074, 75N93019C00062, U01 AI150739, R01 AI130591,
   R35 HL145242, S10 RR028106, F32 AI138392, T32 AI007151, F31 AI145189];
   Dolly Parton COVID-19 Research Fund at Vanderbilt; Vanderbilt Institute
   for Clinical and Translational Research; NCATS/NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002243]; Helen Hay Whitney Foundation; Burroughs Wellcome Fund
   Postdoctoral Enrichment Program AwardBurroughs Wellcome Fund; Merck KGaA
FX We thank A. Jones and the staff of the Vanderbilt Technologies for
   Advanced Genomics (VANTAGE) core laboratory for expedited sequencing; R.
   Trosseth for assistance with data management and analysis; R. Bombardi
   and C. Soto of VUMC for technical consultation on genomics approaches;
   A. Kim, A. Bailey, L. VanBlargan and J. Earnest of WUSTL for
   experimental assistance and key reagents; K. M. Tuffy, S. Diallo, P. M.
   McTamney and L. Clarke of AstraZeneca for the generation of protein and
   pseudovirus reagents and related data; and H. Andersen, M. G. Lewis, R.
   Nityanandam, M. Kirilova and K. Verrington for research assistance with
   the NHP studies. This study was supported by Defense Advanced Research
   Projects Agency (DARPA) grants HR0011-18-2-0001 and HR00 11-18-3-0001;
   NIH contracts 75N93019C00074 and 75N93019C00062; NIH grants U01
   AI150739, R01 AI130591 and R35 HL145242; the Dolly Parton COVID-19
   Research Fund at Vanderbilt; and NIH grant S10 RR028106 for the Next
   Generation Nucleic Acid Sequencer, housed in VANTAGE and the Vanderbilt
   Institute for Clinical and Translational Research with grant support
   from UL1TR002243 from NCATS/NIH. S.J.Z. was supported by NIH T32
   AI095202; J.B.C. was supported by a Helen Hay Whitney Foundation
   postdoctoral fellowship; B.T.M. was supported by NIH F32 AI138392;
   D.R.M. was supported by NIH T32 AI007151 and a Burroughs Wellcome Fund
   Postdoctoral Enrichment Program Award; L.E.W. was supported by NIH F31
   AI145189; E.C.C. was supported by NIH T32 AI138932; and J.E.C. is the
   recipient of the 2019 Future Insight Prize from Merck KGaA, which
   supported this research with a research grant. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the US government or the other sponsors.
CR Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Bepler T., 2019, TOPAZ DENOISE GEN DE, DOI [10.1101/838920, DOI 10.1101/838920]
   Bepler T, 2019, NAT METHODS, V16, P1153, DOI 10.1038/s41592-019-0575-8
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen Z, 2017, J INFECT DIS, V215, P1807, DOI 10.1093/infdis/jix209
   Chng J, 2015, MABS-AUSTIN, V7, P403, DOI 10.1080/19420862.2015.1008351
   Choi JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232757
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Dinnon Kenneth H, 2020, bioRxiv, DOI 10.1101/2020.05.06.081497
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Laha S, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104445
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Mukherjee S, 2016, VIROLOGY, V497, P33, DOI 10.1016/j.virol.2016.06.022
   Niu PH, 2018, J INFECT DIS, V218, P1249, DOI 10.1093/infdis/jiy311
   Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillay TS, 2020, J CLIN PATHOL, V73, P366, DOI 10.1136/jclinpath-2020-206658
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Sheehan KCF, 2006, J INTERF CYTOK RES, V26, P804, DOI 10.1089/jir.2006.26.804
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Siracusano G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01049
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Valk SJ, 2020, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD013600/FULL.32406927
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang LS, 2018, J VIROL, V92, DOI 10.1128/JVI.02002-17
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang SY, 2018, CELL REP, V24, P441, DOI 10.1016/j.celrep.2018.06.041
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 55
TC 36
Z9 35
U1 18
U2 18
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2548-6
EA JUL 2020
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MZ5MD
UT WOS:000559167300001
PM 32668443
OA Bronze
DA 2021-01-01
ER

PT J
AU Atkinson, CL
   McCue, C
   Prier, E
   Atkinson, AM
AF Atkinson, Christopher L.
   McCue, Clifford
   Prier, Eric
   Atkinson, Allison M.
TI Supply Chain Manipulation, Misrepresentation, and Magical Thinking
   During the COVID-19 Pandemic
SO AMERICAN REVIEW OF PUBLIC ADMINISTRATION
LA English
DT Article
DE COVID-19; supply chain interruption; magical thinking; disaster
   response; public health
ID DISASTER
AB The COVID-19 pandemic has placed remarkable stress on all aspects of society, from health care and the economy to the psychological well-being of communities. While the crisis is still playing out in the United States and around the world, it is nevertheless appropriate to begin to assess its impact. This paper asks: What documentable public failures provide a deeper understanding of the U.S. government COVID-19 responses' impact on supply chains? Case examples show that markets were adversely affected in ways that caused avoidable shortages of critical goods and supplies. Moreover, public procurement effectiveness was likely reduced by short-run efforts to obtain political advantage. The article begins with a brief review of disaster procurement, highlighting how public procurement professionals tried to respond to the COVID-19 pandemic. The next section delineates three politically led phenomena that adversely impacted procurement's ability to acquire the needed goods and services, including a lack of cohesive strategy in acquiring essential personal protective equipment; preference for unproven drugs and magical thinking; and cozy relationships between the public and private sectors. The article concludes by discussing the centrality of public sector procurement professionals as a critical link for effective provision of government services, especially in times of crisis.
C1 [Atkinson, Christopher L.] Univ West Florida, Publ Adm Program, Dept Adm & Law, Pensacola, FL USA.
   [Atkinson, Allison M.] Univ West Florida, Appl Behav Anal, Pensacola, FL USA.
   [McCue, Clifford] Florida Atlantic Univ, Sch Publ Adm, Boca Raton, FL 33431 USA.
   [Prier, Eric] Florida Atlantic Univ, Polit Econ, Dept Polit Sci, Boca Raton, FL 33431 USA.
RP Atkinson, CL (corresponding author), Univ West Florida, Dept Adm & Law, 11000 Univ Pkwy, Pensacola, FL 32514 USA.
EM catkinson1@uwf.edu
RI Atkinson, Christopher L./A-2823-2013
OI Atkinson, Christopher L./0000-0001-9574-9695
CR Allen Jonathan, 2020, NBC NEWS
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Asseyer S, 2020, MULT SCLER RELAT DIS, V40, DOI 10.1016/j.msard.2020.101965
   Atkinson C. L., 2014, RESILIENT COMMUNITIE
   Atkinson CL, 2012, J PUBLIC PROCUR, V12, P356, DOI 10.1108/JOPP-12-03-2012-B003
   Berklan J., 2020, MCKNIGHTS LONG TERM
   Bertrand N., 2020, POLITICO
   Bright R., 2020, ADDENDUM COMPLAINT P
   Buor J. K., 2019, INT J DISASTER RISK, V36, P1
   Centers for Disease Control and Prevention, 2018, CRIS EM RISK COMM MA
   Children's Wisconsin, 2020, DON PPE SUPP CHILDR
   Day JM, 2014, INT J PROD RES, V52, P1970, DOI 10.1080/00207543.2013.787496
   Day JM, 2009, J ASSOC INF SYST, V10, P637
   Dunklin R., 2020, ASS PRESS NEWS  0421
   Evon D., 2020, SNOPES          0424
   Federal Emergency Management Agency, 2020, NIMS DOCTR SUPP GUID
   Federal Emergency Management Agency, 2020, STAT DIST MAN COURS
   Fox M, 2020, CNN
   Frauscher K., 2020, 5 PROCUREMENT STRATE
   Garcia V., 2020, FOX NEWS
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gianisa A, 2018, DISASTER PREV MANAG, V27, P74, DOI 10.1108/DPM-10-2017-0238
   Graff G. M., 2020, WIRED
   Harrald J. R., 2012, MEGA CRISES UNDERSTA, P37
   Kruse Michael, 2017, POLITICO
   LeBlanc P, 2020, CNN
   Levin Bess, 2020, VANITY FAIR
   Martin J., 2020, NEWSWEEK
   McCombs B., 2020, US TODAY
   Murphy S., 2020, TIME
   Nikolova E, 2017, COMP POLIT STUD, V50, P1455, DOI 10.1177/0010414016679109
   Palca J, 2020, NPR
   Park A, 2020, BIOL CONSERV, V244, DOI 10.1016/j.biocon.2020.108507
   Perez M., 2020, FORBES
   Roberts A., 2020, KUTV NEWS       0429
   Sayare S., 2020, NY TIMES
   Scott D., 2020, VOX             0316
   Singman B., 2020, FOX NEWS
   Soergel A., 2020, US NEWS WORLD REPORT
   Turley M., 2020, UNDERSTANDING IMPACT
   Valverde M., 2020, POLITIFACT      0311
   Waldrop T, 2020, CNN
   Wallance G. J., 2020, HILL
   Wang HQ, 2020, PHYS PLASMAS, V27, DOI 10.1063/1.5140354
   WebMD, 2020, HYDR SULF
   Wong J.C., 2020, GUARDIAN
   Woodward A, 2020, BUSINESS INSIDER
   Yu G., 2020, CNN
NR 48
TC 0
Z9 0
U1 8
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0275-0740
EI 1552-3357
J9 AM REV PUBLIC ADM
JI Amer. Rev. Public Adm.
PD AUG
PY 2020
VL 50
IS 6-7
SI SI
BP 628
EP 634
AR 0275074020942055
DI 10.1177/0275074020942055
EA JUL 2020
PG 7
WC Public Administration
SC Public Administration
GA ND3VG
UT WOS:000552806200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Opoka-Winiarska, V
   Grywalska, E
   Rolinski, J
AF Opoka-Winiarska, Violetta
   Grywalska, Ewelina
   Rolinski, Jacek
TI Could hemophagocytic lymphohistiocytosis be the core issue of severe
   COVID-19 cases?
SO BMC MEDICINE
LA English
DT Article
DE Coronavirus; Coronavirus disease 2019; Hemophagocytic
   lymphohistiocytosis
ID CLINICAL CHARACTERISTICS; THERAPEUTIC GUIDELINES; ADULT PATIENTS;
   PATHOGENESIS; DIAGNOSIS
AB BackgroundCOVID-19, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), commonly presents as fever, cough, dyspnea, and myalgia or fatigue. Although the majority of patients with COVID-19 have mild symptoms, some are more prone to serious outcomes, including pneumonia, acute respiratory distress syndrome (ARDS), and even death. Hemophagocytic lymphohistiocytosis (HLH) is a severe, life-threatening inflammatory syndrome associated with intense cytokine release (also known as a "cytokine storm"). Similar to COVID-19, HLH is characterized by aggressive course leading to multi-organ failure.Main textThe purpose of this review article is to draw attention to the possibility of the complication of HLH in patients with the severe course of COVID-19. Indeed, some of the clinical characteristics observed in the more severe cases of COVID-19 are reminiscent of secondary HLH (which can be triggered by infections, malignancies, rheumatological diseases, or autoimmune/immunodeficiency conditions). The pathogenesis of SARS-CoV-2 infection also suggests that HLH or a similar hyperinflammatory syndrome is the cause of the severe course of the infection.ConclusionThe pathogenesis and clinical symptoms of severe COVID-19 indicate that an increased inflammatory response corresponding to HLH is occurring. Therefore, patients with severe COVID-19 should be screened for hyperinflammation using standard laboratory tests to identify those for whom immunosuppressive therapy may improve outcomes.
C1 [Opoka-Winiarska, Violetta] Med Univ Lublin, Dept Paediat Pulmonol & Rheumatol, Gebali 6, PL-20093 Lublin, Poland.
   [Grywalska, Ewelina; Rolinski, Jacek] Med Univ Lublin, Dept Clin Immunol & Immunotherapy, Chodzki 4a St, PL-20093 Lublin, Poland.
   [Grywalska, Ewelina; Rolinski, Jacek] St Johns Canc Hosp, Dept Clin Immunol, K Jaczewskiego 7 St, PL-20090 Lublin, Poland.
RP Opoka-Winiarska, V (corresponding author), Med Univ Lublin, Dept Paediat Pulmonol & Rheumatol, Gebali 6, PL-20093 Lublin, Poland.
EM violetta.opoka-winiarska@umlub.pl
OI Grywalska, Ewelina/0000-0002-0451-4741; Opoka-Winiarska,
   Violetta/0000-0003-1644-5568
FU Polish National Science Center [UMO-2016/21/B/NZ6/02279]; Medical
   University of Lublin [DS460, DS461]
FX This work was supported by the Polish National Science Center (grant no.
   UMO-2016/21/B/NZ6/02279) and the Medical University of Lublin (grants
   no. DS460 and DS461).
CR Apodaca E, 2018, CL LYMPH MYELOM LEUK, V18, pE373, DOI 10.1016/j.clml.2018.06.014
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barba T, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002318
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Dropulic LK, 2011, CLIN INFECT DIS, V53, P897, DOI 10.1093/cid/cir610
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han XC, 2017, J CRIT CARE, V39, P72, DOI 10.1016/j.jcrc.2017.02.018
   Hayden A, 2017, BLOOD ADV, V1, P2529, DOI 10.1182/bloodadvances.2017012310
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618
   Li QB, 2020, LEUKEMIA, V34, P2163, DOI 10.1038/s41375-020-0910-1
   Marsh RA, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01902
   Mehta P, 2020, LANCET RHEUMATOL, V2, pE358, DOI 10.1016/S2665-9913(20)30096-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morimoto A, 2016, PEDIATR INT, V58, P817, DOI 10.1111/ped.13064
   Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Otrock ZK, 2015, AM J HEMATOL, V90, P220, DOI 10.1002/ajh.23911
   Ramachandran S, 2017, BLOOD CELL MOL DIS, V64, P53, DOI 10.1016/j.bcmd.2016.10.023
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rodelo JR, 2012, AM J EMERG MED, V30, P1991, DOI 10.1016/j.ajem.2012.04.033
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Seguin A, 2016, CHEST, V149, P1294, DOI 10.1016/j.chest.2015.11.004
   Shakoory B, 2015, CRIT CARE MED, V44, P1
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Shiraishi A, 2012, PEDIATR BLOOD CANCER, V59, P265, DOI 10.1002/pbc.24039
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Usmani GN, 2013, BRIT J HAEMATOL, V161, P609, DOI 10.1111/bjh.12293
   Valade S, 2020, CRIT CARE CLIN, V36, P415, DOI 10.1016/j.ccc.2019.12.004
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhao YC, 2019, HEMATOLOGY, V24, P606, DOI 10.1080/16078454.2019.1660458
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 44
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUL 15
PY 2020
VL 18
IS 1
AR 214
DI 10.1186/s12916-020-01682-y
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ8LK
UT WOS:000553144200001
PM 32664932
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elfiky, AA
AF Elfiky, Abdo A.
TI Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against
   SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking
   study
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; RdRp; Molecular docking; Structural
   bioinformatics; Drug repurposing
ID PROTEIN; OPTIMIZATION; CORONAVIRUS; INHIBITORS; IDX-184; QUALITY;
   BINDING; DRUGS
AB Aims: A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries.
   Main methods: In this study, the RNA-dependent RNA polymerase (RdRp) of the newly emerged coronavirus is modeled, validated, and then targeted using different anti-polymerase drugs currently on the market that have been approved for use against various viruses.
   Key findings: The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. In addition, the results suggest guanosine derivative (IDX-184), Setrobuvir, and YAK as top seeds for antiviral treatments with high potential to fight the SARS-CoV-2 strain specifically.
   Significance: The availability of FDA-approved anti-RdRp drugs can help treat patients and reduce the danger of the mysterious new viral infection COVID-19. The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.
C1 [Elfiky, Abdo A.] Cairo Univ, Dept Biophys, Fac Sci, Giza, Egypt.
RP Elfiky, AA (corresponding author), Cairo Univ, Dept Biophys, Fac Sci, Giza, Egypt.
EM abdo@sci.cu.edu.eg
RI Mohamed, Abdo/H-3595-2019
OI Mohamed, Abdo/0000-0003-4600-6240
FU Abdus Salam International Center for Theoretical Physics (ICTP),
   Trieste, Italy
FX Mrs. Kauther M Shaltoot is appreciated for her kind help and support;
   without her, this work was not possible. Prof. Dr. Wael Elshemey is
   appreciated for guidance and performing the docking calculations on his
   computational facility. This work is done during the Junior associate
   award granted to the author for the period 2016-2021 of the Abdus Salam
   International Center for Theoretical Physics (ICTP), Trieste, Italy.
   Additionally, the author wants to thank LetPub for the free language
   editing of the manuscript as it resembles a work on the newly emerged
   virus.
CR Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bogoch I. I., 2020, J TRAVEL MED, V27
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2018, SAR QSAR ENVIRON RES, V29, P409, DOI 10.1080/1062936X.2018.1454981
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elfiky AA, 2019, FUTURE VIROL, V14, P739, DOI 10.2217/fvl-2019-0076
   Elfiky AA, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116958
   Elfiky AA, 2019, MED CHEM, V15, P130, DOI 10.2174/1573406414666181015152511
   Elfiky AA, 2017, FUTURE VIROL, V12, P720, DOI 10.2217/fvl-2017-0081
   Elfiky AA, 2018, J MED VIROL, V90, P13, DOI 10.1002/jmv.24934
   Elfiky AA, 2017, FUTURE VIROL, V12, P339, DOI 10.2217/fvl-2017-0027
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Elfiky AA, 2016, MED CHEM RES, V25, P1005, DOI 10.1007/s00044-016-1533-y
   Elfiky AA, 2013, PROTEIN J, V32, P75, DOI 10.1007/s10930-013-9462-9
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Hemida MG, 2019, ONE HEALTH-AMSTERDAM, V8, DOI 10.1016/j.onehlt.2019.100102
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ibrahim I.M., 2020, J INFECT
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Leach A. R., 2001, MOL MODELLING PRINCI
   LII JH, 1989, J AM CHEM SOC, V111, P8576, DOI 10.1021/ja00205a003
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Organization W.H., 2019, CLIN MAN SEV AC RESP
   Organization WH, 2016, MIDDL E RESP SYNDR C
   PARRY J, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M56
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Summers KL, 2012, BIOCHEM BIOPH RES CO, V425, P485, DOI 10.1016/j.bbrc.2012.07.141
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   World Health Organization, 2020, LAB TEST HUM SUSP CA
   World Health Organization, 2020, INF PREV CONTR HLTH
   World Health Organization (WHO), 2020, SURV CAS DEF HUM INF
   Wu Canrong, 2020, ACTA PHARM SIN B
   Yang L., 2020, CHINA CONFIRMS HUMAN
NR 45
TC 139
Z9 140
U1 36
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUL 15
PY 2020
VL 253
AR 117592
DI 10.1016/j.lfs.2020.117592
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA MM6PU
UT WOS:000550277500009
PM 32222463
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Piantadosi, S
AF Piantadosi, Steven
TI Highly efficient clinical trial designs for reliable screening of
   under-performing treatments: Application to the COVID-19 Pandemic
SO CLINICAL TRIALS
LA English
DT Article
DE COVID-19; ranking; selection; futility; treatment pooling; trial design
AB Background: The COVID-19 pandemic presents challenges for clinical trials including urgency, disrupted infrastructure, numerous therapeutic candidates, and the need for highly efficient trial and development designs. This paper presents design components and rationale for constructing highly efficient trials to screen potential COVID-19 treatments. Methods: Key trial design elements useful in this circumstance include futility hypotheses, treatment pooling, reciprocal controls, ranking and selection, and platform administration. Assuming most of the many candidates for COVID-19 treatment are likely to be ineffective, these components can be combined to facilitate very efficient comparisons of treatments. Results: Simulations indicate such designs can reliably discard underperforming treatments using sample size to treatment ratios under 30. Conclusions: Methods to create very efficient clinical trial comparisons of treatments for COVID-19 are available. Such designs might be helpful in the pandemic and should be considered for similar needs in the future.
C1 [Piantadosi, Steven] Brigham & Womens Hosp, 221 Longwood, Boston, MA 02115 USA.
RP Piantadosi, S (corresponding author), Brigham & Womens Hosp, 221 Longwood, Boston, MA 02115 USA.
EM spiantadosi@bwh.harvard.edu
FU Alliance For Trials in Oncology Foundation
FX The author received financial support this article from the Alliance For
   Trials in Oncology Foundation.
CR BECHHOFER RE, 1954, ANN MATH STAT, V25, P16, DOI 10.1214/aoms/1177728845
   BYAR DP, 1990, STAT MED, V9, P55, DOI 10.1002/sim.4780090112
   Calderwood SB., 2015, EXAMINING US PUBLIC
   Center for Drug Evaluation and Research Center for Biologics Evaluation and Research US Food and Drug Administration, 2018, MAST PROT EFF CLIN T
   Edwards C., 2020, CORONAVIRUS NIH CDC
   Garber K, 2018, NAT REV DRUG DISCOV, V17, P227, DOI 10.1038/nrd.2018.6
   Kim S-H., 2013, ENCY OPERATIONS RES, P1459, DOI DOI 10.1007/978-1-4419-1153-7_1162
   Kupferschmidt K, 2020, WHO LAUNCHES GLOBAL
   Levin B, 2005, STROKE, V36, P2331, DOI 10.1161/01.STR.0000185722.99167.56
   Naci H, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5542
   National Academies of Sciences Engineering and Medicine, 2020, DRUG DEV PAR ONC P W
   Park JJH, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3664-1
   Piantadosi S., 2017, FACTORIAL DESIGNS
   Powderly WG., 2016, COMMUNICATION
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Urwin SG, 2020, WHAT PROGNOSTIC CLIN
   WHO, 2020, R D BLUEPR NOV COR C
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2020
VL 17
IS 5
BP 483
EP 490
AR 1740774520940227
DI 10.1177/1740774520940227
EA JUL 2020
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU8GJ
UT WOS:000548882200001
PM 32666816
DA 2021-01-01
ER

PT J
AU Djebbari, F
   Panitsas, F
   Sharpley, FA
   Rampotas, A
   Larham, J
   Moore, S
   Gooding, S
   Kothari, J
   Ramasamy, K
AF Djebbari, Faouzi
   Panitsas, Fotios
   Sharpley, Faye A.
   Rampotas, Alexandros
   Larham, Jemma
   Moore, Sally
   Gooding, Sarah
   Kothari, Jaimal
   Ramasamy, Karthik
TI Myeloma care adaptations in the UK during SARS-CoV-2 pandemic:
   Challenges and measurable outcomes
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE COVID-19; infection; myeloma; outcome; SARS-CoV-2; therapy
ID MULTIPLE-MYELOMA; BORTEZOMIB; COVID-19; CANCER
C1 [Djebbari, Faouzi; Sharpley, Faye A.; Rampotas, Alexandros; Larham, Jemma; Moore, Sally; Gooding, Sarah; Kothari, Jaimal; Ramasamy, Karthik] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford OX3 7LE, England.
   [Panitsas, Fotios] Laikon Gen Hosp, Dept Haematol, Athens, Greece.
RP Djebbari, F (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford OX3 7LE, England.
EM faouzi.djebbari@ouh.nhs.uk
OI DJEBBARI, Faouzi/0000-0001-9578-7632; Ramasamy,
   Karthik/0000-0003-3385-3707; Rampotas, Alexandros/0000-0002-2681-5860
CR An G, 2014, HAEMATOLOGICA, V99, P353, DOI 10.3324/haematol.2013.088211
   Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551
   British Society of Haematology (BSH), 2020, UK MYEL FOR GUID SUP
   Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874
   Dawson MA, 2009, CLIN CANCER RES, V15, P714, DOI 10.1158/1078-0432.CCR-08-1022
   Djebbari F, 2020, BRIT J HAEMATOL, V188, pE57, DOI 10.1111/bjh.16324
   European Society for Blood and Marrow Transplantation (EBMT), 2020, COR DIS COVID 19
   European Society for Medical Oncology - ESMO, ESMO MAN TREATM AD R
   Gertz MA, 2018, AM J HEMATOL, V93, P1169, DOI 10.1002/ajh.25149
   International Myeloma Society (IMS), 2020, INT MYEL SOC REC MAN
   International Society of Amyloidosis, 2020, INT SOC AM REC MAN P
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Maiese EM, 2018, CLIN THER, V40, P480, DOI 10.1016/j.clinthera.2018.01.014
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID DE
   National Institute for Health and Care Excellence, 2020, INT TREATM CHANG OPT
   Poortmans PM, 2020, LANCET, V395, P1884, DOI 10.1016/S0140-6736(20)31240-X
   Public Health England, 2020, GUID SHIELD PROT PEO
   Terpos E, 2020, LEUKEMIA, V34, P2000, DOI 10.1038/s41375-020-0876-z
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
NR 19
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD NOV
PY 2020
VL 105
IS 5
BP 662
EP 666
DI 10.1111/ejh.13479
EA JUL 2020
PG 5
WC Hematology
SC Hematology
GA NW8SK
UT WOS:000548267800001
PM 32592210
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Idris, MO
   Yekeen, AA
   Alakanse, OS
   Durojaye, OA
AF Idris, Mukhtar Oluwaseun
   Yekeen, Abeeb Abiodun
   Alakanse, Oluwaseun Suleiman
   Durojaye, Olanrewaju Ayodeji
TI Computer-aided screening for potential TMPRSS2 inhibitors: a combination
   of pharmacophore modeling, molecular docking and molecular dynamics
   simulation approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Pharmacophore modeling; homology modeling; COVID-19; serine protease
ID SPIKE PROTEIN; CORONAVIRUS; EFFICIENT; BINDING; TOOL; CLASSIFICATION;
   OPTIMIZATION; RECOGNITION; DISCOVERY; OUTBREAK
AB Transmembrane serine protease 2 (TMPRSS2) has been established as one of the host proteins that facilitate entry of coronaviruses into host cells. One of the approaches often employed towards preventing the entry and proliferation of viruses is computer-aided inhibition studies to identify potent compounds that can inhibit activity of viral targets in the host through binding at the active site. In this study, we developed a pharmacophore model of reportedly potent drugs against severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV-1 and -2). The model was used to screen the ZINC database for commercially available compounds having similar features with the experimentally tested drugs. The top 3000 compounds retrieved were docked into the active sites of a homology-modelled TMPRSS2. Docking scores of the top binders were validated and the top-ranked compounds were subjected to ADME, Lipinski's and medicinal Chemistry property predictions for druglikeness analyses. Two lead compounds, ZINC64606047 and ZINC05296775, were identified having binding affinities higher than those of the reference inhibitors, favorable interactions with TMPRSS2 active site residues and good ADME and medicinal chemistry properties. Molecular dynamics simulation was used to assess the stability and dynamics of the interactions of these compounds with TMPRSS2. Binding free energy and contribution energy evaluations were determined using MMPBSA method. Analyses of the trajectory dynamics collectively established further that the lead compounds bound and interacted stably with active site residues of TMPRSS2. Nonetheless, experimental studies are needed to further assess the potentials of these compounds as possible therapeutics against coronaviruses. Communicated by Ramaswamy H. Sarma.
C1 [Idris, Mukhtar Oluwaseun; Yekeen, Abeeb Abiodun; Durojaye, Olanrewaju Ayodeji] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   [Alakanse, Oluwaseun Suleiman] Univ Ilorin, Fac Life Sci, Dept Biochem, Ilorin, Nigeria.
RP Yekeen, AA; Durojaye, OA (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
EM yekeenaa@mail.ustc.edu.cn; lanredurojaye@mail.ustc.edu.cn
OI Durojaye, Olanrewaju/0000-0001-8988-8154; Idris,
   Mukhtar/0000-0003-2820-1755
CR Akutsu T, 2000, THEOR COMPUT SCI, V233, P33, DOI 10.1016/S0304-3975(97)00278-8
   Baell JB, 2013, AUST J CHEM, V66, P1483, DOI 10.1071/CH13551
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Brenk R, 2008, CHEMMEDCHEM, V3, P435, DOI 10.1002/cmdc.200700139
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Cereto-Massague A, 2015, METHODS, V71, P58, DOI 10.1016/j.ymeth.2014.08.005
   Clark DE, 2008, EXPERT OPIN DRUG DIS, V3, P841, DOI 10.1517/17460441.3.8.841
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Egan W. J., 2010, DRUG DESIGN STRUCTUR, P165
   Elfiky A., 2020, ANTI SARS ANTI HCV D, DOI [10.21203/rs.2.23280/v1, DOI 10.21203/RS.2.23280/V1]
   Ghose AK, 2012, ACS CHEM NEUROSCI, V3, P50, DOI 10.1021/cn200100h
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guner O.F., 2000, PHARMACOPHORE PERCEP, V2
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Inbar Y., 2007, ANN INT C RES COMP M
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kaeppler U, 2005, J MED CHEM, V48, P6832, DOI 10.1021/jm0501782
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Koes DR, 2012, NUCLEIC ACIDS RES, V40, pW409, DOI 10.1093/nar/gks378
   Koes DR, 2011, J CHEM INF MODEL, V51, P1307, DOI 10.1021/ci200097m
   Kumar A, 2015, METHODS, V71, P26, DOI 10.1016/j.ymeth.2014.07.007
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Laskowski R.A., 2011, LIGPLOT MULTIPLE LIG
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lemkul J., 2019, LIVING J COMPUT MOL, V1, P5068, DOI [10.33011/livecoms.1.1.5068, DOI 10.33011/LIVECOMS.1.1.5068]
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lipinski C., 2002, AM PHARM REV, V5, P82
   Maass P, 2007, J CHEM INF MODEL, V47, P390, DOI 10.1021/ci060094h
   Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Muegge I, 2002, CHEM-EUR J, V8, P1976, DOI 10.1002/1521-3765(20020503)8:9<1976::AID-CHEM1976>3.0.CO;2-K
   Niu C, 2008, BIOORGAN MED CHEM, V16, P293, DOI 10.1016/j.bmc.2007.09.034
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI https://doi.org/10.1186/1758-2946-3-33
   Oprea Tudor I, 2011, Drug Discov Today Ther Strateg, V8, P61
   OriginLab, 2018, OR VERS 2018
   PANDEY B, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-48940-5
   Pollastri M, 2010, CURR PROTOC PHARM, V49, P1, DOI DOI 10.1002/0471141755.ph0912s49
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Robson B, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103749
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sanchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Shatsky M, 2006, J COMPUT BIOL, V13, P407, DOI 10.1089/cmb.2006.13.407
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sree GNSH, 2019, BIOMED PHARMACOTHER, V110, P700, DOI 10.1016/j.biopha.2018.11.127
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Turner P., 2005, XMGRACE VERSION 5 1
   Varma MVS, 2004, CURR DRUG METAB, V5, P375, DOI 10.2174/1389200043335423
   Vedani A, 2015, TOXICOL LETT, V232, P519, DOI 10.1016/j.toxlet.2014.09.004
   Verschueren KHG, 2008, CHEM BIOL, V15, P597, DOI 10.1016/j.chembiol.2008.04.011
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   World Health Organization, 2020, 106 WHO
   World Health Organization, 2020, 76 WHO
   Wu Q, 2018, NUCLEIC ACIDS RES, V46, pW438, DOI 10.1093/nar/gky439
   Xiang ZX, 2006, CURR PROTEIN PEPT SC, V7, P217, DOI 10.2174/138920306777452312
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yang JY, 2013, BIOINFORMATICS, V29, P2588, DOI 10.1093/bioinformatics/btt447
   Yang JY, 2013, NUCLEIC ACIDS RES, V41, pD1096, DOI 10.1093/nar/gks966
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 77
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792346
EA JUL 2020
PG 19
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK7ZL
UT WOS:000549002100001
PM 32672528
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Samad, A
   Ahammad, F
   Nain, Z
   Alam, R
   Imon, RR
   Hasan, M
   Rahman, MS
AF Samad, Abdus
   Ahammad, Foysal
   Nain, Zulkar
   Alam, Rahat
   Imon, Raihan Rahman
   Hasan, Mahadi
   Rahman, Md Shahedur
TI Designing a multi-epitope vaccine against SARS-CoV-2: an
   immunoinformatics approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; multi-epitope vaccine; COVID-19; immunoinformatics; immune
   simulation; dynamics simulation
ID STRUCTURE PREDICTION; PROTEIN; WEB; ADJUVANTS; DATABASE; SPIKE; GENE
AB Ongoing COVID-19 outbreak has raised a drastic challenge to global public health security. Most of the patients with COVID-19 suffer from mild flu-like illnesses such as cold and fever; however, few percentages of the patients progress from severe illness to death, mostly in an immunocompromised individual. The causative agent of COVID-19 is an RNA virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite these debilitating conditions, no medication to stop the disease progression or vaccination is available till now. Therefore, we aimed to formulate a multi-epitope vaccine against SARS-CoV-2 by utilizing an immunoinformatics approach. For this purpose, we used the SARS-CoV-2 spike glycoprotein to determine the immunodominant T- and B-cell epitopes. After rigorous assessment, we designed a vaccine construct using four potential epitopes from each of the three epitope classes such as cytotoxic T-lymphocytes, helper T-lymphocyte, and linear B-lymphocyte epitopes. The designed vaccine was antigenic, immunogenic, and non-allergenic with suitable physicochemical properties and has higher solubility. More importantly, the predicted vaccine structure was similar to the native protein. Further investigations indicated a strong and stable binding interaction between the vaccine and the toll-like receptor (TLR4). Strong binding stability and structural compactness were also evident in molecular dynamics simulation. Furthermore, the computer-generated immune simulation showed that the vaccine could trigger real-life-like immune responses upon administration into humans. Finally, codon optimization based onEscherichia coliK12 resulted in optimal GC content and higher CAI value followed by incorporating it into the cloning vector pET28+(a). Overall, these results suggest that the designed peptide vaccine can serve as an excellent prophylactic candidate against SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Samad, Abdus; Ahammad, Foysal; Alam, Rahat; Imon, Raihan Rahman; Hasan, Mahadi; Rahman, Md Shahedur] Jashore Univ Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh.
   [Ahammad, Foysal] King Abdulaziz Univ, Dept Biol Sci, Jeddah, Saudi Arabia.
   [Nain, Zulkar] East West Univ, Dept Genet Engn & Biotechnol, Dhaka, Bangladesh.
   [Nain, Zulkar] Islamic Univ, Dept Biotechnol & Genet Engn, Kushtia, Bangladesh.
RP Rahman, MS (corresponding author), Jashore Univ Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh.; Ahammad, F (corresponding author), King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia.
EM foysalgebt@gmail.com; ms.rahman@just.edu.bd
RI Samad, Abdus/AAX-8989-2020; ZarrinTaj, Payam/W-7364-2018; Samadi,
   Ali/AAE-4854-2020; Ahammad, Foysal/AAR-5276-2020; Nain,
   Zulkar/AAF-5978-2019; Hasanzadeh, Rezgar/X-9324-2019
OI Samad, Abdus/0000-0003-4336-5600; ZarrinTaj, Payam/0000-0002-1609-7519;
   Samadi, Ali/0000-0002-0172-1980; Ahammad, Foysal/0000-0001-7313-4729;
   Nain, Zulkar/0000-0003-0819-3137; Hasanzadeh,
   Rezgar/0000-0002-1982-438X; Alam, Rahat/0000-0001-9415-9386; Saeb,
   Mohammad Reza/0000-0001-9907-9414
CR ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Abdellrazeq GS, 2020, VACCINE, V38, P2016, DOI 10.1016/j.vaccine.2019.12.052
   AHAMMAD F, 2019, MICROORGANISMS, V7, DOI DOI https://doi.org/10.3390/microorganisms7090296
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bol KF, 2016, CANCER IMMUNOL IMMUN, V65, P327, DOI 10.1007/s00262-016-1796-7
   Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   BORTHWICK N, 2020, VACCINES BASEL, V8, DOI DOI https://doi.org/10.3390/vaccines8010028
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Calisher C, 2020, LANCET, V395, pE42, DOI 10.1016/S0140-6736(20)30418-9
   Castiglione F, 2012, COMPUT MATH METHOD M, DOI 10.1155/2012/842329
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952
   DHANDA SK, 2013, BIOL DIRECT, V8, DOI DOI https://doi.org/10.1186/1745-6150-8-30
   DIMITROV I, 2013, BMC BIOINFORMATIC S6, V14, DOI DOI https://doi.org/10.1186/1471-2105-14-S6-S4
   Dorosti H, 2019, J BIOMOL STRUCT DYN, V37, P3524, DOI 10.1080/07391102.2018.1519460
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Gaafar BBM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6124030
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   Goldberg MF, 2018, IMMUNITY, V49, P1090, DOI 10.1016/j.immuni.2018.10.009
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   KHATOON N, 2017, SCI REP UK, V7, DOI DOI https://doi.org/10.1038/s41598-017-08842-w
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Latysheva NS, 2016, NUCLEIC ACIDS RES, V44, P4487, DOI 10.1093/nar/gkw282
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Lovell SC, 2002, PROTEIN-STRUCT FUNCT, V50, P437, DOI DOI 10.1002/PR0T.10286
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   Manavalan B., 2018, FRONT IMMUNOL, V9
   Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nagpal G, 2017, SCI REP-UK, V7, DOI 10.1038/srep42851
   NAIN Z, 2019, J BIOMOL STRUCT 1119, DOI DOI https://doi.org/10.1080/07391102.2019.1692072
   Nain Z, 2020, MOL IMMUNOL, V120, P146, DOI 10.1016/j.molimm.2020.02.009
   Nugent T, 2014, PROTEINS, V82, P98, DOI 10.1002/prot.24377
   Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Shamriz S, 2016, COMPUT BIOL MED, V76, P24, DOI 10.1016/j.compbiomed.2016.06.015
   SHANG WL, 2020, NPJ VACCINES, V5, DOI DOI https://doi.org/10.1038/s41541-020-0170-0
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Sussman JL, 1998, ACTA CRYSTALLOGR D, V54, P1078, DOI 10.1107/S0907444998009378
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 82
TC 10
Z9 10
U1 4
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792347
EA JUL 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK9IA
UT WOS:000549092000001
PM 32677533
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Javanmard-Emamghissi, H
   Boyd-Carson, H
   Hollyman, M
   Doleman, B
   Adiamah, A
   Lund, JN
   Clifford, R
   Dickerson, L
   Richards, S
   Pearce, L
   Cornish, J
   Hare, S
   Lockwood, S
   Moug, SJ
   Tierney, GM
AF Javanmard-Emamghissi, H.
   Boyd-Carson, H.
   Hollyman, M.
   Doleman, B.
   Adiamah, A.
   Lund, J. N.
   Clifford, R.
   Dickerson, L.
   Richards, S.
   Pearce, L.
   Cornish, J.
   Hare, S.
   Lockwood, S.
   Moug, S. J.
   Tierney, G. M.
CA COVID HAREM Had Appendicitis Resol
TI The management of adult appendicitis during the COVID-19 pandemic: an
   interim analysis of a UK cohort study
SO TECHNIQUES IN COLOPROCTOLOGY
LA English
DT Article; Early Access
DE Appendicitis; COVID-19; Non-operative; Antibiotics; Appendicectomy
ID UNCOMPLICATED ACUTE APPENDICITIS; ANTIBIOTIC-THERAPY; APPENDECTOMY;
   METAANALYSIS
AB Background Acute appendicitis (AA) is the most common general surgical emergency. Early laparoscopic appendicectomy is the gold-standard management. SARS-CoV-2 (COVID-19) brought concerns of increased perioperative mortality and spread of infection during aerosol generating procedures: as a consequence, conservative management was advised, and open appendicectomy recommended when surgery was unavoidable. This study describes the impact of the first weeks of the pandemic on the management of AA in the United Kingdom (UK). Methods Patients 18 years or older, diagnosed clinically and/or radiologically with AA were eligible for inclusion in this prospective, multicentre cohort study. Data was collected from 23rd March 2020 (beginning of the UK Government lockdown) to 1st May 2020 and included: patient demographics, COVID status; initial management (operative and conservative); length of stay; and 30-day complications. Analysis was performed on the first 500 cases with 30-day follow-up. Results The patient cohort consisted of 500 patients from 48 sites. The median age of this cohort was 35 [26-49.75] years and 233 (47%) of patients were female. Two hundred and seventy-one (54%) patients were initially treated conservatively; with only 26 (10%) cases progressing to an operation. Operative interventions were performed laparoscopically in 44% (93/211). Median length of hospital stay was significantly reduced in the conservatively managed group (2 [IQR 1-4] days vs. 3 [2-4],p < 0.001). At 30 days, complications were significantly higher in the operative group (p < 0.001), with no deaths in any group. Of the 159 (32%) patients tested for COVID-19 on admission, only 6 (4%) were positive. Conclusion COVID-19 has changed the management of acute appendicitis in the UK, with non-operative management shown to be safe and effective in the short-term. Antibiotics should be considered as the first line during the pandemic and perhaps beyond.
C1 [Javanmard-Emamghissi, H.; Doleman, B.; Lund, J. N.] Univ Nottingham Derby, Royal Derby Hosp, Derby, England.
   [Boyd-Carson, H.; Tierney, G. M.] Royal Derby Hosp, Derby, England.
   [Hollyman, M.] Musgrove Pk Hosp, Taunton, Somerset, England.
   [Adiamah, A.] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Digest Dis Biomed Res Ctr, Nottingham, England.
   [Clifford, R.; Dickerson, L.] Countess Chester, Chester, Cheshire, England.
   [Richards, S.] Royal United Hosp, Bath, Avon, England.
   [Pearce, L.] Salford Royal NHS Trust, Salford, Lancs, England.
   [Cornish, J.] Cardiff Royal Infirm, Cardiff, Wales.
   [Hare, S.] Medway Maritime Hosp, Gillingham, Kent, England.
   [Lockwood, S.] Bradford Royal Infirm, Bradford, W Yorkshire, England.
   [Moug, S. J.] Royal Alexandra Hosp, Paisley, Renfrew, Scotland.
RP Javanmard-Emamghissi, H (corresponding author), Univ Nottingham Derby, Royal Derby Hosp, Derby, England.
EM Hannah.javanmard@gmail.com
RI Tang, Alethea/AAV-1983-2020
OI Tang, Alethea/0000-0001-9681-9755; Lewis-Lloyd,
   Christopher/0000-0001-9996-3699; Kulkarni, Nikhil/0000-0002-8172-761X;
   Georgiades, Fanourios/0000-0003-0440-2720; Olivier,
   James/0000-0003-3082-8426; Adiamah, Alfred/0000-0002-0624-6197;
   Danwaththa Liyanage, Aloka Suwanna/0000-0003-4973-4809; Gowda,
   Arjun/0000-0001-5578-4250; Wadham, Bianca/0000-0001-5504-4666; Ooi,
   Rucira/0000-0002-1051-780X
FU ASGBI secretariat Vicki Grant
FX Special thanks to Francois Arvin-Berod of NUH Research Information
   Systems, and Lauren Blackburn and Mr Adam Brooks of the East Midlands
   Major Trauma Centre. We would also like to thank Mr Iain Anderson and
   the ASGBI secretariat Vicki Grant and Bhavnita Patel for their support.
CR ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734
   Andersson RE, 2007, ANN SURG, V246, P741, DOI 10.1097/SLA.0b013e31811f3f9f
   Association of Upper GI Surgery of Great Britain and Ireland, 2020, AUGIS GUID MAN ALG P
   Bhangu A, 2016, BRIT J SURG, V103, P971, DOI 10.1002/bjs.10151
   Bickell NA, 2006, J AM COLL SURGEONS, V202, P401, DOI 10.1016/j.jamcollsurg.2005.11.016
   Burn-Murdoch J, 2020, FINANCIAL TIMES
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   COVIDSurg Collaborative, 2020, BRIT J SURG, V107, P1097, DOI 10.1002/bjs.11646
   De Simone B, 2020, ANN ROY COLL SURG, V102, P323, DOI 10.1308/rcsann.2020.0097
   de Wijkerslooth EML, 2019, DIS COLON RECTUM, V62, P1363, DOI 10.1097/DCR.0000000000001466
   Di Saverio S, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00306-3
   Di Saverio S, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0090-5
   Griin M, 2020, JOINT GUIDANCE SURGE
   HAREM Steering Grp, 2020, BRIT J SURG, V107, pE257, DOI 10.1002/bjs.11711
   Harnoss JC, 2017, ANN SURG, V265, P889, DOI 10.1097/SLA.0000000000002039
   Hettiaratchy S, 2020, JOINT GUIDANCE SURGE
   Jaschinski T, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001546.pub4
   Kim K, 2012, NEW ENGL J MED, V366, P1596, DOI 10.1056/NEJMoa1110734
   NHS Digital, 2019, HOSP ADM PAT CAR ACT
   Podda M, 2017, SURG-J R COLL SURG E, V15, P303, DOI 10.1016/j.surge.2017.02.001
   Poon SHT, 2017, WORLD J EMERG SURG, V12, DOI 10.1186/s13017-017-0157-y
   Prechal D, 2019, INT J COLORECTAL DIS, V34, P963, DOI 10.1007/s00384-019-03296-0
   RIFT study group, 2019, BRIT J SURG, V107, P73
   Rollins KE, 2016, WORLD J SURG, V40, P2305, DOI 10.1007/s00268-016-3561-7
   Salminen P, 2018, JAMA-J AM MED ASSOC, V320, P1259, DOI 10.1001/jama.2018.13201
   Sippola S, 2017, BRIT J SURG, V104, P1355, DOI 10.1002/bjs.10575
   Spinelli A, 2020, BRIT J SURG, V107, P785, DOI 10.1002/bjs.11627
   The Association of Surgeons of Great Britain and Ireland, 2014, COMM GUID EM GEN SUR
   Vigneswaran Y, 2020, J GASTROINTEST SURG, V24, P1686, DOI 10.1007/s11605-020-04592-9
   Yang ZY, 2019, BMC SURG, V19, DOI 10.1186/s12893-019-0578-5
NR 30
TC 5
Z9 5
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1123-6337
EI 1128-045X
J9 TECH COLOPROCTOL
JI Tech. Coloproctology
DI 10.1007/s10151-020-02297-4
EA JUL 2020
PG 11
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA MK5MW
UT WOS:000548832300001
PM 32671661
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jiang, JP
   Miao, Y
   Zhao, YN
   Lu, X
   Zhou, P
   Zhou, XJ
   Chen, ZS
   Du, DF
AF Jiang, Jipin
   Miao, Yan
   Zhao, Yuanyuan
   Lu, Xia
   Zhou, Ping
   Zhou, Xiaojun
   Chen, Zhishui
   Du, Dunfeng
TI Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney
   transplant recipient presenting with serve clinical manifestation and
   complex complications
SO CLINICAL TRANSPLANTATION
LA English
DT Letter
C1 [Jiang, Jipin; Miao, Yan; Zhao, Yuanyuan; Lu, Xia; Zhou, Ping; Zhou, Xiaojun; Chen, Zhishui; Du, Dunfeng] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
   [Jiang, Jipin; Miao, Yan; Zhao, Yuanyuan; Lu, Xia; Zhou, Ping; Zhou, Xiaojun; Chen, Zhishui; Du, Dunfeng] Chinese Acad Med Sci, Key Lab Organ Transplantat, Minist Educ, NHC Key Lab Organ Transplantat,Key Lab Organ Tran, Wuhan, Peoples R China.
RP Du, DF (corresponding author), Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
EM dfdu@tjh.tjmu.edu.cn
OI Zhao, Yuanyuan/0000-0003-0217-3290
FU Science and Technology Foundation of Hubei Province [2018CFB554,
   2019CFB659]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81700300]
FX This work was supported by the Science and Technology Foundation of
   Hubei Province (2018CFB554 and 2019CFB659) and the National Natural
   Science Foundation of China (No. 81700300).
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Casadevall A, 2020, JAMA
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 6
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD SEP
PY 2020
VL 34
IS 9
AR e14025
DI 10.1111/ctr.14025
EA JUL 2020
PG 3
WC Surgery; Transplantation
SC Surgery; Transplantation
GA NY6SD
UT WOS:000548419300001
PM 32602952
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aronson, JK
   Auker-Howlett, D
   Ghiara, V
   Kelly, MP
   Williamson, J
AF Aronson, Jeffrey K.
   Auker-Howlett, Daniel
   Ghiara, Virginia
   Kelly, Michael P.
   Williamson, Jon
TI The use of mechanistic reasoning in assessing coronavirus interventions
SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE
LA English
DT Article; Early Access
DE coronavirus; evidence-based medicine; mechanisms; mechanistic reasoning
ID RESPIRATORY SYNDROME CORONAVIRUS; SYNERGISTICALLY INHIBIT;
   MYCOPHENOLIC-ACID; INTERFERON-BETA; RIBAVIRIN; VACCINE; REPLICATION;
   INFECTION; MODELS
AB Rationale Evidence-based medicine (EBM), the dominant approach to assessing the effectiveness of clinical and public health interventions, focuses on the results of association studies. EBM+ is a development of EBM that systematically considers mechanistic studies alongside association studies. Aims and objectives To explore examples of the importance of mechanistic evidence to coronavirus research. Methods We have reviewed the mechanistic evidence in four major areas that are relevant to the management of COVID-19. Results and conclusions (a) Assessment of combination therapy for MERS highlights the need for systematic assessment of mechanistic evidence. (b) That hypertension is a risk factor for severe disease in the case of SARS-CoV-2 suggests that altering hypertension treatment might alleviate disease, but the mechanisms are complex, and it is essential to consider and evaluate multiple mechanistic hypotheses. (c) Confidence that public health interventions will be effective requires a detailed assessment of social and psychological components of the mechanisms of their action, in addition to mechanisms of disease. (d) In particular, if vaccination programmes are to be effective, they must be carefully tailored to the social context; again, mechanistic evidence is crucial. We conclude that coronavirus research is best situated within the EBM+ evaluation framework.
C1 [Aronson, Jeffrey K.] Nuffield Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Oxford, England.
   [Auker-Howlett, Daniel; Ghiara, Virginia; Williamson, Jon] Univ Kent, Sch European Culture & Languages, Dept Philosophy, Canterbury CT2 7NF, Kent, England.
   [Auker-Howlett, Daniel; Ghiara, Virginia; Williamson, Jon] Univ Kent, Sch European Culture & Languages, Ctr Reasoning, Canterbury, Kent, England.
   [Kelly, Michael P.] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Primary Care Unit, Cambridge, England.
RP Auker-Howlett, D (corresponding author), Univ Kent, Sch European Culture & Languages, Dept Philosophy, Canterbury CT2 7NF, Kent, England.
EM dja35@kent.ac.uk
OI Auker-Howlett, Daniel/0000-0002-2477-863X; Aronson,
   Jeffrey/0000-0003-1139-655X; Kelly, Michael/0000-0002-2029-5841
FU Wellcome; MRC: Medical Research CouncilMedical Research Council UK
   (MRC); NIHR: National Institute For Health ResearchNational Institute
   for Health Research (NIHR); Arts and Humanities Research Council
   Consortium for Humanities and Arts South-East England (CHASE) Doctoral
   Training Partnership [AH/L503861/1]; Arts and Humanities Research
   Council [AH/M005917/1]; Leverhulme TrustLeverhulme Trust [RPG-2019-059];
   Marie CurieEuropean Union (EU)
FX Marie Curie; Wellcome; MRC: Medical Research Council; NIHR: National
   Institute For Health Research; Arts and Humanities Research Council
   Consortium for Humanities and Arts South-East England (CHASE) Doctoral
   Training Partnership, Grant/Award Number: AH/L503861/1; Arts and
   Humanities Research Council, Grant/Award Number: AH/M005917/1;
   Leverhulme Trust, Grant/Award Number: RPG-2019-059
CR Abdin AY, 2019, CURR PHARM DESIGN, V25, P1866, DOI 10.2174/1381612825666190628160603
   Al Ghamdi M, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1492-4
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Aronson JK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1313
   Aronson JK, 2018, J EVAL CLIN PRACT, V24, P1166, DOI 10.1111/jep.12960
   Auker-Howlett D, 2020, J EVAL CLIN PRACT, V26, P458, DOI 10.1111/jep.13269
   Baseler L, 2016, VET PATHOL, V53, P521, DOI 10.1177/0300985815620845
   Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056
   Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590
   Bonell C, 2020, J EPIDEMIOL COMMUN H
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Clarke B, 2014, TOPOI-INT REV PHILOS, V33, P339, DOI 10.1007/s11245-013-9220-9
   Cohall D, 2020, J RENIN-ANGIO-ALDO S, V21, DOI 10.1177/1470320320908186
   De Pretis F, 2019, FRONT PHARMACOL, V10, P1
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, CURR OPIN VIROL, V3, P343, DOI 10.1016/j.coviro.2013.04.007
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Fowler N, 2014, AIDS DONT PREJUDICE
   Gardner B, 2010, PSYCHOL HEALTH MED, V15, P220, DOI 10.1080/13548501003623963
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Harvey H, 2015, VACCINE, V33, P2862, DOI 10.1016/j.vaccine.2015.04.085
   HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Isfeld-Kiely H., 2014, EFFECTIVENESS SCH CL
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Kelly MP, 2018, SOCIOL HEALTH ILL, V40, P82, DOI 10.1111/1467-9566.12621
   Kelly MP, 2014, PERSPECT BIOL MED, V57, P308, DOI 10.1353/pbm.2014.0026
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Li G, 2020, HYPERTENS RES, V30, P1
   Marteau TM, 2015, EMERGING BEHAV SOCIA, P105
   McMichael AJ, 1999, AM J EPIDEMIOL, V149, P887
   Merriam S, 2020, INCREASING VACCINE U
   Michie S, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0641-5
   Michie S, 2018, ANN BEHAV MED, V52, P501, DOI 10.1007/s12160-016-9816-6
   Milne-Price S, 2014, PATHOG DIS, V71, P119, DOI 10.1111/2049-632X.12166
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Parkkinen V.-P., 2018, EVALUATING EVIDENCE
   Pinheiro DS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221248
   Risso-Gill Isabelle, 2015, CHILDRENS EBOLA RECO
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Sanchis-Gomar F, 2020, MAYO CLIN PROC, V95, P1222, DOI 10.1016/j.mayocp.2020.03.026
   Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265
   Smith LE, 2017, VACCINE, V35, P1936, DOI 10.1016/j.vaccine.2017.02.031
   Staatz CE, 2014, ARCH TOXICOL, V88, P1351, DOI 10.1007/s00204-014-1247-1
   Steel Daniel, 2008, BOUNDARIES EXTRAPOLA
   Vietri JT, 2012, MED DECIS MAKING, V32, P447, DOI 10.1177/0272989X11427762
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Whittle Jessica S, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12071
   Williamson J, 2020, THEORIA INT J THEORY, DOI [10.1387/theoria.21244, DOI 10.1387/THEORIA.21244]
   Williamson J, 2018, SYNTHESE, DOI [10.1007/s11229-018-1866-9, DOI 10.1007/S11229-018-1866-9]
   Williamson J, 2019, J EVAL CLIN PRACT, V25, P955, DOI 10.1111/jep.13226
   World Health Organization, 2013, GUID TAIL IMM PROGR
NR 64
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-1294
EI 1365-2753
J9 J EVAL CLIN PRACT
JI J. Eval. Clin. Pract.
DI 10.1111/jep.13438
EA JUL 2020
PG 10
WC Health Care Sciences & Services; Medical Informatics; Medicine, General
   & Internal
SC Health Care Sciences & Services; Medical Informatics; General & Internal
   Medicine
GA MJ9NW
UT WOS:000548413500001
PM 32666676
OA Other Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Antony, SJ
   Davis, MA
   Davis, MG
   Almaghlouth, NK
   Guevara, R
   Omar, F
   Del Rey, F
   Hassan, A
   Arian, MU
   Antony, N
   Prakash, BV
AF Antony, Suresh J.
   Davis, Michelle A.
   Davis, Monique G.
   Almaghlouth, Nouf K.
   Guevara, Roberto
   Omar, Fahad
   Del Rey, Fernando
   Hassan, Ali
   Arian, Muhammad U.
   Antony, Nishaal
   Prakash, Bharat, V
TI Early use of tocilizumab in the prevention of adult respiratory failure
   in SARS-CoV-2 infections and the utilization of interleukin-6 levels in
   the management
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE early treatment; IL-6 levels; mechanical ventilation; outcomes;
   SARS-CoV-2
AB Respiratory failure in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appears related to cytokine release syndrome that often results in mechanical ventilation (MV). We investigated the role of tocilizumab (TCZ) on interleukin-6 (IL-6) trends and MV in patients with SARS-CoV-2. In this longitudinal observational study, 112 patients were evaluated from 1 February to 31 May 2020. TCZ was administered followed by methylprednisolone to patients with >3L oxygen requirement and pneumonia severity index score <= 130 with computed tomography scan changes. IL-6, C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, and procalcitonin were monitored on days 0, 3, and 6 of therapy. Statistical analyses were performed with significance <= 0.05. Eighty out of 112 SARS-CoV-2-positive patients (45 males, 56.96%; 34 females, 43.04%) were included in this study. Seven patients expired (8.75%) and nine patients required MV (11.25%). Median IL-6 levels pre-administration of TCZ was 342.50 (78.25-666.25) pg/mL compared with post-administration on day 3 (563; 162-783) pg/mL (P < .00001). On day 6, the median dropped to 545 (333.50-678.50) pg/mL compared with day 3 (P = .709). CRP, ferritin, LDH, and D-dimer levels were reduced after TCZ therapy. Early use of TCZ may reduce the need for MV and decrease CRP, ferritin, LDH, and D-dimer levels. The sequential use of methylprednisolone for 72 hours seems to potentiate the effect and prolong the suppression of the cytokine storm. IL-6 levels may be helpful as a prognostic tool.
C1 [Antony, Suresh J.; Antony, Nishaal; Prakash, Bharat, V] Texas Tech Univ, Dept Med, Hlth Sci Ctr, El Paso, TX USA.
   [Davis, Michelle A.; Davis, Monique G.] Burrell Coll Osteopath Med, Dept Med, Las Cruces, NM USA.
   [Almaghlouth, Nouf K.] Burrell Coll Osteopath Med, Mt View Reg Med Ctr, Dept Med, Las Cruces, NM USA.
   [Guevara, Roberto] Hosp Providence Transmt Campus, Dept Clin Pharm, El Paso, TX USA.
   [Omar, Fahad] Las Palmas Sol Healthcare, Dept Pulm & Crit Care, El Paso, TX USA.
   [Del Rey, Fernando; Hassan, Ali; Arian, Muhammad U.] Las Palmas Sol Healthcare, Dept Med, El Paso, TX USA.
RP Antony, SJ (corresponding author), 1205 N Oregon, El Paso, TX 79902 USA.
EM suresh.antony@att.net
OI Almaghlouth, Nouf/0000-0001-9415-8009
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Chastain DB, 2020, OPEN FORUM INFECT DI
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Fang FC, 2020, CLIN INFECT DIS, V2020
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Issa N, 2020, J MED VIROL, DOI 10.1002/jmv.26110
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   National Heart Lung and Blood Institute, QUAL ASS TOOL CAS SE
   Radbel J, 2020, CHEST
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhang YY, 2020, DRUG DISCOV THER, V14, P100, DOI 10.5582/ddt.2020.03006
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
NR 21
TC 5
Z9 5
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26288
EA JUL 2020
PG 8
WC Virology
SC Virology
GA MJ9MG
UT WOS:000548409300001
PM 32644254
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gomez-Mayordomo, V
   Montero-Escribano, P
   Matias-Guiu, JA
   Gonzalez-Garcia, N
   Porta-Etessam, J
   Matias-Guiu, J
AF Gomez-Mayordomo, Victor
   Montero-Escribano, Paloma
   Matias-Guiu, Jordi A.
   Gonzalez-Garcia, Nuria
   Porta-Etessam, Jesus
   Matias-Guiu, Jorge
TI Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID-19; exacerbation; fingolimod; multiple sclerosis;
   SARS-CoV-2
ID MULTIPLE-SCLEROSIS; REBOUND SYNDROME
AB The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
C1 [Gomez-Mayordomo, Victor; Montero-Escribano, Paloma; Matias-Guiu, Jordi A.; Gonzalez-Garcia, Nuria; Porta-Etessam, Jesus; Matias-Guiu, Jorge] Univ Complutense, Hosp Clin San Carlos, San Carlos Hlth Res Inst IdISSC, Dept Neurol,Inst Neurosci, Prof Martin Lagos S-N, Madrid 28040, Spain.
RP Matias-Guiu, JA (corresponding author), Univ Complutense, Hosp Clin San Carlos, San Carlos Hlth Res Inst IdISSC, Dept Neurol,Inst Neurosci, Prof Martin Lagos S-N, Madrid 28040, Spain.
EM jordimatiasguiu@hotmail.com
RI Gomez-Mayordomo, Victor/ABG-1596-2020; Matias-Guiu, Jordi A./F-6941-2018
OI Gomez-Mayordomo, Victor/0000-0001-9343-8439; Matias-Guiu, Jordi
   A./0000-0001-5520-2708; Montero-Escribano, Paloma/0000-0003-3615-7678;
   PORTA-ETESSAM, JESUS/0000-0002-7034-682X
CR Andrade C, 2016, JAMA NEUROL, V73, P1375, DOI 10.1001/jamaneurol.2016.3507
   Baker D, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102174
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   BURKS JS, 1980, SCIENCE, V209, P933, DOI 10.1126/science.7403860
   Cavone L, 2015, BRAIN BEHAV IMMUN, V50, P78, DOI 10.1016/j.bbi.2015.06.019
   Chakraborty C, 2020, J MED VIROL, V92, P2260, DOI 10.1002/jmv.26078
   Chiarini M, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577282
   Foerch C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102180
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102135
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Giovannoni G, 2017, MULT SCLER RELAT DIS, V15, pA1, DOI 10.1016/j.msard.2017.06.005
   Hatcher SE, 2016, JAMA NEUROL, V73, P790, DOI 10.1001/jamaneurol.2016.0826
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Matias-Guiu J, 2020, NEUROLOGIA, V35, P170, DOI 10.1016/j.nrl.2020.03.001
   Matias-Guiu Jorge, 2020, Mult Scler Relat Disord, V44, P102297, DOI 10.1016/j.msard.2020.102297
   Merschhemke M, 2016, JAMA NEUROL, V73, P1375, DOI 10.1001/jamaneurol.2016.3199
   Montero-Escribano P, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102185
   Valencia-Sanchez C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102182
   Voskuhl R, 2016, JAMA NEUROL, V73, P775, DOI 10.1001/jamaneurol.2016.0934
NR 19
TC 3
Z9 3
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26279
EA JUL 2020
PG 4
WC Virology
SC Virology
GA MK2HM
UT WOS:000548606600001
PM 32644205
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Salacup, G
   Lo, KB
   Gul, F
   Peterson, E
   De Joy, R
   Bhargav, R
   Pelayo, J
   Albano, J
   Azmaiparashvili, Z
   Benzaquen, S
   Patarroyo-Aponte, G
   Rangaswami, J
AF Salacup, Grace
   Lo, Kevin Bryan
   Gul, Fahad
   Peterson, Eric
   De Joy, Robert, III
   Bhargav, Ruchika
   Pelayo, Jerald
   Albano, Jeri
   Azmaiparashvili, Zurab
   Benzaquen, Sadia
   Patarroyo-Aponte, Gabriel
   Rangaswami, Janani
TI Characteristics and clinical outcomes of COVID-19 patients in an
   underserved-inner city population: A single tertiary center cohort
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID-19; inner city hospital; outcomes
ID OBESITY
AB There is limited information describing the characteristics and clinical outcomes of patients infected with coronavirus disease 2019 (COVID-19) especially those in underserved urban area with minority population in the United States. This is a retrospective single-center study for patients who were admitted with COVID-19 infection. Data collection was from 1 March through 24 April 2020. Demographic, clinical, laboratory, and treatment data were presented using descriptive statistics and frequencies. The chi(2)test and multivariate logistic regression were used to determine association of risk factors and clinical outcomes. A total of 242 inpatients were included with a mean age of 66 +/- 14.75 (+/- standard deviation). A total of 50% were female and 70% were African American. Comorbidities included hypertension (74%), diabetes mellitus (49%), and 19% had either COPD or asthma. Older age was associated with higher risk of inpatient death odds ratio (OR): 1.056 (95% confidence interval [CI]: 1.023-1.090;P = .001). Inpatient mortality occurred in 70% who needed mechanical ventilation (OR: 29.51; 95% CI: 13.28-65.60;P < .0001), 58% who required continuous renal replacement therapy/hemodialysis (CRRT/HD) (OR: 6.63; 95% CI: 2.74-16.05;P < .0001), and 69% who needed vasopressors (OR: 30.64; 95% CI: 13.56-69.20;P < .0001). Amongst biomarkers of disease severity, only baseline CRP levels (145 +/- 116 mg/L) were associated with mortality OR: 1.008 (95% CI: 1.003-1.012;P = .002). Majority of hospitalized patients had hypertension and diabetes. Older age was an independent risk factor for inpatient mortality. Requirement of mechanical ventilation, vasopressor use, and CRRT/HD was associated significantly with inpatient mortality. Higher baseline CRP was significantly associated with inpatient death.
C1 [Salacup, Grace; Lo, Kevin Bryan; Gul, Fahad; Peterson, Eric; De Joy, Robert, III; Bhargav, Ruchika; Pelayo, Jerald; Albano, Jeri; Azmaiparashvili, Zurab; Benzaquen, Sadia; Patarroyo-Aponte, Gabriel; Rangaswami, Janani] Einstein Med Ctr Philadelphia, Dept Med, Philadelphia, PA 19141 USA.
   [Benzaquen, Sadia; Patarroyo-Aponte, Gabriel] Einstein Med Ctr Philadelphia, Div Pulm & Crit Care & Sleep Med, Philadelphia, PA 19141 USA.
   [Rangaswami, Janani] Thomas Jefferson Univ, Sidney Kimmel Coll, Philadelphia, PA 19107 USA.
RP Salacup, G (corresponding author), Einstein Med Ctr Philadelphia, 5501 Old York Rd, Philadelphia, PA 19141 USA.
EM salacupg@einstein.edu
OI Lo, Kevin Bryan/0000-0001-7088-6677; Salacup, Grace/0000-0002-0003-2040
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cai QX, 2020, DIABETES CARE, V43, P1392, DOI 10.2337/dc20-0576
   Falagas ME, 2006, LANCET INFECT DIS, V6, P438, DOI 10.1016/S1473-3099(06)70523-0
   Gold JA, 2020, MMWR MORBIDITY MORTA, P69
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19, P21
   John's Hopkins Coronavirus Resource Center, 2020, COVID 19 MAP
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Murrell D, 2020, PHILADELPHIA MAGAZIN
   National Institutes of Health, 2019, COR DIS 2019 COVID 1
   Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Salome CM, 2010, J APPL PHYSIOL, V108, P206, DOI 10.1152/japplphysiol.00694.2009
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.05.14.20101774v1.full.pdf, DOI 10.1101/2020.05.14.20101774V1.FULL.PDF]
   Taylor H, 2014, APPL ENVIRON MICROB, V80, P3034
   World Health Organization (WHO), 2020, NOV COR CHIN
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu X, 2020, EFFECTIVE TREATMENT
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zheng KI, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154244
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 4
Z9 4
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26252
EA JUL 2020
PG 8
WC Virology
SC Virology
GA MJ9LS
UT WOS:000548407900001
PM 32617986
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Stevenson, JD
   Evans, S
   Morris, G
   Tillman, R
   Abudu, A
   Jeys, L
   Parry, M
AF Stevenson, Jonathan D.
   Evans, Scott
   Morris, Guy
   Tillman, Roger
   Abudu, Adesegun
   Jeys, Lee
   Parry, Michael
TI Mortality of high-risk orthopaedic oncology patients during the COVID-19
   pandemic: A prospective cohort study
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE COVID-19; orthopaedic oncology; sarcoma
AB Background and Objectives Should the threshold for orthopaedic oncology surgery during the coronavirus disease-2019 (COVID-19) pandemic be higher, particularly in men aged 70 years and older? This study reports the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during, respiratory complications and 30-day mortality during the COVID-19 pandemic. Methods This prospective observational cohort study included 100 consecutive patients. The primary outcome measure was 14-day symptoms and/or SARS-CoV-2 test. The secondary outcome was 30-day postoperative mortality. Results A total of 100 patients comprising 35 females and 65 males, with a mean age of 52.4 years (range, 16-94 years) included 16 males aged greater than 70 years. The 51% of patients were tested during their admission for SARS-CoV-2; 5% were diagnosed/developed symptoms of SARS-CoV-2 during and until 14 days post-discharge; four were male and one female, mean age 41.2 years (range, 17-75 years), all had primary malignant bone or soft-tissue tumours, four of five had received immunosuppressive therapy pre-operatively. The 30-day mortality was 1% overall and 20% in those with SARS-CoV-2. The pulmonary complication rate was 3% overall. Conclusions With appropriate peri-operative measures to prevent viral transmission, major surgery for urgent orthopaedic oncology patients can continue during the COVID-19 pandemic. These results need validating with national data to confirm these conclusions.
C1 [Stevenson, Jonathan D.; Evans, Scott; Morris, Guy; Tillman, Roger; Abudu, Adesegun; Jeys, Lee; Parry, Michael] Royal Orthopaed Hosp, Oncol Dept, Bristol Rd South, Birmingham B31 2AP, W Midlands, England.
RP Stevenson, JD (corresponding author), Royal Orthopaed Hosp, Oncol Dept, Bristol Rd South, Birmingham B31 2AP, W Midlands, England.
EM jonathan.stevenson@nhs.net
CR [Anonymous], 2020, NAT COVID 19 SURV RE
   Collaborative C, 2020, MORT PULM COMPL PAT, DOI [10.1016/S0140-6736, DOI 10.1016/S0140-6736]
   D'Apolito R, 2020, J ARTHROPLASTY, V35, pS6, DOI 10.1016/j.arth.2020.04.057
   Royal College of Surgeons, 2020, CLIN GUID SURG PRIOR
   Sahbat Y, 2020, J SURG ONCOL, V122, P594, DOI 10.1002/jso.26092
NR 5
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD NOV
PY 2020
VL 122
IS 6
BP 1027
EP 1030
DI 10.1002/jso.26127
EA JUL 2020
PG 4
WC Oncology; Surgery
SC Oncology; Surgery
GA OA0DS
UT WOS:000548416100001
PM 32668015
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rinewalt, D
   Coppolino, A
   Seethala, R
   Sharma, N
   Salim, A
   Keller, S
   Mallidi, HR
AF Rinewalt, Daniel
   Coppolino, Anthony
   Seethala, Raghu
   Sharma, Nirmal
   Salim, Ali
   Keller, Steve
   Mallidi, Hari R.
TI COVID-19 patient bridged to recovery with veno-venous extracorporeal
   membrane oxygenation
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Article
DE cardiovascular pathology; perfusion
ID CORONAVIRUS DISEASE 2019; ECMO
AB Background In severe cases, the coronavirus disease 2019 (COVID-19) viral pathogen produces hypoxic respiratory failure unable to be adequately supported by mechanical ventilation. The role of extracorporeal membrane oxygenation (ECMO) remains unknown, with the few publications to date lacking detailed patient information or management algorithms all while reporting excessive mortality. Methods Case report from a prospectively maintained institutional ECMO database for COVID-19. Results We describe veno-venous (VV) ECMO in a COVID-19-positive woman with hypoxic respiratory dysfunction failing mechanical ventilation support while prone and receiving inhaled pulmonary vasodilator therapy. After 9 days of complex management secondary to her hyperdynamic circulation, ECMO support was successfully weaned to supine mechanical ventilation and the patient was ultimately discharged from the hospital. Conclusions With proper patient selection and careful attention to hemodynamic management, ECMO remains a reasonable treatment option for patients with COVID-19.
C1 [Rinewalt, Daniel; Mallidi, Hari R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02115 USA.
   [Coppolino, Anthony; Mallidi, Hari R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02115 USA.
   [Seethala, Raghu] Harvard Med Sch, Brigham & Womens Hosp, Dept Emergency Med, Div Emergency Crit Care Med, Boston, MA 02115 USA.
   [Sharma, Nirmal; Keller, Steve] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
   [Salim, Ali] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Div Trauma Burn & Surg Crit Care, Boston, MA 02115 USA.
   [Keller, Steve] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
RP Rinewalt, D (corresponding author), Brigham & Womens Hosp, Div Cardiac Surg, 75 Francis St, Boston, MA 02115 USA.
EM drinewalt@bwh.harvard.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K08 HL143342] Funding Source: Medline
CR Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Schmidt M, 2013, INTENS CARE MED, V39, P838, DOI 10.1007/s00134-012-2785-8
NR 6
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD OCT
PY 2020
VL 35
IS 10
BP 2869
EP 2871
DI 10.1111/jocs.14829
EA JUL 2020
PG 3
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA NT5YX
UT WOS:000548407000001
PM 32668041
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, TZ
   Cao, ZH
   Chen, Y
   Cai, MT
   Zhang, LY
   Xu, H
   Zhang, JY
   Ma, CH
   Liu, Y
   Gao, LJ
   Duan, ZH
   Mou, DL
   Liang, LC
AF Li, Tong-Zeng
   Cao, Zhen-Huan
   Chen, Yu
   Cai, Miao-Tian
   Zhang, Long-Yu
   Xu, Hui
   Zhang, Jia-Ying
   Ma, Chun-Hua
   Liu, Yang
   Gao, Li-Juan
   Duan, Zhong-Hui
   Mou, Dan-Lei
   Liang, Lian-Chun
TI Duration of SARS-CoV-2 RNA shedding and factors associated with
   prolonged viral shedding in patients with COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID-19; duration of viral shedding
ID CORTICOSTEROID TREATMENT; SARS
AB To investigate the factors associated with the duration of severe acute respiratory syndrome coronavirus 2 RNA shedding in patients with coronavirus disease 2019 (COVID-19). A retrospective cohort of COVID-19 patients admitted to a designated hospital in Beijing was analyzed to study the factors affecting the duration of viral shedding. The median duration of viral shedding was 11 days (IQR, 8-14.3 days) as measured from illness onset. Univariate regression analysis showed that disease severity, corticosteroid therapy, fever (temperature>38.5 degrees C), and time from onset to hospitalization were associated with prolonged duration of viral shedding (P < .05). Multivariate regression analysis showed that fever (temperature>38.5 degrees C) (OR, 5.1, 95%CI: 1.5-18.1), corticosteroid therapy (OR, 6.3, 95%CI: 1.5-27.8), and time from onset to hospitalization (OR, 1.8, 95%CI: 1.19-2.7) were associated with increased odds of prolonged duration of viral shedding. Corticosteroid treatment, fever (temperature>38.5 degrees C), and longer time from onset to hospitalization were associated with prolonged viral shedding in COVID-19 patients.
C1 [Li, Tong-Zeng; Cao, Zhen-Huan; Cai, Miao-Tian; Zhang, Long-Yu; Xu, Hui; Zhang, Jia-Ying; Ma, Chun-Hua; Liu, Yang; Gao, Li-Juan; Duan, Zhong-Hui; Mou, Dan-Lei; Liang, Lian-Chun] Capital Med Univ, Beijing Youan Hosp, Dept Infect Dis, Beijing 100069, Peoples R China.
   [Chen, Yu] Capital Med Univ, Beijing Youan Hosp, Difficult & Complicated Liver Dis & Artificial Li, Beijing, Peoples R China.
RP Liang, LC (corresponding author), Capital Med Univ, Beijing Youan Hosp, Dept Infect Dis, Beijing 100069, Peoples R China.
EM llctgy44@163.com
FU Scientific Research Project of Beijing Youan Hospital, CCMU, 2020
   [BJYAYY-2020ZQN-06]
FX Scientific Research Project of Beijing Youan Hospital, CCMU, 2020,
   Grant/Award Number: BJYAYY-2020ZQN-06
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Hao SR, 2020, J INFECT DIS, V222, P367, DOI 10.1093/infdis/jiaa311
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Lu YY, 2020, PEDIATR INFECT DIS J, V39, pE95, DOI 10.1097/INF.0000000000002729
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Qi L, 2020, INT J INFECT DIS, V96, P531, DOI 10.1016/j.ijid.2020.05.045
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Weinstock DM, 2003, NEW ENGL J MED, V348, P867, DOI 10.1056/NEJM200302273480923
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 18
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26280
EA JUL 2020
PG 7
WC Virology
SC Virology
GA MJ9LZ
UT WOS:000548408600001
PM 32644223
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lee, M
   Chen, CHS
   Ovbiagele, B
AF Lee, Meng
   Chen, Chi-Hsin Sally
   Ovbiagele, Bruce
TI Covert COVID-19 complications: Continuing the use of evidence-based
   drugs to minimize potentially lethal indirect effects of the pandemic in
   stroke patients
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Letter
DE COVID-19; Stroke; Medication discontinuation
C1 [Lee, Meng] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Neurol,Chiayi Branch, Puzi, Chiayi, Taiwan.
   [Chen, Chi-Hsin Sally] Natl Taiwan Univ, Coll Publ Hlth, Taipei, Taiwan.
   [Ovbiagele, Bruce] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Ovbiagele, B (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco VA Hlth Care Syst, 4150 Clement St, San Francisco, CA 94121 USA.
EM Bruce.Ovbiagele@va.gov
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Diener HC, 2012, LANCET NEUROL, V11, P225, DOI 10.1016/S1474-4422(12)70017-0
   Rodriguez LAG, 2011, NEUROLOGY, V76, P740, DOI 10.1212/WNL.0b013e31820d62b5
   Lee M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005658
   Pezzini A, 2014, CIRCULATION, V129, P1668, DOI 10.1161/CIRCULATIONAHA.113.005663
NR 5
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JUL 15
PY 2020
VL 414
AR 116883
DI 10.1016/j.jns.2020.116883
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LY3WA
UT WOS:000540458100044
PM 32413768
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Denholm, JT
   Davis, J
   Paterson, D
   Roberts, J
   Morpeth, S
   Snelling, T
   Zentner, D
   Rees, M
   O'Sullivan, M
   Price, D
   Bowen, A
   Tong, SYC
AF Denholm, Justin T.
   Davis, Joshua
   Paterson, David
   Roberts, Jason
   Morpeth, Susan
   Snelling, Thomas
   Zentner, Dominica
   Rees, Megan
   O'Sullivan, Matthew
   Price, David
   Bowen, Asha
   Tong, Steven Y. C.
CA ASCOT Investigator Grp
TI The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in
   hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with
   lopinavir/ritonavir and/or hydroxychloroquine compared to standard of
   care: A structured summary of a study protocol for a randomised
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; hydroxychloroquine;
   lopinavir; ritonavir
AB Objectives: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection.
   Trial design: ASCOT is an investigator-initiated, multi-centre, open-label, randomised controlled trial. Participants will have been hospitalised with confirmed COVID-19, and will be randomised 1:1:1:1 to receive lopinavir/ritonavir, hydroxychloroquine, both or neither drug in addition to standard of care management.
   Participants: Participants will be recruited from >80 hospitals across Australia and New Zealand, representing metropolitan and regional centres in both public and private sectors. Admitted patients will be eligible if aged >= 18 years, have confirmed SARS-CoV-2 by nucleic acid testing in the past 12 days and are expected to remain an inpatient for at least 48 hours from the time of randomisation. Potentially eligible participants will be excluded if admitted to intensive care or requiring high level respiratory support, are currently receiving study drugs or their use is contraindicated due to allergy, drug interaction or comorbidities (including baseline QTc prolongation of 470 ms for women or 480ms for men), or death is anticipated imminently.
   Intervention and comparator:
   Participants will be randomised 1:1:1:1 to:
   Group 1: standard of care;
   Group 2: lopinavir (400mg) / ritonavir (100mg) twice daily for 10 days in tablet form;
   Group 3: hydroxychloroquine (800mg) 4x200mg administered 12 hours apart on Day 1, followed by 400mg twice a day for 6 days;
   Group 4: lopinavir /ritonavir plus hydroxychloroquine.
   Main outcomes: Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation) at 15 days after enrolment. A range of clinical and virological secondary outcomes will also be evaluated.
   Randomisation: The randomisation schedule will be generated by an independent statistician. Randomisation will be stratified by site and will be in permuted blocks of variable block size. The randomised sequence allocation will only be accessible to the data management group, and site investigators will have individual participant allocation provided through a web-based trial enrolment platform.
   Blinding (masking): This is an open-label study, with researchers assessing the laboratory outcomes blinded to treatment allocation. No unblinding procedures relating to potential adverse effects are therefore required.
   Numbers to be randomised (sample size): We assumed that 5% of participants receiving standard of care would meet the primary outcome, aimed to evaluate whether interventions could lead to a relative risk of 0.5, assuming no interaction between intervention arms. This corresponds to a required sample size of 610 per arm, with a 5% two-sided significance level (alpha) and 80% power. The total sample size therefore is planned to be 2440.
   Trial Status: ASCOT protocol version 3, May 5, 2020. Recruitment opened April 4, 2020 and is ongoing, with planned completion of enrolment July 31, 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Denholm, Justin T.; Tong, Steven Y. C.] Royal Melbourne Hosp, Victorian Infect Dis Serv, 792 Elizabeth St, Melbourne, Vic, Australia.
   [Denholm, Justin T.; Tong, Steven Y. C.] Univ Melbourne, Doherty Dept, Peter Doherty Inst Infect & Immun, 792 Elizabeth St, Melbourne, Vic, Australia.
   [Davis, Joshua; Tong, Steven Y. C.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia.
   [Davis, Joshua] John Hunter Hosp, Dept Infect Dis, Newcastle, NSW, Australia.
   [Paterson, David; Roberts, Jason] Univ Queensland, Clin Res Ctr, Fac Med, Brisbane, Qld, Australia.
   [Paterson, David; Roberts, Jason] Univ Queensland, Sch Pharm, Ctr Translat Antiinfect Pharmacodynam, Brisbane, Qld, Australia.
   [Paterson, David] Royal Brisbane & Womens Hosp, Dept Infect Dis, Brisbane, Qld, Australia.
   [Roberts, Jason] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia.
   [Roberts, Jason] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia.
   [Roberts, Jason] Univ Montpellier, Univ Nimes Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France.
   [Morpeth, Susan] Middlemore Hosp, Counties Manukau Dist Hlth Board, Auckland, New Zealand.
   [Snelling, Thomas] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia.
   [Zentner, Dominica] Royal Melbourne Hosp, Dept Cardiol, Melbourne, Vic, Australia.
   [Zentner, Dominica] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   [Rees, Megan] Royal Melbourne Hosp, Dept Resp Med, Melbourne, Vic, Australia.
   [Rees, Megan] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   [O'Sullivan, Matthew] Westmead Hosp, Ctr Infect Dis & Microbiol, Westmead, NSW, Australia.
   [O'Sullivan, Matthew] Univ Sydney, Sydney, NSW, Australia.
   [Price, David] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [Price, David] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Reference Lab, Epidemiol Unit, Melbourne, Vic, Australia.
   [Price, David] Univ Melbourne, Melbourne, Vic, Australia.
   [Bowen, Asha] Telehealth Kids Inst, Perth, WA, Australia.
RP Denholm, JT (corresponding author), Royal Melbourne Hosp, Victorian Infect Dis Serv, 792 Elizabeth St, Melbourne, Vic, Australia.; Denholm, JT (corresponding author), Univ Melbourne, Doherty Dept, Peter Doherty Inst Infect & Immun, 792 Elizabeth St, Melbourne, Vic, Australia.
EM justin.denholm@mh.org.au
RI Snelling, Tom/Y-2162-2019; Tong, Steven/N-2353-2013
OI Snelling, Tom/0000-0003-4670-0638; Tong, Steven/0000-0002-1368-8356;
   Denholm, Justin/0000-0002-9214-6431; Littleford,
   Roberta/0000-0003-4868-0132; Paterson, David/0000-0003-2079-4437;
   Verrall, Ayesha/0000-0001-9672-1352
FU New Zealand by the Health Research Council
FX ASCOT has been initially funded in Australia by a variety of
   philanthropic donors, and in New Zealand by the Health Research Council,
   who have no role in study design, analysis and decision to publish.
NR 0
TC 6
Z9 4
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 14
PY 2020
VL 21
IS 1
AR 646
DI 10.1186/s13063-020-04576-9
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NY9GS
UT WOS:000576693900006
PM 32665040
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lai, KSP
   Watt, C
   Ionson, E
   Baruss, I
   Forchuk, C
   Sukhera, J
   Burhan, AM
   Vasudev, A
AF Lai, Ka Sing Paris
   Watt, Christine
   Ionson, Emily
   Baruss, Imants
   Forchuk, Cheryl
   Sukhera, Javeed
   Burhan, Amer M.
   Vasudev, Akshya
TI Breath Regulation and yogic Exercise An online Therapy for calm and
   Happiness (BREATH) for frontline hospital and long-term care home staff
   managing the COVID-19 pandemic: A structured summary of a study protocol
   for a feasibility study for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Healthcare staff; Work
   stress; resiliency; mind-body intervention; yoga
AB Objectives: Objective 1: To determine if it is feasible to conduct an RCT of online Sudarshan Kriya Yoga (SKY) for frontline hospital and long-term care home staff under the constraints imposed by the COVID-19 pandemic and need for remote trial monitoring.
   Objective 2: To assess whether online versions of SKY and/or Health Enhancement Program (HEP) result in improvement in self-rated measures of insomnia, anxiety, depression, and resilience.
   Trial design: This is an open-label feasibility randomized controlled trial (RCT), comparing an online breath based yogic intervention SKY versus an online control mind-body intervention HEP in frontline hospital and long-term care home staff managing the COVID-19 pandemic.
   Participants: Participants will include frontline hospital and long-term care home staff that are involved in the management of COVID-19 patients in London, Ontario, Canada. Participants will be willing and able to attend via online video conferencing software to participate in the study interventions. Participants must have an adequate understanding of English and be able to sit without physical discomfort for 60 minutes.
   Intervention and comparator: Sudarshan Kriya Yoga (SKY): The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher at all times, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 3 hours. Phase I will consist of 5 self-paced online modules of 410 minutes each to learn the breath control techniques. Participants will be sent an online survey in REDCap requesting that they self-confirm completion of the Phase I modules. In Phase II, 2 interactive online sessions of 1 hour each will be held on consecutive days with a certified SKY teacher, during which participants will learn the fast, medium and slow breaths. For ease of scheduling, multiple time windows will be offered for Phase II. There will be at least one back up teacher at all times. Both Phase I and II will be completed in the first week. Health Enhancement Program (HEP): The active control arm, HEP, will consist of time-matched online self-paced modules for Phase I. Phase II will consist of mindfulness-based meditation sessions delivered by mental health staff. HEP will be an active treatment program that incorporates mind-body interventions. HEP will consist of time-matched online self-paced modules with psychoeducation on healthy active living as well as interactive modules comprising of guided de-stressing exercises including music therapy, mindfulness and progressive muscle relaxation. Weekly follow up sessions will be offered to all recruited participants for 30 minutes each for the subsequent 4 weeks in both study arms.
   Main outcomes: The following feasibility outcomes will be measured at the end of the study: (1) rate of participant recruitment, (2) rate of retention, (3) completeness of data entry, (4) cost of interventions, and (5) unexpected costs. Such measures will be collected on a daily basis through-out the study and tabulated 5 weeks later at the end of the study.
   Randomisation: Participants will be randomized after they have electronically signed the consent form and the research staff have confirmed eligibility. We will use REDCap to perform randomization in a 1:1 ratio as well as allocation concealment. REDCap is widely used by health researchers worldwide to significantly reduce data entry and study management errors to improve data fidelity.
   Blinding (masking): All study participants will be blinded to the study hypotheses so as to prevent any expectation bias. Group allocation will be masked during analysis.
   Numbers to be randomised (sample size): This study will randomize a total of 60 participants in a 1:1 ratio to either SKY or HEP interventions.
   Trial Status: Protocol version number 2.0 (June 5, 2020). Recruitment is currently ongoing (starting June 25, 2020). We anticipate to complete recruitment by June 30, 2021 and complete the study by September 30, 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Lai, Ka Sing Paris; Forchuk, Cheryl; Sukhera, Javeed; Burhan, Amer M.; Vasudev, Akshya] Western Univ, Dept Psychiat, 1151 Richmond St, London, ON N6A 3K7, Canada.
   [Watt, Christine; Ionson, Emily] Parkwood Inst Mental Hlth, Dept Psychiat, 550 Wellington Rd, London, ON N6C 5J1, Canada.
   [Baruss, Imants] Western Univ, Kings Univ Coll, Dept Psychol, 266 Epworth Ave, London, ON N6A 2M3, Canada.
RP Vasudev, A (corresponding author), Western Univ, Dept Psychiat, 1151 Richmond St, London, ON N6A 3K7, Canada.
EM akshya.vasudev@lhsc.on.ca
FU Western University
FX This study is funded by start up funds from Western University. There is
   no relationship between the funding body in the design of the study,
   collection, analysis, interpretation of data or in writing the
   manuscript.
NR 0
TC 0
Z9 0
U1 10
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 14
PY 2020
VL 21
IS 1
AR 648
DI 10.1186/s13063-020-04583-w
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NY9GS
UT WOS:000576693900008
PM 32665041
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, YQ
   Tang, SQ
   Xu, XL
   Zeng, YM
   He, XQ
   Li, Y
   Harypursat, V
   Lu, YQ
   Wan, Y
   Zhang, L
   Sun, QZ
   Sun, NN
   Wang, GX
   Yang, ZP
   Chen, YK
AF Huang, Yin-Qiu
   Tang, Sheng-Quan
   Xu, Xiao-Lei
   Zeng, Yan-Ming
   He, Xiao-Qing
   Li, Yao
   Harypursat, Vijay
   Lu, Yan-Qiu
   Wan, Yan
   Zhang, Lu
   Sun, Qiang-Zhong
   Sun, Nan-Nan
   Wang, Gui-Xue
   Yang, Zhong-Ping
   Chen, Yao-Kai
TI No Statistically Apparent Difference in Antiviral Effectiveness Observed
   Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus
   Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus
   Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease
   2019: Results of a Randomized, Open-Labeled Prospective Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE ribavirin; interferon-alpha; lopinavir; ritonavir; mild to moderate
   COVID-19; effectiveness and safety
ID RESPIRATORY SYNDROME; SARS; REPLICATION; INFECTION
AB Background Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiviral treatment regimens in patients with mild to moderate COVID-19. Methods This was a single-center, randomized, open-labeled, prospective clinical trial. Eligible patients with mild to moderate COVID-19 were randomized into three groups: ribavirin (RBV) plus interferon-alpha (IFN-alpha), lopinavir/ritonavir (LPV/r) plus IFN-alpha, and RBV plus LPV/r plus IFN-alpha at a 1:1:1 ratio. Each patient was invited to participate in a 28-d follow-up after initiation of an antiviral regimen. The outcomes include the difference in median interval to SARS-CoV-2 nucleic acid negativity, the proportion of patients with SARS-CoV-2 nucleic acid negativity at day 14, the mortality at day 28, the proportion of patients re-classified as severe cases, and adverse events during the study period. Results In total, we enrolled 101 patients in this study. Baseline clinical and laboratory characteristics of patients were comparable among the three groups. In the analysis of intention-to-treat data, the median interval from baseline to SARS-CoV-2 nucleic acid negativity was 12 d in the LPV/r+IFN-alpha-treated group, as compared with 13 and 15 d in the RBV+IFN-alpha-treated group and in the RBV+LPV/r+ IFN-alpha-treated group, respectively (p=0.23). The proportion of patients with SARS-CoV-2 nucleic acid negativity in the LPV/r+IFN-alpha-treated group (61.1%) was higher than the RBV+ IFN-alpha-treated group (51.5%) and the RBV+LPV/r+IFN-alpha-treated group (46.9%) at day 14; however, the difference between these groups was calculated to be statistically insignificant. The RBV+LPV/r+IFN-alpha-treated group developed a significantly higher incidence of gastrointestinal adverse events than the LPV/r+ IFN-alpha-treated group and the RBV+ IFN-alpha-treated group. Conclusions Our results indicate that there are no significant differences among the three regimens in terms of antiviral effectiveness in patients with mild to moderate COVID-19. Furthermore, the combination of RBV and LPV/r is associated with a significant increase in gastrointestinal adverse events, suggesting that RBV and LPV/r should not be co-administered to COVID-19 patients simultaneously.
C1 [Huang, Yin-Qiu; Yang, Zhong-Ping; Chen, Yao-Kai] Chongqing Publ Hlth Med Ctr, Natl Key Lab Infect Dis Prevent & Treatment Tradi, Chongqing, Peoples R China.
   [Tang, Sheng-Quan; Xu, Xiao-Lei; Zeng, Yan-Ming; He, Xiao-Qing; Li, Yao; Harypursat, Vijay; Lu, Yan-Qiu; Wan, Yan; Zhang, Lu; Chen, Yao-Kai] Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China.
   [Sun, Qiang-Zhong; Sun, Nan-Nan] Chongqing Publ Hlth Med Ctr, Div TB, Chongqing, Peoples R China.
   [Wang, Gui-Xue] Chongqing Univ, Sch Biol Engn, Chongqing, Peoples R China.
RP Yang, ZP; Chen, YK (corresponding author), Chongqing Publ Hlth Med Ctr, Natl Key Lab Infect Dis Prevent & Treatment Tradi, Chongqing, Peoples R China.; Chen, YK (corresponding author), Chongqing Publ Hlth Med Ctr, Div Infect Dis, Chongqing, Peoples R China.
EM 1046580277@qq.com; yaokaichen@hotmail.com
FU National Science and Technology Major Project of China During the 13th
   Five-year Plan Period [2018ZX10302104]; Chongqing Special Research
   Project for Prevention and Control of Novel Coronavirus Pneumonia
   [cstc2020jscx-fyzX0005]; Novel Coronavirus Infection and Prevention
   Emergency Research Project of Chongqing Municipal Education Commission
   [KYYJ202001]
FX We thank staff of Chongqing Public Health Medical Center, for the
   clinical care given to the patients and for facilitating access to the
   relevant medical records. This work was supported by the National
   Science and Technology Major Project of China During the 13th Five-year
   Plan Period (2018ZX10302104); and the Chongqing Special Research Project
   for Prevention and Control of Novel Coronavirus Pneumonia (No.
   cstc2020jscx-fyzX0005); and the Novel Coronavirus Infection and
   Prevention Emergency Research Project of Chongqing Municipal Education
   Commission (KYYJ202001).
CR Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Knowles SR, 2003, CLIN INFECT DIS, V37, P1139, DOI 10.1086/378304
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu J.H, 2013, UNDERGROUND ENG TUNN, V1, P1, DOI DOI 10.3870/yydb.2013.01.001
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Tong J., 1994, MED IMMUNOLOGY MICRO, P178
   Wang E, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.102
   Wang X., 2019, INT J PHARM RES, V6, P456, DOI [10.13220/j.cnki.jipr.2019.06.008, DOI 10.13220/J.CNKI.JIPR.2019.06.008]
   WHO, 2020, GUID CLIN MAN SEV AC
   Yang C., 2015, INT J RADIOL NUCL ME, V39, P191, DOI [10.3760/cma.j.issn.1673-4114.2015.03.001, DOI 10.3760/CMA.J.ISSN.1673-4114.2015.03.001]
   Yeh MF, 2019, INT CONF MACH LEARN, P326
   Zeng YM, 2020, CHINESE MED J-PEKING, V133, P1132, DOI 10.1097/CM9.0000000000000790
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 3
Z9 3
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 14
PY 2020
VL 11
AR 1071
DI 10.3389/fphar.2020.01071
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MW1VO
UT WOS:000556833800001
PM 32765274
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Geller, A
   Yan, J
AF Geller, Anne
   Yan, Jun
TI Could the Induction of Trained Immunity by beta-Glucan Serve as a
   Defense Against COVID-19?
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; trained immunity; beta-glucan; innate immunity
ID T-CELL RESPONSES; DENDRITIC CELLS; CANDIDA-ALBICANS; INFLUENZA-VIRUS;
   CYTOKINE STORM; YEAST (1,3)-(1,6)-BETA-GLUCAN; INTERFERON-GAMMA;
   LOW-VIRULENCE; HOST-DEFENSE; DOUBLE-BLIND
AB As the SARS-CoV-2 virus wreaks havoc on the populations, health care infrastructures and economies of nations around the world, finding ways to protect health care workers and bolster immune responses in the general population while we await an effective vaccine will be the difference between life and death for many people. Recent studies show that innate immune populations may possess a form of memory, termed Trained Immunity (TRIM), where innate immune cells undergo metabolic, mitochondrial, and epigenetic reprogramming following exposure to an initial stimulus that results in a memory phenotype of enhanced immune responses when exposed to a secondary, heterologous, stimulus. Throughout the literature, it has been shown that the induction of TRIM using such inducers as the BCG vaccine and beta-glucan can provide protection through altered immune responses against a range of viral infections. Here we hypothesize a potential role for beta-glucan in decreasing worldwide morbidity and mortality due to COVID-19, and posit several ideas as to how TRIM may actually shape the observed epidemiological phenomena related to COVID-19. We also evaluate the potential effects of beta-glucan in relation to the immune dysregulation and cytokine storm observed in COVID-19. Ultimately, we hypothesize that the use of oral beta-glucan in a prophylactic setting could be an effective way to boost immune responses and abrogate symptoms in COVID-19, though clinical trials are necessary to confirm the efficacy of this treatment and to further examine differential effects of beta-glucan's from various sources.
C1 [Geller, Anne] Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA.
   [Geller, Anne; Yan, Jun] Univ Louisville, Sch Med, Dept Surg, Div Immunotherapy,Immunooncol Program,James Graha, Louisville, KY 40292 USA.
RP Yan, J (corresponding author), Univ Louisville, Sch Med, Dept Surg, Div Immunotherapy,Immunooncol Program,James Graha, Louisville, KY 40292 USA.
EM jun.yan@louisville.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01CA163223, R01CA213990]
FX NIH R01CA213990 and NIH P01CA163223: Both grants supported primary
   research efforts during the writing of this review paper and the
   research conducted from the support of these grants led to first-hand
   knowledge about the subject matter of the review.
CR AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481
   Agrawal S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013418
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Ashraf U, 2016, J GEN VIROL, V97, P1037, DOI 10.1099/jgv.0.000436
   Auinger A, 2013, EUR J NUTR, V52, P1913, DOI 10.1007/s00394-013-0492-z
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Batbayar S, 2012, BIOMOL THER, V20, P433, DOI 10.4062/biomolther.2012.20.5.433
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   BISTONI F, 1988, J MED VET MYCOL, V26, P285
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Brayden DJ, 2005, DRUG DISCOV TODAY, V10, P1145, DOI 10.1016/S1359-6446(05)03536-1
   Caruso C, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-20
   Chan ASH, 2014, J IMMUNOTHER CANC S3, V2, pP191, DOI DOI 10.1186/2051-1426-2-S3-P191
   Chan GCF, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-25
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chaung HC, 2009, VET IMMUNOL IMMUNOP, V131, P147, DOI 10.1016/j.vetimm.2009.04.004
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen X, 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.2002952032301997, DOI 10.1101/2020.02.29.2002952032301997]
   Chen XY, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620926800
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
   Cramer DE, 2008, STEM CELLS, V26, P1231, DOI 10.1634/stemcells.2007-0712
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   de Graaff P, 2018, EXPERT OPIN BIOL TH, V18, P1023, DOI 10.1080/14712598.2018.1523392
   Denney L, 2018, BIOMED J, V41, P218, DOI 10.1016/j.bj.2018.08.004
   Dharsono T, 2019, J AM COLL NUTR, V38, P40, DOI 10.1080/07315724.2018.1478339
   DILUZIO NR, 1978, INFECT IMMUN, V20, P804, DOI 10.1128/IAI.20.3.804-810.1978
   Dominguez-Andres J, 2019, CELL METAB, V29, P211, DOI 10.1016/j.cmet.2018.09.003
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   dos Santos JC, 2019, CELL REP, V28, P2659, DOI 10.1016/j.celrep.2019.08.004
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Elder MJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00791
   Fanucchi S, 2019, NAT GENET, V51, P138, DOI 10.1038/s41588-018-0298-2
   Flajnik MF, 2018, NAT REV IMMUNOL, V18, P438, DOI 10.1038/s41577-018-0003-9
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Fuller R, 2017, NUTRITION, V39-40, P30, DOI 10.1016/j.nut.2017.03.003
   Geller A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153618
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gong J., 2020, CORRELATION ANAL DIS, DOI [10.1101/2020.02.25.20025643, DOI 10.1101/2020.02.25.20025643]
   Graubaum H. J., 2012, Food and Nutrition Sciences, V3, P738, DOI 10.4236/fns.2012.36100
   Hassanzadeh-Kiabi N, 2017, J IMMUNOL, V198, P375, DOI 10.4049/jimmunol.1601143
   Hegarty PK, 2020, EUR UROL ONCOL, V3, P259, DOI 10.1016/j.euo.2020.04.001
   Hole CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10486-5
   Hornick P, 1997, NEPHROL DIAL TRANSPL, V12, P1806, DOI 10.1093/ndt/12.9.1806
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Ishikawa H, 2016, VIROLOGY, V499, P23, DOI 10.1016/j.virol.2016.08.025
   Jesenak M, 2013, INT IMMUNOPHARMACOL, V15, P395, DOI 10.1016/j.intimp.2012.11.020
   Ji T, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa39032255183, DOI 10.1093/CID/CIAA39032255183]
   Jung K, 2004, J VET MED B, V51, P72, DOI 10.1111/j.1439-0450.2004.00732.x
   Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225
   Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019
   Keating ST, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107548
   Kim HS, 2011, IMMUNE NETW, V11, P191, DOI DOI 10.4110/IN.2011.11.4.191
   Kindler E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006195
   Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005
   KRAHENBUHL JL, 1981, INFECT IMMUN, V31, P716, DOI 10.1128/IAI.31.2.716-722.1981
   Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Leonhardt J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02818
   Li B, 2010, CLIN CANCER RES, V16, P5153, DOI 10.1158/1078-0432.CCR-10-0820
   Li MD, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0165-8
   Liao M., 2020, LANDSCAPE LUNG BRONC, P23, DOI [10.1101/2020.02.23.20026690, DOI 10.1101/2020.02.23.20026690]
   Lokugamage KG, 2020, BIORXIV, DOI [10.1101/2020.03.07.98226432511335, DOI 10.1101/2020.03.07.98226432511335]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Medina-Gali RM, 2018, DEV COMP IMMUNOL, V84, P307, DOI 10.1016/j.dci.2018.02.019
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MEO SA, 2020, J KING SAUD UNIV SCI, V32, P2495, DOI DOI 10.1016/J.JKSUS.2020.04.00432292261
   Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Mills EL, 2018, NATURE, V556, P113, DOI [10.1038/nature25986, 10.1038/s41586-018-0353-2]
   Mitroulis I, 2018, CELL, V172, P147, DOI 10.1016/j.cell.2017.11.034
   Murphy EA, 2012, J INTERF CYTOK RES, V32, P362, DOI 10.1089/jir.2011.0067
   Naeslund C., 1931, REV TUBERC, V12, P617
   Nainu F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01220
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Petit J, 2019, J IMMUNOL, V203, P216, DOI 10.4049/jimmunol.1900137
   Pietras EM, 2015, CELL STEM CELL, V17, P35, DOI 10.1016/j.stem.2015.05.003
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Purvis A, 2000, NATURE, V405, P212, DOI 10.1038/35012221
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Quinn KM, 2018, CELL REP, V23, P3512, DOI 10.1016/j.celrep.2018.05.057
   Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006
   Ren K, 2016, J VIROL, V90, P7313, DOI 10.1128/JVI.00563-16
   Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373
   Ribes S, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-14
   Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086
   SAKURAI T, 1992, INT J IMMUNOPHARMACO, V14, P821, DOI 10.1016/0192-0561(92)90080-5
   Sandvik A, 2007, CLIN EXP IMMUNOL, V148, P168, DOI 10.1111/j.1365-2249.2006.03320.x
   Talbott SM, 2012, J AM COLL NUTR, V31, P295, DOI 10.1080/07315724.2012.10720441
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Toida Ichiro, 2007, Kekkaku, V82, P809
   TRIBOULEY J, 1978, CR SOC BIOL, V172, P902
   Turnbull FM, 2002, CLIN INFECT DIS, V34, P447, DOI 10.1086/338462
   van der Meer JWM, 2015, MOL IMMUNOL, V68, P40, DOI 10.1016/j.molimm.2015.06.019
   VANTWOUT JW, 1992, SCAND J IMMUNOL, V36, P713
   VECCHIARELLI A, 1989, CELL IMMUNOL, V124, P334, DOI 10.1016/0008-8749(89)90135-4
   Vetvicka V, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.08
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xie JG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164792
   Yao Y, 2018, CELL, V175, DOI 10.1016/j.cell.2018.09.04230433869
   Yu XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123559
   Yun CH, 2003, FEMS IMMUNOL MED MIC, V35, P67, DOI 10.1016/S0928-8244(02)00460-1
   Zhang BY, 2014, SCIENCE, V346, P861, DOI 10.1126/science.1256999
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 111
TC 3
Z9 3
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 14
PY 2020
VL 11
AR 1782
DI 10.3389/fimmu.2020.01782
PG 11
WC Immunology
SC Immunology
GA MV8DM
UT WOS:000556581400001
PM 32760409
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Harapan, H
   Wagner, AL
   Yufika, A
   Winardi, W
   Anwar, S
   Gan, AK
   Setiawan, AM
   Rajamoorthy, Y
   Sofyan, H
   Mudatsir, M
AF Harapan, Harapan
   Wagner, Abram L.
   Yufika, Amanda
   Winardi, Wira
   Anwar, Samsul
   Gan, Alex Kurniawan
   Setiawan, Abdul Malik
   Rajamoorthy, Yogambigai
   Sofyan, Hizir
   Mudatsir, Mudatsir
TI Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional
   Study in Indonesia
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; SARS-CoV-2; vaccine; vaccination; acceptance
ID INFLUENZA VACCINES; DENGUE VACCINE; COMMUNITY
AB Introduction:Several vaccine candidates are being clinically tested in response to the 2019 coronavirus disease (COVID-19) pandemic. This study was conducted to assess the acceptance of a 50 or 95% effective COVID-19 vaccine, when it becomes available in southeast Asia, among the general population in Indonesia. Methods:A cross-sectional online survey was conducted between March 25 and April 6, 2020. Participants were asked if they would accept a free vaccine which was 95 or 50% effective. Using a logistic regression model, we assessed the associations between sociodemographic characteristics, exposure to COVID-19 information, or perceived risk of infection with acceptance of a hypothetical COVID-19 vaccine. Results:Among 1,359 respondents, 93.3% of respondents (1,268/1,359) would like to be vaccinated for a 95% effective vaccine, but this acceptance decreased to 67.0% (911/1,359) for a vaccine with 50% effectiveness. For a 95% effective vaccine, being a healthcare worker and having a higher perceived risk of COVID-19 infection were associated with higher acceptance, adjusted odds ratio (aOR): 2.01; 95%CI: 1.01, 4.00 and aOR: 2.21; 95%CI: 1.07, 4.59, respectively; compared to civil servants, being retired was associated with less acceptance (aOR: 0.15; 95%CI: 0.04, 0.63). For a 50% effective vaccine, being a healthcare worker was also associated with greater acceptance, aOR: 1.57; 95%CI: 1.12, 2.20. Conclusion:Acceptance of a COVID-19 vaccine was highly influenced by the baseline effectiveness of the vaccine. Preparing the general population to accept a vaccine with relatively low effectiveness may be difficult.
C1 [Harapan, Harapan; Gan, Alex Kurniawan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Trop Dis Ctr, Sch Med, Banda Aceh, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh, Indonesia.
   [Wagner, Abram L.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Yufika, Amanda] Univ Syiah Kuala, Sch Med, Dept Family Med, Banda Aceh, Indonesia.
   [Winardi, Wira] Univ Syiah Kuala, Sch Med, Dept Pulmonol & Resp Med, Banda Aceh, Indonesia.
   [Anwar, Samsul; Sofyan, Hizir] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Stat, Banda Aceh, Indonesia.
   [Setiawan, Abdul Malik] Maulana Malik Ibrah State Islamic Univ Malang, Fac Med & Hlth Sci, Dept Microbiol, Malang, Indonesia.
   [Rajamoorthy, Yogambigai] Univ Tunku Abdul Rahman, Fac Accountancy & Management, Dept Econ, Cheras, Malaysia.
RP Harapan, H (corresponding author), Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh, Indonesia.; Harapan, H (corresponding author), Univ Syiah Kuala, Trop Dis Ctr, Sch Med, Banda Aceh, Indonesia.; Harapan, H (corresponding author), Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh, Indonesia.
EM harapan@unsyiah.ac.id
OI Sofyan, Hizir/0000-0002-0763-5610
CR Bhutta ZA, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1190
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC, 2020, INNL PAST SEAS VACC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chhetri JK, 2020, J NUTR HEALTH AGING, V24, P471, DOI 10.1007/s12603-020-1359-7
   D'souza G, EARLY HERD IMMUNITY
   Fu C, 2020, ACCEPTANCE PREFERENC, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103]
   Gidengil CA, 2012, AM J PUBLIC HEALTH, V102, P672, DOI 10.2105/AJPH.2011.300407
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hadisoemarto PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002427
   Harapan H., 2017, Asian Pacific Journal of Tropical Disease, V7, P193, DOI 10.12980/apjtd.7.2017D6-386
   Harapan H, 2020, ACTA TROP, V206, DOI 10.1016/j.actatropica.2020.105450
   Harapan H, 2020, PATHOG GLOB HEALTH, V114, P68, DOI 10.1080/20477724.2020.1743037
   Harapan H, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4297-4
   Harapan H, 2019, CLIN EPIDEMIOL GLOB, V7, P261, DOI 10.1016/j.cegh.2018.03.007
   Harapan H, 2019, VACCINE, V37, P1398, DOI 10.1016/j.vaccine.2019.01.062
   Harapan H, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3006-z
   Harapan H, 2017, ACTA TROP, V166, P249, DOI 10.1016/j.actatropica.2016.11.035
   Harapan H, 2016, VACCINE, V34, P3670, DOI 10.1016/j.vaccine.2016.05.026
   Harapana H, 2020, CLIN EPIDEMIOL GLOB, V8, P1259, DOI 10.1016/j.cegh.2020.04.024
   Indonesia UNESCO, 2014, COUNTR PROGR DOC 201
   Klonoff EA, 1997, WOMEN HLTH RES GENDE, V3
   Lee JS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003810
   Lim WS, 2020, GERIATR GERONTOL INT, V20, P547, DOI 10.1111/ggi.13939
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ministry of Health, 2020, INF KHUS COVID 19
   Mudatsir Mudatsir, 2019, F1000Res, V8, P1441, DOI 10.12688/f1000research.20144.2
   NICHTER M, 1995, SOC SCI MED, V41, P617, DOI 10.1016/0277-9536(95)00034-5
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Padhi BK, 2020, DETERMINANTS COVID 1, DOI [10.1101/2020.05.27.20114413, DOI 10.1101/2020.05.27.20114413]
   Rajamoorthy Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215125
   Rajamoorthy Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208402
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sun XD, 2020, VACCINE, V38, P1520, DOI 10.1016/j.vaccine.2019.11.062
   Sundaram N, 2015, HUM VACC IMMUNOTHER, V11, P2376, DOI 10.1080/21645515.2015.1062956
   Syiroj ATR, 2019, VACCINE, V37, P6486, DOI 10.1016/j.vaccine.2019.08.081
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Nguyen TTM, 2020, VACCINE, V38, P2045, DOI 10.1016/j.vaccine.2019.12.047
   Vo TQ, 2018, PATIENT PREFER ADHER, V12, P2507, DOI 10.2147/PPA.S188581
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wagner AL, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0900-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yeo HY, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0163-2
   Yufika A, 2020, VACCINE, V38, P2592, DOI 10.1016/j.vaccine.2020.01.072
   Zhao X., INCIDENCE CLIN CHARA, DOI [10.1101/2020.03.17.20037572, DOI 10.1101/2020.03.17.20037572]
NR 47
TC 3
Z9 3
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUL 14
PY 2020
VL 8
AR 381
DI 10.3389/fpubh.2020.00381
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MV7ZP
UT WOS:000556571300001
PM 32760691
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fosbol, EL
   Butt, JH
   Ostergaard, L
   Andersson, C
   Selmer, C
   Kragholm, K
   Schou, M
   Phelps, M
   Gislason, GH
   Gerds, TA
   Torp-Pedersen, C
   Kober, L
AF Fosbol, Emil L.
   Butt, Jawad H.
   ostergaard, Lauge
   Andersson, Charlotte
   Selmer, Christian
   Kragholm, Kristian
   Schou, Morten
   Phelps, Matthew
   Gislason, Gunnar H.
   Gerds, Thomas A.
   Torp-Pedersen, Christian
   Kober, Lars
TI Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin
   Receptor Blocker Use With COVID-19 Diagnosis and Mortality
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID VENTRICULAR DYSFUNCTION; FUNCTIONAL RECEPTOR; HEART-FAILURE; MODULATION;
   SYSTEM; TRIAL; ACE2
AB Importance It has been hypothesized that angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) may make patients more susceptible to coronavirus disease 2019 (COVID-19) and to worse outcomes through upregulation of the functional receptor of the virus, angiotensin-converting enzyme 2.
   Objective To examine whether use of ACEI/ARBs was associated with COVID-19 diagnosis and worse outcomes in patients with COVID-19.
   Design, Setting, and Participants To examine outcomes among patients with COVID-19, a retrospective cohort study using data from Danish national administrative registries was conducted. Patients with COVID-19 from February 22 to May 4, 2020, were identified using ICD-10 codes and followed up from day of diagnosis to outcome or end of study period (May 4, 2020). To examine susceptibility to COVID-19, a Cox regression model with a nested case-control framework was used to examine the association between use of ACEI/ARBs vs other antihypertensive drugs and the incidence rate of a COVID-19 diagnosis in a cohort of patients with hypertension from February 1 to May 4, 2020.
   Exposures ACEI/ARB use was defined as prescription fillings 6 months prior to the index date.
   Main Outcomes and Measures In the retrospective cohort study, the primary outcome was death, and a secondary outcome was a composite outcome of death or severe COVID-19. In the nested case-control susceptibility analysis, the outcome was COVID-19 diagnosis.
   Results In the retrospective cohort study, 4480 patients with COVID-19 were included (median age, 54.7 years [interquartile range, 40.9-72.0]; 47.9% men). There were 895 users (20.0%) of ACEI/ARBs and 3585 nonusers (80.0%). In the ACEI/ARB group, 18.1% died within 30 days vs 7.3% in the nonuser group, but this association was not significant after adjustment for age, sex, and medical history (adjusted hazard ratio [HR], 0.83 [95% CI, 0.67-1.03]). Death or severe COVID-19 occurred in 31.9% of ACEI/ARB users vs 14.2% of nonusers by 30 days (adjusted HR, 1.04 [95% CI, 0.89-1.23]). In the nested case-control analysis of COVID-19 susceptibility, 571 patients with COVID-19 and prior hypertension (median age, 73.9 years; 54.3% men) were compared with 5710 age- and sex-matched controls with prior hypertension but not COVID-19. Among those with COVID-19, 86.5% used ACEI/ARBs vs 85.4% of controls; ACEI/ARB use compared with other antihypertensive drugs was not significantly associated with higher incidence of COVID-19 (adjusted HR, 1.05 [95% CI, 0.80-1.36]).
   Conclusions and Relevance Prior use of ACEI/ARBs was not significantly associated with COVID-19 diagnosis among patients with hypertension or with mortality or severe disease among patients diagnosed as having COVID-19. These findings do not support discontinuation of ACEI/ARB medications that are clinically indicated in the context of the COVID-19 pandemic.
C1 [Fosbol, Emil L.; Butt, Jawad H.; ostergaard, Lauge; Kober, Lars] Univ Hosp Copenhagen, Rigshosp, Ctr Heart, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
   [Andersson, Charlotte] Boston Univ, Sch Med, Dept Med, Sect Cardiovasc Med,Boston Med Ctr, Boston, MA 02118 USA.
   [Selmer, Christian] Bispebjerg & Frederiksberg Hosp, Dept Endocrinol, Copenhagen, Denmark.
   [Kragholm, Kristian] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark.
   [Schou, Morten; Gislason, Gunnar H.] Copenhagen Univ Hosp Herlev & Gentofte, Dept Cardiol, Hellerup, Denmark.
   [Phelps, Matthew; Gislason, Gunnar H.; Gerds, Thomas A.] Danish Heart Fdn, Dept Cardiovasc Epidemiol & Res, Copenhagen, Denmark.
   [Torp-Pedersen, Christian] Hillerod Hosp, Dept Clin Epidemiol, Hillerod, Denmark.
   [Torp-Pedersen, Christian] Hillerod Hosp, Dept Cardiol, Hillerod, Denmark.
RP Fosbol, EL (corresponding author), Univ Hosp Copenhagen, Rigshosp, Ctr Heart, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
EM elf@heart.dk
OI Butt, Jawad Haider/0000-0002-7380-4144; Phelps, Matthew
   David/0000-0003-0344-2026; Kober, Lars/0000-0002-6635-1466
CR Borgan O, 2013, HDB SURVIVAL ANAL
   Bozkurt B, 2020, HARRINGTON R HFSA AC
   Burchill LJ, 2012, CLIN SCI, V123, P649, DOI 10.1042/CS20120162
   Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Group CS., 1987, NEW ENGL J MED, V316, P1429, DOI DOI 10.1056/NEJM198706043162301
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halliday BP, 2019, LANCET, V393, P61, DOI 10.1016/S0140-6736(18)32484-X
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503
   Lakshmanan AP, 2012, MOL CELL ENDOCRINOL, V348, P104, DOI 10.1016/j.mce.2011.07.041
   Li J, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1624, DOI 10.1001/JAMACARDIO.2020.162432324209]
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta N, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1855, DOI 10.1001/JAMACARDIO.2020.185532369097]
   Messerli FH, 2020, CIRCULATION, V141, P2042, DOI 10.1161/CIRCULATIONAHA.120.047022
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   Olesen JB, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d124
   Ozenne BMH, 2020, BIOMETRICAL J, V62, P751, DOI 10.1002/bimj.201800298
   PFLUGFELDER PW, 1993, J AM COLL CARDIOL, V22, P1557, DOI 10.1016/0735-1097(93)90578-O
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Schmidt M, 2019, CLIN EPIDEMIOL, V11, P563, DOI 10.2147/CLEP.S179083
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Sukumaran V, 2012, FREE RADICAL RES, V46, P850, DOI 10.3109/10715762.2012.684878
   Sukumaran V, 2012, MOL CELL ENDOCRINOL, V351, P208, DOI 10.1016/j.mce.2011.12.010
   Sundboll J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012832
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Zhong JC, 2011, REGUL PEPTIDES, V166, P90, DOI 10.1016/j.regpep.2010.09.005
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 68
Z9 68
U1 4
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 14
PY 2020
VL 324
IS 2
BP 168
EP 177
DI 10.1001/jama.2020.11301
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA MQ8RW
UT WOS:000553161000021
PM 32558877
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Imai, M
   Iwatsuki-Horimoto, K
   Hatta, M
   Loeber, S
   Halfmann, PJ
   Nakajima, N
   Watanabe, T
   Ujie, M
   Takahashi, K
   Ito, M
   Yamada, S
   Fan, SF
   Chiba, S
   Kuroda, M
   Guan, LZ
   Takada, K
   Armbrust, T
   Balogh, A
   Furusawa, Y
   Okuda, M
   Ueki, H
   Yasuhara, A
   Sakai-Tagawa, Y
   Lopes, TJS
   Kiso, M
   Yamayoshi, S
   Kinoshita, N
   Ohmagari, N
   Hattori, S
   Takeda, M
   Mitsuya, H
   Krammer, F
   Suzuki, T
   Kawaoka, Y
AF Imai, Masaki
   Iwatsuki-Horimoto, Kiyoko
   Hatta, Masato
   Loeber, Samantha
   Halfmann, Peter J.
   Nakajima, Noriko
   Watanabe, Tokiko
   Ujie, Michiko
   Takahashi, Kenta
   Ito, Mutsumi
   Yamada, Shinya
   Fan, Shufang
   Chiba, Shiho
   Kuroda, Makoto
   Guan, Lizheng
   Takada, Kosuke
   Armbrust, Tammy
   Balogh, Aaron
   Furusawa, Yuri
   Okuda, Moe
   Ueki, Hiroshi
   Yasuhara, Atsuhiro
   Sakai-Tagawa, Yuko
   Lopes, Tiago J. S.
   Kiso, Maki
   Yamayoshi, Seiya
   Kinoshita, Noriko
   Ohmagari, Norio
   Hattori, Shin-ichiro
   Takeda, Makoto
   Mitsuya, Hiroaki
   Krammer, Florian
   Suzuki, Tadaki
   Kawaoka, Yoshihiro
TI Syrian hamsters as a small animal model for SARS-CoV-2 infection and
   countermeasure development
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Syrian hamsters; SARS-CoV-2; infection; countermeasure
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS; REPLICATION; COVID-19; ACE2
AB At the end of 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was detected in Wuhan, China, that spread rapidly around the world, with severe conse-quences for human health and the global economy. Here, we assessed the replicative ability and pathogenesis of SARS-CoV-2 isolates in Syrian hamsters. SARS-CoV-2 isolates replicated effi-ciently in the lungs of hamsters, causing severe pathological lung lesions following intranasal infection. In addition, microcomputed tomographic imaging revealed severe lung injury that shared char-acteristics with SARS-CoV-2-infected human lung, including severe, bilateral, peripherally distributed, multilobular ground glass opacity, and regions of lung consolidation. SARS-CoV-2-infected hamsters mounted neutralizing antibody responses and were protected against subsequent rechallenge with SARS-CoV-2. Moreover, passive transfer of convalescent serum to naive hamsters efficiently suppressed the replication of the virus in the lungs even when the serum was admin-istrated 2 d postinfection of the serum-treated hamsters. Collectively, these findings demonstrate that this Syrian hamster model will be useful for understanding SARS-CoV-2 pathogenesis and testing vaccines and antiviral drugs.
C1 [Imai, Masaki; Iwatsuki-Horimoto, Kiyoko; Watanabe, Tokiko; Ujie, Michiko; Ito, Mutsumi; Yamada, Shinya; Takada, Kosuke; Furusawa, Yuri; Okuda, Moe; Ueki, Hiroshi; Yasuhara, Atsuhiro; Sakai-Tagawa, Yuko; Lopes, Tiago J. S.; Kiso, Maki; Yamayoshi, Seiya; Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan.
   [Hatta, Masato; Halfmann, Peter J.; Fan, Shufang; Chiba, Shiho; Kuroda, Makoto; Guan, Lizheng; Armbrust, Tammy; Balogh, Aaron; Lopes, Tiago J. S.; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Influenza Res Inst, Dept Pathobiol Sci, Madison, WI 53711 USA.
   [Loeber, Samantha] Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA.
   [Nakajima, Noriko; Takahashi, Kenta; Suzuki, Tadaki] Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan.
   [Kinoshita, Noriko; Ohmagari, Norio; Hattori, Shin-ichiro; Mitsuya, Hiroaki] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo 1628655, Japan.
   [Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, Tokyo 2080011, Japan.
   [Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Kawaoka, Yoshihiro] Univ Tokyo, Int Res Ctr Infect Dis, Inst Med Sci, Dept Special Pathogens, Tokyo 1088639, Japan.
RP Kawaoka, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan.; Kawaoka, Y (corresponding author), Univ Wisconsin, Sch Vet Med, Influenza Res Inst, Dept Pathobiol Sci, Madison, WI 53711 USA.; Kawaoka, Y (corresponding author), Univ Tokyo, Int Res Ctr Infect Dis, Inst Med Sci, Dept Special Pathogens, Tokyo 1088639, Japan.
EM yoshihiro.kawaoka@wisc.edu
RI Suzuki, Tadaki/ABH-2661-2020; Krammer, Florian/H-3237-2019; Takeda,
   Makoto/J-2550-2018
OI Krammer, Florian/0000-0003-4121-776X; Takeda,
   Makoto/0000-0002-8194-7727; Loeber, Samantha/0000-0003-4921-2357
FU Research Program on Emerging and Reemerging Infectious Diseases
   [JP19fk0108112, JP19fk0108113, JP19fk0108166]; Project Promoting Support
   for Drug Discovery [JP20nk0101612, JP20nk0101614, JP20nk0101603]; Japan
   Initiative for Global Research Network on Infectious DiseasesMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [JP19fm0108006]; Japan Program for Infectious Diseases Research and
   Infrastructure from the Japan Agency for Medical Research and
   Development [JP20wm0125002]; National Institutes of Allergy and
   Infectious Diseases-funded Center for Research on Influenza Pathogenesis
   [HHSN272201400008C]
FX We thank Susan Watson for scientific editing. We also thank Yuko Sato
   along with Lin Schure, Ashlee McDonald, and Jarin Ryland at the
   Wisconsin Veterinary Diagnostic Laboratory for technical assistance. We
   are grateful to Jun Masumoto, Yuanzhong Li, Toshikazu Ban, and Koichi
   Yamada for help with generation of movies of micro-CT images. This
   research was supported by a Research Program on Emerging and Reemerging
   Infectious Diseases (Grants JP19fk0108112, JP19fk0108113, and
   JP19fk0108166), a Project Promoting Support for Drug Discovery (Grants
   JP20nk0101612, JP20nk0101614, and JP20nk0101603), the Japan Initiative
   for Global Research Network on Infectious Diseases (Grant
   JP19fm0108006), a Japan Program for Infectious Diseases Research and
   Infrastructure (Grant JP20wm0125002) from the Japan Agency for Medical
   Research and Development, and the National Institutes of Allergy and
   Infectious Diseases-funded Center for Research on Influenza Pathogenesis
   (Grant HHSN272201400008C).
CR Capobianchi MR, 2020, CLIN MICROBIOL INFEC, V26, P954, DOI 10.1016/j.cmi.2020.03.025
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   PERLMAN S, 1990, VIROLOGY, V175, P418, DOI 10.1016/0042-6822(90)90426-R
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roberts A, 2006, J INFECT DIS, V193, P685, DOI 10.1086/500143
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Simpson S, 2020, RADIOLOGY, V2, pe200152, DOI [10.1148/ryct.2020200152, DOI 10.1148/RYCT.2020200152]
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Xu DP, 2004, NEW ENGL J MED, V350, P1366, DOI 10.1056/NEJMc032421
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 29
Z9 27
U1 10
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 14
PY 2020
VL 117
IS 28
BP 16587
EP 16595
DI 10.1073/pnas.2009799117/-/DCSupplemental.
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MR0MR
UT WOS:000553288300012
PM 32571934
DA 2021-01-01
ER

PT J
AU Seydoux, E
   Homad, LJ
   MacCamy, AJ
   Parks, KR
   Hurlburt, NK
   Jennewein, MF
   Akins, NR
   Stuart, AB
   Wan, YH
   Feng, JL
   Whaley, RE
   Singh, S
   Boeckh, M
   Cohen, KW
   McElrath, MJ
   Englund, JA
   Chu, HY
   Pancera, M
   McGuire, AT
   Stamatatos, L
AF Seydoux, Emilie
   Homad, Leah J.
   MacCamy, Anna J.
   Parks, K. Rachael
   Hurlburt, Nicholas K.
   Jennewein, Madeleine F.
   Akins, Nicholas R.
   Stuart, Andrew B.
   Wan, Yu-Hsin
   Feng, Junli
   Whaley, Rachael E.
   Singh, Suruchi
   Boeckh, Michael
   Cohen, Kristen W.
   McElrath, M. Juliana
   Englund, Janet A.
   Chu, Helen Y.
   Pancera, Marie
   McGuire, Andrew T.
   Stamatatos, Leonidas
TI Analysis of a SARS-CoV-2-Infected Individual Reveals Development of
   Potent Neutralizing Antibodies with Limited Somatic Mutation
SO IMMUNITY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MONOCLONAL-ANTIBODIES; SARS
   CORONAVIRUS; STRUCTURAL BASIS; B-CELLS; RECEPTOR; SPIKE; PROTEIN
AB Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We isolated B cells specific for the SARSCoV-2 envelope glycoprotein spike (S) from a COVID-19-infected subject 21 days after the onset of clinical disease. 45 S-specific monoclonal antibodies were generated. They had undergone minimal somatic mutation with limited clonal expansion, and three bound the receptor-binding domain (RBD). Two antibodies neutralized SARS-CoV-2. The most potent antibody bound the RBD and prevented binding to the ACE2 receptor, while the other bound outside the RBD. Thus, most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 S-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive and/or therapeutic potential and can serve as templates for vaccine design.
C1 [Seydoux, Emilie; Homad, Leah J.; MacCamy, Anna J.; Parks, K. Rachael; Hurlburt, Nicholas K.; Jennewein, Madeleine F.; Akins, Nicholas R.; Stuart, Andrew B.; Wan, Yu-Hsin; Feng, Junli; Whaley, Rachael E.; Singh, Suruchi; Boeckh, Michael; Cohen, Kristen W.; McElrath, M. Juliana; Pancera, Marie; McGuire, Andrew T.; Stamatatos, Leonidas] Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Parks, K. Rachael; McElrath, M. Juliana; McGuire, Andrew T.; Stamatatos, Leonidas] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Boeckh, Michael] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
   [Boeckh, Michael; McElrath, M. Juliana; Chu, Helen Y.] Univ Washington, Dept Med, Seattle, WA USA.
   [Englund, Janet A.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Englund, Janet A.] Seattle Childrens Res, Seattle, WA USA.
   [Pancera, Marie] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Pancera, M; McGuire, AT; Stamatatos, L (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.; McGuire, AT; Stamatatos, L (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.; Pancera, M (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM mpancera@fredhutch.org; amcguire@fredhutch.org; lstamata@fredhutch.org
OI Hurlburt, Nicholas/0000-0001-9891-916X; MacCamy,
   Anna/0000-0001-5552-9209
FU Vaccine and Infectious Disease Division [CR3022 mAb]
FX We thank Dr. McLellan for providing the SARS-CoV and SARS-CoV-2 S2P and
   RBD plasmids and Dr. Neil King for providing the rhesus ACE2-Fc fusion
   protein and the CR3022 mAb. We thank Todd Haight and Melinda Akoto for
   specimen processing. The repository of samples collected from patients
   infected with endemic corona viruses is supported by the Vaccine and
   Infectious Disease Division. We thank Sarah Ameny for assistance with B
   cell sorting. This work was supported by generous donations to Fred
   Hutch COVID-19 Research Fund.
CR Bernat NV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00660
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Cao ZL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-299
   Charif D., 2007, STRUCTURAL APPROACHE, P207, DOI [DOI 10.1007/978-3-540-35306-5_10, 10.1007/978-3-540-35306-5_10]
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   DeKosky BJ, 2016, P NATL ACAD SCI USA, V113, pE2636, DOI 10.1073/pnas.1525510113
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Niu PH, 2018, J INFECT DIS, V218, P1249, DOI 10.1093/infdis/jiy311
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1024, DOI 10.3201/eid2605.190921
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pages H., 2018, BIOSTRINGS EFFICIENT
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   R Development Core Team, 2017, R LANG ENV STAT COMP
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Snijder J, 2018, IMMUNITY, V48, P799, DOI 10.1016/j.immuni.2018.03.026
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
NR 44
TC 25
Z9 25
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD JUL 14
PY 2020
VL 53
IS 1
BP 98
EP +
DI 10.1016/j.immuni.2020.06.001
PG 13
WC Immunology
SC Immunology
GA MN8UK
UT WOS:000551116800012
PM 32561270
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez-Nava, G
   Trelles-Garcia, DP
   Yanez-Bello, MA
   Chung, CW
   Trelles-Garcia, VP
   Friedman, HJ
AF Rodriguez-Nava, Guillermo
   Trelles-Garcia, Daniela Patricia
   Yanez-Bello, Maria Adriana
   Chung, Chul Won
   Trelles-Garcia, Valeria Patricia
   Friedman, Harvey J.
TI Atorvastatin associated with decreased hazard for death in COVID-19
   patients admitted to an ICU: a retrospective cohort study
SO CRITICAL CARE
LA English
DT Letter
DE COVID-19; Emerging disease; Adjuvant therapies; Critical care;
   Atorvastatin; Statins; Immunomodulators
ID MORTALITY; INFLUENZA
C1 [Rodriguez-Nava, Guillermo; Trelles-Garcia, Daniela Patricia; Yanez-Bello, Maria Adriana; Chung, Chul Won] AMITA Hlth St Francis Hosp, Dept Internal Med, 355 Ridge Ave, Evanston, IL 60202 USA.
   [Trelles-Garcia, Valeria Patricia] John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USA.
   [Friedman, Harvey J.] AMITA Hlth St Francis Hosp, Crit Care Units, Evanston, IL USA.
   [Friedman, Harvey J.] Univ Illinois, Coll Med, Chicago, IL USA.
RP Rodriguez-Nava, G (corresponding author), AMITA Hlth St Francis Hosp, Dept Internal Med, 355 Ridge Ave, Evanston, IL 60202 USA.
EM Guillermo.RodriguezNava@amitahealth.org
OI Rodriguez-Nava, Guillermo/0000-0001-9826-7050
CR Castiglione V., 2020, EUR HEART J CARDIOVA
   Frost FJ, 2007, CHEST, V131, P1006, DOI 10.1378/chest.06-1997
   Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
NR 6
TC 7
Z9 7
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUL 14
PY 2020
VL 24
IS 1
AR 429
DI 10.1186/s13054-020-03154-4
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA MQ8IT
UT WOS:000553137300002
PM 32664990
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, J
   Meng, GP
   Li, W
   Shi, BQ
   Dong, HN
   Su, ZZ
   Huang, Q
   Gao, P
AF Zhang, Jie
   Meng, Guangping
   Li, Wei
   Shi, Bingqing
   Dong, Hongna
   Su, Zhenzhong
   Huang, Qian
   Gao, Peng
TI Relationship of chest CT score with clinical characteristics of 108
   patients hospitalized with COVID-19 in Wuhan, China
SO RESPIRATORY RESEARCH
LA English
DT Article
DE COVID-19; Chest CT score; Inflammation; Glucocorticoid; Treatment
ID RESPIRATORY SYNDROME; CORONAVIRUSES; PNEUMONIA; SARS
AB BackgroundIn December 2019, the outbreak of a disease subsequently termed COVID-19 occurred in Wuhan, China. The number of cases increased rapidly and spread to six continents. However, there is limited information on the chest computed tomography (CT) results of affected patients. Chest CT can assess the severity of COVID-19 and has sufficient sensitivity to assess changes in response to glucocorticoid therapy.ObjectiveAnalyze COVID-19 patients to determine the relationships of clinical characteristics, chest CT score, and levels of inflammatory mediators.MethodsThis retrospective, single-center case series of 108 consecutive hospitalized patients with confirmed COVID-19 at Tongji Hospital, Tongji Medical College of HUST (Wuhan, China) examined patients admitted from January 28 to February 20, 2020. Patient demographics, comorbidities, clinical findings, chest CT results, and CT scores of affected lung parenchyma were recorded. The relationships between chest CT score with levels of systemic inflammatory mediators were determined.ResultsAll patients exhibited signs of significant systemic inflammation, including increased levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, chest CT score, and a decreased lymphocyte (LY) count. Chest CT score had positive associations with white blood cell (WBC) count, CRP, ESR, procalcitonin, and abnormal coagulation function, and a negative association with LY count. Treatment with a glucocorticoid increased the LY count, reduced the CT score and CRP level, and improved coagulation function.ConclusionsCOVID-19 infection is characterized by a systemic inflammatory response that affects the lungs, blood, digestive system, and circulatory systems. The chest CT score is a good indicator of the extent of systemic inflammation. Glucocorticoid treatment appears to reduce systemic inflammation in these patients.
C1 [Zhang, Jie; Meng, Guangping; Li, Wei; Shi, Bingqing; Dong, Hongna; Su, Zhenzhong; Gao, Peng] Jilin Univ, Hosp 2, Dept Resp & Crit Care Med, Changchun, Jilin, Peoples R China.
   [Huang, Qian] Jilin Univ, Hosp 2, Dept Radiol, Changchun, Jilin, Peoples R China.
RP Gao, P (corresponding author), Jilin Univ, Hosp 2, Dept Resp & Crit Care Med, Changchun, Jilin, Peoples R China.
EM gaopeng1234@sina.com
OI Gao, Peng/0000-0001-7328-1235; /0000-0002-7632-8999
CR [Anonymous], 2020, CLIN MANAGEMENT SEVE
   [Anonymous], 2020, NOVEL CORONAVIRUS 20
   [Anonymous], 2020, DIAGNOSIS TREATMENT
   [Anonymous], 2019, REPORT CLUSTERING PN
   [Anonymous], 2020, REPORT AGGREGATED PN
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Feng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093885
   Gambotto A, 2008, LANCET, V371, P1464, DOI 10.1016/S0140-6736(08)60627-3
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Grinblat L, 2003, RADIOLOGY, V228, P802, DOI 10.1148/radiol.2283030671
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li Nan, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P519
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Marchiori E, 2011, EUR J RADIOL, V80, pE500, DOI 10.1016/j.ejrad.2010.10.003
   Pan Y, 2020, EUR RADIOL CHINA
   Pediatric Branch of Hubei Medical Association, 2020, Zhongguo Dang Dai Er Ke Za Zhi, V22, P96
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wauquier N, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000837
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 1
Z9 1
U1 9
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD JUL 14
PY 2020
VL 21
IS 1
AR 180
DI 10.1186/s12931-020-01440-x
PG 11
WC Respiratory System
SC Respiratory System
GA MQ8FL
UT WOS:000553128700001
PM 32664991
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sadegh, S
   Matschinske, J
   Blumenthal, DB
   Galindez, G
   Kacprowski, T
   List, M
   Nasirigerdeh, R
   Oubounyt, M
   Pichlmair, A
   Rose, TD
   Salgado-Albarran, M
   Spath, J
   Stukalov, A
   Wenke, NK
   Yuan, K
   Pauling, JK
   Baumbach, J
AF Sadegh, Sepideh
   Matschinske, Julian
   Blumenthal, David B.
   Galindez, Gihanna
   Kacprowski, Tim
   List, Markus
   Nasirigerdeh, Reza
   Oubounyt, Mhaned
   Pichlmair, Andreas
   Rose, Tim Daniel
   Salgado-Albarran, Marisol
   Spaeth, Julian
   Stukalov, Alexey
   Wenke, Nina K.
   Yuan, Kevin
   Pauling, Josch K.
   Baumbach, Jan
TI Exploring the SARS-CoV-2 virus-host-drug interactome for drug
   repurposing
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ANGIOTENSIN-CONVERTING-ENZYME; MOLECULAR-INTERACTIONS; INHIBITOR;
   DATABASE; WEB
AB Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/. Information developed to understand the molecular mechanisms of SARS-CoV-2 infection for predicting drug repurposing candidates is time-consuming to integrate and explore. Here, the authors develop an interactive online platform for virus-host interactome exploration and drug (target) identification.
C1 [Sadegh, Sepideh; Matschinske, Julian; Blumenthal, David B.; Galindez, Gihanna; Kacprowski, Tim; List, Markus; Nasirigerdeh, Reza; Oubounyt, Mhaned; Salgado-Albarran, Marisol; Spaeth, Julian; Wenke, Nina K.; Yuan, Kevin; Baumbach, Jan] Tech Univ Munich, TUM Sch Life Sci, Chair Expt Bioinformat, Munich, Germany.
   [Pichlmair, Andreas; Stukalov, Alexey] Tech Univ Munich, TUM Sch Med, Inst Virol, Munich, Germany.
   [Rose, Tim Daniel; Pauling, Josch K.] Tech Univ Munich, TUM Sch Life Sci, Chair Expt Bioinformat, LipiTUM, Munich, Germany.
   [Salgado-Albarran, Marisol] Univ Autonoma Metropolitana Cuajimalpa UAM C, Dept Nat Sci, Mexico City 05300, DF, Mexico.
   [Baumbach, Jan] Univ Southern Denmark, Dept Math & Comp Sci, Computat Biomed Lab, Odense, Denmark.
RP Baumbach, J (corresponding author), Tech Univ Munich, TUM Sch Life Sci, Chair Expt Bioinformat, Munich, Germany.; Baumbach, J (corresponding author), Univ Southern Denmark, Dept Math & Comp Sci, Computat Biomed Lab, Odense, Denmark.
EM jan.baumbach@wzw.tum.de
RI ; Kacprowski, Tim/K-8650-2013
OI List, Markus/0000-0002-0941-4168; Yuan, Kevin/0000-0003-1283-2712;
   Wenke, Nina Kerstin/0000-0002-8031-6878; Rose, Tim
   Daniel/0000-0001-5491-7330; Pichlmair, Andreas/0000-0002-0166-1367;
   Blumenthal, David Benjamin/0000-0001-8651-750X; Spath,
   Julian/0000-0003-4562-5816; Kacprowski, Tim/0000-0002-5393-2413
FU H2020 project RepoTrial [777111]; H2020 project FeatureCloud [826078];
   BMBF grant Sys_CARE of the Federal German Ministry of Research and
   EducationFederal Ministry of Education & Research (BMBF) [01ZX1908A];
   BMBF grant SyMBoDFederal Ministry of Education & Research (BMBF)
   [01ZX1910D]; Collaborative Research Centre of the German Research
   Foundation [SFB924]; VILLUM Young Investigator Grant [13154]; Bavarian
   State Ministry of Science and the Arts of the Center
   Digitization.Bavaria; CONACYTConsejo Nacional de Ciencia y Tecnologia
   (CONACyT) [CVU659273]; German Academic Exchange Service, DAADDeutscher
   Akademischer Austausch Dienst (DAAD) [91693321]
FX T.K. and S.S. are grateful for financial support from H2020 project
   RepoTrial (no. 777111). J.M., J.S., N.K.W., and R.N. received funding
   from H2020 project FeatureCloud (no. 826078). J.B., T.K., and M.L. are
   grateful for financial support from BMBF grant Sys_CARE (no.
   01ZX1908A<BOLD>)</BOLD> of the Federal German Ministry of Research and
   Education. J.B.'s BMBF grant SyMBoD (no. 01ZX1910D) also financed parts
   of this project. M.O. is funded by the Collaborative Research Centre
   SFB924 of the German Research Foundation. J.B. was partially funded by
   his VILLUM Young Investigator Grant no. 13154. Contributions by J.K.P.
   and T.D.R. are funded by the Bavarian State Ministry of Science and the
   Arts in the framework of the Center Digitization.Bavaria (ZD.B, grant
   LipiTUM). M.S.-A. is grateful for a Ph.D. fellowship funding from
   CONACYT (CVU659273) and the German Academic Exchange Service, DAAD (ref.
   91693321).
CR Abrahams L, 2020, PREPRINT, DOI [10.31219/osf.io/4wkfy, DOI 10.31219/0SF.I0/4WKFY]
   Alcaraz Nicolas, 2016, F1000Res, V5, P1531, DOI 10.12688/f1000research.9054.1
   [Anonymous], 2004, Drugs R D, V5, P343
   Armstrong JF, 2020, NUCLEIC ACIDS RES, V48, pD1006, DOI 10.1093/nar/gkz951
   Barbarino JM, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1417
   Batra R, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0007-2
   Baumbach J., 2018, SYSTEMS MED, V1, P1, DOI [10.1089/sysm.2017.28999.jba, DOI 10.1089/SYSM.2017.28999.JBA]
   Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]
   Casas AI, 2019, P NATL ACAD SCI USA, V116, P7129, DOI 10.1073/pnas.1820799116
   Charatan F, 2000, BRIT MED J, V320, P668, DOI 10.1136/bmj.320.7236.668
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Dimensions Resources, 2020, DIM COVID 19 PUBL DA
   Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186
   Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guirimand T, 2015, NUCLEIC ACIDS RES, V43, pD583, DOI 10.1093/nar/gku1121
   Guney E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10331
   GYONGYI Z, 2004, P 30 INT C VER LARG, V30, P2004
   Gysi D. M, 2020, ARXIV200407229V1QBIO
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kacprowski T, 2013, BIOINFORMATICS, V29, P1471, DOI 10.1093/bioinformatics/btt164
   Kotlyar M, 2019, NUCLEIC ACIDS RES, V47, pD581, DOI 10.1093/nar/gky1037
   Kuoppala A, 2000, AM J PHYSIOL-HEART C, V278, pH1069
   LEDERMAN HM, 1984, BLOOD, V64, P748
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   National Library of Medicine, 2020, CYT SIGN IMM SYST
   Peixoto T.P., 2014, GRAPH TOOL PYTHON LI, DOI [10.6084/m9.figshare.1164194., DOI 10.6084/M9.FIGSHARE.1164194]
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Piepho RW, 2000, AM J HEALTH-SYST PH, V57, pS3, DOI 10.1093/ajhp/57.suppl_1.S3
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Semantic Scholar, COVID 19 OP RES DAT
   Sun P, 2017, DRUG DISCOV TODAY, V22, P615, DOI 10.1016/j.drudis.2016.10.008
   Talevi A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00205
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   van Vollenhoven R, 2019, ARTHRITIS RHEUMATOL, V71, P685, DOI 10.1002/art.40780
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wenzhong L, 2020, METABOLISM, DOI [10.26434/chemrxiv.11938173.v7, DOI 10.26434/CHEMRXIV.11938173.V7]
   WHOCC, 2016, WHOCC ATC DDD IND
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2020, COR
   Zhang S, 2001, BIOSENS BIOELECTRON, V16, P1119, DOI 10.1016/S0956-5663(01)00240-8
NR 46
TC 6
Z9 6
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 14
PY 2020
VL 11
IS 1
DI 10.1038/s41467-020-17189-2
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MM3LZ
UT WOS:000550062300004
PM 32665542
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Albini, A
   Noonan, DM
   Pelosi, G
   Di Guardo, G
   Lombardo, M
AF Albini, Adriana
   Noonan, Douglas McClain
   Pelosi, Giuseppe
   Di Guardo, Giovanni
   Lombardo, Michele
TI The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell
   types: implications for ACE-inhibitor- and angiotensin II receptor
   blocker-based antihypertensive therapies-reply
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Letter
C1 [Albini, Adriana; Noonan, Douglas McClain] IRCCS MultiMed, Sci & Technol Pole, Milan, Italy.
   [Noonan, Douglas McClain] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [Pelosi, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
   [Pelosi, Giuseppe] IRCCS MultiMed, Inter Hosp Pathol Div, Milan, Italy.
   [Di Guardo, Giovanni] Univ Teramo, Fac Vet Med, I-64100 Teramo, Italy.
   [Lombardo, Michele] San Giuseppe Hosp MultiMed, Cardiol Unit, Milan, Italy.
RP Albini, A (corresponding author), IRCCS MultiMed, Sci & Technol Pole, Milan, Italy.
EM adriana.albini@multimedica.it
CR Albini A, 2020, INTERN EMERG MED, V15, P759, DOI 10.1007/s11739-020-02364-6
   De Cauwer H, 2020, INTERN EMERG MED, V15, P1581, DOI 10.1007/s11739-020-02406-z
   Espinosa Joaquin M, 2020, Cell Rep Med, V1, P100019, DOI 10.1016/j.xcrm.2020.100019
   Gibson WT, 2020, BIORXIV, DOI [10.1101/2020.04.05.026633, DOI 10.1101/2020.04.05.026633]
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
NR 5
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1583
EP 1584
DI 10.1007/s11739-020-02436-7
EA JUL 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000548756900001
PM 32666177
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ibrahim, MAA
   Abdelrahman, AHM
   Hegazy, MEF
AF Ibrahim, Mahmoud A. A.
   Abdelrahman, Alaa H. M.
   Hegazy, Mohamed-Elamir F.
TI In-silicodrug repurposing and molecular dynamics puzzled out potential
   SARS-CoV-2 main protease inhibitors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 main protease; drug repurposing; in-silico drug
   discovery; molecular dynamics
ID DRUG; DOCKING
AB Herein, the DrugBank database which contains 10,036 approved and investigational drugs was explored deeply for potential drugs that target SARS-CoV-2 main protease (M-pro). Filtration process of the database was conducted using three levels of accuracy for molecular docking calculations. The top 35 drugs with docking scores > -11.0 kcal/mol were then subjected to 10 ns molecular dynamics (MD) simulations followed by molecular mechanics-generalized Born surface area (MM-GBSA) binding energy calculations. The results showed that DB02388 and Cobicistat (DB09065) exhibited potential binding affinities towards M(pro)over 100 ns MD simulations, with binding energy values of -49.67 and -46.60 kcal/mol, respectively. Binding energy and structural analyses demonstrated the higher stability of DB02388 over Cobicistat. The potency of DB02388 and Cobicistat is attributed to their abilities to form several hydrogen bonds with the essential amino acids inside the active site of M-pro. Compared to DB02388 and Cobicistat, Darunavir showed a much lower binding affinity of -34.83 kcal/mol. The present study highlights the potentiality of DB02388 and Cobicistat as anti-COVID-19 drugs for clinical trials. Communicated by Ramaswamy H. Sarma.
C1 [Ibrahim, Mahmoud A. A.; Abdelrahman, Alaa H. M.] Menia Univ, Fac Sci, Computat Chem Lab, Dept Chem, Al Minya 61519, Egypt.
   [Hegazy, Mohamed-Elamir F.] Natl Res Ctr, Chem Med Plants Dept, Giza, Egypt.
RP Ibrahim, MAA (corresponding author), Menia Univ, Fac Sci, Computat Chem Lab, Dept Chem, Al Minya 61519, Egypt.
EM m.ibrahim@compchem.net
RI Ibrahim, Mahmoud/J-2936-2014; Abdelrahman, Alaa H. M./AAX-1803-2020;
   Hegazy, Mohamed Elamir/AAA-3454-2019
OI Ibrahim, Mahmoud/0000-0003-4819-2040; Abdelrahman, Alaa H.
   M./0000-0003-3527-0126; Hegazy, Mohamed Elamir/0000-0002-0343-4969
FU Science and Technology Development Fund, STDF, EgyptScience and
   Technology Development Fund (STDF) [5480, 7972]
FX The computational work was completed with resources supported by the
   Science and Technology Development Fund, STDF, Egypt, Grants No. 5480 &
   7972.
CR BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Case D. A., 2016, AMBER 2016
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Deeks ED, 2014, DRUGS, V74, P195, DOI 10.1007/s40265-013-0160-x
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Frisch M. J., 2009, GAUSSIAN 09 VERSION
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Guedes Isabella A, 2014, Biophys Rev, V6, P75, DOI 10.1007/s12551-013-0130-2
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Karaman B, 2019, CURR MED CHEM, V26, P5389, DOI 10.2174/0929867325666180530100332
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   OMEGA, 2013, OMEGA VERS 2 5 1 4
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   PANTSAR T, 2018, MOLECULES, V23, DOI DOI https://doi.org/10.3390/molecules23081899
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Scapin G, 2003, CHEM BIOL, V10, P705, DOI 10.1016/S1074-5521(03)00159-5
   SZYBKI, 2016, SZYBKI VERS 1 9 0 3
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   YELLA JK, 2018, PHARMACEUTICALS, V11, DOI DOI https://doi.org/10.3390/ph11020057
   Zhao Qi, 2013, Recent Pat Antiinfect Drug Discov, V8, P150
NR 41
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1791958
EA JUL 2020
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MM3VV
UT WOS:000550088800001
PM 32684114
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mishra, SS
   Ranjan, S
   Sharma, CS
   Singh, HP
   Kalra, S
   Kumar, N
AF Mishra, Shashank Shekhar
   Ranjan, Shashi
   Sharma, Chandra Shekhar
   Singh, Hemendra Pratap
   Kalra, Sourav
   Kumar, Neeraj
TI Computational investigation of potential inhibitors of novel coronavirus
   2019 through structure-based virtual screening, molecular dynamics and
   density functional theory studies
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; molecular dynamics; virtual screening; synthetic feasibility;
   quantum mechanical calculations
ID PREDICTION; DISCOVERY; DOCKING; BIOLOGY
AB Despite the intensive research efforts towards antiviral drug against COVID-19, no potential drug or vaccines has not yet discovered. Initially, the binding site of COVID-19 main protease was predicted which located between regions 2 and 3. Structure-based virtual screening was performed through a hierarchal mode of elimination technique after generating a grid box. This led to the identification of five top hit molecules that were selected on the basis of docking score and visualization of non-bonding interactions. The docking results revealed that the hydrogen bonding and hydrophobic interactions are the major contributing factors in the stabilization of complexes. The docking scores were found between -7.524 and -6.711 kcal/mol indicating strong ligand-protein interactions. Amino acid residues Phe140, Leu141, Gly143, Asn142, Thr26, Glu166 and Thr190 (hydrogen bonding interactions) and Phe140, Cys145, Cys44, Met49, Leu167, Pro168, Met165, Val42, Leu27 and Ala191 (hydrophobic interactions) formed the binding pocket of COVID-19 main protease. From identified hits, ZINC13144609 and ZINC01581128 were selected for atomistic MD simulation and density functional theory calculations. MD simulation results confirm that the protein interacting with both hit molecules is stabilized in the chosen POPC lipid bilayer membrane. The presence of lowest unoccupied molecular orbital (LUMO) and highest occupied molecular orbital (HOMO) in the hydrophobic region of the hit molecules leads to favorable ligand-protein contacts. The calculated pharmacokinetic descriptors were found to be in their acceptable range and therefore confirming their drug-like properties. Hence, the present investigation can serve as the basis for designing and developing COVID-19 inhibitors. Communicated by Ramaswamy H. Sarma
C1 [Mishra, Shashank Shekhar; Sharma, Chandra Shekhar; Singh, Hemendra Pratap; Kumar, Neeraj] Bhupal Nobles Univ, Dept Pharmaceut Chem, Bhupal Nobles Coll Pharm, Udaipur 313001, Rajasthan, India.
   [Ranjan, Shashi] United Grp Inst, Dept Pharm, Greater Noida, Uttar Pradesh, India.
   [Kalra, Sourav] Cent Univ Punjab, Ctr Human Genet & Mol Med, Bhatinda, India.
RP Kumar, N (corresponding author), Bhupal Nobles Univ, Dept Pharmaceut Chem, Bhupal Nobles Coll Pharm, Udaipur 313001, Rajasthan, India.
EM neerajkumarkamra@gmail.com
RI Kalra, Sourav/F-2273-2019
OI Kalra, Sourav/0000-0002-0651-4825
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Athar M, 2016, J BIOMOL STRUCT DYN, V34, P1282, DOI 10.1080/07391102.2015.1077343
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bochevarov AD, 2013, INT J QUANTUM CHEM, V113, P2110, DOI 10.1002/qua.24481
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Guo ZJ, 2010, CHEM BIOL DRUG DES, V75, P348, DOI 10.1111/j.1747-0285.2010.00951.x
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hajduk PJ, 2005, DRUG DISCOV TODAY, V10, P1675, DOI 10.1016/S1359-6446(05)03624-X
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Kar S, 2013, EXPERT OPIN DRUG DIS, V8, P245, DOI 10.1517/17460441.2013.761204
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kumar N, 2018, J BIOMOL STRUCT DYN, V36, P1691, DOI 10.1080/07391102.2017.1332688
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Rollinger Judith M., 2008, V65
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Shekhar MS, 2019, J BIOMOL STRUCT DYN, V37, P3226, DOI 10.1080/07391102.2018.1513379
   Su PC, 2015, J COMPUT CHEM, V36, P1859, DOI 10.1002/jcc.24011
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Venugopal PP, 2020, PROTEINS, V88, P327, DOI 10.1002/prot.25807
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 29
TC 2
Z9 2
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1791957
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MK7NQ
UT WOS:000548971400001
PM 32666910
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Algeri, P
   Stagnati, V
   Spazzini, MD
   Bellan, C
   Montanelli, A
   Patelli, G
   Ciammella, M
AF Algeri, Paola
   Stagnati, Valentina
   Spazzini, Maria Donata
   Bellan, Cristina
   Montanelli, Alessandro
   Patelli, Gianluigi
   Ciammella, Massimo
TI Considerations on COVID-19 pregnancy: a cases series during outbreak in
   Bergamo Province, North Italy
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article; Early Access
DE COVID-19; new coronavirus-19 infection; pregnancy infection; fetal
   infection
AB Background COVID-19 has rapidly spread worldwide, with severe complications affecting particularly elderly and compromised subjects. Less information about COVID-19 in pregnancy has been reported so far in the literature. Methods Case series on pregnancies complicated by COVID-19. All cases were diagnosed at Bolognini Hospital, Seriate, Italy. These cases are presented to clarify the features of COVID-19 occurring in pregnancy. Results Four women had symptoms of COVID-19 during pregnancy or immediately after delivery. All cases were confirmed by oropharyngeal swab. All patients presented with fever and low saturation levels at the diagnosis. One case was transferred after diagnosis to a tertiary referral center and delivered the day after for worsening clinical conditions. In the other three cases, bilateral pneumonia was documented at the admission. Antithrombotic therapy was used in most cases. No cases of the infected neonate was reported. At 2 month follow-up, all patients were alive, three were asymptomatic while one presented neurological complication. One more case was described because suspicious for COVID-19, however, it was not confirmed by oropharyngeal swab. Conclusions In pregnant women, the peripheral nervous system could be affected. No case of trans-placental passage was reported. The swab could be helpful in diagnosis. The antithrombotic therapy could play a role in the positive course of COVID-19 also in pregnant women.
C1 [Algeri, Paola; Stagnati, Valentina; Spazzini, Maria Donata] ASST Bergamo Est, Dept Obstet & Gynecol, Bolognini Hosp, Via Paderno 21, Bergamo, Italy.
   [Bellan, Cristina] ASST Bergamo Est, Dept Neonatal, Intens Care Unit, Bolognini Hosp, Seriate, Italy.
   [Montanelli, Alessandro] ASST Bergamo Est, Dept Lab Med, Bolognini Hosp, Seriate, Italy.
   [Patelli, Gianluigi] ASST Bergamo Est, Dept Radiol, Bolognini Hosp, Seriate, Italy.
RP Algeri, P (corresponding author), ASST Bergamo Est, Dept Obstet & Gynecol, Bolognini Hosp, Via Paderno 21, Bergamo, Italy.
EM dottoressa.algeri.p@gmail.com
CR Abdollahpour S, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1759540
   Capanna F, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1749258
   Chen DJ, 2020, INT J GYNECOL OBSTET, V149, P130, DOI 10.1002/ijgo.13146
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   Di Mascio D, 2020, AM J OBSTET GYNECOL, DOI [10.1016/j.ajogmf.2020.100107, 10.1016/j.ajogmf.2020.100107., DOI 10.1016/J.AJOGMF.2020.100107]
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   Marty FM, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMvcm2010260
   Mullins E, 2020, ULTRASOUND OBST GYN, V55, P586, DOI 10.1002/uog.22014
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Porfidia A, 2020, J THROMB HAEMOST, V18, P1516, DOI 10.1111/jth.14842
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
NR 14
TC 2
Z9 2
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
DI 10.1080/14767058.2020.1791817
EA JUL 2020
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA MK7JV
UT WOS:000548961500001
PM 32664761
DA 2021-01-01
ER

PT J
AU Degtyarev, E
   Rufibach, K
   Shentu, Y
   Yung, GW
   Casey, M
   Englert, S
   Liu, F
   Liu, Y
   Sailer, O
   Siegel, J
   Sun, S
   Tang, R
   Zhou, JX
AF Degtyarev, Evgeny
   Rufibach, Kaspar
   Shentu, Yue
   Yung, Godwin
   Casey, Michelle
   Englert, Stefan
   Liu, Feng
   Liu, Yi
   Sailer, Oliver
   Siegel, Jonathan
   Sun, Steven
   Tang, Rui
   Zhou, Jiangxiu
CA Ind Working Grp Estimands Oncology
TI Assessing the Impact of COVID-19 on the Clinical Trial Objective and
   Analysis of Oncology Clinical Trials-Application of the Estimand
   Framework
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Coronavirus disease 2019; Estimand; Oncology clinical trial;
   Time-to-event
ID TIME
AB Coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and its broad applicability for future clinical practice. We identify key intercurrent events (ICEs) that may occur due to COVID-19 in oncology clinical trials with a focus on time-to-event endpoints and discuss considerations pertaining to the other estimand attributes introduced in the ICH E9 addendum. We propose strategies to handle COVID-19 related ICEs, depending on their relationship with malignancy and treatment and the interpretability of data after them. We argue that the clinical trial objective from a world without COVID-19 pandemic remains valid. The estimand framework provides a common language to discuss the impact of COVID-19 in a structured and transparent manner. This demonstrates that the applicability of the framework may even go beyond what it was initially intended for.
C1 [Degtyarev, Evgeny] Novartis Pharma AG, CH-4002 Basel, Switzerland.
   [Rufibach, Kaspar] F Hoffmann La Roche, Basel, Switzerland.
   [Shentu, Yue] Merck & Co Inc, Rahway, NJ 07065 USA.
   [Yung, Godwin] Takeda Pharmaceut, Cambridge, MA USA.
   [Casey, Michelle] Pfizer, Collegeville, PA USA.
   [Englert, Stefan] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
   [Liu, Feng] AstraZeneca, Gaithersburg, MD USA.
   [Liu, Yi] Nektar Therapeut, San Francisco, CA USA.
   [Sailer, Oliver] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
   [Siegel, Jonathan] Bayer US Inc, Whippany, NJ USA.
   [Sun, Steven] Janssen R&D, Raritan, NJ USA.
   [Tang, Rui] Servier Pharmaceut, Boston, MA USA.
   [Zhou, Jiangxiu] GlaxoSmithKline, Collegeville, PA USA.
RP Degtyarev, E (corresponding author), Novartis Pharma AG, CH-4002 Basel, Switzerland.
EM evgeny.degtyarev@novartis.com
RI Rufibach, Kaspar/F-1163-2010
OI Rufibach, Kaspar/0000-0002-2634-1167
CR AALEN OO, 1978, SCAND J STAT, V5, P141
   Akach M, 2017, STAT MED, V36, P5, DOI 10.1002/sim.7033
   American Society of Clinical Oncology, 2020, COVID 19 PAT CAR INF
   Bauer P, 2006, STAT MED, V25, P23, DOI 10.1002/sim.2180
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Degtyarev E., 2020, ONCOLOGY ESTIMAND WO
   Degtyarev E., 2019, J CLIN ONCOLOGY PREC, V3, P1, DOI [10.1200/PO.18.00381, DOI 10.1200/PO.18.00381]
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   European Medicines Agency, 2020, POINTS CONS IMPL COR
   European Society of Medical Oncology, 2020, CANC PAT MAN COVID 1
   Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Frangakis CE, 2002, BIOMETRICS, V58, P21, DOI 10.1111/j.0006-341X.2002.00021.x
   Freidlin B, 2019, J CLIN ONCOL, V37, P3455, DOI 10.1200/JCO.19.01681
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Huang B, 2018, PHARM STAT, V17, P202, DOI 10.1002/pst.1846
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jo B, 2009, STAT MED, V28, P2857, DOI 10.1002/sim.3669
   KAY R, 1986, BIOMETRICS, V42, P203, DOI 10.2307/2531258
   Lin RS, 2020, STAT BIOPHARM RES, V12, P187, DOI 10.1080/19466315.2019.1697738
   Lipkovich I, 2016, PHARM STAT, V15, P216, DOI 10.1002/pst.1738
   Lou YY, 2019, STAT MED, V38, P5214, DOI 10.1002/sim.8367
   Meyer RD, 2020, STAT BIOPHARM RES, V12, P399, DOI 10.1080/19466315.2020.1779122
   Ratitch B, 2020, THER INNOV REGUL SCI, V54, P324, DOI 10.1007/s43441-019-00061-x
   Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x
   Royston P, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4153-2
   Rufibach K, 2019, PHARM STAT, V18, P145, DOI 10.1002/pst.1917
   Shet A., 2020, DIFFERENTIAL COVID 1, DOI [10.1101/2020.04.01.20049478, DOI 10.1101/2020.04.01.20049478]
   Singh AG, 2020, HEAD NECK-J SCI SPEC, V42, P1516, DOI 10.1002/hed.26223
   Stegherr R., 2019, 191200263 ARXIV
   Stuart EA, 2015, STAT METHODS MED RES, V24, P657, DOI 10.1177/0962280211421840
   Sun J., 2006, STAT ANAL INTERVAL C
   Unkel S, 2019, PHARM STAT, V18, P166, DOI 10.1002/pst.1915
   Viele K, 2014, PHARM STAT, V13, P41, DOI 10.1002/pst.1589
   World Health Organization (WHO), 2020, 132 WHO
   Yung G, 2019, BIOMETRICS, DOI 10.1111/biom.13196
NR 36
TC 3
Z9 3
U1 3
U2 3
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD OCT 1
PY 2020
VL 12
IS 4
BP 427
EP 437
DI 10.1080/19466315.2020.1785543
EA JUL 2020
PG 11
WC Mathematical & Computational Biology; Statistics & Probability
SC Mathematical & Computational Biology; Mathematics
GA OK5GB
UT WOS:000548963700001
OA Bronze
DA 2021-01-01
ER

PT J
AU Rozanova, J
   Shenoi, S
   Zaviryukha, I
   Zeziulin, O
   Kiriazova, T
   Rich, K
   Mamedova, E
   Yariy, V
AF Rozanova, Julia
   Shenoi, Sheela
   Zaviryukha, Irina
   Zeziulin, Oleksandr
   Kiriazova, Tetiana
   Rich, Katherine
   Mamedova, Elmira
   Yariy, Volodymyr
TI Social Support is Key to Retention in Care during Covid-19 Pandemic
   among Older People with HIV and Substance Use Disorders in Ukraine
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE Social support; medication-assisted treatment; older adults with HIV;
   Covid-19 lockdown; low; and middle-income settings
ID INJECT DRUGS; ANTIRETROVIRAL THERAPY; INITIATION
AB Background Older people with human immunodeficiency virus - HIV (OPWH) defined as >= 50 years old account for a growing proportion of newly diagnosed infections in Ukraine (16% in 2018), but the prevalence of substance use disorder among OPWH in Ukraine remains unknown. Ukraine responded to the Covid-19 pandemic with a comprehensive lockdown in late March 2020.Objectives:We conducted a phone survey among 123 OPWH with substance use disorders (SUD) in Kyiv in May 2020 to learn if these older adults may continue HIV and SUD therapy while coping with the Covid-19 pandemic.Results:Data from the survey demonstrated that while OPWH with SUD maintained HIV and SUD therapy throughout Covid-19 lockdown, social support is critical to avoiding treatment interruption for OPWH with SUD.Conclusions/Importance:During reopening, reduction of support may lead to OPWH feeling even more isolated. Post-Covid-19 pharmacological approaches to SUD treatment without social support are like vehicles without gas. The research agenda for OPWH patients with SUD going forward must include determining the type of telehealth support that will be optimally effective to retain OPWH including people who inject drugs (PWID), provision of support by lay health workers, and cost-effectiveness of such interventions. The lessons learned may be relevant to other countries as well.
C1 [Rozanova, Julia; Shenoi, Sheela] Yale Univ, Dept Internal Med, New Haven, CT USA.
   [Zaviryukha, Irina; Zeziulin, Oleksandr; Kiriazova, Tetiana] Ukrainian Inst Publ Hlth Policy UIPHP, Kiev, Ukraine.
   [Rich, Katherine] Harvard Univ, Sch Med, Boston, MA USA.
   [Mamedova, Elmira] Kyiv City AIDS Ctr, Kiev, Ukraine.
   [Yariy, Volodymyr] Kyiv City Addict Treatment Clin Sociotherapy, Kiev, Ukraine.
RP Rozanova, J (corresponding author), Yale AIDS Program, 135 Coll St,Suite 323, New Haven, CT 06510 USA.
EM julia.rozanova@yale.edu
RI Shenoi, Sheela/Z-2641-2019
OI Shenoi, Sheela/0000-0001-7654-4344
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [K01DA047194-01]; Yale
   Women's Faculty Forum Award; Yale Fund for Lesbian and Gay Studies
   Award; Yale MacMillan International and Area Studies Center Award
FX This work was supported by the National Institutes of Health [grant
   number K01DA047194-01 to J. Rozanova]; the Yale Women's Faculty Forum
   Award to J. Rozanova, the Yale Fund for Lesbian and Gay Studies Award to
   J. Rozanova, and the Yale MacMillan International and Area Studies
   Center Award to S. Shenoi and J. Rozanova.
CR Autenrieth CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207005
   Avert, 2018, HIV AIDS UKR
   Booth RE, 2016, LANCET HIV, V3, pE482, DOI 10.1016/S2352-3018(16)30040-6
   Dugosh K, 2016, J ADDICT MED, V10, P93, DOI 10.1097/ADM.0000000000000193
   Dumchev K, 2017, INT J DRUG POLICY, V48, P44, DOI 10.1016/j.drugpo.2017.05.014
   Edelman EJ, 2014, CURR OPIN HIV AIDS, V9, P317, DOI 10.1097/COH.0000000000000069
   Lancaster KE, 2019, AIDS EDUC PREV, V31, P95, DOI 10.1521/aeap.2019.31.2.95
   Lifson AR, 2017, AIDS, V31, P953, DOI 10.1097/QAD.0000000000001417
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Polcin Douglas L, 2017, J Alcohol Drug Educ, V61, P51
   Rozanova J., 2020, 23 INT AIDS C AIDS 2
   Rozanova J., 2019, 10 INT AIDS SOC C HI
   Rozanova J., 2019, 10 INT HIV AG WORKSH
   Rozanova J, 2017, QUAL HEALTH RES, V27, P2057, DOI 10.1177/1049732317732307
   Rozanova Y., 2018, 22 INT AIDS C 2018 A
   Shipunov O., 2019, COMMUNICATION
   UNAIDS, 2018, COUNTR FACTSH UKR 20
   UNAIDS, 2016, UKR HIV AIDS EST
   UNAIDS, 2018, GLOB AIDS MON 2018
   Volkow ND, 2018, ANN INTERN MED, V169, P190, DOI 10.7326/M18-1397
   Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780
NR 21
TC 3
Z9 3
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PD AUG 3
PY 2020
VL 55
IS 11
BP 1902
EP 1904
DI 10.1080/10826084.2020.1791183
EA JUL 2020
PG 3
WC Substance Abuse; Psychiatry; Psychology
SC Substance Abuse; Psychiatry; Psychology
GA MO1YE
UT WOS:000548977600001
PM 32666857
DA 2021-01-01
ER

PT J
AU Tschope, C
   Van Linthout, S
   Jager, S
   Arndt, R
   Trippel, T
   Muller, I
   Elsanhoury, A
   Rutschow, S
   Anker, SD
   Schultheiss, HP
   Pauschinger, M
   Spillmann, F
   Pappritz, K
AF Tschoepe, Carsten
   Van Linthout, Sophie
   Jaeger, Sebastian
   Arndt, Robert
   Trippel, Tobias
   Mueller, Irene
   Elsanhoury, Ahmed
   Rutschow, Susanne
   Anker, Stefan D.
   Schultheiss, Heinz-Peter
   Pauschinger, Matthias
   Spillmann, Frank
   Pappritz, Kathleen
TI Modulation of the acute defence reaction by eplerenone prevents cardiac
   disease progression in viral myocarditis
SO ESC HEART FAILURE
LA English
DT Article
DE Myocarditis; Mineralocorticoid receptor inhibition; Inflammation;
   Fibrosis; Coxsackievirus B-3; COVID-19
ID INTERFERON-BETA TREATMENT; MATRIX METALLOPROTEINASES; DILATED
   CARDIOMYOPATHY; DIABETIC CARDIOMYOPATHY; OXIDATIVE STRESS; INFLAMMATION;
   ALDOSTERONE; FIBROSIS; DYSFUNCTION; PATHOGENESIS
AB Aims Left ventricular (LV) dysfunction in viral myocarditis is attributed to myocardial inflammation and fibrosis, inducing acute and long-time cardiac damage. Interventions are not established. On the basis of the link between inflammation, fibrosis, aldosterone, and extracellular matrix regulation, we aimed to investigate the effect of an early intervention with the mineralocorticoid receptor antagonist (MRA) eplerenone on cardiac remodelling in a murine model of persistent coxsackievirus B3 (CVB3)-induced myocarditis.
   Methods and results SWR/J mice were infected with 5 x 10(4) plaque-forming units of CVB3 (Nancy strain) and daily treated either with eplerenone (200 mg/kg body weight) or with placebo starting from Day 1. At Day 8 or 28 post infection, mice were haemodynamically characterized and subsequently sacrificed for immunohistological and molecular biology analyses. Eplerenone did not influence CVB3 load. Already at Day 8, 1.8-fold (P < 0.05), 1.4-fold (P < 0.05), 3.2-fold (P < 0.01), and 2.1-fold (P < 0.001) reduction in LV intercellular adhesion molecule 1 expression, presence of monocytes/macrophages, oxidative stress, and apoptosis, respectively, was observed in eplerenone-treated vs. untreated CVB3-infected mice. in vitro, eplerenone led to 1.4-fold (P < 0.01) and 1.2-fold (P < 0.01) less CVB3-induced cardiomyocyte oxidative stress and apoptosis. Furthermore, collagen production was 1.1-fold (P < 0.05) decreased in cardiac fibroblasts cultured with medium of eplerenone-treated vs. untreated CVB3-infected HL-1 cardiomyocytes. These ameliorations were in vivo translated into prevention of cardiac fibrosis, as shown by 1.4-fold (P < 0.01) and 2.1-fold (P < 0.001) lower collagen content in the LV of eplerenone-treated vs. untreated CVB3-infected mice at Days 8 and 28, respectively. This resulted in an early and long-lasting improvement of LV dimension and function, as indicated by reduced LV end-systolic volume and end-diastolic volume, and an increase in LV contractility (dP/dt(max)) and LV relaxation (dP/dt(min)), respectively (P < 0.05).
   Conclusions Early intervention with the MRA eplerenone modulates the acute host and defence reaction and prevents cardiac disease progression in experimental CVB3-induced myocarditis without aggravation of viral load. The findings advocate for an initiation of therapy of viral myocarditis as early as possible, even before the onset of inflammation-induced myocardial dysfunction. This may also have implications for coronavirus disease-19 therapy.
C1 [Tschoepe, Carsten; Van Linthout, Sophie; Mueller, Irene; Elsanhoury, Ahmed; Anker, Stefan D.; Pappritz, Kathleen] Charite Univ Med Berlin, Ctr Regenerat Therapies, Berlin Inst Hlth, Berlin, Germany.
   [Tschoepe, Carsten; Van Linthout, Sophie; Mueller, Irene; Elsanhoury, Ahmed; Anker, Stefan D.; Pappritz, Kathleen] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany.
   [Tschoepe, Carsten; Van Linthout, Sophie; Mueller, Irene; Elsanhoury, Ahmed; Anker, Stefan D.; Pappritz, Kathleen] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany.
   [Tschoepe, Carsten; Trippel, Tobias; Anker, Stefan D.; Spillmann, Frank] Charite Univ Med Berlin, Campus Virchow Klinikum CVK, Dept Cardiol, Berlin, Germany.
   [Jaeger, Sebastian] Alexianer Hosp Hedwigshohe, Dept Cardiol, Berlin, Germany.
   [Arndt, Robert] Charite Univ Med Berlin, Dept Emergency Med, Campus Benjamin Franklin CBF, Berlin, Germany.
   [Rutschow, Susanne] Angiol Johanniter Kliniken, Dept Cardiol, Stendal, Germany.
   [Schultheiss, Heinz-Peter] Inst Cardiac Diagnost & Therapy IKDT, Berlin, Germany.
   [Pauschinger, Matthias] Paracelsus Univ, Klinikum Nurnberg, Dept Cardiol, Nurnberg, Germany.
RP Tschope, C (corresponding author), Charite Univ Med Berlin, Ctr Regenerat Therapies BCRT, Berlin Inst Hlth, CVK, Fohrer Str 15, D-13353 Berlin, Germany.
EM carsten.tschoepe@charite.de
OI TRIPPEL, TOBIAS DANIEL/0000-0001-8575-0019
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB
   Transregio 19 A2, SFB Transregio 19]; PfizerPfizer
FX This study was supported by the Deutsche Forschungsgemeinschaft through
   SFB Transregio 19 (grant SFB Transregio 19 A2) and by research grants
   from Pfizer to C. T. and M. P.
CR Ammirati E, 2019, J AM COLL CARDIOL, V74, P299, DOI 10.1016/j.jacc.2019.04.063
   Aquaro GD, 2017, J AM COLL CARDIOL, V70, P1977, DOI 10.1016/j.jacc.2017.08.044
   Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543
   BRILLA CG, 1992, CARDIOVASC RES, V26, P671, DOI 10.1093/cvr/26.7.671
   BURCH GE, 1968, J AMER MED ASSOC, V203, P1, DOI 10.1001/jama.203.1.1
   Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210
   Cardona A, 2019, INT J CARDIOL, V275, P114, DOI 10.1016/j.ijcard.2018.10.010
   Cooper LT, 2014, GLOB HEART, V9, P121, DOI 10.1016/j.gheart.2014.01.007
   Coronado MJ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.008968
   Corsten MF, 2012, TRENDS MOL MED, V18, P426, DOI 10.1016/j.molmed.2012.05.005
   De Angelis N, 2002, J MOL CELL CARDIOL, V34, P1655, DOI 10.1006/jmcc.2002.2115
   Elsanhoury A, 2020, J CARDIOVASC TRANSL, DOI 10.1007/s12265-020-10025-4
   Esfandiarei M, 2008, ANNU REV PATHOL-MECH, V3, P127, DOI 10.1146/annurev.pathmechdis.3.121806.151534
   Friebel J, 2019, EUR HEART J, V40, P3318, DOI 10.1093/eurheartj/ehz117
   Heymans S, 2006, CIRCULATION, V114, P565, DOI 10.1161/CIRCULATIONAHA.105.591032
   Inciardi RM, 2020, JAMA CARDIOL
   de Giusti CJ, 2015, J MOL CELL CARDIOL, V85, P58, DOI 10.1016/j.yjmcc.2015.05.010
   Kanashiro-Takeuchi RM, 2009, CTS-CLIN TRANSL SCI, V2, P134, DOI 10.1111/j.1752-8062.2009.00094.x
   Kasner M, 2017, INT J CARDIOL, V243, P374, DOI 10.1016/j.ijcard.2017.05.038
   Kraft L, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0719-0
   Kuhl U, 2005, CIRCULATION, V111, P887, DOI 10.1161/01.CIR.0000155616.07901.35
   Kuhl U, 2003, CIRCULATION, V107, P2793, DOI 10.1161/01.CIR.0000072766.67150.51
   Kuster GM, 2005, CIRCULATION, V111, P420, DOI 10.1161/01.CIR.0000153800.09920.40
   Lang C, 2008, J MOL MED-JMM, V86, P49, DOI 10.1007/s00109-007-0249-3
   Lassner D, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1610-8
   Li X, 2000, CIRCULATION, V102, P1690, DOI 10.1161/01.CIR.102.14.1690
   Liao CW, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165627
   Lieber GB, 2013, EUR J PHARMACOL, V718, P290, DOI 10.1016/j.ejphar.2013.08.019
   Lindner D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/519528
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McNamara DM, 2011, J AM COLL CARDIOL, V58, P1112, DOI 10.1016/j.jacc.2011.05.033
   Messaoudi S, 2013, HYPERTENSION, V61, P361, DOI 10.1161/HYPERTENSIONAHA.112.198986
   Muller I, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.004125
   Muller I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182643
   Negrotto S, 2015, J THROMB HAEMOST, V13, P271, DOI 10.1111/jth.12782
   Noguchi K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210971
   Papageorgiou AP, 2012, IMMUNOBIOLOGY, V217, P503, DOI 10.1016/j.imbio.2011.07.011
   Pappritz K, 2018, FASEB J, V32, P6066, DOI 10.1096/fj.201701408R
   Pappritz K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23881-7
   Pauschinger M, 1999, CIRCULATION, V99, P2750, DOI 10.1161/01.CIR.99.21.2750
   Pieske B, 2020, EUR J HEART FAIL, V22, P391, DOI 10.1002/ejhf.1741
   Riad A, 2008, J IMMUNOL, V180, P6954, DOI 10.4049/jimmunol.180.10.6954
   Riad A, 2011, J IMMUNOL, V186, P2561, DOI 10.4049/jimmunol.1002029
   Riad A, 2010, AM J PHYSIOL-HEART C, V298, pH2024, DOI 10.1152/ajpheart.01188.2009
   Rickard AJ, 2012, HYPERTENSION, V60, P1443, DOI 10.1161/HYPERTENSIONAHA.112.203158
   Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001
   Rude MK, 2005, HYPERTENSION, V46, P555, DOI 10.1161/01.HYP.0000176236.55322.18
   Rutschow S, 2006, CARDIOVASC RES, V69, P646, DOI 10.1016/j.cardiores.2005.12.009
   Rutschow S, 2010, EUR J PHARMACOL, V630, P145, DOI 10.1016/j.ejphar.2009.12.019
   Savvatis K, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0449-2
   Savvatis K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041047
   Schultheiss HP, 2016, CLIN RES CARDIOL, V105, P763, DOI 10.1007/s00392-016-0986-9
   Seferovic PM, 2019, EUR J HEART FAIL, V21, P553, DOI 10.1002/ejhf.1461
   Shanbhag SM, 2019, EUR HEART J, V40, P529, DOI 10.1093/eurheartj/ehy713
   Spinale FG, 2007, PHYSIOL REV, V87, P1285, DOI 10.1152/physrev.00012.2007
   Spotnitz MD, 2006, PROG CARDIOVASC DIS, V49, P42, DOI 10.1016/j.pcad.2006.06.001
   Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Trachtenberg BH, 2017, CIRC RES, V121, P803, DOI 10.1161/CIRCRESAHA.117.310221
   Tschope C, 2019, CIRC RES, V124, P1568, DOI 10.1161/CIRCRESAHA.118.313578
   Tschope C, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.003870
   Tschope C, 2004, FASEB J, V18, P828, DOI 10.1096/fj.03-0736com
   Tschope C, 2019, EUR HEART J CASE REP, V3
   Van Linthout S, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/757154
   Westermann D, 2007, DIABETES, V56, P641, DOI 10.2337/db06-1163
   Westermann D, 2011, CIRCULATION, V124, P2082, DOI 10.1161/CIRCULATIONAHA.111.035964
   Westermann D, 2010, J MOL CELL CARDIOL, V48, P468, DOI 10.1016/j.yjmcc.2009.08.019
   Xiao J, 2009, EUR J HEART FAIL, V11, P349, DOI 10.1093/eurjhf/hfp023
NR 68
TC 2
Z9 2
U1 1
U2 1
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 2055-5822
J9 ESC HEART FAIL
JI ESC Heart Fail.
PD OCT
PY 2020
VL 7
IS 5
BP 2838
EP 2852
DI 10.1002/ehf2.12887
EA JUL 2020
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU0FB
UT WOS:000548201500001
PM 32662949
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lebow, JL
AF Lebow, Jay L.
TI The Challenges of COVID-19 for Divorcing and Post-divorce Families
SO FAMILY PROCESS
LA English
DT Article
DE Divorce; COVID-19; Couple Therapy; Family Therapy
AB COVID-19 and the accompanying procedures of shelter-in-place have had a powerful effect on all families but have additional special meanings in the context of families contemplating divorce, divorcing, or carrying out postdivorce arrangements. This paper explores those special meanings for these families. It also offers suggestions for couple and family therapists involved in helping these families during the time of COVID-19.
C1 [Lebow, Jay L.] Family Inst Northwestern, 618 Lib Pl, Evanston, IL 60201 USA.
   [Lebow, Jay L.] Northwestern Univ, Evanston, IL USA.
RP Lebow, JL (corresponding author), Family Inst Northwestern, 618 Lib Pl, Evanston, IL 60201 USA.
EM j-lebow@northwestern.edu
CR Ahrons C. R., 1994, GOOD DIVORCE KEEPING
   Doherty W. J., 2017, HELPING COUPLES BRIN
   Drozd V, 2016, 2016 14TH INTERNATIONAL BALTIC CONFERENCE ON ATOMIC LAYER DEPOSITION (BALD), P2, DOI 10.1109/BALD.2016.7886521
   Emery R. E., 2016, HDB FAMILY THERAPY, P484
   Emery R. E., 2016, 2 HOMES ONE CHILDHOO
   Gottman J. M., 2015, CLIN HDB COUPLE THER
   Greenberg L. R., 2016, PARENTING PLAN EVALU
   Greene S. M., 2003, NORMAL FAMILY PROCES, P96
   LEBOW J, 1982, PSYCHOL BULL, V91, P244, DOI 10.1037/0033-2909.91.2.244
   Lebow J. L., 2019, TREATING DIFFICULT D
   Lebow JL, 2020, FAM PROCESS, V59, P309, DOI 10.1111/famp.12543
   Lebow JL, 2019, FAM PROCESS, V58, P610, DOI 10.1111/famp.12473
   Prasso S., 2020, CHINAS DIVORCE SPIKE
   Russell WP, 2019, FAM PROCESS, V58, P641, DOI 10.1111/famp.12482
   Stanley SM, 2020, FAM PROCESS, V59, P937, DOI 10.1111/famp.12575
NR 15
TC 1
Z9 1
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 967
EP 973
DI 10.1111/famp.12574
EA JUL 2020
PG 7
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000548133800001
PM 32594521
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bartiromo, M
   Borchi, B
   Botta, A
   Bagala, A
   Lugli, G
   Tilli, M
   Cavallo, A
   Xhaferi, B
   Cutruzzula, R
   Vaglio, A
   Bresci, S
   Larti, A
   Bartoloni, A
   Cirami, C
AF Bartiromo, Marilu
   Borchi, Beatrice
   Botta, Annarita
   Bagala, Alfredo
   Lugli, Gianmarco
   Tilli, Marta
   Cavallo, Annalisa
   Xhaferi, Brunilda
   Cutruzzula, Roberta
   Vaglio, Augusto
   Bresci, Silvia
   Larti, Aida
   Bartoloni, Alessandro
   Cirami, Calogero
TI Threatening drug-drug interaction in a kidney transplant patient with
   coronavirus disease 2019 (COVID-19)
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; drug-drug interaction; kidney transplant
AB During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney-transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough, and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after 2 days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.
C1 [Bartiromo, Marilu; Cutruzzula, Roberta; Larti, Aida; Cirami, Calogero] Careggi Univ Hosp, Nephrol Unit, Florence, Italy.
   [Borchi, Beatrice; Cavallo, Annalisa; Bresci, Silvia; Bartoloni, Alessandro] Careggi Univ Hosp, Infect & Trop Dis Unit, Florence, Italy.
   [Botta, Annarita; Bagala, Alfredo; Lugli, Gianmarco; Tilli, Marta; Bartoloni, Alessandro] Univ Florence, Dept Expt & Clin Med, Florence, Italy.
   [Xhaferi, Brunilda] Univ Milano Bicocca, Nephrol Unit, Milan, Italy.
   [Vaglio, Augusto] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy.
   [Vaglio, Augusto] Meyer Childrens Hosp, Nephrol & Dialysis Unit, Florence, Italy.
RP Bartiromo, M (corresponding author), Careggi Univ Hosp, Nephrol Unit, Florence, Italy.
EM bartiromom@aou-careggi.toscana.it
OI Tilli, Marta/0000-0002-2097-2443; Borchi, Beatrice/0000-0002-4063-5225;
   Botta, Annarita/0000-0002-9033-1211; Lugli,
   Gianmarco/0000-0001-6626-3258
CR AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Barau C, 2009, FUND CLIN PHARMACOL, V23, P423, DOI 10.1111/j.1472-8206.2009.00706.x
   Cao B, 2020, NEW ENGL J MED, V382
   Cheng Y, 2020, KIDNEY IMPAIRMENT IS, V02, P20023242
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 10
TC 27
Z9 27
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2020
VL 22
IS 4
AR e13286
DI 10.1111/tid.13286
EA JUL 2020
PG 4
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA ND2PU
UT WOS:000548138400001
PM 32279418
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Arvin, AM
   Fink, K
   Schmid, MA
   Cathcart, A
   Spreafico, R
   Havenar-Daughton, C
   Lanzavecchia, A
   Corti, D
   Virgin, HW
AF Arvin, Ann M.
   Fink, Katja
   Schmid, Michael A.
   Cathcart, Andrea
   Spreafico, Roberto
   Havenar-Daughton, Colin
   Lanzavecchia, Antonio
   Corti, Davide
   Virgin, Herbert W.
TI A perspective on potential antibody-dependent enhancement of SARS-CoV-2
SO NATURE
LA English
DT Article; Early Access
ID RESPIRATORY SYNDROME CORONAVIRUS; HUMAN MONOCLONAL-ANTIBODY;
   PARAINFLUENZA VIRUS-VACCINE; SARS-CORONAVIRUS; CONVALESCENT PLASMA;
   EFFECTOR FUNCTIONS; PROTECTIVE EFFICACY; SPIKE GLYCOPROTEIN;
   IMMUNE-RESPONSE; INFECTION
AB The antibody-dependent enhancement of disease is reviewed, with an emphasis on implications for the prevention and treatment of SARS-CoV-2 infection.
   Antibody-dependent enhancement (ADE) of disease is a general concern for the development of vaccines and antibody therapies because the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in the pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we review observations relevant to the risks of ADE of disease, and their potential implications for SARS-CoV-2 infection. At present, there are no known clinical findings, immunological assays or biomarkers that can differentiate any severe viral infection from immune-enhanced disease, whether by measuring antibodies, T cells or intrinsic host responses. In vitro systems and animal models do not predict the risk of ADE of disease, in part because protective and potentially detrimental antibody-mediated mechanisms are the same and designing animal models depends on understanding how antiviral host responses may become harmful in humans. The implications of our lack of knowledge are twofold. First, comprehensive studies are urgently needed to define clinical correlates of protective immunity against SARS-CoV-2. Second, because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies-regardless of what virus is the causative agent-it will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward.
C1 [Arvin, Ann M.; Fink, Katja; Schmid, Michael A.; Cathcart, Andrea; Spreafico, Roberto; Havenar-Daughton, Colin; Lanzavecchia, Antonio; Corti, Davide; Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA 94158 USA.
   [Arvin, Ann M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Fink, Katja; Schmid, Michael A.; Lanzavecchia, Antonio; Corti, Davide] Humabs Biomed SA, Bellinzona, Switzerland.
   [Virgin, Herbert W.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
RP Arvin, AM; Virgin, HW (corresponding author), Vir Biotechnol, San Francisco, CA 94158 USA.; Arvin, AM (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.; Virgin, HW (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.
EM aarvin@vir.bio; svirgin@vir.bio
OI Virgin, Herbert/0000-0001-8580-7628; Corti, Davide/0000-0002-5797-1364
CR [Anonymous], 2019, VACCINE, V37, P4848, DOI 10.1016/j.vaccine.2018.09.063
   [Anonymous], 2017, REGENERON DISCONTINU
   Aranda SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01006
   Atkinson J. P., 2019, CLIN IMMUNOL, DOI [10.1016/B978-0-7020-6896-6.00021-1, DOI 10.1016/B978-0-7020-6896-6.00021-1]
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009
   Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023
   Braun J, 2020, PREPRINT, DOI [10.1101/2020.04.17.20061440v1, DOI 10.1101/2020.04.17.20061440V1]
   Browne SK, 2020, VACCINE, V38, P101, DOI 10.1016/j.vaccine.2019.10.048
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Chan KH, 2005, CLIN DIAGN LAB IMMUN, V12, P1317, DOI 10.1128/CDLI.12.11.1317-1321.2005
   Chan KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.164, 10.1038/nmicrobiol.2016.164]
   Chan Zuckerberg, LUNG CELL ATL
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen Z, 2017, J INFECT DIS, V215, P1807, DOI 10.1093/infdis/jix209
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957
   Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Co MDT, 2014, VIRAL IMMUNOL, V27, P375, DOI 10.1089/vim.2014.0061
   Corbett KS, 2020, PREPRINT, DOI [10.1101/2020.06.11.145920v1, DOI 10.1101/2020.06.11.145920V1]
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Crowley AR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00697
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   de Alwis R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004386
   de Wit E, 2019, ANTIVIR RES, V163, P70, DOI 10.1016/j.antiviral.2019.01.016
   de Wit E, 2018, ANTIVIR RES, V156, P64, DOI 10.1016/j.antiviral.2018.06.006
   Dekkers G, 2017, MABS-AUSTIN, V9, P767, DOI 10.1080/19420862.2017.1323159
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Domachowske JB, 2018, PEDIATR INFECT DIS J, V37, P886, DOI [10.1097/inf.0000000000001916, 10.1097/INF.0000000000001916]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956
   Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gunn BM, 2018, CELL HOST MICROBE, V24, P221, DOI 10.1016/j.chom.2018.07.009
   Guo X., 2020, PREPRINT, DOI [10.1101/2020.02.12.20021386v1, DOI 10.1101/2020.02.12.20021386V1]
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Ho MS, 2005, EMERG INFECT DIS, V11, P1730, DOI 10.3201/eid1111.040659
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Huang A., 2020, PREPRINT, DOI [10.1101/2020.04.14.20065771v1, DOI 10.1101/2020.04.14.20065771V1]
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Johnson RF, 2016, VIROLOGY, V490, P49, DOI 10.1016/j.virol.2016.01.004
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366
   KIM HW, 1976, PEDIATR RES, V10, P75, DOI 10.1203/00006450-197601000-00015
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lam JH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94500
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lansbury LE, 2017, VACCINE, V35, P1996, DOI 10.1016/j.vaccine.2017.02.059
   Lau Y L, 2012, Hong Kong Med J, V18 Suppl 3, P28
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Lee N, 2006, J CLIN VIROL, V35, P179, DOI 10.1016/j.jcv.2005.07.005
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Martines RB, 2020, EMERG INFECT DIS, V26, P2005, DOI 10.3201/eid2609.202095
   Miyoshi-Akiyama T, 2011, J INFECT DIS, V203, P1574, DOI 10.1093/infdis/jir084
   Munster VJ, 2020, PREPRINT, DOI [10.1101/2020.03.21.001628v1, DOI 10.1101/2020.03.21.001628V1]
   MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Muus C., 2020, INTEGRATED ANAL SING, DOI [10.1101/2020.04.19.049254v2, DOI 10.1101/2020.04.19.049254V2]
   Ng K., 2020, PREPRINT, DOI [10.1101/2020.05.14.095414v1, DOI 10.1101/2020.05.14.095414V1]
   Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x
   Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pedersen NC, 2014, VET J, V201, P123, DOI 10.1016/j.tvjl.2014.04.017
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Quinlan BD, 2020, SARS COV 2 RECEPTOR, DOI DOI 10.1101/2020.04.10.036418V1
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   REED SE, 1984, J MED VIROL, V13, P179, DOI 10.1002/jmv.1890130208
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258
   Smith P, 2012, P NATL ACAD SCI USA, V109, P6181, DOI 10.1073/pnas.1203954109
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Tynell J, 2016, J GEN VIROL, V97, P344, DOI 10.1099/jgv.0.000351
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   VanBlargan LA, 2016, MICROBIOL MOL BIOL R, V80, DOI 10.1128/MMBR.00024-15
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan Y, 2020, J VIROL, V94
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wellcome Sanger Institute, CELL ATL
   Winarski KL, 2019, P NATL ACAD SCI USA, V116, P15194, DOI 10.1073/pnas.1821317116
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu JT, 2010, CLIN INFECT DIS, V51, P1184, DOI 10.1086/656740
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Yu J, 2020, SCIENCE, DOI [10.1126/science.abc62847388591, DOI 10.1126/SCIENCE.ABC62847388591]
   Zandman-Goddard G, 2005, CLIN REV ALLERG IMMU, V29, P219, DOI 10.1385/CRIAI:29:3:219
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhou J, 2005, VACCINE, V23, P3202, DOI 10.1016/j.vaccine.2004.11.075
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zost S. J., 2020, PREPRINT, DOI [10.1101/2020.05.22.111005v1, DOI 10.1101/2020.05.22.111005V1]
NR 139
TC 28
Z9 27
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2538-8
EA JUL 2020
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MZ5MC
UT WOS:000559167200001
PM 32659783
OA Bronze
DA 2021-01-01
ER

PT J
AU Si, DY
   Du, BB
   Ni, LJ
   Yang, B
   Sun, H
   Jiang, N
   Liu, GH
   Masse, S
   Jin, LA
   Nanthakumar, J
   Bhaskaran, A
   Yang, P
   Nanthakumar, K
AF Si, Daoyuan
   Du, Beibei
   Ni, Lujia
   Yang, Bo
   Sun, Huan
   Jiang, Nan
   Liu, Guohui
   Masse, Stephane
   Jin, Lina
   Nanthakumar, Jared
   Bhaskaran, Abhishek
   Yang, Ping
   Nanthakumar, Kumaraswamy
TI Death, discharge and arrhythmias among patients with COVID-19 and
   cardiac injury
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
ID REPOLARIZATION
AB BACKGROUND: Cardiac injury is common in severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. We aimed to study predictors of in-hospital death, characteristics of arrhythmias and the effects of QT-prolonging therapy in patients with cardiac injury. METHODS: We conducted a retrospective cohort study involving patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan, China, between Jan. 29 and Mar. 8, 2020. Among patients who had cardiac injury, which we defined as an elevated level of cardiac troponin I (cTnI), we identified demographic and clinical characteristics associated with mortality and need for invasive ventilation. RESULTS: Among 1284 patients with severe COVID-19, 1159 had a cTnI level measured on admission to hospital, of whom 170 (14.7%) had results that showed cardiac injury. We found that mortality was markedly higher in patients with cardiac injury (71.2% v. 6.6%,p< 0.001). We determined that initial cTnI (per 10-fold increase, hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.06-1.66) and peak cTnI level during illness (per 10-fold increase, HR 1.70, 95% CI 1.38-2.10) were associated with poor survival. Peak cTnI was also associated with the need for invasive ventilation (odds ratio 3.02, 95% CI 1.92-4.98). We found arrhythmias in 44 of the 170 patients with cardiac injury (25.9%), including 6 patients with ventricular tachycardia or fibrillation, all of whom died. We determined that patients who received QT-prolonging drugs had longer QTc intervals than those who did not receive them (difference in medians, 45 ms,p= 0.01), but such treatment was not independently associated with mortality (HR 1.04, 95% CI 0.69-1.57). INTERPRETATION: We found that in patients with COVID-19 and cardiac injury, initial and peak cTnI levels were associated with poor survival, and peak cTnI was a predictor of need for invasive ventilation. Patients with COVID-19 warrant assessment for cardiac injury and monitoring, especially if therapy that can prolong repolarization is started.
C1 [Si, Daoyuan; Du, Beibei; Sun, Huan; Liu, Guohui; Yang, Ping] Third Hosp Jilin Univ, Jilin Prov Mol Biol Res Ctr Precis Med Major Card, Dept Cardiol, Changchun, Peoples R China.
   [Ni, Lujia] Third Hosp Jilin Univ, Dept Ultrasound, Changchun, Peoples R China.
   [Yang, Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Organ Transplantat, Wuhan, Peoples R China.
   [Jiang, Nan] Third Hosp Jilin Univ, Intens Care Unit, Changchun, Peoples R China.
   [Masse, Stephane; Nanthakumar, Jared; Bhaskaran, Abhishek; Nanthakumar, Kumaraswamy] Univ Toronto, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Hull Family Lab, Toronto, ON, Canada.
   [Jin, Lina] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Changchun, Jilin, Peoples R China.
RP Si, DY (corresponding author), Third Hosp Jilin Univ, Jilin Prov Mol Biol Res Ctr Precis Med Major Card, Dept Cardiol, Changchun, Peoples R China.; Nanthakumar, K (corresponding author), Univ Toronto, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Hull Family Lab, Toronto, ON, Canada.
EM sidaoyuan@jlu.edu.cn; kumar.nanthakumar@uhn.ca
OI Du, Beibei/0000-0002-0991-5798
FU Excellent Youth Foundation of Science and Technology of Jilin Province
   [20180520054JH]; "13th Five-Year" Science Project of Jilin Province
   Education Department [JJKH20190062KJ]
FX This work was supported by the grants from Excellent Youth Foundation of
   Science and Technology of Jilin Province (No. 20180520054JH) and "13th
   Five-Year" Science Project of Jilin Province Education Department (No.
   JJKH20190062KJ).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chauhan VS, 2006, AM J PHYSIOL-HEART C, V290, pH79, DOI 10.1152/ajpheart.00648.2005
   Chen C, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P567, DOI 10.3760/cma.j.cn112148-20200225-00123
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007621.2020, DOI 10.1056/NEJMOA2007621.2020]
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Sutton PMI, 2000, HEART, V84, P365, DOI 10.1136/heart.84.4.365
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Yu CM, 2006, POSTGRAD MED J, V82, P140, DOI 10.1136/pgmj.2005.037515
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 4
Z9 4
U1 3
U2 3
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0820-3946
EI 1488-2329
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD JUL 13
PY 2020
VL 192
IS 28
BP E791
EP E798
DI 10.1503/cmaj.200879
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR4BU
UT WOS:000553534700001
PM 32586839
OA Bronze
DA 2021-01-01
ER

PT J
AU Smith, K
   Pace, A
   Ortiz, S
   Kazani, S
   Rottinghaus, S
AF Smith, Keisha
   Pace, Amy
   Ortiz, Stephan
   Kazani, Shamsah
   Rottinghaus, Scott
TI A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the
   Efficacy and Safety of Intravenously Administered Ravulizumab Compared
   with Best Supportive Care in Patients with COVID-19 Severe Pneumonia,
   Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured
   summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; severe acute respiratory distress syndrome coronavirus 2; lung
   injury; acute respiratory distress syndrome; respiratory distress
   syndrome; severe pneumonia; severe acute respiratory syndrome; acute
   pneumonia; viral; ravulizumab; antibodies; monoclonal; humanized;
   complement; complement inhibitor; Ultomiris; hospitalization; randomized
   controlled study; adult
AB Objectives: Primary Objective
   To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19.
   Secondary Objectives
   Number of days free of mechanical ventilation at Day 29
   Duration of intensive care unit stay at Day 29
   Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 29
   Change from baseline in peripheral capillary oxygen saturation/ fraction of inspired oxygen (SpO2 /FiO2) at Day 29
   Duration of hospitalization at Day 29
   Survival (based on all-cause mortality) at Day 60 and Day 90 Safety
   Incidence of treatment-emergent adverse events and treatment-emergent serious adverse events.
   PK/PD/Immunogenicity
   Change in serum ravulizumab concentrations over time
   Change in serum free and total C5 concentrations over time
   Incidence and titer of anti-ALXN1210 antibodies
   Biomarkers
   Change in absolute level of soluble biomarkers in blood associated with complement activation, inflammatory processes, and hypercoagulable states over time
   Exploratory
   Incidence of progression to renal failure requiring dialysis at Day 29
   Time to clinical improvement (based on a modified 6-point ordinal scale) over 29 days
   SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Day 29 (or discharge), Day 60, and Day 90
   EuroQol 5-dimension 5-level (EQ-5D-5L) scores at Day 29 (or discharge), Day 60, and Day 90
   Trial design: This is a multicenter Phase 3, open-label, randomized, controlled, study.
   The study is being conducted in acute care hospital settings in the United States, United Kingdom, Spain, France, Germany, and Japan.
   Participants: Male or female patients at least 18 years of age, weighing >= 40 kg, admitted to a designated hospital facility for treatment will be screened for eligibility in this study.
   Key Inclusion criteria
   Confirmed diagnosis of SARS-CoV-2 infection (eg, via polymerase chain reaction [PCR] and/or antibody test) presenting as severe COVID-19 requiring hospitalization
   Severe pneumonia, acute lung injury, or ARDS confirmed by computed tomography (CT) or X-ray at Screening or within the 3 days prior to Screening, as part of the patient's routine clinical care
   Respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or non-invasive (with continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BiPAP])
   Key Exclusion criteria
   Patient is not expected to survive for more than 24 hours
   Patient is on invasive mechanical ventilation with intubation for more than 48 hours prior to Screening
   Severe pre-existing cardiac disease (ie, NYHA Class 3 or Class 4, acute coronary syndrome, or persistent ventricular tachyarrhythmias)
   Patient has an unresolvedNeisseria meningitidisinfection
   Excluded medications and therapies
   Current treatment with a complement inhibitor
   Intravenous immunoglobulin (IVIg) within 4 weeks prior to randomization on Day 1
   Excluded prior/concurrent clinical study experience
   Treatment with investigational therapy in a clinical study within 30 days before randomization, or within 5 half-lives of that investigational therapy, whichever is greater
   Exceptions
   a. Investigational therapies will be allowed if received as part of best supportive care through an expanded access protocol or emergency approval for the treatment of COVID-19.
   b. Investigational antiviral therapies (such as remdesivir) will be allowed even if received as part of a clinical study.
   Intervention and comparator: The study consists of a Screening Period of up to 3 days, a Primary Evaluation Period of 4 weeks, a final assessment at Day 29, and a Follow-up Period of 8 weeks. For patients randomized to ravulizumab plus BSC, a weight-based dose of ravulizumab (>= 40 to < 60 kg/2400 mg, 60 to < 100 kg/2700 mg, >= 100 kg/3000 mg) will be administered on Day 1. On Day 5 and Day 10, additional doses of 600 mg (>= 40 to <60 kg) or 900 mg (>60 kg) ravulizumab will be administered and on Day 15 patients will receive 900 mg ravulizumab. There is no active or placebo comparator in this open-label clinical trial. The total duration of each patient's participation is anticipated to be approximately 3 months.
   Main outcomes: The primary efficacy outcome of this study is survival (based on all-cause mortality) at Day 29.
   Randomisation: Patients will be randomized in a 2:1 ratio (ravulizumab plus BSC:BSC alone). Randomization will be stratified by intubated or not intubated on Day 1. Computer-generated randomization lists will be prepared by a third party under the direction of the sponsor. Investigators, or designees, will enrol patients and then obtain randomization codes using an interactive voice/web response system. The block size will be kept concealed so that investigators cannot select patients for a particular treatment assignment.
   Blinding (masking):This is an open-label study.
   Numbers to be randomised (sample size): Approximately 270 patients will be randomly assigned in a 2:1 ratio to ravulizumab plus BSC (n=180) or BSC alone (n=90).
   Trial status: Protocol Number: ALXN1210-COV-305
   Original Protocol: 09 Apr 2020
   Protocol Amendment 1 (Global): 13 Apr 2020
   Protocol Amendment 2 (Global): 17 Apr 2020
   Protocol Amendment 3 (Global): 09 Jun 2020
   Recruitment is currently ongoing.
   Recruitment was initiated on 11 May 2020.
   We expect recruitment to be completed by 30 Nov 2020.
C1 [Smith, Keisha] Alex Pharmaceut, Med Writing, Boston, MA USA.
   [Pace, Amy] Alex Pharmaceut, Quantitat Sci, Boston, MA USA.
   [Ortiz, Stephan] Alex Pharmaceut, Clin Pharmacol, Boston, MA USA.
   [Kazani, Shamsah; Rottinghaus, Scott] Alex Pharmaceut Inc, Dept Clin Dev Sci, 121 Seaport Blvd, Boston, MA 02210 USA.
RP Rottinghaus, S (corresponding author), Alex Pharmaceut Inc, Dept Clin Dev Sci, 121 Seaport Blvd, Boston, MA 02210 USA.
EM Scott.Rottinghaus@alexion.com
FU Alexion Pharmaceuticals, Inc.; Boston MA
FX This study was funded by Alexion Pharmaceuticals, Inc. Boston MA. The
   study sponsor is responsible for designing the study. All authors were
   responsible for the development and approval of this Letter.
NR 0
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 13
PY 2020
VL 21
IS 1
AR 639
DI 10.1186/s13063-020-04548-z
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MQ4HD
UT WOS:000552854600002
PM 32660611
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Andrianov, AM
   Kornoushenko, YV
   Karpenko, AD
   Bosko, IP
   Tuzikov, AV
AF Andrianov, Alexander M.
   Kornoushenko, Yuri V.
   Karpenko, Anna D.
   Bosko, Ivan P.
   Tuzikov, Alexander V.
TI Computational discovery of small drug-like compounds as potential
   inhibitors of SARS-CoV-2 main protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus SARS-CoV-2; COVID-19; main protease; SARS-CoV-2 inhibitors;
   virtual screening; molecular docking; quantum chemical calculations;
   antiviral drugs
ID MOLECULAR-DYNAMICS; OPTIMIZATION; MM/PBSA; SYSTEM; SARS
AB A computational approach to insilicodrug discovery was carried out to identify small drug-like compounds able to show structural and functional mimicry of the high affinity ligand X77, potent non-covalent inhibitor of SARS-COV-2 main protease (M-Pro). In doing so, the X77-mimetic candidates were predicted based on the crystal X77-M(Pro)structure by a public web-oriented virtual screening platform Pharmit. Models of these candidates bound to SARS-COV-2 M(Pro)were generated by molecular docking, quantum chemical calculations and molecular dynamics simulations. At the final point, analysis of the interaction modes of the identified compounds with M(Pro)and prediction of their binding affinity were carried out. Calculation revealed 5 top-ranking compounds that exhibited a high affinity to the active site of SARS-CoV-2 M-Pro. Insights into the ligand - M(Pro)models indicate that all identified compounds may effectively block the binding pocket of SARS-CoV-2 M-Pro, in line with the low values of binding free energy and dissociation constant. Mechanism of binding of these compounds to M(Pro)is mainly provided by van der Waals interactions with the functionally important residues of the enzyme, such as His-41, Met-49, Cys-145, Met-165, and Gln-189 that play a role of the binding hot spots assisting the predicted molecules to effectively interact with the M(Pro)active site. The data obtained show that the identified X77-mimetic candidates may serve as good scaffolds for the design of novel antiviral agents able to target the active site of SARS-CoV-2 M-Pro. Communicated by Ramaswamy H. Sarma
C1 [Andrianov, Alexander M.; Kornoushenko, Yuri V.] Natl Acad Sci Belarus, Inst Bioorgan Chem, Minsk, BELARUS.
   [Karpenko, Anna D.; Bosko, Ivan P.; Tuzikov, Alexander V.] Natl Acad Sci Belarus, United Inst Informat Problems, Minsk, BELARUS.
RP Andrianov, AM (corresponding author), Natl Acad Sci Belarus, Inst Bioorgan Chem, Minsk, BELARUS.
EM alexande.andriano@yandex.ru
FU State Program of Scientific Research "Convergence 2020" (subprogram
   "Consolidation", project 3.08); Belarusian Republican Foundation for
   Fundamental Research [X20MC-006]
FX ` This study was funded by grants from the State Program of Scientific
   Research "Convergence 2020" (subprogram "Consolidation", project 3.08)
   and the Belarusian Republican Foundation for Fundamental Research
   (project X20~~-006).
CR Adeoye AO, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1765876
   Alhossary A, 2015, BIOINFORMATICS, V31, P2214, DOI 10.1093/bioinformatics/btv082
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bzowka M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093099
   Case D., 2020, AMBER 2020
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang GG, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P115, DOI 10.1007/978-3-642-03683-5_8
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Durrant JD, 2011, J CHEM INF MODEL, V51, P2897, DOI 10.1021/ci2003889
   Durrant JD, 2011, J MOL GRAPH MODEL, V29, P888, DOI 10.1016/j.jmgm.2011.01.004
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fischer A, 2020, INHIBITORS NOVEL COR, DOI [10.26434/chemrxiv.11923239.v1, DOI 10.26434/CHEMRXIV.11923239.V1]
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Golbraikh A., 2017, HDB COMPUTATIONAL CH, P2303
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.2020.1751300
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Hoyvik IM, 2012, J CHEM THEORY COMPUT, V8, P3137, DOI 10.1021/ct300473g
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Klamt A, 2015, J CHEM THEORY COMPUT, V11, P4220, DOI 10.1021/acs.jctc.5b00601
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Klamt A., 2005, COSMO RS QUANTUM CHE, P246
   Kuseva C, 2019, REGUL TOXICOL PHARM, V105, P51, DOI 10.1016/j.yrtph.2019.03.018
   Lehtola S, 2013, J CHEM THEORY COMPUT, V9, P5365, DOI 10.1021/ct400793q
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu X., 2020, POTENTIAL INHIBITORS, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schultz TW, 2018, METHODS MOL BIOL, V1800, P55, DOI 10.1007/978-1-4939-7899-1_2
   Sharma G, 2009, J BIOL CHEM, V284, P4179, DOI 10.1074/jbc.M808500200
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Strodel B, 2020, HIGH THROUGHPUT VIRT, DOI [10.20944/preprints202004.0161.v1, DOI 10.20944/PREPRINTS202004.0161.V1]
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Vega Valdez IR, 2020, THEORETICAL EVALUATI, DOI [10.26434/chemrxiv.12047346.v1, DOI 10.26434/CHEMRXIV.12047346.V1]
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Xu L, 2013, J PHYS CHEM B, V117, P8408, DOI 10.1021/jp404160y
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yao H., 2020, PATIENT DERIVED MUTA, DOI [10.1101/2020.04.14.20060160, DOI 10.1101/2020.04.14.20060160]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 68
TC 1
Z9 1
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792989
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MN5CW
UT WOS:000550860400001
PM 32662333
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Park, H
   Kim, SH
AF Park, Hojeong
   Kim, Songhee H.
TI A Study on Herd Immunity of COVID-19 in South Korea: Using a Stochastic
   Economic-Epidemiological Model
SO ENVIRONMENTAL & RESOURCE ECONOMICS
LA English
DT Article
DE COVID-19; Vaccination stockpile; SIS; Stochastic disease
AB Vaccination is an effective measure to control the diffusion of infectious disease such as COVID-19. This paper analyzes the basic reproduction number in South Korea which enables us to identify a necessary level of vaccine stockpile to achieve herd immunity. An susceptible-infected-susceptible model is adopted that allows a stochastic diffusion. The result shows that the basic reproduction number of South Korea is approximately 2 which is substantially lower than those of the other regions. The herd immunity calculated from economic-epidemiological model suggests that at least 62% of the susceptible population be vaccinated when COVID-19 vaccine becomes available.
C1 [Park, Hojeong] Korea Univ, Dept Food & Resource Econ, Seoul, South Korea.
   [Park, Hojeong] Korea Univ, KU KIST Energy & Environm Sch, Seoul, South Korea.
   [Kim, Songhee H.] Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea.
   [Kim, Songhee H.] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.
RP Park, H (corresponding author), Korea Univ, Dept Food & Resource Econ, Seoul, South Korea.; Park, H (corresponding author), Korea Univ, KU KIST Energy & Environm Sch, Seoul, South Korea.
EM hjeongpark@korea.ac.kr
CR Alimohamadi Y, 2020, J PREV MED PUBLIC HL
   Bethune Z, 2020, COVID 19 INFECT EXTE
   Bokharaie V.S, 2020, MATH MODEL PREDICT S
   D'Arienzo Marco, 2020, Biosaf Health, V2, P57, DOI 10.1016/j.bsheal.2020.03.004
   Hwang J, 2020, BASIC EFFECTIVE REPR, DOI [10.1101/2020.03.19.20039347, DOI 10.1101/2020.03.19.20039347]
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   NHIS, 2017, STUD SOC COSTS ILLN
   Park H, 2016, ECON MODEL, V53, P187, DOI 10.1016/j.econmod.2015.12.005
   Sanche S, 2020, EMERGING INFECT DIS, V26, P26
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
NR 10
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-6460
EI 1573-1502
J9 ENVIRON RESOUR ECON
JI Environ. Resour. Econ.
PD AUG
PY 2020
VL 76
IS 4
SI SI
BP 665
EP 670
DI 10.1007/s10640-020-00439-8
EA JUL 2020
PG 6
WC Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA NI2YK
UT WOS:000548160400001
PM 32836840
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Paliwal, PR
   Tan, BYQ
   Leow, AST
   Sibi, S
   Chor, DWP
   Chin, AXY
   Yau, YW
   Cross, GB
   Wong, LYH
   Chia, MLJ
   Quak, ZX
   Chua, CYK
   Tang, DKK
   Zune, ET
   Hung, J
   Goh, YH
   Jing, MX
   Gopinathan, A
   Yang, CL
   Ahmad, A
   Khoo, DXL
   Lee, CCM
   Seet, RCS
   Sharma, VK
   Teoh, HL
   Yeo, LLL
   Chan, BPL
AF Paliwal, Prakash R.
   Tan, Benjamin Y. Q.
   Leow, Aloysius S. T.
   Sibi, Sunny
   Chor, Daniel W. P.
   Chin, Amanda X. Y.
   Yau, Ying-Wei
   Cross, Gail B.
   Wong, Lily Y. H.
   Chia, Magdalene L. J.
   Quak, Zhixuan
   Chua, Christopher Y. K.
   Tang, David K. K.
   Zune, Ei The
   Hung, Jennifer
   Goh, Yihui
   Jing, Mingxue
   Gopinathan, Anil
   Yang, Cunli
   Ahmad, Aftab
   Khoo, Deborah X. L.
   Lee, Chang-Chuan M.
   Seet, Raymond C. S.
   Sharma, Vijay K.
   Teoh, Hock-Luen
   Yeo, Leonard L. L.
   Chan, Bernard P. L.
TI Impact of the COVID-19 pandemic on hyperacute stroke treatment:
   experience from a comprehensive stroke centre in Singapore
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article
DE Acute ischaemic stroke; COVID-19; Stroke activation; Recanalization
   therapy
ID ACUTE ISCHEMIC-STROKE
AB The Coronavirus disease 2019 (COVID-19) pandemic is rapidly evolving and affecting healthcare systems across the world. Singapore has escalated its alert level to Disease Outbreak Response System Condition (DORSCON) Orange, signifying severe disease with community spread. We aimed to study the overall volume of AIS cases and the delivery of hyperacute stroke services during DORSCON Orange. This was a single-centre, observational cohort study performed at a comprehensive stroke centre responsible for AIS cases in the western region of Singapore, as well as providing care for COVID-19 patients. All AIS patients reviewed as an acute stroke activation in the Emergency Department (ED) from November 2019 to April 2020 were included. System processes timings, treatment and clinical outcome variables were collected. We studied 350 AIS activation patients admitted through the ED, 206 (58.9%) pre- and 144 during DORSCON Orange. Across the study period, number of stroke activations showed significant decline (p = 0.004, 95% CI 6.513 to - 2.287), as the number of COVID-19 cases increased exponentially, whilst proportion of activations receiving acute recanalization therapy remained stable (p = 0.519, 95% CI - 1.605 to 2.702). Amongst AIS patients that received acute recanalization therapy, early neurological outcomes in terms of change in median NIHSS at 24 h (-4 versus -4,p = 0.685) were largely similar between the pre- and during DORSCON orange periods. The number of stroke activations decreased while the proportion receiving acute recanalization therapy remained stable in the current COVID-19 pandemic in Singapore.
C1 [Paliwal, Prakash R.; Tan, Benjamin Y. Q.; Sibi, Sunny; Chin, Amanda X. Y.; Wong, Lily Y. H.; Chia, Magdalene L. J.; Quak, Zhixuan; Chua, Christopher Y. K.; Tang, David K. K.; Zune, Ei The; Hung, Jennifer; Goh, Yihui; Jing, Mingxue; Seet, Raymond C. S.; Sharma, Vijay K.; Teoh, Hock-Luen; Yeo, Leonard L. L.; Chan, Bernard P. L.] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Neurol, 1E Kent Ridge Rd, Singapore 119228, Singapore.
   [Tan, Benjamin Y. Q.; Cross, Gail B.; Seet, Raymond C. S.; Sharma, Vijay K.; Yeo, Leonard L. L.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Leow, Aloysius S. T.] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Singapore, Singapore.
   [Chor, Daniel W. P.; Yau, Ying-Wei] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Emergency Med, Singapore, Singapore.
   [Cross, Gail B.] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Infect Dis, Singapore, Singapore.
   [Gopinathan, Anil; Yang, Cunli] Natl Univ Hlth Syst, Dept Diagnost Imaging, Div Intervent Radiol, Singapore, Singapore.
   [Ahmad, Aftab] Ng Teng Fong Hosp, Dept Med, Div Neurol, Singapore, Singapore.
   [Khoo, Deborah X. L.; Lee, Chang-Chuan M.] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Anaesthesia, Singapore, Singapore.
RP Yeo, LLL (corresponding author), Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Neurol, 1E Kent Ridge Rd, Singapore 119228, Singapore.; Yeo, LLL (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
EM leonardyeoll@gmail.com
RI ; sharma, Vijay/T-5286-2019
OI WONG, LILY/0000-0002-6772-9053; yeo, leonard/0000-0002-4249-0402;
   sharma, Vijay/0000-0002-8976-5696
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Baracchini C, 2020, NEUROL SCI, V1, P9
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108
   Hill MD, 2004, NEUROLOGY, V62, P2015, DOI 10.1212/01.WNL.0000129482.70315.2F
   Khosravani H, 2020, STROKE
   Lyden P, 2020, STROKE, V51, P1910, DOI 10.1161/STROKEAHA.120.030023
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Morelli N, 2020, EUR NEUROL, V83, P213, DOI 10.1159/000507666
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Roussel Y, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105947
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tan BYQ, 2018, J STROKE CEREBROVASC, V27, P1539, DOI 10.1016/j.jstrokecerebrovasdis.2018.01.005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, INF PREV CONTR HLTH
   Yeo LLL, 2013, JAMA NEUROL, V70, P353, DOI 10.1001/2013.jamaneurol.547
NR 17
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
PD OCT
PY 2020
VL 50
IS 3
BP 596
EP 603
DI 10.1007/s11239-020-02225-1
EA JUL 2020
PG 8
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NS7SM
UT WOS:000548247900001
PM 32661758
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Juno, JA
   Tan, HX
   Lee, WS
   Reynaldi, A
   Kelly, HG
   Wragg, K
   Esterbauer, R
   Kent, HE
   Batten, CJ
   Mordant, FL
   Gherardin, NA
   Pymm, P
   Dietrich, MH
   Scott, NE
   Tham, WH
   Godfrey, DI
   Subbarao, K
   Davenport, MP
   Kent, SJ
   Wheatley, AK
AF Juno, Jennifer A.
   Tan, Hyon-Xhi
   Lee, Wen Shi
   Reynaldi, Arnold
   Kelly, Hannah G.
   Wragg, Kathleen
   Esterbauer, Robyn
   Kent, Helen E.
   Batten, C. Jane
   Mordant, Francesca L.
   Gherardin, Nicholas A.
   Pymm, Phillip
   Dietrich, Melanie H.
   Scott, Nichollas E.
   Tham, Wai-Hong
   Godfrey, Dale, I
   Subbarao, Kanta
   Davenport, Miles P.
   Kent, Stephen J.
   Wheatley, Adam K.
TI Humoral and circulating follicular helper T cell responses in recovered
   patients with COVID-19
SO NATURE MEDICINE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZING ANTIBODIES; SARS-COV-2
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has dramatically expedited global vaccine development efforts(1-3), most targeting the viral 'spike' glycoprotein (S). S localizes on the virion surface and mediates recognition of cellular receptor angiotensin-converting enzyme 2 (ACE2)(4-6). Eliciting neutralizing antibodies that block S-ACE2 interaction(7-9), or indirectly prevent membrane fusion(10), constitute an attractive modality for vaccine-elicited protection(11). However, although prototypic S-based vaccines show promise in animal models(12-14), the immunogenic properties of S in humans are poorly resolved. In this study, we characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19). We found that S-specific antibodies, memory B cells and cTFH are consistently elicited after SARS-CoV-2 infection, demarking robust humoral immunity and positively associated with plasma neutralizing activity. Comparatively low frequencies of B cells or cTFH specific for the receptor binding domain of S were elicited. Notably, the phenotype of S-specific cTFH differentiated subjects with potent neutralizing responses, providing a potential biomarker of potency for S-based vaccines entering the clinic. Overall, although patients who recovered from COVID-19 displayed multiple hallmarks of effective immune recognition of S, the wide spectrum of neutralizing activity observed suggests that vaccines might require strategies to selectively target the most potent neutralizing epitopes.
   In a cohort of recovered patients with COVID-19, virus spike-specific antibodies were consistently elicited, but neutralizing activity was highly variable and inversely correlated with the proportion of CCR6(+)CXCR3(-)spike-specific circulating follicular helper T cells.
C1 [Juno, Jennifer A.; Tan, Hyon-Xhi; Lee, Wen Shi; Kelly, Hannah G.; Wragg, Kathleen; Esterbauer, Robyn; Kent, Helen E.; Batten, C. Jane; Mordant, Francesca L.; Gherardin, Nicholas A.; Scott, Nichollas E.; Godfrey, Dale, I; Subbarao, Kanta; Kent, Stephen J.; Wheatley, Adam K.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Reynaldi, Arnold; Davenport, Miles P.] Univ New South Wales, Kirby Inst, Kensington, NSW, Australia.
   [Kelly, Hannah G.; Esterbauer, Robyn; Kent, Stephen J.; Wheatley, Adam K.] Univ Melbourne, Australian Res Council Ctr Excellence Convergent, Melbourne, Vic, Australia.
   [Kent, Helen E.; Kent, Stephen J.] Monash Univ, Alfred Hosp, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Kent, Helen E.; Kent, Stephen J.] Monash Univ, Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia.
   [Kent, Helen E.; Kent, Stephen J.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia.
   [Gherardin, Nicholas A.; Godfrey, Dale, I] Univ Melbourne, Australian Res Council Ctr Excellence Adv Mol Ima, Melbourne, Vic, Australia.
   [Pymm, Phillip; Dietrich, Melanie H.; Tham, Wai-Hong] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
   [Pymm, Phillip; Dietrich, Melanie H.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.
   [Subbarao, Kanta] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.
RP Kent, SJ; Wheatley, AK (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.; Kent, SJ; Wheatley, AK (corresponding author), Univ Melbourne, Australian Res Council Ctr Excellence Convergent, Melbourne, Vic, Australia.
EM skent@unimelb.edu.au; awheatley@unimelb.edu.au
RI Tham, Wai-Hong/L-3173-2018
OI Tham, Wai-Hong/0000-0001-7950-8699; Batten,
   Caroline/0000-0003-2691-9915; Esterbauer, Robyn/0000-0002-7091-0048;
   Tan, Hyon Xhi/0000-0003-1064-3934; Juno, Jennifer/0000-0002-9072-1017;
   Davenport, Miles/0000-0002-4751-1831; Lee, Wen Shi/0000-0001-7285-4054;
   Mordant, Francesca/0000-0002-3754-2642
FU Victorian Government; Medical Research Future Fund (MRFF) [GNT2002073];
   ARC Centre of Excellence in Convergent Bio-Nano Science and
   TechnologyAustralian Research Council; National Health and Medical
   Research Council (NHMRC)National Health and Medical Research Council of
   Australia [APP1149990]; NHMRCNational Health and Medical Research
   Council of Australia [GNT1162760]; Jack Ma Foundation; A2 Milk Company;
   Howard Hughes Medical Institute-Wellcome Trust International Research
   Scholar [208693/Z/17/Z]; Australian Government Department of
   HealthAustralian GovernmentDepartment of Health & Ageing
FX We thank the generous participation of the trial individuals for
   providing samples. The SARS-CoV-2 RBD expression plasmids were kindly
   provided by F. Krammer (Icahn School of Medicine at Mt. Sinai). The
   human and mouse ACE2 expression plasmids were kindly provided by M.
   Thomas (Monash University). We acknowledge V. Jameson and staff at the
   Melbourne Cytometry Platform (Melbourne Brain Centre node) for provision
   of flow cytometry services. We thank the Melbourne Mass Spectrometry and
   Proteomics Facility of the Bio21 Molecular Science and Biotechnology
   Institute at the University of Melbourne for the support of mass
   spectrometry analysis. This study was supported by the Victorian
   Government and Medical Research Future Fund (MRFF) GNT2002073 (to
   W.-H.T., D.I.G., M.P.D., S.J.K. and A.K.W.), the ARC Centre of
   Excellence in Convergent Bio-Nano Science and Technology (to S.J.K.),
   National Health and Medical Research Council (NHMRC) program grant
   APP1149990 (to S.J.K. and M.P.D.), NHMRC project grant GNT1162760 (to
   A.K.W), the Jack Ma Foundation (to D.I.G., N.A.G. and K.S.) and the A2
   Milk Company (to K.S.). W-H.T. is a Howard Hughes Medical
   Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z).
   J.A.J., D.I.G., M.P.D., W.-H.T., S.J.K. and A.K.W. are supported by
   NHMRC fellowships. The Melbourne WHO Collaborating Centre for Reference
   and Research on Influenza is supported by the Australian Government
   Department of Health.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494
   Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191
   Bern Marshall, 2012, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1320s40
   Braun J., 2020, PRESENCE SARS COV 2
   Brenna E, 2020, CELL REP, V30, P137, DOI 10.1016/j.celrep.2019.12.016
   Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011
   Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318
   Farooq F, 2016, SCI REP-UK, V6, DOI 10.1038/srep27944
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Houser KV, 2016, J INFECT DIS, V213, P1557, DOI 10.1093/infdis/jiw080
   Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596-018-0082-x
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Koutsakos M, 2019, J IMMUNOL, V202, P360, DOI 10.4049/jimmunol.1800986
   Koutsakos M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8405
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau D, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai8153
   Lee LY, 2016, J PROTEOME RES, V15, P3904, DOI 10.1021/acs.jproteome.6b00438
   Liu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08165-y
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Niessl J, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102727
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   van Doremalen N, 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13.093195v1, DOI 10.1101/2020.05.13.093195V1]
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w
   Zhou WM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-433
NR 49
TC 22
Z9 22
U1 4
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2020
VL 26
IS 9
DI 10.1038/s41591-020-0995-0
EA JUL 2020
PG 22
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA PF3EM
UT WOS:000548125100003
PM 32661393
OA Bronze
DA 2021-01-01
ER

PT J
AU Pinky
   Gupta, S
   Krishnakumar, V
   Sharma, Y
   Dinda, AK
   Mohanty, S
AF Pinky
   Gupta, Suchi
   Krishnakumar, Vishnu
   Sharma, Yashvi
   Dinda, Amit Kumar
   Mohanty, Sujata
TI Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics
   and Drug Delivery in Combating COVID-19
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Therapeutics; Drug delivery; Nano-formulation; Lung diseases;
   Immuno-modulation
ID ACUTE LUNG INJURY; EXTRACELLULAR VESICLES; MICROVESICLES; NANOVESICLES;
   THERAPY
AB The recent pandemic situation transpired due to coronavirus novel strain SARS-CoV-2 has become a global concern. This human coronavirus (HCov-19) has put the world on high alert as the numbers of confirmed cases are continuously increasing. The world is now fighting against this deadly virus and is leaving no stone unturned to find effective treatments through testing of various available drugs, including those effective against flu, malaria, etc. With an urgent need for the development of potential strategies, two recent studies from China using Mesenchymal Stem Cells (MSCs) to treat COVID-19 pneumonia have shed some light on a potential cure for the COVID-19 infected patients. However, MSCs, despite being used in various other clinical trials have always been questioned for their tendency to aggregate or form clumps in the injured or disease microenvironment. It has also been reported in various studies that exosomes secreted by these MSCs, contribute towards the cell's biological and therapeutic efficacy. There have been reports evaluating the safety and feasibility of these exosomes in various lung diseases, thereby proposing them as a cell-free therapeutic agent. Also, attractive features like cell targeting, low-immunogenicity, safety, and high biocompatibility distinguish these exosomes from other synthetic nano-vesicles and thus potentiate their role as a drug delivery nano-platform. Building upon these observations, herein, efforts are made to give an overview of stem cell-derived exosomes as an appealing therapeutic agent and drug delivery nano-carrier. In this review, we briefly recapitulate the recent evidence and developments in understanding exosomes as a promising candidate for novel nano-intervention in the current pandemic scenario. Furthermore, this review will highlight and discuss mechanistic role of exosomes to combat severe lung pathological conditions. We have also attempted to dwell into the nano-formulation of exosomes for its better applicability, storage, and stability thereby conferring them as off the shelf therapeutic.
C1 [Pinky; Gupta, Suchi; Krishnakumar, Vishnu; Sharma, Yashvi; Mohanty, Sujata] All India Inst Med Sci, DBT Ctr Excellence Stem Cell Res, Stem Cell Facil, 1st Floor,ORBO Complex, New Delhi, India.
   [Dinda, Amit Kumar] All India Inst Med Sci, Dept Pathol, New Delhi, India.
RP Mohanty, S (corresponding author), All India Inst Med Sci, DBT Ctr Excellence Stem Cell Res, Stem Cell Facil, 1st Floor,ORBO Complex, New Delhi, India.
EM pinkyatwal06@gmail.com; gupta.s1291@gmail.com;
   vishn174106058@iitg.ac.in; yashvi2707@gmail.com; dindaaiims@gmail.com;
   drmohantysujata@gmail.com
OI GUPTA, SUCHI/0000-0002-6525-8147; Sharma, Yashvi/0000-0002-5264-6028
FU All India Institute of Medical Sciences, New Delhi; Department of
   Biotechnology, Government of IndiaDepartment of Biotechnology (DBT)
   India
FX The authors would like to thank Ms. Harshita Sharma, Mr. Vishal, and Mr.
   Atanu Sen for their technical help during the experiment setup. We also
   thank Ms. Sharda Ray for her critical evaluation of this manuscript. The
   work has been supported by the All India Institute of Medical Sciences,
   New Delhi, and the Department of Biotechnology, Government of India.
   Graphical abstract was created using BioRender.com.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Aggarwal G, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100617
   Akuma P, 2019, FRONT SUSTAIN FOOD S, V3, DOI 10.3389/fsufs.2019.00023
   [Anonymous], 2020, REUTERS
   Aqil F, 2016, EXP MOL PATHOL, V101, P12, DOI 10.1016/j.yexmp.2016.05.013
   Bari E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090965
   Bosch S, 2016, SCI REP-UK, V6, DOI 10.1038/srep36162
   Cascella M, 2020, FEATURES EVALUATION
   Chatterjee S., 2020, ENVELOPE MEMBRANE NU
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen Y, 2020, J MED VIROLOGY
   Cheng L, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6305295
   Chew JRJ, 2019, ACTA BIOMATER, V89, P252, DOI 10.1016/j.actbio.2019.03.021
   Cruz FF, 2020, EXPERT REV RESP MED, V14, P31, DOI 10.1080/17476348.2020.1679628
   Cruz T, 2019, STEM CELL BASED THER, P199
   Cui GH, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0150-2
   Du J, 2020, GEN HOSP PSYCHIAT
   Eastman RT, REMDESIVIR REV ITS D
   Fang XN, 2018, ANAL CHEM, V90, P2787, DOI 10.1021/acs.analchem.7b04861
   Ford N., 2020, J INT AIDS SOC
   Gaye B., 2020, EUROPEAN HEART J
   Gennai S, 2015, AM J TRANSPLANT, V15, P2404, DOI 10.1111/ajt.13271
   Gnecchi Massimiliano, 2016, Methods Mol Biol, V1416, P123, DOI 10.1007/978-1-4939-3584-0_7
   Golchin A., 2020, STEM CELL REV REP, P1
   Guo SW, 2019, ACS NANO, V13, P10015, DOI 10.1021/acsnano.9b01892
   Hao Q, 2019, J IMMUNOL, V203, P1961, DOI 10.4049/jimmunol.1801534
   Hegarty PK, 2020, PREPRINT
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Herrero R, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.18
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Hood JL, 2016, NANOMEDICINE-UK, V11, P1745, DOI 10.2217/nnm-2016-0102
   Hood JL, 2014, ANAL BIOCHEM, V448, P41, DOI 10.1016/j.ab.2013.12.001
   Hu CX, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1225-x
   Jeyaram A, 2018, AAPS J, V20, DOI 10.1208/s12248-017-0160-y
   Kamel AM, 2019, IMMUNOBIOLOGY, V224, P659, DOI 10.1016/j.imbio.2019.07.001
   Keshtkar-Jahromi M., 2020, AM J TROP MED HYG
   Kim J, 2020, J MICROBIOL BIOTECHN, V30, P427, DOI 10.4014/jmb.1910.10055
   Kim MS, 2018, NANOMED-NANOTECHNOL, V14, P195, DOI 10.1016/j.nano.2017.09.011
   Kim YS, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.127
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Lakhal S, 2011, BIOESSAYS, V33, P737, DOI 10.1002/bies.201100076
   Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173
   Lee P.-I., 2020, J MICROBIOLOGY IMMUN
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li JW, 2019, EUR J PHARMACOL, V852, P68, DOI 10.1016/j.ejphar.2019.01.022
   Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833
   Li YJ, 2020, ACTA BIOMATER, V101, P519, DOI 10.1016/j.actbio.2019.10.022
   Lim S. K, 2019, United States patent application, Patent No. [US 16/340,948, 16340948]
   Liu CY, 2019, THERANOSTICS, V9, P1015, DOI 10.7150/thno.30853
   Lukomska B, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9628536
   Mehta P., 2020, LANCET
   Melzer C, 2019, CANCERS, V11, DOI 10.3390/cancers11060798
   Mitra P, 2020, INDIAN J CLIN BIOCHE, V35, P257, DOI 10.1007/s12291-020-00886-6
   Monsel A, 2016, EXPERT OPIN BIOL TH, V16, P859, DOI 10.1517/14712598.2016.1170804
   Pedersen SF, 2020, J CLIN INVESTIGATION, V130
   Pelaia C, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20906963
   Piper C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00163
   Ren JH, 2016, BIOMATER SCI-UK, V4, P910, DOI 10.1039/c5bm00583c
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Sahu K. K., 2020, J MED VIROLOGY
   Sarvar DP, 2016, ADV PHARM BULL, V6, P293, DOI 10.15171/apb.2016.041
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Shahabipour F, 2016, ARCH MED SCI, V12, P1324, DOI 10.5114/aoms.2016.62911
   Sheahan TP, 2020, SCI TRANSL MED, V12, P541
   Sun P., 2020, J MED VIROLOGY
   Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015
   ul Qamar M. T., 2020, RES SQUARE
   Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   Vijayvargiya P, 2020, MAYO CLIN P
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Walsh KB, 2011, P NATL ACAD SCI USA, V108, P12018, DOI 10.1073/pnas.1107024108
   Wang QS, 2016, HUM VACC IMMUNOTHER, V12, P85, DOI 10.1080/21645515.2015.1030549
   World Health Organization, 2020, 7 WHO
   Wu J, 2020, TREATMENT STRATEGIES
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yamashita T, 2018, BIOL PHARM BULL, V41, P835, DOI 10.1248/bpb.b18-00133
   Yin K, 2019, BIOMARK RES, V7, DOI 10.1186/s40364-019-0159-x
   Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142
   Zanoni M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163876
   Zeng SL, 2015, MOL MED REP, V12, P2511, DOI 10.3892/mmr.2015.3706
   Zhou YY, 2020, EXOSOMES: A CLINICAL COMPENDIUM, P433, DOI 10.1016/B978-0-12-816053-4.00019-5
   Zhu YG, 2014, STEM CELLS, V32, P116, DOI 10.1002/stem.1504
NR 86
TC 2
Z9 2
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10002-z
EA JUL 2020
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA MJ5CF
UT WOS:000548107400001
PM 32661867
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Haslak, F
   Yildiz, M
   Adrovic, A
   Sahin, S
   Koker, O
   Aliyeva, A
   Barut, K
   Kasapcopur, O
AF Haslak, Fatih
   Yildiz, Mehmet
   Adrovic, Amra
   Sahin, Sezgin
   Koker, Oya
   Aliyeva, Ayten
   Barut, Kenan
   Kasapcopur, Ozgur
TI Management of childhood-onset autoinflammatory diseases during the
   COVID-19 pandemic
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE SARS-CoV-2; Autoinflammatory diseases; Colchicine; Covid-19; Biologic
   drug
ID CLINICAL CHARACTERISTICS; CHILDREN
AB Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based survey investigating the clinical findings and contact histories among pediatric patients with AIDs. Confirmed COVID-19 cases, patients with contact history and those with symptoms which were highly suggestive of COVID-19 were called via phone or recruited to a video or face to face appointment. Data of AIDs were obtained from their medical records, retrospectively. Laboratory and screening findings were confirmed by our national health registry website. There were 404 patients (217 female) eligible for the enrollment. During pandemic, 375 (93%) were on colchicine treatment and 48 (11.8%) were receiving biologic treatment. Twenty-four out of 404 patients were admitted to hospital due to COVID-19 suspicion. Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was identified through rhinopharyngeal swabs in seven patients, six of whom were only on colchicine treatment. Only one patient with no finding of any severe respiratory complications was hospitalized. All of seven patients recovered completely. Among patients on biologic drugs, neither a symptom nor a positive polymerase chain reaction test for COVID 19 was detected. In conclusion, pediatric patients with AIDs, those receiving biologic treatment and/or colchicine, may not be at increased risk for neither being infected nor the severe disease course.
C1 [Haslak, Fatih; Yildiz, Mehmet; Adrovic, Amra; Sahin, Sezgin; Koker, Oya; Aliyeva, Ayten; Barut, Kenan; Kasapcopur, Ozgur] Istanbul Univ Cerrahpasa, Dept Pediat Rheumatol, Cerrahpasa Med Sch, Istanbul, Turkey.
RP Kasapcopur, O (corresponding author), Istanbul Univ Cerrahpasa, Dept Pediat Rheumatol, Cerrahpasa Med Sch, Istanbul, Turkey.
EM drfatihhaslak@gmail.com; yildizmehmet@istanbul.edu.tr;
   amra.adrovic@istanbul.edu.tr; sezgin@istanbul.edu.tr;
   oyakoker@hotmail.com; aesa099@mail.ru; drkenanbarut@hotmail.com;
   ozgurkasapcopur@hotmail.com
RI Kasapcopur, Ozgur/A-8888-2018; Sahin, Sezgin/A-1639-2018; YILDIZ,
   Mehmet/R-1456-2018; Barut, Kenan/S-5966-2017
OI Kasapcopur, Ozgur/0000-0002-1125-7720; Sahin,
   Sezgin/0000-0002-5365-3457; YILDIZ, Mehmet/0000-0002-7834-4909; Haslak,
   Fatih/0000-0002-6963-9668; Barut, Kenan/0000-0001-8459-2872
CR Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Balasubramanian S, 2020, INDIAN PEDIATR, V57, P435, DOI 10.1007/s13312-020-1819-5
   Batu ED, 2020, RHEUMATOL INT, V40, P1193, DOI 10.1007/s00296-020-04612-6
   Bilbul M, 2020, PSYCHOSOMATICS, V61, P411, DOI 10.1016/j.psym.2020.05.006
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Conticini Edoardo, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217681, 10.1136/annrheumdis-2020-218761]
   Cron RQ, 2020, J RHEUMATOL, V47, P1723, DOI [10.3899/jrheum.200744, 10.3899/jrheum.200334]
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Filocamo Giovanni, 2020, J Rheumatol, DOI 10.3899/jrheum.200483
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Gasparyan AY, 2015, EXPERT OPIN DRUG MET, V11, P1781, DOI 10.1517/17425255.2015.1076391
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE), 2020, Mediterr J Rheumatol, V31, P6, DOI 10.31138/mjr.31.1.6
   Haslak F, 2020, BALK MED J, V37, P184, DOI 10.4274/balkanmedj.galenos.2020.2020.4.43
   Hedrich CM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108420
   Kobak Senol, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-217882
   Korkmaz MF, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e236
   La Regina M, 2013, CLIN EXP RHEUMATOL, V31, pS41
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Parra-Medina R, 2020, CLIN RHEUMATOL, V39, P2485, DOI 10.1007/s10067-020-05247-5
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pham-Huy A, 2019, JAMMI, V4, P51
   Piantoni S, 2020, CLIN RHEUMATOL, V39, P2489, DOI 10.1007/s10067-020-05232-y
   Piantoni S, 2020, RHEUMATOLOGY, V59, P1769, DOI 10.1093/rheumatology/keaa217
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
NR 38
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD SEP
PY 2020
VL 40
IS 9
BP 1423
EP 1431
DI 10.1007/s00296-020-04645-x
EA JUL 2020
PG 9
WC Rheumatology
SC Rheumatology
GA MM6FN
UT WOS:000548231000002
PM 32661928
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Filippi, F
   Loi, C
   Evangelista, V
   Bardazzi, F
AF Filippi, Federica
   Loi, Camilla
   Evangelista, Valeria
   Bardazzi, Federico
TI COVID-19 era: A chance to learn something new about monitoring psoriatic
   patients in biological therapy
SO DERMATOLOGIC THERAPY
LA English
DT Letter
C1 [Filippi, Federica; Loi, Camilla; Evangelista, Valeria; Bardazzi, Federico] Univ Bologna, Dept Expt Diagnost & Specialty Med, Dermatol, Via Massarenti 1, I-40138 Bologna, Italy.
RP Loi, C (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Dermatol, Via Massarenti 1, I-40138 Bologna, Italy.
EM camilla.loi30@gmail.com
CR [Anonymous], TRANS MEAS EXT AIFA
   Brunasso AMG, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13695
   Campanati A, 2020, J EUR ACAD DERMATOL, V34, P1626, DOI 10.1111/jdv.16646
   Cartron AM, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13689
   Gisondi P, 2017, J EUR ACAD DERMATOL, V31, P774, DOI 10.1111/jdv.14114
   Patrizi A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13469
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13805
DI 10.1111/dth.13805
EA JUL 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000547745000001
PM 32524715
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Oberemok, VV
   Laikova, KV
   Yurchenko, KA
   Marochkin, NA
   Fomochkina, II
   Kubyshkin, AV
AF Oberemok, V. V.
   Laikova, K., V
   Yurchenko, K. A.
   Marochkin, N. A.
   Fomochkina, I. I.
   Kubyshkin, A., V
TI SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG
   motifs in 'lasso' for the multi-faced virus
SO INFLAMMATION RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19 pandemic; Phosphorothioate oligonucleotides; CpG
   motif; Vaccine
ID HEPATITIS-C-VIRUS; BROADLY NEUTRALIZING ANTIBODIES; CELLULAR
   IMMUNE-RESPONSES; ANTISENSE OLIGONUCLEOTIDES; INFLUENZA VACCINATION; HCV
   INFECTION; BACTERIAL-DNA; HUMAN-CELLS; IN-VITRO; T-CELLS
AB During the current COVID-19 pandemic, the global ratio between the dead and the survivors is approximately 1 to 10, which has put humanity on high alert and provided strong motivation for the intensive search for vaccines and drugs. It is already clear that if we follow the most likely scenario, which is similar to that used to create seasonal influenza vaccines, then we will need to develop improved vaccine formulas every year to control the spread of the new, highly mutable coronavirus SARS-CoV-2. In this article, using well-known RNA viruses (HIV, influenza viruses, HCV) as examples, we consider the main successes and failures in creating primarily highly effective vaccines. The experience accumulated dealing with the biology of zoonotic RNA viruses suggests that the fight against COVID-19 will be difficult and lengthy. The most effective vaccines against SARS-CoV-2 will be those able to form highly effective memory cells for both humoral (memory B cells) and cellular (cross-reactive antiviral memory T cells) immunity. Unfortunately, RNA viruses constantly sweep their tracks and perhaps one of the most promising solutions in the fight against the COVID-19 pandemic is the creation of 'universal' vaccines based on conservative SARS-CoV-2 genome sequences (antigen-presenting) and unmethylated CpG dinucleotides (adjuvant) in the composition of the phosphorothioate backbone of single-stranded DNA oligonucleotides (ODN), which can be effective for long periods of use. Here, we propose a SARS-CoV-2 vaccine based on a lasso-like phosphorothioate oligonucleotide construction containing CpG motifs and the antigen-presenting unique ACG-containing genome sequence of SARS-CoV-2. We found that CpG dinucleotides are the least rare dinucleotides in the genomes of SARS-CoV-2 and other known human coronaviruses, and hypothesized that their higher frequency could be responsible for the unwanted increased lethality to the host, causing a 'cytokine storm' in people who overexpress cytokines through the activation of specific Toll-like receptors in a manner similar to TLR9-CpG ODN interactions. Interestingly, the virus strains sequenced in China (Wuhan) in February 2020 contained on average one CpG dinucleotide more in their genome than the later strains from the USA (New York) sequenced in May 2020. Obviously, during the first steps of the microevolution of SARS-CoV-2 in the human population, natural selection tends to select viral genomes containing fewer CpG motifs that do not trigger a strong innate immune response, so the infected person has moderate symptoms and spreads SARS-CoV-2 more readily. However, in our opinion, unmethylated CpG dinucleotides are also capable of preparing the host immune system for the coronavirus infection and should be present in SARS-CoV-2 vaccines as strong adjuvants.
C1 [Oberemok, V. V.; Laikova, K., V; Yurchenko, K. A.; Marochkin, N. A.; Fomochkina, I. I.; Kubyshkin, A., V] VI Vernadsky Crimean Fed Univ, Simferopol, Russia.
RP Kubyshkin, AV (corresponding author), VI Vernadsky Crimean Fed Univ, Simferopol, Russia.
EM kubyshkin_av@mail.ru
RI Yurchenko, Kseniya/ABA-5778-2020; Kubyshkin, Anatoliy/L-9262-2013
OI Yurchenko, Kseniya/0000-0002-0284-7059; Kubyshkin,
   Anatoliy/0000-0002-1309-4005
FU Ministry of Science and Higher Education of Russian Federation
   [FZEG-2020-0060]
FX This work was supported by state program No FZEG-2020-0060 of the
   Ministry of Science and Higher Education of Russian Federation.
CR Abdel-Hakeem MS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00274
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2017, GLOB HEP REP GEN
   [Anonymous], TYP SEAS INFL VACC
   Ashman RF, 2011, INT IMMUNOL, V23, P203, DOI 10.1093/intimm/dxq473
   Atkinson NJ, 2014, NUCLEIC ACIDS RES, V42, P4527, DOI 10.1093/nar/gku075
   Badr G, 2008, J VIROL, V82, P10017, DOI 10.1128/JVI.01083-08
   Baechlein C, 2015, J VIROL, V89, P7007, DOI 10.1128/JVI.00534-15
   Bailey JR, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92872
   Ball JK, 2014, ANTIVIR RES, V105, P100, DOI 10.1016/j.antiviral.2014.02.013
   Ballas ZK, 1996, J IMMUNOL, V157, P1840
   Batista-Duharte A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020316
   Bengsch B, 2007, J VIROL, V81, P945, DOI 10.1128/JVI.01354-06
   BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0
   Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Brown BK, 2008, VIROLOGY, V375, P529, DOI 10.1016/j.virol.2008.02.022
   Campbell JD, 2017, METHODS MOL BIOL, V1494, P15, DOI 10.1007/978-1-4939-6445-1_2
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Cheng XW, 2011, RESP PHYSIOL NEUROBI, V175, P185, DOI 10.1016/j.resp.2010.11.004
   Cox AL, 2015, SCIENCE, V349, P790, DOI 10.1126/science.aad1302
   Dias N, 2002, MOL CANCER THER, V1, P347
   Dreja H, 2010, J GEN VIROL, V91, P2794, DOI 10.1099/vir.0.024224-0
   Drexler JF, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003438
   El Zowalaty ME, 2020, ONE HLTH, V10, P1
   Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224
   Falade-Nwulia O, 2018, J VIRAL HEPATITIS, V25, P220, DOI 10.1111/jvh.12859
   Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
   Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0
   Forns X, 2002, J HEPATOL, V37, P684, DOI 10.1016/S0168-8278(02)00308-2
   Frey SE, 2010, VACCINE, V28, P6367, DOI 10.1016/j.vaccine.2010.06.084
   Gardner EM, 2006, VACCINE, V24, P1609, DOI 10.1016/j.vaccine.2005.09.058
   Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001
   Ghaffarifar F, 2018, DRUG TODAY, V54, P315, DOI 10.1358/dot.2018.54.5.2807864
   Giang E, 2012, P NATL ACAD SCI USA, V109, P6205, DOI 10.1073/pnas.1114927109
   Glasspool-Malone J, 2002, J GENE MED, V4, P323, DOI 10.1002/jgm.259
   Golden-Mason L, 2006, HEPATOLOGY, V44, P1098, DOI 10.1002/hep.21365
   Gottlieb J, 2016, J HEART LUNG TRANSPL, V35, P213, DOI 10.1016/j.healun.2015.08.012
   Gravitz L, 2011, NATURE, V474, pS2, DOI 10.1038/474S2a
   Greenbaum BD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005969
   Greenbaum BD, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000079
   Guerrier T, 2012, J AUTOIMMUN, V39, P173, DOI 10.1016/j.jaut.2012.05.012
   Gupta PK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005177
   Haas T, 2008, IMMUNITY, V28, P315, DOI 10.1016/j.immuni.2008.01.013
   HAN J, 1994, ANTISENSE RES DEV, V4, P53, DOI 10.1089/ard.1994.4.53
   Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944
   Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617
   He YX, 2005, VIRAL IMMUNOL, V18, P327, DOI 10.1089/vim.2005.18.327
   Heo JY, 2018, HUM VACC IMMUNOTHER, V14, P744, DOI 10.1080/21645515.2017.1405200
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Hodgson J, 2020, NAT BIOTECHNOL, V4, P8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Isakova-Sivak I, 2015, EXPERT REV VACCINES, V14, P1313, DOI 10.1586/14760584.2015.1075883
   Janeway CA, 2020, ANNU REV IMMUNOL, V20, P197
   Jimenez-Baranda S, 2011, J VIROL, V85, P3893, DOI 10.1128/JVI.01908-10
   Kenney RT, 2010, NEW GENERATION VACCI, P250
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   Koup RA, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007252
   Kramps T, 2017, METHODS MOL BIOL, V1499, P1, DOI 10.1007/978-1-4939-6481-9_1
   Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Krieg AM, 1996, TRENDS MICROBIOL, V4, P73, DOI 10.1016/0966-842X(96)81515-0
   Kwong PD, 1994, NATURE, V4, P648
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028
   Lauck M, 2013, J VIROL, V87, P8971, DOI 10.1128/JVI.00888-13
   Law JLM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059776
   Law M, 2008, NAT MED, V14, P25, DOI 10.1038/nm1698
   Li RX, 2016, PHARMACOEPIDEM DR S, V25, P928, DOI 10.1002/pds.3996
   Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Loa CC, 2001, POULTRY SCI, V80, P1416, DOI 10.1093/ps/80.10.1416
   Lobo FP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006282
   Luciw PA, 1996, VIROLOGY
   Thomas ZR, 2015, T ROY SOC TROP MED H, V109, P175, DOI 10.1093/trstmh/tru206
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   McCutchan FE, 2000, AIDS, V14, pS31
   Murad YM, 2009, BIODRUGS, V23, P361, DOI 10.2165/11316930-000000000-00000
   Murasko DM, 2005, IMMUNOL REV, V205, P285, DOI 10.1111/j.0105-2896.2005.00273.x
   Myhr AI, 2017, CURR ISSUES MOL BIOL, V22, P79, DOI 10.21775/cimb.022.079
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026
   Overbaugh J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007039
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Paltrinieri S, 1998, VET IMMUNOL IMMUNOP, V65, P205, DOI 10.1016/S0165-2427(98)00155-X
   Parren PWHI, 1999, AIDS, V13, pS137
   Parrish CR, 2015, J VIROL, V89, P2990, DOI 10.1128/JVI.03146-14
   Pawlotsky JM, 2015, J HEPATOL, V62, pS87, DOI 10.1016/j.jhep.2015.02.006
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115
   Preston BD, 1997, SCIENCE, V275, P228, DOI 10.1126/science.275.5297.228
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Pulendran B., 2010, NEW GENERATION VACCI, P183
   Pybus OG, 2016, CURR OPIN VIROL, V16, P1, DOI 10.1016/j.coviro.2015.10.002
   Ran ZG, 2015, J VIROL, V89, P4818, DOI 10.1128/JVI.00059-15
   Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Roth Y, 2003, ANN OTO RHINOL LARYN, V112, P264, DOI 10.1177/000348940311200313
   Sacher T, 2002, EUR J IMMUNOL, V32, P3628, DOI 10.1002/1521-4141(200212)32:12<3628::AID-IMMU3628>3.0.CO;2-E
   Sarkanen TO, 2017, SLEEP MED REV, V17, P30001
   Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065
   Sharp PM, 2011, MEDICINE, V6, P8
   Shin EC, 2013, J VIROL, V87, P4772, DOI 10.1128/JVI.03122-12
   Shoukry NH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01480
   SHPAER EG, 1990, NUCLEIC ACIDS RES, V18, P5793, DOI 10.1093/nar/18.19.5793
   Siriwardena AN, 2012, J INFECT DIS, V206, P1636, DOI 10.1093/infdis/jis598
   Sridhar S, 2015, VACCINES, V3, P373, DOI 10.3390/vaccines3020373
   STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515
   STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trombetta CM, 2016, EXPERT REV VACCINES, V15, P967, DOI 10.1586/14760584.2016.1164046
   Uchida T, 2011, MICROBIOL IMMUNOL, V55, P19, DOI 10.1111/j.1348-0421.2010.00273.x
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wagner H, 2008, CURR OPIN IMMUNOL, V20, P396, DOI 10.1016/j.coi.2008.06.013
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x
   YAMAMOTO S, 1992, J IMMUNOL, V148, P4072
   Yasuda K, 2005, J IMMUNOL, V174, P6129, DOI 10.4049/jimmunol.174.10.6129
NR 121
TC 1
Z9 1
U1 6
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD SEP
PY 2020
VL 69
IS 9
BP 801
EP 812
DI 10.1007/s00011-020-01377-3
EA JUL 2020
PG 12
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA MT1ND
UT WOS:000547811700001
PM 32656668
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bongini, P
   Trezza, A
   Bianchini, M
   Spiga, O
   Niccolai, N
AF Bongini, Pietro
   Trezza, Alfonso
   Bianchini, Monica
   Spiga, Ottavia
   Niccolai, Neri
TI A possible strategy to fight COVID-19: Interfering with spike
   glycoprotein trimerization
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE COVID-19; S glycoprotein; Quaternary disassembly; Interfering ligands;
   Docking simulation
ID PROTEIN; ALIGNMENT
AB The recent release of COVID-19 spike glycoprotein allows detailed analysis of the structural features that are required for stabilizing the infective form of its quaternary assembly. Trying to disassemble the trimeric structure of COVID-19 spike glycoprotein, we analyzed single protomer surfaces searching for concave moieties that are located at the three protomer-protomer interfaces. The presence of some druggable pockets at these interfaces suggested that some of the available drugs in Drug Bank could destabilize the quaternary spike glycoprotein formation by binding to these pockets, therefore interfering with COVID-19 life cycle. The approach we propose here can be an additional strategy to fight against the deadly virus. Ligands of COVID-19 spike glycoprotein that we have predicted in the present computational investigation, might be the basis for new experimental studies in vitro and in vivo. (C) 2020 Published by Elsevier Inc.
C1 [Bongini, Pietro; Bianchini, Monica] Univ Siena, Dept Informat Engn & Math, I-53100 Siena, Italy.
   [Trezza, Alfonso; Spiga, Ottavia; Niccolai, Neri] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
   [Bongini, Pietro] Univ Florence, Dept Informat Engn, I-50139 Florence, Italy.
   [Niccolai, Neri] Ric BarLume Free Assoc, I-53014 Monteroni Darbia, Italy.
RP Niccolai, N (corresponding author), Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
EM pietro.bongini@gmail.com; trezzaalfonso@gmail.com;
   monica@diism.unisi.it; ottavia.spiga@unisi.it; neri.niccolai@unisi.it
RI Trezza, Alfonso/ABH-3773-2020
OI Bongini, Pietro/0000-0001-9074-0587
CR Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Boratyn GM, 2013, NUCLEIC ACIDS RES, V41, pW29, DOI 10.1093/nar/gkt282
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Eyrisch S, 2007, J MED CHEM, V50, P3457, DOI 10.1021/jm070095g
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Koebel MR, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0139-1
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Mullan L, 2006, BRIEF BIOINFORM, V7, P113, DOI 10.1093/bib/bbk008
   Papadopoulos JS, 2007, BIOINFORMATICS, V23, P1073, DOI 10.1093/bioinformatics/btm076
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Varrazzo D, 2005, BIOINFORMATICS, V21, P2856, DOI 10.1093/bioinformatics/bti444
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
NR 14
TC 3
Z9 3
U1 6
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 12
PY 2020
VL 528
IS 1
BP 35
EP 38
DI 10.1016/j.bbrc.2020.04.007
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LY0XQ
UT WOS:000540247400006
PM 32451080
OA Green Published
DA 2021-01-01
ER

PT J
AU Lecronier, M
   Beurton, A
   Burrel, S
   Haudebourg, L
   Deleris, R
   Le Marec, J
   Virolle, S
   Nemlaghi, S
   Bureau, C
   Mora, P
   De Sarcus, M
   Clovet, O
   Duceau, B
   Grisot, PH
   Pari, MH
   Arzoine, J
   Clarac, U
   Boutolleau, D
   Raux, M
   Delemazure, J
   Faure, M
   Decavele, M
   Morawiec, E
   Mayaux, J
   Demoule, A
   Dres, M
AF Lecronier, Marie
   Beurton, Alexandra
   Burrel, Sonia
   Haudebourg, Luc
   Deleris, Robin
   Le Marec, Julien
   Virolle, Sara
   Nemlaghi, Safaa
   Bureau, Come
   Mora, Pierre
   De Sarcus, Martin
   Clovet, Olivier
   Duceau, Baptiste
   Grisot, Paul Henri
   Pari, Marie Helene
   Arzoine, Jeremy
   Clarac, Ulrich
   Boutolleau, David
   Raux, Mathieu
   Delemazure, Julie
   Faure, Morgane
   Decavele, Maxens
   Morawiec, Elise
   Mayaux, Julien
   Demoule, Alexandre
   Dres, Martin
TI Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of
   care in critically ill patients with SARS-CoV-2 pneumonia: an
   opportunistic retrospective analysis
SO CRITICAL CARE
LA English
DT Article
DE SARS-CoV-2; Intensive care unit; Hydroxychloroquine; Lopinavir;
   ritonavir; Standard of care
ID EPIDEMIOLOGY; CORONAVIRUS; CHLOROQUINE; COVID-19
AB BackgroundThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients.MethodsThe present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only. The primary outcomes were treatment escalation (intubation, extra-corporeal membrane oxygenation support, or renal replacement therapy) after day 1 until day 28. Secondary outcomes included ventilator-free days at day 28, mortality at day 14 and day 28, treatment safety issues and changes in respiratory tracts, and plasma viral load (as estimated by cycle threshold value) between admission and day 7.ResultsEighty patients were treated during a 4-week period and included in the analysis: 22 (28%) received standard of care only, 20 (25%) patients received lopinavir/ritonavir associated to standard of care, and 38 (47%) patients received hydroxychloroquine and standard of care. Baseline characteristics were well balanced between the 3 groups. Treatment escalation occurred in 9 (41%), 10 (50%), and 15 (39%) patients who received standard of care only, standard of care and lopinavir/ritonavir, and standard of care and hydroxychloroquine, respectively (p=0.567). There was no significant difference between groups regarding the number of ventilator-free days at day 28 and mortality at day 14 and day 28. Finally, there was no significant change between groups in viral respiratory or plasma load between admission and day 7.ConclusionIn critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28. Further randomized controlled trials are required to demonstrate whether these drugs may be useful in this context.
C1 [Lecronier, Marie; Beurton, Alexandra; Haudebourg, Luc; Deleris, Robin; Le Marec, Julien; Virolle, Sara; Nemlaghi, Safaa; Bureau, Come; Mora, Pierre; Delemazure, Julie; Faure, Morgane; Decavele, Maxens; Morawiec, Elise; Mayaux, Julien; Demoule, Alexandre; Dres, Martin] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Serv Pneumol Med Intens Reanimat,Dept R3S, Paris, France.
   [Beurton, Alexandra; Bureau, Come; Raux, Mathieu; Decavele, Maxens; Demoule, Alexandre; Dres, Martin] Sorbonne Univ, INSERM, UMR S 1158, Neurophysiol Resp Expt & Clin, Paris, France.
   [Burrel, Sonia; Boutolleau, David] Sorbonne Univ, INSERM, UMR S 1136, Inst Pierre Louis Epidemiol & Sante Publ,Team 3 T, Paris, France.
   [Burrel, Sonia; Boutolleau, David] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Serv Virol,Ctr Natl Reference Herpes Virus, Paris, France.
   [De Sarcus, Martin; Clovet, Olivier; Duceau, Baptiste; Grisot, Paul Henri; Pari, Marie Helene; Arzoine, Jeremy; Clarac, Ulrich; Raux, Mathieu] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Dept Anesthesie Reanimat, Paris, France.
RP Lecronier, M; Dres, M (corresponding author), Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Serv Pneumol Med Intens Reanimat,Dept R3S, Paris, France.; Dres, M (corresponding author), Sorbonne Univ, INSERM, UMR S 1158, Neurophysiol Resp Expt & Clin, Paris, France.
EM marie.lecronier@aphp.fr; martin.dres@aphp.fr
RI Decavele, maxens/ABD-7633-2020
OI Laurent, Maryline/0000-0002-7256-3721
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Nguyen LS, 2020, CIRCULATION
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 21
TC 7
Z9 7
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUL 11
PY 2020
VL 24
IS 1
AR 418
DI 10.1186/s13054-020-03117-9
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA MP1ZB
UT WOS:000552008400003
PM 32653015
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pereira, M
   Paixao, E
   Trajman, A
   de Souza, RA
   da Natividade, MS
   Pescarini, JM
   Pereira, SM
   Barreto, FR
   Ximenes, R
   Dalcomo, M
   Ichihara, MY
   Nunes, C
   Barral-Netto, M
   Barreto, ML
AF Pereira, Marcos
   Paixao, Enny
   Trajman, Anete
   de Souza, Ramon Andrade
   da Natividade, Marcio Santos
   Pescarini, Julia M.
   Pereira, Susan Martins
   Barreto, Florisneide Rodrigues
   Ximenes, Ricardo
   Dalcomo, Margareth
   Ichihara, Maria Yury
   Nunes, Ceuci
   Barral-Netto, Manoel
   Barreto, Mauricio L.
TI The need for fast-track, high-quality and low-cost studies about the
   role of the BCG vaccine in the fight against COVID-19
SO RESPIRATORY RESEARCH
LA English
DT Article
ID INFECTION
AB Bacillus Calmette-Guerin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
C1 [Pereira, Marcos; de Souza, Ramon Andrade; da Natividade, Marcio Santos; Pereira, Susan Martins; Barreto, Florisneide Rodrigues; Barreto, Mauricio L.] Univ Fed Bahia, Inst Collect Hlth, Salvador, BA, Brazil.
   [Paixao, Enny; Pescarini, Julia M.; Ichihara, Maria Yury; Barreto, Mauricio L.] Fiocruz MS, Ctr Data & Knowledge Integrat Hlth CIDACS, Salvador, BA, Brazil.
   [Paixao, Enny] London Sch Hyg & Trop Med, Fac Epidemiol, London, England.
   [Trajman, Anete] Univ Estado Rio de Janeiro, Inst Med Social, Rio De Janeiro, Brazil.
   [Ximenes, Ricardo] Univ Fed Pernambuco, Dept Med Trop, Recife, PE, Brazil.
   [Dalcomo, Margareth] Fundacao Oswaldo Cruz, Ctr Referencia Helio Fraga, Rio De Janeiro, Brazil.
   [Nunes, Ceuci] Secretaria Estadual Saude Bahia, Hosp Couto Maia, Salvador, BA, Brazil.
   [Barral-Netto, Manoel] Fundacao Oswaldo Cruz Fiocruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Barral-Netto, Manoel] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
RP Pereira, M (corresponding author), Univ Fed Bahia, Inst Collect Hlth, Salvador, BA, Brazil.
EM pereira.santosm@yahoo.com
RI ; L. Barreto, Mauricio/B-1752-2008; Barral Netto, Manoel/B-3904-2009
OI Pereira, Marcos/0000-0003-3766-2502; L. Barreto,
   Mauricio/0000-0002-0215-4930; Barral Netto, Manoel/0000-0002-5823-7903
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Curtis N, BCG VACCINATION PROT
   Hensel J, 2020, EXERCISING CAUTION C, DOI [10.1101/2020.04.08.20056051, DOI 10.1101/2020.04.08.20056051]
   Hollm-Delgado MG, 2014, PEDIATRICS, V133, pE73, DOI 10.1542/peds.2013-2218
   Iwasaki A, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012481
   Johns Hopkins University, COR RES CTR MORT AN
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   Shet A., 2020, DIFFERENTIAL COVID 1, DOI [10.1101/2020.04.01.20049478, DOI 10.1101/2020.04.01.20049478]
   Szigeti R., 2020, BCG PROTECTS COVID 1, DOI [10.1101/2020.04.09.20056903, DOI 10.1101/2020.04.09.20056903]
   Ziekenhuis JB, REDUCING HLTH CARE W
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 14
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD JUL 11
PY 2020
VL 21
IS 1
AR 178
DI 10.1186/s12931-020-01439-4
PG 3
WC Respiratory System
SC Respiratory System
GA MP2NV
UT WOS:000552046800001
PM 32653040
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Elia, R
   Davide, S
   Alina, CG
   Corneliu, F
   Pietro, G
AF Elia, Rigamonti
   Davide, Salera
   Alina, Gheorghiu C.
   Corneliu, Fratila
   Pietro, Gianella
TI The many faces of interstitial pneumonia: a case of presumed SARS-CoV-2
   infection
SO SWISS MEDICAL WEEKLY
LA English
DT Article
DE SARS-CoV-2; COVID-19; interstitial pneumonia; case-report; Pneumocystis
   jirovecii pneumonia
ID MANAGEMENT
AB We present the case of an oncology patient admitted to our hospital during the current COVID-19 pandemic with clinical and radiological features strongly suggestive of interstitial pneumonia. Multiple laboratory tests were negative for SARS-CoV-2 (polymerase chain reaction testing of nasopharyngeal swabs, and of induced sputum and stool samples, investigation of serum immunoglobulins G and M). In the setting of an immunocompromised status due to recent chemotherapy cycles for lung adenocarcinoma and prolonged corticosteroid therapy (due to frequent exacerbations of chronic obstructive pulmonary disease in recent months), we actively searched for the pathological agent and found it to be Pneumocystis jirovecii. The patient started specific antibiotic treatment but finally had a negative outcome due to the progression of the lung adenocarcinoma.
   The importance of differential diagnostics in clinical practice should be a given, especially during times of pandemic. The novel coronavirus infection introduced new guidelines for and approaches to the investigation of immunocompromised patients, so it is especially important not to forget the basis of differential diagnosis, to and adopt a thorough approach when assessing these complex patients. We want to stress the importance of thorough investigation to avoid misdiagnosis of atypical pathogens in the current setting of SARS-CoV-2 pandemic.
C1 [Elia, Rigamonti; Davide, Salera; Alina, Gheorghiu C.; Corneliu, Fratila; Pietro, Gianella] Ente Osped Cantonale, Internal Med Dept, Osped Reg Lugano, Bellinzona, Switzerland.
   [Pietro, Gianella] Ente Osped Cantonale, Pneumol Dept, Osped Reg Lugano, Bellinzona, Switzerland.
RP Elia, R (corresponding author), Internal Med Dept, Via Tesserete 46, CH-6900 Lugano, Switzerland.
EM elia.rigamon-ti@eoc.ch
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
   Chua F, 2020, LANCET RESP MED, V8, P438, DOI 10.1016/S2213-2600(20)30132-6
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Flori P, 2004, J MED MICROBIOL, V53, P603, DOI 10.1099/jmm.0.45528-0
   White PL, 2017, EXPERT REV ANTI-INFE, V15, P435, DOI 10.1080/14787210.2017.1305887
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 7
TC 0
Z9 0
U1 0
U2 0
PU E M H SWISS MEDICAL PUBLISHERS LTD
PI MUTTENZ
PA FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND
SN 1424-7860
EI 1424-3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD JUL 11
PY 2020
VL 150
AR w20312
DI 10.4414/smw.2020.20312
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO2FL
UT WOS:000551348500001
PM 32662060
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Puri, N
   Coomes, EA
   Haghbayan, H
   Gunaratne, K
AF Puri, Neha
   Coomes, Eric A.
   Haghbayan, Hourmazd
   Gunaratne, Keith
TI Social media and vaccine hesitancy: new updates for the era of COVID-19
   and globalized infectious diseases
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE Vaccine hesitancy; vaccination; anti-vaccine movement; Twitter;
   Facebook; social media; medicine and media; COVID-19
ID HPV VACCINATION; WEB 2.0; ATTITUDES; PARENTS; OPPORTUNITIES; ACTIVISTS;
   REFUSAL; ONLINE; VIDEOS; IMPACT
AB Despite major advances in vaccination over the past century, resurgence of vaccine-preventable illnesses has led the World Health Organization to identify vaccine hesitancy as a major threat to global health. Vaccine hesitancy may be fueled by health information obtained from a variety of sources, including new media such as the Internet and social media platforms. As access to technology has improved, social media has attained global penetrance. In contrast to traditional media, social media allow individuals to rapidly create and share content globally without editorial oversight. Users may self-select content streams, contributing to ideological isolation. As such, there are considerable public health concerns raised by anti-vaccination messaging on such platforms and the consequent potential for downstream vaccine hesitancy, including the compromise of public confidence in future vaccine development for novel pathogens, such as SARS-CoV-2 for the prevention of COVID-19. In this review, we discuss the current position of social media platforms in propagating vaccine hesitancy and explore next steps in how social media may be used to improve health literacy and foster public trust in vaccination.
C1 [Puri, Neha; Gunaratne, Keith] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Coomes, Eric A.] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON M5G 2C4, Canada.
   [Haghbayan, Hourmazd] Western Univ, London Hlth Sci Ctr, Dept Med, Div Cardiol, London, ON, Canada.
   [Haghbayan, Hourmazd] Univ Laval, Dept Social & Preventat Med, Quebec City, PQ, Canada.
RP Coomes, EA (corresponding author), Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON M5G 2C4, Canada.
EM eric.coomes@mail.utoronto.ca
CR Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049
   Ahmed W, 2020, J MED INTERNET RES, V22, DOI 10.2196/19458
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   [Anonymous], 2019, WHO DIRECTOR GEN STA
   [Anonymous], 2018, HIST SOCIAL MEDIA TI
   [Anonymous], COMBATTING VACCINE M
   [Anonymous], 2020, ERKANS FIELD DIARY
   Arif N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01215
   Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442
   Basch Charles E, 2020, JMIR Public Health Surveill, V6, pe19145, DOI 10.2196/19145
   Basch CH, 2019, HUM VACC IMMUNOTHER, V15, P1476, DOI 10.1080/21645515.2018.1560774
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Bhattacharyya S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43596-7
   Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138
   Brennen SJ, 2020, TYPES SOURCES CLAIMS
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Broniatowski DA, 2016, VACCINE, V34, P3225, DOI 10.1016/j.vaccine.2016.04.044
   Buller DB, 2019, HUM VACC IMMUNOTHER, V15, P1479, DOI 10.1080/21645515.2019.1581555
   Callender D, 2016, HUM VACC IMMUNOTHER, V12, P2464, DOI 10.1080/21645515.2016.1178434
   Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937
   Charron L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125154
   Chen Q, 2020, COMPUT HUM BEHAV, V110, DOI 10.1016/j.chb.2020.106380
   Chen T, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8221
   Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865
   Cinelli M., 2020, COVID 19 SOCIAL MEDI
   Coomes EA, 2019, CAN J CARDIOL, V35, P791, DOI 10.1016/j.cjca.2019.03.015
   D'Souza RS, 2020, GLOB PUBLIC HEALTH, V15, P935, DOI 10.1080/17441692.2020.1761426
   Daley MF, 2018, AM J PREV MED, V55, P44, DOI 10.1016/j.amepre.2018.04.010
   Dannetun E, 2005, SCAND J PRIM HEALTH, V23, P149, DOI 10.1080/02813430510031306
   Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22
   Del Vicario M, 2016, P NATL ACAD SCI USA, V113, P554, DOI 10.1073/pnas.1517441113
   Donovan Joan, 2020, Nature, DOI 10.1038/d41586-020-01107-z
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Dube E, 2019, HUM VACC IMMUNOTHER, V15, P1650, DOI 10.1080/21645515.2018.1564440
   Ekram S, 2019, J PEDIATR ADOL GYNEC, V32, P153, DOI 10.1016/j.jpag.2018.11.001
   Elliott J, TRUMP VS HIMSELF HE
   Faasse K, 2016, VACCINE, V34, P5808, DOI 10.1016/j.vaccine.2016.09.029
   Ferrara E., 2020, COVID 19 TWITTER BOT
   Getman R, 2018, HEALTH EDUC BEHAV, V45, P599, DOI 10.1177/1090198117739673
   Giese H, 2020, VACCINE, V38, P2070, DOI 10.1016/j.vaccine.2019.11.038
   Greenberg Joshua, 2017, PLoS Curr, V9, DOI 10.1371/currents.outbreaks.0561a011117a1d1f9596e24949e8690b
   Gunaratne K, 2020, J GEN INTERN MED, V35, P1926, DOI 10.1007/s11606-019-05454-0
   Gunaratne K, 2019, VACCINE, V37, P4867, DOI 10.1016/j.vaccine.2019.06.086
   Haghbayan H, 2018, JAMA NEUROL, V75, P1286, DOI 10.1001/jamaneurol.2018.1777
   Harvey D, 2019, HELPING YOU FIND REL
   Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741
   Josephson A, 2020, BRAND COMMUNICATIONS
   Kagashe I, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7393
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kortum P, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.986
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   Lee MJ, 2017, HEALTH PROMOT PRACT, V18, P645, DOI 10.1177/1524839916688229
   Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604
   Limaye RJ, 2020, LANCET DIGIT HEALTH, V2, pE277, DOI 10.1016/S2589-7500(20)30084-4
   Lou M, CNN WIRE SERVICE
   Lua A, 2019, 21 TOP SOCIAL MEDIA
   Massey PM, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170320
   Massey PM, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6670
   Meleo-Erwin Z, 2017, HUM VACC IMMUNOTHER, V13, P1895, DOI 10.1080/21645515.2017.1321182
   Mohanty S, 2018, VACCINE, V36, P5955, DOI 10.1016/j.vaccine.2018.08.060
   Nan XL, 2012, HEALTH COMMUN, V27, P829, DOI 10.1080/10410236.2012.661348
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Oehler RL, 2020, CLIN INFECT DIS, V70, P338, DOI 10.1093/cid/ciz656
   Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543
   Ortiz-Ospina E, 2019, RISE SOCIAL MEDIA
   Ozoma I, 2019, BRINGING AUTHORITATI
   Vallejos MJP, 2018, DILEMAS CONTEMP-EDUC, V5
   Pennycook G, 2020, PSYCHOL SCI, V31, P770, DOI 10.1177/0956797620939054
   Perkins RB, 2019, HUM VACC IMMUNOTHER, V15, P1639, DOI 10.1080/21645515.2018.1520592
   Pew Research Center, 2019, SOC MED FACT SHEET
   Reiter Paul L, 2017, JMIR Public Health Surveill, V3, pe33, DOI 10.2196/publichealth.7545
   Robichaud P, 2012, VACCINE, V30, P3763, DOI 10.1016/j.vaccine.2012.03.074
   Rosselli R, 2016, J Prev Med Hyg, V57, pE47
   Roth Y, 2020, UPDATING OUR APPROAC
   Rufai SR, 2020, J PUBLIC HEALTH-UK, V42, P510, DOI 10.1093/pubmed/fdaa049
   Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Shelby A, 2013, HUM VACC IMMUNOTHER, V9, P1795, DOI 10.4161/hv.24828
   Shoup JA, 2015, HEALTH EDUC BEHAV, V42, P302, DOI 10.1177/1090198114557129
   Tustin JL, 2018, JMIR PUBLIC HLTH SUR, V4, P129, DOI 10.2196/10090
   Tustin Jordan Lee, 2017, JMIR Public Health Surveill, V3, pe47, DOI 10.2196/publichealth.6870
   UAlberta Medicine, 2020, AR YOU INT BEING PAR
   Vrdelja M, 2018, EUR J PUBLIC HEALTH, V28, P934, DOI 10.1093/eurpub/cky114
   Warren KE, 2017, J PUBLIC HEALTH-UK, V39, pE73, DOI 10.1093/pubmed/fdw076
   Wilson K, 2014, EXPERT REV VACCINES, V13, P969, DOI 10.1586/14760584.2014.928208
   Wilson K, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2409
   World Health Organisation, 2019, TOP 10 THREATS GLOB
   Yammine S, 2020, NATURE, V581, P345, DOI 10.1038/d41586-020-01356-y
   Yuan XY, 2019, SOC MEDIA SOC, V5, DOI 10.1177/2056305119865465
   Zhang EJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025866
NR 93
TC 0
Z9 0
U1 21
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV 1
PY 2020
VL 16
IS 11
BP 2586
EP 2593
DI 10.1080/21645515.2020.1780846
EA JUL 2020
PG 8
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PC2WP
UT WOS:000550933500001
PM 32693678
OA Bronze
DA 2021-01-01
ER

PT J
AU Rahman, IU
   Ali, N
   Ijaz, F
   Afzal, A
   Abd Allah, EF
AF Rahman, Inayat Ur
   Ali, Niaz
   Ijaz, Farhana
   Afzal, Aftab
   Abd Allah, Elsayed Fathi
TI COVID-19-Important considerations for developing and using a vaccine
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Coronavirus; SARS-CoV-2; COVID-19; global pandemic; vaccine
AB The novel coronavirus SARS-CoV-2 after emerging in China has caused a global pandemic that is risking the lives of millions. COVID-19 has spread across the world at a very rapid rate raising concerns of capacity limitations and lack of unified responses at the global level, particularly from the world's most developed countries. The spread of further infection has been curtailed by lockdown and mass social distancing that has been enforced in most parts of the world. There are no clinical data yet suggesting that any available candidate vaccine will be effective for COVID-19 which will be a critical need for eventually preventing this disease. Extensive research is underway with some success in identification of monoclonal antibodies from COVID-19 recovered patients, which may inform on vaccine development. The clinical evaluations of COVID-19 vaccines need to follow standardized protocols that are essential for safeguarding humans. In absence of a vaccine or a widely available effective therapy, quarantine and other preventive measures are essential in curtailing the risk of pandemic spread.
C1 [Rahman, Inayat Ur; Ali, Niaz; Ijaz, Farhana; Afzal, Aftab] Hazara Univ, Dept Bot, Mansehra 21300, Pakistan.
   [Abd Allah, Elsayed Fathi] King Saud Univ, Coll Food & Agr Sci, Dept Plant Prod, Riyadh, Saudi Arabia.
RP Rahman, IU; Ali, N (corresponding author), Hazara Univ, Dept Bot, Mansehra 21300, Pakistan.
EM hajibotanist@outlook.com; niazalitk25@gmail.com
RI Rahman, Inayat Ur/D-5420-2015
OI Ur Rahman, Inayat/0000-0003-3312-7975; ALI, NIAZ/0000-0003-3814-5531
CR Bangari V, 2020, IEEE J SEL TOP QUANT, V26, DOI 10.1109/JSTQE.2019.2946655
   Barnett-Howell Z., 2020, ARXIV200404867
   Beasley DWC, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.13
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   FDA, 2015, FDA APPR VACC US KNO
   Metz S., 2020, US TODAY
   Naseem A, 2019, J PAK MED ASSOC, V69, P1108
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   World Health Organization, COR DIS 2019 COVID 1
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 11
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1781507
EA JUL 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA MN6GR
UT WOS:000550937900001
PM 32693665
DA 2021-01-01
ER

PT J
AU Cohen, SA
   Kellogg, C
   Equils, O
AF Cohen, Samuel A.
   Kellogg, Caitlyn
   Equils, Ozlem
TI Neutralizing and cross-reacting antibodies: implications for
   immunotherapy and SARS-CoV-2 vaccine development
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19; vaccine; immunotherapy; pregnancy
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; SPIKE; IDENTIFICATION; SARS;
   229E; NL63
AB The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is unclear whether antibodies induced by SARS-CoV-2 have neutralizing capacity and whether they can protect from future infection. Seasonal human coronaviruses (HCoV) have been circulating for decades. It is currently unknown whether antibodies against seasonal HCoV may cross-neutralize SARS-CoV-2. Data from neonates suggest that trans-placental antibodies against HCoV may have neutralizing capacity. Here we briefly review the epidemiologic observations on HCoV and discuss the potential implications for neutralizing and cross-neutralizing antibodies against SARS-CoV-2.
C1 [Cohen, Samuel A.] USC, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   [Cohen, Samuel A.; Kellogg, Caitlyn; Equils, Ozlem] MiOra, Publ Hlth Nonprofit, Encino, CA USA.
   [Kellogg, Caitlyn] Univ Calif San Diego, Sch Med, MiOra Covid 19 Response, Los Angeles, CA USA.
RP Equils, O (corresponding author), MiOra, Encino, CA 91316 USA.
EM ozlem@miora.org
OI Kellogg, Caitlyn/0000-0002-2452-6264; Cohen, Samuel/0000-0002-8816-5015
FU MiOra public health education
FX This work was supported by MiOra public health education nonprofit.
CR Adriana T, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20264
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Boncristiani HF, 2009, ENCY MICROBIOL, V2009, P500, DOI [10.1016/B978-012373944-5.00314-X, DOI 10.1016/B978-012373944-5.00314-X]
   Centers for Disease Control and Prevention, 2020, COVIDVIEW
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   de Assis Rafael R, 2020, bioRxiv, DOI 10.1101/2020.04.15.043364
   Dijkman R, 2008, J CLIN MICROBIOL, V46, P2368, DOI 10.1128/JCM.00533-08
   Dijkman R, 2012, J CLIN VIROL, V53, P135, DOI 10.1016/j.jcv.2011.11.011
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Fouda Genevieve G, 2018, Immunohorizons, V2, P14, DOI 10.4049/immunohorizons.1700057
   Gorse GJ, 2020, J MED VIROL, V92, P512, DOI 10.1002/jmv.25715
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027
   Li F, 2012, J VIROL, V86, P2856, DOI 10.1128/JVI.06882-11
   Lim Y.X., 2016, DISEASES, V4, P26, DOI DOI 10.3390/DISEASES4030026
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Monto AS, 2020, J INFECT DIS, V222, P9, DOI 10.1093/infdis/jiaa161
   Nowak MD, 2020, J MED VIROL, V92, P1699, DOI 10.1002/jmv.25953
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schwartz David A, 2020, Arch Pathol Lab Med, DOI 10.5858/arpa.2020-0901-SA
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Stockman LJ, 2007, PEDIATR INFECT DIS J, V26, P68, DOI 10.1097/01.inf.0000247136.28950.41
   Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27
   Thabet F, 2015, SAUDI MED J, V36, P484, DOI 10.15537/smj.2015.4.10243
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Varghese L, 2018, J PEDIAT INF DIS SOC, V7, P151, DOI 10.1093/jpids/pix027
   Wan WY, 2020, CROSS REACTION SERA, P12, DOI [10.1101/2020.03.17.20034454, DOI 10.1101/2020.03.17.20034454]
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Zhao JC, 2007, CLIN VACCINE IMMUNOL, V14, P839, DOI 10.1128/CVI.00432-06
NR 41
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1787074
EA JUL 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA MM3ST
UT WOS:000550080400001
PM 32678695
OA Bronze
DA 2021-01-01
ER

PT J
AU Santos, GM
   Ackerman, B
   Rao, A
   Wallach, S
   Ayala, G
   Lamontage, E
   Garner, A
   Holloway, IW
   Arreola, S
   Silenzio, V
   Stromdahl, S
   Yu, L
   Strong, C
   Adamson, T
   Yakusik, A
   Doan, TT
   Huang, PY
   Cerasuolo, D
   Bishop, A
   Noori, T
   Pharris, A
   Aung, M
   Dara, M
   Chung, SY
   Hanley, M
   Baral, S
   Beyrer, C
   Howell, S
AF Santos, Glenn-Milo
   Ackerman, Benjamin
   Rao, Amrita
   Wallach, Sara
   Ayala, George
   Lamontage, Erik
   Garner, Alex
   Holloway, Ian W.
   Arreola, Sonya
   Silenzio, Vince
   Stromdahl, Susanne
   Yu, Louis
   Strong, Carol
   Adamson, Tyler
   Yakusik, Anna
   Tran Thu Doan
   Huang, Poyao
   Cerasuolo, Damiano
   Bishop, Amie
   Noori, Teymur
   Pharris, Anastasia
   Aung, Max
   Dara, Masoud
   Chung, Ssu Yu
   Hanley, Marguerite
   Baral, Stefan
   Beyrer, Chris
   Howell, Sean
TI Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of
   COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay
   Men and Other Men Who Have Sex with Men
SO AIDS AND BEHAVIOR
LA English
DT Article; Early Access
DE COVID-19; Economic impact; Mental health; HIV; AIDS; Gay; Men who have
   sex with men
ID ANTIRETROVIRAL THERAPY; LATINO MEN; RISK; SERVICES; UNEMPLOYMENT;
   INTERRUPTION; INSURANCE; STIGMA; ACCESS
AB There is an urgent need to measure the impacts of COVID-19 among gay men and other men who have sex with men (MSM). We conducted a cross-sectional survey with a global sample of gay men and other MSM (n = 2732) from April 16, 2020 to May 4, 2020, through a social networking app. We characterized the economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response, and examined whether sub-groups of our study population are disproportionately impacted by COVID-19. Many gay men and other MSM not only reported economic and mental health consequences, but also interruptions to HIV prevention and testing, and HIV care and treatment services. These consequences were significantly greater among people living with HIV, racial/ethnic minorities, immigrants, sex workers, and socio-economically disadvantaged groups. These findings highlight the urgent need to mitigate the negative impacts of COVID-19 among gay men and other MSM.
C1 [Santos, Glenn-Milo] Univ Calif San Francisco, Community Hlth Syst Dept, San Francisco, CA 94143 USA.
   [Santos, Glenn-Milo] San Francisco Dept Publ Hlth, Ctr Publ Hlth Res, San Francisco, CA 94102 USA.
   [Ackerman, Benjamin] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
   [Rao, Amrita; Wallach, Sara; Adamson, Tyler; Baral, Stefan; Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Baltimore, MD USA.
   [Ayala, George; Arreola, Sonya] MPact Global Act Gay Mens Hlth & Rights, Oakland, CA USA.
   [Lamontage, Erik; Yakusik, Anna] Joint United Nat Programme HIV & AIDS, Geneva, Switzerland.
   [Garner, Alex] Hornet, Los Angeles, CA USA.
   [Holloway, Ian W.] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA USA.
   [Silenzio, Vince] Rutgers Sch Publ Hlth, Piscataway, NJ USA.
   [Stromdahl, Susanne] Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden.
   [Yu, Louis] Gustavus Adolphus Coll, Dept Math Comp Sci & Stat, St Peter, MN 56082 USA.
   [Strong, Carol] Natl Cheng Kung Univ, Dept Publ Hlth, Tainan, Taiwan.
   [Tran Thu Doan; Aung, Max] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Huang, Poyao] Univ Calif San Diego, Dept Commun, San Diego, CA 92103 USA.
   [Cerasuolo, Damiano] Univ Hosp Caen, Caen, France.
   [Bishop, Amie] OutRight Act Int, New York, NY USA.
   [Noori, Teymur; Pharris, Anastasia] European Ctr Dis Prevent & Control, Solna, Sweden.
   [Dara, Masoud] WHO Reg Off Europe, Copenhagen, Denmark.
   [Chung, Ssu Yu; Howell, Sean] LGBT Fdn, San Francisco, CA USA.
   [Hanley, Marguerite] TECH4HIV, San Francisco, CA USA.
   [Lamontage, Erik] Aix Marseille Univ, CNRS, EHESS, Cent Marseille,AMSE, Chemin Chateau Lafarge, F-13290 Les Milles, France.
   [Stromdahl, Susanne] Uppsala Univ, Dept Med Sci, Sect Infect Dis, Uppsala, Sweden.
RP Santos, GM (corresponding author), Univ Calif San Francisco, Community Hlth Syst Dept, San Francisco, CA 94143 USA.; Santos, GM (corresponding author), San Francisco Dept Publ Hlth, Ctr Publ Hlth Res, San Francisco, CA 94102 USA.
EM Glenn-Milo.Santos@ucsf.edu
RI Strong, Carol/E-2127-2016
OI Strong, Carol/0000-0002-2934-5382; Ackerman,
   Benjamin/0000-0003-2522-6623
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R25 HD045810]
   Funding Source: Medline; World Health OrganizationWorld Health
   Organization [001] Funding Source: Medline
CR [Anonymous], 2019, LGBT DEM DAT INT
   [Anonymous], 2016, LANCET INFECT DIS, V16, P565, DOI DOI 10.1016/S1473-3099(15)00536-8
   Arreola S, 2015, AIDS BEHAV, V19, P227, DOI 10.1007/s10461-014-0869-x
   Ayala G, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25130
   Ayala G, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21098
   Bansi-Matharu L, 2019, AIDS, V33, P1385, DOI 10.1097/QAD.0000000000002210
   Baral S, 2018, JMIR PUBLIC HLTH SUR, V4, P289, DOI 10.2196/publichealth.9321
   Baral SD, 2015, LANCET, V385, P260, DOI 10.1016/S0140-6736(14)60801-1
   Beyrer C, 2012, LANCET, V380, P424, DOI 10.1016/S0140-6736(12)61022-8
   Bibbins Domingo K, 2020, ANN INTERN MED
   Bishop A., 2020, VULNERABILITY AMPLIF
   Bourne A, 2019, SEX TRANSM INFECT, V95, P187, DOI 10.1136/sextrans-2018-053705
   Catalani Caricia, 2013, Open AIDS J, V7, P17, DOI 10.2174/1874613620130812003
   Charlton BM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020418
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Conyers LM, 2017, AIDS EDUC PREV, V29, P475, DOI 10.1521/aeap.2017.29.5.475
   Courtemanche C, 2020, HLTH AFF MILLWOOD, DOI 101377hlthaff202000608
   Delpierre C, 2008, SEX TRANSM INFECT, V84, P183, DOI 10.1136/sti.2007.027961
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Earnshaw VA, 2013, AM PSYCHOL, V68, P225, DOI 10.1037/a0032705
   Ecker J, 2019, J HOMOSEXUAL, V66, P297, DOI 10.1080/00918369.2017.1413277
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Gonzalez-Pagan O, 2020, COVID 19 RESOURCES L
   Gonzalez-Sanguino C., 2020, BRAIN BEHAV IMMUN
   Gras G, 2018, MED MALADIES INFECT, V48, P231, DOI 10.1016/j.medmal.2018.01.005
   Han CS, 2015, ARCH SEX BEHAV, V44, P411, DOI 10.1007/s10508-014-0331-1
   Hodson M., 2020, AIDSMAP
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613
   Laurence J, 2020, AIDS PATIENT CARE ST, V34, P247, DOI 10.1089/apc.2020.29005.com
   Laurencin CT, 2020, J RACIAL ETHN HLTH D
   Mann M, 2013, AIDS REV, V15, P15
   Martinez Omar, 2020, EHQUIDAD, V13, P217, DOI 10.15257/ehquidad.2020.0009
   Maulsby C, 2020, AIDS CARE, V32, P735, DOI 10.1080/09540121.2019.1640847
   Maulsby CH, 2020, AIDS BEHAV, V24, P2942, DOI 10.1007/s10461-020-02845-x
   McCann E, 2019, J CLIN NURS, V28, P2061, DOI 10.1111/jocn.14818
   Mizuno Y, 2015, J IMMIGR MINOR HEALT, V17, P47, DOI 10.1007/s10903-013-9894-5
   Poteat T, 2020, ANN EPIDEMIOLOGY
   Rana AI, 2016, AIDS PATIENT CARE ST, V30, P178, DOI 10.1089/apc.2016.0025
   Richardson S., 2020, JAMA
   Riley ED, 2011, AIDS CARE, V23, P822, DOI 10.1080/09540121.2010.538660
   Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0
   Samji H, 2015, HIV MED, V16, P76, DOI 10.1111/hiv.12173
   Sanchez TH, 2020, AIDS BEHAV, V24, P2024, DOI 10.1007/s10461-020-02894-2
   Santos GM, 2017, SEX TRANSM INFECT, V93, P62, DOI 10.1136/sextrans-2015-052386
   Santos GM, 2014, SEX TRANSM INFECT, V90, P250, DOI 10.1136/sextrans-2013-051318
   Schweighardt B, 2002, AIDS, V16, P2342, DOI 10.1097/00002030-200211220-00018
   Sullivan PS, 2012, LANCET, V380, P388, DOI 10.1016/S0140-6736(12)60955-6
   Torres TS, 2019, AIDS CARE, V31, P1193, DOI 10.1080/09540121.2019.1619665
   US Department of Health & Human Services Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Whittington C., 2020, LIVES LIVELIHOODS MA
   Wood S, 2018, AIDS, V32, P895, DOI [10.1097/qad.0000000000001772, 10.1097/QAD.0000000000001772]
   Yang HY, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113045
NR 53
TC 2
Z9 2
U1 8
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
DI 10.1007/s10461-020-02969-0
EA JUL 2020
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA MI3ZY
UT WOS:000547351200001
PM 32654021
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Seiler, NK
   Swamy, R
   Xiao, JH
   Yun, Y
AF Seiler, Natalie Kim
   Swamy, Rajeev
   Xiao, Junhua
   Yun, Yang
TI Tobacco smoking cessation in mental health services during the COVID-19
   pandemic
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE Tobacco; smoking; COVID-19
AB Tobacco smoking is more prevalent among people who experience mental illness. It is therefore a prominent issue for psychiatric inpatient units. The COVID-19 pandemic has meant that many psychiatric inpatient units are no longer granting leave and outdoor smoking breaks, prompting the question of whether to allow tobacco smoking or enforce smoking bans in mental health services. There is currently mixed evidence that tobacco smoking is associated with a higher risk of developing COVID-19 and poorer outcomes for COVID-19 cases, potentially due to current small sample sizes. Considering the benefits of smoking cessation in this vulnerable population, the current pandemic should be used as an opportunity to further enforce smoking cessation in mental health facilities and encourage nicotine replacement therapy alongside cessation counseling.
C1 [Seiler, Natalie Kim] Northern Hlth, Northern Hosp, Melbourne, Vic, Australia.
   [Swamy, Rajeev; Yun, Yang] Melbourne Hlth, Northern Area Mental Hlth Serv, Melbourne, Vic, Australia.
   [Xiao, Junhua] Univ Melbourne, Fac Med Dent & Hlth Sci, Sch Biomed Sci, Melbourne, Vic, Australia.
RP Seiler, NK (corresponding author), Northern Hlth, Northern Hosp, 185 Cooper St, Epping, Vic 3076, Australia.
EM nataliekimseiler@gmail.com
OI Xiao, Junhua/0000-0002-4320-2855
CR Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Campion J, 2008, ADV PSYCHIAT TREAT, V14, P217, DOI [10.1192/apt.bp.108.005710, DOI 10.1192/APT.BP.108.005710]
   FARSALINOS K, 2020, INTERN EMERG ME 0509, DOI DOI 10.32388/Z69O8A.10
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Prochaska JJ, 2017, ANNU REV PUBL HEALTH, V38, P165, DOI 10.1146/annurev-publhealth-031816-044618
   Simons D, SMOKING COVID 19 RAP, DOI [10.32388/VGJCUN, DOI 10.32388/VGJCUN]
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Zuluaga AF, 2020, LAT AM J CLIN SCI ME, P25
NR 10
TC 0
Z9 0
U1 7
U2 7
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD JUL 11
PY 2020
VL 38
IS 4
BP 582
EP 584
DI 10.1080/10550887.2020.1791379
EA JUL 2020
PG 3
WC Substance Abuse
SC Substance Abuse
GA OH9ZJ
UT WOS:000547710700001
PM 32657671
DA 2021-01-01
ER

PT J
AU Hua, CZ
   Miao, ZP
   Zheng, JS
   Huang, Q
   Sun, QF
   Lu, HP
   Su, FF
   Wang, WH
   Huang, LP
   Chen, DQ
   Xu, ZW
   Ji, LD
   Zhang, HP
   Yang, XW
   Li, MH
   Mao, YY
   Ying, MZ
   Ye, S
   Shu, Q
   Chen, EF
   Liang, JF
   Wang, W
   Chen, ZM
   Li, W
   Fu, JF
AF Hua, Chun-Zhen
   Miao, Zi-Ping
   Zheng, Ji-Shan
   Huang, Qian
   Sun, Qing-Feng
   Lu, Hong-Ping
   Su, Fei-Fei
   Wang, Wei-Hong
   Huang, Lie-Ping
   Chen, Da-Qing
   Xu, Zhi-Wei
   Ji, Le-Dan
   Zhang, Hong-Ping
   Yang, Xiao-Wei
   Li, Ming-Hui
   Mao, Yue-Yan
   Ying, Man-Zhen
   Ye, Sheng
   Shu, Qiang
   Chen, En-Fu
   Liang, Jian-Feng
   Wang, Wei
   Chen, Zhi-Min
   Li, Wei
   Fu, Jun-Fen
TI Epidemiological features and viral shedding in children with SARS-CoV-2
   infection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE antiviral therapy; children; COVID-19; epidemiological characteristics;
   SARS-CoV-2; viral clearance; viral excretion
ID PNEUMONIA
AB A pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection broke out all over the world; however, epidemiological data and viral shedding in pediatric patients are limited. We conducted a retrospective, multicenter study, and followed-up with all children from the families with SARS-CoV-2 infected members in Zhejiang Province, China. All infections were confirmed by testing the SARS-CoV-2 RNA with real-time reverse transcription PCR method, and epidemiological data between children and adults in the same families were compared. Effect of antiviral therapy was evaluated observationally and fecal-viral excretion times among groups with different antiviral regiments were compared with Kaplan-Meier plot. By 29 February 2020, 1298 cases from 883 families were confirmed with SARS-CoV-2 infection and 314 of which were families with children. Incidence of infection in child close contacts was significantly lower than that in adult contacts (13.2% vs 21.2%). The mean age of 43 pediatric cases was 8.2 years and mean incubation period was 9.1 days. Forty (93.0%) were family clustering. Thirty-three children had coronavirus disease 2019 (20 pneumonia) with mild symptoms and 10 were asymptomatic. Fecal SARS-CoV-2 RNA detection was positive in 91.4% (32/35) cases and some children had viral excretion time over 70 days. Viral clearance time was not different among the groups treated with different antiviral regiments. No subsequent infection was observed in family contacts of fecal-viral-excreting children. Children have lower susceptibility of SARS-CoV-2 infection, longer incubation, and fecal-viral excretion time. Positive results of fecal SARS-CoV-2 RNA detection were not used as indication for hospitalization or quarantine.
C1 [Hua, Chun-Zhen] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Infect Dis,Natl Clin Res Ctr Child Hlth, Hangzhou, Zhejiang, Peoples R China.
   [Miao, Zi-Ping; Chen, En-Fu] Zhejiang Prov Ctr Dis Control & Prevent, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zheng, Ji-Shan] Ningbo Women & Childrens Hosp, Dept Infect Dis, Ningbo, Zhejiang, Peoples R China.
   [Huang, Qian] Hangzhou Xixi Hosp, Dept Infect Dis, Hangzhou, Zhejiang, Peoples R China.
   [Sun, Qing-Feng] Ruian Peoples Hosp, Dept Infect Dis, Wenzhou, Zhejiang, Peoples R China.
   [Lu, Hong-Ping] Taizhou Hosp, Dept Pediat, Taizhou, Zhejiang, Peoples R China.
   [Su, Fei-Fei] Wenzhou Cent Hosp, Dept Infect Dis, Wenzhou, Zhejiang, Peoples R China.
   [Wang, Wei-Hong] Huzhou Cent Hosp, Dept Infect Dis, Huzhou, Zhejiang, Peoples R China.
   [Huang, Lie-Ping] Zhoushan Women & Childrens Hosp, Dept Pediat, Zhoushan, Zhejiang, Peoples R China.
   [Chen, Da-Qing] Changnan Peoples Hosp, Dept Pediat, Changnan, Zhejiang, Peoples R China.
   [Xu, Zhi-Wei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Infect Dis, Wenzhou, Zhejiang, Peoples R China.
   [Xu, Zhi-Wei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Ji, Le-Dan] Yueqing Peoples Hosp, Dept Pediat, Wenzhou, Zhejiang, Peoples R China.
   [Zhang, Hong-Ping] Wenzhou Peoples Hosp, Dept Pediat, Wenzhou, Zhejiang, Peoples R China.
   [Yang, Xiao-Wei] First Peoples Hosp Wenling, Dept Pediat, Taizhou, Zhejiang, Peoples R China.
   [Li, Ming-Hui] Shaoxing Peoples Hosp, Dept Infect Dis, Shaoxing, Zhejiang, Peoples R China.
   [Mao, Yue-Yan] First Peoples Hosp Yuhang, Dept Pediat, Hangzhou, Zhejiang, Peoples R China.
   [Ying, Man-Zhen] Dongyang Peoples Hosp, Dept Infect Dis, Jinhua, Zhejiang, Peoples R China.
   [Ye, Sheng] Zhejiang Univ, Childrens Hosp, Sch Med, Dept Crit Care Med,Natl Clin Res Ctr Child Hlth, Hangzhou, Peoples R China.
   [Shu, Qiang] Zhejiang Univ, Childrens Hosp, Sch Med, Dept Surg,Natl Clin Res Ctr Child Hlth,Data Infor, Hangzhou, Peoples R China.
   [Liang, Jian-Feng] Zhejiang Univ, Childrens Hosp, Sch Med, Stat Unit,Natl Clin Res Ctr Child Hlth, Hangzhou, Peoples R China.
   [Wang, Wei] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Med Adm, Hangzhou, Peoples R China.
   [Chen, Zhi-Min] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Resp, Hangzhou, Peoples R China.
   [Li, Wei] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Dept Lab Ctr, Hangzhou, Peoples R China.
   [Fu, Jun-Fen] Zhejiang Univ, Childrens Hosp, Sch Med, Natl Clin Res Ctr Child Hlth,Data Informat Ctr,De, Hangzhou, Peoples R China.
RP Chen, EF (corresponding author), Zhejiang Prov Ctr Dis Control & Prevent, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.; Shu, Q (corresponding author), Zhejiang Univ, Sch Med, Childrens Hosp, Data Informat Ctr,Dept Surg,Natl Clin Res Ctr Chi, Hangzhou 310003, Peoples R China.; Fu, JF (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Data Informat Ctr,Dept Endocrinol,Sch Med, Hangzhou 310003, Peoples R China.
EM shuqiang@zju.edu.cn; enfchen@cdc.zj.cn
FU Zhejiang University Special Scientific Research fund for COVID-19
   Prevention and Control; Ruian Science and Technology Bureau [MS2020023]
FX This work was supported by Zhejiang University Special Scientific
   Research fund for COVID-19 Prevention and Control, and funding from
   Ruian Science and Technology Bureau (MS2020023). We acknowledge all
   health-care workers involved in the diagnosis and treatment of patients
   in Zhejiang Province. We thank Cai-Mei Fang, Medical Education Center,
   Health Commission of Zhejiang Province; Yi Jiang, Wenzhou People's
   Hospital; Qiao-Er Luo, Ningbo Women and Children's Hospital; Ming-Bin
   Xu, Changnan Chinese Medicine Hospital; Hui-Li Li, Changnan People's
   Hospital; Zhe Zhang, Ningbo Yinzhou People's Hospital; Shun-Zhi, Chen,
   Shaoxing People's Hospital; Yan-Hua Zheng, Zhoushan Women and Children's
   Hospital; Xiao-Qiang Zhang, The First People's Hospital of Yuhang; for
   their help in data collection. We thank Ying-Jie Lu, Harvard Medical
   School and Boston Children's Hospital, for his critical reading of the
   manuscript.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Chua F, 2020, LANCET RESP MED, V8, P438, DOI 10.1016/S2213-2600(20)30132-6
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kelvin AA, 2020, LANCET INFECT DIS, V20, P633, DOI 10.1016/S1473-3099(20)30236-X
   Li W, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa450., 10.1093/cid/ciaa450, DOI 10.1093/CID/CIAA450]
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Sharif-Askari NS, MOL THER-METH CLIN D, V18, P1, DOI [10.1016/j.omtm.2020.05.013, DOI 10.1016/J.0MTM.2020.05.013]
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 7
Z9 7
U1 63
U2 63
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2804
EP 2812
DI 10.1002/jmv.26180
EA JUL 2020
PG 9
WC Virology
SC Virology
GA NU0EN
UT WOS:000547192100001
PM 32542750
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Menezes, GD
   da Silva, RA
AF de Lima Menezes, Gabriela
   da Silva, Roosevelt Alves
TI Identification of potential drugs against SARS-CoV-2 non-structural
   protein 1 (nsp1)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; non-structural protein 1; molecular dynamics simulation;
   drug design; computational biology; molecular modeling; virtual
   screening
ID RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS; DISCOVERY;
   PREDICTION; COMPOUND
AB Non-structural protein 1 (nsp1) is found in allBetacoronavirusgenus, an important viral group that causes severe respiratory human diseases. This protein has significant role in pathogenesis and it is considered a probably major virulence factor. As it is absent in humans, it becomes an interesting target of study, especially when it comes to the rational search for drugs, since it increases the specificity of the target and reduces possible adverse effects that may be caused to the patient. Using approachesin silicowe seek to study the behavior of nsp1 in solution to obtain its most stable conformation and find possible drugs with affinity to all of them. For this purpose, complete model of nsp1 of SARS-CoV-2 were predicted and its stability analyzed by molecular dynamics simulations in five different replicas. After main pocket validation using two control drugs and the main conformations of nsp1, molecular docking based on virtual screening were performed to identify novel potential inhibitors from DrugBank database. It has been found 16 molecules in common to all five nsp1 replica conformations. Three of them was ranked as the best compounds among them and showed better energy score than control molecules that havein vitroactivity against nsp1 from SARS-CoV-2. The results pointed out here suggest new potential drugs for therapy to aid the rational drug search against COVID-19. Communicated by Ramaswamy H. Sarma
C1 [de Lima Menezes, Gabriela; da Silva, Roosevelt Alves] Univ Fed Goias, Nucleo Colaborat Biosistemas, BR-75801615 Jatai, Go, Brazil.
RP da Silva, RA (corresponding author), Univ Fed Goias, Nucleo Colaborat Biosistemas, BR-75801615 Jatai, Go, Brazil.
EM rooseveltfisicaufg@gmail.com
RI da Silva, Roosevelt Alves/AAF-1577-2019
OI da Silva, Roosevelt Alves/0000-0001-5624-4790; de Lima Menezes,
   Gabriela/0000-0002-8944-8148
FU Ministerio da Ciencia e Tecnologia/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (MCTI/CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado de Goias (FAPEG); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)CAPES; CAPESCAPES
FX This work, performed at Universidade Federal de Goias, was supported by
   the Ministerio da Ciencia e Tecnologia/Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (MCTI/CNPq), Fundacao de Amparo
   a Pesquisa do Estado de Goias (FAPEG), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Additionally, G.L.M. were supported
   by fellowships from CAPES.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Al Hajjar S, 2013, ANN SAUDI MED, V33, P427, DOI 10.5144/0256-4947.2013.427
   Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Cao Y, 2008, BIOINFORMATICS, V24, P1733, DOI 10.1093/bioinformatics/btn307
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chan JFW, 2013, J FORMOS MED ASSOC, V112, P372, DOI 10.1016/j.jfma.2013.05.010
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Childers MC, 2017, MOL SYST DES ENG, V2, P9, DOI [10.1039/C6ME00083E, 10.1039/c6me00083e]
   CHOUDHURY C, 2020, J BIOMOL STRUCT 0527, DOI DOI https://doi.org/10.1080/07391102.2020.1771424
   Costa FG, 2015, ANTIMICROB AGENTS CH, V59, P5581, DOI 10.1128/AAC.04711-14
   da Silva LS, 2019, FUTURE MICROBIOL, V14, P1589, DOI 10.2217/fmb-2019-0166
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   GONCALVES RL, 2019, J BIOMOL STRUCT 1017, DOI DOI https://doi.org/10.1080/07391102.2019.1677504
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hutter J, 2012, WIRES COMPUT MOL SCI, V2, P604, DOI 10.1002/wcms.90
   Iannuzzi M., 2003, PHYS REV LETT, V90, P23, DOI DOI https://doi.org/10.1103/PhysRevLett.90.238302
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468
   Lau SKP, 2015, J VIROL, V89, P3076, DOI 10.1128/JVI.02420-14
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   MENEZES GD, 2019, J BIOMOL STRUCT 1127, DOI DOI https://doi.org/10.1080/07391102.2019.1695673
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nakagawa K, 2018, J VIROL, V92, DOI 10.1128/JVI.01157-18
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Saif LJ, 2019, DIS SWINE, P488, DOI DOI 10.1002/9781119350927.CH31
   Shen Z, 2019, J BIOL CHEM, V294, P13606, DOI 10.1074/jbc.RA119.009713
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 42
TC 4
Z9 3
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1792992
EA JUL 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI9WW
UT WOS:000547749300001
PM 32657643
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zheng, ZS
   Dong, ML
   Hu, K
AF Zheng, Zhishui
   Dong, Minglin
   Hu, Ke
TI A preliminary evaluation on the efficacy of ozone therapy in the
   treatment of COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
C1 [Zheng, Zhishui; Dong, Minglin; Hu, Ke] Wuhan Univ, Dept Resp & Crit Care Med, Renmin Hosp, Zhangzhidong Rd 99, Wuhan 430060, Peoples R China.
RP Hu, K (corresponding author), Wuhan Univ, Dept Resp & Crit Care Med, Renmin Hosp, Zhangzhidong Rd 99, Wuhan 430060, Peoples R China.
EM huke-rmhospital@163.com
OI Hu, Ke/0000-0001-9862-7239
FU Renmin Hospital of Wuhan University; Science and Technology Key Project
   on Novel Coronavirus Pneumonia, Hubei Province, China [2020FCA002]
FX The authors wish to express gratitude to Beijing Sincoheren S&T
   Development Co, Ltd for generously donating one ozone generators for use
   for COVID-19 in East Campus, Renmin Hospital of Wuhan University. None
   of the authors have any financial disclosures to make. This study was
   supported by the Science and Technology Key Project on Novel Coronavirus
   Pneumonia, Hubei Province, China (project number: 2020FCA002).
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM NOV COR
   Ricevuti G, 2020, OZONE THERAPY, V5, DOI [DOI 10.4081/ozone.2020.9014, 10.4081/ozone.2020.9014]
   Rowen R. J., 2016, African Journal of Infectious Diseases, V10, P49, DOI 10.4314/ajid.v10i1.10
   Rowen RJ, 2020, J INFECT DIS EPIDEMI, V6, P113, DOI DOI 10.23937/2474-3658/1510113
   Smith NL, 2017, MED GAS RES, V7, P212, DOI 10.4103/2045-9912.215752
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zaky S, 2011, J ALTERN COMPLEM MED, V17, P259, DOI 10.1089/acm.2010.0016
NR 8
TC 4
Z9 4
U1 5
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2020
VL 92
IS 11
BP 2348
EP 2350
DI 10.1002/jmv.26040
EA JUL 2020
PG 3
WC Virology
SC Virology
GA NU0EN
UT WOS:000547188400001
PM 32437014
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bemtgen, X
   Zotzmann, V
   Benk, C
   Rilinger, J
   Steiner, K
   Asmussen, A
   Bode, C
   Wengenmayer, T
   Maier, S
   Staudacher, DL
AF Bemtgen, Xavier
   Zotzmann, Viviane
   Benk, Christoph
   Rilinger, Jonathan
   Steiner, Katrin
   Asmussen, Alexander
   Bode, Christoph
   Wengenmayer, Tobias
   Maier, Sven
   Staudacher, Dawid L.
TI Thrombotic circuit complications during venovenous extracorporeal
   membrane oxygenation in COVID-19
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE V-V ECMO; COVID-19; Thrombotic complications; Pump head thrombosis
AB The novel coronavirus SARS-CoV-2 and the resulting disease COVID-19 causes pulmonary failure including severe courses requiring venovenous extracorporeal membrane oxygenation (V-V ECMO). Coagulopathy is a known complication of COVID-19 leading to thrombotic events including pulmonary embolism. It is unclear if the coagulopathy also increases thrombotic circuit complications of the ECMO. Aim of the present study therefor was to investigate the rate of V-V ECMO complications in COVID-19. We conducted a retrospective registry study including all patients on V-V ECMO treated at our centre between 01/2018 and 04/2020. COVID-19 cases were compared non- COVID-19 cases. All circuit related complications resulting in partial or complete exchange of the extracorporeal system were registered. In total, 66 patients were analysed of which 11 (16.7%) were SARS-CoV-2 positive. The two groups did not differ in clinical parameters including age (COVID-19 59.4 vs. non-COVID-19 58.1 years), gender (36.4% vs. 40%), BMI (27.8 vs. 24.2) and severity of illness as quantified by the RESP Score (1pt. vs 1pt.). 28 days survival was similar in both groups (72.7% vs. 58.2%). While anticoagulation was similar in both groups (p = 0.09), centrifugal pump head thrombosis was more frequent in COVID-19 (9/11 versus 16/55p < 0.01). Neither the time to first exchange (p = 0.61) nor blood flow at exchange (p = 0.68) did differ in both groups. D-dimer levels prior to the thrombotic events were significantly higher in COVID-19 (mean 15.48 vs 26.59,p = 0.01). The SARS-CoV-2 induced infection is associated with higher rates of thrombotic events of the extracorporeal system during V-V ECMO therapy.
C1 [Bemtgen, Xavier; Zotzmann, Viviane; Rilinger, Jonathan; Steiner, Katrin; Asmussen, Alexander; Bode, Christoph; Wengenmayer, Tobias; Staudacher, Dawid L.] Univ Freiburg, Med Ctr, Fac Med, Dept Med Interdisciplinary Med Intens Care 3, Hugstetter Str 55, D-79106 Freiburg, Germany.
   [Bemtgen, Xavier; Zotzmann, Viviane; Rilinger, Jonathan; Steiner, Katrin; Asmussen, Alexander; Bode, Christoph; Wengenmayer, Tobias; Staudacher, Dawid L.] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Benk, Christoph; Maier, Sven] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Dept Cardiovasc Surg, Freiburg, Germany.
   [Steiner, Katrin] Med Univ Vienna, Dept Anaesthesia Intens Care Med & Pain Med, Vienna, Austria.
RP Bemtgen, X (corresponding author), Univ Freiburg, Med Ctr, Fac Med, Dept Med Interdisciplinary Med Intens Care 3, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM Xavier.bemtgen@uniklinik-freiburg.de
RI Wengenmayer, Tobias/ABD-7064-2020
OI Wengenmayer, Tobias/0000-0002-3659-0407
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR Appelt H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227793
   Archer SL, 2020, CIRCULATION, V120
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hastings SM, 2017, ASAIO J, V63, P86, DOI 10.1097/MAT.0000000000000444
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Lubnow M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112316
   Lubnow M, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.12.008
   Marullo AG, 2020, MINERVA CARDIOANGIOL
   Rajagopal K, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.007175
   Vetter P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1470
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 13
TC 2
Z9 2
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02217-1
EA JUL 2020
PG 7
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA MI4FJ
UT WOS:000547365300001
PM 32653986
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cardona-Ospina, JA
   Arteaga-Livias, K
   Villamil-Gomez, WE
   Perez-Diaz, CE
   Bonilla-Aldana, DK
   Mondragon-Cardona, A
   Solarte-Portilla, M
   Martinez, E
   Millan-Onate, J
   Lopez-Medina, E
   Lopez, P
   Navarro, JC
   Perez-Garcia, L
   Mogollon-Rodriguez, E
   Rodriguez-Morales, AJ
   Paniz-Mondolfi, A
AF Cardona-Ospina, Jaime A.
   Arteaga-Livias, Kovy
   Villamil-Gomez, Wilmer E.
   Perez-Diaz, Carlos E.
   Katterine Bonilla-Aldana, D.
   Mondragon-Cardona, Alvaro
   Solarte-Portilla, Marco
   Martinez, Ernesto
   Millan-Onate, Jose
   Lopez-Medina, Eduardo
   Lopez, Pio
   Navarro, Juan-Carlos
   Perez-Garcia, Luis
   Mogollon-Rodriguez, Euler
   Rodriguez-Morales, Alfonso J.
   Paniz-Mondolfi, Alberto
TI Dengue and COVID-19, overlapping epidemics? An analysis from Colombia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE Colombia; COVID-19; dengue; Latin America; overlapping; SARS-CoV-2;
   syndemic
ID HEALTHY-CHILDREN; EFFICACY; VACCINE
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread throughout Latin America, a region swept by multiple previous and ongoing epidemics. There are significant concerns that the arrival of COVID-19 is currently overlapping with other viruses, particularly dengue, in various endo-epidemic regions across South America. In this report, we analyzed trends for both viral infections in Colombia during the first 20 epidemiological weeks (EWs) of 2020. From 1st January to 16th May 2020 (EWs, 1-20), a total of 52 679 cases of dengue and 14 943 cases of COVID-19 have been confirmed in Colombia. As both conditions may potentially lead to fatal outcomes, especially in patients with chronic co-morbidities, overlapping infections, and co-occurrence may increase the number of patients requiring intensive care and mechanical ventilation. In regions, such as Valle del Cauca, intensified preparation for such scenarios should be pondered, and further studies should be performed to address this critical issue in a timely matter.
C1 [Cardona-Ospina, Jaime A.; Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Amer, Fac Med, Grp Invest Biomed, Pereira, Colombia.
   [Cardona-Ospina, Jaime A.; Katterine Bonilla-Aldana, D.; Rodriguez-Morales, Alfonso J.] Univ Tecnol Pereira, Fac Hlth Sci, Publ Hlth & Infect Res Grp, Pereira, Risaralda, Colombia.
   [Cardona-Ospina, Jaime A.; Rodriguez-Morales, Alfonso J.] Univ Tecnol Pereira, Fac Hlth Sci, Grp Invest Infecc & Inmunidad, Pereira, Risaralda, Colombia.
   [Cardona-Ospina, Jaime A.; Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Amer, Fac Med, Semillero Invest Infecc Emergentes & Med Trop, Pereira, Risaralda, Colombia.
   [Cardona-Ospina, Jaime A.; Rodriguez-Morales, Alfonso J.] Inst Invest Ciencias Biomed Sci Help, Emerging Infect Dis & Trop Med Res Grp, Pereira, Risaralda, Colombia.
   [Cardona-Ospina, Jaime A.; Villamil-Gomez, Wilmer E.; Katterine Bonilla-Aldana, D.; Rodriguez-Morales, Alfonso J.] Asociac Colombiana Infectol, Comittee Trop Med Zoonoses & Travel Med, Bogota, DC, Colombia.
   [Cardona-Ospina, Jaime A.; Arteaga-Livias, Kovy; Villamil-Gomez, Wilmer E.; Katterine Bonilla-Aldana, D.; Navarro, Juan-Carlos; Rodriguez-Morales, Alfonso J.; Paniz-Mondolfi, Alberto] Latin Amer Network Coronavirus Dis 2019 COVID 19, Coordinat, Pereira, Risaralda, Colombia.
   [Arteaga-Livias, Kovy] Univ Nacl Hermilio Valdizan, Fac Med, Huanuco, Peru.
   [Arteaga-Livias, Kovy; Rodriguez-Morales, Alfonso J.] Univ Cient Sur, Clin Epidemiol & Biostat, Lima 15046, Peru.
   [Villamil-Gomez, Wilmer E.] Hosp Univ Sincelejo, Infect Dis & Infect Control Res Grp, Sincelejo, Sucre, Colombia.
   [Villamil-Gomez, Wilmer E.] Univ Atlantico, SUE Caribe, Programa Doctorado Med Trop, Barranquilla, Colombia.
   [Perez-Diaz, Carlos E.] Clin Marly, Infect Dis Dept, Bogota, DC, Colombia.
   [Perez-Diaz, Carlos E.] Hosp La Samaritana, Infect Dis Dept, La Samaritana, DC, Colombia.
   [Katterine Bonilla-Aldana, D.] Fdn Univ Autonoma Amer, Grp Invest BIOECOS, Semillero Invest Zoonosis SIZOO, Pereira, Risaralda, Colombia.
   [Mondragon-Cardona, Alvaro] Fdn Univ Navarra, Fac Med, Neiva, Huila, Colombia.
   [Mondragon-Cardona, Alvaro] Univ Surcolombiana, Fac Med, Neiva, Huila, Colombia.
   [Mondragon-Cardona, Alvaro] Clin EMCOSALUDClin Uros, Internal Med Dept, Neiva, Huila, Colombia.
   [Mondragon-Cardona, Alvaro] Clin EMCOSALUDClin Uros, Intens Care Unit, Neiva, Huila, Colombia.
   [Solarte-Portilla, Marco] Hosp Univ Dept Narino, Internal Med Dept, Pasto, Narino, Colombia.
   [Solarte-Portilla, Marco] ESE Pasto Salud, Dept Epidemiol Surveillance, Program Healthcare Associated Infect, Pasto, Narino, Colombia.
   [Martinez, Ernesto] Univ Valle, Dept Internal Med, Infect Dis, Santiago De Cali, Colombia.
   [Millan-Onate, Jose; Lopez-Medina, Eduardo] Ctr Med Imbanaco, Adult & Pediat Infect Dis, Cali, Valle Del Cauca, Colombia.
   [Lopez-Medina, Eduardo; Lopez, Pio] Ctr Estudios Infectol Pediat, Pediat Infect Dis, Cali, Valle Del Cauca, Colombia.
   [Lopez-Medina, Eduardo; Lopez, Pio] Univ Valle, Dept Pediat, Cali, Valle Del Cauca, Colombia.
   [Navarro, Juan-Carlos] Univ Int SEK, Ctr Biodivers Emerging Dis & Environm Hlth, Master Sch Biomed, Nat Sci & Environm Fac, Quito, Ecuador.
   [Perez-Garcia, Luis; Mogollon-Rodriguez, Euler; Paniz-Mondolfi, Alberto] Incubadora Venezolana Ciencia, Inst Invest Biomed IDB, Cabudare, Edo Lara, Venezuela.
   [Paniz-Mondolfi, Alberto] Inst Estudios Avanzados IDEA, Lab Selializac Celular & Bioquim Parasitos, Caracas, Venezuela.
   [Paniz-Mondolfi, Alberto] Acad Nacl Med, Caracas, Venezuela.
RP Rodriguez-Morales, AJ (corresponding author), Univ Cient Sur, Clin Epidemiol & Biostat, Lima 15046, Peru.
EM arodriguezm@utp.edu.co
RI Cardona-Ospina, Jaime A./ABE-3753-2020
OI Cardona-Ospina, Jaime A./0000-0003-3996-2293; Navarro,
   Juan-Carlos/0000-0002-7692-4248; Perez, Luis/0000-0002-2230-3171;
   Arteaga-Livias, Kovy/0000-0002-0182-703X
CR Perez MA, 2010, PEDIATR INFECT DIS J, V29, P1052, DOI 10.1097/INF.0b013e3181e6c69b
   Azekawa S, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00775
   Biswal S, 2020, LANCET, V395, P1423, DOI 10.1016/S0140-6736(20)30414-1
   Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869
   Bokhari SMMA, 2020, AM J TROP MED HYG, V103, P77, DOI 10.4269/ajtmh.20-0356
   Diaz-Guio DA, 2020, TRAVEL MED INFECT DI, DOI [10.1016/j.tmaid.2020.101746, DOI 10.1016/J.TMAID.2020.101746]
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Haqqi A, 2020, J MED VIROL, DOI 10.1002/jmv.26144
   Lorenz C, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101659
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Navarro JC, 2020, TRAVEL MED INFECT DI
   Hernandez-Fonseca JP, 2015, ARCH VIROL, V160, P2861, DOI 10.1007/s00705-015-2581-1
   PAHO, 2020, EP UPD DENG 7 FEBR 2
   Pinky L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155589
   Quintero-Herrera LL, 2015, J INFECT PUBLIC HEAL, V8, P291, DOI 10.1016/j.jiph.2014.11.005
   Rodriguez JA, 2020, IDCases, V20, DOI 10.1016/j.idcr.2020.e00762
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613
   Rodriguez-Morales AJ, 2019, TRAVEL MED INFECT DI, V27, P5, DOI 10.1016/j.tmaid.2018.10.010
   Sanchez-Duque JA, 2020, ATEN PRIM, V52, P369, DOI 10.1016/j.aprim.2020.04.001
   Sanchez-Duque JA, 2020, J MED VIROL, V92, P2398, DOI 10.1002/jmv.26089
   Villamil-Gomez WE, 2016, J INFECT PUBLIC HEAL, V9, P684, DOI 10.1016/j.jiph.2015.12.002
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1
   Yan G, 2020, LANCET INFECT DIS, V20, P536, DOI 10.1016/S1473-3099(20)30158-4
   Zambrano LI, 2019, TRAVEL MED INFECT DI, V31, DOI 10.1016/j.tmaid.2019.07.012
NR 25
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26194
EA JUL 2020
PG 6
WC Virology
SC Virology
GA MI1HS
UT WOS:000547167000001
PM 32558962
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chen, HZ
   Tang, LL
   Yu, XL
   Zhou, J
   Chang, YF
   Wu, X
AF Chen, Hong-Zhi
   Tang, Ling-Li
   Yu, Xin-Ling
   Zhou, Jie
   Chang, Yun-Feng
   Wu, Xiang
TI Bioinformatics analysis of epitope-based vaccine design against the
   novel SARS-CoV-2
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE SARS-CoV-2; Epitope; Vaccine; Bioinformatics
ID RESPIRATORY SYNDROME CORONAVIRUS; NUCLEOCAPSID PROTEIN;
   IMMUNE-RESPONSES; PNEUMONIA; PREDICTION; SPIKE
AB Background An outbreak of infection caused by SARS-CoV-2 recently has brought a great challenge to public health. Rapid identification of immune epitopes would be an efficient way to screen the candidates for vaccine development at the time of pandemic. This study aimed to predict the protective epitopes with bioinformatics methods and resources for vaccine development. Methods The genome sequence and protein sequences of SARS-CoV-2 were retrieved from the National Center for Biotechnology Information (NCBI) database. ABCpred and BepiPred servers were utilized for sequential B-cell epitope analysis. Discontinuous B-cell epitopes were predicted via DiscoTope 2.0 program. IEDB server was utilized for HLA-1 and HLA-2 binding peptides computation. Surface accessibility, antigenicity, and other important features of forecasted epitopes were characterized for immunogen potential evaluation. Results A total of 63 sequential B-cell epitopes on spike protein were predicted and 4 peptides (Spike(315-324), Spike(333-338), Spike(648-663), Spike(1064-1079)) exhibited high antigenicity score and good surface accessibility. Ten residues within spike protein (Gly(496), Glu(498), Pro(499), Thr(500), Leu(1141), Gln(1142), Pro(1143), Glu(1144), Leu(1145), Asp(1146)) are forecasted as components of discontinuous B-cell epitopes. The bioinformatics analysis of HLA binding peptides within nucleocapsid protein produced 81 and 64 peptides being able to bind MHC class I and MHC class II molecules respectively. The peptides (Nucleocapsid(66-75), Nucleocapsid(104-112)) were predicted to bind a wide spectrum of both HLA-1 and HLA-2 molecules. Conclusions B-cell epitopes on spike protein and T-cell epitopes within nucleocapsid protein were identified and recommended for developing a protective vaccine against SARS-CoV-2.
C1 [Chen, Hong-Zhi] Cent South Univ, Xiangya Hosp 2, Dept Metab & Endocrinol,Metab Syndrome Res Ctr, Key Lab Diabet Immunol,Minist Educ,Natl Clin Res, Changsha 410011, Hunan, Peoples R China.
   [Tang, Ling-Li] Cent South Univ, Xiangya Hosp 2, Dept Lab Med, Changsha 410011, Hunan, Peoples R China.
   [Yu, Xin-Ling; Zhou, Jie] WHO Collaborating Ctr Res & Control Schistosomias, Hunan Inst Parasite Dis, Yueyang 414000, Hunan, Peoples R China.
   [Chang, Yun-Feng] Cent South Univ, Xiangya Sch Basic Med, Dept Forens Med Sci, Changsha 410013, Hunan, Peoples R China.
   [Wu, Xiang] Cent South Univ, Xiangya Sch Basic Med, Dept Parasitol, Changsha 410013, Hunan, Peoples R China.
RP Chen, HZ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Metab & Endocrinol,Metab Syndrome Res Ctr, Key Lab Diabet Immunol,Minist Educ,Natl Clin Res, Changsha 410011, Hunan, Peoples R China.; Chang, YF (corresponding author), Cent South Univ, Xiangya Sch Basic Med, Dept Forens Med Sci, Changsha 410013, Hunan, Peoples R China.; Wu, X (corresponding author), Cent South Univ, Xiangya Sch Basic Med, Dept Parasitol, Changsha 410013, Hunan, Peoples R China.
EM chenhongzhi2013@csu.edu.cn; changyunfeng880@163.com; wxspring@126.com
OI Chen, Hongzhi/0000-0001-6060-3776
FU Changsha Municipal Science and Technology Bureau Emergency Program on
   COVID-19; National Science Fundation of China [81970746, 81371834,
   81828004, 81820108007]; Hunan Provincial Natural Sciences Foundation
   [2018JJ3740]; Major Science and Technology Project of Hunan Province
   [2017SK1020]
FX This work was supported by Changsha Municipal Science and Technology
   Bureau Emergency Program on COVID-19, the National Science Fundation of
   China (No. 81970746, No.81371834, No. 81828004, and No. 81820108007),
   Hunan Provincial Natural Sciences Foundation (No. 2018JJ3740), and Major
   Science and Technology Project of Hunan Province (No. 2017SK1020).
CR Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alexander J, 2004, VACCINE, V22, P2362, DOI 10.1016/j.vaccine.2003.11.061
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Che XY, 2004, EMERG INFECT DIS, V10, P1947, DOI 10.3201/eid1011.040516
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Khan M I, 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Li YH, 2005, J VIROL METHODS, V130, P45, DOI 10.1016/j.jviromet.2005.06.001
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Qiu TY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04171-2
   Rappuoli R, 2016, J EXP MED, V213, P469, DOI 10.1084/jem.20151960
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Surjit M, 2008, INFECT GENET EVOL, V8, P397, DOI 10.1016/j.meegid.2007.07.004
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Veit S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120718
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 2
Z9 2
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD JUL 10
PY 2020
VL 9
IS 1
AR 88
DI 10.1186/s40249-020-00713-3
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA NA8GU
UT WOS:000560056800001
PM 32741372
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Choudhary, S
   Malik, YS
   Tomar, S
AF Choudhary, Shweta
   Malik, Yashpal S.
   Tomar, Shailly
TI Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing
   Usingin silicoStructure-Based Virtual Screening Approach
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE RNA viruses; SARS-CoV-2; receptor-binding domain; ACE2; COVID-19;
   drug-repurposing
ID RECEPTOR-BINDING DOMAIN; CHIKUNGUNYA VIRUS; CORONAVIRUS; INFECTION;
   DOCKING; OPTIMIZATION; MODULATION; MODELS; POTENT; NL63
AB The rapidly spreading, highly contagious and pathogenic SARS-coronavirus 2 (SARS-CoV-2) associated Coronavirus Disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization (WHO). The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycoprotein (S-protein) to cellular angiotensin converting enzyme 2 (ACE2) receptor. The virus specific molecular interaction with the host cell represents a promising therapeutic target for identifying SARS-CoV-2 antiviral drugs. The repurposing of drugs can provide a rapid and potential cure toward exponentially expanding COVID-19. Thereto, high throughput virtual screening approach was used to investigate FDA approved LOPAC library drugs against both the receptor binding domain of spike protein (S-RBD) and ACE2 host cell receptor. Primary screening identified a few promising molecules for both the targets, which were further analyzed in details by their binding energy, binding modes through molecular docking, dynamics and simulations. Evidently, GR 127935 hydrochloride hydrate, GNF-5, RS504393, TNP, and eptifibatide acetate were found binding to virus binding motifs of ACE2 receptor. Additionally, KT203, BMS195614, KT185, RS504393, and GSK1838705A were identified to bind at the receptor binding site on the viral S-protein. These identified molecules may effectively assist in controlling the rapid spread of SARS-CoV-2 by not only potentially inhibiting the virus at entry step but are also hypothesized to act as anti-inflammatory agents, which could impart relief in lung inflammation. Timely identification and determination of an effective drug to combat and tranquilize the COVID-19 global crisis is the utmost need of hour. Further, promptin vivotesting to validate the anti-SARS-CoV-2 inhibition efficiency by these molecules could save lives is justified.
C1 [Choudhary, Shweta; Tomar, Shailly] Indian Inst Technol Roorkee, Dept Biotechnol, Roorkee, Uttar Pradesh, India.
   [Malik, Yashpal S.] Indian Vet Res Inst, Div Biol Standardizat, Bareilly, Uttar Pradesh, India.
RP Tomar, S (corresponding author), Indian Inst Technol Roorkee, Dept Biotechnol, Roorkee, Uttar Pradesh, India.
EM shailly.tomar@bt.iitr.ac.in
FU Council of Scientific & Industrial Research, Government of IndiaCouncil
   of Scientific & Industrial Research (CSIR) - India; Science and
   Engineering Research Board, Department of Science & Technology,
   Government of India [IPA/2020/000054]; Education Division, ICAR, New
   Delhi
FX SC thanks Council of Scientific & Industrial Research, Government of
   India for financial support. ST acknowledges and thank Science and
   Engineering Research Board, Department of Science & Technology,
   Government of India (Proj. ref no. IPA/2020/000054) for supporting this
   study. YM acknowledges support of Education Division, ICAR, New Delhi
   for National Fellowship award. We also thank the Macromolecular
   Crystallographic Facility (MCU) at Indian Institute of Technology
   Roorkee (IIT Roorkee) for computer facility. Authors thank Vikram Dalal
   for his help in critically reading the manuscript that helped us in
   improving the quality of the manuscript. An earlier version of this
   paper (ChemRxiv doi: https://doi.org/10.26434/chemrxiv.12005988.v2) was
   posted on the ChemRxiv.org pre-print server (60).
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bottemanne P, 2019, FASEB J, V33, P7635, DOI 10.1096/fj.201802259R
   Chakraborty A, 2010, CELL, V143, P897, DOI 10.1016/j.cell.2010.11.032
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Cheng H, 2015, J VIROL, V89, P9932, DOI 10.1128/JVI.01337-15
   Choudhary S., 2020, IDENTIFICATION SARS, P1, DOI DOI 10.26434/CHEMRXIV.12005988
   Clark MJ, 2016, CELL CHEM BIOL, V23, P443, DOI 10.1016/j.chembiol.2016.03.010
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Fatma B, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104808
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Hammond LA, 2001, BRIT J CANCER, V85, P453, DOI 10.1054/bjoc.2001.1939
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu KL, 2013, J MED CHEM, V56, P8270, DOI 10.1021/jm400899c
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Q, 2020, FAST ASSESSMENT HUMA, DOI [10.1101/2020.02.01.930537, DOI 10.1101/2020.02.01.930537, 10.1101/2020.02.01.93053750.]
   Kaur R, 2019, VIROLOGY, V526, P91, DOI 10.1016/j.virol.2018.10.009
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kwiatkowski K, 2017, J NEUROIMMUNE PHARM, V12, P402, DOI 10.1007/s11481-017-9729-6
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li GP, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02541
   Liu Z, 2020, J MED VIROL, DOI 10.1002/jmv.2572632100877
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Mudgal R, 2020, FEBS LETT, V594, P678, DOI 10.1002/1873-3468.13642
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Organization WH, 2016, MIDDL E RESP SYNDR C
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Sabbatini P, 2009, MOL CANCER THER, V8, P2811, DOI 10.1158/1535-7163.MCT-09-0423
   Schrodinger L, 2015, MESQUITE MODULAR SYS, V1, P8
   Shang J, 2020, STRUCTURAL BASIS REC, P1, DOI [10.21203/rs.2.24749/v131996437, DOI 10.21203/RS.2.24749/V131996437]
   Sharma R, 2018, VIROLOGY, V515, P223, DOI 10.1016/j.virol.2017.12.020
   Sharma R, 2016, VIROLOGY, V498, P265, DOI 10.1016/j.virol.2016.08.029
   Singh H, 2018, BIOCHIMIE, V149, P51, DOI 10.1016/j.biochi.2018.04.004
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsukuda S, 2015, J BIOL CHEM, V290, P5673, DOI 10.1074/jbc.M114.602540
   Le VB, 2015, AM J RESP CRIT CARE, V191, P804, DOI 10.1164/rccm.201406-1031OC
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   WHO, 2020, 80 WHO
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   World Health Organization, 2015, SUMM PROB SARS CAS
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yan R, 2020, BIORXIV, DOI [10.1101/2020.02.17.95184832132184, DOI 10.1101/2020.02.17.95184832132184]
   Yang D, 2010, RESP PHYSIOL NEUROBI, V170, P253, DOI 10.1016/j.resp.2010.02.002
NR 60
TC 5
Z9 5
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 10
PY 2020
VL 11
AR 1664
DI 10.3389/fimmu.2020.01664
PG 14
WC Immunology
SC Immunology
GA MU6JL
UT WOS:000555777400001
PM 32754161
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Naz, A
   Shahid, F
   Butt, TT
   Awan, FM
   Ali, A
   Malik, A
AF Naz, Anam
   Shahid, Fatima
   Butt, Tariq Tahir
   Awan, Faryal Mehwish
   Ali, Amjad
   Malik, Arif
TI Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease
   2019 (COVID-19) by Employing Immuno-Informatics Approach
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; coronavirus; corona vaccine; spike protein; S1 domain; S2
   domain
ID PROTEIN; IDENTIFICATION; PNEUMONIA; SARS
AB A recent pandemic caused by a single-stranded RNA virus, COVID-19, initially discovered in China, is now spreading globally. This poses a serious threat that needs to be addressed immediately. Genome analysis of SARS-CoV-2 has revealed its close relation to SARS-coronavirus along with few changes in its spike protein. The spike protein aids in receptor binding and viral entry within the host and therefore represents a potential target for vaccine and therapeutic development. In the current study, the spike protein of SARS-CoV-2 was explored for potential immunogenic epitopes to design multi-epitope vaccine constructs. The S1 and S2 domains of spike proteins were analyzed, and two vaccine constructs were prioritized with T-cell and B-cell epitopes. We adapted a comprehensive predictive framework to provide novel insights into immunogenic epitopes of spike proteins, which can further be evaluated as potential vaccine candidates against COVID-19. Prioritized epitopes were then modeled using linkers and adjuvants, and respective 3D models were constructed to evaluate their physiochemical properties and their possible interactions with ACE2, HLA Superfamily alleles, TLR2, and TLR4.
C1 [Naz, Anam; Awan, Faryal Mehwish; Malik, Arif] Univ Lahore UOL, Inst Mol Biol & Biotechnol IMBB, Lahore, Pakistan.
   [Shahid, Fatima; Ali, Amjad] Natl Univ Sci & Technol NUST, Atta Ur Rehman Sch Appl Biosci ASAB, Islamabad, Pakistan.
   [Butt, Tariq Tahir] Khawaja Muhammad Safdar Med Coll, Dept Biochem, Sialkot, Pakistan.
RP Naz, A (corresponding author), Univ Lahore UOL, Inst Mol Biol & Biotechnol IMBB, Lahore, Pakistan.
EM anam.naz88@live.com
RI Ali, Amjad/F-6436-2015
OI Ali, Amjad/0000-0002-0486-4661
FU Atta-ur-Rehman School of Applied Biosciences (ASAB) at the National
   University of Sciences and Technology
FX We want to acknowledge Institute of Molecular Biology and Biotechnology
   (IMBB) at the University of Lahore for providing the facilities and
   confidence to publish this article. We also want to acknowledge
   Atta-ur-Rehman School of Applied Biosciences (ASAB) at the National
   University of Sciences and Technology for collaboration and support.
CR Ahmed S, 2019, ENVIRON URBAN, V31, P443, DOI 10.1177/0956247819866124
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Coleman CM, 2014, J VIROL, V88, P5209, DOI 10.1128/JVI.03488-13
   Dar H, 2016, ASIAN PAC J TROP MED, V9, P822, DOI 10.1016/j.apjtm.2016.07.004
   Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Dowling JK, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.22
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guo JJ, 2015, VACCINE, V33, P1974, DOI 10.1016/j.vaccine.2015.02.053
   Hari A, 2015, EUR J IMMUNOL, V45, P383, DOI 10.1002/eji.201445156
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jiang SB, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.1
   Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773
   Kim J, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1035-2
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Land Henrik, 2018, Methods Mol Biol, V1685, P43, DOI 10.1007/978-1-4939-7366-8_4
   Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027
   Oyarzun P, 2015, VACCINE, V33, P1267, DOI 10.1016/j.vaccine.2015.01.040
   Park MS, 2018, BIOMOL THER, V26, P242, DOI 10.4062/biomolther.2017.172
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Paul M, 2003, FUNDAMENTAL IMMUNOLO
   PAUL S, 2016, CURR PROTOCOLS IMMUN, V114
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Sajjad R, 2020, J MOL GRAPH MODEL, V94, DOI 10.1016/j.jmgm.2019.107477
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Sayers EW, 2012, NUCLEIC ACIDS RES, V40, pD13, DOI 10.1093/nar/gkr1184
   Serruto D, 2009, VACCINE, V27, P3245, DOI 10.1016/j.vaccine.2009.01.072
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 10
PY 2020
VL 11
AR 1663
DI 10.3389/fimmu.2020.01663
PG 13
WC Immunology
SC Immunology
GA MU6LA
UT WOS:000555781500001
PM 32754160
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Clementi, N
   Criscuolo, E
   Diotti, RA
   Ferrarese, R
   Castelli, M
   Dagna, L
   Burioni, R
   Clementi, M
   Mancini, N
AF Clementi, Nicola
   Criscuolo, Elena
   Diotti, Roberta Antonia
   Ferrarese, Roberto
   Castelli, Matteo
   Dagna, Lorenzo
   Burioni, Roberto
   Clementi, Massimo
   Mancini, Nicasio
TI Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine
   Anti-SARS-CoV-2 Effectsin vitro
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE hydroxychloroquine; SARS-CoV-2; COVID-19; prophylaxis; therapy
AB While the SARS-CoV-2 pandemic is heavily hitting the world, it is of extreme importance that significantin vitroobservations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 and Caco-2 cells. This suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.
C1 [Clementi, Nicola; Criscuolo, Elena; Diotti, Roberta Antonia; Ferrarese, Roberto; Castelli, Matteo; Burioni, Roberto; Clementi, Massimo; Mancini, Nicasio] Univ Vita Salute San Raffaele, Lab Microbiol & Virol, Milan, Italy.
   [Clementi, Nicola; Clementi, Massimo; Mancini, Nicasio] IRCCS San Raffaele Sci Inst, Lab Microbiol & Virol, Milan, Italy.
   [Dagna, Lorenzo] Univ Vita Salute San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, IRCCS San Raffaele Sci Inst, Milan, Italy.
RP Mancini, N (corresponding author), Univ Vita Salute San Raffaele, Lab Microbiol & Virol, Milan, Italy.; Mancini, N (corresponding author), IRCCS San Raffaele Sci Inst, Lab Microbiol & Virol, Milan, Italy.
EM mancini.nicasio@hsr.it
RI Clementi, Massimo/F-6646-2013; Clementi, Nicola/AAT-7697-2020
OI Clementi, Nicola/0000-0002-1822-9861; Criscuolo,
   Elena/0000-0003-0185-3147
CR Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hirotsu Y, 2020, DOUBLE QUENCHER PROB, DOI [10.1101/2020.03.17.20037903, DOI 10.1101/2020.03.17.20037903]
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mehra MR, 2020, NEW ENGL J MED, V382, P2582, DOI 10.1056/NEJMc2021225
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Servick K, 2020, SCIENCE, V368, P1041, DOI 10.1126/science.368.6495.1041
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 16
TC 1
Z9 1
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUL 10
PY 2020
VL 11
AR 1704
DI 10.3389/fmicb.2020.01704
PG 8
WC Microbiology
SC Microbiology
GA MU6YF
UT WOS:000555816200001
PM 32754147
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bhaskar, S
   Sinha, A
   Banach, M
   Mittoo, S
   Weissert, R
   Kass, JS
   Rajagopal, S
   Pai, AR
   Kutty, S
AF Bhaskar, Sonu
   Sinha, Akansha
   Banach, Maciej
   Mittoo, Shikha
   Weissert, Robert
   Kass, Joseph S.
   Rajagopal, Santhosh
   Pai, Anupama R.
   Kutty, Shelby
TI Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical
   Considerations, and Therapeutic Approaches: The REPROGRAM Consortium
   Position Paper
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; cytokine storm; immunological mechanisms; autoimmunity;
   neuroimmunology; immunotherapies; guidelines; critical care
ID CORONAVIRUS DISEASE 2019; COVID-19 PNEUMONIA; INFECTION;
   IMMUNOSENESCENCE; TRANSPLANTATION; MANAGEMENT; RESPONSES; IMPROVES;
   INJURY; CELLS
AB Cytokine storm is an acute hyperinflammatory response that may be responsible for critical illness in many conditions including viral infections, cancer, sepsis, and multi-organ failure. The phenomenon has been implicated in critically ill patients infected with SARS-CoV-2, the novel coronavirus implicated in COVID-19. Critically ill COVID-19 patients experiencing cytokine storm are believed to have a worse prognosis and increased fatality rate. In SARS-CoV-2 infected patients, cytokine storm appears important to the pathogenesis of several severe manifestations of COVID-19: acute respiratory distress syndrome, thromboembolic diseases such as acute ischemic strokes caused by large vessel occlusion and myocardial infarction, encephalitis, acute kidney injury, and vasculitis (Kawasaki-like syndrome in children and renal vasculitis in adult). Understanding the pathogenesis of cytokine storm will help unravel not only risk factors for the condition but also therapeutic strategies to modulate the immune response and deliver improved outcomes in COVID-19 patients at high risk for severe disease. In this article, we present an overview of the cytokine storm and its implications in COVID-19 settings and identify potential pathways or biomarkers that could be targeted for therapy. Leveraging expert opinion, emerging evidence, and a case-based approach, this position paper provides critical insights on cytokine storm from both a prognostic and therapeutic standpoint.
C1 [Bhaskar, Sonu; Sinha, Akansha; Banach, Maciej; Mittoo, Shikha; Weissert, Robert; Kass, Joseph S.; Rajagopal, Santhosh; Pai, Anupama R.; Kutty, Shelby] Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, REPROGRAM Immun Sub Comm, Sydney, NSW, Australia.
   [Bhaskar, Sonu] Liverpool Hosp, Dept Neurol & Neurophysiol, Sydney, NSW, Australia.
   [Bhaskar, Sonu] South Western Sydney Local Hlth Dist, Sydney, NSW, Australia.
   [Bhaskar, Sonu] Univ New South Wales, UNSW Med, Neurovasc Imaging Lab, Sydney, NSW, Australia.
   [Bhaskar, Sonu] Univ New South Wales, UNSW Med, NSW Brain Clot Bank, Ingham Inst Appl Med Res, Sydney, NSW, Australia.
   [Sinha, Akansha] Univ New South Wales, UNSW Med, Sydney, NSW, Australia.
   [Banach, Maciej] Polish Mothers Mem Hosp Res Inst, Lodz, Poland.
   [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland.
   [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland.
   [Mittoo, Shikha] Univ Hlth Network, Dept Rheumatol, Toronto, ON, Canada.
   [Mittoo, Shikha] Univ Toronto, Toronto, ON, Canada.
   [Weissert, Robert] Univ Regensburg, Dept Neurol, Regensburg, Germany.
   [Kass, Joseph S.] Baylor Coll Med, Ben Taub Gen Hosp, Dept Neurol, Houston, TX 77030 USA.
   [Kass, Joseph S.] Baylor Coll Med, Alzheimers Dis & Memory Disorders Ctr, Houston, TX 77030 USA.
   [Rajagopal, Santhosh] WHO, Country Off India, NPSP, Madura, India.
   [Pai, Anupama R.] Natl Inst Mental Hlth & Neurosci, Dept Neuromicrobiol, Bengaluru, India.
   [Kutty, Shelby] Johns Hopkins Univ Hosp, Blalock Taussig Thomas Heart Ctr, Dept Pediat & Congenital Cardiol, Baltimore, MD USA.
   [Kutty, Shelby] Johns Hopkins Univ, Sch Med, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Bhaskar, S (corresponding author), Pandem Hlth Syst REsilience PROGRAM REPROGRAM Con, REPROGRAM Immun Sub Comm, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Liverpool Hosp, Dept Neurol & Neurophysiol, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), South Western Sydney Local Hlth Dist, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Univ New South Wales, UNSW Med, Neurovasc Imaging Lab, Sydney, NSW, Australia.; Bhaskar, S (corresponding author), Univ New South Wales, UNSW Med, NSW Brain Clot Bank, Ingham Inst Appl Med Res, Sydney, NSW, Australia.
EM Sonu.Bhaskar@health.nsw.gov.au
RI Bhaskar, Sonu/AAU-1402-2020; Banach, Maciej/A-1271-2009
OI Bhaskar, Sonu/0000-0002-9783-3628; Banach, Maciej/0000-0001-6690-6874
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alhazzani W, 2013, CRIT CARE MED, V41, P2088, DOI 10.1097/CCM.0b013e31828cf104
   American Society of Haematology, COVID 19 VTE ANT FRE
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Banach M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104891
   Banach M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0459-4
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R
   Bhaskar Sonu, 2020, Front Neurol, V11, P664, DOI 10.3389/fneur.2020.00664
   Bhaskar S, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00112
   Bhaskar S, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00579
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Botha-Scheepers SA, 2015, SAMJ S AFR MED J, V105, DOI [10.7196/samj.2015.v105i12.10220, 10.7196/SAMJ.2015.v105i12.10220]
   Bryce C, 2020, PATHOPHYSIOLOGY SARS, DOI [10.1101/2020.05.18.20099960, DOI 10.1101/2020.05.18.20099960]
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Cantini F, 2020, J INFECTION, DOI [10.1016/j.jinf.2020.04.01732333918, DOI 10.1016/J.JINF.2020.04.01732333918]
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Cho SY, 2018, KOREAN J INTERN MED, V33, P256, DOI 10.3904/kjim.2018.036
   Chow R, 2019, RADIOTHER ONCOL, V141, P56, DOI 10.1016/j.radonc.2019.06.037
   Ciavarella C, 2020, MOLECULES, V25, DOI 10.3390/molecules25092076
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Crosby James C, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12081
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   David S, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0208-1
   Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Doyen D, 2020, LANCET, V395, P1516, DOI 10.1016/S0140-6736(20)30912-0
   Dutta A, 2013, J IMMUNOL, V190, P4205, DOI 10.4049/jimmunol.1202434
   European Society of Cardiology (ESC), ESC GUID DIAGN MAN C
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Fox SE, 2020, MEDRXIV, DOI [10.1101/2020.04.06.2005057532473124, DOI 10.1101/2020.04.06.2005057532473124]
   Fu Y, 2020, ACTA PHARMACOL SIN B, V10, P414, DOI 10.1016/j.apsb.2019.08.010
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Gerlach Herwig, 2016, F1000Res, V5, P2909, DOI 10.12688/f1000research.9092.1
   Ghaffari S, 2020, ARCH MED RES, V51, P464, DOI 10.1016/j.arcmed.2020.04.006
   Goldenberg DL, CLIN CAN MANAGE RHEU
   Gomez-Pinedo U, 2020, J MED VIROL, V92, P2354, DOI 10.1002/jmv.26046
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guo T, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1017.32219356, DOI 10.1001/JAMACARDIO.2020.1017.32219356]
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Halyabar O, 2019, PEDIATR RHEUMATOL, V17, DOI 10.1186/s12969-019-0309-6
   Hernandez A, 2020, REV ESP ANEST REANIM, V67, P245, DOI 10.1016/j.redar.2020.03.004
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphreys IR, 2003, J EXP MED, V198, P1237, DOI 10.1084/jem.20030351
   Infectious Diseases Society of America, COVID 19 SPEC CONDS
   Internet Book of Critical Care (IBCC), APPR IMM SERV COVID
   Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503
   Kedzierski L, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004134
   Kennedy RH, 2016, NEUROSCIENCE IN THE 21ST CENTURY: FROM BASIC TO CLINICAL, 2ND EDITION, P601, DOI 10.1007/978-1-4939-3474-4_174
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lee EYP, 2020, LANCET INFECT DIS, V20, P384, DOI 10.1016/S1473-3099(20)30134-1
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li MD, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0165-8
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Lobentanzer S., OSF PREPRINTS, DOI [10.31219/osf.io/3gwmp, DOI 10.31219/OSF.IO/3GWMP]
   Madjid M, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.128632219363, DOI 10.1001/JAMACARDIO.2020.128632219363]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Massachusetts General Hospital (MGH), MASS GEN HOSP MGH CO
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Morichi S, 2014, NEUROCHEM RES, V39, P2143, DOI 10.1007/s11064-014-1409-9
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Moseley CE, 2010, INFLUENZA OTHER RESP, V4, P307, DOI 10.1111/j.1750-2659.2010.00155.x
   MS Australia, COVID 19 INF PEOPL M
   Nath A, 2020, NEUROLOGY, V94, P809, DOI 10.1212/WNL.0000000000009455
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Ostad SP, 2020, ACAD RADIOL, V27, P753, DOI 10.1016/j.acra.2020.03.028
   Ouellette DR, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0049-9
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Panigrahy D, 2020, CANCER METAST REV, V39, P337, DOI 10.1007/s10555-020-09889-4
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Pavelka K, 2016, DRUG AGING, V33, P75, DOI 10.1007/s40266-016-0347-4
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Rabb H, 2020, J CLIN INVEST, V130, P2749, DOI 10.1172/JCI138871
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Robinson CP, 2020, CRIT CARE EXPLOR, V2, DOI 10.1097/CCE.000000000000010732426749
   Rodrigues JCL, 2020, CLIN RADIOL, V75, P323, DOI 10.1016/j.crad.2020.03.003
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rubin GD, 2020, CHEST, V158, P106, DOI 10.1016/j.chest.2020.04.003
   Savarin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03022
   Schulert GS, 2020, GENES IMMUN, V21, P169, DOI 10.1038/s41435-020-0098-4
   Schulze-Koops H, 2020, ANN RHEUM DIS, V79, P840, DOI 10.1136/annrheumdis-2020-217628
   Serrano-Castro PJ, 2020, NEUROLOGIA, V35, P245, DOI 10.1016/j.nrl.2020.04.002
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shoenfeld Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102538
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Sindone A, 2013, AUST FAM PHYSICIAN, V42, P634
   Solomon IH, 2020, NEW ENGL J MED, DOI [10.1056/NEJMc201937332530583, DOI 10.1056/NEJMC201937332530583]
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Tavazzi G, 2020, INTENS CARE MED, V46, P1121, DOI 10.1007/s00134-020-06040-3
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   The Centre for Evidence-Based Medicine (CEBM), COVID 19 REG TRIALS
   Tobar N, 2011, ENDOCRINOLOGY, V152, P4080, DOI 10.1210/en.2011-0249
   U.S. Food & Drug Administration, FDA CAUT US HYDR CHL
   Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Weaver Lehn K, 2017, Curr Treatm Opt Rheumatol, V3, P33, DOI 10.1007/s40674-017-0059-x
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013
   Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114
   Xiong M, 2020, BRIT J HAEMATOL, V189, P1050, DOI 10.1111/bjh.16725
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang J, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-019-0345-7
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhuo Y, 2019, CTS-CLIN TRANSL SCI, V12, P196, DOI 10.1111/cts.12606
   Zimorovat A, 2020, ACTA DIABETOL, V57, P1, DOI 10.1007/s00592-019-01369-8
NR 124
TC 19
Z9 19
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 10
PY 2020
VL 11
AR 1648
DI 10.3389/fimmu.2020.01648
PG 16
WC Immunology
SC Immunology
GA MU6IY
UT WOS:000555776100001
PM 32754159
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Putrino, A
   Raso, M
   Magazzino, C
   Galluccio, G
AF Putrino, Alessandra
   Raso, Mario
   Magazzino, Cosimo
   Galluccio, Gabriella
TI Coronavirus (COVID-19) in Italy: knowledge, management of patients and
   clinical experience of Italian dentists during the spread of contagion
SO BMC ORAL HEALTH
LA English
DT Article
DE 2019 novel coronavirus; COVID-19; Dentistry; Health management;
   Knowledge; Survey
ID PNEUMONIA
AB BackgroundThe coronavirus infection that emerged in China in the last few months of 2019 has now spread globally. Italy registered its first case in the second half of February, and in a short time period, it became the top country in Europe in terms of the number of infected people and the first in the world in terms of deaths. The medical and scientific community has been called upon to manage the emergency and to take measures. Dentists also need to take new precautions during their clinical activity to protect themselves, coworkers and patients from the risks of contagion and to avoid further spread of infection.MethodsFollowing the data published in the international literature as well as the guidelines and directives constantly updated by the WHO and by the national health authorities, a questionnaire to be completed anonymously was submitted online to Italian dentists using social tools and online professional platforms. The collected data were processed statistically, providing descriptive data and analysis of correlations of the most significant parameters using the Pearson's chi 2, the Likelihood-Ratio chi 2, Cramer's V, Fisher's exact test, Goodman and Kruskal's gamma, and Kendall's tau b (p<0.05).ResultsA total of 535 dentists from Italy participated in the survey. A good level of scientific knowledge about coronavirus and the extra precautionary measures needed to limit the spread was related to the age of respondents and their sex. Coming from areas with higher concentrations of cases affected knowledge, level of attention and perception of risk related to dental activity.ConclusionsAt the moment, there are no therapies or vaccines to contain the infection with the new coronavirus that is causing many infections, many of which are fatal, worldwide. Dentists are one of the categories at highest risk of encountering diseases and infections because they work in close proximity with patients, and in their procedures, there is always contact with aerosols with high bacterial and viral potential. Therefore, during this COVID-19 emergency, it is important that dentists are properly informed and take the appropriate precautionary measures.
C1 [Putrino, Alessandra] Univ Sapienza Rome, Adv Training Course Risk Management Healthcare &, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Raso, Mario] Italian Soc Appl & Ind Math SIMAI, Rome, Italy.
   [Magazzino, Cosimo] Univ Roma Tre, Dept Polit Sci, Rome, Italy.
   [Galluccio, Gabriella] Univ Sapienza, Dept Oral & Maxillofacial Sci, Rome, Italy.
RP Putrino, A (corresponding author), Univ Sapienza Rome, Adv Training Course Risk Management Healthcare &, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM alessanda.putrino@gmail.com
RI Magazzino, Cosimo/K-5030-2015; GALLUCCIO, Gabriella/AAR-7459-2020
OI Magazzino, Cosimo/0000-0002-3176-9838; GALLUCCIO,
   Gabriella/0000-0002-6876-8839; Putrino, Alessandra/0000-0001-5278-145X
CR Albarello F, 2020, INT J INFECT DIS, V93, P192, DOI 10.1016/j.ijid.2020.02.043
   [Anonymous], 2020, EL MED CAD NEL CORS
   [Anonymous], 2020, AGG COR
   [Anonymous], 2020, NUOV COR SARS COV 2
   [Anonymous], 2020, COR DIS 2019 COVID 1
   [Anonymous], 2020, COR
   [Anonymous], 2020, EM COR
   Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170
   Centre for Health Protection, SEV RESP DIS ASS NOV
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cramer Harald, 1946, MATH METHODS STAT
   Fisher RA, 1935, J R STAT SOC, V98, P39, DOI 10.2307/2342435
   Gamio L, 2020, NY TIMES
   GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   KENDALL MG, 1945, BIOMETRIKA, V33, P239, DOI 10.1093/biomet/33.3.239
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sabino-Silva R, 2020, CLIN ORAL INVEST, V24, P1619, DOI 10.1007/s00784-020-03248-x
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Tsang OTY, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciia149, DOI 10.1093/CID/CIIA149]
   World Health Organization, 1 WHO
   World Health Organization, 2020, SHORT PERS PROT EQ E
   World Health Organization, COR
   World Health Organization, RAT US PERS PROT EQ
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 32
TC 5
Z9 5
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD JUL 10
PY 2020
VL 20
IS 1
AR 200
DI 10.1186/s12903-020-01187-3
PG 15
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA MP2FN
UT WOS:000552025200003
PM 32650753
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Banerjee, A
   Santra, D
   Maiti, S
AF Banerjee, Amrita
   Santra, Dipannita
   Maiti, Smarajit
TI Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19)
   spike protein by immunoinformatic analysis implicating for a suitable
   vaccine development
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE SARS CoV-2 (COVID 19); Severe global outbreak-Dec 2019; Spike
   glycoprotein; ACE-2 receptor protein; Epitope designing and screening;
   Vaccination
ID PREDICTION; SERVER
AB BackgroundThe recent outbreak by SARS-CoV-2 has generated a chaos in global health and economy and claimed/infected a large number of lives. Closely resembling with SARS CoV, the present strain has manifested exceptionally higher degree of spreadability, virulence and stability possibly due to some unidentified mutations. The viral spike glycoprotein is very likely to interact with host Angiotensin-Converting Enzyme 2 (ACE2) and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation. Few attempts have been made to develop a suitable vaccine or ACE2 blocker or virus-receptor inhibitor within this short period of time.MethodsHere, attempt was taken to develop some therapeutic and vaccination strategies with a comparison of spike glycoproteins among SARS-CoV, MERS-CoV and the SARS-CoV-2. We verified their structure quality (SWISS-MODEL, Phyre2, and Pymol) topology (ProFunc), motifs (MEME Suite, GLAM2Scan), gene ontology based conserved domain (InterPro database) and screened several epitopes (SVMTrip) of SARS CoV-2 based on their energetics, IC50 and antigenicity with regard to their possible glycosylation and MHC/paratope binding (Vaxigen v2.0, HawkDock, ZDOCK Server) effects.ResultsWe screened here few pairs of spike protein epitopic regions and selected their energetic, Inhibitory Concentration50 (IC50), MHC II reactivity and found some of those to be very good target for vaccination. A possible role of glycosylation on epitopic region showed profound effects on epitopic recognition.ConclusionThe present work might be helpful for the urgent development of a suitable vaccination regimen against SARS CoV-2.
C1 [Banerjee, Amrita; Santra, Dipannita; Maiti, Smarajit] Oriental Inst Sci & Technol, Dept Biochem & Biotechnol, Cell & Mol Therapeut Lab, Midnapore, India.
   [Maiti, Smarajit] Agricure Biotech Res Soc, Epidemiol & Human Hlth Div, Midnapore 721101, India.
RP Maiti, S (corresponding author), Oriental Inst Sci & Technol, Dept Biochem & Biotechnol, Cell & Mol Therapeut Lab, Midnapore, India.; Maiti, S (corresponding author), Agricure Biotech Res Soc, Epidemiol & Human Hlth Div, Midnapore 721101, India.
EM maitism@rediffmail.com
CR Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Dashraath P, 2020, AM J OBSTET GYNECOL, V0002-9378, P30343
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Martini S, 2020, IMMUNOGENETICS, V72, P57, DOI 10.1007/s00251-019-01137-6
   Menachery VD, 2016, NAT MED, V22, P446, DOI 10.1038/nm0416-446d
   Mitchell A, 2015, NUCLEIC ACIDS RES, V43, pD213, DOI 10.1093/nar/gku1243
   Moriyama Miyu, 2020, Annu Rev Virol, V7, P83, DOI 10.1146/annurev-virology-012420-022445
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Stano M, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw162
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weng GQ, 2019, NUCLEIC ACIDS RES, V47, pW322, DOI 10.1093/nar/gkz397
   Yao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045152
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 34
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 10
PY 2020
VL 18
IS 1
AR 281
DI 10.1186/s12967-020-02435-4
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP2XS
UT WOS:000552072500003
PM 32650788
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ellenberg, SS
AF Ellenberg, Susan S.
TI Clinical trials in the time of a pandemic
SO CLINICAL TRIALS
LA English
DT Article
DE Clinical trials; COVID-19; pandemic; treatment; vaccines
ID DESIGN
AB The first rumblings about a new coronavirus spreading in China were heard in January 2020. By the end of that month, the World Health Organization, recognizing the severity of the disease and the potential for global spread, had declared a public health emergency. By February 2020, cases had been identified in multiple countries, clinical trials of treatments with some biological plausibility had begun in China, and the initial steps of vaccine development were underway. In mid-March, by which time countries around the world were experiencing rapidly increasing numbers of cases and deaths, the World Health Organization categorized the outbreak as a pandemic. This new coronavirus was designated SARS-COV-2 in recognition of its similarity to the coronavirus responsible for the severe acute respiratory syndrome outbreak in 2002-2003. The race is on to develop treatments that can mitigate the severe consequences of infection and vaccines that can prevent infection and/or diminish the severity of disease in those who do get infected. Many challenges face these development efforts. Some are similar to those faced in the past; others are new. The urgency of finding ways to treat, and ultimately prevent, the consequences of this new and potentially deadly infection has led to unprecedented focus on clinical trials.
C1 [Ellenberg, Susan S.] Univ Penn, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Ellenberg, SS (corresponding author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 611 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM sellenbe@pennmedicine.upenn.edu
FU Perelman School of Medicine, University of Pennsylvania
FX The author received financial support for the research, authorship and
   publication of this article from the Perelman School of Medicine,
   University of Pennsylvania.
CR Basu A, 2020, HEALTH AFFAIR, V39, P1229, DOI 10.1377/hlthaff.2020.00455
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blake Valarie, 2013, Virtual Mentor, V15, P687, DOI 10.1001/virtualmentor.2013.15.8.hlaw1-1308
   Branswell Helen, 2020, STAT
   BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416
   ELLENBERG SS, 1992, J AM STAT ASSOC, V87, P562, DOI 10.2307/2290291
   Ellenberg SS, 2018, CLIN INFECT DIS, V66, P1467, DOI 10.1093/cid/cix1032
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Academies of Sciences Engineering and Medicine Health and Medicine Division; Board on Health Sciences Policy Board on Global Health, 2017, INT CLIN RES EP RESP
   Ni L., 2020, IMMUNITY, V52
   Offitt PA., 2005, CUTTER INCIDENT AM 1
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   World Health Organization, 2020, SOL CLIN TRIAL COVID
NR 20
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2020
VL 17
IS 5
BP 467
EP 471
AR 1740774520939871
DI 10.1177/1740774520939871
EA JUL 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU8GJ
UT WOS:000548551000001
PM 32650672
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, M
   Zhou, WB
   Xu, WW
AF Chen, Min
   Zhou, Weibin
   Xu, Weiwei
TI Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective
   Study
SO THYROID
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; thyroid hormone; TSH; euthyroid sick syndrome
AB Background:Since the outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, it has affected >200 countries, areas, or territories in 6 continents. At present, whether COVID-19 has an effect on thyroid function is unclear. The aim of this study was to evaluate thyroid function in patients with COVID-19. Methods:Clinical manifestations, laboratory results, and chest computed tomography scans were retrospectively reviewed for 50 patients with laboratory-confirmed COVID-19 without a history of thyroid disease who underwent thyroid function testing during their course of COVID-19 infection and after recovery. They were admitted to the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, between January and March 2020. Healthy participants who underwent routine physical checkups and non-COVID-19 pneumonia patients with a similar degree of severity during the same period were included in the study as the control group. Thyroid hormone and thyrotropin (TSH) levels were analyzed and compared between the COVID-19 and control groups. Results:TSH lower than the normal range was present in 56% (28/50) of the patients with COVID-19. The levels of TSH and serum total triiodothyronine (TT3) of the patients with COVID-19 were significantly lower than those of the healthy control group and non-COVID-19 pneumonia patients. The more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance (p < 0.001). The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. The total thyroxine (TT4) level of the patients with COVID-19 was not significantly different from the control group. All the patients did not receive thyroid hormone replacement therapy. After recovery, no significant differences in TSH, TT3, TT4, free triiodothyronine (fT3), and free thyroxine (fT4) levels were found between the COVID-19 and control groups. Conclusions:The changes in serum TSH and TT3 levels may be important manifestations of the courses of COVID-19.
C1 [Chen, Min; Zhou, Weibin; Xu, Weiwei] Zhejiang Univ, Coll Med, Dept Endocrinol, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
RP Zhou, WB (corresponding author), Zhejiang Univ, Coll Med, Dept Endocrinol, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM zhouweibin@zju.edu.cn
OI Xu, Wei-wei/0000-0001-8310-2632
FU Zhejiang medical science and technology projects [2018KY056, 2018KY363]
FX This study was supported by Zhejiang medical science and technology
   projects [Grant Nos. 2018KY056 and 2018KY363].
CR [Anonymous], COR DIS COVID 19 PAN
   Fliers E, 2015, LANCET DIABETES ENDO, V3, P816, DOI 10.1016/S2213-8587(15)00225-9
   General Office of National Health Committee, 2020, NOT ISS PROGR DIAGN
   Van den Berghe G, 2014, THYROID, V24, P1456, DOI 10.1089/thy.2014.0201
   Wang W, 2003, J CHIN ANTITUBERCULO, V25, P232
   Wei L, 2007, HUM PATHOL, V38, P95, DOI 10.1016/j.humpath.2006.06.011
   Wei L, 2010, BIOCHEM CELL BIOL, V88, P723, DOI 10.1139/O10-022
NR 7
TC 7
Z9 7
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
DI 10.1089/thy.2020.0363
EA JUL 2020
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA ML6JB
UT WOS:000549568800001
PM 32600165
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, QW
   Wang, H
   Li, XY
   Zheng, YJ
   Wei, Y
   Zhang, P
   Ding, QY
   Lin, JR
   Tang, S
   Zhao, YK
   Zhao, LH
   Tong, XL
AF Li, Qingwei
   Wang, Han
   Li, Xiuyang
   Zheng, Yujiao
   Wei, Yu
   Zhang, Pei
   Ding, Qiyou
   Lin, Jiaran
   Tang, Shuang
   Zhao, Yikun
   Zhao, Linhua
   Tong, Xiaolin
TI The role played by traditional Chinese medicine in preventing and
   treating COVID-19 in China
SO FRONTIERS OF MEDICINE
LA English
DT Article
DE traditional Chinese medicine; COVID-19; Wuchang pattern; mobile cabin
   hospital; convalescent patients; three formulae and three medicines
AB Traditional Chinese medicine (TCM), an ancient system of alternative medicine, played an active role in the prevention and control of COVID-19 in China. It improved the clinical symptoms of patients, reduced the mortality rate, improved the recovery rate, and effectively relieved the operating pressure on the national medical system during critical conditions. In light of the current global pandemic, TCM-related measures might open up a new channel in the control of COVID-19 in other countries and regions. Here, we summarize the TCM-related measures that were widely used in China, including TCM guidelines, the Wuchang pattern, mobile cabin hospitals, integrated treatment of TCM and modern medicine for critical patients, and non-medicine therapy for convalescent patients, and describe how TCM effectively treated patients afflicted with the COVID-19. Effective TCM therapies could, therefore, be recommended and practiced based on the existing medical evidence from increased scientific studies.
C1 [Li, Qingwei; Wang, Han; Li, Xiuyang; Zheng, Yujiao; Wei, Yu; Zhang, Pei; Ding, Qiyou; Lin, Jiaran; Tang, Shuang; Zhao, Linhua; Tong, Xiaolin] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Endocrinol, Beijing 100056, Peoples R China.
   [Wang, Han] Guangzhou Univ Tradit Chinese Med, Acad Inheritance Workstn Academician Tong Xiaolin, Shenzhen 518034, Peoples R China.
   [Zheng, Yujiao; Wei, Yu; Ding, Qiyou] Beijing Univ Chinese Med, Beijing 100019, Peoples R China.
   [Lin, Jiaran; Tang, Shuang] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China.
   [Zhao, Yikun] Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China.
RP Zhao, LH; Tong, XL (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Endocrinol, Beijing 100056, Peoples R China.
EM melonzhao@163.com; tongxiaolin@vip.163.com
FU National Science and Technology Emergency Research Project-Clinical
   Research on the Prevention and Treatment of COVID-19 with Integrated
   Chinese and Modern Medicine [2020YFC0841600]; National Classification of
   Project "Public Safety Risk Prevention and Emergency Technology
   Equipment" Special Key Project -Clinical Evaluation of Traditional
   Chinese Medical Intervention on Convalescent COVID-19 [2020YFC0845000]
FX This work was supported by National Science and Technology Emergency
   Research Project-Clinical Research on the Prevention and Treatment of
   COVID-19 with Integrated Chinese and Modern Medicine (No.
   2020YFC0841600), National Classification of Project "Public Safety Risk
   Prevention and Emergency Technology Equipment" Special Key Project
   -Clinical Evaluation of Traditional Chinese Medical Intervention on
   Convalescent COVID-19 (No. 2020YFC0845000).
CR [Anonymous], 2020, PEOPLES DAILY
   Bai F, 2019, W J TRADIT CHIN MED, V32, P98
   Cheng D., 2020, WORLD CHIN MED, V15, P150, DOI DOI 10.3969/j.issn.1673-7202.2020.02.006
   Cheng D.Z., 2020, TIANJIN J TRADIT CHI
   Duan C, 2020, J TRADIT CHIN MED
   Ge LL, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033819901117
   Gong PY, 2020, CHIN TRADIT HERB DRU
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   [李晓东 Li Xiaodong], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P928
   National Administration of Traditional Chinese Medicine, 2020, QINGF PAID DEC HAD G
   National Administration of Traditional Chinese Medicine, 2020, PROGR SCREEN RES EFF
   National Administration of Traditional Chinese Medicine, 2020, XIAOL TONG WUCH PATT
   National Administration of Traditional Chinese Medicine, 2020, HUASH BAID GRAN ANC
   National Health Commission of the People's Republic of China, 2020, LAT SIT COVID 19 SIT
   Song P, 2020, J TRADIT CHIN MED
   Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842
   The State Council Information Office of the People's Republic of China, 2020, STAT COUNC INF OFF H
   Wang JP, 2020, TCM ANTIEPIDEMIC 27
   Wang Y, 2020, CHIN J CHIN MAT MED, V45, P2249
   World Health Organization, 2020, 128 WHO
   World Health Organization, 2018, ICD 11 CLASS DIS MAP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   [姚开涛 Yao Kaitao], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P8
   Yao Y, 2019, ACTA PHYSIOL PLANT, V42, DOI 10.1007/s11738-019-2989-4
   Yin Q, 2016, CHIN J CLIN RATIONAL, V9, P10
   Yuan RZ, 2016, CHIN J DIFF CASES, V15, P147
   Zhang B., 2020, STUDY TIMES
   Zhao S, 2020, J HUNAN U CHIN MED, V40, P387
NR 29
TC 2
Z9 2
U1 14
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
PD OCT
PY 2020
VL 14
IS 5
BP 681
EP 688
DI 10.1007/s11684-020-0801-x
EA JUL 2020
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OF6TL
UT WOS:000547235000001
PM 32651936
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Han, GS
   Zhou, YH
AF Han, Guangshu
   Zhou, Yi-Hua
TI Thinking more about therapy with convalescent plasma for COVID-19
   patients
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
C1 [Han, Guangshu] Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Dept Internal Med, Nanjing, Jiangsu, Peoples R China.
   [Zhou, Yi-Hua] Nanjing Drum Tower Hosp, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhou, Yi-Hua] Nanjing Drum Tower Hosp, Dept Infect Dis, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhou, Yi-Hua] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China.
RP Zhou, YH (corresponding author), Nanjing Drum Tower Hosp, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China.; Zhou, YH (corresponding author), Nanjing Drum Tower Hosp, Dept Infect Dis, Nanjing 210008, Jiangsu, Peoples R China.
EM zgr03summer@126.com
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   [Anonymous], COR DIS COVID 19 SIT
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Nigro G, 2005, NEW ENGL J MED, V353, P1350, DOI 10.1056/NEJMoa043337
   Revello MG, 2014, NEW ENGL J MED, V370, P1316, DOI 10.1056/NEJMoa1310214
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 12
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV 1
PY 2020
VL 16
IS 11
BP 2601
EP 2603
DI 10.1080/21645515.2020.1787073
EA JUL 2020
PG 3
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PC2WP
UT WOS:000547620600001
PM 32643512
DA 2021-01-01
ER

PT J
AU Vogt, TM
   Zhang, F
   Banks, M
   Black, C
   Arthur, B
   Kang, YJ
   Lucas, P
   Lamont, B
AF Vogt, Tara M.
   Zhang, Fan
   Banks, Michelle
   Black, Carla
   Arthur, Bayo
   Kang, Yoonjae
   Lucas, Paul
   Lamont, Brock
TI Provision of Pediatric Immunization Services During the COVID-19
   Pandemic: an Assessment of Capacity Among Pediatric Immunization
   Providers Participating in the Vaccines for Children Program - United
   States, May 2020
SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
LA English
DT Article
C1 [Vogt, Tara M.; Zhang, Fan; Banks, Michelle; Black, Carla; Arthur, Bayo; Kang, Yoonjae; Lucas, Paul; Lamont, Brock] CDC, COVID 19 Emergency Response Team, Atlanta, GA 30333 USA.
RP Vogt, TM (corresponding author), CDC, COVID 19 Emergency Response Team, Atlanta, GA 30333 USA.
EM tvogt@cdc.gov
CR Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1
   CDC, 2020, ROUT VACC COVID 19 O
   CDC, 2020, DID YOU KNOW YOUR CH
   CDC, 2020, MAINT CHILDH IMM WEL
   Dunn J, 2020, YOUR KIDS STILL NEED
   Garrett B., 2020, COVID 19 RECESSION C
   O'Leary ST, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1207
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Shelley D, 2020, INDEPENDENT PRIMARY, DOI 18.930748/full/
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 0149-2195
EI 1545-861X
J9 MMWR-MORBID MORTAL W
JI MMWR-Morb. Mortal. Wkly. Rep.
PD JUL 10
PY 2020
VL 69
IS 27
BP 859
EP 863
DI 10.15585/mmwr.mm6927a2
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MJ6RP
UT WOS:000548215500002
PM 32644980
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, SF
   Ma, P
   Zhang, SJ
   Song, SW
   Wang, ZH
   Ma, YL
   Xu, JJ
   Wu, F
   Duan, LM
   Yin, ZR
   Luo, HL
   Xiong, N
   Xu, M
   Zeng, TS
   Jin, Y
AF Wang, Sufei
   Ma, Pei
   Zhang, Shujing
   Song, Siwei
   Wang, Zhihui
   Ma, Yanling
   Xu, Juanjuan
   Wu, Feng
   Duan, Limin
   Yin, Zhengrong
   Luo, Huilin
   Xiong, Nian
   Xu, Man
   Zeng, Tianshu
   Jin, Yang
TI Fasting blood glucose at admission is an independent predictor for
   28-day mortality in patients with COVID-19 without previous diagnosis of
   diabetes: a multi-centre retrospective study
SO DIABETOLOGIA
LA English
DT Article
DE Coronavirus disease 2019; Fasting blood glucose; Mortali
ID INTENSIVE INSULIN THERAPY; ASSOCIATION; DEATH; HYPERGLYCEMIA; INFECTION;
   PNEUMONIA; MELLITUS; OUTCOMES
AB Aims/hypothesis Hyperglycaemia is associated with an elevated risk of mortality in community-acquired pneumonia, stroke, acute myocardial infarction, trauma and surgery, among other conditions. In this study, we examined the relationship between fasting blood glucose (FBG) and 28-day mortality in comnavirus disease 2019 (COVID-19) patients not previously diagnosed as baying diabetes.
   Methods We conducted a retrospective study involving all consecutive COVID-19 patients with a definitive 28-day outcome and FBG measurement at admission from 24 January 2020 to 10 February 2020 in two hospitals based in Wuhan, China. Demographic and clinical data, 28-day outcomes, in-hospital complications and CRB-65 scores of COVID-19 patients in the two hospitals were analysed. CRB-65 is an effective measure for assessing the severity of pneumonia and is based on four indicators, i.e. confusion, respiratory rate (>30/min), systolic blood pressure (<= 90 mmHg) or diastolic blood pressure (<= 60 mmHg), and age (>= 65 years).
   Results Six hundred and five COVID-19 patients were enrolled, including 114 who died in hospital. Multivariable Cox regression analysis showed that age (HR 1.02 [95% CI 1.00, 1.04]), male sex (HR 1.75 [95% CI 1.17, 2.60]), CRB-65 score 1-2 (HR 2.68 [95% CI 1.56, 4.59]), CRB-65 score 3-4 (HR 5.25 [95% CI 2.05, 13.43]) and FBG >= 7.0 mmol/l (HR 2.30 [95% CI 1.49, 3.55]) were independent predictors for 28-day mortality. The OR for 28-day in-hospital complications in those with FBG >= 7.0 mmol/l and 6.1-6.9 mmol/l vs <6.1 mmol/l was 3.99 (95% CI 2.71, 5.88) or 2.61 (95% CI 1.64, 4.41), respectively.
   Conclusions/interpretation FBG >= 7.0 mmol/l at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes. Glycaemic testing and control are important to all COVID-19 patients even where they have no pre-existing diabetes, as most COVID-19 patients are prone to glucose metabolic disorders.
C1 [Wang, Sufei; Ma, Pei; Zhang, Shujing; Song, Siwei; Ma, Yanling; Xu, Juanjuan; Wu, Feng; Duan, Limin; Yin, Zhengrong; Jin, Yang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Resp & Crit Care Med, NHC Key Lab Pulm Dis,Union Hosp, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
   [Wang, Zhihui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Sci Res, Wuhan, Hubei, Peoples R China.
   [Luo, Huilin] Wuhan Red Cross Hosp, Dept Anesthesia, Wuhan, Hubei, Peoples R China.
   [Xiong, Nian] Huazhong Univ Sci & Technol, Union Hosp, Dept Neurol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Xu, Man] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth HUST, Wuhan, Hubei, Peoples R China.
   [Xu, Man] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Environm Protect, Wuhan, Hubei, Peoples R China.
   [Xu, Man] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, State Key Lab Environm Hlth Incubat, Wuhan, Hubei, Peoples R China.
   [Zeng, Tianshu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Endocrinol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
RP Jin, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Resp & Crit Care Med, NHC Key Lab Pulm Dis,Union Hosp, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
EM tszeng@126.com; whuhjy@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041018, 81770096]; Major Projects of the
   National Science and Technology [2019ZX09301001]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82041018; No. 81770096) and Major Projects of the National
   Science and Technology (No. 2019ZX09301001).
CR Alanazi KH, 2020, EMERG INFECT DIS, V26, P166, DOI 10.3201/eid2601.190952
   Bar-Or D, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00054
   Bauer TT, 2006, J INTERN MED, V260, P93, DOI 10.1111/j.1365-2796.2006.01657.x
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Bragg F, 2017, JAMA-J AM MED ASSOC, V317, P280, DOI 10.1001/jama.2016.19720
   Burcelin R, 2015, NAT REV ENDOCRINOL, V11, P385, DOI 10.1038/nrendo.2015.75
   Chen Q, 2019, PROCEEDINGS OF THE 2019 INTERNATIONAL CONFERENCE ON INDUSTRIAL ENGINEERING AND SYSTEMS MANAGEMENT (IESM 2019), P207
   Ehrlich SF, 2010, DIABETES CARE, V33, P55, DOI 10.2337/dc09-0880
   Ewig S, 2009, THORAX, V64, P1062, DOI 10.1136/thx.2008.109785
   Ewig S, 2013, EUR RESPIR J, V41, P917, DOI 10.1183/09031936.00065212
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Gregg EW, 2018, LANCET, V391, P2430, DOI [10.1016/s0140-6736(18)30314-3, 10.1016/S0140-6736(18)30314-3]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johns EC, 2019, NAT REV ENDOCRINOL, V15, P379, DOI 10.1038/s41574-019-0212-8
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Lepper PM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3397
   McAlister FA, 2005, DIABETES CARE, V28, P810, DOI 10.2337/diacare.28.4.810
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PLAN CO
   Pearson-Stuttard J, 2016, LANCET DIABETES ENDO, V4, P148, DOI 10.1016/S2213-8587(15)00379-4
   Schneider GT, 2020, NEUROLOGIC NEURODEGE, P215
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Stapleton RD, 2020, UPTODATE GLYCEMIC CO
   Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, CLIN MAN SERV AC RES
   World Health Organization, 2020, LAB TEST COR DIS 201
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 35
TC 27
Z9 28
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD OCT
PY 2020
VL 63
IS 10
BP 2102
EP 2111
DI 10.1007/s00125-020-05209-1
EA JUL 2020
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NK5IG
UT WOS:000546842800001
PM 32647915
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Stanley, SM
   Markman, HJ
AF Stanley, Scott M.
   Markman, Howard J.
TI Helping Couples in the Shadow of COVID-19Palabras clave(sic)(sic)(sic)
SO FAMILY PROCESS
LA English
DT Article
DE Couples Therapy; Relationship Education; COVID-19
ID PRE-ENGAGEMENT COHABITATION; MARITAL DISTRESS; MARRIAGE; COMMITMENT;
   STRESS; DISORDERS; DIVORCE; QUALITY; LIFE
AB The pandemic caused by the SARS-CoV-2 virus (coronavirus) and the associated illness, COVID-19, has caused a level of worldwide upheaval unlike any most people now living have seen in their lifetimes. This crisis affects people in their most important, committed, and intimate relationships. Although this crisis has damaged the health and well-being of individuals, crushed economies, and led to an extensive period of uncertainty about the future, there may also be positive outcomes in the motivation people have to protect their relationships. In this paper, we focus on strategies that therapists and relationship educators can use to help couples preserve and protect their relationships during such a time. We describe four foundations of safety that allow relationships to thrive: physical, emotional, commitment, and community. We then highlight three keys from our body of work that can help guide individuals and couples in protecting their relationships on a day-to-day and moment-to-moment basis: (1) decide, don't slide; (2) make it safe to connect; (3) do your part.
C1 [Stanley, Scott M.; Markman, Howard J.] Univ Denver, Denver, CO USA.
RP Stanley, SM (corresponding author), Univ Denver, Dept Psychol, 2155 South Race St, Denver, CO 80208 USA.
EM scott.stanley@du.edu
CR Amato P. R., 2007, ALONE TOGERTHER
   Balzarini R.N., 2020, LOVE TIME COVID PERC, DOI [10.31234/osf.io/e3fh4, DOI 10.31234/OSF.IO/E3FH4]
   Baucom DH, 1990, COGNITIVE BEHAV MARI
   Beach SRH, 2012, J MARITAL FAM THER, V38, P201, DOI 10.1111/j.1752-0606.2011.00243.x
   Bodenmann G, 1997, SWISS J PSYCHOL, V56, P156
   BOLGER N, 1989, J MARRIAGE FAM, V51, P175, DOI 10.2307/352378
   BRADBURY TN, 1990, PSYCHOL BULL, V107, P3, DOI 10.1037/0033-2909.107.1.3
   Christensen A., 2020, INTEGRATIVE BEHAV CO
   Cohan CL, 2002, J FAM PSYCHOL, V16, P14, DOI 10.1037//0893-3200.16.1.14
   Cohen PN, 2014, POPUL RES POLICY REV, V33, P615, DOI 10.1007/s11113-014-9323-z
   Conger R. D., 1994, FAMILIES TROUBLED TI
   CONGER RD, 1990, J MARRIAGE FAM, V52, P643, DOI 10.2307/352931
   Cordova JV, 2005, J SOC CLIN PSYCHOL, V24, P218, DOI 10.1521/jscp.24.2.218.62270
   COWAN P, 2007, RES HUMAN DEV, V4, P181, DOI DOI 10.1080/15427600701663007
   Crasta D., 2020, CLARIFYING MEASUREME
   Dictionary.com, 2020, DEF CRIS
   Epstein N. B., 2002, ENHANCED COGNITIVE B
   Fincham FD, 2001, BLACKWELL HDB SOCIAL, P3
   Fincham FD, 2007, J MARRIAGE FAM, V69, P275, DOI 10.1111/j.1741-3737.2007.00362.x
   Finkel E. J., 2017, ALL NOTHING MARRIAGE
   Fischer M. S., 2018, APA HDB PSYCHOPATHOL, P661, DOI [10.1037/0000064-027, DOI 10.1037/0000064-027]
   Gottman J., 1993, J FAMILY PSYCHOL, V7, P57, DOI DOI 10.1037/0893-3200.7.1.57
   Greenberg L. S., 2013, EMOTIONALLY FOCUSED
   Halpern-Meekin S., 2019, SOCIAL POVERTY
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037/0022-3514.52.3.511
   HOLTZWORTHMUNROE A, 1994, PSYCHOL BULL, V116, P476, DOI 10.1037/0033-2909.116.3.476
   Johnson MP, 2000, J MARRIAGE FAM, V62, P948, DOI 10.1111/j.1741-3737.2000.00948.x
   Johnson S., 1996, PRACTICE EMOTIONALLY
   Karney BR, 2005, CURR DIR PSYCHOL SCI, V14, P171, DOI 10.1111/j.0963-7214.2005.00358.x
   Kavitha C, 2014, J CLIN DIAGN RES, V8, pWC1, DOI [10.7860/JCDR/2014/9326.4888, 10.7860/JCDR/2014/9692.4752]
   Kline GH, 2004, J FAM PSYCHOL, V18, P311, DOI 10.1037/0893-3200.18.2.311
   Lewandowski G., 2020, WILL PANDEMIC RUIN Y
   Markman H. J., 2010, FIGHTING YOUR MARRIA
   MARKMAN HJ, 1993, CLIN PSYCHOL REV, V13, P29, DOI 10.1016/0272-7358(93)90006-8
   Neff LA, 2004, PERS SOC PSYCHOL B, V30, P134, DOI 10.1177/0146167203255984
   O'Leary K. D., 1993, CURRENT CONTROVERSIE, P7
   Putnam RD, 2000, BOWLING ALONE
   Reis HT, 2004, HANDBOOK OF CLOSENESS AND INTIMACY, P201
   Rhoades GK, 2009, J FAM PSYCHOL, V23, P107, DOI 10.1037/a0014358
   Stanley S., 2014, LASTING PROMISE CHRI
   Stanley S. M., 2020, PROTECTING YOUR RELA
   Stanley S. M., 2017, PREP 8 0 LEADER MANU
   Stanley SM, 2006, FAM RELAT, V55, P499, DOI 10.1111/j.1741-3729.2006.00418.x
   Stanley SM, 2020, FAM RELAT, V69, P497, DOI 10.1111/fare.12419
   Stanley Scott M, 2010, J Fam Theory Rev, V2, P243, DOI 10.1111/j.1756-2589.2010.00060.x
   Stanley SM, 2002, FAM PROCESS, V41, P659, DOI 10.1111/j.1545-5300.2002.00659.x
   STANLEY SM, 1992, J MARRIAGE FAM, V54, P595, DOI 10.2307/353245
   Stanley SM, 2001, FAM RELAT, V50, P272, DOI 10.1111/j.1741-3729.2001.00272.x
   Straus M. A., 1990, PHYS VIOLENCE AM FAM, DOI DOI 10.4324/9781315126401
   Taub A., 2020, NY TIMES
   Tribune News Service, 2020, COR PAND FUELS INCR
   Weiss R. L., 1980, ADV FAMILY INTERVENT, V1, P229, DOI DOI 10.1111/J.1475-6811.2008.00215.X
   Whisman MA, 2007, J ABNORM PSYCHOL, V116, P638, DOI 10.1037/0021-843X.116.3.638
   Wieselquist J, 1999, J PERS SOC PSYCHOL, V77, P942, DOI 10.1037/0022-3514.77.5.942
   Wilcox W. B., 2011, GREAT RECESSION MARR
NR 55
TC 2
Z9 2
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-7370
EI 1545-5300
J9 FAM PROCESS
JI Fam. Process
PD SEP
PY 2020
VL 59
IS 3
BP 937
EP 955
DI 10.1111/famp.12575
EA JUL 2020
PG 19
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5AR
UT WOS:000546707900001
PM 32589263
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Siwiak, M
   Szczesny, P
   Siwiak, M
AF Siwiak, Marian
   Szczesny, Pawel
   Siwiak, Marlena
TI From the index case to global spread: the global mobility based
   modelling of the COVID-19 pandemic implies higher infection rate and
   lower detection ratio than current estimates
SO PEERJ
LA English
DT Article
DE COVID19; SARS-CoV-2; Pandemic modelling; Outbreak modelling; Global
   COVID19 model; Analytic parametrization
ID CORONAVIRUS DISEASE 2019; OUTBREAK
AB Background: Since the outbreak of the COVID-19 pandemic, multiple efforts of modelling of the geo-temporal transmissibility of the virus have been undertaken, but none describes the pandemic spread at the global level. The aim of this research is to provide a high-resolution global model of the pandemic that overcomes the problem of biased country-level data on the number of infected cases. To achieve this we propose a novel SIR-type metapopulation transmission model and a set of analytically derived model parameters. We used them to perform a simulation of the disease spread with help of the Global Epidemic and Mobility (GLEAM) framework embedding actual population densities, commute patterns and long-range travel networks. The simulation starts on 17 November 2019 with the index case (presymptomatic, yet infectious) in Wuhan, China, and results in an accurate prediction of the number of diagnosed cases after 154 days in multiple countries across five continents. In addition, the model outcome shows high compliance with the results of a random screening test conducted on pregnant women in the New York area.
   Methods: We have built a modified SIR metapopulation transmission model and parameterized it analytically either by setting the values of the parameters based on the literature, or by assuming their plausible values. We compared our results with the number of diagnosed cases in twenty selected countries, ones which provide reliable statistics but differ substantially in terms of strength and speed of undertaken Non-Drug Interventions. The obtained 95% confidence intervals for the predictions are in agreement with the empirical data.
   Results: The parameters that successfully model the pandemic are: the basic reproduction number R-0, 4.4; a latent non-infectious period of 1.1. days followed by 4.6 days of the presymptomatic infectious period; the probability of developing severe symptoms, 0.01; the probability of being diagnosed when presenting severe symptoms of 0.6; the probability of diagnosis for cases with mild symptoms or asymptomatic, 0.001.
   Discussion: Parameters that successfully reproduce the observed number of cases indicate that both R-0 and the prevalence of the virus might be underestimated. This is in concordance with the newest research on undocumented COVID-19 cases. Consequently, the actual mortality rate is putatively lower than estimated. Confirmation of the pandemic characteristic by further refinement of the model and screening tests is crucial for developing an effective strategy for the global epidemiological crisis.
C1 [Siwiak, Marian; Szczesny, Pawel; Siwiak, Marlena] Data 3 0 Ltd, Sevenoaks, England.
RP Siwiak, M (corresponding author), Data 3 0 Ltd, Sevenoaks, England.
EM siwiak@data30.co.uk
CR Balcan D, 2010, J COMPUT SCI-NETH, V1, P132, DOI 10.1016/j.jocs.2010.07.002
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Chen TM, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00640-3
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Ganyani T, 2020, EUROSURVEILLANCE, V25, P12, DOI 10.2807/1560-7917.ES.2020.25.17.2000257
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Imai N., 2020, 3 IMP COLL
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lavezzo E, 2020, SUPPRESSION COVID 19, DOI [10.1101/2020.04.17.20053157, DOI 10.1101/2020.04.17.20053157]
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Majumder Maimuna S, 2020, SSRN, P3524675, DOI 10.2139/ssrn.3524675
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Ota Miyo, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0316-3
   Pan Y, 2020, CLIN CHEM, V66, P794, DOI 10.1093/clinchem/hvaa091
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   South Korean Ministry of Health and Welfare, 2020, COR DIS 19 COVID 19
   Streeck H, 2020, PRELIMINARY RESULT C
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Tizzoni M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-165
   Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198
   Van den Broeck W, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-37
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   Woelfel R., 2020, CLIN PRESENTATION VI, DOI [DOI 10.1101/2020.03.05.20030502, 10.1101/2020.03.05.20030502]
   World Health Organization, 2020, M INT HLTH REG 2005
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
   Zhao S, 2020, BIORXIV, DOI [10.1101/2020.01.23.916395, DOI 10.1101/2020.01.23.916395, 10.1101/2020.01.23.916395.]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 41
TC 0
Z9 0
U1 8
U2 8
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUL 10
PY 2020
VL 8
AR e9548
DI 10.7717/peerj.9548
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MI3TI
UT WOS:000547333000012
PM 32728498
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Qin, CL
   Feng, WS
   Chu, YJ
   Lee, JB
   Berton, M
   Bettonte, S
   Teo, YY
   Stocks, MJ
   Fischer, PM
   Gershkovich, P
AF Qin, Chaolong
   Feng, Wanshan
   Chu, YenJu
   Lee, Jong Bong
   Berton, Mattia
   Bettonte, Sara
   Teo, Yeong Yeu
   Stocks, Michael J.
   Fischer, Peter M.
   Gershkovich, Pavel
TI Development and validation of a cost-effective and sensitive
   bioanalytical HPLC-UV method for determination of lopinavir in rat and
   human plasma
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article
DE HIV; lopinavir; preclinical pharmacokinetics; SARS-CoV-2; therapeutic
   drug monitoring
ID HIV-PROTEASE INHIBITORS; REVERSE-TRANSCRIPTASE INHIBITORS;
   QUANTITATIVE-DETERMINATION; RITONAVIR; LOPINAVIR/RITONAVIR; SAQUINAVIR;
   VARIABILITY; INDINAVIR; DRUGS; PHARMACOKINETICS
AB A simple, sensitive and cost-effective HPLC-UV bioanalytical method for determination of lopinavir (LPV) in rat and human plasma was developed and validated. The plasma sample preparation procedure includes a combination of protein precipitation using cold acetonitrile and liquid-liquid extraction withn-hexane-ethyl acetate (7:3,v/v). A good chromatographic separation was achieved with a Phenomenex Gemini column (C-18, 150 mm x 2.0 mm, 5 mu m) at 40 degrees C with gradient elution, at 211 nm. Calibration curves were linear in the range 10-10,000 ng/mL, with a lower limit of quantification of 10 ng/mL using 100 mu L of plasma. The accuracy and precision in all validation experiments were within the criteria range set by the guidelines of the Food and Drug Administration. This method was successfully applied to a preliminary pharmacokinetic study in rats following an intravenous bolus administration of LPV. Moreover, the method was subsequently fully validated for human plasma, allowing its use in therapeutic drug monitoring (TDM). In conclusion, this novel, simple and cost-efficient bioanalytical method for determination of LPV is useful for pharmacokinetic and drug delivery studies in rats, as well as TDM in human patients.
C1 [Qin, Chaolong; Feng, Wanshan; Chu, YenJu; Lee, Jong Bong; Berton, Mattia; Bettonte, Sara; Teo, Yeong Yeu; Stocks, Michael J.; Fischer, Peter M.; Gershkovich, Pavel] Univ Nottingham, Sch Pharm, Nottingham, England.
   [Berton, Mattia; Bettonte, Sara] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy.
RP Gershkovich, P (corresponding author), Univ Nottingham, Sch Pharm, Biodiscovery Inst BDI, Univ Pk, Nottingham NG7 2RD, England.
EM pavel.gershkovich@nottingham.ac.uk
RI ; Gershkovich, Pavel/O-3847-2014
OI Lee, Jong Bong/0000-0002-8404-0581; Qin, Chaolong/0000-0003-1161-5580;
   Gershkovich, Pavel/0000-0003-3136-0933
CR Barry MG, 1998, BRIT J CLIN PHARMACO, V45, P501
   Boffito M, 2005, ANTIVIR THER, V10, P375
   Breilh D, 2004, AIDS, V18, P1305, DOI 10.1097/00002030-200406180-00009
   D'Avolio A, 2011, J PHARMACEUT BIOMED, V54, P779, DOI 10.1016/j.jpba.2010.10.011
   Dunnington K., 2018, APPL PHARMACOKINETIC, DOI [10.5772/intechopen.74189, DOI 10.5772/INTECHOPEN.74189]
   Egge-Jacobsen W, 2004, THER DRUG MONIT, V26, P546, DOI 10.1097/00007691-200410000-00014
   Else L, 2010, J CHROMATOGR B, V878, P1455, DOI 10.1016/j.jchromb.2010.03.036
   Eron JJ, 2004, J INFECT DIS, V189, P265, DOI 10.1086/380799
   Estrela RCE, 2008, RAPID COMMUN MASS SP, V22, P657, DOI 10.1002/rcm.3411
   Faux J, 2001, CHROMATOGRAPHIA, V54, P469, DOI 10.1007/BF02491201
   Ford J, 2004, J ANTIMICROB CHEMOTH, V54, P982, DOI 10.1093/jac/dkh487
   Gutierrez F, 2003, JAIDS-J ACQ IMM DEF, V33, P594, DOI 10.1097/00126334-200308150-00007
   Hill A, 2009, AIDS REV, V11, P30
   Isin EM, 2012, CHEM RES TOXICOL, V25, P532, DOI 10.1021/tx2005212
   Justesen US, 2003, J CHROMATOGR B, V783, P491, DOI 10.1016/S1570-0232(02)00728-6
   Kumar GN, 2004, PHARM RES-DORDR, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d
   Lee JB, 2017, J CHROMATOGR B, V1040, P73, DOI 10.1016/j.jchromb.2016.11.024
   Limsreng S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160306
   Martin J, 2009, J CHROMATOGR B, V877, P3072, DOI 10.1016/j.jchromb.2009.07.031
   Masquelier B, 2002, ANTIMICROB AGENTS CH, V46, P2926, DOI 10.1128/AAC.46.9.2926-2932.2002
   Montes ML, 2005, J ANTIMICROB CHEMOTH, V55, P800, DOI 10.1093/jac/dki063
   Notari S, 2006, J CHROMATOGR B, V831, P258, DOI 10.1016/j.jchromb.2005.12.016
   Oldfield V, 2006, DRUGS, V66, P1275, DOI 10.2165/00003495-200666090-00012
   Phelps BR, 2011, PEDIATR DRUGS, V13, P175, DOI 10.2165/11587300-000000000-00000
   Poirier JM, 2005, THER DRUG MONIT, V27, P186, DOI 10.1097/01.ftd.0000152680.36517.5d
   Puthanakit T, 2010, PEDIATR INFECT DIS J, V29, P79, DOI 10.1097/INF.0b013e3181b21040
   Ray J, 2002, J CHROMATOGR B, V775, P225, DOI 10.1016/S1570-0232(02)00295-7
   Regazzi MB, 1999, BRIT J CLIN PHARMACO, V47, P379, DOI 10.1046/j.1365-2125.1999.00919.x
   Rezk NL, 2004, J CHROMATOGR B, V805, P241, DOI 10.1016/j.jchromb.2004.03.002
   Ribera E, 2004, ANTIMICROB AGENTS CH, V48, P4256, DOI 10.1128/AAC.48.11.4256-4262.2004
   Temghare GA, 2009, E-J CHEM, V6, P223, DOI 10.1155/2009/709478
   Thrivikraman KV, 2002, BRAIN RES PROTOC, V10, P84, DOI 10.1016/S1385-299X(02)00185-X
   TJOTTA E, 1991, J MED VIROL, V35, P223, DOI 10.1002/jmv.1890350402
   UNAIDS, 2019, GLOB HIV AIDS STAT F
   van der Leur MR, 2006, THER DRUG MONIT, V28, P650, DOI 10.1097/01.ftd.0000245681.12092.d6
   Vats Rahul, 2011, Sci Pharm, V79, P849, DOI 10.3797/scipharm.1107-24
   Weller DR, 2007, J CHROMATOGR B, V848, P369, DOI 10.1016/j.jchromb.2006.10.022
   Wen SP, 2019, IEEE T SYST MAN CY-S, V49, P1787, DOI 10.1109/TSMC.2018.2825021
   WHO, 2018, UPD REC 1 LIN 2 LIN
   WHO, 2006, ANT THER HIV INF AD
   World Health Organization, 2019, UPD 1 2 LI ANT REG
   World Precision Instruments, 2019, EZ AN IS
   Zgair A, 2015, J PHARMACEUT BIOMED, V114, P145, DOI 10.1016/j.jpba.2015.05.019
NR 43
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-3879
EI 1099-0801
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD NOV
PY 2020
VL 34
IS 11
AR e4934
DI 10.1002/bmc.4934
EA JUL 2020
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA OB5KT
UT WOS:000546647600001
PM 32598032
OA Green Accepted, Other Gold
DA 2021-01-01
ER

PT J
AU Saab, R
   Obeid, A
   Gachi, F
   Boudiaf, H
   Sargsyan, L
   Al-Saad, K
   Javakhadze, T
   Mehrvar, A
   Abbas, SS
   Al-Agele, YSA
   Al-Haddad, S
   Al Ani, MH
   Al-Sweedan, S
   Al Kofide, A
   Jastaniah, W
   Khalifa, N
   Bechara, E
   Baassiri, M
   Noun, P
   El-Houdzi, J
   Khattab, M
   Sharma, KS
   Wali, Y
   Mushtaq, N
   Batool, A
   Faizan, M
   Raza, MR
   Najajreh, M
   Abdallah, MAM
   Sousan, G
   Ghanem, KM
   Kocak, U
   Kutluk, T
   Demir, HA
   Hodeish, H
   Muwakkit, S
   Belgaumi, A
   Al-Rawas, AH
   Jeha, S
AF Saab, Raya
   Obeid, Anas
   Gachi, Fatiha
   Boudiaf, Houda
   Sargsyan, Lilit
   Al-Saad, Khulood
   Javakhadze, Tamar
   Mehrvar, Azim
   Abbas, Sawsan Sati
   Al-Agele, Yasir Saadoon Abed
   Al-Haddad, Salma
   Al Ani, Mouroge Hashim
   Al-Sweedan, Suleiman
   Al Kofide, Amani
   Jastaniah, Wasil
   Khalifa, Nisreen
   Bechara, Elie
   Baassiri, Malek
   Noun, Peter
   El-Houdzi, Jamila
   Khattab, Mohammed
   Sharma, Krishna Sagar
   Wali, Yasser
   Mushtaq, Naureen
   Batool, Aliya
   Faizan, Mahwish
   Raza, Muhammad Rafie
   Najajreh, Mohammad
   Abdallah, Mohammed Awad Mohammed
   Sousan, Ghada
   Ghanem, Khaled M.
   Kocak, Ulker
   Kutluk, Tezer
   Demir, Hac Ahmet
   Hodeish, Hamoud
   Muwakkit, Samar
   Belgaumi, Asim
   Al-Rawas, Abdul-Hakim
   Jeha, Sima
TI Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric
   oncology care in the Middle East, North Africa, and West Asia Region: A
   report from the Pediatric Oncology East and Mediterranean (POEM) Group
SO CANCER
LA English
DT Article
DE care delivery; coronavirus disease 2019 (COVID-19); middle-income
   countries; pandemic; pediatric oncology
AB Background Childhood cancer is a highly curable disease when timely diagnosis and appropriate therapy are provided. A negative impact of the coronavirus disease 2019 (COVID-19) pandemic on access to care for children with cancer is likely but has not been evaluated. METHODS A 34-item survey focusing on barriers to pediatric oncology management during the COVID-19 pandemic was distributed to heads of pediatric oncology units within the Pediatric Oncology East and Mediterranean (POEM) collaborative group, from the Middle East, North Africa, and West Asia. Responses were collected on April 11 through 22, 2020. Corresponding rates of proven COVID-19 cases and deaths were retrieved from the World Health Organization database. Results In total, 34 centers from 19 countries participated. Almost all centers applied guidelines to optimize resource utilization and safety, including delaying off-treatment visits, rotating and reducing staff, and implementing social distancing, hand hygiene measures, and personal protective equipment use. Essential treatments, including chemotherapy, surgery, and radiation therapy, were delayed in 29% to 44% of centers, and 24% of centers restricted acceptance of new patients. Clinical care delivery was reported as negatively affected in 28% of centers. Greater than 70% of centers reported shortages in blood products, and 47% to 62% reported interruptions in surgery and radiation as well as medication shortages. However, bed availability was affected in <30% of centers, reflecting the low rates of COVID-19 hospitalizations in the corresponding countries at the time of the survey. Conclusions Mechanisms to approach childhood cancer treatment delivery during crises need to be re-evaluated, because treatment interruptions and delays are expected to affect patient outcomes in this otherwise largely curable disease.
C1 [Saab, Raya; Obeid, Anas; Muwakkit, Samar] Amer Univ Beirut, Childrens Canc Inst, Dept Pediat & Adolescent Med, Med Ctr, Riad Solh St, Beirut 11072020, Lebanon.
   [Jeha, Sima] St Jude Childrens Res Hosp, Dept Global Pediat Med, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
   [Gachi, Fatiha] Pierre & Marie Curie Ctr, Dept Pediat, Algiers, Algeria.
   [Boudiaf, Houda] Mustapha Pacha Hosp, Dept Pediat, Moustapha, Algeria.
   [Sargsyan, Lilit] Prof RH Yeolyan Hematol Ctr, Pediat Canc & Blood Disorders Ctr Armenia, Yerevan, Armenia.
   [Al-Saad, Khulood] Salmaniya Med Complex, Dept Pediat, Manama, Bahrain.
   [Javakhadze, Tamar] Lashvili Childrens Cent Hosp, Dept Pediat, Tbilisi, Georgia.
   [Mehrvar, Azim] MAHAK Pediat Canc Treatment & Res Ctr, Tehran, Iran.
   [Abbas, Sawsan Sati] Al Imamian Al Kadhimiyain Med City, Dept Pediat, Baghdad, Iraq.
   [Al-Agele, Yasir Saadoon Abed] Ibn Al Athir Teaching Hosp Children, Dept Pediat, Al Mausil, Iraq.
   [Al-Haddad, Salma] Children Welf Teaching Hosp, Dept Pediat, Baghdad, Iraq.
   [Al Ani, Mouroge Hashim] Nanakaly Hosp Blood Dis, Dept Pediat, Kurdistan, Iraq.
   [Al-Sweedan, Suleiman] King Abdullah Univ Hosp, Dept Pediat, Ar Ramtha, Jordan.
   [Al Kofide, Amani] King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia.
   [Jastaniah, Wasil] Minist Natl Guard Hlth Affairs Western Reg, Princess Noorah Oncol Ctr, King Abdulaziz Med City, Jeddah, Saudi Arabia.
   [Jastaniah, Wasil] Umm AlQura Univ, Coll Med, Mecca, Saudi Arabia.
   [Khalifa, Nisreen] Kuwait Childrens Hosp, Natl Bank, Kuwait, Kuwait.
   [Bechara, Elie] Lebanese Hosp Geitaoui, Dept Pediat, Beirut, Lebanon.
   [Baassiri, Malek] Makassed Gen Hosp, Dept Pediat, Beirut, Lebanon.
   [Baassiri, Malek] Hammoud Hosp Univ, Dept Pediat, Med Ctr, Saida, Lebanon.
   [Noun, Peter] St George Hosp Univ, Dept Pediat, Med Ctr, Beirut, Lebanon.
   [El-Houdzi, Jamila] Mohammed VI Marrakech Univ Hosp Ctr, Dept Pediat Hematol Oncol, Marrakech, Morocco.
   [Khattab, Mohammed] Ibn Sina Univ Hosp Ctr, Pediat Hematol & Oncol Ctr, Rabat, Morocco.
   [Sharma, Krishna Sagar] BP Koirala Mem Canc Hosp, Dept Med Oncol, Bharatpur, Nepal.
   [Wali, Yasser; Al-Rawas, Abdul-Hakim] Sultan Qaboos Univ Hosp, Child Hlth Dept, Muscat, Oman.
   [Mushtaq, Naureen; Belgaumi, Asim] Aga Khan Univ Hosp, Dept Pediat, Karachi, Pakistan.
   [Batool, Aliya] Dr Akbar Niazi Teaching Hosp, Pediat Hematol Oncol & Bone Marrow Transplant Uni, Islamabad, Pakistan.
   [Faizan, Mahwish] Childrens Hosp & Inst Child Hlth, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Lahore, Pakistan.
   [Raza, Muhammad Rafie] Indus Hosp, Dept Pediat Oncol, Karachi, Pakistan.
   [Najajreh, Mohammad] Beit Jala Govt Hosp, Huda Al Masri Pediat Canc Dept, Beit Jala, Palestine.
   [Abdallah, Mohammed Awad Mohammed] Khartoum Oncol Hosp, Dept Pediat, Khartoum, Sudan.
   [Sousan, Ghada] Al Bairouni Hosp, Dept Pediat, Damascus, Syria.
   [Ghanem, Khaled M.] Al Bairouni Hosp, Basma Pediat Oncol Unit, Damascus, Syria.
   [Kocak, Ulker] Gazi Univ Hosp, Dept Pediat, Ankara, Turkey.
   [Kutluk, Tezer] Hacettepe Univ, Dept Pediat Oncol, Canc Inst, Ankara, Turkey.
   [Kutluk, Tezer] Hacettepe Univ, Fac Med, Ankara, Turkey.
   [Demir, Hac Ahmet] Private Mem Ankara Hosp, Dept Pediat Hematol Oncol, Ankara, Turkey.
   [Hodeish, Hamoud] Natl Oncol Ctr, Pediat Oncol Dept, Sanaa, Yemen.
RP Saab, R (corresponding author), Amer Univ Beirut, Childrens Canc Inst, Dept Pediat & Adolescent Med, Med Ctr, Riad Solh St, Beirut 11072020, Lebanon.; Jeha, S (corresponding author), St Jude Childrens Res Hosp, Dept Global Pediat Med, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM rs88@aub.edu.lb; sima.jeha@stjude.org
RI Raza, Rizwan/B-4526-2012
OI Raza, Rizwan/0000-0003-0599-3630; Saab, Raya/0000-0001-5776-2303;
   Faizan, Mahwish/0000-0002-3543-9094
FU American Lebanese Syrian Associated Charities (ALSAC)/St Jude Global; UK
   Research and Innovation Global Challenges Research Fund grant Research
   for Health in Conflict (R4HC-MENA) [ES/P010962/1]
FX Pediatric Oncology East and Mediterranean (POEM) group central office
   and activities are partially funded by American Lebanese Syrian
   Associated Charities (ALSAC)/St Jude Global. Tezer Kutluk receives
   funding from the UK Research and Innovation Global Challenges Research
   Fund grant Research for Health in Conflict (R4HC-MENA; ES/P010962/1).
CR Al-Quteimat OM, 2020, AM J CLIN ONCOL-CANC, V43, P452, DOI 10.1097/COC.0000000000000712
   Basbous M, 2020, CANCER EPIDEMIOL, DOI [10.1016/j.canep.2020.10727, DOI 10.1016/J.CANEP.2020.10727]
   Bouffet E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28327
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Hrusak O, 2020, EUR J CANCER, V132, P11, DOI 10.1016/j.ejca.2020.03.021
   Indini A, 2020, EUR J CANCER, V132, P17, DOI 10.1016/j.ejca.2020.03.024
   Kattan C, 2020, FUTURE ONCOL, V16, P1157, DOI 10.2217/fon-2020-0313
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   NELSON B, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1544
   Pediatric Oncology East and Mediterranean Group, PED ONC E MED POEM G
   Peng L, 2020, EUR J CANCER, V132, P5, DOI 10.1016/j.ejca.2020.03.028
   Rasmussen SA, 2020, JAMA PEDIATR, V174, P743, DOI 10.1001/jamapediatrics.2020.1224
   Saab R, 2020, PEDIATR HEMAT ONCOL, V5, P3, DOI [10.1016/j.phoj.2020.03.002, DOI 10.1016/J.PH0J.2020.03.002]
   St. Jude Global, 2020, GLOB COVID 19 OBS RE
   Sullivan M, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28409
   United Nations, 2019, WORLD POP PROSP 2019
   World Health Organization, COR DIS COVID 2019 S
   World Health Organization, 2020, 94 WHO
   World Health Organization, 2020, 82 WHO
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
NR 22
TC 2
Z9 2
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 15
PY 2020
VL 126
IS 18
BP 4235
EP 4245
DI 10.1002/cncr.33075
EA JUL 2020
PG 11
WC Oncology
SC Oncology
GA NE0HS
UT WOS:000546720200001
PM 32648950
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Morgan, AK
AF Morgan, Anthony Kwame
TI Making COVID-19 prevention etiquette of social distancing a reality for
   the homeless and slum dwellers in Ghana: lessons for consideration
SO LOCAL ENVIRONMENT
LA English
DT Article
DE Novel coronavirus disease (COVID-19); Ghana; informal settlements; slum
   dwellers; social distancing
AB As the world awaits a cure or a vaccine for the deadly Coronavirus disease (COVID-19), prevention etiquette of social distancing is being championed as a mechanism of reducing the rate of infections. This prevention etiquette (social distancing), however, has become an unattainable goal for the majority of slum dwellers and the homeless in Ghana, owing to the absence of standardized housing conditions and basic services that support such a practice. This article sheds light on some strategic actions that must be adopted by government and other groups (Non-Governmental Organisations and Civil Society Organizations inclusive) towards making COVID-19 prevention etiquette of social distancing a reality for the homeless and slum dwellers in Ghana. Among other things, the paper recommends that instant moratorium should be placed on evictions of slum dwellers during the span of the pandemic since their displacement would predispose the evicted to the vulnerability of COVID-19 infection. Additionally, basic human needs such as water and sanitation should be provided for the slum dwellers while dilapidated classrooms and community centres are used to house the homeless and decongest the slums and provide for social distancing.
C1 [Morgan, Anthony Kwame] Kwame Nkrumah Univ Sci & Technol KNUST, Dept Geog & Rural Dev, Duncanson Rd,Private Mail Bag, Kumasi, Ghana.
RP Morgan, AK (corresponding author), Kwame Nkrumah Univ Sci & Technol KNUST, Dept Geog & Rural Dev, Duncanson Rd,Private Mail Bag, Kumasi, Ghana.
EM anthoniomorgano280@gmail.com
OI Morgan, Anthony Kwame/0000-0001-7904-9955
CR Abu-Salia R., 2015, CURRENT URBAN STUDIE, V3, P105, DOI [10.4236/cus.2015.32010, DOI 10.4236/CUS.2015.32010]
   Adams AM, 2015, HEALTH POLICY PLANN, V30, pi32, DOI 10.1093/heapol/czu094
   Deola Claudio, 2014, Disaster Health, V2, P92, DOI 10.4161/21665044.2014.990306
   Du J, 2020, TACKLING INEQUALITY
   Florida R., 2017, NEW URBAN CRISIS OUR
   Kouadio IK, 2012, EXPERT REV ANTI-INFE, V10, P95, DOI [10.1586/eri.11.155, 10.1586/ERI.11.155]
   MyJoyonline.com, 2020, MYJOYONLINE     0415
   Osorio L, 2004, AM J TROP MED HYG, V71, P380, DOI 10.4269/ajtmh.2004.71.380
   van de Vijver S, 2015, LANCET, V386, P2114, DOI 10.1016/S0140-6736(15)00385-2
   WHO, 2020, MOD TRANSM VIR CAUS
   World Health Organization and the United Nations Children''s Fund (WHO and UNICEF), 2020, WHO2019NCOVIPCWASH20
NR 11
TC 1
Z9 1
U1 9
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1354-9839
EI 1469-6711
J9 LOCAL ENVIRON
JI Local Environ.
PD JUL 2
PY 2020
VL 25
IS 7
BP 536
EP 539
DI 10.1080/13549839.2020.1789854
EA JUL 2020
PG 4
WC Green & Sustainable Science & Technology; Environmental Studies;
   Geography; Regional & Urban Planning; Urban Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology;
   Geography; Public Administration; Urban Studies
GA MM2BB
UT WOS:000547027200001
DA 2021-01-01
ER

PT J
AU Thammathiwat, T
   Tungsanga, S
   Tiankanon, K
   Torvorapanit, P
   Chumpangern, W
   Udomkarnjananun, S
   Avihingsanon, Y
   Sriprasart, T
   Srisawat, N
   Jutivorakool, K
   Paitoonpong, L
   Putcharoen, O
   Townamchai, N
AF Thammathiwat, Theerachai
   Tungsanga, Somkanya
   Tiankanon, Kanitha
   Torvorapanit, Pattama
   Chumpangern, Worawat
   Udomkarnjananun, Suwasin
   Avihingsanon, Yingyos
   Sriprasart, Thitiwat
   Srisawat, Nattachai
   Jutivorakool, Kamonwan
   Paitoonpong, Leilani
   Putcharoen, Opass
   Townamchai, Natavudh
TI A case of successful treatment of severe COVID-19 pneumonia with
   favipiravir and tocilizumab in post-kidney transplant recipient
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE COVID-19; favipiravir; kidney transplant recipient; tocilizumab
AB We report a case of COVID-19 in kidney transplant patient in Thailand. A 58-year-old 2 years post-kidney transplant recipient, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil (MMF), and prednisolone, presented with acute diarrhea which followed by fever on day 12. Symptoms of pneumonia together with lymphopenia from complete blood count were developed on day 7 after onset of fever with the x-ray finding of bilateral multifocal patchy infiltration. COVID-19 infection has been confirmed by reverse real-time polymerase chain reaction (PCR) in nasal swab as well as found in stool. Darunavir together with ritonavir, hydroxychloroquine, azithromycin, and favipiravir was initiated on the first day of admission at primary hospital. Patient has been transferred to our hospital on day 2 of admission in which tacrolimus together with MMF was discontinued. High-flow nasal cannula oxygen therapy was required on days 4-5 of hospitalization. Tocilizumab was administered after rising of serum IL-6 level. Symptoms of pneumonia were improved in which no oxygen treatment required from day 10 of hospitalization. Drug interaction between tacrolimus and anti-viral treatment leads to severely high level of tacrolimus which caused reversible acute kidney injury (AKI) after supportive treatment.
C1 [Thammathiwat, Theerachai; Tungsanga, Somkanya; Tiankanon, Kanitha; Torvorapanit, Pattama; Chumpangern, Worawat; Udomkarnjananun, Suwasin; Avihingsanon, Yingyos; Sriprasart, Thitiwat; Srisawat, Nattachai; Jutivorakool, Kamonwan; Paitoonpong, Leilani; Putcharoen, Opass; Townamchai, Natavudh] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok, Thailand.
   [Thammathiwat, Theerachai; Tungsanga, Somkanya; Tiankanon, Kanitha; Torvorapanit, Pattama; Chumpangern, Worawat; Udomkarnjananun, Suwasin; Avihingsanon, Yingyos; Sriprasart, Thitiwat; Srisawat, Nattachai; Jutivorakool, Kamonwan; Paitoonpong, Leilani; Putcharoen, Opass; Townamchai, Natavudh] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
   [Thammathiwat, Theerachai] Naresuan Univ, Fac Med, Dept Med, Div Nephrol, Phitsanulok, Thailand.
   [Udomkarnjananun, Suwasin; Avihingsanon, Yingyos; Townamchai, Natavudh] King Chulalongkorn Mem Hosp, Excellence Ctr Solid Organ Transplantat, Bangkok, Thailand.
   [Udomkarnjananun, Suwasin; Avihingsanon, Yingyos; Townamchai, Natavudh] Chulalongkorn Univ, Renal Immunol & Renal Transplant Res Unit, Bangkok, Thailand.
   [Srisawat, Nattachai] King Chulalongkorn Mem Hosp, Excellence Ctr Crit Care Nephrol, Thai Red Cross Soc, Bangkok, Thailand.
   [Paitoonpong, Leilani; Putcharoen, Opass] Chulalongkorn Univ, King Mem Hosp, Fac Med, Emerging Infect Dis Clin Ctr, Bangkok, Thailand.
RP Townamchai, N (corresponding author), King Chulalongkorn Mem Hosp, Bangkok, Thailand.; Townamchai, N (corresponding author), Chulalongkorn Univ, Fac Med, Dept Med, Div Nephrol, Bangkok, Thailand.
EM ntownamchai@gmail.com
OI Thammathiwat, Theerachai/0000-0002-5134-7106
CR [Anonymous], 2020, CORONAVIRUS DIS COVI
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Li XY, 2020, CLIN RES HEPATOL GAS, V44, P284, DOI 10.1016/j.clinre.2020.03.017
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Matsushita K, 2020, RELATIONSHIP COVID 1, DOI [10.1101/2020.04.05.20054155, DOI 10.1101/2020.04.05.20054155]
   Mertz D, 2009, AM J KIDNEY DIS, V54, pE1, DOI 10.1053/j.ajkd.2009.01.268
   Romanelli A, 2020, AM J TRANSPLANT, V20, P1947, DOI 10.1111/ajt.15905
   Ulhaq ZS, 2020, MED MALADIES INFECT, V50, P382, DOI 10.1016/j.medmal.2020.04.002
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 4
Z9 4
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13388
DI 10.1111/tid.13388
EA JUL 2020
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA MH3FH
UT WOS:000546616100001
PM 32585765
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rowan, NJ
   Laffey, JG
AF Rowan, Neil J.
   Laffey, John G.
TI Challenges and solutions for addressing critical shortage of supply
   chain for personal and protective equipment (PPE) arising from
   Coronavirus disease (COVID19) pandemic - Case study from the Republic of
   Ireland
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE COVID19; PPE; Sterilization; Healthcare workers; Resource utilization;
   Sustainability
ID TRANSMISSION STAGES EFFICACY; TREATED-WATER; PULSED-LIGHT; INACTIVATION;
   DECONTAMINATION; UV; INFLUENZA; IMPACT; FOOD
AB Coronavirus (COVID-19) is highly infectious agent that causes fatal respiratory illnesses, which is of great global public health concern. Currently, there is no effective vaccine for tackling this COVID19 pandemic where disease countermeasures rely upon preventing or slowing person-to-person transmission. Specifically, there is increasing efforts to prevent or reduce transmission to front-line healthcare workers (HCW). However, there is growing international concern regarding the shortage in supply chain of critical one-time-use personal and protective equipment (PPE). PPE are heat sensitive and are not, by their manufacturer's design, intended for reprocessing. Most conventional sterilization technologies used in hospitals, or in terminal medical device sterilization providers, cannot effectively reprocess PPE due to the nature and severity of sterilization modalities. Contingency planning for PPE stock shortage is important. Solutions in the Republic of Ireland include use of smart communication channels to improve supply chain, bespoke production of PPE to meets gaps, along with least preferred option, use of sterilization or high-level disinfection for PPE reprocessing. Reprocessing PPE must consider material composition, functionality post treatment, along with appropriate disinfection. Following original manufacturer of PPE and regulatory guidance is important. Technologies deployed in the US, and for deployment in the Republic of Ireland, are eco-friendly, namely vaporised hydrogen peroxide (VH2O2), such as for filtering facepiece respirators and UV irradiation and High-level liquid disinfection (Actichlor+) is also been pursed in Ireland. Safeguarding supply chain of PPE will sustain vital healthcare provision and will help reduce mortality. (C) 2020 The Authors. Published by Elsevier B.V.
C1 [Rowan, Neil J.] Athlone Inst Technol, Dept Nursing & Healthcare, Athlone, Ireland.
   [Rowan, Neil J.] Athlone Inst Technol, Ctr Disinfect Sterilizat & Biosecur, Athlone, Ireland.
   [Laffey, John G.] Natl Univ Ireland Galway, CURAM Ctr Med Devices, Lung Biol Grp, Regenerat Med Inst, Galway, Ireland.
   [Laffey, John G.] Univ Hosp Galway, Anaesthesia & Intens Care Med, Galway, Ireland.
RP Rowan, NJ (corresponding author), Athlone Inst Technol, CDSB, Athlone, Ireland.
EM nrowan@ait.ie
OI Rowan, Neil/0000-0003-1228-3733
FU Science Foundation Ireland -Rapid COVID19 fund GrantScience Foundation
   Ireland; CURAM edical device Centre
FX Science Foundation Ireland -Rapid COVID19 fund Grant with CURAM edical
   device Centre.
CR 3M Science of Life, 2020, DIS FILT FAC RESP
   Barrett M, 2016, SCI TOTAL ENVIRON, V568, P1026, DOI 10.1016/j.scitotenv.2016.06.067
   Bergman MS, 2010, J ENG FIBER FABR, V5, P33
   Carty M.F., 2020, PROG CARDIOVASC DIS, DOI [10.1016/j.pcad.202.02.007availableonline., DOI 10.1016/J.PCAD.202.02.007]
   Chen YY, 2019, POLYMER, V183, DOI 10.1016/j.polymer.2019.121870
   Deng LZ, 2020, CRIT REV FOOD SCI, V60, P2481, DOI 10.1080/10408398.2019.1649633
   Farrell H, 2011, J MICROBIOL METH, V84, P317, DOI 10.1016/j.mimet.2010.12.021
   FDA, 2020, ENF POL FAC MASKS
   FDA, 2020, FIN REP BIOQ HYDR PE
   Fisher EM, 2011, J APPL MICROBIOL, V110, P287, DOI 10.1111/j.1365-2672.2010.04881.x
   Franssen F, 2019, TRENDS FOOD SCI TECH, V83, P114, DOI 10.1016/j.tifs.2018.11.009
   Garvey M, 2015, WATER ENVIRON J, V29, P27, DOI 10.1111/wej.12073
   Gerard C, 2019, TRENDS FOOD SCI TECH, V91, P12, DOI 10.1016/j.tifs.2019.06.015
   Hayes J, 2013, J MICROBIOL METH, V94, P325, DOI 10.1016/j.mimet.2013.07.012
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   McEvoy B, 2019, J APPL MICROBIOL, V127, P1403, DOI 10.1111/jam.14412
   Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507
   Mitchell R, 2012, AM J INFECT CONTROL, V40, P611, DOI 10.1016/j.ajic.2012.01.011
   Moore G., 2012, BMC INFECT DIS, V3, P12
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rowan NJ, 2019, TRENDS FOOD SCI TECH, V88, P316, DOI 10.1016/j.tifs.2019.03.027
   Rowan NJ, 2015, TRENDS FOOD SCI TECH, V44, P79, DOI 10.1016/j.tifs.2015.03.006
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Swaminathan A, 2007, EMERG INFECT DIS, V13, P1541, DOI 10.3201/eid1310.070033
   U.S. Centers for Disease Control and Prevention (CDC), 2008, DIS HEALTHC EQ GUID
   Viscusi DJ, 2009, ANN OCCUP HYG, V53, P815, DOI 10.1093/annhyg/mep070
   Viscusi DJ, 2009, AM J INFECT CONTROL, V37, P381, DOI 10.1016/j.ajic.2008.09.021
   Viscusi DJ, 2007, J INT SOC RESP PROTE, V24, P93
   Wendt C., 2015, MANUAL CLIN MICROBIO, DOI 10.1128/9781555817381.ch13.
NR 30
TC 40
Z9 41
U1 32
U2 49
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD JUL 10
PY 2020
VL 725
AR 138532
DI 10.1016/j.scitotenv.2020.138532
PG 9
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA LT7JN
UT WOS:000537243100006
PM 32304970
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhao, Y
   Qin, L
   Zhang, P
   Li, K
   Liang, LC
   Sun, JP
   Xu, B
   Dai, YC
   Li, XM
   Zhang, C
   Peng, YC
   Feng, YM
   Li, A
   Hu, ZJ
   Xiang, HP
   Ogg, G
   Ho, LP
   McMichael, A
   Jin, RH
   Knight, JC
   Dong, T
   Zhang, YH
AF Zhao, Yan
   Qin, Ling
   Zhang, Ping
   Li, Kang
   Liang, Lianchun
   Sun, Jianping
   Xu, Bin
   Dai, Yanchao
   Li, Xuemei
   Zhang, Chi
   Peng, Yanchun
   Feng, Yingmei
   Li, Ang
   Hu, Zhongjie
   Xiang, Haiping
   Ogg, Graham
   Ho, Ling-Pei
   McMichael, Andrew
   Jin, Ronghua
   Knight, Julian C.
   Dong, Tao
   Zhang, Yonghong
TI Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease
   severity and RANTES with mild disease
SO JCI INSIGHT
LA English
DT Article
ID INFLUENZA-VIRUS; CORONAVIRUSES; REPLICATION; PROTECTION; IMMUNITY
AB BACKGROUND. Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation, and drug development. Here, we present a temporal analysis of key immune mediators, cytokines, and chemokines in blood of hospitalized COVID-19 patients from serial sampling and follow-up over 4 weeks.
   METHODS. A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You'an Hospital in China with either mild (53 patients) or severe (18 patients) disease were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines, and chemokines in peripheral blood every 4-7 days over 1 month per patient using a bioplex multiplex immunoassay.
   RESULTS. We found that the chemokine RANTES (CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1 receptor antagonist (IL-1RA), and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF-alpha and GM-CSF showed no significant differences between severe and mild cases.
   CONCLUSION. Together, our data suggest that early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1RA and IL-10 in blood individually and in combination, might be useful prognostic biomarkers to guide treatment strategies.
C1 [Zhao, Yan; Qin, Ling; Li, Kang; Liang, Lianchun; Sun, Jianping; Xu, Bin; Dai, Yanchao; Li, Xuemei; Zhang, Chi; Feng, Yingmei; Li, Ang; Hu, Zhongjie; Xiang, Haiping; Jin, Ronghua; Zhang, Yonghong] Capital Med Univ, Beijing Youan Hosp, 8 Xitoutiao,Youanmenwai St, Beijing 100069, Peoples R China.
   [Zhang, Ping; Knight, Julian C.] Wellcome Ctr Human Genet, Oxford, England.
   [Peng, Yanchun; Ogg, Graham; Ho, Ling-Pei; McMichael, Andrew; Knight, Julian C.; Dong, Tao; Zhang, Yonghong] Chinese Acad Med Sci Oxford Inst COI, Oxford, England.
   [Peng, Yanchun; Ogg, Graham; Ho, Ling-Pei; Dong, Tao] Univ Oxford, MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
RP Zhang, YH (corresponding author), Capital Med Univ, Beijing Youan Hosp, 8 Xitoutiao,Youanmenwai St, Beijing 100069, Peoples R China.; Dong, T (corresponding author), JR Hosp, MRC Weatheral Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
EM tao.dong@imm.ox.ac.uk; 13810108505@163.com
FU National Key R&D Program of China [2020YFE0202400]; Beijing Natural
   Science FoundationBeijing Natural Science Foundation [7191004, 7202069];
   Beijing Municipal Science & Technology CommissionBeijing Municipal
   Science & Technology Commission [Z171100001017078]; Beijing municipal
   administration of hospitals [DFL20181701, ZYLX201711]; Beijing Key
   Laboratory [BZ0373]; Chinese Academy of Medical Sciences Innovation Fund
   for Medical Sciences (CIFMS), China [2018-I2M-2-002]; Medical Research
   Council (MRC), UKMedical Research Council UK (MRC) [MR/L018942/1];
   Medical Research Council (MRC), UK (MRC Human Immunology Unit
   Core)Medical Research Council UK (MRC); Nuffield Department of Medicine,
   Oxford University; Wellcome Trust Investigator AwardWellcome Trust
   [204969/Z/16/Z]; NIHR Oxford Biomedical Research CentreNational
   Institute for Health Research (NIHR)
FX This work was supported by the National Key R&D Program of China
   (2020YFE0202400), Beijing Natural Science Foundation (7191004 and
   7202069), Beijing Municipal Science & Technology Commission
   (Z171100001017078), Beijing municipal administration of hospitals
   (DFL20181701 and ZYLX201711), Beijing Key Laboratory (BZ0373), and
   Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
   (CIFMS), China (2018-I2M-2-002). TD is supported by Medical Research
   Council (MRC), UK (MR/L018942/1 and MRC Human Immunology Unit Core), and
   Nuffield Department of Medicine, Oxford University. JCK is supported by
   a Wellcome Trust Investigator Award (204969/Z/16/Z). JCK, LPH, and GO
   are, in part, supported by the NIHR Oxford Biomedical Research Centre.
   We would like acknowledge Richard Newman and Lucy Li for reading through
   the manuscript and for providing very helpful comments and suggestions.
CR Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27
   Benedict CA, 2003, CYTOKINE GROWTH F R, V14, P349, DOI 10.1016/S1359-6101(03)00030-3
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Cole SL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91868
   Commission CNH, 2020, NEW COR PNEUM DIAGN
   Crawford A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002098
   Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hayney MS, 2017, J CLIN VIROL, V90, P32, DOI 10.1016/j.jcv.2017.03.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu YX, 2020, NATL SCI REV, V7, P1003, DOI 10.1093/nsr/nwaa037
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Oleksowicz Leslie, 1994, Am J Ther, V1, P107, DOI 10.1097/00045391-199408000-00002
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843
   WHO, COR DIS COVID 19 PAN
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2433
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 8
Z9 8
U1 0
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JUL 9
PY 2020
VL 5
IS 13
AR e139834
DI 10.1172/jci.insight.139834
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NN5BS
UT WOS:000568804600001
PM 32501293
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU McKay, PF
   Hu, K
   Blakney, AK
   Samnuan, K
   Brown, JC
   Penn, R
   Zhou, J
   Bouton, CR
   Rogers, P
   Polra, K
   Lin, PJC
   Barbosa, C
   Tam, YK
   Barclay, WS
   Shattock, RJ
AF McKay, Paul F.
   Hu, Kai
   Blakney, Anna K.
   Samnuan, Karnyart
   Brown, Jonathan C.
   Penn, Rebecca
   Zhou, Jie
   Bouton, Clement R.
   Rogers, Paul
   Polra, Krunal
   Lin, Paulo J. C.
   Barbosa, Christopher
   Tam, Ying K.
   Barclay, Wendy S.
   Shattock, Robin J.
TI Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate
   induces high neutralizing antibody titers in mice
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CORONAVIRUS; DELIVERY
AB The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle (LNP) as a vaccine. We observe remarkably high and dose-dependent SARS-CoV-2 specific antibody titers in mouse sera, as well as robust neutralization of both a pseudo-virus and wild-type virus. Upon further characterization we find that the neutralization is proportional to the quantity of specific IgG and of higher magnitude than recovered COVID-19 patients. saRNA LNP immunizations induce a Th1-biased response in mice, and there is no antibody-dependent enhancement (ADE) observed. Finally, we observe high cellular responses, as characterized by IFN-gamma production, upon re-stimulation with SARS-CoV-2 peptides. These data provide insight into the vaccine design and evaluation of immunogenicity to enable rapid translation to the clinic. Here, the authors develop a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle as a vaccine candidate and show induction of neutralization antibody titers in mice that are comparable to titers in convalescent sera of patients.
C1 [McKay, Paul F.; Hu, Kai; Blakney, Anna K.; Samnuan, Karnyart; Brown, Jonathan C.; Penn, Rebecca; Zhou, Jie; Bouton, Clement R.; Rogers, Paul; Polra, Krunal; Barclay, Wendy S.; Shattock, Robin J.] Imperial Coll London, Dept Infect Dis, Norfolk Pl, London W2 1PG, England.
   [Lin, Paulo J. C.; Barbosa, Christopher; Tam, Ying K.] Acuitas Therapeut, Vancouver, BC V6T 1Z3, Canada.
RP Shattock, RJ (corresponding author), Imperial Coll London, Dept Infect Dis, Norfolk Pl, London W2 1PG, England.
EM r.shattock@imperial.ac.uk
OI Brown, Jonathan/0000-0001-6849-3962; Barclay, Wendy/0000-0002-3948-0895;
   Blakney, Anna/0000-0002-5812-9689; Rogers, Paul/0000-0002-3945-7708;
   McKay, Paul/0000-0001-5195-6254; Bouton, Clement/0000-0001-9607-6533
FU Marie Skodowska Curie Individual Fellowship - European Commission H2020
   [794059]; Department of Health and Social Care; Engineering and Physical
   Sciences Research Council (EPSRC)Engineering & Physical Sciences
   Research Council (EPSRC) [EP/R013764/1]; NIHR Biomedical Research Centre
   of Imperial College Healthcare NHS Trust; Dormeur Investment Services
   Ltd
FX We gratefully acknowledge Graham Taylor, Graham Cooke, Rachael Quinlan,
   Charlotte Short, and Carolina Rosadas de Oliveira for providing the
   samples from recovered COVID-19 patients, and Jonathan Yeow for
   providing the polymers used in these studies. We thank Andrew Davidson
   and David Matthews, University of Bristol UK for supplying the VeroE6
   cells used in this study. AKB is supported by a Marie Skodowska Curie
   Individual Fellowship funded by the European Commission H2020 (No.
   794059). P.F.M., K.H., K.S., C.R.B., K.P., P.R. and R.J.S. are funded by
   the Department of Health and Social Care using UK Aid funding and is
   managed by the Engineering and Physical Sciences Research Council
   (EPSRC, grant number: EP/R013764/1, note: the views expressed in this
   publication are those of the author(s) and not necessarily those of the
   Department of Health and Social Care). This work was supported in part
   by the NIHR Biomedical Research Centre of Imperial College Healthcare
   NHS Trust. We also acknowledge Dormeur Investment Services Ltd for
   providing funds to purchase equipment used in these studies.
CR Al-Omari A, 2019, DIAGN MICR INFEC DIS, V93, P265, DOI 10.1016/j.diagmicrobio.2018.10.011
   Badamchi-Zadeh A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141209
   Blakney AK, 2020, ACS NANO, V14, P5711, DOI 10.1021/acsnano.0c00326
   Blakney AK, 2019, GENE THER, V26, P363, DOI 10.1038/s41434-019-0095-2
   Branca MA, 2018, NAT BIOTECHNOL, V36, P772, DOI 10.1038/nbt0818-772c
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Hu K, 2013, J IMMUNOL, V191, P1935, DOI 10.4049/jimmunol.1300120
   Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124
   Organization W. H., 2020, GLOB COVID 19 STAT
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wright E, 2008, J GEN VIROL, V89, P2204, DOI 10.1099/vir.0.2008/000349-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 22
TC 9
Z9 9
U1 12
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 9
PY 2020
VL 11
IS 1
AR 3523
DI 10.1038/s41467-020-17409-9
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MY8PY
UT WOS:000558681600002
PM 32647131
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chae, SH
   Kim, Y
   Lee, KS
   Park, HS
AF Chae, Sang Hoon
   Kim, Yushin
   Lee, Kyoung-Soub
   Park, Hyung-Soon
TI Development and Clinical Evaluation of a Web-Based Upper Limb Home
   Rehabilitation System Using a Smartwatch and Machine Learning Model for
   Chronic Stroke Survivors: Prospective Comparative Study
SO JMIR MHEALTH AND UHEALTH
LA English
DT Article
DE home-based rehabilitation; artificial intelligence; machine learning;
   wearable device; smartwatch; chronic stroke
ID RANDOMIZED CONTROLLED-TRIAL; THERAPY; RECOGNITION; DEPRESSION; SYMPTOMS;
   SHOULDER; EXERCISE; IMPACT; RISK
AB Background: Recent advancements in wearable sensor technology have shown the feasibility of remote physical therapy at home. In particular, the current COVID-19 pandemic has revealed the need and opportunity of internet-based wearable technology in future health care systems. Previous research has shown the feasibility of human activity recognition technologies for monitoring rehabilitation activities in home environments; however, few comprehensive studies ranging from development to clinical evaluation exist.
   Objective: This study aimed to (1) develop a home-based rehabilitation (HBR) system that can recognize and record the type and frequency of rehabilitation exercises conducted by the user using a smartwatch and smartphone app equipped with a machine learning (ML) algorithm and (2) evaluate the efficacy of the home-based rehabilitation system through a prospective comparative study with chronic stroke survivors.
   Methods: The HBR system involves an off-the-shelf smartwatch, a smartphone, and custom-developed apps. A convolutional neural network was used to train the ML algorithm for detecting home exercises. To determine the most accurate way for detecting the type of home exercise, we compared accuracy results with the data sets of personal or total data and accelerometer, gyroscope, or accelerometer combined with gyroscope data. From March 2018 to February 2019, we conducted a clinical study with two groups of stroke survivors. In total, 17 and 6 participants were enrolled for statistical analysis in the HBR group and control group, respectively. To measure clinical outcomes, we performed the Wolf Motor Function Test (WMFT), Fugl-Meyer Assessment of Upper Extremity, grip power test, Beck Depression Inventory, and range of motion (ROM) assessment of the shoulder joint at 0, 6, and 12 months, and at a follow-up assessment 6 weeks after retrieving the HBR system.
   Results: The ML model created with personal data involving accelerometer combined with gyroscope data (5590/5601, 99.80%) was the most accurate compared with accelerometer (5496/5601, 98.13%) or gyroscope data (5381/5601, 96.07%). In the comparative study, the drop-out rates in the control and HBR groups were 40% (4/10) and 22% (5/22) at 12 weeks and 100% (10/10) and 45% (10/22) at 18 weeks, respectively. The HBR group (n=17) showed a significant improvement in the mean WMFT score (P=.02) and ROM of flexion (P=.004) and internal rotation (P=.001). The control group (n=6) showed a significant change only in shoulder internal rotation (P=.03).
   Conclusions: This study found that a home care system using a commercial smartwatch and ML model can facilitate participation in home training and improve the functional score of the WMFT and shoulder ROM of flexion and internal rotation in the treatment of patients with chronic stroke. This strategy can possibly be a cost-effective tool for the home care treatment of stroke survivors in the future.
C1 [Chae, Sang Hoon; Park, Hyung-Soon] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea.
   [Kim, Yushin] Cheongju Univ, Major Sports Hlth Rehabil, Cheongju, South Korea.
   [Lee, Kyoung-Soub; Park, Hyung-Soon] Korea Adv Inst Sci & Technol, Dept Mech Engn, 291 Daehak Ro, Daejeon 34141, South Korea.
RP Park, HS (corresponding author), Korea Adv Inst Sci & Technol, Dept Mech Engn, 291 Daehak Ro, Daejeon 34141, South Korea.
EM hyungspark@kaist.ac.kr
RI Park, Hyung-Soon/B-3334-2010
OI Park, Hyung-Soon/0000-0003-4274-7420; Lee,
   Kyoung-Soub/0000-0003-3690-5269; Chae, Sang-Hoon/0000-0002-7143-5074
FU Korea Advanced Institute of Science and Technology-funded Global
   Singularity Research Program
FX This paper is based on research that has been conducted as part of the
   Korea Advanced Institute of Science and Technology-funded Global
   Singularity Research Program (2020).
CR Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031
   Bort-Roig J, 2014, SPORTS MED, V44, P671, DOI 10.1007/s40279-014-0142-5
   Boysen G, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2810
   Cameron JI, 2011, STROKE, V42, P302, DOI 10.1161/STROKEAHA.110.597963
   Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001
   Chaiyawat P, 2012, PSYCHOGERIATRICS, V12, P193, DOI 10.1111/j.1479-8301.2012.00412.x
   Chen PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216357
   Chen YR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/183624
   Denno MS, 2013, ARCH PHYS MED REHAB, V94, P1731, DOI 10.1016/j.apmr.2013.03.014
   Dobkin BH, 2017, NEUROREHAB NEURAL RE, V31, P217, DOI 10.1177/1545968316680490
   Fisher RJ, 2011, STROKE, V42, P1392, DOI 10.1161/STROKEAHA.110.606285
   Hiengkaew V, 2016, HOME HLTH CARE MAN P, V28, P209, DOI 10.1177/1084822316630278
   Holden A, 2015, BRIT HCI 2015 2015 B
   Hsieh YW, 2018, ARCH PHYS MED REHAB, V99, P2399, DOI 10.1016/j.apmr.2018.03.017
   Huynh QT, 2015, J SENSORS, V2015, DOI 10.1155/2015/452078
   Johansson T, 2011, J TELEMED TELECARE, V17, P1, DOI 10.1258/jtt.2010.100105
   Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI 10.1016/S1474-4422(19)30034-1
   Kim Y, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4738
   Krishnan NC, 2014, PERVASIVE MOB COMPUT, V10, P138, DOI 10.1016/j.pmcj.2012.07.003
   Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD
   Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x
   Lee KS, 2019, 2019 IEEE 16 INT C R
   Legg L, 2004, LANCET, V363, P352
   Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341
   Maglaveras N, 2003, AMIA Annu Symp Proc, P415
   Margarito J, 2016, IEEE T BIO-MED ENG, V63, P788, DOI 10.1109/TBME.2015.2471094
   Markopoulos P, 2011, IEEE ENG MED BIO, P5182, DOI 10.1109/IEMBS.2011.6091283
   Marshall IJ, 2015, LANCET NEUROL, V14, P1206, DOI 10.1016/S1474-4422(15)00200-8
   Miyoshi H, 2015, 6 EUR C INT FED MED, P661, DOI 10.1007%2F978-3-319-11128-5_165#citeas
   Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615
   Mortazavi B, 2014, 2014 11TH INTERNATIONAL CONFERENCE ON WEARABLE AND IMPLANTABLE BODY SENSOR NETWORKS (BSN), P33, DOI 10.1109/BSN.2014.21
   Ordonez FJ, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16010115
   Patrick H, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-18
   Psychoula Ismini, 2018, 2018 IEEE International Conference on Pervasive Computing and Communications Workshops (PerCom Workshops), P710, DOI 10.1109/PERCOMW.2018.8480247
   Rajsic S, 2019, EUR J HEALTH ECON, V20, P107, DOI 10.1007/s10198-018-0984-0
   Ramezani R, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/14090
   Rastogi V, 2018, CLIN MED RES, V16, P16, DOI 10.3121/cmr.2017.1379a
   Reeder B, 2016, J BIOMED INFORM, V63, P269, DOI 10.1016/j.jbi.2016.09.001
   Sackley C, 2008, STROKE, V39, P3329, DOI 10.1161/STROKEAHA.108.518563
   Sin H, 2013, AM J PHYS MED REHAB, V92, P871, DOI 10.1097/PHM.0b013e3182a38e40
   Singh D, 2017, LECT NOTES COMPUT SC, V10410, P267, DOI 10.1007/978-3-319-66808-6_18
   Swayne OBC, 2008, CEREB CORTEX, V18, P1909, DOI 10.1093/cercor/bhm218
   Thorsen AM, 2005, STROKE, V36, P297, DOI 10.1161/01.STR.0000152288.42701.a6
   Visser-Meily A, 2008, PATIENT EDUC COUNS, V73, P153, DOI 10.1016/j.pec.2008.03.011
   Wade D, 2016, CLIN REHABIL, V30, P109, DOI 10.1177/0269215515601177
   Wang Q, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0229-y
   Webster D, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-108
   Weiss G, 2016, 2016 IEEE EMBS INT C
   Wenderoth N., 2004, NEUROBEHAVIORAL DETE
   Wilkins KB, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00284
   Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635
NR 51
TC 0
Z9 0
U1 10
U2 11
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2291-5222
J9 JMIR MHEALTH UHEALTH
JI JMIR mHealth uHealth
PD JUL 9
PY 2020
VL 8
IS 7
AR e17216
DI 10.2196/17216
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA MU8FP
UT WOS:000555903500001
PM 32480361
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, YH
   Zeng, T
   Chen, L
   Ding, SJ
   Huang, T
   Cai, YD
AF Zhang, YuHang
   Zeng, Tao
   Chen, Lei
   Ding, ShiJian
   Huang, Tao
   Cai, Yu-Dong
TI Identification of COVID-19 Infection-Related Human Genes Based on a
   Random Walk Model in a Virus-Human Protein Interaction Network
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID DEPENDENT RNA-POLYMERASE; CORONAVIRUS; SARS; MERS; TRANSMISSION; COMPLEX
AB Coronaviruses are specific crown-shaped viruses that were first identified in the 1960s, and three typical examples of the most recent coronavirus disease outbreaks include severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19. Particularly, COVID-19 is currently causing a worldwide pandemic, threatening the health of human beings globally. The identification of viral pathogenic mechanisms is important for further developing effective drugs and targeted clinical treatment methods. The delayed revelation of viral infectious mechanisms is currently one of the technical obstacles in the prevention and treatment of infectious diseases. In this study, we proposed a random walk model to identify the potential pathological mechanisms of COVID-19 on a virus-human protein interaction network, and we effectively identified a group of proteins that have already been determined to be potentially important for COVID-19 infection and for similar SARS infections, which help further developing drugs and targeted therapeutic methods against COVID-19. Moreover, we constructed a standard computational workflow for predicting the pathological biomarkers and related pharmacological targets of infectious diseases.
C1 [Zhang, YuHang; Ding, ShiJian; Cai, Yu-Dong] Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China.
   [Zhang, YuHang; Huang, Tao] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, Shanghai 200031, Peoples R China.
   [Zeng, Tao] Chinese Acad Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai 200031, Peoples R China.
   [Chen, Lei] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China.
RP Cai, YD (corresponding author), Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China.; Huang, T (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth, Shanghai 200031, Peoples R China.
EM zhangyh825@163.com; zengtao@sibs.ac.cn; chen_lei1@163.com;
   1727445350@qq.com; tohuangtao@126.com; cai_yud@126.com
RI Zhang, Yu-Hang/O-9774-2015; Zeng, Tao/A-1711-2012; Chen, Lei/A-2275-2011
OI Zhang, Yu-Hang/0000-0003-3825-0796; Zeng, Tao/0000-0002-0295-3994; cai,
   yudong/0000-0001-5664-7979; Chen, Lei/0000-0003-3068-1583
FU Shanghai Municipal Science and Technology Major Project [2017SHZDZX01];
   National Key R&D Program of China [2018YFC0910403]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [31701151]; Natural Science Foundation of ShanghaiNatural Science
   Foundation of Shanghai [17ZR1412500]; Shanghai Sailing Program
   [16YF1413800]; Youth Innovation Promotion Association of Chinese Academy
   of Sciences (CAS) [2016245]
FX This study was supported by the Shanghai Municipal Science and
   Technology Major Project (2017SHZDZX01), the National Key R&D Program of
   China (2018YFC0910403), the National Natural Science Foundation of China
   (31701151), the Natural Science Foundation of Shanghai (17ZR1412500),
   the Shanghai Sailing Program (16YF1413800), and the Youth Innovation
   Promotion Association of Chinese Academy of Sciences (CAS) (2016245).
CR Ahmed T., 2020, CORONAVIRUS DIS 2019
   Al-Khedhairy AAA, 2004, J BIOCHEM MOL BIOL, V37, P144
   Azzi A, 2004, PROTEINS, V57, P12, DOI 10.1002/prot.20194
   Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343
   Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179
   Chen L, 2018, BBA-MOL BASIS DIS, V1864, P2228, DOI 10.1016/j.bbadis.2017.12.019
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   Elliman S. J., 2019, US Patent Application, Patent No. [16/070,202, 16070202]
   Fast E., 2020, POTENTIAL T CELL B C
   Fedrigo O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012545
   Griffith M, 2013, PHARMACOGENOMICS J, V13, P148, DOI 10.1038/tpj.2011.65
   Groneberg DA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kohler S, 2008, AM J HUM GENET, V82, P949, DOI 10.1016/j.ajhg.2008.02.013
   Kuwabara N, 2015, J BIOL CHEM, V290, P9387, DOI 10.1074/jbc.M114.631804
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang HY, 2020, COMPUT MATH METHOD M, V2020, DOI 10.1155/2020/1573543
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   MAHY BWJ, 1983, J GEN VIROL, V64, P103, DOI 10.1099/0022-1317-64-1-103
   Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342
   Misawa A, 2017, CANCER SCI, V108, P373, DOI 10.1111/cas.13151
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Munir S, 2015, MOL IMMUNOL, V64, P190, DOI 10.1016/j.molimm.2014.11.015
   Park JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5484-8
   Peng K, 2020, OSTEOPOROSIS INT, V31, P1545, DOI 10.1007/s00198-020-05393-1
   Ramaiah A., 2016, DYSREGULATION LONG N
   Saha S, 2006, J GEN VIROL, V87, P1991, DOI 10.1099/vir.0.81768-0
   SCHWENGER B, 1993, GENOMICS, V16, P241, DOI 10.1006/geno.1993.1165
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   Skowronski DA, 2005, ANNU REV MED, V56, P357, DOI 10.1146/annurev.med.56.091103.134135
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tani H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181628
   TANNOCK GA, 1978, J GEN VIROL, V39, P29, DOI 10.1099/0022-1317-39-1-29
   Vekariya U, 2018, LIFE SCI, V214, P158, DOI 10.1016/j.lfs.2018.10.068
   Wandtke T, 2017, J ED HLTH SPORT, V7, P607
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289
   Xiao Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03986-1
   Xu Y, 2012, CELL REP, V2, P1633, DOI 10.1016/j.celrep.2012.11.010
   Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu XT, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2188-7
   Yuan F, 2018, BBA-MOL BASIS DIS, V1864, P2284, DOI 10.1016/j.bbadis.2017.11.018
   Zhang J, 2018, BBA-MOL BASIS DIS, V1864, P2369, DOI 10.1016/j.bbadis.2017.11.017
   Zhang N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/239462
   Zhang YH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177017
   Zhou SM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0544-9
NR 53
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUL 9
PY 2020
VL 2020
AR 4256301
DI 10.1155/2020/4256301
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA MT5TP
UT WOS:000555037800005
PM 32685484
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chitranshi, N
   Gupta, VK
   Rajput, R
   Godinez, A
   Pushpitha, K
   Shen, T
   Mirzaei, M
   You, YY
   Basavarajappa, D
   Gupta, V
   Graham, SL
AF Chitranshi, Nitin
   Gupta, Vivek K.
   Rajput, Rashi
   Godinez, Angela
   Pushpitha, Kanishka
   Shen, Ting
   Mirzaei, Mehdi
   You, Yuyi
   Basavarajappa, Devaraj
   Gupta, Veer
   Graham, Stuart L.
TI Evolving geographic diversity in SARS-CoV2 and in silico analysis of
   replicating enzyme 3CL(pro)targeting repurposed drug candidates
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; SARS-CORONAVIRUS; INTERACTIVE TREE;
   MOLECULAR-INTERACTIONS; ONLINE TOOL; LIFE ITOL; INHIBITOR; DISPLAY;
   ANNOTATION; PROTEINASE
AB Background Severe acute respiratory syndrome (SARS) has been initiating pandemics since the beginning of the century. In December 2019, the world was hit again by a devastating SARS episode that has so far infected almost four million individuals worldwide, with over 200,000 fatalities having already occurred by mid-April 2020, and the infection rate continues to grow exponentially. SARS coronavirus 2 (SARS-CoV-2) is a single stranded RNA pathogen which is characterised by a high mutation rate. It is vital to explore the mutagenic capability of the viral genome that enables SARS-CoV-2 to rapidly jump from one host immunity to another and adapt to the genetic pool of local populations. Methods For this study, we analysed 2301 complete viral sequences reported from SARS-CoV-2 infected patients. SARS-CoV-2 host genomes were collected from The Global Initiative on Sharing All Influenza Data (GISAID) database containing 9 genomes from pangolin-CoV origin and 3 genomes from bat-CoV origin, Wuhan SARS-CoV2 reference genome was collected from GeneBank database. The Multiple sequence alignment tool, Clustal Omega was used for genomic sequence alignment. The viral replicating enzyme, 3-chymotrypsin-like cysteine protease (3CL(pro)) that plays a key role in its pathogenicity was used to assess its affinity with pharmacological inhibitors and repurposed drugs such as anti-viral flavones, biflavanoids, anti-malarial drugs and vitamin supplements. Results Our results demonstrate that bat-CoV shares > 96% similar identity, while pangolin-CoV shares 85.98% identity with Wuhan SARS-CoV-2 genome. This in-depth analysis has identified 12 novel recurrent mutations in South American and African viral genomes out of which 3 were unique in South America, 4 unique in Africa and 5 were present in-patient isolates from both populations. Using state of the art in silico approaches, this study further investigates the interaction of repurposed drugs with the SARS-CoV-2 3CL(pro)enzyme, which regulates viral replication machinery. Conclusions Overall, this study provides insights into the evolving mutations, with implications to understand viral pathogenicity and possible new strategies for repurposing compounds to combat the nCovid-19 pandemic.
C1 [Chitranshi, Nitin; Gupta, Vivek K.; Rajput, Rashi; Godinez, Angela; Pushpitha, Kanishka; Shen, Ting; Mirzaei, Mehdi; You, Yuyi; Basavarajappa, Devaraj; Graham, Stuart L.] Macquarie Univ, Fac Med Hlth & Human Sci, F10A,2 Technol Pl, N Ryde, NSW 2109, Australia.
   [Mirzaei, Mehdi] Macquarie Univ, Australian Proteome Anal Facil, N Ryde, NSW 2109, Australia.
   [Gupta, Veer] Deakin Univ, Sch Med, Melbourne, Vic, Australia.
   [Graham, Stuart L.] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
RP Chitranshi, N; Gupta, VK (corresponding author), Macquarie Univ, Fac Med Hlth & Human Sci, F10A,2 Technol Pl, N Ryde, NSW 2109, Australia.
EM nitin.chitranshi@mq.edu.au; vivek.gupta@mq.edu.au
OI Mirzaei, Mehdi/0000-0001-8727-4984; Gupta, Vivek/0000-0002-0202-7843;
   Chitranshi, Nitin/0000-0002-6508-9865; Shen, Ting/0000-0002-0057-232X;
   Graham, Stuart/0000-0001-7519-969X; Basavarajappa,
   Devaraj/0000-0003-0997-0196
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Basavarajappa DK, 2011, MOL CELL BIOL, V31, P3975, DOI 10.1128/MCB.05659-11
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao B, 2020, NEW ENGL J MED, V382
   Chitranshi N, 2019, J CELL BIOCHEM, V120, P11745, DOI 10.1002/jcb.28455
   Chitranshi N, 2017, GENE REP, V6, P142, DOI 10.1016/j.genrep.2016.08.008
   Chitranshi N, 2013, FUTUR NEUROL, V8, P469, DOI 10.2217/FNL.13.26
   Chitranshi N, 2016, DATA BRIEF, V6, P776, DOI 10.1016/j.dib.2016.01.016
   Chitranshi N, 2015, INT J MOL SCI, V16, P21087, DOI 10.3390/ijms160921087
   Chitranshi N, 2013, MED CHEM RES, V22, P2328, DOI 10.1007/s00044-012-0227-3
   Conti P, 2020, J BIOL REGUL HOMEOST, V34, P2, DOI DOI 10.23812/EDIT0RIAL-C0NTI-2
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   de Haan CAM, 1999, J VIROL, V73, P7441, DOI 10.1128/JVI.73.9.7441-7452.1999
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Eurosurveillance Editorial T, 2020, EURO SURVEILL, V25, p200131e
   Gadlage MJ, 2010, J VIROL, V84, P6894, DOI 10.1128/JVI.00752-10
   Giacomelli A, 2020, CLIN INFECT DIS
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gupta V, 2014, BIOCHEM BIOPH RES CO, V454, P381, DOI 10.1016/j.bbrc.2014.10.087
   Gupta VK, 2008, BIOCHIMIE, V90, P749, DOI 10.1016/j.biochi.2008.01.004
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Hung LS, 2003, J ROY SOC MED, V96, P374, DOI 10.1258/jrsm.96.8.374
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Letunic I, 2007, BIOINFORMATICS, V23, P127, DOI 10.1093/bioinformatics/btl529
   Letunic I, 2019, NUCLEIC ACIDS RES, V47, pW256, DOI 10.1093/nar/gkz239
   Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290
   Letunic I, 2011, NUCLEIC ACIDS RES, V39, pW475, DOI 10.1093/nar/gkr201
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Marik PE, 2020, MED DRUG DISCOV, V29
   Marinho PM, 2020, LANCET, V395, P1610, DOI 10.1016/S0140-6736(20)31014-X
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pavone P, 2020, EUR REV MED PHARMACO, V24, P4572, DOI 10.26355/eurrev_202004_21043
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Subramanian S, 2019, PEERJ, V7, DOI 10.7717/peerj.8213
   To KKW, 2013, J THORAC DIS, V5, pS103, DOI 10.3978/j.issn.2072-1439.2013.06.02
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 66
TC 2
Z9 2
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 9
PY 2020
VL 18
IS 1
AR 278
DI 10.1186/s12967-020-02448-z
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MO8LK
UT WOS:000551769900001
PM 32646487
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marschner, S
   Corradini, S
   Rauch, J
   Zacharias, R
   Sujic, A
   Mayerle, J
   Petru, R
   Grabein, B
   Keppler, OT
   Boelke, E
   Belka, C
   Niyazi, M
AF Marschner, Sebastian
   Corradini, Stefanie
   Rauch, Josefine
   Zacharias, Richard
   Sujic, Ana
   Mayerle, Julia
   Petru, Raluca
   Grabein, Beatrice
   Keppler, Oliver T.
   Boelke, Edwin
   Belka, Claus
   Niyazi, Maximilian
TI SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and
   consequences for clinical routine
SO RADIATION ONCOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Coronavirus; Radiation oncology; Radiotherapy;
   Screening; PCR
ID COVID-19; ONCOLOGY
AB BackgroundStarting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase chain reaction) testing becomes a crucial pillar of medical systems. Aim of the present study was to report on the first results of the measures taken in a large German Department of Radiation Oncology, including PCR testing of asymptomatic cancer patients.MethodsPandemic-adapted hygiene regulations and prevention measures for patients and staff were implemented. A visiting ban on both wards was implemented from the beginning and medical staff and patients were required to wear face masks at all times. The waiting rooms were rearranged to ensure distance between patients of at least 1.5m. Clinical follow up was mainly done by telephone and all patients had to complete a questionnaire regarding symptoms and contacts with COVID-19 patients before entering our department. Educational documents were created for patients to raise awareness of symptoms and avoidance strategies for interactions with other people. Indications for therapy and fractionation schemes were adapted when possible. In a subsequent step, all new asymptomatic patients were tested via nasopharyngeal swab at our screening station shortly before their simulation CT.ResultsAll these measures and implementations have been well accepted semiquantitatively measured by the consent received from patients and staff. Regarding the PCR testing, only 1 out of 139 asymptomatic patients of our cohort so far tested positive for SARS-CoV-2, reflecting a prevalence of 0.72% in this cancer patient population. Up to this point no staff members was tested positive. The start of the treatment for the PCR-positive patient was deferred for 2 weeks.ConclusionDue to the pandemic-adapted implementations, our department seems well prepared during this crisis. The initial screening helps to identify asymptomatic COVID-19 patients in order to protect other patients and our staff from infection and the observed PCR prevalence is in line with comparable studies. A regular PCR testing (e.g. twice a week) of all patients and staff would in principle be desirable but is limited due to testing capacities at present.
C1 [Marschner, Sebastian; Corradini, Stefanie; Rauch, Josefine; Zacharias, Richard; Sujic, Ana; Belka, Claus; Niyazi, Maximilian] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany.
   [Marschner, Sebastian; Belka, Claus; Niyazi, Maximilian] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany.
   [Mayerle, Julia] Ludwig Maximilians Univ Munchen, Dept Internal Med 2, Univ Hosp, Munich, Germany.
   [Petru, Raluca] LMU Univ Hosp, WHO Collaborating Ctr Occupat Hlth, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany.
   [Petru, Raluca] LMU Univ Hosp, Occupat Med Ctr, Munich, Germany.
   [Grabein, Beatrice] Ludwig Maximilians Univ Munchen, Dept Clin Microbiol & Hosp Hyg, Univ Hosp, Munich, Germany.
   [Keppler, Oliver T.] Ludwig Maximilians Univ Munchen, Max von Pettenkofer Inst, Fac Med, Virol, D-80336 Munich, Germany.
   [Boelke, Edwin] Heinrich Heine Univ Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany.
RP Niyazi, M (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany.; Niyazi, M (corresponding author), German Canc Consortium DKTK, Partner Site Munich, Munich, Germany.
EM Maximilian.niyazi@med.uni-muenchen.de
CR American Society of Clinical Oncology (ASCO), 2020, COVID 19 PAT CAR INF
   [Anonymous], 2020, INF RAT MUN
   [Anonymous], 2020, COVID 19 FAQS
   [Anonymous], 2020, DEGRO COVID 19
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Baumann M, 2020, RADIOTHER ONCOL, V146, P221, DOI 10.1016/j.radonc.2020.04.043
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Combs SE, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01527-1
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Go YY, 2020, ELSEVIER HAS CREATED
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang C, 2019, LANCET, V2020, P395
   Kolifarhood G, 2020, ARCH ACAD EMERG MED, V8
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   M C, 2020, FEAT EV TREATM COR C, P1
   Ma XT, 2020, CELL ONCOL, V43, P751, DOI 10.1007/s13402-020-00512-w
   Madjid M, 2020, JAMA CARDIOL, V10, P1
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Miura F, 2018, J EPIDEMIOL, V28, P382, DOI 10.2188/jea.JE20170040
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Mizumoto K, 2018, EUROSURVEILLANCE, V23, P8, DOI 10.2807/1560-7917.ES.2018.23.24.1800239
   Ning MS, 2020, RADIOTHER ONCOL, V148, P252, DOI 10.1016/j.radonc.2020.05.037
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Simcock R, 2020, CLIN TRANSL RAD ONCO
   Slotman BJ, 2020, RADIOTHERAPY TIME CR
   Streeck H, 2020, INFECT FATALITY RATE, DOI [10.1101/2020.05.04.20090076v2, DOI 10.1101/2020.05.04.20090076V2]
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, REP WHO CHIN JOINT M
   World Health Organization, 2020, WHO COR DIS COVID 19
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P10239
   Yam WC, 2003, J CLIN MICROBIOL, V41, P4521, DOI 10.1128/JCM.41.10.4521-4524.2003
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493v2, DOI 10.1101/2020.02.11.20021493V2]
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao S, 2020, COVID 19 RESOURCE CT
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   2015, METHOD MOL BIOL, V1282, P1, DOI DOI 10.1007/978-1-4939-2438-7_1
NR 46
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1748-717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD JUL 9
PY 2020
VL 15
IS 1
AR 165
DI 10.1186/s13014-020-01609-0
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MP2RA
UT WOS:000552055100001
PM 32646505
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saiz-Rodriguez, M
   Pena, T
   Lazaro, L
   Gonzalez, A
   Martinez, A
   Cordero, JA
   Vicente, JT
   Richard, F
   Coma, MJ
   de Frutos, M
   Labrador, J
   Pueyo, A
AF Saiz-Rodriguez, Miriam
   Pena, Teresa
   Lazaro, Lourdes
   Gonzalez, Angel
   Martinez, Andres
   Cordero, Jose A.
   Vicente, Juan T.
   Richard, Fernando
   Coma, Maria Jesus
   de Frutos, Martin
   Labrador, Jorge
   Pueyo, Ana
TI Outpatient treatment of COVID-19 with steroids in the phase of mild
   pneumonia without the need for admission as an opportunity to modify the
   course of the disease: A structured summary of a randomised controlled
   trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; Protocol; Early pulmonary;
   Prednisone; Outpatients
AB Objectives: The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission criteria.
   Trial design: Randomized clinical trial, controlled, open, parallel group, to evaluate the effectiveness of steroids in adult patients with confirmed COVID-19, with incipient pulmonary involvement, without hospital admission criteria. Patients will be stratified by the presence or not of radiological data on pneumonia.
   Participants: We will include patients with early stage SARS-Cov-2 pneumonia who do not meet hospital admission criteria from the reference hospital, the Hospital Universitario de Burgos, in the region of Castilla y Leon, Spain. Patients will be followed-up by specialist physicians and Primary Health Care professionals. Inclusion criteria:
   - Men and women.
   - Age between 18 and 75 years old.
   - Diagnosed SARS-CoV-2 infection, by PCR and/or IgM+ antibody test and/or antigen test. - Clinical diagnosis of lung involvement: (respiratory symptoms +/- pathological auscultation +/- O2 desaturation)
   - Chest X-ray with mild-moderate alterations or normal.
   - Patients who give their verbal informed consent in front of witnesses, which will be reflected in the patients' medical records.
   Exclusion criteria:
   - Oxygen desaturation below 93% or P0(2)< 62.
   - Moderate-severe dyspnea or significant respiratory or general deterioration that makes admission advisable.
   - Chest X-ray with multifocal infiltrates.
   - Insulin-dependent diabetes with poor control or glycaemia in the emergency room test greater than 300 mg/ml (fasting or not).
   - Other significant comorbidities: Severe renal failure (creatinine clearance < 30 mL/min); cirrhosis or chronic liver disease, poorly controlled hypertension.
   - Heart rhythm disturbances (including prolonged QT).
   - Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents); cancer. - Pregnant or breast-feeding women.
   - Patients under use of glucocorticoids for other diseases.
   - History of allergy or intolerance to any of the drugs in the study (prednisone, azithromycin or hydroxychloroquine).
   - Patients who took one or more of the study drugs in the 7 days prior to study inclusion.
   - Patients taking non-suppressible drugs with risk of QT prolongation or significant interactions.
   - Patients unwilling or unable to participate until study completion.
   - Participation in another study.
   Intervention and comparator: Eligible patients will be randomized to receive standard outpatient treatment only (group 1) or standard outpatient treatment plus prednisone (group 2).
   - Group 1: paracetamol 1 g/8 h (on demand) + hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days.
   - Group 2: paracetamol 1 g/8 h (on demand) + hydroxychloroquine 400 mg/12h the first day, 200 mg/12 h for 4 days + azithromycin 500 mg/24h for 5 days + prednisone 60 mg / 24 h for 3 days, 30 mg / 24 h for 3 days and 15 mg / 24 h for 3 days. Main outcomes
   If the patient requires ambulatory observation, according to the protocol established in this respect in the Emergency Department, meets all the criteria for inclusion and none for exclusion, data will be taken by the person responsible on the data collection sheet. The main result is admission after 30 days. Secondary outcomes are 30-day ICU admission and hospital stay. The safety variable will be the occurrence of clinical symptoms or delirium related to the steroids.
   Also, the possible decompensations of diabetes will be measured. All tests will be on an intention-to-treat basis.
   Randomisation: Treatment will be assigned according to stratified randomization by the presence or absence of radiological data of lung involvement (previously performed by random sequence 1:1 generated with Epidat and kept hidden by opaque, sealed envelopes, which will only be opened after inclusion and basal measurement).
   Blinding (masking): Participants, caregivers and personnel responsible for outcomes measurement will not be blinded to group assignment, once the patient is included and the basal measurement performed, as per protocol design.
   Numbers to be randomised (sample size): The percentage of patients with incipient lung involvement is unknown, but given that pulmonary involvement already exists it is estimated to be around 20%. We consider that the intervention could reduce this percentage to 5%, so the necessary sample size would be 200 subjects (100 per group), with a power of 80% and an estimated loss percentage of 10%.
   Trial Status: The protocol with code TAC-COVID-19, version 2.0 on date: April 16, 2020 is approved by the Spanish Drug Agency (AEMPS) and the local Ethics Committee. The trial is in the recruitment phase. Recruitment began 19 April, 2020 and is anticipated to be complete by April 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Saiz-Rodriguez, Miriam; Coma, Maria Jesus; de Frutos, Martin; Labrador, Jorge] Hosp Univ Burgos, Res Unit, Burgos, Spain.
   [Pena, Teresa; Lazaro, Lourdes; Pueyo, Ana] Hosp Univ Burgos, Neumol Dept, Avda Islas Baleares 3, Burgos, Spain.
   [Gonzalez, Angel; Martinez, Andres] Gerencia Atenc Primaria Burgos, Burgos, Spain.
   [Cordero, Jose A.] Inst Invest Sanitaria Bioaraba, Vitoria, Alava, Spain.
   [Vicente, Juan T.; Richard, Fernando] Hosp Univ Burgos, Emergency Dept, Burgos, Spain.
   [Labrador, Jorge] Hosp Univ Burgos, Hematol Dept, Burgos, Spain.
RP Pueyo, A (corresponding author), Hosp Univ Burgos, Neumol Dept, Avda Islas Baleares 3, Burgos, Spain.
EM pueyo@saludcastillayleon.es
OI Saiz Rodriguez, Miriam/0000-0002-1660-3135
NR 0
TC 0
Z9 0
U1 10
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 9
PY 2020
VL 21
IS 1
AR 632
DI 10.1186/s13063-020-04575-w
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP2ON
UT WOS:000552048600001
PM 32646502
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yan, VC
   Muller, FL
AF Yan, Victoria C.
   Muller, Florian L.
TI Advantages of the Parent Nucleoside GS-441524 over Remdesivir for
   Covid-19 Treatment
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Prodrug; Covid-19; remdesivir; drug delivery; metabolism
ID PRODRUG; VIRUS; GS-5734; EBOLA
AB While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment.
C1 [Yan, Victoria C.; Muller, Florian L.] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77054 USA.
RP Yan, VC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77054 USA.
EM victoriacyanida@gmail.com
OI Yan, Victoria/0000-0003-0837-5184; Muller, Florian/0000-0001-7568-2948
FU American Cancer SocietyAmerican Cancer Society [RSG-15-145-01-CDD]
FX We thank Niels Pedersen, Steve Kirsch, and David PiwnicaWorms for
   helpful discussions, Cong-Dat Pham for assistance with research, and Pat
   Skerrett for assistance with our general audience article published in
   STAT. This work was supported by the American Cancer Society
   (RSG-15-145-01-CDD).
CR Addie D, 2009, J FELINE MED SURG, V11, P594, DOI 10.1016/j.jfms.2009.05.008
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alanazi AS, 2019, ACS MED CHEM LETT, V10, P2, DOI 10.1021/acsmedchemlett.8b00586
   Bahar FG, 2012, J PHARM SCI-US, V101, P3979, DOI 10.1002/jps.23258
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Chou TF, 2007, MOL PHARMACEUT, V4, P208, DOI 10.1021/mp060070y
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cohen E, 2020, CNN
   Cooke A. M., 1963, SECTION MED SECTION, V56
   Dickinson PJ, 2020, J VET INTERN MED, V34, P1587, DOI 10.1111/jvim.15780
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Jarvis L. M., 2020, C EN
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Murakami E, 2014, ANTIMICROB AGENTS CH, V58, P1943, DOI 10.1128/AAC.02350-13
   Murphy BG, 2018, VET MICROBIOL, V219, P226, DOI 10.1016/j.vetmic.2018.04.026
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Pruijssers Andrea J, 2020, bioRxiv, DOI 10.1101/2020.04.27.064279
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Testa B., 2003, HYDROLYSIS DRUG PROD
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Williamson B.N., 2020, BIORXIV
   Williamson BN, 2020, NATURE, DOI 10.1038/s41586-020-2423-5
   Yan V. C., 2020, STAT
   YONG JM, 1967, J CLIN PATHOL, V20, P647, DOI 10.1136/jcp.20.4.647
NR 29
TC 9
Z9 9
U1 5
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUL 9
PY 2020
VL 11
IS 7
BP 1361
EP 1366
DI 10.1021/acsmedchemlett.0c00316
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA MN3TN
UT WOS:000550767000003
PM 32665809
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jiang, RD
   Liu, MQ
   Chen, Y
   Shan, C
   Zhou, YW
   Shen, XR
   Li, Q
   Zhang, L
   Zhu, Y
   Si, HR
   Wang, Q
   Min, J
   Wang, X
   Zhang, W
   Li, B
   Zhang, HJ
   Baric, RS
   Zhou, P
   Yang, XL
   Shi, ZL
AF Jiang, Ren-Di
   Liu, Mei-Qin
   Chen, Ying
   Shan, Chao
   Zhou, Yi-Wu
   Shen, Xu-Rui
   Li, Qian
   Zhang, Lei
   Zhu, Yan
   Si, Hao-Rui
   Wang, Qi
   Min, Juan
   Wang, Xi
   Zhang, Wei
   Li, Bei
   Zhang, Hua-Jun
   Baric, Ralph S.
   Zhou, Peng
   Yang, Xing-Lou
   Shi, Zheng-Li
TI Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human
   Angiotensin-Converting Enzyme 2
SO CELL
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; INFECTION; SARS; PNEUMONIA; MODELS;
   WUHAN; CHINA
AB COVID-19 has spread worldwide since 2019 and is now a severe threat to public health. We previously identified the causative agent as a novel SARS-related coronavirus (SARS-CoV-2) that uses human angiotensin-converting enzyme 2 (hACE2) as the entry receptor. Here, we successfully developed a SARS-CoV-2 hACE2 transgenic mouse (HFH4-hACE2 in C3B6 mice) infection model. The infected mice generated typical interstitial pneumonia and pathology that were similar to those of COVID-19 patients. Viral quantification revealed the lungs as the major site of infection, although viral RNA could also be found in the eye, heart, and brain in some mice. Virus identical to SARS-CoV-2 in full-genome sequences was isolated from the infected lung and brain tissues. Last, we showed that pre-exposure to SARS-CoV-2 could protect mice from severe pneumonia. Our results show that the hACE2 mouse would be a valuable tool for testing potential vaccines and therapeutics.
C1 [Jiang, Ren-Di; Liu, Mei-Qin; Chen, Ying; Shan, Chao; Shen, Xu-Rui; Li, Qian; Zhang, Lei; Zhu, Yan; Si, Hao-Rui; Wang, Qi; Min, Juan; Wang, Xi; Zhang, Wei; Li, Bei; Zhang, Hua-Jun; Zhou, Peng; Yang, Xing-Lou; Shi, Zheng-Li] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, CAS Key Lab Special Pathogens, Wuhan, Hubei, Peoples R China.
   [Jiang, Ren-Di; Liu, Mei-Qin; Chen, Ying; Shen, Xu-Rui; Li, Qian; Si, Hao-Rui; Wang, Xi] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Zhou, Yi-Wu] Huazhong Univ Sci & Technol, Dept Forens Med, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Baric, Ralph S.] Univ N Carolina, Chapel Hill, NC 27515 USA.
RP Yang, XL; Shi, ZL (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, CAS Key Lab Special Pathogens, Wuhan, Hubei, Peoples R China.
EM yangxl@wh.iov.cn; zlshi@wh.iov.cn
RI yang, xinglou/AAW-6969-2020
FU Strategic Priority Research Program of the Chinese Academy of
   SciencesChinese Academy of Sciences [XDB29010101]; China Natural Science
   FoundationNational Natural Science Foundation of China (NSFC)
   [31770175]; Youth innovation promotion association of CAS [2019328]
FX We thank He Zhao and Xue-Fang An from the animal center of the Wuhan
   Institute of Virology for the transgenic mouse breeding. We thank Tao Du
   and Ge Gao from the Center for Biosafety Mega-Science for their
   essential support. We also thank Ding Gao from the core facility of the
   Wuhan Institute of Virology for their technical support. We also thank
   the support of Shenzhen MGI Tech Co., Ltd. for their sequencing service
   using MGISEQ-2000RS FAST platform. This work was jointly supported by
   the Strategic Priority Research Program of the Chinese Academy of
   Sciences (XDB29010101 to Z.-L.S.), China Natural Science Foundation
   (31770175 to Z.-L.S.), and a Youth innovation promotion association of
   CAS (2019328 to X.-L.Y.).
CR Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cockrell AS, 2018, MAMM GENOME, V29, P367, DOI 10.1007/s00335-018-9760-9
   Colavita F, 2020, ANN INTERN MED, V173, P242, DOI 10.7326/M20-1176
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ostrowski LE, 2003, MOL THER, V8, P637, DOI 10.1016/S1525-0016(03)00221-1
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Shantha JG, 2018, EBIOMEDICINE, V30, P217, DOI 10.1016/j.ebiom.2018.03.020
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   ZHENG Y, 2020, ZHONGHUA YU FANG YI, V54, DOI DOI 10.1016/J.YOFTE.2019.102127
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 37
TC 55
Z9 52
U1 26
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUL 9
PY 2020
VL 182
IS 1
BP 50
EP +
DI 10.1016/j.cell.2020.05.027
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA ML0RP
UT WOS:000549184500007
PM 32516571
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Dashti-Khavidaki, S
   Mohammadi, K
   Khalili, H
   Abdollahi, A
AF Dashti-Khavidaki, Simin
   Mohammadi, Keyhan
   Khalili, Hossein
   Abdollahi, Azin
TI Pharmacotherapeutic considerations in solid organ transplant patients
   with COVID-19
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Article
DE Coronavirus disease 2019; COVID-19; drug interaction; solid organ
   transplantation
AB Introduction Coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. While there are presently a few case reports/series on COVID-19 amongst solid organ transplant (SOT) patients, there is no official guideline for the management of SOT patients. Areas covered The authors discuss the pharmacotherapeutic management of SOT patients during the COVID-19 outbreak and provide their expert perspectives. Expert opinion Prophylactic reduction of immunosuppression because of fear of COVID-19 is not suggested in SOT patients. With maintenance immunosuppressive regimens, corticosteroids can be continued during COVID-19. Continuing other immunosuppressive drugs with lowest effective dose/blood concentration is suggested for patients with mild to moderate COVID-19. Discontinuation of antimetabolites and perhaps inhibitors of mammalian target of rapamycin (mTOR) is suggested in moderate to severe COVID-19. Calcineurin inhibitors (CNIs) may be continued or substituted for mTOR inhibitors with lowest therapeutic concentrations in moderate to severe COVID-19. If continued in patients with COVID-19, therapeutic drug monitoring of CNIs/mTOR inhibitors and appropriate dose reduction is recommended in co-administration with protease inhibitors, hydroxychloroquine/chloroquine, or interleukin (IL)-1/IL-6 receptor antagonists. Complete blood count monitoring is recommended in patients who continue taking antimetabolites or mTOR inhibitors. Dose modification/avoidance should be considered for chloroquine, atazanavir, oseltamivir, ribavirin, anakinra, and Janus associated kinase inhibitors in patients with organ function impairment.
C1 [Dashti-Khavidaki, Simin; Mohammadi, Keyhan; Khalili, Hossein; Abdollahi, Azin] Univ Tehran Med Sci, Fac Pharm, POB 1417614411, Tehran, Iran.
RP Dashti-Khavidaki, S (corresponding author), Univ Tehran Med Sci, Fac Pharm, POB 1417614411, Tehran, Iran.
EM dashtis@sina.tums.ac.ir
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, LEXICOMP
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bowman LJ, 2018, TRANSPLANTATION, V102, pS50, DOI [10.1097/TP.0000000000001777, 10.1097/tp.0000000000001777]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Fanouriakis A, 2020, ANN RHEUM DIS, P1
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hoek RAS, 2020, TRANSPL INT, V33, P1099, DOI 10.1111/tri.13662
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Manitpisitkul W, 2014, KIDNEY TRANSPLANTATI
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Moes DJAR, 2015, DRUG DISCOV TODAY, V20, P1243, DOI 10.1016/j.drudis.2015.05.006
   Nankivell BJ, 2016, TRANSPLANTATION, V100, P1723, DOI 10.1097/TP.0000000000001243
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Qin JJ, 2020, HEPATOLOGY, V72, P1491, DOI 10.1002/hep.31257
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Timsit JF, 2019, INTENS CARE MED, V45, P573, DOI 10.1007/s00134-019-05597-y
   Zhong ZB, 2020, AM J TRANSPLANT, V20, P1916, DOI 10.1111/ajt.15928
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 27
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD OCT 12
PY 2020
VL 21
IS 15
BP 1813
EP 1819
DI 10.1080/14656566.2020.1790526
EA JUL 2020
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OM8IQ
UT WOS:000548020600001
PM 32659126
OA Bronze
DA 2021-01-01
ER

PT J
AU Talamonti, M
   Tofani, L
   Bianchi, L
   Galluzzo, M
AF Talamonti, M.
   Tofani, L.
   Bianchi, L.
   Galluzzo, M.
TI Optimizing care for psoriatic patients requiring systemic therapies: how
   will COVID-19 disease transform risk perceptions?
SO ARCHIVES OF DERMATOLOGICAL RESEARCH
LA English
DT Letter; Early Access
C1 [Talamonti, M.; Tofani, L.; Bianchi, L.; Galluzzo, M.] Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy.
   [Talamonti, M.; Tofani, L.; Bianchi, L.] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
   [Galluzzo, M.] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy.
RP Talamonti, M (corresponding author), Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy.; Talamonti, M (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
EM talamonti.marina@gmail.com
RI Talamonti, Marina/L-6190-2016
OI Talamonti, Marina/0000-0002-3070-4071; BIANCHI,
   LUCA/0000-0001-8697-6896; , Lorenzo/0000-0003-1286-9507
CR Epicentro ISS, EP COVID 19
   Gisondi P, 2017, J EUR ACAD DERMATOL, V31, P774, DOI 10.1111/jdv.14114
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-3696
EI 1432-069X
J9 ARCH DERMATOL RES
JI Arch. Dermatol. Res.
DI 10.1007/s00403-020-02103-z
EA JUL 2020
PG 2
WC Dermatology
SC Dermatology
GA MH6KW
UT WOS:000546836500001
PM 32647977
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ruan, ZJ
   Liu, C
   Guo, YT
   He, ZQ
   Huang, XH
   Jia, X
   Yang, T
AF Ruan, Zijing
   Liu, Chao
   Guo, Yuting
   He, Zhenqing
   Huang, Xinhe
   Jia, Xu
   Yang, Tai
TI SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors
   targeting RNA-dependent RNA polymerase activity (NSP12)
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE antiviral drugs; COVID-19; drug candidates; NSP12-NSP7-NSP8; SARS-CoV;
   SARS-CoV-2
ID CORONAVIRUS; FILIBUVIR; RIBAVIRIN; COMPLEX
AB Since the outbreak of severe acute respiratory syndrome (SARS) in 2003, the harm caused by coronaviruses to the world cannot be underestimated. Recently, a novel coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) initially found to trigger human severe respiratory illness in Wuhan City of China in 2019, has infected more than six million people worldwide by 21 June 2020, and which has been recognized as a public health emergency of international concern as well. And the virus has spread to more than 200 countries around the world. However, the effective drug has not yet been officially licensed or approved to treat SARS-Cov-2 and SARS-Cov infection. NSP12-NSP7-NSP8 complex of SARS-CoV-2 or SARS-CoV, essential for viral replication and transcription, is generally regarded as a potential target to fight against the virus. According to the NSP12-NSP7-NSP8 complex (PDB ID: 7BW4) structure of SARS-CoV-2 and the NSP12-NSP7-NSP8 complex (PDB ID: 6NUR) structure of SARS-CoV, NSP12-NSP7 interface model, and NSP12-NSP8 interface model were established for virtual screening in the present study. Eight compounds (Nilotinib, Saquinavir, Tipranavir, Lonafarnib, Tegobuvir, Olysio, Filibuvir, and Cepharanthine) were selected for binding free energy calculations based on virtual screening and docking scores. All eight compounds can combine well with NSP12-NSP7-NSP8 in the crystal structure, providing drug candidates for the treatment and prevention of coronavirus disease 2019 and SARS.
C1 [Ruan, Zijing; Liu, Chao; Guo, Yuting; He, Zhenqing; Jia, Xu] Chengdu Med Coll, Sci & Technol Dept, Noncoding RNA & Drug Discovery Key Lab Sichuan Pr, Chengdu 610500, Sichuan, Peoples R China.
   [Ruan, Zijing; Huang, Xinhe] Southwest Jiaotong Univ, Sch Life Sci & Engn, 111,North 1st Sect,2nd Ring Rd, Chengdu 610031, Sichuan, Peoples R China.
   [Yang, Tai] Chengdu Med Coll, Sch Pharm, Chengdu 610500, Sichuan, Peoples R China.
RP Jia, X (corresponding author), Chengdu Med Coll, Sci & Technol Dept, Noncoding RNA & Drug Discovery Key Lab Sichuan Pr, Chengdu 610500, Sichuan, Peoples R China.; Huang, XH (corresponding author), Southwest Jiaotong Univ, Sch Life Sci & Engn, 111,North 1st Sect,2nd Ring Rd, Chengdu 610031, Sichuan, Peoples R China.; Yang, T (corresponding author), Chengdu Med Coll, Sch Pharm, Chengdu 610500, Sichuan, Peoples R China.
EM xinhehuang@swjtu.edu.cn; jiaxu@cmc.edu.cn; taiyang@cmc.edu.cn
FU "1000 Talent Plan" of Sichuan Province [980, 1060]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [31870135, 31600116]
FX The "1000 Talent Plan" of Sichuan Province, Grant/Award Numbers: 980,
   1060; The National Natural Science Foundation of China, Grant/Award
   Numbers: 31870135, 31600116
CR Ananthula HK, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0270-x
   Asselah T, 2020, LIVER INT, V40, P54, DOI 10.1111/liv.14356
   Beaulieu PL, 2010, IDRUGS, V13, P938
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Erdag TK, 2015, TURK ARCH OTORHINOL, V53, P112, DOI 10.5152/tao.2015.1352
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Hebner CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039163
   Hussain T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050506
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Kandula Vijayabhaskar Reddy, 2005, Expert Rev Anti Infect Ther, V3, P9, DOI 10.1586/14787210.3.1.9
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   la Porte CJL, 2009, EXPERT OPIN DRUG MET, V5, P1313, DOI 10.1517/17425250903273160
   Liu Xinjian, 2004, Zhong Yao Cai, V27, P107
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Rodriguez-Torres M, 2014, ANN HEPATOL, V13, P364, DOI 10.1016/S1665-2681(19)30843-9
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Traynor K, 2014, AM J HEALTH-SYST PH, V71, P6, DOI [10.1093/ajhp/71.1.6, 10.2146/news140001]
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Wang H, 2020, LIFE SCI, V27
   Weber Carina, 2019, Alkaloids Chem Biol, V81, P1, DOI 10.1016/bs.alkal.2018.07.001
   Wong NS, 2012, EXPERT OPIN INV DRUG, V21, P1043, DOI 10.1517/13543784.2012.688950
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yang L, 2020, ONCOL RES TREAT, V43, P4
   Zeuzem S, 2012, HEPATOLOGY, V55, P749, DOI 10.1002/hep.24744
   Zhang ZW, 2020, ZHONGHUA YU FANG YI, V54, pE001
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 32
TC 6
Z9 6
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26222
EA JUL 2020
PG 12
WC Virology
SC Virology
GA MI5JG
UT WOS:000547443400001
PM 32579254
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Sinkeler, FS
   Berger, FA
   Muntinga, HJ
   Jansen, MMPM
AF Sinkeler, F. S.
   Berger, F. A.
   Muntinga, H. J.
   Jansen, M. M. P. M.
TI The risk of QTc-interval prolongation in COVID-19 patients treated with
   chloroquine
SO NETHERLANDS HEART JOURNAL
LA English
DT Article
DE Chloroquine; COVID-19; Electrocardiography; QTc interval
ID CORONAVIRUS
AB Background Chloroquine, a quinolone antimalarial drug, is known to potentially inhibit pH-dependent viral replication of the SARS-CoV-2 infection. Therefore, chloroquine is considered as a treatment option for coronavirus disease 2019 (COVID-19). Chloroquine is known for prolonging the QT interval, but limited data are available on the extent of this QT-prolonging effect. Objective To assess the QTc-prolonging potential of chloroquine in COVID-19 patients and to evaluate whether this prolongation increases with the cumulative dose of chloroquine and is associated with the peak plasma concentration of chloroquine. Furthermore, the number of patients who prematurely discontinued treatment or had an adjustment in dose due to QTc-interval prolongation was established. Methods A retrospective, observational study was performed in patients aged over 18 years, hospitalised for a suspected or proven infection with COVID-19, and therefore treated with chloroquine, with a baseline electrocardiogram (ECG) performed prior to the start of treatment and at least one ECG after starting the treatment. Results In total, 397 patients were included. The mean increase in QTc interval throughout the treatment with chloroquine was 33 & x202f;ms. Nineteen out of 344 patients unnecessarily had their treatment prematurely discontinued or adjusted due to a prolonged QTc interval based on the computerised interpretation of the ECG. Conclusion Chloroquine treatment in COVID-19 patients gradually increased the QTc interval. Due to a significant number of overestimated QTc intervals by computer analysis, it is advisable to measure the QTc interval manually before adjusting the dose or withdrawing this potentially beneficial medication.
C1 [Sinkeler, F. S.; Jansen, M. M. P. M.] Elisabeth TweeSteden Hosp, Dept Clin Pharm, Tilburg, Netherlands.
   [Muntinga, H. J.] Elisabeth TweeSteden Hosp, Dept Cardiol, Tilburg, Netherlands.
   [Berger, F. A.] Meander Med Ctr, Dept Clin Pharm, Amersfoort, Netherlands.
RP Sinkeler, FS (corresponding author), Elisabeth TweeSteden Hosp, Dept Clin Pharm, Tilburg, Netherlands.
EM f.sinkeler@etz.nl
CR Daher A, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2950-4
   Garg A, 2013, CIRC-ARRHYTHMIA ELEC, V6, P76, DOI 10.1161/CIRCEP.112.976803
   He ZX, 2008, ANTIMICROB AGENTS CH, V52, P2653, DOI 10.1128/AAC.01329-07
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006
   Postema PG, 2014, CURR CARDIOL REV, V10, P287, DOI 10.2174/1573403X10666140514103612
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   Sandau KE, 2017, CIRCULATION, V136, pE273, DOI 10.1161/CIR.0000000000000527
   Shiryaev SA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15467-6
   Smit C, 2020, CLIN PHARMACOKINET, V59, P659, DOI 10.1007/s40262-020-00891-1
   van den Broek MPH, 2020, NETH HEART J, V28, P406, DOI 10.1007/s12471-020-01429-7
   Vollaard A, MEDICAMENTEUZE BEHAN
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woosley RL, QTDRUGS LIST
NR 14
TC 6
Z9 6
U1 0
U2 0
PU BOHN STAFLEU VAN LOGHUM BV
PI HOUTEN
PA POSTBUS 246, 3990 GA HOUTEN, NETHERLANDS
SN 1568-5888
EI 1876-6250
J9 NETH HEART J
JI Neth. Heart J.
PD JUL
PY 2020
VL 28
IS 7-8
BP 418
EP 423
DI 10.1007/s12471-020-01462-6
EA JUL 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MP0XT
UT WOS:000546813700001
PM 32648153
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lewis, D
   Fisler, G
   Schneider, J
   Sweberg, T
   Murphy, K
   Sathya, C
   Silver, P
   Taylor, MD
AF Lewis, Deirdre
   Fisler, Grace
   Schneider, James
   Sweberg, Todd
   Murphy, Kristina
   Sathya, Chethan
   Silver, Peter
   Taylor, Matthew D.
TI Veno-venous extracorporeal membrane oxygenation for COVID-19-associated
   pediatric acute respiratory distress syndrome
SO PERFUSION-UK
LA English
DT Article
DE COVID-19; extracorporeal membrane oxygenation; veno-venous
   extracorporeal membrane oxygenation; pediatric critical care; acute
   respiratory distress syndrome
ID CORONAVIRUS DISEASE 2019; ECMO; ARDS
AB Background: The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) coronavirus has emerged as a highly contagious respiratory pathogen causing severe acute lung injury. Extracorporeal membrane oxygenation is a standard tool for the management of life-threatening acute respiratory distress syndrome, but the use of this resource-intensive therapy has come into question due to strained medical systems and limited proven treatments for COVID-19. Case summary: A 16-year-old female with obesity presented with fever, myalgias, cough, and tachypnea and was diagnosed with COVID-19. She progressed to severe pediatric acute respiratory distress syndrome requiring intubation on hospital day 4 and cannulation to veno-venous extracorporeal membrane oxygenation on hospital day 6. The patient received remdesivir, steroids, and anakinra. The patient was successfully decannulated on hospital day 12 and was discharged home on hospital day 21. Conclusion: We report the use of veno-venous extracorporeal membrane oxygenation as a bridge to lung recovery in a pediatric patient with severe pediatric acute respiratory distress syndrome due to COVID-19.
C1 [Lewis, Deirdre; Fisler, Grace; Schneider, James; Sweberg, Todd; Murphy, Kristina; Silver, Peter; Taylor, Matthew D.] Northwell Hlth, Dept Pediat, Div Crit Care Med, Steven & Alexandra Cohen Childrens Med Ctr, 269-01 76th St, New Hyde Pk, NY 11040 USA.
   [Sathya, Chethan] Northwell Hlth, Dept Pediat, Div Pediat Surg, Steven & Alexandra Cohen Childrens Med Ctr, New Hyde Pk, NY 11040 USA.
RP Taylor, MD (corresponding author), Northwell Hlth, Dept Pediat, Div Crit Care Med, Steven & Alexandra Cohen Childrens Med Ctr, 269-01 76th St, New Hyde Pk, NY 11040 USA.
EM mtaylor15@northwell.edu
OI Fisler, Grace/0000-0001-7001-000X
FU NIH NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [K08GM132794]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: M.D.T. is
   supported by funding from the NIH NIGMS K08GM132794.
CR Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Hong XY, 2020, INT J INFECT DIS, V94, P78, DOI 10.1016/j.ijid.2020.03.058
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lan TQ, 2020, IND CROP PROD, V145, DOI 10.1016/j.indcrop.2020.112128
   Li X, 2020, ASAIO J, V66, P475, DOI 10.1097/MAT.0000000000001172
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Namendys-Silva SA, 2020, HEART LUNG, V49, P348, DOI 10.1016/j.hrtlng.2020.03.012
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0267-6591
EI 1477-111X
J9 PERFUSION-UK
JI Perfusion-UK
PD SEP
PY 2020
VL 35
IS 6
SI SI
BP 550
EP 553
AR 0267659120939757
DI 10.1177/0267659120939757
EA JUL 2020
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MX5SE
UT WOS:000548302700001
PM 32643551
OA Bronze
DA 2021-01-01
ER

PT J
AU Chauhan, V
   Rungta, T
   Rawat, M
   Goyal, K
   Gupta, Y
   Singh, MP
AF Chauhan, Varun
   Rungta, Tripti
   Rawat, Manmeet
   Goyal, Kapil
   Gupta, Yash
   Singh, Mini P.
TI Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine
   synthesis using immunoinformatics approach
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE dynamics simulations; immunoinformatics; molecular docking; promiscuous;
   SARS-CoV-2
ID PREDICTION
AB Since the outbreak of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in December 2019 in China, there has been an upsurge in the number of deaths and infected individuals throughout the world, thereby leading to the World Health Organization declaration of a pandemic. Since no specific therapy is currently available for the same, the present study was aimed to explore the SARS-CoV-2 genome for the identification of immunogenic regions using immunoinformatics approach. A series of computational tools were applied in a systematic way to identify the epitopes that could be utilized in vaccine development. The screened-out epitopes were passed through several immune filters, such as promiscuousity, conservancy, antigenicity, nonallergenicity, population coverage, nonhomologous to human proteins, and affinity with human leukocyte antigen alleles, to screen out the best possible ones. Further, a construct comprising 11 CD4, 12 CD8, 3 B cell, and 3 interferon-gamma epitopes, along with an adjuvant beta-defensin, was designed in silico, resulting in the formation of a multiepitope vaccine. The in silico immune simulation and population coverage analysis of the vaccine sequence showed its capacity to elicit cellular, humoral, and innate immune cells and to cover up a worldwide population of more than 97%. Further, the interaction analysis of the vaccine construct with Toll-like receptor 3 (immune receptor) was carried out by docking and dynamics simulations, revealing high affinity, constancy, and pliability between the two. The overall findings suggest that the vaccine may be highly effective, and is therefore required to be tested in the lab settings to evaluate its efficacy.
C1 [Chauhan, Varun; Rungta, Tripti; Goyal, Kapil; Singh, Mini P.] Post Grad Inst Med Educ & Res PGIMER, Dept Virol, Chandigarh 160012, India.
   [Rawat, Manmeet] Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Internal Med GI, Albuquerque, NM 87131 USA.
   [Gupta, Yash] Loyola Univ, Med Ctr, Dept Internal Med, Chicago, IL 60611 USA.
RP Chauhan, V; Singh, MP (corresponding author), Post Grad Inst Med Educ & Res PGIMER, Dept Virol, Chandigarh 160012, India.
EM varunc1784@gmail.com; minipsingh@gmail.com
OI Chauhan, Dr Varun/0000-0001-6769-8691; Rawat,
   Manmeet/0000-0002-8325-3390
CR Abbas G, 2020, EUR J PHARM SCI, V142, DOI 10.1016/j.ejps.2019.105160
   Athanasiou E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00684
   Bazhan SI, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020034
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chauhan V, 2016, INDO AM J PHARM RES, V6, P4639
   Chauhan V, 2020, EUR J PHARM SCI, V147
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Chauhan V, 2018, INFECT GENET EVOL, V61, P24, DOI 10.1016/j.meegid.2018.03.004
   Chauhan V, 2018, BIOLOGICALS, V53, P63, DOI 10.1016/j.biologicals.2018.02.003
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Damfo SA, 2017, J MOL GRAPH MODEL, V78, P195, DOI 10.1016/j.jmgm.2017.10.004
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   He JL, 2019, IMMUNOLOGY, V156, P94, DOI 10.1111/imm.13007
   Heinson AI, 2015, INT HEALTH, V7, P85, DOI 10.1093/inthealth/ihv002
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Nezafat N., 2014, J THEOR BIOL, V21, P349
   Ojha R, 2019, J CELL PHYSIOL, V234, P6437, DOI 10.1002/jcp.27380
   Pance A, 2019, NAT REV MICROBIOL, V17, P129, DOI 10.1038/s41579-018-0148-3
   Pandey RK, 2019, J CELL PHYSIOL, V234, P8717, DOI 10.1002/jcp.27531
   Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110
   Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Ravichandran L, 2019, J CELL BIOCHEM, V120, P7082, DOI 10.1002/jcb.27979
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7
   Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2021
VL 236
IS 2
BP 1131
EP 1147
DI 10.1002/jcp.29923
EA JUL 2020
PG 17
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA OU0IY
UT WOS:000546317900001
PM 32643158
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Watson, JA
   Tarning, J
   Hoglund, RM
   Baud, FJ
   Megarbane, B
   Clemessy, JL
   White, NJ
AF Watson, James A.
   Tarning, Joel
   Hoglund, Richard M.
   Baud, Frederic J.
   Megarbane, Bruno
   Clemessy, Jean-Luc
   White, Nicholas J.
TI Concentration-dependent mortality of chloroquine in overdose
SO ELIFE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CARDIAC SAFETY; ARRHYTHMIA; RISK; DRUG
AB Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally safe they are potentially lethal in overdose. In-vitro data suggest that high concentrations and thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence of clinical efficacy. Bayesian regression models were fitted to survival outcomes and electrocardiograph QRS durations from 302 prospectively studied French patients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took 620 mg base chloroquine single doses. Whole blood concentrations of 13.5 mu mol/L (95% credible interval 10.1-17.7) were associated with 1% mortality. Prolongation of ventricular depolarization is concentration-dependent with a QRS duration >150 msec independently highly predictive of mortality in chloroquine self-poisoning. Pharmacokinetic modeling predicts that most high dose regimens trialled in COVID-19 are unlikely to cause serious cardiovascular toxicity.
C1 [Watson, James A.; Tarning, Joel; Hoglund, Richard M.; White, Nicholas J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [Watson, James A.; Tarning, Joel; Hoglund, Richard M.; White, Nicholas J.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.
   [Baud, Frederic J.; Clemessy, Jean-Luc] AP HP, Paris, France.
   [Baud, Frederic J.] Univ Paris, Paris, France.
   [Megarbane, Bruno] Univ Paris, INSERM, UMRS 11 44, Paris, France.
   [Megarbane, Bruno; Clemessy, Jean-Luc] Hop Lariboisiere, Reanimat Med & Toxicol, Paris, France.
   [Clemessy, Jean-Luc] Clin Sport, Paris, France.
RP Watson, JA; White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.; Watson, JA; White, NJ (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.
EM jwatowatson@gmail.com; nickw@tropmedres.ac
OI Tarning, Joel/0000-0003-4566-4030
FU Wellcome Trust Principal Research FellowshipWellcome Trust
   [093956/Z/10/C]
FX Wellcome Trust Principal Research Fellowship 093956/Z/10/C Nicholas J
   White
CR [Anonymous], 2020, STRAITS TIMES
   Ball DE, 2002, J APPL TOXICOL, V22, P311, DOI 10.1002/jat.864
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bourre-Tessier J, 2015, ARTHRIT CARE RES, V67, P128, DOI 10.1002/acr.22370
   Carpenter Bob, 2017, J STAT SOFTW, DOI [10.18637/jss.v076.i01, DOI 10.18637/JSS.V076.I01]
   Chan XHS, 2018, LANCET INFECT DIS, V18, P913, DOI 10.1016/S1473-3099(18)30297-4
   Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181-020-00777-5
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Chu CS, 2018, CLIN INFECT DIS, V67, P1543, DOI 10.1093/cid/ciy319
   CLEMESSY JL, 1995, LANCET, V346, P877, DOI 10.1016/S0140-6736(95)92711-5
   Clemessy JL, 1996, CRIT CARE MED, V24, P1189, DOI 10.1097/00003246-199607000-00021
   CONAN NJ, 1949, AM J MED, V6, P309, DOI 10.1016/0002-9343(49)90167-9
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   FILIPEK A, 2020, CARDIOVASC RES, V13, DOI DOI 10.1093/CVR/CVAA106
   Gawalko M, 2020, CIRC J, V84, P685, DOI 10.1253/circj.CJ-19-0705
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Guillon C, 1982, SUICIDE MODE DEMPLOI
   Gunja N, 2009, ANAESTH INTENS CARE, V37, P130, DOI 10.1177/0310057X0903700112
   HARRIS L, 1988, CAN J CARDIOL, V4, P295
   Hoglund R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1181-1
   Jeevaratnam K, 2020, EUR HEART J-CARD PHA, V6, P256, DOI 10.1093/ehjcvp/pvaa041
   Kang Y, 2020, HEART, V106, P1132, DOI 10.1136/heartjnl-2020-317056
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Megarbane B, 2007, INTENS CARE MED, V33, P758, DOI 10.1007/s00134-007-0568-4
   Megarbane B, 2020, J CLIN PHARMACOL, V60, P808, DOI 10.1002/jcph.1646
   Megarbane B, 2010, CLIN TOXICOL, V48, P904, DOI 10.3109/15563650.2010.518969
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Monzani A, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13258
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Szekely Y, 2020, HEART RHYTHM, V17, P1452, DOI 10.1016/j.hrthm.2020.04.046
   Teixeira RA, 2014, EUROPACE, V16, P887, DOI 10.1093/europace/eut290
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   van den Broek MPH, 2020, NETH HEART J, V28, P406, DOI 10.1007/s12471-020-01429-7
   Vicente J, 2018, CLIN PHARMACOL THER, V103, P54, DOI 10.1002/cpt.896
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Watson JA, 2020, CHLOROQUINE CONCENTR
   White NJ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003252
   World Health Organization, 2015, GUID TREATM MAL
   Wozniacka A, 2006, LUPUS, V15, P521, DOI 10.1191/0961203306lu2345oa
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 51
TC 1
Z9 1
U1 0
U2 0
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUL 8
PY 2020
VL 9
AR e58631
DI 10.7554/eLife.58631
PG 27
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA ND7UH
UT WOS:000562108100001
PM 32639233
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, X
   Wang, Y
   Agostinis, P
   Rabson, A
   Melino, G
   Carafoli, E
   Shi, YF
   Sun, EW
AF Li, Xing
   Wang, Ying
   Agostinis, Patrizia
   Rabson, Arnold
   Melino, Gerry
   Carafoli, Ernesto
   Shi, Yufang
   Sun, Erwei
TI Is hydroxychloroquine beneficial for COVID-19 patients?
SO CELL DEATH & DISEASE
LA English
DT Article
ID ANTIMALARIAL-DRUGS; CHLOROQUINE; INFECTION; INHIBIT; CELLS
AB The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world(1-3), the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020(4). The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir(5), to control the disease and halt the pandemic.
C1 [Li, Xing; Sun, Erwei] Southern Med Univ, Affiliated Hosp 3, Dept Rheumatol & Immunol, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China.
   [Wang, Ying; Shi, Yufang] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.
   [Agostinis, Patrizia] Katholieke Univ Leuven, VIB KU Leuven Ctr Canc Biol, Leuven, Belgium.
   [Rabson, Arnold] Rutgers State Univ, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA.
   [Melino, Gerry] Univ Roma Tor Vergata, TOR, I-00133 Rome, Italy.
   [Carafoli, Ernesto] Univ Padua, Venetian Inst Mol Med, Rome, Italy.
   [Shi, Yufang] Soochow Univ, State Key Lab Radiat Med & Protect, Affiliated Hosp 1, Inst Translat Med,Med Coll, Suzhou, Peoples R China.
   [Sun, Erwei] Southern Med Univ, Shunde Hosp, Dept Rheumatol & Immunol, Peoples Hosp Shunde 1, Foshan 528000, Guangdong, Peoples R China.
RP Sun, EW (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Rheumatol & Immunol, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China.; Shi, YF (corresponding author), Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Shi, YF (corresponding author), Soochow Univ, State Key Lab Radiat Med & Protect, Affiliated Hosp 1, Inst Translat Med,Med Coll, Suzhou, Peoples R China.; Sun, EW (corresponding author), Southern Med Univ, Shunde Hosp, Dept Rheumatol & Immunol, Peoples Hosp Shunde 1, Foshan 528000, Guangdong, Peoples R China.
EM yfshi@suda.edu.cn; sunew@smu.edu.cn
RI Agostinis, Patrizia/ABI-1177-2020
OI Agostinis, Patrizia/0000-0003-1314-2115; MELINO,
   GENNARO/0000-0001-9428-5972; Shi, Yufang/0000-0001-8964-319X; Sun,
   Erwei/0000-0001-5664-513X
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   An J, 2015, J IMMUNOL, V194, P4089, DOI 10.4049/jimmunol.1402793
   [Anonymous], 2020, LANCET, V395, pE102, DOI 10.1016/S0140-6736(20)31290-3
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580-019-0185-4
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chung Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1229-y
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   Costedoat-Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016-015-8469-8
   Costedoat-Chalumeau N, 2014, PRESSE MED, V43, pE167, DOI 10.1016/j.lpm.2014.03.007
   Dai CS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1136-2
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Fiehn C, 2020, Z RHEUMATOL, V79, P186, DOI 10.1007/s00393-020-00751-0
   Funck-Brentano Christian, 2020, Lancet, DOI 10.1016/S0140-6736(20)31174-0
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gunst J, 2018, CRIT CARE CLIN, V34, P573, DOI 10.1016/j.ccc.2018.06.004
   Han JC, 2018, BIOMED PHARMACOTHER, V97, P838, DOI 10.1016/j.biopha.2017.10.132
   Indian Council for Medical Research, REC EMP US HYDR PROP
   Jorge A, 2018, NAT REV RHEUMATOL, V14, P693, DOI 10.1038/s41584-018-0111-8
   Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Li XQ, 2019, CELL DEATH DIFFER, V26, P382, DOI 10.1038/s41418-018-0207-3
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morawski PA, 2017, TRENDS IMMUNOL, V38, P373, DOI 10.1016/j.it.2017.02.001
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rubin EJ, 2020, NEW ENGL J MED, V382, P2464, DOI 10.1056/NEJMe2020822
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
   Sawa T, 2020, CBC
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Shu C, 2014, CYTOKINE GROWTH F R, V25, P641, DOI 10.1016/j.cytogfr.2014.06.006
   Singh N, 2016, J ALLERGY CLIN IMMUN, V137, P1325, DOI 10.1016/j.jaci.2015.12.1326
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   Tang TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0378-3
   U.S. Department of Health and Human Services, HHS ACC DON MED STRA
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696
   Volpe E, 2019, CELL DEATH DIFFER, V26, P1169, DOI 10.1038/s41418-018-0201-9
   WALLACE DJ, 1994, J RHEUMATOL, V21, P375
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang SL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1634-x
   Wang TF, 2016, HEMATOL-AM SOC HEMAT, P714, DOI 10.1182/asheducation-2016.1.714
   Warri A, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0105-y
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Yam J. C. S., 2006, Hong Kong Medical Journal, V12, P294
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zamora A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2181-1
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang X, 2014, CELL REP, V6, P421, DOI 10.1016/j.celrep.2014.01.003
   Zhitomirsky B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1227-0
NR 68
TC 12
Z9 12
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 8
PY 2020
VL 11
IS 7
AR 512
DI 10.1038/s41419-020-2721-8
PG 6
WC Cell Biology
SC Cell Biology
GA MP2QC
UT WOS:000552052700001
PM 32641681
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sharma, A
   Sharma, SK
   Shi, YF
   Bucci, E
   Carafoli, E
   Melino, G
   Bhattacherjee, A
   Das, G
AF Sharma, Abhibhav
   Sharma, Saurabh Kumar
   Shi, Yufang
   Bucci, Enrico
   Carafoli, Ernesto
   Melino, Gerry
   Bhattacherjee, Arnab
   Das, Gobardhan
TI BCG vaccination policy and preventive chloroquine usage: do they have an
   impact on COVID-19 pandemic?
SO CELL DEATH & DISEASE
LA English
DT Article
ID EFFICACY; TUBERCULOSIS
AB Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic. Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been proposed. Here we discuss the plausibility of two of them: the universal vaccination with Bacillus Calmette-Guerin (BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic; we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no longer recommend it officially for the fight against malaria, due to the development of resistance to Plasmodium, but its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.
C1 [Sharma, Abhibhav; Sharma, Saurabh Kumar] Jawaharlal Nehru Univ, Sch Comp & Syst Sci, New Delhi, India.
   [Shi, Yufang] Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou, Peoples R China.
   [Bucci, Enrico] Resis Srl, I-10010 Samone, TO, Italy.
   [Bucci, Enrico] Temple Univ, Sbarro Hlth Res Org, Philadelphia, PA 19122 USA.
   [Carafoli, Ernesto] Univ Padua, Venetian Inst Mol Med, Padua, Italy.
   [Melino, Gerry] Univ Roma Tor Vergata, TOR, Dept Expt Med, I-00133 Rome, Italy.
   [Bhattacherjee, Arnab] Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi, India.
   [Das, Gobardhan] Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi, India.
RP Bhattacherjee, A (corresponding author), Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi, India.; Das, G (corresponding author), Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi, India.
EM arnab@jnu.ac.in; gobardhan.das07@gmail.com
RI Bucci, Enrico/G-4338-2013
OI Bucci, Enrico/0000-0002-3317-8003; MELINO, GENNARO/0000-0001-9428-5972;
   Bhattacherjee, Arnab/0000-0002-7714-2619; Shi,
   Yufang/0000-0001-8964-319X; Sharma, Abhibhav/0000-0001-5513-6210
FU DST India (DST PURSE) [DST/INSPIRE/04/2013/000100, DST
   SERBCRG/2019/001001]; DBT CoE research grant
FX We gratefully acknowledge the insightful discussions and critical review
   done by Dr. Jyoti Das of National Institute of Malaria Research, New
   Delhi, India. A.B. gratefully acknowledges the financial support to
   perform the research from DST India (DST PURSE,
   DST/INSPIRE/04/2013/000100, DST SERBCRG/2019/001001), and DBT CoE
   research grant.
CR Alavi-Moghaddam M, 2020, ARCH ACAD EMERG MED, V8
   Alhunaidi O, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.905
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, CORONAVIRUS UPDATE
   [Anonymous], 2020, COMMUNICATION, DOI [10.5281/zenodo.3864691, DOI 10.5281/ZENODO.3864691]
   [Anonymous], 2020, OLD TB VACCINE FINDS
   Asahara M., 2020, EFFECT BCG VACCINATI, DOI [10.1101/2020.04.17.20068601, DOI 10.1101/2020.04.17.20068601]
   BAKER DM, 1993, EPIDEMIOL INFECT, V111, P21, DOI 10.1017/S0950268800056636
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chung Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1229-y
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Craven J, 2020, COVID 19 VACCINE TRA
   Dai CS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1136-2
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Frosch AEP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-116
   Funck-Brentano C, 2020, LANCET LOND ENGL, VS0140-6736, P31174
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032
   Li XQ, 2019, CELL DEATH DIFFER, V26, P382, DOI 10.1038/s41418-018-0207-3
   Luca Simona, 2013, Maedica (Bucur), V8, P53
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Oettinger T., 1999, Tubercle and Lung Disease, V79, P243, DOI 10.1054/tuld.1999.0206
   Phillips RO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003457
   Rathi S, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30313-3
   Ritz N, 2009, TUBERCULOSIS, V89, P248, DOI 10.1016/j.tube.2009.03.002
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Sjodin H, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.13.2000280
   Tang TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0378-3
   Usher NT, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12014
   Volpe E, 2019, CELL DEATH DIFFER, V26, P1169, DOI 10.1038/s41418-018-0201-9
   Wang SL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1634-x
   Wardhana, 2011, Acta Med Indones, V43, P185
   Warri A, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0105-y
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zamora A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2181-1
   Zar J. H., 1998, BIOSTATISTICAL ANAL
   Zhitomirsky B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1227-0
NR 48
TC 7
Z9 7
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 8
PY 2020
VL 11
IS 7
AR 516
DI 10.1038/s41419-020-2720-9
PG 10
WC Cell Biology
SC Cell Biology
GA MP2QC
UT WOS:000552052700005
PM 32641762
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yousuf, H
   Corbin, J
   Sweep, G
   Hofstra, M
   Scherder, E
   van Gorp, E
   Zwetsloot, PP
   Zhao, JY
   van Rossum, B
   Jiang, T
   Lindemans, JW
   Narula, J
   Hofstra, L
AF Yousuf, Hamza
   Corbin, Jonathan
   Sweep, Govert
   Hofstra, Martijn
   Scherder, Erik
   van Gorp, Eric
   Zwetsloot, Peter Paul
   Zhao, Jiayu
   van Rossum, Bert
   Jiang, Ting
   Lindemans, Jan-Willem
   Narula, Jagat
   Hofstra, Leonard
TI Association of a Public Health Campaign About Coronavirus Disease 2019
   Promoted by News Media and a Social Influencer With Self-reported
   Personal Hygiene and Physical Distancing in the Netherlands
SO JAMA NETWORK OPEN
LA English
DT Article
ID BEHAVIOR
AB Importance In the absence of a vaccine and therapeutic agent, personal hygiene and physical distancing are essential measures to contain the coronavirus disease 2019 pandemic.
   Objective To determine whether a social media campaign, targeted at the gaps in behavior on personal hygiene and physical distancing and distributed nationwide via digital news media, may be an effective method to improve behavior and help to inhibit person-to-person transmission of severe acute respiratory syndrome coronavirus 2.
   Design, Setting, and Participants This survey study was designed to uncover self-reported gaps in behavior regarding personal hygiene and physical distancing in the Netherlands. A diagnostic survey was distributed by a large national newspaper (De Telegraaf) and a popular social influencer (Govert Sweep) on March 17, 2020, and was completed by 16 072 participants. Analysis of these outcomes showed that coughing and sneezing in the elbow was done well, but that handwashing, face touching, and physical distancing showed serious gaps compared with advised behavior. This diagnostic information was used to design infographics and a video targeted at repairing these gaps in behavior. The video and infographics were distributed on a national level on March 21, 2020, followed by a postcampaign survey to measure the results on March 24, 2020. Data analysis was performed from March to April 2020.
   Exposure Exposed participants were those who viewed the infographics and/or video.
   Main Outcomes and Measures Improvement on the extent of handwashing in all areas, handwashing duration of 20 seconds or longer, awareness on face touching, and physical distancing were measured according to responses on the postcampaign survey.
   Results A total of 17 189 participants (mean [SD] age, 47.61 [13.57] years; 9100 women [52.9%]) responded to the postcampaign survey. The news article in De Telegraaf was read more than 2 million times, and the influencer video was watched more than 80 000 times. Cross-sectional analysis of the postcampaign survey using logistic regression correcting for age, gender, and educational level showed that exposure to the video plus infographics (827 participants) (adjusted odds ratio [OR], 2.14; 95% CI, 1.83-2.50; P < .001) and to the infographics alone (11 348 participants) (adjusted OR, 1.31; 95% CI, 1.22-1.40; P < .001) were positively associated with washing hands in all areas compared with the unexposed group (4751 participants). In addition, exposure to the video plus infographics (adjusted OR, 1.86; 95% CI, 1.59-2.16; P < .001) and to the infographics alone (adjusted OR, 1.27; 95% CI, 1.19-1.36; P < .001) were positively associated with washing hands long enough compared with the unexposed group. Exposure to the video alone was not associated with improved handwashing. Compared with the unexposed group, exposure to the infographics alone and video plus infographics were associated with improvements in physical distancing when the participant had COVID-19 syptoms (infographics alone, adjusted OR, 1.10; 95% CI, 1.03-1.17; P = .006; video plus infographics, adjusted OR, 0.79; 95% CI, 0.69-0.91; P = .001) and face touching (infographics alone, adjusted OR, 1.29; 95% CI, 1.22-1.38; P < .001; infographics and video, adjusted OR, 1.49, 95% CI, 1.30-1.71; P < .001).
   Conclusions and Relevance These findings suggest that a targeted behavioral change campaign, promoted by a news platform and social media, was associated with self-reported improvement in personal hygiene with the aim to prevent person-to-person transmission of severe acute respiratory syndrome coronavirus 2. This method of evidence-based campaigning may be an effective way to improve critical public health issues, such as the coronavirus disease 2019 pandemic.
C1 [Yousuf, Hamza; van Rossum, Bert; Hofstra, Leonard] Vrije Univ Amsterdam, Dept Cardiol, Amsterdam Univ Med Ctr, Med Ctr, Amsterdam, Netherlands.
   [Corbin, Jonathan; Zhao, Jiayu; Jiang, Ting; Lindemans, Jan-Willem] Duke Univ, Ctr Adv Hindsight, 334 Blackwell St,Ste 320, Durham, NC 27701 USA.
   [Sweep, Govert; Hofstra, Martijn] Erasmus Univ, Econometr Inst, Rotterdam, Netherlands.
   [Scherder, Erik] Vrije Univ Amsterdam, Dept Clin Neuropsychol, Amsterdam, Netherlands.
   [van Gorp, Eric] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Zwetsloot, Peter Paul] UMCU, Dept Cardiol, Utrecht, Netherlands.
   [Narula, Jagat] Mt Sinai Hosp, St Lukes Hosp, Icahn Sch Med, New York, NY 10029 USA.
RP Hofstra, L (corresponding author), Amsterdam Univ Med Ctr, Dept Cardiol, VUMC De Boelelaan 1117,1118, NL-1081 HV Amsterdam, Netherlands.; Lindemans, JW (corresponding author), Duke Univ, Ctr Adv Hindsight, 334 Blackwell St,Ste 320, Durham, NC 27701 USA.
EM jan.lindemans@duke.edu; jan.lindemans@duke.edu
OI Yousuf, Hamza/0000-0001-9973-1927
FU Fred Foundation; Noaber Foundation; HAPPY Foundation
FX This study was supported by grants from the Fred Foundation, Noaber
   Foundation, and HAPPY Foundation.
CR American Association for Public Opinion Research, 2016, STAND DEF FIN DISP C
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Burgess J., 2018, YOUTUBE ONLINE VIDEO
   Cadario R, 2020, MARKET SCI, V39, P465, DOI 10.1287/mksc.2018.1128
   Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015
   Dickie R, 2018, PSYCHOL HEALTH MED, V23, P154, DOI 10.1080/13548506.2017.1338736
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huber AC, 2014, APPL PSYCHOL-HLTH WE, V6, P96, DOI 10.1111/aphw.12018
   Ladhari R, 2020, J RETAIL CONSUM SERV, V54, DOI 10.1016/j.jretconser.2019.102027
   Mantel A, 2020, NEDERLAND PROOI CORO
   Merchant RM, 2020, JAMA-J AM MED ASSOC, V323, P2011, DOI 10.1001/jama.2020.4469
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   RIVM, 2020, COVID 19 NIEUW COR
   Sweep G, 2020, CORONA VIRUS GOVERT
   The World Bank, INT TEL UN WORLD TEL
   World Health Organization, 2020, COUNT MIS COVID 19
   World Health Organization, 2020, COR DIS COVID 19 ADV
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yousuf H, 2019, LANCET, V394, P119, DOI 10.1016/S0140-6736(19)30250-8
NR 19
TC 1
Z9 1
U1 7
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD JUL 8
PY 2020
VL 3
IS 7
DI 10.1001/jamanetworkopen.2020.14323
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA MP3HC
UT WOS:000552096900007
PM 32639569
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Duska, F
   Waldauf, P
   Halacova, M
   Zvonicek, V
   Bala, J
   Balik, M
   Benes, J
   Klementova, O
   Kozakova, I
   Kubricht, V
   Le Roy, A
   Vymazal, T
   Rehorova, V
   Cerny, V
AF Duska, Frantisek
   Waldauf, Petr
   Halacova, Milada
   Zvonicek, Vaclav
   Bala, Jakub
   Balik, Martin
   Benes, Jan
   Klementova, Olga
   Kozakova, Irena
   Kubricht, Viktor
   Le Roy, Anne
   Vymazal, Tomas
   Rehorova, Veronika
   Cerny, Vladimir
CA Czech Anaesthesia Clinical Trials
TI Azithromycin added to hydroxychloroquine for patients admitted to
   intensive care due to coronavirus disease 2019 (COVID-19)-protocol of
   randomised controlled trial AZIQUINE-ICU
SO TRIALS
LA English
DT Article
DE Novel coronavirus; COVID-19; SARS-CoV-2; Azithromycin;
   Hydroxychloroquine; Respiratory failure
AB BackgroundNovel coronavirus SARS-CoV-2 is known to be susceptible in vitro to exposure to hydroxychloroquine and its effect has been found to be potentiated by azithromycin. We hypothesise that early administration of hydroxychloroquine alone or in combination with azithromycin can prevent respiratory deterioration in patients admitted to intensive care due to rapidly progressive COVID-19 infection.MethodsDesign: Prospective, multi-centre, double-blind, randomised, controlled trial (RCT). Participants: Adult (>18years) within 24h of admission to the intensive care unit with proven or suspected COVID-19 infection, whether or not mechanically ventilated. Exclusion criteria include duration symptoms of febrile disease for >= 1week, treatment limitations in place or moribund patients, allergy or intolerance of any study treatment, and pregnancy. Interventions: Patients will be randomised in 1:1:1 ratio to receive Hydroxychloroquine 800mg orally in two doses followed by 400mg daily in two doses and azithromycin 500mg orally in one dose followed by 250mg in one dose for a total of 5days (HC-A group) or hydroxychloroquine + placebo (HC group) or placebo + placebo (C-group) in addition to the best standard of care, which may evolve during the trial period but will not differ between groups. Primary outcome is the composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14. Secondary outcomes: The percentage of patients who were prevented from needing intubation until day 14, ICU length of stay, and mortality (in hospital) at day 28 and 90.DiscussionAlthough both investigational drugs are often administered off label to patients with severe COVID-19, at present, there is no data from RCTs on their safety and efficacy. In vitro and observational trial suggests their potential to limit viral replication and the damage to lungs as the most common reason for ICU admission. Therefore, patients most likely to benefit from the treatment are those with severe but early disease. This trial is designed and powered to investigate whether the treatment in this cohort of patients leads to improved clinical patient-centred outcomes, such as mechanical ventilation-free survival.Trial registrationClinical trials.gov: NCT04339816 (Registered on 9 April 2020, amended on 22 June 2020); Eudra CT number: 2020-001456-18 (Registered on 29 March 2020).
C1 [Duska, Frantisek; Waldauf, Petr; Halacova, Milada; Kozakova, Irena; Kubricht, Viktor; Le Roy, Anne; Rehorova, Veronika] Charles Univ Prague, Dept Anaesthesia & Intens Care, Fac Med 3, Prague, Czech Republic.
   [Duska, Frantisek; Waldauf, Petr; Halacova, Milada; Kozakova, Irena; Kubricht, Viktor; Le Roy, Anne; Rehorova, Veronika] FNKV Univ Hosp, Prague, Czech Republic.
   [Zvonicek, Vaclav] Masaryk Univ, Med Fac, Brno, Czech Republic.
   [Zvonicek, Vaclav] U Svate Anny Univ Hosp, Brno, Czech Republic.
   [Bala, Jakub] Bulovce Hosp, Prague, Czech Republic.
   [Balik, Martin] Charles Univ Prague, Fac Med 1, Prague, Czech Republic.
   [Balik, Martin] VFN Univ Hosp Prague, Prague, Czech Republic.
   [Benes, Jan] Charles Univ Prague, Med Fac, Plzen, Czech Republic.
   [Benes, Jan] Univ Hosp Plzen, Plzen, Czech Republic.
   [Klementova, Olga] Palacky Univ, Med Fac, Olomouc, Czech Republic.
   [Klementova, Olga] Olomouc Univ Hosp, Olomouc, Czech Republic.
   [Vymazal, Tomas] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic.
   [Cerny, Vladimir] Masaryks Hosp, Czech Anaesthesia Clin Trials & Audit Network, Usti Nad Labem, Czech Republic.
   [Cerny, Vladimir] Masaryks Hosp, Dept Anaesthesia & Intens Care, Usti Nad Labem, Czech Republic.
RP Duska, F (corresponding author), Charles Univ Prague, Dept Anaesthesia & Intens Care, Fac Med 3, Prague, Czech Republic.; Duska, F (corresponding author), FNKV Univ Hosp, Prague, Czech Republic.
EM frantisek.duska@lf3.cuni.cz
OI Duska, Frantisek/0000-0003-1559-4078; Waldauf, Petr/0000-0003-4668-5837
FU Donatio Intensivistam Endowment Fund under Municipal Court in Prague
   [0907206, N1795]; COVID-19 GAMA-2 scheme of Technology Agency of the
   Czech Republic
FX The trial is funded by Donatio Intensivistam Endowment Fund,
   www.donatio-intensivistam.cz, VAT No 0907206 Registered under No N1795
   by Municipal Court in Prague on 2 April 2020, trial drugs were provided
   as a kind gift of Zentiva, a.s. and application has been made for a
   rapid grant from COVID-19 GAMA-2 scheme of Technology Agency of the
   Czech Republic.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Cheng VC, 2020, LAST UPDATED APRIL 1
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Gautret P, HYDROXYCHLOROQUINE A, DOI [10.1016/j.ijantimicag.2020.105949, DOI 10.1016/J.IJANTIMICAG.2020.105949]
   Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
   Jansen TC, 2007, INTENS CARE MED, V33, P894, DOI 10.1007/s00134-007-0580-8
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP, P1
   Yao X, 2020, CLIN INFECT DIS
   Zhou F., 2020, LANCET
NR 11
TC 1
Z9 1
U1 12
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 8
PY 2020
VL 21
IS 1
AR 631
DI 10.1186/s13063-020-04566-x
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP0MN
UT WOS:000551908000012
PM 32641163
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kulkarni, S
   Fisk, M
   Kostapanos, M
   Banham-Hall, E
   Bond, S
   Hernan-Sancho, E
   Norton, S
   Cheriyan, J
   Cope, A
   Galloway, J
   Hall, F
   Jayne, D
   Wilkinson, IB
AF Kulkarni, Spoorthy
   Fisk, Marie
   Kostapanos, Michalis
   Banham-Hall, Edward
   Bond, Simon
   Hernan-Sancho, Elena
   Norton, Sam
   Cheriyan, Joseph
   Cope, Andrew
   Galloway, James
   Hall, Frances
   Jayne, David
   Wilkinson, Ian B.
TI Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients -
   mulTi-Arm Therapeutic study in pre-ICu patients admitted with
   Covid-19-Repurposed Drugs (TACTIC-R): A structured summary of a study
   protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Baricitinib;
   Ravulizumab; Open-label; Adaptive trial; Repurposed drugs
AB ObjectivesTo determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC).Trial designRandomised, parallel 3-arm (1:1:1 ratio), open-label, Phase IV platform trial of immunomodulatory therapies in patients with late stage 1 or stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical and/or radiological assessment.ParticipantsPatients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a Risk count (as defined below) >3 OR >= 3 if risk count includes "Radiographic severity score >3". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x10(9)/L, age >40 years and CRP >40 mg/L.Patients should be considered an appropriate subject for intervention with immunomodulatory therapies in the opinion of the investigator and be able to be maintained on venous thromboembolism prophylaxis during the inpatient dosing period, according to local guidelines. The complete inclusion and exclusion criteria as detailed in the additional file 1 should be fulfilled. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres including initially at Cambridge University Hospitals NHS Foundation Trust, King's College Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, University Hospital of Wales, Gloucestershire Royal Hospitals NHS Foundation Trust and The Royal Wolverhampton NHS Trust.Intervention and comparatorEach active comparator arm will be compared against standard of care (SoC). The immunomodulatory drugs were selected from a panel of licenced candidates by a drug evaluation committee, which considered potential efficacy, potential toxicity, scalability and novelty of each strategy. The initial active arms comprise baricitinib and ravulizumab.Baricitinib will be given 4 mg orally (once daily (OD)) on days 1-14 or until day of discharge. The dose will be reduced to 2 mg OD for patients aged > 75 years and those with an estimated Cockcroft Gault creatinine clearance of 30-60 ml/min.Ravulizumab will be administered intravenously once according to the licensed weight-based dosing regimen (see Additional file 1).Each active arm will be compared with standard of care alone. No comparisons will be made between active arms in this platform trial.Main outcomesThe primary outcome is the incidence (from baseline up to Day 14) of any one of the events (whichever comes first): death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min).RandomisationEligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or SoC.Blinding (masking)This is an open-label trial. Data analysis will not be blinded.Numbers to be randomised (sample size)There is no fixed sample size for this study. Serial interim analyses will be triggered by an Independent Data Monitoring Committee (IDMC), including analysis after 125 patients are recruited to each arm, 375 in total assuming 3 arms.
   Additional interim analyses are projected after 229 patients per arm, and potentially then after 469 per arm, but additional analyses may be triggered by the IDMC.Trial StatusTACTIC-R Protocol version number 2.0 date May 20, 2020, recruitment began May 7, 2020 and the end trial will be the date 18 months after the last patient's last visit. The recruitment end date cannot yet be accurately predicted.Trial registrationRegistered on EU Clinical Trials Register EudraCT Number: 2020-001354-22 Registered: 6 May 2020It was registered on ClinicalTrials.gov (NCT04390464) and on ISRCTN (ISRCTN11188345)Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Kulkarni, Spoorthy; Fisk, Marie; Kostapanos, Michalis; Banham-Hall, Edward; Bond, Simon; Hernan-Sancho, Elena; Cheriyan, Joseph; Hall, Frances] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Biomed Campus,Hills Rd, Cambridge CB2 0QQ, England.
   [Norton, Sam; Cope, Andrew; Galloway, James] Kings Coll London, London WC2R 2LS, England.
   [Jayne, David; Wilkinson, Ian B.] Univ Cambridge, Old Sch, Trinity Lane, Cambridge CB2 1TN, England.
RP Kulkarni, S (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Cambridge Biomed Campus,Hills Rd, Cambridge CB2 0QQ, England.
EM Spoorthy.kulkarni@addenbrookes.nhs.uk
RI Norton, Sam J/A-1898-2009
OI Norton, Sam J/0000-0003-1714-9963; Kostapanos,
   Michalis/0000-0002-7513-5319
FU UK Research and Innovation; Eli Lilly and Company UK Ltd.; Alexion
   Pharmaceuticals UK; Cambridge University Hospitals NHS Foundation Trust;
   National Institute for Health ResearchNational Institute for Health
   Research (NIHR)
FX The trial is funded by UK Research and Innovation, Eli Lilly and Company
   UK Ltd. and Alexion Pharmaceuticals UK. The trial is sponsored by
   Cambridge University Hospitals NHS Foundation Trust. The trial is
   supported by the National Institute for Health Research. The funding
   bodies had no role in the design of the study and collection, analysis,
   and interpretation of data and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 8
PY 2020
VL 21
IS 1
AR 626
DI 10.1186/s13063-020-04535-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP0MN
UT WOS:000551908000007
PM 32641154
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, X
   Chen, HL
   Shang, YQ
   Zhu, HQ
   Chen, GQ
   Chen, YL
   Liu, SX
   Zhou, YY
   Huang, MX
   Hong, ZS
   Xia, JY
AF Liu, Xi
   Chen, Huili
   Shang, Yuqi
   Zhu, Hongqiong
   Chen, Gongqi
   Chen, Yuanli
   Liu, Shaoxuan
   Zhou, Yaoyong
   Huang, Mingxing
   Hong, Zhongsi
   Xia, Jinyu
TI Efficacy of chloroquine versus lopinavir/ritonavir in mild/general
   COVID-19 infection: a prospective, open-label, multicenter, randomized
   controlled clinical study
SO TRIALS
LA English
DT Article
DE COVID-19; Chloroquine; Lopinavir; ritonavir; Randomized controlled
   clinical study; Efficacy
ID CORONAVIRUS; INHIBITION; ENTRY; DRUG
AB BackgroundThe outbreak of COVID-19 (caused by SARS-Cov-2) is very serious, and no effective antiviral treatment has yet been confirmed. The adage "old drug, new trick" in this context may suggest the important therapeutic potential of existing drugs. We found that the lopinavir/ritonavir treatment recommended in the fifth edition of the Treatment Plan of China can only help to improve a minority of throat-swab nucleic-acid results (3/15) in hospitals. Our previous use of chloroquine to treat patients with COVID-19 infection showed an improvement in more throat-swab nucleic-acid results (5/10) than the use of lopinavir/ritonavir.Methods/designThis is a prospective, open-label, randomized controlled, multicenter clinical study. The study consists of three phases: a screening period, a treatment period of no more than 10days, and a follow-up period for each participant. Participants with COVID-19 infection who are eligible for selection for the study will be randomly allocated to the trial group or the control group. The control group will be given lopinavir/ritonavir treatment for no more than 10days. The trial group will be given chloroquine phosphate treatment for no more than 10days. The primary outcome is the clinical recovery time at no more than 28days after the completion of therapy and follow-up. The secondary outcomes include the rate of treatment success after the completion of therapy and follow-up, the time of treatment success after no more than 28days, the rate of serious adverse events during the completion of therapy and follow-up, and the time to return to normal temperature (calculated from the onset of illness) during the completion of therapy and follow-up. Comparisons will be performed using two-sided tests with a statistical significance level of 5%.DiscussionThis experiment should reveal the efficacy and safety of using chloroquine versus lopinavir/ritonavir for patients with mild/general COVID-19 infection. If the new treatment including chloroquine shows a higher rate of throat-swab SARS-CoV-2 real-time fluorescent reverse transcription polymerase chain reaction (RT-PCR) negativity and is safe, it could be tested as a future COVID-19 treatment.Trial registrationChinese Clinical Trial Registry, ID: ChiCTR2000029741. Registered on 11 February 2020.
C1 [Liu, Xi; Chen, Huili; Shang, Yuqi; Zhu, Hongqiong; Chen, Gongqi; Zhou, Yaoyong; Huang, Mingxing; Hong, Zhongsi; Xia, Jinyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China.
   [Chen, Yuanli] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Hosp Infect Control, Zhuhai, Peoples R China.
   [Liu, Shaoxuan] Sun Yat Sen Univ, Affiliated Hosp 5, Off Clin Res Ctr, Zhuhai, Peoples R China.
RP Huang, MX; Hong, ZS; Xia, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Peoples R China.
EM huangmx5@mail.sysu.edu.cn; hongzhs@sysu.edu.cn;
   xiajinyu@mail.sysu.edu.cn
FU National key Research and Development (R&D plan "public security risk
   prevention and control and emergency technical equipment": Novel
   coronavirus infection pneumonia diagnosis and control key technology
   research) [2020YFC082400]; Guangdong Research and Development (R&D)
   Program in Key Areas: Guangdong Scientific and Technological Research
   Special fund for Prevention and Treatment of COVID19; Special fund for
   emergency research on SARS-CoV-2 from the Guangzhou Regenerative
   Medicine and Health Guangdong Laboratory; Cultivation Project of "Three
   Major Scientific Research Projects" of Sun Yatsen University in 2020;
   Emergency Project of New Coronavirus Prevention and Control Science and
   Technology of Sun Yat-sen University
FX This work was supported in part by National key Research and Development
   (R&D plan "public security risk prevention and control and emergency
   technical equipment": Novel coronavirus infection pneumonia diagnosis
   and control key technology research (2020YFC082400), Guangdong Research
   and Development (R&D) Program in Key Areas: Guangdong Scientific and
   Technological Research Special fund for Prevention and Treatment of
   COVID19, Special fund for emergency research on SARS-CoV-2 from the
   Guangzhou Regenerative Medicine and Health Guangdong Laboratory,
   Cultivation Project of "Three Major Scientific Research Projects" of Sun
   Yatsen University in 2020, Emergency Project of New Coronavirus
   Prevention and Control Science and Technology of Sun Yat-sen University.
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Diaz-Griffero F, 2002, J VIROL, V76, P12866, DOI 10.1128/JVI.76.24.12866-12876.2002
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GonzalezDunia D, 1998, J VIROL, V72, P783, DOI 10.1128/JVI.72.1.783-788.1998
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Legssyer R, 2003, J INORG BIOCHEM, V94, P36, DOI 10.1016/S0162-0134(02)00633-5
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Naarding MA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-6
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Zhang SN, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104547
NR 20
TC 3
Z9 3
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 8
PY 2020
VL 21
IS 1
AR 622
DI 10.1186/s13063-020-04478-w
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP0MN
UT WOS:000551908000003
PM 32641091
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sun, SH
   Chen, Q
   Gu, HJ
   Yang, G
   Wang, YX
   Huang, XY
   Liu, SS
   Zhang, NN
   Li, XF
   Xiong, R
   Guo, Y
   Deng, YQ
   Huang, WJ
   Liu, Q
   Liu, QM
   Shen, YL
   Zhou, Y
   Yang, X
   Zhao, TY
   Fan, CF
   Zhou, YS
   Qin, CF
   Wang, YC
AF Sun, Shi-Hui
   Chen, Qi
   Gu, Hong-Jing
   Yang, Guan
   Wang, Yan-Xiao
   Huang, Xing-Yao
   Liu, Su-Su
   Zhang, Na-Na
   Li, Xiao-Feng
   Xiong, Rui
   Guo, Yan
   Deng, Yong-Qiang
   Huang, Wei-Jin
   Liu, Quan
   Liu, Quan-Ming
   Shen, Yue-Lei
   Zhou, Yong
   Yang, Xiao
   Zhao, Tong-Yan
   Fan, Chang-Fa
   Zhou, Yu-Sen
   Qin, Cheng-Feng
   Wang, You-Chun
TI A Mouse Model of SARS-CoV-2 Infection and Pathogenesis
SO CELL HOST & MICROBE
LA English
DT Article
ID SYNDROME CORONAVIRUS INFECTION; PNEUMONIA; VIRUS
AB Since December 2019, a novel coronavirus SARS-CoV-2 has emerged and rapidly spread throughout the world, resulting in a global public health emergency. The lack of vaccine and antivirals has brought an urgent need for an animal model. Human angiotensin-converting enzyme II (ACE2) has been identified as a functional receptor for SARS-CoV-2. In this study, we generated a mouse model expressing human ACE2 (hACE2) by using CRISPR/Cas9 knockin technology. In comparison with wild-type C57BL/6 mice, both young and aged hACE2 mice sustained high viral loads in lung, trachea, and brain upon intranasal infection. Although fatalities were not observed, interstitial pneumonia and elevated cytokines were seen in SARS-CoV-2 infected-aged hACE2 mice. Interestingly, intragastric inoculation of SARS-CoV-2 was seen to cause productive infection and lead to pulmonary pathological changes in hACE2 mice. Overall, this animal model described here provides a useful tool for studying SARS-CoV-2 transmission and pathogenesis and evaluating COVID-19 vaccines and therapeutics.
C1 [Sun, Shi-Hui; Chen, Qi; Gu, Hong-Jing; Huang, Xing-Yao; Zhang, Na-Na; Li, Xiao-Feng; Guo, Yan; Deng, Yong-Qiang; Zhao, Tong-Yan; Zhou, Yu-Sen; Qin, Cheng-Feng] Acad Mil Med Sci AMMS, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Yang, Guan; Wang, Yan-Xiao; Yang, Xiao] Beijing Inst Life, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing 102206, Peoples R China.
   [Liu, Su-Su; Xiong, Rui; Liu, Quan; Liu, Quan-Ming; Fan, Chang-Fa] Natl Inst Food & Drug Control, Inst Lab Anim Resources, Div Anim Model Res, Beijing 102629, Peoples R China.
   [Huang, Wei-Jin; Wang, You-Chun] Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.
   [Shen, Yue-Lei] Beijing Biocytogen Co Ltd, Beijing 101111, Peoples R China.
   [Zhou, Yong] Chongqing Weisiteng Biotech Transnatl Res Inst, Chongqing 400039, Peoples R China.
RP Zhou, YS; Qin, CF (corresponding author), Acad Mil Med Sci AMMS, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.; Fan, CF (corresponding author), Natl Inst Food & Drug Control, Inst Lab Anim Resources, Div Anim Model Res, Beijing 102629, Peoples R China.; Wang, YC (corresponding author), Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.
EM fancf@nifdc.org.cn; yszhou@bmi.ac.cn; qincf@bmi.ac.cn;
   wangyc@nifdc.org.cn
RI Qin, Cheng-Feng/I-6839-2019; huang, weijin/AAY-5028-2020; Liu,
   Quan/ABH-2947-2020
OI Qin, Cheng-Feng/0000-0002-0632-2807; Huang, Weijin/0000-0002-4246-8889
FU National Key Research and Development Project of China, China
   [2016YFD0500304, 2020YFA0707801]; National Science and Technology Major
   Project of China, China [2017ZX103304402, 2018ZX09711003]; National
   Natural Science Foundation of China, ChinaNational Natural Science
   Foundation of China (NSFC) [82041006, 31871476]; Guangdong Pearl River
   talent plan, China [2019CX01N111]; National Science Fund for
   Distinguished Young Scholar, ChinaNational Natural Science Foundation of
   China (NSFC)National Science Fund for Distinguished Young Scholars
   [81925025]; Innovative Research Group from the National Natural Science
   Foundation of China, ChinaNational Natural Science Foundation of China
   (NSFC) [81621005]; Innovation Fund for Medical Sciences from the Chinese
   Academy of Medical Sciences, China [2019-I2M-5-049]
FX This work was supported by the National Key Research and Development
   Project of China, China (2016YFD0500304, 2020YFA0707801); the National
   Science and Technology Major Project of China, China (No.
   2017ZX103304402, 2018ZX09711003); the National Natural Science
   Foundation of China, China (82041006, 31871476); and Guangdong Pearl
   River talent plan, China (2019CX01N111). C.F.Q. was supported by the
   National Science Fund for Distinguished Young Scholar, China (No.
   81925025); the Innovative Research Group (No. 81621005) from the
   National Natural Science Foundation of China, China; and the Innovation
   Fund for Medical Sciences (No. 2019-I2M-5-049) from the Chinese Academy
   of Medical Sciences, China.
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   van den Brand JMA, 2010, J INFECT DIS, V201, P993, DOI 10.1086/651132
   van Doremalen N, 2013, EUROSURVEILLANCE, V18, P7, DOI 10.2807/1560-7917.ES2013.18.38.20590
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 39
TC 54
Z9 52
U1 11
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD JUL 8
PY 2020
VL 28
IS 1
BP 124
EP +
DI 10.1016/j.chom.2020.05.020
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA MK6ZV
UT WOS:000548935100016
PM 32485164
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Conforti, A
   Marra, E
   Roscilli, G
   Palombo, F
   Ciliberto, G
   Aurisicchio, L
AF Conforti, Antonella
   Marra, Emanuele
   Roscilli, Giuseppe
   Palombo, Fabio
   Ciliberto, Gennaro
   Aurisicchio, Luigi
TI Are Genetic Vaccines the Right Weapon against COVID-19?
SO MOLECULAR THERAPY
LA English
DT Letter
C1 [Conforti, Antonella] Evvivax, Via Castel Romano 100, I-00128 Rome, Italy.
   [Marra, Emanuele; Roscilli, Giuseppe; Palombo, Fabio; Aurisicchio, Luigi] Takis, Rome, Italy.
   [Ciliberto, Gennaro] IRCCS Regina Elena Natl Canc Inst, Rome, Italy.
   [Conforti, Antonella; Marra, Emanuele; Roscilli, Giuseppe; Palombo, Fabio; Aurisicchio, Luigi] Vitares, Rome, Italy.
RP Conforti, A (corresponding author), Evvivax, Via Castel Romano 100, I-00128 Rome, Italy.
EM conforti@evvivax.com
RI Ciliberto, Gennaro/J-4131-2017
OI Ciliberto, Gennaro/0000-0003-2851-8605
CR Allen A, 2018, CANCER IMMUNOL IMMUN, V67, P627, DOI 10.1007/s00262-017-2111-y
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Kennedy SB, 2017, NEW ENGL J MED, V377, P1438, DOI 10.1056/NEJMoa1614067
   Laurie KL, 2015, J INFECT DIS, V212, P1701, DOI 10.1093/infdis/jiv260
   Lee J, 2018, ACTA BIOMATER, V80, P31, DOI 10.1016/j.actbio.2018.08.033
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037
   Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Zhang WW, 2018, HUM GENE THER, V29, P160, DOI 10.1089/hum.2017.218
NR 11
TC 1
Z9 1
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD JUL 8
PY 2020
VL 28
IS 7
BP 1555
EP 1556
DI 10.1016/j.ymthe.2020.06.007
PG 2
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA MJ8YZ
UT WOS:000548374800003
PM 32553431
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Imperatori, C
   Dakanalis, A
   Farina, B
   Pallavicini, F
   Colmegna, F
   Mantovani, F
   Clerici, M
AF Imperatori, Claudio
   Dakanalis, Antonios
   Farina, Benedetto
   Pallavicini, Federica
   Colmegna, Fabrizia
   Mantovani, Fabrizia
   Clerici, Massimo
TI Global Storm of Stress-Related Psychopathological Symptoms: A Brief
   Overview on the Usefulness of Virtual Reality in Facing the Mental
   Health Impact of COVID-19
SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING
LA English
DT Article
DE COVID-19; trauma and stress-related disorders; virtual reality; PTSD
ID EXPOSURE THERAPY; PSYCHOLOGICAL IMPACT; DISORDER; INTERVENTION;
   TECHNOLOGY; RELAXATION; CHINA; CARE; WORKERS
AB The coronavirus disease 2019 (COVID-19) pandemic is a global health emergency requiring clinicians to be prepared to cope with the increase in the future incidence of trauma and stress-related psychopathological symptoms. The early detection of psychological distress and timely intervention are strongly recommended. Clinicians should also consider integrating new technologies such as virtual reality (VR) in the treatment of these trauma and stress-related psychopathological symptoms. Here we provide a brief overview of how VR can help to cope with the potential short-term and long-term mental health consequences related to this global emergency.
C1 [Imperatori, Claudio; Farina, Benedetto] European Univ Rome, Dept Human Sci, Cognit & Clin Psychol Lab, Via Aldobrandeschi 190, I-00163 Rome, Italy.
   [Dakanalis, Antonios; Clerici, Massimo] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy.
   [Pallavicini, Federica; Mantovani, Fabrizia] Univ Milano Bicocca, Dept Human Sci Educ Riccardo Massa, Milan, Italy.
   [Colmegna, Fabrizia] San Gerardo Monza Hlth & Social Care Trust, Mental Hlth Dept, Monza, Italy.
RP Imperatori, C (corresponding author), European Univ Rome, Dept Human Sci, Cognit & Clin Psychol Lab, Via Aldobrandeschi 190, I-00163 Rome, Italy.
EM claudio.imperatori@unier.it
FU Italian Cariplo FoundationFondazione Cariplo [2019-3396]
FX This article was supported by a grant (2019-3396) from the Italian
   Cariplo Foundation, which had not any involvement in manuscript
   preparation, or decision to submit the article for publication.
CR Albott CS, 2020, ANESTH ANALG, V131, P43, DOI 10.1213/ANE.0000000000004912
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   Anderson AP, 2017, AEROSP MED HUM PERF, V88, P520, DOI 10.3357/AMHP.4747.2017
   Bailenson JN, 2008, J LEARN SCI, V17, P102, DOI 10.1080/10508400701793141
   Bauerle A, 2020, J PUBLIC HLTH, pfdaa058
   Beck JG, 2007, BEHAV THER, V38, P39, DOI 10.1016/j.beth.2006.04.001
   Botella C, 2015, NEUROPSYCH DIS TREAT, V11, P2533, DOI 10.2147/NDT.S89542
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Cheng P, 2020, COMMUNITY MENT HLT J, V56, P786, DOI 10.1007/s10597-020-00624-5
   Cole CL, 2020, COGN BEH THER, V13, DOI 10.1017/S1754470X20000148
   de Freitas S, 2010, BRIT J EDUC TECHNOL, V41, P69, DOI 10.1111/j.1467-8535.2009.01024.x
   Difede J, 2007, J CLIN PSYCHIAT, V68, P1639, DOI 10.4088/JCP.v68n1102
   Difede J, 2014, NEUROPSYCHOPHARMACOL, V39, P1052, DOI 10.1038/npp.2013.317
   Donker T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061614
   Donker T, 2019, JAMA PSYCHIAT, V76, P682, DOI 10.1001/jamapsychiatry.2019.0219
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Duan YY, 2019, CURR MED SCI, V39, P690, DOI 10.1007/s11596-019-2093-4
   Freeman D, 2018, LANCET PSYCHIAT, V5, P625, DOI 10.1016/S2215-0366(18)30226-8
   Gaggioli A, 2014, J MED INTERNET RES, V16, P54, DOI 10.2196/jmir.3235
   Gerardi M, 2008, J TRAUMA STRESS, V21, P209, DOI 10.1002/jts.20331
   Gorini A, 2010, ANN GEN PSYCHIATR, V9, DOI 10.1186/1744-859X-9-30
   Gradl S, 2018, INT CONF WEARAB IMPL, P152, DOI 10.1109/BSN.2018.8329681
   Hoffman HG, 2004, SCI AM, V291, P58, DOI 10.1038/scientificamerican0804-58
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Li Z, 2020, BRAIN BEHAV IMMUNITY
   Lindner P, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00132
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Maples-Keller JL, 2017, HARVARD REV PSYCHIAT, V25, P103, DOI 10.1097/HRP.0000000000000138
   Goodman-Casanov JM, 2020, J MED INTERNET RES, V22, DOI 10.2196/19434
   Matthewson J, 2020, OCCUPATIONAL MED, pkqaa095
   McAlonan GM, 2007, CAN J PSYCHIAT, V52, P241, DOI 10.1177/070674370705200406
   McLay RN, 2011, CYBERPSYCH BEH SOC N, V14, P223, DOI 10.1089/cyber.2011.0003
   Meichenbaum D, 1985, STRESS INOCULATION T
   Meichenbaum D., 1996, CLIN PSYCHOL, V49, P4, DOI DOI 10.1037/E555362011-002
   Meichenbaum D, 1997, COGNITIVE BEHAV MODI
   Oflaz F, 2008, J CLIN NURS, V17, P677, DOI 10.1111/j.1365-2702.2007.02047.x
   Oing Theodore, 2018, JMIR Serious Games, V6, pe10965, DOI 10.2196/10965
   Pai A, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7010007
   Pallavicini F, 2009, J CYBERTHERAPY REHAB, V2, P315
   Pallavicini F, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-52
   Park MJ, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00505
   Parong J, 2018, J EDUC PSYCHOL, V110, P785, DOI 10.1037/edu0000241
   Pedram S, 2020, COMPUT HUM BEHAV, V105, DOI 10.1016/j.chb.2019.106223
   Pizzoli SFM, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00479
   Repetto C, 2009, JOVE-J VIS EXP, V33, pe1554
   Riva G, 2020, COVID FEEL GOOD AN E
   Riva G, 2020, CYBERPSYCH BEH SOC N, V23, P277, DOI 10.1089/cyber.2020.29183.gri
   Riva Giuseppe, 2012, Stud Health Technol Inform, V173, P369
   Rizzo A, 2010, ANN NY ACAD SCI, V1208, P114, DOI 10.1111/j.1749-6632.2010.05755.x
   Rockstroh C, 2019, INT J HUM-COMPUT ST, V130, P209, DOI 10.1016/j.ijhcs.2019.06.011
   ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626
   Rothbaum BO, 1999, J TRAUMA STRESS, V12, P263, DOI 10.1023/A:1024772308758
   Schmid L, 2016, STROKE RES TREAT, V2016, DOI 10.1155/2016/6210508
   Serino S, 2014, VIRTUAL REAL-LONDON, V18, P73, DOI 10.1007/s10055-013-0237-6
   Serrano B, 2016, COMPUT HUM BEHAV, V55, P1, DOI 10.1016/j.chb.2015.08.007
   Stefana A, EUROPEAN ARCH PSYCHI
   Stetz MC, 2011, MIL MED, V176, P1065, DOI 10.7205/MILMED-D-10-00393
   Villani D., 2009, INT J HUM-COMPUT INT, V1, P1
   Villani D, 2008, PSYCHNOLOGY J, V6, P7
   Villani D, 2012, CYBERPSYCH BEH SOC N, V15, P24, DOI 10.1089/cyber.2011.0141
   Walshe DG, 2003, CYBERPSYCHOL BEHAV, V6, P329, DOI 10.1089/109493103322011641
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Watkins LE, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00258
   Wechsler TF, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01758
   Wei N, 2020, J ZHEJIANG UNIV-SC B, V21, P400, DOI 10.1631/jzus.B2010013
   Zgueb Y, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113042
NR 67
TC 2
Z9 2
U1 17
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-2715
EI 2152-2723
J9 CYBERPSYCH BEH SOC N
JI Cyberpsychology Behav. Soc. Netw.
PD NOV 1
PY 2020
VL 23
IS 11
BP 782
EP 788
DI 10.1089/cyber.2020.0339
EA JUL 2020
PG 7
WC Psychology, Social
SC Psychology
GA OQ2KK
UT WOS:000547915500001
PM 32640852
DA 2021-01-01
ER

PT J
AU Sharma, A
   Sasser, T
   Gonzalez, ES
   Vander Stoep, A
   Myers, K
AF Sharma, Aditi
   Sasser, Tyler
   Gonzalez, Erin Schoenfelder
   Vander Stoep, Ann
   Myers, Kathleen
TI Implementation of Home-Based Telemental Health in a Large Child
   Psychiatry Department During the COVID-19 Crisis
SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
LA English
DT Article
DE telepsychiatry; home-based telemental health; COVID-19 pandemic; crisis
ID RISK-MANAGEMENT; TELEPSYCHIATRY; TELEHEALTH; DELIVERY; BEHAVIOR;
   THERAPY; SAFETY; TRIAL
AB Objective:Telemental health (TMH) is not well described for mental health service delivery during crises. Most child and adolescent psychiatry training programs have not integrated TMH into their curricula and are ill equipped to respond during crises to their patients' needs. In this study, we present the implementation of a home-based TMH (HB-TMH) service during the COVID-19 pandemic. Methods:We describe the technological, administrative, training, and clinical implementation components involved in transitioning a comprehensive outpatient child and adolescent psychiatry program to a HB-TMH virtual clinic. Results:The transition was accomplished in 6 weeks. Most in-clinic services were rapidly moved off campus to the home. Owing to challenges encountered with each implementation component, phone sessions bridged the transition from in-clinic to reliable virtual appointments. Within 3 weeks (March 20, 2020) of planning for HB-TMH, 67% of all appointments were conducted at home, and within 4 weeks (March 27, 2020), 90% were conducted at home. By week 6 (April 3, 2020), reliable HB-TMH appointments were implemented. Conclusions:The COVID-19 pandemic crisis created the opportunity to innovate a solution to disrupted care for our established patients and to create a resource for youth who developed problems during the crisis. Our department was experienced in providing TMH services that facilitated the transition to HB-TMH, yet still had to overcome known and unanticipated challenges. Our experience provides a roadmap for establishing a HB-TMH service with focus on rapid implementation. It also demonstrates a role for TMH during (rather than after) future crises when usual community resources are not available.
C1 [Sharma, Aditi; Sasser, Tyler; Gonzalez, Erin Schoenfelder; Vander Stoep, Ann; Myers, Kathleen] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Sharma, Aditi; Sasser, Tyler; Gonzalez, Erin Schoenfelder; Myers, Kathleen] Seattle Childrens Hosp, Dept Psychiat & Behav Med, 4800 Sand Point Way NE,MS OA-5-154, Seattle, WA 98105 USA.
   [Vander Stoep, Ann] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
   [Myers, Kathleen] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA.
RP Sharma, A (corresponding author), Seattle Childrens Hosp, Dept Psychiat & Behav Med, 4800 Sand Point Way NE,MS OA-5-154, Seattle, WA 98105 USA.
EM aditi.sharma@seattlechildrens.org
CR Accreditation Council for Graduate Medical Education, 2020, ACGME RESP COR COVID
   Amer Acad Of Child Adolescent, 2017, J AM ACAD CHILD PSY, V56, P875, DOI 10.1016/j.jaac.2017.07.008
   Bedford T., 2020, CRYPTIC TRANSMISSION
   CDC (Centers for Disease Control and Prevention), 2020, COR DIS 2019 CAS US
   Center for Medicare and Medicaid Services, 2020, TEL
   Comer JS, 2017, J CONSULT CLIN PSYCH, V85, P909, DOI 10.1037/ccp0000230
   Comer JS, 2014, J CLIN CHILD ADOLESC, V43, P74, DOI 10.1080/15374416.2013.855127
   Gates B, 2018, NEW ENGL J MED, V378, P2057, DOI 10.1056/NEJMp1806283
   Glueck D, 2013, ELSEV INSIGHT, P29, DOI 10.1016/B978-0-12-416048-4.00003-8
   Himle MB, 2012, BEHAV RES THER, V50, P565, DOI 10.1016/j.brat.2012.05.009
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Jefee-Bahloul H, 2014, J TELEMED TELECARE, V20, P167, DOI 10.1177/1357633X14527709
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Kim TJ, 2013, TELEMED E-HEALTH, V19, P200, DOI 10.1089/tmj.2012.0100
   Kramer GM, 2016, J CHILD ADOL PSYCHOP, V26, P198, DOI 10.1089/cap.2015.0018
   Lauer S.A., 2020, ANN INTERN MED
   Luxton DD, 2014, INT J PSYCHIAT MED, V48, P19, DOI 10.2190/PM.48.1.c
   Luxton DD, 2012, TELEMED E-HEALTH, V18, P629, DOI [10.1089/tmj.2012.0004, 10.1089/tmj.20120004]
   Luxton DD, 2010, TELEMED J E-HEALTH, V16, P705, DOI 10.1089/tmj.2009.0179
   Medicines San Frontieres, 2016, TEL HELPS BRIDG GAP
   Mishkind M, 2018, TELEPSYCHIATRY AND HEALTH TECHNOLOGIES: A GUIDE FOR MENTAL HEALTH PROFESSIONALS, P31
   Myers K, 2017, LEWISS CHILD ADOLESC
   Myers K, 2015, J AM ACAD CHILD PSY, V54, P263, DOI 10.1016/j.jaac.2015.01.009
   Myers KM, 2008, TELEMED J E-HEALTH, V14, P131, DOI 10.1089/tmj.2007.0035
   Myers KM, 2007, PSYCHIAT SERV, V58, P1493, DOI 10.1176/appi.ps.58.11.1493
   Qadir TF, 2016, LANCET PSYCHIAT, V3, P1016, DOI 10.1016/S2215-0366(16)30323-6
   Reese RM, 2013, TELEMED E-HEALTH, V19, P671, DOI 10.1089/tmj.2012.0312
   Reese RJ, 2012, PSYCHOL SERV, V9, P320, DOI 10.1037/a0026193
   Ripton JT, 2016, TELEMEDICINE IS BECO
   Roth DE, 2020, TELEHEALTH HOME DR R
   Shore JH, 2018, TELEMED E-HEALTH, V24, P827, DOI 10.1089/tmj.2018.0237
   Soron TR, 2019, LANCET PSYCHIAT, V6, P374, DOI 10.1016/S2215-0366(19)30137-3
   Stephan S, 2016, J CHILD ADOL PSYCHOP, V26, P266, DOI 10.1089/cap.2015.0019
   Storch EA, 2011, PSYCHIAT RES, V189, P407, DOI 10.1016/j.psychres.2011.05.047
   Tse YJ, 2015, TELEMED E-HEALTH, V21, P451, DOI 10.1089/tmj.2014.0132
   US Department of Health and Human Services, 2020, NOT ENF DISCR TEL RE
   van Doremalen N, 2020, N ENGL J MED
   Vo AH, 2010, TELEMED J E-HEALTH, V16, P627, DOI 10.1089/tmj.2009.0162
   Wacker DP, 2013, J DEV PHYS DISABIL, V25, P35, DOI 10.1007/s10882-012-9314-0
   Washington State Department of Health, 2020, REP CAS 2019 NOV COR
   World Health Organization, 2020, 2 M INT HLTH REG 200
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xie YH, 2013, TELEMED E-HEALTH, V19, P192, DOI 10.1089/tmj.2012.0108
   Yanicelli LM, 2020, J TELEMED TELECARE, DOI 10.1177/1357633X19899261
   Yellowlees PM, 2016, E MENTAL HLTH, P233, DOI DOI 10.1007/978-3-319-20852-7_12
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 4
Z9 4
U1 6
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5463
EI 1557-8992
J9 J CHILD ADOL PSYCHOP
JI J. Child Adolesc. Psychopharmacol.
PD SEP 1
PY 2020
VL 30
IS 7
BP 404
EP 413
DI 10.1089/cap.2020.0062
EA JUL 2020
PG 10
WC Pediatrics; Pharmacology & Pharmacy; Psychiatry
SC Pediatrics; Pharmacology & Pharmacy; Psychiatry
GA NI7GG
UT WOS:000547926100001
PM 32639849
OA Bronze
DA 2021-01-01
ER

PT J
AU Gerussi, A
   Rigamonti, C
   Elia, C
   Cazzagon, N
   Floreani, A
   Pozzi, R
   Pozzoni, P
   Claar, E
   Pasulo, L
   Fagiuoli, S
   Cristoferi, L
   Carbone, M
   Invernizzi, P
AF Gerussi, Alessio
   Rigamonti, Cristina
   Elia, Chiara
   Cazzagon, Nora
   Floreani, Annarosa
   Pozzi, Roberta
   Pozzoni, Pietro
   Claar, Ernesto
   Pasulo, Luisa
   Fagiuoli, Stefano
   Cristoferi, Laura
   Carbone, Marco
   Invernizzi, Pietro
TI Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From
   Immunosuppressed Patients
SO HEPATOLOGY COMMUNICATIONS
LA English
DT Article
ID WITHDRAWAL
AB Chronic immunosuppression is associated with increased and more severe viral infections. However, little is known about the association between immunosuppression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to describe the clinical course of patients with immunosuppressed autoimmune hepatitis (AIH) during coronavirus disease 2019 (COVID-19) infection in Italy. Our study is a case series of patients with AIH treated with immunosuppression, who tested positive for SARS-CoV-2 in March 2020 during the outbreak of COVID-19. Ten patients from seven different hospitals in Italy were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020. Seven subjects were female (70%), and age ranged from 27 to 73 years. Before the onset of SARS-CoV-2 infection, all patients were taking immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other patients had recent acute onset of their AIH, and consequently started high-dose steroids, as per induction protocol. All patients had a respiratory syndrome and a positive nasal swab for SARS-CoV-2. Five patients developed a computed tomography-confirmed COVID-19 pneumonia. Six subjects received a combination of antiretroviral and antimalarial drugs. In seven patients, the dosage of immunosuppressive medication was changed. Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases; they remained within the normal range in all cases, and improved in the two acute cases treated with high-dose steroids. The clinical outcome was comparable to the reported cases occurring in non-immunosuppressed subjects.Conclusion:Patients under immunosuppressive therapy for AIH developing COVID-19 show a disease course presumptively similar to that reported in the non-immunosuppressed population. These data might aid in medical decisions when dealing with SARS-CoV-2 infection in immunocompromised patients.
C1 [Gerussi, Alessio; Cristoferi, Laura; Carbone, Marco; Invernizzi, Pietro] Univ Milano Bicocca, Div Gastroenterol, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.
   [Gerussi, Alessio; Cristoferi, Laura; Carbone, Marco; Invernizzi, Pietro] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.
   [Gerussi, Alessio; Cristoferi, Laura; Carbone, Marco; Invernizzi, Pietro] San Gerardo Hosp, European Reference Network Hepatol Dis, Monza, Italy.
   [Rigamonti, Cristina] Univ Piemonte Orientale UPO, Dept Translat Med, Novara, Italy.
   [Rigamonti, Cristina] AOU Maggiore Carita, Div Internal Med, Novara, Italy.
   [Elia, Chiara] Cardinal Massaia Hosp, Gastroenterol Unit, Asti, Italy.
   [Cazzagon, Nora; Floreani, Annarosa] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy.
   [Cazzagon, Nora] Azienda Osped Univ Padova, Gastroenterol Unit, European Reference Network Hepatol Dis, Padua, Italy.
   [Floreani, Annarosa] IRCCS Negrar, Verona, Italy.
   [Pozzi, Roberta; Pozzoni, Pietro] ASST Lecco, Internal Med Unit, Lecce, Italy.
   [Claar, Ernesto] Evangelico Betania Hosp, Liver Unit, Naples, Italy.
   [Pasulo, Luisa; Fagiuoli, Stefano] ASST Papa Giovanni XXIII, Gastroenterol Hepatol & Liver Transplantat Unit, Dept Med, Bergamo, Italy.
RP Invernizzi, P (corresponding author), Univ Milano Bicocca, Div Gastroenterol, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.; Invernizzi, P (corresponding author), Univ Milano Bicocca, Ctr Autoimmune Liver Dis, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.
EM pietro.invernizzi@unimib.it
OI Floreani, Annarosa/0000-0003-2630-7054; Rigamonti,
   Cristina/0000-0003-2089-4139; Fagiuoli, Stefano/0000-0001-8308-0701;
   CRISTOFERI, LAURA/0000-0001-9846-7474
FU Biocompatible Nano-assemblies to Increase the Safety and the Efficacy of
   Steroid Treatment Against Liver Inflammation [GR-2018-12367794]; Role of
   Auto-reactive Hepatic Natural Killer Cells in the Pathogenesis of
   Primary Biliary Cholangitis [PE-2016-02363915]
FX Supported by the Biocompatible Nano-assemblies to Increase the Safety
   and the Efficacy of Steroid Treatment Against Liver Inflammation
   (Grant/Award Number GR-2018-12367794) and the Role of Auto-reactive
   Hepatic Natural Killer Cells in the Pathogenesis of Primary Biliary
   Cholangitis (Grant/Award Number PE-2016-02363915).
CR Bayoumy AB, 2020, EXPERT OPIN DRUG MET, V16, P111, DOI 10.1080/17425255.2020.1719996
   EASL Clinical Practice, 2018, J HEPATOL, V69, P406, DOI DOI 10.1016/j.jhep.2018.03.024
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Kaltsas A, 2012, CURR OPIN INFECT DIS, V25, P423, DOI 10.1097/QCO.0b013e328355660b
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Mehta P, 2020, LANCET, V6736, P19
   Montano-Loza AJ, 2007, LIVER INT, V27, P507, DOI 10.1111/j.1478-3231.2007.01444.x
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   van Gerven NMF, 2013, J HEPATOL, V58, P141, DOI 10.1016/j.jhep.2012.09.009
   Vogelin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155218
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 16
TC 2
Z9 2
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 2471-254X
J9 HEPATOL COMMUN
JI Hepatol. Commun.
PD SEP
PY 2020
VL 4
IS 9
BP 1257
EP 1262
DI 10.1002/hep4.1557
EA JUL 2020
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO7ID
UT WOS:000547850800001
PM 32838102
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jones, CM
   Radhakrishna, G
   Aitken, K
   Bridgewater, J
   Corrie, P
   Eatock, M
   Goody, R
   Ghaneh, P
   Good, J
   Grose, D
   Holyoake, D
   Hunt, A
   Jamieson, NB
   Palmer, DH
   Soonawalla, Z
   Valle, JW
   Hawkins, MA
   Mukherjee, S
AF Jones, Christopher M.
   Radhakrishna, Ganesh
   Aitken, Katharine
   Bridgewater, John
   Corrie, Pippa
   Eatock, Martin
   Goody, Rebecca
   Ghaneh, Paula
   Good, James
   Grose, Derek
   Holyoake, Daniel
   Hunt, Arabella
   Jamieson, Nigel B.
   Palmer, Daniel H.
   Soonawalla, Zahir
   Valle, Juan W.
   Hawkins, Maria A.
   Mukherjee, Somnath
TI Considerations for the treatment of pancreatic cancer during the
   COVID-19 pandemic: the UK consensus position
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
ID ADJUVANT CHEMOTHERAPY; DUCTAL ADENOCARCINOMA; GEMCITABINE; THERAPY;
   PROGRESSION; FOLFIRINOX; TIME; RISK
AB The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk-benefit balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this, we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the risk-benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches.
C1 [Jones, Christopher M.] Univ Leeds, Fac Biol Sci, Leeds, W Yorkshire, England.
   [Jones, Christopher M.; Goody, Rebecca] Univ Leeds, Fac Med & Hlth, Radiotherapy Res Grp, Leeds, W Yorkshire, England.
   [Jones, Christopher M.; Goody, Rebecca] Leeds Teaching Hosp NHS Trust, Leeds Canc Ctr, Leeds, W Yorkshire, England.
   [Radhakrishna, Ganesh; Valle, Juan W.] Christie NHS Fdn Trust, Manchester, Lancs, England.
   [Aitken, Katharine; Hunt, Arabella] Royal Marsden NHS Fdn Trust, Royal Marsden Hosp, London, England.
   [Aitken, Katharine; Hunt, Arabella] Inst Canc Res, London, England.
   [Bridgewater, John] UCL, Canc Inst, London, England.
   [Corrie, Pippa] Cambridge Univ Hosp NHS Fdn Trust, Dept Oncol, Cambridge, England.
   [Eatock, Martin] Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland.
   [Ghaneh, Paula] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Good, James] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.
   [Grose, Derek] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
   [Holyoake, Daniel] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England.
   [Jamieson, Nigel B.] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland.
   [Palmer, Daniel H.] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Palmer, Daniel H.] Univ Liverpool, Liverpool Expt Canc Med Ctr, Liverpool, Merseyside, England.
   [Soonawalla, Zahir] Oxford Univ Hosp NHS Fdn Trust, Oxford, England.
   [Valle, Juan W.] Univ Manchester, Div Canc Sci, Manchester, Lancs, England.
   [Hawkins, Maria A.] UCL, Dept Med Phys & Biomed Engn, London, England.
   [Mukherjee, Somnath] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England.
RP Mukherjee, S (corresponding author), Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England.
EM somnath.mukherjee@oncology.ox.ac.uk
RI ; Hawkins, Maria Andreia/A-9404-2013
OI Corrie, Pippa/0000-0003-4875-7021; Hawkins, Maria
   Andreia/0000-0002-6669-0628; Bridgewater, John/0000-0001-9186-1604
FU Wellcome Trust Clinical Research FellowshipWellcome Trust; NHS; Cancer
   research UK Clinician Scientist FellowshipCancer Research UK
   [C55370/A25813]; NIHR Biomedical Research Centre at University College
   London Hospitals NHS Foundation Trust and University College London;
   NIHR Oxford Biomedical Research CentreNational Institute for Health
   Research (NIHR)
FX C.M.J. is supported by a Wellcome Trust Clinical Research Fellowship.
   K.A. and A.H. acknowledge NHS funding to the NIHR Biomedical Research
   Centre at The Royal Marsden and the Institute of Cancer Research. N.B.J.
   is supported by a Cancer research UK Clinician Scientist Fellowship
   (C55370/A25813). M.A.H. is supported by funding from the NIHR Biomedical
   Research Centre at University College London Hospitals NHS Foundation
   Trust and University College London. S.M. is supported by funding from
   the NIHR Oxford Biomedical Research Centre.
CR Ahn SJ, 2017, J GASTROINTEST CANC, V48, P164, DOI 10.1007/s12029-016-9876-7
   American College of Surgeons, 2020, COVID 19 REC MAN EL
   British Society of Gastroenterology, 2020, END ACT COVID 19 BSG
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Filippi AR, 2020, INT J RADIAT ONCOL, VS0360-3016, P30930
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Holyoake DLP, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2765-4
   Jones B., 2020, ADDITIONAL GUIDANCE
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, VS0923-7534, P39303
   National Institute for Health and Care Excellence (NICE), 2020, COVID 19 RAP GUID DE
   National Institute for Health & Care Excellence (NICE), COVID 19 RAP GUID DE
   Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   NHS England, 2020, CLIN GUID MAN CANC P
   Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201
   Petrelli F, 2017, INT J RADIAT ONCOL, V97, P313, DOI 10.1016/j.ijrobp.2016.10.030
   Prior Jr. P.W, 2018, INT J RADIAT ONCOL, V102, DOI [10.1016/jijrobp.2018.06.250, DOI 10.1016/JIJR0BP.2018.06.250]
   Robinson Andrew G, 2020, Nat Rev Clin Oncol, P1, DOI 10.1038/s41571-020-0394-y
   Royal College of Surgeons, 2020, INT GEN SURG GUID CO
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Suker M, 2016, LANCET ONCOL, V17, P801, DOI 10.1016/S1470-2045(16)00172-8
   Tchelebi LT, 2020, CANCER-AM CANCER SOC, V126, P2120, DOI 10.1002/cncr.32756
   Valle JW, 2014, J CLIN ONCOL, V32, P504, DOI 10.1200/JCO.2013.50.7657
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Versteijne E, 2020, J CLIN ONCOL, V38, P1763, DOI 10.1200/JCO.19.02274
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xiang M, 2020, RADIOTHER ONCOL, V143, P101, DOI 10.1016/j.radonc.2020.01.007
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Yu J, 2015, GUT, V64, P1783, DOI 10.1136/gutjnl-2014-308653
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
   Zhan HX, 2017, CANCER MED-US, V6, P1201, DOI 10.1002/cam4.1071
NR 36
TC 3
Z9 3
U1 3
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD SEP 1
PY 2020
VL 123
IS 5
BP 709
EP 713
DI 10.1038/s41416-020-0980-x
EA JUL 2020
PG 5
WC Oncology
SC Oncology
GA OS4YB
UT WOS:000546539200001
PM 32641867
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cingolani, A
   Tummolo, AM
   Montemurro, G
   Gremese, E
   Larosa, L
   Cipriani, MC
   Pasciuto, G
   Liperoti, R
   Murri, R
   Pirronti, T
   Cauda, R
   Fantoni, M
AF Cingolani, A.
   Tummolo, A. M.
   Montemurro, G.
   Gremese, E.
   Larosa, L.
   Cipriani, M. C.
   Pasciuto, G.
   Liperoti, R.
   Murri, R.
   Pirronti, T.
   Cauda, R.
   Fantoni, M.
CA COVID 2 Columbus Working Grp
TI Baricitinib as rescue therapy in a patient with COVID-19 with no
   complete response to sarilumab
SO INFECTION
LA English
DT Article
DE Baricitinib; SARS-CoV-2; Sarilumab; COVID-19; Immunotherapy
AB A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.
C1 [Cingolani, A.; Murri, R.; Cauda, R.; Fantoni, M.] Fdn Policlin Gemelli IRCCS, Dipartimento Sci Lab & Infettivol, Rome, Italy.
   [Cingolani, A.; Murri, R.; Cauda, R.; Fantoni, M.] Univ Cattolica S Cuore, Dipartimento Sicurezza & Bioet, Milan, Italy.
   [Tummolo, A. M.; Cipriani, M. C.; Liperoti, R.] Fdn Policlin Gemelli IRCCS, Dipartimento Sci Invecchiamento, Rome, Italy.
   [Montemurro, G.; Gremese, E.; Pasciuto, G.] Fdn Policlin Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Rome, Italy.
   [Gremese, E.; Liperoti, R.] Univ Cattolica S Cuore, Dipartimento Sci Geriatr & Ortoped, Milan, Italy.
   [Larosa, L.; Pirronti, T.] Fdn Policlin Gemelli IRCCS, Dipartimento Diagnost Immagini, Rome, Italy.
   [Pirronti, T.] Univ Cattolica S Cuore, Dipartimento Sci Radiol & Ematol, Milan, Italy.
   [Tummolo, A. M.] Univ Cattolica S Cuore, Fdn Policlin Gemelli, Div Infect Dis, IRCCS,Covid 2 Columbus, Lgo A Gemelli 8, I-00167 Rome, Italy.
RP Tummolo, AM (corresponding author), Fdn Policlin Gemelli IRCCS, Dipartimento Sci Invecchiamento, Rome, Italy.; Tummolo, AM (corresponding author), Univ Cattolica S Cuore, Fdn Policlin Gemelli, Div Infect Dis, IRCCS,Covid 2 Columbus, Lgo A Gemelli 8, I-00167 Rome, Italy.
EM anita.tummolo@gmail.com
CR Bhimraj A, 2020, INFECT DIS SOC AM GU
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   European Medicines Agency, 2020, OL SUMM PROD CHAR
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Richardson P, 2020, LANCET INFECT DIS, DOI [10.1016/S1473-3099(20)30270, DOI 10.1016/S1473-3099(20)30270]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhu H, 2020, CHINA EMERG MICROB I, V9, P313, DOI [10.1080/22221751.2020.1725399, DOI 10.1080/22221751.2020.1725399]
NR 15
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD OCT
PY 2020
VL 48
IS 5
BP 767
EP 771
DI 10.1007/s15010-020-01476-7
EA JUL 2020
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NT0QS
UT WOS:000546513000001
PM 32642806
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shahidi-Dadras, M
   Abdollahimajd, F
   Ohadi, L
   Tabary, M
   Araghi, F
   Mozafari, N
   Toosi, P
   Dadkhahfar, S
AF Shahidi-Dadras, Mohammad
   Abdollahimajd, Fahimeh
   Ohadi, Laya
   Tabary, Mohammadreza
   Araghi, Farnaz
   Mozafari, Nikoo
   Toosi, Parviz
   Dadkhahfar, Sahar
TI COVID-19 in pemphigus vulgaris patients with previous rituximab therapy:
   a tele-medicine experience
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Letter; Early Access
C1 [Shahidi-Dadras, Mohammad; Abdollahimajd, Fahimeh; Ohadi, Laya; Araghi, Farnaz; Mozafari, Nikoo; Toosi, Parviz; Dadkhahfar, Sahar] Shahid Beheshti Univ Med Sci, Skin Res Ctr, Tehran, Iran.
   [Tabary, Mohammadreza] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
   [Mozafari, Nikoo] Shahid Beheshti Univ Med Sci, Loghman Hakim Hosp, Dept Dermatol, Tehran, Iran.
RP Dadkhahfar, S (corresponding author), Shahid Beheshti Univ Med Sci, Skin Res Ctr, Tehran, Iran.
EM Sahar.dadkhahfar@gmail.com
RI Abdollahimajd, Fahimeh/AAZ-4160-2020; araghi, farnaz/AAY-8322-2020
OI Abdollahimajd, Fahimeh/0000-0002-9463-0665; Tabary,
   Mohammadreza/0000-0002-3746-7371; Ohadi, Laya/0000-0001-7480-8975
CR Abdollahimajd F, 2020, ARCH ACAD EMERG MED, V8
   Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3
   Kasperkiewicz M, 2020, J EUR ACAD DERMATOL, V34, pE302, DOI 10.1111/jdv.16525
   Kasperkiewicz M, 2012, J DTSCH DERMATOL GES, V10, P727, DOI 10.1111/j.1610-0387.2012.07931.x
NR 4
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1789041
EA JUL 2020
PG 2
WC Dermatology
SC Dermatology
GA MI1FJ
UT WOS:000547160900001
PM 32594787
DA 2021-01-01
ER

PT J
AU Vijayaraj, R
   Altaff, K
   Rosita, AS
   Ramadevi, S
   Revathy, J
AF Vijayaraj, R.
   Altaff, K.
   Rosita, A. Sherlin
   Ramadevi, S.
   Revathy, J.
TI Bioactive compounds from marine resources against novel corona virus
   (2019-nCoV):in silicostudy for corona viral drug
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Early Access
DE 2019-nCoV; Antiviral drug; Bioactive Compounds; Esculetin ethyl ester
ID NATURAL-PRODUCTS
AB Present research reports the molecular docking analysis of 2019-nCoV inhibition by antiviral compounds from marine natural resources. For this study, the structure of ligand (antiviral compound) and 2019-nCoV main protease (M-pro) was received from the databases of PubChem and Protein Data Bank (PDB), respectively. Molecular Docking was performed by Autodock version 4.2.6 software. Eight antiviral compounds identified showed inhibitory activities against novel 2019-nCoV protease. Of these compounds, Esculetin ethyl ester (-8.42 kcal/mol) from Marine SpongesAxinella cf. corrugata, has the strongest interaction with the protease enzyme of 2019-nCoV and it may be considered as an effective 2019-nCoV antiprotease drug.
C1 [Vijayaraj, R.; Altaff, K.] AMET Univ, Dept Marine Biotechnol, Chennai, Tamil Nadu, India.
   [Rosita, A. Sherlin] Bishop Heber Coll, Dept Bioinformat, Trichy, India.
   [Ramadevi, S.; Revathy, J.] Bonsecours Coll Women, Dept Biotechnol, Thanjavur, India.
RP Altaff, K (corresponding author), AMET Univ, Dept Marine Biotechnol, Chennai, Tamil Nadu, India.
EM kaltaff@gmail.com
OI Radha, Vijayaraj/0000-0002-4170-1685
CR de Lira SP, 2007, J BRAZIL CHEM SOC, V18, P440, DOI 10.1590/S0103-50532007000200030
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Li KN, 2020, CURR DRUG TARGETS, V21, P3, DOI 10.2174/1389450120666190923162203
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Nannou C, 2020, SCI TOTAL ENVIRON, V699, DOI 10.1016/j.scitotenv.2019.134322
   Rabaan A, 2020, SARS COV 2 COVID 19
   Sagar S, 2010, MAR DRUGS, V8, P2619, DOI 10.3390/md8102619
   Sampangi-Ramaiah MH, 2020, CURR SCI INDIA, V118, P1087, DOI 10.18520/cs/v118/i7/1087-1092
   Shaghaghi N., 2020, PREPRINT
   Tambo E, 2020, J INFECT PUBLIC HEAL, V13, P674, DOI 10.1016/j.jiph.2020.01.313
   Uzair B, 2011, BIOIMPACTS, V1, P203, DOI 10.5681/bi.2011.029
   Vijayaraj R., 2019, Journal of Biologically Active Products from Nature, V9, P445, DOI 10.1080/22311866.2020.1714478
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 15
TC 1
Z9 1
U1 15
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
DI 10.1080/14786419.2020.1791115
EA JUL 2020
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA MI0JU
UT WOS:000547104800001
PM 32643410
DA 2021-01-01
ER

PT J
AU Lima, B
   Gibson, GT
   Vullaganti, S
   Malhame, K
   Maybaum, S
   Hussain, ST
   Shah, S
   Majure, DT
   Wallach, F
   Jang, K
   Bijol, V
   Esposito, MJ
   Williamson, AK
   Thomas, RM
   Bhuiya, TA
   Fernandez, HA
   Stevens, GR
AF Lima, Brian
   Gibson, Gregory T.
   Vullaganti, Sirish
   Malhame, Kathryn
   Maybaum, Simon
   Hussain, Syed T.
   Shah, Samit
   Majure, David T.
   Wallach, Fran
   Jang, Kristine
   Bijol, Vanesa
   Esposito, Michael J.
   Williamson, Alex K.
   Thomas, Rebecca M.
   Bhuiya, Tawfiqul A.
   Fernandez, Harold A.
   Stevens, Gerin R.
TI COVID-19 in recent heart transplant recipients: Clinicopathologic
   features and early outcomes
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; heart transplant
AB Background The impact of COVID-19 on heart transplant (HTx) recipients remains unclear, particularly in the early post-transplant period. Methods We share novel insights from our experience in five HTx patients with COVID-19 (three within 2 months post-transplant) from our institution at the epicenter of the pandemic. Results: All five exhibited moderate (requiring hospitalization, n = 3) or severe (requiring ICU and/or mechanical ventilation, n = 2) illness. Both cases with severe illness were transplanted approximately 6 weeks before presentation and acquired COVID-19 through community spread. All five patients were on immunosuppressive therapy with mycophenolate mofetil (MMF) and tacrolimus, and three that were transplanted within the prior 2 months were additionally on prednisone. The two cases with severe illness had profound lymphopenia with markedly elevated C-reactive protein, procalcitonin, and ferritin. All had bilateral ground-glass opacities on chest imaging. MMF was discontinued in all five, and both severe cases received convalescent plasma. All three recent transplants underwent routine endomyocardial biopsies, revealing mild (n = 1) or no acute cellular rejection (n = 2), and no visible viral particles on electron microscopy. Within 30 days of admission, the two cases with severe illness remain hospitalized but have clinically improved, while the other three have been discharged. Conclusions COVID-19 appears to negatively impact outcomes early after heart transplantation.
C1 [Lima, Brian; Malhame, Kathryn; Hussain, Syed T.; Fernandez, Harold A.] Northwell Hlth, North Shore Univ Hosp, Dept Cardiovasc & Thorac Surg, Manhasset, NY USA.
   [Gibson, Gregory T.; Vullaganti, Sirish; Maybaum, Simon; Shah, Samit; Majure, David T.; Jang, Kristine; Stevens, Gerin R.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Cardiol, Manhasset, NY USA.
   [Wallach, Fran] Northwell Hlth & Zucker Sch Med Hofstra Northwell, Div Infect Dis, Hempstead, NY USA.
   [Bijol, Vanesa; Esposito, Michael J.; Williamson, Alex K.; Thomas, Rebecca M.; Bhuiya, Tawfiqul A.] Northwell Hlth, Dept Pathol & Lab Med, Hempstead, NY USA.
   [Bijol, Vanesa; Esposito, Michael J.; Williamson, Alex K.; Thomas, Rebecca M.; Bhuiya, Tawfiqul A.] Zucker Sch Med Hofstra Northwell, Hempstead, NY USA.
RP Lima, B (corresponding author), North Shore Univ Hosp, Dept Cardiovasc & Thorac Surg, 300 Community Dr, Manhasset, NY 11030 USA.
EM blima@northwell.edu
OI Gibson, Gregory/0000-0002-6538-1583; Lima, Brian/0000-0002-2555-2229
CR Akalin E, 2020, N ENGL J MED
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Chapman AR, 2020, CIRCULATION, V141, P1733, DOI 10.1161/CIRCULATIONAHA.120.047008
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cheng P, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01293-2
   DeFilippis EM, 2020, CIRCULATION, V141, P2048, DOI 10.1161/CIRCULATIONAHA.120.047096
   Dong NG, 2020, JACC-HEART FAIL, V8, P515, DOI 10.1016/j.jchf.2020.04.001
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gandhi RT, 2020, N ENGL J MED
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hendren NS, 2020, CIRCULATION, V141, P1903, DOI 10.1161/CIRCULATIONAHA.120.047349
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Johns Hopkins University, JS HOPK U COVID 19 M
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liu PP, 2020, CIRCULATION
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Romanelli A, 2020, AM J TRANSPLANT
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Stachel MW, 2020, J HEART LUNG TRANSPL, V39, P612, DOI 10.1016/j.healun.2020.04.008
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 32
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13382
DI 10.1111/tid.13382
EA JUL 2020
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000546106200001
PM 32583620
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lario, ARV
   Vega-Diez, D
   Gonzalez-Canete, M
   Polo-Rodriguez, I
   Piteiro-Bermejo, AB
   Herrero-Fernandez, M
   Arevalo-Serrano, J
   Trasobares-Marugan, L
   Medina-Montalvo, S
AF Lario, A. Rodriguez-Villa
   Vega-Diez, D.
   Gonzalez-Canete, M.
   Polo-Rodriguez, I.
   Piteiro-Bermejo, A. B.
   Herrero-Fernandez, M.
   Arevalo-Serrano, J.
   Trasobares-Marugan, L.
   Medina-Montalvo, S.
TI Patient's perspective: psychological burden of the COVID-19 pandemic in
   146 psoriatic patients treated with biological drugs and small molecules
   in real clinical practice
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Letter; Early Access
C1 [Lario, A. Rodriguez-Villa; Vega-Diez, D.; Gonzalez-Canete, M.; Polo-Rodriguez, I.; Piteiro-Bermejo, A. B.] Principe Asturias Univ Hosp, Dept Dermatol, Madrid, Spain.
   [Herrero-Fernandez, M.] Principe Asturias Univ Hosp, Dept Pharm, Madrid, Spain.
   [Arevalo-Serrano, J.] Principe Asturias Univ Hosp, Dept Med, Madrid, Spain.
   [Trasobares-Marugan, L.; Medina-Montalvo, S.] Principe Asturias Univ Hosp, Dept Dermatol, Madrid, Spain.
RP Lario, ARV (corresponding author), Principe Asturias Univ Hosp, Dept Dermatol, Madrid, Spain.
EM anarvlario@gmail.com
OI RODRIGUEZ-VILLA LARIO, ANA/0000-0001-6156-4115; Vega Diez,
   David/0000-0001-8639-9718; Medina, Susana/0000-0003-3165-5387; Gonzalez
   Canete, Marta/0000-0002-8330-4215; HERRERO FERNANDEZ,
   MARTA/0000-0002-3688-9265; Piteiro Bermejo, Ana
   Belen/0000-0002-9193-2027
CR Jakovljevic M, 2020, PSYCHIAT DANUB, V32, P6, DOI 10.24869/psyd.2020.6
   Megna M, 2020, J DERMATOL TREAT, DOI [10.1080/09546634.2020.1781044, 10.1080/09546634.2020.1757605]
   Ozamiz-Etxebarria N, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00054020, 10.1590/0102-311x00054020]
NR 3
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1790485
EA JUL 2020
PG 3
WC Dermatology
SC Dermatology
GA MI0TR
UT WOS:000547130500001
PM 32643475
DA 2021-01-01
ER

PT J
AU Bherwani, H
   Anjum, S
   Kumar, S
   Gautam, S
   Gupta, A
   Kumbhare, H
   Anshul, A
   Kumar, R
AF Bherwani, Hemant
   Anjum, Saima
   Kumar, Suman
   Gautam, Sneha
   Gupta, Ankit
   Kumbhare, Himanshu
   Anshul, Avneesh
   Kumar, Rakesh
TI Understanding COVID-19 transmission through Bayesian probabilistic
   modeling and GIS-based Voronoi approach: a policy perspective
SO ENVIRONMENT DEVELOPMENT AND SUSTAINABILITY
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; Bayesian probability; Change point analysis;
   Voronoi diagram
ID RESPIRATORY SYNDROME
AB Originating from Wuhan, China, COVID-19 is spreading rapidly throughout the world. The transmission rate is reported to be high for this novel strain of coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as compared to its predecessors. Major strategies in terms of clinical trials of medicines and vaccines, social distancing, use of personal protective equipment (PPE), and so on are being implemented in order to control the spread. The current study concentrates on lockdown and social distancing policy followed by the Indian Government and evaluates its effectiveness using Bayesian probability model (BPM). The change point analysis (CPA) done through the above approach suggests that the states which implemented the lockdown before the exponential rise of cases are able to control the spread of the disease in a much better and efficient way. The analysis has been done for states of Maharashtra, Gujarat, Madhya Pradesh, Rajasthan, Tamil Nadu, West Bengal, Uttar Pradesh, and Delhi as union territory. The highest value of Delta (delta) is reported for Gujarat and Madhya Pradesh with a value of 9.6 weeks, while the lowest value is 4.7, evidently for Maharashtra which is the worst affected. All of the states indicate a significant correlation (p < 0.05, tstat > tcritical) for Delta, i.e., the difference in the time period of CPA and lockdown with cases per population (CPP) and cases per unit area (CPUA), while weak correlation (p < 0.1 and tstat < tcritical) is exhibited by delta and cases per unit population density (CPD). For both CPP and CPUA, tstat > tcritical indicating a significant correlation, while Pearson's correlation indicates the direction to be negative. Further analysis in terms of identification of high-risk areas has been studied from the Voronoi approach of GIS based on the inputs from BPM. All the states follow the above pattern of high population, high case scenario, and the boundaries of risk zones can be identified by Thiessen polygon (TP) constructed therein. The findings of the study help draw strategic and policy-driven response for India, toward tackling COVID-19 pandemic.
C1 [Bherwani, Hemant; Anjum, Saima; Kumar, Suman; Gupta, Ankit; Kumbhare, Himanshu; Anshul, Avneesh; Kumar, Rakesh] CSIR Natl Environm Engn Res Inst CSIR NEERI, Nehru Marg, Nagpur, Maharashtra, India.
   [Bherwani, Hemant; Gupta, Ankit; Kumar, Rakesh] Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.
   [Gautam, Sneha] Karunya Inst Technol & Sci, Coimbatore, Tamil Nadu, India.
RP Bherwani, H (corresponding author), CSIR Natl Environm Engn Res Inst CSIR NEERI, Nehru Marg, Nagpur, Maharashtra, India.; Bherwani, H (corresponding author), Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.
EM h.bherwani@neeri.res.in
OI Bherwani, Hemant/0000-0002-0043-2589; Kumbhare,
   Himanshu/0000-0001-9371-9687
CR Alhogbani T, 2016, ANN SAUDI MED, V36, P78, DOI 10.5144/0256-4947.2016.78
   [Anonymous], COVID 19 CONF CAS DE
   Asadi S, 2020, AEROSOL SCI TECH, V54, P635, DOI 10.1080/02786826.2020.1749229
   Bherwani H, 2020, AIR QUAL ATMOS HLTH, V13, P683, DOI 10.1007/s11869-020-00845-3
   Carvajal G, 2017, WATER RES, V109, P144, DOI 10.1016/j.watres.2016.11.008
   Chakraborty T, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109850
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Dubois G., 2000, J GEOGRAPHIC INFORM, V4, P1
   Fan Cuifang, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa226
   Gautam S, 2020, AIR QUAL ATMOS HLTH, V13, P853, DOI 10.1007/s11869-020-00842-6
   Gautam S, 2020, B ENVIRON CONTAM TOX, V104, P724, DOI 10.1007/s00128-020-02877-y
   Gautam S, 2020, ENVIRON DEV SUSTAIN, V22, P3867, DOI 10.1007/s10668-020-00739-5
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Ho AD, 2015, EDUC PSYCHOL MEAS, V75, P365, DOI 10.1177/0013164414548576
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2014, CURR OPIN PULM MED, V20, P233, DOI 10.1097/MCP.0000000000000046
   Inglesby TV, 2020, JAMA-J AM MED ASSOC, V323, P2186, DOI 10.1001/jama.2020.7878
   Jain N, 2020, GLOBAL J TRANSFUSION, V5, P22, DOI [10.4103/GJTM.GJTM_24_20, DOI 10.4103/GJTM.GJTM_24_20]
   Jribi S, 2020, ENVIRON DEV SUSTAIN, V22, P3939, DOI 10.1007/s10668-020-00740-y
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kass-Hout TA, 2012, J AM MED INFORM ASSN, V19, P1075, DOI 10.1136/amiajnl-2011-000793
   Liu Yang, 2020, EClinicalMedicine, V22, P100354, DOI 10.1016/j.eclinm.2020.100354
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Mu L, 2004, PROF GEOGR, V56, P223
   Nagai M, 2011, J AM SOC HYPERTENS, V5, P184, DOI 10.1016/j.jash.2011.03.001
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051
   SALVATIER J, 2016, PEERJ COMPUT SCI APR, DOI DOI 10.7287/peerj.preprints.1686v1
   Sarkodie SA, 2020, ENVIRON DEV SUSTAIN, DOI 10.1007/s10668-020-00801-2
   Schulman L, 2007, J BIOGEOGR, V34, P1388, DOI 10.1111/j.1365-2699.2007.01716.x
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Texier G, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0271-x
   Tindale L., 2020, TRANSMISSION INTERVA, DOI [10.1101/2020.03.03.20029983, DOI 10.1101/2020.03.03.20029983]
   Tomar A, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138762
   Wetzels R, 2012, PSYCHON B REV, V19, P1057, DOI 10.3758/s13423-012-0295-x
   Wheeler DC, 2010, SPAT SPATIO-TEMPORAL, V1, P151, DOI 10.1016/j.sste.2010.03.009
   WHO, 2020, DIR GEN OP REM
   World Health Organization (WHO), 2020, 142 WHO
   Xiao YH, 2020, LANCET INFECT DIS, V20, P523, DOI 10.1016/S1473-3099(20)30152-3
   Yamada I., 2016, INT ENCY GEOGRAPHY P, P1, DOI DOI 10.1002/9781118786352.WBIEG0157
   Yang J, 2007, WATER RESOUR RES, V43, DOI 10.1029/2006WR005497
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 47
TC 8
Z9 8
U1 5
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-585X
EI 1573-2975
J9 ENVIRON DEV SUSTAIN
JI Environ. Dev. Sustain.
DI 10.1007/s10668-020-00849-0
EA JUL 2020
PG 19
WC Green & Sustainable Science & Technology; Environmental Sciences
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA MH1ZF
UT WOS:000546531300001
PM 32837277
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hwang, JM
   Kim, JH
   Park, JS
   Chang, MC
   Park, D
AF Hwang, Jong-moon
   Kim, Ju-Hyun
   Park, Jin-Sung
   Chang, Min Cheol
   Park, Donghwi
TI Neurological diseases as mortality predictive factors for patients with
   COVID-19: a retrospective cohort study
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Alzheimer's dementia; Chronic lung disease; Coronavirus
ID T-CELLS; INFLAMMATION; CORONAVIRUS; AGE
AB Introduction In the current study, we evaluated factors that increase the coronavirus disease (COVID-19) patient death rate by analyzing the data from two cohort hospitals. In addition, we studied whether underlying neurological diseases are risk factors for death. Methods In this retrospective cohort study, we included 103 adult inpatients (aged >= 18 years). We evaluated differences in demographic data between surviving and non-surviving COVID-19 patients. Results In a multivariate logistic analysis, age and the presence of chronic lung disease and Alzheimer's dementia (AD) were the only significant parameters for predicting COVID-19 non-survival (p < 0.05). However, hypertension, coronary vascular disease, dyslipidemia, chronic kidney disease, diabetes, and history of taking angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), were not significantly associated with the death of COVID-19 patients. The optimal cutoff value obtained from the maximum Youden index was 70 (sensitivity, 80.77%; specificity, 61.04%), and the odds ratio of non-survival increased 1.055 fold for every year of age. Conclusions Clinicians should closely monitor and manage the symptoms of COVID-19 patients who are over the age of 70 years or have chronic lung disease or AD.
C1 [Hwang, Jong-moon; Kim, Ju-Hyun] Kyungpook Natl Univ Hosp, Dept Rehabil Med, Daegu, South Korea.
   [Hwang, Jong-moon] Kyungpook Natl Univ, Sch Med, Dept Rehabil Med, Daegu, South Korea.
   [Park, Jin-Sung] Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea.
   [Chang, Min Cheol] Yeungnam Univ, Dept Rehabil Med, Coll Med, Daegu, South Korea.
   [Chang, Min Cheol] Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.
   [Park, Donghwi] Univ Ulsan, Coll Med, Dept Phys Med & Rehabil, Ulsan Univ Hosp, 877 Bangeojinsunghwndo Ro, Ulsan 44033, South Korea.
RP Chang, MC (corresponding author), Yeungnam Univ, Dept Rehabil Med, Coll Med, Daegu, South Korea.; Chang, MC (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.; Park, D (corresponding author), Univ Ulsan, Coll Med, Dept Phys Med & Rehabil, Ulsan Univ Hosp, 877 Bangeojinsunghwndo Ro, Ulsan 44033, South Korea.
EM wheel633@ynu.ac.kr; bdome@hanmail.net
FU National Research Foundation of Korea - Korean governmentNational
   Research Foundation of KoreaKorean Government [NRF-2019M3E5D1A02068106]
FX The present study was supported by a National Research Foundation of
   Korea grant funded by the Korean government (grant no.
   NRF-2019M3E5D1A02068106).
CR Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967
   Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R
   Busse M, 2017, J ALZHEIMERS DIS, V58, P1303, DOI 10.3233/JAD-161304
   Cascella M, 2020, FEATURES EVALUATION
   Chang MC, 2020, AM J PHYS MED REHAB, V99, P583, DOI 10.1097/PHM.0000000000001471
   Chang MC, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8020145
   Chang MC, 2020, AM J PHYS MED REHAB, V99, P475, DOI 10.1097/PHM.0000000000001428
   Chang MC, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01577-8
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Chung HY, 2019, AGING DIS, V10, P367, DOI 10.14336/AD.2018.0324
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e88
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lippi G, 2020, J MED VIROL, V92, P1759, DOI 10.1002/jmv.25860
   McManus RM, 2020, LANCET NEUROL, V19, P285, DOI 10.1016/S1474-4422(20)30076-4
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Salam N, 2013, INDIAN J MED RES, V138, P595
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Town T, 2005, NEUROMOL MED, V7, P255, DOI 10.1385/NMM:7:3:255
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 10
Z9 10
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD SEP
PY 2020
VL 41
IS 9
BP 2317
EP 2324
DI 10.1007/s10072-020-04541-z
EA JUL 2020
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MY3NO
UT WOS:000546505900003
PM 32643133
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tanhehco, YC
   Schwartz, J
AF Tanhehco, Yvette C.
   Schwartz, Joseph
TI How theCOVID-19 pandemic changed cellular therapy at Columbia University
   Irving Medical Center/NewYork-PresbyterianHospital
SO TRANSFUSION
LA English
DT Article
AB New York is at the epicenter of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus. Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH) had to make changes to its cellular therapy operations to ensure patient, donor, and staff safety and well-being. In this article, we discuss the process changes we instituted for cellular therapy clinical care, collection, processing, and cryopreservation to cope with the rapidly evolving pandemic.
C1 [Tanhehco, Yvette C.; Schwartz, Joseph] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
RP Tanhehco, YC (corresponding author), Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, Div Transfus Med & Cellular Therapy, 622W 168th St,Harkness Pavil 4-418A, New York, NY 10032 USA.
EM yct2103@cumc.columbia.edu
CR AABB's Transfusion Transmitted Diseases Committee, 2020, UPD IMP 2019 NOV COR
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Covid-19 statistics, 2020, COR DIS COVID 19 WOR
   Hamed EM, 2019, CURR DRUG TARGETS, V20, P1603, DOI 10.2174/1389450120666190726155733
   Kwon SY, 2020, VOX SANG, V115, P601, DOI 10.1111/vox.12925
   National Marrow Donor Program, 2020, UPD TRANSPL CTR COOP
   NYC, 2020, COVID 19 DAT
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2020
VL 60
IS 9
BP 1905
EP 1909
DI 10.1111/trf.15956
EA JUL 2020
PG 5
WC Hematology
SC Hematology
GA NM9YS
UT WOS:000546294200001
PM 32583465
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Meschia, JF
   Barrett, KM
   Brown, RD
   Turan, TN
   Howard, VJ
   Voeks, JH
   Lal, BK
   Howard, G
   Brott, TG
AF Meschia, James F.
   Barrett, Kevin M.
   Brown, Robert D.
   Turan, Tanya N.
   Howard, Virginia J.
   Voeks, Jenifer H.
   Lal, Brajesh K.
   Howard, George
   Brott, Thomas G.
TI The CREST-2 experience with the evolving challenges of COVID-19: A
   clinical trial in a pandemic
SO NEUROLOGY
LA English
DT Article
ID TELEPHONE
AB The coronavirus disease 2019 pandemic has disrupted the lives of whole communities and nations. The multinational multicenter National Institute of Neurological Disorders and Stroke Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial stroke prevention trial rapidly experienced the effects of the pandemic and had to temporarily suspend new enrollments and shift patient follow-up activities from in-person clinic visits to telephone contacts. There is an ethical obligation to the patients to protect their health while taking every feasible step to ensure that the goals of the trial are successfully met. Here, we describe the effects of the pandemic on the trial and steps that are being taken to mitigate the effects of the pandemic so that trial objectives can be met.
C1 [Meschia, James F.; Barrett, Kevin M.; Brott, Thomas G.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
   [Brown, Robert D.] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Turan, Tanya N.; Voeks, Jenifer H.] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
   [Howard, Virginia J.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
   [Howard, George] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA.
   [Lal, Brajesh K.] Univ Maryland, Dept Surg, College Pk, MD 20742 USA.
RP Meschia, JF (corresponding author), Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
EM meschia.james@mayo.edu
RI Howard, Virginia J/AAY-7648-2020
OI Howard, Virginia J/0000-0003-4912-9975; Meschia,
   James/0000-0002-4475-8142
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [U01NS080168, U01NS080165]
FX CREST-2 is funded by grants from the National Institute of Neurological
   Disorders and Stroke (U01NS080168 and U01NS080165).
CR Bernabe RDLC, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0106-4
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273
   CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferguson N.M., 2020, 9 IMP COLL LOND
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Howard VJ, 2017, INT J STROKE, V12, P770, DOI 10.1177/1747493017706238
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1089
   Meschia JF, 2000, STROKE, V31, P1076, DOI 10.1161/01.STR.31.5.1076
   Murray CJ, FORECASTING COVID 19
   Trachtman H, 2018, CONTEMP CLIN TRIALS, V68, P146, DOI 10.1016/j.cct.2018.03.009
   Tucker KL, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002389
   Warttig SL, 2013, J HEALTH PSYCHOL, V18, P1617, DOI 10.1177/1359105313508346
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUL 7
PY 2020
VL 95
IS 1
BP 29
EP 36
DI 10.1212/WNL.0000000000009698
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA NA3YH
UT WOS:000559750000007
PM 32358216
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, JP
   Wang, X
   Zhang, ST
   Lin, B
   Wu, XQ
   Wang, YF
   Wang, XQ
   Yang, M
   Sun, JQ
   Xie, YL
AF Chen, Jianpu
   Wang, Xiang
   Zhang, Shutong
   Lin, Bin
   Wu, Xiaoqing
   Wang, Yanfang
   Wang, Xiaoqi
   Yang, Ming
   Sun, Jianqing
   Xie, Yuanliang
TI Characteristics of Acute Pulmonary Embolism in Patients With COVID-19
   Associated Pneumonia From the City of Wuhan
SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
LA English
DT Article
DE pulmonary embolism; SAR-CoV-2; COVID-19
ID CT ANGIOGRAPHY; THROMBOSIS
AB The aim of this study was to describe clinical, imaging, and laboratory features of acute pulmonary embolism (APE) in patients with COVID-19 associated pneumonia. Patients with COVID-19 associated pneumonia who underwent a computed tomography pulmonary artery (CTPA) scan for suspected APE were retrospectively studied. Laboratory data and CTPA images were collected. Imaging characteristics were analyzed descriptively. Laboratory data were analyzed and compared between patients with and without APE. A series of 25 COVID-19 patients who underwent CTPA between January 2020 and February 2020 were enrolled. The median D-dimer level founded in these 25 patients was 6.06 mu g/mL (interquartile range [IQR] 1.90-14.31 mu g/mL). Ten (40%) patients with APE had a significantly higher level of D-dimer (median, 11.07 mu g/mL; IQR, 7.12-21.66 vs median, 2.44 mu g/mL; IQR, 1.68-8.34, respectively,P= .003), compared with the 15 (60%) patients without APE. No significant differences in other laboratory data were found between patients with and without APE. Among the 10 patients with APE, 6 (60%) had a bilateral pulmonary embolism, while 4 had a unilateral embolism. The thrombus-prone sites were the right lower lobe (70%), the left upper lobe (60%), both upper lobe (40%) and the right middle lobe (20%). The thrombus was partially or completely absorbed after anticoagulant therapy in 3 patients who underwent a follow-up CTPA. Patients with COVID-19 associated pneumonia have a risk of developing APE during the disease. When the D-dimer level abnormally increases in patients with COVID-19 pneumonia, CTPA should be performed to detect and assess the severity of APE.
C1 [Chen, Jianpu; Wang, Xiang; Zhang, Shutong; Lin, Bin; Wu, Xiaoqing; Wang, Yanfang; Xie, Yuanliang] Huazhong Univ Sci & Technol, COVID 19 Invest & Res Team, Dept Radiol, Tongji Med Coll,Cent Hosp Wuhan, Wuhan, Hubei, Peoples R China.
   [Wang, Xiaoqi] Philips Healthcare, Beijing, Peoples R China.
   [Yang, Ming] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, COVID 19 Invest & Res Team, Wuhan, Hubei, Peoples R China.
   [Sun, Jianqing] Philips Healthcare, Shanghai, Peoples R China.
RP Xie, YL (corresponding author), Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Dept Radiol, Tongji Med Coll, 26 Shengli St, Wuhan 430014, Hubei, Peoples R China.
EM drxieyuanliang@163.com
OI Xie, Yuanliang/0000-0002-4190-794X
CR Albrecht MH, 2017, AM J ROENTGENOL, V208, P495, DOI 10.2214/AJR.16.17202
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dang X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00411
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Delvaeye M, 2009, BLOOD, V114, P2367, DOI 10.1182/blood-2009-05-199208
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Engelke C, 2004, BRIT J RADIOL, V77, P623, DOI 10.1259/bjr/52485284
   Frigini LA, 2017, J AM COLL RADIOL, V14, P637, DOI 10.1016/j.jacr.2017.01.013
   Grillet F., 2020, RADIOLOGY
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Le Berre A, 2020, DIAGN INTERV IMAG, V101, P321, DOI 10.1016/j.diii.2020.04.003
   Leonard-Lorant I., 2020, RADIOLOGY, V61
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Mayo J, 2013, AM J ROENTGENOL, V200, P522, DOI 10.2214/AJR.12.9928
   National Health Commission of People's Republic of China, 2020, DIAGN TREATM GUID CO
   Ng KHL, 2005, POSTGRAD MED J, V81, DOI 10.1136/pgmj.2004.030049
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Righini M, 2017, J THROMB HAEMOST, V15, P1251, DOI 10.1111/jth.13694
   Roy PM, 2006, ANN INTERN MED, V144, P157, DOI 10.7326/0003-4819-144-3-200602070-00003
   Toplis E, 2010, AUST FAM PHYSICIAN, V29, P22
   Visseren FLJ, 2000, THROMB HAEMOSTASIS, V84, P319
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2019, MIDDL E RESP SYNDR C
   Wichmann D, 2020, ANN INTERN MED
   World Health Organization, 2020, 126 WHO
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zu Zi Yue, 2020, RADIOLOGY
NR 35
TC 2
Z9 2
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1076-0296
EI 1938-2723
J9 CLIN APPL THROMB-HEM
JI Clin. Appl. Thromb.-Hemost.
PD JUL 7
PY 2020
VL 26
AR 1076029620936772
DI 10.1177/1076029620936772
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NC8VQ
UT WOS:000561490700001
PM 32726134
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wu, J
   Zhang, JQ
   Sun, XH
   Wang, LJ
   Xu, YF
   Zhang, YY
   Liu, XX
   Dong, C
AF Wu, Jing
   Zhang, Jingqi
   Sun, Xiaohua
   Wang, Lijuan
   Xu, Yunfang
   Zhang, Yuanyuan
   Liu, Xingxiang
   Dong, Chen
TI Influence of diabetes mellitus on the severity and fatality of
   SARS-CoV-2 (COVID-19) infection
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE COVID-19; diabetes; fatality; severity
ID RESPIRATORY SYNDROME CORONAVIRUS
AB Aim To evaluate the influence of diabetes on the severity and fatality of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Materials and Methods The medical records of 66 hospitalized coronavirus disease 2019 (COVID-19) patients were collected and classified into non-severe (mild/moderate cases) and severe (severe/critical cases) groups. Logistic regression analysis was used to estimate the risk of severe COVID-19 (severe/critical infection). In addition, a meta-analysis including published studies reported the impact of diabetes on the severity and fatality of COVID-19. The current study was conducted using fixed effects models. Results There were 22 diabetes and 44 non-diabetes cases among the 66 hospitalized COVID-19 patients. Seven patients with diabetes (31.82%) were diagnosed as severe COVID-19 cases, which was significantly higher than that in the non-diabetes group (4/44, 9.09%,P= .033). After adjustment for age and gender, diabetes was significantly associated with COVID-19 severity (OR: 5.29, 95% CI: 1.07-26.02). A meta-analysis further confirmed the positive association between diabetes and COVID-19 severity (pooled OR = 2.58, 95% CI: 1.93-3.45). Moreover, the patients with diabetes infected with SARS-CoV-2 had a 2.95-fold higher risk of fatality compared with those patients without diabetes (95% CI: 1.93-4.53). Conclusions Our findings provide new evidence that diabetes is associated with a higher risk of severity and fatality of COVID-19. Therefore, intensive monitoring and antidiabetic therapy should be considered in patients with diabetes with SARS-CoV-2 infection.
C1 [Wu, Jing; Zhang, Jingqi; Dong, Chen] Soochow Univ, Sch Publ Hlth, Jiangsu Key Lab & Translat Med Geriatr Dis, Dept Epidemiol & Stat,Med Coll, Suzhou, Peoples R China.
   [Sun, Xiaohua] Soochow Univ, Soochow Univ Hosp, Suzhou, Peoples R China.
   [Wang, Lijuan; Xu, Yunfang; Zhang, Yuanyuan; Liu, Xingxiang] Huaian Fourth Peoples Hosp, Dept Clin Lab, Huaian, Peoples R China.
RP Dong, C (corresponding author), Soochow Univ, Dept Epidemiol & Stat, Jiangsu Key Lab & Translat Med Geriatr Dis, Sch Publ Hlth,Med Coll, 199 Renai Rd, Suzhou 215123, Peoples R China.
EM cdong@suda.edu.cn
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81773507]
FX The National Natural Science Foundation of China (NSFC), Grant/Award
   Number: 81773507
CR Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340
   Barra NG, 2010, EXPERT REV VACCINES, V9, P1143, DOI 10.1586/ERV.10.119
   Bindom SM, 2009, MOL CELL ENDOCRINOL, V302, P193, DOI 10.1016/j.mce.2008.09.020
   Blind E, 2018, DIABETES OBES METAB, V20, P2059, DOI 10.1111/dom.13349
   Bloomgarden ZT, 2020, J DIABETES, V12, P347, DOI 10.1111/1753-0407.13027
   Casey K, 2020, AM J EMERG MED
   Chen C, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P567, DOI 10.3760/cma.j.cn112148-20200225-00123
   Chen G., 2020, CLIN IMMUNOLOGIC FEA, DOI [10.1101/2020.02.16.20023903, DOI 10.1101/2020.02.16.20023903]
   Chen L, 2019, DIGIT COMMUN NETW, V5, P203, DOI 10.1016/j.dcan.2019.11.002
   Cheng K, 2020, SHANGHAI MED J, V1, P1
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Davis TME, 2005, J DIABETES COMPLICAT, V19, P259, DOI 10.1016/j.jdiacomp.2005.03.003
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang Xiao-wei, 2020, Chinese Pharmacological Bulletin, V36, P453, DOI 10.3969/j.issn.1001-1978.2020.04.002
   Fu L., 2020, INFLUENCE FACTORS DE, DOI [10. 1101/2020.03.13.20035329., DOI 10.1101/2020.03.13.20035329]
   Garbati MA, 2016, PLOS ONE, V11, DOI [10.1371/journal.Pone.0165978, 10.1371/journal.pone.0165978]
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, COMORBIDITY ITS IMPA, DOI [10.1101/2020.02.25.20027664, DOI 10.1101/2020.02.25.20027664]
   He ZJ, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01551-8
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708
   Klekotka Renata Barbara, 2015, Pneumonol Alergol Pol, V83, P401, DOI 10.5603/PiAP.2015.0065
   Liu J, 2020, NEUTROPHIL TO LYMPHO, DOI [10.1101/2020.02.10.20021584, DOI 10.1101/2020.02.10.20021584]
   Liu L, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.20.20025536, DOI 10.1101/2020.02.20.20025536]
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   National Health Commission of the People's Republic of China, DIAGN TREATM NEW COR
   Saito T, 2000, J VET MED SCI, V62, P575, DOI 10.1292/jvms.62.575
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   [万秋 Wan Qiu], 2020, [中华临床感染病杂志, Chinese Journal of Clinical Infectious Diseases], V13, P16
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   [向天新 Xiang Tianxin], 2020, [中国呼吸与危重监护杂志, Chinese Journal of Respiratory and Critical Care Medicine], V19, P154
   Xu M, 2020, CHIN CRIT CARE MED, V32, pE010
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 43
TC 12
Z9 12
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD OCT
PY 2020
VL 22
IS 10
BP 1907
EP 1914
DI 10.1111/dom.14105
EA JUL 2020
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NK1QY
UT WOS:000554993900001
PM 32496012
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aftab, SO
   Ghouri, MZ
   Masood, MU
   Haider, Z
   Khan, Z
   Ahmad, A
   Munawar, N
AF Aftab, Syed Ovais
   Ghouri, Muhammad Zubair
   Masood, Muhammad Umer
   Haider, Zeshan
   Khan, Zulqurnain
   Ahmad, Aftab
   Munawar, Nayla
TI Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential
   therapeutic drug target using a computational approach
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE RdRp; SARS-CoV-2; Phylogenetic tree; Homology modeling; Molecular
   Docking; Active site
ID ANTI-HCV DRUGS; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; CORONAVIRUS;
   VIRUS; SARS; BATS; REVEALS; RECOMBINATION; INHIBITORS
AB Background The Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) outbreak originating in Wuhan, China, has raised global health concerns and the pandemic has now been reported on all inhabited continents. Hitherto, no antiviral drug is available to combat this viral outbreak. Methods Keeping in mind the urgency of the situation, the current study was designed to devise new strategies for drug discovery and/or repositioning against SARS-CoV-2. In the current study, RNA-dependent RNA polymerase (RdRp), which regulates viral replication, is proposed as a potential therapeutic target to inhibit viral infection. Results Evolutionary studies of whole-genome sequences of SARS-CoV-2 represent high similarity (> 90%) with other SARS viruses. Targeting the RdRp active sites, ASP760 and ASP761, by antiviral drugs could be a potential therapeutic option for inhibition of coronavirus RdRp, and thus viral replication. Target-based virtual screening and molecular docking results show that the antiviral Galidesivir and its structurally similar compounds have shown promise against SARS-CoV-2. Conclusions The anti-polymerase drugs predicted here-CID123624208 and CID11687749-may be considered for in vitro and in vivo clinical trials.
C1 [Aftab, Syed Ovais; Ghouri, Muhammad Zubair; Masood, Muhammad Umer; Haider, Zeshan] Univ Agr Faisalabad, Ctr Agr Biochem & Biotechnol CABB, Faisalabad, Pakistan.
   [Aftab, Syed Ovais; Ghouri, Muhammad Zubair; Ahmad, Aftab] Univ Agr Faisalabad, Ctr Adv Studies Agr & Food Secur CAS AFS, Faisalabad, Pakistan.
   [Khan, Zulqurnain] MNS Univ Agr, Inst Plant Breeding & Biotechnol, Multan, Pakistan.
   [Ahmad, Aftab] Univ Agr Faisalabad, Dept Biochem, Faisalabad, Pakistan.
   [Munawar, Nayla] United Arab Emirates Univ, Dept Chem, Al Ain, U Arab Emirates.
RP Ghouri, MZ (corresponding author), Univ Agr Faisalabad, Ctr Agr Biochem & Biotechnol CABB, Faisalabad, Pakistan.; Ghouri, MZ; Ahmad, A (corresponding author), Univ Agr Faisalabad, Ctr Adv Studies Agr & Food Secur CAS AFS, Faisalabad, Pakistan.; Ahmad, A (corresponding author), Univ Agr Faisalabad, Dept Biochem, Faisalabad, Pakistan.
EM zubair.ghouri@uaf.edu.pk; aftab.ahmad@uaf.edu.pk
RI Ghouri, Muhammad Zubair/AAW-4277-2020; Aftab, Ovais/ABB-6433-2020;
   Ahmad, Aftab/L-9718-2015; Khan, Zulqurnain/ABI-1156-2020
OI Ghouri, Muhammad Zubair/0000-0002-1502-2961; Aftab,
   Ovais/0000-0002-2962-9959; Ahmad, Aftab/0000-0002-2792-9771; Khan,
   Zulqurnain/0000-0002-6910-7389
FU Office of Research, Innovations and Commercialization (ORIC), University
   of Agriculture, Faisalabad, Punjab, Pakistan
FX We are thankful to Office of Research, Innovations and Commercialization
   (ORIC), University of Agriculture, Faisalabad, Punjab, Pakistan for
   provision of funds to conduct this research work.
CR Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3
   Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Boulos MN, GEOGRAPHICAL TRACKIN
   Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034
   Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653
   Cascella M, 2020, STATPEARLS
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chan JF-W, 2020, LANCET
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chatterjee S, 2020, KEY STEPS EARLY EVOL
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   Dwivedi VD, 2013, NETW MODEL ANAL HLTH, V2, P209, DOI 10.1007/s13721-013-0036-8
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Elfiky AA, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116958
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Ezat Ahmed A., 2019, VirusDisease, V30, P207, DOI 10.1007/s13337-019-00516-7
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gerlach P, 2015, CELL, V161, P1267, DOI 10.1016/j.cell.2015.05.006
   Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jung S.M, 2020, EPIDEMIOLOGICAL IDEN
   Kieny MP., 2015, EBOLA BLUEPRINT EMER
   Kinsella E, 2004, VIROLOGY, V321, P23, DOI 10.1016/j.virol.2003.09.046
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liang B, 2015, CELL, V162, P314, DOI 10.1016/j.cell.2015.06.018
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Markland W, 2000, ANTIMICROB AGENTS CH, V44, P859, DOI 10.1128/AAC.44.4.859-866.2000
   McQuaid T, 2015, J CLIN TRANSL HEPATO, V3, P27, DOI 10.14218/JCTH.2014.00041
   Nguyen TM, 2020, CELL RES, V30, P189, DOI 10.1038/s41422-020-0290-0
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Sarwar MW, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01303
   Smertina E, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01280
   Stoermer M., 2020, PREPRINT, DOI DOI 10.26434/CHEMRXIV.11799705.V1
   Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8
   ul Qamar MT, 2019, SCI REP, V9, P1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   ul Qamar MT, 2016, INT J PHARMACOL, V12, P621, DOI 10.3923/ijp.2016.621.632
   Wang M, 2020, CELL RES, V1, P3, DOI DOI 10.1038/CR.1990.1
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong S, 2007, REV MED VIROL, V17, P67, DOI 10.1002/rmv.520
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Woo PCY, 2005, MICROBIOL IMMUNOL, V49, P899, DOI 10.1111/j.1348-0421.2005.tb03681.x
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu JQ, 2015, INT J MOL SCI, V16, P12943, DOI 10.3390/ijms160612943
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Yang L, 2013, EMERG INFECT DIS, V19, P989, DOI 10.3201/eid1906.121648
   Yang PL, 2011, CURR OPIN VIROL, V1, P607, DOI 10.1016/j.coviro.2011.10.019
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu WC, 2004, THORAX, V59, P643, DOI 10.1136/thx.2003.017665
   Zhou Y, 2020, CELL DISCOV, V14, P6, DOI DOI 10.1038/S41421-020-0153
NR 66
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 7
PY 2020
VL 18
IS 1
AR 275
DI 10.1186/s12967-020-02439-0
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MP7JJ
UT WOS:000552377400001
PM 32635935
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shan, C
   Yao, YF
   Yang, XL
   Zhou, YW
   Gao, G
   Peng, Y
   Yang, L
   Hu, X
   Xiong, J
   Jiang, RD
   Zhang, HJ
   Gao, XX
   Peng, C
   Min, J
   Chen, Y
   Si, HR
   Wu, J
   Zhou, P
   Wang, YY
   Wei, HP
   Pang, W
   Hu, ZF
   Lv, LB
   Zheng, YT
   Shi, ZL
   Yuan, ZM
AF Shan, Chao
   Yao, Yan-Feng
   Yang, Xing-Lou
   Zhou, Yi-Wu
   Gao, Ge
   Peng, Yun
   Yang, Lian
   Hu, Xue
   Xiong, Jin
   Jiang, Ren-Di
   Zhang, Hua-Jun
   Gao, Xiao-Xiao
   Peng, Cheng
   Min, Juan
   Chen, Ying
   Si, Hao-Rui
   Wu, Jia
   Zhou, Peng
   Wang, Yan-Yi
   Wei, Hong-Ping
   Pang, Wei
   Hu, Zheng-Fei
   Lv, Long-Bao
   Zheng, Yong-Tang
   Shi, Zheng-Li
   Yuan, Zhi-Ming
TI Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus
   macaques
SO CELL RESEARCH
LA English
DT Article
AB The 2019 novel coronavirus (SARS-CoV-2) outbreak is a major challenge for public health. SARS-CoV-2 infection in human has a broad clinical spectrum ranging from mild to severe cases, with a mortality rate of similar to 6.4% worldwide (based on World Health Organization daily situation report). However, the dynamics of viral infection, replication and shedding are poorly understood. Here, we show that Rhesus macaques are susceptible to the infection by SARS-CoV-2. After intratracheal inoculation, the first peak of viral RNA was observed in oropharyngeal swabs one day post infection (1 d.p.i.), mainly from the input of the inoculation, while the second peak occurred at 5 d.p.i., which reflected on-site replication in the respiratory tract. Histopathological observation shows that SARS-CoV-2 infection can cause interstitial pneumonia in animals, characterized by hyperemia and edema, and infiltration of monocytes and lymphocytes in alveoli. We also identified SARS-CoV-2 RNA in respiratory tract tissues, including trachea, bronchus and lung; and viruses were also re-isolated from oropharyngeal swabs, bronchus and lung, respectively. Furthermore, we demonstrated that neutralizing antibodies generated from the primary infection could protect the Rhesus macaques from a secondround challenge by SARS-CoV-2. The non-human primate model that we established here provides a valuable platform to study SARS-CoV-2 pathogenesis and to evaluate candidate vaccines and therapeutics.
C1 [Shan, Chao; Yao, Yan-Feng; Yang, Xing-Lou; Gao, Ge; Peng, Yun; Hu, Xue; Xiong, Jin; Jiang, Ren-Di; Zhang, Hua-Jun; Gao, Xiao-Xiao; Peng, Cheng; Min, Juan; Chen, Ying; Si, Hao-Rui; Wu, Jia; Zhou, Peng; Wang, Yan-Yi; Wei, Hong-Ping; Shi, Zheng-Li; Yuan, Zhi-Ming] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Megasci, Wuhan 430071, Hubei, Peoples R China.
   [Shan, Chao; Hu, Xue] Chinese Acad Sci, State Key Lab Virol, Wuhan 430071, Hubei, Peoples R China.
   [Zhou, Yi-Wu] Huazhong Univ Sci & Technol, Dept Forens Med, Tongji Med Coll, 13 Hangkong Rd, Wuhan 430074, Hubei, Peoples R China.
   [Yang, Lian] Huazhong Univ Sci & Technol, Union Hosp, Dept Radiol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   [Jiang, Ren-Di; Chen, Ying] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Pang, Wei; Zheng, Yong-Tang] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.
   [Hu, Zheng-Fei; Lv, Long-Bao] Chinese Acad Sci, Kunming Inst Zool, Kunming Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China.
RP Shan, C; Shi, ZL; Yuan, ZM (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Megasci, Wuhan 430071, Hubei, Peoples R China.; Shan, C (corresponding author), Chinese Acad Sci, State Key Lab Virol, Wuhan 430071, Hubei, Peoples R China.
EM shanchao@wh.iov.cn; zlshi@wh.iov.cn; yzm@wh.iov.cn
RI yang, xinglou/AAW-6969-2020
OI Shan, Chao/0000-0002-3953-3782
FU National Key R&D Program of China [2020YFC0842000, 2020YFC0842100];
   Strategic Priority Research Program of the Chinese Academy of
   SciencesChinese Academy of Sciences [XDB29010101]; Youth Innovation
   Promotion Association of the Chinese Academy of Sciences [2019328];
   Mega-project of Infectious diseases control [2017ZX10302301-005]
FX We thank all colleagues from National Biosafety Laboratory (Wuhan),
   Chinese Academy of Sciences for their support during the study. This
   study was supported by the National Key R&D Program of China
   (2020YFC0842000 to Z.-M.Y.; 2020YFC0842100 to C.S.), the Strategic
   Priority Research Program of the Chinese Academy of Sciences
   (XDB29010101 to Z.-L.S.), Youth Innovation Promotion Association of the
   Chinese Academy of Sciences (2019328 to X.-L.Y.), and the Mega-project
   of Infectious diseases control (2017ZX10302301-005 to H.-P.W. and J.X.).
   We also thank Lei Zhang (Center for Instrumental Rectalysis and
   Metrology), and XueFang An, Fan Zhang and He Zhao (Center for Animal
   Experiment, Wuhan Institute of Virology, Chinese Academy of Sciences).
CR Bao L., 2020, J INFECT DIS, DOI [10.1093/infdis/jiaa281, DOI 10.1093/INFDIS/JIAA281]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Munster Vincent J, 2020, bioRxiv, DOI 10.1101/2020.03.21.001628
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, 2 M INT HLTH REG 200
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 19
Z9 19
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD AUG
PY 2020
VL 30
IS 8
BP 670
EP 677
DI 10.1038/s41422-020-0364-z
EA JUL 2020
PG 8
WC Cell Biology
SC Cell Biology
GA MU8ZE
UT WOS:000555032600001
PM 32636454
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU d'Ettorre, G
   Ceccarelli, G
   Marazzato, M
   Campagna, G
   Pinacchio, C
   Alessandri, F
   Ruberto, F
   Rossi, G
   Celani, L
   Scagnolari, C
   Mastropietro, C
   Trinchieri, V
   Recchia, GE
   Mauro, V
   Antonelli, G
   Pugliese, F
   Mastroianni, CM
AF d'Ettorre, Gabriella
   Ceccarelli, Giancarlo
   Marazzato, Massimiliano
   Campagna, Giuseppe
   Pinacchio, Claudia
   Alessandri, Francesco
   Ruberto, Franco
   Rossi, Giacomo
   Celani, Luigi
   Scagnolari, Carolina
   Mastropietro, Cristina
   Trinchieri, Vito
   Recchia, Gregorio Egidio
   Mauro, Vera
   Antonelli, Guido
   Pugliese, Francesco
   Mastroianni, Claudio Maria
TI Challenges in the Management of SARS-CoV2 Infection: The Role of Oral
   Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the
   Progression of COVID-19
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; bacteriotherapy; probiotic; lactobacillus;
   gut-lung axis; gut
ID VIRUS; MICROBIOTA; DISEASE
AB Background:Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods:We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation. Results:The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral bacteriotherapy. Conclusions:A specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients positive for SARS-CoV-2 infection. These results also stress the importance of the gut-lung axis in controlling the COVID-19 disease.
C1 [d'Ettorre, Gabriella; Ceccarelli, Giancarlo; Marazzato, Massimiliano; Pinacchio, Claudia; Celani, Luigi; Mastropietro, Cristina; Trinchieri, Vito; Recchia, Gregorio Egidio; Mauro, Vera; Mastroianni, Claudio Maria] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.
   [Campagna, Giuseppe] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy.
   [Alessandri, Francesco; Ruberto, Franco; Pugliese, Francesco] Sapienza Univ Rome, Dept Anesthesia & Intens Care Med, Rome, Italy.
   [Rossi, Giacomo] Vet Med Univ Camerino, Sch Biosci, Camerino, Italy.
   [Scagnolari, Carolina; Antonelli, Guido] Sapienza Univ Rome, Ist Pasteur Italia, Dept Mol Med, Lab Virol,Cenci Bolognetti Fdn, Rome, Italy.
RP Ceccarelli, G (corresponding author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.
EM giancarlo.ceccarelli@uniroma1.it
RI Ceccarelli, Giancarlo/K-6454-2016; Ceccarelli, Giancarlo/ABD-8347-2020
OI Ceccarelli, Giancarlo/0000-0001-5921-3180; Ceccarelli,
   Giancarlo/0000-0001-5921-3180; Alessandri,
   Francesco/0000-0003-3989-4964; Celani, Luigi/0000-0002-9181-3212
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anand S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02147
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Barr W, 2014, AM FAM PHYSICIAN, V89, P180
   Bingula R, 2017, J ONCOL, V2017, DOI 10.1155/2017/5035371
   Cait A, 2018, MUCOSAL IMMUNOL, V11, P785, DOI 10.1038/mi.2017.75
   Castelli V, 2020, AGING-US, V12, P4641, DOI 10.18632/aging.102927
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chiu L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01678
   Devadas K, 2006, J IMMUNOL, V176, P4252, DOI 10.4049/jimmunol.176.7.4252
   Dumas A, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12966
   Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009
   Espinoza JA, 2017, J IMMUNOL, V199, P212, DOI 10.4049/jimmunol.1601414
   Feng Z, 2020, SMALL INTESTINE UNDE, DOI [10.20944/preprints202003.0161.v1, DOI 10.20944/PREPRINTS202003.0161.V1]
   Freedman SB, 2020, JAMA-J AM MED ASSOC, V323, P823, DOI 10.1001/jama.2019.22268
   Hashiba T, 2001, GENE THER, V8, P1499, DOI 10.1038/sj.gt.3301540
   Hill-Batorski L, 2013, J VIROL, V87, P13795, DOI 10.1128/JVI.02422-13
   Hosakote YM, 2011, AM J RESP CRIT CARE, V183, P1550, DOI 10.1164/rccm.201010-1755OC
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Laviolette L, 2014, EUR RESPIR J, V43, P1750, DOI 10.1183/09031936.00092613
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Leyer GJ, 2009, PEDIATRICS, V124, pE172, DOI 10.1542/peds.2008-2666
   Li N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01551
   McAleer JP, 2018, EUR J IMMUNOL, V48, P39, DOI 10.1002/eji.201646721
   SIAARTI, 2020, PERC ASS PAZ AFF COV
   Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444
   Tseng CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep32176
   Wilson N, 2020, ROUTL STUD CRIT REAL, P3
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Yu L, 2020, MEDRXIV, DOI [10.1101/2020.03.03.20030650, DOI 10.1101/2020.03.03.20030650]
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
NR 31
TC 7
Z9 7
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 7
PY 2020
VL 7
AR 389
DI 10.3389/fmed.2020.00389
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MP8KL
UT WOS:000552448300001
PM 32733907
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tzouvelekis, A
   Karampitsakos, T
   Krompa, A
   Markozannes, E
   Bouros, D
AF Tzouvelekis, Argyrios
   Karampitsakos, Theodoros
   Krompa, Anastasia
   Markozannes, Evangelos
   Bouros, Demosthenes
TI False Positive COVID-19 Antibody Test in a Case of Granulomatosis With
   Polyangiitis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; granulomatosis with polyangiitis; false positive;
   cross-reactivity; antibodies
AB Collateral damage due to 2019 novel coronavirus disease (COVID-19) represents an emerging issue. Symptoms of COVID-19 are not disease-specific. Differential diagnosis is challenging and the exclusion of other life-threatening diseases has major caveats. In the era of this pandemic, diagnosis of other life-threatening diseases might delay treatment. The Food and Drug Administration has recently authorized the first antibody-based test for COVID-19; however, RT-PCR of nasopharyngeal or oropharyngeal swabs remains the recommended test for diagnosis. We present the first report of a false positive COVID-19 antibody test in a case of Granulomatosis with Polyangiitis (GPA). Specifically, the case concerns an 82-year-old female, never smoker, who was admitted to our hospital with symptoms of fever and general fatigue that had lasted 7 days. She already had a positive IgM test for COVID-19, yet multiple RT-PCR tests had returned as negative for SARS-CoV-2. In the following days, her renal function deteriorated, while hematuria and proteinuria with active urinary sediment developed. Based on high clinical suspicion for ANCA-associated vasculitis, we performed a complete immunologic profile which revealed positive c-ANCA with elevated titers of anti-PR3. Pulses of methylprednisolone along with cyclophosphamide were applied. At day 10, treatment response was noticed as indicated by respiratory and renal function improvement. This report highlights the need for meticulous patient evaluation in order to avoid misdiagnosis in the era of COVID-19.
C1 [Tzouvelekis, Argyrios; Karampitsakos, Theodoros; Krompa, Anastasia; Markozannes, Evangelos; Bouros, Demosthenes] Natl & Kapodistrian Univ Athens, Acad Dept Resp Med 1, Athens, Greece.
RP Tzouvelekis, A (corresponding author), Natl & Kapodistrian Univ Athens, Acad Dept Resp Med 1, Athens, Greece.
EM argyrios.tzouvelekis@fleming.gr
CR Alba MA, 2018, SEMIN RESP CRIT CARE, V39, P413, DOI 10.1055/s-0038-1673386
   De Carolis S, 2010, LUPUS, V19, P844, DOI 10.1177/0961203310361350
   Herrmann K, 2015, Open Rheumatol J, V9, P71, DOI 10.2174/1874312901409010071
   Karampitsakos T, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00041
   Landry ML, 2016, CLIN VACCINE IMMUNOL, V23, P540, DOI 10.1128/CVI.00211-16
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Savige J, 2000, KIDNEY INT, V57, P846, DOI 10.1046/j.1523-1755.2000.057003846.x
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Szer J, 2020, BONE MARROW TRANSPL, V55, P2043, DOI 10.1038/s41409-020-0873-x
   Tzouvelekis A, 2019, CLIN CHEST MED, V40, P679, DOI 10.1016/j.ccm.2019.06.002
   Wang YS, 2004, CELL MOL IMMUNOL, V1, P304
NR 11
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 7
PY 2020
VL 7
AR 399
DI 10.3389/fmed.2020.00399
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MP8KS
UT WOS:000552449000001
PM 32733908
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, PP
   Blet, A
   Smyth, D
   Li, HL
AF Liu, Peter P.
   Blet, Alice
   Smyth, David
   Li, Hongliang
TI The Science Underlying COVID-19 Implications for the Cardiovascular
   System
SO CIRCULATION
LA English
DT Article
DE angiotensin converting enzyme 2; heart failure; human coronavirus;
   inflammation; myocarditis; severe acute respiratory syndrome; vasculitis
ID ANGIOTENSIN-CONVERTING ENZYME-2; ACUTE RESPIRATORY SYNDROME; SARS
   CORONAVIRUS INFECTION; T-CELLS; ACE2; RECEPTOR; INNATE; MICE;
   INFLAMMATION; MYOCARDITIS
AB The coronavirus disease 2019 (COVID-19) pandemic has affected health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of severe acute respiratory syndrome coronavirus 2 is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S-spike protein. The continued viral shedding in the asymptomatic and presymptomatic individuals enhances its community transmission. The virus uses the angiotensin converting enzyme 2 receptor for internalization, aided by transmembrane protease serine 2 protease. The tissue localization of the receptors correlates with COVID-19 presenting symptoms and organ dysfunction. Virus-induced angiotensin converting enzyme 2 downregulation may attenuate its function, diminish its anti-inflammatory role, and heighten angiotensin II effects in the predisposed patients. Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Appropriate type I interferon pathway activation is critical for virus attenuation and balanced immune response. Persistent immune activation in predisposed patients, such as elderly adults and those with cardiovascular risk, can lead to hemophagocytosis-like syndrome, with uncontrolled amplification of cytokine production, leading to multiorgan failure and death. In addition to the airways and lungs, the cardiovascular system is often involved in COVID-19 early, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all extremely prognostic, in particular, in those showing continued rise, along with cytokines such as interleukin-6. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death. Aggressive support based on early prognostic indicators with expectant management can potentially improve recovery. Appropriate treatment for heart failure, arrhythmias, acute coronary syndrome, and thrombosis remain important. Specific evidence-based treatment strategies for COVID-19 will emerge with ongoing global collaboration on multiple approaches being evaluated. To protect the wider population, antibody testing and effective vaccine will be needed to make COVID-19 history.
C1 [Liu, Peter P.; Blet, Alice; Smyth, David] Univ Ottawa, Heart Inst, 40 Ruskin St,Rm H2238, Ottawa, ON K1Y 4W7, Canada.
   [Liu, Peter P.; Smyth, David] Univ Ottawa, Dept Med & Cellular & Mol Med, Ottawa, ON, Canada.
   [Blet, Alice] Univ Paris, Lariboisiere St Louis Hosp, AP HP Nord, Dept Anesthesiol,Crit Care & Burn Ctr,DMU Parabol, Paris, France.
   [Blet, Alice] Univ Paris, INSERM, Cardiovasc Markers Stress Condit MASCOT, UMR S 942, Paris, France.
   [Li, Hongliang] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Li, Hongliang] Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan, Peoples R China.
   [Li, Hongliang] Wuhan Univ, Basic Med Sch, Wuhan, Peoples R China.
RP Liu, PP (corresponding author), Univ Ottawa, Heart Inst, 40 Ruskin St,Rm H2238, Ottawa, ON K1Y 4W7, Canada.
EM peter.liu@utoronto.ca
RI Alice, Blet/V-7940-2017
OI Alice, Blet/0000-0003-3885-9569
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR); Heart & Stroke FoundationHeart & Stroke Foundation of
   Canada; University of Ottawa of Heart Institute
FX This work is supported in part by research grants from the Canadian
   Institutes of Health Research, the Heart & Stroke Foundation, and
   Research Funds from the University of Ottawa of Heart Institute.
CR Acosta-Ramirez E, 2008, IMMUNOLOGY, V124, P186, DOI 10.1111/j.1365-2567.2007.02753.x
   BANERJEE A, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/V11020152
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Boisrame-Helms J, 2013, CURR VASC PHARMACOL, V11, P150
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chapman AR, 2020, CIRCULATION, V141, P1733, DOI 10.1161/CIRCULATIONAHA.120.047008
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Epelman S, 2015, NAT REV IMMUNOL, V15, P117, DOI 10.1038/nri3800
   Fagyas M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087844
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072
   Fisman DN, 2000, EMERG INFECT DIS, V6, P601, DOI 10.3201/eid0606.000608
   Fuse K, 2005, CIRCULATION, V112, P2276, DOI 10.1161/CIRCULATIONAHA.105.536433
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grubaugh ND, 2019, NAT MICROBIOL, V4, P10, DOI 10.1038/s41564-018-0296-2
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   Liu P, 2000, NAT MED, V6, P429
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Nencioni A, 2009, INTERN EMERG MED, V4, P413, DOI 10.1007/s11739-009-0297-5
   Opavsky MA, 2002, J CLIN INVEST, V109, P1561, DOI 10.1172/JCI200213971
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5
   Pavlovich SS, 2018, CELL, V173, P1098, DOI 10.1016/j.cell.2018.03.070
   Pedersen KB, 2015, ENDOCRINOLOGY, V156, P4411, DOI 10.1210/en.2015-1556
   Sagar S, 2012, LANCET, V379, P738, DOI 10.1016/S0140-6736(11)60648-X
   Scheuplein VA, 2015, J VIROL, V89, P3859, DOI 10.1128/JVI.03607-14
   Schultheiss HP, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0084-1
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shi Y, 2010, CIRCULATION, V121, P2624, DOI 10.1161/CIRCULATIONAHA.109.893248
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Soro-Paavonen A, 2012, J HYPERTENS, V30, P375, DOI 10.1097/HJH.0b013e32834f04b6
   Thomas MC, 2010, CIRC RES, V107, P888, DOI 10.1161/CIRCRESAHA.110.219279
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206
   Uri K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087845
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Valaperti A, 2013, CIRCULATION, V128, P1542, DOI 10.1161/CIRCULATIONAHA.113.002275
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang EY, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007716
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang KM, 2020, CIRCULATION, V142, P426, DOI 10.1161/CIRCULATIONAHA.120.047049
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09536-z
   Xu M, 2019, PHYSIOL REV, V99, P893, DOI 10.1152/physrev.00065.2017
   Ye MH, 2004, HYPERTENSION, V43, P1120, DOI 10.1161/01.HYP.0000126192.27644.76
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 68
TC 109
Z9 109
U1 26
U2 34
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD JUL 7
PY 2020
VL 142
IS 1
BP 68
EP 78
DI 10.1161/CIRCULATIONAHA.120.047549
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA MM4RL
UT WOS:000550145600017
PM 32293910
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Gbesemete, D
   Barker, M
   Lawrence, WT
   Watson, D
   de Graaf, H
   Read, RC
AF Gbesemete, D.
   Barker, M.
   Lawrence, W. T.
   Watson, D.
   de Graaf, H.
   Read, R. C.
TI Exploring the acceptability of controlled human infection with
   SARSCoV2-a public consultation
SO BMC MEDICINE
LA English
DT Article
DE Controlled human infection model; SARSCoV2; COVID-19; Public
   consultation
ID CHALLENGE
AB Rapid development of an effective vaccine for SARSCoV2 is a global priority. A controlled human infection model (CHIM) would accelerate the efficacy assessment of candidate vaccines. This strategy would require deliberate exposure of volunteers to SARSCoV2 with no currently available treatment and a small but definite risk of serious illness or death. This raises complex questions about the social and ethical acceptability of risk to individuals, given the potential benefit to the wider population, and as such, a study cannot be done without public involvement. We conducted a structured public consultation with 57 individuals aged 20-40 years to understand public attitudes to a CHIM, and pre-requisites for enrolment. The overall response to this strategy was positive, and many would volunteer altruistically. Carefully controlled infection is viewed as safer than natural exposure to wild virus. The prolonged social isolation required for the proposed CHIM is considered an obstacle but not insurmountable, with reasonable compensation and supportive care. Given the significant level of public interest, a CHIM should be done as open science with regular, controlled dissemination of information into the public domain. Importantly, there was a strong view that the final decision whether to conduct a CHIM should be in the hands of qualified and experienced clinician-scientists and the authorities.
C1 [Gbesemete, D.; de Graaf, H.] Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Fac Med, Tremona Rd, Southampton SO16 6YD, England.
   [Gbesemete, D.; de Graaf, H.] Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Inst Life Sci, Tremona Rd, Southampton SO16 6YD, England.
   [Gbesemete, D.; de Graaf, H.] Univ Hosp Southampton NHS Fdn Trust, Univ Hosp Southampton NHS Fdn Trust Mailpoint 218, NIHR Southampton Biomed Res Ctr, Tremona Rd, Southampton SO16 6YD, England.
   [Barker, M.; Lawrence, W. T.] Univ Southampton, D08 Inst Dev Sci, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Barker, M.; Lawrence, W. T.] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England.
   [Barker, M.; Lawrence, W. T.] Univ Hosp Southampton NHS Fdn Trust Southampton, Southampton, Hants, England.
   [Watson, D.] Univ Southampton, Univ Hosp Southampton NHS Fdn Trust, D08 Inst Dev Sci, Sch Human Dev & Hlth,Fac Med, Southampton, Hants, England.
   [Read, R. C.] Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Fac Med, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.
   [Read, R. C.] Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Inst Life Sci, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.
   [Read, R. C.] Univ Southampton, Southampton Gen Hosp, Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Biomed Res Ctr, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.
RP Read, RC (corresponding author), Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Fac Med, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.; Read, RC (corresponding author), Univ Southampton, Sch Clin & Expt Sci, NIHR Clin Res Facil, Inst Life Sci, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.; Read, RC (corresponding author), Univ Southampton, Southampton Gen Hosp, Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Biomed Res Ctr, South Acad Block,Mailpoint 814,Tremona Rd, Southampton SO16 6YD, England.
EM r.c.read@soton.ac.uk
OI Watson, Daniella/0000-0001-6353-7495; Read, Robert/0000-0002-4297-6728;
   Lawrence, Wendy/0000-0003-1264-0438; Barker, Mary/0000-0003-2976-0217
FU NIHR Southampton BRC
FX This public consultation was funded by the NIHR Southampton BRC. The
   funding body had no further role in the public consultation or writing
   of the manuscript.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2017, WHO TECHN REP SER, V1004
   [Anonymous], 2020, KEY CRITERIA ETHICAL
   [Anonymous], 2005, MICROBIAL CHALLENGE
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Collins AM, 2015, AM J RESP CRIT CARE, V192, P853, DOI 10.1164/rccm.201503-0542OC
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gibani MM, 2019, CLIN INFECT DIS, V68, P1265, DOI 10.1093/cid/ciy670
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Pollard AJ, 2012, LANCET INFECT DIS, V12, P903, DOI 10.1016/S1473-3099(12)70292-X
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Sauerwein RW, 2011, NAT REV IMMUNOL, V11, P57, DOI 10.1038/nri2902
   Shirley Debbie-Ann T, 2011, Vaccine (Auckl), V2011, P3
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   2020, MMWR MORBID MORTAL W, V69, P343
NR 18
TC 2
Z9 2
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUL 7
PY 2020
VL 18
IS 1
AR 209
DI 10.1186/s12916-020-01670-2
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA ML0EB
UT WOS:000549149300001
PM 32635912
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Kache, S
   Chisti, MJ
   Gumbo, F
   Mupere, E
   Zhi, X
   Nallasamy, K
   Nakagawa, S
   Lee, JH
   Di Nardo, M
   de la Oliva, P
   Katyal, C
   Anand, KJS
   de Souza, DC
   Lanziotti, VS
   Carcillo, J
AF Kache, Saraswati
   Chisti, Mohammod Jobayer
   Gumbo, Felicity
   Mupere, Ezekiel
   Zhi, Xia
   Nallasamy, Karthi
   Nakagawa, Satoshi
   Lee, Jan Hau
   Di Nardo, Matteo
   de la Oliva, Pedro
   Katyal, Chhavi
   Anand, Kanwaljeet J. S.
   de Souza, Daniela Carla
   Lanziotti, Vanessa Soares
   Carcillo, Joseph
TI COVID-19 PICU guidelines: for high- and limited-resource settings
SO PEDIATRIC RESEARCH
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; ACUTE LUNG INJURY; DISTRESS-SYNDROME
   PROCEEDINGS; POSITIVE AIRWAY PRESSURE; DISEASE 2019 COVID-19;
   RESPIRATORY-DISTRESS; CONVALESCENT PLASMA; SEPTIC SHOCK; ORGAN
   DYSFUNCTION; FLUID BOLUS
AB Background Fewer children than adults have been affected by the COVID-19 pandemic, and the clinical manifestations are distinct from those of adults. Some children particularly those with acute or chronic co-morbidities are likely to develop critical illness. Recently, a multisystem inflammatory syndrome (MIS-C) has been described in children with some of these patients requiring care in the pediatric ICU. Methods An international collaboration was formed to review the available evidence and develop evidence-based guidelines for the care of critically ill children with SARS-CoV-2 infection. Where the evidence was lacking, those gaps were replaced with consensus-based guidelines. Results This process has generated 44 recommendations related to pediatric COVID-19 patients presenting with respiratory distress or failure, sepsis or septic shock, cardiopulmonary arrest, MIS-C, those requiring adjuvant therapies, or ECMO. Evidence to explain the milder disease patterns in children and the potential to use repurposed anti-viral drugs, anti-inflammatory or anti-thrombotic therapies are also described. Conclusion Brief summaries of pediatric SARS-CoV-2 infection in different regions of the world are included since few registries are capturing this data globally. These guidelines seek to harmonize the standards and strategies for intensive care that critically ill children with COVID-19 receive across the world. Impact
   At the time of publication, this is the latest evidence for managing critically ill children infected with SARS-CoV-2. Referring to these guidelines can decrease the morbidity and potentially the mortality of children effected by COVID-19 and its sequalae. These guidelines can be adapted to both high- and limited-resource settings.
C1 [Kache, Saraswati] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA.
   [Chisti, Mohammod Jobayer] Int Ctr Diarrhoea Dis Res Bangladesh Icddr B, Intens Care Unit & Clin Res, Dhaka, Bangladesh.
   [Gumbo, Felicity] Univ Zimbabwe, Dept Pediat & Child Hlth, Coll Hlth Sci, Harare, Zimbabwe.
   [Mupere, Ezekiel] Makerere Univ, Sch Med Coll Hlth Sci, Dept Pediat & Child Hlth, Kampala, Uganda.
   [Zhi, Xia] Maternal & Child Hlth Hosp Hubei Prov, Dept Pediat, Intens Care Unit, Wuhan, Hubei, Peoples R China.
   [Nallasamy, Karthi] Postgrad Inst Med Educ & Res, Dept Pediat, Chandigarh, Punjab, India.
   [Nakagawa, Satoshi] Natl Ctr Child Hlth & Dev, Crit Care Med, Tokyo, Japan.
   [Lee, Jan Hau] Duke NUS Med Sch, KK Womens & Childrens Hosp, Childrens Intens Care Unit, Singapore, Singapore.
   [Di Nardo, Matteo] Childrens Hosp Bambino Gesu, Pediat Intens Care Unit, Rome, Italy.
   [de la Oliva, Pedro] Univ Autonoma Madrid, Pediat Intens Care Dept, Hosp Univ La Paz, Dept Pediat,Med Sch, Madrid, Spain.
   [Katyal, Chhavi] Albert Einstein Coll Med, Pediat Crit Care Med, Childrens Hosp Montefiore, Bronx, NY 10467 USA.
   [Anand, Kanwaljeet J. S.] Stanford Univ, Sch Med, Dept Pediat Anesthesiol Perioperat & Pain Med, Palo Alto, CA 94304 USA.
   [de Souza, Daniela Carla] Univ Sao Paulo, Pediat Intens Care Unit, Sao Paulo, Brazil.
   [de Souza, Daniela Carla] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Lanziotti, Vanessa Soares] Univ Fed Rio de Janeiro, Pediat Intens Care Unit, Rio De Janeiro, Brazil.
   [Lanziotti, Vanessa Soares] Univ Fed Rio de Janeiro, Res & Educ Div, Maternal & Child Hlth Postgrad Program, Rio De Janeiro, Brazil.
   [Carcillo, Joseph] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Carcillo, Joseph] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
RP Kache, S (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA.
EM skache@stanford.edu
RI Di NARDO, Matteo/AAI-1781-2019
OI de la Oliva, Pedro/0000-0003-2444-0556
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, PER CONS 2019 NOV CO, P2020
   [Anonymous], 2020, COVID 19 B EPIDEMIOL
   [Anonymous], 2020, COR DIS 2019 COVID 1
   [Anonymous], 2020, COV 19 PER
   [Anonymous], 2020, COR COVD 19 CON INF
   [Anonymous], 2020, CORONAVIRUS DIS 2019
   [Anonymous], 2020, COVID 19 DATA N AM P
   [Anonymous], 2020, COR COVID 19 GLOB CA
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Atri Deepak, 2020, JACC Basic Transl Sci, V5, P518, DOI 10.1016/j.jacbts.2020.04.002
   Balasubramanian S, 2020, Indian Pediatr, V57, P681
   Balasubramanian S, 2020, INDIAN PEDIATR, V57, P435, DOI 10.1007/s13312-020-1819-5
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   BENETEAUBURNAT B, 1990, CLIN CHEM, V36, P344
   Gamez-Gonzalez LB, 2018, PEDIATR INT, V60, P781, DOI 10.1111/ped.13614
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Bubenik GA, 2011, J PHYSIOL PHARMACOL, V62, P13
   Canelli R, 2020, NEW ENGL J MED, V382, P1957, DOI 10.1056/NEJMc2007589
   CDC Health Alert, 2020, MULT INFL SYNDR CHIL
   Cheifetz IM, 2017, RESP CARE, V62, P718, DOI 10.4187/respcare.05591
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chisti MJ, 2015, LANCET, V386, P1057, DOI 10.1016/S0140-6736(15)60249-5
   D'Silva DF, 2020, BRIT J ANAESTH, V125, pE192, DOI 10.1016/j.bja.2020.03.016
   de Jager P, 2014, CRIT CARE MED, V42, P2461, DOI 10.1097/CCM.0000000000000546
   de Souza T. H., 2020, PEDIAT PULMONOL, P1
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   ECRI Institute, 2020, MECH VENT SARS PAT L
   Edelson DP, 2020, CIRCULATION, V395, P497
   Ekhaguere OA, 2019, PAEDIATR RESPIR REV, V29, P31, DOI 10.1016/j.prrv.2018.04.004
   ELSO, 2017, ELSO GUID EXTR LIF S
   ELSO, 2020, ELSO GUID DOC ECMO C
   EpiCentro, 2020, COVID 19 INT SURV KE
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Guang C, 2012, ARCH CARDIOVASC DIS, V105, P373, DOI 10.1016/j.acvd.2012.02.010
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Gupta Nivedita, 2020, Indian J Med Res, V151, P236, DOI 10.4103/ijmr.IJMR_1035_20
   Hall D, 2020, ANAESTHESIA, V120, P173
   Han H, 2020, CLIN CHEM LAB MED, V0, P3
   Henry BM, 2020, CLIN CHEM LAB MED, V0, P415
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Imber DA, 2019, PEDIATR CRIT CARE ME, V20, pE145, DOI 10.1097/PCC.0000000000001846
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Institute of Epidemiology, 2020, COVID 19 UPD
   Inwald DP, 2019, ARCH DIS CHILD, V104, P426, DOI 10.1136/archdischild-2018-314924
   Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC
   Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158
   Kain T, 2020, EMERG INFECT DIS, V26, P1102, DOI 10.3201/eid2606.200037
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Li SR, 2020, EUR J CLIN MICROBIOL, V39, P1021, DOI 10.1007/s10096-020-03883-y
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Luo J, 2019, J PEDIATR-US, V215, P199, DOI 10.1016/j.jpeds.2019.07.059
   Lyu Xiaochun, 2015, Zhonghua Yi Xue Za Zhi, V95, P496
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   Martindale R., 2020, NUTR THERAPY PATIENT
   Matava CT, 2020, ANESTH ANALG, V131, P61, DOI 10.1213/ANE.0000000000004872
   Mazer SP, 2003, RESUSCITATION, V57, P279, DOI 10.1016/S0300-9572(03)00037-6
   Menendez JJ, 2016, J THROMB HAEMOST, V14, P2158, DOI 10.1111/jth.13478
   Misra DP, 2020, CLIN RHEUMATOL, V11, P65
   Morand A, 2020, ARCH PEDIATRIE, V27, P117, DOI 10.1016/j.arcped.2020.03.001
   Nguyen TC, 2008, CRIT CARE MED, V36, P2878, DOI 10.1097/CCM.0b013e318186aa49
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Ong J. S. M., 2020, PEDIATR CRIT CARE ME, V1, P607
   Patel SK, 2013, CLIN EXP PHARMACOL P, V40, P551, DOI 10.1111/1440-1681.12069
   Raffini L, 2009, PEDIATRICS, V124, P1001, DOI 10.1542/peds.2009-0768
   Ramsi M, 2018, BMJ CASE REP, V2018, pbcr
   Red Nacional de Vigilancia Epidemiologica, 2020, INF SIT COVIE 19 ESP
   Rimensberger PC, 2015, PEDIATR CRIT CARE ME, V16, pS51, DOI 10.1097/PCC.0000000000000433
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC
   Sampson AK, 2012, GENDER MED, V9, P21, DOI 10.1016/j.genm.2011.12.003
   Sankar J, 2017, PEDIATR CRIT CARE ME, V18, pE435, DOI 10.1097/PCC.0000000000001269
   Sante Publique France, 2020, COVID 19 POINT EP
   Santhanam I, 2008, PEDIATR EMERG CARE, V24, P647, DOI 10.1097/PEC.0b013e31818844cf
   Santschi M, 2010, PEDIATR CRIT CARE ME, V11, P681, DOI 10.1097/PCC.0b013e3181d904c0
   Schlapbach LJ, 2017, INTENS CARE MED, V43, P1085, DOI 10.1007/s00134-017-4701-8
   Shekar K, 2020, ASAIO J, P1
   Shen Q, 2020, PEDIAT PULMONOL, V323, P707
   Song RF, 2012, PEDIATR RES, V71, P13, DOI 10.1038/pr.2011.7
   South AM, 2020, NAT REV NEPHROL, V395, P1054
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Tamburro RF, 2015, PEDIATR CRIT CARE ME, V16, pS61, DOI 10.1097/PCC.0000000000000434
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LL, 2020, ACTA POLYM SIN, V51, P1, DOI 10.11777/j.issn1000-3304.2020.19165
   Weiss SL, 2020, PEDIATR CRIT CARE ME, V21, pE52, DOI 10.1097/PCC.0000000000002198
   WHO, 2020, CLIN MAN SEV AC RESP
   WHO, 2013, POCK BOOK HOSP CAR C
   Wilson PT, 2017, LANCET GLOB HEALTH, V5, pE615, DOI 10.1016/s2214-109x(17)30145-6
   World Health Organization, 2016, OX THER CHILDR MAN H
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
   Yin S, 2020, J THROMB THROMBOLYS, V395, P507
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou X, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1617-1
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu L, 2020, PEDIATR RES, V36, P344
NR 109
TC 4
Z9 4
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2020
VL 88
IS 5
BP 705
EP 716
DI 10.1038/s41390-020-1053-9
EA JUL 2020
PG 12
WC Pediatrics
SC Pediatrics
GA OE4OM
UT WOS:000548495500001
PM 32634818
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Al-Sehemi, AG
   Pannipara, M
   Parulekar, RS
   Patil, O
   Choudhari, PB
   Bhatia, MS
   Zubaidha, PK
   Tamboli, Y
AF Al-Sehemi, Abdullah G.
   Pannipara, Mehboobali
   Parulekar, Rishikesh S.
   Patil, Omkar
   Choudhari, Prafulla B.
   Bhatia, M. S.
   Zubaidha, P. K.
   Tamboli, Yasinalli
TI Potential of NO donor furoxan as SARS-CoV-2 main protease (M-pro)
   inhibitors:in silicoanalysis
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2 M(pro)inhibition; nitric oxide; furoxan; in silico
   analysis
ID NITRIC-OXIDE; INHIBITION
AB The sharp spurt in positive cases of novel coronavirus-19 (SARS-CoV-2) worldwide has created a big threat to human. In view to expedite new drug leads for COVID-19, Main Proteases (M-pro) of novel Coronavirus (SARS-CoV-2) has emerged as a crucial target for this virus. Nitric oxide (NO) inhibits the replication cycle of SARS-CoV. Inhalation of nitric oxide is used in the treatment of severe acute respiratory syndrome. Herein, we evaluated the phenyl furoxan, a well-known exogenous NO donor to identify the possible potent inhibitors throughin silicostudies such as molecular docking as per target analysis for candidates bound to substrate binding pocket of SARS-COV-2 M-pro. Molecular dynamics (MD) simulations of most stable docked complexes (M-pro-22and M-pro-26) helped to confirm the notable conformational stability of these docked complexes under dynamic state. Furthermore, Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) calculations revealed energetic contributions of key residues of M(pro)in binding with potent furoxan derivatives22,26. In the present study to validate the molecular docking, MD simulation and MM-PBSA results, crystal structure of M(pro)bound to experimentally known inhibitor X77 was used as control and the obtained results are presented herein. We envisaged that spiro-isoquinolino-piperidine-furoxan moieties can be used as effective ligand for SARS-CoV-2 M(pro)inhibition due to the presence of key isoquinolino-piperidine skeleton with additional NO effect. Communicated by Ramaswamy H. Sarma
C1 [Al-Sehemi, Abdullah G.; Pannipara, Mehboobali] King Khalid Univ, Res Ctr Adv Mat Sci, Abha, Saudi Arabia.
   [Al-Sehemi, Abdullah G.; Pannipara, Mehboobali] King Khalid Univ, Dept Chem, Abha, Saudi Arabia.
   [Parulekar, Rishikesh S.; Patil, Omkar; Choudhari, Prafulla B.; Bhatia, M. S.] Bharati Vidyapeeth Coll Pharm, Dept Pharmaceut Chem, Kolhapur, Maharashtra, India.
   [Zubaidha, P. K.; Tamboli, Yasinalli] SRTM Univ, Sch Chem Sci, Nanded 431606, Maharashtra, India.
RP Tamboli, Y (corresponding author), SRTM Univ, Sch Chem Sci, Nanded 431606, Maharashtra, India.
EM yasinmedchem@gmail.com
RI al-sehemi, Abdullah/AAM-4039-2020; Al-Sehemi, Abdullah/AAK-5902-2020
OI Al-Sehemi, Abdullah/0000-0002-6793-3038; Bhatia, Dr. Manish
   S./0000-0003-4045-5280; Parulekar, Rishikesh/0000-0001-9568-9039;
   Tamboli, Yasinalli/0000-0002-5161-0170
FU Institute of research and consulting studies at King Khalid University
   [3-N-20/21]; Research center for advanced materials Science
FX The authors are thankful to V life Sciences, Pune for providing trial
   version of software for research work. The authors are thankful to the
   Institute of research and consulting studies at King Khalid University
   for funding this research through grant number 3-N-20/21 and the support
   of Research center for advanced materials Science is highly
   acknowledged.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ABDELLI I, 2020, J BIOMOL STRUCT 0513, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1763199
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Akerstrom S, 2009, VIROLOGY, V395, P1, DOI 10.1016/j.virol.2009.09.007
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Gasco A, 2004, PURE APPL CHEM, V76, P973, DOI 10.1351/pac200476050973
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mannick JB, 1995, RES IMMUNOL, V146, P693, DOI 10.1016/0923-2494(96)84920-0
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Parulekar RS, 2018, J CELL BIOCHEM, V119, P2679, DOI 10.1002/jcb.26435
   Parulekar RS, 2018, J CELL BIOCHEM, V119, P9444, DOI 10.1002/jcb.27261
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PRABHULING S, 2020, BIOMEDICINES, V8, DOI DOI https://doi.org/10.3390/biomedicines8050121
   Pudukulatham Z, 2016, MOL PAIN, V12, DOI 10.1177/1744806916641678
   Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998
   SARMA P, 2020, J BIOMOL STRUCT 0516, DOI DOI https://doi.org/10.1080/07391102.2020.1753580
   Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5
   Serafim RAM, 2012, CURR MED CHEM, V19, P386, DOI 10.2174/092986712803414321
   SINHA SK, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762741
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 44
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1790038
EA JUL 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MJ1MV
UT WOS:000547859100001
PM 32643550
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, MAA
   Abdeljawaad, KAA
   Abdelrahman, AHM
   Hegazy, MEF
AF Ibrahim, Mahmoud A. A.
   Abdeljawaad, Khlood A. A.
   Abdelrahman, Alaa H. M.
   Hegazy, Mohamed-Elamir F.
TI Natural-like products as potential SARS-CoV-2
   M(pro)inhibitors:in-silicodrug discovery
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; main protease; natural-like product; molecular docking;
   molecular dynamics; drug-likeness
ID GENERATION
AB In December 2019, a COVID-19 epidemic was discovered in Wuhan, China, and since has disseminated around the world impacting human health for millions. Herein,in-silicodrug discovery approaches have been utilized to identify potential natural products (NPs) as Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (M-pro) inhibitors. The MolPort database that contains over 100,000 NPs was screened and filtered using molecular docking techniques. Based on calculated docking scores, the top 5,000 NPs/natural-like products (NLPs) were selected and subjected to molecular dynamics (MD) simulations followed by molecular mechanics-generalized Born surface area (MM-GBSA) binding energy calculations. Combined 50 ns MD simulations and MM-GBSA calculations revealed nine potent NLPs with binding affinities (Delta G(binding)) > -48.0 kcal/mol. Interestingly, among the identified NLPs, four bis([1,3]dioxolo)pyran-5-carboxamide derivatives showed Delta G(binding)> -56.0 kcal/mol, forming essential short hydrogen bonds with HIS163 and GLY143 amino acids via dioxolane oxygen atoms. Structural and energetic analyses over 50 ns MD simulation demonstrated NLP-M(pro)complex stability. Drug-likeness predictions revealed the prospects of the identified NLPs as potential drug candidates. The findings are expected to provide a novel contribution to the field of COVID-19 drug discovery. Communicated by Ramaswamy H. Sarma
C1 [Ibrahim, Mahmoud A. A.; Abdeljawaad, Khlood A. A.; Abdelrahman, Alaa H. M.] Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt.
   [Hegazy, Mohamed-Elamir F.] Natl Res Ctr, Chem Med Plants Dept, El Tahrir St, Giza, Egypt.
RP Ibrahim, MAA (corresponding author), Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt.
EM m.ibrahim@compchem.net
RI Abdelrahman, Alaa H. M./AAX-1803-2020; Ibrahim, Mahmoud/J-2936-2014;
   Hegazy, Mohamed Elamir/AAA-3454-2019
OI Abdelrahman, Alaa H. M./0000-0003-3527-0126; Ibrahim,
   Mahmoud/0000-0003-4819-2040; Hegazy, Mohamed Elamir/0000-0002-0343-4969
FU Science and Technology Development Fund, STDF, EgyptScience and
   Technology Development Fund (STDF) [5480, 7972]
FX The computational work was completed with resources supported by the
   Science and Technology Development Fund, STDF, Egypt, Grants No. 5480 &
   7972.
CR ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   [Anonymous], 2016, SZYBKI VERS 1 9 0 3
   [Anonymous], 2013, OMEGA VERS 2 5 1 4
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Case D.A., 2016, AMBER 2016
   Clark AM, 1996, PHARM RES-DORDR, V13, P1133, DOI 10.1023/A:1016091631721
   Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   De Vivo M, 2016, J MED CHEM, V59, P4035, DOI 10.1021/acs.jmedchem.5b01684
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Frisch M. J., 2009, GAUSSIAN 09 VERSION
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   GENTILE D, 2020, MAR DRUGS, V18, DOI DOI https://doi.org/10.3390/md18040225
   Gonzalez-Paz L. A., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-21206/v1, DOI 10.21203/RS.3.RS-21206/V1]
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
   Hondermarck Hubert, 2020, FASEB Bioadv, V2, P296, DOI 10.1096/fba.2020-00015
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kerrigan John E, 2013, Methods Mol Biol, V993, P95, DOI 10.1007/978-1-62703-342-8_7
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kurapati KRV, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01444
   Li R, 2019, J CELL BIOCHEM, V120, P11265, DOI 10.1002/jcb.28404
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mashour NH, 1998, ARCH INTERN MED, V158, P2225, DOI 10.1001/archinte.158.20.2225
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   MULLARD A, 2018, NAT REV DRUG DISCOV, V17, P777
   Quinn RJ, 2008, J NAT PROD, V71, P464, DOI 10.1021/np070526y
   Roux B, 1999, BIOPHYS CHEM, V78, P1, DOI 10.1016/S0301-4622(98)00226-9
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Thomas GL, 2011, CURR OPIN CHEM BIOL, V15, P516, DOI 10.1016/j.cbpa.2011.05.022
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   WELLS TNC, 2011, MALARIA J S1, V10, DOI DOI https://doi.org/10.1186/1475-2875-10-S1-S3
   Zhao YH, 2002, PHARM RES-DORDR, V19, P1446, DOI 10.1023/A:1020444330011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1790037
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI1GI
UT WOS:000547163400001
PM 32643529
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mateen, FJ
   Rezaei, S
   Alakel, N
   Gazdag, B
   Kumar, AR
   Vogel, A
AF Mateen, Farrah J.
   Rezaei, Shawheen
   Alakel, Nicholas
   Gazdag, Brittany
   Kumar, Aditya Ravi
   Vogel, Andre
TI Impact of COVID-19 on US and Canadian neurologists' therapeutic approach
   to multiple sclerosis: a survey of knowledge, attitudes, and practices
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Multiple sclerosis; COVID-19; Immunosuppression; Health behaviors;
   Neuroimmunology; Neurologist; Disease-modifying therapy
ID ADHERENCE
AB Objective To report the understanding and decision-making of neuroimmunologists and their treatment of patients with multiple sclerosis (MS) during the early stages of the SARS-CoV-2 (COVID-19) outbreak. Methods A survey instrument was designed and distributed online to neurologists in April 2020. Results There were 250 respondents (response rate 21.8%). 243 saw > = 10 MS patients in the prior 6 months (average 197 patients) and were analyzed further (92% USA, 8% Canada; average practice duration 16 years; 5% rural, 17% small city, 38% large city, 40% highly urbanized). Patient volume dropped an average of 79% (53-11 per month). 23% were aware of patients self-discontinuing a DMT due to fear of COVID-19 with 43% estimated to be doing so against medical advice. 65% of respondents reported deferring > = 1 doses of a DMT (49%), changing the dosing interval (34%), changing to home infusions (20%), switching a DMT (9%), and discontinuing DMTs altogether (8%) as a result of COVID-19. Changes in DMTs were most common with the high-efficacy therapies alemtuzumab, cladribine, ocrelizumab, rituximab, and natalizumab. 35% made no changes to DMT prescribing. 98% expressed worry about their patients contracting COVID-19 and 78% expressed the same degree of worry about themselves. > 50% believed high-efficacy DMTs prolong viral shedding of SARS-CoV-2 and that B-cell therapies might prevent protective vaccine effects. Accelerated pace of telemedicine and practice model changes were identified as major shifts in practice. Conclusions Reported prescribing changes and practice disruptions due to COVID-19 may be temporary but could have a lasting influence on MS care.
C1 [Mateen, Farrah J.; Rezaei, Shawheen; Vogel, Andre] Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,Off 627, Boston, MA 02114 USA.
   [Mateen, Farrah J.] Harvard Med Sch, Boston, MA 02115 USA.
   [Alakel, Nicholas; Gazdag, Brittany; Kumar, Aditya Ravi] ZoomRx, Boston, MA USA.
RP Mateen, FJ (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,Off 627, Boston, MA 02114 USA.; Mateen, FJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM fmateen@mgh.harvard.edu
OI Mateen, Farrah/0000-0002-4293-8115
FU Biogen, Inc.Biogen
FX This study was supported by an unrestricted investigatorinitiated grant
   from Biogen, Inc.
CR [Anonymous], TREAT MS
   [Anonymous], MS TREATM GUID COR
   Berger JR, 2017, NEUROL-CLIN PRACT, V7, P246, DOI 10.1212/CPJ.0000000000000360
   Bhatia D, 2020, ANN INDIAN ACAD NEUR, V23, P9, DOI 10.4103/aian.AIAN_519_19
   Brown JWL, 2019, JAMA-J AM MED ASSOC, V321, P175, DOI 10.1001/jama.2018.20588
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Centers for Disease Control and Prevention, COR COVID 19
   Erbay O, 2018, J NEUROSCI NURS, V50, P291, DOI 10.1097/JNN.0000000000000395
   Fuller T., 2020, NY TIMES
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365
   Menzin J, 2013, J MANAGE CARE PHARM, V19, pS24, DOI 10.18553/jmcp.2013.19.s1.S24
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Schreiber K, 2018, PATIENT PREFER ADHER, V12, P1139, DOI 10.2147/PPA.S166278
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Statistics Canada, TABL 13 10 0467 01 N, DOI [10.25318/1310046701-eng., DOI 10.25318/1310046701-ENG]
   Waldman G, 2020, NEUROLOGY, V94, P886, DOI 10.1212/WNL.0000000000009519
   Wallin MT, 2019, NEUROLOGY, V92, pE1029, DOI 10.1212/WNL.0000000000007035
   Willis MD, 2020, J NEUROL, V267, P1567, DOI 10.1007/s00415-020-09822-3
NR 21
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD DEC
PY 2020
VL 267
IS 12
BP 3467
EP 3475
DI 10.1007/s00415-020-10045-9
EA JUL 2020
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA PC1WD
UT WOS:000546246100003
PM 32638107
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Parker, JE
   Martinez, A
   Deutsch, GK
   Prabhakar, V
   Lising, M
   Kapphahn, KI
   Anidi, CM
   Neuville, R
   Coburn, M
   Shah, NE
   Bronte-Stewart, HM
AF Parker, Jordan E.
   Martinez, Amaris
   Deutsch, Gayle K.
   Prabhakar, Varsha
   Lising, Melanie
   Kapphahn, Kristopher I.
   Anidi, Chioma M.
   Neuville, Raumin
   Coburn, Maria
   Shah, Neil
   Bronte-Stewart, Helen M.
TI Safety of Plasma Infusions in Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE infusions; Parkinson's disease; plasma; young plasma
ID TUMOR-NECROSIS-FACTOR; CONVALESCENT PLASMA; DIAGNOSTIC-CRITERIA; VERBAL
   FLUENCY; TNF-ALPHA; RECEPTORS; STIGMA; SCALE
AB Background Young plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson's disease (PD) is unknown. Objectives The objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD. Methods A total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4 weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4 weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson's Disease Rating Scale Part IIIoffmedication, neuropsychological battery, Parkinson's Disease Questionnaire-39, inflammatory markers (tumor necrosis factor-alpha, interleukin-6), uric acid, and quantitative kinematics. Results Adherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P= 0.002) and in the Parkinson's Disease Questionnaire-39 stigma subscore (P= 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor-alpha levels decreased 4 weeks after the infusions ended. Conclusions Young fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID-19. (c) 2020 The Authors.Movement Disorderspublished by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.
C1 [Parker, Jordan E.; Martinez, Amaris; Deutsch, Gayle K.; Lising, Melanie; Coburn, Maria; Bronte-Stewart, Helen M.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
   [Prabhakar, Varsha] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Kapphahn, Kristopher I.] Stanford Univ, Sch Med, Quantitat Sci Unit, Stanford, CA 94305 USA.
   [Anidi, Chioma M.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
   [Neuville, Raumin] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
   [Coburn, Maria; Bronte-Stewart, Helen M.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
   [Bronte-Stewart, Helen M.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
RP Bronte-Stewart, HM (corresponding author), Stanford Univ, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.
EM hbs@stanford.edu
OI Anidi, Chioma/0000-0002-2457-2893
FU Smart Family Foundation; National Institute of Neurological Disorders
   and Stroke (NINDS)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [UH3 NS107709]; National
   Institute of Neurological Disorders and StrokeUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS) [UH3
   NS107709]; John E. Cahill Family Foundation
FX J.E.P. received funding from the Smart Family Foundation and National
   Institute of Neurological Disorders and Stroke (NINDS) UH3 NS107709.
   R.N. received funding from a private philanthropic donor. H.M.B.S.
   received funding from National Institute of Neurological Disorders and
   Stroke UH3 NS107709 and the John E. Cahill Family Foundation. A.M.,
   G.K.D., V.P., M.L., K.I.K., C.M.A., M.C., and N.S. have nothing to
   report.
CR Barcia C, 2005, PARKINSONISM RELAT D, V11, P435, DOI 10.1016/j.parkreldis.2005.05.006
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X
   Bouchard J, 2015, J NEUROCHEM, V132, P5, DOI 10.1111/jnc.12969
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   De Virgilio A, 2016, AUTOIMMUN REV, V15, P1005, DOI 10.1016/j.autrev.2016.07.022
   Deng JW, 2020, J CLIN APHERESIS, V35, P294, DOI 10.1002/jca.21790
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Ellfolk U, 2014, J NEURAL TRANSM, V121, P33, DOI 10.1007/s00702-013-1073-2
   Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Helmich RC, 2020, J PARKINSON DIS, V10, P351, DOI 10.3233/JPD-202038
   Henry JD, 2004, J INT NEUROPSYCH SOC, V10, P608, DOI 10.1017/S1355617704104141
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   Hunot S, 1999, J NEUROSCI, V19, P3440
   Jaywant A, 2014, J CLIN EXP NEUROPSYC, V36, P278, DOI 10.1080/13803395.2014.889089
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Kim HJ, 2014, J ORTHOP RES, V32, P551, DOI 10.1002/jor.22532
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kulkarni R., 2020, DYNAMICS IMMUNE ACTI, P9, DOI [10.1007/978-981-15-1045-8_2, DOI 10.1007/978-981-15-1045-8_2]
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Litvan I, 2012, MOVEMENT DISORD, V27, P349, DOI 10.1002/mds.24893
   Lunemann JD, 2015, NAT REV NEUROL, V11, P80, DOI 10.1038/nrneurol.2014.253
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Ma HI, 2016, QUAL LIFE RES, V25, P3037, DOI 10.1007/s11136-016-1329-z
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006
   Middeldorp J, 2016, JAMA NEUROL, V73, P1325, DOI 10.1001/jamaneurol.2016.3185
   Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458
   Mogi M, 2000, LIFE SCI, V67, P1197, DOI 10.1016/S0024-3205(00)00705-0
   Nagatsu T, 2005, CURR PHARM DESIGN, V11, P999, DOI 10.2174/1381612053381620
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Pandey S, 2012, TRANSFUSION, V52, p65S, DOI 10.1111/j.1537-2995.2012.03663.x
   Papa SM, 2020, MOVEMENT DISORD, V35, P711, DOI 10.1002/mds.28067
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   R Core Team, 2018, R LANG ENV STAT COMP
   Rao D, 2009, QUAL LIFE RES, V18, P585, DOI 10.1007/s11136-009-9475-1
   Sha SJ, 2019, JAMA NEUROL, V76, P35, DOI 10.1001/jamaneurol.2018.3288
   Shahani L, 2012, MED CLIN N AM, V96, P421, DOI 10.1016/j.mcna.2012.04.001
   Shao Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00772
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shulman LM, 2010, ARCH NEUROL-CHICAGO, V67, P64, DOI 10.1001/archneurol.2009.295
   Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje
   Trager MH, 2016, NEUROBIOL DIS, V96, P22, DOI 10.1016/j.nbd.2016.08.003
   Troster AI, 2017, ARCH CLIN NEUROPSYCH, V32, P810, DOI 10.1093/arclin/acx090
   Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   Xie AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/648740
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
NR 50
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD NOV
PY 2020
VL 35
IS 11
BP 1905
EP 1913
DI 10.1002/mds.28198
EA JUL 2020
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA OT2AV
UT WOS:000545764700001
PM 32633860
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wang, ZY
   Wang, YF
   Vilekar, P
   Yang, SP
   Gupta, M
   Oh, MI
   Meek, A
   Doyle, L
   Villar, L
   Brennecke, A
   Liyanage, I
   Reed, M
   Barden, C
   Weaver, DF
AF Wang, Zhiyu
   Wang, Yanfei
   Vilekar, Prachi
   Yang, Seung-Pil
   Gupta, Mayuri
   Oh, Myong In
   Meek, Autumn
   Doyle, Lisa
   Villar, Laura
   Brennecke, Anja
   Liyanage, Imindu
   Reed, Mark
   Barden, Christopher
   Weaver, Donald F.
TI Small molecule therapeutics for COVID-19: repurposing of inhaled
   furosemide
SO PEERJ
LA English
DT Article
DE Furosemide; COVID-19; Cytokine storm; Hypercytokinemia; Coronavirus;
   Anti-inflammatory
ID NF-KAPPA-B; METABISULFITE-INDUCED BRONCHOCONSTRICTION; INFLAMMATION;
   ACTIVATION; PROTEIN; ACID
AB The novel coronavirus SARS-CoV-2 has become a global health concern. The morbidity and mortality of the potentially lethal infection caused by this virus arise from the initial viral infection and the subsequent host inflammatory response. The latter may lead to excessive release of pro-inflammatory cytokines, IL-6 and IL-8, as well as TNF-alpha ultimately culminating in hypercytokinemia ("cytokine storm"). To address this immuno-inflammatory pathogenesis, multiple clinical trials have been proposed to evaluate anti-inflammatory biologic therapies targeting specific cytokines. However, despite the obvious clinical utility of such biologics, their specific applicability to COVID-19 has multiple drawbacks, including they target only one of the multiple cytokines involved in COVID-19's immunopathy. Therefore, we set out to identify a small molecule with broad-spectrum anti-inflammatory mechanism of action targeting multiple cytokines of innate immunity. In this study, a library of small molecules endogenous to the human body was assembled, subjected to in silico molecular docking simulations and a focused in vitro screen to identify anti-pro-inflammatory activity via interleukin inhibition. This has enabled us to identify the loop diuretic furosemide as a candidate molecule. To pre-clinically evaluate furosemide as a putative COVID-19 therapeutic, we studied its anti-inflammatory activity on RAW264.7, THP-1 and SIM-A9 cell lines stimulated by lipopolysaccharide (LPS). Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the Ml polarization, including IL-6 and TNF-alpha release. In addition, we found that furosemide promotes the production of anti-inflammatory cytokine products (IL-1RA, arginase), indicating M2 polarization. Accordingly, we conclude that furosemide is a reasonably potent inhibitor of IL-6 and TNF-alpha that is also safe, inexpensive and well-studied. Our pre-clinical data suggest that it may be a candidate for repurposing as an inhaled therapy against COVID-19.
C1 [Wang, Zhiyu; Wang, Yanfei; Vilekar, Prachi; Yang, Seung-Pil; Gupta, Mayuri; Oh, Myong In; Meek, Autumn; Doyle, Lisa; Villar, Laura; Brennecke, Anja; Liyanage, Imindu; Reed, Mark; Barden, Christopher; Weaver, Donald F.] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada.
   [Wang, Zhiyu; Weaver, Donald F.] Univ Toronto, Fac Pharm, Toronto, ON, Canada.
   [Liyanage, Imindu; Weaver, Donald F.] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Reed, Mark] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
RP Weaver, DF (corresponding author), Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada.; Weaver, DF (corresponding author), Univ Toronto, Fac Pharm, Toronto, ON, Canada.; Weaver, DF (corresponding author), Univ Toronto, Fac Med, Toronto, ON, Canada.
EM dweaver@uhnres.utoronto.ca
RI Gupta, Mayuri/ABG-7017-2020
OI Gupta, Mayuri/0000-0001-8588-1262; Wang, Zhiyu/0000-0001-9352-0504;
   Meek, Autumn/0000-0002-6902-4620
FU Canada Research Chair ProgramCanada Research Chairs
FX This work was supported by the Canada Research Chair Program (Donald F.
   Weaver, Canadian Research Chair Tier 1). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Armagan G, 2012, FREE RADICAL RES, V46, P726, DOI 10.3109/10715762.2012.669836
   Boyce EG, 2018, ANN PHARMACOTHER, V52, P780, DOI 10.1177/1060028018761599
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Furst DE, 2003, J RHEUMATOL, V30, P2563
   Grogono JC, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0886-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta M, 2020, ACS CHEM NEUROSCI, V11, P205, DOI 10.1021/acschemneuro.9b00650
   Hardman J. G., 2001, GOODMAN GILMANS PHAR
   Hosseinimehr SJ, 2015, RADIAT ONCOL J, V33, P256, DOI 10.3857/roj.2015.33.3.256
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung CM, 2018, BIOCHEM PHARMACOL, V156, P60, DOI 10.1016/j.bcp.2018.08.013
   Inokuchi R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0621-y
   Lee WS, 2013, INT IMMUNOPHARMACOL, V17, P721, DOI 10.1016/j.intimp.2013.08.018
   Liao QJ, 2005, ACTA BIOCH BIOPH SIN, V37, P607, DOI 10.1111/j.1745-7270.2005.00082.x
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Molecular Operating Environment (MOE), 2019, INT COMP AID MOL DES
   OCONNOR BJ, 1991, AM REV RESPIR DIS, V143, P1329, DOI 10.1164/ajrccm/143.6.1329
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Panigrahi SK, 2007, PROTEINS, V67, P128, DOI 10.1002/prot.21253
   Plewczynski D, 2011, J COMPUT CHEM, V32, P742, DOI 10.1002/jcc.21643
   Prandota Joseph, 2002, Am J Ther, V9, P317, DOI 10.1097/00045391-200207000-00009
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ramirez D, 2018, MOLECULES, V23, DOI 10.3390/molecules23051038
   Sebba A, 2008, AM J HEALTH-SYST PH, V65, P1413, DOI 10.2146/ajhp070449
   Waskiw-Ford M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00086
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   YEO CT, 1992, EUR RESPIR J, V5, P1184
   Yuengsrigul A, 1999, ANN ALLERG ASTHMA IM, V83, P559, DOI 10.1016/S1081-1206(10)62870-0
NR 32
TC 0
Z9 0
U1 2
U2 2
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUL 7
PY 2020
VL 8
AR e9533
DI 10.7717/peerj.9533
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MG2MI
UT WOS:000545868100011
PM 32704455
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Reuben, RC
   Danladi, MMA
   Saleh, DA
   Ejembi, PE
AF Reuben, Rine Christopher
   Danladi, Margaret M. A.
   Saleh, Dauda Akwai
   Ejembi, Patricia Ene
TI Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological
   Survey in North-Central Nigeria
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article; Early Access
DE COVID-19; Public health; Knowledge; Attitude; Practice; North-central
   Nigeria
ID OUTBREAK; EBOLA
AB The COVID-19 pandemic has become a major public health challenge globally with countries of the world adopting unprecedented infection prevention and control (IPC) measures to urgently curtail the spread of the COVID-19 virus. The knowledge, attitudes and practices (KAP) of the people toward COVID-19 is critical to understanding the epidemiological dynamics of the disease and the effectiveness, compliance and success of IPC measures adopted in a country. This study sought to determine the levels of KAP toward COVID-19 among residents of north-central Nigeria. A cross-sectional online survey with a semi-structured questionnaire using a Snowball sampling technique was conducted during the national lockdown. Data collected were analyzed using descriptive statistics, analysis of variance (ANOVA), Pearson's correlation and regression tests. From a total of 589 responses received, 80.6, 59.6, 90.4 and 56.2% were from respondents between ages 18-39 years, males, had a college (Bachelor) degree or above and reside in urban areas respectively. Respondents had good knowledge (99.5%) of COVID-19, gained mainly through the internet/social media (55.7%) and Television (27.5%). The majority of the respondents (79.5%) had positive attitudes toward the adherence of government IPC measures with 92.7, 96.4 and 82.3% practicing social distancing/self-isolation, improved personal hygiene and using face mask respectively. However, 52.1% of the respondents perceived that the government is not doing enough to curtail COVID-19 in Nigeria. Pearson's correlation showed significant relationship between knowledge of COVID-19 and attitude towards preventive measures (r = 0.177, p = 0.004, r = 0.137, p = 0.001). Although 61.8% of the respondents have no confidence in the present intervention by Chinese doctors, only 29.0% would accept COVID-19 vaccines when available. This study recorded good knowledge and attitudes among participants, however, community-based health campaigns are necessary to hold optimistic attitudes and practice appropriate intervention measures devoid of misconceptions.
C1 [Reuben, Rine Christopher] Nasarawa State Polytech, Dept Sci Lab Technol, Lafia, Nigeria.
   [Danladi, Margaret M. A.] Plateau State Univ, Dept Microbiol, Bokkos, Nigeria.
   [Saleh, Dauda Akwai] Plateau State Univ, Dept Psychol, Bokkos, Nigeria.
   [Ejembi, Patricia Ene] Univ Jos, Dept Microbiol, Jos, Nigeria.
RP Reuben, RC (corresponding author), Nasarawa State Polytech, Dept Sci Lab Technol, Lafia, Nigeria.
EM reubenrine@yahoo.com
OI Reuben, Rine/0000-0001-8084-2387
CR Abati R, 2020, CORONA BLUES
   Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7
   Anadolu Agency (AA), 2020, COVID 19 NIG DOCT OP
   Austrian K., 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.260281, DOI 10.2471/BLT.20.260281]
   Azlan AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233668
   Banerjee D, 2020, INT J GERIATR PSYCH, V35, P1466, DOI 10.1002/gps.5320
   CDC, 2020, NOV COR
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Etokidem AJ, 2018, AFR HEALTH SCI, V18, P55, DOI 10.4314/ahs.v18i1.9
   Giao H, 2020, ASIAN PAC J TROP MED, V13, P260, DOI 10.4103/1995-7645.280396
   Ige AM, 2014, EDUC 3-13, V42, P637, DOI 10.1080/03004279.2012.759603
   Internet World Stat (IWS), 2020, INT PEN AFR 2020 Q1
   Ioannidis JPA, 2020, EUR J CLIN INVEST, V50, DOI [10.1111/eci.13222, 10.1111/eci.13223]
   Makoni M, 2020, LANCET, V395, P483, DOI 10.1016/S0140-6736(20)30355-X
   Nemati M, 2020, ARCH CLIN INFECT DIS, V15, DOI 10.5812/archcid.102848
   Nigerian Centre for disease control (NCDC), 2020, FREQ ASK QUEST COR
   Nigerian Centre for disease control (NCDC), 2020, 54 NCDC
   Olapegba PO, 2020, BMJ-BRIT MED J, DOI 10.1101/2020.04.11.20061408
   Rahman S, 2020, INT J INFECT, V7, DOI 10.5812/iji.102184.
   Reuben C.R., 2016, INT J PUBLIC HLTH EP, V2, P14
   Roy D, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102083
   Saqlain M, 2020, J HOSP INFECT, V105, P419, DOI 10.1016/j.jhin.2020.05.007
   Unhale SS, 2020, INT J PHARM LIFE SCI, V6, P109
   Vigdor N, 2020, NY TIMES
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Winter S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3875-9
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   World Health Organization, 2020, 126 WHO
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 29
TC 9
Z9 9
U1 10
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
DI 10.1007/s10900-020-00881-1
EA JUL 2020
PG 14
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA MG7UA
UT WOS:000546234200001
PM 32638198
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Beigmohammadi, MT
   Bitarafan, S
   Hoseindokht, A
   Abdollahi, A
   Amoozadeh, L
   Abadi, MMA
   Foroumandi, M
AF Beigmohammadi, Mohammad Taghi
   Bitarafan, Sama
   Hoseindokht, Azin
   Abdollahi, Alireza
   Amoozadeh, Laya
   Abadi, Maedeh Mahmoodi Ali
   Foroumandi, Morteza
TI Impact of vitamins A, B, C, D, and E supplementation on improvement and
   mortality rate in ICU patients with coronavirus-19: a structured summary
   of a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomized controlled trial; Protocol; Vitamin B; Vitamin A;
   Vitamin D; Vitamin E; Vitamin C; Supplementation; Mortality rate;
   Intensive care unit
AB ObjectivesThis study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19.Trial designThis study is a randomized, single-blinded, two-arm (1:1 ratio) parallel group clinical trial.ParticipantsWe are conducting this study in patients with COVID-19 admitted to intensive care units at the Imam Khomeini Hospital Complex in Tehran, Iran.The inclusion criteria are as follows: (1) aged between 20 and 60years, (2) both male and female patients with COVID-19, (3) clinical or definitive diagnosis (using polymerase chain reaction (PCR) test), (4) patients have not participated in other clinical trials, and (5) no renal or hepatic abnormalities.The exclusion criteria are as follows: (1) patients with specific and rare viral diseases such as HIV and (2) patients who have been undergoing chemotherapy for the past month.Intervention and comparatorDuration of intervention: 7days from randomizationIntervention in the treatment group: Vitamin A 25,000IU dailyVitamin D 600,000IU once during studyVitamin E 300IU twice dailyVitamin C is taken four times per dayB vitamins are taken as a daily Soluvit [which included thiamine nitrate 3.1mg, sodium riboflavin phosphate 4.9mg (corresponding to vitamin B2 3.6mg), nicotinamide 40mg, pyridoxine hydrochloride 4.9mg (corresponding to vitamin B6 4.0mg), sodium pantothenate 16.5mg (corresponding to pantothenic acid 15 mg), sodium ascorbate 113mg (corresponding to vitamin C 100mg), biotin 60 mu g, folic acid 400 mu g, and cyanocobalamin 5 mu g]The control group will not receive any supplements or placebo.All supplements are made in Iran except for Soluvit (from Fresenius Kabi, New Zealand).Main outcomes list list-type="order">Weight, height, and BMISeverity of pulmonary involvement according to CT scanRespiratory support (invasive or non-invasive)Percentage of oxygen saturation (SpO2 level)Serum levels of WBC, CRP, ESR, IL6, IFN-G, and TNF-alpha The patient's body temperatureThe presence or absence of involvement of organs other than the lungs (e.g., heart, liver, kidneys)Duration of hospitalizationMortality rateRandomizationAt baseline, eligible patients were randomly assigned to a 1:1 ratio to one of two groups: intervention and control. Block randomization is used based on the gender of patients.Blinding (masking)Patients are unaware of being placed in the intervention or control groups after signing consent. All treatment staff will be aware of which group each of the patients is in due to the specific conditions of the ICU and the absence of placebo for the control group.Numbers to be randomized (sample size)The researchers plan to include 60 patients in total, with 30 patients in each group.Trial statusThis is the first version of the protocol which started on April 2, 2020. Recruitment began April 2, 2020, and is expected to be complete by July 4, 2020.Trial registrationThe Iranian Registry of Clinical Trials IRCT20200319046819N1. Registered on April 4, 2020Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol (Fig. 1, Table 1).
C1 [Bitarafan, Sama] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Neurosci Inst, Iranian Ctr Neurol Res ICNR, Keshavarz Blvd, Tehran 1419733141, Iran.
   [Beigmohammadi, Mohammad Taghi; Hoseindokht, Azin; Amoozadeh, Laya; Foroumandi, Morteza] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Anaesthesiol & Intens Care Dept, Tehran, Iran.
   [Abdollahi, Alireza] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Sch Med, Dept Pathol, Tehran, Iran.
   [Abdollahi, Alireza] Univ Tehran Med Sci, Breast Dis Res Ctr BDRC, Tehran, Iran.
   [Abadi, Maedeh Mahmoodi Ali] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Dept Lab, Tehran, Iran.
RP Bitarafan, S (corresponding author), Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Neurosci Inst, Iranian Ctr Neurol Res ICNR, Keshavarz Blvd, Tehran 1419733141, Iran.
EM bitarafans@gmail.com
FU Tehran University of Medical Sciences & Health ServicesTehran University
   of Medical Sciences [99-1-101-47104]
FX We are grateful to Tehran University of Medical Sciences & Health
   Services for supporting the present research with COVID-19 grant number:
   99-1-101-47104. Tehran University of Medical Sciences confirmed the
   study design, data collection, analysis, and interpretation of data and
   writing of the manuscript that are done honestly by the researchers
   alone.
NR 0
TC 3
Z9 3
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 6
PY 2020
VL 21
IS 1
DI 10.1186/s13063-020-04547-0
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MM3KX
UT WOS:000550058700004
PM 32631405
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wu, MY
   Yao, L
   Wang, Y
   Zhu, XY
   Wang, XF
   Tang, PJ
   Chen, C
AF Wu, Mei-ying
   Yao, Lin
   Wang, Yi
   Zhu, Xin-yun
   Wang, Xia-fang
   Tang, Pei-jun
   Chen, Cheng
TI Clinical evaluation of potential usefulness of serum lactate
   dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia
SO RESPIRATORY RESEARCH
LA English
DT Article
DE COVID-19; Pneumonia; LDH; Chest CT
ID CANCER
AB Background There was much evidence suggesting that the serum lactate dehydrogenase (LDH) levels reflect the extent of various pathophysiological processes. However, the current information about dynamic change of LDH in COVID-19 pneumonia has not been well investigated. Methods Study was performed in 87 cases confirmed by COVID-19 infection. The serum LDH levels were determined at diagnosis and follow-up visits. The evaluation of clinical response to therapy was based on chest CT scan. We selected the value of LDH around the data of chest CT scan (- 1 similar to + 1 day). Results At diagnosis, significant differences in LDH levels were found between non-severe and severe group (P < 0.05). It was demonstrated that increase or decrease of LDH was indicative of radiographic progress or improvement (P < 0.05). The time to LDH normalization (5.67 +/- 0.55, days) was positively correlated with the time to radiographic absorption (5.57 +/- 0.65 days, r = 0.53,P < 0.05). Applying the cut-off value of the increase in LDH has good specificity to predict disease progression. Conclusions Serum LDH was validated for its potential usefulness as markers for evaluating clinical severity and monitoring treatment response in COVID-19 pneumonia.
C1 [Wu, Mei-ying; Yao, Lin; Wang, Yi; Wang, Xia-fang; Tang, Pei-jun] Fifth Peoples Hosp Suzhou, Dept Pulm, 10 Guangqian Rd, Suzhou 215000, Peoples R China.
   [Wu, Mei-ying; Yao, Lin; Wang, Yi; Wang, Xia-fang; Tang, Pei-jun] Soochow Univ, Affiliated Infect Hosp, Dept Pulm, 10 Guangqian Rd, Suzhou 215000, Peoples R China.
   [Zhu, Xin-yun; Chen, Cheng] Soochow Univ, Affiliated Hosp 1, Dept Resp & Crit Med, 899 Pinghai Rd, Suzhou 215000, Peoples R China.
   [Chen, Cheng] Soochow Univ, Inst Resp Dis, 708 Renmin Rd, Suzhou 215006, Peoples R China.
RP Tang, PJ (corresponding author), Fifth Peoples Hosp Suzhou, Dept Pulm, 10 Guangqian Rd, Suzhou 215000, Peoples R China.; Tang, PJ (corresponding author), Soochow Univ, Affiliated Infect Hosp, Dept Pulm, 10 Guangqian Rd, Suzhou 215000, Peoples R China.; Chen, C (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Resp & Crit Med, 899 Pinghai Rd, Suzhou 215000, Peoples R China.; Chen, C (corresponding author), Soochow Univ, Inst Resp Dis, 708 Renmin Rd, Suzhou 215006, Peoples R China.
EM tangpeipei001@163.ccm; chencheng@suda.edu.cn
FU Jiangsu Youth Medical Talents Project [QNRC2016226]; Jiangsu Provincial
   Health Commission Scientific Research Project [LGY2019014, LGY2019083]
FX This work was supported by the Jiangsu Youth Medical Talents Project
   (QNRC2016226) and Jiangsu Provincial Health Commission Scientific
   Research Project (LGY2019014, LGY2019083). The funders had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams A, 2019, LAB MED, V50, P145, DOI 10.1093/labmed/lmy056
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Jovanovic S, 2009, INT J BIOCHEM CELL B, V41, P2295, DOI 10.1016/j.biocel.2009.05.012
   Kim HS, 2014, PATHOBIOLOGY, V81, P78, DOI 10.1159/000357017
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696
   Ooi GC, 2004, RADIOLOGY, V230, P836, DOI 10.1148/radiol.2303030853
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Scartozzi M, 2012, BRIT J CANCER, V106, P799, DOI 10.1038/bjc.2012.17
   Sharma LK, 2018, J LAB PHYS, V10, P346, DOI 10.4103/JLP.JLP_151_17
   Uchide N, 2009, INTERVIROLOGY, V52, P164, DOI 10.1159/000224644
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wimazal F, 2008, ANN ONCOL, V19, P970, DOI 10.1093/annonc/mdm595
NR 15
TC 2
Z9 2
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465-993X
J9 RESP RES
JI Respir. Res.
PD JUL 6
PY 2020
VL 21
IS 1
AR 171
DI 10.1186/s12931-020-01427-8
PG 6
WC Respiratory System
SC Respiratory System
GA MM2JQ
UT WOS:000549983700001
PM 32631317
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Im, JH
   Nahm, CH
   Baek, JH
   Kwon, HY
   Lee, JS
AF Im, Jae Hyoung
   Nahm, Chung Hyun
   Baek, Ji Hyeon
   Kwon, Hea Yoon
   Lee, Jin-Soo
TI Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report
   and Suggestions to Overcome Obstacles
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19 Serotherapy; Immunization, Passive; Transfusion Reaction;
   Transfusion-Related Acute Lung Injury
ID ACUTE LUNG INJURY; TRANSFUSION; BLOOD
AB Coronavirus disease 2019 (COVID-19) is rapidly spreading around the world, causing much morbidity and mortality everywhere. However, effective treatments or vaccines are still not available. Although convalescent plasma (CP) therapy can be useful in the treatment of COVID-19, it has not been widely used in Korea because of the concerns about adverse effects and the difficulty in matching patients to donors. The use of ABO-incompatible plasma is not contraindicated in treatment, but can be hesitated due to the lack of experience of physicians. Here, we describe a 68-year old man with COVID-19 who was treated ABO-incompatible plasma therapy; additionally, we comment on the acute side effects associated with ABO mismatch transfusion. To overcome the obstacles of donor-recipient connections (schedule and distance), we propose the storage of frozen plasma, modification of the current Blood Management Law, and the establishment of a CP bank. We suggest that experience gained in CP therapy will be useful for not only the treatment of COVID-19, but also for coping with new emerging infectious diseases.
C1 [Im, Jae Hyoung; Baek, Ji Hyeon; Kwon, Hea Yoon; Lee, Jin-Soo] Inha Univ, Div Infect Dis, Dept Internal Med, Sch Med, 100 Inha Ro, Incheon 22212, South Korea.
   [Nahm, Chung Hyun] Inha Univ, Dept Lab Med, Sch Med, Incheon, South Korea.
RP Lee, JS (corresponding author), Inha Univ, Div Infect Dis, Dept Internal Med, Sch Med, 100 Inha Ro, Incheon 22212, South Korea.
EM ljinsoo@inha.ac.kr
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Berseus O, 2013, TRANSFUSION, V53, p114S, DOI 10.1111/trf.12045
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chapman CE, 2008, TRANSFUS MED HEMOTH, V35, P93, DOI 10.1159/000119116
   EBERT RV, 1946, J CLIN INVEST, V25, P627, DOI 10.1172/JCI101745
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x
   Lee JH, 2010, J KOREAN MED SCI, V25, P1398, DOI 10.3346/jkms.2010.25.9.1398
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yoo JH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e221
   Yoo JH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e150
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 3
Z9 3
U1 2
U2 2
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD JUL 6
PY 2020
VL 35
IS 26
AR e239
DI 10.3346/jkms.2020.35.e239
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ7AM
UT WOS:000548239300007
PM 32627442
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, DW
   Byeon, KH
   Kim, J
   Cho, KD
   Lee, N
AF Kim, Dong Wook
   Byeon, Kyeong Hyang
   Kim, Jaiyong
   Cho, Kyu Dong
   Lee, Nakyoung
TI The Correlation of Comorbidities on the Mortality in Patients with
   COVID-19: an Observational Study Based on the Korean National Health
   Insurance Big Data
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; Comorbidities; Chronic Diseases; Mortality Risk
AB Background: Mortality of coronavirus disease 2019 (COVID-19) is a major concern for quarantine departments in all countries. This is because the mortality of infectious diseases determines the basic policy stance of measures to prevent infectious diseases. Early screening of high-risk groups and taking action are the basics of disease management. This study examined the correlation of comorbidities on the mortality of patients with COVID-19.
   Methods: We constructed epidemiologic characteristics and medical history database based on the Korean National Health Insurance Service Big Data and linked COVID-19 registry data of Korea Centers for Disease Control & Prevention (KCDC) for this emergent observational cohort study. A total of 9,148 patients with confirmed COVID-19 were included. Mortalities by sex, age, district, income level and all range of comorbidities classified by International Classification of Diseases-10 based 298 categories were estimated.
   Results: There were 3,556 male confirmed cases, 67 deaths, and crude death rate (CDR) of 1.88%. There were 5,592 females, 63 deaths, and CDR of 1.13%. The most confirmed cases were 1,352 patients between the ages of 20 to 24, followed by 25 to 29. As a result of multivariate logistic regression analysis that adjusted epidemiologic factors to view the risk of death, the odds ratio of death would be hemorrhagic conditions and other diseases of blood and blood-forming organs 3.88-fold (95% confidence interval [CI], 1.52-9.88), heart failure 3.17-fold (95% CI, 1.88-5.34), renal failure 3.07-fold (95% CI, 1.43-6.61), prostate malignant neoplasm 2.88-fold (95% CI, 1.01-8.22), acute myocardial infarction 2.38-fold (95% CI, 1.03-5.49), diabetes was 1.82-fold (95% CI, 1.25-2.67), and other ischemic heart disease 1.71-fold (95% CI, 1.09-2.66).
   Conclusion: We hope that this study could provide information on high risk groups for preemptive interventions. In the future, if a vaccine for COVID-19 is developed, it is expected that this study will be the basic data for recommending immunization by selecting those with chronic disease that had high risk of death, as recommended target diseases for vaccination.
C1 [Kim, Dong Wook; Cho, Kyu Dong] Natl Hlth Insurance Serv, Hlth Insurance Res Inst, Wonju, South Korea.
   [Byeon, Kyeong Hyang; Lee, Nakyoung] Hanyang Univ, Dept Prevent Med, Coll Med, Seoul, South Korea.
   [Byeon, Kyeong Hyang; Lee, Nakyoung] Hanyang Univ, Grad Sch, Dept Publ Hlth, Seoul, South Korea.
   [Kim, Jaiyong] Yonsei Univ, Inst Artificial Intelligence & Big Data Med, Wonju Coll Med, 20 Ilsan Ro, Wonju 26426, South Korea.
RP Kim, J (corresponding author), Yonsei Univ, Inst Artificial Intelligence & Big Data Med, Wonju Coll Med, 20 Ilsan Ro, Wonju 26426, South Korea.
EM dockjy2@gmail.com
OI kim, dong wook/0000-0002-4478-3794; Kim, Jaiyong/0000-0003-0985-7871;
   Lee, Nakyoung/0000-0002-3867-4508
FU Governmentwide R&D Fund project for infectious disease research,
   Republic of Korea [HG18C0088]
FX This study was supported by the Governmentwide R&D Fund project for
   infectious disease research (HG18C0088), Republic of Korea.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Baek JH, 2014, KOREAN J INTERN MED, V29, P265, DOI 10.3904/kjim.2014.29.2.265
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Jianya G., CLIN CHARACTERISTICS, DOI 10.1101/2020.02.20.20025536v1
   Korea Centers for Disease Control and Prevention, CURR STAT COV 19 KOR
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Yang J, INT J INFECT DIS
NR 9
TC 2
Z9 2
U1 4
U2 4
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD JUL 6
PY 2020
VL 35
IS 26
AR e243
DI 10.3346/jkms.2020.35.e243
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ7AM
UT WOS:000548239300008
PM 32627443
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vazquez, AG
   Verde, JM
   Dal Mas, F
   Palermo, M
   Cobianchi, L
   Marescaux, J
   Gallix, B
   Dallemagne, B
   Perretta, S
   Gimenez, ME
AF Vazquez, Alain Garcia
   Verde, Juan M.
   Dal Mas, Francesca
   Palermo, Mariano
   Cobianchi, Lorenzo
   Marescaux, Jacques
   Gallix, Benoit
   Dallemagne, Bernard
   Perretta, Silvana
   Gimenez, Mariano E.
TI Image-Guided Surgical e-Learning in the Post-COVID-19 Pandemic Era: What
   Is Next?
SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
LA English
DT Article
DE e-learning; surgical education; surgical learning; training; online
   training
AB The current unprecedented coronavirus 2019 (COVID-19) crisis has accelerated and enhanced e-learning solutions. During the so-called transition phase, efforts were made to reorganize surgical services, reschedule elective surgical procedures, surgical research, academic education, and careers to optimize results. The intention to switch to e-learning medical education is not a new concern. However, the current crisis triggered an alarm to accelerate the transition. Efforts to consider e-learning as a teaching and training method for medical education have proven to be efficient. For image-guided therapies, the challenge requires more effort since surgical skills training is combined with image interpretation training, thus the challenge is to cover quality educational content with a balanced combination of blended courses (online/onsite). Several e-resources are currently available in the surgical scenario; however, further efforts to enhance the current system are required by accelerating the creation of new learning solutions to optimize complex surgical education needs in the current disrupted environment.
C1 [Vazquez, Alain Garcia; Verde, Juan M.; Gallix, Benoit; Perretta, Silvana; Gimenez, Mariano E.] IHU Strasbourg, Dept Image Guided Liver Intervent, Inst Image Guided Surg, Strasbourg, France.
   [Vazquez, Alain Garcia; Verde, Juan M.; Marescaux, Jacques; Dallemagne, Bernard; Perretta, Silvana; Gimenez, Mariano E.] IRCAD, Dept Minimally Invas Surg, Res Inst Canc Digest Syst, Strasbourg, France.
   [Dal Mas, Francesca] Univ Lincoln, Lincoln Int Business Sch, Dept Strategy & Enterprise, Lincoln, England.
   [Palermo, Mariano; Gimenez, Mariano E.] DAICIM Fdn, Dept Percutaneous Surg, Assistance Minimally Invas Surg, Teaching,Res, Buenos Aires, DF, Argentina.
   [Cobianchi, Lorenzo] Univ Pavia, Dept Clin Diagnost & Pediat Sci, Pavia, Italy.
RP Vazquez, AG (corresponding author), IHU Strasbourg, Inst Image Guided Surg, 1 Pl Hop, F-67091 Strasbourg, France.
EM alain.garcia@ihu-strasbourg.eu
RI Garcia, Alain/AAY-7159-2020
OI Cobianchi, Lorenzo/0000-0002-6773-5453
FU French National Research Agency (ANR) under the ''investissements
   d'avenir'' programFrench National Research Agency (ANR) [ANR-10-IAHU-02]
FX This study benefited from state aid managed by the French National
   Research Agency (ANR) under the ''investissements d'avenir'' program
   with the reference ANR-10-IAHU-02.
CR [Anonymous], 2020, COVID 19 PAND HAS CH
   [Anonymous], 2020, E LEARN MARK TRENDS
   Blanco-Colino R, 2020, ANN SURG, V272, pE24, DOI 10.1097/SLA.0000000000003929
   Cobianchi L, 2020, ANN SURG, V272, pE49, DOI 10.1097/SLA.0000000000004083
   Crocetti L, 2020, CARDIOVASC INTER RAD, V43, P951, DOI 10.1007/s00270-020-02471-z
   Ehrlich H, 2020, WORLD J SURG, V44, P2053, DOI 10.1007/s00268-020-05574-3
   Fellander-Tsai L, 2004, ACTA ORTHOP SCAND, V75, P511, DOI 10.1080/00016470410001358-1
   GEWIN V, 2019, NATURE, V576, pS72
   Hew KF, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1144-z
   Kissler SM, 2020, SOCIAL DISTANCING ST
   McKechnie T, 2020, ANN SURG, V272, pE153, DOI 10.1097/SLA.0000000000003999
   Melicherikova Z, 2012, 2012 IEEE 10 INT C E, DOI [10.1109/iceta.2012.6418325, DOI 10.1109/ICETA.2012.6418325]
   Pei LS, 2019, MED EDUC ONLINE, V24, DOI 10.1080/10872981.2019.1666538
   Rasmussen NK, 2019, ULTRASCHALL MED, V40, P584, DOI 10.1055/a-0896-2714
   Woolston C, 2020, NATURE, V582, P135, DOI 10.1038/d41586-020-01489-0
NR 15
TC 2
Z9 2
U1 3
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1092-6429
EI 1557-9034
J9 J LAPAROENDOSC ADV S
JI J. Laparoendosc. Adv. Surg. Tech.
PD SEP 1
PY 2020
VL 30
IS 9
BP 993
EP 997
DI 10.1089/lap.2020.0535
EA JUL 2020
PG 5
WC Surgery
SC Surgery
GA NO2NA
UT WOS:000547947800001
PM 32628558
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, TY
   Farghaly, S
   Cham, S
   Tatem, LL
   Sin, JH
   Rauda, R
   Ribisi, M
   Sumrani, N
AF Chen, Tracy Yixin
   Farghaly, Sara
   Cham, Samantha
   Tatem, Luis Lantigua
   Sin, Jonathan H.
   Rauda, Roberto
   Ribisi, Maria
   Sumrani, Nabil
TI COVID-19 pneumonia in kidney transplant recipients: Focus on
   immunosuppression management
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; immunosuppression; kidney transplantation; viral pneumonia
ID IMMUNE-RESPONSES
AB Background The coronavirus disease of 2019, also known as COVID-19, has been declared a global pandemic. Significant controversies exist regarding treatment modalities for this novel disease, especially in immunocompromised patients. Experience with management of COVID-19 in kidney transplant recipients is scarce; effects of this virus on immunosuppressed individuals are not well understood. Methods We identified 30 renal transplant recipients with confirmed COVID-19 pneumonia who were admitted to inpatient between March 2020 and April 2020. All patients received a 5-day course of hydroxychloroquine and azithromycin; half of the patients received methylprednisolone. During hospitalization, calcineurin inhibitors and antimetabolites were held; prednisone was continued. Results Clinical presentation of flu-like symptoms was similar to those in the general population. Hyponatremia, lymphopenia, acute kidney injury, and elevated inflammatory markers were common. Over the course of follow-up, 23 have been discharged home with a functioning allograft and in stable condition; 4 experienced acute kidney injury requiring renal replacement therapy; 7 patients were intubated, and 6 expired. The mortality rate in our cohort was 20%. Conclusion Our findings described the characteristics and outcomes of this highly fatal illness in a multi-ethnic kidney transplant cohort, with insights on immunosuppression management that could further our understanding of this unique disease in immunocompromised populations.
C1 [Chen, Tracy Yixin; Farghaly, Sara; Cham, Samantha; Sin, Jonathan H.; Ribisi, Maria] SUNY Downstate Hlth Sci Univ Hosp, Dept Pharm, Brooklyn, NY 11203 USA.
   [Tatem, Luis Lantigua] SUNY Downstate Hlth Sci Univ Hosp, Dept Infect Dis, Brooklyn, NY USA.
   [Rauda, Roberto; Sumrani, Nabil] SUNY Downstate Hlth Sci Univ Hosp, Dept Surg, Brooklyn, NY USA.
RP Chen, TY (corresponding author), SUNY Downstate Hlth Sci Univ Hosp, Dept Pharm, Brooklyn, NY 11203 USA.
EM TracyChenTXP@gmail.com
OI Sin, Jonathan/0000-0003-3155-6039; Sumrani, Nabil/0000-0001-7704-9847;
   Lantigua Tatem, Luis/0000-0002-9351-4443; Chen, Tracy
   Yixin/0000-0001-7678-5332
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   [Anonymous], 111 COVID WHO
   Ata P, 2013, TRANSPL P, V45, P929, DOI 10.1016/j.transproceed.2013.02.092
   Boyd A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128714
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   Centers for Disease Control and Prevention (CDC), CAS US
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Durvasula R, 2020, AM J KIDNEY DIS, V76, P4, DOI 10.1053/j.ajkd.2020.04.001
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Fuhrmann S, 2012, IMMUNOLOGY, V136, P408, DOI 10.1111/j.1365-2567.2012.03594.x
   Kahan SM, 2015, VIROLOGY, V479, P180, DOI 10.1016/j.virol.2014.12.033
   Kang S, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e33
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Machado FP, 2018, EINSTEIN-SAO PAULO, V16, DOI [10.31744/einstein_journal/2018ao4278, 10.31744/einstein_journal/2018AO4278]
   Moon Chang, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0304-7
   Nanmoku K, 2019, TRANSPL P, V51, P2602, DOI 10.1016/j.transproceed.2019.02.051
   Omer SB, 2020, JAMA-J AM MED ASSOC, V323, P1767, DOI 10.1001/jama.2020.5788
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Romanelli A, 2020, AM J TRANSPLANT, V20, P1947, DOI 10.1111/ajt.15905
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Styrc B, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13680
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhavoronkov A, 2020, AGING-US, V12, P6492, DOI 10.18632/aging.102988
NR 28
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13378
DI 10.1111/tid.13378
EA JUL 2020
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000547659500001
PM 32573882
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tripathi, MK
   Singh, P
   Sharma, S
   Singh, TP
   Ethayathulla, AS
   Kaur, P
AF Tripathi, Manish Kumar
   Singh, Pushpendra
   Sharma, Sujata
   Singh, Tej P.
   Ethayathulla, A. S.
   Kaur, Punit
TI Identification of bioactive molecule fromWithania somnifera(Ashwagandha)
   as SARS-CoV-2 main protease inhibitor
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-2019; SARS-CoV-2; Ashwagandha; Withania somnifera; molecular
   docking; MD simulation
ID WITHANIA-SOMNIFERA DUN; WITHANOSIDE-IV; CELL-LINES; WITHANOLIDES;
   CONSTITUENTS; CORONAVIRUS; WITHAFERIN; ROOTS; APOPTOSIS; RESPONSES
AB SARS-CoV-2 is the causative agent of COVID-19 and has been declared as pandemic disease by World Health Organization. Lack of targeted therapeutics and vaccines for COVID-2019 have triggered the scientific community to develop new vaccines or drugs against this novel virus. Many synthetic compounds and antimalarial drugs are undergoing clinical trials. The traditional medical practitioners widely use Indian medicinal plantWithania somnifera(Ashwagandha) natural constituents, called withanolides for curing various diseases. The main protease (M-pro) of SARS-CoV-2 plays a vital role in disease propagation by processing the polyproteins which are required for its replication. Hence, it denotes a significant target for drug discovery. In the present study, we evaluate the potential of 40 natural chemical constituents of Ashwagandha to explore a possible inhibitor against main protease of SARS-CoV-2 by adopting the computational approach. The docking study revealed that four constituents of Ashwagandha; Withanoside II (-11.30 Kcal/mol), Withanoside IV (-11.02 Kcal/mol), Withanoside V (-8.96 Kcal/mol) and Sitoindoside IX (-8.37 Kcal/mol) exhibited the highest docking energy among the selected natural constituents. Further, MD simulation study of 100 ns predicts Withanoside V possess strong binding affinity and hydrogen-bonding interactions with the protein active site and indicates its stability in the active site. The binding free energy score also correlates with the highest score of -87.01 +/- 5.01 Kcal/mol as compared to other selected compounds. In conclusion, our study suggests that Withanoside V in Ashwagandha may be serve as a potential inhibitor against M(pro)of SARS-CoV-2 to combat COVID-19 and may have an antiviral effect on nCoV. Communicated by Ramaswamy H. Sarma
C1 [Tripathi, Manish Kumar; Sharma, Sujata; Singh, Tej P.; Ethayathulla, A. S.; Kaur, Punit] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
   [Singh, Pushpendra] ICAR Natl Inst High Secur Anim Dis, Bhopal, Madhya Pradesh, India.
RP Kaur, P (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
EM punitkaur1@hotmail.com
RI Singh, Pushpendra/A-5632-2017
OI Singh, Pushpendra/0000-0002-9619-0659; Tripathi, Dr. Manish
   Kumar/0000-0003-2546-9123
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abou-Douh AM, 2002, ARCH PHARM, V335, P267, DOI 10.1002/1521-4184(200208)335:6&lt;267::AID-ARDP267&gt;3.0.CO;2-E
   ABRAHAM A, 1975, PHYTOCHEMISTRY, V14, P189, DOI 10.1016/0031-9422(75)85035-7
   Ahlawat S, 2017, PLANT PHYSIOL BIOCH, V114, P19, DOI 10.1016/j.plaphy.2017.02.013
   Ahmad M, 2017, SUSTAINED ENERGY FOR ENHANCED HUMAN FUNCTIONS AND ACTIVITY, P137, DOI 10.1016/B978-0-12-805413-0.00008-9
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ben Bakrim W, 2018, PHARM BIOL, V56, P505, DOI 10.1080/13880209.2018.1499781
   BESSALLE R, 1992, PHYTOCHEMISTRY, V31, P3648, DOI 10.1016/0031-9422(92)83749-O
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Cai Z, 2015, CELL BIOCHEM BIOPHYS, V72, P727, DOI 10.1007/s12013-015-0524-9
   Cardenas J., 2012, FORTSCHRITTE CHEM OR
   Dar NJ, 2017, MOL NEUROBIOL, V54, P5061, DOI 10.1007/s12035-016-0044-7
   Das Chaurasiya N, 2008, PHYTOCHEM ANALYSIS, V19, P148, DOI 10.1002/pca.1029
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   DRAGAR C, 1988, TETRAHEDRON LETT, V29, P3115, DOI 10.1016/0040-4039(88)85100-1
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   GANGULY B, 2018, J ANIM SCI TECHNOL, V60, DOI DOI https://doi.org/10.1186/s40781-017-0156-2
   GLOTTER E, 1973, TETRAHEDRON, V29, P1353, DOI 10.1016/S0040-4020(01)83156-2
   GLOTTER E, 1966, J CHEM SOC C, P1765, DOI 10.1039/j39660001765
   Green MS, 2020, LANCET, V395, P1034, DOI 10.1016/S0140-6736(20)30630-9
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Henrich CJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.38
   HIRAYAMA M, 1982, TETRAHEDRON LETT, V23, P4725, DOI 10.1016/S0040-4039(00)85697-X
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jain J, 2018, J EVID-BASED INTEGR, V23, DOI 10.1177/2156587218757661
   Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   KACZOR AA, 2015, J MOL MODEL, V21, DOI DOI https://doi.org/10.1007/s00894-015-2789-8
   KIRSON I, 1975, J CHEM SOC PERK T 1, P2136, DOI 10.1039/p19750002136
   Kour K, 2009, INT IMMUNOPHARMACOL, V9, P1137, DOI 10.1016/j.intimp.2009.05.011
   Kuboyama T, 2006, EUR J NEUROSCI, V23, P1417, DOI 10.1111/j.1460-9568.2006.04664.x
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   KUMAR V, 2020, J BIOMOL STRUCT 0530, DOI DOI https://doi.org/10.1080/07391102.2020.1772108
   Lee W, 2012, TOXICOL APPL PHARM, V262, P91, DOI 10.1016/j.taap.2012.04.025
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   LLanos GG, 2012, EUR J MED CHEM, V54, P499, DOI 10.1016/j.ejmech.2012.05.032
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968-0896(01)00024-4
   Ministry of Ayush, 2020, AYURV IMM BOOST MEAS
   Mondal S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034277
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nakano D, 2013, J NAT MED-TOKYO, V67, P415, DOI 10.1007/s11418-012-0700-9
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Reddy SVG, 2015, J BIOMOL STRUCT DYN, V33, P2695, DOI 10.1080/07391102.2015.1004834
   Remya C, 2016, FRONT LIFE SCI, V9, P201, DOI 10.1080/21553769.2016.1207569
   Sargsyan K, 2017, J CHEM THEORY COMPUT, V13, P1518, DOI 10.1021/acs.jctc.7b00028
   Schrodinger, 2018, REL 2018 2 LIGPREP
   SCHROTER HB, 1966, TETRAHEDRON, V22, P2895, DOI 10.1016/S0040-4020(01)99082-9
   Singh B., 2020, SECONDARY METABOLITE
   SINGH G, 2016, SCI REP UK, V6, DOI DOI https://doi.org/10.1038/srep25562
   Soman S, 2013, EPILEPSY BEHAV, V27, P484, DOI 10.1016/j.yebeh.2013.01.007
   Stobart CC, 2012, J VIROL, V86, P4801, DOI 10.1128/JVI.06754-11
   Subbaraju GV, 2006, J NAT PROD, V69, P1790, DOI 10.1021/np060147p
   Tong XQ, 2011, PHYTOCHEM LETT, V4, P411, DOI 10.1016/j.phytol.2011.04.016
   TURRINI E, 2016, TOXINS, V8, DOI DOI https://doi.org/10.3390/toxins8050147
   Vetvicka V, 2011, N AM J MED SCI, V3, P320, DOI 10.4297/najms.2011.3320
   Wadegaonkar VP, 2013, J BIOTECHNOL, V168, P229, DOI 10.1016/j.jbiotec.2013.08.028
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   White PT, 2016, ADV EXP MED BIOL, V928, P329, DOI 10.1007/978-3-319-41334-1_14
   WHO, 2020, COR DIS COVID 19 SIT
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao J, 2002, CHEM PHARM BULL, V50, P760, DOI 10.1248/cpb.50.760
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 72
TC 5
Z9 5
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1790425
EA JUL 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI0FZ
UT WOS:000547094900001
PM 32643552
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Su, QD
   Yi, Y
   Zou, YN
   Jia, ZY
   Qiu, F
   Wang, F
   Yin, WJ
   Zhou, WT
   Zhang, S
   Yu, PC
   Bi, SL
   Shen, LP
   Wu, GZ
AF Su, Qiu-dong
   Yi, Yao
   Zou, Ye-ning
   Jia, Zhi-yuan
   Qiu, Feng
   Wang, Feng
   Yin, Wen-jiao
   Zhou, Wen-ting
   Zhang, Shuang
   Yu, Peng-cheng
   Bi, Sheng-li
   Shen, Li-ping
   Wu, Gui-zhen
TI The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
SO VACCINE
LA English
DT Article
DE Biological characteristics; Spike protein Pro330-Leu650; SARS-CoV-2
AB SARS-CoV-2 is the cause of the worldwide outbreak of COVID-19 that has been characterized as a pandemic by the WHO. Since the first report of COVID-19 on December 31, 2019, 179,111 cases were confirmed in 160 countries/regions with 7426 deaths as of March 17, 2020. However, there have been no vaccines approved in the world to date. In this study, we analyzed the biological characteristics of the SARS-CoV-2 Spike protein, Pro330-Leu650 (SARS-CoV-2-SPL), using biostatistical methods. SARS-CoV-2-SPL possesses a receptor-binding region (RBD) and important B (Ser438-Gln506, Thr553-Glu583, Gly404-Aps427, Thr345-Ala352, and Lys529-Lys535) and T (9 CD4 and 11 CD8 T cell antigenic determinants) cell epitopes. High homology in this region between SARS-CoV-2 and SARS-CoV amounted to 87.7%, after taking the biological similarity of the amino acids into account and eliminating the receptor-binding motif (RBM). The overall topology indicated that the complete structure of SARS-CoV-2-SPL was with RBM as the head, and RBD as the trunk and the tail region. SARS-CoV-2-SPL was found to have the potential to elicit effective B and T cell responses. Our findings may provide meaningful guidance for SARS-CoV-2 vaccine design. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Su, Qiu-dong; Yi, Yao; Jia, Zhi-yuan; Qiu, Feng; Wang, Feng; Yin, Wen-jiao; Zhou, Wen-ting; Zhang, Shuang; Yu, Peng-cheng; Bi, Sheng-li; Shen, Li-ping; Wu, Gui-zhen] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
   [Zou, Ye-ning] Sinovac Biotech Co Ltd, Beijing, Peoples R China.
RP Bi, SL; Shen, LP; Wu, GZ (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
EM bisl@ivdc.chinacdc.cn; shenlp@ivdc.chinacdc.cn; wugz@ivdc.chinacdc.cn
FU Chinese Center of Disease Control and Prevention
FX This study was supported by a grant from Chinese Center of Disease
   Control and Prevention. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. We also thanked International Science Editing
   (http://www.internationalscienceediting.com) very much for polishing
   this manuscript freely.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Chen BB, 2019, NAT BIOTECHNOL, V37, P1332, DOI 10.1038/s41587-019-0280-2
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Feng Y, 2020, MULTIEPITOPE VACCINE, DOI [10.1101/2020.03.03.962332 %J bioRxiv, DOI 10.1101/2020.03.03.962332]
   Ju B, 2020, POTENT HUMAN NEUTRAL, DOI [10.1101/2020.03.21.990770, DOI 10.1101/2020.03.21.990770, 10.1101/2020.03.21.990770.]
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Lan J, 2020, BIORXIV, DOI [10.1101/2020.02.19.956235, DOI 10.1101/2020.02.19.956235]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rappuoli R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2888
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   [伊瑶 Yang Huanming], 2003, [病毒学报, Chinese Journal of Virology], V19, P267
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 6
PY 2020
VL 38
IS 32
BP 5071
EP 5075
DI 10.1016/j.vaccine.2020.04.070
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA MC4YT
UT WOS:000543295000021
PM 32513514
OA Green Published
DA 2021-01-01
ER

PT J
AU Aras-Atik, E
   Tecen-Yucel, K
   Bayraktar-Ekincioglu, A
AF Aras-Atik, Elif
   Tecen-Yucel, Kamer
   Bayraktar-Ekincioglu, Aygin
TI Are we aware of potential interactions between drugs used in lung cancer
   and drugs used in the treatment of COVID-19?
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Letter
ID ALPHA-1-ANTITRYPSIN
C1 [Aras-Atik, Elif; Tecen-Yucel, Kamer; Bayraktar-Ekincioglu, Aygin] Hacettepe Univ, Fac Pharm, Dept Clin Pharm, TR-06100 Ankara, Turkey.
RP Aras-Atik, E (corresponding author), Hacettepe Univ, Fac Pharm, Dept Clin Pharm, TR-06100 Ankara, Turkey.
EM eczelifaras@gmail.com
OI Bayraktar-Ekincioglu, Aygin/0000-0002-3481-0074; ARAS-ATIK,
   Elif/0000-0001-8667-6623
CR [Anonymous], 2020, SHORT TERM REC NONS
   Becker PS, 2020, NCCN GUIDELINES HEMA
   BRANTLY M, 1988, AM J MED, V84, P13
   CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8
   Hu LY, 2019, CURR NEUROPHARMACOL, V17, P184, DOI 10.2174/1570159X15666170915143217
   Kluwer Wolters, 2020, LEXICOMP DRUG INTERA
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   McDonnell Anne M, 2013, J Adv Pract Oncol, V4, P263
   Obach RS, 2004, J CLIN PHARMACOL, V44, P7, DOI 10.1177/0091270003260336
   Passaro A, 2020, ANN ONCOL, V31, P832, DOI 10.1016/j.annonc.2020.04.002
   Robinson SA, 2020, ROUTL RES EDUC EQUAL, P1
   de Serres F, 2014, J INTERN MED, V276, P311, DOI 10.1111/joim.12239
   Yang K, 2020, CTS-CLIN TRANSL SCI, V13, P842, DOI 10.1111/cts.12815
   Zhao YL, 2015, BRIT J CLIN PHARMACO, V80, P1076, DOI 10.1111/bcp.12644
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD OCT
PY 2020
VL 26
IS 7
BP 1807
EP 1817
AR 1078155220935506
DI 10.1177/1078155220935506
EA JUL 2020
PG 11
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA OC6XO
UT WOS:000546122500001
PM 32623965
OA Bronze
DA 2021-01-01
ER

PT J
AU Pastino, G
AF Pastino, Gina
TI Critical Need for Implementation of Clinical Pharmacology Principles in
   Developing Drugs for the Treatment or Prevention of COVID-19
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Letter
C1 [Pastino, Gina] PRA Hlth Sci, 731 Arbor Way, Blue Bell, PA 19422 USA.
RP Pastino, G (corresponding author), PRA Hlth Sci, 731 Arbor Way, Blue Bell, PA 19422 USA.
EM pastinogina@prahs.com
CR [Anonymous], CTR SYST SCI ENG CSS
   Baker EH, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14416
   Casadevall A, 2016, MBIO, V7, DOI 10.1128/mBio.01902-16
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
NR 5
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2700
EI 1552-4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD AUG
PY 2020
VL 60
IS 8
BP 979
EP 979
DI 10.1002/jcph.1690
EA JUL 2020
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MK2OH
UT WOS:000545326700001
PM 32535939
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Shishak, M
   Sarkar, R
AF Shishak, Mansak
   Sarkar, Rashmi
TI Dermatological therapies with relevance toCOVID-19
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE COVID-19; dermatological therapies; hydroxychloroquine; SARS-CoV-2
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel single-stranded RNA virus that has gripped humanity all over. It affects primarily the respiratory system, but is not limited to it, causing widespread involvement of many organ systems. The cases are still rising at an exponential rate and manifold trials are on to test different agents with the hope for potential limitation of spread and control of symptoms. Various classes of drugs have been tried; some with moderate success while many are yet to be proven to be of definite benefit. We have observed that the drugs used in dermatology practice are featured in more than a few of such studies. Here, we wish to highlight the ones that we are familiar with, which has featured at some point, in the management of this very challenging pandemic.
C1 [Shishak, Mansak] Indian Spinal Injuries Multispecialty Ctr, Opposite Vasant Valley Sch, New Delhi 110070, India.
   [Sarkar, Rashmi] Lady Hardinge Med Coll & Hosp, Dept Dermatol, New Delhi, India.
RP Shishak, M (corresponding author), Indian Spinal Injuries Multispecialty Ctr, Opposite Vasant Valley Sch, New Delhi 110070, India.
EM mansakshishak@gmail.com
CR Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Carlos G, 2020, ANDROGEN DRIVEN COVI, DOI [10.13140/RG.2.2.21254.11848, DOI 10.13140/RG.2.2.21254.11848]
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Jakhar D, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0853-0
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mugheddu C, 2020, J EUR ACAD DERMATOL, V34, pE376, DOI 10.1111/jdv.16625
   Olisova OY, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13668
   Pasquale P, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa320, DOI 10.1093/CID/CIAA320]
   Rathi S, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30313-3
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Tang C, 2020, LANCET, V395, P1759, DOI 10.1016/S0140-6736(20)30749-2
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 20
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e13813
DI 10.1111/dth.13813
EA JUL 2020
PG 3
WC Dermatology
SC Dermatology
GA MF4VE
UT WOS:000545341100001
PM 32526093
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kastritis, E
   Wechalekar, A
   Schonland, S
   Sanchorawala, V
   Merlini, G
   Palladini, G
   Minnema, M
   Roussel, M
   Jaccard, A
   Hegenbart, U
   Kumar, S
   Cibeira, MT
   Blade, J
   Dimopoulos, MA
AF Kastritis, Efstathios
   Wechalekar, Ashutosh
   Schoenland, Stefan
   Sanchorawala, Vaishali
   Merlini, Giampaolo
   Palladini, Giovanni
   Minnema, Monique
   Roussel, Murielle
   Jaccard, Arnaud
   Hegenbart, Ute
   Kumar, Shaji
   Cibeira, Maria T.
   Blade, Joan
   Dimopoulos, Meletios A.
TI Challenges in the management of patients with systemic light chain (AL)
   amyloidosis during the COVID-19 pandemic
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE amyloidosis; COVID-19; hydroxychloroquine; tocilizumab; remdesivir
ID PROGNOSTIC-FACTORS; RENAL-RESPONSE; HYDROXYCHLOROQUINE; RISK;
   CYCLOPHOSPHAMIDE; DARATUMUMAB; OUTCOMES; INJURY
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality.
C1 [Kastritis, Efstathios; Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Plasma Cell Dyscrasia Unit, Athens, Greece.
   [Wechalekar, Ashutosh] Natl Amyloidosis Ctr, London, England.
   [Schoenland, Stefan; Hegenbart, Ute] Univ Hosp Heidelberg, Med Dept 5, Amyloidosis Ctr, Heidelberg, Germany.
   [Sanchorawala, Vaishali] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA 02118 USA.
   [Sanchorawala, Vaishali] Boston Univ, Boston Med Ctr, Boston, MA 02215 USA.
   [Merlini, Giampaolo; Palladini, Giovanni] Univ Pavia, Fdn Ist Ricovero & Cura Carattere Sci IRCCS Polic, Amyloidosis Res & Treatment Ctr, Dept Mol Med, Pavia, Italy.
   [Minnema, Monique] UMC Utrecht Canc Ctr, Dept Hematol, Utrecht, Netherlands.
   [Roussel, Murielle] CHU Toulouse, IUC Oncopole, Clin Hematol, Toulouse, France.
   [Jaccard, Arnaud] CHU Poitiers, Poitiers, France.
   [Kumar, Shaji] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA.
   [Cibeira, Maria T.; Blade, Joan] Univ Barcelona, Hosp Clin Barcelona, Hematol Dept, Amyloidosis & Myeloma Unit,IDIBAPS, Barcelona, Spain.
RP Kastritis, E (corresponding author), Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Plasma Cell Dyscrasia Unit, Athens, Greece.
EM ekastritis@med.uoa.gr
RI Kastritis, Efstathios/AAD-3656-2019; Schonland, Stefan/AAV-5607-2020;
   Palladini, Giovanni/G-1763-2010
OI Kastritis, Efstathios/0000-0001-8191-5832; Schonland,
   Stefan/0000-0002-4853-5579; Palladini, Giovanni/0000-0001-5994-5138;
   Sanchorawala, Vaishali/0000-0002-6307-2445
CR Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Angel-Korman A, 2019, KIDNEY INT, V95, P405, DOI 10.1016/j.kint.2018.09.021
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bai G, 2020, J GEN INTERN MED, V35, P2818, DOI 10.1007/s11606-020-05929-5
   Banna G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000765
   Barr H, 2018, LEUKEMIA, V32, P2495, DOI 10.1038/s41375-018-0120-2
   Batsman E, 2017, J ONCOL PHARM PRACT, V23, P545, DOI 10.1177/1078155216657680
   Beigel J. H., 2020, N ENGL J MED
   Bever KM, 2016, HAEMATOLOGICA, V101, P86, DOI 10.3324/haematol.2015.133900
   Brenner DA, 2004, CIRC RES, V94, P1008, DOI 10.1161/01.RES.0000126569.75419.74
   Chai X, 2020, SPECIFIC ACE2 EXPRES
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Choufani EB, 2001, BLOOD, V97, P1885, DOI 10.1182/blood.V97.6.1885
   Ciceri F., 2020, CRIT CARE RESUSC
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   DAmico F, 2020, CLIN GASTROENTEROL H
   Dispenzieri A, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124409
   Drayson MT, 2019, LANCET ONCOL, V20, P1760, DOI 10.1016/S1470-2045(19)30506-6
   Driggin E, 2020, J AM COLL CARDIOL
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giles JT, 2020, ARTHRITIS RHEUMATOL, V72, P31, DOI 10.1002/art.41095
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Grein J, 2020, NEW ENGL J MED, V382
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL
   Han H, 2020, CLIN CHEM LAB MED
   Hanff TC, 2020, CLIN INFECT DIS
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hu H, 2020, EUR HEART J
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   KASTRITIS E, 2016, BLOOD, V128
   Kastritis E, 2017, AM J HEMATOL, V92, P632, DOI 10.1002/ajh.24738
   Kimmich CR, 2020, BLOOD, V135, P1517, DOI 10.1182/blood.2019003633
   Kliger AS, 2020, CLIN J AM SOC NEPHRO, V15, P707, DOI 10.2215/CJN.03340320
   Kokotis P, 2020, AMYLOID, V27, P103, DOI 10.1080/13506129.2020.1713081
   Kos CA, 2007, AM J HEMATOL, V82, P363, DOI 10.1002/ajh.20829
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Kristinsson SY, 2012, HAEMATOL-HEMATOL J, V97, P854, DOI 10.3324/haematol.2011.054015
   Larocca A, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111796
   Leung N, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfv294
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lousada I, 2015, ADV THER, V32, P920, DOI 10.1007/s12325-015-0250-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Madjid M, 2020, JAMA CARDIOL
   Manwani R, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0137-9
   Mao L, 2020, JAMA NEUROL
   Maurer MS, 2017, CIRCULATION, V135, P1357, DOI 10.1161/CIRCULATIONAHA.116.024438
   MCLACHLAN AJ, 1993, EUR J CLIN PHARMACOL, V44, P481, DOI 10.1007/BF00315548
   Mehra M, 2020, LANCET
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merlini G, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0034-3
   Migrino RQ, 2011, AM J PHYSIOL-HEART C, V301, pH2305, DOI 10.1152/ajpheart.00503.2011
   Mikhael JR, 2012, BLOOD, V119, P4391, DOI 10.1182/blood-2011-11-390930
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Palladini G, 2020, BLOOD
   Palladini G, 2019, BLOOD ADV, V3, P212, DOI 10.1182/bloodadvances.2018021253
   Palladini G, 2014, BLOOD, V124, P2325, DOI 10.1182/blood-2014-04-570010
   Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Perinel S, 2020, CLIN INFECT DIS
   Pietrantonio F, 2020, JAMA ONCOL, V11
   Pudusseri A, 2019, AM J HEMATOL, V94, P1098, DOI 10.1002/ajh.25576
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Roussel M, 2020, BLOOD, V135, P1531, DOI 10.1182/blood.2019004369
   Sanchorawala V, 2020, BLOOD, V135, P1541, DOI 10.1182/blood.2019004436
   Sanchorawala V, 2019, BLOOD ADV, V3, P216, DOI 10.1182/bloodadvances.2018021261
   Sattianayagam PT, 2013, HAEMATOL-HEMATOL J, V98, P136, DOI 10.3324/haematol.2012.070359
   Sharpley FA, 2020, EUR J HAEMATOL, V104, P230, DOI 10.1111/ejh.13366
   Shi S, 2020, JAMA CARDIOL
   Sidana S, 2019, BRIT J HAEMATOL, V185, P701, DOI 10.1111/bjh.15832
   Stamatelopoulos K, 2019, CIRC RES, V125, P744, DOI 10.1161/CIRCRESAHA.119.314862
   STRUCK RF, 1987, CANCER RES, V47, P2723
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   TETT S, 1993, AGENT ACTION SUPPL, V44, P145
   Thorogood N, 2007, POSTGRAD MED J, V83, DOI 10.1136/pgmj.2007.063735
   Trachtenberg BH, 2019, AM J TRANSPLANT, V19, P2900, DOI 10.1111/ajt.15487
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wechalekar AD, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.26
   Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X
   Wechalekar AD, 2013, BLOOD, V121, P3420, DOI 10.1182/blood-2012-12-473066
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
   Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334
   Yu J, 2020, JAMA ONCOL
   Zagouri F, 2011, AM J HEMATOL, V86, P882, DOI 10.1002/ajh.22135
   Zappasodi P, 2007, J CLIN ONCOL, V25, P3380, DOI 10.1200/JCO.2006.10.0164
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang L., 2020, ANN ONCOL
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 102
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2020
VL 190
IS 3
BP 346
EP 357
DI 10.1111/bjh.16898
EA JUL 2020
PG 12
WC Hematology
SC Hematology
GA MT0RK
UT WOS:000545977000001
PM 32480420
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dotzauer, R
   Bohm, K
   Brandt, MP
   Sparwasser, P
   Haack, M
   Frees, SK
   Kamal, MM
   Mager, R
   Jager, W
   Hofner, T
   Tsaur, I
   Haferkamp, A
   Borgmann, H
AF Dotzauer, Robert
   Boehm, Katharina
   Brandt, Maximilian Peter
   Sparwasser, Peter
   Haack, Maximilian
   Frees, Sebastian Karl
   Kamal, Mohamed Mostafa
   Mager, Rene
   Jaeger, Wolfgang
   Hoefner, Thomas
   Tsaur, Igor
   Haferkamp, Axel
   Borgmann, Hendrik
TI Global change of surgical and oncological clinical practice in urology
   during early COVID-19 pandemic
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE Coronavirus; SARS-CoV-2; Healthcare; Triage
ID CANCER; GUIDELINES; CYSTECTOMY; OUTBREAK; THERAPY; TIME
AB Objectives While the coronavirus disease 2019 (COVID-19) pandemic captures healthcare resources worldwide, data on the impact of prioritization strategies in urology during pandemic are absent. We aimed to quantitatively assess the global change in surgical and oncological clinical practice in the early COVID-19 pandemic. Methods In this cross-sectional observational study, we designed a 12-item online survey on the global effects of the COVID-19 pandemic on clinical practice in urology. Demographic survey data, change of clinical practice, current performance of procedures, and current commencement of treatment for 5 conditions in medical urological oncology were evaluated. Results 235 urologists from 44 countries responded. Out of them, 93% indicated a change of clinical practice due to COVID-19. In a 4-tiered surgery down-escalation scheme, 44% reported to make first cancellations, 23% secondary cancellations, 20% last cancellations and 13% emergency cases only. Oncological surgeries had low cancellation rates (%): transurethral resection of bladder tumor (27%), radical cystectomy (21-24%), nephroureterectomy (21%), radical nephrectomy (18%), and radical orchiectomy (8%). (Neo)adjuvant/palliative treatment is currently not started by more than half of the urologists. COVID-19 high-risk-countries had higher total cancellation rates for non-oncological procedures (78% vs. 68%,p = 0.01) and were performing oncological treatment for metastatic diseases at a lower rate (35% vs. 48%,p = 0.02). Conclusion The COVID-19 pandemic has affected clinical practice of 93% of urologists worldwide. The impact of implementing surgical prioritization protocols with moderate cancellation rates for oncological surgeries and delay or reduction in (neo)adjuvant/palliative treatment will have to be evaluated after the pandemic.
C1 [Dotzauer, Robert; Boehm, Katharina; Brandt, Maximilian Peter; Sparwasser, Peter; Haack, Maximilian; Frees, Sebastian Karl; Kamal, Mohamed Mostafa; Mager, Rene; Jaeger, Wolfgang; Hoefner, Thomas; Tsaur, Igor; Haferkamp, Axel; Borgmann, Hendrik] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Urol, Langenbeckstr 1, D-55131 Mainz, Germany.
RP Dotzauer, R (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Urol, Langenbeckstr 1, D-55131 Mainz, Germany.
EM robert.dotzauer@unimedizin-mainz.de;
   katharina.boehm@unimedizin-mainz.de;
   maximilian.brandt@unimedizin-mainz.de;
   peter.sparwasser@unimedizin-mainz.de;
   maximilian.haack@unimedizin-mainz.de; frees@urologie-gonsenheim.de;
   mohamedkamal.gheith@unimedizin-mainz.de; rene.mager@unimedizin-mainz.de;
   wolfgang.jaeger@unimedizin-mainz.de; thomas.hoefner@unimedizin-mainz.de;
   igor.tsaur@unimedizin-mainz.de; axel.haferkamp@unimedizin-mainz.de;
   hendrik.borgmann@unimedizin-mainz.de
RI Borgmann, Hendrik/F-4658-2015
OI Borgmann, Hendrik/0000-0002-3955-564X
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL. The authors wish to thank
   all survey responders for their contribution.
CR Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508
   Boeri L, 2019, EUR UROL ONCOL, V2, P390, DOI 10.1016/j.euo.2018.09.004
   Bourgade V, 2014, WORLD J UROL, V32, P475, DOI 10.1007/s00345-013-1045-z
   Burki TK, 2020, LANCET ONCOL, V21, P628, DOI 10.1016/S1470-2045(20)30201-1
   Chan VWS, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03246-4
   Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Froehner M, 2016, UROLOGY, V90, pE1, DOI 10.1016/j.urology.2015.12.043
   Gillessen S, 2020, EUR UROL, V77, P667, DOI 10.1016/j.eururo.2020.03.026
   Goldman HB, 2020, J UROLOGY, V204, P11, DOI 10.1097/JU.0000000000001067
   John Hopkins University, 2020, COR RES CTR
   Jones DS, 2020, NEW ENGL J MED, V382, P1681, DOI 10.1056/NEJMp2004361
   Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5
   Lee CT, 2006, J UROLOGY, V175, P1262, DOI 10.1016/S0022-5347(05)00644-0
   Margel David, 2020, Eur Urol Focus, DOI 10.1016/j.euf.2020.05.001
   Mejean A, 2018, NEW ENGL J MED, V379, P417, DOI 10.1056/NEJMoa1803675
   Naspro R, 2020, NAT REV UROL, V17, P251, DOI 10.1038/s41585-020-0312-1
   Nepogodiev D, 2020, BRIT J SURG, V107, P1440, DOI 10.1002/bjs.11746
   Niud Y, 2020, LANCET GLOB HEALTH, V8, pE452, DOI 10.1016/S2214-109X(20)30085-1
   Oderda M, 2020, EUR UROL, V78, P124, DOI 10.1016/j.eururo.2020.04.036
   Phe V, 2020, EUR UROL, V78, P4, DOI 10.1016/j.eururo.2020.04.031
   Proietti S, 2020, EUR UROL, V78, P131, DOI 10.1016/j.eururo.2020.03.042
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Silva DS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-241
   Stensland KD, 2020, EUR UROL, V77, P663, DOI 10.1016/j.eururo.2020.03.027
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   WHO, 2020, ETH STAND RES PUBL H
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
   Zehnder P, 2013, CURR OPIN UROL, V23, P423, DOI 10.1097/MOU.0b013e328363e46f
NR 30
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03333-6
EA JUL 2020
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA MF3YR
UT WOS:000545282600003
PM 32623500
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mercurio, I
   Tragni, V
   Busto, F
   De Grassi, A
   Pierri, CL
AF Mercurio, Ivan
   Tragni, Vincenzo
   Busto, Francesco
   De Grassi, Anna
   Pierri, Ciro Leonardo
TI Protein structure analysis of the interactions between SARS-CoV-2 spike
   protein and the human ACE2 receptor: from conformational changes to
   novel neutralizing antibodies
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; n-CoV19; Coronavirus; Spike; Receptor binding
   domain; Neutralizing antibodies; Spike post-fusion conformation; ACE2
   and ACE inhibitors; Fold recognition tools; Comparative modeling
ID CRYSTAL-STRUCTURE; X-RAY; BINDING; INTERFACE; DRUGS; HIV-1; SARS
AB The recent severe acute respiratory syndrome, known as Coronavirus Disease 2019 (COVID-19) has spread so much rapidly and severely to induce World Health Organization (WHO) to declare a state of emergency over the new coronavirus SARS-CoV-2 pandemic. While several countries have chosen the almost complete lock-down for slowing down SARS-CoV-2 spread, the scientific community is called to respond to the devastating outbreak by identifying new tools for diagnosis and treatment of the dangerous COVID-19. With this aim, we performed an in silico comparative modeling analysis, which allows gaining new insights into the main conformational changes occurring in the SARS-CoV-2 spike protein, at the level of the receptor-binding domain (RBD), along interactions with human cells angiotensin-converting enzyme 2 (ACE2) receptor, that favor human cell invasion. Furthermore, our analysis provides (1) an ideal pipeline to identify already characterized antibodies that might target SARS-CoV-2 spike RBD, aiming to prevent interactions with the human ACE2, and (2) instructions for building new possible neutralizing antibodies, according to chemical/physical space restraints and complementary determining regions (CDR) mutagenesis of the identified existing antibodies. The proposed antibodies show in silico high affinity for SARS-CoV-2 spike RBD and can be used as reference antibodies also for building new high-affinity antibodies against present and future coronaviruses able to invade human cells through interactions of their spike proteins with the human ACE2. More in general, our analysis provides indications for the set-up of the right biological molecular context for investigating spike RBD-ACE2 interactions for the development of new vaccines, diagnostic kits, and other treatments based on the targeting of SARS-CoV-2 spike protein.
C1 [Mercurio, Ivan; Busto, Francesco; De Grassi, Anna; Pierri, Ciro Leonardo] Univ Bari, Lab Biochem Mol & Struct Biol, Dept Biosci Biotechnol Biopharmaceut, Via E Orabona 4, I-70125 Bari, Italy.
   [Tragni, Vincenzo] Univ Bari Aldo Moro, Dept Soil Plant & Food Sci, Via Amendola 165-A, I-70126 Bari, Italy.
   [De Grassi, Anna; Pierri, Ciro Leonardo] Univ Aldo Moro Bari, Dept Biosci Biotechnol Biopharmaceut, BROWSer Srl, Via E Orabona 4, I-70126 Bari, Italy.
RP Pierri, CL (corresponding author), Univ Bari, Lab Biochem Mol & Struct Biol, Dept Biosci Biotechnol Biopharmaceut, Via E Orabona 4, I-70125 Bari, Italy.; Pierri, CL (corresponding author), Univ Aldo Moro Bari, Dept Biosci Biotechnol Biopharmaceut, BROWSer Srl, Via E Orabona 4, I-70126 Bari, Italy.
EM ciro.pierri@uniba.it
OI Pierri, Ciro Leonardo/0000-0003-1816-548X
FU MIUR (Italian Ministry for Education, University and Research)Ministry
   of Education, Universities and Research (MIUR) [PONa3_00052, CUP
   H92H18000160006]
FX Authors would like to thank the Italian Association for Mitochondrial
   Research (http://www.mitoairm.it), IT resources made available by ReCaS,
   a project funded by the MIUR (Italian Ministry for Education, University
   and Research) in the "PON Ricerca e Competitivita 2007-2013-Azione
   I-Interventi di rafforzamento strutturale" PONa3_00052, Avviso 254/Ric,
   University of Bari ("Fondi Ateneo ex-60%"2016"; "ProgettoCompetitivo
   2018" and "FFABR 2017-2018"). Authors would like to thank MIUR for
   having funded the project "Salute, alimentazione, qualita della vita":
   individuazione di un set di biomarker dell'apoptosi" for an innovative
   industrial Ph.D. course-PON RI 2014-2020, CUP H92H18000160006. Authors
   would also like to thank Angelo Onofrio (Biotechnologist), Luna Laera
   (Biotechnologist), and Daniela Tortorella (Biotechnologist) for critical
   reading and/or stimulating discussions.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alford RF, 2017, J CHEM THEORY COMPUT, V13, P3031, DOI 10.1021/acs.jctc.7b00125
   Alifano M, 2020, BIOCHIMIE, V174, P30, DOI 10.1016/j.biochi.2020.04.008
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Bazzoli A, 2017, PROTEINS, V85, P1994, DOI 10.1002/prot.25353
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bonner A, 2009, J BIOL CHEM, V284, P5077, DOI 10.1074/jbc.M807529200
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Chiara M, 2020, COMP GENOMICS SUGGES, DOI [10.1101/2020.03.30.016790, DOI 10.1101/2020.03.30.016790]
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Consiglio A, 2011, CURR PROTEIN PEPT SC, V12, P448, DOI 10.2174/138920311796391052
   Conway P, 2014, PROTEIN SCI, V23, P47, DOI 10.1002/pro.2389
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Deshotels MR, 2014, HYPERTENSION, V64, P1368, DOI 10.1161/HYPERTENSIONAHA.114.03743
   Duquerroy S, 2005, VIROLOGY, V335, P276, DOI 10.1016/j.virol.2005.02.022
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guex N, 2001, Curr Protoc Protein Sci, VChapter 2, DOI 10.1002/0471140864.ps0208s23
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joyce MG, 2020, CRYPTIC SITE VULNERA, DOI [10.1101/2020.03.15.992883v1, DOI 10.1101/2020.03.15.992883V1]
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324
   Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570
   Kumar N, 2020, SCIENCE, V367, P1008, DOI 10.1126/science.aaz5807
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Law GL, 2013, CURR OPIN IMMUNOL, V25, P588, DOI 10.1016/j.coi.2013.08.004
   Lei C., 2020, POTENT NEUTRALIZATIO, DOI [10.1101/2020.02.01.929976, DOI 10.1101/2020.02.01.929976]
   Lewis SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020872
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lobley A, 2009, BIOINFORMATICS, V25, P1761, DOI 10.1093/bioinformatics/btp302
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Martin ACR, 1996, J MOL BIOL, V263, P800, DOI 10.1006/jmbi.1996.0617
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Natesh R, 2004, BIOCHEMISTRY-US, V43, P8718, DOI 10.1021/bi049480n
   Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370
   Nivon LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059004
   Ordog R, 2008, BIOINFORMATION, V2, P346, DOI 10.6026/97320630002346
   Palese L. L., 2020, STRUCTURAL LANDSCAPE, DOI [10.26434/chemrxiv.12209744.v1, DOI 10.26434/CHEMRXIV.12209744.V1]
   Park T, 2020, SPIKE PROTEIN BINDIN, DOI [10.1101/2020.02.22.951178, DOI 10.1101/2020.02.22.95117]
   Persson B, 2000, EXS, V88, P215
   Pierri CL, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.197
   Pierri CL, 2010, BBA-PROTEINS PROTEOM, V1804, P1695, DOI 10.1016/j.bbapap.2010.04.008
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Quagliariello V, 2019, INT J CARDIOL, V292, P171, DOI 10.1016/j.ijcard.2019.05.028
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Sanchez R, 2000, METH MOL B, V143, P97
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Savarino A, 2005, J CLIN VIROL, V34, P170, DOI 10.1016/j.jcv.2005.03.005
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   SODHI M, 2020, PHARMACOTHERAPY 0504, DOI DOI 10.1016/j.chest.2020.03.040
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stranges PB, 2013, PROTEIN SCI, V22, P74, DOI 10.1002/pro.2187
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Trisolini L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122117
   van der Linden L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004733
   Van Durme J, 2011, BIOINFORMATICS, V27, P1711, DOI 10.1093/bioinformatics/btr254
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Yan L, 2018, ACTA CRYSTALLOGR D, V74, P841, DOI 10.1107/S2059798318008318
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang Jianyi, 2015, Curr Protoc Bioinformatics, V52, DOI 10.1002/0471250953.bi0508s52
   Yates CJ, 2014, J BIOL CHEM, V289, P1798, DOI 10.1074/jbc.M113.512335
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zeitlin L, 1999, EMERG INFECT DIS, V5, P54, DOI 10.3201/eid0501.990107
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 108
TC 8
Z9 8
U1 13
U2 13
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
DI 10.1007/s00018-020-03580-1
EA JUL 2020
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MF4BW
UT WOS:000545290900001
PM 32623480
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, ACM
AF Li, Arthur Cheuk-Man
TI Living Through COVID-19: A Perspective From Hong Kong
SO JOURNAL OF HUMANISTIC PSYCHOLOGY
LA English
DT Article
DE logotherapy; meaning; global crisis; Hong Kong
AB Hong Kong has been affected by the new coronavirus (COVID-19) since January 2020, almost 3 months earlier than most of the places around the globe. Once the epicenter of the severe acute respiratory syndrome (SARS) outbreak, the people of Hong Kong learned from their painful past and responded to the current epidemic quickly and accordingly. The creativity, mobility, compassion, and resilience demonstrated by Hong Kongers are understood and discussed through Viktor Frankl's paradigm of the meaning triangle. The influence of COVID-19 on clinical practice, particularly the wearing of face masks during face-to-face therapy sessions is also briefly discussed.
C1 [Li, Arthur Cheuk-Man] Souling Counselling & Holist Dev Ctr, Kowloon, 76-82 Castle Peak Rd, Hong Kong, Peoples R China.
RP Li, ACM (corresponding author), Souling Counselling & Holist Dev Ctr, Kowloon, 76-82 Castle Peak Rd, Hong Kong, Peoples R China.
EM drarthurcmli@gmail.com
OI Li, Arthur Cheuk Man/0000-0002-6211-9053
CR Centre for Health Protection The Government of the Hong Kong Special Adminis-trative Region., 2020, COUNTR AR REP CAS CO
   Chan K, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.12903
   Cheung T., 2020, S CHINA MORNING POST
   Division of Counselling Psychology Hong Kong Psychological Society, 2020, FAC JYUN YIP JIK BO
   Economic Digest, 2020, ECONOMIC DIGEST
   FRANKL V., 1988, WILL MEANING FDN APP
   Frankl V.E., 2006, MANS SEARCH MEANING
   Geller SM, 2014, J PSYCHOTHER INTEGR, V24, P178, DOI 10.1037/a0037511
   Graber A. V., 2004, VIKTOR FRANKLS LOGOT
   Hill C. E., 2001, HELPING SKILLS EMPIR, P195, DOI [10.1037/10412-011, DOI 10.1037/10412-011]
   Hon L. C., 2003 NIAN CHUN TIAN
   Ivey A. E., 2013, INTENTIONAL INTERVIE
   Krug O. T., 2019, WILEY WORLD HDB EXIS, P257, DOI DOI 10.1002/9781119167198.CH15
   Kwan C. F., 2020, AM730
   Lau C, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1686319
   Lau JTF, 2006, J INFECTION, V53, P114, DOI 10.1016/j.jinf.2005.10.019
   Lhatoo Y., 2019, S CHINA MORNING POST
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   McLaughlin T., 2020, ATLANTIC
   Ngai C., 2020, MESSAGE HONG KONG WH
   Pao J., 2020, ASIA TIMES
   Sala I. M., 2020, QUARTZ          0212
   Schneider K., 2015, EXISTENTIAL ANAL, V26, P304
   Sharpley CF, 2006, COUNS PSYCHOL Q, V19, P343, DOI 10.1080/09515070601058706
   Taber I., 1997, MODERN PSYCHOL STUDI, V5, P33
   The Government of the Hong Kong Special Administrative Region, WE FIGHT VIRUS
   Vogler S, 2019, MEDICINE PRICE SURVEYS, ANALYSES AND COMPARISONS: EVIDENCE AND METHODOLOGY GUIDANCE, P247, DOI 10.1016/B978-0-12-813166-4.00014-0
   Walsh B., 2020, AXIOS
   Wong B., 2020, THE DIPLOMAT
   Wong J., 2020, BLOOMBERG
   Wong Natalie, 2020, S CHINA MORNING POST
   Wong PTP, 2014, MEANING IN POSITIVE AND EXISTENTIAL PSYCHOLOGY, P149, DOI 10.1007/978-1-4939-0308-5_10
   Yam S. Y. S., 2020, HONG KONG FREE 0303
   Yau C., 2020, S CHINA MORNING POST
   Zhao Y., 2020, THE STANDARD
NR 35
TC 2
Z9 2
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-1678
EI 1552-650X
J9 J HUMANIST PSYCHOL
JI J. Humanist. Psychol.
PD SEP
PY 2020
VL 60
IS 5
SI SI
BP 672
EP 681
AR 0022167820938487
DI 10.1177/0022167820938487
EA JUL 2020
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA MS6KN
UT WOS:000545367000001
OA Bronze
DA 2021-01-01
ER

PT J
AU Liu, LW
   Gu, JQ
   Shao, FM
   Liang, XL
   Yue, LX
   Cheng, QM
   Zhang, LZ
AF Liu, Luwen
   Gu, Jianqin
   Shao, Fengmin
   Liang, Xinliang
   Yue, Lixia
   Cheng, Qiaomei
   Zhang, Lianzhong
TI Application and Preliminary Outcomes of Remote Diagnosis and Treatment
   During the COVID-19 Outbreak: Retrospective Cohort Study
SO JMIR MHEALTH AND UHEALTH
LA English
DT Article
DE coronavirus disease; COVID-19; remote diagnosis and treatment;
   telemedicine; online outpatient visit; offline drug delivery; pandemic
   management; China; Henan Province
ID CARE
AB Background: The coronavirus disease (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in the self-quarantine of countless people due to possible infection. This situation makes telemedicine necessary as it can overcome geographical barriers, increase the number of people served, and provide online clinical support for patients. However, the outcomes of telemedicine have not yet been evaluated.
   Objective: The aim of our study is to describe the epidemiological features and clinical symptoms of patients receiving remote diagnosis and treatment at the online outpatient clinic of our hospital, as well as to analyze the outcomes and advantages of telemedicine, during the COVID-19 pandemic.
   Methods: Data from patients receiving remote diagnosis and treatment via consultation services for COVID-19 concerns at the online outpatient clinic of Henan Provincial People's Hospital from January 24 to February 17, 2020, were collected. A retrospective analysis was performed on epidemiological features, clinical symptoms, and preliminary outcomes.
   Results: Online inquiry, consultation, and suggestions were provided for patient concerns related to COVID-19. Our hospital also offered offline noncontact drug delivery services following online ordering and payment. A total of 4589 patients receiving remote diagnosis and treatment were recruited. The daily number of online outpatient visits initially increased and then decreased, reaching its peak on January 28 when the daily number of online outpatient visits totaled 612. Of 4589 patients, 1940 (42.3%) were males and 2649 (57.7%) were females (age range: 78 days to 85 years). Most patients were aged 20-39 years (n=3714, 80.9%) and came from Henan Province (n=3898, 84.9%). The number of patients from other provinces was 691 (15.1%). During the online consultations, patients discussed the following symptoms: fever (n=2383), cough (n=1740), nasal obstruction (n=794), fatigue (n=503), and diarrhea (n=276). A total of 873 orders of noncontact drug delivery following online payment was completed. The daily number of such orders gradually stabilized after the initial, steady increase. For offline drug delivery orders, the median (IQR) was 36 (58). An online satisfaction survey was filled out postconsultation by patients; of the 985 responses received, 98.1% (n=966) of respondents were satisfied with the service they received.
   Conclusions: Remote diagnosis and treatment offered via online outpatient consultations effectively reduced the burden on hospitals, prevented overcrowding, reduced the risk of cross-infection, and relieved patients' anxiety during the COVID-19 outbreak. This plays an essential role in pandemic management.
C1 [Liu, Luwen; Gu, Jianqin; Shao, Fengmin; Liang, Xinliang; Yue, Lixia; Cheng, Qiaomei; Zhang, Lianzhong] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, 7 Weiwu Rd, Zhengzhou, Peoples R China.
RP Zhang, LZ (corresponding author), Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, 7 Weiwu Rd, Zhengzhou, Peoples R China.
EM llw0624@gs.zzu.edu.cn
OI Shao, Fengmin/0000-0003-2905-4312
CR Frid SA, 2019, STUD HEALTH TECHNOL, V264, P586, DOI 10.3233/SHTI190290
   [Anonymous], 2019, 44 CHIN STAT REP INT
   [Anonymous], EP PREV CONTR TRENDS
   Britton N, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00244
   Centers for Disease Control and Prevention (CDC), 2020, 1 TRAV REL CAS 2019
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Currie K, 2016, J HOSP INFECT, V92, P253, DOI 10.1016/j.jhin.2015.10.018
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Gong K, 2020, J MED INTERNET RES, V22, DOI 10.2196/18908
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Giunta DH, 2017, REV MED CHILE, V145, P557, DOI 10.4067/S0034-98872017000500001
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu LW, 2019, JMIR MED INF, V7, DOI 10.2196/14248
   Lugn NE, 2006, J TELEMED TELECARE, V12, P109, DOI 10.1258/135763306776738576
   Lv J, 2004, CHINESE J HLTH ED, V20, P924, DOI [10.3969/j.issn.1002-9982.2004.10.021, DOI 10.3969/J.ISSN.1002-9982.2004.10.021]
   Markwell H, 2004, VISITOR RESTRICTIONS
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM SCHEM N
   National Health Committee of the People's Republic of China, 2020, DIAGN TREATM PLAN PN
   Tian H Y, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P235, DOI 10.3760/cma.j.issn.0253-9624.2020.03.002
   Wang C, 2020, CHINESE GEN NURSING, V18, P309, DOI [10.12104/j.issn.1674-4748.2020.03.016, DOI 10.12104/J.ISSN.1674-4748.2020.03.016]
   Wei Q, 2020, CHIN J DISINFECT, V37, P59, DOI DOI 10.11726/J.ISSN.1001-7658.2020.01.019
   WHO, 2020, NOV COR REP KOR EXCH
   World Health Organization (WHO), 2020, NOV COR THAIL EXCH
   World Health Organization (WHO), 2020, NOV COR CHIN
   World Health Organization (WHO), 2020, NOV COR JAP EXCH
   [向虎 XIANG Hu], 2008, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V8, P918
   Xiao JQ, 2007, CHINESE HLTH EC, V26, P20, DOI DOI 10.3969/J.ISSN.1003-0743.2007.03.006
   Yin H, 2004, SHANGHAI NURS, V4, P49
NR 28
TC 2
Z9 2
U1 1
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2291-5222
J9 JMIR MHEALTH UHEALTH
JI JMIR mHealth uHealth
PD JUL 3
PY 2020
VL 8
IS 7
AR e19417
DI 10.2196/19417
PG 9
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA MU7ZO
UT WOS:000555887600001
PM 32568722
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU McDonald, KA
   Holtz, RB
AF McDonald, Karen A.
   Holtz, R. Barry
TI From Farm to Finger Prick-A Perspective on How Plants Can Help in the
   Fight Against COVID-19
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE COVID-19; plant made pharmaceuticals; diagnostic test; SARS-CoV-2;
   crops; plant made SARS-CoV-2 antigens
ID TRANSIENT EXPRESSION; PROTEIN
AB As a consequence of the COVID-19 pandemic crisis, farmers across the country are plowing under their fields and laying off workers. Plant biomass has been shown by the DARPA "Blue Angel" project in 2010 to be an efficient way to rapidly make vaccines and diagnostics. This technology could pivot some areas of agriculture toward biomedical products to aid in the COVID-19 pandemic response.
C1 [McDonald, Karen A.] Univ Calif Davis, Dept Chem Engn, Davis, CA 95616 USA.
   [McDonald, Karen A.] Ctr Utilizat Biol Engn Space, Berkeley, CA 94612 USA.
   [McDonald, Karen A.] Global HealthShare Initiat, Davis, CA 95616 USA.
   [Holtz, R. Barry] Holtz Biopharma Consulting, Austin, TX USA.
   [Holtz, R. Barry] Ctr Utilizat Biol Engn Space, Sci Advisory Comm, Berkeley, CA USA.
RP McDonald, KA (corresponding author), Univ Calif Davis, Dept Chem Engn, Davis, CA 95616 USA.; McDonald, KA (corresponding author), Ctr Utilizat Biol Engn Space, Berkeley, CA 94612 USA.; McDonald, KA (corresponding author), Global HealthShare Initiat, Davis, CA 95616 USA.
EM kamcdonald@ucdavis.edu
FU Translational Research Institute through NASA [NNX16AO69A]; NSFNational
   Science Foundation (NSF) [EEC-1840476]; UC Davis COVID-19 Research
   Accelerator Fund Project Award
FX This work is supported by the Translational Research Institute through
   NASA NNX16AO69A, NSF EEC-1840476, and a UC Davis COVID-19 Research
   Accelerator Fund Project Award. Any opinions, findings, and conclusions
   or recommendations expressed in this material are those of the authors
   and do not necessarily reflect the views of the National Aeronautics and
   Space Administration (NASA), the Translational Research Institute for
   Space Health (TRISH) or UC Davis.
CR Bennett LD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020421
   Blake M., 2020, CALIFORNIA FARMER PL
   Castilho A, 2010, J BIOL CHEM, V285, P15923, DOI 10.1074/jbc.M109.088401
   Esposito D, 2020, PROTEIN EXPRES PURIF, V174, DOI 10.1016/j.pep.2020.105686
   Fujiuchi N, 2016, BIOTECHNOL BIOENG, V113, P901, DOI 10.1002/bit.25854
   Girard P, 2002, CYTOTECHNOLOGY, V38, P15, DOI 10.1023/A:1021173124640
   Holtz BR, 2015, PLANT BIOTECHNOL J, V13, P1180, DOI 10.1111/pbi.12469
   Ikram NKBK, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.01966
   Joh LD, 2005, BIOTECHNOL BIOENG, V91, P861, DOI 10.1002/bit.20557
   Jung SK, 2016, BIOTECHNOL BIOPROC E, V21, P726, DOI 10.1007/s12257-016-0410-3
   Kommineni V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010194
   Krause NM, 2019, PUBLIC OPIN QUART, V83, P817, DOI 10.1093/poq/nfz041
   Lomonossoff GP, 2016, SCIENCE, V353, P1237, DOI 10.1126/science.aaf6638
   Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901
   Plesha MA, 2009, BIOTECHNOL PROGR, V25, P722, DOI 10.1002/btpr.149
   Pogue GP, 2002, ANNU REV PHYTOPATHOL, V40, P45, DOI 10.1146/annurev.phyto.40.021102.150133
   Pogue GP, 2010, PLANT BIOTECHNOL J, V8, P638, DOI 10.1111/j.1467-7652.2009.00495.x
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
NR 19
TC 1
Z9 1
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD JUL 3
PY 2020
VL 8
AR 782
DI 10.3389/fbioe.2020.00782
PG 5
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA MR9YB
UT WOS:000553943600001
PM 32714921
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ong, E
   Wong, MU
   Huffman, A
   He, YQ
AF Ong, Edison
   Wong, Mei U.
   Huffman, Anthony
   He, Yongqun
TI COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and
   Machine Learning
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; S protein; non-structural protein 3; vaccine; reverse
   vaccinology; machine learning; vaxign; vaxign-ML
ID ACUTE RESPIRATORY SYNDROME; MONOCLONAL-ANTIBODIES; SEQUENCE ALIGNMENT;
   IMMUNE-RESPONSES; CELL RESPONSES; SARS-COV; PROTEIN; VIRUS; PREDICTION;
   IMMUNIZATION
AB To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS. However, these vaccine candidates might lack the induction of complete protection and have safety concerns. We then applied the Vaxign and the newly developed machine learning-based Vaxign-ML reverse vaccinology tools to predict COVID-19 vaccine candidates. Our Vaxign analysis found that the SARS-CoV-2 N protein sequence is conserved with SARS-CoV and MERS-CoV but not from the other four human coronaviruses causing mild symptoms. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10), were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity. Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation. The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals. The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and the predicted linear B-cell epitopes were found to be localized on the surface of the protein. Our predicted vaccine targets have the potential for effective and safe COVID-19 vaccine development. We also propose that an "Sp/Nsp cocktail vaccine" containing a structural protein(s) (Sp) and a non-structural protein(s) (Nsp) would stimulate effective complementary immune responses.
C1 [Ong, Edison; Huffman, Anthony; He, Yongqun] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Wong, Mei U.; He, Yongqun] Univ Michigan, Dept Microbiol & Immunol, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.
RP He, YQ (corresponding author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; He, YQ (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.
EM yongqunh@med.umich.edu
OI Ong, Edison/0000-0002-5159-414X
FU NIH-NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [1R01AI081062, 1UH2AI132931]; Unit for
   Laboratory Animal Medicine (ULAM) in the University of Michigan
FX This work has been supported by the NIH-NIAID grants 1R01AI081062 and
   1UH2AI132931. The article-processing charge for this article was paid by
   a discretionary fund from Dr. William King, the director of the Unit for
   Laboratory Animal Medicine (ULAM) in the University of Michigan. This
   manuscript has been released as a pre-print at
   https://www.biorxiv.org/content/10.1101/2020.03.20.000141v2 (86).
CR Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875
   Bairoch A, 2007, NUCLEIC ACIDS RES, V35, pD193, DOI 10.1093/nar/gkl929
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bowman BN, 2011, VACCINE, V29, P8156, DOI 10.1016/j.vaccine.2011.07.142
   Cabeca TK, 2013, INFLUENZA OTHER RESP, V7, P1040, DOI 10.1111/irv.12101
   Cafaro A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030099
   Capra JA, 2007, BIOINFORMATICS, V23, P1875, DOI 10.1093/bioinformatics/btm270
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen HR, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0462-0
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Chou KC, 2000, BIOCHEM BIOPH RES CO, V278, P477, DOI 10.1006/bbrc.2000.3815
   Coleman CM, 2017, J VIROL, V91, DOI 10.1128/JVI.01825-16
   Dalsass M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00113
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   DUBCHAK I, 1995, P NATL ACAD SCI USA, V92, P8700, DOI 10.1073/pnas.92.19.8700
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Feng ZP, 2000, J PROTEIN CHEM, V19, P269, DOI 10.1023/A:1007091128394
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
   Gao Q, 2020, RAPID DEV INACTIVATE, DOI [10.1101/2020.04.17.046375v1, DOI 10.1101/2020.04.17.046375V1]
   GIBSON CA, 1988, VACCINE, V6, P7, DOI 10.1016/0264-410X(88)90004-7
   Glansbeek HL, 2002, J GEN VIROL, V83, P1, DOI 10.1099/0022-1317-83-1-1
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   He YQ, 2014, NUCLEIC ACIDS RES, V42, pD1124, DOI 10.1093/nar/gkt1133
   He YQ, 2010, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2010/218590
   Heinson AI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020312
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lefort V, 2017, MOL BIOL EVOL, V34, P2422, DOI 10.1093/molbev/msx149
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503
   Lin Z, 2001, J PROTEIN CHEM, V20, P217, DOI 10.1023/A:1010967008838
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McKay PF, 2020, SELF AMPLIFYING RNA, DOI [10.1101/2020.04.22.055608v1, DOI 10.1101/2020.04.22.055608V1]
   MILLET P, 1993, AM J TROP MED HYG, V48, P424, DOI 10.4269/ajtmh.1993.48.424
   Navarro-Quiroz E., 2018, GLOB J HLTH SCI, V10, P148
   Ong E, 2020, COVID 19 CORONAVIRUS, DOI [10.1101/2020.03.20.000141v2, DOI 10.1101/2020.03.20.000141V2]
   Ong E, 2020, BIOINFORMATICS, V36, P3185, DOI 10.1093/bioinformatics/btaa119
   Ong E, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3194-6
   Ong E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01382
   Ong SAK, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-300
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Peng P, 2014, MOL THER, V22, P881, DOI 10.1038/mt.2013.287
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Plotkin SA, 2020, VACCINE, V38, P2250, DOI 10.1016/j.vaccine.2019.10.046
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Ribet D, 2015, MICROBES INFECT, V17, P173, DOI 10.1016/j.micinf.2015.01.004
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x
   Sachdeva G, 2005, BIOINFORMATICS, V21, P483, DOI 10.1093/bioinformatics/bti028
   Salat J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010081
   SCHLESINGER JJ, 1985, J IMMUNOL, V135, P2805
   Schrodinger L, 2015, MESQUITE MODULAR SYS, V1, P8
   Sealy R, 2009, INT REV IMMUNOL, V28, P49, DOI 10.1080/08830180802495605
   See RH, 2008, J GEN VIROL, V89, P2136, DOI 10.1099/vir.0.2008/001891-0
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Singh R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00158
   Sokal RR, 2006, AM J PHYS ANTHROPOL, V129, P121, DOI 10.1002/ajpa.20250
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   van Doremalen N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8399
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiang ZS, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S4-S2
   Yang B, 2011, NUCLEIC ACIDS RES, V39, pD1073, DOI 10.1093/nar/gkq944
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Zha L, 2020, DEV COVID 19 VACCINE, DOI [10.1101/2020.05.06.079830v2, DOI 10.1101/2020.05.06.079830V2]
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
   Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792
NR 85
TC 4
Z9 4
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 3
PY 2020
VL 11
AR 1581
DI 10.3389/fimmu.2020.01581
PG 13
WC Immunology
SC Immunology
GA MR8DM
UT WOS:000553821400001
PM 32719684
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Assi, T
   Samra, B
   Dercle, L
   Rassy, E
   Kattan, J
   Ghosn, M
   Houot, R
   Ammari, S
AF Assi, Tarek
   Samra, Bachar
   Dercle, Laurent
   Rassy, Elie
   Kattan, Joseph
   Ghosn, Marwan
   Houot, Roch
   Ammari, Samy
TI Screening Strategies for COVID-19 in Patients With Hematologic
   Malignancies
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE hematologic malignancies; hematology; COVID-19; coronavirus; screening;
   polymerase chain reaction; CT scan
ID T-CELL THERAPY; INFECTIONS; MANAGEMENT; TRANSPLANT; DIAGNOSIS; DISEASES;
   ADULTS
AB COVID-19 has been declared a pandemic by the world health organization. Patients with cancer, and particularly hematologic malignancies may be at higher risk for severe complications due to their malignancy, immune dysregulation, therapy, and associated comorbidities. The oncology community has been proactive in issuing practice guidelines to help optimize management, and limit infection risk and complications from SARS-COV-2. Although hematologic malignancies account for only 10% of all cancers, their management is particularly complex, especially in the time of COVID-19. Screening or early detection of COVID-19 are central for preventative/mitigation strategy, which is the best current strategy in our battle against COVID-19. Herein, we provide an overview of COVID-19 screening strategies and highlight the unique aspects of treating patients with hematologic malignancies.
C1 [Assi, Tarek; Rassy, Elie; Kattan, Joseph; Ghosn, Marwan] St Joseph Univ, Fac Med, Dept Hematol & Med Oncol, Beirut, Lebanon.
   [Samra, Bachar] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Dercle, Laurent] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Radiol Dept, New York, NY USA.
   [Houot, Roch] Univ Rennes, Dept Hematol, CHU Rennes, Rennes, France.
   [Houot, Roch] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Ammari, Samy] Gustave Roussy Canc Campus, Radiol Dept, Villejuif, France.
   [Ammari, Samy] Univ Paris Saclay, INSERM CEA CNRS, UMR1281, BIOMAPS, Paris, France.
RP Ammari, S (corresponding author), Gustave Roussy Canc Campus, Radiol Dept, Villejuif, France.; Ammari, S (corresponding author), Univ Paris Saclay, INSERM CEA CNRS, UMR1281, BIOMAPS, Paris, France.
EM samy.ammari@gustaveroussy.fr
RI Dercle, Laurent/C-9740-2018
OI Dercle, Laurent/0000-0002-1322-0710; Rassy, Elie/0000-0002-7906-0991
CR ACR, 2020, ACR REC US CHEST RAD
   ADVANI SH, 1980, CANCER, V45, P2843, DOI 10.1002/1097-0142(19800601)45:11<2843::AID-CNCR2820451121>3.0.CO;2-C
   Ai T, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200642, DOI 10.1148/RADI0L.2020200642.[EPUB]
   Al Saleh AS, 2020, ACTA HAEMATOL, DOI [10.1159/000507690, DOI 10.1159/000507690.[EPUB]
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], 2020, CLIN GUID MAN CANC P
   [Anonymous], 2020, 1 REPORT PREVALENCE, DOI DOI 10.1101/2020.03.12.20034876V2
   [Anonymous], 2020, COVID19 REGISTRY
   Anthimopoulos M, 2016, IEEE T MED IMAGING, V35, P1207, DOI 10.1109/TMI.2016.2535865
   ASH Guidelines, 2020, COVID 19 CLL FREQ AS
   ASTCT (American Society for Transplantation and Cellular Therapy), 2020, GUID BMT CTR FUNCT D
   Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Bai HX, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200823, DOI 10.1148/RADI0L.2020200823.[EPUB]
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bao CP, 2020, J AM COLL RADIOL, V17, P701, DOI 10.1016/j.jacr.2020.03.006
   Bullock J., 2020, MAPPING LANDSCAPE AR
   BURKE PJ, 1976, JOHNS HOPKINS MED J, V139, P1
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Dholaria B, 2020, BRIT J HAEMATOL, V189, P239, DOI 10.1111/bjh.16597
   Dignan FL, 2016, BRIT J HAEMATOL, V173, P380, DOI 10.1111/bjh.14027
   ecancer, 2020, WHAT EXPECT ONCOLOGY
   EHA guidelines, 2020, REC SPEC HEM MAL
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   FDA, 2020, COR COVID 19 UPD SER
   Frey NV, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01892
   GANDHI M, 2020, MASS MED SOC, V382, P2158, DOI DOI 10.1056/NEJME2009758
   Garnica M, 2020, HEMATOL TRANSF CELL, V42, P111, DOI 10.1016/j.htct.2020.04.001
   Gavillet M, 2020, LEUKEMIA RES, V92, DOI 10.1016/j.leukres.2020.106353
   Griggio V, 2017, ONCOTARGET, V8, P3274, DOI 10.18632/oncotarget.13712
   Guo L, 2020, CLIN INFECT DIS PUBL, DOI [10.1093/cid/ciaa310, DOI 10.1093/CID/CIAA310.[EPUB]
   Hakki M, 2015, J CLIN VIROL, V68, P1, DOI 10.1016/j.jcv.2015.04.012
   Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Kennedy-Nasser AA, 2011, PEDIATR HEMAT ONCOL, V28, P176, DOI 10.3109/08880018.2011.557261
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kligerman SJ, 2013, RADIOGRAPHICS, V33, P1951, DOI 10.1148/rg.337130057
   Lambertini M, 2020, EMSO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Leukemia and lymphoma society, 2020, FACTS STAT
   Li L, 2020, CT RADIOLOGY, V284, P574, DOI DOI 10.1148/RADI0L.2020200905
   Liang T., 2020, HDB COVID 19 PREVENT
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mascaretti L, 2020, BLOOD TRANSFUS-ITALY, V18, P77, DOI 10.2450/2020.0071-20
   Mian H, 2020, J GERIATR ONCOL, V11, P764, DOI 10.1016/j.jgo.2020.04.008
   Noonan K, 2011, CANCER MICROENVIRON, V4, P313, DOI 10.1007/s12307-011-0086-3
   Perini GF, 2020, HEMATOL TRANSF CELL, V42, P103, DOI 10.1016/j.htct.2020.04.002
   Portnoy J, 2020, J ALLER CL IMM-PRACT, V8, P1489, DOI 10.1016/j.jaip.2020.03.008
   Raptis CA, 2020, AM J ROENTGENOL, V215, P839, DOI 10.2214/AJR.20.23202
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shi F, 2020, REV ARTIFICIAL INTEL, DOI [10.1109/RBME.2020.2987975, DOI 10.1109/RBME.2020.2987975.[EPUB]
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Styczynski JMM, 2020, EBMT RECOMMENDATION
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
   Wong H., 2020, RADIOLOGY, DOI [10.1148/radiol.2020201160, DOI 10.1148/RADI0L.2020201160]
   World Health Organization, 2020, MAINT SAF AD BLOOD S
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zic JA, 2020, J AM ACAD DERMATOL, DOI [10.1016/j.jaad.2020.04.049, DOI 10.1016/J.JAAD.2020.04.049.[EPUB]
NR 66
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 3
PY 2020
VL 10
AR 1267
DI 10.3389/fonc.2020.01267
PG 9
WC Oncology
SC Oncology
GA MS0QG
UT WOS:000553990900001
PM 32719749
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ye, XN
   Xiao, XF
   Li, B
   Zhu, WG
   Li, YJ
   Wu, JG
   Huang, X
   Jin, JX
   Chen, D
   Jin, J
   Huang, J
AF Ye, Xingnong
   Xiao, Xiaofang
   Li, Bin
   Zhu, Weigang
   Li, Youjiang
   Wu, Jianguo
   Huang, Xin
   Jin, Jingxia
   Chen, Dan
   Jin, Jie
   Huang, Jian
TI Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a
   COVID-19 Patient With CLL During a 69-Day Follow-Up
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE coronavirus disease-2019; chronic lymphocytic leukemia; humoral
   immunity; ineffective clearance; follow-up
ID CHRONIC LYMPHOCYTIC-LEUKEMIA
AB Background:A recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), which began in Wuhan, China, with a high level of human-to-human transmission has been reported. There are limited data available on Coronavirus Disease 2019 (COVID-19) patients with hematological malignancies with more than 60 days of follow-up. This study describes the clinical characteristics, including multiple recurrences of COVID-19, in a patient with chronic lymphocytic leukemia (CLL) during 69 days of follow-up. Case Presentation:A 72-year-old female was admitted to hospital isolation after being infected with COVID-19 as part of a family cluster on January 30, 2020. Apart from SARS-Cov-2 virus infection, laboratory results revealed lymphocytosis of uncertain etiology and abnormal distribution of T lymphocytes. On blood smears, small blue lymphocytes with scant cytoplasm were observed, and the presence of high levels of circulating clonal B cells was also demonstrated by flow cytometry. The patient was diagnosed with COVID-19 and CLL. Among her family members, she had the highest viral loads and the fastest progression on lung injury and developed severe pneumonia. Serological results showed she had both 2019-nCoV-specific IgM and IgG antibodies; however, only IgG antibodies were detected in her husband's plasma. Results:A combination regimen of antiviral therapy and high-dose intravenous immunoglobulin (IVIG) in the early stage seemed to be effective for treating CLL and SARS-Cov-2 infection. Because of the low humoral immune response, the CLL patient could not effectively clear the SARS-Cov-2 infection and suffered from recurrence twice during the 69-day follow-up. Conclusion:In CLL, a neoplastic antigen-specific B-cell clone proliferates, and the progeny cells accumulate and outgrow other B cells, leading to immune deficiency. Considering the low humoral immune response and ineffective clearance of SARS-Cov-2 in CLL patients, the follow-up and home quarantine period should be extended. We need further studies to clarify suspending or continuing CLL therapy during COVID infection. For those patients who are prone to progression to severe disease, administering humoral immunity therapies can help to prevent disease progression and quickly meet the cure criteria.
C1 [Ye, Xingnong; Xiao, Xiaofang; Jin, Jingxia; Chen, Dan; Huang, Jian] Zhejiang Univ, Dept Hematol, Affiliated Hosp 4, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Ye, Xingnong; Huang, Xin; Jin, Jie; Huang, Jian] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Ye, Xingnong; Huang, Xin; Jin, Jie; Huang, Jian] Key Lab Hematol Malignancies Diag & Treatment, Hangzhou, Peoples R China.
   [Li, Bin] Zhejiang Univ, Dept Infect Dis, Affiliated Hosp 4, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Zhu, Weigang; Li, Youjiang; Wu, Jianguo] Zhejiang Univ, Dept Lab Med, Affiliated Hosp 4, Sch Med, Hangzhou, Zhejiang, Peoples R China.
RP Huang, J (corresponding author), Zhejiang Univ, Dept Hematol, Affiliated Hosp 4, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Huang, J (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Huang, J (corresponding author), Key Lab Hematol Malignancies Diag & Treatment, Hangzhou, Peoples R China.
EM househuang@zju.edu.cn
FU academician workstation of the Fourth Affiliated Hospital of the
   Zhejiang University School of Medicine (2019-2024); Public Technology
   Research Projects of Yiwu, China [2016S05]; Key Project of Jinhua
   Science and Technology Plan [2020XG-29]; Key Medical Discipline of Yiwu,
   China; Key Medical Discipline of Jinhua, China; Project of Educational
   Commission of Zhejiang Province of China [Y201942124]
FX The research was supported by the academician workstation of the Fourth
   Affiliated Hospital of the Zhejiang University School of Medicine
   (2019-2024) and by funding from the Public Technology Research Projects
   of Yiwu, China (2016S05), the Key Project of Jinhua Science and
   Technology Plan (2020XG-29), the Key Medical Discipline of Yiwu, China
   (Hematology, 2018-2020), the Key Medical Discipline of Jinhua, China
   (Hematology, 2019-2021), and the Project of Educational Commission of
   Zhejiang Province of China (Y201942124).
CR Allegra A, 2020, CANCERS, V12, DOI 10.3390/cancers12020524
   Andersen BL, 2018, CANCER-AM CANCER SOC, V124, P3240, DOI 10.1002/cncr.31538
   [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Asslaber D, 2019, BLOOD, V134, P1717, DOI 10.1182/blood.2019000973
   Baliakas P, 2019, BLOOD, V133, P1205, DOI 10.1182/blood-2018-09-873083
   Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121
   Crassini KR, 2018, BRIT J HAEMATOL, V181, P97, DOI 10.1111/bjh.15146
   Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388
   Gorgun G, 2005, J CLIN INVEST, V115, P1797, DOI 10.1172/JCI24176
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hallek M, 2018, BLOOD, V131, P2745, DOI 10.1182/blood-2017-09-806398
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jurado-Camino T, 2015, J IMMUNOL, V194, P719, DOI 10.4049/jimmunol.1402272
   Kwok M, 2020, BLOOD, V135, P411, DOI 10.1182/blood.2019001262
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Ramsay AG, 2013, BLOOD, V121, P2704, DOI 10.1182/blood-2012-08-448332
   Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569
   van Bruggen JAC, 2019, BLOOD, V134, P44, DOI 10.1182/blood.2018885863
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zent CS, 2016, BLOOD, V128, P1908, DOI 10.1182/blood-2016-08-734475
NR 21
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 3
PY 2020
VL 10
AR 1272
DI 10.3389/fonc.2020.01272
PG 7
WC Oncology
SC Oncology
GA MS0PZ
UT WOS:000553990200001
PM 32719750
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Raina, R
   Chakraborty, R
   Sethi, SK
   Bunchman, T
AF Raina, Rupesh
   Chakraborty, Ronith
   Sethi, Sidharth Kumar
   Bunchman, Timothy
TI Kidney Replacement Therapy in COVID-19 Induced Kidney Failure and Septic
   Shock: A Pediatric Continuous Renal Replacement Therapy [PCRRT] Position
   on Emergency Preparedness With Resource Allocation
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE COVID-19; extracorporeal therapy; kidney replacement therapy;
   pediatrics; acute kidney injury
ID HIGH-VOLUME HEMOFILTRATION; CORONAVIRUS; PNEUMONIA; OUTBREAK; CHILDREN;
   SEPSIS; IL-6
AB The recent worldwide pandemic of COVID-19 has had a detrimental worldwide impact on people of all ages. Although data from China and the United States indicate that pediatric cases often have a mild course and are less severe in comparison to adults, there have been several cases of kidney failure and multisystem inflammatory syndrome reported. As such, we believe that the world should be prepared if the severity of cases begins to further increase within the pediatric population. Therefore, we provide here a position paper centered on emergency preparation with resource allocation for critical COVID-19 cases within the pediatric population, specifically where renal conditions worsen due to the onset of AKI.
C1 [Raina, Rupesh; Chakraborty, Ronith] Cleveland Clin Akron Gen, Akron Nephrol Associates, Dept Nephrol, Akron, OH 44307 USA.
   [Raina, Rupesh] Akron Childrens Hosp, Dept Nephrol, Akron, OH 44308 USA.
   [Sethi, Sidharth Kumar] Medicity Hosp, Medanta, Kidney & Urol Inst, Pediat Nephrol & Pediat Kidney Transplantat, Gurgaon, India.
   [Bunchman, Timothy] Virginia Commonwealth Univ, Childrens Hosp Richmond, Pediat Nephrol & Transplantat, Richmond, VA USA.
RP Raina, R (corresponding author), Cleveland Clin Akron Gen, Akron Nephrol Associates, Dept Nephrol, Akron, OH 44307 USA.; Raina, R (corresponding author), Akron Childrens Hosp, Dept Nephrol, Akron, OH 44308 USA.
EM rraina@akronchildrens.org
CR Ankawi G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2181-z
   [Anonymous], 2020, HAN ARCH 00432
   [Anonymous], 2020, COVID 19 CYTOSORB TH
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Baxter Obtains U.S, 2020, FDA EM US AUTH OX BL
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   BONNARDEAUX A, 1992, AM J KIDNEY DIS, V19, P31, DOI 10.1016/S0272-6386(12)70199-3
   Bunchman TE, 2003, AM J KIDNEY DIS, V42, P1248, DOI 10.1053/j.ajkd.2003.08.026
   Chen H, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0675-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Dallan C, 2020, LANCET CHILD ADOLESC, V4, pE21, DOI 10.1016/S2352-4642(20)30164-4
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Ghani RA, 2006, NEPHROLOGY, V11, P386, DOI 10.1111/j.1440-1797.2006.00600.x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han F, 2015, AM J MED SCI, V349, P199, DOI 10.1097/MAJ.0000000000000379
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   John JC, 2019, KIDNEY RES CLIN PRAC, V38, P455, DOI 10.23876/j.krcp.19.060
   Kacar CK, 2020, BLOOD PURIFICAT, V49, P448, DOI 10.1159/000505565
   Karkar A, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0648-y
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Li Z, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3559601, DOI 10.2139/SSRN.3559601]
   Liu CB, 2017, EXP THER MED, V14, P3093, DOI 10.3892/etm.2017.4843
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Maxvold NJ, 2000, CRIT CARE MED, V28, P1161, DOI 10.1097/00003246-200004000-00041
   MEHTA RL, 1990, KIDNEY INT, V38, P976, DOI 10.1038/ki.1990.300
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Peng L, 2020, 2019 NOVEL CORONAVIR, DOI [10.1101/2020.02.21.20026179., DOI 10.1101/2020.02.21.20026179]
   Raina R, 2020, NAT REV NEPHROL, V16, P471, DOI 10.1038/s41581-020-0267-8
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Ronco C, 2003, ARTIF ORGANS, V27, P792, DOI 10.1046/j.1525-1594.2003.07289.x
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Song JC, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00247-7
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XF, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0287-0
   Yang Wenmin, 2016, Glob Pediatr Health, V3, p2333794X16645699, DOI 10.1177/2333794X16645699
   Yang Y, 2020, EFFECT CONTINUOUS RE, DOI [10.1101/2020.03.16.20036780., DOI 10.1101/2020.03.16.20036780]
   You B, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2095-9
   Zhang G, 2020, CLIN FEATURES OUTCOM, DOI [10.1101/2020.03.02.20030452, DOI 10.1101/2020.03.02.20030452]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zick M, 2020, CAN COVID 19 CAUSE S
NR 49
TC 1
Z9 1
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD JUL 3
PY 2020
VL 8
AR 413
DI 10.3389/fped.2020.00413
PG 9
WC Pediatrics
SC Pediatrics
GA MR9RS
UT WOS:000553927100001
PM 32719758
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Salimi, A
   ElHawary, H
   Diab, N
   Smith, L
AF Salimi, Ali
   ElHawary, Hassan
   Diab, Nermin
   Smith, Lee
TI The North American Layman's Understanding of COVID-19: Are We Doing
   Enough?
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; coronavirus; pandemic; public health; global health;
   knowledge; risk perception; behavior
ID RISK PERCEPTION; SARS; EPIDEMIC; OUTBREAK
AB Background:In the absence of an effective vaccine, public health policies are aimed at awareness, and education of the general public in order to contain the quickly spreading COVID-19 pandemic. Most of the recommended precautionary measures are dependent on human behaviors and therefore their effectiveness largely depends on peoples' perception and attitudes toward the disease. This study aimed to assess the level of knowledge, risk perception, and precautionary measures taken in response to COVID-19 in North America. Methods:In this cross-sectional observational study, an online survey targeted to North Americans focused on the public's knowledge of COVID-19, risk perception, and precautionary behaviors taken in response to this pandemic. Descriptive analyses were performed for the whole population and the subgroup analyses contrasted the differences between Americans and Canadians. Results:The cohort comprised 1,264 relatively young participants with an average age of 28.6 +/- 9.8 years. The vast majority (>90%) were knowledgeable about COVID-19. Regarding risk perception, about a quarter assumed to be at less risk to contract the disease, and 42.8% considered themselves to be less contagious than others. While the vast majority avoided performing risky behaviors, only a small proportion (13.2%) wore a face mask-which is in line with the public health recommendations of the two countries at the time of data collection. Overall, a larger proportion of Canadian participants (55.8%) were satisfied with the performance of their national public health in response to the current pandemic, compared to their American counterparts (12.2%). Discussion:Data regarding the public's knowledge of COVID-19, risk perception, and behaviors in response to this pandemic is limited. The results of this study highlight that this relatively young and educated sample of North Americans had a high level of knowledge about COVID-19 and a large proportion of them were taking the precautionary measures against this pandemic. However, a significant number of individuals believe to be at less risk of contracting the disease compared to the general population. Educating the public that no one is safe from this disease, could play a role in further limiting risky behaviors and ultimately facilitating disease containment.
C1 [Salimi, Ali] McGill Univ, Fac Med, Dept Ophthalmol, Montreal, PQ, Canada.
   [ElHawary, Hassan] McGill Univ, Fac Med, Div Plast & Reconstruct Surg, Montreal, PQ, Canada.
   [Diab, Nermin] Univ Toronto, Fac Med, Div Respirol, Toronto, ON, Canada.
   [Smith, Lee] Anglia Ruskin Univ, Cambridge Ctr Sport & Exercise Sci, Cambridge, England.
RP Salimi, A (corresponding author), McGill Univ, Fac Med, Dept Ophthalmol, Montreal, PQ, Canada.
EM ali.salimi@mail.mcgill.ca
RI Salimi, Ali/AAG-9670-2020
OI Salimi, Ali/0000-0003-0016-3478
CR Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   Brug J, 2009, INT J BEHAV MED, V16, P3, DOI 10.1007/s12529-008-9000-x
   Chen W, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P239, DOI 10.3760/cma.j.issn.0253-9624.2020.03.003
   Davis MDM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1756-8
   de Zwart O, 2009, INT J BEHAV MED, V16, P30, DOI 10.1007/s12529-008-9008-2
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Ing E B, 2020, Occup Med (Lond), V70, P370, DOI 10.1093/occmed/kqaa088
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Lau JTF, 2003, J EPIDEMIOL COMMUN H, V57, P864, DOI 10.1136/jech.57.11.864
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu XP, 2020, INFLUENZA OTHER RESP, V14, P472, DOI 10.1111/irv.12740
   Macdonald S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5341-9
   Morrell RW, 2000, HUM FACTORS, V42, P175, DOI 10.1518/001872000779656444
   Public Health Agency of Canada, 2020, COR DIS COVID 19 PRE
   Tuite AR, 2020, ANN INTERN MED, V172, P699, DOI 10.7326/M20-0696
   Vartti AM, 2009, INT J BEHAV MED, V16, P41, DOI 10.1007/s12529-008-9004-6
   Wang Q, 2020, INFECT CONT HOSP EP, V41, P746, DOI 10.1017/ice.2020.83
   Weinstein ND, 2005, TOB CONTROL, V14, P55, DOI 10.1136/tc.2004.008375
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Yang S, 2017, AM J INFECT CONTROL, V45, pE53, DOI 10.1016/j.ajic.2017.02.013
NR 26
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUL 3
PY 2020
VL 8
AR 358
DI 10.3389/fpubh.2020.00358
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MR8KH
UT WOS:000553839300001
PM 32719768
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Assenza, G
   Lanzone, J
   Brigo, F
   Coppola, A
   Di Gennaro, G
   Di Lazzaro, V
   Ricci, L
   Romigi, A
   Tombini, M
   Mecarelli, O
AF Assenza, Giovanni
   Lanzone, Jacopo
   Brigo, Francesco
   Coppola, Antonietta
   Di Gennaro, Giancarlo
   Di Lazzaro, Vincenzo
   Ricci, Lorenzo
   Romigi, Andrea
   Tombini, Mario
   Mecarelli, Oriano
TI Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors
   for Seizure Worsening
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE epilepsy; COVID-19; sleep; depression; anxiety
ID GENERALIZED ANXIETY DISORDER; SLEEP QUALITY INDEX; OVERTREATMENT;
   EPIDEMIOLOGY; DEPRIVATION; PREVALENCE; COMMUNITY; PEOPLE; AGE
AB Objective:In early 2020, Italy struggled with an unprecedented health emergency related to the COVID-19 pandemic. Medical care of chronic neurological diseases, such as epilepsy, is being sorely neglected. In this national survey, we aimed at understanding the impact of COVID-19 lockdown on the care of people with epilepsy (PwE) and identifying PwE risk factors for seizure worsening to direct telemedicine efforts. Methods:We administered a 48-items online survey (published on April 11, 2020) including socio-demographic, epilepsy-related, and psychometric variables (BDI-II for depression, GAD-7 for anxiety, and PSQI for sleep) to PwE and people without epilepsy (PwoE). Regression analysis identified predictors of seizure worsening. Results:We collected responses from 456 PwE (344 females) and 472 PwoE (347 females). Outpatient examinations of PwE were postponed in 95% of cases. One-third of PwE complained of issues with epilepsy management, but only 71% of them reached the treating physician and solved their problems. PwE had worse depressive and anxiety symptoms (higher BDI-II and GAD-7 scores;p< 0.001) than PwoE. Sleep quality was equally compromised in both groups (47 and 42%). Sixty-seven PwE (18%) reported seizure worsening, which was best explained by the number of anti-seizure medications (ASM) of chronic therapy and the severity of sleep disorder. Conclusions:During the current COVID-19 pandemic, a significant percentage of PwE experienced difficulties in follow-up and a seizure number increase, in particular those chronically taking more ASMs and with poor sleep quality. This dramatic experience outlines the urgent need for validation and implementation of telemedicine services for epileptic patients in order to provide regular follow-up.
C1 [Assenza, Giovanni; Lanzone, Jacopo; Di Lazzaro, Vincenzo; Ricci, Lorenzo; Tombini, Mario] Univ Campus Biomed Rome, Unit Neurol, Dept Med, Neurophysiol,Neurobiol, Rome, Italy.
   [Brigo, Francesco] Franz Tappeiner Hosp, Div Neurol, Merano, Italy.
   [Coppola, Antonietta] Univ Federico II Naples, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy.
   [Di Gennaro, Giancarlo] IRCCS NEUROMED, Epilepsy Surg Ctr, Pozzilli, Italy.
   [Romigi, Andrea] IRCCS NEUROMED, Sleep Med Ctr, Pozzilli, Italy.
   [Mecarelli, Oriano] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
RP Assenza, G (corresponding author), Univ Campus Biomed Rome, Unit Neurol, Dept Med, Neurophysiol,Neurobiol, Rome, Italy.
EM g.assenza@unicampus.it
RI Lanzone, Jacopo/AAN-8566-2020
OI Lanzone, Jacopo/0000-0001-7217-6281
CR Alexandre V, 2011, EPILEPTIC DISORD, V13, P56, DOI 10.1684/epd.2011.0411
   Beck A. T., 1996, BECK DEPRESSION INVE, V78, P490, DOI DOI 10.1037/T00742-000
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Chou KL, 2011, J CLIN PSYCHIAT, V72, P1468, DOI 10.4088/JCP.10m06019gry
   Curcio G, 2013, NEUROL SCI, V34, P511, DOI 10.1007/s10072-012-1085-y
   Daley JT, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0534-1
   EASTWOOD MR, 1978, ARCH GEN PSYCHIAT, V35, P769
   Fisher RS, 2012, EPILEPSY BEHAV, V24, P304, DOI 10.1016/j.yebeh.2012.04.128
   Frucht MM, 2000, EPILEPSIA, V41, P1534
   Gemignani A, 2014, INT J PSYCHOPHYSIOL, V93, P211, DOI 10.1016/j.ijpsycho.2014.04.008
   Gutter T, 2019, SEIZURE-EUR J EPILEP, V69, P298, DOI 10.1016/j.seizure.2019.04.019
   Holt K, 2013, EUR J COMMUN, V28, P19, DOI 10.1177/0267323112465369
   Khan S, 2018, INT J GENOMICS, V2018, DOI 10.1155/2018/8576890
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Madrid-Valero JJ, 2017, GAC SANIT, V31, P18, DOI 10.1016/j.gaceta.2016.05.013
   Malek N, 2017, ACTA NEUROL SCAND, V135, P507, DOI 10.1111/ane.12703
   Malhi GS, 2018, LANCET, V392, P2299, DOI 10.1016/S0140-6736(18)31948-2
   Manganotti P, 2006, J NEUROL NEUROSUR PS, V77, P56, DOI 10.1136/jnnp.2004.041137
   Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009
   Neufeld M Y, 1994, Seizure, V3, P135, DOI 10.1016/S1059-1311(05)80204-3
   Perucca E, 2005, CNS DRUGS, V19, P897, DOI 10.2165/00023210-200519110-00001
   PRATT KL, 1968, ELECTROEN CLIN NEURO, V24, P11, DOI 10.1016/0013-4694(68)90061-8
   Ramsawh HJ, 2009, J PSYCHIATR RES, V43, P926, DOI 10.1016/j.jpsychires.2009.01.009
   Ribot R, 2019, EPILEPSY BEHAV, V98, P298, DOI 10.1016/j.yebeh.2019.01.026
   Ruscio AM, 2017, JAMA PSYCHIAT, V74, P465, DOI 10.1001/jamapsychiatry.2017.0056
   Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Swinkels WAM, 1998, EPILEPSIA, V39, P1203, DOI 10.1111/j.1528-1157.1998.tb01312.x
   Tombini M, 2020, EPILEPSY BEHAV, V107, DOI 10.1016/j.yebeh.2020.107073
   Tombini M, 2019, EPILEPSY BEHAV, V98, P66, DOI 10.1016/j.yebeh.2019.06.026
   Pham T, 2017, EPILEPSIA, V58, pE107, DOI 10.1111/epi.13817
   Tsuno N, 2005, J CLIN PSYCHIAT, V66, P1254, DOI 10.4088/JCP.v66n1008
NR 32
TC 11
Z9 11
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD JUL 3
PY 2020
VL 11
AR 737
DI 10.3389/fneur.2020.00737
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MR8MD
UT WOS:000553844100001
PM 32719655
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Scheirer, W
AF Scheirer, Walter
TI A pandemic of bad science
SO BULLETIN OF THE ATOMIC SCIENTISTS
LA English
DT Article
DE Pseudoscience; disinformation; predatory journals; preprint servers;
   coronavirus; photo editing
ID CORONAVIRUS
AB What can epidemiological models tell us about our potential exposure to COVID-19? What progress is being made with regard to coronavirus vaccine development? These days, the general public is asking these questions and more as the COVID-19 pandemic rages on. That there is an extraordinary level of interest in coronavirus news should come as no surprise, but this elevated interest society now has in pandemic-related science has unintended consequences that shouldn't be ignored. Studies are being rushed to publication even in well-regarded journals. Unvetted articles on so-called preprint servers have received enormous attention. Predatory journals are giving anyone with the ability to pay the opportunity to publish pseudoscience that can be amplified by mainstream news sources. Marketers are exploiting the public's desperation for protection against COVID-19 and adding a scientific sheen to dubious products. And perhaps-well-meaning experts in data science are producing a raft of arguably meaningless research, creating a distraction at best and wasting valuable resources at worst.
C1 [Scheirer, Walter] Univ Notre Dame, Dept Comp Sci & Engn, Notre Dame, IN 46556 USA.
RP Scheirer, W (corresponding author), Univ Notre Dame, Dept Comp Sci & Engn, Notre Dame, IN 46556 USA.
EM walter.scheirer@nd.edu
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, REUTERS
   [Anonymous], 2020, BEW FRAUD COR TESTS
   [Anonymous], 2020, NY TIMES
   Atwater AL, 2020, PALAEONTOL ELECTRON, V23, DOI 10.26879/993
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Beall's List, 2019, POTENTIAL PREDATORY
   Bengio Y., 2020, PEER TO PEER AI TRAC
   Berruyer O., 2020, LES CRISES      0415
   C-SPAN, 2020, DEF DEP BRIEF COR RE
   Callaway E., 2020, NATURE
   Caltech, 2020, OP ACC PRED PUBL QUE
   Channel Fox News, 2020, FOX NEWS CHANNEL
   Collins V., 2020, FORBES
   Crim F. F., 2020, DEAR COLL LETT CORON
   David R., 2020, WHATS WRONG COVID 19
   de Jesus E. G., 2020, SCI
   Fetters K. A., 2019, US NEWS WEEKLY  0927
   Green A, 2020, LANCET, V395, P682, DOI 10.1016/S0140-6736(20)30382-2
   Grudniewicz A, 2019, NATURE, V576, P210, DOI 10.1038/d41586-019-03759-y
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jeung R., 2020, NEWS ACCOUNTS COVID
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Kaggle, 2020, COVID 19 OP RES DAT
   Kelland K, 2020, REUTERS
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lubba C., 2015, 4 CULT HIGHL PAL YOU
   Marantz A., 2020, NEW YORKER
   Margolin J., 2020, ABC NEWS
   Mas L., 2020, FRANCE 24
   Matt, 2020, KNOW YOUR MEME
   Mehta A, 2018, DEFENSE NEWS
   Palmer James., 2020, FOREIGN POLICY
   Philippe G., 2020, HYDROXYCHLOROQUINE A
   RT, 2020, RT              0124
   Rupera P., 2020, TIMES INDIA
   Saharan P., 2020, ACTA SCI MICROBIOLOG, V3, P188, DOI [10.31080/ASMI.2020.03.0567, DOI 10.31080/ASMI.2020.03.0567]
   Sciama Y., 2020, SCIENCE
   St Cavish C, 2020, LOS ANGELES TIMES
   U.S. Health and Human Services Department, 2020, HHS ANN UPC FUND ACT
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   Woolley S. C., 2019, COMPUTATIONAL PROPAG
   Xiang J., 2020, POTENTIAL BIOCH MARK, DOI DOI 10.1101/2020.03.19.20034447V1
   Yale, 2020, CHOOS J PUBL ART LIS
   Yankoski M, 2020, B ATOM SCI, V76, P85, DOI 10.1080/00963402.2020.1728976
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 47
TC 0
Z9 0
U1 6
U2 6
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0096-3402
EI 1938-3282
J9 B ATOM SCI
JI Bull. Atom. Scient.
PD JUL 3
PY 2020
VL 76
IS 4
BP 175
EP 184
DI 10.1080/00963402.2020.1778361
PG 10
WC International Relations; Social Issues
SC International Relations; Social Issues
GA MN0KS
UT WOS:000550535700003
OA Bronze
DA 2021-01-01
ER

PT J
AU Ancy, I
   Sivanandam, M
   Kumaradhas, P
AF Ancy, Iruthayaraj
   Sivanandam, Mugudeeswaran
   Kumaradhas, Poomani
TI Possibility of HIV-1 protease inhibitors-clinical trial drugs as
   repurposed drugs for SARS-CoV-2 main protease: a molecular docking,
   molecular dynamics and binding free energy simulation study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-COV-2M(pro); HIV-1 protease clinical trial drugs; drug repurposing;
   molecular docking; molecular dynamics; binding free energy
AB Initially, the SARS-CoV-2 virus was emerged from Wuhan, China and rapidly spreading across the world and urges the scientific community to develop antiviral therapeutic agents. Among several strategies, drug repurposing will help to react immediately to overcome the COVID-19 pandemic. In the present study, we have chosen two clinical trial drugs against HIV-1 protease namely, TMB607 and TMC310911 to use as the inhibitors of SARS-CoV-2 main protease (M-pro) enzyme. To make use of these two inhibitors as the repurposed drugs for COVID-19, it is essential to know the molecular basis of the binding mechanism of these two molecules with the SARS-CoV-2 M-pro. To understand the binding mechanism, we have performed molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations against the SARS-CoV-2 M-pro. The docking results indicate that both molecules form intermolecular interactions with the active site amino acids of M(pro)enzyme. However, during the MD simulations, TMB607 forms strong interaction with the key amino acids of M-pro, and remains intact. The RMSD and RMSF values of both complexes were stable throughout the MD simulations. The MM-GBSA binding free energy values of both complexes are -43.7 and -34.9 kcal/mol, respectively. Thisin silicostudy proves that the TMB607 molecule binds strongly with the SARS-CoV-2 M(pro)enzyme and it may be suitable for the drug repurposing of COVID-19 and further drug designing. Communicated by Ramaswamy H. Sarma
C1 [Ancy, Iruthayaraj; Sivanandam, Mugudeeswaran; Kumaradhas, Poomani] Periyar Univ, Dept Phys, Lab Biocrystallog & Computat Mol Biol, Salem 636011, India.
RP Ancy, I (corresponding author), Periyar Univ, Dept Phys, Lab Biocrystallog & Computat Mol Biol, Salem 636011, India.
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   ADEOYE AO, 2020, J BIOMOL STRUCT 0514, DOI DOI HTTPS://DOI.ORG/10.1080/07391102.2020.1765876
   ALKHAFAJI K, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764392
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bolcato G, RES SQ, P1, DOI [10.21203/rs.3.rs-20948/v1, DOI 10.21203/RS.3.RS-20948/V1]
   BOOPATHI S, 2020, J BIOMOL STRUCT 0429, DOI DOI https://doi.org/10.1080/07391102.2020.1758788
   Case D. A., 2014, AMBER 14
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Daniel RR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI DOI 10.1021/ct400341p
   DAS S, 2020, J BIOMOL STRUCT 0511, DOI DOI https://doi.org/10.1080/07391102.2020.1763201
   Dassault Systemes BIOVIA, 2017, DISC STUD MOD ENV RE
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   ENMOZHI SK, 2020, J BIOMOL STRUCT 0504, DOI DOI https://doi.org/10.1080/07391102.2020.1760136
   Frisch M. J., 2004, GAUSSIAN 03 REVISION
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   ISLAM R, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1761883
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jinzi J., 2006, 46 ANN ICAAC INT C A
   Jones A, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3626941
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   KUMAR D, 2020, J BIOMOL STRUCT 0503, DOI DOI https://doi.org/10.1080/07391102.2020.1752310
   Li-Sheng W., 2020, INT J ANTIMICROB AG, V55, P105948, DOI 10.1016/j.ijantimicag.2020
   LOBOGALO N, 2020, J BIOMOL STRUCT 0513, DOI DOI https://doi.org/10.1080/07391102.2020.1764393
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Martyna GJ, 1999, J CHEM PHYS, V110, P3275, DOI 10.1063/1.478193
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Parr R.G., 1989, DENSITY FUNCTIONAL T
   Stellbrink HJ, 2014, JAIDS-J ACQ IMM DEF, V65, P283, DOI 10.1097/QAI.0000000000000003
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   WAHEDI HM, 2020, J BIOMOL STRUCT 0507, DOI DOI https://doi.org/10.1080/07391102.2020.1762743
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yamamoto N., 2020, BIORXIV, DOI [10.1101/2020.04.06.026476, DOI 10.1101/2020.04.06.026476]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou L, 2006, J MED CHEM, V49, P3440, DOI 10.1021/jm0602357
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 2
Z9 2
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1786459
EA JUL 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MI8MI
UT WOS:000547654200001
PM 32627689
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gao, Q
   Bao, LL
   Mao, HY
   Wang, L
   Xu, KW
   Yang, MN
   Li, YJ
   Zhu, L
   Wang, N
   Lv, Z
   Gao, H
   Ge, XQ
   Kan, B
   Hu, YL
   Liu, JN
   Cai, F
   Jiang, DY
   Yin, YH
   Qin, CF
   Li, J
   Gong, XJ
   Lou, XY
   Shi, W
   Wu, DD
   Zhang, HM
   Zhu, L
   Deng, W
   Li, YR
   Lu, JX
   Li, CG
   Wang, XX
   Yin, WD
   Zhang, YJ
   Qin, C
AF Gao, Qiang
   Bao, Linlin
   Mao, Haiyan
   Wang, Lin
   Xu, Kangwei
   Yang, Minnan
   Li, Yajing
   Zhu, Ling
   Wang, Nan
   Lv, Zhe
   Gao, Hong
   Ge, Xiaoqin
   Kan, Biao
   Hu, Yaling
   Liu, Jiangning
   Cai, Fang
   Jiang, Deyu
   Yin, Yanhui
   Qin, Chengfeng
   Li, Jing
   Gong, Xuejie
   Lou, Xiuyu
   Shi, Wen
   Wu, Dongdong
   Zhang, Hengming
   Zhu, Lang
   Deng, Wei
   Li, Yurong
   Lu, Jinxing
   Li, Changgui
   Wang, Xiangxi
   Yin, Weidong
   Zhang, Yanjun
   Qin, Chuan
TI Development of an inactivated vaccine candidate for SARS-CoV-2
SO SCIENCE
LA English
DT Article
ID CORONAVIRUS
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
C1 [Gao, Qiang; Wang, Lin; Li, Yajing; Ge, Xiaoqin; Hu, Yaling; Cai, Fang; Jiang, Deyu; Yin, Yanhui; Li, Jing; Gong, Xuejie; Wu, Dongdong; Zhang, Hengming; Zhu, Lang; Li, Yurong; Yin, Weidong] Sinovac Biotech Ltd, Beijing, Peoples R China.
   [Bao, Linlin; Gao, Hong; Liu, Jiangning; Deng, Wei; Qin, Chuan] Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Key Lab Human Dis Comparat Med,Chinese Minist Hlt, Beijing, Peoples R China.
   [Bao, Linlin; Gao, Hong; Liu, Jiangning; Deng, Wei; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China.
   [Mao, Haiyan; Lou, Xiuyu; Shi, Wen; Zhang, Yanjun] Zhejiang Prov Ctr Dis Control & Prevent, Dept Microbiol, Hangzhou, Peoples R China.
   [Xu, Kangwei; Li, Changgui] Natl Inst Food & Drug Control, Div Resp Virus Vaccines, Beijing, Peoples R China.
   [Yang, Minnan; Zhu, Ling; Wang, Nan; Lv, Zhe; Wang, Xiangxi] Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Natl Lab Macromol, Beijing, Peoples R China.
   [Kan, Biao; Lu, Jinxing] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China.
   [Qin, Chengfeng] Acad Mil Med Sci, Inst Microbiol & Epidemiol, Beijing, Peoples R China.
RP Yin, WD (corresponding author), Sinovac Biotech Ltd, Beijing, Peoples R China.; Qin, C (corresponding author), Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, Key Lab Human Dis Comparat Med,Chinese Minist Hlt, Beijing, Peoples R China.; Qin, C (corresponding author), Peking Union Med Coll, Comparat Med Ctr, Beijing, Peoples R China.; Zhang, YJ (corresponding author), Zhejiang Prov Ctr Dis Control & Prevent, Dept Microbiol, Hangzhou, Peoples R China.; Li, CG (corresponding author), Natl Inst Food & Drug Control, Div Resp Virus Vaccines, Beijing, Peoples R China.; Wang, XX (corresponding author), Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Natl Lab Macromol, Beijing, Peoples R China.; Lu, JX (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China.
EM lujinxing@icdc.cn; changguili@aliyun.com; xiangxi@ibp.ac.cn;
   yinwd@sinovac.com; yjzhang@cdc.zj.cn; qinchuan@pumc.edu.cn
RI Qin, Cheng-Feng/I-6839-2019; qin, chuan/ABG-4508-2020; kangwei,
   xu/B-2185-2018
OI Qin, Cheng-Feng/0000-0002-0632-2807; kangwei, xu/0000-0002-1375-0586;
   Wang, Nan/0000-0002-9936-9179; LV, zhe/0000-0001-5777-1605
FU National Key Research and Development Program [2020YFC0842100,
   2020YFA0707500]; CAMS initiative for Innovative Medicine of China
   [2016-I2M-2-006]; National Key Research and Development Project of China
   [2016YFD0500304]; Zhejiang Province Science and Technology Major Project
   [2020C03124]; Beijing science and technology plan [Z201100005420006];
   Ten Thousand Talent Program; NSFS Innovative Research Group [81921005];
   Strategic Priority Research ProgramChinese Academy of Sciences
   [XDB29010000]; National Mega projects of China for Major Infectious
   Diseases [2017ZX10304402]
FX This work was supported by the National Key Research and Development
   Program (2020YFC0842100, 2020YFA0707500), the Strategic Priority
   Research Program (XDB29010000), the CAMS initiative for Innovative
   Medicine of China (Grant No. 2016-I2M-2-006), National Mega projects of
   China for Major Infectious Diseases (2017ZX10304402), National Key
   Research and Development Project of China (Grant No. 2016YFD0500304),
   Zhejiang Province Science and Technology Major Project (2020C03124), and
   the Beijing science and technology plan (Z201100005420006). X.W. was
   supported by the Ten Thousand Talent Program and the NSFS Innovative
   Research Group (grant no. 81921005).
CR Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Liu L., 2020, PRELIMINARY STUDY SE
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Miller J, 2001, PERCEPT PSYCHOPHYS, V63, P1399, DOI 10.3758/BF03194551
   Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Sabuzi F, 2020, MOLECULES, V25, DOI 10.3390/molecules25010133
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   Tseng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053096
   Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125
   Wang N, 2019, SCIENCE, V366, P640, DOI 10.1126/science.aaz1439
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Yu GC, 2017, METHODS ECOL EVOL, V8, P28, DOI 10.1111/2041-210X.12628
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zhao JC, 2015, J VIROL, V89, P6117, DOI 10.1128/JVI.00446-15
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 24
TC 156
Z9 151
U1 48
U2 63
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUL 3
PY 2020
VL 369
IS 6499
BP 77
EP +
DI 10.1126/science.abc1932
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK4IZ
UT WOS:000548751700048
PM 32376603
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Nasb, M
   Shah, ZAS
   Huang, LJ
   Li, Q
   Chen, H
AF Nasb, Mohammad
   Sayed Shah, Zulfiqar Ali
   Huang, Liangjiang
   Li, Qian
   Chen, Hong
TI The curative effects of shortwave diathermy on treating Novel
   coronavirus (COVID-19) pneumonia: A structured summary of a study
   protocol for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; Randomised controlled trial; Protocol; Coronavirus; Ultra
   short-wave diathermy; Pneumonia
AB Objectives To evaluate the therapeutic effects of ultra-short-wave diathermy (SWD) on COVID-19 pneumonia. The hypothesis is that SWD may minimise pneumonic inflammation and shorten the duration of the time to positive-to-negative conversion of COVID-19 nucleic acid test. Trial design This is a single centre, 2-arm (1:1 ratio), evaluator blinded, parallel group design superiority randomised, controlled clinical trial. Participants The inclusion criteria were: (1) Age 18-65 years, (2) COVID-19 nucleic acid test is positive, (3) Lung CT showed multiple patchy ground glass shadows or other typical manifestations of both lungs. The exclusion criteria were: (1) Patients who need ICU management, (2) Positive tests for other pathogens such as Tuberculosis, Mycoplasma, (3) Patients with respiratory failure or requiring mechanical ventilation, (4) Patients with metal implants or pacemakers, (5) Those with shock (6) Those that have bleeding tendency or active bleeding in the lungs, (7) Patients with multiple organ failure who need ICU monitoring and treatment, (8) Cancer patients and those with severe underlying diseases, (9) Pregnant or lactating women, (10) Patients with severe cognitive impairment who cannot follow the instructions to complete the treatment, (11) Those without signed informed consent and (12) Those with other contraindications to short wave. This study will be conducted in Tongji Hospital, Caidian, Wuhan, People's Republic of China. Intervention and comparator The experimental group will be given the nationally recommended standard medical treatment + ultra-short-wave diathermy treatment. Ultra-short-wave therapy treatment will be performed through application of ultra-short-wave therapy machine electrodes on the anterior and posterior parts of the trunk for 10 minutes, twice a day for 12 consecutive days. The comparator will be the control, not receiving ultra-short-wave therapy, and will be given only the nationally recommended standard medical treatment. Main outcomes The primary outcome measures will be time to positive-to-negative conversion of COVID-19 nucleic acid test by pharyngeal swab, in days assessed at 7(th), 14(th),21(st)and 28(th)days. The secondary outcome measures include nucleic acid test rate and recovery from symptoms, Vital signs assessment, Computed Tomography, Complete blood count, serum analysis and SIRS scale scores. Blinded evaluation will be at baseline (the day of starting ultra-short-wave diathermy) and after 28 days following the interventions. Randomisation A Randomization plan will be generated online onusing permuted blocks method, by a statistician who will not be part of the study. Small blocks of various sizes will be used. Patients will be randomized (1:1) between the experimental and control groups Blinding (masking) This will be an evaluator blinded study. Due to the nature of the intervention, blinding of patients and healthcare workers is not possible. Numbers to be randomised (sample size) A total of 410 patients will be randomised in 1:1 ratio to two groups: experimental group (n=205) and control group (n=205). Trial Status Protocol version 1 was approved on 02/12/2020. Recruitment for this trial began on 02/18/2020 and will be ongoing till the required sample size is reached. The analysis deadline is August 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1).
   In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2).
C1 [Nasb, Mohammad; Sayed Shah, Zulfiqar Ali; Huang, Liangjiang; Li, Qian; Chen, Hong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rehabil Med, Wuhan 430030, Peoples R China.
   [Nasb, Mohammad] Albaath Univ, Hlth Sci Fac, Dept Phys Therapy, Homs, Syria.
   [Huang, Liangjiang; Li, Qian; Chen, Hong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, WHO Collaborating Ctr Training & Res Rehabil, Wuhan 430030, Peoples R China.
RP Chen, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rehabil Med, Wuhan 430030, Peoples R China.; Chen, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, WHO Collaborating Ctr Training & Res Rehabil, Wuhan 430030, Peoples R China.
EM chenhong1129@hust.edu.cn
OI shah, sayed/0000-0002-9555-1539; Nasb, MO/0000-0002-0617-9035; Chen,
   Hong/0000-0002-8848-282X
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC)
FX The National Natural Science Foundation, an external peer-review took
   place during the funding process. The funder had no role in the design
   and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; and decision to submit the manuscript for publication.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 3
PY 2020
VL 21
IS 1
AR 609
DI 10.1186/s13063-020-04534-5
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MK4UV
UT WOS:000548784900001
PM 32620144
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Amin, M
   Abbas, G
AF Amin, Muhammad
   Abbas, Ghazanfar
TI Docking study of chloroquine and hydroxychloroquine interaction with RNA
   binding domain of nucleocapsid phospho-protein - anin silicoinsight into
   the comparative efficacy of repurposing antiviral drugs
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronaviruses; SARS-CoV-2; docking studies; chloroquine; RNA binding
   domain of nucleocapsid phosphoprotein; hydroxychloroquine
ID ACUTE RESPIRATORY SYNDROME; N-TERMINAL DOMAIN; SYNDROME-CORONAVIRUS;
   SPIKE
AB Recent outbreak of novel Coronavirus disease () pandemic around the world is associated with severe acute respiratory syndrome. The death toll associated with the pandemic is increasing day by day. SARS-CoV-2 is an enveloped virus and its N terminal domain (NTD) of Nucleocapsid protein (N protein) binds to the viral (+) sense RNA and results in virus ribonucleoprotien complex, essential for the virus replication. The N protein is composed of a serine-rich linker region sandwiched between NTD and C terminal (CTD). These terminals play a role in viral entry and its processing post entry. The NTD of SARS-CoV-2 N protein forms orthorhombic crystals and binds to the viral genome. Therefore, there is always a quest to target RNA binding domain of nucleocapsid phosphoprotein (NTD-N-protein which in turn may help in controlling diseases caused by SARS-CoV-2 in humans. The role of Chloroquine and Hydroxychloroquine as potential treatments for is still under debate globally because of some side effects associated with it. This study involves theIn silicointeractions of Chloroquine and Hydroxychloroquine with the NTD-N-protein of SARS-CoV-2. With the help of various computational methods, we have explored the potential role of both of these antiviral drugs for the treatment of patients by comparing the efficacy of both of the drugs to bind to NTD-N-protein. In our research Hydroxychloroquine exhibited potential inhibitory effects of NTD-N-protein with binding energy -7.28 kcal/mol than Chloroquine (-6.30 kcal/mol) at SARS-CoV-2 receptor recognition of susceptible cells. The outcomes of this research strongly appeal forin vivotrials of Hydroxychloroquine for the patients infected with . Furthermore, the recommended doses of Hydroxychloroquine may reduce the chances of catching to the healthcare workers and staff who are in contact with or delivering direct care to coronavirus patients as long as they have not been diagnosed with . We further hypothesize that the comparative NTD-N-protein -drug docking interactions may help to understand the comparative efficacy of other candidate repurposing drugs until discovery of a proper vaccine. Communicated by Ramaswamy H. Sarma
C1 [Amin, Muhammad; Abbas, Ghazanfar] Univ Sargodha, Dept Chem, Sargodha 40100, Pakistan.
RP Amin, M (corresponding author), Univ Sargodha, Dept Chem, Sargodha 40100, Pakistan.
EM amin.bakhsh@uos.edu.pk
OI Khan, Mobushir Riaz/0000-0002-6533-0743
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Accelrys, 2018, ACC DISC STUD
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chang C., 2020, CRYSTAL STRUCTURE RN, DOI [10.2210/pdb6vyo/pdb, DOI 10.2210/PDB6VY0/PDB]
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.2020.1751300
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Gupta MK, 2020, J BIOMOL STRUCT DYN, V38, P137, DOI 10.1080/07391102.2019.1567391
   Heng L., 2020, INT J ANTIMICROB AG, V55, P105951, DOI https://doi.org/10.1016/j.ijantimicag.2020.105951
   Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUSSAIN CM, 2020, MOD ENV ANAL TECHN, P1, DOI DOI 10.1080/07391102.2020.1762743
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Maryam E., 2020, J BIOMOLECULAR STRUC, P1, DOI [10.1080/07391102.2020.1756411, DOI 10.1080/07391102.2020.1756411]
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   Nisha M., 2020, J BIOMOLECULAR STRUC, DOI [10.1080/07391102.2020.1752802, DOI 10.1080/07391102.2020.1752802]
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Rajan D, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002655
   Robin E. F., 2020, BMJ-BRIT MED J, V369, pm1432, DOI [https://doi.org/10.1136/bmj.m1432, DOI 10.1136/BMJ.M1432]
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shing CM, 2014, EUR J APPL PHYSIOL, V114, P93, DOI 10.1007/s00421-013-2748-y
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Tan YW, 2006, NUCLEIC ACIDS RES, V34, P4816, DOI 10.1093/nar/gkl650
   Tang TK, 2005, PROTEOMICS, V5, P925, DOI 10.1002/pmic.200401204
   UPDIKE SJ, 1967, AM J MED SCI, V254, P69, DOI 10.1097/00000441-196707000-00008
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu JT, 2020, LANCET
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeng YC, 2008, BIOCHEM BIOPH RES CO, V369, P287, DOI 10.1016/j.bbrc.2008.01.096
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 57
TC 4
Z9 4
U1 3
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1775703
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MG9AH
UT WOS:000546324600001
PM 32469265
OA Bronze
DA 2021-01-01
ER

PT J
AU Makatsariya, AD
   Slukhanchuk, EV
   Bitsadze, VO
   Khizroeva, JKH
   Tretyakova, MV
   Tsibizova, VI
   Elalamy, I
   Gris, JC
   Grandone, E
   Makatsariya, NA
   Mashkova, T
AF Makatsariya, A. D.
   Slukhanchuk, E., V
   Bitsadze, V. O.
   Khizroeva, J. K. H.
   Tretyakova, M., V
   Tsibizova, V., I
   Elalamy, I
   Gris, J-C
   Grandone, E.
   Makatsariya, N. A.
   Mashkova, T.
TI Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with
   pregnancy prothrombotic state
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article; Early Access
DE COVID-19 and coagulopathy; prothrombotic state in pregnancy; thrombotic
   microangiopathy and COVID-19; DIC-syndrome; complement system activation
ID VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI;
   NEUTROPHILS; MUTATIONS; CLEAVAGE
AB For last months, humanity has faced a formidable unknown enemy, which is presented as a new coronavirus infection. Despite the fact that the causative agents of new diseases appear at a certain frequency and that the virus SARS-CoV-2 has certain common properties with its predecessors, at the moment we are dealing with a new unknown pathogenesis of the development of severe complications in patients with risk factors. A final understanding of pathological process mechanisms is the goal of the scientific community. Summarizing research data from different countries, it became obvious that in severe cases of viral infection, we are dealing with a combination of the systemic inflammatory response syndrome, disseminated intravascular coagulation and thrombotic microangiopathy (TMA). Thrombotic microangiopathy is represented by a group of different conditions in which thrombocytopenia, hemolytic anemia, and multiple organ failure occur. The article reflects the main types of TMA, pathogenesis and principles of therapy. The main participants in the process are described in detail, including the von Willebrand factor and ADAMTS-13. Based on the knowledge available, as well as new data obtained from patients with COVID-19, we proposed possible models for the implementation of conditions such as sepsis, TMA, and DIC in patients with severe new coronavirus infection. Through a deeper understanding of pathogenesis, it will be possible to develop more effective diagnosis and therapy.
C1 [Makatsariya, A. D.; Bitsadze, V. O.; Khizroeva, J. K. H.; Elalamy, I; Gris, J-C; Grandone, E.; Makatsariya, N. A.; Mashkova, T.] Sechenov Univ, IM Sechenov Moscow State Med Univ 1, Obstet & Gynecol, Moscow, Russia.
   [Slukhanchuk, E., V] Petrovsky Natl Res Ctr Surg, Gynecol Unit, Moscow, Russia.
   [Tretyakova, M., V] Med Ctr LLC, Gynecol Dept, Moscow, Russia.
   [Tsibizova, V., I] Hlth Minist Russian Federat, Almazov Natl Med Res Ctr, St Petersburg, Russia.
   [Elalamy, I] Med Sorbonne Univ, Thrombosis Ctr, Hematol Dept, Paris, France.
   [Gris, J-C] Univ Montpellier, Montpellier, France.
   [Grandone, E.] Fdn IRCCS Casa Sollievo Sofferenza, Hemostasis & Thrombosis Unit, Puglia, Italy.
RP Makatsariya, AD (corresponding author), Sechenov Univ, IM Sechenov Moscow State Med Univ 1, Dept Obstet & Gynecol, Trubetskaya Str 8-2, Moscow 119991, Russia.
EM gemostasis@mail.ru
RI ; GRIS, Jean-Christophe/AAA-2923-2019; Khizroeva, Jamilya/F-8384-2017
OI Slukhanchuk, Ekaterina/0000-0001-7441-2778; Tsibizova,
   Valentina/0000-0001-5888-0774; GRIS,
   Jean-Christophe/0000-0002-9899-9910; Khizroeva,
   Jamilya/0000-0002-0725-9686
CR Acosta CD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012323
   Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012
   Baud D, 2020, JAMA-J AM MED ASSOC, V323, P2198, DOI 10.1001/jama.2020.7233
   BRANDT JR, 1994, J PEDIATR-US, V125, P519, DOI 10.1016/S0022-3476(94)70002-8
   Cao WJ, 2008, P NATL ACAD SCI USA, V105, P7416, DOI 10.1073/pnas.0801735105
   Capanna F, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1749258
   Chaturvedi S, 2020, BLOOD, V135, P239, DOI 10.1182/blood.2019003863
   Chen JM, 2010, BLOOD, V115, P706, DOI 10.1182/blood-2009-03-213967
   Davis AK, 2009, TRANSFUSION, V49, P206, DOI 10.1111/j.1537-2995.2008.01978.x
   Di Renzo GC, 2020, AM J OBSTET GYNECOL, V223, P135, DOI 10.1016/j.ajog.2020.04.017
   Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015
   Escobar M, 2017, EMERG INFECT DIS, V23, P1777, DOI 10.3201/eid2311.170480
   Fakhouri F, 2012, CLIN J AM SOC NEPHRO, V7, P2100, DOI 10.2215/CJN.13121211
   Fontana S, 2006, VOX SANG, V90, P245, DOI 10.1111/j.1423-0410.2006.00747.x
   George JN, 2015, HEMATOL-AM SOC HEMAT, P644, DOI 10.1182/asheducation-2015.1.644
   Gragnano F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5620314
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Hovinga JAK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.20
   Hovinga JAK, 2010, BLOOD, V115, P1500, DOI 10.1182/blood-2009-09-243790
   Htet Z, 2020, J ROY COLL PHYS EDIN, V50, P25, DOI 10.4997/JRCPE.2020.107
   Hyseni A, 2014, BLOOD, V123, P2153, DOI 10.1182/blood-2013-08-508093
   Hyun J, 2009, THROMB RES, V124, P75, DOI 10.1016/j.thromres.2008.11.020
   Iijima K, 2008, CLIN EXP NEPHROL, V12, P16, DOI 10.1007/s10157-007-0007-4
   Kerchberger VE, 2020, SEMIN NEPHROL, V40, P148, DOI 10.1016/j.semnephrol.2020.01.006
   Leffler J, 2017, J INNATE IMMUN, V9, P12, DOI 10.1159/000450609
   Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
   Lenting PJ, 2012, J THROMB HAEMOST, V10, P2428, DOI 10.1111/jth.12008
   Liu X, 2020, THERAPEUTIC EFFECTS, DOI [10.1101/2020.02.27.20027557, DOI 10.1101/2020.02.27.20027557]
   Loirat C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-60
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mannucci Pier Mannuccio, 2007, Hematology Am Soc Hematol Educ Program, P121
   Martin K, 2007, CRIT CARE MED, V35, P2375, DOI 10.1097/01.CCM.0000284508.05247.B3
   Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023
   Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528
   Morrell CN, 2019, CIRC RES, V125, P520, DOI 10.1161/CIRCRESAHA.119.315601
   Noris M, 2017, AM J KIDNEY DIS, V70, P754, DOI 10.1053/j.ajkd.2017.08.005
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Page EE, 2017, BLOOD ADV, V1, P590, DOI 10.1182/bloodadvances.2017005124
   Petruzziello-Pellegrini TN, 2012, CURR OPIN NEPHROL HY, V21, P433, DOI 10.1097/MNH.0b013e328354a62e
   Poon LC, 2020, INT J GYNECOL OBSTET, V149, P273, DOI 10.1002/ijgo.13156
   Sakamaki Y, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-260
   Salvadori Maurizio, 2013, World J Nephrol, V2, P56, DOI 10.5527/wjn.v2.i3.56
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2
   Tersteeg C, 2015, ARTERIOSCL THROM VAS, V35, P2336, DOI 10.1161/ATVBAHA.115.306014
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tsai HM, 2006, ANNU REV MED, V57, P419, DOI 10.1146/annurev.med.57.061804.084505
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Wen WX, 2017, ADV THER, V34, P1245, DOI 10.1007/s12325-017-0547-2
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamashita CM, 2011, AM J PATHOL, V179, P1733, DOI 10.1016/j.ajpath.2011.06.041
   Yen YT, 2006, J VIROL, V80, P2684, DOI 10.1128/JVI.80.6.2684-2693.2006
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
DI 10.1080/14767058.2020.1786811
EA JUL 2020
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA MG9AM
UT WOS:000546325100001
PM 32627622
OA Bronze
DA 2021-01-01
ER

PT J
AU Sharma, A
   Malviya, R
   Kumar, V
   Gupta, R
   Awasthi, R
AF Sharma, Akanksha
   Malviya, Rishabha
   Kumar, Vinod
   Gupta, Ramji
   Awasthi, Rajendra
TI Severity and risk ofCOVID-19 in cancer patients: An evidence-based
   learning
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE cancer; COVID-19 virus; health care; malignancy; patient care
AB The immune system of cancer patient gets compromised because of cancer therapy, surgery, and malignancy and thus the probability of infection are increased than the general patients. Immunosuppression can expose cancer patients to serious complications which can lead to delay in diagnosis and unnecessary hospitalizations that may adversely affect the prognosis of the disease. Patients who received chemotherapy or surgery within the 30 days before novel coronavirus disease pandemic have more risk of infection than the patients who had not undergone chemotherapy or surgery.
C1 [Sharma, Akanksha; Malviya, Rishabha; Gupta, Ramji] Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Plot 02,Sector 17-A, Gautam Buddha Nagar, Uttar Pradesh, India.
   [Kumar, Vinod] BS Coll Pharm, Fatehullapur, Uttar Pradesh, India.
   [Awasthi, Rajendra] Amity Univ Uttar Pradesh, Amity Inst Pharm, Sect 125, Noida, Uttar Pradesh, India.
RP Malviya, R (corresponding author), Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Plot 02,Sector 17-A, Gautam Buddha Nagar, Uttar Pradesh, India.; Awasthi, R (corresponding author), Amity Univ Uttar Pradesh, Amity Inst Pharm, Sect 125, Noida, Uttar Pradesh, India.
EM rishabhamalviya19@gmail.com; awasthi02@gmail.com
RI Malviya, Rishabha/K-4884-2019
OI Malviya, Rishabha/0000-0003-2874-6149; Awasthi, Dr
   Rajendra/0000-0002-1286-1874; Gupta, Ramji/0000-0002-7947-705X
CR Al-Quteimat OM, 2020, AM J CLIN ONCOL-CANC, V43, P452, DOI 10.1097/COC.0000000000000712
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], 2020, WHO REPORT CORONAVIR
   [Anonymous], 2020, WHO CORONAVIRUS DIS
   Brunetti O, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00734
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kosko K., COVID 19 AFFECTS PAT
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Sahu KK, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102439
   Saini KS, 2020, LANCET HAEMATOL, V7, pE432, DOI 10.1016/S2352-3026(20)30123-X
   Singh AK, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13591
   Uzzo RG, 2020, CORONAVIRUS DIS 2019
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
NR 15
TC 3
Z9 3
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD SEP
PY 2020
VL 33
IS 5
SI SI
AR e13778
DI 10.1111/dth.13778
EA JUL 2020
PG 3
WC Dermatology
SC Dermatology
GA OB4SO
UT WOS:000545779700001
PM 32515033
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zheng, GL
   Wang, BQ
   Zhang, H
   Xie, CX
   Zhang, YH
   Wen, ZH
   Guo, QY
   Zhu, H
   Ye, GJ
   Liang, JY
   Meng, Q
   Xie, JQ
   Jiang, SH
   Liu, GJ
   Gao, WN
   Wang, YH
   Guo, YX
AF Zheng, Guilang
   Wang, Bangqin
   Zhang, Hua
   Xie, Chuxing
   Zhang, Yuehua
   Wen, Zhihong
   Guo, Qingyun
   Zhu, Hong
   Ye, Guojing
   Liang, Jiayi
   Meng, Qiong
   Xie, Jingquan
   Jiang, Suhua
   Liu, Guojun
   Gao, Wenjun
   Wang, Yanhao
   Guo, Yuxiong
TI Clinical characteristics of acute respiratory syndrome with SARS-CoV-2
   infection in children in South China
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE 2019-nCoV; children; COVID-19; SARS-CoV-2
AB Background A retrospective study was conducted to summarize the clinical information of childhood infections during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. Methods Children with SARS-CoV-2 infection in 11 hospitals from three provinces of South China were included in the study. Clinical information was collected and compared with children and adults infected by SARS-CoV-2 in Wuhan. Results In total, 52 children were enrolled, including 28 boys. The median age was 9 years (interquartile range [IQR], 4-12); 44.2% cases were of clustered occurrences, 40.4% patients had fever, 48.1% had cough, and 46.2% had a high lymphocyte count. No abnormalities were found in the liver and kidney function. Also, 82.7% of patients received antiviral therapy, but such therapy did not shorten the time to virus negativity or hospital stay (P = .082). The time to virus negativity was 12.0 days (IQR, 8.0-16.8) and hospital stay was 14.5 days (IQR, 10.3-17.9). Compared with reports in Wuhan, there were more acute upper respiratory tract infection (AURTI) and fewer pneumonia cases (P = .000). Compared with the non-ICU adult COVID-19 in Wuhan, these children's diseases were relatively mild, with fewer complications. Conclusions Children with SARS-CoV-2 infection had a mild fever, lymphocyte elevation was more common than reduction, and antiviral treatment had no obvious effect. The overall clinical manifestations were mild, and the prognosis was good.
C1 [Zheng, Guilang; Liang, Jiayi; Guo, Yuxiong] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp GDPH, Dept Pediat, Pediat Intens Care Unit, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China.
   [Wang, Bangqin; Wen, Zhihong] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Rheumatol, Nanning, Peoples R China.
   [Zhang, Hua; Zhu, Hong] Sanya Cent Hosp, Dept Pediat, Sanya, Peoples R China.
   [Xie, Chuxing] Dongguan Childrens Hosp, Pediat Resp Dept, Dongguan, Peoples R China.
   [Zhang, Yuehua] Cent South Univ, Xiangya Med Coll, Affiliated Haikou Hosp, Dept Pediat Infect Dis, Changsha, Peoples R China.
   [Guo, Qingyun] Jiangmen Cent Hosp, Dept Pediat, Jiangmen, Peoples R China.
   [Ye, Guojing] Huizhou Third Peoples Hosp, Dept Pediat, Huizhou, Peoples R China.
   [Meng, Qiong] Second Peoples Hosp Guangdong Prov, Dept Pediat, Guangzhou, Peoples R China.
   [Xie, Jingquan; Gao, Wenjun] ZhongShan Second Peoples Hosp, Comprehens Dept Liver Dis, Gangkou Town 528447, Zhongshan, Peoples R China.
   [Jiang, Suhua] First Peoples Hosp Foshan, Dept Pediat, Foshan, Peoples R China.
   [Wang, Yanhao] Ninth Peoples Hosp Dongguan, Dept Infect Dis, 88 Shaditang, Dongguan 532016, Peoples R China.
RP Guo, YX (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp GDPH, Dept Pediat, Pediat Intens Care Unit, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China.; Gao, WN (corresponding author), ZhongShan Second Peoples Hosp, Comprehens Dept Liver Dis, Gangkou Town 528447, Zhongshan, Peoples R China.; Wang, YH (corresponding author), Ninth Peoples Hosp Dongguan, Dept Infect Dis, 88 Shaditang, Dongguan 532016, Peoples R China.
EM gaowenjun888@163.com; 58121444@qq.com; 2003Kellylaw@163.com
FU Medical Scientific Research Foundation of Guangdong Province of China
   [A2017066, A2017046]; Matching funds for Distinguished Young Medical
   Talents of "Climbing" program in Guangdong, China [KJ012019451]; Natural
   Science Foundation of Guangdong Province of ChinaNational Natural
   Science Foundation of Guangdong Province [2017A030310605]
FX Medical Scientific Research Foundation of Guangdong Province of China,
   Grant/Award Numbers: A2017066, A2017046; Matching funds for
   Distinguished Young Medical Talents of "Climbing" program in Guangdong,
   China, Grant/Award Number: KJ012019451; Natural Science Foundation of
   Guangdong Province of China, Grant/Award Number: 2017A030310605
CR Cai J H, 2020, Zhonghua Er Ke Za Zhi, V58, pE002, DOI 10.3760/cma.j.issn.0578-1310.2020.0002
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   DeBiasi RL, 2020, J PEDIATR-US, V223, P199, DOI 10.1016/j.jpeds.2020.05.007
   Deng CX, 2020, INT J BIOL SCI, V16, P1676, DOI 10.7150/ijbs.45587
   Goldman RD, 2020, CAN FAM PHYSICIAN, V66, P332
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li H, 2020, DIABETES CARE, V43, pE8, DOI 10.2337/dc19-1802
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ming LL, 2020, CHIN J VIRAL DIS, V10, P82
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang SS, 2020, CLIN INFECT DIS, V71, P853, DOI 10.1093/cid/ciaa225
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P469, DOI 10.1097/INF.0000000000002700
NR 25
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD SEP
PY 2020
VL 55
IS 9
BP 2419
EP 2426
DI 10.1002/ppul.24921
EA JUL 2020
PG 8
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA MV5EU
UT WOS:000545434600001
PM 32579293
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xu, JY
   Huang, CL
   Fan, GH
   Liu, ZB
   Shang, LH
   Zhou, F
   Wang, YM
   Yu, JP
   Yang, LN
   Xie, K
   Huang, ZS
   Huang, LX
   Gu, XY
   Li, H
   Zhang, Y
   Wang, YM
   Hayden, FG
   Horby, PW
   Cao, B
   Wang, C
AF Xu, Jiuyang
   Huang, Chaolin
   Fan, Guohui
   Liu, Zhibo
   Shang, Lianhan
   Zhou, Fei
   Wang, Yeming
   Yu, Jiapei
   Yang, Luning
   Xie, Ke
   Huang, Zhisheng
   Huang, Lixue
   Gu, Xiaoying
   Li, Hui
   Zhang, Yi
   Wang, Yimin
   Hayden, Frederick G.
   Horby, Peter W.
   Cao, Bin
   Wang, Chen
TI Use of angiotensin-converting enzyme inhibitors and angiotensin II
   receptor blockers in context of COVID-19 outbreak: a retrospective
   analysis
SO FRONTIERS OF MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; hypertension; angiotensin-converting enzyme
   inhibitor; angiotensin II receptor blocker
ID RESPIRATORY-DISTRESS-SYNDROME; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS;
   ACE2; EXPRESSION; PROTEIN
AB The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%,P= 0.46), ICU admission (20% vs. 28%,P= 0.37) or invasive mechanical ventilation (18% vs. 26%,P= 0.31) between patients with or without ACEI/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available.
C1 [Xu, Jiuyang; Yu, Jiapei; Yang, Luning] Tsinghua Univ, Dept Basic Med Sci, Sch Med, Beijing 100084, Peoples R China.
   [Huang, Chaolin] Jinyintan Hosp, Dept Infect Dis, Wuhan 430030, Peoples R China.
   [Fan, Guohui; Liu, Zhibo; Shang, Lianhan; Zhou, Fei; Wang, Yeming; Xie, Ke; Huang, Zhisheng; Huang, Lixue; Gu, Xiaoying; Li, Hui; Zhang, Yi; Wang, Yimin; Cao, Bin; Wang, Chen] China Japan Friendship Hosp, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China.
   [Fan, Guohui; Liu, Zhibo; Shang, Lianhan; Zhou, Fei; Wang, Yeming; Gu, Xiaoying; Li, Hui; Zhang, Yi; Wang, Yimin; Cao, Bin; Wang, Chen] Chinese Acad Med Sci & Peking Union Med Coll, Inst Resp Med, Beijing 100730, Peoples R China.
   [Fan, Guohui; Gu, Xiaoying] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing 100029, Peoples R China.
   [Shang, Lianhan] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
   [Wang, Yeming; Xie, Ke; Huang, Lixue; Cao, Bin] Capital Med Univ, Dept Resp Med, Beijing 100029, Peoples R China.
   [Huang, Zhisheng] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing 100730, Peoples R China.
   [Hayden, Frederick G.] Univ Virginia, Dept Med, Sch Med, Charlottesville, VA 22904 USA.
   [Horby, Peter W.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford OX1 2JD, England.
   [Cao, Bin; Wang, Chen] Tsinghua Univ Peking Univ Joint Ctr Life Sci, Beijing 100084, Peoples R China.
   [Wang, Chen] Chinese Acad Engn, Beijing 100088, Peoples R China.
RP Cao, B; Wang, C (corresponding author), China Japan Friendship Hosp, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China.; Cao, B; Wang, C (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Resp Med, Beijing 100730, Peoples R China.; Cao, B (corresponding author), Capital Med Univ, Dept Resp Med, Beijing 100029, Peoples R China.; Cao, B; Wang, C (corresponding author), Tsinghua Univ Peking Univ Joint Ctr Life Sci, Beijing 100084, Peoples R China.; Wang, C (corresponding author), Chinese Acad Engn, Beijing 100088, Peoples R China.
EM caobin_ben@163.com; wangchen@pumc.edu.cn
FU Major Projects of National Science and Technology on New Drug Creation
   and Development [2020ZX09201001, 2020ZX09201012]; Chinese Academy of
   Medical Sciences (CAMS) Emergency Project of COVID-19 [2020HY320001]
FX We acknowledge all health-care workers involved in the diagnosis and
   treatment of patients in Jinyintan Hospital in Wuhan, China. This work
   was supported by Major Projects of National Science and Technology on
   New Drug Creation and Development (Nos. 2020ZX09201001 and
   2020ZX09201012); Chinese Academy of Medical Sciences (CAMS) Emergency
   Project of COVID-19 (No. 2020HY320001).
CR Abe M, 2015, J RENIN-ANGIO-ALDO S, V16, P159, DOI 10.1177/1470320314551443
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gallagher PE, 2008, AM J PHYSIOL-HEART C, V295, pH2373, DOI 10.1152/ajpheart.00426.2008
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Gu A, 2019, CLIN MED INSIGHTS-CA, V13, DOI 10.1177/1179546819839418
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang ZY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.229
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   KDIGO, 2012, CLIN PRACT GUID AC K
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lia Y, 2020, J CLIN CARDIOL, V36, P201
   Liu Jun, 2010, Biol Sex Differ, V1, P6, DOI 10.1186/2042-6410-1-6
   Liu LS, 2019, J GERIATR CARDIOL, V16, P182, DOI 10.11909/j.issn.1671-5411.2019.03.014
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Mortensen EM, 2012, CLIN INFECT DIS, V55, P1466, DOI 10.1093/cid/cis733
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Schouten LR, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0529-4
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Soro-Paavonen A, 2012, J HYPERTENS, V30, P375, DOI 10.1097/HJH.0b013e32834f04b6
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan YW, 2015, SCI CHINA LIFE SCI, V58, P208, DOI 10.1007/s11427-015-4814-7
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 50
TC 4
Z9 4
U1 10
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
PD OCT
PY 2020
VL 14
IS 5
BP 601
EP 612
DI 10.1007/s11684-020-0800-y
EA JUL 2020
PG 12
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA OF6TL
UT WOS:000545185700002
PM 32621202
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Khan, A
   Khan, M
   Saleem, S
   Babar, Z
   Ali, A
   Khan, AA
   Sardar, Z
   Hamayun, F
   Ali, SS
   Wei, DQ
AF Khan, Abbas
   Khan, Mazhar
   Saleem, Shoaib
   Babar, Zainib
   Ali, Arif
   Khan, Abdul Aziz
   Sardar, Zain
   Hamayun, Fahad
   Ali, Syed Shujait
   Wei, Dong-Qing
TI Phylogenetic Analysis and Structural Perspectives of RNA-Dependent
   RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products
SO INTERDISCIPLINARY SCIENCES-COMPUTATIONAL LIFE SCIENCES
LA English
DT Article
DE RdRp; SARs-CoV-2; Phylogenetic; Virtual screening; Simulation; Free
   energy
ID RESPIRATORY SYNDROME CORONAVIRUS; FREE-ENERGY CALCULATIONS;
   MOLECULAR-DYNAMICS; SOFTWARE; DOCKING; PROTEIN
AB Most recently, an outbreak of severe pneumonia caused by the infection of SARS-CoV-2, a novel coronavirus first identified in Wuhan, China, imposes serious threats to public health. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. Therefore, the role and inhibition of nsp12 are indispensable. A cryo-EM structure of RdRp from SARs-CoV-2 was used to identify novel drugs from Northern South African medicinal compounds database (NANPDB) by using computational virtual screening and molecular docking approaches. Considering Remdesivir as the control, 42 compounds were shortlisted to have docking score better than Remdesivir. The top 5 hits were validated by using molecular dynamics simulation approach and free energy calculations possess strong inhibitory properties than the Remdesivir. Thus, this study paved a way for designing novel drugs by decoding the architecture of an important enzyme and its inhibition with compounds from natural resources. This disclosing of necessary knowledge regarding the screening and the identification of top hits could help to design effective therapeutic candidates against the coronaviruses and design robust preventive measurements.
   [GRAPHICS]
   .
C1 [Khan, Abbas; Ali, Arif; Hamayun, Fahad; Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China.
   [Khan, Mazhar] Univ Sci & Technol China USTC, Hefei Natl Lab Phys Sci Microscale, Sch Life Sci,CAS Key Lab Innate Immun & Chron Dis, Collaborat Innovat Ctr Genet & Dev,CAS Ctr Excell, Hefei 230027, Anhui, Peoples R China.
   [Saleem, Shoaib] Quaid I Azam Univ, Natl Ctr Bioinformat, Islamabad 45320, Pakistan.
   [Babar, Zainib] Shanghai Jiao Tong Univ, Sch Agr & Biol, Ctr Viticulture & Enol, Shanghai 200240, Peoples R China.
   [Khan, Abdul Aziz] Quaid I Azam Univ, Dept Anim Sci, Islamabad 45320, Pakistan.
   [Sardar, Zain; Ali, Syed Shujait] Univ Swat, Ctr Biotechnol & Microbiol, Swat, KP, Pakistan.
   [Wei, Dong-Qing] Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Joint Lab Int Cooperat Metab & Dev Sci,Minist Edu, Shanghai 200030, Peoples R China.
   [Wei, Dong-Qing] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China.
   [Wei, Dong-Qing] Peng Cheng Lab, Vanke Cloud City Phase 1 Bldg 8,Xili St, Shenzhen 518055, Guangdong, Peoples R China.
RP Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biol Stat, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China.; Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai Islamabad Belgrade Joint Innovat Ctr Ant, Joint Lab Int Cooperat Metab & Dev Sci,Minist Edu, Shanghai 200030, Peoples R China.; Wei, DQ (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China.; Wei, DQ (corresponding author), Peng Cheng Lab, Vanke Cloud City Phase 1 Bldg 8,Xili St, Shenzhen 518055, Guangdong, Peoples R China.
EM dqwei@sjtu.edu.cn
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2016YFA0501703]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [61832019,
   61503244]; Natural Science Foundation of Henan Province [162300410060];
   Joint Research Funds for Medical and Engineering and Scientific Research
   at Shanghai Jiao Tong University [YG2017ZD14]
FX Dong-Qing Wei is supported by the grants from the Key Research Area
   Grant 2016YFA0501703 of the Ministry of Science and Technology of China,
   the National Natural Science Foundation of China (Contract No. 61832019,
   61503244), the Natural Science Foundation of Henan Province
   (162300410060) and Joint Research Funds for Medical and Engineering and
   Scientific Research at Shanghai Jiao Tong University (YG2017ZD14). The
   computations were partially performed at the Center for High-Performance
   Computing, Shanghai Jiao Tong University.
CR Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Davidchack RL, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3149788
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Dong T, 2019, MICRO NANO TECHNOL, P1
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Junaid M, 2019, J BIOMOL STRUCT DYN, V37, P4035, DOI 10.1080/07391102.2018.1537895
   Khan A, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00159
   Khan A, 2019, RSC ADV, V9, P10326, DOI 10.1039/c9ra01007f
   Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484
   Khan A, 2018, J MOL GRAPH MODEL, V82, P37, DOI 10.1016/j.jmgm.2018.03.004
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lin YQ, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978807
   Lu R, 2020, LANCET, V6736, P1, DOI DOI 10.1016/S0140-6736(20)30251-30258
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Ntie-Kang F, 2017, J NAT PROD, V80, P2067, DOI 10.1021/acs.jnatprod.7b00283
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Release S, 2017, 1 MAESTRO
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Toukmaji A, 1996, P INT C PAR DISTR PR, P33
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vassetti D, 2019, J CHEM THEORY COMPUT, V15, P1983, DOI 10.1021/acs.jctc.8b01039
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wang YQ, 2019, J BIOMOL STRUCT DYN, V37, P4051, DOI 10.1080/07391102.2018.1537896
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 42
TC 5
Z9 6
U1 5
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1913-2751
EI 1867-1462
J9 INTERDISCIP SCI
JI Interdiscip. Sci.
PD SEP
PY 2020
VL 12
IS 3
BP 335
EP 348
DI 10.1007/s12539-020-00381-9
EA JUL 2020
PG 14
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA MW5OI
UT WOS:000545053500001
PM 32617855
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Krupanidhi, S
   Peele, KA
   Venkateswarulu, TC
   Ayyagari, VS
   Bobby, MN
   Babu, DJ
   Narayana, AV
   Aishwarya, G
AF Krupanidhi, S.
   Abraham Peele, K.
   Venkateswarulu, T. C.
   Ayyagari, Vijaya Sai
   Nazneen Bobby, Md.
   John Babu, D.
   Venkata Narayana, A.
   Aishwarya, G.
TI Screening of phytochemical compounds ofTinospora cordifoliafor their
   inhibitory activity on SARS-CoV-2: anin silicostudy
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Main protease; docking; Tinospora cordifolia; tinosponone; xanosporic
   acid
ID PROTEASE
AB In the present study, we explored phytochemical constituents ofTinospora cordifoliain terms of its binding affinity targeting the active site pocket of the main protease (3CL pro) of SARS-CoV-2 using molecular docking study and assessed the stability of top docking complex of tinosponone and 3CL pro using molecular dynamics simulations with GROMACS 2020.2 version. Out of 11 curated screened compounds, we found the significant docking score for tinosponone, xanosporic acid, cardiofolioside B, tembetarine and berberine inTinospora cordifolia. Based on the findings of the docking study, it was confirmed that tinosponone is the potent inhibitor of main protease of SARS-CoV-2 with the best binding affinity of -7.7 kcal/mol. Further, ADME along with toxicity analysis was studied to predict the pharmacokinetics and drug-likeness properties of five top hits compounds. The molecular dynamics simulation analysis confirmed the stability of tinosponone and 3CL pro complex with a random mean square deviation (RMSD) value of 0.1 nm. The computer-aided drug design approach proved that the compound tinosponone fromT. cordifoliais a potent inhibitor of 3CL main protease of SARS-CoV-2. Further, thein vitroandin vivo-based testing will be required to confirm its inhibitory effect on SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Krupanidhi, S.; Abraham Peele, K.; Venkateswarulu, T. C.; Ayyagari, Vijaya Sai; Nazneen Bobby, Md.; John Babu, D.; Venkata Narayana, A.; Aishwarya, G.] Vignans Fdn Sci Technol & Res, Dept Biotechnol, Guntur, Andhra Pradesh, India.
RP Venkateswarulu, TC (corresponding author), Vignans Fdn Sci Technol & Res, Guntur 522213, Andhra Pradesh, India.
EM venki_biotech327@yahoo.com
OI Ayyagari, Vijaya Sai/0000-0001-5438-2268; Walters,
   Glenn/0000-0002-7219-1542
CR Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Joshi G, 2016, INT J PHARM SCI RES, V7, P890, DOI 10.13040/IJPSR.0975-8232.7(3).890-97
   Lauber C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003500
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   MOHANRAJ K, 2018, SCI REP UK, V8, DOI DOI https://doi.org/10.1038/s41598-018-22631-z
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Philip S, 2018, J PHARM PHARMACOL, V70, P1113, DOI 10.1111/jphp.12932
   Shanker AKK, 2020, NEW J CHEM, V44, P9202, DOI 10.1039/d0nj00974a
   Sharma P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02437
   Singh D, 2017, NAT PROD COMMUN, V12, P299
   TIWARI P, 2018, SYST REV PHARM, V9, P70, DOI DOI 10.5530/SRP.2018.1.14
   Upadhyay Avnish K, 2010, Int J Ayurveda Res, V1, P112, DOI 10.4103/0974-7788.64405
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yanez M, 2017, CURR PHARM DESIGN, V23, P6347, DOI 10.2174/1381612823666170510124348
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 17
TC 2
Z9 2
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1787226
EA JUL 2020
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MG8JQ
UT WOS:000546278000001
PM 32627715
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Quintaliani, G
   Reboldi, G
   Di Napoli, A
   Nordio, M
   Limido, A
   Aucella, F
   Messa, P
   Brunori, G
AF Quintaliani, Giuseppe
   Reboldi, Gianpaolo
   Di Napoli, Anteo
   Nordio, Maurizio
   Limido, Aurelio
   Aucella, Filippo
   Messa, Piergiorgio
   Brunori, Giuliano
CA Italian Soc Nephrology COVID-19 Re
TI Exposure to novel coronavirus in patients on renal replacement therapy
   during the exponential phase of COVID-19 pandemic: survey of the Italian
   Society of Nephrology
SO JOURNAL OF NEPHROLOGY
LA English
DT Article
DE COVID-19; Hemodialysis; Peritoneal dialysis; Renal transplant; Survey
AB Background Between February and April 2020, Italy experienced an overwhelming growth of the COVID-19 pandemic. Little is known, at the country level, where and how patients on renal replacement therapy (RRT) have been mostly affected. Methods Survey of the network of Nephrology centers using a simplified 17 items electronic questionnaire designed by Italian Society of Nephrology COVID-19 Research Group. We used spatial epidemiology and geographical information systems to map SARS-CoV-2 spread among RRT patients in Italy. Results On April 9th 2020, all nephrology centers (n = 454) listed in the DialMap database were invited to complete the electronic questionnaire. Within 11 days on average, 365 centers responded (80.4% response rate; 2.3% margin of error) totaling 60,441 RRT patients. The surveyed RRT population included 30,821 hemodialysis (HD), 4139 peritoneal dialysis (PD), and 25,481 transplanted (Tx) patients respectively. The proportion of SARS-CoV-2 positive RRT patients in Italy was 2.26% (95% CI 2.14-2.39) with significant differences according to treatment modality (p < 0.001). The proportion of patients positive for SARS-CoV-2 was significantly higher in HD (3.55% [95% CI 3.34-3.76]) than PD (1.38% [95% CI 1.04-1.78] and Tx (0.86% [95% CI 0.75-0.98]) (p < 0.001), with substantial heterogeneity across regions and along the latitude gradient (p < 0.001). In RRT patients the highest rate was in the north-west (4.39% [95% CI 4.11-4.68], followed by the north-east (IR 2.06% [1.79-2.36]), the center (0.91% [0.75-1.09]), the main islands (0.67% [0.47-0.93]), and the south (0.59% [0.45-0.75]. During the COVID-19 pandemic, among SARS-Cov-2 positive RRT patients the fatality rate was 32.8%, as compared to 13.3% observed in the Italian population as of April 23rd. Conclusions A substantial proportion of the 60,441 surveyed RRT patients in Italy were SARS-Cov-2 positive and subsequently died during the exponential phase of COVID-19 pandemic. Infection risk and rates seems to differ substantially across regions, along geographical latitude, and by treatment modality.
C1 [Quintaliani, Giuseppe; Brunori, Giuliano] Italian Soc Nephrol, Viale Univ 11, I-00185 Rome, RM, Italy.
   [Reboldi, Gianpaolo] Univ Perugia, Dept Med, Perugia, Italy.
   [Di Napoli, Anteo] Natl Inst Hlth Migrat & Poverty INMP, Rome, Italy.
   [Nordio, Maurizio] Gen Hosp, Unit Nephrol, Piazzale Osped 23, I-31100 Treviso, Italy.
   [Limido, Aurelio] ASST Fatebenefratelli & Oftalm, Nephrol & Dialysis Unit, Milan, Italy.
   [Aucella, Filippo] IRCCS Casa Sollievo Sofferenza, Nephrol & Dialysis Unit, Sci Inst Res & Hlth Care, San Giovanni Rotondo, Italy.
   [Messa, Piergiorgio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Nephrol Dialysis & Renal Transplantat, Milan, Italy.
   [Brunori, Giuliano] Hosp Trento, Nephrol & Dialysis Unit, Trento, Italy.
RP Brunori, G (corresponding author), Italian Soc Nephrol, Viale Univ 11, I-00185 Rome, RM, Italy.; Brunori, G (corresponding author), Hosp Trento, Nephrol & Dialysis Unit, Trento, Italy.
EM giuliano.brunori@apss.tn.it
RI Nordio, Maurizio/ABH-1719-2020; Di Napoli, Anteo/AAN-1659-2020
OI Nordio, Maurizio/0000-0002-9054-1593; Di Napoli,
   Anteo/0000-0003-3207-8761; Aucella, Filippo/0000-0003-1027-7049; Reis,
   AlessanRSS/0000-0001-8486-7469
CR Agarwal R, 2020, NEPHROL DIAL TRANSPL, V35, P904, DOI 10.1093/ndt/gfaa094
   Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Center for Systems Science Engineering Johns Hopkins University, 2020, COVID 19 WORLD MAP
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Cochran WG, 1977, WILEY SERIES PROBABI
   Cummings P, 2019, ANAL INCIDENCE RATES
   EpiCentro Istituto Superiore di Sanita, 2020, COVID 19 INT SURV KE
   ERA-EDTA, 2020, ERACODA ERA EDTA COV
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Fleiss Joseph L., 2003, WILEY SERIES PROBABI
   Gambaro G, 2020, J NEPHROL, V33, P633, DOI 10.1007/s40620-020-00756-7
   Gruppo di Lavoro ISS Diagnostica e sorveglianza microbiologica COVID-19, 2020, REC SAMPL STOR AN OR, P7
   Istituto Nazionale di Statistica-ISTAT, 2020, CONF UN AMM FIN STAT
   Kelley K, 2003, INT J QUAL HEALTH C, V15, P261, DOI 10.1093/intqhc/mzg031
   Kirby RS, 2017, ANN EPIDEMIOL, V27, P1, DOI 10.1016/j.annepidem.2016.12.001
   La Milia V, 2020, KIDNEY INT REP, V5, P1095, DOI 10.1016/j.ekir.2020.05.019
   Lavrakas P.J., 2008, ENCY SURVEY RES METH
   Malberti F, 2020, J NEPHROL, V33, P625, DOI 10.1007/s40620-020-00743-y
   Manganaro M, 2020, J NEPHROL, V33, P393, DOI 10.1007/s40620-020-00732-1
   Meijers B, 2020, BLOOD PURIFICAT, V49, P259, DOI 10.1159/000507537
   Moriyama Miyu, 2020, Annu Rev Virol, V7, P83, DOI 10.1146/annurev-virology-012420-022445
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rombola G, 2020, J NEPHROL, V33, P401, DOI 10.1007/s40620-020-00737-w
   Rombola G, 2020, J NEPHROL, V33, P193, DOI 10.1007/s40620-020-00727-y
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Sajadi MM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11834
   SARS-CoV-2 Surveillance Group Istituto Superiore di Sanita, 2020, CHAR COVID 19 PAT DY
   Societa Italian di Nefrologia, 2020, DIALMAP NAT MAP NEPH
   Societa Italiana di Nefrologia, 2020, SIN COV SURV PHAS 1
   Societa Italiana di Nefrologia, 2020, COR DIS COVID 19 PAN
   Vistoli F, 2020, J NEPHROL, V33, P667, DOI 10.1007/s40620-020-00755-8
   WHO, 2020, COR DIS COVID 19 PAN
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
NR 37
TC 6
Z9 6
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1121-8428
EI 1724-6059
J9 J NEPHROL
JI J. Nephrol.
PD AUG
PY 2020
VL 33
IS 4
BP 725
EP 736
DI 10.1007/s40620-020-00794-1
EA JUL 2020
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA MP2LC
UT WOS:000545192200001
PM 32621109
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Prieto-Perez, L
   Fortes, J
   Soto, C
   Vidal-Gonzalez, A
   Alonso-Riano, M
   Lafarga, M
   Cortti, MJ
   Lazaro-Garcia, A
   Perez-Tanoira, R
   Trascasa, A
   Antonio, A
   Cordoba, R
   Rodriguez-Pinilla, SM
   Cedeno, O
   Peces-Barba, G
   Fernandez-Ormaechea, I
   Medrano, MJD
   de Las Heras, ML
   Cabello, A
   Petkova, E
   Alvarez, B
   Carrillo, I
   Silva, AM
   Castellanos, M
   Calpena, S
   Valverde-Monge, M
   Fresneda, D
   Rubio-Martin, R
   Cornejo, I
   de Cordova, LAB
   de la Fuente, S
   Recuero, S
   Gorgolas, M
   Piris, MA
AF Prieto-Perez, Laura
   Fortes, Jose
   Soto, Carlos
   Vidal-Gonzalez, Anxela
   Alonso-Riano, Marina
   Lafarga, Miguel
   Cortti, Maria Jose
   Lazaro-Garcia, Alberto
   Perez-Tanoira, Ramon
   Trascasa, Alvaro
   Antonio, Anabel
   Cordoba, Raul
   Rodriguez-Pinilla, Socorro Maria
   Cedeno, Oderay
   Peces-Barba, German
   Fernandez-Ormaechea, Itziar
   Diez Medrano, Maria Jose
   Lopez de Las Heras, Marta
   Cabello, Alfonso
   Petkova, Elizabet
   Alvarez, Beatriz
   Carrillo, Irene
   Silva, Andres M.
   Castellanos, Marina
   Calpena, Silvia
   Valverde-Monge, Marcela
   Fresneda, Diana
   Rubio-Martin, Rafael
   Cornejo, Ignacio
   Astilleros Blanco de Cordova, Laura
   de la Fuente, Soraya
   Recuero, Sheila
   Gorgolas, Miguel
   Piris, Miguel A.
TI Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage
   in COVID-19 infection
SO MODERN PATHOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CYTOKINE STORM; SYNDROME SARS; PATHOLOGY
AB The spectrum of COVID-19 infection includes acute respiratory distress syndrome (ARDS) and macrophage activation syndrome (MAS), although the histological basis for these disorders has not been thoroughly explored. Post-mortem pulmonary and bone marrow biopsies were performed in 33 patients. Samples were studied with a combination of morphological and immunohistochemical techniques. Bone marrow studies were also performed in three living patients. Bone marrow post-mortem studies showed striking lesions of histiocytic hyperplasia with hemophagocytosis (HHH) in most (16/17) cases. This was also observed in three alive patients, where it mimicked the changes observed in hemophagocytic histiocytosis. Pulmonary changes included a combination of diffuse alveolar damage with fibrinous microthrombi predominantly involving small vessels, in particular the alveolar capillary. These findings were associated with the analytical and clinical symptoms, which helps us understand the respiratory insufficiency and reveal the histological substrate for the macrophage activation syndrome-like exhibited by these patients. Our results confirm that COVID-19 infection triggers a systemic immune-inflammatory disease and allow specific therapies to be proposed.
C1 [Prieto-Perez, Laura; Fortes, Jose; Soto, Carlos; Vidal-Gonzalez, Anxela; Alonso-Riano, Marina; Lafarga, Miguel; Cortti, Maria Jose; Lazaro-Garcia, Alberto; Perez-Tanoira, Ramon; Trascasa, Alvaro; Antonio, Anabel; Cordoba, Raul; Rodriguez-Pinilla, Socorro Maria; Cedeno, Oderay; Peces-Barba, German; Fernandez-Ormaechea, Itziar; Diez Medrano, Maria Jose; Lopez de Las Heras, Marta; Cabello, Alfonso; Petkova, Elizabet; Alvarez, Beatriz; Carrillo, Irene; Silva, Andres M.; Castellanos, Marina; Calpena, Silvia; Valverde-Monge, Marcela; Fresneda, Diana; Rubio-Martin, Rafael; Cornejo, Ignacio; Astilleros Blanco de Cordova, Laura; de la Fuente, Soraya; Recuero, Sheila; Gorgolas, Miguel; Piris, Miguel A.] Fdn Jimenez Diaz, Serv Med Interna, Ciberonc, UCI,Hematol,Anat,Patol, Madrid, Spain.
   [Prieto-Perez, Laura] Hosp Univ Fdn Jimenez Diaz, Div Enfermedades Infecciosas, Serv Med Interna, Madrid 28040, Spain.
RP Prieto-Perez, L (corresponding author), Fdn Jimenez Diaz, Serv Med Interna, Ciberonc, UCI,Hematol,Anat,Patol, Madrid, Spain.; Prieto-Perez, L (corresponding author), Hosp Univ Fdn Jimenez Diaz, Div Enfermedades Infecciosas, Serv Med Interna, Madrid 28040, Spain.
EM lprietope@fjd.es
OI Valverde-Monge, Marcela/0000-0002-0172-3951
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III; Ministerio
   de Economia, Industria y Competitividad [PIE15/0081, PIE16/01294];
   Ministerio de Economia, Industria y Competitividad [CIBERONCISCIII,
   ISCIII-MINECO-AES-FEDER (Plan Estatal I+D+I 2013-2016)]
   [SAF2013-47416-R]; Asociacion Espanola Contra el Cancer [AECC
   PROYE18054PIRI]; Comunidad Autonoma de MadridComunidad de Madrid [CAM
   B2017/BMD-3778, PIC97/2017_FJD]
FX MA Piris received grants from the Instituto de Salud Carlos III, from
   the Ministerio de Economia, Industria y Competitividad [PIE15/0081 and
   PIE16/01294; SAF2013-47416-R, CIBERONCISCIII, ISCIII-MINECO-AES-FEDER
   (Plan Estatal I+D+I 2013-2016)], the Asociacion Espanola Contra el
   Cancer [AECC PROYE18054PIRI], and the Comunidad Autonoma de Madrid [CAM
   B2017/BMD-3778, PIC97/2017_FJD].
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Strauss R, 2004, CRIT CARE MED, V32, P1316, DOI 10.1097/01.CCM.0000127779.24232.15
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Xu X, 2020, CHEST, DOI [10.1016/j.chest.2020.03.060, DOI 10.1016/J.CHEST.2020.03.060]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao X, 2020, CHINESE J PATHOL, V49, pE009
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
NR 22
TC 5
Z9 5
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD NOV
PY 2020
VL 33
IS 11
BP 2139
EP 2146
DI 10.1038/s41379-020-0613-1
EA JUL 2020
PG 8
WC Pathology
SC Pathology
GA OF2UZ
UT WOS:000545199100002
PM 32620916
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ueffing, M
   Bayyoud, T
   Schindler, M
   Ziemssen, F
AF Ueffing, Marius
   Bayyoud, Tarek
   Schindler, Michael
   Ziemssen, Focke
TI Basic principles of replication and immunology of SARS-CoV-2
SO OPHTHALMOLOGE
LA German
DT Article; Early Access
DE Binding affinity; Immune response; SARS-CoV-2; Seroconversion; Viral
   replication
ID SARS CORONAVIRUS
AB Coronaviruses are a genetically highly variable family of viruses that infect vertebrates and have succeeded in infecting humans many times by overcoming the species barrier. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which initially appeared in China at the end of 2019, exhibits a high infectivity and pathogenicity compared to other coronaviruses. As the viral coat and other viral components are recognized as being foreign by the immune system, this can lead to initial symptoms, which are induced by the very efficiently working immune defense system via the respiratory epithelium. During severe courses a systemically expressed proinflammatory cytokine storm and subsequent changes in the coagulation and complement systems can occur. Virus-specific antibodies, the long-term expression of which is ensured by the formation of B memory cell clones, generate a specific immune response that is also detectable in blood (seroconversion). Specifically effective cytotoxic CD8+ T-cell populations are also formed, which recognize viral epitopes as pathogen-specific patterns in combination with MHC presentation on the cell surface of virus-infected cells and destroy these cells. At the current point in time it is unclear how regular, robust and durable this immune status is constructed. Experiences with other coronavirus infections (SARS and Middle East respiratory syndrome, MERS) indicate that the immunity could persist for several years. Based on animal experiments, already acquired data on other coronavirus types and plausibility assumptions, it can be assumed that seroconverted patients have an immunity of limited duration and only a very low risk of reinfection. Knowledge of the molecular mechanisms of viral cycles and immunity is an important prerequisite for the development of vaccination strategies and development of effective drugs.
C1 [Ueffing, Marius; Bayyoud, Tarek; Ziemssen, Focke] Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Forschungsinst Augenheilkunde, Dept Augenheilkunde, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Ueffing, Marius; Bayyoud, Tarek; Ziemssen, Focke] Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Dept Augenheilkunde, Augenklin, Tubingen, Germany.
   [Schindler, Michael] Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Inst Med Virol & Epidemiol, Sekt Mol Virol, Tubingen, Germany.
RP Ueffing, M (corresponding author), Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Forschungsinst Augenheilkunde, Dept Augenheilkunde, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
EM mue@klinikum.uni-tuebingen.de
CR Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Miesbach WA, 2020, DTSCH ARZTEBL, V117, pA
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Robert-Koch-Institut, 2020, SARS COV 2 STECKBR C
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Sit THC, 2020, NATURE, DOI 10.1038/s41586-020-2334-5
   Song WC, 2020, J CLIN INVEST, V130, P3950, DOI 10.1172/JCI140183
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Stein RA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13512
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 41
TC 2
Z9 1
U1 13
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
DI 10.1007/s00347-020-01155-w
EA JUL 2020
PG 6
WC Ophthalmology
SC Ophthalmology
GA MF2RP
UT WOS:000545195100002
PM 32613257
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bachevski, D
   Damevska, K
   Simeonovski, V
   Dimova, M
AF Bachevski, Dimitri
   Damevska, Katerina
   Simeonovski, Viktor
   Dimova, Maja
TI Back to the basics: Propolis andCOVID-19
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE COVID-19; prevention; propolis; quercetin; SARS-CoV-2
AB The epidemiological burden of COVID-19 is a healthcare challenge throughout the world, not only in terms of testing the limits of medical capacities, but also as an enigma considering preventive strategies and methods. The upper respiratory tract mucosa is the first line of defense, as a physical barrier, as well as through multiple innate and adaptive immune mechanisms which are crucial for efficient antiviral responses. Identifying methods able to reduce or prevent colonization, viral adhesion, and promote virus shedding on mucous membranes or have the ability to inactivate pathogens and thus reduce virus dose and/or increase immune response would be essential in the management of COVID-19 outbreak and help in flattening the curve. We review the effects of propolis, an old remedy with proven antiviral properties, as a possible low-cost inhibitor of SARS-CoV-2 in the oropharyngeal niche, prophylaxis, or adjuvant therapy.
C1 [Bachevski, Dimitri; Damevska, Katerina; Simeonovski, Viktor; Dimova, Maja] Ss Cyril & Methodius Univ, Fac Med, Univ Clin Dermatol, Ul Majka Tereza 31, Skopje 1000, North Macedonia.
RP Simeonovski, V (corresponding author), Ss Cyril & Methodius Univ, Fac Med, Univ Clin Dermatol, Ul Majka Tereza 31, Skopje 1000, North Macedonia.
EM viktor93@gmail.com
RI Damevska, Katerina/AAV-8453-2020
OI Damevska, Katerina/0000-0003-4745-3747; Simeonovski,
   Viktor/0000-0003-2956-0928
CR AMOROS M, 1992, J NAT PROD, V55, P1732, DOI 10.1021/np50090a003
   Anjum SI, 2019, SAUDI J BIOL SCI, V26, P1695, DOI 10.1016/j.sjbs.2018.08.013
   Gonzalez-Burquez MD, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/7092416
   DEBIAGGI M, 1990, MICROBIOLOGICA, V13, P207
   Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555
   Eggers M, 2018, INFECT DIS THER, V7, P249, DOI 10.1007/s40121-018-0200-7
   Kitamura T, 2007, INTERNAL MED, V46, P1623, DOI 10.2169/internalmedicine.46.0104
   Kurek-Gorecka A, 2020, MOLECULES, V25, DOI 10.3390/molecules25030556
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Maruta H, 2020, MED DRUG DISCOV, V6
   Pascoal AX, 2014, MICROBIOLOGY SURG IN, P221
   Polansky H, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0222-0
   Shevchenko LF, 1972, CHEM ABSTR, V82, P11
   Syed S, 2004, LAB MED, V35, P112, DOI 10.1309/3YHRVBB7CB3LUFL6
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 4
Z9 4
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13780
DI 10.1111/dth.13780
EA JUL 2020
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000544958300001
PM 32506775
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chand, GB
   Banerjee, A
   Azad, GK
AF Chand, Gyanendra Bahadur
   Banerjee, Atanu
   Azad, Gajendra Kumar
TI Identification of novel mutations in RNA-dependent RNA polymerases of
   SARS-CoV-2 and their implications on its protein structure
SO PEERJ
LA English
DT Article
DE COVID-19; SARS-CoV-2; RNA-dependent RNA polymerases (RdRp); Nsp12;
   Mutation; Indian geographical area
AB The rapid development of the SARS-CoV-2 mediated COVID-19 pandemic has been the cause of significant health concern, highlighting the immediate need for effective antivirals. SARS-CoV-2 is an RNA virus that has an inherently high mutation rate. These mutations drive viral evolution and genome variability, thereby facilitating viruses to have rapid antigenic shifting to evade host immunity and to develop drug resistance. Viral RNA-dependent RNA polymerases (RdRp) perform viral genome duplication and RNA synthesis. Therefore, we compared the available RdRp sequences of SARS-CoV-2 from Indian isolates and the 'Wuhan wet sea food market virus' sequence to identify, if any, variation between them. Our data revealed the occurrence of seven mutations in Indian isolates of SARS-CoV-2. The secondary structure prediction analysis of these seven mutations shows that three of them cause alteration in the structure of RdRp. Furthermore, we did protein modelling studies to show that these mutations can potentially alter the stability of the RdRp protein. Therefore, we propose that RdRp mutations in Indian SARS-CoV-2 isolates might have functional consequences that can interfere with RdRp targeting pharmacological agents.
C1 [Chand, Gyanendra Bahadur; Azad, Gajendra Kumar] Patna Univ, Dept Zool, Patna, Bihar, India.
   [Banerjee, Atanu] Samastipur Coll, Dept Zool, Samastipur, Bihar, India.
RP Azad, GK (corresponding author), Patna Univ, Dept Zool, Patna, Bihar, India.
EM gkazad@patnauniversity.ac.in
OI Azad, Gajendra Kumar/0000-0001-5478-526X
CR Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8
   Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980
   Delang L, 2012, ANTIVIR RES, V93, P30, DOI 10.1016/j.antiviral.2011.10.012
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goethe M, 2015, J CHEM THEORY COMPUT, V11, P351, DOI 10.1021/ct500696p
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon DE, 2020, BIORXIV
   Irwin KK, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew014
   Jensen S, 2012, J VIROL, V86, P2900, DOI 10.1128/JVI.05738-11
   Kumar T.A., 2013, WIDE SPECTRUM, V1, P15, DOI DOI 10.5281/ZENODO.50733
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   McKeegan KS, 2002, TRENDS MICROBIOL, V10, pS8, DOI 10.1016/S0966-842X(02)02429-0
   Rodrigues CHM, 2018, NUCLEIC ACIDS RES, V46, pW350, DOI 10.1093/nar/gky300
   Sackman AM, 2017, MOL BIOL EVOL, V34, P3243, DOI 10.1093/molbev/msx257
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
NR 20
TC 1
Z9 1
U1 2
U2 2
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD JUL 3
PY 2020
VL 8
AR e9492
DI 10.7717/peerj.9492
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MF3TW
UT WOS:000545270100011
PM 32685291
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Granic, I
   Morita, H
   Scholten, H
AF Granic, Isabela
   Morita, Hiromitsu
   Scholten, Hanneke
TI Young People's Digital Interactions from a Narrative Identity
   Perspective: Implications for Mental Health and Wellbeing
SO PSYCHOLOGICAL INQUIRY
LA English
DT Article
DE Adolescence; identity; digital; video games; social media; mental
   health; wellbeing
ID COGNITIVE-BEHAVIORAL THERAPY; SELF-DETERMINATION THEORY; CHILDHOOD
   ANXIETY; CHILDREN; INTERVENTIONS; AFFIRMATION; DEPRESSION; INTERNET;
   ADOLESCENTS; MOTIVATION
AB The current response article began by situating this journal volume in the current COVID-19 pandemic context which has driven young people into digital spaces for far longer periods of time than ever. Many scholars, policy makers, and the public at large are recognizing that these social digital spaces may be the only outlet by which youth and their families can remain safe (at least physically), while also participating in some important social outlets. We discussed the notion of hybrid reality and argued that young people themselves often do not experience their digital and physical contexts as functionally distinct, despite there being good scientific reasons for examining these contexts separately. We then considered whether or not digital activity (at least some) should be considered pathological or inherently unhealthy for young people. Like most of the commentators, we advocated for a nuanced approach and emphasized the importance of a functional, developmental lens. In the second half of our response, we turned to the narrative identity framework itself and clarified misconceptions about what we considered novel about our approach. We found it particularly useful to explain why self-determination theory can be regarded as a constituent of the identity development framework, but that it does not subsume it. We moved on to discuss how the new insights provided by the commentators could be synthesized and suggested directions for new research studies and methodologies. Finally, we ended with an examination of how a more elaborated narrative identity framework offers specific directions for designing new digital interventions for promoting young people's mental health and wellbeing. It is our hope that the target article with its detailed articulation of the narrative identity framework, together with the thoughtful commentaries and this response, can together inform future research, practice, and policy relevant to digital activity and its impact on young people's mental health and wellbeing.
C1 [Granic, Isabela; Morita, Hiromitsu; Scholten, Hanneke] Radboud Univ Nijmegen, Behav Sci Inst, POB 9104, NL-6500 HE Nijmegen, Netherlands.
RP Granic, I (corresponding author), Radboud Univ Nijmegen, Behav Sci Inst, POB 9104, NL-6500 HE Nijmegen, Netherlands.
EM i.granic@pwo.ru.nl
FU European Research Council (ERC) under the European Union's Horizon 2020
   research and innovation programEuropean Research Council (ERC) [683262]
FX This project has received funding from the European Research Council
   (ERC) under the European Union's Horizon 2020 research and innovation
   program [grant agreement No 683262].
CR Adler JM, 2012, J PERS SOC PSYCHOL, V102, P367, DOI 10.1037/a0025289
   Ali K, 2015, JMIR MENT HEALTH, V2, DOI 10.2196/mental.4418
   Alwin D. F., 1991, POLITICAL ATTITUDES
   Andalibi N, 2017, CSCW'17: PROCEEDINGS OF THE 2017 ACM CONFERENCE ON COMPUTER SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING, P1485, DOI 10.1145/2998181.2998243
   Anderson K. M, 2019, SOC WORK GROUPS, V42, P43, DOI DOI 10.1080/01609513.2017.1413616
   Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006
   [Anonymous], TEENS AR COP CONN TI
   Anthes E, 2016, NATURE, V532, P20, DOI 10.1038/532020a
   Arseniev-Koehler A, 2016, J ADOLESCENT HEALTH, V58, P659, DOI 10.1016/j.jadohealth.2016.02.012
   Baer J., CONVINCE CONVERT
   Beaunoyer E, 2020, COMPUT HUM BEHAV, V111, DOI 10.1016/j.chb.2020.106424
   BELL V., 2007, J MENTAL HLTH, V16, P445, DOI DOI 10.1080/09638230701482378
   Bennett K, 2016, CLIN PSYCHOL REV, V50, P80, DOI 10.1016/j.cpr.2016.09.006
   Berryman C, 2018, PSYCHIAT QUART, V89, P307, DOI 10.1007/s11126-017-9535-6
   Bethune Brian, 2017, MACLEANS
   boyd d., 2014, ITS COMPLICATED SOCI
   Brady LM, 2018, P NATL ACAD SCI USA, V115, P11406, DOI 10.1073/pnas.1803526115
   Chandler Michael, 1994, V64, P55
   Chareonwongsak K., 2002, TECHNOL SOC, V24, P191
   Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024
   Choukas-Bradley S, 2020, BODY IMAGE, V33, P164, DOI 10.1016/j.bodyim.2020.02.017
   Clarke AM, 2015, J YOUTH ADOLESCENCE, V44, P90, DOI 10.1007/s10964-014-0165-0
   Cohen GL, 2014, ANNU REV PSYCHOL, V65, P333, DOI 10.1146/annurev-psych-010213-115137
   Cohen GL, 2009, SCIENCE, V324, P400, DOI 10.1126/science.1170769
   Cook JE, 2012, J PERS SOC PSYCHOL, V102, P479, DOI 10.1037/a0026312
   Crone EA, 2012, NAT REV NEUROSCI, V13, P636, DOI 10.1038/nrn3313
   Crowe K, 2017, J ANXIETY DISORD, V49, P76, DOI 10.1016/j.janxdis.2017.04.001
   Das JK, 2016, J ADOLESCENT HEALTH, V59, pS49, DOI 10.1016/j.jadohealth.2016.06.020
   Davies EB, 2014, J MED INTERNET RES, V16, P18, DOI 10.2196/jmir.3142
   Davis K, 2017, ADV HUM SOC ASPEC T, P1, DOI 10.4018/978-1-5225-1856-3.ch001
   De Rubeis S, 2009, PERS INDIV DIFFER, V46, P477, DOI 10.1016/j.paid.2008.11.019
   Drane C, 2020, IMPACT LEARNING HOME
   Dubois E, 2018, INFORM COMMUN SOC, V21, P729, DOI 10.1080/1369118X.2018.1428656
   Dunbar RIM, 2003, ANNU REV ANTHROPOL, V32, P163, DOI 10.1146/annurev.anthro.32.061002.093158
   Dweck CS, 2017, PSYCHOL REV, V124, P689, DOI 10.1037/rev0000082
   Elhai JD, 2018, PERS INDIV DIFFER, V133, P21, DOI 10.1016/j.paid.2017.04.051
   Erikson E. H., 1968, IDENTITY YOUTH CRISI
   Erikson E. H., 1959, IDENTITY LIFE CYCLE
   Eysenbach G, 2004, BMJ-BRIT MED J, V328, P1166, DOI 10.1136/bmj.328.7449.1166
   Fegert JM, 2020, CHILD ADOL PSYCH MEN, V14, DOI 10.1186/s13034-020-00329-3
   Ferguson CJ, 2019, J YOUTH ADOLESCENCE, V48, P1439, DOI 10.1007/s10964-019-01069-0
   Fried E, 2020, MENTAL HLTH SOCIAL C, DOI [10.31234/osf.io/36xkp., DOI 10.31234/OSF.IO/36XKP, 10.31234/osf.io/36xkp]
   Gillani N, 2018, WEB CONFERENCE 2018: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW2018), P823, DOI 10.1145/3178876.3186130
   Golberstein E, 2020, JAMA PEDIATR, V174, P819, DOI 10.1001/jamapediatrics.2020.1456
   Granic I, 2000, NEW IDEAS PSYCHOL, V18, P93, DOI 10.1016/S0732-118X(99)00039-2
   Griffin L. K., 2017, DEV SELF DETERMINATI
   Hamilton J. L., 2020, PSYARXIV, DOI [10.31234/osf.io/5stx4, DOI 10.31234/OSF.IO/5STX4]
   Harari Y.N., 2015, SAPIENS BRIEF HIST H
   Heffer T, 2019, CLIN PSYCHOL SCI, V7, P462, DOI 10.1177/2167702618812727
   Henrich J, 2010, BEHAV BRAIN SCI, V33, P61, DOI 10.1017/S0140525X0999152X
   Hilgard J, 2017, PSYCHOL BULL, V143, P757, DOI 10.1037/bul0000074
   Hofmann SG, 2012, COGNITIVE THER RES, V36, P427, DOI 10.1007/s10608-012-9476-1
   Hollis C, 2017, J CHILD PSYCHOL PSYC, V58, P474, DOI 10.1111/jcpp.12663
   Jensen M, 2019, CLIN PSYCHOL SCI, V7, P1416, DOI 10.1177/2167702619859336
   Juarascio Adrienne S, 2010, Eat Disord, V18, P393, DOI 10.1080/10640266.2010.511918
   Kelly K, 2016, INEVITABLE UNDERSTAN
   Kemp S., 2019, DIGITAL 2019 GLOBAL
   Kim D, 2020, J COMPUT EDUC, DOI 10.1007/s40692-020-00170-9
   Koeze E., 2020, NY TIMES
   Kumpulainen K, 2018, SPRINGER INT HBK ED, P107, DOI 10.1007/978-3-319-71054-9_7
   La Guardia JG, 2002, ADOLESCENCE EDUC, P193
   Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7
   Lee-Leugner J. H. L., 2013, THESIS
   LEVINE MP, 2011, BODY IMAGE HDB SCI P, P101
   Lindhiem O., 2018, TECHNOLOGY ADOLESCEN, P255
   Livingstone S, 2008, NEW MEDIA SOC, V10, P393, DOI 10.1177/1461444808089415
   Livingstone S, 2017, NEW MEDIA SOC, V19, P657, DOI 10.1177/1461444816686318
   Loevinger J., 1976, EGO DEV CONCEPTIONS
   Lyubomirsky S., 2010, HDB ADULT RESILIENCE, P450
   MARCIA JE, 1966, J PERS SOC PSYCHOL, V3, P551, DOI 10.1037/h0023281
   Marwick AE, 2011, NEW MEDIA SOC, V13, P114, DOI 10.1177/1461444810365313
   McAdams DP, 2013, CURR DIR PSYCHOL SCI, V22, P233, DOI 10.1177/0963721413475622
   Metcalf A., 2008, J COMMUNITY CITIZENS, V4, P1
   Murdoch I., 1997, EXISTENTIALISTS MYST
   Mychailyszyn MP, 2012, CLIN PSYCHOL-SCI PR, V19, P129, DOI 10.1111/j.1468-2850.2012.01279.x
   Nesi J, 2018, CLIN CHILD FAM PSYCH, V21, P295, DOI 10.1007/s10567-018-0262-9
   Odgers CL, 2020, J CHILD PSYCHOL PSYC, V61, P336, DOI 10.1111/jcpp.13190
   Ofcom, 2019, CHILDR PAR MED US AT
   Orben A, 2020, PERSPECT PSYCHOL SCI, V15, P1143, DOI 10.1177/1745691620919372
   Orben A, 2019, PSYCHOL SCI, V30, P682, DOI 10.1177/0956797619830329
   Orben A, 2019, NAT HUM BEHAV, V3, P173, DOI 10.1038/s41562-018-0506-1
   Oud M, 2019, EUR PSYCHIAT, V57, P33, DOI 10.1016/j.eurpsy.2018.12.008
   Pandita R, 2017, INT J INFORM DISSEMI, V7, P83, DOI DOI 10.5958/2249-5576.2017.00001.2
   Pennant ME, 2015, BEHAV RES THER, V67, P1, DOI 10.1016/j.brat.2015.01.009
   Pennebaker JW, 1997, PSYCHOL SCI, V8, P162, DOI 10.1111/j.1467-9280.1997.tb00403.x
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Podina IR, 2016, J RATION-EMOT COGN-B, V34, P31, DOI 10.1007/s10942-015-0228-5
   Poushter J, 2016, SMARTPHONE OWNERSHIP
   Ramsetty Anita, 2020, J Am Med Inform Assoc, V27, P1147, DOI 10.1093/jamia/ocaa078
   Reinecke L, 2014, J COMMUN, V64, P569, DOI 10.1111/jcom.12107
   Rodriguez-Meirinhos A, 2020, J YOUTH ADOLESCENCE, V49, P352, DOI 10.1007/s10964-019-01151-7
   Rooksby M, 2015, J ANXIETY DISORD, V29, P83, DOI 10.1016/j.janxdis.2014.11.006
   Ryan R. M., 2017, SELF DETERMINATION T
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Ryan RM, 2016, DEV PSYCHOPATHOL, P385, DOI [DOI 10.1002/9781119125556.DEVPSY109, DOI 10.1002/9781119125556]
   Sacks O., 1985, MAN WHO MISTOOK HIS
   Scholten H, 2019, J MED INTERNET RES, V21, DOI 10.2196/11528
   Schoneveld EA, 2018, PREV SCI, V19, P220, DOI 10.1007/s11121-017-0843-8
   Schwartz SJ, 2012, NEW DIR CHILD ADOLES, V138, P1, DOI 10.1002/cad.20019
   Sclater M, 2014, J YOUTH STUD, V17, P1, DOI 10.1080/13676261.2013.847908
   Sherman DK, 2006, ADV EXP SOC PSYCHOL, V38, P183, DOI 10.1016/S0065-2601(06)38004-5
   Sherman DK, 2013, J PERS SOC PSYCHOL, V104, P591, DOI 10.1037/a0031495
   Shore JH, 2020, JAMA PSYCHIAT, V77, P1211, DOI 10.1001/jamapsychiatry.2020.1643
   Siegel D. J., 2020, DEV MIND RELATIONSHI
   Silver L., 2019, SMARTPHONE OWNERSHIP
   Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302
   Steele C. M., 1988, ADV EXPT SOCIAL PSYC, V21, P261, DOI DOI 10.1016/S0065-2601(08)60229-4
   Stiles-Shields C, 2016, DIGIT HEALTH, V2, DOI 10.1177/2055207616675706
   Sugimura K, 2020, CHILD DEV PERSPECT, V14, P71, DOI 10.1111/cdep.12359
   Sugimura K, 2016, ASIAN J SOC PSYCHOL, V19, P362, DOI 10.1111/ajsp.12154
   Thelen E., 1994, DYNAMIC SYSTEMS APPR
   Tolentino Jia, 2019, TRICK MIRROR REFLECT
   Unicef, 2017, STAT WORLDS CHILDR 2
   VALIMAKI M, 2017, J MED INTERNET RES, V5, P180
   Valkenburg PM, 2013, J COMMUN, V63, P221, DOI 10.1111/jcom.12024
   van der Linden C, 2017, J ELECT PUBLIC OPIN, V27, P9, DOI 10.1080/17457289.2016.1268144
   van der Linden W. C., 2019, THESIS
   Van Lancker W, 2020, LANCET PUBLIC HEALTH, V5, pE243, DOI 10.1016/S2468-2667(20)30084-0
   Viens A., 2019, VISUAL CAPITALIST
   Weinstein N, 2012, J RES PERS, V46, P397, DOI 10.1016/j.jrp.2012.03.007
   Werner-Seidler A, 2017, CLIN PSYCHOL REV, V51, P30, DOI 10.1016/j.cpr.2016.10.005
   Wilson S., 2020, HARVARD BUSINESS REV
   Wilson T. D., 2011, REDIRECT SURPRISING
   Wols A, 2018, J PSYCHOPATHOL BEHAV, V40, P655, DOI 10.1007/s10862-018-9684-4
   World Bank Group, 2018, MOB CELL SUBSCR PER
   Ye XB, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-313
   Yeshua-Katz D, 2015, QUAL HEALTH RES, V25, P1347, DOI 10.1177/1049732315570123
NR 127
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1047-840X
EI 1532-7965
J9 PSYCHOL INQ
JI Psychol. Inq.
PD JUL 2
PY 2020
VL 31
IS 3
BP 258
EP 270
DI 10.1080/1047840X.2020.1820225
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA OM4ZY
UT WOS:000586036100008
OA Other Gold
DA 2021-01-01
ER

PT J
AU Huang, LY
   Wang, YR
   Wang, LS
   Lv, YM
   Liu, QQ
AF Huang, Luyan
   Wang, Yiru
   Wang, Lisheng
   Lv, Yongman
   Liu, Qingquan
TI Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient
   A case report
SO MEDICINE
LA English
DT Article
DE 2019 novel coronavirus disease; coronavirus; hemodialysis; pneumonia;
   uremia
ID ACUTE RESPIRATORY SYNDROME; SARS
AB Rationale: The 2019 novel coronavirus disease (COVID-19) causes a novel, atypical pneumonia that has brought huge public health challenges across the globe. There is limited data about patients with end-stage renal disease who also suffer from COVID-19. In this report, we discuss the case of a hemodialysis patient who developed COVID-19 pneumonia in the clinical course. Patient concerns: A 79-year-old man who had end-stage renal disease (ESRD) and was taking regular hemodialysis was admitted to hospital for a fever and dry cough. The patient, who also had cardiovascular disease, had no history of contact with COVID-2019 patients. Diagnosis: The patient was diagnosed with COVID-2019 by the reverse-transcriptase polymerase chain reaction (RT-PCR), and his pharyngeal swab for SARS-CoV-2 was positive. Intervention: The treatment was mainly supportive and the patient was intensively monitored. He was treated with oxygen, broad-spectrum antibiotics, antiviral drugs, and methylprednisolone. The patient took continuous renal replacement therapy (CRRT) every 2 days. Outcomes: After 19 days, an RT-PCR assay for SARS-CoV-2 was negative, and computed tomography (CT) of the patient's thorax indicated that the pulmonary inflammatory exudation was absorbed and pulmonary infection improved significantly. He was discharged on day 29 after recovering from COVID-2019 pneumonia. Lessons: The courses of disease and treatment options for this individual were significantly more complicated than those for ordinary patients. Therefore, it was necessary to monitor the condition of the patient closely and to protect the dialysis unit staff from being infected. Compared with other severe COVID-2019 cases, this patient recovered more quickly following treatment, which was likely due to the removal of inflammatory mediators by CRRT. This implies that blood purification might be an important option for hemodialysis patients with COVID-19.
C1 [Huang, Luyan] Wuhan Hosp Tradit Chinese Med, Dept Anesthesiol, Hanyang Branch, Wuhan, Peoples R China.
   [Wang, Yiru; Wang, Lisheng; Lv, Yongman; Liu, Qingquan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, Wuhan, Peoples R China.
   [Lv, Yongman] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hlth Management Ctr, Wuhan, Peoples R China.
RP Liu, QQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China.
EM qqliutj@163.com
FU National Natural Science Foundation of P.R. ChinaNational Natural
   Science Foundation of China (NSFC) [81800609]
FX This study was supported by the grant from National Natural Science
   Foundation of P.R. China (No. 81800609).
CR Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x
   Fu Dian, 2020, Nephron, V144, P245, DOI 10.1159/000507261
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kwan BCH, 2003, AM J KIDNEY DIS, V42, P1069, DOI 10.1016/j.ajkd.2003.07.022
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P332
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Peng ZY, 2010, CONTRIB NEPHROL, V165, P322, DOI 10.1159/000313773
   Slessarev M, 2019, HEMODIAL INT, V23, P325, DOI 10.1111/hdi.12760
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   Wong PN, 2003, AM J KIDNEY DIS, V42, P1075, DOI 10.1016/j.ajkd.2003.08.005
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 16
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 2
PY 2020
VL 99
IS 27
AR 20956
DI 10.1097/MD.0000000000020956
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX1TE
UT WOS:000557508900082
PM 32629703
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Frigault, MJ
   Nikiforow, S
   Mansour, MK
   Hu, ZH
   Horowitz, MM
   Riches, ML
   Hematti, P
   Turtle, CJ
   Zhang, MJ
   Perales, MA
   Pasquini, MC
AF Frigault, Matthew J.
   Nikiforow, Sarah
   Mansour, Michael K.
   Hu, Zhen-Huan
   Horowitz, Mary M.
   Riches, Marcie L.
   Hematti, Peiman
   Turtle, Cameron J.
   Zhang, Mei-Jie
   Perales, Miguel-Angel
   Pasquini, Marcelo C.
TI Tocilizumab not associated with increased infection risk after CAR
   T-cell therapy: implications for COVID-19?
SO BLOOD
LA English
DT Letter
ID CYTOKINE RELEASE SYNDROME
C1 [Frigault, Matthew J.] Massachusetts Gen Hosp, Cellular Immunotherapy Program, Boston, MA 02114 USA.
   [Nikiforow, Sarah] Dana Farber Canc Inst, Dept Med, Div Hematol Malignancies, Boston, MA 02115 USA.
   [Mansour, Michael K.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
   [Hu, Zhen-Huan; Horowitz, Mary M.; Zhang, Mei-Jie; Pasquini, Marcelo C.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.
   [Horowitz, Mary M.; Pasquini, Marcelo C.] Med Coll Wisconsin, Blood & Marrow Transplant & Cellular Therapy Prog, Milwaukee, WI 53226 USA.
   [Riches, Marcie L.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27515 USA.
   [Hematti, Peiman] Univ Wisconsin, Dept Med, Div Hematol Oncol Bone Marrow Transplantat, Madison, WI USA.
   [Turtle, Cameron J.] Univ Washington, Dept Med, Seattle, WA USA.
   [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Adult Blood & Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA.
RP Pasquini, MC (corresponding author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA.
EM mpasquini@mcw.edu
OI Riches, Marcie/0000-0003-0257-0990
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U24CA233032, U24CA076518]; NovartisNovartis; Kite
   Pharma; National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [U24CA076518];
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [U24CA076518]; National
   Institute of Allergy and Infectious DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U24CA076518]; Dana-Farber/Harvard Cancer Consortium National Institutes
   of HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K12CA087723]
FX The authors acknowledge all centers that report CAR T-cell data to the
   Center for International Blood and Marrow Transplant Research. The
   Center for International Blood and Marrow Transplant Research cellular
   therapy registry receives research support from the National Cancer
   Institute (Cellular Immunotherapy Data Resource, U24CA233032), Novartis,
   and Kite Pharma. The Center for International Blood and Marrow
   Transplant Research is also supported by Public Health Service
   U24CA076518 from the National Institutes of Health, National Cancer
   Institute, National Heart, Lung, and Blood Institute, and National
   Institute of Allergy and Infectious Diseases.; M.J.F. is supported by
   Dana-Farber/Harvard Cancer Consortium National Institutes of Health
   project K12CA087723.
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Center for International Blood and Marrow Transplant Research, CELL IMM DAT RES CID
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Faguer S, 2016, HEMATOL ONCOL, V34, P55, DOI 10.1002/hon.2174
   Frigault MJ, 2020, J CLIN INVEST, V130, P1586, DOI 10.1172/JCI129208
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michot JM, ANN ONCOL
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Schiff MH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3455
   Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980
   Seguin A, 2016, CHEST, V149, P1294, DOI 10.1016/j.chest.2015.11.004
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Yokota S, 2015, J RHEUMATOL, V42, P712, DOI 10.3899/jrheum.140288
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
NR 21
TC 4
Z9 4
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUL 2
PY 2020
VL 136
IS 1
BP 137
EP 139
DI 10.1182/blood.2020006216
PG 3
WC Hematology
SC Hematology
GA MM8CN
UT WOS:000550379200017
PM 32457999
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Palamar, JJ
   Acosta, P
AF Palamar, Joseph J.
   Acosta, Patricia
TI On the efficacy of online drug surveys during the time of COVID-19
SO SUBSTANCE ABUSE
LA English
DT Letter
DE Survey reliability; online surveys; COVID-19
ID REPRESENTATIVENESS
AB Most human subjects research involving contact with participants has been halted in the US due to the COVID-19 crisis. We have been testing an online method to recruit and survey participants as a temporary replacement for our street-intercept survey method. Online surveys already generate less generalizable findings than other surveys, but offering compensation for online survey completion further reduces generalizability because this increases mischievous submissions. In this letter we discuss methods to help detect invalid responses, such as utilizing a screener to test for eligibility and using flags to detect mischievous responses and repeat submissions. We recommend that researchers approach online recruitment and surveying with caution.
C1 [Palamar, Joseph J.; Acosta, Patricia] NYU, Dept Populat Hlth, Grossman Sch Med, 180 Madison Ave,Room 1752, New York, NY 10016 USA.
RP Palamar, JJ (corresponding author), NYU, Dept Populat Hlth, Grossman Sch Med, 180 Madison Ave,Room 1752, New York, NY 10016 USA.
EM joseph.palamar@nyulangone.org
OI Palamar, Joseph/0000-0002-8565-9415
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 DA044207]
FX This project was funded by the National Institutes of Health [R01
   DA044207, PI: Palamar]. The funding organization had no role in the
   design and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; and decision to submit the manuscript for publication.
CR Barratt MJ, 2017, SUBST ABUS-RES TREAT, V11, DOI 10.1177/1178221817716391
   Ebrahim S, 2013, INT J EPIDEMIOL, V42, P1022, DOI 10.1093/ije/dyt105
   Fernandez-Calderon F, 2018, ADDICT BEHAV, V78, P85, DOI 10.1016/j.addbeh.2017.11.004
   Furlong MJ, 2017, SCHOOL PSYCHOL QUART, V32, P320, DOI 10.1037/spq0000168
   Keiding N, 2016, J R STAT SOC A STAT, V179, P319, DOI 10.1111/rssa.12136
   Miller PG, 2010, ADDICTION, V105, P1557, DOI 10.1111/j.1360-0443.2010.02992.x
   Nohr EA, 2013, INT J EPIDEMIOL, V42, P1016, DOI 10.1093/ije/dyt102
   Palamar JJ, 2020, AM J DRUG ALCOHOL AB, V46, P708, DOI 10.1080/00952990.2020.1745219
   Palamar JJ, 2019, DRUG ALCOHOL REV, V38, P798, DOI 10.1111/dar.12982
   Palamar JJ, 2020, SUBST ABUS, V41, P382, DOI [10.1080/08897077.2019.1635966, 10.1080/10826084.2018.1529186]
   Richiardi L, 2013, INT J EPIDEMIOL, V42, P1018, DOI 10.1093/ije/dyt103
   Rothman KJ, 2013, INT J EPIDEMIOL, V42, P1026, DOI 10.1093/ije/dyt124
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PD JUL 2
PY 2020
VL 41
IS 3
BP 283
EP 285
DI 10.1080/08897077.2020.1784362
PG 3
WC Substance Abuse
SC Substance Abuse
GA MN6PI
UT WOS:000550960400003
PM 32697173
DA 2021-01-01
ER

PT J
AU Melamed, OC
   Hauck, TS
   Buckley, L
   Selby, P
   Mulsant, BH
AF Melamed, Osnat C.
   Hauck, Tanya S.
   Buckley, Leslie
   Selby, Peter
   Mulsant, Benoit H.
TI COVID-19 and persons with substance use disorders: Inequities and
   mitigation strategies
SO SUBSTANCE ABUSE
LA English
DT Article
DE COVID-19; pandemic; substance use disorders; addiction; clinical care;
   clinical research; alcohol; tobacco; opioids; cannabis; cocaine
ID MENTAL-HEALTH; DRUG-ABUSE; SMOKING; STRESS; PREVALENCE; ADDICTION;
   ALCOHOL; DEPENDENCE; DELIVERY; RELAPSE
AB The COVID-19 pandemic disproportionately disrupts the daily lives of marginalized populations. Persons with substance use disorders are a particularly vulnerable population because of their unique social and health care needs. They face significant harm from both the pandemic itself and its social and economic consequences, including marginalization in health care and social systems. Hence, we discuss: (1) why persons with substance use disorders are at increased risk for infection with COVID-19 and a severe illness course; (2) anticipated adverse consequences of COVID-19 in persons with substance use disorders; (3) challenges to health care delivery and substance use treatment programs during and after the COVID-19 pandemic; and (4) the potential impact on clinical research in substance use disorders. We offer recommendations for clinical, public health, and social policies to mitigate these challenges and to prevent negative outcomes.
C1 [Melamed, Osnat C.; Hauck, Tanya S.; Buckley, Leslie; Selby, Peter; Mulsant, Benoit H.] Ctr Addict & Mental Hlth, Addict Res Grp, Toronto, ON, Canada.
   [Melamed, Osnat C.; Selby, Peter] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.
   [Hauck, Tanya S.; Buckley, Leslie; Selby, Peter; Mulsant, Benoit H.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   [Selby, Peter] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
RP Selby, P (corresponding author), Ctr Addict & Mental Hlth, 175 Coll St, Toronto, ON M5T 1P7, Canada.
EM Peter.Selby@camh.ca
OI Melamed, Osnat/0000-0002-9663-2226
CR Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   al'Absi M, 2007, INT J PSYCHOPHYSIOL, V66, P109, DOI 10.1016/j.ijpsycho.2007.03.016
   American Society of Addiction Medicine, 2020, PLAC CRIT
   American Society of Addiction Medicine, 2020, DEF ADD
   Bauer CMT, 2013, CHEST, V143, P196, DOI 10.1378/chest.12-0930
   Becker W. C., 2020, ANN INTERN MED
   Blaine SK, 2017, NEUROPHARMACOLOGY, V122, P136, DOI 10.1016/j.neuropharm.2017.01.037
   Bonnet U, 2017, SUBST ABUSE REHABIL, V8, P9, DOI 10.2147/SAR.S109576
   Brown EE, 2020, AM J GERIATR PSYCHIA
   Cava MA, 2005, PUBLIC HEALTH NURS, V22, P398, DOI 10.1111/j.0737-1209.2005.220504.x
   Chao T, 2018, DRUG ALCOHOL DEPEN, V185, P23, DOI 10.1016/j.drugalcdep.2017.11.021
   Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129
   Compton WM, 2007, ARCH GEN PSYCHIAT, V64, P566, DOI 10.1001/archpsyc.64.5.566
   Druss BG, 2006, GEN HOSP PSYCHIAT, V28, P145, DOI 10.1016/j.genhosppsych.2005.10.006
   Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Galea S, 2002, PUBLIC HEALTH REP, V117, pS135
   Gates P, 2014, RESPIROLOGY, V19, P655, DOI 10.1111/resp.12298
   Goeders NE, 2004, CURR DIR PSYCHOL SCI, V13, P33, DOI 10.1111/j.0963-7214.2004.01301009.x
   Green TC, 2020, SUBST ABUS, V41, P147, DOI 10.1080/08897077.2020.1752351
   Guydish J, 2016, ADDICTION, V111, P220, DOI 10.1111/add.13099
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Joudrey PJ, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0145-5
   Kendler KS, 2017, SOC PSYCH PSYCH EPID, V52, P877, DOI 10.1007/s00127-017-1398-5
   Kim TW, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008508
   Kozloff N, 2020, SCHIZOPHR B
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Legha RK, 2020, TELEMED E-HEALTH, V26, P905, DOI 10.1089/tmj.2019.0131
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Loftis JM, 2013, PHARMACOL THERAPEUT, V139, P289, DOI 10.1016/j.pharmthera.2013.04.011
   Marsch LA, 2012, PSYCHIAT CLIN N AM, V35, P481, DOI 10.1016/j.psc.2012.03.009
   Matkin W, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub4
   McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689
   National Institutes of Health, 2020, GUID NIH FUND CLIN T
   Palmer F, 2012, PRIM CARE RESP J, V21, P377, DOI 10.4104/pcrj.2012.00069
   Preston KL, 2011, PSYCHOPHARMACOLOGY, V218, P29, DOI 10.1007/s00213-011-2183-x
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Quanbeck A, 2014, ALCOHOL RES-CURR REV, V36, P111
   Substance Abuse and Mental Health Services Administration, 2014, HHS PUBL, VH-48, P1
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1090
   Taylor GMJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007078.pub5
   Tsai J, 2020, LANCET PUBLIC HEALTH, V5, pE186, DOI 10.1016/S2468-2667(20)30053-0
   van Boekel LC, 2015, INT J SOC PSYCHIATR, V61, P539, DOI 10.1177/0020764014562051
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Varker T, 2019, PSYCHOL SERV, V16, P621, DOI 10.1037/ser0000239
   Volkow ND, 2020, ANN INTERN MED
   Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480
   Walker PP, 2015, CHEST, V148, P1156, DOI 10.1378/chest.15-0236
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
   Zaheer S, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/10224
NR 52
TC 2
Z9 2
U1 12
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
PD JUL 2
PY 2020
VL 41
IS 3
BP 286
EP 291
DI 10.1080/08897077.2020.1784363
PG 6
WC Substance Abuse
SC Substance Abuse
GA MN6PI
UT WOS:000550960400004
PM 32697172
DA 2021-01-01
ER

PT J
AU Kar, T
   Narsaria, U
   Basak, S
   Deb, D
   Castiglione, F
   Mueller, DM
   Srivastava, AP
AF Kar, Tamalika
   Narsaria, Utkarsh
   Basak, Srijita
   Deb, Debashrito
   Castiglione, Filippo
   Mueller, David M.
   Srivastava, Anurag P.
TI A candidate multi-epitope vaccine against SARS-CoV-2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; TOXIN-B-SUBUNIT; PEPTIDE VACCINE; T-CELLS;
   HARNESSING BIOINFORMATICS; PROTEIN-STRUCTURE; RECENT INSIGHTS; WEB
   SERVER; I-TASSER; CORONAVIRUS
AB In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stability of the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors. The in silico cloning and codon optimization supported the proficient expression of the designed vaccine in E. coli expression system. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.
C1 [Kar, Tamalika; Narsaria, Utkarsh; Basak, Srijita; Deb, Debashrito; Srivastava, Anurag P.] Garden City Univ, Dept Life Sci, Bangalore, Karnataka, India.
   [Castiglione, Filippo] Natl Res Council Italy, Inst Appl Comp, Via Taurini, Rome, Italy.
   [Mueller, David M.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Ctr Genet Dis, N Chicago, IL USA.
RP Srivastava, AP (corresponding author), Garden City Univ, Dept Life Sci, Bangalore, Karnataka, India.
EM anurag.srivastava@gardencity.university
RI Castiglione, Filippo/B-1366-2010; Srivastava, Anurag/I-6118-2018
OI Castiglione, Filippo/0000-0002-1442-3552; Basak,
   Srijita/0000-0001-6947-128X; Srivastava, Anurag/0000-0003-3493-1375
FU Innovative Medicines Initiative 2 Joint Undertaking [853989]; European
   Union's Horizon 2020 research and innovation program; EFPIA; Global
   Alliance for TBDrug Development non profit organization Bill &
   D.M.Melinda Gates Foundation; University of Dundee; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R35 GM131731]
FX The authors thank Dr. Joseph V.G., Chancellor Garden City University for
   his constant support to carry out this research work. FC acknowledges
   partial support from the Innovative Medicines Initiative 2 Joint
   Undertaking under grant agreement No. 853989 (Project ERA4TB). This
   Joint Undertaking receives support from the European Union's Horizon
   2020 research and innovation program and EFPIA and Global Alliance for
   TBDrug Development non profit organization Bill & D.M.Melinda Gates
   Foundation and University of Dundee. D.M.M was supported by a grant from
   NIH, R35 GM131731.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahlers JD, 2010, TRENDS MOL MED, V16, P478, DOI 10.1016/j.molmed.2010.07.007
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Atapour A, 2019, INT J PEPT RES THER, V25, P861, DOI 10.1007/s10989-018-9735-4
   Bazhan SI, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020034
   Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343
   Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Cao YM, 2017, ANTIVIR RES, V140, P133, DOI 10.1016/j.antiviral.2017.01.023
   Carty M, 2010, CLIN EXP IMMUNOL, V161, P397, DOI 10.1111/j.1365-2249.2010.04196.x
   Castiglione F, 2012, COMPUT MATH METHOD M, DOI 10.1155/2012/842329
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Chen JC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005053
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Dar HA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030088
   Davies MN, 2007, DRUG DISCOV TODAY, V12, P389, DOI 10.1016/j.drudis.2007.03.010
   de Haan CAM, 1999, J VIROL, V73, P7441, DOI 10.1128/JVI.73.9.7441-7452.1999
   Tosta SFD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1707120
   de Vries SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017695
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dey AK, 2014, EXPERT REV VACCINES, V13, P671, DOI 10.1586/14760584.2014.907528
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123
   Dorosti H, 2019, J BIOMOL STRUCT DYN, V37, P3524, DOI 10.1080/07391102.2018.1519460
   Dosch SF, 2009, VIRUS RES, V142, P19, DOI 10.1016/j.virusres.2009.01.005
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Faisal ARM, 2017, BIOINFORMATION, V13, P417, DOI 10.6026/97320630013417
   Foroutan M, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101413
   Getzoff ED, 1998, ADV IMMUNOL, P1
   Goodman AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025938
   Groothuis TAM, 2005, IMMUNOL REV, V207, P60, DOI 10.1111/j.0105-2896.2005.00305.x
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guo L, 2014, APPL MICROBIOL BIOT, V98, P3495, DOI 10.1007/s00253-013-5408-6
   He R, 2018, CELL MOL IMMUNOL, V15, P815, DOI 10.1038/cmi.2017.3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou J, 2014, HUM VACC IMMUNOTHER, V10, P1274, DOI 10.4161/hv.28371
   Hu WC, 2012, VIRAL IMMUNOL, V25, P277, DOI 10.1089/vim.2011.0099
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895
   Ilinskaya AN, 2016, TOXICOL APPL PHARM, V299, P70, DOI 10.1016/j.taap.2016.01.005
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Jabbar B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03000
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jiang PF, 2017, VACCINE, V35, P3096, DOI 10.1016/j.vaccine.2017.04.031
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Jutras I, 2005, ANNU REV CELL DEV BI, V21, P511, DOI 10.1146/annurev.cellbio.20.010403.102755
   Kaliamurthi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010063
   Kamthania M, 2019, INT J PEPT RES THER, V25, P1627, DOI 10.1007/s10989-018-09805-z
   Kavoosi M, 2007, BIOTECHNOL BIOENG, V98, P599, DOI 10.1002/bit.21396
   Kim HJ, 2007, ARCH PHARM RES, V30, P366, DOI 10.1007/BF02977620
   Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Krogsgaard M, 2005, NAT IMMUNOL, V6, P239, DOI 10.1038/ni1173
   Kumar N, 2020, J CHEM INF MODEL, V60, P421, DOI 10.1021/acs.jcim.9b01051
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu CY, 2017, BRIT J HAEMATOL, V178, P413, DOI 10.1111/bjh.14686
   Lu IN, 2017, CELL MOL IMMUNOL, V14, P511, DOI 10.1038/cmi.2016.20
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahmoodi S, 2016, CURR PHARM BIOTECHNO, V17, P1100, DOI 10.2174/1389201017666160914191106
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Messaoudi A, 2013, THEOR BIOL MED MODEL, V10, DOI 10.1186/1742-4682-10-22
   Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313
   Mishra S, 2009, J BIOMOL STRUCT DYN, V27, P293, DOI 10.1080/07391102.2009.10507317
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Nain Z, 2019, IMMUNOINFORMATIC DYN, DOI [10.1101/758219, DOI 10.1101/758219]
   Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Nielsen H, 2017, METHODS MOL BIOL, V1611, P59, DOI 10.1007/978-1-4939-7015-5_6
   Nosrati M, 2019, J BIOMED INFORM, V93, DOI 10.1016/j.jbi.2019.103160
   Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944
   Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209
   Patel MC, 2014, FUTURE VIROL, V9, P811, DOI 10.2217/fvl.14.70
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Phongsisay V, 2015, MOL IMMUNOL, V66, P463, DOI 10.1016/j.molimm.2015.05.008
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sbai H., 2001, Current Drug Targets - Infectious Disorders, V1, P303, DOI 10.2174/1568005014605955
   Sette A, 2003, CURR OPIN IMMUNOL, V15, P461, DOI 10.1016/S0952-7915(03)00083-9
   Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199
   Shastri N, 2005, IMMUNOL REV, V207, P31, DOI 10.1111/j.0105-2896.2005.00321.x
   Slingluff CL, 2013, CLIN CANCER RES, V19, P4228, DOI 10.1158/1078-0432.CCR-13-0002
   Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   TAMURA S, 1989, VACCINE, V7, P503, DOI 10.1016/0264-410X(89)90273-9
   Testa JS, 2012, FUTURE VIROL, V7, P1077, DOI 10.2217/FVL.12.108
   Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Turner P., 2005, XMGRACE VERSION 5 1
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Vangone A, 2019, BIOINFORMATICS, V35, P1585, DOI 10.1093/bioinformatics/bty816
   Vangone A, 2015, ELIFE, V4, DOI 10.7554/eLife.07454
   Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316
   Walker J M, 2005, PROTEOMICS PROTOCOLS
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wilson CC, 2001, J VIROL, V75, P4195, DOI 10.1128/JVI.75.9.4195-4207.2001
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Xagorari Angeliki, 2008, Open Microbiol J, V2, P49, DOI 10.2174/1874285800802010049
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Yang JY, 2020, P NATL ACAD SCI USA, V117, P1496, DOI 10.1073/pnas.1914677117
   Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yin DH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1552-9
   Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92
   Zhou WY, 2009, VACCINE, V27, P5013, DOI 10.1016/j.vaccine.2009.05.009
   Zhu SL, 2014, APPL MICROBIOL BIOT, V98, P4107, DOI 10.1007/s00253-014-5517-x
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 129
TC 5
Z9 5
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 2
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-67749-1
PG 130
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MM2QW
UT WOS:000550002500003
PM 32616763
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Song, SH
   Chen, TL
   Deng, LP
   Zhang, YX
   Mo, PZ
   Gao, SC
   Hu, WJ
   Xiong, Y
   Ma, ZY
AF Song, Shi-Hui
   Chen, Tie-Long
   Deng, Li-Ping
   Zhang, Yong-Xi
   Mo, Ping-Zheng
   Gao, Shi-Cheng
   Hu, Wen-Jia
   Xiong, Yong
   Ma, Zhi-Yong
TI Clinical characteristics of four cancer patients with SARS-CoV-2
   infection in Wuhan, China
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE Severe acute respiratory syndrome coronavirus 2; Coronavirus disease
   2019; Cancer; Wuhan
ID CORONAVIRUS; PNEUMONIA
AB Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the outbreak of pneumonia in Wuhan. The virus is highly infectious. Patients with cancer might be susceptible to the viral infection because of the immunosuppressive state cause by therapies on tumors. Case presentation We present the clinical features of four cancer patients who were infected with SARS-CoV-2 in late January of 2020 in our hospital. Cases 1 and 3 were diagnosed as mild and common type of coronavirus disease 2019 (COVID-2019) and survived from the viral infection. They acquired SARS-CoV-2 infection during their staying in hospital under radiotherapy and surgery of the tumors. Cases 2 and 4 suffered from severe type of COVID-19, and Case 2 was dead owning to the advanced age, uncontrolled chronic B cell lymphocytic leukemia and many other underlying diseases. The immunosuppressive state induced by liver transplantation and anti-rejection therapy might contribute to the severity of COVID-19 in Case 4, who suffered from hepatitis B related hepatocellular carcinoma. However, Case 4 was recovered from COVID-19 after a combination therapy against virus, bacteria and fungi, and also respiratory support. Nearly all patients showed a decrease in lymphocytes including total CD3(+)T cells, B cells, and natural killer cells after infection of the virus. Conclusions The severity of COVID-19 might be influenced by immune system state and underlying diseases in cancer patients. And the treatment of SARS-CoV-2 infection in cancer patients is challenged by the immunosuppressive state of these patients under chemotherapy or surgery.
C1 [Song, Shi-Hui; Chen, Tie-Long; Deng, Li-Ping; Zhang, Yong-Xi; Mo, Ping-Zheng; Gao, Shi-Cheng; Hu, Wen-Jia; Xiong, Yong; Ma, Zhi-Yong] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Donghu Rd 169, Wuhan 430071, Peoples R China.
RP Ma, ZY (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Donghu Rd 169, Wuhan 430071, Peoples R China.
EM mzy2001pl@163.com
OI xiong, yong/0000-0003-0678-4064
FU Medical Science Advancement Program (Basic Medical Sciences) of Wuhan
   University [TFJC2018002]; National Natural Science Foundation,
   ChinaNational Natural Science Foundation of China (NSFC) [81401663]
FX This research was supported by the Medical Science Advancement Program
   (Basic Medical Sciences) of Wuhan University, Grant No. TFJC2018002 (to
   Y.X.) and by a grant from the National Natural Science Foundation,
   China, Grant No. 81401663 (to Z.M.).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   World Health Organization, COR DIS COVID 2019 S
   Xu B, 2020, CHINA J INFECT, VS0163-4453, P30223
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 16
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD JUL 2
PY 2020
VL 9
IS 1
AR 82
DI 10.1186/s40249-020-00707-1
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA MK4PF
UT WOS:000548769500001
PM 32616030
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez, R
   Garcia-Otero, L
   Pons-Duran, C
   Marban-Castro, E
   Gonce, A
   Llurba, E
   Gil, MD
   Rodriguez-Zambrano, MA
   Chen, HL
   Ramirez, M
   Bardaji, A
   Menendez, C
AF Gonzalez, Raquel
   Garcia-Otero, Laura
   Pons-Duran, Clara
   Marban-Castro, Elena
   Gonce, Anna
   Llurba, Elisa
   Gil, Maria del Mar
   Rodriguez-Zambrano, Miguel Angel
   Chen, Haily
   Ramirez, Maximo
   Bardaji, Azucena
   Menendez, Clara
TI Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2
   infection and COVID-19 disease severity during pregnancy (COVID-Preg): a
   structured summary of a study protocol for a randomised placebo
   controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Protocol; Hydroxychloroquine;
   Pregnant; Women
AB Objectives: The primary objectives of the study are:
   1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms.
   2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case.
   3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women.
   The secondary objectives are:
   1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women.
   2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women.
   3. To assess the safety and tolerability of HCQ in pregnant women.
   4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy.
   5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group.
   6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2.
   Trial design: Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1.
   Participants: Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case.
   Inclusion criteria
   Women will be invited to participate in the trial and sign an informed consent if they meet the following inclusion criteria.
   Presenting with fever (>= 37.5 degrees C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact* of a SARS-CoV-2 confirmed or suspected case in the past 14 days
   More than 12 weeks of gestation (dated by ultrasonography)
   Agreement to deliver in the study hospitals
   Exclusion criteria
   Known hypersensitivity to HCQ or other 4-amonoquinoline compounds
   History of retinopathy of any aetiology
   Concomitant use of digoxin, cyclosporine, cimetidine
   Known liver disease
   Clinical history of cardiac pathology including known long QT syndrome
   Unable to cooperate with the requirements of the study
   Participating in other intervention studies
   Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours)
   The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants to study groups will be as follows:
   SARS-CoV-2-PCR confirmed, infected pregnant women:
   a. symptomatic (n=100)
   b. asymptomatic (n=100)
   SARS-CoV-2 PCR negative pregnant women in contact* with a SARS-CoV-2-infected confirmed or suspected case (n=514).
   *The ECDC definition of close contact will be followed.
   The trial will be conducted in five hospitals in Spain: Hospital Clinic of Barcelona, Hospital Sant Joan de Deu and Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejon, in Madrid.
   Intervention and comparator: Participants will be randomized to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days).
   Main outcomes: The primary outcome is the number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is completed).
   Randomisation: Allocation of participants to study arms will be done centrally by the trial's Sponsor (the Barcelona Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms. The electronic CRF will automatically assign a study number to each participant, depending on her study group and recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms.
   Blinding (masking): Participants, caregivers, investigators and those assessing the outcomes will be blinded to group assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles.
   Numbers to be randomised (sample size): This study requires 200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm.
   Trial Status: Protocol version 1.0, from May 8th, 2020. Recruitment is ongoing (first patient recruited the 19th May 2020 and recruitment end anticipated by December 2020).
   Trial registration: EudraCT number: 2020-001587-29, registered 2 April 2020.
   Clinicaltrials.gov identifier: NCT04410562, retrospectively registered 1 June 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Gonzalez, Raquel; Garcia-Otero, Laura; Pons-Duran, Clara; Marban-Castro, Elena; Chen, Haily; Ramirez, Maximo; Bardaji, Azucena; Menendez, Clara] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain.
   [Gonzalez, Raquel; Pons-Duran, Clara; Marban-Castro, Elena; Bardaji, Azucena; Menendez, Clara] Consorcio Invest Biomed Red Epidemiol & Salud Pub, Barcelona, Spain.
   [Gonzalez, Raquel; Garcia-Otero, Laura; Bardaji, Azucena; Menendez, Clara] Manhica Hlth Res Ctr CISM, Manhica, Mozambique.
   [Gonce, Anna] Hosp Clin Barcelona, BCNATAL Barcelona Ctr Maternal Fetal & Neonatal M, Barcelona, Spain.
   [Llurba, Elisa] Hosp Santa Creu & Sant Pau, Obstet & Gynecol Dept, Barcelona, Spain.
   [Gil, Maria del Mar] Hosp Univ Torrejon, Obstet & Gynecol Dept, Madrid, Spain.
   [Gil, Maria del Mar] Univ Francisco de Vitoria, Sch Med, Madrid, Spain.
   [Rodriguez-Zambrano, Miguel Angel] HM Puerta Sur, Madrid, Spain.
RP Gonzalez, R (corresponding author), Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain.; Gonzalez, R (corresponding author), Consorcio Invest Biomed Red Epidemiol & Salud Pub, Barcelona, Spain.; Gonzalez, R (corresponding author), Manhica Hlth Res Ctr CISM, Manhica, Mozambique.
EM raquel.gonzalez@isglobal.org
RI ; Bardaji, Azucena/V-5978-2018
OI Marban-Castro, Elena/0000-0002-9715-0595; Bardaji,
   Azucena/0000-0002-5135-0540
FU Instituto de Salud Carlos III from the Spanish Ministry of Science and
   Innovation [COV20/286]
FX The trial is funded by the Instituto de Salud Carlos III from the
   Spanish Ministry of Science and Innovation extraordinary research call
   on SARS-COV-2 and COVID-19. Project code: COV20/286 (approved on April
   17th, 2020). The funding body has no role in the design of the study,
   collection of data and in writing the manuscript.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 2
PY 2020
VL 21
IS 1
AR 607
DI 10.1186/s13063-020-04557-y
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MK7DV
UT WOS:000548945600004
PM 32616063
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gao, KF
   Nguyen, DD
   Chen, JH
   Wang, R
   Wei, GW
AF Gao, Kaifu
   Duc Duy Nguyen
   Chen, Jiahui
   Wang, Rui
   Wei, Guo-Wei
TI Repositioning of 8565 Existing Drugs for COVID-19
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID DESIGN
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 7.1 million people and led to over 0.4 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than 10 years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental data set for SARS-CoV-2 or SARS-CoV 3CL (main) protease inhibitors. On the basis of this data set, we develop validated machine learning models with relatively low root-mean-square error to screen 1553 FDA-approved drugs as well as another 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 3CL protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.
C1 [Wei, Guo-Wei] Michigan State Univ, Dept Math, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
   [Gao, Kaifu; Chen, Jiahui; Wang, Rui] Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.
   [Duc Duy Nguyen] Univ Kentucky, Dept Math, Lexington, KY 40506 USA.
RP Wei, GW (corresponding author), Michigan State Univ, Dept Math, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.; Wei, GW (corresponding author), Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
EM wei@math.msu.edu
OI Wei, Guowei/0000-0002-5781-2937
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM126189]; NSFNational Science
   Foundation (NSF) [DMS-1721024, DMS-1761320, IIS1900473]; Michigan
   Economic Development Corporation; Bristol-Myers SquibbBristol-Myers
   Squibb; PfizerPfizer
FX This work was supported in part by NIH Grant GM126189; NSF Grants
   DMS-1721024, DMS-1761320, and IIS1900473; Michigan Economic Development
   Corporation; Bristol-Myers Squibb; and Pfizer. The authors thank The IBM
   TJ Watson Research Center, The COVID-19 High Performance Computing
   Consortium, NVIDIA, and MSU HPCC for computational assistance supporting
   this work.
CR Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Amelio I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.9
   Bacha U, 2008, CHEM BIOL DRUG DES, V72, P34, DOI 10.1111/j.1747-0285.2008.00679.x
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Brown AS, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.29
   Cang ZX, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005929
   Nguyen DD, 2020, J COMPUT AID MOL DES, V34, P131, DOI 10.1007/s10822-019-00237-5
   Gao KF, 2020, PHYS CHEM CHEM PHYS, V22, P8373, DOI 10.1039/d0cp00305k
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Lee CC, 2009, J BIOL CHEM, V284, P7646, DOI 10.1074/jbc.M807947200
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Li H., 2020, WILEY INTERDISCIP RE
   Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   MacIntyre C. R., 2019, GLOB BIOSECUR, V1, P1, DOI [10.31646/gbio.51., DOI 10.31646/GBIO.51]
   Patwardhan B, 2016, INNOVATIVE APPROACHE
   Peon A, 2019, CHEM BIOL DRUG DES, V94, P1390, DOI 10.1111/cbdd.13516
   Sheridan RP, 2016, J CHEM INF MODEL, V56, P2353, DOI 10.1021/acs.jcim.6b00591
   Sidorov P, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00509
   Soufan O., 2018, SCI REP, V8, P1
   Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y
   Wang RX, 2004, J MED CHEM, V47, P2977, DOI 10.1021/jm030580l
   Weston S., 2020, BIORXIV, DOI [10.1101/2020.03.25.008482, DOI 10.1101/2020.03.25.008482]
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z., 2020, NELFINAVIR WAS PREDI
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 31
TC 3
Z9 3
U1 1
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD JUL 2
PY 2020
VL 11
IS 13
BP 5373
EP 5382
DI 10.1021/acs.jpclett.0c01579
PG 10
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA MI5SW
UT WOS:000547468400066
PM 32543196
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bhatnager, R
   Bhasin, M
   Arora, J
   Dang, AMS
AF Bhatnager, Richa
   Bhasin, Maheshwar
   Arora, Jyoti
   Dang, Amita S.
TI Epitope based peptide vaccine against SARS-COV2: an immune-informatics
   approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-COV2; COVID 19; epitope mapping; population coverage; insilico
   cloning
ID WEB SERVER; PREDICTION; PROTEINS; SPIKE
AB World is witnessing exponential growth of SARS-CoV2 and fatal outcomes of COVID 19 has proved its pandemic potential already by claiming more than 3 lakhs deaths globally. If not controlled, this ongoing pandemic can cause irreparable socio-economic and psychological impact worldwide. Therefore a safe and effective vaccine against COVID 19 is exigent. Recent advances in immunoinformatics approaches could potentially decline the attrition rate and accelerate the process of vaccine development in these unprecedented times. In the present study, a multivalent subunit vaccine targeting S2 subunit of the SARS-CoV2 S glycoprotein has been designed using open source, immunoinformatics tools. Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) and Interferon gamma. physiologically, vaccine construct is predicted to be thermostable, antigenic, immunogenic, non allergen and non toxic in nature. According to population coverage analysis, designed multiepitope vaccine covers 99.26% population globally. 3D structure of vaccine construct was designed, validated and refined to obtain high quality structure. Refined structure was docked against Toll like receptors to confirm the interactions between them. Vaccine peptide sequence was reverse transcribed, codon optimized and cloned in pET vector. Ourin-silicostudy suggests that proposed vaccine against fusion domain of virus has the potential to elicit an innate as well as humoral immune response in human and restrict the entry of virus inside the cell. Results of the study offer a framework for in-vivo analysis that may hasten the process of development of therapeutic tools against COVID 19. Communicated by Ramaswamy H. Sarma
C1 [Bhatnager, Richa; Arora, Jyoti; Dang, Amita S.] Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
   [Bhasin, Maheshwar] Lady Hardinge Med Coll & Associated Hosp, Dept Neonatol, New Delhi, India.
RP Dang, AMS (corresponding author), Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
EM suneja_a@yahoo.co.in
RI Bhasin, Maheshwar/ABI-1499-2020
OI Bhasin, Maheshwar/0000-0002-9511-6991; Dang, Amita/0000-0002-5015-3502
CR Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, WHO SIT REP
   Bairoch A, 2008, NUCLEIC ACIDS RES, V36, pD190, DOI 10.1093/nar/gkm895
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Hajighahramani N, 2019, MOL CELL PROBE, V46, DOI 10.1016/j.mcp.2019.06.004
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Liu IH, 2011, NUCLEIC ACIDS RES, V39, pW254, DOI 10.1093/nar/gkr434
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magnan CN, 2014, BIOINFORMATICS, V30, P2592, DOI 10.1093/bioinformatics/btu352
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   Mukonyora M., 2015, J CLIN CELL IMMUNOL, V6, P358
   NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226
   Ong E., 2020, COVID 19 CORONAVIRUS, DOI [10.1101/2020.03.20.000141, DOI 10.1101/2020.03.20.000141]
   Park C. Y., 2020, UPDATED ASSESSMENT P, DOI [10.22617/BRF200144-2, DOI 10.22617/BRF200144-2]
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Reche Pedro A., 2007, V409, P185, DOI 10.1007/978-1-60327-118-9_13
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tignanelli CJ, 2020, LANCET RESP MED, V8, pE30, DOI 10.1016/S2213-2600(20)30153-3
   von Tigerstrom B, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002629
   Wachyuni S. S., 2020, J ED SOC BEHAV SCI, P67, DOI DOI 10.9734/JESBS/2020/V33I430219
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   World Health Organization, 2020, PROT ASS POT RISK FA
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
NR 45
TC 5
Z9 5
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1787227
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MG8SF
UT WOS:000546302000001
PM 32619134
OA Bronze
DA 2021-01-01
ER

PT J
AU Sasidharan, S
   Selvaraj, C
   Singh, SK
   Dubey, VK
   Kumar, S
   Fialho, AM
   Saudagar, P
AF Sasidharan, Santanu
   Selvaraj, Chandrabose
   Singh, Sanjeev Kumar
   Dubey, Vikash Kumar
   Kumar, Sachin
   Fialho, Arsenio M.
   Saudagar, Prakash
TI Bacterial protein azurin and derived peptides as potential
   anti-SARS-CoV-2 agents: insights from molecular docking and molecular
   dynamics simulations
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; azurin; p28; coronavirus; molecular dynamic simulation
ID RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE; MAIN PROTEASE;
   SIGNALING PATHWAY; SPIKE PROTEIN; INHIBITORS; IDENTIFICATION; DESIGN;
   VIRUS; COV
AB The current pandemic SARS-CoV-2 has wreaked havoc in the world, and neither drugs nor vaccine is available for the treatment of this disease. Thus, there is an immediate need for novel therapeutics that can combat this deadly infection. In this study, we report the therapeutic assessment of azurin and its peptides: p18 and p28 against the viral structural S-protein and non-structural 3CL(pro)and PL(pro)proteins. Among the analyzed complexes, azurin docked relatively well with the S2 domain of S-protein compared to the other viral proteins. The derived peptide p18 bound to the active site domain of the PL(pro)protein; however, in other complexes, lesser interactions were recorded. The second azurin derived peptide p28, fared the best among the docked proteins. p28 interacted with all the three viral proteins and the host ACE-2 receptor by forming several electrostatic and hydrogen bonds with the S-protein, 3CL(pro), and PLpro. MD simulations indicated that p28 exhibited a strong affinity to S-protein and ACE-2 receptor, indicating a possibility of p28 as a protein-protein interaction inhibitor. Our data suggest that the p28 has potential as an anti-SARS-CoV-2 agent and can be further exploited to establish its validity in the treatment of current and future SARS-CoV crisis. Communicated by Ramaswamy H. Sarma
C1 [Sasidharan, Santanu; Saudagar, Prakash] Natl Inst Technol, Dept Biotechnol, Warangal 506004, Telangana, India.
   [Selvaraj, Chandrabose; Singh, Sanjeev Kumar] Alagappa Univ, Dept Bioinformat, Comp Aided Drug Design & Mol Modeling Lab, Karaikkudi, Tamil Nadu, India.
   [Dubey, Vikash Kumar] Indian Inst Technol BHU, Sch Biochem Engn, Varanasi, Uttar Pradesh, India.
   [Kumar, Sachin] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati, Assam, India.
   [Fialho, Arsenio M.] Univ Lisbon, Inst Bioengn & Biosci iBB, Inst Super Tecn, Dept Bioengn, Lisbon, Portugal.
RP Saudagar, P (corresponding author), Natl Inst Technol, Dept Biotechnol, Warangal 506004, Telangana, India.
EM ps@nitw.ac.in
RI Sasidharan, Santanu/M-3429-2016; Fialho, Arsenio/A-6246-2008; Saudagar,
   Prakash/ABE-7270-2020; Selvaraj, Chandrabose/F-4168-2012
OI Sasidharan, Santanu/0000-0002-0204-0263; Fialho,
   Arsenio/0000-0002-8066-5787; Saudagar, Prakash/0000-0001-7211-0581;
   Selvaraj, Chandrabose/0000-0002-8115-0486
FU NIT Warangal; RUSA-Phase 2.0 Policy (TNmulti-Gen), Dept. of Edn, Govt.
   of India [F.24-51/2014-U]
FX The author SS acknowledges research fellowship from NIT Warangal. CS and
   SKS thankfully acknowledge RUSA-Phase 2.0 Policy (TNmulti-Gen), Dept. of
   Edn, Govt. of India (Grant No: F.24-51/2014-U).
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abdelli I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763199
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bohra N, 2020, MOL SIMULAT, V46, P419, DOI 10.1080/08927022.2020.1720916
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chakrabarty AM, 2016, CELL CYCLE, V15, P1665, DOI 10.1080/15384101.2016.1179034
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chaudhari A, 2006, CELL CYCLE, V5, P1642, DOI 10.4161/cc.5.15.2992
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XJ, 2014, PROTEIN CELL, V5, P369, DOI 10.1007/s13238-014-0026-3
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   CHINNASAMY S, 2019, J BIOMOL STRUCT 1011, DOI DOI https://doi.org/10.1080/07391102.2019.1674695
   Chinnasamy S, 2020, INT J BIOL MACROMOL, V144, P53, DOI 10.1016/j.ijbiomac.2019.12.091
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duncan AL, 2016, P NATL ACAD SCI USA, V113, P8687, DOI 10.1073/pnas.1608396113
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Gupta MK, 2020, J BIOMOL STRUCT DYN, V38, P137, DOI 10.1080/07391102.2019.1567391
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   HABAULT J, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24050927
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Garzon JI, 2009, BIOINFORMATICS, V25, P2544, DOI 10.1093/bioinformatics/btp447
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kalita P, 2019, INT J BIOL MACROMOL, V138, P224, DOI 10.1016/j.ijbiomac.2019.07.024
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li SW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050678
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   Mittal A, 2020, INT J PEPT RES THER, V0, P1
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Naguleswaran A, 2008, ANTIMICROB AGENTS CH, V52, P402, DOI 10.1128/AAC.01005-07
   Naskar D, 2020, ACM T INFORM SYST, V38, DOI 10.1145/3379340
   Nava M, 2018, J COMPUT CHEM, V39, P2126, DOI 10.1002/jcc.25386
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Padhi A. K., 2020, HIGH THROUGHPUT DESI, P1
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Qi RX, 2018, METHODS MOL BIOL, V1777, P101, DOI 10.1007/978-1-4939-7811-3_5
   Ramirez-Aportela E, 2016, BIOINFORMATICS, V32, P2386, DOI 10.1093/bioinformatics/btw141
   Rana G, 2020, J BIOMOL STRUCT DYN, V38, P124, DOI 10.1080/07391102.2019.1568303
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sasidharan S, 2020, SPECTROCHIM ACTA A, V232, DOI 10.1016/j.saa.2020.118133
   Sasidharan S, 2019, FEBS OPEN BIO, V9, P1769, DOI 10.1002/2211-5463.12715
   Selvaraj C, 2018, FOOD CHEM TOXICOL, V112, P495, DOI 10.1016/j.fct.2017.08.028
   Selvaraj C, 2014, J MOL RECOGNIT, V27, P696, DOI 10.1002/jmr.2395
   Selvaraj C, 2014, APPL BIOCHEM BIOTECH, V172, P1790, DOI 10.1007/s12010-013-0641-0
   SHAFIQUE S, 2019, SCI REP UK, V9, DOI DOI https://doi.org/10.1038/s41598-019-43392-3
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Shukla R, 2018, J BIOMOL STRUCT DYN, V36, P3541, DOI 10.1080/07391102.2017.1392897
   Shukla R, 2018, J BIOMOL STRUCT DYN, V36, P2147, DOI 10.1080/07391102.2017.1344141
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Taylor BN, 2009, CANCER RES, V69, P537, DOI 10.1158/0008-5472.CAN-08-2932
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xia S, 2014, VIRUS RES, V194, P200, DOI 10.1016/j.virusres.2014.10.007
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong N, 2008, J VIROL, V82, P4227, DOI 10.1128/JVI.02612-07
   Zhou PL, 2020, PLANT MOL BIOL REP, V38, P1, DOI 10.1007/s11105-019-01167-0
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 88
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1787864
EA JUL 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MG8OU
UT WOS:000546292200001
PM 32619162
OA Bronze
DA 2021-01-01
ER

PT J
AU Santibanez-Moran, MG
   Lopez-Lopez, E
   Prieto-Martinez, FD
   Sanchez-Cruz, N
   Medina-Franco, JL
AF Santibanez-Moran, Marisa G.
   Lopez-Lopez, Edgar
   Prieto-Martinez, Fernando D.
   Sanchez-Cruz, Norberto
   Medina-Franco, Jose L.
TI Consensus virtual screening of dark chemical matter and food chemicals
   uncover potential inhibitors of SARS-CoV-2 main protease
SO RSC ADVANCES
LA English
DT Article
ID SARS; DOCKING; COMBINATION; FUSION
AB The pandemic caused by SARS-CoV-2 (COVID-19 disease) has claimed more than 500 000 lives worldwide, and more than nine million people are infected. Unfortunately, an effective drug or vaccine for its treatment is yet to be found. The increasing information available on critical molecular targets of SARS-CoV-2 and active compounds against related coronaviruses facilitates the proposal (or repurposing) of drug candidates for the treatment of COVID-19, with the aid ofin silicomethods. As part of a global effort to fight the COVID-19 pandemic, herein we report a consensus virtual screening of extensive collections of food chemicals and compounds known as dark chemical matter. The rationale is to contribute to global efforts with a description of currently underexplored chemical space regions. The consensus approach included combining similarity searching with various queries and fingerprints, molecular docking with two docking protocols, and ADMETox profiling. We propose compounds commercially available for experimental testing. The full list of virtual screening hits is disclosed.
C1 [Santibanez-Moran, Marisa G.; Prieto-Martinez, Fernando D.; Sanchez-Cruz, Norberto; Medina-Franco, Jose L.] Univ Nacl Autonoma Mexico, Sch Chem, Dept Pharm, DIFACQUIM Res Grp, Mexico City, DF, Mexico.
   [Lopez-Lopez, Edgar] Natl Polytech Inst CINVESTAV, Ctr Res & Adv Studies, Dept Pharmacol, Mexico City, DF, Mexico.
RP Medina-Franco, JL (corresponding author), Univ Nacl Autonoma Mexico, Sch Chem, Dept Pharm, DIFACQUIM Res Grp, Mexico City, DF, Mexico.
EM medinajl@unam.mx
RI Medina-Franco, Jose/AAJ-1633-2020; Sanchez-Cruz, Norberto/ABF-2765-2020;
   Prieto-Martinez, Fernando D./ABF-3882-2020
OI Medina-Franco, Jose/0000-0003-4940-1107; Sanchez-Cruz,
   Norberto/0000-0003-2707-3966; Prieto-Martinez, Fernando
   D./0000-0002-0054-0862; LOPEZ LOPEZ, EDGAR/0000-0002-7422-6059;
   Santibanez-Moran, Marisa G./0000-0002-6173-7271
FU CONACyT (Consejo Nacional de Ciencia y Tecnologia, Mexico)Consejo
   Nacional de Ciencia y Tecnologia (CONACyT) [762342]; CONACYTConsejo
   Nacional de Ciencia y Tecnologia (CONACyT) [660465/576637, 335997];
   NUATEI (Nuevas Alternativas para el Tratamiento de Enfermedades
   Infecciosas) program IBT-UNAM
FX E. Lopez-Lopez thanks CONACyT (Consejo Nacional de Ciencia y Tecnologia,
   Mexico) for the scholarship granted: 762342. F. D. Prieto-Martinez and
   N. Sanchez-Cruz are also grateful to CONACYT for the PhD scholarship
   granted, No. 660465/576637, and 335997, respectively. We thank the
   financial support of the NUATEI (Nuevas Alternativas para el Tratamiento
   de Enfermedades Infecciosas) program IBT-UNAM to purchase MOE license.
   Valuable discussions with Artem Cherkasov and members of the DIFACQUIM
   research group, in particular Noemi Angeles Duran-Iturbide and Alejandro
   Gomez-Garcia, are greatly acknowledged. Authors would like to thank
   Kenia Morales-Bermeo for help designing Fig. 2.
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Ali J, 2012, J CHEM INF MODEL, V52, P420, DOI 10.1021/ci200387c
   Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x
   Andrade B., 2020, PREPRINTS, DOI [10.20944/preprints202004.0003.v1, DOI 10.20944/PREPRINTS202004.0003.V1]
   Duran-Iturbide NA, 2020, ACS OMEGA, V5, P16076, DOI 10.1021/acsomega.0c01581
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], MET INN CTR FOODB VE
   Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3
   Ballante F, 2020, J MED CHEM, V63, P613, DOI 10.1021/acs.jmedchem.9b01560
   Beisken S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-257
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Bobrowski Tesia, 2020, ChemRxiv, DOI 10.26434/chemrxiv.12153594.v1
   CAI Q, 2020, ALLERGY 0417, DOI DOI 10.1101/2020.02.17.20024018
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen BN, 2010, MOL INFORM, V29, P533, DOI 10.1002/minf.201000050
   Chen H., 2020, PREPRINTS, DOI [10.20944/preprints202001.0358.v3, DOI 10.20944/PREPRINTS202001.0358.V3]
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Fischer A., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.11923239.v1, DOI 10.26434/CHEMRXIV.11923239.V1]
   Fischer A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103626
   Gardiner E. J., 2009, STAT ANAL DATA MIN, V2, P103, DOI DOI 10.1002/SAM.10037
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gonzalez-Medina M, 2017, RSC ADV, V7, P54153, DOI 10.1039/c7ra11831g
   Hu L., 2020, MEDRXIV, DOI [10.1101/2020.03.25.20037721, DOI 10.1101/2020.03.25.20037721]
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kim Y, 2013, ANTIVIR RES, V97, P161, DOI 10.1016/j.antiviral.2012.11.005
   Lee H, 2014, BIOORGAN MED CHEM, V22, P167, DOI 10.1016/j.bmc.2013.11.041
   Li Y., 2020, MEDRXIV, DOI [10.1101/2020.03.19.20038984, DOI 10.1101/2020.03.19.20038984]
   Liu S, 2020, BIOINFORMATICS, V36, P1066, DOI 10.1093/bioinformatics/btz725
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Lopez-Lopez Edgar, 2020, Adv Protein Chem Struct Biol, V122, P203, DOI 10.1016/bs.apcsb.2020.04.001
   Medina-Franco JL, 2007, CHEM BIOL DRUG DES, V70, P393, DOI 10.1111/j.1747-0285.2007.00579.x
   Medina-Franco JL, 2009, J CHEM INF MODEL, V49, P477, DOI 10.1021/ci800379q
   Molecular Materials Informatics Inc, ASS CENTR PRED
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Naveja J Jesus, 2018, F1000Res, V7, DOI 10.12688/f1000research.15440.2
   Neuman BW, 2016, ADV VIRUS RES, V96, P1, DOI 10.1016/bs.aivir.2016.08.005
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Pena-Castillo A, 2018, APPLIED CHEMOINFORMATICS: ACHIEVEMENTS AND FUTURE OPPORTUNITIES, P501
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Prieto-Martinez FD, 2019, SILICO DRUG DESIGN, P19, DOI DOI 10.1016/B978-0-12-816125-8.00002-X
   Prieto-Martinez Fernando D., 2018, TIP Revista Especializada en Ciencias Quimico-Biologicas, V21, P65, DOI 10.22201/fesz.23958723e.2018.0.143
   Santibanez-Moran M. S., 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12420860.v1, DOI 10.26434/CHEMRXIV.12420860.V1]
   Selhub J, 2016, BIOCHIMIE, V126, P71, DOI 10.1016/j.biochi.2016.04.010
   Senathilake K., 2020, PREPRINTS, DOI [10.20944/preprints202003.0042.v2, DOI 10.20944/PREPRINTS202003.0042.V2]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vuong W., 2020, BIORXIV, DOI [10.1101/2020.05.03.073080, DOI 10.1101/2020.05.03.073080]
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wassermann Anne Mai, 2017, Drug Discov Today Technol, V23, P69, DOI 10.1016/j.ddtec.2016.11.004
   Wassermann AM, 2015, NAT CHEM BIOL, V11, P958, DOI 10.1038/nchembio.1936
   Willett P, 2013, J CHEM INF MODEL, V53, P1, DOI 10.1021/ci300547g
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.01.27.921627., DOI 10.1101/2020.01.27.921627]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yan D., 2020, MEDRXIV, DOI [10.1101/2020.03.22.20040832, DOI 10.1101/2020.03.22.20040832]
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
NR 66
TC 4
Z9 4
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JUL 2
PY 2020
VL 10
IS 42
BP 25089
EP 25099
DI 10.1039/d0ra04922k
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA MF5BL
UT WOS:000545357500029
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Vacchiano, V
   Riguzzi, P
   Volpi, L
   Tappata, M
   Avoni, P
   Rizzo, G
   Guerra, L
   Zaccaroni, S
   Cortelli, P
   Michelucci, R
   Liguori, R
AF Vacchiano, Veria
   Riguzzi, P.
   Volpi, L.
   Tappata, M.
   Avoni, P.
   Rizzo, G.
   Guerra, L.
   Zaccaroni, S.
   Cortelli, P.
   Michelucci, R.
   Liguori, R.
TI Early neurological manifestations of hospitalized COVID-19 patients
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Neurological manifestations; Headache; Test and smell
   disorders; Muscle pain
AB Introduction Neurological manifestations can occur during coronavirus disease 19 (COVID-19). Several pathogenic mechanisms have been hypothesized, without conclusive results. In this study, we evaluated the most frequent neurological symptoms in a cohort of hospitalized COVID-19 patients, and also investigated the possible relationship between plasmatic inflammatory indices and olfactory disorders (ODs) and between muscle pain and creatine kinase (CK). Methods We consecutively enrolled hospitalized COVID-19 patients. A structured questionnaire concerning typical and neurological symptoms, focusing on headache, dizziness, ODs, taste disorders (TDs), and muscle pain, was administrated by telephone interviews. Results Common neurological symptoms were reported in the early phase of the disease, with a median onset ranging from 1 to 3 days. Headache showed tension-type features and was more frequently associated with a history of headache. Patients with ODs less frequently needed oxygen therapy. Inflammatory indices did not significantly differ between patients with and without ODs. Muscle pain did not show any association with CK level but was more frequently associated with arthralgia and headache. Conclusion In our cohort, ODs were an early symptom of COVID-19, more frequently reported by patients with milder forms of disease. Headache in association with arthralgia and muscle pain seems to reflect the common symptoms of the flu-like syndrome, and not COVID-19 infection-specific.
C1 [Vacchiano, Veria; Riguzzi, P.; Volpi, L.; Tappata, M.; Avoni, P.; Rizzo, G.; Cortelli, P.; Michelucci, R.; Liguori, R.] IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
   [Avoni, P.; Rizzo, G.; Cortelli, P.; Liguori, R.] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy.
   [Guerra, L.; Zaccaroni, S.] Azienda USL Bologna, Dipartimento Med Osped Bellaria, Unita Med Interna, Bologna, Italy.
RP Vacchiano, V (corresponding author), IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
EM veriavacchiano@gmail.com
OI Rizzo, Giovanni/0000-0002-9718-2044
CR Brann DH, 2020, 20200325009084 BIORX
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Filippis C, 2020, EUR ARCH OTORHINOLAR, P6
   Henkin RI, 2013, JAMA OTOLARYNGOL, V139, P728, DOI 10.1001/jamaoto.2013.3392
   Jaime-Lara RB, 2020, ALLERGY RHINOL, V11, DOI 10.1177/2152656720928245
   Lai CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062196
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   MARLOWE NI, 1992, J PSYCHOSOM RES, V36, P17, DOI 10.1016/0022-3999(92)90110-N
   Yan CH, 2020, INT FORUM ALLERGY RH, P24
NR 9
TC 8
Z9 9
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD AUG
PY 2020
VL 41
IS 8
BP 2029
EP 2031
DI 10.1007/s10072-020-04525-z
EA JUL 2020
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MN9HP
UT WOS:000545949600005
PM 32617738
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bai, J
   Xu, T
   Ji, AP
   Sun, W
   Huang, MW
AF Bai, Jie
   Xu, Tao
   Ji, Ai-Ping
   Sun, Wei
   Huang, Ming-Wei
TI Impact of COVID-19 on oral emergency services
SO INTERNATIONAL DENTAL JOURNAL
LA English
DT Article; Early Access
DE COVID-19; oral; emergency
ID HEALTH-CARE; DENTAL-CARE; INFECTION; DENTISTRY; OUTBREAK
AB Objective To retrospectively review the impact of the outbreak of coronavirus disease 2019 (COVID-19) on services in the oral emergency room. Materials and methods A statistical analysis of epidemiological characteristics and the patients' diagnoses and treatments in the Emergency Department of Peking University Hospital of Stomatology during the outbreak of COVID-19 in 2020 compared with those in 2019 in Beijing, China. Results There were fewer total visits in 2020 than in 2019 (P = 0.001), and the proportions of patients who were children, adolescents and elderly people were lower in 2020 than in 2019 (P < 0.001). The proportions of patients with acute toothache and infections were higher in 2020 than in 2019, and the proportions of patients with maxillofacial trauma and non-emergencies were lower in 2020 than in 2019 (P < 0.001). Drug treatment for acute pulpitis was used more often in 2020 than in 2019, and endodontic treatment and examination consultations were less common in 2020 than in 2019 (P = 0.022). Conclusions The outbreak of COVID-19 affected the patient population and structure of disease types and oral services in the emergency room. The number of visits to the oral emergency room and the proportions of the patients who were children, adolescents and elderly people were reduced, meanwhile the percentage of emergency cases, except trauma, and conservative treatments increased during the outbreak of COVID-19.
C1 [Bai, Jie; Xu, Tao; Ji, Ai-Ping; Sun, Wei] Peking Univ, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing Key Lab Digital Stomatol, Dept Oral Emergency,Sch & Hosp Stomatol, Beijing, Peoples R China.
   [Huang, Ming-Wei] Peking Univ, Natl Engn Lab Digital & Mat Technol Stomatol, Natl Clin Res Ctr Oral Dis,Beijing Key Lab Digita, Dept Oral & Maxillofacial Surg,Sch & Hosp Stomato, Beijing, Peoples R China.
RP Huang, MW (corresponding author), Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.
EM hmwd97@126.com
OI Xu, Tao/0000-0001-8782-5010
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81502652]
FX This study was supported by National Natural Science Foundation of
   China, (Grant Number 81502652).
CR Cleveland JL, 2016, J AM DENT ASSOC, V147, P729, DOI 10.1016/j.adaj.2016.03.020
   Day Christian J, 2006, Dent Update, V33, P601
   Farmakis ETR, 2016, INT DENT J, V66, P280, DOI 10.1111/idj.12245
   General Office of National Health Commission of the People's Republic of China and General Office of National Administration of Traditional Chinese Medicine, GEN OFF NAT HLTH COM
   Harrel SK, 2004, J AM DENT ASSOC, V135, P429, DOI 10.14219/jada.archive.2004.0207
   Hoelscher M., 2020, NEW ENGL J MED, V382, P970, DOI [10.1056/NEJMc2001468, DOI 10.1056/NEJMC2001468]
   Huang JY, 2019, J DENT SCI, V14, P395, DOI 10.1016/j.jds.2019.08.003
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Liu L, 2011, J VIROL, V85, P4025, DOI 10.1128/JVI.02292-10
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Marshman Z, 2017, COMMUNITY DENT ORAL, V45, P49, DOI 10.1111/cdoe.12258
   National Health Commission of the People's Republic of China, NAT HLTH COMM PEOPL
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Shqair AQ, 2012, BRAZ ORAL RES, V26, P50, DOI 10.1590/S1806-83242012000100009
   Smales FC, 2003, BRIT DENT J, V195, P557, DOI 10.1038/sj.bdj.4810723
   Tramini P, 2010, SPEC CARE DENT, V30, P66, DOI 10.1111/j.1754-4505.2009.00125.x
   Xia B, 2006, J MODERN STOMATOL, V20, P214
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 18
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-6539
EI 1875-595X
J9 INT DENT J
JI Int. Dent. J.
DI 10.1111/idj.12603
EA JUL 2020
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA ME8LS
UT WOS:000544905400001
PM 32617968
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Clemens, J
AF Clemens, J.
TI Danger of Drug Nebulisation with COVID-19: much Smoke for nothing?
SO NOTFALL & RETTUNGSMEDIZIN
LA German
DT Letter
ID SARS
C1 [Clemens, J.] Klinikum Frankfurt Hochst GmbH, Klin Anasthesiol, Gotenstr 6-8, D-65929 Frankfurt, Germany.
RP Clemens, J (corresponding author), Klinikum Frankfurt Hochst GmbH, Klin Anasthesiol, Gotenstr 6-8, D-65929 Frankfurt, Germany.
EM jannickclemens@web.de
CR Devenport L(2020, 2020, TOP 10 MUST DOS COVI
   Farkas J., 2020, INTERNET BOOK CRITIC
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   WHO, 2020, WHO SCI BRIEF MOD TR
   Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452
NR 8
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1434-6222
EI 1436-0578
J9 NOTFALL RETTUNGSMED
JI Notfall Rettungsmed.
PD AUG
PY 2020
VL 23
IS 5
SI SI
BP 380
EP 381
DI 10.1007/s10049-020-00738-z
EA JUL 2020
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA MO4OA
UT WOS:000545058800001
PM 32837301
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xing, JM
   Loureiro, J
   Patel, MT
   Mikhailov, D
   Gusev, AI
AF Xing, Jinming
   Loureiro, Joseph
   Patel, Michael T.
   Mikhailov, Dmitri
   Gusev, Arkady I.
TI Evaluation of a novel blood microsampling device for clinical trial
   sample collection and protein biomarker analysis
SO BIOANALYSIS
LA English
DT Article
DE biomarkers; COVID-19; DBS; microsampling; patient-centric sampling;
   proteomics; sampling device; SomaScan; TAP; VAMS
ID DRIED-BLOOD; LC-MS/MS; QUANTITATIVE BIOANALYSIS; STABILITY; CAPILLARY;
   PLASMA; QUANTIFICATION; ACYLCARNITINES; MICRONEEDLE; SCALE
AB Aim: Evaluation of a novel microsampling device for its use in clinical sample collection and biomarker analysis. Methodology: Matching samples were collected from 16 healthy donors (ten females, six males; age 42 +/- 20) via K2EDTA touch activated phlebotomy (TAP) device and phlebotomy. The protein profile differences between sampling groups was evaluated using aptamer-based proteomic assay SomaScan and selected ELISA. Conclusion: Somascan signal concordance between phlebotomy- and TAP-generated samples was studied and comparability of protein abundances between these blood sample collection methods was demonstrated. Statistically significant correlation in selected ELISA assays also confirmed the TAP device applicability to the quantitative analysis of protein biomarkers in clinical trials.
C1 [Xing, Jinming; Patel, Michael T.; Mikhailov, Dmitri; Gusev, Arkady I.] Novartis Inst BioMed Res, Biomarker Dev, 220 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Loureiro, Joseph] Novartis Inst BioMed Res, Chem Biol & Therapeut, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Patel, Michael T.] Massachusetts Coll Pharm & Hlth Sci Univ, Biopharmaceut Ind Fellowship Program, 179 Longwood Ave, Boston, MA 02115 USA.
RP Gusev, AI (corresponding author), Novartis Inst BioMed Res, Biomarker Dev, 220 Massachusetts Ave, Cambridge, MA 02139 USA.
EM arkady.gusev@novartis.com
OI LOUREIRO, JOSEPH/0000-0001-7222-9160; Xing, Jinming/0000-0003-0501-6207
FU NovartisNovartis
FX Novartis is among the investors of Seventh Sense Biosystems, have
   provided financing to the company and is among Seventh Sense board
   members. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Abu-Rabie P, 2019, BIOANALYSIS, V11, P1737, DOI 10.4155/bio-2019-0190
   Adam BW, 2011, CLIN BIOCHEM, V44, P1445, DOI 10.1016/j.clinbiochem.2011.09.010
   [Anonymous], 2017, SOMASCAN DAT STAND
   Blicharz TM, 2018, NAT BIOMED ENG, V2, P151, DOI 10.1038/s41551-018-0194-1
   Borno HT, 2018, ONCOLOGIST, V23, P1242, DOI 10.1634/theoncologist.2017-0628
   Catala A, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1395-z
   Chace DH, 1999, CLIN CHEM, V45, P1269
   Chambers AG, 2015, MOL CELL PROTEOMICS, V14, P3094, DOI 10.1074/mcp.O115.049957
   Cheng SK, 2010, CLIN CANCER RES, V16, P5557, DOI 10.1158/1078-0432.CCR-10-0133
   Cookson P, 2004, VOX SANG, V87, P264, DOI 10.1111/j.1423-0410.2004.00566.x
   Cullen T, 2015, CYTOKINE, V71, P397, DOI 10.1016/j.cyto.2014.10.011
   De Kesel PMM, 2015, ANAL CHIM ACTA, V881, P65, DOI 10.1016/j.aca.2015.04.056
   Denniff P, 2015, J PHARMACEUT BIOMED, V108, P61, DOI 10.1016/j.jpba.2015.01.052
   Denniff P, 2014, ANAL CHEM, V86, P8489, DOI 10.1021/ac5022562
   Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327
   Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population, 2008, EUR J HLTH LAW, V15, P223
   Fingerhut R, 2009, ANAL CHEM, V81, P3571, DOI 10.1021/ac8022235
   Getz KA, 2017, NAT REV DRUG DISCOV, V16, P307, DOI 10.1038/nrd.2017.65
   Gold L, 2012, NEW BIOTECHNOL, V29, P543, DOI 10.1016/j.nbt.2011.11.016
   GUTHRIE R, 1963, PEDIATRICS, V32, P338
   Hartweg J, 2007, CLIN CHEM, V53, P1858, DOI 10.1373/clinchem.2006.076380
   Houbart V, 2015, BIOANALYSIS, V7, P2789, DOI 10.4155/bio.15.181
   Kauffmann Audrey, 2009, Bioinformatics, V25, P415, DOI 10.1093/bioinformatics/btn647
   Li CG, 2013, BIOMED MICRODEVICES, V15, P17, DOI 10.1007/s10544-012-9683-2
   Linder C, 2017, CLIN BIOCHEM, V50, P418, DOI 10.1016/j.clinbiochem.2016.12.008
   Lonsdale J, 2020, GUIDELINES CHOICE BL
   Mehan MR, 2013, ADV EXP MED BIOL, V735, P283, DOI 10.1007/978-1-4614-4118-2_20
   Mercolini L, 2016, J PHARMACEUT BIOMED, V123, P186, DOI 10.1016/j.jpba.2016.02.015
   Ozbek N, 2000, ACTA HAEMATOL-BASEL, V103, P226, DOI 10.1159/000041056
   Palmer OMP, 2017, SHOCK, V47, P715, DOI 10.1097/SHK.0000000000000805
   Pischon T, 2003, CLIN CHEM, V49, P650, DOI 10.1373/49.4.650
   Protti M, 2017, J CHROMATOGR B, V1044, P77, DOI 10.1016/j.jchromb.2016.12.038
   Savuto P, 2017, APPL CLIN TRIALS, V26, P34
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Strnadova KA, 2007, CLIN CHEM, V53, P717, DOI 10.1373/clinchem.2006.076679
   Sully BGO, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-166
   Tanaka Y, 2001, CLIN CHEM, V47, P1829
   Topping J, 2019, PREHOSP DISASTER MED, V34, P506, DOI 10.1017/S1049023X19004850
   Trufelli H, 2011, MASS SPECTROM REV, V30, P491, DOI 10.1002/mas.20298
   US FDA, 2019, TAP BLOOD COLL DEV 5
   Walters SJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015276
   Wittbrodt MT, 2015, CLIN CHEM LAB MED, V53, P1613, DOI 10.1515/cclm-2014-1006
NR 42
TC 2
Z9 2
U1 4
U2 4
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
EI 1757-6199
J9 BIOANALYSIS
JI Bioanalysis
PD JUL
PY 2020
VL 12
IS 13
BP 919
EP 935
DI 10.4155/bio-2020-0063
PG 17
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA PE7IL
UT WOS:000598536300007
PM 32686955
DA 2021-01-01
ER

PT J
AU Lubetzky, M
   Aull, MJ
   Craig-Schapiro, R
   Lee, JR
   Marku-Podvorica, J
   Salinas, T
   Gingras, L
   Lee, JB
   Sultan, S
   Kodiyanplakkal, RP
   Hartono, C
   Saal, S
   Muthukumar, T
   Kapur, S
   Suthanthiran, M
   Dadhania, DM
AF Lubetzky, Michelle
   Aull, Meredith J.
   Craig-Schapiro, Rebecca
   Lee, John R.
   Marku-Podvorica, Jehona
   Salinas, Thalia
   Gingras, Laura
   Lee, Jun B.
   Sultan, Samuel
   Kodiyanplakkal, Rosy Priya
   Hartono, Choli
   Saal, Stuart
   Muthukumar, Thangamani
   Kapur, Sandip
   Suthanthiran, Manikkam
   Dadhania, Darshana M.
TI Kidney allograft recipients, immunosuppression, and coronavirus
   disease-2019: a report of consecutive cases from a New York City
   transplant center
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE immunosuppression; kidney transplantation; SARS-CoV-2
ID REPLICATION; COVID-19
AB Background. Kidney graft recipients receiving immunosuppressive therapy may be at heightened risk for coronavirus disease 2019 (Covid-19) and adverse outcomes. It is therefore important to characterize the clinical course and outcome of Covid-19 in this population and identify safe therapeutic strategies.
   Methods. We performed a retrospective chart review of 73 adult kidney graft recipients evaluated for Covid-19 from 13 March to 20 April 2020. Primary outcomes included recovery from symptoms, acute kidney injury, graft failure and case fatality rate.
   Results. Of the 73 patients screened, 54 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-39 with moderate to severe symptoms requiring hospital admission and 15 with mild symptoms managed in the ambulatory setting. Hospitalized patients were more likely to be male, of Hispanic ethnicity and to have cardiovascular disease. In the hospitalized group, tacrolimus dosage was reduced in 46% of patients and mycophenolate mofetil (MMF) therapy was stopped in 61% of patients. None of the ambulatory patients had tacrolimus reduction or discontinuation of MMF. Azithromycin or doxycycline was prescribed at a similar rate among hospitalized and ambulatory patients (38% versus 40%). Hydroxychloroquine was prescribed in 79% of hospitalized patients. Graft failure requiring hemodialysis occurred in 3 of 39 hospitalized patients (8%) and 7 patients died, resulting in a case fatality rate of 13% among Covid-19-positive patients and 18% among hospitalized Covid-19-positive patients.
   Conclusions. Data from our study suggest that a strategy of systematic triage to outpatient or inpatient care, early management of concurrent bacterial infections and judicious adjustment of immunosuppressive drugs rather than cessation is feasible in kidney transplant recipients with Covid-19.
C1 [Lubetzky, Michelle; Lee, John R.; Salinas, Thalia; Lee, Jun B.; Hartono, Choli; Saal, Stuart; Muthukumar, Thangamani; Suthanthiran, Manikkam; Dadhania, Darshana M.] Weill Cornell Med, Div Nephrol & Hypertens, New York, NY 10065 USA.
   [Lubetzky, Michelle; Aull, Meredith J.; Lee, John R.; Lee, Jun B.; Hartono, Choli; Saal, Stuart; Muthukumar, Thangamani; Kapur, Sandip; Suthanthiran, Manikkam; Dadhania, Darshana M.] Weill Cornell Med, Dept Transplantat Med, New York Presbyterian Hosp, New York, NY 10065 USA.
   [Aull, Meredith J.; Craig-Schapiro, Rebecca; Marku-Podvorica, Jehona; Sultan, Samuel; Kapur, Sandip] Weill Cornell Med, Div Transplant Surg, New York, NY USA.
   [Gingras, Laura] Weill Cornell Med, Dept Internal Med, New York, NY USA.
   [Kodiyanplakkal, Rosy Priya] Weill Cornell Med, Div Infect Dis, New York, NY USA.
RP Lubetzky, M (corresponding author), Weill Cornell Med, Div Nephrol & Hypertens, New York, NY 10065 USA.; Lubetzky, M (corresponding author), Weill Cornell Med, Dept Transplantat Med, New York Presbyterian Hosp, New York, NY 10065 USA.
EM mil9044@med.cornell.edu
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Lemahieu W, 2005, AM J TRANSPLANT, V5, P1383, DOI 10.1111/j.1600-6143.2005.00844.x
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Timothy F, 2020, CARDIOL MAGAZ
   Wang JP, 2020, EUR UROL, V77, P769, DOI 10.1016/j.eururo.2020.03.036
   Willicombe M, 2020, J AM SOC NEPHROL, V31, P1145, DOI 10.1681/ASN.2020030348
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhong ZB, 2020, AM J TRANSPLANT, V20, P1916, DOI 10.1111/ajt.15928
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 30
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JUL
PY 2020
VL 35
IS 7
BP 1250
EP 1261
DI 10.1093/ndt/gfaa154
PG 12
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA OW8GK
UT WOS:000593117800023
PM 32678882
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cohen, SP
   Baber, ZB
   Buvanendran, A
   McLean, BC
   Chen, YA
   Hooten, WM
   Laker, SR
   Wasan, AD
   Kennedy, DJ
   Sandbrink, F
   King, SA
   Fowler, IM
   Stojanovic, MP
   Hayek, SM
   Phillips, CR
AF Cohen, Steven P.
   Baber, Zafeer B.
   Buvanendran, Asokumar
   McLean, Brian C.
   Chen, Yian
   Hooten, W. Michael
   Laker, Scott R.
   Wasan, Ajay D.
   Kennedy, David J.
   Sandbrink, Friedhelm
   King, Scott A.
   Fowler, Ian M.
   Stojanovic, Milan P.
   Hayek, Salim M.
   Phillips, Christopher R.
TI Pain Management Best Practices from Multispecialty Organizations During
   the COVID-19 Pandemic and Public Health Crises
SO PAIN MEDICINE
LA English
DT Article
DE COVID-19; Pandemic; SARS-CoV-2; Pain Management; Public Health Crisis
ID EPIDURAL STEROID INJECTIONS; QUALITY-OF-LIFE; OPIOID THERAPY;
   PSYCHOLOGICAL IMPACT; UNITED-STATES; PRESCRIBING OPIOIDS; HOSPITAL
   EMPLOYEES; RISK-FACTORS; DISEASE; ADULTS
AB Background. It is nearly impossible to overestimate the burden of chronic pain, which is associated with enormous personal and socioeconomic costs. Chronic pain is the leading cause of disability in the world, is associated with multiple psychiatric comorbidities, and has been causally linked to the opioid crisis. Access to pain treatment has been called a fundamental human right by numerous organizations. The current COVID-19 pandemic has strained medical resources, creating a dilemma for physicians charged with the responsibility to limit spread of the contagion and to treat the patients they are entrusted to care for. Methods. To address these issues, an expert panel was convened that included pain management experts from the military, Veterans Health Administration, and academia. Endorsement from stakeholder societies was sought upon completion of the document within a one-week period. Results. In these guidelines, we provide a framework for pain practitioners and institutions to balance the often-conflicting goals of risk mitigation for health care providers, risk mitigation for patients, conservation of resources, and access to pain management services. Specific issues discussed include general and intervention-specific risk mitigation, patient flow issues and staffing plans, telemedicine options, triaging recommendations, strategies to reduce psychological sequelae in health care providers, and resource utilization. Conclusions. The COVID-19 public health crisis has strained health care systems, creating a conundrum for patients, pain medicine practitioners, hospital leaders, and regulatory officials. Although this document provides a framework for pain management services, systems-wide and individual decisions must take into account clinical considerations, regional health conditions, government and hospital directives, resource availability, and the welfare of health care providers.
C1 [Cohen, Steven P.] Johns Hopkins Sch Med, Pain Med, Anesthesiol Neurol & Phys Med & Rehabil, Baltimore, MD USA.
   [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Anesthesiol & Phys Med & Rehabil, Bethesda, MD 20814 USA.
   [Baber, Zafeer B.] Beth Israel Lahey Hlth, Div Anesthesiol & Intervent Pain Management, Lahey Hosp & Med Ctr, Burlington, MA USA.
   [Buvanendran, Asokumar] Rush Univ, Anesthesiol & Orthoped Surg, Coll Med, Chicago, IL 60612 USA.
   [McLean, Brian C.] Tripler Army Med Ctr, Dept Anesthesiol, Pain Management, Honolulu, HI 96859 USA.
   [Chen, Yian] Johns Hopkins Sch Med, Dept Anesthesiol, Baltimore, MD USA.
   [Hooten, W. Michael] Mayo Sch Med, Anesthesiol & Psychiat, Rochester, MN USA.
   [Laker, Scott R.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA.
   [Wasan, Ajay D.] Univ Pittsburgh, Pain Med, Anesthesiol & Psychiat, Sch Med, Pittsburgh, PA USA.
   [Kennedy, David J.] Vanderbilt Univ, Sch Med, Dept Phys Med & Rehabil, Nashville, TN 37212 USA.
   [Sandbrink, Friedhelm] Washington DC VA Med Ctr, Vet Hlth Adm, Washington, DC USA.
   [Fowler, Ian M.] Naval Med Ctr San Diego, Surg Serv, San Diego, CA USA.
   [Stojanovic, Milan P.] Harvard Med Sch, Anesthesiol Crit Care & Pain Med Serv, Intervent Pain Med, VA Boston Healthcare Syst,Edith Nourse Rogers Mem, Boston, MA 02115 USA.
   [Hayek, Salim M.] Case Western Reserve Univ, Univ Hosp, Dept Anesthesiol, Cleveland, OH 44106 USA.
   [Phillips, Christopher R.] Naval Med Ctr San Diego, Dept Surg, Anesthesiol Serv, San Diego, CA USA.
RP Cohen, SP (corresponding author), Dept Anesthesiol & Crit Care Med, 550 N Broadway,Suite 301, Baltimore, MD 21205 USA.
EM scohen40@jhmi.edu
OI Reis, AlessanRSS/0000-0001-8486-7469; Cohen, Steven/0000-0001-5928-2127
FU MIRROR, Uniformed Services University of the Health Sciences, US
   Department of Defense [HU00011920011]
FX SPC is funded by MIRROR, Uniformed Services University of the Health
   Sciences, US Department of Defense, grant #HU00011920011.
CR Abdul AJ, 2017, PAIN PHYSICIAN, V20, pE991
   Ahadian FM, 2011, REGION ANESTH PAIN M, V36, P572, DOI 10.1097/AAP.0b013e318232e843
   Ahmadi Jamshid, 2017, Indian J Psychol Med, V39, P445, DOI 10.4103/0253-7176.211765
   Almirall J, 2017, RESPIRATION, V94, P299, DOI 10.1159/000479089
   Altevogt BM, 2009, GUIDANCE ESTABLISHIN
   [Anonymous], 2020, COVID 19 GUID TRIAG
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Arteta J, 2016, PAIN MED, V17, P295, DOI 10.1111/pme.12886
   Bazyar Jafar, 2019, Open Access Maced J Med Sci, V7, P482, DOI 10.3889/oamjms.2019.119
   Bicket MC, 2015, PAIN MANAG, V5, P129, DOI [10.2217/PMT.14.53, 10.2217/pmt.14.53]
   Bicket MC, 2013, ANESTHESIOLOGY, V119, P907, DOI 10.1097/ALN.0b013e31829c2ddd
   Brennan F, 2016, PAIN MED, V17, P1785, DOI 10.1093/pm/pnw222
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Burgstaller JM, 2016, SPINE, V41, pE1053, DOI 10.1097/BRS.0000000000001544
   Casanova L, 2010, INFECT CONT HOSP EP, V31, DOI 10.1086/652452
   Cauda F, 2014, NEUROIMAGE-CLIN, V4, P676, DOI 10.1016/j.nicl.2014.04.007
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Centers for Disease Control, HOSP PAND INFL PLAN
   Centers for Disease Control and Prevention, QUEST ANSW REG RESP
   Centers for Disease Control and Prevention, STRAT OPT SUPPL N95
   Centers for Disease Control and Prevention, PAND REC GUID EXT LT
   Centers for Disease Control and Prevention, 2020, AR YOU HIGH RISK SEV
   Centers for Disease Control and Prevention, GET YOUR CLIN READ C
   Centers for DiseaseControl and Prevention, INT INF PREV CONTR R
   Centers for Medicare and Medicaid Services, 2020, MED TEL HLTH CAR PRO
   Cheatle MD, 2015, PAIN MED, V16, pS22, DOI 10.1111/pme.12910
   Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16-2458
   Cohen SP, 2006, NAT CLIN PRACT NEURO, V2, P580, DOI 10.1038/ncpneuro0342
   Cohen SP, 2020, REGION ANESTH PAIN M, V45, P424, DOI 10.1136/rapm-2019-101243
   Cohen SP, 2019, MAYO CLIN PROC, V94, P2385, DOI 10.1016/j.mayocp.2019.10.006
   Cohen SP, 2013, REGION ANESTH PAIN M, V38, P175, DOI 10.1097/AAP.0b013e31828ea086
   Cohen SP, 2012, SPINE J, V12, P833, DOI 10.1016/j.spinee.2011.10.010
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   Cummings TM, 2001, ARCH PHYS MED REHAB, V82, P986, DOI 10.1053/apmr.2001.24023
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Donelan K, 2019, AM J MANAG CARE, V25, P40
   Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Dublin S, 2011, J AM GERIATR SOC, V59, P1899, DOI 10.1111/j.1532-5415.2011.03586.x
   EGSMOSE C, 1984, SCAND J RHEUMATOL, V13, P238, DOI 10.3109/03009748409100392
   European Medicines Agency, 2020, EMA GIV ADV US NONST
   Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364
   Federation of State Medical Boards, 2019, TEL POL
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001
   Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009
   Hines L, 2014, AM J INFECT CONTROL, V42, P240, DOI 10.1016/j.ajic.2013.09.013
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113
   Hooten WM, 2016, MAYO CLIN PROC, V91, P955, DOI 10.1016/j.mayocp.2016.04.029
   Hyman SM, 2007, EXP CLIN PSYCHOPHARM, V15, P134, DOI 10.1037/1064-1297.15.2.134
   Institute of Medicine, 2006, REUS FAC INFL PAND F
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Johnson AC, 2014, J PHARMACOL EXP THER, V351, P327, DOI 10.1124/jpet.114.218065
   Jukic Marko, 2018, Acta Med Acad, V47, P18, DOI 10.5644/ama2006-124.211
   Kang SS, 2011, PAIN PHYSICIAN, V14, P361
   KAUFFMAN RE, 1992, AM J DIS CHILD, V146, P622, DOI 10.1001/archpedi.1992.02160170102024
   Koenig KL, 2006, ACAD EMERG MED, V13, P195, DOI 10.1197/j.aem.2005.10.007
   Kyu HH, 2018, LANCET, V392, P1859, DOI 10.1016/s0140-6736(18)32335-3
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Mathersul DC, 2018, GLOB ADV HLTH MED, V7
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002
   National Center for Health Statistics, 2011, SPEC FEAT DEATH DYIN
   National Institute for Occupational Safety and Health, 2018, RESP TRUST SOURC INF
   Page GG, 2005, J PAIN SYMPTOM MANAG, V29, pS25, DOI 10.1016/j.jpainsymman.2005.01.006
   Page GG, MADAME CURIE BIOSCIE
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Pollard EM, 2019, J PAIN RES, V12, P1311, DOI 10.2147/JPR.S186662
   Popescu A, 2019, PAIN MED, V20, P1248, DOI 10.1093/pm/pny310
   Popma JW, 2015, J RHEUMATOL, V42, P1865, DOI 10.3899/jrheum.141630
   Quinten C, 2009, LANCET ONCOL, V10, P865, DOI 10.1016/S1470-2045(09)70200-1
   Rabinovitch DL, 2009, SPINE J, V9, P509, DOI 10.1016/j.spinee.2009.03.003
   Racine M, 2018, PROG NEURO-PSYCHOPH, V87, P269, DOI 10.1016/j.pnpbp.2017.08.020
   Rosen IM, 2019, J CLIN SLEEP MED, V15, P1671, DOI 10.5664/jcsm.8062
   Santarpia JL, 2020, TRANSMISSION POTENTI, DOI [10.1101/2020.03.23.20039446, DOI 10.1101/2020.03.23.20039446]
   Schafer AGM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9465
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Smith D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099048
   St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020
   Sullivan MD, 2018, CLIN J PAIN, V34, P878, DOI 10.1097/AJP.0000000000000603
   Sun L, 2020, PREVALENCE RISK FACT, V2020, p200620032425, DOI [10.1101/ 2020.03.06.20032425, DOI 10.1101/2020.03.06.20032425, 10.1101/2020.03.06.20032425]
   Sundararaman LV, 2017, REGION ANESTH PAIN M, V42, P488, DOI 10.1097/AAP.0000000000000621
   Swedish Council on Health Technology Assessment, 2006, 17712 SBU
   Sytsma Terin T, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P194, DOI 10.1016/j.mayocpiqo.2018.01.005
   Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859
   Thornton JD, 2017, QUAL LIFE RES, V26, P1955, DOI 10.1007/s11136-017-1538-0
   US Department of Health and Human Services, NOT ENF DISCR TEL RE
   US Food and Drug Administration, FDA ADV PAT US NONST
   Vadivelu N, 2017, OCHSNER J, V17, P173
   Van Boxem K, 2019, PAIN PRACT, V19, P61, DOI 10.1111/papr.12709
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wang C, 2020, INT J ENV RES PUBLIC, V17
   White RL, 2007, ANESTHESIOLOGY, V107, P1003, DOI 10.1097/01.anes.0000290605.55736.e1
   World Health Organization, 59 WHO
   Wu P, 2008, ALCOHOL ALCOHOLISM, V43, P706, DOI 10.1093/alcalc/agn073
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yovell Y, 2016, AM J PSYCHIAT, V173, P491, DOI 10.1176/appi.ajp.2015.15040535
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 102
TC 25
Z9 26
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JUL
PY 2020
VL 21
IS 7
BP 1331
EP 1346
DI 10.1093/pm/pnaa127
PG 16
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA OW8QH
UT WOS:000593143900009
PM 32259247
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tabrizi, S
   Trippa, L
   Cagney, D
   Tanguturi, S
   Ventz, S
   Fell, G
   Wen, PY
   Alexander, BM
   Rahman, R
AF Tabrizi, Shervin
   Trippa, Lorenzo
   Cagney, Daniel
   Tanguturi, Shyam
   Ventz, Steffen
   Fell, Geoffrey
   Wen, Patrick Y.
   Alexander, Brian M.
   Rahman, Rifaquat
TI A quantitative framework for modeling COVID-19 risk during adjuvant
   therapy using published randomized trials of glioblastoma in the elderly
SO NEURO-ONCOLOGY
LA English
DT Article
DE COVID-19; elderly; glioblastoma; randomized controlled trials
ID RADIATION-THERAPY; PHASE-III; TEMOZOLOMIDE; RADIOTHERAPY; CONCOMITANT;
   SURVIVAL; OLDER
AB Background. During the ongoing COVID-19 pandemic, contact with the health care system for cancer treatment can increase risk of infection and associated mortality. Treatment recommendations must consider this risk for elderly and vulnerable cancer patients. We reanalyzed trials in elderly glioblastoma (GBM) patients, incorporating COVID-19 risk, in order to provide a quantitative framework for comparing different radiation (RT) fractionation schedules on patient outcomes.
   Methods. We extracted individual patient-level data for 1321 patients from Kaplan-Meier curves from 5 randomized trials on treatment of elderly GBM patients including available subanalyses based on O-6-methylguanine-DNA methyltransferase (MGMT) methylation status. We simulated trial data with incorporation of COVID-19-associated mortality risk in several scenarios (low, medium, and high infection and mortality risks). Median overall survival and hazard ratios were calculated for each simulation replicate.
   Results. Our simulations reveal how COVID-19-associated risks affect survival under different treatment regimens. Hypofractionated RT with concurrent and adjuvant temozolomide (TMZ) demonstrated the best outcomes in low and medium risk scenarios. In frail elderly patients, shorter courses of RT are preferable. In patients with methylated MGMT receiving single modality treatment, TMZ-alone treatment approaches may be an option in settings with high COVID-19-associated risk.
   Conclusions. Incorporation of COVID-19-associated risk models into analysis of randomized trials can help guide clinical decisions during this pandemic. In elderly GBM patients, our results support prioritization of hypofractionated RT and highlight the utility of MGMT methylation status in decision making in pandemic scenarios. Our quantitative framework can serve as a model for assessing COVID-19 risk associated with treatment across neuro-oncology.
C1 [Tabrizi, Shervin] Harvard Radiat Oncol Program, Boston, MA USA.
   [Tabrizi, Shervin; Cagney, Daniel; Tanguturi, Shyam; Alexander, Brian M.; Rahman, Rifaquat] Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
   [Trippa, Lorenzo; Ventz, Steffen; Fell, Geoffrey] Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA.
   [Wen, Patrick Y.] Harvard Med Sch, Ctr Neurooncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Rahman, R (corresponding author), 75 Francis St,ASB L2, Boston, MA 02115 USA.
EM rrahman@bwh.harvard.edu
OI Tabrizi, Shervin/0000-0003-2780-8432
CR Achard V, 2020, INT J RADIAT ONCOL, V107, P600, DOI 10.1016/j.ijrobp.2020.03.008
   [Anonymous], COR COVID 19 CANC TR
   [Anonymous], SUMM COVID 19 RES
   [Anonymous], 2020, WHO DIRECTOR GEN OP
   Braunstein LZ, 2020, ADV RADIAT ONCOL, V5, P582, DOI 10.1016/j.adro.2020.03.013
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Kalra B, 2020, J NEURO-ONCOL, V146, P311, DOI 10.1007/s11060-019-03375-w
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Keime-Guibert F, 2007, NEW ENGL J MED, V356, P1527, DOI 10.1056/NEJMoa065901
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Malmstrom A, 2012, LANCET ONCOL, V13, P916, DOI 10.1016/S1470-2045(12)70265-6
   Nassiri F, 2020, CLIN CANCER RES, V26, P2664, DOI 10.1158/1078-0432.CCR-19-3359
   Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977
   Rahman R, 2019, ANN ONCOL, V30, P1005, DOI 10.1093/annonc/mdz087
   Rahman R, 2019, CLIN CANCER RES, V25, P6339, DOI 10.1158/1078-0432.CCR-18-3999
   Roa W, 2004, J CLIN ONCOL, V22, P1583, DOI 10.1200/JCO.2004.06.082
   Roa W, 2015, J CLIN ONCOL, V33, P4145, DOI 10.1200/JCO.2015.62.6606
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wick A, 2020, NEURO-ONCOLOGY, V22, P1162, DOI 10.1093/neuonc/noaa033
   Wick W, 2012, LANCET ONCOL, V13, P707, DOI 10.1016/S1470-2045(12)70164-X
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
   Zarnett OJ, 2015, JAMA NEUROL, V72, P589, DOI 10.1001/jamaneurol.2014.3739
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 31
TC 3
Z9 3
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUL
PY 2020
VL 22
IS 7
BP 918
EP 927
DI 10.1093/neuonc/noaa111
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA OU9IT
UT WOS:000591837500008
PM 32339235
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bernhardt, D
   Wick, W
   Weiss, SE
   Sahgal, A
   Lo, SS
   Suh, JH
   Chang, EL
   Foote, M
   Perry, J
   Meyer, B
   Vajkoczy, P
   Wen, PY
   Straube, C
   Pigorsch, S
   Wilkens, JJ
   Combs, SE
AF Bernhardt, Denise
   Wick, Wolfgang
   Weiss, Stephanie E.
   Sahgal, Arjun
   Lo, Simon S.
   Suh, John H.
   Chang, Eric L.
   Foote, Matthew
   Perry, James
   Meyer, Bernhard
   Vajkoczy, Peter
   Wen, Patrick Y.
   Straube, Christoph
   Pigorsch, Steffi
   Wilkens, Jan J.
   Combs, Stephanie E.
TI Neuro-oncology management during the COVID-19 pandemic with a focus on
   WHO grades III and IV gliomas
SO NEURO-ONCOLOGY
LA English
DT Article
DE COVID-19; glioblastoma; high-grade glioma; neuro-oncology; SARS-CoV-2
ID NEWLY-DIAGNOSED GLIOBLASTOMA; RADIATION-THERAPY; OLDER PATIENTS;
   TEMOZOLOMIDE; RADIOTHERAPY; MULTIFORME; SURVIVAL
AB Background. Because of the increased risk in cancer patients of developing complications caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), physicians have to balance the competing risks of the negative impact of the pandemic and the primary tumor disease. In this consensus statement, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGGs) during the coronavirus disease 2019 (COVID-19) pandemic.
   Methods. Sixteen international experts in the treatment of HGG contributed to this consensus-based practice recommendation, including neuro-oncologists, neurosurgeons, radiation oncologists, and a medical physicist. Generally, treatment of neuro-oncological patients cannot be significantly delayed and initiating therapy should not be outweighed by COVID-19. We present detailed interdisciplinary treatment strategies for molecular subgroups in 2 pandemic scenarios, a scale-up phase and a crisis phase.
   Conclusion. This practice recommendation presents a pragmatic framework and consensus-based mitigation strategies for the treatment of HGG patients during the SARS-CoV-2 pandemic.
C1 [Bernhardt, Denise; Straube, Christoph; Pigorsch, Steffi; Wilkens, Jan J.; Combs, Stephanie E.] Tech Univ Munich TUM, Sch Med, Dept Radiat Oncol, D-81675 Munich, Germany.
   [Bernhardt, Denise; Meyer, Bernhard; Straube, Christoph; Pigorsch, Steffi; Wilkens, Jan J.; Combs, Stephanie E.] Klinikum Rechts Der Isar, D-81675 Munich, Germany.
   [Bernhardt, Denise; Straube, Christoph; Pigorsch, Steffi; Combs, Stephanie E.] Inst Radiat Med IRM, Dept Radiat Sci DRS, Neuherberg, Germany.
   [Bernhardt, Denise; Straube, Christoph; Pigorsch, Steffi; Combs, Stephanie E.] Deutsch Konsortium Translat Krebsforsch DKTK, Partner Site Munich, Munich, Germany.
   [Wick, Wolfgang] Heidelberg Univ, Neurol Clin, Heidelberg, Germany.
   [Wick, Wolfgang] German Canc Res Ctr, Heidelberg, Germany.
   [Weiss, Stephanie E.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Sahgal, Arjun] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
   [Lo, Simon S.] Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA USA.
   [Suh, John H.] Cleveland Clin Fdn, Taussig Canc Inst, Dept Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Chang, Eric L.] Univ Southern Calif, Keck Sch Med, Dept Radiat Oncol, Los Angeles, CA 90007 USA.
   [Foote, Matthew] Univ Queensland, Princess Alexandra Hosp, Dept Radiat Oncol, Woolloongabba, Qld, Australia.
   [Perry, James] Univ Toronto, Odette Canc Ctr, Dept Med, Div Neurol, Toronto, ON, Canada.
   [Perry, James] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON, Canada.
   [Meyer, Bernhard] Tech Univ Munich TUM, Sch Med, Dept Neurosurg, D-81675 Munich, Germany.
   [Vajkoczy, Peter] Charite Univ Med Berlin, Dept Neurosurg, D-13353 Berlin, Germany.
   [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
RP Bernhardt, D (corresponding author), Tech Univ Munich TUM, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaninger Str 22, D-81675 Munich, Germany.
EM denise.bernhardt@mri.tum.de
CR Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Cenciarini M, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00065
   Gaber MH, 2018, J NUCL MED RAD THER, V9, P1
   Gay HA, 2019, PRACT RADIAT ONCOL, V9, P305, DOI 10.1016/j.prro.2019.03.007
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Herrlinger U, 2019, LANCET, V393, P678, DOI 10.1016/S0140-6736(18)31791-4
   Institute of Medicine, 2010, CRIS STAND CAR SUMM
   LEHNE G, 1990, ACTA ONCOL, V29, P113, DOI 10.3109/02841869009126530
   Liao GX, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01017
   Malmstrom A, 2012, LANCET ONCOL, V13, P916, DOI 10.1016/S1470-2045(12)70265-6
   Mukherjee R K, 2003, Australas Radiol, V47, P143, DOI 10.1046/j.0004-8461.2003.01165.x
   Nabors LB, 2017, J NATL COMPR CANC NE, V15, P1331, DOI 10.6004/jnccn.2017.0166
   Navarria P, 2017, ONCOTARGET, V8, P67696, DOI 10.18632/oncotarget.18809
   Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977
   Phillips C, 2003, RADIOTHER ONCOL, V68, P23, DOI 10.1016/S0167-8140(03)00206-8
   Roa W, 2004, J CLIN ONCOL, V22, P1583, DOI 10.1200/JCO.2004.06.082
   Roa W, 2015, J CLIN ONCOL, V33, P4145, DOI 10.1200/JCO.2015.62.6606
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718
   Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669
   Tan BH, 2005, REV MED VIROL, V15, P57, DOI 10.1002/rmv.458
   Wang H, 2020, LANCET ONCOL
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
   Wick W, 2012, LANCET ONCOL, V13, P707, DOI 10.1016/S1470-2045(12)70164-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 8
Z9 8
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUL
PY 2020
VL 22
IS 7
BP 928
EP 935
DI 10.1093/neuonc/noaa113
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA OU9IT
UT WOS:000591837500009
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fugazzola, P
   Favi, F
   Tomasoni, M
   Zaghi, C
   Casadei, C
   Prosperi, E
   Sermonesi, G
   Corbella, D
   Coccolini, F
   Pratico, B
   Agnoletti, V
   Ansaloni, L
AF Fugazzola, Paola
   Favi, Francesco
   Tomasoni, Matteo
   Zaghi, Claudia
   Casadei, Chiara
   Prosperi, Enrico
   Sermonesi, Giacomo
   Corbella, Davide
   Coccolini, Federico
   Pratico, Beniamino
   Agnoletti, Vanni
   Ansaloni, Luca
TI Development and Validation of a New Risk Score for Infection with
   Coronavirus (Ri.SICo) Obtained from Treating Coronavirus Disease
   (COVID-19) Patients on the Field
SO IRANIAN RED CRESCENT MEDICAL JOURNAL
LA English
DT Article
DE Early Diagnosis; Score; Mass Casualty Incidents; Pandemic
ID DIAGNOSIS
AB Background: The Coronavirus Disease 2019 (COVID-19) pandemic has necessitated the alteration of the organization of entire hospitals to try to prevent them from becoming epidemiological clusters. The adopted diagnostic tools lack sensitivity or specificity.
   Objectives: The aim of the study was to create an easy-to-get risk score (Ri.S.I.Co., risk score for infection with the new coronavirus) developed on the field to stratify patients admitted to hospitals according to their risk of COVID-19 infection.
   Methods: In this prospective study, we included all patients who were consecutively admitted to the suspected COVID-19 department of the Bufalini Hospital, Cesena (Italy). All clinical, radiological, and laboratory predictors were included in the multivariate logistic regression model to create a risk model. A simplified model was internally and externally validated, and two score thresholds for stratifying the probability of COVID-19 infection were introduced.
   Results: From 11th March to 5th April 2020, 200 patients were consecutively admitted. A Ri.S.I.Co lower than 2 showed a higher sensitivity than SARS-Cov-2 nucleic acid detection (96.2% vs. 65.4%; P < 0.001). The presence of ground-glass pattern on the lung-CT scan had a lower sensitivity than a Ri.S.I.Co lower than 2 (88.5% vs. 96.2%; P < 0.001) and a lower specificity than a Ri.S.I.Co higher than 6 (75.0% vs. 96.9%; P < 0.001).
   Conclusions: We believe that the Ri.S.I.Co could allow to stratify admitted patients according to their risk, preventing hospitals from becoming the main COVID-19 carriers themselves. Furthermore, it could guide clinicians in starting therapies early in severeonset cases with a high probability of COVID-19, before molecular SARS-CoV-2 infection is confirmed.
C1 [Fugazzola, Paola; Favi, Francesco; Tomasoni, Matteo; Zaghi, Claudia; Casadei, Chiara; Prosperi, Enrico; Sermonesi, Giacomo; Ansaloni, Luca] Bufalini Hosp, Gen & Emergency Surg Dept, I-47521 Cesena, Italy.
   [Corbella, Davide] ASST Papa Giovanni XXIII, Intens Care Unit, Bergamo, Italy.
   [Coccolini, Federico] State Univ Pisa, Cisanello Hosp, Emergency Surg Unit, Pisa, Italy.
   [Pratico, Beniamino] Bufalini Hosp, Internal Med Unit, Cesena, Italy.
   [Agnoletti, Vanni] Bufalini Hosp, Intens Care Unit, Cesena, Italy.
RP Fugazzola, P (corresponding author), Bufalini Hosp, Gen & Emergency Surg Dept, I-47521 Cesena, Italy.
EM paola.fugazzola@gmail.com
CR ACR, 2020, ACR REC US CHEST RAD
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Andersson M, 2008, WORLD J SURG, V32, P1843, DOI 10.1007/s00268-008-9649-y
   [Anonymous], 2020, WHO DIR GEN OP REM M
   British Society of Thoracic Imaging, 2020, THOR IM COVID 19 INF
   Catena F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-0293-7
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698
   Nacoti M, 2020, NEJM CATALYST INNOVA, V1
   Ren LL, 2020, CHIN MED J
   Song C.-Y., 2020, COVID 19 EARLY WARNI, DOI [10.1101/2020.03.05.20031906, DOI 10.1101/2020.03.05.20031906]
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   World Health Organization (WHO), 2020, NOV COR CHIN
   Xu X, 2020, BMJ, V368
NR 14
TC 0
Z9 0
U1 0
U2 0
PU KOWSARMEDICAL
PI LIMBURG
PA 13 KERKRADERWEG, HEERLEN, LIMBURG, NETHERLANDS
SN 2074-1804
EI 2074-1812
J9 IRAN RED CRESCENT ME
JI Iran. Red Crescent Med. J.
PD JUL
PY 2020
VL 22
IS 7
AR e106473
DI 10.5812/ircmj.106473
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OQ4BV
UT WOS:000588731400018
OA Other Gold
DA 2021-01-01
ER

PT J
AU Myint, A
   Jones, T
AF Myint, Aung
   Jones, Trevor
TI Is the production of a Covid-19 vaccine using transformed Pasteurella
   plausible? RESPOND
SO VETERINARY RECORD
LA English
DT Letter
C1 [Myint, Aung] Livestock Breeding & Vet Dept, Bacterial Vaccine Prod, 111 Sabe Rd,POB 11013, Insein, Myanmar.
EM dr.aungmyint@gmail.com; farmlab@supanet.com
CR Davidsen T, 2004, NUCLEIC ACIDS RES, V32, P1050, DOI 10.1093/nar/gkh255
   Myint Aung, 2020, Vet Rec, V186, P419, DOI 10.1136/vr.m1302
   Myint PP, 2000, THESIS
NR 3
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD JUL
PY 2020
VL 187
IS 1
DI 10.1136/vr.m2424
PG 2
WC Veterinary Sciences
SC Veterinary Sciences
GA OR4JK
UT WOS:000589438500005
PM 32591368
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rycroft, AN
   Smith, KC
   Noad, R
   Werling, D
AF Rycroft, Andrew N.
   Smith, Ken C.
   Noad, Rob
   Werling, Dirk
TI Is the production of a Covid-19 vaccine using transformed Pasteurella
   plausible?
SO VETERINARY RECORD
LA English
DT Letter
ID MULTOCIDA
C1 [Rycroft, Andrew N.; Smith, Ken C.; Noad, Rob; Werling, Dirk] Royal Vet Coll, Hawkshead Lane, N Mymms AL9 7TA, Herts, England.
RP Rycroft, AN (corresponding author), Royal Vet Coll, Hawkshead Lane, N Mymms AL9 7TA, Herts, England.
EM arycroft@rvc.ac.uk
CR BILLS MM, 1993, PLASMID, V30, P268, DOI 10.1006/plas.1993.1058
   Bosse JT, 2009, FEMS MICROBIOL LETT, V298, P124, DOI 10.1111/j.1574-6968.2009.01706.x
   CARTER GR, 1955, AM J VET RES, V16, P481
   JABLONSKI L, 1992, MICROB PATHOGENESIS, V12, P63, DOI 10.1016/0882-4010(92)90066-W
   Myint A, 2020, VET REC, V186, P388, DOI 10.1136/vr.m1193
   Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1111/j.1574-6976.1999.tb00404.x
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD JUL
PY 2020
VL 187
IS 1
DI 10.1136/vr.m2423
PG 1
WC Veterinary Sciences
SC Veterinary Sciences
GA OR4JK
UT WOS:000589438500004
PM 32591367
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Waterhouse, DM
   Harvey, RD
   Hurley, P
   Levit, LA
   Kim, ES
   Klepin, HD
   Mileham, KF
   Nowakowski, G
   Schenkel, C
   Davis, C
   Bruinooge, SS
   Schilsky, RL
AF Waterhouse, David M.
   Harvey, R. Donald
   Hurley, Patricia
   Levit, Laura A.
   Kim, Edward S.
   Klepin, Heidi D.
   Mileham, Kathryn Finch
   Nowakowski, Grzegorz
   Schenkel, Caroline
   Davis, Courtney
   Bruinooge, Suanna S.
   Schilsky, Richard L.
TI Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and
   Long-Term Opportunities for Transformation: Findings From an American
   Society of Clinical Oncology Survey
SO JCO ONCOLOGY PRACTICE
LA English
DT Article
AB The coronavirus disease 2019 (COVID-19) pandemic has disrupted all aspects of clinical care, including cancer clinical trials. In March 2020, ASCO launched a survey of clinical programs represented on its Cancer Research Committee and Research Community Forum Steering Group and taskforces to learn about the types of changes and challenges that clinical trial programs were experiencing early in the pandemic. There were 32 survey respondents; 14 represented academic programs, and 18 represented community-based programs. Respondents indicated that COVID-19 is leading programs to halt or prioritize screening and/or enrollment for certain clinical trials and cease research-only visits. Most reported conducting remote patient care where possible and remote visits and monitoring with sponsors and/or contract research organizations (CROs); respondents viewed this shift positively. Numerous challenges with conducting clinical trials were reported, including enrollment and protocol adherence difficulties with decreased patient visits, staffing constraints, and limited availability of ancillary services. Interactions with sponsors and CROs about modifying trial procedures were also challenging. The changes in clinical trial procedures identified by the survey could serve as strategies for other programs attempting to maintain their clinical trial portfolios during the COVID-19 pandemic. Additionally, many of the adaptations to trials made during the pandemic provide a long-term opportunity to improve and transform the clinical trial system. Specific improvements could be expanded use of more pragmatic or streamlined trial designs, fewer clinical trial-related patient visits, and minimized sponsor and CRO visits to trial programs.
C1 [Waterhouse, David M.] Oncol Hematol Care, Cincinnati, OH USA.
   [Harvey, R. Donald] Emory Univ, Sch Med, Atlanta, GA USA.
   [Hurley, Patricia; Levit, Laura A.; Schenkel, Caroline; Davis, Courtney; Bruinooge, Suanna S.; Schilsky, Richard L.] Amer Soc Clin Oncol, 2318 Mill Rd, Alexandria, VA 22314 USA.
   [Kim, Edward S.; Mileham, Kathryn Finch] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA.
   [Klepin, Heidi D.] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA.
   [Nowakowski, Grzegorz] Mayo Clin, Rochester, MN USA.
RP Hurley, P (corresponding author), Amer Soc Clin Oncol, 2318 Mill Rd, Alexandria, VA 22314 USA.
EM Patricia.Hurley@asco.org
CR American Cancer Society Cancer Action Network, BARR PAT ENR THER CL
   American Society of Clinical Oncology, ADV PRIOR
   American Society of Clinical Oncology, ASCO CLIN TRIAL SIT
   American Society of Clinical Oncology, ASCO SURV COVID 19 O
   American Society of Clinical Oncology, ASCO COR RES
   American Society of Clinical Oncology (ASCO), 2020, COR COVID 19 COMM FO
   Clinical Trials Transformation Initiative, WEB REC AV LIST BEST
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Food and Drug Administration, OV CLIN INV RISK BAS
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Markham MJ, CORONAVIRUS COVID 19
   Marron JM, 2020, J CLIN ONCOL, V38, P2201, DOI 10.1200/JCO.20.00960
   McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689
   Mooney M, 2020, INTERIM GUIDANCE PAT
   Sidley.com, CONS SPONS ONG CLIN
   US Food and Drug Administration, US EL INF CONS QUEST
   US Food and Drug Administration, FDA GUID COND CLIN T
   Winkfield KM, 2018, J CLIN ONCOL, V36, P3331, DOI 10.1200/JCO.18.01132
   Yancy CW, 2020, JAMA
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 21
TC 19
Z9 19
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 2688-1527
EI 2688-1535
J9 JCO ONCOL PRACT
JI JCO Oncol. Pract.
PD JUL 1
PY 2020
VL 16
IS 7
BP 417
EP +
DI 10.1200/OP.20.00275
PG 6
WC Oncology
SC Oncology
GA OJ1LW
UT WOS:000583730100012
PM 32396491
DA 2021-01-01
ER

PT J
AU Gupta, T
   Singh, VP
   Balasubramian, A
   Menon, H
   Kurkure, PA
   Kumar, S
   Jalali, R
AF Gupta, Tejpal
   Singh, Varindera P.
   Balasubramian, Anandh
   Menon, Hari
   Kurkure, Purna A.
   Kumar, Shaleen
   Jalali, Rakesh
TI ISNO Position Statement on Treatment Guidance in Neuro-oncology During
   Pandemics
SO NEUROLOGY INDIA
LA English
DT Article
DE COVID-19; neuro-oncology; pandemics; prioritizationKey Messages:
   Widespread disruption of healthcare systems caused by COVID-19 pandemic
   mandates urgent reassessment of benefit-risk ratio of standard treatment
   guidelines with a view to formulate pragmatic COVID-context neuro-
   oncology care considerations and recommendations
ID HYPOFRACTIONATED RADIOTHERAPY; TEMOZOLOMIDE; GLIOBLASTOMA
AB The entire world including India is currently fighting the coronavirus disease 19 (COVID-19) pandemic that threatens to disrupt healthcare systems globally in terms of capacity and resources. This outbreak necessitates an urgent review of existing management guidelines for commonly encountered tumors of the brain and central nervous system (CNS). Such a review should include a reassessment of benefit-risk ratio to align with local, national, and international priorities without compromising on delivery of care in terms of safety, compassion, efficiency, and effectiveness. Towards this end, the Indian Society of Neuro-Oncology (ISNO) constituted an online expert panel with adequate representation from all major treatment modalities (neuro-surgery, radiation oncology, and pediatric/medical oncology) to formulate a "COVID-19 context" position statement to guide the care of neuro-oncology patients during the ongoing crisis. The ISNO position statement suggests graded prioritization (based on clinical presentation, type of tumor, expected prognosis, and relevance of immediate therapy) for efficient utilization of resources and provides a framework through a set of general considerations, treatment modality-based considerations, and disease-specific considerations for the guidance of healthcare professionals involved in the delivery of care and services to patients with CNS tumors. The views expressed herein represent the current consensus of key opinion leaders from within the Indian neuro-oncology community and should not be in any case considered binding medically or legally to individual physicians and/or hospitals who may formulate their guidelines based on local setup and health-environment and update them periodically based on emerging evidence through the COVID-19 pandemic.
C1 [Gupta, Tejpal] Tata Mem Hosp, Dept Radiat Oncol, Indian Soc Neurooncol ISNO, Mumbai, Maharashtra, India.
   [Kurkure, Purna A.] SRCC Childrens Hosp, Div Pediat Hematol Oncol BMT, Mumbai, Maharashtra, India.
   [Singh, Varindera P.] Medanta Medic, Inst Neurosci, Delhi, India.
   [Balasubramian, Anandh] Yashoda Hosp, Neurosurg, Hyderabad, Telangana, India.
   [Menon, Hari] Cytecare Hosp, Dept Med Oncol, Bengaluru, Karnataka, India.
   [Kumar, Shaleen] Super Special Canc Inst & Hosp, Lucknow, Uttar Pradesh, India.
   [Jalali, Rakesh] Apollo Proton Canc Ctr, Chennai, Tamil Nadu, India.
RP Gupta, T (corresponding author), Homi Bhabha Natl Inst HBNI, Dept Radiat Oncol, Indian Soc Neurooncol ISNO, ACTREC,Tata Mem Ctr, Navi Mumbai 400012, Maharashtra, India.
EM tejpalgupta@rediffmail.com
CR Bernhardt Denise, 2020, Neuro Oncol, DOI 10.1093/neuonc/noaa113
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Gupta P, 2020, NEUROL INDIA, V68, P246, DOI 10.4103/0028-3886.283130
   Gupta T, 2019, CLIN ONCOL-UK, V31, P539, DOI 10.1016/j.clon.2019.05.018
   Gupta T, 2010, J CANCER RES THER, V6, P272, DOI 10.4103/0973-1482.73353
   Hegi ME, 2015, NEURO-ONCOLOGY, V17, P1425, DOI 10.1093/neuonc/nov198
   Jenkinson M, ADULT NEUROONCOLOGY
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Malmstrom A, 2012, LANCET ONCOL, V13, P916, DOI 10.1016/S1470-2045(12)70265-6
   Mohile NA, 2020, NEURO-ONCOLOGY, DOI 10.1093/neuonc/noaa090
   Mukherjee R K, 2003, Australas Radiol, V47, P143, DOI 10.1046/j.0004-8461.2003.01165.x
   Patil Vijay M, 2018, CNS Oncol, V7, pCNS14, DOI 10.2217/cns-2017-0024
   Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977
   Ramakrishna R, 2020, J NEURO-ONCOL, V147, P525, DOI 10.1007/s11060-020-03488-7
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   van den Bent MJ, COVID 19 NEUROONCOLO
   VANDENBENT MJ, 2019, J CLIN ONCOL S, V37
   Wang ZJ, 2020, JAMA ONCOL, V6, P631, DOI 10.1001/jamaoncol.2020.1198
   Williams M., NEUROONCOLOGY TREATM
   Zaghloul MS, 2014, RADIOTHER ONCOL, V111, P35, DOI 10.1016/j.radonc.2014.01.013
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0028-3886
EI 1998-4022
J9 NEUROL INDIA
JI Neurol. India
PD JUL-AUG
PY 2020
VL 68
IS 4
BP 769
EP 773
DI 10.4103/0028-3886.293460
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA OO6HZ
UT WOS:000587479900007
PM 32859812
DA 2021-01-01
ER

PT J
AU Maurya, SP
   Das, N
   Gautam, H
   Singh, R
   Das, BK
AF Maurya, Shesh Prakash
   Das, Namrata
   Gautam, Hitender
   Singh, Ravinder
   Das, Bimal Kumar
TI The narrow road to a COVID-19 vaccine
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Letter
ID EPIDEMIOLOGY
C1 [Maurya, Shesh Prakash; Gautam, Hitender; Singh, Ravinder; Das, Bimal Kumar] All India Inst Med Sci, Dept Microbiol & Infect Dis, Natl HIV Reference Lab & Immunol Lab, New Delhi, India.
   [Das, Namrata] Maharishi Markandeshwar Med Coll & Hosp, Dept Med, Solan, Himachal Prades, India.
RP Das, BK (corresponding author), All India Inst Med Sci, Dept Microbiol & Infect Dis, Natl HIV Reference Lab & Immunol Lab, New Delhi, India.
EM tezpur.bimal@gmail.com
FU Indian Council of Medical Research, New DelhiIndian Council of Medical
   Research (ICMR)
FX We are thankful to the Indian Council of Medical Research, New Delhi,
   for granting fellowship to Dr. Shesh Prakash Maurya.
CR Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Lokman SM, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104389
   Nickbakhsh S, 2020, J INFECT DIS, V222, P17, DOI 10.1093/infdis/jiaa185
   Wan Y, 2020, J VIROL, V94
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253-7613
EI 1998-3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD JUL-AUG
PY 2020
VL 52
IS 4
BP 333
EP 334
AR PMID 33078736
DI 10.4103/ijp.IJP_709_20
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OJ3MS
UT WOS:000583870000012
PM 33078736
DA 2021-01-01
ER

PT J
AU Yethindra, V
   Tagaev, T
AF Yethindra, Vityala
   Tagaev, Tugolbai
TI Decreased mortality among hospitalized coronavirus disease 2019 patients
   who underwent anticoagulant therapy with heparin
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Letter
C1 [Yethindra, Vityala; Tagaev, Tugolbai] Int Univ Kyrgyzstan, Int Higher Sch Med, Dept Pathol, Bishkek, Kyrgyzstan.
RP Yethindra, V (corresponding author), 2-5-168,Opposite Maruthi Towers, Warangal 506001, Telangana, India.
EM yethindravityala10@gmail.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cattaneo M, 2020, THROMB HAEMOSTASIS, V120, P1230, DOI 10.1055/s-0040-1712097
   Iba T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017046
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253-7613
EI 1998-3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD JUL-AUG
PY 2020
VL 52
IS 4
BP 337
EP 338
AR PMID 33078738
DI 10.4103/ijp.IJP_584_20
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OJ3MS
UT WOS:000583870000014
PM 33078738
DA 2021-01-01
ER

PT J
AU Yanowsky-Escatell, FG
   Osuna-Padilla, IA
AF Yanowsky-Escatell, Francisco G.
   Osuna-Padilla, Ivan A.
TI Nutritional therapy optimization in COVID-19 critically ill patients
SO GACETA MEDICA DE MEXICO
LA Spanish
DT Letter
ID CARE; KNOWLEDGE
C1 [Yanowsky-Escatell, Francisco G.] Hosp Civil Guadalajara Dr Juan I Menchaca, Dept Med Interna, Guadalajara, Jalisco, Mexico.
   [Osuna-Padilla, Ivan A.] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Mexico City, DF, Mexico.
RP Osuna-Padilla, IA (corresponding author), Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Mexico City, DF, Mexico.
EM ivan.osuna@cieni.org.mx
RI Yanowsky Escatell, Francisco Gerardo/I-7367-2016
OI Yanowsky Escatell, Francisco Gerardo/0000-0002-0621-5075
CR Allen K, 2019, NUTR CLIN PRACT, V34, P540, DOI 10.1002/ncp.10242
   Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   Barker LA, 2011, INT J ENV RES PUB HE, V8, P514, DOI 10.3390/ijerph8020514
   Bear D, 2020, CRITICAL CARE SPECIA
   Elke G, 2019, CLIN NUTR ESPEN, V33, P220, DOI 10.1016/j.clnesp.2019.05.002
   Grammatikopoulou MG, 2019, NUTRITION, V57, P69, DOI 10.1016/j.nut.2018.05.013
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Lee ZY, 2019, NUTR CLIN PRACT, V34, P96, DOI 10.1002/ncp.10214
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Mowe M, 2008, CLIN NUTR, V27, P196, DOI 10.1016/j.clnu.2007.10.014
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Robinson MK, 2015, CRIT CARE MED, V43, P87, DOI 10.1097/CCM.0000000000000602
   Ruiz AJ, 2019, CLIN NUTR, V38, P1310, DOI 10.1016/j.clnu.2018.05.016
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Tappenden KA, 2013, JPEN-PARENTER ENTER, V37, P482, DOI 10.1177/0148607113484066
   Terblanche Ella, 2019, J Intensive Care Soc, V20, P255, DOI 10.1177/1751143718774715
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ACAD NACIONAL MEDICINA MEXICO
PI MEXICO
PA CENTRO MEDICO NACIONAL SIGLO XXI, UNIDAD CONGRESOS, GLOQUE B, PROMER
   PISO, MEXICO, DF 06725, MEXICO
SN 0016-3813
J9 GAC MED MEX
JI Gac. Med. Mex.
PD JUL-AUG
PY 2020
VL 156
IS 4
BP 360
EP 362
DI 10.24875/GMM.20000177
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF2WQ
UT WOS:000581075100020
PM 32831340
OA Bronze
DA 2021-01-01
ER

PT J
AU Klok, FA
   Kruip, MJHA
   van der Meer, NJM
   Arbous, MS
   Gommers, D
   Kant, KM
   Kaptein, FHJ
   van Paassen, J
   Stals, MAM
   Huisman, MV
   Endeman, H
AF Klok, F. A.
   Kruip, M. J. H. A.
   van der Meer, N. J. M.
   Arbous, M. S.
   Gommers, D.
   Kant, K. M.
   Kaptein, F. H. J.
   van Paassen, J.
   Stals, M. A. M.
   Huisman, M. V.
   Endeman, H.
TI Confirmation of the high cumulative incidence of thrombotic
   complications in critically ill ICU patients with COVID-19: An updated
   analysis
SO THROMBOSIS RESEARCH
LA English
DT Article
DE Venous thromboembolism; Pulmonary embolism; Deep vein thrombosis;
   COVID-19; Stroke
AB Introduction: We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses.
   Methods: We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first.
   Results: We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8).
   Conclusion: In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia.
C1 [Klok, F. A.; Kaptein, F. H. J.; Stals, M. A. M.; Huisman, M. V.] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Albinusdreef 2, NL-2300 RC Leiden, Netherlands.
   [Kruip, M. J. H. A.] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands.
   [van der Meer, N. J. M.] Amphia Hosp Breda, Dept Anesthesiol & Crit Care, Oosterhout, Netherlands.
   [van der Meer, N. J. M.] Tilburg Univ, TIAS, Tilburg, Netherlands.
   [Arbous, M. S.; van Paassen, J.] Leiden Univ, Med Ctr, Dept Intens Care Med, Leiden, Netherlands.
   [Gommers, D.; Endeman, H.] Erasmus MC, Dept Adult Intens Care, Rotterdam, Netherlands.
   [Kant, K. M.] Amphia Hosp, Dept Intens Care, Breda, Netherlands.
RP Klok, FA (corresponding author), Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Albinusdreef 2, NL-2300 RC Leiden, Netherlands.
EM f.a.klok@LUMC.nl
RI Arbous, Sesmu/ABI-1083-2020; Klok, Erik/U-4870-2019
OI Klok, Erik/0000-0001-9961-0754
CR Ciavarella A, 2020, THROMB RES, V191, P29, DOI 10.1016/j.thromres.2020.04.023
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huisman MV, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.28
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Middeldorp S., 2020, INCIDENCE VENOUS THR, DOI [10.20944/preprints202004., DOI 10.20944/PREPRINTS202004.0345.V1]
   Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 11
TC 231
Z9 235
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
EI 1879-2472
J9 THROMB RES
JI Thromb. Res.
PD JUL
PY 2020
VL 191
BP 148
EP 150
DI 10.1016/j.thromres.2020.04.041
PG 3
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OG7JD
UT WOS:000582054800029
PM 32381264
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kamarajah, SK
   Markar, SR
   Singh, P
   Griffiths, EA
AF Kamarajah, Sivesh K.
   Markar, Sheraz R.
   Singh, Pritam
   Griffiths, Ewen A.
CA Oesophagogastric Anastomosis Audit
TI The influence of the SARS-CoV-2 pandemic on esophagogastric cancer
   services: an international survey of esophagogastric surgeons
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE COVID-19; esophageal cancer; esophageal surgery; gastric cancer;
   pandemic; SARS-CoV-2
ID SURGICAL SMOKE; DEFINITIVE CHEMORADIOTHERAPY; ESOPHAGEAL CANCER;
   CETUXIMAB
AB Background Several guidelines to guide clinical practice among esophagogastric surgeons during the COVID-19 pandemic were produced. However, none provide reflection of current service provision. This international survey aimed to clarify the changes observed in esophageal and gastric cancer management and surgery during the COVID-19 pandemic. Methods An online survey covering key areas for esophagogastric cancer services, including staging investigations and oncological and surgical therapy before and during (at two separate time-points-24th March 2020 and 18th April 2020) the COVID-19 pandemic were developed. Results A total of 234 respondents from 225 centers and 49 countries spanning six continents completed the first round of the online survey, of which 79% (n =184) completed round 2. There was variation in the availability of staging investigations ranging from 26.5% for endoscopic ultrasound to 62.8% for spiral computed tomography scan. Definitive chemoradiotherapy was offered in 14.8% (adenocarcinoma) and 47.0% (squamous cell carcinoma) of respondents and significantly increased by almost three-fold and two-fold, respectively, in both round 1 and 2. There were uncertainty and heterogeneity surrounding prioritization of patients undergoing cancer resections. Of the surgeons symptomatic with COVID-19, only 40.2% (33/82) had routine access to COVID-19 polymerase chain reaction testing for staff. Of those who had testing available (n =33), only 12.1% (4/33) had tested positive. Conclusions These data highlight management challenges and several practice variations in caring for patients with esophagogastric cancers. Therefore, there is a need for clear consistent guidelines to be in place in the event of a further pandemic to ensure a standardized level of oncological care for patients with esophagogastric cancers.
C1 [Kamarajah, Sivesh K.] Royal Victoria Infirm, Northern Oesophagogastr Unit, Newcastle Upon Tyne, Tyne & Wear, England.
   [Markar, Sheraz R.] Imperial Coll London, Dept Upper Gastrointestinal Surg, St Marys Campus, London, England.
   [Markar, Sheraz R.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
   [Singh, Pritam] Royal Surrey Cty Hosp, Dept Upper Gastrointestinal Surg, London, England.
   [Griffiths, Ewen A.] Queen Elizabeth Hosp, Dept Upper Gastrointestinal Surg, Birmingham, W Midlands, England.
RP Kamarajah, SK (corresponding author), Royal Victoria Infirm, Northern Oesophagogastr Unit, Newcastle Upon Tyne, Tyne & Wear, England.
RI Baili, Efstratia/AAE-3367-2019; Sosa Duran, Erik Efrain/H-3864-2016
OI Baili, Efstratia/0000-0001-8745-2269; Underwood,
   Tim/0000-0001-9455-2188; Sosa Duran, Erik Efrain/0000-0003-3039-9211;
   VISWANATH, YKS/0000-0003-3880-1172; Kamarajah, Sivesh
   K/0000-0002-2748-0011
CR ACoS (ACS), 2020, COVID 19 EL CAS TRIA
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alp E, 2006, J HOSP INFECT, V62, P1, DOI 10.1016/j.jhin.2005.01.014
   Barbieri L, 2020, DIS ESOPHAGUS, V3692, P30758
   Brindle ME, 2020, ANN SURG
   Choi SH, 2014, SURG ENDOSC, V28, P2374, DOI 10.1007/s00464-014-3472-3
   Coronavirus NEaNI, 2020, SPEC GUID PAT MAN
   COVIDSurg Collaborative, 2020, BRIT J SURG, V107, P1097, DOI 10.1002/bjs.11646
   Crosby T, 2017, BRIT J CANCER, V116, P709, DOI 10.1038/bjc.2017.21
   Crosby T, 2013, LANCET ONCOL, V14, P627, DOI 10.1016/S1470-2045(13)70136-0
   Edinburgh TRCoSo, 2020, INT GEN SURG GUID CO
   Grasselli G, 2020, JAMA
   Ireland AoUGSoGBa, 2020, SURG PRIOR OES GASTR
   Kamarajah S K, 2020, ANN SURG
   Klevebro F, 2020, BRIT J SURG, DOI 10.1002/bjs.11998
   Kwak HD, 2016, OCCUP ENVIRON MED, V73, P857, DOI 10.1136/oemed-2016-103724
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mariette C, 2019, NEW ENGL J MED, V380, P152, DOI 10.1056/NEJMoa1805101
   Nilsson M., 2020, TIMING RESECTIVE SUR
   Oba A, 2020, ANN SURG
   Pellino G, 2020, DIS COLON RECTUM
   Prachand VN., 2020, J AM COLL SURG, VS1072, P30317
   Qadan M, 2020, ANN SURG
   Qin Q, 2018, INT J SURG, V59, P11, DOI 10.1016/j.ijsu.2018.09.013
   Rackley T, 2014, CLIN ONCOL-UK, V26, P533, DOI 10.1016/j.clon.2014.06.001
   Roser M., 2020, CORONAVIRUS PANDEMIC
   SoAGaES (SAGES), 2020, SAGES EAES REC REG S
   Thoracic Surgery Outcomes Research Network Inc, 2020, ANN THORAC SURG, V22
   Turaga K K, 2020, ANN SURG
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   World Health Organization, 2020, COR DIS 2019 COVID 1, P103
NR 32
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD JUL
PY 2020
VL 33
IS 7
AR doaa054
DI 10.1093/dote/doaa054
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OF1UJ
UT WOS:000581001600007
PM 32500134
OA Green Published
DA 2021-01-01
ER

PT J
AU Alqutob, R
   Al Nsour, M
   Tarawneh, MR
   Ajlouni, M
   Khader, Y
   Aqel, I
   Kharabsheh, S
   Obeidat, N
AF Alqutob, Raeda
   Al Nsour, Mohannad
   Tarawneh, Mohammed Rasoul
   Ajlouni, Musa
   Khader, Yousef
   Aqel, Ibrahim
   Kharabsheh, Saad
   Obeidat, Nathir
TI COVID-19 Crisis in Jordan: Response, Scenarios, Strategies, and
   Recommendations
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Article
DE infection; prevention; public health; pandemic; Jordan; virus; COVID-19
AB As of April 12, 2020, a total of 389 cases of coronavirus disease were confirmed in Jordan. To control this imminent threat, Jordan has enforced public health infection prevention and control measures, called for social distancing, seized all forms of inbound and outbound movement and international travel, and enacted the Defence Law that transferred the authority to the Minister of Defence to work and formulate orders according to the situation. In an effort to support the government in anticipating the requirements of the health system in the upcoming period, an in-depth reflection and examination of different scenarios of the disease spread were developed. This viewpoint suggests different strategies and measures for case detection and contact tracing, clinical management of cases, public health system functioning, and civil society organizations' contribution. It is necessary to accelerate containment of the disease to protect the economy and to maintain the continuity of some activities to mitigate the subsequent social, economic, and financial impacts. This requires finding a coping mechanism for a period that may be prolonged until laboratories develop a vaccine. Specifically, it is strongly recommended to promote community health awareness toward public health prevention and control measures, increase the efficiency and comprehensiveness of the epidemiological investigation and active and passive surveillance, and employ technology and digital health solutions to track cases and contacts. It is also recommended to increase and expand resources of intensive care units including respirators, increase the capacity and the number of trained health staff in the area of public health and epidemiology, ensure continued provision of essential public health programs, and mobilize the resources of nongovernmental sectors and donors to provide services for refugees and vulnerable populations.
C1 [Alqutob, Raeda; Obeidat, Nathir] Jordan Univ, Dept Internal Med, Amman, Jordan.
   [Al Nsour, Mohannad] Global Hlth Dev Eastern Mediterranean Publ Hlth, Amman, Jordan.
   [Tarawneh, Mohammed Rasoul; Ajlouni, Musa; Kharabsheh, Saad] Jordan Publ Hlth Forum, Amman, Jordan.
   [Khader, Yousef] Jordan Univ Sci & Technol, Dept Publ Hlth, Alramtha Irbid St, Irbid 22110, Jordan.
   [Aqel, Ibrahim] King Hussein Fdn, Inst Family Hlth, Amman, Jordan.
RP Khader, Y (corresponding author), Jordan Univ Sci & Technol, Dept Publ Hlth, Alramtha Irbid St, Irbid 22110, Jordan.
EM yskhader@just.edu.jo
RI Nsour, Mohannad Al/ABE-8741-2020; Khader, Yousef/AAE-9620-2019
OI Nsour, Mohannad Al/0000-0003-1212-1611; Khader,
   Yousef/0000-0002-7830-6857; tarawneh, mohammed
   Rasoul/0000-0001-7540-2600; Aqel, Ibrahim/0000-0002-7558-7059
CR [Anonymous], 2020, JORDAN TIMES
   Johns Hopkins University, COVID 19 DASHB CTR S
   The Center for Strategic Studies, 2020, JORD IND POLL SER MA
   The Higher Population Council, 2020, SCEN COVID 19 OUTBR
   WHO, 2020, 83 WHO
NR 5
TC 3
Z9 3
U1 0
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD JUL-SEP
PY 2020
VL 6
IS 3
BP 6
EP 11
AR e19332
DI 10.2196/19332
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OC1UL
UT WOS:000578947300001
PM 32407289
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Lusignan, S
   Jones, N
   Dorward, J
   Byford, R
   Liyanage, H
   Briggs, J
   Ferreira, F
   Akinyemi, O
   Amirthalingam, G
   Bates, C
   Bernal, JL
   Dabrera, G
   Eavis, A
   Elliot, AJ
   Feher, M
   Krajenbrink, E
   Hoang, U
   Howsam, G
   Leach, J
   Okusi, C
   Nicholson, B
   Nieri, P
   Sherlock, J
   Smith, G
   Thomas, M
   Thomas, N
   Tripathy, M
   Victor, W
   Williams, J
   Wood, I
   Zambon, M
   Parry, J
   O'Hanlon, S
   Joy, M
   Butler, C
   Marshall, M
   Hobbs, R
AF de Lusignan, Simon
   Jones, Nicholas
   Dorward, Jienchi
   Byford, Rachel
   Liyanage, Harshana
   Briggs, John
   Ferreira, Filipa
   Akinyemi, Oluwafunmi
   Amirthalingam, Gayatri
   Bates, Chris
   Bernal, Jamie Lopez
   Dabrera, Gavin
   Eavis, Alex
   Elliot, Alex J.
   Feher, Michael
   Krajenbrink, Else
   Hoang, Uy
   Howsam, Gary
   Leach, Jonathan
   Okusi, Cecilia
   Nicholson, Brian
   Nieri, Philip
   Sherlock, Julian
   Smith, Gillian
   Thomas, Mark
   Thomas, Nicholas
   Tripathy, Manasa
   Victor, William
   Williams, John
   Wood, Ian
   Zambon, Maria
   Parry, John
   O'Hanlon, Shaun
   Joy, Mark
   Butler, Chris
   Marshall, Martin
   Hobbs, Richard
TI The Oxford Royal College of General Practitioners Clinical Informatics
   Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and
   Trial Platforms
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Article
DE primary health care; general practice; medical record systems;
   computerized; sentinel surveillance; public health surveillance;
   clinical trials as a topic; adaptive clinical trials; severe acute
   respiratory syndrome coronavirus 2; COVID-19
ID PROTECTION; CLOUD; CARE
AB Background: Routinely recorded primary care data have been used for many years by sentinel networks for surveillance. More recently, real world data have been used for a wider range of research projects to support rapid, inexpensive clinical trials. Because the partial national lockdown in the United Kingdom due to the coronavirus disease (COVID-19) pandemic has resulted in decreasing community disease incidence, much larger numbers of general practices are needed to deliver effective COVID-19 surveillance and contribute to in-pandemic clinical trials.
   Objective: The aim of this protocol is to describe the rapid design and development of the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance Platform will provide extended primary care surveillance, while the Trials Platform is a streamlined clinical trials platform that will be integrated into routine primary care practice.
   Methods: We will apply the FAIR (Findable, Accessible, Interoperable, and Reusable) metadata principles to a new, integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical trials and provide enhanced communicable disease surveillance. The hub will be findable through membership in Health Data Research UK and European metadata repositories. Accessibility through an online application system will provide access to study-ready data sets or developed custom data sets. Interoperability will be facilitated by fixed linkage to other key sources such as Hospital Episodes Statistics and the Office of National Statistics using pseudonymized data. All semantic descriptors (ie, ontologies) and code used for analysis will be made available to accelerate analyses. We will also make data available using common data models, starting with the US Food and Drug Administration Sentinel and Observational Medical Outcomes Partnership approaches, to facilitate international studies. The Surveillance Platform will provide access to data for health protection and promotion work as authorized through agreements between Oxford, the Royal College of General Practitioners, and Public Health England. All studies using the Trials Platform will go through appropriate ethical and other regulatory approval processes.
   Results: The hub will be a bottom-up, professionally led network that will provide benefits for member practices, our health service, and the population served. Data will only be used for SQUIRE (surveillance, quality improvement, research, and education) purposes. We have already received positive responses from practices, and the number of practices in the network has doubled to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling of the number of virology sites to 293 (target 300), which has aided the collection of the largest ever weekly total of surveillance swabs in the United Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older PeopLE) trial, and these participants will be followed up through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an extended national digital health hub.
   Conclusions: ORCHID will provide equitable and innovative use of big data through a professionally led national primary care network and the application of FAIR principles. The secure data hub will host routinely collected general practice data linked to other key health care repositories for clinical trials and support enhanced in situ surveillance without always requiring large volume data extracts. ORCHID will support rapid data extraction, analysis, and dissemination with the aim of improving future research and development in general practice to positively impact patient care.
C1 [de Lusignan, Simon; Jones, Nicholas; Dorward, Jienchi; Byford, Rachel; Liyanage, Harshana; Briggs, John; Ferreira, Filipa; Akinyemi, Oluwafunmi; Feher, Michael; Hoang, Uy; Okusi, Cecilia; Nicholson, Brian; Nieri, Philip; Sherlock, Julian; Tripathy, Manasa; Williams, John; Joy, Mark; Butler, Chris; Hobbs, Richard] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Primary Care Bldg,Woodstock Rd, Oxford OX2 6GG, England.
   [de Lusignan, Simon; Krajenbrink, Else; Howsam, Gary; Leach, Jonathan; Thomas, Mark; Thomas, Nicholas; Victor, William; Wood, Ian; Marshall, Martin] Royal Coll Gen Practitioners, London, England.
   [Amirthalingam, Gayatri; Bernal, Jamie Lopez; Dabrera, Gavin; Zambon, Maria] Publ Hlth England, London, England.
   [Bates, Chris; Parry, John] TPP SystmOne, Leeds, W Yorkshire, England.
   [Eavis, Alex; Wood, Ian; O'Hanlon, Shaun] EMIS Grp, Leeds, W Yorkshire, England.
   [Elliot, Alex J.; Smith, Gillian] Publ Hlth England, Field Serv, Real Time Syndr Surveillance Team, Birmingham, W Midlands, England.
RP de Lusignan, S (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Radcliffe Primary Care Bldg,Woodstock Rd, Oxford OX2 6GG, England.
EM simon.delusignan@phc.ox.ac.uk
RI Dorward, Jienchi/P-7100-2019
OI Dorward, Jienchi/0000-0001-6072-1430; Liyanage,
   Harshana/0000-0001-9738-6349; Jones, Nicholas/0000-0002-0352-3785;
   Ferreira, Filipa/0000-0002-7717-8486; Akinyemi,
   Oluwafunmi/0000-0003-0401-0145; Tripathy, Manasa/0000-0001-9840-3876;
   Elliot, Alex/0000-0002-6414-3065; de Lusignan,
   Simon/0000-0002-8553-2641; Okusi, Cecilia/0000-0002-5575-8527
FU Public Health England; UK Research and Innovation; Department of Health
   and Social Care through the National Institute for Health Research; PHE;
   Wellcome Biomedical resources grant [212763/Z/18/Z]; Wellcome
   TrustWellcome Trust [216421/Z/19/Z]; National Institute for Health
   Research (NIHR) School for Primary Care ResearchNational Institute for
   Health Research (NIHR); NIHR Collaboration for Leadership in Health
   Research and Care (CLARHC) Oxford; NIHR Oxford Biomedical Research
   Centre (BRC); NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative
   (MIC)
FX The RCGP RSC is principally funded by Public Health England. The
   PRINCIPLE trial is funded by UK Research and Innovation and the
   Department of Health and Social Care through the National Institute for
   Health Research. SdL is the Director of the Oxford Oxon-RCGP RSC; RB,
   JS, FF, and EK are partially funded by PHE; and CO and AC are funded by
   a Wellcome Biomedical resources grant (212763/Z/18/Z). JD and NJ are
   funded by the Wellcome Trust (216421/Z/19/Z). FDRH is partially funded
   by the National Institute for Health Research (NIHR) School for Primary
   Care Research, the NIHR Collaboration for Leadership in Health Research
   and Care (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre
   (BRC), and the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative
   (MIC). We acknowledge the contributions of Myer Glickman (ONS), Nick
   Andrews (PHE), Matthew Swindells (Visiting Professor, University of
   London), and Ming Tang (NHS England and Improvement).
CR Butler C, 2020, ISRCTN REGISTRY 2020
   Charlebois K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164347
   Cook DJ, 2020, JAMA-J AM MED ASSOC, V323, P1559, DOI 10.1001/jama.2020.5775
   Correa A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011092
   Davidoff F, 2008, QUAL SAF HEALTH CARE, V17, P3, DOI 10.1136/qshc.2008.029066
   de Lusignan S, 2007, INT J MED INFORM, V76, P261, DOI 10.1016/j.ijmedinf.2005.11.003
   de Lusignan S, 2019, JMIR RES PROTOC, V8, DOI 10.2196/14186
   de Lusignan S, 2017, BRIT J GEN PRACT, V67, P440, DOI 10.3399/bjgp17X692645
   de Lusignan S, 2017, BRIT J GEN PRACT, V67, pE29, DOI 10.3399/bjgp16X688573
   de Lusignan S, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-61
   de SM, 2019, DATACITE 2019 DATACI
   Ison MG, 2018, OPEN FORUM INFECT S1, pS764, DOI [DOI 10.1093/OFID/OFY229.2190, 10.1093/ofid/ofy229.2190]
   Langmead B, 2018, NAT REV GENET, V19, P208, DOI 10.1038/nrg.2017.113
   Last JM, 2013, INT J EPIDEMIOL, V42, P1608, DOI 10.1093/ije/dyt113
   Lemanska Agnieszka, 2017, Tech Innov Patient Support Radiat Oncol, V2, P5, DOI 10.1016/j.tipsro.2017.06.001
   Lin HC, 2020, COMPUT METH PROG BIO, V191, DOI 10.1016/j.cmpb.2020.105409
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3
   McGuire AL, 2019, J LAW MED ETHICS, V47, P12, DOI 10.1177/1073110519840480
   Moltu C, 2012, DISABIL REHABIL, V34, P1608, DOI 10.3109/09638288.2012.656792
   Observational Health Data Sciences and Informatics. GitHub, 2020, OBSERVATIONAL HLTH D
   Ping PP, 2018, CIRC RES, V122, P1290, DOI 10.1161/CIRCRESAHA.117.310967
   Schols AMR, 2018, BRIT J GEN PRACT, V68, P362, DOI 10.3399/bjgp18X698033
   Stanton N, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X544104
   Taylor MJ, 2015, MED LAW REV, V23, P348, DOI 10.1093/medlaw/fwv018
   The Nuffield Department of Primary Care Health Sciences. Primary Care Clinical Trials Unit, 2020, PRINCIPLE TRIAL EV P
   Wennberg JE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1513
   Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18
NR 27
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD JUL-SEP
PY 2020
VL 6
IS 3
BP 130
EP 143
AR e19773
DI 10.2196/19773
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OC1UL
UT WOS:000578947300012
PM 32484782
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Husain, I
   Briggs, B
   Lefebvre, C
   Cline, DM
   Stopyra, JP
   O'Brien, MC
   Vaithi, R
   Gilmore, S
   Countryman, C
AF Husain, Iltifat
   Briggs, Blake
   Lefebvre, Cedric
   Cline, David M.
   Stopyra, Jason P.
   O'Brien, Mary Claire
   Vaithi, Ramupriya
   Gilmore, Scott
   Countryman, Chase
TI Fluctuation of Public Interest in COVID-19 in the United States:
   Retrospective Analysis of Google Trends Search Data
SO JMIR PUBLIC HEALTH AND SURVEILLANCE
LA English
DT Article
DE Infodemiology; COVID-19; SARS-CoV-2; digital health; Google Trends;
   trend; internet; public health
ID OUTBREAK
AB Background: In the absence of vaccines and established treatments, nonpharmaceutical interventions (NPIs) are fundamental tools to control coronavirus disease (COVID-19) transmission. NPIs require public interest to be successful. In the United States, there is a lack of published research on the factors that influence public interest in COVID-19. Using Google Trends, we examined the US level of public interest in COVID-19 and how it correlated to testing and with other countries.
   Objective: The aim of this study was to determine how public interest in COVID-19 in the United States changed over time and the key factors that drove this change, such as testing. US public interest in COVID-19 was compared to that in countries that have been more successful in their containment and mitigation strategies.
   Methods: In this retrospective study, Google Trends was used to analyze the volume of internet searches within the United States relating to COVID-19, focusing on dates between December 31, 2019, and March 24, 2020. The volume of internet searches related to COVID-19 was compared to that in other countries.
   Results: Throughout January and February 2020, there was limited search interest in COVID-19 within the United States. Interest declined for the first 21 days of February. A similar decline was seen in geographical regions that were later found to be experiencing undetected community transmission in February. Between March 9 and March 12, 2020, there was a rapid rise in search interest. This rise in search interest was positively correlated with the rise of positive tests for SARS-CoV-2 (6.3, 95% CI -2.9 to 9.7; P<.001). Within the United States, it took 52 days for search interest to rise substantially after the first positive case; in countries with more successful outbreak control, search interest rose in less than 15 days.
   Conclusions: Containment and mitigation strategies require public interest to be successful. The initial level of COVID-19 public interest in the United States was limited and even decreased during a time when containment and mitigation strategies were being established. A lack of public interest in COVID-19 existed in the United States when containment and mitigation policies were in place. Based on our analysis, it is clear that US policy makers need to develop novel methods of communicating COVID-19 public health initiatives.
C1 [Husain, Iltifat; Briggs, Blake; Lefebvre, Cedric; Cline, David M.; Stopyra, Jason P.; O'Brien, Mary Claire; Vaithi, Ramupriya; Countryman, Chase] Wake Forest Univ, Bowman Gray Sch Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.
   [Gilmore, Scott] Tuba City Reg Healthcare, Tuba City, AZ USA.
RP Husain, I (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM ihusain@wakehealth.edu
OI Briggs, Blake/0000-0002-5524-3291; Stopyra, Jason/0000-0001-7457-3969;
   Gilmore, Scott/0000-0003-3797-3167
CR Aledort JE, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-208
   [Anonymous], 2020, CHIN CDC WEEKL
   [Anonymous], 2020, PROCL SUSP ENTR IMM
   Arora VS, 2019, HEALTH POLICY, V123, P338, DOI 10.1016/j.healthpol.2019.01.001
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bociurkiw Michael, 2020, CNN
   Bragazzi NL, 2017, CLIN RHEUMATOL, V36, P1911, DOI 10.1007/s10067-016-3513-5
   Buchanan L., 2020, NY TIMES
   Centers for Disease Control and Prevention, 2020, PUBL HLTH SCREEN BEG
   Centers for Disease Control and Prevention, 2020, CDC EM OP CTR ACT
   Centers for Disease Control and Prevention, 2020, 1 TRAV REL CAS 2019
   Cetron M, 2004, I MED US FOR MICR TH
   Coyle J., 2020, ABC NEWS
   Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Fink Sheri, 2020, NY TIMES
   Goldstein J., 2020, NY TIMES
   Google Trends, FAQ GOOGL TRENDS DAT
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hartley DM, 2020, JAMA-J AM MED ASSOC, V323, P1908, DOI 10.1001/jama.2020.5910
   Hilbert M, 2011, SCIENCE, V332, P60, DOI 10.1126/science.1200970
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu DT, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.011003
   Husnayain A, 2020, INT J INFECT DIS, V95, P221, DOI 10.1016/j.ijid.2020.03.021
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Lee VJ, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa039
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Meyer R., 2020, ATLANTIC
   National Basketball Association, 2020, NBA SUSP SEAS FOLL W
   Net Marketshare, BROWS MARK SHAR
   Nuti SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109583
   NYC Health, COVID 19 DAT
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Owens C., 2020, WHY US IS SO FAR COR
   Parodi SM, 2020, JAMA-J AM MED ASSOC, V323, P1441, DOI 10.1001/jama.2020.3882
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa030
   Rogers S., 2016, GOOGLE NEWS LAB 0701
   Shariatpanahi SP, 2017, TELEMAT INFORM, V34, P904, DOI 10.1016/j.tele.2017.03.007
   Strzelecki A, 2020, BRAIN BEHAV IMMUN, V88, P950, DOI 10.1016/j.bbi.2020.04.042
   Tay J, 2010, ANN ACAD MED SINGAP, V39, P313
   Taylor D.B., 2020, NY TIMES
   Washington State Department ofHealth, 2019, 2019 NOV COR OUTBR C
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   World Health Organisation, 2020, WHO DIR GEN STAT IHR
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
NR 46
TC 2
Z9 2
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 2369-2960
J9 JMIR PUBLIC HLTH SUR
JI JMIR Public Health Surveill.
PD JUL-SEP
PY 2020
VL 6
IS 3
BP 256
EP 265
AR e19969
DI 10.2196/19969
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OC1UL
UT WOS:000578947300025
PM 32501806
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bridwell, R
   Long, B
   Gottlieb, M
AF Bridwell, Rachel
   Long, Brit
   Gottlieb, Michael
TI Neurologic complications of COVID-19
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE COVID-19; Coronavirus; Infectious disease; Neurologic; HLH;
   Cerebrovascular disease; Encephalopathy
ID GUILLAIN-BARRE-SYNDROME; STROKE; CORONAVIRUS; INFECTION; DIAGNOSIS
AB Background: Much of the focus regarding the global pandemic of coronavirus disease of 2019 (COVID-19) has been on the cardiovascular, pulmonary, and hematologic complications. However, neurologic complications have arisen as an increasingly recognized area of morbidity and mortality.
   Objective: This brief report summarizes the neurologic complications associated with COVID-19 with an emphasis on the emergency medicine clinician.
   Discussion: COVID-19 has infected over 3.5 million people and killed over 240,000 people worldwide. While pulmonary complications are profound, the neurologic system is also significantly impacted, with complications including acute cerebrovascular events, encephalitis, Guillain-Barre syndrome, acute necrotizing hemorrhagic encephalopathy, and hemophagocytic lymphohistiocytosis. Additionally, patients on immunosuppressive medications for pre-existing neurologic issues are at an increased risk for complications with COVID-19 infection, and many of the currently proposed COVID-19 therapies can interact with these medications.
   Conclusions: When caring for COVID-19 patients, emergency medicine clinicians should be aware of the neurologic complications from COVID-19. Published by Elsevier Inc.
C1 [Bridwell, Rachel; Long, Brit] Brooke Army Med Ctr, Dept Emergency Med, San Antonio, TX USA.
   [Gottlieb, Michael] Rush Univ, Med Ctr, Dept Emergency Med, Chicago, IL 60612 USA.
RP Long, B (corresponding author), 3841 Roger Brooke Dr, Houston, TX 78234 USA.
EM Brit.long@yahoo.com
CR AbbVie Inc, 2013, KALETRA OR FILM COAT
   Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Al-Samkari H, 2018, ANNU REV PATHOL-MECH, V13, P27, DOI 10.1146/annurev-pathol-020117-043625
   Alsolami A, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx145
   Baig AM, 2020, ACS CHEM NEROSCI, DOI [10.1021/acschemsneuro.0c00181, DOI 10.1021/ACSCHEMSNEURO.0C00181]
   Centers for Disease Control and Prevention (CDC), CAS US
   Chavez Summer, 2020, Am J Emerg Med, DOI 10.1016/j.ajem.2020.03.036
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Consoli D, 2015, EUR J NEUROL, V22, P514, DOI 10.1111/ene.12601
   Dafer RM, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104881
   Das G, 2020, ACS CHEM NEUROSCI, V11, P1206, DOI 10.1021/acschemneuro.0c00201
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Ellul M, 2018, CLIN MED, V18, P155, DOI 10.7861/clinmedicine.18-2-155
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Fraser JF, 2020, J NEUROINTERV SURG, V12, P539, DOI 10.1136/neurintsurg-2020-016098
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gonzalez-Pinto T, 2020, EUR J NEUROL, V27, pE35, DOI 10.1111/ene.14286
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Herman C, 2020, NEUROLOGY, V95, P77, DOI 10.1212/WNL.0000000000009673
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Khosravani H, 2020, STROKE, DOI [10.1161/STROKEAHA.120, DOI 10.1161/STROKEAHA.120]
   Klok FA, 2020, THROMB RES, DOI [10.1016/j.thromres.2020.04.013., DOI 10.1016/J.THROMRES.2020.04.013.]
   Li Y, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3550025, DOI 10.2139/SSRN.3550025]
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Maxwell NM, 2015, CLIN CASE REP, V3, P379, DOI 10.1002/ccr3.238
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Nath A, 2020, NEUROLOGY, V94, P809, DOI 10.1212/WNL.0000000000009455
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pistell PJ, 2010, ANTIVIR RES, V88, P334, DOI 10.1016/j.antiviral.2010.10.006
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rossi A, 2008, NEUROIMAG CLIN N AM, V18, P149, DOI 10.1016/j.nic.2007.12.007
   Russo MW, 2003, GASTROENTEROLOGY, V124, P1711, DOI 10.1016/S0016-5085(03)00394-9
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sellner J, 2020, EUR J NEUROL, V27, pE31, DOI 10.1111/ene.14257
   Siniscalchi A, 2016, CURR VASC PHARMACOL, V14, P98, DOI 10.2174/1570161113666150923111329
   Siniscalchi Antonio, 2014, Journal of Basic and Clinical Physiology and Pharmacology, V25, P131, DOI 10.1515/jbcpp-2013-0121
   Sleijfer S, 2005, PHARM WORLD SCI, V27, P423, DOI 10.1007/s11096-005-1319-7
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, COR DIS COVID 19 SIT
   Wong AM, 2006, AM J NEURORADIOL, V27, P1919
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Ye MX, 2020, BRAIN BEHAV IMMUN, V88, P945, DOI 10.1016/j.bbi.2020.04.017
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
NR 59
TC 6
Z9 6
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD JUL
PY 2020
VL 38
IS 7
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA NZ3QU
UT WOS:000577012400081
DA 2021-01-01
ER

PT J
AU Rahi, M
   Das, P
   Sharma, A
AF Rahi, Manju
   Das, Payal
   Sharma, Amit
TI COVID-19 Mitigation Steps Provide a Blueprint for Malaria Control and
   Elimination
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB Most countries around the world have responded promptly to the novel coronavirus disease (COVID-19) challenge by adopting considered and scientifically guided strategies for its containment. However, the situation is more complex for nations where malaria is endemic, as they now have the additional burden of COVID-19. In such nations, the healthcare systems are either in the preparatory or containment phase of the current pandemic. This enforced, sudden, and sharp public health refocus is likely to result in the disruption of annual malaria control activities such as distribution of insecticide-impregnated bed nets, indoor residual spraying of insecticide, maintenance of malaria surveillance, and mass provision of antimalarial drugs. Nonetheless, we feel that the best facets of COVID-19 public health management can become new guiding principles in malaria-endemic countries to improve malaria control and hasten malaria elimination. Redirection against malaria of the best public health initiatives used in COVID-19 containment could fast-track the global goal of a malaria-free world. Such public health advancement could be one positive outcome from the scourge of COVID-19.
C1 [Rahi, Manju; Das, Payal] Indian Council Med Res, New Delhi, India.
   [Sharma, Amit] ICMR Natl Inst Malaria Res, Sect 8, New Delhi 110077, India.
   [Sharma, Amit] Int Ctr Genet Engn & Biotechnol, New Delhi, India.
RP Sharma, A (corresponding author), ICMR Natl Inst Malaria Res, Sect 8, New Delhi 110077, India.
EM drmanjurahi@gmail.com; daspayal006@gmail.com; directornimr@gmail.com
OI Das, Dr Payal/0000-0003-3459-1278
FU DSTDepartment of Science & Technology (India)
FX We thank DST for the JC Bose fellowship to A. S. and Rai Sharma for his
   inspiration. Publication charges for this article were waived due to the
   ongoing pandemic of COVID-19.
CR Chanda-Kapata P, 2020, INT J INFECT DIS, V94, P151, DOI 10.1016/j.ijid.2020.04.007
   Ministry of Health and FamilyWelfare, 2020, ADVISORY QUARANTINE
   Patel R, 2020, MBIO, V11, DOI 10.1128/mBio.00722-20
   The Global fund, 2020, COVID 19 IMPACT HLTH
   Wang JG, 2020, LANCET, V395, P1094, DOI 10.1016/S0140-6736(20)30561-4
   WHO, 2019, WORLD MALARIA REPORT
   World Health Organization, 2020, GLOBAL MALARIA PROGR
NR 7
TC 3
Z9 3
U1 2
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2020
VL 103
IS 1
BP 28
EP 30
DI 10.4269/ajtmh.20-0394
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NZ6BJ
UT WOS:000577191000012
PM 32383431
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Luo, P
   Qiu, L
   Liu, Y
   Liu, XL
   Zheng, JL
   Xue, HY
   Liu, WH
   Liu, D
   Li, J
AF Luo, Pan
   Qiu, Lin
   Liu, Yi
   Liu, Xiu-lan
   Zheng, Jian-ling
   Xue, Hui-ying
   Liu, Wen-hua
   Liu, Dong
   Li, Juan
TI Metformin Treatment Was Associated with Decreased Mortality in COVID-19
   Patients with Diabetes in a Retrospective Analysis
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, P = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), P = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated.
C1 [Luo, Pan; Qiu, Lin; Liu, Yi; Liu, Xiu-lan; Zheng, Jian-ling; Xue, Hui-ying; Liu, Dong; Li, Juan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
   [Liu, Wen-hua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Clin Res Ctr, Wuhan, Peoples R China.
RP Liu, D; Li, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pharm, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM luopan106@126.com; qiulin_20000@163.com; 124460526@qq.com;
   liuxiulankl@163.com; archerzjl@163.com; jennie_xhy@qq.com;
   liuwh_2013@126.com; l_d2069@163.com; lijuan@tjh.tjmu.edu.cn
CR Ahmed S, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9010021
   Ba W, 2019, CELL BIOCHEM FUNCT, V37, P4, DOI 10.1002/cbf.3367
   Burgos-Moron E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091385
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coelho HJ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3957958
   Hill MA, 2020, METABOLISM, V107, DOI 10.1016/j.metabol.2020.154217
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Ouyang J, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00267-2
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Schuiveling M, 2018, CURR DRUG TARGETS, V19, P945, DOI 10.2174/1389450118666170613081730
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Yew WW, 2019, TUBERCULOSIS, V115, P76, DOI 10.1016/j.tube.2019.02.004
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 14
TC 22
Z9 23
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2020
VL 103
IS 1
BP 69
EP 72
DI 10.4269/ajtmh.20-0375
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NZ6BJ
UT WOS:000577191000021
PM 32446312
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gnegel, G
   Hauk, C
   Neci, R
   Mutombo, G
   Nyaah, F
   Wistuba, D
   Hafele-Abah, C
   Heide, L
AF Gnegel, Gesa
   Hauk, Cathrin
   Neci, Richard
   Mutombo, Georges
   Nyaah, Fidelis
   Wistuba, Dorothee
   Haefele-Abah, Christine
   Heide, Lutz
TI Identification of Falsified Chloroquine Tablets in Africa at the Time of
   the COVID-19 Pandemic
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB Reports that chloroquine and hydroxychloroquine may be effective against COVID-19 have received worldwide attention, increasing the risk of the introduction of falsified versions of these medicines. Five different types of falsified chloroquine tablets were discovered between March 31, 2020 and April 4, 2020, in Cameroon and the Democratic Republic of Congo by locally conducted thin layer chromatographic analysis. Subsequent investigation by liquid chromatography and mass spectrometry in Germany proved the absence of detectable amounts of chloroquine and the presence of undeclared active pharmaceutical ingredients, that is, paracetamol and metronidazole, in four of the samples. The fifth sample contained chloroquine, but only 22% of the declared amount. Such products represent a serious risk to patients. Their occurrence exemplifies that once medicines or vaccines against COVID-19 may be developed, falsified products will enter the market immediately, especially in low- and middle-income countries (LMICs). Timely preparations for the detection of such products are required, including the establishment of appropriate screening technologies in LMICs.
C1 [Gnegel, Gesa; Hauk, Cathrin; Heide, Lutz] Eberhard Karls Univ Tuebingen, Pharmaceut Inst, Morgenstelle 8, D-72076 Tubingen, Germany.
   [Gnegel, Gesa; Haefele-Abah, Christine] German Inst Med Miss Difaem, Tubingen, Germany.
   [Neci, Richard] Ecumen Pharmaceut Network, Nairobi, Kenya.
   [Neci, Richard; Mutombo, Georges] Le Depo Cent Medicopharmaceut 8e CEPAC DCMP, Bukavu, DEM REP CONGO.
   [Nyaah, Fidelis] Cent Pharm, Presbyterian Church Cameroon PCC, Limbe, Cameroon.
   [Wistuba, Dorothee] Eberhard Karls Univ Tuebingen, Inst Organ Chem, Tubingen, Germany.
RP Heide, L (corresponding author), Eberhard Karls Univ Tuebingen, Pharmaceut Inst, Morgenstelle 8, D-72076 Tubingen, Germany.
EM gesa.gnegel@uni-tuebingen.de; cathrin.hauk@uni-tuebingen.de;
   richard.neci@epnetwork.org; georgesmutombo@dcmp8ecepac.org;
   nyaahngoh@gmail.com; dorothee.wistuba@uni-tuebingen.de;
   haefele@difaem.de; heide@uni-tuebingen.de
OI Heide, Lutz/0000-0001-7809-7453
FU University of Tuebingen
FX This study was funded by the University of Tuebingen.
CR Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Jahnke WO, 2020, MANUAL ACCOMPANYING
   Jakhar D, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0853-0
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Management Sciences for Health, 2015, INT MED PROD PRIC GU
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   Petersen A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184165
   Schafermann S, 2020, AM J TROP MED HYG, V103, P894, DOI 10.4269/ajtmh.20-0184
   United States Pharmacopeia 42 NF 37, 2019, MON CHLOR PHOSPH TAB
   Vickers S, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000725
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, FALS CHLOR PROD CIRC
   WHO, 2017, FALS PEN 5 CIRC CAM
   WHO, 2017, GLOB SURV MON SYST S
   Xinhua, 2020, CAM CUST SEIZ 210 CA
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 18
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2020
VL 103
IS 1
BP 73
EP 76
DI 10.4269/ajtmh.20-0363
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA NZ6BJ
UT WOS:000577191000022
PM 32400349
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lindsley, AW
   Schwartz, JT
   Rothenberg, ME
AF Lindsley, Andrew W.
   Schwartz, Justin T.
   Rothenberg, Marc E.
TI Eosinophil responses during COVID-19 infections and coronavirus
   vaccination
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; eosinophils; immunopathology; immunopotentiation;
   SARS; vaccines
ID ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; SARS-COV; ANTIVIRAL
   IMMUNITY; SEVERE ASTHMA; MICE; CHILDREN; SPIKE; ACTIVATION; PROTECTION
AB Eosinophils are circulating and tissue-resident leukocytes that have potent proinflammatory effects in a number of diseases. Recently, eosinophils have been shown to have various other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key coronavirus disease 2019 (COVID-19)-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophiliaassociated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question because eosinopenia is associated with acute respiratory deterioration during infection with the severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.
C1 [Lindsley, Andrew W.; Schwartz, Justin T.; Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA.
RP Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM Rothenberg@cchmc.org
FU CURED Foundation
FX Dr Rothenberg thanks the CURED Foundation and Dave and Denise Bunning
   Fund for kind donations, and the authors thank Shawna Hottinger for
   editorial assistance.
CR Arden KE, 2010, J MED VIROL, V82, P1458, DOI 10.1002/jmv.21819
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   BASS DA, 1975, J CLIN INVEST, V56, P870, DOI 10.1172/JCI108166
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bjerregaard A, 2017, CLIN EXP ALLERGY, V47, P1007, DOI 10.1111/cea.12935
   Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Burris D, 2019, J ALLER CL IMM-PRACT, V7, P2750, DOI 10.1016/j.jaip.2019.05.011
   Busse W, 2019, J ALLERGY CLIN IMMUN, V143, P190, DOI 10.1016/j.jaci.2018.08.031
   Busse WW, 2019, LANCET RESP MED, V7, P46, DOI 10.1016/S2213-2600(18)30406-5
   Butterfield JH, 2007, IMMUNOL ALLERGY CLIN, V27, P493, DOI 10.1016/j.iac.2007.06.003
   Castilow EM, 2007, IMMUNOL RES, V39, P225, DOI 10.1007/s12026-007-0071-6
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Clark CM, 2017, CURR CLIN MICROBIOL, V4, P202, DOI 10.1007/s40588-017-0074-6
   Clay C, 2012, J VIROL, V86, P4234, DOI 10.1128/JVI.06791-11
   Davoine F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00570
   DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322
   Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358
   Drake MG, 2016, AM J RESP CELL MOL, V55, P387, DOI 10.1165/rcmb.2015-0405OC
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025
   FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
   Flores-Torres AS, 2019, VIRAL IMMUNOL, V32, P198, DOI 10.1089/vim.2018.0150
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haagmans BL, 2005, 10 INT NID S COL SPR
   Handzel ZT, 1998, J IMMUNOL, V160, P1279
   Hassani M, 2020, J LEUKOCYTE BIOL, V108, P1665, DOI 10.1002/JLB.1AB1219-493R
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Ishii K, 2009, MICROBIOL IMMUNOL, V53, P75, DOI 10.1111/j.1348-0421.2008.00097.x
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   Jackson DJ, 2020, DRUG SAFETY, V43, P409, DOI 10.1007/s40264-020-00926-3
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025
   Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601
   Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Katial RK, 2017, J ALLER CL IMM-PRACT, V5, pS1, DOI 10.1016/j.jaip.2016.11.029
   Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Laidlaw TM, 2020, ANN ALLERG ASTHMA IM, V124, P326, DOI 10.1016/j.anai.2019.12.001
   Lavoignet CE, 2019, EUR J CLIN MICROBIOL, V38, P1523, DOI 10.1007/s10096-019-03583-2
   Li X, J ALLERGY CLIN IMMUN, DOI [10.1016/j.jaci.2020.04., DOI 10.1016/J.JACI.2020.04.]
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Lugogo N, 2016, CLIN THER, V38, P2058, DOI 10.1016/j.clinthera.2016.07.010
   Malinczak CA, 2019, MUCOSAL IMMUNOL, V12, P969, DOI 10.1038/s41385-019-0171-3
   Mansson A, 2010, INT ARCH ALLERGY IMM, V151, P118, DOI 10.1159/000236001
   Mo P, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa270, DOI 10.1093/CID/CIAA270.]
   Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977
   Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340
   Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qiu MF, 2005, MICROBES INFECT, V7, P882, DOI 10.1016/j.micinf.2005.02.006
   Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691
   Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206
   Samarasinghe AE, 2017, J IMMUNOL, V198, P3214, DOI 10.4049/jimmunol.1600787
   Schwartz JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01944
   Silveira JS, 2019, ASIA PAC ALLERGY, V9, DOI 10.5415/apallergy.2019.9.e32
   Su YC, 2015, J VIROL, V89, P1564, DOI 10.1128/JVI.01536-14
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Weller PF, 2017, NAT REV IMMUNOL, V17, P746, DOI 10.1038/nri.2017.95
   Winthrop KL, 2018, CLIN MICROBIOL INFEC, V24, pS21, DOI 10.1016/j.cmi.2018.02.002
   Wong CK, 2007, AM J RESP CELL MOL, V37, P85, DOI 10.1165/rcmb.2006-0457OC
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yousefi S, 2018, J LEUKOCYTE BIOL, V104, P205, DOI 10.1002/JLB.3AB1117-455R
   Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 77
TC 35
Z9 35
U1 2
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2020
VL 146
IS 1
BP 1
EP 7
DI 10.1016/j.jaci.2020.04.021
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA OC5BB
UT WOS:000579170500001
PM 32344056
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ward, S
   Lindsley, A
   Courter, J
   Assa'ad, A
AF Ward, Stephanie
   Lindsley, Andrew
   Courter, Josh
   Assa'ad, Amal
TI Clinical testing for COVID-19
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; coronavirus; SARS-CoV-2; viral genes; S protein; N protein; E
   protein; M protein; RT-PCR; test; point-of-care; prioritization;
   guidance; Centers for Disease Control and Prevention; Food and Drug
   Administration; World Health Organization; nucleic acid test; serologic
   test
ID IGA
AB As the novel coronavirus severe acute respiratory syndrome coronavirus 2 caused coronavirus disease 2019 cases in the United States, the initial test was developed and performed at the Centers for Disease Control and Prevention. As the number of cases increased, the demand for tests multiplied, leading the Centers for Disease Control and Prevention to use the Emergency Utilization Authorization to allow clinical and commercial laboratories to develop tests to detect the presence of the virus. Many nucleic acid tests based on RT-PCR were developed, each with different techniques, specifications, and turnaround time. As the illnesses turned into a pandemic, testing became more crucial. The test supply became inadequate to meet the need and so it had to be prioritized according to guidance. For surveillance, the need for serologic tests emerged. Here, we review the timeline of test development, the turnaround times, and the various approved tests, and compare them as regards the genes they detect. We concentrate on the point-of-care tests and discuss the basis for new serologic tests. We discuss the testing guidance for prioritization and their application in a hospital setting.
C1 [Ward, Stephanie; Lindsley, Andrew; Assa'ad, Amal] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Courter, Josh] Cincinnati Childrens Hosp Med Ctr, Div Pharm, Cincinnati, OH 45229 USA.
RP Assa'ad, A (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM amal.assaad@cchmc.org
CR [Anonymous], 2020, INTERIM GUIDANCE
   Backer JA, 2020, EURO SURVEILL, V25
   Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458
   Brady PW, 2018, J PEDIAT INF DIS SOC, V7, P100, DOI 10.1093/jpids/pix077
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Miller JM, 2018, CLIN INFECT DIS, V67, P813, DOI 10.1093/cid/ciy584
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Nie SP, 2014, J CLIN MICROBIOL, V52, P3339, DOI 10.1128/JCM.01132-14
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026
   Provost LP, 2011, HLTH CARE DATA GUIDE
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wyllie AL, 2020, SALIVA IS MORE SENSI
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
NR 27
TC 3
Z9 3
U1 5
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2020
VL 146
IS 1
BP 23
EP 34
DI 10.1016/j.jaci.2020.05.012
PG 12
WC Allergy; Immunology
SC Allergy; Immunology
GA OC5BB
UT WOS:000579170500004
PM 32445839
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Forster-Ruhrmann, U
   Szczepek, AJ
   Bachert, C
   Olze, H
AF Foerster-Ruhrmann, Ulrike
   Szczepek, Agnieszka J.
   Bachert, Claus
   Olze, Heidi
TI COVID-19 in a patient with severe chronic rhinosinusitis with nasal
   polyps during therapy with dupilumab
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
C1 [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany.
   [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Free Univ Berlin, Berlin, Germany.
   [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Humboldt Univ, Berlin, Germany.
   [Foerster-Ruhrmann, Ulrike; Szczepek, Agnieszka J.; Olze, Heidi] Berlin Inst Hlth, Berlin, Germany.
   [Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium.
   [Bachert, Claus] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium.
RP Olze, H (corresponding author), Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany.; Olze, H (corresponding author), Free Univ Berlin, Berlin, Germany.; Olze, H (corresponding author), Humboldt Univ, Berlin, Germany.; Olze, H (corresponding author), Berlin Inst Hlth, Berlin, Germany.
EM heidi.olze@charite.de
CR Achuthan A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0332-4
   Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1
   Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Wollenberg A, 2020, BRIT J DERMATOL, V182, P1120, DOI 10.1111/bjd.18434
NR 8
TC 4
Z9 4
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2020
VL 146
IS 1
BP 218
EP 220
DI 10.1016/j.jaci.2020.05.005
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA OC5BB
UT WOS:000579170500035
PM 32417136
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pullen, MF
   Skipper, CP
   Hullsiek, KH
   Bangdiwala, AS
   Pastick, KA
   Okafor, EC
   Lofgren, SM
   Rajasingham, R
   Engen, NW
   Galdys, A
   Williams, DA
   Abassi, M
   Boulware, DR
AF Pullen, Matthew F.
   Skipper, Caleb P.
   Hullsiek, Kathy H.
   Bangdiwala, Ananta S.
   Pastick, Katelyn A.
   Okafor, Elizabeth C.
   Lofgren, Sarah M.
   Rajasingham, Radha
   Engen, Nicole W.
   Galdys, Alison
   Williams, Darlisha A.
   Abassi, Mahsa
   Boulware, David R.
TI Symptoms of COVID-19 Outpatients in the United States
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE coronavirus; COVID-19; SARS-CoV-2
AB Background. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pathogen causing the current world-wide coronavirus disease 2019 (COVID-19) pandemic. Due to insufficient diagnostic testing in the United States, there is a need for clinical decision-making algorithms to guide testing prioritization.
   Methods. We recruited participants nationwide for a randomized clinical trial. We categorized participants into 3 groups: (1) those with confirmed SARS-CoV-2 infection, (2) those with probable SARS-CoV-2 infection (pending test or not tested but with a confirmed COVID-19 contact), and (3) those with possible SARS-CoV-2 infection (pending test or not tested and with a contact for whom testing was pending or not performed). We compared the frequency of self-reported symptoms in each group and categorized those reporting symptoms in early infection (0-2 days), midinfection (3-5 days), and late infection (>5 days).
   Results. Among 1252 symptomatic persons screened, 316 had confirmed, 393 had probable, and 543 had possible SARS-CoV-2 infection. In early infection, those with confirmed and probable SARS-CoV-2 infection shared similar symptom profiles, with fever most likely in confirmed cases (P = .002). Confirmed cases did not show any statistically significant differences compared with un-confirmed cases in symptom frequency at any time point. The most commonly reported symptoms in those with confirmed infection were cough (82%), fever (67%), fatigue (62%), and headache (60%), with only 52% reporting both fever and cough.
   Conclusions. Symptomatic persons with probable SARS-CoV-2 infection present similarly to those with confirmed SARS-CoV-2 infection. There was no pattern of symptom frequency over time.
C1 [Pullen, Matthew F.; Skipper, Caleb P.; Pastick, Katelyn A.; Okafor, Elizabeth C.; Lofgren, Sarah M.; Rajasingham, Radha; Galdys, Alison; Williams, Darlisha A.; Abassi, Mahsa; Boulware, David R.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
   [Hullsiek, Kathy H.; Bangdiwala, Ananta S.; Engen, Nicole W.; Boulware, David R.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
RP Pullen, MF (corresponding author), 689 SE 23rd Ave,MRF 4-103, Minneapolis, MN 55455 USA.
EM pullen@umn.edu
OI Pullen, Matthew/0000-0002-4644-7487; Okafor,
   Elizabeth/0000-0003-1495-4596; Engen, Nicole/0000-0003-1118-4194;
   Boulware, David/0000-0002-4715-0060; Skipper, Caleb/0000-0002-0000-8876;
   Lofgren, Sarah M/0000-0001-6717-2614
FU Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF);
   National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [K23MH121220]; Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [D43TW009345]; National Institute of Allergy and Infectious
   DiseaseUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [K23AI138851, T32AI055433]; Alliance of
   Minnesota Chinese Organizations; Minnesota Chinese Chamber of Commerce;
   University of MinnesotaUniversity of Minnesota System
FX This work was supported by Jan and David Baszucki, Steve Kirsch, the
   Alliance of Minnesota Chinese Organizations, the Minnesota Chinese
   Chamber of Commerce, and the University of Minnesota. Personnel were
   supported through the Doris Duke Charitable Foundation through a grant
   supporting the Doris Duke International Clinical Research Fellows
   Program at the University of Minnesota. Katelyn Pastick and Elizabeth
   Okafor are Doris Duke International Clinical Research Fellows. Sarah
   Lofgren is supported by the National Institute of Mental Health
   (K23MH121220). Caleb Skipper is supported by the Fogarty International
   Center (D43TW009345). Drs. Radha Raiasingham and Matthew Pullen are
   supported by the National Institute of Allergy and Infectious Disease
   (K23AI138851, T32AI055433).
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   CDC COVID-19 Response Team, 2020, MMWR Morb Mortal Wkly Rep, V69, P477, DOI 10.15585/mmwr.mm6915e6
   Centers for Disease Control and Prevention, 2020, EV TEST PERS COR DIS
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Gane SB, 2020, RHINOLOGY, V58, P299, DOI 10.4193/Rhin20.114
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771
   Wang X, 2020, CLIN MICROBIOL INFEC, V26, P1063, DOI 10.1016/j.cmi.2020.03.032
   WHO, 2020, REP WHO CHIN JOINT M
NR 11
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD JUL
PY 2020
VL 7
IS 7
AR ofaa271
DI 10.1093/ofid/ofaa271
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5UR
UT WOS:000577171200042
PM 33117855
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schiffer, JT
   Johnston, C
   Wald, A
   Corey, L
AF Schiffer, Joshua T.
   Johnston, Christine
   Wald, Anna
   Corey, Lawrence
TI An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome
   Coronavirus 2
SO OPEN FORUM INFECTIOUS DISEASES
LA English
DT Article
DE antiviral therapy; COVID-19; SARS CoV-2
ID ANTIRETROVIRAL THERAPY; INFLUENZA
AB As coronavirus disease 2019 cases and deaths continue to expand globally, there is an urgent need to develop, test, and approve effective antiviral therapies. Currently, a majority of clinical trials are evaluating therapies in patients who are already hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. Given that the median time between development of symptoms and need for hospitalization is 1 week, a golden opportunity to intervene early is being missed. Indeed, for many other viral infections, early treatment soon after development of symptoms is associated with decreased mortality, lower hospitalization rates, and lower likelihood of transmission to others. In this study, we advocate for randomized, double-blind, placebo controlled, clinical trials to evaluate promising agents early during SARS CoV-2 infection.
C1 [Schiffer, Joshua T.; Johnston, Christine; Wald, Anna; Corey, Lawrence] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Schiffer, Joshua T.] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Schiffer, Joshua T.; Johnston, Christine; Wald, Anna; Corey, Lawrence] Univ Washington, Dept Med, Seattle, WA USA.
   [Wald, Anna; Corey, Lawrence] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Wald, Anna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Schiffer, JT (corresponding author), 1100 Eastlake Ave E, Seattle, WA 98109 USA.
EM jschiffe@fredhutch.org
OI Schiffer, Joshua/0000-0002-2598-1621
FU Fred Hutchinson Cancer Research Center internal grant
FX J.T.S. receives COVID-19 research funding from a Fred Hutchinson Cancer
   Research Center internal grant.
CR Agyemang E, 2018, J INFECT DIS, V218, P1691, DOI 10.1093/infdis/jiy372
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen JM, 2013, GASTROENTEROLOGY, V144, P1450, DOI 10.1053/j.gastro.2013.02.039
   Choi SM, 2011, BLOOD, V117, P5050, DOI 10.1182/blood-2010-11-319186
   Chu H, 2019, OFID, V6, pS1002, DOI DOI 10.1093/0FID/0FZ415.2504
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144
   Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068
   Fry AM, 2015, LANCET INFECT DIS, V15, P654, DOI 10.1016/S1473-3099(15)70041-1
   Gilbert Peter B, 2017, Stat Commun Infect Dis, V9, DOI 10.1515/scid-2016-0001
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e132
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Mayer BT, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020171
   McMichael TM, 2020, MMWR-MORBID MORTAL W, V69, P339, DOI 10.15585/mmwr.mm6912e1
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Murray JS, 1999, AIDS, V13, P797, DOI 10.1097/00002030-199905070-00008
   Nacoti M, 2020, NEJM CATALYST, DOI [10.1056/CAT.20.0080, DOI 10.1056/CAT.20.0080, 10.1056/CAT.20.0080#]
   Natori Y, 2018, CLIN INFECT DIS, V66, P617, DOI 10.1093/cid/cix793
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Patrick GT, 2020, GLOBAL IMPACT COVID
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 2328-8957
J9 OPEN FORUM INFECT DI
JI Open Forum Infect. Dis.
PD JUL
PY 2020
VL 7
IS 7
AR ofaa232
DI 10.1093/ofid/ofaa232
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5UR
UT WOS:000577171200019
PM 32661497
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ghahramani-Asl, R
   Porouhan, P
   Mehrpouyan, M
   Welsh, JS
   Calabrese, EJ
   Kapoor, R
   Dhawan, G
   Javadinia, SA
AF Ghahramani-Asl, Ruhollah
   Porouhan, Pejman
   Mehrpouyan, Mohammad
   Welsh, James S.
   Calabrese, Edward J.
   Kapoor, Rachna
   Dhawan, Gaurav
   Javadinia, Seyed Alireza
TI Feasibility of Treatment Planning System in Localizing the COVID-19
   Pneumonia Lesions and Evaluation of Volume Indices of Lung Involvement
SO DOSE-RESPONSE
LA English
DT Article
DE low dose radiotherapy; treatment planning system; 3 dimensional (3D)
   conformal radiation therapy; COVID-19; SARS-CoV-2; acute respiratory
   distress syndrome (ARDS)
ID X-RAYS; RADIATION-THERAPY; HISTORICAL USE; RADIOTHERAPY
AB Background and purpose: To assess the feasibility of a treatment planning system in localizing, contouring, and targeting lung lesions along with an evaluation of volume indices of lung involvement in patients with COVID-19 pneumonia. Methods: We evaluated 10 patients with PCR-confirmed COVID-19 pneumonia. The CT images were imported into the ISOgray (R) treatment planning system to anatomically define and contour the volumes of the pulmonary lesions, the lungs, and other nearby organs. Results: The ratio of lung lesion volume to lung volume in this study was 0.11 +/- 0.13 (11.13%). The highest mean biosynthesis ratio of lung lesions was 0.36. The ratio of lesion volume in the left lung of patients with the highest volume of involvement, was 0.44, and the ratio of lesion volume in the right lung of these patients was 0.27 (approximately 1.5 times more in the left lung than the right lung). On average, CTDIvol and DLP for all patients studied in our study were 11.22 +/- 2.47 mGy and 354.20 +/- 65.11 mGy.cm Conclusion: We reported the feasibility of using a treatment planning system in localizing COVID-19 pulmonary lesions and its validity in the volumetric assessment of infected lung regions.
C1 [Ghahramani-Asl, Ruhollah; Mehrpouyan, Mohammad] Sabzevar Univ Med Sci, Fac Paramed, Dept Med Phys & Radiat Sci, Sabzevar, Iran.
   [Ghahramani-Asl, Ruhollah] Sabzevar Univ Med Sci, Hosp Res Dev Comm, Clin Res Dev Unit, Sabzevar, Iran.
   [Porouhan, Pejman] Sabzevar Univ Med Sci, Vasei Educ Hosp, Dept Radiat Oncol, Sabzevar, Iran.
   [Welsh, James S.] Loyola Univ Chicago, Edward Hines Jr VA Hosp, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL USA.
   [Calabrese, Edward J.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Environm Hlth Sci, Amherst, MA USA.
   [Kapoor, Rachna] St Francis Hosp & Med Ctr, Hartford, CT USA.
   [Dhawan, Gaurav] MedSurg Urgent Care, Gilbertsville, PA USA.
   [Javadinia, Seyed Alireza] Sabzevar Univ Med Sci, Cellular & Mol Res Ctr, Sabzevar, Iran.
RP Javadinia, SA (corresponding author), Vasei Educ Hosp, TohidShar BLV, Sabzevar 9617747431, Razavi Khorasan, Iran.
EM javadinia.alireza@gmail.com
RI Dhawan, Gaurav/I-7098-2019
OI Dhawan, Gaurav/0000-0003-0511-7323
FU Sabzevar University of Medical Sciences [99003]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by Sabzevar University of Medical Sciences [grant number
   99003;2020. Recipient: Ruhollah Ghahramani-Asl].
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Bernheim A, 2020, RADIOLOGY, V295, P3
   Calabrese EJ, 2019, HUM EXP TOXICOL, V38, P888, DOI 10.1177/0960327119846925
   Calabrese EJ, 2014, HUM EXP TOXICOL, V33, P542, DOI 10.1177/0960327113493303
   Calabrese EJ, 2017, DOSE-RESPONSE, V15, DOI 10.1177/1559325817704760
   Calabrese EJ, 2015, RADIAT RES, V184, P180, DOI 10.1667/RR14080.1
   Calabrese EJ, 2014, ARCH TOXICOL, V88, P1503, DOI 10.1007/s00204-014-1295-6
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Calabrese EJ, 2013, DOSE-RESPONSE, V11, P469, DOI 10.2203/dose-response.13-004.Calabrese
   Calabrese EJ, 2013, HUM EXP TOXICOL, V32, P817, DOI 10.1177/0960327112467046
   Calabrese EJ, 2012, DOSE-RESPONSE, V10, P626, DOI 10.2203/dose-response.12-016.Calabrese
   Caruso D, 2020, RADIOLOGY, V296, pE79, DOI 10.1148/radiol.2020201237
   Dhawan G, 2020, RADIOTHER ONCOL, V147, P212, DOI 10.1016/j.radonc.2020.05.002
   Dhawan G, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819871757
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Hani C, 2020, DIAGN INTERV IMAG, V101, P263, DOI 10.1016/j.diii.2020.03.014
   Huda W., 2016, REV RADIOLOGIC PHYS, P169
   Kanne JP, 2020, RADIOLOGY, V295, P16, DOI 10.1148/radiol.2020200241
   Kirsch DG, 2020, RADIOTHER ONCOL, V147, P217, DOI 10.1016/j.radonc.2020.04.060
   Lazzari G, 2020, RADIOTHER ONCOL, V147, P222, DOI 10.1016/j.radonc.2020.04.027
   Majidi Hadi, 2020, Am J Emerg Med, V38, P2730, DOI 10.1016/j.ajem.2020.04.016
   Podgorsak E. B., 2005, RAD ONCOLOGY PHYS, P123
   Qanadli SD, 2001, AM J ROENTGENOL, V176, P1415, DOI 10.2214/ajr.176.6.1761415
   Trott KR, 2020, RADIOTHER ONCOL, V147, P210, DOI 10.1016/j.radonc.2020.05.003
   WHO, 2020, REP WHO CHIN JOINT M
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1559-3258
J9 DOSE-RESPONSE
JI Dose-Response
PD JUL
PY 2020
VL 18
IS 3
AR 1559325820962600
DI 10.1177/1559325820962600
PG 8
WC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
SC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
GA NY5OH
UT WOS:000576438100001
PM 33088245
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rossi, PG
   Grilli, R
   Marino, M
   Formisano, D
   Costantini, M
   Formoso, G
   Bedeschi, M
   Perilli, C
   Venturi, I
   Bisaccia, E
   La Rosa, E
   Campari, C
   Gioia, F
   Broccoli, S
   Ottone, M
   Pattacini, P
   Besutti, G
   Lotti, V
   Spaggiari, L
   Mancuso, P
   Nitrosi, A
   Foracchia, M
   Colla, R
   Zerbini, A
   Massari, M
   Ferrari, AM
   Pinotti, M
   Facciolongo, N
   Lattuada, I
   Trabucco, L
   De Pietri, S
   Danelli, GF
   Albertazzi, L
   Bellesia, E
   Canovi, S
   Corradini, M
   Fasano, T
   Magnani, E
   Pilia, A
   Polese, A
   Incerti, SS
   Zaldini, P
   Bonelli, E
   Orsola, B
   Revelli, M
   Salvarani, C
   Venturelli, F
AF Rossi, Paolo Giorgi
   Grilli, Roberto
   Marino, Massimiliano
   Formisano, Debora
   Costantini, Massimo
   Formoso, Giulio
   Bedeschi, Manuela
   Perilli, Cinzia
   Venturi, Ivano
   Bisaccia, Eufemia
   La Rosa, Elisabetta
   Campari, Cinzia
   Gioia, Francesco
   Broccoli, Serena
   Ottone, Marta
   Pattacini, Pierpaolo
   Besutti, Giulia
   Lotti, Valentina
   Spaggiari, Lucia
   Mancuso, Pamela
   Nitrosi, Andrea
   Foracchia, Marco
   Colla, Rossana
   Zerbini, Alessandro
   Massari, Marco
   Ferrari, Anna Maria
   Pinotti, Mirco
   Facciolongo, Nicola
   Lattuada, Ivana
   Trabucco, Laura
   De Pietri, Stefano
   Danelli, Giorgio Francesco
   Albertazzi, Laura
   Bellesia, Enrica
   Canovi, Simone
   Corradini, Mattia
   Fasano, Tommaso
   Magnani, Elena
   Pilia, Annalisa
   Polese, Alessandra
   Incerti, Silvia Storchi
   Zaldini, Piera
   Bonelli, Efrem
   Orsola, Bonanno
   Revelli, Matteo
   Salvarani, Carlo
   Venturelli, Francesco
CA Reggio Emilia Covid-19 Working Grp
TI Prevalence of SARS-CoV-2 (Covid-19) in Italians and in immigrants in an
   area of Northern Italy (Reggio Emilia)
SO EPIDEMIOLOGIA & PREVENZIONE
LA English
DT Article
DE SARS-CoV-2 (Covid-19); migrant health; women's health; BCG vaccine
ID BCG VACCINATION; INFECTION
AB It has been hypothesized that bacille Calmette-Guerin (BCG), the anti-tuberculosis vaccine, can be protective against Covid-19. Using data of performed swabs and RT-PCR results for SARS-CoV-2 in the Reggio Emilia province (Emilia-Romagna Region, Northern Italy) from March 6th to March 26th, 2020, we computed age, gender, and place of birth (Italy or abroad) specific risk of being tested, prevalence of positive tests, and probability of testing positive given that a swab has been taken during the epidemic peak.
   We report that immigrants resident in Reggio Emilia province, mostly coming from Countries with high BCG vaccination coverage, and Italians had a similar prevalence of infection (odds ratio - OR 0.99; 95%CI 0.82-1.20) and similar probability of being tested (OR 0.93; 95%CI 0.81-1.10). Our data do not support the hypothesis that immigrants from Countries where BCG vaccination is recommended have a lower risk of Covid-19 infection.
C1 [Rossi, Paolo Giorgi] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
   [Rossi, Paolo Giorgi; Grilli, Roberto; Marino, Massimiliano; Formisano, Debora; Costantini, Massimo; Formoso, Giulio; Bedeschi, Manuela; Perilli, Cinzia; Venturi, Ivano; Bisaccia, Eufemia; La Rosa, Elisabetta; Campari, Cinzia; Gioia, Francesco; Broccoli, Serena; Ottone, Marta; Pattacini, Pierpaolo; Besutti, Giulia; Lotti, Valentina; Spaggiari, Lucia; Mancuso, Pamela; Nitrosi, Andrea; Foracchia, Marco; Colla, Rossana; Zerbini, Alessandro; Massari, Marco; Ferrari, Anna Maria; Pinotti, Mirco; Facciolongo, Nicola; Lattuada, Ivana; Trabucco, Laura; De Pietri, Stefano; Danelli, Giorgio Francesco; Albertazzi, Laura; Bellesia, Enrica; Canovi, Simone; Corradini, Mattia; Fasano, Tommaso; Magnani, Elena; Pilia, Annalisa; Polese, Alessandra; Incerti, Silvia Storchi; Zaldini, Piera; Bonelli, Efrem; Orsola, Bonanno; Revelli, Matteo; Salvarani, Carlo; Venturelli, Francesco; Reggio Emilia Covid-19 Working Grp] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
RP Rossi, PG (corresponding author), Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy.
EM paolo.giorgirossi@ausl.re.it
RI Rossi, Paolo Giorgi/K-6367-2016
OI Rossi, Paolo Giorgi/0000-0001-9703-2460
FU Azienda USL - IRCCS di Reggio Emilia
FX this study has been conducted only with institutional funds of the
   Azienda USL - IRCCS di Reggio Emilia.
CR Abundance Fundation. Abundance Fundation, MOR EV SUPP RES BCG
   [Anonymous], 2018, Wkly Epidemiol Rec, V93, P73
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Ballotari P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219965
   Ballotari P, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-458
   Cereda D., 2020, EARLY PHASE COVID 19
   Farchi S, 2005, Ann Ig, V17, P335
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kamat AM, 2016, J CLIN ONCOL, V34, P1935, DOI 10.1200/JCO.2015.64.4070
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   MENZIES R, 1992, AM REV RESPIR DIS, V146, P752, DOI 10.1164/ajrccm/146.3.752
   Petrelli A, 2019, EPIDEMIOL PREV, V43, P1, DOI 10.19191/EP19.1.S1.002
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Shet A., 2020, DIFFERENTIAL COVID 1, DOI [10.1101/2020.04.01.20049478, DOI 10.1101/2020.04.01.20049478]
   Spina S, 2020, LANCET, V395, pE49, DOI 10.1016/S0140-6736(20)30493-1
   Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3
NR 16
TC 0
Z9 0
U1 1
U2 1
PU INFERENZE SCARL
PI MILANO
PA VIA RICCIARELLI N 29, MILANO, 20148, ITALY
SN 1120-9763
EI 2385-1937
J9 EPIDEMIOL PREV
JI Epidemiol. Prev.
PD JUL-AUG
PY 2020
VL 44
IS 4
BP 304
EP 307
DI 10.19191/EP20.4.P304.061
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NX0VL
UT WOS:000575436900016
PM 32921037
DA 2021-01-01
ER

PT J
AU Ndjeka, N
   Conradie, F
   Meintjes, G
   Reuter, A
   Hughes, J
   Padanilam, X
   Ismail, N
   Kock, Y
   Master, I
   Romero, R
   te Riele, J
   Enwerem, M
   Ferreira, H
   Maartens, G
AF Ndjeka, Norbert
   Conradie, Francesca
   Meintjes, Graeme
   Reuter, Anja
   Hughes, Jennifer
   Padanilam, Xavier
   Ismail, Nazir
   Kock, Yulene
   Master, Iqbal
   Romero, Rodolfo
   te Riele, Julian
   Enwerem, Martin
   Ferreira, Hannetjie
   Maartens, Gary
TI Responding to SARS-CoV-2 in South Africa: what can we learn from
   drug-resistant tuberculosis?
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
C1 [Ndjeka, Norbert; Kock, Yulene] Drug Resistant TB Directorate, Natl Dept Hlth, Pretoria, South Africa.
   [Conradie, Francesca] Univ Witwatersrand, Dept Clin Med, Fac Hlth Sci, Johannesburg, South Africa.
   [Meintjes, Graeme; Maartens, Gary] Univ Cape Town, Dept Med, Inst Infect Dis & Mol Med, Rondebosch, South Africa.
   [Meintjes, Graeme; Maartens, Gary] Univ Cape Town, Wellcome Ctr Infect Dis Res Africa, Inst Infect Dis & Mol Med, Rondebosch, South Africa.
   [Reuter, Anja] Med Sans Frontieres, Khayelitsha, South Africa.
   [Hughes, Jennifer] Stellenbosch Univ, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Fac Med & Hlth Sci, Cape Town, South Africa.
   [Padanilam, Xavier] Sizwe Trop Dis Hosp, Dept Hlth, Gauteng, South Africa.
   [Ismail, Nazir] Natl Inst Communicable Dis, Ctr TB, Johannesburg, South Africa.
   [Master, Iqbal] King Dinuzulu Hosp, Kwazulu Natal Prov Dept Hlth, Durban, South Africa.
   [Romero, Rodolfo] Dist Clin Specialist Team, Namakwa, South Africa.
   [te Riele, Julian] Brooklyn Chest Hosp, Metro TB Hosp Ctr, Cape Town, South Africa.
   [Enwerem, Martin] Witbank TB Specialized Hosp, Witbank, South Africa.
   [Ferreira, Hannetjie] Klerksdorp Tshepong Hosp, Klerksdorp, South Africa.
RP Ndjeka, N (corresponding author), Natl TB Programme, P Bag X828, ZA-0001 Pretoria, South Africa.
EM Norbert.Ndjeka@health.gov.za
OI Hughes, Jennifer/0000-0002-5349-9509
CR Borisov S, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01522-2019
   Conradie F, 2014, SAMJ S AFR MED J, V104, P164, DOI 10.7196/SAMJ.7263
   Johns Hopkins University, J HOPK COR DASHB TRA
   Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002
   Ndjeka N, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01528-2018
   Schnippel K, 2018, LANCET RESP MED, V6, P699, DOI 10.1016/S2213-2600(18)30235-2
   Sinanovic E, 2015, INT J TUBERC LUNG D, V19, P172, DOI 10.5588/ijtld.14.0421
   Tadolini M, 2020, EUR RESPIR J, V56
   World Health Organization, ROLL UPD COR DIS COV
   World Health Organization, 2019, GLOB TB REP
NR 10
TC 1
Z9 1
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL 1
PY 2020
VL 56
IS 1
AR 2001369
DI 10.1183/13993003.01369-2020
PG 3
WC Respiratory System
SC Respiratory System
GA NW3XZ
UT WOS:000574944800033
PM 32471936
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hage, R
   Steinack, C
   Schuurmans, MM
AF Hage, Rene
   Steinack, Carolin
   Schuurmans, Mace M.
TI Calcineurin inhibitors revisited: A new paradigm for COVID-19?
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Cytokine storm; Hyperinflammation; Transplantation; ARDS
ID COV
AB The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Hage, Rene; Steinack, Carolin; Schuurmans, Mace M.] Univ Hosp Zurich, Div Pulmonol, Zurich, Switzerland.
   [Hage, Rene; Steinack, Carolin; Schuurmans, Mace M.] Univ Zurich, Fac Med, Zurich, Switzerland.
RP Hage, R (corresponding author), Univ Hosp Zurich, Div Pulmonol, Zurich, Switzerland.; Hage, R (corresponding author), Univ Zurich, Fac Med, Zurich, Switzerland.
EM rene.hage@usz.ch
RI Steinack, Carolin/AAY-4241-2020; Hage, Rene/AAO-8251-2020
OI Steinack, Carolin/0000-0003-1561-2870; Hage, Rene/0000-0002-1994-7443;
   Schuurmans, Mace M./0000-0001-5404-7566
CR AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Hage K, 2020, TRANSPLANTOLOGY, V1, P1
   Han WL, 2020, ANN SURG, V272, pE33, DOI 10.1097/SLA.0000000000003955
   McGonagle D, 2020, LANCET RHEUMATOLOGY
   Siddiqi HK, 2020, J HEART LUNG TRANSPL
   Tian S, 2020, J THORAC ONCOL
   van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555
   Ye ZJ, 2020, CELL CYCLE, V19, P2906, DOI 10.1080/15384101.2020.1827511
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JUL-AUG
PY 2020
VL 24
IS 4
BP 365
EP 367
DI 10.1016/j.bjid.2020.06.005
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA NW2JT
UT WOS:000574836900015
PM 32603679
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Romao, VC
   Cordeiro, I
   Macieira, C
   Oliveira-Ramos, F
   Romeu, JC
   Rosa, CM
   Saavedra, MJ
   Saraiva, F
   Vieira-Sousa, E
   Fonseca, JE
AF Romao, Vasco C.
   Cordeiro, Ines
   Macieira, Carla
   Oliveira-Ramos, Filipa
   Romeu, Jose Carlos
   Rosa, Carlos Miranda
   Saavedra, Maria Joao
   Saraiva, Fernando
   Vieira-Sousa, Elsa
   Fonseca, Joao Eurico
TI Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view
SO RMD OPEN
LA English
DT Article
DE Lupus Erythematosus; Systemic; Sjogren's Syndrome; Synovitis;
   Vaccination; Arthritis; Rheumatoid; Juvenile Idiopathic Arthritis;
   Outcomes research; Disease Activity; Rheumatoid Arthritis;
   Spondyloarthritis
ID INFECTIONS; ARTHRITIS
AB The coronavirus disease 2019 (COVID-19) pandemic has come with many challenges for healthcare providers and patients alike. In addition to the direct burden it has placed on societies and health systems, it had a significant impact in the care of patients with chronic diseases, as healthcare resources were deployed to fight the crisis, and major travel and social restrictions were adopted. In the field of rheumatology, this has required notable efforts from departments and clinicians to adapt to the novel status quo and assure the follow-up of patients with rheumatic and musculoskeletal diseases. In the present viewpoint, we provide a practical approach to tackle this reality. Key measures include setting up preventive team management strategies, optimising communication with patients and reorganising patient care in all its dimensions. We then anticipate the nuances of rheumatology practice as restrictive measures are progressively lifted, while an effective vaccine is still pending. This includes the need to reimpose the same strategy as further waves unfold. Finally, we look ahead and address the lessons we can incorporate into post-COVID-19 rheumatology.
C1 [Romao, Vasco C.; Cordeiro, Ines; Macieira, Carla; Oliveira-Ramos, Filipa; Romeu, Jose Carlos; Rosa, Carlos Miranda; Saavedra, Maria Joao; Saraiva, Fernando; Vieira-Sousa, Elsa; Fonseca, Joao Eurico] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon Acad Med Ctr, Dept Rheumatol, Lisbon, Portugal.
   [Romao, Vasco C.; Cordeiro, Ines; Oliveira-Ramos, Filipa; Saavedra, Maria Joao; Saraiva, Fernando; Vieira-Sousa, Elsa; Fonseca, Joao Eurico] Univ Lisbon, Rheumatol Res Unit, Inst Med Mol Joao Lobo Antunes, Fac Med, Lisbon, Portugal.
RP Fonseca, JE (corresponding author), Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon Acad Med Ctr, Dept Rheumatol, Lisbon, Portugal.; Fonseca, JE (corresponding author), Univ Lisbon, Rheumatol Res Unit, Inst Med Mol Joao Lobo Antunes, Fac Med, Lisbon, Portugal.; Fonseca, JE (corresponding author), Ctr Hosp Univ Lisboa Norte, Dept Rheumatol, Hosp Santa Maria, Ave Prof Egas Moniz, P-1649035 Lisbon, Portugal.
EM jecfonseca@gmail.com
RI Romao, Vasco C/O-8224-2014; Romeu, Jose C/D-3003-2016
OI Romao, Vasco C/0000-0002-5603-9436; Romeu, Jose C/0000-0002-9582-2343;
   Fonseca, Joao/0000-0003-1432-3671
CR American Cancer Society Cancer Action Network, 2020, COVID 19 PAND IMP CA
   American Medical Association, 2020, CAR OUR CAR COVID 19
   [Anonymous], WHO COR DIS COVID 20
   Atzeni F, 2008, CLIN EXP RHEUMATOL, V26, pS67
   AV H, 2020, ANN INTERN MED
   Black JRM, 2020, LANCET, V395, P1418, DOI 10.1016/S0140-6736(20)30917-X
   Canhao H, 2011, ACTA REUMATOL PORT, V36, P45
   Centers for Disease Control and Prevention, 2020, CRIT RET WORK HEALTH
   Centers for Disease Control and Prevention (US), 2020, US CLOTH FAC COV HEL
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   D'Silva KM, 2020, ANN RHEUM DIS, V2019, P1
   EMA, 2020, GUID MAN CLIN TRIALS
   European Centre for Disease Prevention and Control, 2020, GUID DISCH END IS CO
   European Centre for Disease Prevention and Control, 2020, INF PREV CONTR PREP
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gewin V, 2020, NATURE, V580, P549, DOI 10.1038/d41586-020-01027-y
   Gianfrancesco M, 2020, ANN RHEUM DIS, P1
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Heinzerling A, 2020, MMWR-MORBID MORTAL W, V69, P472, DOI 10.15585/mmwr.mm6915e5
   Hsu CY, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1997-5
   Kellam P, 2020, J GEN VIROL
   Khasnis AA, 2011, SEMIN ARTHRITIS RHEU, V41, P236, DOI 10.1016/j.semarthrit.2011.01.008
   Klompas M, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006372
   Kontou PI, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050319
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lim AYN, 2015, INT J INTEGR CARE, V15
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   McInnes IB, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2020-217494
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, P1
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Pinto AJ, 2020, NAT REV RHEUMATOL, V16, P347, DOI 10.1038/s41584-020-0427-z
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Rose S, 2020, JAMA-J AM MED ASSOC, V323, P2131, DOI 10.1001/jama.2020.5227
   Saini KS, 2020, LANCET HAEMATOL, V2019, P2019
   Schett G, 2016, ANN RHEUM DIS, V75, P1428, DOI 10.1136/annrheumdis-2016-209201
   Shanafelt T, 2020, JAMA-J AM MED ASSOC, V2019, P2019
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Villar J, 2020, CRIT CARE EXPL, V2
   Walker PG, 2020, GLOBAL IMPACT COVID, V2020, P1, DOI [10.25561/77735., DOI 10.25561/77735]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Xie Y, 2020, J INFECT
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 67
TC 1
Z9 1
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2056-5933
J9 RMD OPEN
JI RMD Open
PD JUL
PY 2020
VL 6
IS 2
AR e001314
DI 10.1136/rmdopen-2020-001314
PG 7
WC Rheumatology
SC Rheumatology
GA NV7LZ
UT WOS:000574499500005
PM 32584782
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Giavina-Bianchi, P
   Aun, MV
   Agondi, RCA
   Kalil, J
AF Giavina-Bianchi, Pedro
   Aun, Marcelo Vivolo
   Agondi, Rosana C. Amara
   Kalil, Jorge
TI Debate on drugs that may aggravate COVID-19
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
C1 [Giavina-Bianchi, Pedro; Aun, Marcelo Vivolo; Agondi, Rosana C. Amara; Kalil, Jorge] Univ Sao Paulo, Clin Immunol & Allergy Div, Fac Med, Sao Paulo, Brazil.
RP Giavina-Bianchi, P (corresponding author), Univ Sao Paulo, Clin Immunol & Allergy, R Prof Artur Ramos 178 Ap 211a, Sao Paulo, Brazil.
EM pbianchi@usp.br
CR Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Shaker MS, 2020, J ALLER CL IMM-PRACT, V8, P1477, DOI 10.1016/j.jaip.2020.03.012
   Taddei S, 2016, AM J CARDIOVASC DRUG, V16, P309, DOI 10.1007/s40256-016-0173-4
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2020
VL 8
IS 7
BP 2452
EP 2453
DI 10.1016/j.jaip.2020.04.037
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA NS8DH
UT WOS:000572486000056
PM 32344190
OA Green Published
DA 2021-01-01
ER

PT J
AU Bezzio, C
   Saibeni, S
   Variola, A
   Allocca, M
   Massari, A
   Gerardi, V
   Casini, V
   Ricci, C
   Zingone, F
   Amato, A
   Caprioli, F
   Lenti, MV
   Vigano, C
   Ascolani, M
   Bossa, F
   Castiglione, F
   Cortelezzi, C
   Grossi, L
   Milla, M
   Morganti, D
   Pastorelli, L
   Ribaldone, DG
   Sartini, A
   Soriano, A
   Manes, G
   Danese, S
   Fantini, M
   Armuzzi, A
   Daperno, M
   Fiorino, G
AF Bezzio, Cristina
   Saibeni, Simone
   Variola, Angela
   Allocca, Mariangela
   Massari, Alessandro
   Gerardi, Viviana
   Casini, Valentina
   Ricci, Chiara
   Zingone, Fabiana
   Amato, Arnaldo
   Caprioli, Flavio
   Lenti, Marco Vincenzo
   Vigano, Chiara
   Ascolani, Marta
   Bossa, Fabrizio
   Castiglione, Fabiana
   Cortelezzi, Claudio
   Grossi, Laurino
   Milla, Monica
   Morganti, Daniela
   Pastorelli, Luca
   Ribaldone, Davide Giuseppe
   Sartini, Alessandro
   Soriano, Alessandra
   Manes, Gianpiero
   Danese, Silvio
   Fantini, Massimo
   Armuzzi, Alessandro
   Daperno, Marco
   Fiorino, Gionata
CA Italian Grp Study Inflammatory Bo
TI Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
SO GUT
LA English
DT Article
DE IBD; epidemiology
ID CORONAVIRUS; THERAPY
AB Objectives COVID-19 has rapidly become a major health emergency worldwide. Patients with IBD are at increased risk of infection, especially when they have active disease and are taking immunosuppressive therapy. The characteristics and outcomes of COVID-19 in patients with IBD remain unclear.
   Design This Italian prospective observational cohort study enrolled consecutive patients with an established IBD diagnosis and confirmed COVID-19. Data regarding age, sex, IBD (type, treatments and clinical activity), other comorbidities (Charlson Comorbidity Index (CCI)), signs and symptoms of COVID-19 and therapies were compared with COVID-19 outcomes (pneumonia, hospitalisation, respiratory therapy and death).
   Results Between 11 and 29 March 2020, 79 patients with IBD with COVID-19 were enrolled at 24 IBD referral units. Thirty-six patients had COVID-19-related pneumonia (46%), 22 (28%) were hospitalised, 7 (9%) required non-mechanical ventilation, 9 (11%) required continuous positive airway pressure therapy, 2 (3%) had endotracheal intubation and 6 (8%) died. Four patients (6%) were diagnosed with COVID-19 while they were being hospitalised for a severe flare of IBD. Age over 65 years (p=0.03), UC diagnosis (p=0.03), IBD activity (p=0.003) and a CCI score >1 (p=0.04) were significantly associated with COVID-19 pneumonia, whereas concomitant IBD treatments were not. Age over 65 years (p=0.002), active IBD (p=0.02) and higher CCI score were significantly associated with COVID-19-related death.
   Conclusions Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not. Preventing acute IBD flares may avoid fatal COVID-19 in patients with IBD. Further research is needed.
C1 [Bezzio, Cristina; Saibeni, Simone] ASST Rhodense, Gastroenterol Unit, Rho Hosp, Rho MI, Garbagnate Milanese, Italy.
   [Variola, Angela] Don Calabria Sacred Heart Hosp, IBD Unit, Negrar, Veneto, Italy.
   [Allocca, Mariangela; Danese, Silvio; Fiorino, Gionata] Humanitas Clin & Res Ctr IRCCS, Gastroenterol, IBD Ctr, Milan, Italy.
   [Allocca, Mariangela; Danese, Silvio; Fiorino, Gionata] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Massari, Alessandro] ASST Fatebenefratelli Sacco, Gastroenterol Unit, Milan, Lombardia, Italy.
   [Gerardi, Viviana] Poliambulanza Brescia Hosp, Med Gastroenterol & Digest Endoscopy Dept, Brescia, Lombardia, Italy.
   [Casini, Valentina] ASST Bergamo Est, UOC Gastroenterol & Digest Endoscopy, Seriate, Lombardia, Italy.
   [Ricci, Chiara] ASST Spedali Civili Brescia, Gastroenterol Unit, Brescia, Lombardia, Italy.
   [Zingone, Fabiana] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Veneto, Italy.
   [Amato, Arnaldo] Valduce Hosp, Div Digest Endoscopy & Gastroenterol, Como, Italy.
   [Caprioli, Flavio] La Fdn IRCCS Ca Granda Osped Maggiore Milano Poli, Gastroenterol & Endoscopy Unit, Milan, Lombardia, Italy.
   [Caprioli, Flavio] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Lombardia, Italy.
   [Lenti, Marco Vincenzo] Univ Pavia, Dept Internal Med 1, Pavia, Lombardia, Italy.
   [Vigano, Chiara] Azienda Osped San Gerardo, Gastroenterol Unit, Monza, Lombardia, Italy.
   [Ascolani, Marta] Osped Santa Maria Ca Foncello, Gastroenterol Unit, Treviso, Veneto, Italy.
   [Bossa, Fabrizio] IRCCS Osped Casa Sollievo Sofferenza, Div Gastroenterol, San Giovanni Rotondo, Puglia, Italy.
   [Castiglione, Fabiana] Federico II Univ Hosp, Gastroenterol, Naples, Italy.
   [Cortelezzi, Claudio] ASST Sette Laghi, Gastroenterol Uniit, Varese, Lombardia, Italy.
   [Grossi, Laurino] Univ Gabriele dAnnunzio Chieti & Pescara, Dept Med & Aging Sci, Chieti, Abruzzo, Italy.
   [Milla, Monica] Azienda Osped Univ Careggi, Gastroenterol Unit, Florence, Toscana, Italy.
   [Morganti, Daniela] ASST Rhodense, Gastreonterol Unit, Garbagnate Milanese, Lombardia, Italy.
   [Pastorelli, Luca] IRCCS Policlin San Danato, Gastreonterol Unit, San Donato Milanese, Lombardia, Italy.
   [Ribaldone, Davide Giuseppe] Univ Turin, Dept Med Sci, Div Gastroenterol, Turin, Italy.
   [Sartini, Alessandro] AUSL Romagna, Bufalini Hosp, Gastroenterol Unit, Internal Med, Cesena, Italy.
   [Soriano, Alessandra] Arcispedale S Maria Nuova, Gastroenterol Div, Reggio Emilia, Emilia Romagna, Italy.
   [Manes, Gianpiero] ASST Rhodense, Gastroenterol Unit, Garbagnate Milanese, Lombardia, Italy.
   [Fantini, Massimo] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Gastroenterol, Cagliari, Sardegna, Italy.
   [Armuzzi, Alessandro] Policlin Univ Agostino Gemelli, IBD Unit, Rome, Lazio, Italy.
   [Armuzzi, Alessandro] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Rome, Lazio, Italy.
   [Daperno, Marco] Azienda Osped Ordine Mauriziano Torino, Gastroenterol Unit, Turin, Piemonte, Italy.
RP Bezzio, C (corresponding author), ASST Rhodense, Gastroenterol Unit, Rho Hosp, Rho MI, Garbagnate Milanese, Italy.
EM cribezzio03@yahoo.it
RI Saibeni, Simone/AAA-3663-2019; Caprioli, Flavio/AAB-5176-2019; Sartini,
   Alessandro/AAN-3396-2020; Lenti, Marco Vincenzo/F-9044-2018; Danese,
   Silvio/ABH-9571-2020; Amato, Arnaldo/ABC-5688-2020; Ribaldone, Davide
   Giuseppe/H-3478-2019; Zingone, Fabiana/O-5361-2018
OI Saibeni, Simone/0000-0001-5677-2534; Caprioli,
   Flavio/0000-0002-8077-8175; Sartini, Alessandro/0000-0003-1573-6451;
   Lenti, Marco Vincenzo/0000-0002-6654-4911; Danese,
   Silvio/0000-0001-7341-1351; Amato, Arnaldo/0000-0002-4397-4142;
   Ribaldone, Davide Giuseppe/0000-0002-9421-3087; Zingone,
   Fabiana/0000-0003-1133-1502
CR Beaugerie L, 2019, CLIN GASTROENTEROL H, V17, P370, DOI 10.1016/j.cgh.2018.07.013
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   D'Haens G, 2007, GASTROENTEROLOGY, V132, P763, DOI 10.1053/j.gastro.2006.12.038
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Fiorino G, 2020, J CROHNS COLITIS, DOI [10.1093/ecco-jcc/jjaa058, DOI 10.1093/ECC0-JCC/JJAA058]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HARVEY RF, 1980, LANCET, V1, P514
   International Organization for the study of Inflammatory Bowel Disease (IOIBD), 2020, IOIBD UPD COVID 19 P
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Ministero della Salute, 2020, COVID 19 AGG DEF CAS
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ping A, 2020, LANCET
   Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603
   Ungaro RC, 2020, CLIN GASTROENTEROL H, V18, P1409, DOI 10.1016/j.cgh.2020.03.020
   WHO, 2020, NOV COR COVID 19 SIT
   World Health Organization, 2020, COR SEC COR
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 51
Z9 52
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUL
PY 2020
VL 69
IS 7
BP 1213
EP 1217
DI 10.1136/gutjnl-2020-321411
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO7GB
UT WOS:000569655200011
PM 32354990
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Neurath, MF
AF Neurath, Markus F.
TI COVID-19 and immunomodulation in IBD
SO GUT
LA English
DT Article
DE inflammatory bowel disease; inflammation; cytokines
ID JANUS KINASE INHIBITOR; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY;
   RANDOMIZED-TRIAL; CROHNS-DISEASE; CORONAVIRUS; USTEKINUMAB; VEDOLIZUMAB;
   INDUCTION; INFLAMMATION
AB The current coronavirus pandemic is an ongoing global health crisis due to COVID-19, caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to COVID-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of COVID-19. Here, the current understanding of the pathophysiology of COVID-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.
C1 [Neurath, Markus F.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, D-91052 Erlangen, Germany.
   [Neurath, Markus F.] Friedrich Alexander Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI, D-91052 Erlangen, Germany.
   [Neurath, Markus F.] Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.
RP Neurath, MF (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, D-91052 Erlangen, Germany.; Neurath, MF (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Deutsch Zentrum Immuntherapie DZI, D-91052 Erlangen, Germany.
EM markus.neurath@uk-erlangen.de
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG SFB
   643, SFB1181, TRR241, FOR2438, KFO257]
FX This study was funded by Deutsche Forschungsgemeinschaft (DFG SFB 643;
   SFB1181; TRR241; FOR2438; KFO257).
CR An P, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3543590, DOI 10.2139/SSRN.3543590]
   Atreya R, 2014, NAT MED, V20, P313, DOI 10.1038/nm.3462
   Balestrieri P, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020372
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Beaugerie L, 2020, CLIN GASTROENTEROL H, V18, P1324, DOI 10.1016/j.cgh.2020.02.009
   Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Byrareddy SN, 2016, SCIENCE, V354, P197, DOI 10.1126/science.aag1276
   Byrnes JJ, 2009, INFLAMM RES, V58, P819, DOI 10.1007/s00011-009-0053-3
   Cerniello FM, 2017, HYPERTENSION, V70, P982, DOI 10.1161/HYPERTENSIONAHA.117.09789
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen SY, 2020, J MED VIROL, V92, P1556, DOI 10.1002/jmv.25789
   Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Croxford AL, 2012, EUR J IMMUNOL, V42, P2263, DOI 10.1002/eji.201242598
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Danese S, 2019, GUT, V68, P40, DOI 10.1136/gutjnl-2017-314562
   De Nitto D, 2010, CURR PHARM DESIGN, V16, P3656, DOI 10.2174/138161210794079164
   Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773
   Feagan BG, 2013, NEW ENGL J MED, V369, P699, DOI 10.1056/NEJMoa1215734
   Fiorino G, 2020, J CROHNS COLITIS, V14, P1330, DOI 10.1093/ecco-jcc/jjaa058
   Fischer A, 2016, GUT, V65, P1642, DOI 10.1136/gutjnl-2015-310022
   Forbes A, 2017, CLIN NUTR, V36, P321, DOI 10.1016/j.clnu.2016.12.027
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Garg M, 2015, J RENIN-ANGIO-ALDO S, V16, P559, DOI 10.1177/1470320314521086
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holmer A, 2019, EXPERT REV CLIN IMMU, V15, P969, DOI 10.1080/1744666X.2019.1646127
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012
   Jablaoui A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00021
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   Khajah MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150861
   Kotze PG, 2018, J INFLAMM RES, V11, P35, DOI 10.2147/JIR.S157358
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lv S, 2014, INT J CLIN PRACT, V68, P520, DOI 10.1111/ijcp.12382
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003
   Mehta P., 2020, LANCET
   Monteleone G, 2020, J CROHNS COLITIS, V307, DOI [10.1093/ecco-jcc/jjaa061, DOI 10.1093/ECC0-JCC/JJAA061]
   Moschen AR, 2019, NAT REV GASTRO HEPAT, V16, P185, DOI 10.1038/s41575-018-0084-8
   Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0
   Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661
   Ng SC, 2018, INFLAMM BOWEL DIS, V24, P2431, DOI 10.1093/ibd/izy153
   Ning LG, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3950628
   Panahi L, 2020, ARCH ACAD EMERG MED, V8
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Piovani D, 2020, ALIMENT PHARM THER, V51, P820, DOI 10.1111/apt.15692
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014
   Sandborn WJ, 2014, CLIN GASTROENTEROL H, V12, P1485, DOI 10.1016/j.cgh.2014.01.029
   Sandborn WJ, 2013, NEW ENGL J MED, V369, P711, DOI 10.1056/NEJMoa1215739
   Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572
   Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168
   Sands BE, 2019, NEW ENGL J MED, V381, P1215, DOI 10.1056/NEJMoa1905725
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shimoda M, 2016, EBIOMEDICINE, V5, P114, DOI 10.1016/j.ebiom.2016.02.007
   Singh S, 2020, CLIN GASTROENTEROL H, V18, P69, DOI 10.1016/j.cgh.2019.02.044
   Sneller MC, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax3447
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Uzzan M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau4711
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Weisshof R, 2019, DIGEST DIS SCI, V64, P1945, DOI 10.1007/s10620-019-05492-y
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong E, 2016, SCI REP-UK, V6, DOI 10.1038/srep35598
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yoon JY, 2019, INTEST RES, V17, P463, DOI 10.5217/ir.2019.00078
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zundler S, 2017, INFLAMM BOWEL DIS, V23, P379, DOI 10.1097/MIB.0000000000001029
NR 97
TC 36
Z9 39
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUL
PY 2020
VL 69
IS 7
BP 1335
EP 1342
DI 10.1136/gutjnl-2020-321269
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO7GB
UT WOS:000569655200023
PM 32303609
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Su, YCF
   Anderson, DE
   Young, BE
   Linster, M
   Zhu, F
   Jayakumar, J
   Zhuang, Y
   Kalimuddin, S
   Low, JGH
   Tan, CW
   Chia, WN
   Mak, TM
   Octavia, S
   Chavatte, JM
   Lee, RTC
   Pada, S
   Tan, SY
   Sun, L
   Yan, GZ
   Maurer-Stroh, S
   Mendenhall, IH
   Leo, YS
   Lye, DC
   Wang, LF
   Smith, GJD
AF Su, Yvonne C. F.
   Anderson, Danielle E.
   Young, Barnaby E.
   Linster, Martin
   Zhu, Feng
   Jayakumar, Jayanthi
   Zhuang, Yan
   Kalimuddin, Shirin
   Low, Jenny G. H.
   Tan, Chee Wah
   Chia, Wan Ni
   Mak, Tze Minn
   Octavia, Sophie
   Chavatte, Jean-Marc
   Lee, Raphael T. C.
   Pada, Surinder
   Tan, Seow Yen
   Sun, Louisa
   Yan, Gabriel Z.
   Maurer-Stroh, Sebastian
   Mendenhall, Ian H.
   Leo, Yee-Sin
   Lye, David Chien
   Wang, Lin-Fa
   Smith, Gavin J. D.
TI Discovery and Genomic Characterization of a 382-Nucleotide Deletion in
   ORF7b and ORF8 during the Early Evolution of SARS-CoV-2
SO MBIO
LA English
DT Article
DE COVID-19; ORF8; natural selection; phylogeny; vaccines
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; BATS; TRANSCRIPTION
AB To date, limited genetic changes in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome have been described. Here, we report a 382-nucleotide (nt) deletion in SARS-CoV-2 that truncates open reading frame 7b (ORF7b) and ORF8, removing the ORF8 transcription regulatory sequence (TRS) and eliminating ORF8 transcription. The earliest 382-nt deletion variant was detected in Singapore on 29 January 2020, with the deletion viruses circulating in the country and accounting for 23.6% (45/191) of SARS-CoV-2 samples screened in this study. SARS-CoV-2 with the same deletion has since been detected in Taiwan, and other ORF7b/8 deletions of various lengths, ranging from 62 nt to 345 nt, have been observed in other geographic locations, including Australia, Bangladesh, and Spain. Mutations or deletions in ORF8 of SARS-CoV have been associated with reduced replicative fitness and virus attenuation. In contrast, the SARS-CoV-2 382-nt deletion viruses showed significantly higher replicative fitness in vitro than the wild type, while no difference was observed in patient viral load, indicating that the deletion variant viruses retained their replicative fitness. A robust antibody response to ORF8 has been observed in SARS-CoV-2 infection, suggesting that the emergence of ORF8 deletions may be due to immune-driven selection and that further deletion variants may emerge during the sustained transmission of SARS-CoV-2 in humans.
   IMPORTANCE During the SARS epidemic in 2003/2004, a number of deletions were observed in ORF8 of SARS-CoV, and eventually deletion variants became predominant, leading to the hypothesis that ORF8 was an evolutionary hot spot for adaptation of SARS-CoV to humans. However, due to the successful control of the SARS epidemic, the importance of these deletions for the epidemiological fitness of SARS-CoV in humans could not be established. The emergence of multiple SARS-CoV-2 strains with ORF8 deletions, combined with evidence of a robust immune response to ORF8, suggests that the lack of ORF8 may assist with host immune evasion. In addition to providing a key insight into the evolutionary behavior of SARS-CoV-2 as the virus adapts to its new human hosts, the emergence of ORF8 deletion variants may also impact vaccination strategies.
C1 [Su, Yvonne C. F.; Anderson, Danielle E.; Linster, Martin; Zhu, Feng; Jayakumar, Jayanthi; Zhuang, Yan; Kalimuddin, Shirin; Low, Jenny G. H.; Tan, Chee Wah; Chia, Wan Ni; Mendenhall, Ian H.; Wang, Lin-Fa; Smith, Gavin J. D.] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.
   [Young, Barnaby E.; Mak, Tze Minn; Octavia, Sophie; Chavatte, Jean-Marc; Leo, Yee-Sin; Lye, David Chien] Natl Ctr Infect Dis, Singapore, Singapore.
   [Young, Barnaby E.; Leo, Yee-Sin; Lye, David Chien] Tan Tock Seng Hosp, Singapore, Singapore.
   [Young, Barnaby E.; Leo, Yee-Sin; Lye, David Chien] Lee Kong Chian Sch Med, Singapore, Singapore.
   [Kalimuddin, Shirin; Low, Jenny G. H.] Singapore Gen Hosp, Singapore, Singapore.
   [Lee, Raphael T. C.; Maurer-Stroh, Sebastian] ASTAR, Bioinformat Inst, Singapore, Singapore.
   [Pada, Surinder] Ng Teng Fong Gen Hosp, Singapore, Singapore.
   [Tan, Seow Yen] Changi Gen Hosp, Singapore, Singapore.
   [Sun, Louisa] Alexandra Hosp, Singapore, Singapore.
   [Yan, Gabriel Z.] Natl Univ Singapore Hosp, Singapore, Singapore.
   [Maurer-Stroh, Sebastian] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   [Mendenhall, Ian H.; Wang, Lin-Fa; Smith, Gavin J. D.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Leo, Yee-Sin] SingHlth Duke NUS Global Hlth Inst, Singapore, Singapore.
   [Leo, Yee-Sin; Lye, David Chien] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Wang, Lin-Fa; Smith, Gavin J. D.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.
RP Wang, LF; Smith, GJD (corresponding author), Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.; Wang, LF; Smith, GJD (corresponding author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.; Wang, LF; Smith, GJD (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.
EM linfa.wang@duke-nus.edu.sg; gavin.smith@duke-nus.edu.sg
RI Zhu, Feng/ABG-4866-2020; Linster, Martin/AAY-9088-2020
OI Zhu, Feng/0000-0002-8131-1219; Lye, David/0000-0003-0324-0205; Chavatte,
   Jean-Marc/0000-0002-0003-541X; Yan, Gabriel/0000-0003-3513-428X;
   Linster, Martin/0000-0003-2636-2512; Maurer-Stroh,
   Sebastian/0000-0003-0813-9640; Su, Yvonne/0000-0003-4349-9211
FU Duke-NUS Signature Research Programme - Ministry of Health,
   SingaporeMinistry of Health-SingaporeNational University of Singapore;
   National Medical Research CouncilMedical Research Council UK (MRC)
   [COVID19RF-001, COVID19RF-004]; National Research Foundation
   SingaporeSingapore National Research Foundation [NRF2016NRFNSFC002-013];
   A*STARAgency for Science Technology & Research (ASTAR); National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, U.S. Department of Health and Human ServicesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [HHSN272201400006C]
FX This study was supported by the Duke-NUS Signature Research Programme
   funded by the Ministry of Health, Singapore; by the National Medical
   Research Council under its COVID-19 Research Fund (NMRC project no.
   COVID19RF-001 and COVID19RF-004); and by National Research Foundation
   Singapore grant NRF2016NRFNSFC002-013 (Combating the Next SARS-or
   MERS-Like Emerging Infectious Disease Outbreak by Improving Active
   Surveillance). R.T.C.L. and S.M.-S. were supported by A*STAR. Y.C.F.S.
   and G.J.D.S. are supported by contract HHSN272201400006C from the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, U.S. Department of Health and Human Services.
CR Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Chiu RWK, 2005, EMERG INFECT DIS, V11, P168, DOI 10.3201/eid1101.040544
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Duchene S, 2020, BIORXIV, DOI [DOI 10.1101/2020.05.04.077735, 10.1101/2020.05.04.077735]
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Geoghegan JL, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170189
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hachim A, 2020, SPIKE IDENTIFICATION, DOI [10.1101/2020.04.30.20085670, DOI 10.1101/2020.04.30.20085670]
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Lamers MM, 2016, EMERG INFECT DIS, V22, P716, DOI 10.3201/eid2204.152065
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08
   Pfefferle S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-131
   Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6
   Rambaut A, 2020, DYNAMIC NOMENCLATURE, DOI [10.1101/2020.04.17.046086, DOI 10.1101/2020.04.17.046086]
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Sims AC, 2013, J VIROL, V87, P3885, DOI 10.1128/JVI.02520-12
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
   Tang JW, 2006, J INFECT DIS, V194, P808, DOI 10.1086/507044
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Warren CJ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000217
   World Health Organization, 2020, COR DIS COVID 2019 S
   Xu L, 2016, VIROL SIN, V31, P69, DOI 10.1007/s12250-016-3727-3
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 33
TC 13
Z9 13
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD JUL-AUG
PY 2020
VL 11
IS 4
AR e01610-20
DI 10.1128/mBio.01610-20
PG 9
WC Microbiology
SC Microbiology
GA NS1ZO
UT WOS:000572064700005
PM 32694143
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vaillancourt, M
   Jorth, P
AF Vaillancourt, Mylene
   Jorth, Peter
TI The Unrecognized Threat of Secondary Bacterial Infections with COVID-19
SO MBIO
LA English
DT Article
DE COVID-19; SARS-CoV-2; antibiotic resistance; coinfection; secondary
   bacterial infection
ID ACUTE RESPIRATORY SYNDROME; RESISTANT STAPHYLOCOCCUS-AUREUS;
   COINFECTION; INFLUENZA; OUTBREAK; INCREASE
AB Coronavirus disease 2019 (COVID-19) is the greatest pandemic of our generation, with 16 million people affected and 650,000 deaths worldwide so far. One of the risk factors associated with COVID-19 is secondary bacterial pneumonia. In recent studies on COVID-19 patients, secondary bacterial infections were significantly associated with worse outcomes and death despite antimicrobial therapies. In the past, the intensive use of antibiotics during the severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic led to increases in the prevalence of multidrug-resistant bacteria. The rising number of antibiotic-resistant bacteria and our decreasing capacity to eradicate them not only render us more vulnerable to bacterial infections but also weaken us during viral pandemics. The COVID-19 pandemic reminds us of the great health challenges we are facing, especially regarding antibiotic-resistant bacteria.
C1 [Vaillancourt, Mylene; Jorth, Peter] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.
RP Jorth, P (corresponding author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA.
EM peter.jorth@cshs.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K22AI127473, UL1TR001881]; Cystic
   Fibrosis Foundation [JORTH17F5, JORTH19I0, JORTH19P0]
FX We declare no competing interests. P.J. was supported by grants from the
   NIH (K22AI127473 and UL1TR001881) and the Cystic Fibrosis Foundation
   (JORTH17F5, PROMISE, JORTH19I0, JORTH19P0).
CR Chertow DS, 2013, JAMA-J AM MED ASSOC, V309, P275, DOI 10.1001/jama.2012.194139
   Cui W, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-145
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Finelli L, 2008, PEDIATRICS, V122, P805, DOI 10.1542/peds.2008-1336
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Klein EY, 2016, INFLUENZA OTHER RESP, V10, P394, DOI 10.1111/irv.12398
   Lai CC, 2015, J MICROBIOL IMMUNOL, V48, P431, DOI 10.1016/j.jmii.2013.10.008
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Randolph AG, 2011, PEDIATRICS, V128, pE1450, DOI 10.1542/peds.2011-0774
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   World Health Organization, 2020, COVID 19 SIT REP
   Yap FHY, 2004, CLIN INFECT DIS, V39, P511, DOI 10.1086/422641
   Zahariadis George, 2006, Can Respir J, V13, P17
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu XJ, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198005
NR 16
TC 1
Z9 1
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD JUL-AUG
PY 2020
VL 11
IS 4
AR e01806-20
DI 10.1128/mBio.01806-20
PG 3
WC Microbiology
SC Microbiology
GA NS1ZD
UT WOS:000572063200003
PM 32769090
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Biryukov, J
   Boydston, JA
   Dunning, RA
   Yeager, JJ
   Wood, S
   Reese, AL
   Ferris, A
   Miller, D
   Weaver, W
   Zeitouni, NE
   Phillips, A
   Freeburger, D
   Hooper, I
   Ratnesar-Shumate, S
   Yolitz, J
   Krause, M
   Williams, G
   Dawson, DG
   Herzog, A
   Dabisch, P
   Wahl, V
   Hevey, MC
   Altamura, LA
AF Biryukov, Jennifer
   Boydston, Jeremy A.
   Dunning, Rebecca A.
   Yeager, John J.
   Wood, Stewart
   Reese, Amy L.
   Ferris, Allison
   Miller, David
   Weaver, Wade
   Zeitouni, Nathalie E.
   Phillips, Aaron
   Freeburger, Denise
   Hooper, Idris
   Ratnesar-Shumate, Shanna
   Yolitz, Jason
   Krause, Melissa
   Williams, Gregory
   Dawson, David G.
   Herzog, Artemas
   Dabisch, Paul
   Wahl, Victoria
   Hevey, Michael C.
   Altamura, Louis A.
TI Increasing Temperature and Relative Humidity Accelerates Inactivation of
   SARS-CoV-2 on Surfaces
SO MSPHERE
LA English
DT Article
DE COVID-19; SARS-CoV-2; contamination; coronavirus; fomite; half-life;
   humidity; temperature; transmission
ID SURVIVAL
AB Coronavirus disease 2019 (COVID-19) was first identified in China in late 2019 and is caused by newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Previous studies had reported the stability of SARS-CoV-2 in cell culture media and deposited onto surfaces under a limited set of environmental conditions. Here, we broadly investigated the effects of relative humidity, temperature, and droplet size on the stability of SARS-CoV-2 in a simulated clinically relevant matrix dried on nonporous surfaces. The results show that SARS-CoV-2 decayed more rapidly when either humidity or temperature was increased but that droplet volume (1 to 50 mu l) and surface type (stainless steel, plastic, or nitrile glove) did not significantly impact decay rate. At room temperature (24 degrees C), virus half-life ranged from 6.3 to 18.6 h depending on the relative humidity but was reduced to 1.0 to 8.9 h when the temperature was increased to 35 degrees C. These findings suggest that a potential for fomite transmission may persist for hours to days in indoor environments and have implications for assessment of the risk posed by surface contamination in indoor environments.
   IMPORTANCE Mitigating the transmission of SARS-CoV-2 in clinical settings and public spaces is critically important to reduce the number of COVID-19 cases while effective vaccines and therapeutics are under development. SARS-CoV-2 transmission is thought to primarily occur through direct person-to-person transfer of infectious respiratory droplets or through aerosol-generating medical procedures. However, contact with contaminated surfaces may also play a significant role. In this context, understanding the factors contributing to SARS-CoV-2 persistence on surfaces will enable a more accurate estimation of the risk of contact transmission and inform mitigation strategies. To this end, we have developed a simple mathematical model that can be used to estimate virus decay on nonporous surfaces under a range of conditions and which may be utilized operationally to identify indoor environments in which the virus is most persistent.
C1 [Biryukov, Jennifer; Boydston, Jeremy A.; Dunning, Rebecca A.; Yeager, John J.; Wood, Stewart; Reese, Amy L.; Ferris, Allison; Miller, David; Weaver, Wade; Zeitouni, Nathalie E.; Phillips, Aaron; Freeburger, Denise; Hooper, Idris; Ratnesar-Shumate, Shanna; Yolitz, Jason; Krause, Melissa; Williams, Gregory; Dawson, David G.; Dabisch, Paul; Wahl, Victoria; Hevey, Michael C.; Altamura, Louis A.] Natl Biodef Anal & Countermeasures Ctr NBACC, Ft Detrick, MD 21702 USA.
   [Herzog, Artemas] Censeo Consulting Grp Inc, Washington, DC USA.
RP Altamura, LA (corresponding author), Natl Biodef Anal & Countermeasures Ctr NBACC, Ft Detrick, MD 21702 USA.
EM Louis.Altamura@nbacc.dhs.gov
OI Ratnesar-Shumate, Shanna/0000-0001-5181-7772; Miller,
   David/0000-0002-5746-3909
FU DHS S&T Directorate for the management and operation of the NBACC
   [HSHQDC-15-C-00064]
FX This work was funded under agreement no. HSHQDC-15-C-00064 awarded to
   Battelle National Biodefense Institute (BNBI) by DHS S&T Directorate for
   the management and operation of the NBACC, a federally funded research
   and development center.
CR Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Chau Nguyen Van Vinh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa711
   Chia PY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16670-2
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Corman V, DIAGNOSTIC DETECTION
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Ratnesar-Shumate S, 2020, J INFECT DIS, V222, P214, DOI 10.1093/infdis/jiaa274
   Schuit M, 2020, J INFECT DIS, V221, P372, DOI 10.1093/infdis/jiz582
   Schuit M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148476
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   van Doremalen N, 2013, EUROSURVEILLANCE, V18, P7, DOI 10.2807/1560-7917.ES2013.18.38.20590
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Woo MH, 2010, J AEROSOL SCI, V41, P944, DOI 10.1016/j.jaerosci.2010.07.003
   Wu SJ, 2020, AM J INFECT CONTROL, V48, P910, DOI 10.1016/j.ajic.2020.05.003
   Ye GM, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.04.034
   Zuo ZL, 2014, APPL ENVIRON MICROB, V80, P2796, DOI 10.1128/AEM.00056-14
NR 21
TC 10
Z9 11
U1 13
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD JUL-AUG
PY 2020
VL 5
IS 4
AR e00441-20
DI 10.1128/mSphere.00441-20
PG 9
WC Microbiology
SC Microbiology
GA NR8CR
UT WOS:000571787800008
PM 32611701
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Evans, NG
AF Evans, Nicholas G.
TI Human Infection Challenge Studies: a Test for the Social Value Criterion
   of Research Ethics
SO MSPHERE
LA English
DT Article
DE COVID-19; challenge studies; coronavirus; global health; research ethics
ID CORONAVIRUS INFECTION
AB Human infection challenge studies involving the intentional infection of research participants with a disease-causing agent have recently been suggested as a means to speed up the search for a vaccine for the ongoing coronavirus disease 2019 (COVID-19) outbreak. Calls for challenge studies, however, rely on the expected social value of these studies. This value represents more than the simple possibility that a successful study will lead to the rapid development and dissemination of vaccines but also some expectation that this will actually occur. I show how this expectation may not be realistic in the current political moment and offer potential ways to make sure that any challenge trials that arise actually achieve their goals.
C1 [Evans, Nicholas G.] Univ Massachusetts, Dept Philosophy, Lowell, MA 01854 USA.
RP Evans, NG (corresponding author), Univ Massachusetts, Dept Philosophy, Lowell, MA 01854 USA.
EM nicholas_evans@uml.edu
OI Evans, Nicholas/0000-0002-3330-0224
FU NSFNational Science Foundation (NSF) [1734521]; Greenwall Foundation
FX N.G.E. receives funding from the NSF (no. 1734521) and the Greenwall
   Foundation. Thanks to Anna Muldoon for assistance with some sources and
   for comments on a previous draft of this paper.
CR Ahmed AK, 2020, OXFORD ASTRAZENECA C
   Brown R, 2017, J MED ETHICS, V43, P118, DOI 10.1136/medethics-2015-103125
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Cohen E., 2020, FAUCI SAYS COVID 19
   Cornwall W, 2020, SCIENCE
   Eccleston-Turner M, 2017, MED LAW INT, V17, P227, DOI [10.1177/0968533217723683, DOI 10.1177/0968533217723683]
   EYAL N, 2020, AIDS BEHAV 0626, DOI DOI 10.1007/S10461-020
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   HIGGINS PG, 1983, ANTIMICROB AGENTS CH, V24, P713, DOI 10.1128/AAC.24.5.713
   Hoare C., 2020, CORONAVIRUS STUDY ID
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   Johnson T., 2020, GET READY VACCINE IN
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Miller FG, 2001, CLIN INFECT DIS, V33, P1028, DOI 10.1086/322664
   Owens C., 2020, EXPT INCIDENTALLY PA
   Palacios R, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3843-0
   Parasidis E, 2016, J HEALTH POLIT POLIC, V41, P1137, DOI 10.1215/03616878-3666204
   Rauhala Emily, 2020, WASHINGTON POST
   Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076
   Thombre AC, 2017, INT CONF COMPUT
   TYRRELL DAJ, 1992, ANTIVIR RES, V18, P105, DOI 10.1016/0166-3542(92)90032-Z
NR 21
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD JUL-AUG
PY 2020
VL 5
IS 4
AR e00669-20
DI 10.1128/mSphere.00669-20
PG 4
WC Microbiology
SC Microbiology
GA NR8CR
UT WOS:000571787800020
PM 32669462
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Roman, RG
   Wang, LF
   Lee, B
   Halpin, K
   de Wit, E
   Broder, CC
   Rahman, M
   Kristiansen, P
   Saville, M
AF Roman, Raul Gomez
   Wang, Lin-Fa
   Lee, Benhur
   Halpin, Kim
   de Wit, Emmie
   Broder, Christopher C.
   Rahman, Mahmudur
   Kristiansen, Paul
   Saville, Melanie
TI Nipah@20: Lessons Learned from Another Virus with Pandemic Potential
SO MSPHERE
LA English
DT Article
DE CEPI; COVID-19; Hendra virus; Nipah virus; epidemic; henipavirus;
   pandemic; paramyxovirus; public health; surveillance studies; vaccines;
   zoonotic infections
AB Nipah disease is listed as one of the WHO priority diseases that pose the greatest public health risk due to their epidemic potential. More than 200 experts from around the world convened in Singapore last year to mark the 20th anniversary of the first Nipah virus outbreaks in Malaysia and Singapore. Most of these experts are now involved in responding to the coronavirus disease 2019 (COVID-19) pandemic. Here, members of the Organizing Committee of the 2019 Nipah Virus International Conference review highlights from the Nipah@20 Conference and reflect on key lessons learned from Nipah that could be applied to the understanding of the COVID-19 pandemic and to preparedness against future emerging infectious diseases (EIDs) of pandemic potential.
C1 [Roman, Raul Gomez] Coalit Epidem Preparedness & Innovat CEPI, Oslo, Norway.
   [Wang, Lin-Fa] Duke NUS Med Sch, Singapore, Singapore.
   [Lee, Benhur] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Halpin, Kim] Australian Ctr Dis Preparedness ACDP, Geelong, Vic, Australia.
   [de Wit, Emmie] NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT USA.
   [Broder, Christopher C.] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD USA.
   [Kristiansen, Paul; Saville, Melanie] Coalit Epidem Preparedness Innovat CEPI, London, England.
RP Roman, RG (corresponding author), Coalit Epidem Preparedness & Innovat CEPI, Oslo, Norway.; Lee, B (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
EM raul.gomezroman@cepi.net; benhur.lee@mssm.edu
FU Intramural Research Program of NIAID, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
FX We thank Tung Thanh Le for his comments on the preparation of this
   summary. Emmie de Wit is supported by the Intramural Research Program of
   NIAID, NIH.
CR Arunkumar G, 2019, J INFECT DIS, V219, P1867, DOI 10.1093/infdis/jiy612
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Coalition for Epidemic Preparedness and Innovations, 2019, P NIP VIR INT C SING
   Coalition for Epidemic Preparedness and Innovations, 2019, CEPI JOINT COORD GRO
   Cohen J., 2020, SCIENCE
   Daszak Peter, 2020, Biosaf Health, V2, P6, DOI 10.1016/j.bsheal.2020.01.003
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Playford EG, 2020, LANCET INFECT DIS, V20, P445, DOI 10.1016/S1473-3099(19)30634-6
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   van Doremalen N, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007462
   World Health Organization, 2020, WHO PRIOR DIS
   World Health Organization, 2019, NIP DIAGN TARG PROD
   World Health Organization, 2019, WHO R D BLUEPR PRIOR
   World Health Organization, 2020, WHO S E AS REG M VAC
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 17
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD JUL-AUG
PY 2020
VL 5
IS 4
AR e00602-20
DI 10.1128/mSphere.00602-20
PG 6
WC Microbiology
SC Microbiology
GA NR8CR
UT WOS:000571787800022
PM 32641430
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borges, LM
   Barnes, SM
   Farnsworth, JK
   Drescher, KD
   Walser, RD
AF Borges, Lauren M.
   Barnes, Sean M.
   Farnsworth, Jacob K.
   Drescher, Kent D.
   Walser, Robyn D.
TI A contextual behavioral approach for responding to moral dilemmas in the
   age of COVID-19
SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE
LA English
DT Article
ID COMMITMENT THERAPY; DESIGN PRINCIPLES; ACCEPTANCE; DISTRESS; INJURY;
   EMOTIONS; NURSES; HEALTH
AB Prior pandemics and current news stories suggest that a "second pandemic" of potentially devastating mental health consequences will follow the COVID-19 pandemic. Given the changing contextual demands associated with the pandemic for many people, the mental health consequences of COVID-19 are likely to include exposure to a range of moral dilemmas. Such dilemmas may set the stage for the development of moral distress and moral injury in a broad range of contexts from the ER to the grocery store. In the current paper we offer an approach to responding to moral dilemmas presented by COVID-19. We propose a contextual behavioral model of moral injury that is relevant to those experiencing moral pain associated with the COVID-19 pandemic. Based on this model, we offer two different approaches to intervening on COVID-19-related moral dilemmas. First, we propose the use of Acceptance and Commitment Therapy for Moral Injury (ACT-MI) among individuals suffering from moral injury. Second, to intervene on moral dilemmas at the level of the group, we propose the use of the Prosocial intervention. We offer case examples describing ACT-MI and Prosocial to highlight how these interventions might be applied to moral-dilemma-related concerns during the COVID-19 pandemic and discuss implications for future research.
C1 [Borges, Lauren M.; Barnes, Sean M.] Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, Aurora, CO USA.
   [Borges, Lauren M.; Barnes, Sean M.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA.
   [Farnsworth, Jacob K.] Rocky Mt Reg VA Med Ctr, Aurora, CO USA.
   [Drescher, Kent D.; Walser, Robyn D.] Natl Ctr PTSD, White River Jct, VT USA.
   [Drescher, Kent D.; Walser, Robyn D.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Walser, Robyn D.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA.
RP Borges, LM (corresponding author), Rocky Mt MIRECC, 1700 N Wheeling St, Aurora, CO 80045 USA.
EM Lauren.Borges2@va.gov
CR Atkins P. W. B., 2019, PROSOCIAL USING EVOL
   Battles A. R., 2018, TRAUMATOLOGY, V24, P246, DOI [10.1037/trm0000153, DOI 10.1037/TRM0000153]
   Bhattarai A., 2020, WASHINGTON POST
   Borges LM, 2020, PSYCHOL TRAUMA-US, V12, pS138, DOI 10.1037/tra0000698
   Borges LM, 2020, J CLIN PSYCHOL, V76, P377, DOI 10.1002/jclp.22887
   Borges LM, 2019, J CONTEXT BEHAV SCI, V13, P134, DOI 10.1016/j.jcbs.2019.08.002
   Bryan CJ, 2018, PSYCHOL TRAUMA-US, V10, P36, DOI 10.1037/tra0000290
   Centers for Disease Control and Prevention (CDC), 2020, COVID 19 RAC ETHN MI
   Chaplo SD, 2019, J TRAUMA STRESS, V32, P448, DOI 10.1002/jts.22408
   Cohen S., 2020, PLEASE DONT EAT YOUR
   Currier JM, 2019, J TRAUMA STRESS, V32, P382, DOI 10.1002/jts.22367
   Currier JM, 2015, J CLIN PSYCHOL, V71, P229, DOI 10.1002/jclp.22134
   Drescher KD, 2008, REFLECTIVE PRACTICE, V28, P85
   Epstein Elizabeth G, 2019, AJOB Empir Bioeth, V10, P113, DOI 10.1080/23294515.2019.1586008
   Evans W. R., 2020, MORAL INJURY WORKBOO
   Farnsworth J. K., 2020, ACCEPTANCE COMMITMEN
   Farnsworth JK, 2017, J CONTEXT BEHAV SCI, V6, P391, DOI 10.1016/j.jcbs.2017.07.003
   Farnsworth JK, 2014, REV GEN PSYCHOL, V18, P249, DOI 10.1037/gpr0000018
   Follette WC, 1996, J CONSULT CLIN PSYCH, V64, P1120, DOI 10.1037/0022-006X.64.6.1120
   Godoy M., 2020, NEW CORONAVIRUS DIS
   Hamaideh SH, 2014, INT J MENT HEALTH NU, V23, P33, DOI 10.1111/inm.12000
   Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152
   Hossain M.M., 2020, MENTAL HLTH OUTCOMES
   Jameton A, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P542
   Jordan Miriam, 2020, NY TIMES
   Keltner D, 2008, ADV EXP SOC PSYCHOL, V40, P151, DOI 10.1016/S0065-2601(07)00003-2
   Lamiani G, 2017, J HEALTH PSYCHOL, V22, P51, DOI 10.1177/1359105315595120
   Litz BT, 2009, CLIN PSYCHOL REV, V29, P695, DOI 10.1016/j.cpr.2009.07.003
   Luoma JB, 2012, J CONSULT CLIN PSYCH, V80, P43, DOI 10.1037/a0026070
   Mak IWC, 2009, GEN HOSP PSYCHIAT, V31, P318, DOI 10.1016/j.genhosppsych.2009.03.001
   Mitton Craig, 2010, Healthc Policy, V6, P99
   Musto Lynn, 2012, Issues Ment Health Nurs, V33, P137, DOI 10.3109/01612840.2011.641069
   Oh Y, 2015, NURS ETHICS, V22, P15, DOI 10.1177/0969733013502803
   Ohnishi K, 2010, NURS ETHICS, V17, P726, DOI 10.1177/0969733010379178
   OSTROM E, 1993, WATER RESOUR RES, V29, P1907, DOI 10.1029/92WR02991
   Purcell N, 2016, COUNS PSYCHOL, V44, P1062, DOI 10.1177/0011000016666156
   Saslow E., 2020, VOICES PANDEMIC IT W
   Schuppe J., 2020, NBC NEWS
   Shay J., 1994, SCRIBNER, V20
   Steinmetz SE, 2019, J TRAUMA STRESS, V32, P437, DOI 10.1002/jts.22377
   Stewart C, 2016, J CONTEXT BEHAV SCI, V5, P16, DOI 10.1016/j.jcbs.2016.01.001
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Van Kleef GA, 2009, CURR DIR PSYCHOL SCI, V18, P184, DOI 10.1111/j.1467-8721.2009.01633.x
   Walser RD, 2015, BEHAV RES THER, V74, P25, DOI 10.1016/j.brat.2015.08.012
   Watkins A., 2020, TOP ER DOCTOR WHO TR
   Whitehead PB, 2015, J NURS SCHOLARSHIP, V47, P117, DOI 10.1111/jnu.12115
   Wilson DS, 2014, BEHAV BRAIN SCI, V37, P395, DOI 10.1017/S0140525X13001593
   Wilson DS, 2013, J ECON BEHAV ORGAN, V90, pS21, DOI 10.1016/j.jebo.2012.12.010
   Wilson DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027826
NR 49
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1447
EI 2212-1455
J9 J CONTEXT BEHAV SCI
JI J. Contextual Behav. Sci.
PD JUL
PY 2020
VL 17
BP 95
EP 101
DI 10.1016/j.jcbs.2020.06.006
PG 7
WC Psychology, Clinical
SC Psychology
GA NM9SU
UT WOS:000568431000014
PM 32834968
OA Green Published
DA 2021-01-01
ER

PT J
AU Pakenham, KI
   Landi, G
   Boccolini, G
   Furlani, A
   Grandi, S
   Tossani, E
AF Pakenham, Kenneth I.
   Landi, Giulia
   Boccolini, Giada
   Furlani, Annalisa
   Grandi, Silvana
   Tossani, Eliana
TI The moderating roles of psychological flexibility and inflexibility on
   the mental health impacts of COVID-19 pandemic and lockdown in Italy
SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE
LA English
DT Article
DE COVID-19 pandemic; Peritraumatic distress; Depression; Anxiety;
   Psychological flexibility; Psychological inflexibility; Lockdown
ID GENERALIZED ANXIETY DISORDER; COMMITMENT THERAPY; EXPERIENTIAL
   AVOIDANCE; ACCEPTANCE; VALIDATION; STRESS; METAANALYSIS; MINDFULNESS;
   PREDICTORS; DEPRESSION
AB The Moderating Roles of Psychological Flexibility and Inflexibility on the Mental Health Impacts of COVID-19 Pandemic and Lockdown in Italy.
   Preliminary data suggest the COVID-19 pandemic has adverse effects on mental health in approximately a quarter of the general population. Few prior studies have identified contextual risk factors and no published study has explored factors that might moderate their adverse effects on mental health. Psychological flexibility is the cornerstone of psychological health and resiliency. This study investigated the roles of psychological flexibility and inflexibility in moderating the effects of COVID-19 risk factors on three mental health outcomes: COVID-19 peritraumatic distress, anxiety, depression. We hypothesized that psychological flexibility would mitigate and psychological inflexibility would exacerbate the adverse effects of COVID-19 risk factors on mental health. During the Italian national lockdown (M = 39.29 days, SD = 11.26), 1035 adults (79% female, M = 37.5 years, SD = 12.3) completed an online survey. Twelve COVID-19 risk factors were identified (e.g. lockdown duration, family infected by COVID-19, increase in domestic violence and in unhealthy lifestyle behaviours) and constituted a COVID-19 Lockdown Index. As predicted, results showed that after controlling for sociodemographic variables, global psychological flexibility and four of its sub-processes (self-as context, defusion, values, committed action), mitigated the detrimental impacts of COVID-19 risk factors on mental health. In contrast and as expected, global psychological inflexibility and four of its sub-processes (lack of contact with present moment, fusion, self-as-content, lack of contact with personal values) exacerbated the detrimental impacts of COVID-19 risk factors on mental health. Findings converge with those from the broader psychological flexibility literature providing robust support for the use of ACT-based interventions to promote psychological flexibility and mental health during the COVID-19 pandemic.
C1 [Pakenham, Kenneth I.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.
   [Landi, Giulia; Grandi, Silvana; Tossani, Eliana] Univ Bologna, Dept Psychol, Viale Berti Pichat 5, I-40127 Bologna, Italy.
   [Landi, Giulia; Boccolini, Giada; Furlani, Annalisa; Grandi, Silvana; Tossani, Eliana] Univ Bologna, Lab Psychosomat & Clinimetr, Dept Psychol, Viale Europa 115, I-47023 Cesena, Italy.
RP Landi, G (corresponding author), Univ Bologna, Dept Psychol, Viale Berti Pichat 5, I-40127 Bologna, Italy.
EM giulia.landi7@unibo.it
RI Tossani, Eliana/ABH-9643-2020; Landi, Giulia/J-5718-2016
OI Tossani, Eliana/0000-0002-6197-4496; Landi, Giulia/0000-0002-2576-3528
CR A-Tjak JGL, 2015, PSYCHOTHER PSYCHOSOM, V84, P30, DOI 10.1159/000365764
   Asmundson GJG, 2020, J ANXIETY DISORD, V71, DOI 10.1016/j.janxdis.2020.102211
   Bradbury-Jones C, 2020, J CLIN NURS, V29, P2047, DOI 10.1111/jocn.15296
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Clutton S, 1999, PSYCHOL HEALTH, V14, P263
   Cohen J., 1988, STAT POWER ANAL BEHA
   Fledderus M, 2010, AM J PUBLIC HEALTH, V100, P2372, DOI 10.2105/AJPH.2010.196196
   Flesia L., 2020, STABLE PSYCHOL TRAIT, DOI [10.31234/osf.io/yb2h8, DOI 10.31234/OSF.IO/YB2H8]
   Fonseca S, 2020, CLIN PSYCHOL-UK, V24, P82, DOI 10.1111/cp.12194
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Girdhar R, 2020, J GERIATRIC CARE RES, V7, P29, DOI DOI 10.1056/NEJMP2008017
   Gloster AT, 2017, J CONTEXT BEHAV SCI, V6, P166, DOI 10.1016/j.jcbs.2017.02.003
   Gold SD, 2007, BEHAV RES THER, V45, P549, DOI 10.1016/j.brat.2006.05.006
   Hawkes AL, 2013, J CLIN ONCOL, V31, P2313, DOI 10.1200/JCO.2012.45.5873
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Hayes A.F., 2018, INTRO MEDIATION MODE
   Hayes AF, 2017, BEHAV RES THER, V98, P39, DOI 10.1016/j.brat.2016.11.001
   Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hyland P., 2020, ANXIETY DEPRESSION R, DOI [10.31234/osf.io/8yqxr, DOI 10.31234/OSF.IO/8YQXR]
   Italian Ministry of Health, 2020, COV 19 CAS IT APR 25
   Jeong H, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016048
   Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001
   Kashdan TB, 2011, PERS INDIV DIFFER, V50, P84, DOI 10.1016/j.paid.2010.08.028
   Kelley K, 2012, PSYCHOL METHODS, V17, P137, DOI 10.1037/a0028086
   Kroenke K., 2010, INSTRUCTION MANUAL I
   Kumpula MJ, 2011, J ABNORM PSYCHOL, V120, P617, DOI 10.1037/a0023927
   Lazarus RS, 1984, STRESS APPRAISAL COP
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Lin YY, 2020, J CONTEXT BEHAV SCI, V15, P73, DOI 10.1016/j.jcbs.2019.11.008
   Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093
   Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829
   Marshall EJ, 2016, J COGN PSYCHOTHER, V30, P60, DOI 10.1891/0889-8391.30.1.60
   Mazzotti E, 2003, ITAL J PSYCHOPATHOL, V9, P235
   Pakenham K. I., 2011, OXFORD HDB STRESS HL, P242
   Pakenham KI, 2013, J BEHAV MED, V36, P389, DOI 10.1007/s10865-012-9434-0
   Pappa S, 2020, BRAIN BEHAV IMMUN, V88, P901, DOI 10.1016/j.bbi.2020.05.026
   Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005
   Polizzi C, 2020, CLIN NEUROPSYCHIATR, V17, P59, DOI 10.36131/CN20200204
   Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790
   Presti G, 2020, CLIN NEUROPSYCHIATR, V17, P65, DOI 10.36131/CN20200206
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   RAZAI MS, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1904
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Ren SY, 2020, WORLD J CLIN CASES, V8, P652, DOI 10.12998/wjcc.v8.i4.652
   Rogge RD, 2019, J CONTEXT BEHAV SCI, V14, P90, DOI 10.1016/j.jcbs.2019.10.001
   Rolffs JL, 2018, ASSESSMENT, V25, P458, DOI 10.1177/1073191116645905
   Rossi R, 2020, COVID 19 PANDEMIC LO, DOI [10.1101/2020.04.09.20057802., DOI 10.1101/2020.04.09.20057802, 10.1101/2020.04.09.20057802]
   Ruiz FJ, 2010, INT J PSYCH PSYCHOL, V10, P125, DOI DOI 10.1080/028457199439937
   Seidler D, 2020, J CONTEXT BEHAV SCI, V17, P23, DOI 10.1016/j.jcbs.2020.04.007
   Sonino N, 1998, POSTGRAD MED J, V74, P408, DOI 10.1136/pgmj.74.873.408
   Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stabbe OK, 2019, J CONTEXT BEHAV SCI, V12, P106, DOI 10.1016/j.jcbs.2019.03.003
   Swain J, 2013, CLIN PSYCHOL REV, V33, P965, DOI 10.1016/j.cpr.2013.07.002
   Taylor S, 2020, FEM PSYCHOL, V30, P63, DOI 10.1177/0959353519864390
   Tol WA, 2020, LANCET GLOB HEALTH, V8, pE254, DOI 10.1016/S2214-109X(19)30504-2
   Trindade IA, 2020, J CONTEXT BEHAV SCI, V15, P68, DOI 10.1016/j.jcbs.2019.12.001
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
   Wang GH, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30547-X
NR 63
TC 1
Z9 1
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1447
EI 2212-1455
J9 J CONTEXT BEHAV SCI
JI J. Contextual Behav. Sci.
PD JUL
PY 2020
VL 17
BP 109
EP 118
DI 10.1016/j.jcbs.2020.07.003
PG 10
WC Psychology, Clinical
SC Psychology
GA NM9SU
UT WOS:000568431000016
PM 32834969
OA Green Published
DA 2021-01-01
ER

PT J
AU Dawson, DL
   Golijani-Moghaddam, N
AF Dawson, David L.
   Golijani-Moghaddam, Nima
TI COVID-19: Psychological flexibility, coping, mental health, and
   wellbeing in the UK during the pandemic
SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE
LA English
DT Article
DE COVID-19; Coronavirus; Psychological flexibility; Coping; Mental health;
   Wellbeing
ID ACUTE RESPIRATORY SYNDROME; FUNCTIONAL DIMENSIONAL APPROACH; GENERALIZED
   ANXIETY DISORDER; QUALITY-OF-LIFE; EXPERIENTIAL AVOIDANCE; COMMITMENT
   THERAPY; ACCEPTANCE; DEPRESSION; SURVIVORS; VALIDATION
AB The COVID-19 pandemic has profoundly altered the daily lives of many people across the globe, both through the direct interpersonal cost of the disease, and the governmental restrictions imposed to mitigate its spread and impact. The UK has been particularly affected and has one of the highest mortality rates in Europe. In this paper, we examine the impact of COVID-19 on psychological health and well-being in the UK during a period of 'lockdown' (15th-21st May 2020) and the specific role of Psychological Flexibility as a potential mitigating process.
   We observed clinically high levels of distress in our sample (N = 555). However, psychological flexibility was significantly and positively associated with greater wellbeing, and inversely related to anxiety, depression, and COVID-19-related distress. Avoidant coping behaviour was positively associated with all indices of distress and negatively associated with wellbeing, while engagement in approach coping only demonstrated weaker associations with outcomes of interest. No relationship between adherence to government guidelines and psychological flexibility was found.
   In planned regression models, psychological flexibility demonstrated incremental predictive validity for all distress and wellbeing outcomes (over and above both demographic characteristics and COVID-19-specific coping responses). Furthermore, psychological flexibility and COVID-19 outcomes were only part-mediated by coping responses to COVID-19, supporting the position that psychological flexibility can be understood as an overarching response style that is distinct from established conceptualisations of coping. We conclude that psychological flexibility represents a promising candidate process for understanding and predicting how an individual may be affected by, and cope with, both the acute and longer-term challenges of the pandemic.
C1 [Dawson, David L.; Golijani-Moghaddam, Nima] Univ Lincoln, Sch Psychol, Lincoln LN5 7AY, England.
RP Golijani-Moghaddam, N (corresponding author), Univ Lincoln, Sch Psychol, Lincoln LN5 7AY, England.
EM ddawson@lincoln.ac.uk; nmoghaddam@lincoln.ac.uk
OI Moghaddam, Nima/0000-0002-8657-4341
CR Bardeen JR, 2013, BEHAV THER, V44, P459, DOI 10.1016/j.beth.2013.04.001
   Bluett EJ, 2014, J ANXIETY DISORD, V28, P612, DOI 10.1016/j.janxdis.2014.06.008
   Bonanno GA, 2004, PSYCHOL SCI, V15, P482, DOI 10.1111/j.0956-7976.2004.00705.x
   Bonanno GA, 2008, HEALTH PSYCHOL, V27, P659, DOI 10.1037/0278-6133.27.5.659
   Brooks SK, 2020, LANCET
   Brown M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6200
   Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6
   Chan AOM, 2004, OCCUP MED-OXFORD, V54, P190, DOI 10.1093/occmed/kqh027
   Chawla N, 2007, J CLIN PSYCHOL, V63, P871, DOI 10.1002/jclp.20400
   Cheng C, 2001, J PERS SOC PSYCHOL, V80, P814, DOI 10.1037//3415.80.5.814
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Dattalo P, 2013, ANAL MULTIPLE DEPEND
   Eisenberg SA, 2012, J BEHAV MED, V35, P253, DOI 10.1007/s10865-011-9358-0
   Fat LN, 2017, QUAL LIFE RES, V26, P1129, DOI 10.1007/s11136-016-1454-8
   Fonseca S, 2020, CLIN PSYCHOL-UK, V24, P82, DOI 10.1111/cp.12194
   Francis AW, 2016, J CONTEXT BEHAV SCI, V5, P134, DOI 10.1016/j.jcbs.2016.05.003
   Gilbody S, 2007, BRIT J GEN PRACT, V57, P650
   Giorgi G, 2015, PSYCHOL RES BEHAV MA, V8, P99, DOI 10.2147/PRBM.S73901
   Gloster AT, 2017, J CONTEXT BEHAV SCI, V6, P166, DOI 10.1016/j.jcbs.2017.02.003
   Gloster AT, 2011, PSYCHOL ASSESSMENT, V23, P970, DOI 10.1037/a0024135
   Gonzalez-Sanguino C., 2020, BRAIN BEHAV IMMUNITY
   Hacker T, 2016, J AFFECT DISORDERS, V190, P551, DOI 10.1016/j.jad.2015.10.053
   Hayes A. F., 2017, INTRO MEDIATION MODE
   Hayes S. C., 2009, ACCEPTANCE COMMITMEN
   Hayes SC, 1996, J CONSULT CLIN PSYCH, V64, P1152, DOI 10.1037/0022-006X.64.6.1152
   Hayes SC, 2011, ANNU REV CLIN PSYCHO, V7, P141, DOI 10.1146/annurev-clinpsy-032210-104449
   Holmes E.A., 2020, LANCET PSYCHIAT
   Hudson NW, 2020, ASSESSMENT, V27, P102, DOI 10.1177/1073191117744660
   Hui DS, 2005, CHEST, V128, P2247, DOI 10.1378/chest.128.4.2247
   Hulbert-Williams NJ, 2015, EUR J CANCER CARE, V24, P15, DOI 10.1111/ecc.12223
   Karekla M, 2011, J BEHAV THER EXP PSY, V42, P163, DOI 10.1016/j.jbtep.2010.10.002
   Kashdan TB, 2006, BEHAV RES THER, V44, P1301, DOI 10.1016/j.brat.2005.10.003
   Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kwek SK, 2006, J PSYCHOSOM RES, V60, P513, DOI 10.1016/j.jpsychores.2005.08.020
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Lee EB, 2015, DRUG ALCOHOL DEPEN, V155, P1, DOI 10.1016/j.drugalcdep.2015.08.004
   Levis B, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1476
   Liu XH, 2012, COMPR PSYCHIAT, V53, P15, DOI 10.1016/j.comppsych.2011.02.003
   Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093
   Masuda A, 2012, J EVID-BASED INTEGR, V17, P66, DOI 10.1177/2156587211423400
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   McCracken LM, 2014, J PAIN, V15, P221, DOI 10.1016/j.jpain.2013.10.014
   McManus S., 2009, ADULT PSYCHIAT MORBI
   Morris J., 2019, DEV VALIDATION SHORT
   Nielsen E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159854
   Odriozola-Gonzalez P., 2020, PSYCHOL SYMPTOMS OUT
   *ONS, 2020, COR SOC IMP GREAT BR
   Orgiles M, 2020, CURR PSYCHOL, DOI 10.1007/s12144-020-00849-3
   Ozamiz-Etxebarria N, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00054020, 10.1590/0102-311x00054020]
   Pieters R, 2017, J CONSUM RES, V44, P692, DOI 10.1093/jcr/ucx081
   Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rueda B., 2020, INT J COGN THER, P1
   Schonbrodt FD, 2013, J RES PERS, V47, P609, DOI 10.1016/j.jrp.2013.05.009
   Sim K, 2010, J PSYCHOSOM RES, V68, P195, DOI 10.1016/j.jpsychores.2009.04.004
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stewart-Brown S, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-15
   Thoresen S, 2010, SOC PSYCH PSYCH EPID, V45, P405, DOI 10.1007/s00127-009-0073-x
   Tyndall I, 2020, BEHAV MODIF, V44, P365, DOI 10.1177/0145445518820036
   Veehof MM, 2011, PAIN, V152, P533, DOI 10.1016/j.pain.2010.11.002
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Weiss D.S., 2007, IMPACT EVENT SCALE R
   Wu KK, 2005, J TRAUMA STRESS, V18, P39, DOI 10.1002/jts.20004
   Zimmer-Gennbeck MJ, 2018, COGENT PSYCHOL, V5, DOI 10.1080/23311908.2018.1537908
NR 65
TC 2
Z9 2
U1 17
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1447
EI 2212-1455
J9 J CONTEXT BEHAV SCI
JI J. Contextual Behav. Sci.
PD JUL
PY 2020
VL 17
BP 126
EP 134
DI 10.1016/j.jcbs.2020.07.010
PG 9
WC Psychology, Clinical
SC Psychology
GA NM9SU
UT WOS:000568431000018
PM 32834970
OA Green Published
DA 2021-01-01
ER

PT J
AU Rhodes, A
   Martin, S
   Guarna, J
   Vowles, K
   Allen, T
AF Rhodes, Amanda
   Martin, Staci
   Guarna, Joel
   Vowles, Kevin
   Allen, Taryn
TI A contextual-behavioral perspective on chronic pain during the COVID-19
   pandemic and future times of mandated physical distancing
SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE
LA English
DT Article
DE Chronic pain; Acceptance and commitment therapy; COVID-19; Pandemic;
   Telehealth
ID MENTAL-HEALTH DISORDERS; COMMITMENT THERAPY; UNITED-STATES; ACCEPTANCE;
   MINDFULNESS; COMORBIDITY; PREVALENCE; TELEHEALTH; ADULTS; LONELINESS
AB For people who struggle with chronic pain, the COVID-19 pandemic poses new challenges in treatment accessibility and may heighten pre-existing anxiety related to their health condition. Likewise, many mental health providers are struggling to adapt to a new way of caring for these individuals. The current paper aims to provide evidence of the ways in which COVID-19 is impacting people with pain and to offer a contextual-behavioral perspective on treatment of patients with chronic pain during the current pandemic and any future periods of mandated physical distancing. Past research shows that adolescents and adults with chronic pain struggle with loneliness and social isolation, which emphasizes the importance of remaining connected with these patients while they are remaining at home. Further, many individuals with chronic pain have physical and mental health comorbidities that may increase the risk of COVID-19 infection and/or morbidity and mortality. Specific functional-contextual and biopsychosocial concepts common in multidisciplinary treatment of chronic pain can be usefully incorporated into a telehealth model of ACT treatment for pain. These include the use of pandemic-related metaphors, modeling acceptance of technical glitches that occur during telehealth sessions, and mindfully observing facial expressions on the computer screen when the patient is in pain. Moreover, powerful experiential exercises that make use of pandemic-related themes (e.g., wearing a mask, washing hands) are described. While barriers to the widespread implementation of ACT-consistent telehealth exist, connecting with patients in new and creative ways will be essential as the field moves forward.
C1 [Rhodes, Amanda; Martin, Staci] NCI, Pediactr Oncol Branch, Ctr Canc Res, 9030 Old Georgetown Rd,107, Bethesda, MD 20892 USA.
   [Guarna, Joel] Maine Med Ctr Family Med Residency, Portland, ME 04101 USA.
   [Guarna, Joel] Northern Light Mercy Hosp, Pain Ctr, Portland, ME 04101 USA.
   [Vowles, Kevin] Queens Univ Belfast, Sch Psychol, David Keir Bldg,18-30 Malone Rd, Belfast, Antrim, North Ireland.
   [Allen, Taryn] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
RP Rhodes, A (corresponding author), NCI, Pediactr Oncol Branch, Ctr Canc Res, 9030 Old Georgetown Rd,107, Bethesda, MD 20892 USA.
EM amanda.rhodes@nih.gov
OI Vowles, Kevin/0000-0003-4255-9067
FU NCI Center for Cancer Research IRP; National Cancer Institute, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [HHSN261200800001E]
FX The content of this publication does not necessarily reflect the views
   or policies of the Department of Health and Human Services nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the U.S. Government.Funding information This work was
   funded, in part, by the NCI Center for Cancer Research IRP. This project
   has been funded in whole or in part with federal funds from the National
   Cancer Institute, National Institutes of Health, under Contract No.
   HHSN261200800001E.
CR Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611
   Andres-Rodriguez L, 2019, BRAIN BEHAV IMMUN, V80, P109, DOI 10.1016/j.bbi.2019.02.030
   [Anonymous], 2020, STAT TEL LAW REIMB P
   Batley S, 2019, EUR J PEDIATR, V178, P275, DOI 10.1007/s00431-018-3291-y
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Buhrman M, 2013, BEHAV RES THER, V51, P307, DOI 10.1016/j.brat.2013.02.010
   Burton KLO, 2018, PAIN PRACT, V18, P979, DOI 10.1111/papr.12696
   Canadian Medical Association, 2019, VIRT CAR CAN
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Clauw DJ, 2011, MAYO CLIN PROC, V86, P907, DOI 10.4065/mcp.2011.0206
   Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X
   Creswell JD, 2012, BRAIN BEHAV IMMUN, V26, P1095, DOI 10.1016/j.bbi.2012.07.006
   Dahl J., 2005, ACCEPTANCE COMMITMEN
   Dahl J., 2006, LIVING YOUR PAIN USI
   De Ridder Benjamin, 2018, JMIR Cardio, V2, pe4, DOI 10.2196/cardio.8802
   Devan H, 2019, J PAIN RES, V12, P2457, DOI 10.2147/JPR.S206539
   Dindo L, 2018, J PAIN, V19, P1211, DOI 10.1016/j.jpain.2018.04.016
   Emerson K, 2018, J AGING HEALTH, V30, P1450, DOI 10.1177/0898264317721348
   Faust-Christmann CA, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13703
   Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364
   Feliu-Soler A, 2018, J PAIN RES, V11, P2145, DOI 10.2147/JPR.S144631
   Fernandez-Pena R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082706
   Garland EL, 2019, J CONSULT CLIN PSYCH, V87, P927, DOI 10.1037/ccp0000390
   Gatchel RJ, 2004, AM PSYCHOL, V59, P795, DOI 10.1037/0003-066X.59.8.795
   Goebel A, 2013, AUTOIMMUN REV, V12, P682, DOI 10.1016/j.autrev.2012.10.015
   Gonzalez MLS, 2019, J CLIN PSYCHOL, V75, P260, DOI 10.1002/jclp.22719
   Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9
   Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014
   Hestbaek L, 2003, J MANIP PHYSIOL THER, V26, P243, DOI 10.1016/S0161-4754(03)00003-4
   Hughes LS, 2017, CLIN J PAIN, V33, P552, DOI 10.1097/AJP.0000000000000425
   Hunter JF, 2019, JMIR SERIOUS GAMES, V7, DOI 10.2196/15974
   Jaremka LM, 2014, HEALTH PSYCHOL, V33, P948, DOI 10.1037/a0034012
   Jarvela-Reijonen E, 2020, INT J BEHAV MED, V27, P539, DOI 10.1007/s12529-020-09891-8
   Kabat-Zinn K., 1994, WHEREVER YOU GO THER
   Kato K, 2006, ARCH INTERN MED, V166, P1649, DOI 10.1001/archinte.166.15.1649
   Kimmel PL, 2017, J AM SOC NEPHROL, V28, P3658, DOI 10.1681/ASN.2017010098
   Kober H, 2019, SOC COGN AFFECT NEUR, V14, P1147, DOI 10.1093/scan/nsz104
   Kratz AL, 2018, CLIN J PAIN, V34, P357, DOI 10.1097/AJP.0000000000000550
   Leong IY, 2007, J GERONTOL A-BIOL, V62, P550, DOI 10.1093/gerona/62.5.550
   Liu MM, 2017, ANESTHESIOLOGY, V127, P166, DOI 10.1097/ALN.0000000000001659
   Mariano TY, 2019, J TELEMED TELECARE, DOI 10.1177/1357633X19871746
   McCracken LM, 2014, AM PSYCHOL, V69, P178, DOI 10.1037/a0035623
   McGeary DD, 2012, PAIN PRACT, V12, P570, DOI 10.1111/j.1533-2500.2012.00534.x
   Medicine F.o. P., 2020, FPM RESPONSE CONCERN
   Meins AR, 2015, J PAIN RELIEF, V4, DOI [10.4172/2167-0846.1000177, DOI 10.4172/2167-0846.1000177]
   Mellon RD, 1998, J NEUROIMMUNOL, V83, P19, DOI 10.1016/S0165-5728(97)00217-8
   Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002
   National Health Service, 2020, ONL VERS NHS LONG TE
   Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Oliveira VC, 2015, EUR J PAIN, V19, P538, DOI 10.1002/ejp.578
   Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
   Pierce B, 2016, J CONTEXT BEHAV SCI, V5, P215, DOI 10.1016/j.jcbs.2016.08.001
   Polk K. L., 2014, ACT MATRIX NEW APPRO
   Public Health England, 2020, GUID SHIELD PROT PEO
   Richardson LP, 2012, J ADOLESCENT HEALTH, V50, P553, DOI 10.1016/j.jadohealth.2011.11.011
   Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078
   Roberts M. H., 2013, AM J RESP CRITICAL M, V187
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Rowbotham S, 2015, HEALTH COMMUN, V30, P70, DOI 10.1080/10410236.2013.836070
   Scanzello CR, 2008, CURR OPIN RHEUMATOL, V20, P565, DOI 10.1097/BOR.0b013e32830aba34
   Schopflocher D, 2011, PAIN RES MANAG, V16, P445, DOI 10.1155/2011/876306
   Scott KM, 2009, PSYCHOL MED, V39, P33, DOI 10.1017/S0033291708003188
   Shanthanna H, 2020, ANAESTHESIA, V75, P935, DOI 10.1111/anae.15076
   Shanthanna H, 2020, RECOMMENDATIONS CHRO
   Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444
   Spears Charis A, 2020, Spine (Phila Pa 1976), V45, pE1333, DOI 10.1097/BRS.0000000000003572
   Stinson J, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0108-2
   Totsch SK, 2017, MOL PAIN, V13, DOI 10.1177/1744806917724559
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   Trompetter HR, 2015, BEHAV RES THER, V74, P50, DOI 10.1016/j.brat.2015.09.001
   Tsai S, 2018, DIGIT HEALTH, V4, DOI 10.1177/2055207618772669
   Veehof MM, 2016, COGN BEHAV THERAPY, V45, P5, DOI 10.1080/16506073.2015.1098724
   Von Korff M, 2005, PAIN, V113, P331, DOI 10.1016/j.pain.2004.11.010
   Vowles K. E., J PAIN
   Vowles K. E., 2011, MINDFULNESS ACCEPTAN
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Westrup D., 2014, ADV ACCEPTANCE COMMI
   WHO, 2020, COR DIS COVID 19 SIT
   Wilson FA, 2017, J TELEMED TELECARE, V23, P497, DOI 10.1177/1357633X16652288
   Young SD, 2018, J ADDICT DIS, V37, P96, DOI 10.1080/10550887.2018.1557992
   Zheng ZH, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/1841690
NR 82
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1447
EI 2212-1455
J9 J CONTEXT BEHAV SCI
JI J. Contextual Behav. Sci.
PD JUL
PY 2020
VL 17
BP 152
EP 158
DI 10.1016/j.jcbs.2020.07.009
PG 7
WC Psychology, Clinical
SC Psychology
GA NM9SU
UT WOS:000568431000021
DA 2021-01-01
ER

PT J
AU Cuttler, JM
AF Cuttler, Jerry M.
TI The LNT Issue Is About Politics and Economics, Not Safety
SO DOSE-RESPONSE
LA English
DT Article
DE LNT model; ionizing radiation; low-dose radiation medical therapies;
   nuclear energy; precautionary principle; radiophobia
ID RADIATION; REMEDY
AB The Sykes commentary advocates "a more sensible, graded approach for protection from low dose ionizing radiation" until the LNT dose-response issue is resolved. It urges scientists to stop criticizing the LNT model that links radiation to a risk of cancer and accept regulatory use of the threshold model to "protect" people, but with higher limits. It fails to mention the 120-year history of successful low-dose treatments of a wide variety of serious diseases, including cancers. The commentary ignores published evidence of a threshold at 1.1 Gy for radiogenic leukemia and a dose-rate threshold at about 0.6 Gy per year for lifespan shortening. LNT came from politicized science, replete with scientific misconduct and conflict of interest. Its acceptance created a false cancer scare that was likely intended to stop atomic bomb testing, but it has severely damaged human welfare. Many vitally important low-dose therapies were discarded when the radiation scare was disseminated in 1956. The rapid growth of nuclear energy ended with the media-inflamed public panic after the Three Mile Island accident in 1979. Extreme implementation of the precautionary principle made it uneconomic. Availability of a low-dose therapy for lung inflammation could have dramatically decreased the impact of the COVID-19 pandemic.
C1 [Cuttler, Jerry M.] Cuttler & Associates Inc, 1104-11 Townsgate Dr, Vaughan, ON L4J8G4, Canada.
RP Cuttler, JM (corresponding author), Cuttler & Associates Inc, 1104-11 Townsgate Dr, Vaughan, ON L4J8G4, Canada.
EM jerrycuttler@rogers.com
CR Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841
   Ameri A, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-40507/v1, DOI 10.21203/RS.3.RS-40507/V1]
   Calabrese E. J., 2017, TOXICOL RES APPL, V1, DOI [10.1177/2397847317694998, DOI 10.1177/2397847317694998]
   Calabrese EJ, 2020, ENVIRON RES, V186, DOI 10.1016/j.envres.2020.109559
   Calabrese EJ, 2019, CHEM-BIOL INTERACT, V301, P6, DOI 10.1016/j.cbi.2018.11.020
   Calabrese EJ, 2015, ENVIRON RES, V142, P432, DOI 10.1016/j.envres.2015.07.011
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Centers for Disease Control and Prevention, 2014, RAD YOUR HLTH NRI GE
   Cuttler JM, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325819895739
   Cuttler JM, 2014, DOSE-RESPONSE, V12, P170, DOI 10.2203/dose-response.13-055.Cuttler
   Cuttler JM, 2018, DOSE-RESPONSE, V16, P1
   Cuttler JM, 2020, COMMUNICATION   0320
   Cuttler JM, 2015, LEUKEMIA, V3, P4, DOI [10. 4172/2329-6917. 1000202, DOI 10.4172/2329-6917.1000202]
   Dhawan G, 2020, RADIOTHER ONCOL, V147, P212, DOI 10.1016/j.radonc.2020.05.002
   Fisher DR, 2017, HEALTH PHYS, V113, P102, DOI 10.1097/HP.0000000000000674
   Hess CB, 2020, LOW DOSE WHOLE LUNG, DOI [10.1101/2020.07.11.20147793, DOI 10.1101/2020.07.11.20147793]
   Ichiseki H, 2013, LANCET, V381, P204, DOI 10.1016/S0140-6736(13)60091-4
   Jaworowski Z, 2012, COMMENTS REPRESENTAT, P131
   Jaworowski Z, 2010, HUM EXP TOXICOL, V29, P263, DOI 10.1177/0960327110363974
   Johns Hopkins University, COVID 19 DASHB CSSE
   LEWIS EB, 1957, SCIENCE, V125, P965, DOI 10.1126/science.125.3255.965
   National Academy of Sciences (NAS)/National Research Council (NRC), 1956, SCIENCE, V124, P1157
   National Cancer Institute, 2003, NAS RAD IRR NRI CANC
   National Library of Medicine, 2020, REG CLIN TRIALS COVI
   Oakley PA, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325820921641
   Sykes PJ, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325820921651
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1559-3258
J9 DOSE-RESPONSE
JI Dose-Response
PD JUL
PY 2020
VL 18
IS 3
AR 1559325820949066
DI 10.1177/1559325820949066
PG 4
WC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
SC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
GA NM8WI
UT WOS:000568372600001
PM 32952483
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mungmunpuntipantip, R
   Wiwanitkit, V
AF Mungmunpuntipantip, Rujittika
   Wiwanitkit, Viroj
TI Bioinformatics analysis of Wuhan novel coronavirus pathogen: A clue for
   finding antiviral drug against Wuhan novel coronavirus
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Letter
C1 [Mungmunpuntipantip, Rujittika] 26 Med Ctr, Bangkok, Thailand.
   [Wiwanitkit, Viroj] Hainan Med Univ, Dept Trop Med, Haikou, Hainan, Peoples R China.
   [Wiwanitkit, Viroj] Dr DY Patil Univ, Dept Community Med, Pune, Maharashtra, India.
RP Mungmunpuntipantip, R (corresponding author), 26 Med Ctr, Bangkok, Thailand.
EM rujittika@gmail.com
CR Hsia W, 2020, CASE STUDY CASE REP, V10, P8, DOI 10.1016/S2213-2600(20)30079-5
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Sigrist CJA, 2010, NUCLEIC ACIDS RES, V38, pD161, DOI 10.1093/nar/gkp885
   Yasri S, 2019, ADV TROP MED PUB HLT, V9, P1, DOI DOI 10.5530/ijmedph.2019.1.1
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1735-1995
EI 1735-7136
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD JUL
PY 2020
VL 25
DI 10.4103/jrms.JRMS_109_20
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA NM2NP
UT WOS:000567939000005
PM 33088307
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schwartz, RA
   Suskind, RM
AF Schwartz, Robert A.
   Suskind, Robert M.
TI Azithromycin andCOVID-19: Promptearly use at first signs of this
   infection in adults and children, an approach worthy of consideration
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE azithromycin; COVID-19; hydroxychloroquine; macrolide; SARS-CoV-2
AB The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID-19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu-like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID-19 infection. There is one clinical trial initiated, the individually randomized, telemedicine-based, "Azithromycin for COVID-19 Treatment in Outpatients Nationwide" based at the University of California San Francisco. This placebo-controlled trial is designed to determine the efficacy of a single 1.2-g dose of oral azithromycin to prevent COVID-19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID-19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.
C1 [Schwartz, Robert A.] Rutgers State Univ, New Jersey Med Sch, Dermatol & Pathol, Newark, NJ 07103 USA.
   [Suskind, Robert M.] Calif Univ Sci Med, Pediat, San Bernardino, CA USA.
   [Suskind, Robert M.] Calif Univ Sci Med, San Bernardino, CA USA.
RP Schwartz, RA (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dermatol, 185 South Orange Ave, Newark, NJ 07103 USA.
EM roschwar@cal.berkeley.edu
OI Schwartz, Robert/0000-0003-3036-3825
CR Almutairi N, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13544
   Asensio E, 2020, J INTERV CARD ELECTR, V59, P315, DOI 10.1007/s10840-020-00765-3
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Carlton CN, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01783
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Fan BE, 2020, AM J HEMATOL, V95, P723, DOI 10.1002/ajh.25785
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101094
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Gupta M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13329
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2378
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13481
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13380
NR 15
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13785
DI 10.1111/dth.13785
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000567418100330
PM 32510734
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aleixandre-Benavent, R
   Castello-Cogollos, L
   Valderrama-Zurian, JC
AF Aleixandre-Benavent, Rafael
   Castello-Cogollos, Lourdes
   Valderrama-Zurian, Juan-Carlos
TI Information and communication during the early months of Covid-19:
   infodemics, misinformation, and the role of information professionals
SO PROFESIONAL DE LA INFORMACION
LA Spanish
DT Article
DE Covid-19; Coronavirus; Pandemics; Infodemics; Health information;
   Overinformation; Fake news; Scientific publications; Research projects;
   Co-word networks; International collaboration; Information professionals
ID EBOLA; DISSEMINATION; EPIDEMIC; OUTBREAK
AB The Covid-19 pandemic has introduced challenges throughout the world and is endangering people's prosperity. To these health, economic, political, and social challenges have been added those related to the management and dissemination of information, mainly concerning its exponential growth, veracity, and dissemination. Providing objective evidence-based information contributes to meeting these challenges. Social media and social networks are playing a key role in informing society about the evolution of the pandemic and progress towards its eradication. However, social networks are also a vehicle for the transmission of biased or false news that can endanger people's health. Information professionals play a key role in correcting misinformation if they are able to filter out untruthful information and make resources with proven quality available to the population. In addition, they must manage scientific information about the pandemic, which is advancing at an accelerated pace. Currently, China is the leader while Spain is in fifth place in the development of research projects and scientific publications. The scientific research focuses on epidemiological aspects, respiratory diseases, drug treatments, and diagnostic tests. Many journals, databases, repositories, and other information systems have made their publications and other information resources available in record time to encourage the progress of such research.
C1 [Aleixandre-Benavent, Rafael] Univ Politecn Valencia, CSIC, Unidad Invest & Informac Social & Sanitaria UISYS, UV,Ingenio, Placa Cisneros 4, Valencia 46003, Spain.
   [Castello-Cogollos, Lourdes] Univ Politecn Valencia, CSIC, Unidad Invest & Informac Social & Sanitaria UISYS, UV,Depe Hist Ciencia & Doc, Placa Cisneros 4, Valencia 46003, Spain.
   [Valderrama-Zurian, Juan-Carlos] Univ Politecn Valencia, CSIC, Unidad Invest & Informac Social & Sanitaria UISYS, UV,Depe Sociol & Antropol Social, Placa Cisneros 4, Valencia 46003, Spain.
RP Aleixandre-Benavent, R (corresponding author), Univ Politecn Valencia, CSIC, Unidad Invest & Informac Social & Sanitaria UISYS, UV,Ingenio, Placa Cisneros 4, Valencia 46003, Spain.
EM rafael.aleixandre@uv.es; lourdes.castello@uv.es; juan.valderrama@uv.es
CR Adhanom-Ghebreyesus T., 2020, PAIS
   Ali MY, 2020, HEALTH INFO LIBR J, V37, P158, DOI 10.1111/hir.12307
   [Anonymous], 2020, PERIODICO       0327
   [Anonymous], 2020, DIARIO SANITARI 0703
   Arroyo Jesus, 2020, REDACCION MED   0323
   ASHRAFIRIZI H, 2020, ARCH ACAD EMERGENCY, V8
   Basch CH, 2020, AM J INFECT CONTROL, V48, P714, DOI 10.1016/j.ajic.2019.11.014
   Bora K, 2018, PATHOG GLOB HEALTH, V112, P320, DOI 10.1080/20477724.2018.1507784
   Casero-Ripolles A, 2020, PROF INFORM, V29, DOI 10.3145/epi.2020.mar.23
   Centro Cochrane lberoamericano, 2020, OOCHRANE IBEROA 0330
   Chadwick L., 2020, EURONEWS
   Comision Europea, 2020, LUCH DES
   Consejo Europeo, 2020, CRON ACT CONS REL CO
   Covolo L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-83
   Dube E, 2016, LANCET INFECT DIS, V16, P518, DOI 10.1016/S1473-3099(16)00028-1
   Dyer C, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1378
   Fung ICH, 2016, PUBLIC HEALTH REP, V131, P461, DOI 10.1177/003335491613100312
   Grange ES, 2020, APPL CLIN INFORM, V11, P265, DOI 10.1055/s-0040-1709715
   Hernandez-Garcia I, 2020, JMIR PUBLIC HLTH SUR, V6, P110, DOI 10.2196/18717
   Hossain M. M., 2020, SSRN, DOI [10.2139/ssrn.3547824, DOI 10.2139/SSRN.3547824]
   Husnayain A, 2020, INT J INFECT DIS, V95, P221, DOI 10.1016/j.ijid.2020.03.021
   Ioannidis JPA, 2020, EUR J CLIN INVEST, V50, DOI [10.1111/eci.13222, 10.1111/eci.13223]
   Kao Audiey C., 2020, AMA J ETHICS, V22, pe179
   Bonilla-Aldana DK, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101566
   Kenis P, 2019, RISK HAZARDS CRISIS, V10, P275, DOI 10.1002/rhc3.12176
   Khatri P, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101636
   Kickbusch I, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m406
   Lahoz Paula, 2020, EL DIARIO
   Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w
   Lenert L, 2020, J AM MED INFORM ASSN, V27, P963, DOI 10.1093/jamia/ocaa039
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Liang LL, 2020, PSYCHIAT QUART, V91, P841, DOI 10.1007/s11126-020-09744-3
   Lin CY, 2020, J HOSP INFECT, V105, P197, DOI 10.1016/j.jhin.2020.03.027
   Liu M, 2020, WASHINGTON POST
   Lou J, 2020, EUR REV MED PHARMACO, V24, P3411, DOI 10.26355/eurrev_202003_20712
   Martin-Barato Amelia, 2020, ESCUELA ANDALUZ 0415
   Nagpal SJS, 2015, TRAVEL MED INFECT DI, V13, P338, DOI 10.1016/j.tmaid.2015.05.002
   Nasab Fateme-Rafiei, 2020, BIBLIOMETRIC ANAL GL, DOI DOI 10.1101/2020.03.19.20038752
   OMS, 2020, COV 19 CRON ACT OMS
   OPS, 2020, COM RIESG SAL COV 19
   Organizacion Mundial de la Salud (OMS), 2020, BROT ENF COR COVID 1
   Organizacion Mundial de la Salud (OMS), 2020, AL AP DIR GEN OMS RU
   Parrish RK, 2020, AM J OPHTHALMOL, V213, pA1, DOI 10.1016/j.ajo.2020.02.014
   Petride H., 2004, ICJ, V2, P302, DOI DOI 10.1023/B:AUR0.0000016865.35796.E9
   Ramirez-Martin-Salas Veronica, 2020, SEXTA           0416
   Roca Jose -Luis, 2020, PERIODICO       0408
   Rodriguez-Veiga Diego, 2020, ESPAFIOL        0401
   ROETZEL PG, 2019, BUS RES, V12, P479, DOI DOI 10.1007/s40685-018-0069-z
   Rosenberg H, 2020, CAN J EMERG MED, V22, P418, DOI 10.1017/cem.2020.361
   Santos CF, 2020, BRAZ J PSYCHIAT, V42, P329, DOI 10.1590/1516-4446-2020-0981
   Shimizu K, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30357-3
   Shultz JM, 2015, JAMA-J AM MED ASSOC, V313, P567, DOI 10.1001/jama.2014.17934
   Song PP, 2020, BIOSCI TRENDS, V14, P1, DOI 10.5582/bst.2020.01056
   Sriwijitalai W, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13226
   Tandoc E. C., 2020, CHANNEL NEW ASI 0404
   Tesini Brenda L., 2020, CORONAVIRUS SINDROME
   Theiwall M, 2020, PROF INFORM, V29, DOI 10.3145/epi.2020.mar.16
   Torres-Salinas D, 2020, PROF INFORM, V29, DOI 10.3145/epi.2020.mar.15
   Trump Donald J., 2020, INT J ANTIMICROBIAL
   WHO, 2020, NAM COR DIS COV 19 V
   WHO, 2020, INT CLIN TRIALS REG
   Wu AW, 2020, ANN INTERN MED, V172, P822, DOI 10.7326/M20-1236
   Cuan-Baltazar JY, 2020, JMIR PUBLIC HLTH SUR, V6, P176, DOI 10.2196/18444
   ZHANG LW, 2020, HEALTHCARE-J DEL SCI, V8, DOI DOI 10.3390/HEALTHCARE8010064
NR 64
TC 2
Z9 2
U1 17
U2 17
PU  EDICIONES PROFESIONALES INFORMACION SL-EPI
PI BARCELONA
PA MISTRAL, 36, BARCELONA, ALBOLOTE, SPAIN
SN 1386-6710
J9 PROF INFORM
JI Prof. Inf.
PD JUL-AUG
PY 2020
VL 29
IS 4
AR e290408
DI 10.3145/epi.2020.jul.08
PG 17
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA NK5HY
UT WOS:000566763500003
OA Bronze
DA 2021-01-01
ER

PT J
AU Goldstein, MR
   Poland, GA
   Graeber, CW
AF Goldstein, M. R.
   Poland, G. A.
   Graeber, C. W.
TI Are certain drugs associated with enhanced mortality in COVID-19?
SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Goldstein, M. R.] Ctr Hlth Living, NCH Phys Grp, 132 Moorings Pk Dr, Naples, FL 34105 USA.
   [Poland, G. A.] Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, 611C Guggenheim Bldg, Rochester, MN 55905 USA.
   [Graeber, C. W.] Mayo Clin, Coll Med & Sci, Naples, FL 34102 USA.
   [Graeber, C. W.] Univ Cent Florida, Coll Med, Naples, FL 34102 USA.
   [Graeber, C. W.] NCH Healthcare Syst Internal Med Residency, Naples, FL 34102 USA.
   [Graeber, C. W.] Mayo Clin, Sch Med & Sci, Naples, FL 34102 USA.
RP Goldstein, MR (corresponding author), Ctr Hlth Living, NCH Phys Grp, 132 Moorings Pk Dr, Naples, FL 34105 USA.
EM markrgoldstein@comcast.net
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hilal-Dandan R., 2018, GOODMAN GILMANS PHAR, P471
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kaplanski G, 2018, IMMUNOL REV, V281, P138, DOI 10.1111/imr.12616
   Rogers AJ, 2019, CRIT CARE MED, V47, P1089, DOI 10.1097/CCM.0000000000003816
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 6
TC 13
Z9 13
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1460-2725
EI 1460-2393
J9 QJM-INT J MED
JI QJM-An Int. J. Med.
PD JUL
PY 2020
VL 113
IS 7
BP 509
EP 510
DI 10.1093/qjmed/hcaa103
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NN6JE
UT WOS:000568891600018
PM 32219440
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mishra, AK
   Sahu, KK
   Sargent, J
AF Mishra, A. K.
   Sahu, K. K.
   Sargent, J.
TI Cardiac drugs and outcome in COVID-19
SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Mishra, A. K.; Sahu, K. K.] St Vincent Hosp, Dept Internal Med, 123 Summer St, Worcester, MA 01608 USA.
   [Sargent, J.] Univ Massachusetts, St Vincent Hosp, Dept Internal Med, Med Sch, 123 Summer St, Worcester, MA 01608 USA.
RP Mishra, AK (corresponding author), St Vincent Hosp, Dept Internal Med, 123 Summer St, Worcester, MA 01608 USA.
EM ajay.mishra@stvincenthospital.com
RI Mishra, ajay kumar/I-4314-2019; Sahu, Kamal Kant/AAI-2858-2020
OI Mishra, ajay kumar/0000-0003-4862-5053; Sahu, Kamal
   Kant/0000-0002-0382-6882
CR Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Goldstein MR, 2020, QJM-INT J MED, V113, P509, DOI 10.1093/qjmed/hcaa103
   Mishra AK, 2020, J MED VIROL, V92, P1747, DOI 10.1002/jmv.25847
   Mishra AK, 2015, CASE REPORTS, V2015
   Mishra AK, 2020, J MED VIROL
   Sahu KK, 2020, QJM-INT J MED, V113, P384, DOI 10.1093/qjmed/hcaa081
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 9
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1460-2725
EI 1460-2393
J9 QJM-INT J MED
JI QJM-An Int. J. Med.
PD JUL
PY 2020
VL 113
IS 7
BP 523
EP 524
DI 10.1093/qjmed/hcaa127
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NN6JE
UT WOS:000568891600025
PM 32289168
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Goldstein, MR
   Poland, GA
   Graeber, CW
AF Goldstein, M. R.
   Poland, G. A.
   Graeber, C. W.
TI Response to: Cardiac drugs and outcome in COVID-19
SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Goldstein, M. R.] Ctr Hlth Living, NCH Phys Grp, 132 Moorings Pk Dr, Naples, FL 34105 USA.
   [Poland, G. A.] Mayo Clin & Mayo Fdn, Mayo Vaccine Res Grp, 611C Guggenheim Bldg, Rochester, MN 55905 USA.
   [Graeber, C. W.] Mayo Clin, Coll Med & Sci, Naples, FL 34102 USA.
   [Graeber, C. W.] Univ Cent Florida, Coll Med, Naples, FL 34102 USA.
   [Graeber, C. W.] NCH Healthcare Syst Internal Med Residency, Naples, FL 34102 USA.
   [Graeber, C. W.] Mayo Clin, Sch Med & Sci, Naples, FL 34102 USA.
RP Goldstein, MR (corresponding author), Ctr Hlth Living, NCH Phys Grp, 132 Moorings Pk Dr, Naples, FL 34105 USA.
EM markrgoldstein@comcast.net
CR Goldstein MR, 2020, QJM-INT J MED, V113, P509, DOI 10.1093/qjmed/hcaa103
   Guo T, 2020, JAMA CARDIOL, DOI [10.1001/jamacardiol.2020.1017, DOI 10.1001/JAMACARDIOL.2020.1017]
   Mishra AK, 2020, QJM-INT J MED, V113, P523, DOI 10.1093/qjmed/hcaa127
   Rogers AJ, 2019, CRIT CARE MED, V47, P1089, DOI 10.1097/CCM.0000000000003816
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Xiao H, 2018, EUR HEART J, V39, P60, DOI 10.1093/eurheartj/ehx261
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 8
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1460-2725
EI 1460-2393
J9 QJM-INT J MED
JI QJM-An Int. J. Med.
PD JUL
PY 2020
VL 113
IS 7
BP 525
EP 526
DI 10.1093/qjmed/hcaa128
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NN6JE
UT WOS:000568891600026
PM 32289171
OA Green Accepted, Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharma, S
   Keswani, P
   Bhargava, A
   Sharma, R
   Shekhawat, A
   Bhandari, S
AF Sharma, Shrikant
   Keswani, Prakash
   Bhargava, Abhishek
   Sharma, Ramji
   Shekhawat, Ajeet
   Bhandari, Sudhir
TI Overview of Early Cases of Coronavirus Disease 2019 (COVID-19) at a
   Tertiary Care Centre in North India
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Article
DE Acute respiratory distress syndrome; Cytokine release syndrome;
   Interleukin-6; Lopinavir-ritonavir; Lymphopaenia
ID WUHAN; CHINA
AB Introduction: As the coronavirus disease 2019 (COVID-19) pandemic continues to spread on an unprecedented scale from around the world, we described our experience in treating early COVID-19 cases in India. Materials and Methods: An observational study of COVID-19 patients admitted to a tertiary care centre in North India between 2 March-4 April 2020 was performed. The clinical, epidemiological, laboratory, treatment and outcome data of patients were evaluated. Results,: A total of 75 patients were treated and 56 (74.66%) were men. The clinical spectrum of COVID-19 ranged from asymptomatic to acute respiratory distress syndrome (ARDS). Fever (85.36%) was the most common symptom followed by cough (56.09%) and dyspnoea (19.51%). Findings from hemogram analysis showed that 32 degrees A 21.33% and 18.67% of patients had lymphopaenia, eosinopenia and thrombocytopaenia, respectively. inflammatory markers such as C-reactive protein, D-dimer, ferritin, fibrin degradation product and interleukin-6 were significantly elevated (P <0.05) in patients who required oxygen therapy than those who did not require it, suggesting the potential role such markers could play in predicting prognosis in patients. Mean hospital stay was 9.2 days and 72 (96%) patients made a complete recovery, but 3 (4%) patients demised after progressing to ARDS. Conclusion: The clinical and epidemiological spectrum of COVID-19 has jeopardised the health system in India. Without a proven therapy to combat this pandemic and with no sight of vaccines in the near future, a preventive strategy should be adopted to contain the spread of this infectious disease.
C1 [Sharma, Shrikant; Keswani, Prakash; Bhargava, Abhishek; Sharma, Ramji; Shekhawat, Ajeet; Bhandari, Sudhir] SMS Med Coll & Hosp, Dept Med, Vijaybarisikar Rd,Plot 47 Path 6, Jaipur 302039, Rajasthan, India.
RP Sharma, S (corresponding author), SMS Med Coll & Hosp, Dept Med, Vijaybarisikar Rd,Plot 47 Path 6, Jaipur 302039, Rajasthan, India.
EM Skant_sunita@yahoo.co.in
CR Bhandari S, 2020, ANN ACAD MED SINGAP, V49, P393
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Koh D, 2020, ANN ACAD MED SINGAP, V49, P161
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu T., 2020, POTENTIAL ROLE IL 6, DOI [10.1101/2020.03.01.20029769, DOI 10.1101/2020.03.01.20029769]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ministry of Health and Family Welfare India, COVID 19 STAT STAT
   Paquette SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038214
   Rojo JMC, 2020, CLIN CHARACTERISTICS, V2020, DOI [10.1101/2020.05.24.20111971., DOI 10.1101/2020.05.24.20111971]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhao Y, 2020, AM J RESP CRIT CARE, V202, P756, DOI 10.1164/rccm.202001-0179LE
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD JUL
PY 2020
VL 49
IS 7
BP 449
EP 455
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK0ZY
UT WOS:000566470800003
PM 33000107
DA 2021-01-01
ER

PT J
AU Yang, HZ
   Chen, HD
   Gao, BA
   Xiong, WN
   Zhang, XJ
   Hogarth, DK
   Sun, JY
   Ke, MY
   Herth, FJF
AF Yang, Huizhen
   Chen, Huidong
   Gao, Baoan
   Xiong, Weining
   Zhang, Xiaoju
   Hogarth, D. Kyle
   Sun, Jiayuan
   Ke, Mingyao
   Herth, Felix J. F.
TI Expert panel consensus statement on the applications and precaution
   strategies of bronchoscopy in patients with COVID-19
SO ENDOSCOPIC ULTRASOUND
LA English
DT Article
DE bronchoscopy; consensus; coronavirus disease 2019
ID BRONCHOALVEOLAR LAVAGE; PULMONARY; DIAGNOSIS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus with higher transmissibility compared with SARS coronavirus (SARS-CoV) and Middle East respiratory distress syndrome coronavirus. Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an unprecedented global crisis that has not been experienced, which is still disrupting health systems, economies, and societies around the world by the rapid spread. Bronchoscopy plays an important role in diagnosis and therapy of pulmonary diseases, especially in patients with severe pulmonary infection, however, application of bronchoscopy in patients suspected or confirmed SARS-CoV-2 infection is extremely limited for the potential airborne transmission from aerosol generated during the procedure. This consensus statement was completed by expert panel of Interventional & Minimally Invasive Respiratory Committee of China Medical Education Association, and the issues were summarized as seven key topics to define the indications of bronchoscopy and matters needing attentions on the bronchoscopy procedures in patients with COVID-19, as well as the protective precaution strategies to avoid nosocomial SARS-CoV-2 infection.
C1 [Yang, Huizhen; Zhang, Xiaoju] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Dept Resp & Crit Care Med, Zhengzhou, Henan, Peoples R China.
   [Yang, Huizhen; Sun, Jiayuan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp Endoscopy & Resp & Crit Care Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.
   [Chen, Huidong] Jinyintan Hosp Wuhan, Dept Resp Endoscopy, Wuhan, Hubei, Peoples R China.
   [Gao, Baoan] China Three Gorges Univ, Yichang Cent Hosp, Inst Resp Dis, Yichang, Sichuan, Peoples R China.
   [Xiong, Weining] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Hogarth, D. Kyle] Univ Chicago Med, Dept Med, Chicago, IL USA.
   [Sun, Jiayuan] Shanghai Engn Res Ctr Resp Endoscopy, Shanghai, Peoples R China.
   [Ke, Mingyao] Xiamen Med Coll, Affiliated Hosp 2, Dept Resp Ctr, Xiamen, Fujian, Peoples R China.
   [Herth, Felix J. F.] Heidelberg Univ, Dept Pneumol & Crit Care Med, Thoraxklin, 1 Rontgenstr St, D-69126 Heidelberg, Germany.
RP Sun, JY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Resp Endoscopy & Resp & Crit Care Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.; Herth, FJF (corresponding author), Heidelberg Univ, Dept Pneumol & Crit Care Med, Thoraxklin, 1 Rontgenstr St, D-69126 Heidelberg, Germany.; Ke, MY (corresponding author), Xiamen Med Coll, Affiliated Hosp 2, Resp Ctr, 566 Shengguang Rd, Xiamen 361000, Peoples R China.
EM xkyyjysun@163.com; 13860166866@163.com;
   felix.herth@med.uni-heidelberg.de
FU Shanghai Jiao Tong University "Biomedical Engineering Cross Research
   Fund" Project [YG2020YQ11]
FX This work is supported by Shanghai Jiao Tong University "Biomedical
   Engineering Cross Research Fund" Project (YG2020YQ11).
CR Centers for Disease Control and Prevention, 2020, INTERIM GUIDELINES F
   Chaudhuri Arunabha D, 2013, Lung India, V30, P27, DOI 10.4103/0970-2113.106130
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guidry CA, 2014, SURG INFECT, V15, P527, DOI 10.1089/sur.2013.142
   Hage CA, 2019, AM J RESP CRIT CARE, V200, P535, DOI 10.1164/rccm.201906-1185ST
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Izumo T, 2015, EUR RESPIR J, V45, P1661, DOI 10.1183/09031936.00167914
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kuo CH, 2011, ULTRASOUND MED BIOL, V37, P1755, DOI 10.1016/j.ultrasmedbio.2011.07.007
   Lee HW, 2015, RESPIROLOGY, V20, P1115, DOI 10.1111/resp.12590
   Meyer KC, 2012, AM J RESP CRIT CARE, V185, P1004, DOI 10.1164/rccm.201202-0320ST
   Mouritsen JM, 2020, ANAESTHESIA, V75, P529, DOI 10.1111/anae.14891
   National Health Commission of the People' Republic of China National Administration of Traditional Chinese Medicine, 2020, CLIN EDUC GENERAL PR, V18, P100
   Ofstead CL, 2020, INFECT CONT HOSP EP, V41, P862, DOI 10.1017/ice.2020.102
   PINGLETON SK, 1983, AM REV RESPIR DIS, V128, P1035
   Sakurai A, 2019, OPEN FORUM INFECT DI, V6, pS753
   Scala R, 2010, CRIT CARE, V14, DOI 10.1186/cc8993
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Wahidi MM, 2020, CHEST, V158, P1268, DOI 10.1016/j.chest.2020.04.036
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zaidi SR, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0421-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 24
TC 0
Z9 0
U1 5
U2 5
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 2303-9027
EI 2226-7190
J9 ENDOSC ULTRASOUND
JI Endosc. Ultrasound
PD JUL-AUG
PY 2020
VL 9
IS 4
BP 211
EP 219
DI 10.4103/eus.eus_45_20
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NK1ZJ
UT WOS:000566536900002
PM 32769235
OA Green Published
DA 2021-01-01
ER

PT J
AU Giacomelli, E
   Dorigo, W
   Fargion, A
   Calugi, G
   Cianchi, G
   Pratesi, C
AF Giacomelli, Elena
   Dorigo, Walter
   Fargion, Aaron
   Calugi, Gianmarco
   Cianchi, Giovanni
   Pratesi, Carlo
TI Acute Thrombosis of an Aortic Prosthetic Graft in a Patient with Severe
   COVID-19-Related Pneumonia
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article
AB Background: COVID-19 infection has been reported to be related with an increased risk of thrombotic complications because of the hypercoagulability state and inflammation. At the moment, no reports are available regarding thrombosis of prosthetic vascular grafts. We present the case of a patient with COVID-19-related pneumonia, who suffered from the acute thrombosis of a previously implanted aortic graft.
   Methods and results: A 67-year-old male patient, who had undergone open repair of an abdominal aortic aneurysm with a bifurcated graft 6 years before, was admitted to the emergency department with high fever for a week without cough or dyspnea. Thoracic ultrasound showed signs of bilateral interstitial pneumonia, and the Sars-Cov-2 swab was positive. Antiretroviral therapy and prophylactic low molecular weight heparin treatment were initiated. Owing to the progressive impairment of the respiratory function, the patient was intubated after eight days from the admission, the day after he showed signs of bilateral acute limb ischemia. A duplex ultrasound demonstrated the complete thrombosis of the aortic graft without flow at the femoral level. An urgent angio-computed tomography scan for revascularization purpose was requested, but the patient died on the arrival in the radiological suite.
   Conclusions: Acute thrombosis of vascular prosthetic grafts is a possible, catastrophic complication of COVID-19 infection. In COVID-19 patients with prosthetic graft, an aggressive antithrombotic treatment could be considered to prevent such an event.
C1 [Giacomelli, Elena; Dorigo, Walter; Fargion, Aaron; Calugi, Gianmarco; Pratesi, Carlo] Univ Florence, Dept Vasc Surg, Largo Brambilla 3, I-50134 Florence, Italy.
   [Cianchi, Giovanni] Careggi Teaching Hosp, Intens Care Unit, Florence, Italy.
RP Dorigo, W (corresponding author), Univ Florence, Dept Vasc Surg, Largo Brambilla 3, I-50134 Florence, Italy.
EM walter.dorigo@unifi.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Boon GJAM, 2020, RES PRACT THROMB HAE, V4, P958, DOI 10.1002/rth2.12404
   Brewster DC, 1994, VASCULAR DIS SURG IN, P1151
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Marone EM, 2020, J VASC SURG VENOUS L
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Spiezia L, 2020, THROMB HAEMOST
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Zhou B, 2020, J THROMB THROMBOLYS, V50, P229, DOI 10.1007/s11239-020-02084-w
NR 9
TC 10
Z9 10
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0890-5096
EI 1615-5947
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD JUL
PY 2020
VL 66
BP 8
EP 10
DI 10.1016/j.avsg.2020.04.040
PG 3
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA NJ2EX
UT WOS:000565859400004
PM 32360432
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU De Spiegeleer, A
   Bronselaer, A
   Teo, JT
   Byttebier, G
   De Tre, G
   Belmans, L
   Dobson, R
   Wynendaele, E
   Van de Wiele, C
   Vandaele, F
   Van Dijck, D
   Bean, D
   Fedson, D
   De Spiegeleer, B
AF De Spiegeleer, Anton
   Bronselaer, Antoon
   Teo, James T.
   Byttebier, Geert
   De Tre, Guy
   Belmans, Luc
   Dobson, Richard
   Wynendaele, Evelien
   Van de Wiele, Christophe
   Vandaele, Filip
   Van Dijck, Diemer
   Bean, Dan
   Fedson, David
   De Spiegeleer, Bart
TI The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19
   Infection Among Nursing Home Residents
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Angiotensin-converting enzyme inhibitors; angiotensin II receptor
   blockers; statins; COVID-19; nursing home residents
ID INHIBITORS
AB Objectives: Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.
   Design: We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction).
   Setting and participants: A total of 154 COVID-19-positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks.
   Measures: Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.
   Results: We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio [OR] 2.91; confidence interval [CI] 1.27-6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59-25.1) or serious clinical outcome (OR 0.48; CI 0.10-1.97).
   Conclusions and Implications: Our data indicate that statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs needs to be further explored in larger observational studies as well as randomized clinical trials. (C) 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
C1 [De Spiegeleer, Anton; Wynendaele, Evelien; De Spiegeleer, Bart] Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat Grp, Ghent, Belgium.
   [De Spiegeleer, Anton] Ghent Univ Hosp, Dept Geriatr, Fac Med & Hlth Sci, Ghent, Belgium.
   [De Spiegeleer, Anton] VIB Ctr Inflammat Res, Unit Mol Immunol & Inflammat, Ghent, Belgium.
   [Bronselaer, Antoon; De Tre, Guy] Univ Ghent, Dept Telecommun & Informat Proc, DDCM Lab, Fac Engn & Architecture, Ghent, Belgium.
   [Teo, James T.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Clin Neurosci, London, England.
   [Byttebier, Geert] Bioconstat BV, Ghent, Belgium.
   [Belmans, Luc] Ghent Univ Hosp, Dept Publ Hlth & Primary Care, Fac Med & Hlth Sci, Ghent, Belgium.
   [Dobson, Richard; Bean, Dan] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat & Hlth Informat, London, England.
   [Van de Wiele, Christophe] Ghent Univ Hosp, Dept Diagnost Sci, Fac Med & Hlth Sci, Ghent, Belgium.
   [Vandaele, Filip] VZW Zorg Saam Zusters Kindsheid Jesu, Ghent, Belgium.
   [Van Dijck, Diemer] Corilus Hlth IT Ctr, Ghent, Belgium.
   [Fedson, David] 57 Chemin Lavoir, Sergy Haut, France.
RP De Spiegeleer, B (corresponding author), Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat Grp, Ghent, Belgium.
EM bart.despiegeleer@ugent.be
RI Teo, James TH/D-9696-2011; Teo, James T/ABA-1819-2020; dobson,
   richard/C-9269-2011
OI Teo, James TH/0000-0002-6899-8319; Teo, James T/0000-0002-6899-8319;
   dobson, richard/0000-0003-4224-9245
FU Research Foundation Flanders(FWO)FWO [1158818N]
FX A.D.S. is supported by a grant of Research Foundation Flanders(FWO)
   (grant number 1158818N).
CR Abdulhak AAB, 2009, PERITON DIALYSIS INT, V29, P554
   Aktas S, 2018, DIABETES RES CLIN PR, V135, P88, DOI 10.1016/j.diabres.2017.11.004
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bean D, 2020, TREATMENT ACE INHIBI
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cox CE, ANTICOAGULANTS MAY A
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guang Y, 2020, ANGIOTENSIN II RECEP
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lovato A, 2020, EAR NOSE THROAT J
   McGonagle D., 2020, LANCET RHEUM
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Mortensen E, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.OA3329
   Mortensen EM, 2012, CLIN INFECT DIS, V55, P1466, DOI 10.1093/cid/cis733
   ODOWD A, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1727
   Onder G, 2020, JAMA
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Schol-Gelok S, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13130
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   van de Veerdonk FNMGN, 2020, KININS CYTOKINES COV
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wosten-van Asperen RM, 2013, PEDIATR CRIT CARE ME, V14, pE438, DOI 10.1097/PCC.0b013e3182a55735
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Yingxia L, 2020, ANTIHYPERTENSIVE ANG
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhu J, 2014, FRONT GENET, V5, DOI [10.3389/fgene.2014.00149, 10.3389/fgene.2014.00187]
NR 36
TC 15
Z9 15
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUL
PY 2020
VL 21
IS 7
BP 909
EP +
DI 10.1016/j.jamda.2020.06.018
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NJ2CY
UT WOS:000565854300007
PM 32674818
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Calvani, R
   Picca, A
   Landi, F
   Marzetti, E
AF Calvani, Riccardo
   Picca, Anna
   Landi, Francesco
   Marzetti, Emanuele
TI Plasma Therapies and Parabiosis in the COVID-19 Era
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Letter
C1 [Calvani, Riccardo; Picca, Anna; Landi, Francesco; Marzetti, Emanuele] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy.
   [Landi, Francesco; Marzetti, Emanuele] Univ Cattolica Sacro Cuore, Rome, Italy.
RP Calvani, R (corresponding author), Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy.
RI Picca, Anna/K-2305-2018; Calvani, Riccardo/K-2011-2018; Marzetti,
   Emanuele/A-9430-2010
OI Picca, Anna/0000-0001-7032-3487; Calvani, Riccardo/0000-0001-5472-2365;
   Marzetti, Emanuele/0000-0001-9567-6983
CR Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cesari M, 2020, J AM MED DIR ASSOC, V21, P576, DOI 10.1016/j.jamda.2020.03.025
   Cohen J, 2020, SCIENCE, V368, P564, DOI 10.1126/science.368.6491.564
   Conboy IM, 2012, CELL CYCLE, V11, P2260, DOI 10.4161/cc.20437
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Lehallier B, 2019, NAT MED, V25, P1843, DOI 10.1038/s41591-019-0673-2
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Promislow DEL, 2020, J GERONTOL A-BIOL, V75, pE30, DOI 10.1093/gerona/glaa094
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUL
PY 2020
VL 21
IS 7
BP 994
EP 995
DI 10.1016/j.jamda.2020.05.066
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NJ2CY
UT WOS:000565854300040
PM 32674834
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brandt, N
   Chou, J
AF Brandt, Nicole
   Chou, Joshua
TI Optimizing Medication Management During the COVID-19 Pandemic: It Takes
   a Village
SO JOURNAL OF GERONTOLOGICAL NURSING
LA English
DT Article
ID OLDER-ADULTS
AB Coronavirus disease 2019 (COVID-19) is an unprecedented pandemic that has particularly affected nursing homes and long-term care facilities. To support frontline health care professionals caring for older adults, the current article provides guidance on strategies to optimize medication management within nursing homes and long-term care facilities. In addition, the article reviews two medications that have been granted U.S. Food and Drug Administration emergency use authorization for treatment of COVID-19: hydroxychloroquine and remdesivir. Finally, this article highlights resources and strategies for improving communication among an interprofessional team during the ongoing pandemic, as well as education on COVID-19. Although the COVID-19 pandemic has had many negative implications, it has also brought to attention opportunities to improve the delivery of care and increase the importance of working as an interprofessional team ("village") during these challenging times.
C1 [Brandt, Nicole; Chou, Joshua] Univ Maryland, Sch Pharm, Peter Lamy Ctr Drug Therapy & Aging, Baltimore, MD USA.
   [Brandt, Nicole; Chou, Joshua] MedStar Good Samaritan Hosp, Ctr Successful Aging, Baltimore, MD USA.
RP Brandt, N (corresponding author), Univ Maryland, Sch Pharm, 220 Arch St,12th Floor, Baltimore, MD 21201 USA.
EM nbrandt@rx.umaryland.edu
CR American College of Cardiology, 2020, VENT ARRH RISK DUE H
   Awad K, 2017, J CLIN LIPIDOL, V11, P972, DOI 10.1016/j.jacl.2017.06.001
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brandt N, 2020, J AM GERIATR SOC, V68, P1362, DOI 10.1111/jgs.16573
   Cao J, 2016, JAMA INTERN MED, V176, P705, DOI 10.1001/jamainternmed.2016.0142
   Centers for Medicare & Medicaid Services, 2020, UPC REQ NOT CONF COV
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chidambaram P., 2020, STATE REPORTING CASE
   Grabowski DC, 2020, JAMA-J AM MED ASSOC, V324, P23, DOI 10.1001/jama.2020.8524
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Gupta R, 2020, DIABETES METAB SYND, V14, P251, DOI 10.1016/j.dsx.2020.03.012
   Infectious Diseases Society of America, 2020, INF DIS SOC AM GUID
   Kaasalainen S, 2010, CAN J NURS RES, V42, P59
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Lavorini F, 2016, DRUG AGING, V33, P461, DOI 10.1007/s40266-016-0377-y
   Liebel DV, 2005, AM J NURS, V105, P63, DOI 10.1097/00000446-200512000-00034
   Lipska KJ, 2016, JAMA-J AM MED ASSOC, V315, P1034, DOI 10.1001/jama.2016.0299
   Munanga A, 2020, J GERONTOL NURS, V46, P3, DOI 10.3928/00989134-20200511-03
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Ouslander JG, 2020, J AM GERIATR SOC, V68, P682, DOI 10.1111/jgs.16395
   Peter Lamy Center on Drug Therapy and Aging, 2020, OPT MED MAN COVID 19
   Reeve E, 2016, BRIT J GEN PRACT, V66, pE552, DOI 10.3399/bjgp16X685669
   Scott-Cawiezell Jill, 2007, Clin Nurs Res, V16, P72, DOI 10.1177/1054773806295241
   Sluggett JK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041053
   Thomson MS, 2009, J AM GERIATR SOC, V57, P266, DOI 10.1111/j.1532-5415.2008.02101.x
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0098-9134
EI 1938-243X
J9 J GERONTOL NURS
JI J. Gerontol. Nurs.
PD JUL
PY 2020
VL 46
IS 7
BP 3
EP 8
DI 10.3928/00989134-20200605-02
PG 6
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA NJ1JD
UT WOS:000565797400002
PM 32597995
DA 2021-01-01
ER

PT J
AU Brocalero-Camacho, A
   Perez-Borrego, YA
   Soto-Leon, V
   Rodriguez-Matas, MJ
   Foffani, G
   Oliviero, A
AF Brocalero-Camacho, Angela
   Perez-Borrego, Yolanda A.
   Soto-Leon, Vanesa
   Jesus Rodriguez-Matas, Maria
   Foffani, Guglielmo
   Oliviero, Antonio
TI Effects of COVID-19 lockdown on chronic drug-resistant pain patients
   treated using brain stimulation approaches
SO BRAIN STIMULATION
LA English
DT Article
DE Transcranial direct current stimulation; Motor cortex; Pain; COVID-19;
   Lockdown
C1 [Brocalero-Camacho, Angela; Perez-Borrego, Yolanda A.; Soto-Leon, Vanesa; Oliviero, Antonio] Hosp Nacl Paraplej, SESCAM, FENNSI Grp, Toledo, Spain.
   [Jesus Rodriguez-Matas, Maria] Complejo Hosp Toledo, SESCAM, Toledo, Spain.
   [Foffani, Guglielmo] Univ CEU San Pablo, Hosp Univ HM Puerta Sur, CINAC, Madrid, Spain.
RP Oliviero, A (corresponding author), Hosp Nacl Paraplej, FENNSI Grp, Finca La Peraleda S-N, Toledo 45071, Spain.
EM antonioo@sescam.jccm.es
RI Foffani, Guglielmo/ABD-5897-2020; Oliviero, Antonio/ABH-4485-2020
OI Oliviero, Antonio/0000-0001-7723-0478; Soto Leon,
   Vanesa/0000-0002-2534-5369
CR Lefaucheur JP, 2020, CLIN NEUROPHYSIOL, V131, P474, DOI 10.1016/j.clinph.2019.11.002
   Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087
   Lefaucheur Jean-Pascal, 2013, Handb Clin Neurol, V116, P423, DOI 10.1016/B978-0-444-53497-2.00035-8
   Lefaucheur JP, 2008, BRAIN STIMUL, V1, P337, DOI 10.1016/j.brs.2008.07.003
NR 4
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD JUL-AUG
PY 2020
VL 13
IS 4
BP 1089
EP 1090
DI 10.1016/j.brs.2020.05.003
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NH3ME
UT WOS:000564577000027
PM 32389838
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Scully, EP
   Haverfield, J
   Ursin, RL
   Tannenbaum, C
   Klein, SL
AF Scully, Eileen P.
   Haverfield, Jenna
   Ursin, Rebecca L.
   Tannenbaum, Cara
   Klein, Sabra L.
TI Considering how biological sex impacts immune responses and COVID-19
   outcomes
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; PLASMACYTOID DENDRITIC CELLS;
   IFN-ALPHA PRODUCTION; T-CELLS; MEDIATED RESPONSE; INFLUENZA;
   SUSCEPTIBILITY; CHROMOSOME; GENDER; DIMORPHISM
AB A male bias in mortality has emerged in the COVID-19 pandemic, which is consistent with the pathogenesis of other viral infections. Biological sex differences may manifest themselves in susceptibility to infection, early pathogenesis, innate viral control, adaptive immune responses or the balance of inflammation and tissue repair in the resolution of infection. We discuss available sex-disaggregated epidemiological data from the COVID-19 pandemic, introduce sex-differential features of immunity and highlight potential sex differences underlying COVID-19 severity. We propose that sex differences in immunopathogenesis will inform mechanisms of COVID-19, identify points for therapeutic intervention and improve vaccine design and increase vaccine efficacy.
C1 [Scully, Eileen P.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD 21218 USA.
   [Haverfield, Jenna; Tannenbaum, Cara] Canadian Inst Hlth Res, Inst Gender & Hlth, Montreal, PQ, Canada.
   [Ursin, Rebecca L.; Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.
   [Tannenbaum, Cara] Univ Montreal, Fac Med, Inst Univ Geriatr Montreal, Ctr Rech, Montreal, PQ, Canada.
   [Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
RP Klein, SL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.; Klein, SL (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
EM sklein2@jhu.edu
OI Haverfield, Jenna/0000-0002-4893-7797; Ursin,
   Rebecca/0000-0002-3398-331X
CR Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Alosaimi B, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154895
   Asselta R, 2020, ACE2 TMPRSS2 VARIANT, DOI [10.1101/2020.03.30.20047878, DOI 10.1101/2020.03.30.20047878]
   Baratchian Mehdi, 2020, bioRxiv, DOI 10.1101/2020.04.21.051201
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bartz D, 2020, JAMA INTERN MED, V180, P574, DOI 10.1001/jamainternmed.2019.7194
   Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bischof E, 2020, J CLIN INVEST, V130, P3350, DOI 10.1172/JCI139306
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bongen E, 2019, CELL REP, V29, P1961, DOI 10.1016/j.celrep.2019.10.019
   Bynoe MS, 2000, P NATL ACAD SCI USA, V97, P2703, DOI 10.1073/pnas.040577497
   Canadian Institutes of Health Research, 2020, WHY SEX GEND NEED BE
   Carrel L, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0355
   Case LK, 2013, GENOME RES, V23, P1474, DOI 10.1101/gr.156703.113
   Centers for Disease Control and Prevention, 2020, MULT INFL SYNDR CHIL
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dragin N, 2016, J CLIN INVEST, V126, P1525, DOI 10.1172/JCI81894
   Dudley JP, 2020, CLIN INFECT DIS, V71, P863, DOI 10.1093/cid/ciaa354
   Dumanski J. P., 2020, IMMUNE CELLS LACKING, DOI [10.1101/673459, DOI 10.1101/673459]
   Ellegren H, 2007, NAT REV GENET, V8, P689, DOI 10.1038/nrg2167
   Eshima N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019409
   Falagas ME, 2007, RESP MED, V101, P1845, DOI 10.1016/j.rmed.2007.04.011
   Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gibson WT, 2020, BIORXIV, DOI [10.1101/2020.04.05.026633, DOI 10.1101/2020.04.05.026633]
   Golden LC, 2019, P NATL ACAD SCI USA, V116, P26779, DOI 10.1073/pnas.1910072116
   Griesbeck M, 2015, J IMMUNOL, V195, P5327, DOI 10.4049/jimmunol.1501684
   Grimaldi CM, 2006, J IMMUNOL, V176, P2703, DOI 10.4049/jimmunol.176.5.2703
   Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hall OJ, 2017, MUCOSAL IMMUNOL, V10, P1097, DOI 10.1038/mi.2017.35
   Hall OJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02160-16
   Hall OJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005840
   Halter S, 2020, ANAESTH CRIT CARE PA, V39, P35, DOI 10.1016/j.accpm.2019.07.014
   Heffernan DS, 2011, J TRAUMA, V71, P878, DOI 10.1097/TA.0b013e31822c0d31
   Hewagama A, 2009, GENES IMMUN, V10, P509, DOI 10.1038/gene.2009.12
   Hill L, 2011, MOL MED, V17, P211, DOI 10.2119/molmed.2010.00172
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2012, ANNU REV MICROBIOL, V66, P177, DOI 10.1146/annurev-micro-092611-150203
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2015, P NATL ACAD SCI USA, V112, P5257, DOI 10.1073/pnas.1502843112
   Klein SL, PLOS PATHOG
   Koff WC, 2020, NEW ENGL J MED, V383, P804, DOI 10.1056/NEJMp2006761
   Krementsov DN, 2017, P NATL ACAD SCI USA, V114, P3491, DOI 10.1073/pnas.1620889114
   Laffont S, 2014, J IMMUNOL, V193, P5444, DOI 10.4049/jimmunol.1303400
   Leng SX, 2020, CELL IMMUNOL, V348, DOI 10.1016/j.cellimm.2019.104024
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Liu Jun, 2010, Biol Sex Differ, V1, P6, DOI 10.1186/2042-6410-1-6
   Liu T, 2015, AM J SURG, V210, P911, DOI 10.1016/j.amjsurg.2015.03.021
   Marina S, 2020, LANCET, DOI [10.2139/ssrn.3576790, DOI 10.2139/SSRN.3576790]
   Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006
   Marquez EJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14396-9
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004
   Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520
   Ministry of Health and Welfare of South Korea, 2020, DOM OCC STAT
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   NYC, 2020, COVID 19 DAT
   Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Page ST, 2006, AM J PHYSIOL-ENDOC M, V290, pE856, DOI 10.1152/ajpendo.00484.2005
   Pauklin S, 2009, J EXP MED, V206, P99, DOI 10.1084/jem.20080521
   Peckham H, 2020, SEX BIAS COVID 19 ME, DOI [10.21203/rs.3.rs-23651/v2, DOI 10.21203/RS.3.RS-23651/V2]
   Peretz J, 2016, AM J PHYSIOL-LUNG C, V310, pL415, DOI 10.1152/ajplung.00398.2015
   Piasecka B, 2018, P NATL ACAD SCI USA, V115, pE488, DOI 10.1073/pnas.1714765115
   Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227
   Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6
   Qu K, 2015, CELL SYST, V1, P51, DOI 10.1016/j.cels.2015.06.003
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Robinson Dionne P, 2011, Biol Sex Differ, V2, P8, DOI 10.1186/2042-6410-2-8
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakiani S, 2013, NAT REV ENDOCRINOL, V9, P56, DOI 10.1038/nrendo.2012.206
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022
   Schurz H, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0185-z
   Seillet C, 2012, BLOOD, V119, P454, DOI 10.1182/blood-2011-08-371831
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Souyris M, 2019, SEMIN IMMUNOPATHOL, V41, P153, DOI 10.1007/s00281-018-0712-y
   Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai P, 2008, J CELL PHYSIOL, V214, P456, DOI 10.1002/jcp.21221
   Tannenbaum C, 2019, NATURE, V575, P137, DOI 10.1038/s41586-019-1657-6
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   vom Steeg LG, 2019, SEMIN IMMUNOPATHOL, V41, P189, DOI 10.1007/s00281-018-0718-5
   vom Steeg LG, 2017, HORM BEHAV, V88, P45, DOI 10.1016/j.yhbeh.2016.10.016
   vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374
   Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong KC, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3681-4
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yee Mon Kristel Joy, 2019, Immunohorizons, V3, P121, DOI 10.4049/immunohorizons.1800066
   Zhang Q, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012917
   Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhu ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11350
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 116
TC 39
Z9 39
U1 10
U2 12
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
PD JUL
PY 2020
VL 20
IS 7
BP 442
EP 447
DI 10.1038/s41577-020-0348-8
PG 6
WC Immunology
SC Immunology
GA NI4DD
UT WOS:000565303700014
PM 32528136
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wright, LS
AF Wright, Linda S.
TI Basic Immunology: An Overview
SO NEPHROLOGY NURSING JOURNAL
LA English
DT Article
DE Innate immune system; adaptive immune system; immunization; herd
   immunity; COVID-19; coronavirus; nephrology nurse; vaccine
ID CONVALESCENT PLASMA; HERD-IMMUNITY; THERAPY
AB The COVID-19 pandemic has caused certain immunological concepts to enter the public consciousness, as the scientific and health care communities, and the population in general, seek a path forward in this extraordinary time. Nephrology nurses are uniquely situated to assist their patients in understanding these concepts but may not feel confident in their own knowledge. The following is a high-level overview of basic immunology that can assist the nephrology nurse in the care and education of patients with kidney failure, as well as those in the community who may seek guidance and clarification of the issues that are inherent in the global response to COVID-19.
C1 [Wright, Linda S.] Thomas Jefferson Univ Hosp, Abdominal Organ Transplant, Philadelphia, PA 19107 USA.
RP Wright, LS (corresponding author), Thomas Jefferson Univ Hosp, Abdominal Organ Transplant, Philadelphia, PA 19107 USA.
CR Bhoosreddy G.L., 2010, BASIC IMMUNOLOGY
   Cano RL, 2013, AUTOIMMUNITY BENCH B
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention (CDC), PRINC VACC
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299
   Delves PJ, 2017, ROITTS ESSENTIAL IMM
   Doan T., 2012, IMMUNOLOGY
   Ducloux D, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0121-z
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Grignolio A., 2018, VACCINES ARE THEY WO
   Hall G, 2015, LITERATURE AND LANGUAGE LEARNING IN THE EFL CLASSROOM, P13
   Jacofsky D, 2020, J ARTHROPLASTY, V35, pS74, DOI 10.1016/j.arth.2020.04.055
   Klimov V.V., 2019, BASIC CLIN IMMUNOLOG
   Leo O., 2011, PERSPECT VACCINOL, V1, P25, DOI DOI 10.1016/J.PERVAC.2011.05.002
   Leon-Sicairos N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/476534
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   National Institutes of Health (NIH), 2020, PHAS 3 CLIN TRIAL IN
   Nongnuch A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227719
   Quintana LF, 2013, INFLUENZA OTHER RESP, V7, P809, DOI 10.1111/irv.12024
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Saco TV, 2018, ANN ALLERG ASTHMA IM, V121, P320, DOI 10.1016/j.anai.2018.03.017
   Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046
   Slifka MK, 2014, VACCINE, V32, P2948, DOI 10.1016/j.vaccine.2014.03.078
   Sompayrac L. M., 2019, IMMUNE SYSTEM WORKS
   Udomkarnjananun S, 2020, J NEPHROL, V33, P343, DOI 10.1007/s40620-019-00668-1
   United States Renal Data System (USRDS), 2019, 2019 USRDS ANN DAT R
   Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263
   World Health Organization, IMM
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Zhang CX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02888
NR 31
TC 0
Z9 0
U1 0
U2 0
PU JANNETTI PUBLICATIONS, INC
PI PITMAN
PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA
SN 1526-744X
EI 2163-5390
J9 NEPHROL NURS J
JI Nephrol. Nurs. J.
PD JUL-AUG
PY 2020
VL 47
IS 4
BP 299
EP 304
DI 10.37526/1526-744X.2020.47.4.299
PG 6
WC Nursing; Urology & Nephrology
SC Nursing; Urology & Nephrology
GA NI4GM
UT WOS:000565312400003
PM 32830935
DA 2021-01-01
ER

PT J
AU Sukhanov, YV
   Vorotelyak, EA
   Lyadova, IV
   Vasiliev, AV
AF Sukhanov, Yu. V.
   Vorotelyak, E. A.
   Lyadova, I. V.
   Vasiliev, A. V.
TI Mesenchymal Stem Cell Therapy-Is the Vessel Half Full or Half Empty?
SO RUSSIAN JOURNAL OF DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE mesenchymal stem cells; MSCs; SARS-CoV-2; pneumonia; COVID-19;
   inflammation; cytokines; clinical trials; biomedical cell products
AB The urgency of the search and introduction into medical practice of the method for the therapy of severe forms of pneumonia COVID-19 is due to the lack of effective treatment methods that can destroy the pathogen. Expectations of a good clinical effect from the application of mesenchymal stem cells (MSCs) are not groundless: there is a scientific justification in using MSCs for the treatment of inflammatory diseases and of the proven mechanisms of their action. Along with this, there are very little reliable data about the mechanism of MSCs' action when they are systemically administrated to a human or on the distribution of cells in the body and the long-term consequences of such administration. Data from model experiments are contradictory both concerning the specific action of MSCs and their safety. If clinical studies show an acceptable risk/benefit ratio for the application of MSCs, countries in which such studies have been conducted can expect their introduction into medical practice. In Russia, it is necessary to initiate experimental verification of the specific action of MSCs and the risks of their use in COVID-19 conditions in a sufficient quantity, and, in parallel, to create a mechanism for accelerated but justified admission of biomedical cell products into practice.
C1 [Sukhanov, Yu. V.; Vorotelyak, E. A.; Lyadova, I. V.; Vasiliev, A. V.] Russian Acad Sci, Koltzov Inst Dev Biol, Moscow 119334, Russia.
RP Sukhanov, YV (corresponding author), Russian Acad Sci, Koltzov Inst Dev Biol, Moscow 119334, Russia.
EM yuri.sukhanov@gmail.com
RI Vasiliev, Andrey V/G-6495-2019
FU Koltzov Institute of Developmental Biology of Russian Academy of
   SciencesRussian Academy of Sciences [0108-2019-0004]
FX The research was performed within the framework of a State Assignment of
   Koltzov Institute of Developmental Biology of Russian Academy of
   Sciences, no. 0108-2019-0004. 2020.
CR Ahn SY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1559-4
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   COPPIN L, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/cells8101160
   Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gomez-Salazar M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00148
   Gotts JE, 2014, AM J PHYSIOL-LUNG C, V307, pL395, DOI 10.1152/ajplung.00110.2014
   Han JB, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5432134
   Horak J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00126
   Jiang W, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12712
   Kennelly H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38207
   Lyadova I.V., 2016, J IMMUNOL RES, V2016, P7121580
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Nenasheva T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178983
   Perlee D, 2018, STEM CELLS, V36, P1778, DOI 10.1002/stem.2891
   Silachev DN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030258
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Tatsumi K, 2013, BIOCHEM BIOPH RES CO, V431, P203, DOI 10.1016/j.bbrc.2012.12.134
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1062-3604
EI 1608-3326
J9 RUSS J DEV BIOL+
JI Russ. J. Dev. Biol.
PD JUL
PY 2020
VL 51
IS 4
BP 267
EP 270
DI 10.1134/S1062360420040104
PG 4
WC Developmental Biology
SC Developmental Biology
GA NI2ID
UT WOS:000565178300007
PM 32904919
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Passos, HD
   Alves, MC
   Baumworcel, L
   Vieira, JPC
   Garcez, JDS
   Sousa, ACS
AF Passos, Hellen Dutra
   Alves, Mariana Carvalho
   Baumworcel, Leonardo
   Cerqueira Vieira, Joao Paulo
   Seabra Garcez, Juliane Dantas
   Sobral Sousa, Antonio Carlos
TI SARS-Cov-2 Infection and Pulmonary Thromboembolism - The Prothrombotic
   State in COVID-19
SO ARQUIVOS BRASILEIROS DE CARDIOLOGIA
LA English
DT Article
DE Coronavirus; COVID-19; Pulmonary Embolism; Severe Acute Respiratory
   Syndrome; Anticoagulants; Diagnostic; Imaging
AB Introduction
   The COVID-19 caused by new coronavirus, named by the World Health Organization as Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), has spread all over the world with astonishing speed.(1) In Brazil, the spread risk (RO) of COVID-19 has been 3.0, which explains its rapid dissemination all over the states.(2)
   Individuals with cardiovascular diseases, systemic arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and immunosuppressed patients are at higher risk for adverse outcomes.(3)
   A relatively high incidence of thrombotic and thromboembolic disease has been observed in COVID-19 carriers, probably due to direct effects of the SARS-CoV-2 or indirect mechanisms of the infection. Interactions between COVID-19 therapies and anti platelet agents or anticoagulants and the inadvertent use of anticoagulants may contribute to the prothrombotic state of the disease.(4)
   Objectives
   Here we describe a patient diagnosed with SARS-CoV-2 progressing with pulmonary thrornboernbolism and no evidence off peripheral thrombosis.
   Methods
   The data here reported were obtained by review of electronic medical records, complementary tests, and literature review.
C1 [Passos, Hellen Dutra; Alves, Mariana Carvalho; Baumworcel, Leonardo; Cerqueira Vieira, Joao Paulo; Seabra Garcez, Juliane Dantas; Sobral Sousa, Antonio Carlos] Clin & Hosp Sao Lucas Rede DOr, Aracaju, SE, Brazil.
   [Seabra Garcez, Juliane Dantas; Sobral Sousa, Antonio Carlos] Univ Fed Sergipe, Div Cardiol Hosp Univ, Sao Cristovao, Sergipe, Brazil.
   [Sobral Sousa, Antonio Carlos] Univ Fed Sergipe, Dept Med, Sao Cristovao, SE, Brazil.
   [Sobral Sousa, Antonio Carlos] Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Sao Cristovao, Sergipe, Brazil.
RP Sousa, ACS (corresponding author), Hosp Sao Lucas Rede DOr Sao Luiz, Ctr Ensino & Pesquisa, Av Goncalo Prado Rollemberg 211,Sala 208, BR-49010410 Aracaju, SE, Brazil.
EM acssousa@terra.com.br
OI Sobral Sousa, Antonio Carlos/0000-0002-4158-9726
CR [Anonymous], 2020, CARDIOLOGY MAGA 0422
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Iba T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017046
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Shi S, 2020, J ETHNOPHARMACOL, V256, DOI 10.1016/j.jep.2020.112780
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ARQUIVOS BRASILEIROS CARDIOLOGIA
PI RIO DE JANEIRO
PA AVENIDA MARECHAL CAMARA 160-330 CENTRO, RIO DE JANEIRO, RJ 20 020-907,
   BRAZIL
SN 0066-782X
J9 ARQ BRAS CARDIOL
JI Arq. Bras. Cardiol.
PD JUL
PY 2020
VL 115
IS 1
BP 142
EP 145
DI 10.36660/abc.20200427
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NG4WF
UT WOS:000563983400025
PM 32813826
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Klimek, L
   Jutel, M
   Akdis, C
   Bousquet, J
   Akdis, M
   Bachert, C
   Agache, I
   Ansotegui, I
   Bedbrook, A
   Bosnic-Anticevich, S
   Canonica, GW
   Chivato, T
   Cruz, AA
   Czarlewski, W
   Del Giacco, S
   Du, H
   Fonseca, JA
   Gao, YD
   Haahtela, T
   Hoffmann-Sommergruber, K
   Ivancevich, JC
   Khaltaev, N
   Knol, EF
   Kuna, P
   Larenas-Linnemann, D
   Melen, E
   Mullol, J
   Naclerio, R
   Ohta, K
   Okamoto, Y
   O'Mahony, L
   Onorato, GL
   Papadopoulos, NG
   Pawankar, R
   Pfaar, O
   Samolinski, B
   Schwarze, J
   Toppila-Salmi, S
   Shamji, MH
   Ventura, MT
   Valiulis, A
   Yorgancioglu, A
   Matricardi, P
   Zuberbier, T
AF Klimek, Ludger
   Jutel, Marek
   Akdis, Cezmi
   Bousquet, Jean
   Akdis, Mubeccel
   Bachert, Claus
   Agache, Ioana
   Ansotegui, Ignacio
   Bedbrook, Anna
   Bosnic-Anticevich, Sinthia
   Canonica, G. Walter
   Chivato, Tomas
   Cruz, Alvaro A.
   Czarlewski, Wienia
   Del Giacco, Stefano
   Du, Hui
   Fonseca, Joao A.
   Gao, Yadong
   Haahtela, Tari
   Hoffmann-Sommergruber, Karin
   Ivancevich, Juan-Carlos
   Khaltaev, Nikolai
   Knol, Edward F.
   Kuna, Piotr
   Larenas-Linnemann, Desiree
   Melen, Erik
   Mullol, Joaquim
   Naclerio, Robert
   Ohta, Ken
   Okamoto, Yoshitaka
   O'Mahony, Liam
   Onorato, Gabrielle L.
   Papadopoulos, Nikos G.
   Pawankar, Ruby
   Pfaar, Oliver
   Samolinski, Boleslaw
   Schwarze, Jurgen
   Toppila-Salmi, Sanna
   Shamji, Mohamed H.
   Ventura, Maria Teresa
   Valiulis, Arunas
   Yorgancioglu, Arzu
   Matricardi, Paolo
   Zuberbier, Torsten
CA ARIA-MASK Study Grp
TI Handling of allergen immunotherapy in the COVID-19 pandemic: An
   ARIA-EAACI statement
SO ALLERGY
LA English
DT Article
DE allergy treatment; clinical immunotherapy; immunotherapy vaccines and
   mechanisms
ID VENOM ALLERGY; ASTHMA; MECHANISMS; VACCINES
AB The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
C1 [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany.
   [Jutel, Marek] Wroclaw Med Univ, ALL MED Med Res Inst, Dept Clin Immunol, Wroclaw, Poland.
   [Akdis, Cezmi; Akdis, Mubeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.
   [Bousquet, Jean] Charite Univ Med Berlin, Humboldt Univ Berlin, Berlin, Germany.
   [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany.
   [Bousquet, Jean] Univ Hosp, Montpellier, France.
   [Bousquet, Jean; Bedbrook, Anna; Onorato, Gabrielle L.] MACVIA France, Montpellier, France.
   [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium.
   [Agache, Ioana] Transylvania Univ Brasov, Brasov, Romania.
   [Ansotegui, Ignacio] Hosp Quironsalud Bizkaia, Dept Allergy & Immunol, Erandio, Spain.
   [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Emphysema Ctr, Woolcock Inst Med Res, Glebe, NSW, Australia.
   [Bosnic-Anticevich, Sinthia] Univ Sydney, Sydney Local Hlth Dist, Glebe, NSW, Australia.
   [Canonica, G. Walter] Humanitas Univ, Humanitas Res Hosp, Personalized Med Clin Asthma & Allergy, Milan, Italy.
   [Canonica, G. Walter] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy.
   [Chivato, Tomas] Univ CEU San Pablo, Sch Med, Madrid, Spain.
   [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil.
   [Cruz, Alvaro A.] WHO GARD Planning Grp, Salvador, BA, Brazil.
   [Czarlewski, Wienia] Med Consulting Czarlewski Levallois & MASK Air, Montpellier, France.
   [Del Giacco, Stefano] Univ Cagliari, Univ Hosp Duilio Casula, Dept Med Sci & Publ Hlth, Unit Allergy & Clin Immunol, Cagliari, Italy.
   [Du, Hui] Tongji Med Univ, Dept Resp Med, Wuhan, Peoples R China.
   [Fonseca, Joao A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, Porto, Portugal.
   [Fonseca, Joao A.] Inst CUF Porto, Allergy Unit, Porto, Portugal.
   [Fonseca, Joao A.] Hosp CUF Porto, Porto, Portugal.
   [Fonseca, Joao A.] Univ Porto, Fac Med, Hlth Informat & Decis Sci Dept CIDES, Porto, Portugal.
   [Fonseca, Joao A.] Univ Porto, Fac Med, Porto, Portugal.
   [Gao, Yadong] Wuhan Univ, Dept Allergol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Haahtela, Tari; Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
   [Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria.
   [Ivancevich, Juan-Carlos] Clin Santa Isabel, Serv Alergia & Immunol, Buenos Aires, DF, Argentina.
   [Khaltaev, Nikolai] GARD Chairman, Geneva, Switzerland.
   [Knol, Edward F.] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands.
   [Knol, Edward F.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.
   [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland.
   [Larenas-Linnemann, Desiree] Med Sur Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico.
   [Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
   [Melen, Erik] Sachs Childrens Hosp, Stockholm, Sweden.
   [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain.
   [Mullol, Joaquim] Hosp Clin Barcelona, Smell Clin, Barcelona, Spain.
   [Mullol, Joaquim] Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
   [Naclerio, Robert] Johns Hopkins Sch Med, Baltimore, MD USA.
   [Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan.
   [Okamoto, Yoshitaka] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan.
   [O'Mahony, Liam] Univ Coll Cork, Dept Med, APC Microbiome Ireland, Cork, Ireland.
   [O'Mahony, Liam] Univ Coll Cork, Dept Microbiol, APC Microbiome Ireland, Cork, Ireland.
   [Papadopoulos, Nikos G.] Univ Manchester, Royal Manchester Childrens Hosp, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Tokyo, Japan.
   [Pfaar, Oliver] Phillipps Univ Marburg, Univ Hosp Marburg, Dept Otorhinolaryngol Head & Neck Surg, Sect Rhinol & Allergy, Marburg, Germany.
   [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland.
   [Schwarze, Jurgen] Univ Edinburgh, Ctr Inflammat Res Child Life & Hlth, Edinburgh, Midlothian, Scotland.
   [Shamji, Mohamed H.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, Natl Heart & Lung Inst, Immunomodulat & Tolerance Grp,Allergy & Clin Immu, London, England.
   [Ventura, Maria Teresa] Univ Bari, Unit Geriatr Immunoallergol, Med Sch, Bari, Italy.
   [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Fac Med, Vilnius, Lithuania.
   [Valiulis, Arunas] Vilnius Univ, Inst Hlth Sci, Vilnius, Lithuania.
   [Valiulis, Arunas] European Acad Paediat EAP UEMS SP, Brussels, Belgium.
   [Yorgancioglu, Arzu] Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey.
   [Matricardi, Paolo] Charite Univ Med Berlin, Berlin, Germany.
   [Zuberbier, Torsten] Charite Univ Med Berlin, Freie Univ Berlin, Humboldt Univ Berlin, Berlin, Germany.
   [Zuberbier, Torsten] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, GA2LEN, Berlin, Germany.
RP Klimek, L (corresponding author), Ctr Rhinol & Allergol, Wiesbaden, Germany.
EM ludger.klimek@allergiezentrum.org
RI O'Mahony, Liam/AAG-5838-2019; Fonseca, Joao Almeida/B-7562-2008; Yusuf,
   M Osman/AAI-1142-2020; Toppila-Salmi, Sanna/ABF-5840-2020; canonica,
   giorgio walter/ABF-2037-2020
OI O'Mahony, Liam/0000-0003-4705-3583; Fonseca, Joao
   Almeida/0000-0002-0887-8796; Yusuf, M Osman/0000-0002-8067-1204;
   Toppila-Salmi, Sanna/0000-0003-0890-6686; VENTURA, Maria
   Teresa/0000-0002-2637-4583
CR Ahmetaj L, 2018, TURKISH J IMMUNOL, V45, P323
   Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963
   Asaria M, 2018, ALLERGY, V73, P269, DOI 10.1111/all.13254
   Blumchen K, 2019, J ALLER CL IMM-PRACT, V7, P479, DOI 10.1016/j.jaip.2018.10.048
   Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu DK, 2019, LANCET, V393, P2222, DOI 10.1016/S0140-6736(19)30420-9
   Dhami S, 2017, ALLERGY, V72, P1825, DOI 10.1111/all.13208
   Dhami S, 2017, ALLERGY, V72, P1597, DOI 10.1111/all.13201
   Dhami S, 2017, ALLERGY, V72, P342, DOI 10.1111/all.13077
   DONG X, 2020, ALLERGY 0406, DOI DOI 10.1111/ALL.14289
   Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973
   Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iemoli E, 2016, ALLERGY, V71, P412, DOI 10.1111/all.12713
   Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919
   Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004
   Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300
   Jutel M, 2013, ALLERGOL INT, V62, P425, DOI 10.2332/allergolint.13-RAI-0608
   Klimek L, 2019, ALLERGO J INT, V28, P78
   Klimek L, 2019, ALLERGO J INT, V28, P107
   Klimek L, 2018, ALLERGO J, V27, P22, DOI 10.1007/s40629-018-0074-y
   Krohn IK, 2018, ALLERGY, V73, P837, DOI 10.1111/all.13340
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270
   Nurmatov U, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0159-6
   Pfaar O, 2019, ALLERGY, V74, P3, DOI 10.1111/all.14077
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Queisser A, 2017, ONCOGENE, V36, P1573, DOI 10.1038/onc.2016.325
   Reuter S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007595
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ruan Q, 2020, INTENSIVE CARE MED
   Storni F, 2020, J ALLERGY CLIN IMMUN, V145, P1240, DOI 10.1016/j.jaci.2019.12.007
   WHO, REP WHO CHIN JOINT M
   Woehlk C, 2018, ANN ALLERG ASTHMA IM, V120, P169, DOI 10.1016/j.anai.2017.11.015
   Xiang J., 2020, EVALUATION ENZYME LI
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 20
Z9 20
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUL
PY 2020
VL 75
IS 7
BP 1546
EP 1554
DI 10.1111/all.14336
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA NE8FB
UT WOS:000562838200001
PM 32329930
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, JJ
   Dong, X
   Cao, YY
   Yuan, YD
   Yang, YB
   Yan, YQ
   Akdis, CA
   Gao, YD
AF Zhang, Jin-jin
   Dong, Xiang
   Cao, Yi-yuan
   Yuan, Ya-dong
   Yang, Yi-bin
   Yan, You-qin
   Akdis, Cezmi A.
   Gao, Ya-dong
TI Clinical characteristics of 140 patients infected with SARS-CoV-2 in
   Wuhan, China
SO ALLERGY
LA English
DT Article
DE allergy; COVID-19; eosinophil; risk factor; SARS-CoV-2
ID ALLERGIC SENSITIZATION; EARLY-LIFE; ASTHMA; RHINOVIRUS; VIRUS; SARS;
   PREVALENCE; RESPONSES; BACTERIA; RECEPTOR
AB BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the clinical characteristic and allergy status of patients infected with SARS-CoV-2.
   MethodsElectronic medical records including demographics, clinical manifestation, comorbidities, laboratory data, and radiological materials of 140 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection, were extracted and analyzed.
   ResultsAn approximately 1:1 ratio of male (50.7%) and female COVID-19 patients was found, with an overall median age of 57.0 years. All patients were community-acquired cases. Fever (91.7%), cough (75.0%), fatigue (75.0%), and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities. Drug hypersensitivity (11.4%) and urticaria (1.4%) were self-reported by several patients. Asthma or other allergic diseases were not reported by any of the patients. Chronic obstructive pulmonary disease (COPD, 1.4%) patients and current smokers (1.4%) were rare. Bilateral ground-glass or patchy opacity (89.6%) was the most common sign of radiological finding. Lymphopenia (75.4%) and eosinopenia (52.9%) were observed in most patients. Blood eosinophil counts correlate positively with lymphocyte counts in severe (r = .486, P < .001) and nonsevere (r = .469, P < .001) patients after hospital admission. Significantly higher levels of D-dimer, C-reactive protein, and procalcitonin were associated with severe patients compared to nonsevere patients (all P < .001).
   ConclusionDetailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis. Allergic diseases, asthma, and COPD are not risk factors for SARS-CoV-2 infection. Older age, high number of comorbidities, and more prominent laboratory abnormalities were associated with severe patients.
C1 [Zhang, Jin-jin; Dong, Xiang; Gao, Ya-dong] Wuhan Univ, Dept Allergol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Cao, Yi-yuan] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Yuan, Ya-dong] Hebei Med Univ, Dept Resp & Crit Care Med, Hosp 2, Shijiazhuang, Hebei, Peoples R China.
   [Yang, Yi-bin] Wuhan Univ, Dept Resp & Crit Care Med, Zhongnan Hosp, Wuhan, Peoples R China.
   [Yan, You-qin] 7 Hosp Wuhan, Dept Infect Dis, Wuhan, Peoples R China.
   [Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.
RP Gao, YD (corresponding author), Wuhan Univ, Dept Allergol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
EM gaoyadong@whu.edu.cn
OI Dong, Xiang/0000-0002-5241-4307
CR Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005
   Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Erdem SB, 2018, ALLERGOL IMMUNOPATH, V46, P119, DOI 10.1016/j.aller.2017.04.003
   Gavala ML, 2013, CURR ALLERGY ASTHM R, V13, P298, DOI 10.1007/s11882-013-0344-1
   Gavala ML, 2011, IMMUNOL REV, V242, P69, DOI 10.1111/j.1600-065X.2011.01031.x
   Gilles S, 2020, ALLERGY, V75, P576, DOI 10.1111/all.14047
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Greenberg SB, 2016, SEMIN RESP CRIT CARE, V37, P555, DOI 10.1055/s-0036-1584797
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Han MY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120682
   Holt PG, 2012, CURR OPIN ALLERGY CL, V12, P151, DOI 10.1097/ACI.0b013e3283520166
   [胡盛寿 Hu Shengshou], 2019, [中国循环杂志, Chinese Circulation Journal], V34, P209
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X
   Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Kurai D, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00293
   Leino A, 2019, ALLERGY, V74, P518, DOI 10.1111/all.13593
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu M, 2019, DIABETES METAB, V45, P286, DOI 10.1016/j.diabet.2018.08.008
   Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x
   Rambaut A, PRELIMINARY PHYLOGEN
   Rowe RK, 2015, IMMUNOL ALLERGY CLIN, V35, P115, DOI 10.1016/j.iac.2014.09.012
   Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049
   Seys LJM, 2018, CLIN INFECT DIS, V66, P45, DOI 10.1093/cid/cix741
   Svensson A, 2012, SCAND J IMMUNOL, V75, P409, DOI 10.1111/j.1365-3083.2012.02676.x
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Wang C, 2018, LANCET, V391, P1706, DOI [10.1016/S0140-6736(18)30841-9, 10.1016/s0140-6736(18)30841-9]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang XD, 2016, ALLERGY, V71, P1170, DOI 10.1111/all.12874
   World Health Organization, COR DIS COVID 2019 S
   World Health Organization, 2017, WHO REP GLOB TOB EP
   Wu YH, 2020, ALLERGY, V75, P818, DOI 10.1111/all.14091
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y
NR 40
TC 738
Z9 753
U1 28
U2 55
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUL
PY 2020
VL 75
IS 7
BP 1730
EP 1741
DI 10.1111/all.14238
PG 12
WC Allergy; Immunology
SC Allergy; Immunology
GA NE8EB
UT WOS:000562835500016
PM 32077115
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Cuttler, JM
   Bevelacqua, JJ
   Mortazavi, SMJ
AF Cuttler, Jerry M.
   Bevelacqua, Joseph J.
   Mortazavi, S. M. J.
TI Unethical not to Investigate Radiotherapy for COVID-19
SO DOSE-RESPONSE
LA English
DT Article
DE low dose radiation; lung radiotherapy; COVID-19; pneumonia
AB The primum non nocere letter by Boon et al. urged caution and careful examination of the evidence and logistics of low-dose radiotherapy in COVID-19 patients. This is exactly what was requested in March and what has occurred since late April 2020 when the first phase I/II clinical trial was approved at the Winship Cancer Institute, Emory University Hospital. The preprint of day-7 interim results by the investigators concluded, "In a small pilot trial of 5 oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity or worsening the cytokine storm. Low-dose whole-lung radiation appears to be safe, shows early promise of efficacy, and warrants larger prospective trials." Preliminary results from another clinical trial gave similar results. In conclusion, the authors believe it would be unethical not to investigate radiotherapy as a potential remedy against COVID-19 induced pneumonia
C1 [Cuttler, Jerry M.] Cuttler & Associates, 1104-11 Townsgate Dr, Vaughan, ON L4J 8G4, Canada.
   [Bevelacqua, Joseph J.] Bevelacqua Resources, Washington, DC USA.
   [Mortazavi, S. M. J.] Shiraz Univ Med Sci, Sch Med, Med Phys & Engn Dept, Shiraz, Iran.
RP Cuttler, JM (corresponding author), Cuttler & Associates, 1104-11 Townsgate Dr, Vaughan, ON L4J 8G4, Canada.
EM jerrycuttler@rogers.com
OI Cuttler, Jerry/0000-0001-9532-9818
CR Ameri A, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-40507/v1, DOI 10.21203/RS.3.RS-40507/V1]
   Boon IS, 2020, RADIOTHER ONCOL, V149, P236, DOI 10.1016/j.radonc.2020.05.046
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Centers for Disease Control and Prevention, 2014, RAD YOUR HLTH NRI GE
   Cuttler JM, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325819895739
   Hess CB, 2020, LOW DOES WHOLE LUNG, DOI [10.1101/2020.06.03.20116988v1, DOI 10.1101/2020.06.03.20116988V1]
   Johns Hopkins University, COVID 19 DASHB CSSE
   National Cancer Institute, 2003, NAS RAD IRR NRI CANC
   Tubiana Maurice, 2011, Health Phys, V100, P296, DOI 10.1097/HP.0b013e31820a1b35
   US National Library of Medicine . ClinicalTrials.gov, 2020, SEARCH CRIT COVID 19
NR 10
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1559-3258
J9 DOSE-RESPONSE
JI Dose-Response
PD JUL
PY 2020
VL 18
IS 3
AR 1559325820950104
DI 10.1177/1559325820950104
PG 2
WC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
SC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
GA NF3RD
UT WOS:000563214700001
PM 32868978
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Battistoni, A
   Volpe, M
AF Battistoni, Allegra
   Volpe, Massimo
TI Might renin-angiotensin system blockers play a role in the COVID-19
   pandemic?
SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
LA English
DT Article
DE SARS-CoV-2; Hypertension; RAS system
ID CONVERTING ENZYME 2; ACE2; CORONAVIRUS; RECEPTOR; PNEUMONIA
AB Since December 2019, a new coronavirus, named SARS-CoV-2, has spread globally, affecting >200 000 people worldwide with the so-called COVID-19 disease. The scientific community is actively and constantly working to identify the mechanisms involved in the diffusion of this virus and the pathogenesis of the infection, with its most frequent and severe complication, namely interstitial pneumonia. To date, SARS-CoV-2 is known to enter the host cells via the angiotensin-converting enzyme 2 protein. For this reason, the hypothesis that drugs capable of increasing the expression of this protein may have a role in the spread of the virus and in the symptomatology of affected patients has taken hold. The purpose of this Editorial is to briefly show the evidence currently available in this regard and to provide ideas for future research.
C1 [Battistoni, Allegra; Volpe, Massimo] Sapienza Univ Rome, Fac Med & Psychol, Dept Clin & Mol Med, Rome, Italy.
   [Volpe, Massimo] IRCCS Neuromed, Pozzilli, Italy.
RP Battistoni, A (corresponding author), Sapienza Univ Rome, Fac Med & Psychol, Dept Clin & Mol Med, Rome, Italy.
EM allegra.battistoni@uniroma1.it
OI Volpe, Massimo/0000-0002-9642-8380
CR Abassi Z, 2020, AM J PHYSIOL-HEART C, V318, pH1080, DOI 10.1152/ajpheart.00215.2020
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cole-Jeffrey CT, 2015, J CARDIOVASC PHARM, V66, P540, DOI 10.1097/FJC.0000000000000307
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Jakovac H, 2020, AM J PHYSIOL-LUNG C, V318, pL1025, DOI 10.1152/ajplung.00119.2020
   Karram T, 2005, AM J PHYSIOL-HEART C, V289, pH1351, DOI 10.1152/ajpheart.01186.2004
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Li YC, 2015, SHOCK, V43, P395, DOI 10.1097/SHK.0000000000000302
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Phadke M.A., 2020, BMJ-BRIT MED J, V368, pm406, DOI [10.1136/bmj.m406, DOI 10.1136/BMJ.M406]
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 8
Z9 8
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2055-6837
EI 2055-6845
J9 EUR HEART J-CARD PHA
JI EUR. HEART J.-CARDIOVASC. PHARMACOTHER.
PD JUL
PY 2020
VL 6
IS 4
BP 248
EP 251
DI 10.1093/ehjcvp/pvaa030
PG 4
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA NE1QR
UT WOS:000562372100007
PM 32286607
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Castiglione, V
   Chiriaco, M
   Emdin, M
   Taddei, S
   Vergaro, G
AF Castiglione, Vincenzo
   Chiriaco, Martina
   Emdin, Michele
   Taddei, Stefano
   Vergaro, Giuseppe
TI Statin therapy in COVID-19 infection
SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
LA English
DT Letter
C1 [Castiglione, Vincenzo; Chiriaco, Martina; Emdin, Michele; Vergaro, Giuseppe] Scuola Super Sant Anna, Inst Life Sci, Pisa, Italy.
   [Chiriaco, Martina; Taddei, Stefano] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Emdin, Michele; Vergaro, Giuseppe] Fdn Toscana Gabriele Monasterio, Pisa, Italy.
RP Vergaro, G (corresponding author), Scuola Super Sant Anna, Piazza Martiri Liberta 33, I-56127 Pisa, Italy.
EM vergaro@ftgm.it
OI Chiriaco, Martina/0000-0003-0174-4549; Castiglione,
   Vincenzo/0000-0002-9285-2328
CR Chansrichavala P, 2009, ASIAN PAC J ALLERGY, V27, P49
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Eckard AR, 2015, CURR HIV-AIDS REP, V12, P305, DOI 10.1007/s11904-015-0273-9
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fedson DS, 2013, ANTIVIR RES, V99, P417, DOI 10.1016/j.antiviral.2013.06.018
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Pertzov B, 2019, CLIN MICROBIOL INFEC, V25, P280, DOI 10.1016/j.cmi.2018.11.003
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Yuan X, 2014, BIOCHEM BIOPH RES CO, V446, P292, DOI 10.1016/j.bbrc.2014.02.091
   Zeiser R, 2018, IMMUNOLOGY, V154, P69, DOI 10.1111/imm.12902
NR 10
TC 25
Z9 24
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2055-6837
EI 2055-6845
J9 EUR HEART J-CARD PHA
JI EUR. HEART J.-CARDIOVASC. PHARMACOTHER.
PD JUL
PY 2020
VL 6
IS 4
BP 258
EP 259
DI 10.1093/ehjcvp/pvaa042
PG 2
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA NE1QR
UT WOS:000562372100012
PM 32347925
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bauernschmitt, R
   Gabriel, P
   Gottardi, R
   Sodian, R
AF Bauernschmitt, Robert
   Gabriel, Philip
   Gottardi, Roman
   Sodian, Ralf
TI Valve-in-valve transcatheter aortic valve replacement in a young patient
   with a suspected COVID-19 infection: a surgical dilemma in the era of
   the COVID-19 pandemic
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article
DE COVID-19; Valve in valve; TAVI
AB We report on a case of a 57-year-old male patient, who underwent full root replacement in 2005 and now presented with high grade aortic insufficiency. On admission, the patient underwent a computed tomography scan which demonstrated interstitial infiltration in the left lung, highly suspicious for a COVID-19 infection that could not be confirmed by reverse transcription polymerase chain reaction (RT-PCR) testing. As there usually is a delay between infection and positive RT-PCR test results, the initial decision was to perform additional testing. However, the patient deteriorated quickly in spite of optimal medical therapy making urgent aortic valve replacement necessary. We decided to perform transcatheter aortic valve replacement to avoid cardiopulmonary bypass with shorter operative times, presumably shorter ventilation times and duration of intensive care unit stay, and thus a lesser risk for pulmonary complications.
C1 [Bauernschmitt, Robert; Gottardi, Roman; Sodian, Ralf] MediClin Heart Inst Lahr Baden, Dept Cardiovasc & Thorac Surg, Lahr, Germany.
   [Gabriel, Philip] MediClin Heart Inst Lahr Baden, Dept Anesthesiol & Crit Care Med, Lahr, Germany.
RP Gottardi, R (corresponding author), MediClin Heart Inst Lahr Baden, Dept Cardiac Surg, Hohbergweg 2, D-77933 Lahr, Germany.
EM roman.gottardi@gmail.com
OI Gottardi, Roman/0000-0001-9716-3655
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Hani C, 2020, DIAGN INTERV IMAG, V101, P263, DOI 10.1016/j.diii.2020.03.014
   Sondergaard L, 2019, J AM COLL CARDIOL, V73, P546, DOI 10.1016/j.jacc.2018.10.083
NR 3
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD JUL
PY 2020
VL 58
IS 1
BP 188
EP 189
DI 10.1093/ejcts/ezaa193
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA NE2DI
UT WOS:000562407200024
PM 32510155
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Stroppa, EM
   Toscani, I
   Citterio, C
   Anselmi, E
   Zaffignani, E
   Codeluppi, M
   Cavanna, L
AF Stroppa, Elisa Maria
   Toscani, Ilaria
   Citterio, Chiara
   Anselmi, Elisa
   Zaffignani, Elena
   Codeluppi, Mauro
   Cavanna, Luigi
TI Coronavirus disease-2019 in cancer patients. A report of the first 25
   cancer patients in a western country (Italy)
SO FUTURE ONCOLOGY
LA English
DT Article
DE cancer patients and COVID-19; cobicistat; darunavir; hydroxychloroquine;
   infection and cancer; lopinavir; oncology and coronavirus; ritonavir
AB Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: 25 cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: 20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.
C1 [Stroppa, Elisa Maria; Toscani, Ilaria; Citterio, Chiara; Anselmi, Elisa; Zaffignani, Elena; Cavanna, Luigi] Piacenza Gen Hosp, Oncol & Hematol Dept, Oncol Unit, Via Taverna 49, I-29121 Piacenza, Italy.
   [Codeluppi, Mauro] Piacenza Gen Hosp, Infect Dis Unit, Via Taverna 49, I-29121 Piacenza, Italy.
RP Cavanna, L (corresponding author), Piacenza Gen Hosp, Oncol & Hematol Dept, Oncol Unit, Via Taverna 49, I-29121 Piacenza, Italy.
EM l.cavanna@ausl.pc.it
OI CAVANNA, LUIGI/0000-0002-0303-3778
CR [Anonymous], 2020, TIME
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2020, INT GUID COLL HANDL
   Cifre I, 2020, PAP PHYS-LA PLATA, V12, DOI 10.4279/PIP.120003
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luzzani A, 2003, CRIT CARE MED, V31, P1737, DOI 10.1097/01.CCM.0000063440.19188.ED
   National Health Commission, 2020, GUID DIAGN TREATM NO
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Sica A, 2017, J AUTOIMMUN, V85, P117, DOI 10.1016/j.jaut.2017.07.010
   Silverstein WK, 2020, LANCET, V395, P734, DOI 10.1016/S0140-6736(20)30370-6
   SIMIT, 2020, VAD CUR PERS CON MAL
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 19
TC 13
Z9 13
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD JUL
PY 2020
VL 16
IS 20
BP 1425
EP 1432
DI 10.2217/fon-2020-0369
PG 8
WC Oncology
SC Oncology
GA NC6CI
UT WOS:000561303800004
PM 32403946
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Assi, T
   Ibrahim, N
   Abboud, RMK
   Kattan, C
   Rassy, E
   Nemr, E
   Kattan, J
AF Assi, Tarek
   Ibrahim, Nathalie
   Abboud, Rita-Maria K.
   Kattan, Clarisse
   Rassy, Elie
   Nemr, Elie
   Kattan, Joseph
TI The management of patients with metastatic prostate cancer during the
   COVID-19 pandemic
SO FUTURE ONCOLOGY
LA English
DT Article
DE castrate resistant; coronavirus; COVID-19; hormone sensitive;
   immunosuppression; metastatic; prostate cancer
ID MITOXANTRONE PLUS PREDNISONE; ANDROGEN-DEPRIVATION THERAPY; ABIRATERONE
   ACETATE; DOUBLE-BLIND; SURVIVAL ANALYSIS; OPEN-LABEL; DOCETAXEL;
   ENZALUTAMIDE; CABAZITAXEL; PHASE-3
AB During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer.
C1 [Assi, Tarek; Ibrahim, Nathalie; Abboud, Rita-Maria K.; Kattan, Clarisse; Rassy, Elie; Kattan, Joseph] St Joseph Univ, Dept Hematol Oncol, Fac Med, BP 17-5208, Beirut, Lebanon.
   [Nemr, Elie] St Joseph Univ, Dept Urol, Fac Med, BP 17-5208, Beirut, Lebanon.
RP Rassy, E (corresponding author), St Joseph Univ, Dept Hematol Oncol, Fac Med, BP 17-5208, Beirut, Lebanon.
EM elie.rassy@hotmail.com
OI Nemr, Elie/0000-0003-0409-1643; Rassy, Elie/0000-0002-7906-0991
CR Akaza H, 2009, CANCER, V115, P3437, DOI 10.1002/cncr.24395
   Akladios C, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101729
   Aoun F, 2017, FUTURE ONCOL, V13, P2785, DOI 10.2217/fon-2017-0445
   Banna G, 2020, ESMO OPEN, V5, P2, DOI DOI 10.1136/ESM00-PEN-2020-00076564
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
   Bitar N, 2020, FUTURE ONCOL, V16, P615, DOI 10.2217/fon-2020-0252
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307
   Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
   de Wit R, 2019, NEW ENGL J MED, V381, P2506, DOI 10.1056/NEJMoa1911206
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237
   Duga S., 2020, IMPACT ANTI ANDROGEN, DOI [10.1101/2020.04.20.20068056, DOI 10.1101/2020.04.20.20068056]
   Eisenberger M, 2017, J CLIN ONCOL, V35, P3198, DOI 10.1200/JCO.2016.72.1076
   EMA, 2020, GUID SPONS MAN CLIN
   Fizazi K, 2019, LANCET ONCOL, V20, P686, DOI 10.1016/S1470-2045(19)30082-8
   Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gravis G, 2013, LANCET ONCOL, V14, P149, DOI 10.1016/S1470-2045(12)70560-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
   Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
   Khan MM, 2016, IMMUNOPHARMACOLOGY, P131, DOI [10.1007/978-3-319-30273-7_4, DOI 10.1007/978-3-319-30273-7_4]
   Kourie HR, 2015, J BONE ONCOL, V4, P77, DOI 10.1016/j.jbo.2015.09.001
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Parker CC, 2018, LANCET, V392, P2353, DOI 10.1016/S0140-6736(18)32486-3
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Rassy E, 2020, WHAT ONCOLOGIST NEED, DOI [10.2217/fon-2020-0312, DOI 10.2217/FON-2020-0312]
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   SMALL EJ, 1994, UROLOGY, V43, P408, DOI 10.1016/0090-4295(94)90092-2
   Sweeney C, 2016, ANN ONCOL S, V27, P243
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Sydes MR, 2018, ANN ONCOL, V29, P1235, DOI 10.1093/annonc/mdy072
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 101 WHO
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
   Zhang H-Y, 2020, MULTICENTRE STUDY 20
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 54
TC 1
Z9 1
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD JUL
PY 2020
VL 16
IS 20
BP 1455
EP 1462
DI 10.2217/fon-2020-0361
PG 8
WC Oncology
SC Oncology
GA NC6CI
UT WOS:000561303800007
PM 32412310
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hu, XS
   Hu, CH
   Zhong, P
   Wen, YJ
   Yang, Y
   Chen, J
   Chen, XY
AF Hu, Xingsheng
   Hu, Chunhong
   Zhong, Ping
   Wen, Yajing
   Yang, Yong
   Chen, Juan
   Chen, Xiangyu
TI Finding the Best Antiviral Regimen for COVID-19: A Double-Center
   Retrospective Cohort Study of 207 Cases in Hunan, China
SO DOSE-RESPONSE
LA English
DT Article
DE COVID-19; antiviral drugs; virus clearance time; length of
   hospitalization
ID RESPIRATORY SYNDROME; THERAPY; SARS
AB Objective: To compare the efficacy of 3/4-drugs' group with 1-drug's or 2-drugs' groups in coronavirus disease 2019 (COVID-19). Methods: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs. Results: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug's or 2-drugs' groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug's or 2-drugs' groups (both were 9 days) (P < 0.001). The patients' discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug's or 2 drugs' group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05). Conclusion: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.
C1 [Hu, Xingsheng; Hu, Chunhong] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China.
   [Zhong, Ping] Nanchong Cent Hosp, Dept Dermatol, Nanchong, Peoples R China.
   [Wen, Yajing] Chengdu Med Coll, Dept Clin Med, Chengdu, Peoples R China.
   [Yang, Yong] Nanhua Univ, Changsha Cent Hosp, Dept Intens Care Unit, Changsha, Peoples R China.
   [Chen, Juan] Cent Hosp Xiangtan, Dept Radiol, Xiangtan, Peoples R China.
   [Chen, Xiangyu] Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha 410011, Hunan, Peoples R China.
RP Chen, XY (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Radiol, Changsha 410011, Hunan, Peoples R China.
EM chenxiangyu@csu.edu.cn
OI Chen, xiangyu/0000-0002-4233-8822
CR [Anonymous], 2020, BACK OBTAINING URGEN
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2019, CLIN INFECT DIS, V70, P1837, DOI DOI 10.1093/cid/ciz544
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chinese Government, 2020, DIAGN TREATM PROT NO
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Kiselev OI, 2015, TERAPEVT ARKH, V87, P88, DOI 10.17116/terarkh201587188-96
   Li M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-8
   Li YP, 2020, INT J PROD RES, DOI 10.1080/00207543.2020.1788736
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Organization WH, 2019, COR DIS COVID 19 TEC
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Saha A, 2020, INT J MOD PHYS C, V31, DOI 10.1142/S012918312050059X
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tang W., 2020, HYDROXYCHLOROQUINE P
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhuang MW, 2020, INFECT J MED VIROL, DOI [10.1002/jmv.26139, DOI 10.1002/JMV.26139]
   缪晓辉, 2004, [中华传染病杂志, Chinese Journal of Infections Diseases], V22, P66
NR 23
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1559-3258
J9 DOSE-RESPONSE
JI Dose-Response
PD JUL
PY 2020
VL 18
IS 3
AR 1559325820949740
DI 10.1177/1559325820949740
PG 11
WC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
SC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
GA ND1KL
UT WOS:000561664800001
PM 32855629
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nicholls, SJ
   Nelson, M
   Astley, C
   Briffa, T
   Brown, A
   Clark, R
   Colquhoun, D
   Gallagher, R
   Hare, DL
   Inglis, S
   Jelinek, M
   O'Neil, A
   Tirimacco, R
   Vale, M
   Redfern, J
AF Nicholls, Stephen J.
   Nelson, Mark
   Astley, Carolyn
   Briffa, Tom
   Brown, Alex
   Clark, Robyn
   Colquhoun, David
   Gallagher, Robyn
   Hare, David L.
   Inglis, Sally
   Jelinek, Michael
   O'Neil, Adrienne
   Tirimacco, Rosy
   Vale, Margarite
   Redfern, Julie
TI Optimising Secondary Prevention and Cardiac Rehabilitation for
   Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A
   Position Statement From the Cardiac Society of Australia and New Zealand
   (CSANZ)
SO HEART LUNG AND CIRCULATION
LA English
DT Article
DE COVID-19; Secondary prevention; Cardiac rehabilitation; Atherosclerosis;
   Cardiovascular disease; Telehealth
ID NATIONAL HEART FOUNDATION; CLINICAL GUIDELINES; CORONARY; DEPRESSION;
   MANAGEMENT; CARE
AB Background The coronavirus disease 2019 (COVID-19) pandemic has introduced a major disruption to the delivery of routine health care across the world. This provides challenges for the use of secondary prevention measures in patients with established atherosclerotic cardiovascular disease (CVD). The aim of this Position Statement is to review the implications for effective delivery of secondary prevention strategies during the COVID-19 pandemic.
   Challenges The COVID-19 pandemic has introduced limitations for many patients to access standard health services such as visits to health care professionals, medications, imaging and blood tests as well as attendance at cardiac rehabilitation. In addition, the pandemic is having an impact on lifestyle habits and mental health. Taken together, this has the potential to adversely impact the ability of practitioners and patients to adhere to treatment guidelines for the prevention of recurrent cardiovascular events.
   Recommendations Every effort should be made to deliver safe, ongoing access to health care professionals and the use of evidenced based therapies in individuals with CVD. An increase in use of a range of electronic health platforms has the potential to transform secondary prevention. Integrating research programs that evaluate the utility of these approaches may provide important insights into how to develop more optimal approaches to secondary prevention beyond the pandemic.
C1 [Nicholls, Stephen J.] Monash Univ, Melbourne, Vic, Australia.
   [Nelson, Mark] Univ Tasmania, Hobart, Tas, Australia.
   [Astley, Carolyn; Clark, Robyn] Flinders Univ S Australia, Adelaide, SA, Australia.
   [Briffa, Tom] Univ Western Australia, Perth, WA, Australia.
   [Brown, Alex] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Brown, Alex] Univ Adelaide, Adelaide, SA, Australia.
   [Colquhoun, David] Univ Queensland, Brisbane, Qld, Australia.
   [Gallagher, Robyn; Redfern, Julie] Univ Sydney, Sydney, NSW, Australia.
   [Hare, David L.; Jelinek, Michael; Vale, Margarite] Univ Melbourne, Melbourne, Vic, Australia.
   [Hare, David L.] Austin Hlth, Melbourne, Vic, Australia.
   [Inglis, Sally] Univ Technol Sydney, Sydney, NSW, Australia.
   [Jelinek, Michael] St Vincents Hosp, Melbourne, Vic, Australia.
   [O'Neil, Adrienne] Deakin Univ, Melbourne, Vic, Australia.
   [Tirimacco, Rosy] Country Hlth SA Local Hlth Network, Adelaide, SA, Australia.
   [Vale, Margarite] COACH Program, Melbourne, Vic, Australia.
RP Nicholls, SJ (corresponding author), Monash Cardiovasc Res Ctr, 246 Clayton Rd, Clayton, Vic 3168, Australia.
EM stephen.nicholls@monash.edu
CR Alharbi M, 2016, EUR J PREV CARDIOL, V23, P1476, DOI 10.1177/2047487316634883
   Bagot KL, 2015, J TELEMED TELECARE, V21, P443, DOI 10.1177/1357633X15610722
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Briffa TG, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003813
   Chew DP, 2016, HEART LUNG CIRC, V25, P895, DOI 10.1016/j.hlc.2016.06.789
   Chew DP, 2016, MED J AUSTRALIA, V205, P128, DOI 10.5694/mja16.00368
   Chow CK, 2015, JAMA-J AM MED ASSOC, V314, P1255, DOI 10.1001/jama.2015.10945
   Colquhoun DM, 2013, MED J AUSTRALIA, V198, P483, DOI 10.5694/mja13.10153
   Deshmukh A, 2012, AM HEART J, V164, P66, DOI 10.1016/j.ahj.2012.03.020
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fox KAA, 2020, NAT REV CARDIOL, V17, P9, DOI 10.1038/s41569-019-0233-y
   Gandhi S, 2017, CAN J CARDIOL, V33, P219, DOI 10.1016/j.cjca.2016.08.017
   Grant PJ, 2019, EUR HEART J, V40, P3215, DOI 10.1093/eurheartj/ehz687
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hare DL, 2014, EUR HEART J, V35, P1365, DOI 10.1093/eurheartj/eht462
   Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5
   Jin K, 2019, EUR J CARDIOVASC NUR, V18, P260, DOI 10.1177/1474515119826510
   Jordan HT, 2011, PREV MED, V53, P370, DOI 10.1016/j.ypmed.2011.10.014
   Laviano A, 2020, NUTRITION
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Ma WQ, 2019, CORONARY ARTERY DIS, V30, P367, DOI 10.1097/MCA.0000000000000711
   Neubeck L, 2015, NAT REV CARDIOL, V12, P350, DOI 10.1038/nrcardio.2015.34
   O'Neil A, 2019, J AFFECT DISORDERS, V247, P73, DOI 10.1016/j.jad.2018.12.078
   O'Neil Adrienne, 2018, Prev Med Rep, V10, P15, DOI 10.1016/j.pmedr.2018.01.006
   Patwardhan P., 2020, BJGP OPEN
   Person B, 2004, EMERG INFECT DIS, V10, P358, DOI 10.3201/eid1002.030750
   Redfern J, 2011, INT J CARDIOL, V146, P1, DOI 10.1016/j.ijcard.2010.08.046
   Santo K, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017540
   Schwamm LH, 2017, CIRCULATION, V135, pE24, DOI 10.1161/CIR.0000000000000475
   Smith SC, 2011, J AM COLL CARDIOL, V58, P2432, DOI 10.1016/j.jacc.2011.10.824
   TAYLOR CB, 1986, J PSYCHOSOM RES, V30, P581, DOI 10.1016/0022-3999(86)90031-0
   Tirimacco R, 2014, GLOB HEART, V9, pe336
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vale MJ, 2003, ARCH INTERN MED, V163, P2775, DOI 10.1001/archinte.163.22.2775
   Varnfield M, 2014, HEART, V100, P1770, DOI 10.1136/heartjnl-2014-305783
   WHO, 2020, 85 WHO
   Xiang YT, 2020, JAMA PSYCHIAT
   Zulkifli NA, 2020, MALAY J PSYCHIAT, V29
NR 38
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1443-9506
EI 1444-2892
J9 HEART LUNG CIRC
JI Heart Lung Circ.
PD JUL
PY 2020
VL 29
IS 7
BP E99
EP E104
DI 10.1016/j.hlc.2020.04.007
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NA7NM
UT WOS:000560003600005
PM 32473781
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhou, D
   Dai, SM
   Tong, Q
AF Zhou, Dan
   Dai, Sheng-Ming
   Tong, Qiang
TI COVID-19: a recommendation to examine the effect of hydroxychloroquine
   in preventing infection and progression
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID ANTIMALARIAL-DRUGS; CHLOROQUINE; INHIBIT; RISK
AB A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.
C1 [Zhou, Dan] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai, Peoples R China.
   [Zhou, Dan] Fudan Univ, Shanghai Pudong Hosp, Ctr Med Res & Innovat, Shanghai, Peoples R China.
   [Dai, Sheng-Ming; Tong, Qiang] Shanghai Jiao Tong Univ, Dept Rheumatol Immunol, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.
RP Tong, Q (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai, Peoples R China.; Tong, Q (corresponding author), Shanghai Jiao Tong Univ, Dept Rheumatol Immunol, Affiliated Peoples Hosp 6, Shanghai, Peoples R China.
EM jasontong1985@outlook.com
OI ZHOU, DAN/0000-0002-2306-3456
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   An J, 2015, J IMMUNOL, V194, P4089, DOI 10.4049/jimmunol.1402793
   Ewald SE, 2008, NATURE, V456, P658, DOI 10.1038/nature07405
   Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J
   Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   Jorge A, 2018, NAT REV RHEUMATOL, V14, P693, DOI 10.1038/s41584-018-0111-8
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Lisney AR, 2017, ANN RHEUM DIS, V76, P1476, DOI 10.1136/annrheumdis-2016-210927
   LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Ruiz-Irastorza G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2764
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vollmer J, 2005, J EXP MED, V202, P1575, DOI 10.1084/jem.20051696
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1393-y
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
NR 24
TC 145
Z9 149
U1 7
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUL
PY 2020
VL 75
IS 7
BP 1667
EP 1670
DI 10.1093/jac/dkaa114
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NE2EX
UT WOS:000562411300002
PM 32196083
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Avataneo, V
   de Nicolo, A
   Cusato, J
   Antonucci, M
   Manca, A
   Palermiti, A
   Waitt, C
   Walimbwa, S
   Lamorde, M
   di Perri, G
   D'Avolio, A
AF Avataneo, Valeria
   de Nicolo, Amedeo
   Cusato, Jessica
   Antonucci, Miriam
   Manca, Alessandra
   Palermiti, Alice
   Waitt, Catriona
   Walimbwa, Stephen
   Lamorde, Mohammed
   di Perri, Giovanni
   D'Avolio, Antonio
TI Development and validation of a UHPLC-MS/MS method for quantification of
   the prodrug remdesivir and its metabolite GS-441524: a tool for clinical
   pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID BLOOD MONONUCLEAR-CELLS; PHOSPHORYLATED-RIBAVIRIN; STANDARD; GS-5734;
   DRUGS
AB Background: Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, following IV administration, remdesivir is rapidly distributed into PBMCs and converted within 2h to the active nucleoside triphosphate form, while GS-441524 is detectable in plasma for up to 24h. Nevertheless, remdesivir pharmacokinetics and pharmacodynamics in humans are still unexplored, highlighting the need for a precise analytical method for remdesivir and GS-441524 quantification.
   Objectives: The validation of a reliable UHPLC-MS/MS method for remdesivir and GS-441524 quantification in human plasma.
   Methods: Remdesivir and GS-441524 standards and quality controls were prepared in plasma from healthy donors. Sample preparation consisted of protein precipitation, followed by dilution and injection into the QSight 220 UHPLC-MS/MS system. Chromatographic separation was obtained through an Acquity HSS T3 1.8 mu m, 2.1x50mm column, with a gradient of water and acetonitrile with 0.05% formic acid. The method was validated using EMA and FDA guidelines.
   Results: Analyte stability has been evaluated and described in detail. The method successfully fulfilled the validation process and it was demonstrated that, when possible, sample thermal inactivation could be a good choice in order to improve biosafety.
   Conclusions: This method represents a useful tool for studying remdesivir and GS-441524 clinical pharmacokinetics, particularly during the current COVID-19 outbreak.
C1 [Avataneo, Valeria; de Nicolo, Amedeo; Cusato, Jessica; Antonucci, Miriam; Manca, Alessandra; Palermiti, Alice; di Perri, Giovanni; D'Avolio, Antonio] Univ Turin, Amedeo di Savoia Hosp, Dept Med Sci, Lab Clin Pharmacol & Pharmacogenet, Turin, Italy.
   [Waitt, Catriona] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Waitt, Catriona; Walimbwa, Stephen; Lamorde, Mohammed] Makerere Univ, Infect Dis Inst, Coll Hlth Sci, POB 22418, Kampala, Uganda.
   [di Perri, Giovanni; D'Avolio, Antonio] CoQua Lab, Turin, Italy.
RP Avataneo, V (corresponding author), Univ Turin, Amedeo di Savoia Hosp, Dept Med Sci, Lab Clin Pharmacol & Pharmacogenet, Turin, Italy.
EM valeria.avataneo@unito.it
RI ; CUSATO, JESSICA/K-8927-2016
OI Avataneo, Valeria/0000-0002-4102-5218; CUSATO,
   JESSICA/0000-0003-1977-9694; De Nicolo, Amedeo/0000-0002-5973-9948
FU European UnionEuropean Union (EU) [RIA2018EF-083]
FX This research is part of the EDCTP2 programme supported by the European
   Union (RIA2018EF-083).
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Agnesod D, 2014, J PHARMACEUT BIOMED, V90, P119, DOI 10.1016/j.jpba.2013.11.027
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Avataneo V, 2019, J PHARMACEUT BIOMED, V166, P40, DOI 10.1016/j.jpba.2018.12.040
   Bixler Sandra L, 2017, Curr Treat Options Infect Dis, V9, P299, DOI 10.1007/s40506-017-0130-z
   D'Avolio A, 2012, J PHARMACEUT BIOMED, V66, P376, DOI 10.1016/j.jpba.2012.03.030
   De Nicolo A, 2017, BIOANALYSIS, V9, P1093, DOI 10.4155/bio-2017-0059
   De Nicolo A, 2017, J PHARMACEUT BIOMED, V142, P279, DOI 10.1016/j.jpba.2017.05.018
   De Nicolo A, 2016, J PHARMACEUT BIOMED, V118, P64, DOI 10.1016/j.jpba.2015.10.017
   EMA, 2016, MED PROD DEV TREATM
   European Medicines Agency (EMA), 2011, GUID BIOAN METH VAL
   Futami J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12748-y
   Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Mice Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), 2013, GUID IND BIOAN METH
   Lindegardh N, 2008, J CHROMATOGR B, V876, P54, DOI 10.1016/j.jchromb.2008.10.021
   Liu X, 2010, EXPERT OPIN DRUG SAF, V9, P743, DOI 10.1517/14740331003767395
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lynch KL, 2016, CLIN CHEM, V62, P24, DOI 10.1373/clinchem.2015.238626
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Punyawudho B, 2016, EXPERT REV CLIN PHAR, V9, P1583, DOI 10.1080/17512433.2016.1235972
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Taylor PJ, 2005, CLIN BIOCHEM, V38, P328, DOI 10.1016/j.clinbiochem.2004.11.007
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHO, 2018, APP 4 AD HOC EXP CON
   Yin X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126864
NR 28
TC 5
Z9 5
U1 12
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUL
PY 2020
VL 75
IS 7
BP 1772
EP 1777
DI 10.1093/jac/dkaa152
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NE2EX
UT WOS:000562411300017
PM 32361744
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Velez, BES
   Meneses, CP
   Felix, M
   Vanegas, E
   Mata, VL
   Castillo, HR
   Alvear, JWO
   Bolona, E
   Posligua, MA
   Bardi, LRL
   Paz, CV
   Cherrez-Ojeda, I
AF Sabando Velez, Brenner Elias
   Plaza Meneses, Carlos
   Felix, Miguel
   Vanegas, Emanuel
   Mata, Valeria L.
   Romero Castillo, Horacio
   Oliveros Alvear, Jorge W.
   Bolona, Enrique
   Alejandra Posligua, Maria
   Layedra Bardi, Luis Renato
   Vera Paz, Carlos
   Cherrez-Ojeda, Ivan
TI A practical approach for the compassionate use of convalescent plasma in
   patients with severe COVID-19 in developing countries
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE coronavirus; COVID-19; developing countries; plasmapheresis;
   convalescent plasma
AB The COVID-19 pandemic has affected 187 countries, representing a global public health problem. The increasing number of critically ill patients and deaths have fueled a desperate search for treatments that can halt the course of the disease. Currently, there are several experimental therapies with demonstrated in vitro activity against COVID-19 used in clinical practice, including hydroxychloroquine, remdesivir, interleukin-6 pathway inhibitors, and convalescent plasma; however, to date no agent has proven efficacy against COVID-19. In the case of convalescent plasma, this therapy consists in obtaining neutralizing antibodies from previously infected individuals by plasmapheresis and administering them to patients with severe disease. Recently, the use of convalescent plasma has shown promising results in preliminary studies, with case series reporting a decrease in temperature, and viral load, as well as improvement in clinical parameters among patients receiving this treatment. However, there are still unmet needs regarding the safety profile, tolerability, dosage, and timing this therapy should be given. Based on this, the objective of our study was to develop and propose a practical approach for the compassionate use of convalescent plasma for the treatment of patients with severe COVID-19, given the constrains and limitations of developing countries. We encourage health professionals in developing countries to use the current evidence and approaches to experimental treatments for patients with COVID-19, adapting them to their conditions, and always based on a thorough risk-benefit evaluation for each patient, and whenever possible to design and promote the much needed research in this field.
C1 [Sabando Velez, Brenner Elias; Plaza Meneses, Carlos; Oliveros Alvear, Jorge W.; Alejandra Posligua, Maria; Layedra Bardi, Luis Renato] Hosp Luis Vernaza, Dept Hematol, Guayaquil, Ecuador.
   [Plaza Meneses, Carlos; Bolona, Enrique] Clin Guayaquil, Guayaquil, Ecuador.
   [Felix, Miguel; Vanegas, Emanuel; Mata, Valeria L.; Vera Paz, Carlos; Cherrez-Ojeda, Ivan] Univ Espiritu Santo, Km 2-5 Via La Puntilla, Samborondon 0901952, Ecuador.
   [Felix, Miguel; Vanegas, Emanuel; Mata, Valeria L.; Vera Paz, Carlos; Cherrez-Ojeda, Ivan] Respiralab, Respiralab Res Grp, Guayaquil, Ecuador.
   [Romero Castillo, Horacio] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Cherrez-Ojeda, I (corresponding author), Univ Espiritu Santo, Km 2-5 Via La Puntilla, Samborondon 0901952, Ecuador.
EM ivancherrez@gmail.com
RI Felix, Miguel/AAF-4228-2019
OI Felix, Miguel/0000-0002-2243-3646
FU Universidad Espiritu Santo
FX Special thanks to Luis Vernaza Hospital, Clinica Guayaquil, and
   Universidad Espiritu Santo for their support in the research and
   development of this manuscript.
CR Accorsi P, 2020, BLOOD TRANSFUS-ITALY, V18, P163, DOI 10.2450/2020.0124-20
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), 2020, COR COVID 19 GLOB CA
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Domanovic D, 2019, BLOOD TRANSFUS-ITALY, V17, P433, DOI 10.2450/2019.0288-19
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   El Universo, 2020, EL UNIVERSO
   European Commission Directorate-General for Health and Food Safety, 2020, EU PROGR COVID 19 CO
   European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), 2017, GUIDE PREPARATION US
   Florescu DF, 2015, CLIN INFECT DIS, V61, P969, DOI 10.1093/cid/civ395
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim AY, 2020, CORONAVIRUS DIS 2019
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Oxford Analytica, 2020, COVID 19 WILL HAV DE
   Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI 10.3345/cep.2020.00493
   Public Health Ministry of Ecuador, 2020, UPD COR CAS EC
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2020, INV COVID 19 CONV PL
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2019, WHO TECH REP SER, V1016, P1
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 0
Z9 0
U1 1
U2 1
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD JUL
PY 2020
VL 14
IS 7
BP 737
EP 741
DI 10.3855/jidc.12827
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NB6YB
UT WOS:000560659400012
PM 32794463
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hafiz, M
   Icksan, AG
   Harlivasari, AD
   Aulia, R
   Susanti, F
   Eldinia, L
AF Hafiz, Muhammad
   Icksan, Aziza Ghanie
   Harlivasari, Annisa Dian
   Aulia, Rizky
   Susanti, Febrina
   Eldinia, Lourisa
TI Clinical, Radiological Features and Outcome of COVID-19 patients in a
   Secondary Hospital in Jakarta, Indonesia
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Diagnosis; Covid-19; Limited resources
AB Introduction: The numbers of people infected with SARS-CoV-2 in Indonesia especially in Jakarta as the epicenter continue to rise. Limited published clinical data, scarcity and long turn over time of diagnostic testing put clinician in dilemma to make diagnosis.
   Methodology: This is an observational case series study from confirmed COVID-19 patient in our hospital from first case admission on 17 March 30 April, 2020. We collected patient's demography, symptoms, comorbidities, therapy, laboratory, chest x-ray and ECG consecutively.
   Results: Between 17 March 2020 and 30 April 2020, there were 30 confirmed COVID-19 cases, 16 (53.3%) were male. Clinical symptoms were dyspnea in 22 (73.3%) and dry cough 16 (53.3%). Comorbidities were diabetes in 14 (46.6%), hypertension 10 (33.3%) and Coronary Artery Disease (CAD) in 10 (33.3%) patients respectively. Laboratory findings showed lymphopenia in 21 (70%) patients, increased inflammation marker in Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Lactate Dehydrogenase (LDH) 21 (70%), 23 (76.6%) and 12 (40%) patients respectively. Twenty-seven (90%) cases had abnormal Chest X-Ray (CXR) and mostly severe 18 (60%). Descriptive finding for images included consolidation 16 (53.3%) and Ground Glass Opacities (GGO) in 10 (33.3%) patients.
   Conclusions: Based on our findings, most cases of COVID-19 admitted in secondary referral hospital were already in moderate to severe stages. This is most likely due to late referral from primary care and unspecific clinical features resemblance of other infectious diseases. Inflammation marker and CXR are cost effective findings and can be used as marker to determine further referral.
C1 [Hafiz, Muhammad; Harlivasari, Annisa Dian; Susanti, Febrina] Budhi Asih Hosp, Dept Pulmonol & Resp Med, Jakarta, Indonesia.
   [Icksan, Aziza Ghanie] Univ Pembangunan Nas, Persahabatan Hosp, Dept Radiol, Fac Med, Jakarta, Indonesia.
   [Aulia, Rizky] Budhi Asih Hosp, Dept Cardiol, Jakarta, Indonesia.
   [Eldinia, Lourisa] Budhi Asih Hosp, Dept Emergency Med, Jakarta, Indonesia.
RP Hafiz, M (corresponding author), Budhi Asih Hosp, Dept Pulmonol & Resp Med, Jalan Saleh,14 Rt 005 North Sukabumi, West Jakarta 11540, Indonesia.
EM mhafiz.alkaf@gmail.com
CR Akhmerov A, 2020, CIRC RES, V4, P1
   [Anonymous], 2020, GUID DIAGN MAN CV DI
   [Anonymous], COR DIS COVID 19 SIT
   [Anonymous], 2020, DATA PEMANTAUAN COVI
   Atkinson B, 2020, LANCET, V395, P1339, DOI 10.1016/S0140-6736(20)30868-0
   Chavez S, 2020, AM J EMERG MED, V20, P1
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Feng Y, 2020, AM J RESP CRIT CARE, V4, P1
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Rodrigues JCL, 2020, CLIN RADIOL, V75, P323, DOI 10.1016/j.crad.2020.03.003
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   WANG L., 2020, EUR RESP J
   Warren MA, 2018, THORAX, V73, P840, DOI 10.1136/thoraxjnl-2017-211280
   Weinstock MB, 2020, J URGENT CARE MED, V14, P13
   Wong HYF, 2019, RADIOLOGY
   Zeng FR, 2020, INT J INFECT DIS, V96, P467, DOI 10.1016/j.ijid.2020.05.055
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 0
Z9 0
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD JUL
PY 2020
VL 14
IS 7
BP 750
EP 757
DI 10.3855/jidc.12911
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA NB6YB
UT WOS:000560659400015
PM 32794466
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Huang, ZQ
   Fu, FY
   Ye, HL
   Gao, HH
   Tan, B
   Wang, RT
   Lin, N
   Qin, L
   Chen, WH
AF Huang, Zeqing
   Fu, Fanyu
   Ye, Hengli
   Gao, Huanhuan
   Tan, Biao
   Wang, Rongtian
   Lin, Na
   Qin, Ling
   Chen, Weiheng
TI Chinese herbal Huo-Gu formula for the treatment of steroid-associated
   osteonecrosis of femoral head: A 14-year follow-up of convalescent SARS
   patients
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Chinese herbal medicine; Huo-Gu formula; Osteonecrosis of the femoral
   head; SARS; Steroid-related osteonecrosis
ID ACUTE RESPIRATORY SYNDROME; MARROW STROMAL CELLS; NONTRAUMATIC
   OSTEONECROSIS; CORE DECOMPRESSION; DOUBLE-BLIND; COLLAPSE; HIP;
   DIFFERENTIATION; MULTICENTER; ALENDRONATE
AB Purpose: The coronavirus disease 2019 (COVID-19) reminds us of the severe acute respiratory syndrome (SARS) outbreak in 2003, and up to date, corticosteroid is commonly administrated to severe patients with COVID-19. Osteonecrosis of the femoral head (ONFH) is a common disabling complication among convalescent SARS patients who received corticosteroid therapy. In China, a considerable number of convalescent SARS patients with steroid-associated ONFH had undergone conservative treatment by traditional Chinese medicine, and this study aims to evaluate the long-term results of a spleen-invigorating Huo-Gu formula (HGF) therapy in these patients.
   Participants and methods: A total of 33 convalescent SARS patients (9 males and 24 females) with bilateral steroidassociated ONFH (66 hips) were enrolled in this study. All patients received oral HGF therapy for 6 months when they were confirmed the diagnosis of steroid-associated ONFH. They had been regularly followed up at an interval of 1 year. Harris hip score and medical imaging modalities, including plain radiography, computed tomography and magnetic resonance imaging, were performed to evaluate the outcomes.
   Results: Based on average 14 years of follow-up of HGF therapy(ranging from 6 to 16 years), 38 hips(57%) among the 66 hips developed definite osteoarthritis, and 14 hips (26%) in 53 precollapse hips (Association Research Circulation Osseous [ARCO] Stage I or II) progressed to femoral headcollapse (ARCOStage III or IV). Only five patients (also 5 hips) underwent total hip arthroplasty, and the mean hip survival time was over 15 years by the Kaplan-Meier analysis. We observed a mean Harris hip score of 63 points, which represented the reserve of 55% in pain score and 70% in physical function score. The severity of groin pain was not correlated to the severity of osteoarthritis.
   Conclusion: Chinese herbal HGF therapy demonstrates beneficial effects on preventing femoral head collapse, delaying total hip arthroplasty, and maintaining physical function in the treatment of steroid-associated ONFH. HGF therapy might be therefore a good alternative for the treatment of steroid-associated ONFH secondary to rheumatologic and infection diseases.
   Translational potential of the article: HGF therapy might be a good alternative for the treatment of steroid-associated ONFH secondary to rheumatologic and infectious diseases.
C1 [Huang, Zeqing; Gao, Huanhuan; Tan, Biao] China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China.
   [Fu, Fanyu; Ye, Hengli] Guizhou Univ Tradit Chinese Med, Guiyang, Peoples R China.
   [Wang, Rongtian; Chen, Weiheng] Beijing Univ Chinese Med, Affiliated Hosp 3, Orthopaed Ctr, Beijing, Peoples R China.
   [Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Qin, Ling] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab,Innovat Orthopaed Biomat, Hong Kong, Peoples R China.
   [Qin, Ling] Chinese Acad Sci, Translat Med R&D Ctr, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
RP Chen, WH (corresponding author), Beijing Univ Chinese Med, Affiliated Hosp 3, 51 Anwai Xiaoguanjie, Beijing 100029, Peoples R China.; Qin, L (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp,Shatin, Li Ka Shing Inst Hlth,Innovat Orthopaed Biomat &, Dept Orthopaed & Traumatol,Musculoskeletal Res La, Rm74026,5-F Clin Sci Bldg, Hong Kong, Peoples R China.
EM lingqin@cuhk.edu.hk; drchenweiheng@bucm.edu.cn
RI Huang, Zeqing/AAK-7095-2020
OI Tan, Biao/0000-0001-7262-9850
FU "Twelfth Five-Year" National Science and Technology Support
   ProgramChinese Academy of Sciences [2015BAI04B03]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81473695, 81973888]; Beijing Municipal Natural Science
   FoundationBeijing Natural Science Foundation [7182186]
FX This study was supported by grants from "Twelfth Five-Year" National
   Science and Technology Support Program (No. 2015BAI04B03), National
   Natural Science Foundation of China (No. 81473695 and 81973888) and
   Beijing Municipal Natural Science Foundation (No. 7182186).
CR [Anonymous], 1993, ARCO NEWS LETT, V5, P79
   Cao HJ, 2016, J ORTHOP TRANSL, V4, P57, DOI 10.1016/j.jot.2015.09.005
   Cao L, 2017, CLIN ORTHOP RELAT R, V475, P2230, DOI 10.1007/s11999-017-5374-x
   Chen CH, 2012, ARTHRITIS RHEUM-US, V64, P1572, DOI 10.1002/art.33498
   Chen JY, 2017, ORTHOP SURG, V9, P3, DOI 10.1111/os.12302
   Chen W, 2006, CHIN MED MODERN DIST, V4, P55
   Chen WH, 2012, CHIN J INTEGR MED, V18, P378, DOI 10.1007/s11655-012-1086-y
   Dobson F, 2017, OSTEOARTHR CARTILAGE, V25, P1792, DOI 10.1016/j.joca.2017.06.006
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo X., 1992, P CHIN S AS OST FEM, P310
   Haberal B, 2018, EKLEM HAST CERRAHISI, V29, P159, DOI 10.5606/ehc.2018.61348
   Hao YQ, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012674, 10.1097/md.0000000000012674]
   HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012
   Hong YC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/716538
   Hua KC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1359-7
   Jiang YN, 2014, J TRADIT CHIN MED, V34, P342, DOI 10.1016/S0254-6272(14)60100-X
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kong XY, 2017, INT J BIOL SCI, V13, P480, DOI 10.7150/ijbs.18430
   Kong XY, 2016, REJUV RES, V19, P509, DOI 10.1089/rej.2015.1795
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Lee YK, 2015, J BONE JOINT SURG AM, V97A, P1142, DOI 10.2106/JBJS.N.01157
   Lee Yun Jong, 2019, J Bone Metab, V26, P13, DOI 10.11005/jbm.2019.26.1.13
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Li ZR, 2018, J ORTHOP TRANSL, V12, P36, DOI 10.1016/j.jot.2017.11.001
   Liu XH, 2012, COMPR PSYCHIAT, V53, P15, DOI 10.1016/j.comppsych.2011.02.003
   Min BW, 2008, CLIN ORTHOP RELAT R, V466, P1087, DOI 10.1007/s11999-008-0191-x
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Mont MA, 2010, J BONE JOINT SURG AM, V92A, P2165, DOI 10.2106/JBJS.I.00575
   Nilsdotter A, 2011, ARTHRIT CARE RES, V63, pS200, DOI 10.1002/acr.20549
   Tsang K, 2003, RESPIROLOGY, V8, pS25, DOI 10.1046/j.1440-1843.2003.00525.x
   van der Jagt D, 2015, J AM ACAD ORTHOP SUR, V23, P69, DOI 10.5435/JAAOS-D-14-00431
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang J, 2013, AM J CHINESE MED, V41, P253, DOI 10.1142/S0192415X13500183
   Wang WG, 2018, INT ORTHOP, V42, P1551, DOI 10.1007/s00264-018-3907-x
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Xue ZP, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1364-x
   Zhang B, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012003
   Zhao De-wei, 2012, Orthop Surg, V4, P125, DOI 10.1111/j.1757-7861.2012.00192.x
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
NR 41
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214-031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JUL
PY 2020
VL 23
BP 122
EP 131
DI 10.1016/j.jot.2020.03.014
PG 10
WC Orthopedics
SC Orthopedics
GA NA7CZ
UT WOS:000559976200017
PM 32292697
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grover, S
   Mehra, A
   Sahoo, S
   Avasthi, A
   Tripathi, A
   D'Souza, A
   Saha, G
   Jagadhisha, A
   Gowda, M
   Vaishnav, M
   Singh, O
   Dalal, PK
   Kumar, P
AF Grover, Sandeep
   Mehra, Aseem
   Sahoo, Swapnajeet
   Avasthi, Ajit
   Tripathi, Adarsh
   D'Souza, Avinash
   Saha, Gautam
   Jagadhisha, A.
   Gowda, Mahesh
   Vaishnav, Mrugesh
   Singh, Omprakash
   Dalal, P. K.
   Kumar, Parmod
TI State of mental health services in various training centers in India
   during the lockdown and COVID-19 pandemic
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE COVID-19; mental health services; pandemic
AB Background: There is some information from different developed coutries that mental health services have been badly affected by the COVID-19 pandemic. Little information is available from India.
   Aim: The aim of this study was to evaluate the impact of lockdown and COVID-19 pandemic on mental health services in India's various training centers.
   Materials and Methods: In an online survey, information was collected from various training centers of India through E-mail or WhatsApp.
   Results: Responses were received from 109 institutes. The majority of the responses were received from state-funded government medical colleges and private medical colleges. Since the lockdown and COVID-19 pandemic, brain stimulation treatments have completed stopped. Other, most affected services included electroconvulsive therapy, inpatient services, outpatient services, and psychotherapy services. However, there was an expansion of teleconsultations services because of the lockdown and the COVID-19 pandemic. In three-fourth of the centers mental health services were being provided to the patients with COVID-19 infection. In most of the institutes, mental health professionals were involved at different levels in the COVID-19 responsibilities. These included providing helpline services to the general public, screening people in quarantine for mental health issues, providing clinical care to COVID-19 patients, screening health care workers (HCWs) for mental health issues, and training the HCWs.
   Conclusion: COVID-19 pandemic and lockdown have led to the collapse of regular mental health services. The present study also shows that mental health professionals are playing a significant role in addressing the prevailing psychiatric morbidity, specifically related to the COVID-19 related issues, and taking care of the HCWs.
C1 [Grover, Sandeep; Mehra, Aseem; Sahoo, Swapnajeet] Postgrad Inst Med Educ & Res, Mohali, Punjab, India.
   [Avasthi, Ajit] Fortis Hosp, Mohali, Punjab, India.
   [Avasthi, Ajit] CMC, Chandigarh, India.
   [Tripathi, Adarsh; Dalal, P. K.] King Georges Med Univ, Lucknow, Uttar Pradesh, India.
   [D'Souza, Avinash] Lokmanya Tilak Municipal Gen Hosp & Med Coll, Mumbai, Maharashtra, India.
   [Saha, Gautam] Clin Brain Neuropsychiat Inst & Res Ctr, Bengaluru, Karnataka, India.
   [Jagadhisha, A.] Abhaya Hosp, Bengaluru, Karnataka, India.
   [Gowda, Mahesh] Spandana Hlth Care, Bengaluru, Karnataka, India.
   [Vaishnav, Mrugesh] Samvedana Grp Hosp & Res Ctr, Ahmadabad, Gujarat, India.
   [Singh, Omprakash] NRS Med Coll, Kolkata, W Bengal, India.
   [Kumar, Parmod] Dr Parmod Clin, Chandigarh, India.
RP Grover, S (corresponding author), Postgrad Inst Med Educ & Res, Dept Psychiat, Chandigarh, India.
EM drsandeepg2002@yahoo.com
RI Dalal, Pronob Kumar/AAQ-2603-2020; Tripathi, Adarsh/AAP-9697-2020;
   SAHOO, SWAPNAJEET/AAZ-5445-2020
OI Dalal, Pronob Kumar/0000-0001-7317-4480; Tripathi,
   Adarsh/0000-0002-3885-6475; SAHOO, SWAPNAJEET/0000-0003-0365-7086;
   Grover, Sandeep/0000-0002-2714-2055
CR Bojdani E, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113069
   D'Agostino A, 2020, LANCET PSYCHIAT, V7, P385, DOI 10.1016/S2215-0366(20)30133-4
   Ghosh S, 2020, INDIAN J PEDIATR, V87, P1085, DOI 10.1007/s12098-020-03340-w
   Grover S, 2020, INDIAN J PSYCHIAT, V62, P354, DOI 10.4103/psychiatry.IndianJPsychiatry_427_20
   Grover S, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102147
   Grover S, 2018, INDIAN J PSYCHIAT, V60, P300, DOI 10.4103/psychiatry.IndianJPsychiatry_256_17
   Gupta R, 2020, INDIAN J PSYCHIAT, V62, P370, DOI 10.4103/psychiatry.IndianJPsychiatry_523_20
   Kavoor AR, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102051
   Kumar Krishan, 2020, Asian J Psychiatr, V53, P102252, DOI 10.1016/j.ajp.2020.102252
   Li W, 2020, INT J BIOL SCI, V16, P1732, DOI 10.7150/ijbs.45120
   Thome J, 2020, PSYCHIAT CLIN NEUROS, V74, P407, DOI 10.1111/pcn.13019
   Xiang YT, 2020, LANCET, V395, P684, DOI 10.1016/S0140-6736(20)30375-5
NR 12
TC 5
Z9 5
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD JUL-AUG
PY 2020
VL 62
IS 4
BP 363
EP 369
DI 10.4103/psychiatry.IndianJPsychiatry_567_20
PG 7
WC Psychiatry
SC Psychiatry
GA NA3WO
UT WOS:000559745200004
PM 33165355
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abbasi-Oshaghi, E
   Mirzaei, F
   Farahani, F
   Khodadadi, I
   Tayebinia, H
AF Abbasi-Oshaghi, Ebrahim
   Mirzaei, Fatemeh
   Farahani, Farhad
   Khodadadi, Iraj
   Tayebinia, Heidar
TI Diagnosis and treatment of coronavirus disease 2019 (COVID-19):
   Laboratory, PCR, and chest CT imaging findings
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Article
DE Chloroquine; Coronavirus; Coronavirus infection; COVID-19 vaccine;
   Respiratory tract infections; Viral pneumonia
ID ACE2
AB Since December 2019, more than 3 million cases of coronavirus disease 2019 (COVID-19) and about 200,000 deaths have been reported worldwide. The outbreak of this novel disease has become a global health emergency and continues to rapidly spread around the world. Based on the clinical data, approved cases are divided into four classes including mild, moderate, severe, and critical. About 5% of cases were considered critically ill and 14% were considered to have the severe classification of the disease. In China, the fatality rate of this infection was about 4%. This review focuses on currently available information on the etiology, clinical symptoms, diagnosis, and mechanism of action of COVID-19. Furthermore, we present an overview of diagnostic approaches and treatment of this disease according to available findings. This review paper will help the physician to diagnose and successfully treat COVID-19.
C1 [Abbasi-Oshaghi, Ebrahim; Mirzaei, Fatemeh] Hamadan Univ Med Sci, Neurophysiol Res Ctr, Hamadan, Hamadan, Iran.
   [Abbasi-Oshaghi, Ebrahim] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran.
   [Mirzaei, Fatemeh] Hamadan Univ Med Sci, Sch Med, Dept Anat Sci, Hamadan, Hamadan, Iran.
   [Farahani, Farhad] Hamadan Univ Med Sci, Hearing Impairment Res Ctr, Hamadan, Hamadan, Iran.
   [Khodadadi, Iraj] Hamadan Univ Med Sci, Nutr Hlth Res Ctr, Hamadan, Hamadan, Iran.
   [Tayebinia, Heidar] Hamadan Univ Med Sci, Dept Clin Biochem, Hamadan, Hamadan, Iran.
RP Abbasi-Oshaghi, E (corresponding author), Hamadan Univ Med Sci, Neurophysiol Res Ctr, Hamadan, Hamadan, Iran.
EM a.oshaghi@umsha.ac.ir
CR Abbasi-Oshaghi E, 2018, NANOMEDICINE-UK, V13, P2791, DOI 10.2217/nnm-2018-0202
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XD, 2020, ANESTHESIOLOGY, V132, P1307, DOI 10.1097/ALN.0000000000003301
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00307-2
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Ghaffari H, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0563-4
   Givi B, 2020, JAMA OTOLARYNGOL, V146, P579, DOI 10.1001/jamaoto.2020.0780
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120
   Kassaee SM, 2018, JUNDISHAPUR J NAT PH, V13, DOI 10.5812/jjnpp.38414
   Kim H, 2020, EUR RADIOL, V30, P3266, DOI 10.1007/s00330-020-06748-2
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Liu Z., 2020, INDIAN J SURG, V3, P133, DOI [10.3779/j.issn.1009-3419.2020.03.01, DOI 10.3779/J.ISSN.1009-3419.2020.03.01]
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Mardani R., 2020, ARCH ACAD EMERGENCY, V8, P43, DOI DOI 10.22037/AAEM.V8I1.632.G775
   Ng M-Y, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200034, DOI 10.1148/RYCT.2020200034]
   Oshaghi EA, 2017, CRIT REV CL LAB SCI, V54, P267, DOI 10.1080/10408363.2017.1343274
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Pan YY, 2020, EUR RADIOL, V30, P3612, DOI 10.1007/s00330-020-06713-z
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Ravan Alireza Pouyandeh, 2017, Journal of Basic and Clinical Physiology and Pharmacology, V28, P463, DOI 10.1515/jbcpp-2016-0181
   Sahin A., 2020, EURASIAN J MED ONCOL, V4, P1, DOI DOI 10.14744/ejmo.2020.12220
   Smith T., 2020, COVID 19 DRUG THERAP
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, EP CHAR OUTBR 2019 N, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei JP, 2020, KOREAN J RADIOL, V21, P501, DOI 10.3348/kjr.2020.0112
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu YT, 2020, VIROL SIN, V35, P256, DOI 10.1007/s12250-020-00205-6
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
   Yu XB, 2016, CELL PHYSIOL BIOCHEM, V38, P1055, DOI 10.1159/000443056
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 53
TC 11
Z9 11
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD JUL
PY 2020
VL 79
BP 143
EP 153
DI 10.1016/j.ijsu.2020.05.018
PG 11
WC Surgery
SC Surgery
GA NA7VP
UT WOS:000560025500046
PM 32422384
OA Green Published
DA 2021-01-01
ER

PT J
AU Liu, XY
   Li, Z
   Liu, S
   Sun, J
   Chen, ZH
   Jiang, M
   Zhang, QL
   Wei, YH
   Wang, X
   Huang, YY
   Shi, YY
   Xu, YH
   Xian, HF
   Bai, F
   Ou, CX
   Xiong, B
   Lew, AM
   Cui, J
   Fang, RL
   Huang, H
   Zhao, JC
   Hong, XC
   Zhang, YX
   Zhou, FL
   Luo, HB
AF Liu, Xiaoyan
   Li, Zhe
   Liu, Shuai
   Sun, Jing
   Chen, Zhanghua
   Jiang, Min
   Zhang, Qingling
   Wei, Yinghua
   Wang, Xin
   Huang, Yi-You
   Shi, Yinyi
   Xu, Yanhui
   Xian, Huifang
   Bai, Fan
   Ou, Changxing
   Xiong, Bei
   Lew, Andrew M.
   Cui, Jun
   Fang, Rongli
   Huang, Hui
   Zhao, Jincun
   Hong, Xuechuan
   Zhang, Yuxia
   Zhou, Fuling
   Luo, Hai-Bin
TI Potential therapeutic effects of dipyridamole in the severely ill
   patients with COVID-19
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Dipyridamole; SARS-CoV-2; COVID-19; Treatment; D-dimer; Severe cases
ID ANGIOTENSIN-CONVERTING ENZYME-2; ACE2; INHIBITION; PNEUMONIA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Liu, Xiaoyan; Liu, Shuai; Xiong, Bei; Zhou, Fuling] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Li, Zhe; Huang, Yi-You; Luo, Hai-Bin] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Peoples R China.
   [Liu, Shuai; Shi, Yinyi] Dawu Cty Peoples Hosp, Xiaogan 432826, Peoples R China.
   [Sun, Jing; Zhang, Qingling; Ou, Changxing; Zhao, Jincun] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou 510120, Peoples R China.
   [Chen, Zhanghua; Xu, Yanhui; Xian, Huifang; Fang, Rongli; Zhang, Yuxia] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou 510623, Peoples R China.
   [Chen, Zhanghua; Bai, Fan] Peking Univ, Sch Life Sci, Biomed Pioneering Innovat Ctr BIOPIC, Beijing 100871, Peoples R China.
   [Jiang, Min; Wei, Yinghua] Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China.
   [Jiang, Min; Wei, Yinghua] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat, Nanning 530021, Peoples R China.
   [Wang, Xin] Ocean Univ China, Sch Med & Pharm, Ctr Innovat Marine Drug Screening & Evaluat QNLM, Qingdao 266100, Peoples R China.
   [Lew, Andrew M.] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.
   [Lew, Andrew M.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
   [Cui, Jun] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510006, Peoples R China.
   [Huang, Hui] Sun Yat Sen Univ, Affiliated Hosp 8, Cardiovasc Dept, Shenzhen 518000, Peoples R China.
   [Hong, Xuechuan] Tibet Univ, Coll Med, State Key Lab Virol,Coll Sci, Innovat Ctr Tradit Tibetan Med Modernizat & Qual, Lhasa 850000, Peoples R China.
   [Hong, Xuechuan] Wuhan Univ, Sch Pharmaceut Sci, Key Lab Combinatorial Biosynth & Drug Discovery, MOE,Hubei Prov Engn & Technol Res Ctr Fluorinated, Wuhan 430071, Peoples R China.
RP Zhou, FL (corresponding author), Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Luo, HB (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Peoples R China.; Zhao, JC (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou 510120, Peoples R China.; Zhang, YX (corresponding author), Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou 510623, Peoples R China.; Hong, XC (corresponding author), Tibet Univ, Coll Med, State Key Lab Virol,Coll Sci, Innovat Ctr Tradit Tibetan Med Modernizat & Qual, Lhasa 850000, Peoples R China.; Hong, XC (corresponding author), Wuhan Univ, Sch Pharmaceut Sci, Key Lab Combinatorial Biosynth & Drug Discovery, MOE,Hubei Prov Engn & Technol Res Ctr Fluorinated, Wuhan 430071, Peoples R China.
EM zhaojincun@gird.cn; xhy78@whu.edu.cn; yuxia.zhang@gwcmc.org;
   zhoufuling@whu.edu.cn; luohb77@mail.sysu.edu.cn
OI Li, Zhe/0000-0002-9357-6839; Zhang, Yuxia/0000-0003-2715-0925
FU National Key R&D Program of China [2017YFB0202600, 2020YFC0841400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [91742109, 8152204, 31770978, 81773674,
   21877134]; National Health & Medical Research of Australia [1080321,
   1143976, 1150425]; Science Foundation of Guangzhou City (China)
   [201904020023]; Guangdong Provincial Key Laboratory of Construction
   Foundation (China) [2017B030314030]; Local Innovative and Research Teams
   Project of Guangdong Pearl River Talents Program (China) [2017BT01Y093]
FX We cordially acknowledge Tencent Cloud and National Supercomputing
   centers in Guangzhou, Shenzhen, and Tianjin, China for providing HPC
   resources for virtual screening and free energy perturbation
   calculations, and Prof. H. Ke at the University of North Carolina,
   Chapel Hill, NC, USA for comments. We cordially acknowledge National Key
   R&D Program of China (2017YFB0202600 and 2020YFC0841400), National
   Natural Science Foundation of China (91742109, 8152204, 31770978,
   81773674, and 21877134), National Health & Medical Research of Australia
   (1080321, 1143976 and 1150425), Science Foundation of Guangzhou City
   (201904020023, China), Guangdong Province Higher Vocational Colleges and
   Schools Pearl River Scholar Funded Scheme (2016 and 2019, China),
   Guangdong Provincial Key Laboratory of Construction Foundation
   (2017B030314030, China), Local Innovative and Research Teams Project of
   Guangdong Pearl River Talents Program (2017BT01Y093, China), Zhejiang
   University special scientific research fund for COVID-19 prevention and
   control (China), National Health & Medical Research of Australia
   (1080321, 1143976, and 1150425), Taikang Insurance Group Co., Ltd. and
   Beijing Taikang Yicai Foundation (Beijing, China), and philanthropy
   donation from individuals. The funders had no roles in the design and
   execution of the study.
CR Adedeji AO, 2014, CURR OPIN VIROL, V8, P45, DOI 10.1016/j.coviro.2014.06.002
   Adekanmbi O, 2019, PAN AFR MED J, V34, DOI 10.11604/pamj.2019.34.74.20373
   Aldeghi M, 2016, CHEM SCI, V7, P207, DOI 10.1039/c5sc02678d
   BENNETT CH, 1976, J COMPUT PHYS, V22, P245, DOI 10.1016/0021-9991(76)90078-4
   BJORNSSON TD, 1983, THROMB RES, P93
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung T, 2007, J THROMB HAEMOST, V5, P918, DOI 10.1111/j.1538-7836.2007.02461.x
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Fata-Hartley CL, 2005, J VIROL, V79, P11062, DOI 10.1128/JVI.79.17.11062-11070.2005
   General Office of National Health Committee, 2020, DIAGN TREATM SCHEM N
   Gresele P, 2011, BRIT J CLIN PHARMACO, V72, P634, DOI 10.1111/j.1365-2125.2011.04034.x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu X, 1995, CHIN J HOSP PHARM, V15, P401, DOI DOI 10.1016/j.apsb.2020.04.008
   Huang B, 2019, CELL, V179, P1160
   Huang B, 2019, CELL, V179, P1160, DOI 10.1016/j.cell.2019.10.027
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Insel PA, 2012, BRIT J PHARMACOL, V166, P447, DOI 10.1111/j.1476-5381.2012.01847.x
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kalinowski L, 2002, HYPERTENSION, V40, P521, DOI 10.1161/01.HYP.0000034745.98129.EC
   Kline JA, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.119.005753
   KOZHUKHAROVA MS, 1987, VOP VIRUSOL+, P294
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   KUZMOV K, 1985, ZH MIKROB EPID IMMUN, P26
   Li Z, 2019, J MED CHEM, V62, P2099, DOI 10.1021/acs.jmedchem.8b01763
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marshall RP, 2003, CURR PHARM DESIGN, V9, P715, DOI 10.2174/1381612033455431
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   R Core Team, 2013, R LANG ENV STAT COMP
   Schefold JC, 2020, CRIT CARE MED, V48, pE270, DOI 10.1097/CCM.0000000000004204
   Serebruany V, 2009, THROMB HAEMOSTASIS, V102, P538, DOI 10.1160/TH09-03-0158
   Sui Y, 2014, MED FORUM, P4360
   SZEBENI J, 1989, P NATL ACAD SCI USA, V86, P3842, DOI 10.1073/pnas.86.10.3842
   Tenser RB, 2001, ANTIMICROB AGENTS CH, V45, P3657, DOI 10.1128/AAC.45.12.3657-3659.2001
   TONEW E, 1982, ACTA VIROL, V26, P125
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xie H, 2010, CHIN J SCH DOCTOR, V24, P921
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018527
NR 53
TC 36
Z9 37
U1 7
U2 8
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1205
EP 1215
DI 10.1016/j.apsb.2020.04.008
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200006
PM 32318327
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cui, C
   Zhang, M
   Yao, XT
   Tu, SQ
   Hou, Z
   En, VSJ
   Xiang, XQ
   Lin, J
   Cai, T
   Shen, N
   Song, CL
   Qiao, J
   Zhang, S
   Li, HY
   Liu, DY
AF Cui, Cheng
   Zhang, Miao
   Yao, Xueting
   Tu, Siqi
   Hou, Zhe
   En, Valerie Sia Jie
   Xiang, Xiaoqiang
   Lin, Jing
   Cai, Ting
   Shen, Ning
   Song, Chunli
   Qiao, Jie
   Zhang, Shun
   Li, Haiyan
   Liu, Dongyang
TI Dose selection of chloroquine phosphate for treatment of COVID-19 based
   on a physiologically based pharmacokinetic model
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE COVID-19; Chloroquine phosphate; PBPK; Dosing strategy
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; PROTEIN-BINDING;
   METABOLISM; DESETHYLCHLOROQUINE; CORONAVIRUS; DISPOSITION; PREGNANCY;
   PLASMA
AB Chloroquine (CQ) phosphate has been suggested to be clinically effective in the treatment of coronavirus disease 2019 ( COVID-19). To develop a physiologically-based pharmacokinetic (PBPK) model for predicting tissue distribution of CQ and apply it to optimize dosage regimens, a PBPK model, with parameterization of drug distribution extrapolated from animal data, was developed to predict human tissue distribution of CQ. The physiological characteristics of time-dependent accumulation was mimicked through an active transport mechanism. Several dosing regimens were proposed based on PBPK simulation combined with known clinical exposureeresponse relationships. The model was also validated by clinical data from Chinese patients with COVID-19. The novel PBPK model allows in-depth description of the pharmacokinetics of CQ in several key organs (lung, heart, liver, and kidney), and was applied to design dosing strategies in patients with acute COVID-19 (Day 1: 750 mg BID, Days 2 -5: 500 mg BID, CQ phosphate), patients with moderate COVID-19 (Day 1: 750 mg and 500 mg, Days 2 -3: 500 mg BID, Days 4-5: 250 mg BID, CQ phosphate), and other vulnerable populations (e.g., renal and hepatic impairment and elderly patients, Days 1-5: 250 mg BID, CQ phosphate). A PBPK model of CQ was successfully developed to optimize dosage regimens for patients with COVID-19. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Cui, Cheng; Zhang, Miao; Yao, Xueting; Tu, Siqi; Hou, Zhe; En, Valerie Sia Jie; Li, Haiyan; Liu, Dongyang] Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing 100191, Peoples R China.
   [Xiang, Xiaoqiang] Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai 201203, Peoples R China.
   [Lin, Jing; Cai, Ting; Zhang, Shun] Univ Chinese Acad Sci, HwaMei Hosp, Ningbo Hosp 2, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Ningbo 315010, Peoples R China.
   [Shen, Ning] Peking Univ Third Hosp, Dept Respirator, Beijing 100191, Peoples R China.
   [Song, Chunli] Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.
   [Qiao, Jie] Peking Univ Third Hosp, Dept Obstet & Gynecol, Ctr Reprod Med, Beijing 100191, Peoples R China.
   [Li, Haiyan] Peking Univ Third Hosp, Dept Cardiol, Beijing 100191, Peoples R China.
   [Li, Haiyan] Peking Univ Third Hosp, Inst Vasc Med, Beijing 100191, Peoples R China.
RP Li, HY; Liu, DY (corresponding author), Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing 100191, Peoples R China.; Zhang, S (corresponding author), Univ Chinese Acad Sci, HwaMei Hosp, Ningbo Hosp 2, Key Lab Diag & Treatment Digest Syst Tumors Zheji, Ningbo 315010, Peoples R China.; Li, HY (corresponding author), Peking Univ Third Hosp, Dept Cardiol, Beijing 100191, Peoples R China.; Li, HY (corresponding author), Peking Univ Third Hosp, Inst Vasc Med, Beijing 100191, Peoples R China.
EM zhangshun@ucas.ac.cn; haiyanli1027@hotmail.com; liudongyang@vip.sina.com
FU "13th Five-Year" National Science and Technology Major Project (China)
   [2017ZX09101001-002-001, 2017ZX09304012]; Bill & Melinda Gates
   Foundation (USA)Bill & Melinda Gates Foundation [OPP1204780]
FX We thank Drs. Eleanor Howgate and Maurice Dickins for the development of
   the original chloroquine PBPK base model, and thank Lisa Almond, Alice
   Ke and Mian Zhang for providing the initial model and constructive
   discussions. We thank Dr. Ping Zhao, Dr. Gaohua Lu and Dr. Hoi-Kei Lon
   for the scientific suggestion and proofreading. This work was supported
   by the "13th Five-Year" National Science and Technology Major Project
   (grant Nos. 2017ZX09101001-002-001 and 2017ZX09304012, China) and Bill &
   Melinda Gates Foundation (OPP1204780, USA).
CR ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   Bergman KL, 2015, CLIN PHARMACOL THER, V98, P365, DOI 10.1002/cpt.172
   BERNSTEIN H, 1963, INVEST OPHTH VISUAL, V2, P384
   Charman SA, 2020, MALARIA J, V19, DOI 10.1186/s12936-019-3075-5
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   EDWARDS G, 1988, BRIT J CLIN PHARMACO, V25, P477, DOI 10.1111/j.1365-2125.1988.tb03332.x
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   FRISKHOLMBERG M, 1979, CLIN PHARMACOL THER, V25, P345
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gaohua L, 2015, CPT-PHARMACOMET SYST, V4, P605, DOI 10.1002/psp4.12034
   GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   HUNT CM, 1992, MECH AGEING DEV, V64, P189, DOI 10.1016/0047-6374(92)90106-N
   Jeong H, 2010, EXPERT OPIN DRUG MET, V6, P689, DOI 10.1517/17425251003677755
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Leecharoen Sukanya, 2007, Journal of the Medical Association of Thailand, V90, P52
   Liang H, 2020, ACTA OBSTET GYN SCAN, V99, P439, DOI 10.1111/aogs.13836
   MCLACHLAN MSF, 1978, LANCET, V2, P143
   OFORIADJEI D, 1986, THER DRUG MONIT, V8, P457, DOI 10.1097/00007691-198612000-00014
   OFORIADJEI D, 1986, BRIT J CLIN PHARMACO, V22, P356, DOI 10.1111/j.1365-2125.1986.tb02900.x
   Olafuyi O, 2019, J PHARM SCI-US, V108, P661, DOI 10.1016/j.xphs.2018.10.056
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Puavilai S, 1999, INT J DERMATOL, V38, P934, DOI 10.1046/j.1365-4362.1999.00849.x
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Sinha V, 2014, CLIN PHARMACOL THER, V95, P478, DOI 10.1038/clpt.2014.46
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Soma-Pillay P, 2016, CARDIOVASC J AFR, V27, P89, DOI 10.5830/CVJA-2016-021
   WALKER O, 1987, BRIT J CLIN PHARMACO, V23, P295, DOI 10.1111/j.1365-2125.1987.tb03048.x
   WALKER O, 1983, BRIT J CLIN PHARMACO, V15, P375, DOI 10.1111/j.1365-2125.1983.tb01513.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Willmann S, 2007, J PHARMACOKINET PHAR, V34, P401, DOI 10.1007/s10928-007-9053-5
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 37
TC 3
Z9 3
U1 4
U2 4
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1216
EP 1227
DI 10.1016/j.apsb.2020.04.007
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200007
PM 32834950
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kang, SS
   Yang, M
   Hong, ZS
   Zhang, LP
   Huang, ZX
   Chen, XX
   He, SH
   Zhou, ZL
   Zhou, ZC
   Chen, QY
   Yan, Y
   Zhang, CS
   Shan, H
   Chen, SD
AF Kang, Sisi
   Yang, Mei
   Hong, Zhongsi
   Zhang, Liping
   Huang, Zhaoxia
   Chen, Xiaoxue
   He, Suhua
   Zhou, Ziliang
   Zhou, Zhechong
   Chen, Qiuyue
   Yan, Yan
   Zhang, Changsheng
   Shan, Hong
   Chen, Shoudeng
TI Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
   reveals potential unique drug targeting sites
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2; Nucleocapsid protein; RNA binding
   domain; Crystal structure; Antiviral targeting site
ID N-TERMINAL DOMAIN; ACUTE RESPIRATORY SYNDROME; REGULATORY SEQUENCE TRS;
   SYNDROME-CORONAVIRUS; VIRUS; SARS; IDENTIFICATION; DETERMINANTS
AB The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually lead to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 angstrom crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Kang, Sisi; Yang, Mei; Huang, Zhaoxia; Chen, Xiaoxue; He, Suhua; Zhou, Ziliang; Zhou, Zhechong; Chen, Qiuyue; Yan, Yan; Shan, Hong; Chen, Shoudeng] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Biomed Imaging, Mol Imaging Ctr, Zhuhai 519000, Peoples R China.
   [Hong, Zhongsi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Infect Dis, Zhuhai 519000, Peoples R China.
   [Zhang, Liping; Zhang, Changsheng] Chinese Acad Sci, South China Sea Inst Oceanol, Key Lab Trop Marine Bioresources & Ecol, Inst South China Sea Ecol & Environm Engn,Key Lab, Guangzhou 510301, Peoples R China.
   [Shan, Hong; Chen, Shoudeng] Sun Yat Sen Univ, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai 519000, Peoples R China.
   [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Med, Zhuhai 519000, Peoples R China.
   [Chen, Shoudeng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Expt Med, Zhuhai 519000, Peoples R China.
RP Shan, H; Chen, SD (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Biomed Imaging, Mol Imaging Ctr, Zhuhai 519000, Peoples R China.; Shan, H; Chen, SD (corresponding author), Sun Yat Sen Univ, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai 519000, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Med, Zhuhai 519000, Peoples R China.; Chen, SD (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Expt Med, Zhuhai 519000, Peoples R China.
EM shanhong@mail.sysu.edu.cn; chenshd5@mail.sysu.edu.cn
RI Zhang, Changsheng/B-5965-2012
OI Zhang, Changsheng/0000-0003-2349-3138; Zhou, Ziliang/0000-0002-6801-4180
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31770801, 81430041, 81620108017, 81870019];
   Special Fund for Scientific and Technological Innovation Strategy of
   Guangdong Province of China [2018B030306029, 2017A030313145]; National
   Key Basic Research Program, China [SQ2018YFC090075]
FX We thank Guangdong Medical Laboratory Animal Center for providing the
   N-protein encoding gene plasmids, Dr. Yongzhi Lu from Guangzhou
   Institutes of Biomedicine and Health (Chinese Academy of Sciences) for
   the initial crystals X-ray diffraction screening, supports of Dr. Xuan
   Ma from South China Sea Institute of Oceanology (Chinese Academy of
   Sciences) for home source X-ray diffraction facility. This work was
   supported by National Natural Science Foundation of China (31770801) and
   Special Fund for Scientific and Technological Innovation Strategy of
   Guangdong Province of China (2018B030306029 and 2017A030313145) to
   Shoudeng Chen, National Natural Science Foundation of China (81430041,
   81620108017) and National Key Basic Research Program, China
   (SQ2018YFC090075) to Hong Shan, National Natural Science Foundation of
   China (81870019) to Yan Yan.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Chang CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061196
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Chen IJ, 2013, BBA-PROTEINS PROTEOM, V1834, P1054, DOI 10.1016/j.bbapap.2013.03.003
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Grossoehme NE, 2009, J MOL BIOL, V394, P544, DOI 10.1016/j.jmb.2009.09.040
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hatcher EL, 2017, NUCLEIC ACIDS RES, V45, pD482, DOI 10.1093/nar/gkw1065
   Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005
   Jayaram H, 2006, J VIROL, V80, P6612, DOI 10.1128/JVI.00157-06
   Keane SC, 2012, J BIOL CHEM, V287, P7063, DOI 10.1074/jbc.M111.287763
   Lau YL, 2005, CURR OPIN IMMUNOL, V17, P404, DOI 10.1016/j.coi.2005.05.009
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   MASTERS PS, 1990, ADV EXP MED BIOL, V276, P235
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   Ramajayam R, 2011, BIOCHEM SOC T, V39, P1371, DOI 10.1042/BST0391371
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Shang B, 2005, BIOCHEM BIOPH RES CO, V336, P110, DOI 10.1016/j.bbrc.2005.08.032
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Tan YJ, 2005, ANTIVIR RES, V65, P69, DOI 10.1016/j.antiviral.2004.10.001
   Tan YW, 2006, NUCLEIC ACIDS RES, V34, P4816, DOI 10.1093/nar/gkl650
   Tang TK, 2005, PROTEOMICS, V5, P925, DOI 10.1002/pmic.200401204
   Volkamer A, 2012, BIOINFORMATICS, V28, P2074, DOI 10.1093/bioinformatics/bts310
   Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227
   WHO, 2020, COVID 2019 SIT REP
   Wootton SK, 2002, J VIROL, V76, P10569, DOI 10.1128/JVI.76.20.10569-10576.2002
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 48
TC 34
Z9 33
U1 4
U2 7
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1228
EP 1238
DI 10.1016/j.apsb.2020.04.009
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200008
PM 32363136
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shi, YL
   Zhang, XB
   Mu, KJ
   Peng, C
   Zhu, ZD
   Wang, XY
   Yang, YQ
   Xu, ZJ
   Zhu, WL
AF Shi, Yulong
   Zhang, Xinben
   Mu, Kaijie
   Peng, Cheng
   Zhu, Zhengdan
   Wang, Xiaoyu
   Yang, Yanqing
   Xu, Zhijian
   Zhu, Weiliang
TI D3Targets-2019-nCoV: a webserver for predicting drug targets and for
   multi-target and multi-site based virtual screening against COVID-19
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE COVID-19; SARS-CoV-2; Target prediction; Multi-conformation; Multi-site;
   Docking; D3Targets-2019-nCoV
ID DOCKING; VIRUS; CORONAVIRUS
AB A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 angstrom(3) on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easy to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Shi, Yulong; Zhang, Xinben; Mu, Kaijie; Peng, Cheng; Zhu, Zhengdan; Wang, Xiaoyu; Yang, Yanqing; Xu, Zhijian; Zhu, Weiliang] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   [Shi, Yulong; Peng, Cheng; Zhu, Zhengdan; Yang, Yanqing; Xu, Zhijian; Zhu, Weiliang] Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China.
   [Mu, Kaijie] Univ Sci & Technol China, Nano Sci & Technol Inst, Suzhou 215123, Peoples R China.
RP Xu, ZJ; Zhu, WL (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Key Lab Receptor Res, Shanghai 201203, Peoples R China.; Xu, ZJ; Zhu, WL (corresponding author), Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China.
EM zjxu@simm.ac.cn; wlzhu@simm.ac.cn
FU National Key Research and Development Program of China [2017YFB0202601,
   2016YFA0502301]
FX This work was supported by the National Key Research and Development
   Program of China (2017YFB0202601 and 2016YFA0502301).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Aliev AE, 2014, PROTEINS, V82, P195, DOI 10.1002/prot.24350
   Anh-Tien T, 2020, MOL INF, V39
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Chen ZQ, 2019, J CHEM INF MODEL, V59, P3353, DOI 10.1021/acs.jcim.9b00332
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/Chemrxiv.11847381.V1., DOI 10.26434/CHEMRXIV.11847381.V1, 10.26434/chemrxiv.11847381.v1]
   Cui QH, 2020, POSSIBLE INHIBITORS, DOI [10.20944/Preprints202002.0047.V1, DOI 10.20944/PREPRINTS202002.0047.V1]
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   EARNSHAW DL, 1992, ANTIMICROB AGENTS CH, V36, P2747, DOI 10.1128/AAC.36.12.2747
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Gerek ZN, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002154
   Guo HY, 2015, J CONTROL RELEASE, V209, P27, DOI 10.1016/j.jconrel.2015.04.016
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kharkar PS, 2014, FUTURE MED CHEM, V6, P333, DOI 10.4155/fmc.13.207
   Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Li H, 2020, FURIN POTENTIAL THER, DOI [10.12074/202002.00062, DOI 10.12074/202002.00062]
   Li HL, 2006, NUCLEIC ACIDS RES, V34, pW219, DOI 10.1093/nar/gkl114
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Ma XM, 2016, J CHEM INF MODEL, V56, P1725, DOI 10.1021/acs.jcim.6b00039
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nguyen Duc Duy, 2020, bioRxiv, DOI 10.1101/2020.02.05.936013
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0
   Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang JN, 2020, BIOPHYS J, V118, P1009, DOI 10.1016/j.bpj.2020.01.001
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiong R., 2020, BIORXIV, DOI [10.1101/2020.03.11.983056, DOI 10.1101/2020.03.11.983056]
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yu Wai C, 2020, PREDICTION SARS COV, DOI [10.26434/chemrxiv, DOI 10.26434/CHEMRXIV]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 6
Z9 7
U1 6
U2 7
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1239
EP 1248
DI 10.1016/j.apsb.2020.04.006
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200009
PM 32318328
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jin, TR
   Liu, MY
AF Jin, Tianru
   Liu, Mingyao
TI Letter to the editor: Comment on GLP-1-based drugs and COVID-19
   treatment
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Letter
ID MODEL
C1 [Jin, Tianru; Liu, Mingyao] Univ Toronto, Dept Med, Fac Med, Toronto, ON M5G 1V7, Canada.
   [Jin, Tianru; Liu, Mingyao] Univ Toronto, Dept Physiol, Fac Med, Toronto, ON M5G 1V7, Canada.
   [Jin, Tianru; Liu, Mingyao] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5G 1V7, Canada.
   [Jin, Tianru; Liu, Mingyao] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 1V7, Canada.
   [Jin, Tianru] Univ Toronto, Fac Med, Best Diabet Ctr, Toronto, ON M5G 1V7, Canada.
   [Liu, Mingyao] Univ Toronto, Fac Med, Dept Surg, Toronto, ON M5G 1V7, Canada.
RP Jin, TR; Liu, MY (corresponding author), Univ Toronto, Dept Med, Fac Med, Toronto, ON M5G 1V7, Canada.; Jin, TR; Liu, MY (corresponding author), Univ Toronto, Dept Physiol, Fac Med, Toronto, ON M5G 1V7, Canada.; Jin, TR; Liu, MY (corresponding author), Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5G 1V7, Canada.; Jin, TR; Liu, MY (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON M5G 1V7, Canada.; Jin, TR (corresponding author), Univ Toronto, Fac Med, Best Diabet Ctr, Toronto, ON M5G 1V7, Canada.; Liu, MY (corresponding author), Univ Toronto, Fac Med, Dept Surg, Toronto, ON M5G 1V7, Canada.
EM tianru.jin@utoronto.ca; mingyuao.liu@utoronto.ca
CR Bloomgarden ZT, 2020, J DIABETES, V12, P347, DOI 10.1111/1753-0407.13027
   Bullock BP, 1996, ENDOCRINOLOGY, V137, P2968, DOI 10.1210/en.137.7.2968
   Han B, 2012, LAB INVEST, V92, P1285, DOI 10.1038/labinvest.2012.92
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim M, 2013, NAT MED, V19, P567, DOI 10.1038/nm.3128
   Purwana I, 2014, DIABETES, V63, P4197, DOI 10.2337/db14-0153
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Viby NE, 2013, ENDOCRINOLOGY, V154, P4503, DOI 10.1210/en.2013-1666
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
NR 10
TC 4
Z9 4
U1 0
U2 0
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1249
EP 1250
DI 10.1016/j.apsb.2020.05.006
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200010
PM 32834951
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bian, JW
   Zhao, RS
   Zhai, SD
   Li, ZJ
AF Bian, Jingwei
   Zhao, Rongsheng
   Zhai, Suodi
   Li, Zijian
TI Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Letter
ID RECEPTOR
C1 [Bian, Jingwei; Zhao, Rongsheng; Zhai, Suodi; Li, Zijian] Peking Univ Third Hosp, Dept Pharm, Beijing 100083, Peoples R China.
   [Bian, Jingwei; Li, Zijian] Peking Univ Third Hosp, Dept Cardiol, Beijing 100083, Peoples R China.
   [Bian, Jingwei; Li, Zijian] Peking Univ Third Hosp, Inst Vasc Med, Beijing 100083, Peoples R China.
   [Bian, Jingwei; Li, Zijian] Minist Hlth, Key Lab Cardiovasc Mol Biol & Regulatory Peptides, Beijing 100083, Peoples R China.
   [Bian, Jingwei; Li, Zijian] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China.
   [Bian, Jingwei; Li, Zijian] Beijing Key Lab Cardiovasc Receptors Res, Beijing 100083, Peoples R China.
RP Li, ZJ (corresponding author), Peking Univ Third Hosp, Dept Pharm, Beijing 100083, Peoples R China.; Li, ZJ (corresponding author), Peking Univ Third Hosp, Dept Cardiol, Beijing 100083, Peoples R China.; Li, ZJ (corresponding author), Peking Univ Third Hosp, Inst Vasc Med, Beijing 100083, Peoples R China.; Li, ZJ (corresponding author), Minist Hlth, Key Lab Cardiovasc Mol Biol & Regulatory Peptides, Beijing 100083, Peoples R China.; Li, ZJ (corresponding author), Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China.; Li, ZJ (corresponding author), Beijing Key Lab Cardiovasc Receptors Res, Beijing 100083, Peoples R China.
EM lizijian@bjmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [91939301, 81820108031, 91539123, 81471893];
   Beijing Municipal Natural Science FoundationBeijing Natural Science
   Foundation [7172235]
FX The authors acknowledge funding support from the National Natural
   Science Foundation of China (91939301, 81820108031, 91539123, and
   81471893) and Beijing Municipal Natural Science Foundation (7172235,
   China).
CR Burchill LJ, 2012, CLIN SCI, V123, P649, DOI 10.1042/CS20120162
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Cui Q., 2020, AGTR2 ONE POSSIBLE N, DOI DOI 10.20944/PREPRINTS202002.0194.V1
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Igase M, 2008, HYPERTENS RES, V31, P553, DOI 10.1291/hypres.31.553
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
NR 10
TC 7
Z9 7
U1 0
U2 0
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD JUL
PY 2020
VL 10
IS 7
BP 1251
EP 1252
DI 10.1016/j.apsb.2020.04.013
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC5VE
UT WOS:000561284200011
PM 32363137
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Islam, A
   Rafiq, S
   Karim, S
   Laher, I
   Rashid, H
AF Islam, Amin
   Rafiq, Shafquat
   Karim, Sabina
   Laher, Ismail
   Rashid, Harunor
TI Convalescent plasma therapy in the treatment of COVID-19: Practical
   considerations
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Letter
DE Convalescent plasma; Convalescent plasma therapy; COVID-19; Neutralising
   antibody
C1 [Islam, Amin] Mid & South Essex Univ Hosp Grp NHS Trust, Westcliff On Sea SS0 0RY, Prittlewell Cha, England.
   [Islam, Amin] Queen Mary Univ, Fac Med & Dent, Dept Haematol & Oncol, London E1 4NS, England.
   [Islam, Amin] Anglia Ruskin Med Sch, Bishop Hall Ln, Chelmsford CM1 1SQ, Essex, England.
   [Rafiq, Shafquat] East Kent Univ Hosp NHS Trust, Dept Gastroenterol, Kennington Rd, Ashford TN24 0LZ, Kent, England.
   [Karim, Sabina] Natl Inst Canc Res & Hosp, Dept Paediat Haematol & Oncol, Dhaka 1212, Bangladesh.
   [Laher, Ismail] Univ British Columbia, Dept Pharmacol & Therapeut, Fac Med, 2176 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
   [Rashid, Harunor] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW 2145, Australia.
   [Rashid, Harunor] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sch Biol Sci, Sydney, NSW, Australia.
   [Rashid, Harunor] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
RP Rashid, H (corresponding author), Univ Sydney, Natl Ctr Immunisat Res & Surveillance NCIRS, Discipline Child & Adolescent Hlth, Kids Res Inst,Childrens Hosp Westmead, Cnr Hawkesbury Rd & Hainsworth St,Locked Bag 4001, Westmead, NSW 2145, Australia.
EM harunor.rashid@health.nsw.gov.au
OI Rashid, Harunor/0000-0003-2286-5139
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 6
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD JUL
PY 2020
VL 79
BP 204
EP 205
DI 10.1016/j.ijsu.2020.05.079
PG 2
WC Surgery
SC Surgery
GA NA7UN
UT WOS:000560022400012
PM 32502707
OA Green Published
DA 2021-01-01
ER

PT J
AU Oualla, K
   Nouiakh, L
   Acharfi, N
   Amaadour, I
   Benbrahim, Z
   Arifi, S
   Mellas, N
AF Oualla, Karima
   Nouiakh, Lamiae
   Acharfi, Nisrine
   Amaadour, Iamiae
   Benbrahim, Zineb
   Arifi, Samia
   Mellas, Nawfel
TI How Is Morocco Reacting to COVID-19 Crisis in Anticancer Centers?
SO CANCER CONTROL
LA English
DT Article
DE Cancer; COVID-19; Africa; Morocco; challenges
AB The world is facing the pandemic linked to COVID-19 virus infection that has rapidly spread worldwide, and severe complications have been reported to occur in around a third of patients. To date, there is no approved vaccine or specific therapy against COVID-19, but many trials are ongoing with some of them showing promising results. It has been shown recently that patients with cancer are at high risk of infection and they are more susceptible to develop severe events such as the necessity of invasive ventilation and death. Therefore, this crisis presents a real challenge for health systems especially in low- and middle-income countries where the health systems are already fragile such as African countries. In this article, we describe the epidemiological situation of the infection in Morocco and the different challenges in cancer centers in the era of COVID-19, in addition to various strategies that have been implemented to prevent and control the infection spread in oncological units in order to ensure the continuation of adequate cancer care.
C1 [Oualla, Karima; Nouiakh, Lamiae; Acharfi, Nisrine; Amaadour, Iamiae; Benbrahim, Zineb; Arifi, Samia; Mellas, Nawfel] Univ Sidi Mohamed Ben Abdellah, Hassan Univ Hosp 2, Dept Med Oncol, Fes, Morocco.
RP Oualla, K (corresponding author), Univ Sidi Mohamed Ben Abdellah, Hassan Univ Hosp 2, Dept Med Oncol, Fes, Morocco.
EM karimarauf@hotmail.com
CR [Anonymous], COVID 19 B EP, V8
   [Anonymous], CANC FAC PAND COVID
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mayor S, 2020, LANCET ONCOL, V21, P633, DOI 10.1016/S1470-2045(20)30240-0
   Souadka A, 2020, LANCET ONCOL, V21, P237, DOI 10.1016/S1470-2045(20)30216-3
NR 6
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-2748
J9 CANCER CONTROL
JI Cancer Control
PD JUL
PY 2020
VL 27
IS 3
AR 1073274820941973
DI 10.1177/1073274820941973
PG 4
WC Oncology
SC Oncology
GA NA8EX
UT WOS:000560051700001
PM 32755231
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Barcellini, A
   Vitolo, V
   Cobianchi, L
   Valvo, F
   Vischioni, B
   Bonora, M
   Fiore, MR
   Iannalfi, A
   Riva, G
   Ronchi, S
   Tornari, E
   Orlandi, E
AF Barcellini, Amelia
   Vitolo, Viviana
   Cobianchi, Lorenzo
   Valvo, Francesca
   Vischioni, Barbara
   Bonora, Maria
   Fiore, Maria Rosaria
   Iannalfi, Alberto
   Riva, Giulia
   Ronchi, Sara
   Tornari, Elena
   Orlandi, Ester
TI Pancreatic cancer: Does a short course of carbon ion radiotherapy worth
   during COVID-19 outbreak?
SO PANCREATOLOGY
LA English
DT Letter
DE Covid-19; Pancreatic cancer; Carbon ion radiotherapy
ID RADIATION-THERAPY
C1 [Barcellini, Amelia; Vitolo, Viviana; Valvo, Francesca; Vischioni, Barbara; Bonora, Maria; Fiore, Maria Rosaria; Iannalfi, Alberto; Riva, Giulia; Ronchi, Sara; Orlandi, Ester] Natl Ctr Oncol Hadrontherapy, Fdn CNAO, Str Campeggi 53, Pavia, Italy.
   [Cobianchi, Lorenzo] Fdn IRCCS, Policlin San Matteo, Gen Surg Dept, Pavia, Italy.
   [Cobianchi, Lorenzo] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
RP Vitolo, V (corresponding author), Natl Ctr Oncol Hadrontherapy, Fdn CNAO, Str Campeggi 53, Pavia, Italy.
EM vitolo@cnao.it
OI Vischioni, Barbara/0000-0003-4920-2239; Cobianchi,
   Lorenzo/0000-0002-6773-5453; Barcellini, Amelia/0000-0002-1595-104X;
   Sarra Fiore, Massimo/0000-0002-3453-9907
CR Bogani G, 2020, J MINIM INVAS GYN, V27, P1221, DOI 10.1016/j.jmig.2020.04.010
   Ebner DK, 2017, INT J RADIAT ONCOL, V99, pS144, DOI 10.1016/j.ijrobp.2017.06.334
   Facoetti A, 2019, ANTICANCER RES, V39, P4613, DOI 10.21873/anticanres.13641
   Jereczek-Fossa BA, 2020, CLIN ONCOL-UK, V32, pE160, DOI 10.1016/j.clon.2020.04.007
   Kawashiro S, 2018, INT J RADIAT ONCOL, V101, P1212, DOI 10.1016/j.ijrobp.2018.04.057
   Tchelebi LT, 2020, RADIOTHER ONCOL, V148, P194, DOI 10.1016/j.radonc.2020.04.010
   Tchelebi LT, 2020, CANCER-AM CANCER SOC, V126, P2120, DOI 10.1002/cncr.32756
   Vitolo V, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6108-0
   Wu LL, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01543
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1424-3903
EI 1424-3911
J9 PANCREATOLOGY
JI Pancreatology
PD JUL
PY 2020
VL 20
IS 5
BP 1004
EP 1005
DI 10.1016/j.pan.2020.05.007
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ND0DD
UT WOS:000561578200030
PM 32418757
OA Green Published
DA 2021-01-01
ER

PT J
AU Davidescu, EI
   Odajiu, I
   Bunea, T
   Sandu, G
   Stratan, L
   Arama, V
   Popescu, BO
AF Davidescu, Eugenia Irene
   Odajiu, Irina
   Bunea, Teodora
   Sandu, Georgiana
   Stratan, Laurentiu
   Arama, Victoria
   Popescu, Bogdan Ovidiu
TI TREATMENT WITH HYDROXYCHLOROQUINE IN PATIENTS WITH COVID-19. EXPERIENCE
   OF A NEUROLOGY DEPARTMENT
SO FARMACIA
LA English
DT Article
DE hydroxychloroquine; COVID-19; SARS-CoV2; treatment; pandemic
ID CHLOROQUINE; AZITHROMYCIN; PNEUMONIA; TOXICITY
AB The novel coronavirus has generated the Coronavirus Disease 2019 (COVID-19) pandemic, which has become the new challenge for the healthcare systems, since there is no etiological treatment and the infectiousness of SARS-CoV2 is exceeding the expectations. Therefore, various treatments have been tried in an attempt to stop the spread of the virus and to enhance the early recovery of the patients. Hydroxychloroquine, an antimalarial drug used for decades, has been one of the first drugs tried to reduce the infectivity of the virus. First data were promising, but afterwards, adverse events and long-term evolution of patients outweighed the potential benefits, and its utility was questioned. In this article we are reviewing literature regarding the use of Hydroxychloroquine during the COVID-19 pandemic and we present the experience of its use in the Neurology Department in Colentina Clinical Hospital, Bucharest, Romania.
C1 [Davidescu, Eugenia Irene; Odajiu, Irina; Bunea, Teodora; Sandu, Georgiana; Popescu, Bogdan Ovidiu] Colentina Clin Hosp, Dept Neurol, Bucharest, Romania.
   [Davidescu, Eugenia Irene; Stratan, Laurentiu; Arama, Victoria; Popescu, Bogdan Ovidiu] Carol Davila Univ Med & Pharm, Bucharest, Romania.
   [Popescu, Bogdan Ovidiu] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest, Romania.
   Matei Bals Natl Inst Infect Dis, Bucharest, Romania.
RP Davidescu, EI (corresponding author), Colentina Clin Hosp, Dept Neurol, Bucharest, Romania.; Davidescu, EI (corresponding author), Carol Davila Univ Med & Pharm, Bucharest, Romania.
EM eugenia.davidescu@umfcd.ro
OI Davidescu, Eugenia Irene/0000-0001-6862-5515
CR Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Catrinoiu D, 2020, FARMACIA, V68, P377, DOI 10.31925/farmacia.2020.3.1
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   LANDEWE RBM, 1995, CLIN EXP IMMUNOL, V102, P144
   Lee TC, 2020, INT J INFECT DIS, V98, P216, DOI 10.1016/j.ijid.2020.06.095
   Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656
   Littlejohn Emily, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc011
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   MAKIN AJ, 1994, GUT, V35, P569, DOI 10.1136/gut.35.4.569
   Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mohammad FS, 2020, FARMACIA, V68, P384, DOI 10.31925/farmacia.2020.3.2
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Murphy M, 2001, CLIN EXP DERMATOL, V26, P457, DOI 10.1046/j.1365-2230.2001.00857-3.x
   Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029
   PAN YY, 2020, CLIN INFECT DIS, V20, DOI DOI 10.1093/CID/CIAA237
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Ruan SG, 2020, LANCET INFECT DIS, V20, P630, DOI 10.1016/S1473-3099(20)30257-7
   Seckin U, 2000, RHEUMATOL INT, V19, P203, DOI 10.1007/s002960000054
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017
   Stein M, 2000, J RHEUMATOL, V27, P2927
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Trichonas TJSG, 2019, CHLOROQUINE HYDROXYC
   U.S. Food and Drug Administration (FDA), HYDR SULF HLTH CAR P
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Voss Andreas, OFFICIAL STATEMENT I
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P775, DOI 10.1002/acr.20133
   World Health Organization, 2020, DIR GEN REM MED BRIE
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yam J. C. S., 2006, Hong Kong Medical Journal, V12, P294
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   York G., GLOBE MAIL
   Zhang CT, 2020, J MED VIROL, V92, P1441, DOI 10.1002/jmv.25788
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 51
TC 0
Z9 0
U1 3
U2 3
PU SOC STIINTE FARMACEUTICE ROMANIA
PI BUCURESTI
PA BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA
SN 0014-8237
EI 2065-0019
J9 FARMACIA
JI Farmacia
PD JUL-AUG
PY 2020
VL 68
IS 4
BP 597
EP 605
DI 10.31925/farmacia.2020.4.3
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MX5UC
UT WOS:000557786900004
OA Bronze
DA 2021-01-01
ER

PT J
AU Daniel, HH
   Begona, ASE
AF Daniel, Hernandez-Huerta
   Elena Begona, Alonso-Sanchez
TI Access barriers to electroconvulsive therapy during COVID-19 pandemic
SO PSYCHIATRY RESEARCH
LA English
DT Letter
ID CHALLENGES
C1 [Daniel, Hernandez-Huerta; Elena Begona, Alonso-Sanchez] Ramon & Cajal Univ Hosp, Dept Psychiat, Ctr Colmenar Viejo,Km 9,100, Madrid 28034, Spain.
RP Begona, ASE (corresponding author), Ramon & Cajal Univ Hosp, Dept Psychiat, Ctr Colmenar Viejo,Km 9,100, Madrid 28034, Spain.
EM daniel.hernandez@salud.madrid.org
FU Division Of Mathematical SciencesNational Science Foundation (NSF)NSF -
   Directorate for Mathematical & Physical Sciences (MPS) [1304250] Funding
   Source: National Science Foundation
CR Arango C, 2020, BIOL PSYCHIAT, V88, pE33, DOI 10.1016/j.biopsych.2020.04.003
   Bernardo M, 2015, REV PSIQUIATR SALUD, V8, P51, DOI 10.1016/j.rpsm.2015.01.002
   Colbert Sally-Anne, 2020, J ECT, DOI 10.1097/YCT.0000000000000688
   Shalev D, 2020, GEN HOSP PSYCHIAT, V64, P68, DOI 10.1016/j.genhosppsych.2020.03.009
   Xiang YT, 2020, INT J BIOL SCI, V16, P1741, DOI 10.7150/ijbs.45072
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD JUL
PY 2020
VL 289
AR 113057
DI 10.1016/j.psychres.2020.113057
PG 2
WC Psychiatry
SC Psychiatry
GA MY4XV
UT WOS:000558423200050
OA Green Published
DA 2021-01-01
ER

PT J
AU Rehm, GB
   Woo, SH
   Chen, XLG
   Kuhn, BT
   Cortes-Puch, I
   Anderson, NR
   Adams, JY
   Chuah, CN
AF Rehm, Gregory B.
   Woo, Sang Hoon
   Chen, Xin Luigi
   Kuhn, Brooks T.
   Cortes-Puch, Irene
   Anderson, Nicholas R.
   Adams, Jason Y.
   Chuah, Chen-Nee
TI Leveraging IoTs and Machine Learning for Patient Diagnosis and
   Ventilation Management in the Intensive Care Unit
SO IEEE PERVASIVE COMPUTING
LA English
DT Article
DE Medical services; Feature extraction; Lung; Training; Biomedical
   monitoring; Couplings; Monitoring
ID MECHANICAL VENTILATION
AB Future healthcare systems will rely heavily on clinical decision support systems (CDSS) to improve the decision-making processes of clinicians. To explore the design of future CDSS, we developed a research-focused CDSS for the management of patients in the intensive care unit that leverages Internet of Things devices capable of collecting streaming physiologic data from ventilators and other medical devices. We then created machine learning models that could analyze the collected physiologic data to determine if the ventilator was delivering potentially harmful therapy and if a deadly respiratory condition, acute respiratory distress syndrome (ARDS), was present. We also present work to aggregate these models into a mobile application that can provide responsive, real-time alerts of changes in ventilation to providers. As illustrated in the recent COVID-19 pandemic, being able to accurately predict ARDS in newly infected patients can assist in prioritizing care. We show that CDSS may be used to analyze physiologic data for clinical event recognition and automated diagnosis, and we also highlight future research avenues for hospital CDSS.
C1 [Rehm, Gregory B.] Univ Calif Davis, Comp Sci, Davis, CA 95616 USA.
   [Woo, Sang Hoon; Chen, Xin Luigi] Univ Calif Davis, Davis, CA 95616 USA.
   [Kuhn, Brooks T.; Cortes-Puch, Irene; Adams, Jason Y.] Univ Calif Davis, Sch Med, Davis, CA 95616 USA.
   [Anderson, Nicholas R.] Univ Calif Davis, Publ Hlth Serv Dept, Davis, CA 95616 USA.
   [Anderson, Nicholas R.] Univ Calif Davis, Div Hlth Informat, Davis, CA 95616 USA.
   [Chuah, Chen-Nee] Univ Calif Davis, Elect & Comp Engn, Davis, CA 95616 USA.
RP Rehm, GB (corresponding author), Univ Calif Davis, Comp Sci, Davis, CA 95616 USA.
EM grehm@ucdavis.edu; tswoo@ucdavis.edu; luxchen@ucdavis.edu;
   btkuhn@ucdavis.edu; icortespuch@ucdavis.edu; nranderson@ucdavis.edu;
   jyadams@ucdavis.edu; chuah@ucdavis.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [F31 HL144028] Funding Source: Medline
CR Adams J., 2019, B24 CRIT CARE GONE W, V73
   Adams J. Y., 2017, SCI REP, V7, P1
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Berner E, 2007, CLIN DECISION SUPPOR, P3, DOI DOI 10.1007/978-0-387-38319-4_
   Blanch L, 2015, INTENS CARE MED, V41, P633, DOI 10.1007/s00134-015-3692-6
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Gholami B, 2018, COMPUT BIOL MED, V97, P137, DOI 10.1016/j.compbiomed.2018.04.016
   Halpern NA, 2013, CRIT CARE MED, V41, P2754, DOI 10.1097/CCM.0b013e318298a6fb
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   McKown AC, 2019, J INTENSIVE CARE MED, V34, P946, DOI 10.1177/0885066617720159
   Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1
   Ramirez II, 2017, RESP CARE, V62, P144, DOI 10.4187/respcare.04750
   Rehm GB, 2018, METHOD INFORM MED, V57, P208, DOI 10.3414/ME17-02-0012
   Rehm GB, 2018, J AM MED INFORM ASSN, V25, P295, DOI 10.1093/jamia/ocx116
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Sottile PD, 2018, CRIT CARE MED, V46, pE151, DOI 10.1097/CCM.0000000000002849
NR 16
TC 0
Z9 0
U1 3
U2 3
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA
SN 1536-1268
EI 1558-2590
J9 IEEE PERVAS COMPUT
JI IEEE Pervasive Comput.
PD JUL-SEP
PY 2020
VL 19
IS 3
BP 68
EP 78
DI 10.1109/MPRV.2020.2986767
PG 11
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA MX4LH
UT WOS:000557694700003
PM 32754005
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Berger, JR
   Brandstadter, R
   Bar-Or, A
AF Berger, Joseph R.
   Brandstadter, Rachel
   Bar-Or, Amit
TI COVID-19 and MS disease-modifying therapies
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
ID MULTIPLE-SCLEROSIS PATIENTS; CORONAVIRUS; INTERFERONS
AB Objective To address concerns regarding the effect of MS disease-modifying therapies (DMTs) on the expression of coronavirus 2019 (COVID-19). Methods Review of the current state of knowledge regarding the viral etiology of COVID-19, mechanisms of injury by SARS-CoV-2 infection, and the effect of individual DMTs on the risk of infection and COVID-19 disease expression. Results Although data are limited, MS DMTs do not obviously increase the risk of acquiring symptomatic SARS-CoV-2 infection. The severe morbidity and mortality of SARS-CoV-2 appear to be largely the consequence of an overly robust immune response rather than the consequence of unchecked viral replication. The effects of specific MS DMTs on the immune response that may increase the risk of impaired viral clearance and their potential counterbalancing beneficial effects on the development of COVID-19-associated acute respiratory distress syndrome are reviewed. Conclusion Although there is currently insufficient real-world experience to definitively answer the question of the effect of a specific MS DMT on COVID-19, registries presently in nascent form should provide these answers. This review provides an approach to addressing these concerns while the data are being accumulated. Early insights suggest that the risk of infection and associated morbidity of COVID-19 in this population is little different than that of the population at large.
C1 [Berger, Joseph R.; Brandstadter, Rachel; Bar-Or, Amit] Univ Penn, Div Multiple Sclerosis, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
RP Berger, JR (corresponding author), Univ Penn, Div Multiple Sclerosis, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
EM joseph.berger@pennmedicine.upenn.edu
CR Abbas AK, 2015, CELLULAR MOL IMMUNOL, P339
   Berger B, 2015, J NEUROIMMUNOL, V282, P118, DOI 10.1016/j.jneuroim.2015.03.022
   de Best R, COVID 19 DEATH RATES
   Delbue S, 2007, J NEUROVIROL, V13, P73, DOI 10.1080/13550280601094563
   Ditkoff M, 50 AWESOME QUOTES RI
   Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970
   Engineering CCfSSa, COR COVID 19 GLOB CA
   Faissner S, 2015, THER ADV NEUROL DISO, V8, P233, DOI 10.1177/1756285615594575
   Gonzalez-Suarez I, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.671
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Grebenciucova E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0800-8
   Guan WJ, 2020, N ENGL J MED
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hong J, 2002, MULT SCLER J, V8, P237, DOI 10.1191/1352458502ms794oa
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khademi M, 2000, J NEUROIMMUNOL, V103, P202, DOI 10.1016/S0165-5728(99)00184-8
   Kim HJ, 2004, J IMMUNOL, V172, P7144, DOI 10.4049/jimmunol.172.11.7144
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luna G., 2019, JAMA NEUROL
   McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787
   Miller CS, 2012, J NEUROVIROL, V18, P411, DOI 10.1007/s13365-012-0107-0
   Minden SL, 2004, NEUROREHABILITATION, V19, P55
   Oikonen MK, 2008, NEUROEPIDEMIOLOGY, V30, P13, DOI 10.1159/000113301
   PANITCH HS, 1994, ANN NEUROL, V36, pS25, DOI 10.1002/ana.410360709
   PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455
   Qin C, 2020, CLIN INFECT DIS
   Rieckmann P, 2004, DRUG SAFETY, V27, P745, DOI 10.2165/00002018-200427100-00005
   Rothuizen LE, 1999, J NEUROIMMUNOL, V99, P131, DOI 10.1016/S0165-5728(99)00029-6
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Sorensen PS, 2014, J NEUROL, V261, P1170, DOI 10.1007/s00415-014-7325-8
   Tian S, 2020, J INFECT
   Vaira LA, 2020, LARYNGOSCOPE, V130, P1787, DOI 10.1002/lary.28692
   Veldhuis TB, 2003, J CEREBR BLOOD F MET, V23, P1060, DOI 10.1097/01.WCB.0000080701.47016.24
   Wallin MT, 2019, NEUROLOGY, V92, pE1029, DOI 10.1212/WNL.0000000000007035
   Wang Z, 2020, CLIN INFECT DIS
   Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620
   Wygrecka M, 2008, THROMB HAEMOSTASIS, V99, P494, DOI 10.1160/TH07-11-0666
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD JUL
PY 2020
VL 7
IS 4
AR e761
DI 10.1212/NXI.0000000000000761
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MZ6LX
UT WOS:000559239400027
PM 32414755
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Drozdzal, S
   Rosik, J
   Lechowicz, K
   Machaj, F
   Szostak, B
   Majewski, P
   Rotter, I
   Kotfis, K
AF Drozdzal, Sylwester
   Rosik, Jakub
   Lechowicz, Kacper
   Machaj, Filip
   Szostak, Bartosz
   Majewski, Pawel
   Rotter, Iwona
   Kotfis, Katarzyna
TI COVID-19: Pain Management in Patients with SARS-CoV-2
   Infection-Molecular Mechanisms, Challenges, and Perspectives
SO BRAIN SCIENCES
LA English
DT Article
DE coronavirus; neuropathy; myalgia; arthralgia; headache; opioids; NSAIDs;
   CPOT; BPS
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; KILLER-CELL CYTOTOXICITY; CARE-UNIT
   PATIENTS; EXERCISE TOLERANCE; OBSERVATION TOOL; MORPHINE; FENTANYL;
   BREATHLESSNESS; IMMUNOSUPPRESSION; INFLAMMASOME
AB Since the end of 2019, the whole world has been struggling with the pandemic of the new Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2). Available evidence suggests that pain is a common symptom during Coronavirus Disease 2019 (COVID-19). According to the World Health Organization, many patients suffer from muscle pain (myalgia) and/or joint pain (arthralgia), sore throat and headache. The exact mechanisms of headache and myalgia during viral infection are still unknown. Moreover, many patients with respiratory failure get admitted to the intensive care unit (ICU) for ventilatory support. Pain in ICU patients can be associated with viral disease itself (myalgia, arthralgia, peripheral neuropathies), may be caused by continuous pain and discomfort associated with ICU treatment, intermittent procedural pain and chronic pain present before admission to the ICU. Undertreatment of pain, especially when sedation and neuromuscular blocking agents are used, prone positioning during mechanical ventilation or extracorporeal membrane oxygenation (ECMO) may trigger delirium and cause peripheral neuropathies. This narrative review summarizes current knowledge regarding challenges associated with pain assessment and management in COVID-19 patients. A structured prospective evaluation should be undertaken to analyze the probability, severity, sources and adequate treatment of pain in patients with COVID-19 infection.
C1 [Drozdzal, Sylwester] Pomeranian Med Univ, Dept Pharmacokinet & Monitored Therapy, PL-70111 Szczecin, Poland.
   [Rosik, Jakub; Machaj, Filip; Szostak, Bartosz] Pomeranian Med Univ, Dept Physiol, PL-70111 Szczecin, Poland.
   [Lechowicz, Kacper; Kotfis, Katarzyna] Pomeranian Med Univ, Dept Anesthesiol Intens Therapy & Acute Intoxicat, PL-70111 Szczecin, Poland.
   [Majewski, Pawel] Reg Specialist Hosp, Dept Anesthesiol & Intens Therapy, PL-72300 Gryfice, Poland.
   [Majewski, Pawel] Ceynowa Hosp, Dept Cardiac Surg, PL-84200 Wejherowo, Poland.
   [Rotter, Iwona] Pomeranian Med Univ, Dept Med Rehabil & Clin Physiotherapy, PL-71210 Szczecin, Poland.
RP Kotfis, K (corresponding author), Pomeranian Med Univ, Dept Anesthesiol Intens Therapy & Acute Intoxicat, PL-70111 Szczecin, Poland.
EM starkdrozd@wp.pl; jakubrosik97@gmail.com; kacper.lechowicz@gmail.com;
   machajf@gmail.com; bartszost1@gmail.com; lek.majewski.pawel@gmail.com;
   iwona.rotter@pum.edu.pl; katarzyna.kotfis@pum.edu.pl
RI Kotfis, Katarzyna/O-4355-2014; Rosik, Jakub/P-6960-2018
OI Kotfis, Katarzyna/0000-0001-8430-1369; Rosik, Jakub/0000-0001-7377-4566;
   Lechowicz, Kacper/0000-0002-0807-8510; Drozdzal,
   Sylwester/0000-0002-4082-2696
CR Abdelnour L, 2020, J FORMOS MED ASSOC, V119, P1119, DOI 10.1016/j.jfma.2020.04.024
   Accord Healthcare Limited, PREG ACC SMPC
   Acharya A, 2020, J NEUROIMMUNE PHARM, V15, P167, DOI 10.1007/s11481-020-09924-9
   [Anonymous], GEN OP REM MED BRIEF
   Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Banzett RB, 2011, AM J RESP CRIT CARE, V184, P920, DOI 10.1164/rccm.201101-0005OC
   Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011
   Bein B, 2020, GEBURTSH FRAUENHEILK, V80, P491, DOI 10.1055/a-1156-3991
   Boziki MK, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10060345
   Cata J.P., 2017, BASIC SCI ANESTH, V7, P123, DOI [10.1007/978-3-319-62067-1_7, DOI 10.1007/978-3-319-62067-1_7]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davis MP, 2020, ANN PALLIAT MED, V9, P611, DOI 10.21037/apm.2020.01.12
   Davis MP, 2018, DRUGS, V78, P1211, DOI 10.1007/s40265-018-0953-z
   Davis Mellar P, 2012, J Support Oncol, V10, P209, DOI 10.1016/j.suponc.2012.05.002
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Devlin John W, 2020, Crit Care Explor, V2, pe0139, DOI 10.1097/CCE.0000000000000139
   Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X
   Eccleston C, 2020, PAIN, V161, P889, DOI 10.1097/j.pain.0000000000001885
   Egunsola O, 2019, ANESTH ANALG, V128, P811, DOI 10.1213/ANE.0000000000003936
   Ekstrom M, 2015, ANN AM THORAC SOC, V12, P1079, DOI 10.1513/AnnalsATS.201501-034OC
   Evavold CL, 2018, J MOL BIOL, V430, P217, DOI 10.1016/j.jmb.2017.09.019
   Fausto J, 2020, J PAIN SYMPTOM MANAG, V60, pE21, DOI 10.1016/j.jpainsymman.2020.03.025
   Fiebich BL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00260
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   FLORES LR, 1995, J PHARMACOL EXP THER, V272, P1246
   Forget P, 2010, EUR J ANAESTH, V27, P233, DOI 10.1097/EJA.0b013e32832d540e
   Friedewald VE, 2010, AM J CARDIOL, V106, P873, DOI 10.1016/j.amjcard.2010.04.006
   Gelinas C, 2006, AM J CRIT CARE, V15, P420
   Gelinas C, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.01.013
   Goesling J, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0421-0
   Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018
   Hanidziar D, 2020, ANESTH ANALG, V131, pE40, DOI 10.1213/ANE.0000000000004887
   Hao Dong, 2005, Zhonghua Nei Ke Za Zhi, V44, P890
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   HERNANDEZ MC, 1993, J PHARMACOL EXP THER, V267, P1336
   Hoffmann S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113764
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hulot JS, 2020, ARCH CARDIOVASC DIS, V113, P225, DOI 10.1016/j.acvd.2020.03.009
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Kaluzna-Oleksy M, 2020, KARDIOL POL, V78, P618, DOI 10.33963/KP.15359
   Kessler TL., 2017, CLIN PHARM, V9, P1, DOI [10.1211/CP.2017.20203641, DOI 10.1211/CP.2017.20203641]
   Khan S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174262
   Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009
   Kishor K, 2020, J PAK MED ASSOC, V70, pS77, DOI 10.5455/JPMA.14
   Kotfis K, 2020, ANAESTH INTENSIVE TH, V52, P132, DOI 10.5114/ait.2020.95164
   Kotfis K, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02882-x
   Kotfis K, 2020, ANAESTH INTENSIVE TH, V52, P171, DOI 10.5114/ait.2020.93867
   Kotfis K, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012443
   Kotfis K, 2018, ARCH MED SCI, V14, P880, DOI 10.5114/aoms.2017.69752
   Kotfis K, 2017, ANAESTH INTENSIVE TH, V49, P66, DOI 10.5603/AIT.2017.0010
   Kotsiou OS, 2017, RESP MED, V123, P28, DOI 10.1016/j.rmed.2016.12.005
   Kuo A, 2015, BRIT J PHARMACOL, V172, P532, DOI 10.1111/bph.12696
   Lampl C, 2014, SCHMERZ, V28, P584, DOI 10.1007/s00482-014-1490-7
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   LIGHT RW, 1989, AM REV RESPIR DIS, V139, P126, DOI 10.1164/ajrccm/139.1.126
   Lim H, 2013, J BIOL CHEM, V288, P7572, DOI 10.1074/jbc.M112.414904
   Madhok J, 2020, ANESTH ANALG, V131, pE123, DOI 10.1213/ANE.0000000000004960
   Manjavachi MN, 2010, PAIN, V151, P345, DOI 10.1016/j.pain.2010.07.018
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Mercadante S, 2020, J PAIN SYMPTOM MANAG, V60, pE79, DOI 10.1016/j.jpainsymman.2020.04.025
   Micallef J, 2020, THERAPIE, V75, P355, DOI 10.1016/j.therap.2020.05.003
   Montalvan V, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105921
   Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246
   Narahara H, 2013, J ANESTH, V27, P676, DOI 10.1007/s00540-013-1597-5
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Omar A., 2020, MOL DOCKING REVEALS, DOI [10.26434/chemrxiv.12061302.v1., DOI 10.26434/CHEMRXIV.12061302.V1]
   Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pettus K, 2020, J PAIN SYMPTOM MANAG, V60, pE48, DOI 10.1016/j.jpainsymman.2020.04.153
   PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0
   Piraccini E, 2020, J CLIN ANESTH, V65, DOI 10.1016/j.jclinane.2020.109852
   Pleasure SJ, 2020, JAMA NEUROL, V77, P679, DOI 10.1001/jamaneurol.2020.1065
   Pop-Busui R, 2017, DIABETES CARE, V40, P136, DOI 10.2337/dc16-2042
   Rinott E, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.06.003
   Rozen T, 2007, HEADACHE, V47, P1050, DOI 10.1111/j.1526-4610.2006.00722.x
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Schaefer L, 2014, J BIOL CHEM, V289, P35237, DOI 10.1074/jbc.R114.619304
   Schonhofer P, 2003, LANCET, V361, P968, DOI 10.1016/S0140-6736(03)12751-1
   Shanthanna H, 2020, ANAESTHESIA, V75, P935, DOI 10.1111/anae.15076
   Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444
   Sheraton M, 2020, CUREUS, V12, DOI 10.7759/cureus.8192
   Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373
   Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Su S, 2020, BRAIN BEHAV IMMUN, V87, P159, DOI 10.1016/j.bbi.2020.05.025
   The British Pain Society, PAIN MAN COVID 19 VI
   Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609
   Villa A, 2019, FRONT NEUROENDOCRIN, V52, P156, DOI 10.1016/j.yfrne.2018.11.003
   Vozoris NT, 2020, ANN AM THORAC SOC, V17, P965, DOI 10.1513/AnnalsATS.201910-760OC
   Vozoris NT, 2020, ANN PALLIAT MED, V9, P571, DOI 10.21037/apm.2019.11.04
   Vozoris NT, 2016, EUR RESPIR J, V48, P683, DOI 10.1183/13993003.01967-2015
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wang LY, 2016, SPRINGER PROTOC HAND, P3, DOI 10.1007/978-1-4939-3414-0_1
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, CLIN MAN SEV AC RESP
   Wiese AD, 2019, CLIN INFECT DIS, V68, P1862, DOI 10.1093/cid/ciy809
   Wong SSY, 2008, J ANTIMICROB CHEMOTH, V62, P437, DOI 10.1093/jac/dkn243
   WOODCOCK AA, 1981, NEW ENGL J MED, V305, P1611, DOI 10.1056/NEJM198112313052703
   World Health Organization, US NONST ANT DRUGS N
   Yamaguchi T, 2019, J PAIN SYMPTOM MANAG, V58, P672, DOI 10.1016/j.jpainsymman.2019.06.006
   Yamamoto Y, 2018, JPN J CLIN ONCOL, V48, P748, DOI 10.1093/jjco/hyy079
   Yardeni Israel Z, 2008, J Opioid Manag, V4, P27
   Yousefifard M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13557
   Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077
   Zhang XS, 2008, J VIROL, V82, P4420, DOI 10.1128/JVI.02190-07
   Zilliox Lindsay A, 2017, Continuum (Minneap Minn), V23, P512, DOI 10.1212/CON.0000000000000462
NR 115
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3425
J9 BRAIN SCI
JI Brain Sci.
PD JUL
PY 2020
VL 10
IS 7
AR 465
DI 10.3390/brainsci10070465
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA MW6YQ
UT WOS:000557179900001
PM 32698378
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gervasoni, S
   Vistoli, G
   Talarico, C
   Manelfi, C
   Beccari, AR
   Studer, G
   Tauriello, G
   Waterhouse, AM
   Schwede, T
   Pedretti, A
AF Gervasoni, Silvia
   Vistoli, Giulio
   Talarico, Carmine
   Manelfi, Candida
   Beccari, Andrea R.
   Studer, Gabriel
   Tauriello, Gerardo
   Waterhouse, Andrew Mark
   Schwede, Torsten
   Pedretti, Alessandro
TI A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2
   Therapeutically Relevant Proteins by Combining Pocket and Docking
   Searches as Implemented in Pockets 2.0
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE SARS-CoV-2; pocket search; pocket druggability; docking simulations;
   virtual screening; blind docking
ID CORONAVIRUS NUCLEOCAPSID PROTEIN; DEPENDENT RNA-POLYMERASE;
   SARS-CORONAVIRUS; STRUCTURAL BASIS; ALLOSTERIC INHIBITORS;
   MOLECULAR-DYNAMICS; ANTIVIRAL ACTIVITY; BINDING-SITES; OPTIMIZATION;
   MECHANISM
AB (1) Background: Virtual screening studies on the therapeutically relevant proteins of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) require a detailed characterization of their druggable binding sites, and, more generally, a convenient pocket mapping represents a key step for structure-based in silico studies; (2) Methods: Along with a careful literature search on SARS-CoV-2 protein targets, the study presents a novel strategy for pocket mapping based on the combination of pocket (as performed by the well-known FPocket tool) and docking searches (as performed by PLANTS or AutoDock/Vina engines); such an approach is implemented by the Pockets 2.0 plug-in for the VEGA ZZ suite of programs; (3) Results: The literature analysis allowed the identification of 16 promising binding cavities within the SARS-CoV-2 proteins and the here proposed approach was able to recognize them showing performances clearly better than those reached by the sole pocket detection; and (4) Conclusions: Even though the presented strategy should require more extended validations, this proved successful in precisely characterizing a set of SARS-CoV-2 druggable binding pockets including both orthosteric and allosteric sites, which are clearly amenable for virtual screening campaigns and drug repurposing studies. All results generated by the study and the Pockets 2.0 plug-in are available for download.
C1 [Gervasoni, Silvia; Vistoli, Giulio; Pedretti, Alessandro] Univ Milan, Dipartimento Sci Farmaceut, Via Mangiagalli 25, I-20133 Milan, Italy.
   [Talarico, Carmine; Manelfi, Candida; Beccari, Andrea R.] Dompe Farmaceut SpA, Via Campo Pile, I-67100 Laquila, Italy.
   [Studer, Gabriel; Tauriello, Gerardo; Waterhouse, Andrew Mark; Schwede, Torsten] Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.
   [Studer, Gabriel; Tauriello, Gerardo; Waterhouse, Andrew Mark; Schwede, Torsten] Univ Basel, SIB Swiss Inst Bioinformat, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.
RP Pedretti, A (corresponding author), Univ Milan, Dipartimento Sci Farmaceut, Via Mangiagalli 25, I-20133 Milan, Italy.
EM silvia.gervasoni@unimi.it; giulio.vistoli@unimi.it;
   carmine.talarico@dompe.com; candida.manelfi@dompe.com;
   andrea.beccari@dompe.com; gabriel.studer@unibas.ch;
   gerardo.tauriello@unibas.ch; andrew.waterhouse@unibas.ch;
   torsten.schwede@unibas.ch; alessandro.pedretti@unimi.it
RI Schwede, Torsten/A-4650-2008
OI Schwede, Torsten/0000-0003-2715-335X; Talarico,
   Carmine/0000-0003-4789-0955; Tauriello, Gerardo/0000-0002-5921-7007;
   BECCARI, ANDREA ROSARIO/0000-0001-6830-2695; PEDRETTI,
   ALESSANDRO/0000-0001-5916-2029; Gervasoni, Silvia/0000-0002-5731-3396
FU EUEuropean Union (EU) [101003551]
FX This research was conducted under the project "EXaSCale smArt pLatform
   Against paThogEns for Corona Virus-Exscalate4CoV" founded by the EU's
   H2020-SC1-PHE-CORONAVIRUS-2020 call, grant N. 101003551.
CR Abdurakhmanov E, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060151
   AminJafari A, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106455
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Benvenuto D., 2020, SSRN ELECT J, V163, P4453, DOI [10.2139/ssrn.3558013, DOI 10.2139/SSRN.3558013]
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chakrabarti S, 2011, MOL CELL, V41, P693, DOI 10.1016/j.molcel.2011.02.010
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Cottam EM, 2014, AUTOPHAGY, V10, P1426, DOI 10.4161/auto.29309
   Davis BC, 2015, BIOPHYS J, V108, P1785, DOI 10.1016/j.bpj.2015.03.005
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Deore RR, 2010, CURR MED CHEM, V17, P3806
   Di Marco S, 2005, J BIOL CHEM, V280, P29765, DOI 10.1074/jbc.M505423200
   Dias S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223596
   Dias SED, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1913-4
   Eastman P, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005659
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   Hendlich M, 1997, J MOL GRAPH MODEL, V15, P359, DOI 10.1016/S1093-3263(98)00002-3
   Heo Lim, 2020, bioRxiv, DOI 10.1101/2020.03.25.008904
   Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1
   Hussein HA, 2017, DRUG DISCOV TODAY, V22, P404, DOI 10.1016/j.drudis.2016.11.021
   Ismail NSM, 2017, J RECEPT SIG TRANSD, V37, P341, DOI 10.1080/10799893.2016.1248293
   Jacome R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139001
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kawabata T, 2010, PROTEINS, V78, P1195, DOI 10.1002/prot.22639
   Kellenberger E, 2006, J CHEM INF MODEL, V46, P717, DOI 10.1021/ci050372x
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Korb O, 2009, J CHEM INF MODEL, V49, P84, DOI 10.1021/ci800298z
   Krivov GG, 2009, PROTEINS, V77, P778, DOI 10.1002/prot.22488
   KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Le Guilloux V, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-168
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li H, 2006, BIOORG MED CHEM LETT, V16, P4834, DOI 10.1016/j.bmcl.2006.06.065
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lundin A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004166
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Macari G, 2019, J COMPUT AID MOL DES, V33, P887, DOI 10.1007/s10822-019-00235-7
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065
   Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000
   Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2
   Pedretti A, 2002, J MOL GRAPH MODEL, V21, P47, DOI 10.1016/S1093-3263(02)00123-7
   Perot S, 2010, DRUG DISCOV TODAY, V15, P656, DOI 10.1016/j.drudis.2010.05.015
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Ponnusamy R, 2008, J MOL BIOL, V383, P1081, DOI 10.1016/j.jmb.2008.07.071
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Saalau-Bethell SM, 2012, NAT CHEM BIOL, V8, P920, DOI [10.1038/nchembio.1081, 10.1038/NCHEMBIO.1081]
   Shadrick WR, 2013, J BIOMOL SCREEN, V18, P761, DOI 10.1177/1087057113482586
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shaw AN, 2009, BIOORG MED CHEM LETT, V19, P4350, DOI 10.1016/j.bmcl.2009.05.091
   Stank A, 2016, ACCOUNTS CHEM RES, V49, P809, DOI 10.1021/acs.accounts.5b00516
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Studer G, 2020, BIOINFORMATICS, V36, P1765, DOI 10.1093/bioinformatics/btz828
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xi JB, 2005, 2005 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P247
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang LQ, 2018, J VIROL, V92, DOI 10.1128/JVI.00893-18
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 70
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 14
AR 5152
DI 10.3390/ijms21145152
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MX4PV
UT WOS:000557707300001
PM 32708196
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sakaida, T
   Tanimoto, I
   Matsubara, A
   Nakamura, M
   Morita, A
AF Sakaida, Takashi
   Tanimoto, Isao
   Matsubara, Akihiro
   Nakamura, Motoki
   Morita, Akimichi
TI Unique skin manifestations of COVID-19: Is drug eruption specific to
   COVID-19?
SO JOURNAL OF DERMATOLOGICAL SCIENCE
LA English
DT Letter
C1 [Sakaida, Takashi] Inazawa Kosei Hosp, Div Dermatol, Inazawa City, Japan.
   [Tanimoto, Isao] Inazawa Kosei Hosp, Div Internal Med, Inazawa City, Japan.
   [Sakaida, Takashi; Matsubara, Akihiro; Nakamura, Motoki; Morita, Akimichi] Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan.
RP Morita, A (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
EM amorita@med.nagoya-cu.ac.jp
OI Nakamura, Motoki/0000-0003-4431-7782
CR Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng Y, 2020, J EUR ACAD DERMATOL, V34, pE210, DOI 10.1111/jdv.16390
NR 5
TC 5
Z9 6
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0923-1811
EI 1873-569X
J9 J DERMATOL SCI
JI J. Dermatol. Sci.
PD JUL
PY 2020
VL 99
IS 1
BP 62
EP 64
DI 10.1016/j.jdermsci.2020.05.002
PG 3
WC Dermatology
SC Dermatology
GA MZ1BD
UT WOS:000558856100008
PM 32425356
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sinha, S
   Cheng, KY
   Schaffer, AA
   Aldape, K
   Schiff, E
   Ruppin, E
AF Sinha, Sanju
   Cheng, Kuoyuan
   Schaffer, Alejandro A.
   Aldape, Kenneth
   Schiff, Eyal
   Ruppin, Eytan
TI In vitroandin vivoidentification of clinically approved drugs that
   modifyACE2expression
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
DE angiotensin I-converting enzyme 2; coronavirus disease 2019;
   dexamethasone; drug-modifyingACE2expression; severe acute respiratory
   syndrome coronavirus 2
ID CONVERTING ENZYME 2; RECEPTOR BLOCKERS; ANGIOTENSIN; INHIBITORS; VIRUS
AB TheCOVID-19 pandemic caused bySARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor forSARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated withACEinhibitors (ACEIs) or angiotensin receptor blockers have a higher risk ofCOVID-19 infection as these drugs could upregulateACE2, motivating the study ofACE2modulation by drugs in current clinical use. Here, we mined published datasets to determine the effects of hundreds of clinically approved drugs onACE2expression. We find thatACEIs are enriched forACE2-upregulating drugs, while antineoplastic agents are enriched forACE2-downregulating drugs. Vorinostat and isotretinoin are the topACE2up/downregulators, respectively, in cell lines. Dexamethasone, a corticosteroid used in treating severe acute respiratory syndrome andCOVID-19, significantly upregulatesACE2bothin vitroandin vivo. Further topACE2regulatorsin vivoor in primary cells include erlotinib and bleomycin in the lung and vancomycin, cisplatin, and probenecid in the kidney. Our study provides leads for future work studyingACE2expression modulators.
C1 [Sinha, Sanju; Cheng, Kuoyuan; Schaffer, Alejandro A.; Ruppin, Eytan] NCI, Canc Data Sci Lab CDSL, NIH, Bethesda, MD 20892 USA.
   [Sinha, Sanju; Cheng, Kuoyuan] Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA.
   [Aldape, Kenneth] NCI, Lab Pathol, NIH, Bethesda, MD 20892 USA.
   [Schiff, Eyal] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Dept Obstet Gynecol & Reprod Sci, Tel Aviv, Israel.
RP Ruppin, E (corresponding author), NCI, Canc Data Sci Lab CDSL, NIH, Bethesda, MD 20892 USA.
EM eyruppin@gmail.com
OI Schaffer, Alejandro/0000-0002-2147-8033; Cheng,
   Kuoyuan/0000-0001-8118-5243
FU Intramural Research Program of the National Institutes of Health, NCI;
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); NCI-UMD Partnership for Integrative Cancer Research
   Program
FX This research was supported in part by the Intramural Research Program
   of the National Institutes of Health, NCI, and used the computational
   resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov).We
   acknowledge and thank the National Cancer Institute for providing
   financial and infrastructural support. S.S and K.C. are supported by the
   NCI-UMD Partnership for Integrative Cancer Research Program. We thank
   Dr. Fiorella Schischlik, Sanna Madan, and Dr. Brid Ryan for constructive
   comments on this study.
CR Bekerman E, 2017, J CLIN INVEST, V127, P1338, DOI 10.1172/JCI89857
   Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5
   Brielle E. S., 2020, VIRUSES, V12, P497
   Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dimou C, 2019, J HUM HYPERTENS, V33, P188, DOI 10.1038/s41371-018-0138-y
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gorpelioglu C, 2010, INT J DERMATOL, V49, P87, DOI 10.1111/j.1365-4632.2009.04232.x
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Jiang F, 2014, NAT REV CARDIOL, V11, P413, DOI 10.1038/nrcardio.2014.59
   Korotkevich G., 2019, FAST GENE SET ENRICH, DOI [10.1101/060012, DOI 10.1101/060012]
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Liang YX, 2015, KIDNEY BLOOD PRESS R, V40, P101, DOI 10.1159/000368486
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lyu X, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319862697
   Maher TM, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1161-4
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Paz Ocaranza Maria, 2020, Nat Rev Cardiol, V17, P116, DOI 10.1038/s41569-019-0244-8
   Perwitasari O, 2013, ANTIMICROB AGENTS CH, V57, P475, DOI 10.1128/AAC.01532-12
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Uhal B, 2010, ALVEOLAR EPITHELIAL, VA58, P1, DOI [10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1979, DOI 10.1164/AJRCCM-CONFERENCE.2010.181.1_MEETINGABSTRACTS.A1979]
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World health Organization (last), 2006, WHO COLL CTR DRUG ST
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520
NR 35
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD JUL
PY 2020
VL 16
IS 7
AR e9628
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MX1HO
UT WOS:000557477800007
PM 32729248
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Olubiyi, OO
   Olagunju, M
   Keutmann, M
   Loschwitz, J
   Strodel, B
AF Olubiyi, Olujide O.
   Olagunju, Maryam
   Keutmann, Monika
   Loschwitz, Jennifer
   Strodel, Birgit
TI High Throughput Virtual Screening to Discover Inhibitors of the Main
   Protease of the Coronavirus SARS-CoV-2
SO MOLECULES
LA English
DT Article
DE COVID-19; docking; drug repurposing; natural products; in silico drug
   design; viral replication inhibition
ID RESPIRATORY SYNDROME-CORONAVIRUS; COV 3CL PROTEASE; ANTIVIRAL
   ACTIVITIES; FORCE-FIELD; SARS; ZINC; BIFLAVONOIDS; DOCKING; CHEMISTRY;
   EFFICIENT
AB We use state-of-the-art computer-aided drug design (CADD) techniques to identify prospective inhibitors of the main protease enzyme, 3CL(pro)of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19. From our screening of over one million compounds including approved drugs, investigational drugs, natural products, and organic compounds, and a rescreening protocol incorporating enzyme dynamics via ensemble docking, we have been able to identify a range of prospective 3CL(pro)inhibitors. Importantly, some of the identified compounds had previously been reported to exhibit inhibitory activities against the 3CL(pro)enzyme of the closely related SARS-CoV virus. The top-ranking compounds are characterized by the presence of multiple bi- and monocyclic rings, many of them being heterocycles and aromatic, which are flexibly linked allowing the ligands to adapt to the geometry of the 3CL(pro)substrate site and involve a high amount of functional groups enabling hydrogen bond formation with surrounding amino acid residues, including the catalytic dyad residues H41 and C145. Among the top binding compounds we identified several tyrosine kinase inhibitors, which include a bioflavonoid, the group of natural products that binds best to 3CL(pro). Another class of compounds that decently binds to the SARS-CoV-2 main protease are steroid hormones, which thus may be endogenous inhibitors and might provide an explanation for the age-dependent severity of COVID-19. Many of the compounds identified by our work show a considerably stronger binding than found for reference compounds with in vitro demonstrated 3CL(pro)inhibition and anticoronavirus activity. The compounds determined in this work thus represent a good starting point for the design of inhibitors of SARS-CoV-2 replication.
C1 [Olubiyi, Olujide O.; Olagunju, Maryam; Keutmann, Monika; Loschwitz, Jennifer; Strodel, Birgit] Forschungszentrum Julich, Inst Biol Informat Proc Struct Biochem, D-52428 Julich, Germany.
   [Olubiyi, Olujide O.] Obafemi Awolowo Univ, Fac Pharm, Dept Pharmaceut Chem, Ife 220005, Nigeria.
   [Loschwitz, Jennifer; Strodel, Birgit] Heinrich Heine Univ Dusseldorf, Inst Theoret & Computat Chem, D-40225 Dusseldorf, Germany.
RP Olubiyi, OO; Strodel, B (corresponding author), Forschungszentrum Julich, Inst Biol Informat Proc Struct Biochem, D-52428 Julich, Germany.; Olubiyi, OO (corresponding author), Obafemi Awolowo Univ, Fac Pharm, Dept Pharmaceut Chem, Ife 220005, Nigeria.; Strodel, B (corresponding author), Heinrich Heine Univ Dusseldorf, Inst Theoret & Computat Chem, D-40225 Dusseldorf, Germany.
EM olubiyioo@oauife.edu.ng; m.olagunju@fz-juelich.de;
   Monika.Keutmann@uni-duesseldorf.de;
   Jennifer.Loschwitz@uni-duesseldorf.de; b.strodel@fz-juelich.de
RI Strodel, Birgit/H-5449-2013
OI Strodel, Birgit/0000-0002-8734-7765; Olubiyi,
   Olujide/0000-0002-9412-6776; Loschwitz, Jennifer/0000-0002-9066-1923
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German
   Research Foundation (DFG) [INST 208/704-1 FUGG]; Zentrum fur
   Informations-und Medientechnologie (ZIM) at Heinrich-Heine University
FX The authors gratefully acknowledge the computing time granted through
   JARA-HPC (project COVID19MD) on the supercomputer JURECA at
   Forschungszentrum Julich [80], the hybrid computer cluster purchased
   from funding by the Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) project number INST 208/704-1 FUGG, and the Zentrum
   fur Informations-und Medientechnologie (ZIM) at Heinrich-Heine
   University. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2015, PYMOL MOL GRAPH SYST
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bennardo F, 2020, ORAL ONCOL, V106, DOI 10.1016/j.oraloncology.2020.104659
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cetina-Montejo L, 2019, ARCH VIROL, V164, P1543, DOI 10.1007/s00705-019-04223-y
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Chen HJ, 2019, POULTRY SCI, V98, P6367, DOI 10.3382/ps/pez465
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Coulerie P, 2013, PLANTA MED, V79, P1313, DOI 10.1055/s-0033-1350672
   CSSE J, 2020, COR COVID 19 GLOB CA
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DerMarderosian A., 2012, REV NATURAL PRODUCTS
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v1, DOI 10.26434/CHEMRXIV.12032712.V1]
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Gebre-Mariam T, 2006, J ETHNOPHARMACOL, V104, P182, DOI 10.1016/j.jep.2005.08.071
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guo YJ, 2015, MOL NEUROBIOL, V52, P1547, DOI 10.1007/s12035-014-8947-7
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Ivani I, 2016, NAT METHODS, V13, P55, DOI [10.1038/NMETH.3658, 10.1038/nmeth.3658]
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Jurrus E, 2018, PROTEIN SCI, V27, P112, DOI 10.1002/pro.3280
   Katayama H, 2005, Patent No. [JP2005314316A, 2005314316]
   Krause D, 2018, J LARGE SCALE RES FA, V4, P132, DOI [10.17815/jlsrf-4-121-1, DOI 10.17815/JLSRF-4-121-1]
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   LI F, 2019, VIRUSES-BASEL, V11, DOI DOI 10.3390/v11050466
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lin YM, 1999, PLANTA MED, V65, P120, DOI 10.1055/s-1999-13971
   Lin YM, 1997, J NAT PROD, V60, P884, DOI 10.1021/np9700275
   Ma SC, 2001, BIOL PHARM BULL, V24, P311, DOI 10.1248/bpb.24.311
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Miki K, 2007, BIOORG MED CHEM LETT, V17, P772, DOI 10.1016/j.bmcl.2006.10.075
   Ohba M, 2017, J ANTIBIOT, V70, P443, DOI 10.1038/ja.2016.128
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P2386, DOI 10.1001/jama.2020.8946
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Santos-Martins D, 2014, J CHEM INF MODEL, V54, P2371, DOI 10.1021/ci500209e
   Schlagenhauf P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101658
   Schroeder M., 2020, MAJORITY MALE PATIEN, DOI [10.1101/2020.05.07.20073817, DOI 10.1101/2020.05.07.20073817]
   Shastri A, 2020, DELAYED CLEARANCE SA, DOI [10.1101/2020.04.16.20060566., 10.1101/2020.04.16.20060566, DOI 10.1101/2020.04.16.20060566]
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   Singh N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2320
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Streeck HBS, 2020, INFECT FATALITY RATE, DOI [10.1101/2020.05.04.20090076, DOI 10.1101/2020.05.04.20090076]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang QM, 1997, ANAL BIOCHEM, V252, P238, DOI 10.1006/abio.1997.2315
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wilsky S, 2012, ARCH VIROL, V157, P259, DOI 10.1007/s00705-011-1164-z
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yeo SG, 2015, ARCH PHARM RES, V38, P193, DOI 10.1007/s12272-014-0390-9
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 78
TC 6
Z9 6
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2020
VL 25
IS 14
AR 3193
DI 10.3390/molecules25143193
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MW8MM
UT WOS:000557286200001
PM 32668701
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dumonteil, E
   Herrera, C
AF Dumonteil, Eric
   Herrera, Claudia
TI Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic
   Antigens: Implications for Immune Evasion and Serologic Diagnostic
   Performance
SO PATHOGENS
LA English
DT Article
DE antigenic drift; diversifying selection; coronavirus; immune evasion;
   diversity
AB The ongoing SARS-CoV-2 pandemic has triggered multiple efforts for serological tests and vaccine development. Most of these tests and vaccines are based on the Spike glycoprotein (S) or the Nucleocapsid (N) viral protein. Conservation of these antigens among viral strains is critical to ensure optimum diagnostic test performance and broad protective efficacy, respectively. We assessed N and S antigen diversity from 17,853 SARS-CoV-2 genome sequences and evaluated selection pressure. Up to 6-7 incipient phylogenetic clades were identified for both antigens, confirming early variants of the S antigen and identifying new ones. Significant diversifying selection was detected at multiple sites for both antigens. Some sequence variants have already spread in multiple regions, in spite of their low frequency. In conclusion, the N and S antigens of SARS-CoV-2 are well-conserved antigens, but new clades are emerging and may need to be included in future diagnostic and vaccine formulations.
C1 [Dumonteil, Eric; Herrera, Claudia] Tulane Univ, Dept Trop Med, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA.
   [Dumonteil, Eric; Herrera, Claudia] Tulane Univ, Vector Borne & Infect Dis Res Ctr, New Orleans, LA 70112 USA.
RP Dumonteil, E; Herrera, C (corresponding author), Tulane Univ, Dept Trop Med, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA.; Dumonteil, E; Herrera, C (corresponding author), Tulane Univ, Vector Borne & Infect Dis Res Ctr, New Orleans, LA 70112 USA.
EM edumonte@tulane.edu; cherrera@tulane.edu
OI Dumonteil, Eric/0000-0001-9376-0209
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   ALGER J, 2020, MATERN CHILD HL 0716, DOI DOI 10.21203/rs.3.rs-34571/v1
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Ngandu NK, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-164
   Oliveira ERA, 2019, FEBS LETT, V593, P3496, DOI 10.1002/1873-3468.13682
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pond SLK, 2020, MOL BIOL EVOL, V37, P295, DOI 10.1093/molbev/msz197
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Sashittal P., 2020, BIORXIV, DOI [10.1101/2020.05.07.083410, DOI 10.1101/2020.05.07.083410]
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Vemula SV, 2017, EXPERT REV VACCINES, V16, P1141, DOI 10.1080/14760584.2017.1379396
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Whitman Jeffrey D, 2020, medRxiv, DOI 10.1101/2020.04.25.20074856
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD JUL
PY 2020
VL 9
IS 7
AR 584
DI 10.3390/pathogens9070584
PG 10
WC Microbiology
SC Microbiology
GA MW7FA
UT WOS:000557196500001
PM 32709055
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Czernek, J
   Brus, J
AF Czernek, Jiri
   Brus, Jiri
TI Polymorphic Forms of Valinomycin Investigated by NMR Crystallography
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE valinomycin; antiviral; 2019-nCoV; solid-state NMR; NMR crystallography;
   DFT; GIPAW
ID O-17 NMR; CRYSTAL; CONFORMATION; PARAMETERS
AB A dodecadepsipeptide valinomycin (VLM) has been most recently reported to be a potential anti-coronavirus drug that could be efficiently produced on a large scale. It is thus of importance to study solid-phase forms of VLM in order to be able to ensure its polymorphic purity in drug formulations. The previously available solid-state NMR (SSNMR) data are combined with the plane-wave DFT computations in the NMR crystallography framework. Structural/spectroscopical predictions (the PBE functional/GIPAW method) are obtained to characterize four polymorphs of VLM. Interactions which confer a conformational stability to VLM molecules in these crystalline forms are described in detail. The way how various structural factors affect the values of SSNMR parameters is thoroughly analyzed, and several SSNMR markers of the respective VLM polymorphs are identified. The markers are connected to hydrogen bonding effects upon the corresponding (C-13/N-15/H-1) isotropic chemical shifts of (C-O, N-amid, H-amid, H-alpha) VLM backbone nuclei. These results are expected to be crucial for polymorph control of VLM and in probing its interactions in dosage forms.
C1 [Czernek, Jiri; Brus, Jiri] Czech Acad Sci, Inst Macromol Chem, Heyrovsky Sq 2, Prague 16206, Czech Republic.
RP Czernek, J (corresponding author), Czech Acad Sci, Inst Macromol Chem, Heyrovsky Sq 2, Prague 16206, Czech Republic.
EM czernek@imc.cas.cz; brus@imc.cas.cz
RI Brus, Jiri/G-3459-2014; Czernek, Jiri/H-6708-2014
OI Brus, Jiri/0000-0003-2692-612X; 
FU Ministry of Education, Youth and Sports of the Czech RepublicMinistry of
   Education, Youth & Sports - Czech Republic [LTAUSA18011]
FX Ministry of Education, Youth and Sports of the Czech Republic project
   LTAUSA18011.
CR AHLRICHS R, 1989, CHEM PHYS LETT, V162, P165, DOI 10.1016/0009-2614(89)85118-8
   Ahn JM, 2017, COMPREHENSIVE MEDICINAL CHEMISTRY III, VOL 6: BIOLOGICS MEDICINE, P66, DOI 10.1016/B978-0-12-409547-2.12413-8
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, SCIENCEDAILY
   Awosanya EO, 2020, ANGEW CHEM INT EDIT, V59, P3554, DOI 10.1002/anie.201915110
   BIOVIA, MAT STUD DASS SYST
   Bonhomme C, 2018, CHEM COMMUN, V54, P9591, DOI 10.1039/c8cc05193c
   Bonhomme C, 2012, CHEM REV, V112, P5733, DOI 10.1021/cr300108a
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Carnevale D, 2018, COMMUN CHEM, V1, DOI 10.1038/s42004-018-0072-5
   Cheng YQ, 2006, CHEMBIOCHEM, V7, P471, DOI 10.1002/cbic.200500425
   Clark SJ, 2005, Z KRISTALLOGR, V220, P567, DOI 10.1524/zkri.220.5.567.65075
   Czernek J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082700
   Czernek J, 2019, MOLECULES, V24, DOI 10.3390/molecules24091731
   Czernek J, 2018, CRYSTALS, V8, DOI 10.3390/cryst8100378
   Czernek J, 2012, CHEM PHYS LETT, V527, P31, DOI 10.1016/j.cplett.2012.01.013
   DITCHFIELD R, 1974, MOL PHYS, V27, P789, DOI 10.1080/00268977400100711
   Eichkorn K, 1997, THEOR CHEM ACC, V97, P119, DOI 10.1007/s002140050244
   Frish M.J., 2013, GAUSSIAN 09 REVISION
   Harris R.K., 2009, NMR CRYSTALLOGRAPHY
   Hilfkier R., 2019, POLYM PHARM IND SOLI
   Hodgkinson P, 2020, PROG NUCL MAG RES SP, V118-119, P10, DOI 10.1016/j.pnmrs.2020.03.001
   Kameda T, 2004, J BIOMOL NMR, V29, P281, DOI 10.1023/B:JNMR.0000032557.71691.a2
   KARLE IL, 1988, J AM CHEM SOC, V110, P3253, DOI 10.1021/ja00218a040
   KARLE IL, 1975, J AM CHEM SOC, V97, P4379, DOI 10.1021/ja00848a041
   Kong XQ, 2013, J PHYS CHEM B, V117, P9643, DOI 10.1021/jp405233f
   Kraus J, 2020, CHEMPHYSCHEM, V21, P1436, DOI 10.1002/cphc.202000249
   Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758
   Lu J.S, 2017, ANGEW CHEM, V129, P6262, DOI [10.1002/ange.201700488, DOI 10.1002/ANGE.201700488]
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   NEUPERTLAVES K, 1975, HELV CHIM ACTA, V58, P432, DOI 10.1002/hlca.19750580212
   Paruzzo FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06972-x
   Paulino J, 2020, P NATL ACAD SCI USA, V117, P11908, DOI 10.1073/pnas.2001083117
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   PETERSON KA, 1994, J CHEM PHYS, V100, P7410, DOI 10.1063/1.466884
   Pickard CJ, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.245101
   Profeta M, 2003, J AM CHEM SOC, V125, P541, DOI 10.1021/ja027124r
   Quinn CM, 2018, METHODS MOL BIOL, V1688, P1, DOI 10.1007/978-1-4939-7386-6_1
   Rossi F, 2019, MAGN RESON CHEM, V57, P294, DOI 10.1002/mrc.4841
   Segall MD, 2002, J PHYS-CONDENS MAT, V14, P2717, DOI 10.1088/0953-8984/14/11/301
   Sivanathan S, 2014, MOLECULES, V19, P12368, DOI 10.3390/molecules190812368
   SMITH GD, 1975, J AM CHEM SOC, V97, P7242, DOI 10.1021/ja00858a008
   Su ZF, 2019, LANGMUIR, V35, P16935, DOI 10.1021/acs.langmuir.9b03064
   Tatton AS, 2013, MOL PHARMACEUT, V10, P999, DOI 10.1021/mp300423r
   Tkatchenko A, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.073005
   VAHTRAS O, 1993, CHEM PHYS LETT, V213, P514, DOI 10.1016/0009-2614(93)89151-7
   Vibhute AM, 2018, CHEM COMMUN, V54, P4629, DOI 10.1039/c8cc01653d
   Wang XL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113843
   WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005
   Wu G, 2019, PROG NUCL MAG RES SP, V114, P135, DOI 10.1016/j.pnmrs.2019.06.002
   Wu K, 2018, J PHARM SCI-US, V107, P3070, DOI 10.1016/j.xphs.2018.08.002
   Xu YJ, 2020, COORDIN CHEM REV, V411, DOI 10.1016/j.ccr.2020.213237
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yates JR, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.024401
   Zhuang L, 2020, METAB ENG, V60, P37, DOI 10.1016/j.ymben.2020.03.009
NR 55
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 14
AR 4907
DI 10.3390/ijms21144907
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MW6SE
UT WOS:000557163100001
PM 32664570
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Byrd, KM
   Beckwith, CG
   Garland, JM
   Johnson, JE
   Aung, S
   Cu-Uvin, S
   Farmakiotis, D
   Flanigan, T
   Gillani, FS
   Macias-Gil, R
   Mileno, M
   Ramratnam, B
   Rybak, NR
   Sanchez, M
   Tashima, K
   Mylonakis, E
   Kantor, R
AF Byrd, Katrina M.
   Beckwith, Curt G.
   Garland, Joseph M.
   Johnson, Jennie E.
   Aung, Su
   Cu-Uvin, Susan
   Farmakiotis, Dimitrios
   Flanigan, Timothy
   Gillani, Fizza S.
   Macias-Gil, Raul
   Mileno, Maria
   Ramratnam, Bharat
   Rybak, Natasha R.
   Sanchez, Martha
   Tashima, Karen
   Mylonakis, Eleftherios
   Kantor, Rami
TI SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island,
   United States
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE SARS-CoV-2; HIV; COVID-19; coinfection; preparedness
AB Introduction Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected >6 million people worldwide since December 2019. Global reports of HIV/SARS-CoV-2 coinfection are limited. To better understand the impact of the coronavirus disease 2019 (COVID-19) pandemic on persons with HIV and improve their care, we present an outpatient and inpatient clinical experience of HIV/SARS-CoV-2 coinfection from Rhode Island, US. Methods We describe outpatient and inpatient preparedness for the COVID-19 pandemic, and present a case series of all known patients with HIV/SARS-CoV-2 coinfection at The Miriam Hospital and Rhode Island Hospital, and The Miriam Hospital Infectious Diseases and Immunology Center, in Providence, Rhode Island, US. Results and discussion The Infectious Diseases and Immunology Center rapidly prepared for outpatient and inpatient care of persons with HIV and SARS-CoV-2. Between 30 March and 20 May 2020, 27 patients with HIV were diagnosed with SARS-CoV-2. Twenty were male, six female and one transgender female; average age was 49 years; 13/27 were Hispanic and 6/27 were African American. All had HIV viral load <200 copies/mL and were on antiretroviral therapy with CD4 count range 87 to 1441 cells/mu L. Twenty-six of the 27 had common COVID-19 symptoms for one to twenty-eight days and most had other co-morbidities and/or risk factors. Nine of the 27 were hospitalized for one to thirteen days; of those, three lived in a nursing home, six received remdesivir through a clinical trial or emergency use authorization and tolerated it well; eight recovered and one died. Overall, 17% of known Center people had HIV/SARS-CoV-2 coinfection, whereas the comparable state-wide prevalence was 9%. Conclusions We highlight challenges of outpatient and inpatient HIV care in the setting of the COVID-19 pandemic and present the largest detailed case series to date from the United States on HIV/SARS-CoV-2 coinfection, adding to limited global reports. The aggregated clinical findings suggest that the clinical presentation and outcomes of COVID-19 appear consistent with those without HIV. Whether SARS-CoV-2 infection is more frequent among persons with HIV remains to be determined. More data are needed as we develop our understanding of how HIV and antiretroviral therapy are affected by or have an impact on this pandemic.
C1 [Kantor, Rami] Miriam Hosp, RISE Bldg,Room 154,164 Summit Ave, Providence, RI 02906 USA.
   Brown Alpert Med Sch, Dept Med, Div Infect Dis, Providence, RI USA.
RP Kantor, R (corresponding author), Miriam Hosp, RISE Bldg,Room 154,164 Summit Ave, Providence, RI 02906 USA.
EM rkantor@brown.edu
OI Byrd, Katrina/0000-0001-5678-480X
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [K24 AI134359, P30 AI042853]
FX This study was supported by National Institute of Allergy and Infectious
   Diseases (K24 AI134359; P30 AI042853).
CR [Anonymous], 2018, RHOD ISL HIV SEX TRA
   [Anonymous], 2020, INT GUID COVID 19 PE
   Beigel J. H., 2020, N ENGL J MED
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2019, HIV SURVEILLANCE S, V24
   Centers for Disease Control and Prevention, 2020, GEOGR DIFF COVID 19
   Chen JX, 2020, J MED VIROL, V92, P1774, DOI 10.1002/jmv.25879
   Farber T, 2020, HIV TB LESS DEADLY D
   Gervasoni C., 2020, CLIN INFECT DIS
   Guo W, 2020, SSRN ELECT J
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Malan M, 2020, BHEKISISA WEBINAR
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   Ridgway JP, 2020, AIDS BEHAV, V24, P2770, DOI 10.1007/s10461-020-02905-2
   Vizcarra P, 2020, LANCET HIV
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 20
TC 4
Z9 4
U1 2
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
IS 7
AR e25573
DI 10.1002/jia2.25573
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MV9XX
UT WOS:000556702700011
PM 32657527
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Holloway, IW
   Spaulding, AC
   Ochoa, AM
   Randall, LA
   King, AR
   Frew, PM
AF Holloway, Ian W.
   Spaulding, Anne C.
   Ochoa, Ayako Miyashita
   Randall, Laura A.
   King, Adrian R.
   Frew, Paula M.
CA HBOU Study Team
TI COVID-19 vulnerability among people who use drugs: recommendations for
   global public health programmes and policies
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE COVID-19; substance use; opioid crisis; homelessness; social
   determinants
C1 [Holloway, Ian W.; Ochoa, Ayako Miyashita] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Dept Social Welf, Los Angeles, CA USA.
   [Spaulding, Anne C.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Randall, Laura A.; King, Adrian R.; Frew, Paula M.] Univ Nevada, UNLV Sch Publ Hlth, Las Vegas, NV 89154 USA.
   [Randall, Laura A.; King, Adrian R.; Frew, Paula M.; HBOU Study Team] Univ Nevada, UNLV Populat Hlth & Hlth Equ Initiat, Las Vegas, NV 89154 USA.
RP Holloway, IW (corresponding author), 3250 Publ Affairs Bldg,Box 951656, Los Angeles, CA 90095 USA.
EM holloway@luskin.ucla.edu
OI Holloway, Ian/0000-0001-7454-8632; King, Adrian/0000-0003-1418-6494
FU California HIV/AIDS Research Program [RP15-LA-007]; UCLA Center for
   Identification, Prevention and Treatment Services [P30 MH 58107]
FX Drs. Holloway and Miyashita are supported by the California HIV/AIDS
   Research Program (RP15-LA-007) and UCLA Center for Identification,
   Prevention and Treatment Services (P30 MH 58107).
CR Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   [Anonymous], WID RANG ONL DAT EP
   [Anonymous], 2020, COVID 19 TRAD POL
   [Anonymous], 2018, FACT SHEET INF SHEET
   [Anonymous], 2014, CDC REPORT NARCAN KI
   Black M, 2020, COVID 19 IS IMPACTIN
   Cahill Sean, 2009, SYRINGE EXCHANGE PRO
   Canan CE, 2018, JAIDS-J ACQ IMM DEF, V78, P283, DOI 10.1097/QAI.0000000000001690
   CDC, 2020, DRUG OV DEATHS DRUG
   Covid-19 Dashboard, 2020, COVID 19 DASHB
   Culhane Dennis Dan, 2020, ESTIMATED EMERGENCY
   Dukhovlinova E, 2015, AIDS RES HUM RETROV, V31, P608, DOI [10.1089/aid.2014.0150, 10.1089/AID.2014.0150]
   Glick SN, 2020, AIDS BEHAV, V24, P2466, DOI 10.1007/s10461-020-02886-2
   Griffin O, 2020, REUTERS
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Jurgens R, 2010, LANCET, V376, P475, DOI 10.1016/S0140-6736(10)60830-6
   Kinner SA, 2020, LANCET PUBLIC HEALTH, V5, pE188, DOI 10.1016/S2468-2667(20)30058-X
   Lemons A, 2019, JAIDS-J ACQ IMM DEF, V80, P127, DOI 10.1097/QAI.0000000000001889
   Linthicum K, 2020, LOS ANGELES TIMES
   Priest KC, 2019, INT J DRUG POLICY, V74, P257, DOI 10.1016/j.drugpo.2019.01.020
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Vasilev Georgi, 2016, Curr Treat Options Psychiatry, V3, P293
   Walmsley R, 2005, INT J PRISON HEALTH, V1, P9, DOI 10.1080/17449200500156897
   World Health Organization, COR DIS COVID 19 ADV
NR 24
TC 2
Z9 2
U1 2
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
IS 7
AR e25551
DI 10.1002/jia2.25551
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MV9XX
UT WOS:000556702700010
PM 32640098
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vasylyeva, TI
   Smyrnov, P
   Strathdee, S
   Friedman, SR
AF Vasylyeva, Tetyana, I
   Smyrnov, Pavlo
   Strathdee, Steffanie
   Friedman, Samuel R.
TI Challenges posed by COVID-19 to people who inject drugs and lessons from
   other outbreaks
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE people who inject drugs; COVID-19; infectious disease; outbreak; harm
   reduction; inequality
ID A STREPTOCOCCAL INFECTIONS; HEPATITIS-A; RESISTANT TUBERCULOSIS; USERS;
   RISK; HIV; VIRUS; DISEASE; EPIDEMIC; SERVICES
AB Introduction In light of the COVID-19 pandemic, considerable effort is going into identifying and protecting those at risk. Criminalization, stigmatization and the psychological, physical, behavioural and economic consequences of substance use make people who inject drugs (PWID) extremely vulnerable to many infectious diseases. While relationships between drug use and blood-borne and sexually transmitted infections are well studied, less attention has been paid to other infectious disease outbreaks among PWID. Discussion COVID-19 is likely to disproportionally affect PWID due to a high prevalence of comorbidities that make the disease more severe, unsanitary and overcrowded living conditions, stigmatization, common incarceration, homelessness and difficulties in adhering to quarantine, social distancing or self-isolation mandates. The COVID-19 pandemic also jeopardizes essential for PWID services, such as needle exchange or substitution therapy programmes, which can be affected both in a short- and a long-term perspective. Importantly, there is substantial evidence of other infectious disease outbreaks in PWID that were associated with factors that enable COVID-19 transmission, such as poor hygiene, overcrowded living conditions and communal ways of using drugs. Conclusions The COVID-19 crisis might increase risks of homelessnes, overdoses and unsafe injecting and sexual practices for PWID. In order to address existing inequalities, consultations with PWID advocacy groups are vital when designing inclusive health response to the COVID-19 pandemic.
C1 [Vasylyeva, Tetyana, I] Univ Oxford, Dept Zool, Oxford, England.
   [Smyrnov, Pavlo] Alliance Publ Hlth, Kiev, Ukraine.
   [Strathdee, Steffanie] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Friedman, Samuel R.] NYU, Dept Populat Hlth, New York, NY USA.
RP Vasylyeva, TI (corresponding author), 1 Vasylyeva,Medawar Bldg,South Parks Rd, Oxford OX1 3SY, England.
EM tetyana.vasylyeva@zoo.ox.ac.uk
OI Friedman, Sam/0000-0003-2083-1226; Vasylyeva,
   Tetyana/0000-0002-9736-7022
FU Branco Weiss Fellowship at the New College, University of Oxford; Junior
   Research Fellowship at the New College, University of Oxford; NIDA MERIT
   Award [R37DA019829]; NIDAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Drug Abuse (NIDA) [P30DA011041]; NIH/NIDAUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Drug Abuse (NIDA) [4UH3DA044829]
FX TIV is supported by the Branco Weiss Fellowship and Junior Research
   Fellowship at the New College, University of Oxford. SS is supported by
   a NIDA MERIT Award R37DA019829. SRF is supported by NIDA grant
   P30DA011041 and NIH/NIDA grant #4UH3DA044829.
CR Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610
   Altice FL, 2016, LANCET, V388, P1228, DOI 10.1016/S0140-6736(16)30856-X
   Appel PW, 2004, AM J DRUG ALCOHOL AB, V30, P129, DOI 10.1081/ADA-120029870
   Armenta RF, 2017, INT J TUBERC LUNG D, V21, P425, DOI 10.5588/ijtld.16.0434
   Asghar RJ, 2009, J URBAN HEALTH, V86, P776, DOI 10.1007/s11524-009-9378-z
   Baussano I, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000381
   Bick JA, 2007, CLIN INFECT DIS, V45, P1047, DOI 10.1086/521910
   Bishay A, 2008, CHEST, V133, P549, DOI 10.1378/chest.07-0805
   Bohlen LM, 2000, EMERG INFECT DIS, V6, P175
   Boissay F, 2020, BIS B, V7, P1
   Bowman S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-820
   Brookmeyer KA, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.105779
   Bubba L, 2019, J INFECTION, V79, P435, DOI 10.1016/j.jinf.2019.08.009
   Burr CK, 2014, PUBLIC HEALTH REP, V129, P26, DOI 10.1177/00333549141291S105
   CDC, 2020, PEOPL WHO AR HIGH RI
   Collier MG, 2015, VACCINE, V33, P2808, DOI 10.1016/j.vaccine.2015.04.019
   Conover C, 2001, INT J TUBERC LUNG D, V5, P59
   CURTIS R, 1994, PUBLIC HEALTH REP, V109, P319
   de Vries G, 2006, EUR J PUBLIC HEALTH, V16, P133, DOI 10.1093/eurpub/cki203
   Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3
   Deiss RG, 2009, CLIN INFECT DIS, V48, P72, DOI 10.1086/594126
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   EMCDDA, 2020, COVID 19 PEOPL WHO U
   Fischer B, 2004, CAN MED ASSOC J, V171, P235, DOI 10.1503/cmaj.1031416
   Franco E, 2003, VACCINE, V21, P2224, DOI 10.1016/S0264-410X(03)00137-3
   Friedland G, 2010, JAIDS-J ACQ IMM DEF, V55, pS37, DOI 10.1097/QAI.0b013e3181f9c0b6
   Friedman H, 2003, CLIN MICROBIOL REV, V16, P209, DOI 10.1128/CMR.16.2.209-219.2003
   Friedman SR, 2013, AIDS BEHAV, V17, P1915, DOI 10.1007/s10461-013-0475-3
   Friedman SR, 1997, AM J PUBLIC HEALTH, V87, P1289, DOI 10.2105/AJPH.87.8.1289
   Glick SNPS, 2020, AIDS BEHAV, V24, P1
   GRIERSON J., 2020, GUARDIAN
   Grinde B, 1997, J MED VIROL, V53, P69, DOI 10.1002/(SICI)1096-9071(199709)53:1&lt;69::AID-JMV12&gt;3.0.CO;2-S
   Hamilton I, 2020, WHAT WILL COVID 19 M
   Harris M, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00369-0
   Harris RE, 2018, INT J DRUG POLICY, V52, P56, DOI 10.1016/j.drugpo.2017.11.005
   Hawks L, 2020, INTERNAL MED, pE1
   Hermosilla S, 2015, PUBLIC HEALTH, V129, P569, DOI 10.1016/j.puhe.2015.01.022
   Hidden Toll AA, 2020, MEXICO IGNORES WAVE
   Hurley R, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h390
   Hutin YJF, 2000, AM J EPIDEMIOL, V152, P186, DOI 10.1093/aje/152.2.186
   INPUD, 2020, COVID 19 CRIS HARM R
   Jenkins WD, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12442
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Jozaghi Ehsan, 2020, Can J Public Health, P1, DOI 10.17269/s41997-020-00326-1
   Kaushik KS, 2011, J MED MICROBIOL, V60, P408, DOI 10.1099/jmm.0.027540-0
   Korobchuk A, 2019, J INFECT DEV COUNTR, V13, p103S, DOI 10.3855/jidc.11273
   Lamagni TL, 2008, CLIN MICROBIOL INFEC, V14, P1002, DOI 10.1111/j.1469-0691.2008.02076.x
   Lechot P, 2001, SCAND J INFECT DIS, V33, P41, DOI 10.1080/003655401750064059
   Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020
   Mackey TK, 2015, SUBST USE MISUSE, V50, P885, DOI 10.3109/10826084.2015.983008
   McElroy RD, 2003, INT J TUBERC LUNG D, V7, pS486
   Meacham MC, 2015, SUBST USE MISUSE, V50, P1351, DOI 10.3109/10826084.2015.1013132
   Medina-Mora ME, 2003, SALUD MENT, V26, P1
   Merrill J, 2002, J GEN INTERN MED, V17, P327, DOI 10.1007/s11606-002-0034-5
   Munckhof WJ, 2003, INT J TUBERC LUNG D, V7, P860
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Paquette CE, 2018, INT J DRUG POLICY, V57, P104, DOI 10.1016/j.drugpo.2018.04.004
   Passaro DJ, 2002, EPIDEMIOL INFECT, V129, P471, DOI 10.1017/S0950268802007823
   Radke J, 2014, CLIN REV ALLERG IMMU, V46, P54, DOI 10.1007/s12016-013-8373-z
   REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruddy MC, 2004, THORAX, V59, P279, DOI 10.1136/thx.2003.010405
   Sierra JM, 2006, MEDICINE, V85, P139, DOI 10.1097/01.md.0000224707.24392.52
   Spada E, 2005, J HEPATOL, V43, P958, DOI 10.1016/j.jhep.2005.06.012
   Strathdee SA, 2003, DRUG ALCOHOL DEPEN, V71, P17, DOI 10.1016/S0376-8716(03)00072-3
   SUNDKVIST T, 1985, SCAND J INFECT DIS, V17, P1, DOI 10.3109/00365548509070411
   Sutherland R, 2016, DRUG ALCOHOL DEPEN, V159, P35, DOI 10.1016/j.drugalcdep.2015.10.035
   Ti Lianping, 2015, AM J PUBLIC HLTH, V105, pe53, DOI 10.2105/AJPH.2015.302885
   Townsend M., 2020, GUARDIAN
   Tyrrell GJ, 2010, CLIN INFECT DIS, V51, P1290, DOI 10.1086/657068
   Vong S, 2005, VACCINE, V23, P1021, DOI 10.1016/j.vaccine.2004.07.038
   Wang ZC, 2020, NAT MED, P19, DOI 10.1038/s41591-020-0823-6
   Williams LD, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25330
   Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X
   Young AM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-537
NR 75
TC 6
Z9 6
U1 4
U2 4
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2020
VL 23
IS 7
AR e25583
DI 10.1002/jia2.25583
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MV9XX
UT WOS:000556702700008
PM 32697423
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gibson, KM
   Steiner, MC
   Rentia, U
   Bendall, ML
   Perez-Losada, M
   Crandall, KA
AF Gibson, Keylie M.
   Steiner, Margaret C.
   Rentia, Uzma
   Bendall, Matthew L.
   Perez-Losada, Marcos
   Crandall, Keith A.
TI Validation of Variant Assembly Using HAPHPIPE with Next-Generation
   Sequence Data from Viruses
SO VIRUSES-BASEL
LA English
DT Article
DE bioinformatics; validation; simulation; viruses; consensus; haplotypes;
   HIV; HCV; SARS-CoV-2
ID HIV TYPE-1 STRAINS; FULL-LENGTH GENOMES; T-CELL RESPONSES; PHYLOGENETIC
   ANALYSIS; SUBTYPE-C; VIRAL DIVERSITY; DRUG-RESISTANCE; READ ALIGNMENT;
   MBEYA REGION; SEX WORKERS
AB Next-generation sequencing (NGS) offers a powerful opportunity to identify low-abundance, intra-host viral sequence variants, yet the focus of many bioinformatic tools on consensus sequence construction has precluded a thorough analysis of intra-host diversity. To take full advantage of the resolution of NGS data, we developed HAplotype PHylodynamics PIPEline (HAPHPIPE), an open-source tool for the de novo and reference-based assembly of viral NGS data, with both consensus sequence assembly and a focus on the quantification of intra-host variation through haplotype reconstruction. We validate and compare the consensus sequence assembly methods of HAPHPIPE to those of two alternative software packages, HyDRA and Geneious, using simulated HIV and empirical HIV, HCV, and SARS-CoV-2 datasets. Our validation methods included read mapping, genetic distance, and genetic diversity metrics. In simulated NGS data, HAPHPIPE generatedpolconsensus sequences significantly closer to the true consensus sequence than those produced by HyDRA and Geneious and performed comparably to Geneious for HIVgp120sequences. Furthermore, using empirical data from multiple viruses, we demonstrate that HAPHPIPE can analyze larger sequence datasets due to its greater computational speed. Therefore, we contend that HAPHPIPE provides a more user-friendly platform for users with and without bioinformatics experience to implement current best practices for viral NGS assembly than other currently available options.
C1 [Gibson, Keylie M.; Steiner, Margaret C.; Rentia, Uzma; Bendall, Matthew L.; Perez-Losada, Marcos; Crandall, Keith A.] George Washington Univ, Milken Inst Sch Publ Hlth, Computat Biol Inst, Washington, DC 20052 USA.
   [Perez-Losada, Marcos; Crandall, Keith A.] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Biostat & Bioinformat, Washington, DC 20052 USA.
   [Perez-Losada, Marcos] Univ Porto, Ctr Invest Biodiversidade & Recursos Genet, CIBIO InBIO, Campus Agr Vairao, P-4169007 Vairao, Portugal.
RP Gibson, KM (corresponding author), George Washington Univ, Milken Inst Sch Publ Hlth, Computat Biol Inst, Washington, DC 20052 USA.
EM kmgibson@gwu.edu; steinerm@gwmail.gwu.edu; uzma_rentia@gwmail.gwu.edu;
   mlb4001@med.cornell.edu; mlosada@gwu.edu; kcrandall@gwu.edu
RI Perez-Losada, Marcos/I-4407-2013; Bendall, Matthew/ABF-8123-2020
OI Perez-Losada, Marcos/0000-0002-2585-4657; Bendall,
   Matthew/0000-0001-9816-5425; Steiner, Margaret/0000-0002-1062-1228;
   Crandall, Keith/0000-0002-0836-3389; Gibson, Keylie/0000-0003-1909-3596
FU DC D-CFAR pilot award; 2015 HIV Phylodynamics Supplement award from the
   District of Columbia for AIDS Research, an NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI117970]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI076059,
   UL1TR001876]
FX This study was supported by a DC D-CFAR pilot award, a 2015 HIV
   Phylodynamics Supplement award from the District of Columbia for AIDS
   Research, an NIH funded program (AI117970), and NIH grants AI076059 and
   UL1TR001876. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH.
CR Abayasingam A, 2019, INFECT GENET EVOL, V71, P36, DOI 10.1016/j.meegid.2019.02.032
   Abecasis AB, 2007, J VIROL, V81, P8543, DOI 10.1128/JVI.00463-07
   Alampalli SV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188603
   Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005
   Alves BM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00749
   Alves BM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120392
   Ambler S.W, 2002, AGILE MODELING
   Amogne W, 2016, AIDS RES HUM RETROV, V32, P471, DOI 10.1089/aid.2015.0380
   An MH, 2012, J VIROL, V86, P12402, DOI 10.1128/JVI.00262-12
   Andresen BS, 2007, AIDS RES HUM RETROV, V23, P1442, DOI 10.1089/aid.2007.0111
   Aralaguppe SG, 2016, J VIROL METHODS, V236, P98, DOI 10.1016/j.jviromet.2016.07.010
   Archer J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001022
   Arias A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081697
   Arroyo MA, 2004, AIDS RES HUM RETROV, V20, P895, DOI 10.1089/0889222041725235
   Avila-Rios S, 2016, LANCET HIV, V3, pE579, DOI 10.1016/S2352-3018(16)30119-9
   Babcock GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100325
   Banin AN, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040317
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Bendall M.L., 2020, MOL BIOL EVOL
   Berg Michael G, 2016, J Clin Microbiol, V54, P868, DOI 10.1128/JCM.02479-15
   Bertels F, 2019, MOL BIOL EVOL, V36, P2019, DOI 10.1093/molbev/msz155
   Billings E, 2017, AIDS RES HUM RETROV, V33, P373, DOI [10.1089/aid.2016.0111, 10.1089/AID.2016.0111]
   Billings E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135124
   Blanco M, 2015, MEDICC REV, V17, P25
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bonnaud EM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007799
   Bruner KM, 2016, NAT MED, V22, P1043, DOI 10.1038/nm.4156
   Carr JK, 1999, AIDS, V13, P1819, DOI 10.1097/00002030-199910010-00003
   Carrion G, 2004, AIDS RES HUM RETROV, V20, P1022, DOI 10.1089/aid.2004.20.1022
   Cevallos CG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189705
   Charpentier C, 2017, J ANTIMICROB CHEMOTH, V72, P2831, DOI 10.1093/jac/dkx233
   Chen Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167839
   Cho YK, 2013, AIDS RES HUM RETROV, V29, P738, DOI [10.1089/aid.2012.0298, 10.1089/AID.2012.0298]
   Cornelissen M, 2017, VIRUS RES, V239, P10, DOI 10.1016/j.virusres.2016.08.004
   Crandall KA, 1999, ANIM CONSERV, V2, P317, DOI 10.1111/j.1469-1795.1999.tb00078.x
   Cuevas MT, 2010, AIDS RES HUM RETROV, V26, P1019, DOI 10.1089/aid.2010.0018
   Dalmat RR, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01443-18
   Derache A, 2019, J ANTIMICROB CHEMOTH, V74, P473, DOI 10.1093/jac/dky428
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   Dinno A., 2017, DUNN TEST DUNNS TEST, P1
   Dudley DM, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0122-8
   Edlefsen PT, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1003973
   Eliseev A, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104277
   Eltahla AA, 2017, SCI REP-UK, V7, DOI 10.1038/srep41719
   Eshleman SH, 2011, J INFECT DIS, V204, P1918, DOI 10.1093/infdis/jir651
   Eyzaguirre LM, 2013, VIROLOGY, V443, P306, DOI 10.1016/j.virol.2013.05.019
   Fonager J, 2015, J CLIN VIROL, V73, P95, DOI 10.1016/j.jcv.2015.11.009
   Frahm N, 2007, J IMMUNOL, V179, P6638, DOI 10.4049/jimmunol.179.10.6638
   Gaspareto KV, 2016, ARCH VIROL, V161, P2161, DOI 10.1007/s00705-016-2889-5
   GHOSH K, 1993, VIROLOGY, V194, P858, DOI 10.1006/viro.1993.1331
   Gibson KM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58410-y
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Grossmann S, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20035
   Gunther T, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008302
   Han XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065337
   Harris ME, 2002, AIDS RES HUM RETROV, V18, P1281, DOI 10.1089/088922202320886325
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hiener B, 2018, JOVE-J VIS EXP, DOI 10.3791/58016
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Hoelscher M, 2001, AIDS, V15, P1461, DOI 10.1097/00002030-200108170-00002
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hora B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157340
   Huang WC, 2012, BIOINFORMATICS, V28, P593, DOI 10.1093/bioinformatics/btr708
   Hunt M, 2015, BIOINFORMATICS, V31, P2374, DOI 10.1093/bioinformatics/btv120
   Ibe S, 2008, AIDS RES HUM RETROV, V24, P1121, DOI 10.1089/aid.2008.0090
   Iles JC, 2015, J CLIN MICROBIOL, V53, P3155, DOI 10.1128/JCM.00483-15
   Inzaule SC, 2018, J ANTIMICROB CHEMOTH, V73, P1167, DOI 10.1093/jac/dky005
   Isaacs SR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30322-y
   Ishida Y, 2019, JAIDS-J ACQ IMM DEF, V80, P350, DOI 10.1097/QAI.0000000000001919
   Ji HZ, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25193
   Kafando A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189999
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kijak GH, 2004, AIDS RES HUM RETROV, V20, P521, DOI 10.1089/088922204323087778
   Kijak Gustavo H, 2019, Biomol Detect Quantif, V17, P100080, DOI 10.1016/j.bdq.2019.01.002
   Kijak GH, 2013, J VIROL, V87, P7265, DOI 10.1128/JVI.03070-12
   Knyazev S, 2018, BIORXIV, P1, DOI [10.1101/264242, DOI 10.1101/264242]
   Korber B, 1998, HUMAN RETROVIRUSES A, pIII102
   Kousiappa I, 2011, AIDS RES HUM RETROV, V27, P1183, DOI [10.1089/AID.2011.0060, 10.1089/aid.2011.0060]
   Kousiappa I, 2009, AIDS RES HUM RETROV, V25, P727, DOI 10.1089/aid.2008.0239
   KREUTZ R, 1992, AIDS RES HUM RETROV, V8, P1619, DOI 10.1089/aid.1992.8.1619
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
   Kuiken C, 2006, HEPATOLOGY, V44, P1355, DOI 10.1002/hep.21377
   Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Laukkanen T, 1999, AIDS RES HUM RETROV, V15, P293, DOI 10.1089/088922299311475
   Leal E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011833
   Li B, 2007, J VIROL, V81, P193, DOI 10.1128/JVI.01231-06
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li Z, 2012, AIDS, V26, P877, DOI 10.1097/QAD.0b013e328351430d
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Majumdar M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01956
   Matume ND, 2018, J CLIN VIROL, V103, P81, DOI 10.1016/j.jcv.2018.02.008
   Mbondji-Wonje C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195661
   McDonald JH, 2014, HDB BIOL STAT
   Mikhail M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-41
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Nagarajan N, 2013, NAT REV GENET, V14, P157, DOI 10.1038/nrg3367
   Neogi U, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06860-2
   Nguyen T, 2018, J ANTIMICROB CHEMOTH, V73, P2485, DOI 10.1093/jac/dky198
   Nickle DC, 2003, SCIENCE, V299, P1515
   Nikolenko SI, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S1-S7
   Noguera-Julian M, 2017, J INFECT DIS, V216, pS829, DOI 10.1093/infdis/jix397
   Novelli P, 2000, AIDS RES HUM RETROV, V16, P1175, DOI 10.1089/088922200415027
   Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002
   Nurk S, 2013, J COMPUT BIOL, V20, P714, DOI 10.1089/cmb.2013.0084
   Oelrichs R, 1998, AIDS RES HUM RETROV, V14, P811, DOI 10.1089/aid.1998.14.811
   Ogishi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119145
   Pagan I, 2018, INFECT GENET EVOL, V65, P187, DOI 10.1016/j.meegid.2018.07.033
   Perez-Losada M, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104208
   Perrier M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198334
   Pessoa R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185559
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Pessoa R, 2015, TRANSFUSION, V55, P980, DOI 10.1111/trf.12936
   Pineda-Pena AC, 2013, INFECT GENET EVOL, V19, P337, DOI 10.1016/j.meegid.2013.04.032
   Posada-Cespedes S, 2017, VIRUS RES, V239, P17, DOI 10.1016/j.virusres.2016.09.016
   Prabhakaran S, 2014, IEEE ACM T COMPUT BI, V11, P182, DOI 10.1109/TCBB.2013.145
   Prosperi MCF, 2013, SCI REP-UK, V3, DOI 10.1038/srep02837
   Qiu ZZ, 2005, AIDS RES HUM RETROV, V21, P1051, DOI 10.1089/aid.2005.21.1051
   R Core Team, 2013, R LANG ENV STAT COMP
   Ratmann O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09139-4
   Ratmann O, 2017, MOL BIOL EVOL, V34, P185, DOI 10.1093/molbev/msw217
   Raymond HF, 2017, JAIDS-J ACQ IMM DEF, V75, pS276, DOI 10.1097/qai.0000000000001422
   Redd AD, 2012, J INFECT DIS, V206, P267, DOI 10.1093/infdis/jis325
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   Rodgers MA, 2017, J VIROL, V91, DOI [10.1128/jvi.01841-16, 10.1128/JVI.01841-16]
   Rodrigo C, 2019, J VIRAL HEPATITIS, V26, P476, DOI 10.1111/jvh.13051
   Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316
   Rousseau CM, 2006, J VIROL METHODS, V136, P118, DOI 10.1016/j.jviromet.2006.04.009
   Rozas J, 2017, MOL BIOL EVOL, V34, P3299, DOI 10.1093/molbev/msx248
   RStudio Team, 2015, RSTUDIO INT DEV R
   Saad MD, 2005, AIDS RES HUM RETROV, V21, P644, DOI 10.1089/aid.2005.21.644
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Salgado M, 2014, J VIROL, V88, P3340, DOI 10.1128/JVI.03380-13
   Saliou A, 2011, ANTIMICROB AGENTS CH, V55, P2831, DOI 10.1128/AAC.00091-11
   Salmela L, 2016, J COMPUT BIOL, V23, P347, DOI 10.1089/cmb.2015.0197
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227
   Simpson JT, 2015, ANNU REV GENOM HUM G, V16, P153, DOI 10.1146/annurev-genom-090314-050032
   Stelzl E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181273
   Strimmer K., 2012, PHYLOGENETIC HDB, P111, DOI [10.1017/cbo9780511819049.006, DOI 10.1017/CBO9780511819049.006]
   Taylor T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45328-3
   Thomson E, 2016, J CLIN MICROBIOL, V54, P2470, DOI 10.1128/JCM.00330-16
   Nguyen T, 2019, JAIDS-J ACQ IMM DEF, V82, P105, DOI 10.1097/QAI.0000000000002099
   Tongo Marcel, 2015, Evolution Medicine and Public Health, P254, DOI 10.1093/emph/eov022
   Tovanabutra S, 2010, AIDS RES HUM RETROV, V26, P123, DOI 10.1089/aid.2009.0115
   Treurnicht FK, 2010, VIROLOGY, V396, P213, DOI 10.1016/j.virol.2009.10.002
   Triques K, 2000, AIDS RES HUM RETROV, V16, P139, DOI 10.1089/088922200309485
   Tully DC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005619
   Tumiotto C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185211
   Turnbull EL, 2009, J IMMUNOL, V182, P7131, DOI 10.4049/jimmunol.0803658
   Vinoles J, 2005, AM J TROP MED HYG, V72, P495, DOI 10.4269/ajtmh.2005.72.495
   Wang YYE, 2009, J VIROL, V83, P1845, DOI 10.1128/JVI.01061-08
   Welzel TM, 2017, J HEPATOL, V67, P224, DOI 10.1016/j.jhep.2017.03.014
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP
   Wilkinson E, 2015, AIDS RES HUM RETROV, V31, P412, DOI [10.1089/aid.2014.0230, 10.1089/AID.2014.0230]
   Woolson R.F., 2008, WILEY ENCY CLINCAL T, P7
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamaguchi J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02150
   Yang X, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-475
   Zanini F, 2015, ELIFE, V4, DOI 10.7554/eLife.11282
NR 160
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUL
PY 2020
VL 12
IS 7
AR 758
DI 10.3390/v12070758
PG 38
WC Virology
SC Virology
GA MW5TV
UT WOS:000557099800001
PM 32674515
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kang, K
   Kim, HH
   Choi, Y
AF Kang, Keunsoo
   Kim, Hoo Hyun
   Choi, Yoonjung
TI Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through
   Transcriptome-Based Comprehensive Molecular Pathway Analysis
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; COVID-19; tiotropium; molecular pathways; RNA-seq; COPD
ID CELL-DEATH; BROMIDE; MODEL; NORMALIZATION; INHIBITION; INFECTION;
   CYTOKINES; DISEASES; ASTHMA; BLOOD
AB The coronavirus disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects almost everyone in the world in many ways. We previously predicted antivirals (atazanavir, remdesivir and lopinavir/ritonavir) and non-antiviral drugs (tiotropium and rapamycin) that may inhibit the replication complex of SARS-CoV-2 using our molecular transformer-drug target interaction (MT-DTI) deep-learning-based drug-target affinity prediction model. In this study, we dissected molecular pathways upregulated in SARS-CoV-2-infected normal human bronchial epithelial (NHBE) cells by analyzing an RNA-seq data set with various bioinformatics approaches, such as gene ontology, protein-protein interaction-based network and gene set enrichment analyses. The results indicated that the SARS-CoV-2 infection strongly activates TNF and NF kappa B-signaling pathways through significant upregulation of theTNF,IL1B,IL6,IL8,NFKB1,NFKB2andRELBgenes. In addition to these pathways, lung fibrosis, keratinization/cornification, rheumatoid arthritis, and negative regulation of interferon-gamma production pathways were also significantly upregulated. We observed that these pathologic features of SARS-CoV-2 are similar to those observed in patients with chronic obstructive pulmonary disease (COPD). Intriguingly, tiotropium, as predicted by MT-DTI, is currently used as a therapeutic intervention in COPD patients. Treatment with tiotropium has been shown to improve pulmonary function by alleviating airway inflammation. Accordingly, a literature search summarized that tiotropium reduced expressions ofIL1B,IL6,IL8,RELA, NFKB1and TNF in vitro or in vivo, and many of them have been known to be deregulated in COPD patients. These results suggest that COVID-19 is similar to an acute mode of COPD caused by the SARS-CoV-2 infection, and therefore tiotropium may be effective for COVID-19 patients.
C1 [Kang, Keunsoo; Kim, Hoo Hyun] Dankook Univ, Coll Sci & Technol, Dept Microbiol, Cheonan 31116, South Korea.
   [Choi, Yoonjung] Deargen Inc, Munji Dong 103-6, Daejeon, South Korea.
RP Kang, K (corresponding author), Dankook Univ, Coll Sci & Technol, Dept Microbiol, Cheonan 31116, South Korea.; Choi, Y (corresponding author), Deargen Inc, Munji Dong 103-6, Daejeon, South Korea.
EM kangk1204@dankook.ac.kr; rlagngus@gmail.com; yoonjungc@deargen.me
FU Dankook University
FX The present research was conducted by the research fund of Dankook
   University in 2020.
CR Ahmed SSSJ, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00802
   Anzalone G, 2016, LIFE SCI, V152, P107, DOI 10.1016/j.lfs.2016.03.031
   Araya J, 2007, J CLIN INVEST, V117, P3551, DOI 10.1172/JCI32526
   Asano Kazuhito, 2010, Int J Chron Obstruct Pulmon Dis, V5, P277
   Babon JJ, 2014, SEMIN IMMUNOL, V26, P13, DOI 10.1016/j.smim.2013.12.004
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bucher H, 2016, J PHARMACOL EXP THER, V357, P606, DOI 10.1124/jpet.116.232009
   Buels Kalmia S, 2012, Handb Exp Pharmacol, P317, DOI 10.1007/978-3-642-23274-9_14
   Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Datta S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-397
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Decramer M, 2009, LANCET, V374, P1171, DOI 10.1016/S0140-6736(09)61298-8
   Delgado-Ortega M, 2013, VET IMMUNOL IMMUNOP, V151, P1, DOI 10.1016/j.vetimm.2012.11.008
   Eckhart L, 2013, BBA-MOL CELL RES, V1833, P3471, DOI 10.1016/j.bbamcr.2013.06.010
   Eraldemir FC, 2016, INT J CLIN EXP MED, V9, P22824
   Fielhaber JA, 2012, J IMMUNOL, V188, P4535, DOI 10.4049/jimmunol.1003655
   Finney L.J., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.06.13.149039, DOI 10.1101/2020.06.13.149039]
   Hackett NR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018378
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Halpin DMG, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0119-y
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Houssaini A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.93203
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iesato K, 2008, RESPIRATION, V76, P434, DOI 10.1159/000151729
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iqbal A, 2015, CLIN DRUG INVEST, V35, P685, DOI 10.1007/s40261-015-0322-6
   Jain A, 2005, PATTERN RECOGN, V38, P2270, DOI 10.1016/j.patcog.2005.01.012
   Kaparianos A, 2011, CURR MED CHEM, V18, P3506, DOI 10.2174/092986711796642562
   Kerstjens HAM, 2016, EXPERT OPIN DRUG SAF, V15, P1115, DOI 10.1080/14740338.2016.1199682
   Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kolahian S, 2014, EXP LUNG RES, V40, P272, DOI 10.3109/01902148.2014.905657
   Korotkevich G., 2019, FAST GENE SET ENRICH
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Litonjua AA, 2010, PHARMACOGENET GENOM, V20, P64, DOI 10.1097/FPC.0b013e328333dae6
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01843
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luo W., 2020, CLIN PATHOLOGY CRITI
   Lv J, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2431705
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Olsen KC, 2011, AM J RESP CRIT CARE, V184, P699, DOI 10.1164/rccm.201101-0013OC
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Radovanovic D, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0094-3
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931
   Ruan QR, 2020, INTENS CARE MED, V46, P1294, DOI 10.1007/s00134-020-06028-z
   Shin B, 2019, MACH LEARN HEALTHC C, V106, P230
   Suzaki I, 2011, INT J CHRONIC OBSTR, V6, P439, DOI 10.2147/COPD.S23695
   Szekely GJ, 2005, J CLASSIF, V22, P151, DOI 10.1007/s00357-005-0012-9
   Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Toumpanakis D, 2017, INT J CHRONIC OBSTR, V12, P2207, DOI 10.2147/COPD.S137587
   Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014
   Vacca G, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-24
   Wollin L, 2010, PULM PHARMACOL THER, V23, P345, DOI 10.1016/j.pupt.2010.03.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamaya M, 2012, EUR RESPIR J, V40, P122, DOI 10.1183/09031936.00065111
   Yum HK, 2014, TUBERC RESPIR DIS, V77, P167, DOI 10.4046/trd.2014.77.4.167
   Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang J, 2012, J CELL MOL MED, V16, P1522, DOI 10.1111/j.1582-4934.2011.01492.x
   Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20156
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhou Y, 2017, NEW ENGL J MED, V377, P923, DOI 10.1056/NEJMoa1700228
NR 73
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUL
PY 2020
VL 12
IS 7
AR 776
DI 10.3390/v12070776
PG 16
WC Virology
SC Virology
GA MW5UI
UT WOS:000557101100001
PM 32698440
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Osterrieder, N
   Bertzbach, LD
   Dietert, K
   Abdelgawad, A
   Vladimirova, D
   Kunec, D
   Hoffmann, D
   Beer, M
   Gruber, AD
   Trimpert, J
AF Osterrieder, Nikolaus
   Bertzbach, Luca D.
   Dietert, Kristina
   Abdelgawad, Azza
   Vladimirova, Daria
   Kunec, Dusan
   Hoffmann, Donata
   Beer, Martin
   Gruber, Achim D.
   Trimpert, Jakob
TI Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters
SO VIRUSES-BASEL
LA English
DT Article
DE coronavirus; Mesocricetus auratus; animal model; COVID-19; pneumonia;
   age-related disease; histopathology; in situ hybridization; cellular
   tropism; serology
ID COVID-19; SARS; MERS; PERSPECTIVE
AB In late 2019, an outbreak of a severe respiratory disease caused by an emerging coronavirus, SARS-CoV-2, resulted in high morbidity and mortality in infected humans. Complete understanding of COVID-19, the multi-faceted disease caused by SARS-CoV-2, requires suitable small animal models, as does the development and evaluation of vaccines and antivirals. Since age-dependent differences of COVID-19 were identified in humans, we compared the course of SARS-CoV-2 infection in young and aged Syrian hamsters. We show that virus replication in the upper and lower respiratory tract was independent of the age of the animals. However, older hamsters exhibited more pronounced and consistent weight loss. In situ hybridization in the lungs identified viral RNA in bronchial epithelium, alveolar epithelial cells type I and II, and macrophages. Histopathology revealed clear age-dependent differences, with young hamsters launching earlier and stronger immune cell influx than aged hamsters. The latter developed conspicuous alveolar and perivascular edema, indicating vascular leakage. In contrast, we observed rapid lung recovery at day 14 after infection only in young hamsters. We propose that comparative assessment in young versus aged hamsters of SARS-CoV-2 vaccines and treatments may yield valuable information, as this small-animal model appears to mirror age-dependent differences in human patients.
C1 [Osterrieder, Nikolaus; Bertzbach, Luca D.; Abdelgawad, Azza; Vladimirova, Daria; Kunec, Dusan; Trimpert, Jakob] Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.
   [Dietert, Kristina; Gruber, Achim D.] Free Univ Berlin, Inst Vet Pathol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.
   [Dietert, Kristina] Free Univ Berlin, Tiermed Zentrum Resistenzforsch, D-14195 Berlin, Germany.
   [Hoffmann, Donata; Beer, Martin] Friedrich Loeffler Inst, Inst Virusdiagnost, Sudufer 10, D-17493 Greifswald, Germany.
   [Osterrieder, Nikolaus] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Kowloon, 5-F,Block 1,Yuen Bldg 31 To Yuen St, Hong Kong, Peoples R China.
RP Trimpert, J (corresponding author), Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.
EM no.34@fu-berlin.de; luca.bertzbach@fu-berlin.de;
   kristina.dietert@fu-berlin.de; azza.abdelgawad@fu-berlin.de;
   daria.vladimirova@fu-berlin.de; dusan.kunec@fu-berlin.de;
   donata.hoffmann@fli.de; martin.beer@fli.de; achim.gruber@fu-berlin.de;
   trimpert.jakob@fu-berlin.de
RI Bertzbach, Luca/ABB-9013-2020
OI Bertzbach, Luca/0000-0002-0698-5395; Dietert,
   Kristina/0000-0002-5667-6750; Osterrieder, Nikolaus/0000-0002-5313-2176;
   Gruber, Achim/0000-0002-4502-0393; Trimpert, Jakob/0000-0003-1616-0810;
   Hoffmann, Donata/0000-0003-4552-031X
FU Freie Universitat Berlin; Berlin University Alliance; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB-TR84]
FX This research was supported by COVID-19 grants from Freie Universitat
   Berlin and Berlin University Alliance to N.O. as well as Deutsche
   Forschungsgemeinschaft grant SFB-TR84 awarded to A.D.G. The publication
   of this article was funded by Freie Universitat Berlin.
CR Ackermann M., 2020, NJEM, DOI [10.1056/NEJMoa2015432, DOI 10.1056/NEJMOA2015432]
   Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Deng W., 2020, OCULAR CONJUNCTIVAL, DOI [10.1101/2020.03.13.990036, DOI 10.1101/2020.03.13.990036]
   Dietert K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188251
   Dinnon Kenneth H, 2020, bioRxiv, DOI 10.1101/2020.05.06.081497
   Erickson NA, 2020, J COMP PATHOL, V174, P39, DOI 10.1016/j.jcpa.2019.10.193
   Gong Shu-Ran, 2018, Animal Model Exp Med, V1, P125, DOI 10.1002/ame2.12017
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Gu H., 2020, BIORXIV, DOI [10.1101/2020.05.02.073411, DOI 10.1101/2020.05.02.073411]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Nakamura T, 2017, J VET MED SCI, V79, P1230, DOI 10.1292/jvms.17-0210
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Pach S., 2020, ACE2 VARIANTS INDICA, DOI [10.1101/2020.05.14.092767., DOI 10.1101/2020.05.14.092767, 10.1101/2020.05.14.092767]
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Reppe K, 2015, INFECT IMMUN, V83, P4617, DOI 10.1128/IAI.00948-15
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Schauer AE, 2017, J INNATE IMMUN, V9, P403, DOI 10.1159/000469661
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Subbarao K, 2006, TRENDS MICROBIOL, V14, P299, DOI 10.1016/j.tim.2006.05.007
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Yuan LZ, 2020, EMERG MICROBES INFEC, V9, P949, DOI 10.1080/22221751.2020.1764871
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zivcec M, 2011, J IMMUNOL METHODS, V368, P24, DOI 10.1016/j.jim.2011.02.004
NR 40
TC 8
Z9 7
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUL
PY 2020
VL 12
IS 7
AR 779
DI 10.3390/v12070779
PG 11
WC Virology
SC Virology
GA MW5KT
UT WOS:000557076200001
PM 32698441
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Enriquez-Flores, S
   Flores-Lopez, LA
   Garcia-Torres, I
   de la Mora-de la Mora, I
   Cabrera, N
   Gutierrez-Castrellon, P
   Martinez-Perez, Y
   Lopez-Velazquez, G
AF Enriquez-Flores, Sergio
   Flores-Lopez, Luis Antonio
   Garcia-Torres, Itzhel
   de la Mora-de la Mora, Ignacio
   Cabrera, Nallely
   Gutierrez-Castrellon, Pedro
   Martinez-Perez, Yoalli
   Lopez-Velazquez, Gabriel
TI Deamidated Human Triosephosphate Isomerase is a Promising Druggable
   Target
SO BIOMOLECULES
LA English
DT Article
DE protein structure; triosephosphate isomerase; Glycolysis; AGEs;
   SARS-CoV-2; omeprazole; docking
ID TRIOSE-PHOSPHATE ISOMERASE; CHEMICAL-MODIFICATION; TRYPANOSOMA-CRUZI;
   GIARDIA-LAMBLIA; METHYLGLYOXAL; INTERFACE; DESIGN; SUSCEPTIBILITY;
   INACTIVATION; ACCUMULATION
AB Therapeutic strategies for the treatment of any severe disease are based on the discovery and validation of druggable targets. The human genome encodes only 600-1500 targets for small-molecule drugs, but posttranslational modifications lead to a considerably larger druggable proteome. The spontaneous conversion of asparagine (Asn) residues to aspartic acid or isoaspartic acid is a frequent modification in proteins as part of the process called deamidation. Triosephosphate isomerase (TIM) is a glycolytic enzyme whose deamidation has been thoroughly studied, but the prospects of exploiting this phenomenon for drug design remain poorly understood. The purpose of this study is to demonstrate the properties of deamidated human TIM (HsTIM) as a selective molecular target. Using in silico prediction, in vitro analyses, and a bacterial model lacking thetimgene, this study analyzed the structural and functional differences between deamidated and nondeamidated HsTIM, which account for the efficacy of this protein as a druggable target. The highly increased permeability and loss of noncovalent interactions of deamidated TIM were found to play a central role in the process of selective enzyme inactivation and methylglyoxal production. This study elucidates the properties of deamidated HsTIM regarding its selective inhibition by thiol-reactive drugs and how these drugs can contribute to the development of cell-specific therapeutic strategies for a variety of diseases, such as COVID-19 and cancer.
C1 [Enriquez-Flores, Sergio; Flores-Lopez, Luis Antonio; Garcia-Torres, Itzhel; de la Mora-de la Mora, Ignacio; Lopez-Velazquez, Gabriel] Inst Nacl Pediat, Secretaria Salud, Lab EIMyT, Grp Invest Biomol & Salud Infantil, Mexico City 04530, DF, Mexico.
   [Flores-Lopez, Luis Antonio] CONACYT, Inst Nacl Pediat, Secretaria Salud, Mexico City 04530, DF, Mexico.
   [Cabrera, Nallely] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim & Biol Estruct, Mexico City 04510, DF, Mexico.
   [Gutierrez-Castrellon, Pedro] Hosp Gen Dr Manuel Gea Gonzalez, Mexico City 14080, DF, Mexico.
   [Martinez-Perez, Yoalli] Univ Nacl Autonoma Mexico, Unidad Invest Med Expt, Fac Med, Mexico City 04510, DF, Mexico.
RP Enriquez-Flores, S; Lopez-Velazquez, G (corresponding author), Inst Nacl Pediat, Secretaria Salud, Lab EIMyT, Grp Invest Biomol & Salud Infantil, Mexico City 04530, DF, Mexico.
EM sergioenriquez@ciencias.unam.mx; luisbiolexp@gmail.com;
   garcia.itzhel@gmail.com; ignaciodelamora@yahoo.com.mx;
   ncabrera@ifc.unam.mx; inpcochrane@gmail.com; yoalli89@gmail.com;
   glv_1999@ciencias.unam.mx
RI ; Lopez-Velazquez, Gabriel/F-2411-2013
OI de la Mora de la Mora, Jose Ignacio/0000-0002-5654-8089;
   Fernandez-Lainez, Cynthia/0000-0003-4664-2722; Lopez-Velazquez,
   Gabriel/0000-0003-0470-1069
FU Recursos Fiscales para Investigacion Program from the Instituto Nacional
   de Pediatria [2019/072]
FX This research was funded by the Recursos Fiscales para Investigacion
   Program from the Instituto Nacional de Pediatria, S.S. Grant Number
   2019/072.
CR Al-Motawa M., 2020, VULNERABILITIES SARS, DOI [10.2139/ssrn.3582068, DOI 10.2139/SSRN.3582068]
   Beaumatin F, 2017, BBA-MOL CELL RES, V1864, P1734, DOI 10.1016/j.bbamcr.2017.06.012
   Cabrera N, 2018, BBA-GEN SUBJECTS, V1862, P1401, DOI 10.1016/j.bbagen.2018.03.019
   Cheng LS, 2008, J MED CHEM, V51, P3878, DOI 10.1021/jm8001197
   Codo AC, 2020, CELL METAB, DOI [10.2139/ssrn.3606770, DOI 10.2139/SSRN.3606770]
   Curnis F, 2006, J BIOL CHEM, V281, P36466, DOI 10.1074/jbc.M604812200
   de la Mora-de la Mora I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123379
   De La Mora ID, 2013, BBA-PROTEINS PROTEOM, V1834, P2702, DOI 10.1016/j.bbapap.2013.08.012
   DECKER RS, 1985, BIOCHEM GENET, V23, P267, DOI 10.1007/BF00504324
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6
   Enriquez-Flores S, 2008, MOL BIOCHEM PARASIT, V157, P179, DOI 10.1016/j.molbiopara.2007.10.013
   Enriquez-Flores S, 2011, PROTEINS, V79, P2711, DOI 10.1002/prot.23100
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Garcia-Torres I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26845-z
   Garza-Ramos G, 1998, EUR J BIOCHEM, V253, P684, DOI 10.1046/j.1432-1327.1998.2530684.x
   GEIGER T, 1987, J BIOL CHEM, V262, P785
   GILBERT RP, 1975, ANAL CHEM, V47, P2418, DOI 10.1021/ac60364a003
   Gkogkolou P, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22028
   Gomez-Manzo S, 2014, INT J MOL SCI, V15, P21179, DOI 10.3390/ijms151121179
   Hipkiss AR, 2019, AGING DIS, V10, P1328, DOI 10.14336/AD.2019.0611
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5
   Kold-Christensen R, 2020, TRENDS ENDOCRIN MET, V31, P81, DOI 10.1016/j.tem.2019.10.003
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Le L, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000939
   Lopez-Velazquez G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45529-w
   Magami K, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107930
   Mainfroid V, 1996, J MOL BIOL, V257, P441, DOI 10.1006/jmbi.1996.0174
   Maithal K, 2002, J BIOL CHEM, V277, P25106, DOI 10.1074/jbc.M202419200
   Matafome P, 2017, MED RES REV, V37, P368, DOI 10.1002/med.21410
   Moraes J, 2011, INSECT BIOCHEM MOLEC, V41, P400, DOI 10.1016/j.ibmb.2011.02.009
   Orosz F, 2009, BBA-MOL BASIS DIS, V1792, P1168, DOI 10.1016/j.bbadis.2009.09.012
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120
   Park JS, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010163
   Perez-Montfort R, 1999, BIOCHEMISTRY-US, V38, P4114, DOI 10.1021/bi982425s
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PLAUT B, 1972, BIOCHEM J, V129, P311, DOI 10.1042/bj1290311
   Pravda L, 2018, NUCLEIC ACIDS RES, V46, pW368, DOI 10.1093/nar/gky309
   Reyes-Vivas H, 2014, ANTIMICROB AGENTS CH, V58, P7072, DOI 10.1128/AAC.02900-14
   Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198
   Rodriguez-Almazan C, 2008, J BIOL CHEM, V283, P23254, DOI 10.1074/jbc.M802145200
   Rodriguez-Romero A, 2002, J MOL BIOL, V322, P669, DOI 10.1016/S0022-2836(02)00809-4
   Romo-Mancillas A, 2011, J MOL GRAPH MODEL, V30, P90, DOI 10.1016/j.jmgm.2011.06.009
   Sadakane Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082449
   Sinha S, 2009, PROTEIN SCI, V18, P1573, DOI 10.1002/pro.173
   Soulby AJ, 2015, PROTEIN SCI, V24, P850, DOI 10.1002/pro.2659
   Spicer CD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5740
   Sullivan BJ, 2011, J MOL BIOL, V413, P195, DOI 10.1016/j.jmb.2011.08.001
   SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X
   Tajes M, 2014, J ALZHEIMERS DIS, V41, P273, DOI 10.3233/JAD-131685
   TOLLEFSBOL TO, 1984, J GERONTOL, V39, P398, DOI 10.1093/geronj/39.4.398
   Vrouenraets M, 2006, BIOPHYS J, V90, P1202, DOI 10.1529/biophysj.105.072298
   YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6
NR 54
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD JUL
PY 2020
VL 10
IS 7
AR 1050
DI 10.3390/biom10071050
PG 19
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MV6FR
UT WOS:000556451800001
PM 32679775
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sayed, AM
   Alhadrami, HA
   El-Gendy, AO
   Shamikh, YI
   Belbahri, L
   Hassan, HM
   Abdelmohsen, UR
   Rateb, ME
AF Sayed, Ahmed M.
   Alhadrami, Hani A.
   El-Gendy, Ahmed O.
   Shamikh, Yara, I
   Belbahri, Lassaad
   Hassan, Hossam M.
   Abdelmohsen, Usama Ramadan
   Rateb, Mostafa E.
TI Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main
   Protease (M-pro)
SO MICROORGANISMS
LA English
DT Article
DE SARS-CoV-2; Covid-19; M-pro; microbial natural products; docking;
   molecular dynamic simulation
ID MOLECULAR-DYNAMICS; DRUG DISCOVERY; BIOSYNTHESIS; GUI
AB The main protease (M-pro) of the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was subjected to hyphenated pharmacophoric-based and structural-based virtual screenings using a library of microbial natural products (>24,000 compounds). Subsequent filtering of the resulted hits according to the Lipinski's rules was applied to select only the drug-like molecules. Top-scoring hits were further filtered out depending on their ability to show constant good binding affinities towards the molecular dynamic simulation (MDS)-derived enzyme's conformers. Final MDS experiments were performed on the ligand-protein complexes (compounds1-12, Table S1) to verify their binding modes and calculate their binding free energy. Consequently, a final selection of six compounds (1-6) was proposed to possess high potential as anti-SARS-CoV-2 drug candidates. Our study provides insight into the role of the M(pro)structural flexibility during interactions with the possible inhibitors and sheds light on the structure-based design of anti-coronavirus disease 2019 (COVID-19) therapeutics targeting SARS-CoV-2.
C1 [Sayed, Ahmed M.] Nanda Univ, Fac Pharm, Dept Pharmacognosy, Bani Suwayf 62513, Egypt.
   [Alhadrami, Hani A.] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah 21589, Saudi Arabia.
   [Alhadrami, Hani A.] King Abdulaziz Univ, King Fand Med Res Ctr, Special Infect Agent Unit, Jeddah 21589, Saudi Arabia.
   [El-Gendy, Ahmed O.] Beni Suef Univ, Fac Pharm, Dept Microbiol, Bani Suwayf 62514, Egypt.
   [Shamikh, Yara, I] Nanda Univ, Dept Microbiol & Immunol, Bani Suwayf 62513, Egypt.
   [Shamikh, Yara, I] Egypt Ctr Res & Regenerat Med ECRRM, Dept Virol, Cairo 11517, Egypt.
   [Belbahri, Lassaad] Univ Neuchatel, Dept Biol, Lab Soil Biol, CH-2000 Neuchatel, Switzerland.
   [Hassan, Hossam M.] Beni Suef Univ, Fac Pharm, Dept Pharmacognosy, Bani Suwayf 62514, Egypt.
   [Abdelmohsen, Usama Ramadan] Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt.
   [Abdelmohsen, Usama Ramadan] Deraya Univ, Fac Pharm, Dept Pharmacognosy, New Minia 61111, Egypt.
   [Rateb, Mostafa E.] Univ West Scotland, Sch Comp Engn & Phys Sci, Paisley PA1 2BE, Renfrew, Scotland.
RP Abdelmohsen, UR (corresponding author), Menia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya 61519, Egypt.; Abdelmohsen, UR (corresponding author), Deraya Univ, Fac Pharm, Dept Pharmacognosy, New Minia 61111, Egypt.; Rateb, ME (corresponding author), Univ West Scotland, Sch Comp Engn & Phys Sci, Paisley PA1 2BE, Renfrew, Scotland.
EM ahmedpharma8530@gmail.com; hanialhadrami@kau.edu.sa;
   ahmed.elgendy@pharm.bsu.edu.eg; yara.shamikh@nub.edu.eg;
   lassaad.belbahri@unine.ch; abuh20050@yahoo.com; usama.ramadan@mu.edu.eg;
   Mostafa.Rateb@uws.ac.uk
RI Alhadrami, Hani A./ABE-4279-2020; Abdelmohsen, Usama
   Ramadan/AAX-9874-2020; Rateb, Mostafa E/D-1411-2013; Lassaad,
   Belbahri/E-1648-2015; El-Gendy, Ahmed/K-1500-2017
OI Alhadrami, Hani A./0000-0002-4822-1895; Abdelmohsen, Usama
   Ramadan/0000-0002-1014-6922; Rateb, Mostafa E/0000-0003-4043-2687;
   Shamikh, Yara/0000-0001-7535-459X; Belbahri,
   Lassaad/0000-0001-7040-4500; El-Gendy, Ahmed/0000-0002-0980-5185
FU Ministry of Health, Kingdom of Saudi Arabia [16581700012, 581]; Ministry
   of HealthMinistry of Health - Turkey
FX This project was funded by Ministry of Health, Kingdom of Saudi Arabia,
   under grant number 16581700012-project number 581. The authors,
   therefore, gratefully acknowledge Ministry of Health support.
CR Abdelmohsen UR, 2014, NAT PROD REP, V31, P381, DOI 10.1039/c3np70111e
   Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chen HY, 2014, TETRAHEDRON-ASYMMETR, V25, P113, DOI 10.1016/j.tetasy.2013.11.013
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Ciliberto G, 2020, DRUG DISCOV TODAY, V25, P946, DOI 10.1016/j.drudis.2020.04.005
   El Sayed K. A., 2000, STUDIES NATURAL PROD, V24, P473, DOI DOI 10.1016/S1572-5995(00)80051-4
   El-Neketi M, 2013, J NAT PROD, V76, P1099, DOI 10.1021/np4001366
   FARMER PB, 1972, BIOCHEMISTRY-US, V11, P911, DOI 10.1021/bi00755a034
   Fiedler HP, 2008, J ANTIBIOT, V61, P158, DOI 10.1038/ja.2008.125
   Gambichler T, 2007, ARCH DERMATOL RES, V299, P517, DOI 10.1007/s00403-007-0793-2
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou XM, 2016, NAT PROD RES, V30, P2274, DOI 10.1080/14786419.2016.1163695
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Irlinger B, 2005, HELV CHIM ACTA, V88, P1472, DOI 10.1002/hlca.200590118
   Jimenez J, 2018, J CHEM INF MODEL, V58, P287, DOI 10.1021/acs.jcim.7b00650
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Jo S, 2013, J CHEM INF MODEL, V53, P267, DOI 10.1021/ci300505n
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Ngwa W, 2020, MOLECULES, V25, DOI 10.3390/molecules25112707
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Seley-Radtke KL, 2018, ANTIVIR RES, V154, P66, DOI 10.1016/j.antiviral.2018.04.004
   Slynko I, 2014, J CHEM INF MODEL, V54, P138, DOI 10.1021/ci400628q
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   van Santen JA, 2019, ACS CENTRAL SCI, V5, P1824, DOI 10.1021/acscentsci.9b00806
   WHO, 2002, SUMM TABL SARS CAS C
   Williams DE, 1999, TETRAHEDRON LETT, V40, P7171, DOI 10.1016/S0040-4039(99)01495-1
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e
   World Health Organization, NEW CAS LAB CONF SAR
   World Health Organization, AL VER PUBL HLTH MAN
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 44
TC 4
Z9 4
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD JUL
PY 2020
VL 8
IS 7
AR 970
DI 10.3390/microorganisms8070970
PG 14
WC Microbiology
SC Microbiology
GA MV6DM
UT WOS:000556446100001
PM 32610445
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Javed, A
   Mohandas, E
   De Sousa, A
AF Javed, Afzal
   Mohandas, E.
   De Sousa, Avinash
TI The interface of psychiatry and COVID-19: Challenges for management of
   psychiatric patients
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE COVID; psychiatric medication; pandemic; telepsychiatry; telemedicine
ID CHLOROQUINE; HYDROXYCHLOROQUINE; DEPRESSION
AB COVID-19 is a viral infection that has multisystemic physical and psychological complications. The following paper looks at the various challenges seen while treating psychiatric patients during the COVID pandemic. There is a need for physician to be aware of the drug interactions between psychiatric medications and the medications used routinely in the management of COVID. There is also the concern of psychiatric side effects of medications used to manage COVID and medical complications caused by some side effects of psychiatric drugs. The telepsychiatry and telemedicine paradigm has made it mandatory for physicians to be vigilant of the same.
C1 [Javed, Afzal; Mohandas, E.] Asian Federat Psychiat Assoc, Lahore, Pakistan.
   [Javed, Afzal] Pakistan Psychiat Res Ctr, Fountain House, Lahore, Pakistan.
   [Mohandas, E.] Sun Med & Res Ctr, Trichur, Kerala, India.
   [De Sousa, Avinash] Lokmanya Tilak Municipal Gen Hosp & Med Coll, Dept Psychiat, Mumbai, Maharashtra, India.
RP De Sousa, A (corresponding author), Carmel 18,St Francis Rd,SV Rd, Mumbai 400054, Maharashtra, India.
EM avinashdes888@gmail.com
CR AKHTAR S, 1993, INT J PSYCHIAT MED, V23, P349, DOI 10.2190/8DRE-DBNH-MXXG-7AJF
   Alisky JM, 2006, MED HYPOTHESES, V67, P1090, DOI 10.1016/j.mehy.2006.01.059
   Bessiere F., 2020, JAMA CARDIOL
   Bilbul M, 2020, PSYCHOSOMATICS
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Ribeiro NPD, 2013, COMPR PSYCHIAT, V54, P1185, DOI 10.1016/j.comppsych.2013.05.010
   De Sousa A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102128
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Dubovsky AN, 2012, PSYCHOSOMATICS, V53, P103, DOI 10.1016/j.psym.2011.12.007
   Fan BE, 2020, AM J HEMATOL
   Gupta L, 2020, INDIAN J RHEUMATOL, V15, P65, DOI 10.4103/injr.injr_64_20
   Haider II, 2020, PAK J MED SCI, V36, pS90, DOI 10.12669/pjms.36.COVID19-S4.2756
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Kunal S, 2020, MONALDI ARCH CHEST D, V90, P231, DOI 10.4081/monaldi.2020.1305
   LaHue SC, 2020, J AM GERIATR SO 0411
   Leung JG, 2020, SCHIZOPHR RES
   Manzo Ciro, 2017, Drug Saf Case Rep, V4, P6, DOI 10.1007/s40800-017-0048-x
   Mohan D, 1981, J Natl Med Assoc, V73, P1073
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Sahoo Saddichha, 2007, Am J Ther, V14, P406, DOI 10.1097/MJT.0b013e31802e4b0e
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sato K, 2020, BIOSCI TRENDS, V14, P139, DOI 10.5582/bst.2020.03082
   Siskind D, 2020, J PSYCHIATR NEUROSCI, V45, DOI [10.1503/jpn.200061, DOI 10.1503/JPN.200061]
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Telles-Correia Diogo, 2017, World J Gastrointest Pharmacol Ther, V8, P26, DOI 10.4292/wjgpt.v8.i1.26
   Uthman OA, 2014, CURR HIV-AIDS REP, V11, P291, DOI 10.1007/s11904-014-0220-1
   Vermeulen JM, 2019, SCHIZOPHRENIA BULL, V45, P315, DOI 10.1093/schbul/sby052
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang Y., 2020, LANCET
NR 32
TC 0
Z9 0
U1 1
U2 1
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD JUL-AUG
PY 2020
VL 36
IS 5
BP 1133
EP 1136
DI 10.12669/pjms.36.5.3073
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MW9NN
UT WOS:000557358000023
PM 32704300
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hotez, PJ
   Bottazzi, ME
AF Hotez, Peter J.
   Bottazzi, Maria Elena
TI Developing a low-cost and accessible COVID-19 vaccine for global health
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
C1 [Hotez, Peter J.; Bottazzi, Maria Elena] Baylor Coll Med, Natl Sch Trop Med, Texas Childrens Ctr Vaccine Dev, Dept Pediat & Mol Virol, Houston, TX 77030 USA.
   [Hotez, Peter J.; Bottazzi, Maria Elena] Baylor Coll Med, Natl Sch Trop Med, Texas Childrens Ctr Vaccine Dev, Dept Microbiol, Houston, TX 77030 USA.
   [Hotez, Peter J.; Bottazzi, Maria Elena] Baylor Univ, Dept Biol, Waco, TX 76798 USA.
   [Hotez, Peter J.] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA.
   [Hotez, Peter J.] Texas A&M Univ, Scowcroft Inst Int Affairs, Bush Sch Govt & Publ Serv, College Stn, TX 77843 USA.
   [Hotez, Peter J.] Rice Univ, James Baker III Inst Publ Policy, Houston, TX 77251 USA.
RP Hotez, PJ; Bottazzi, ME (corresponding author), Baylor Coll Med, Natl Sch Trop Med, Texas Childrens Ctr Vaccine Dev, Dept Pediat & Mol Virol, Houston, TX 77030 USA.; Hotez, PJ; Bottazzi, ME (corresponding author), Baylor Coll Med, Natl Sch Trop Med, Texas Childrens Ctr Vaccine Dev, Dept Microbiol, Houston, TX 77030 USA.; Hotez, PJ; Bottazzi, ME (corresponding author), Baylor Univ, Dept Biol, Waco, TX 76798 USA.; Hotez, PJ (corresponding author), Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX 77843 USA.; Hotez, PJ (corresponding author), Texas A&M Univ, Scowcroft Inst Int Affairs, Bush Sch Govt & Publ Serv, College Stn, TX 77843 USA.; Hotez, PJ (corresponding author), Rice Univ, James Baker III Inst Publ Policy, Houston, TX 77251 USA.
EM hotez@bcm.edu; bottazzi@bcm.edu
OI Bottazzi, Maria Elena/0000-0002-8429-0476
CR Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Chen WH, 2020, BIORXIV, DOI [10.1101/2020.05.15.09807932511385, DOI 10.1101/2020.05.15.09807932511385]
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0358-6
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Hotez PJ, 2020, MICROBES INFECT, V22, P165, DOI 10.1016/j.micinf.2020.04.005
   Hotez PJ, 2020, POVERTY IMPACT COVID
   Igoe M., WILL VACCINES REACH
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Love KR, 2018, CURR OPIN BIOTECH, V53, P50, DOI 10.1016/j.copbio.2017.12.010
   Regan H, 2020, MILLIONS INDIA CORON
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Tai WB, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104820
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   World Health Organization, 2020, COVID 19 SIT REP
   Wrapp D, 2020, BIORXIV, DOI [10.1101/2020.02.11.94446232511295, DOI 10.1101/2020.02.11.94446232511295]
   XU ZJ, 2020, GEROSCIENCE 0611, DOI DOI 10.1126/SCIENCE.ABC1932
NR 19
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2020
VL 14
IS 7
AR e0008548
DI 10.1371/journal.pntd.0008548
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA MV9YW
UT WOS:000556705600001
PM 32726304
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Greve, JMD
   Brech, GC
   Quintana, M
   Soares, ALD
   Alonso, AC
AF D'Andrea Greve, Julia Maria
   Brech, Guilherme Carlos
   Quintana, Marilia
   de Seixas Soares, Andre Luiz
   Alonso, Angelica Castilho
TI IMPACTS OF COVID-19 ON THE IMMUNE, NEUROMUSCULAR, AND MUSCULOSKELETAL
   SYSTEMS AND REHABILITATION
SO REVISTA BRASILEIRA DE MEDICINA DO ESPORTE
LA English
DT Article
DE COVID-19; Neuromuscular manifestations; Musculoskeletal system; Exercise
   therapy; Immune system
ID INFLUENZA-A VIRUS; CORONAVIRUS INFECTION; MUSCLE; RECOVERY; CARE; ICU
AB The new coronavirus, which causes the infectious disease named COVID-19 by the World Health Organization (WHO), was notified in 2020 in China. The main clinical manifestations in infected patients are fever, cough and dyspnoea. These patients are prone to developing cardiac changes, diffuse myopathy, decreased pulmonary function, decreased inspiratory muscle strength, and a deterioration in functional capacity. Thus, it is expected that patients affected by COVID-19 will suffer musculoskeletal consequences as a result of the inflammatory process and loss of muscle mass caused by immobility, generating motor incapacities that are not yet quantifiable. It is important to understand the clinical implications caused by COVID-19, in order to have better rehabilitation strategies for these patients. The aim of this study was to conduct a reflective analysis of the impact of COVID-19 on the immune, neuromuscular and musculoskeletal systems, and its rehabilitation process. This is a reflexive analysis, developed in the Laboratory for the Study of Movement of the Institute of Orthopaedics' and Traumatology, at the Universidade de Sao Paulo School of Medicine, SP, Brazil. In this analysis, we reflect on the following topics related to COVID-19: immunological mechanisms, impact on the neuromuscular and musculoskeletal systems, and the rehabilitation of patients.
C1 [D'Andrea Greve, Julia Maria; Brech, Guilherme Carlos; de Seixas Soares, Andre Luiz; Alonso, Angelica Castilho] Univ Sao Paulo, Fac Med, Orthoped & Traumatol Dept, Sao Paulo, SP, Brazil.
   [Brech, Guilherme Carlos; Quintana, Marilia; Alonso, Angelica Castilho] Univ Sao Judas Tadeu, Postgrad Program Sci Aging, Sao Paulo, SP, Brazil.
   [Quintana, Marilia; Alonso, Angelica Castilho] Univ Anhembi Morumbi, Sao Paulo, SP, Brazil.
RP Greve, JMD (corresponding author), Hosp Clin Sao Paulo, Inst Ortopedia & Traumatol, Lab Studies Movement LEM, Rua Ovidio Pires de Campos 333, BR-05403010 Sao Paulo, SP, Brazil.
EM jgreve@usp.br
RI Brech, Guilherme C/I-6100-2012; Greve, Julia/I-3444-2015
OI Brech, Guilherme C/0000-0002-0403-0632; Greve,
   Julia/0000-0003-1778-0448; Castilho Alonso, angelica/0000-0002-9644-5068
FU Coordination for the Improvement of Higher Education Personnel -Brazil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordination for the Improvement
   of Higher Education Personnel -Brazil (CAPES) -Finance Code 001.
CR Applegate WB, 2020, J AM GERIATR SOC, V68, P681, DOI 10.1111/jgs.16426
   Arentson-Lantz EJ, 2016, J APPL PHYSIOL, V120, P965, DOI 10.1152/japplphysiol.00799.2015
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Baig AM, 2020, CNS NEUROSCI THER, V26, P499, DOI 10.1111/cns.13372
   Barker-Davies RM, 2020, BRIT J SPORT MED, P1, DOI [10.1136/bjsports-2020-1025964, DOI 10.1136/BJSP0RTS-2020-102596]
   Brasil [Ministerio da Saude], 2020, COR PLAT INT VIG SAU
   Brasil [Ministerio da Saude], 2020, B EPIDEMIOLOGICO, V2, P1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dantas Camila Moura, 2012, Rev. bras. ter. intensiva, V24, P173, DOI 10.1590/S0103-507X2012000200013
   De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329
   DeFelice FG, 2020, TRENDS NEUROSCI, P1
   Deftereos SG, 2020, HELL J CARDIOL
   Demangel R, 2017, J PHYSIOL-LONDON, V595, P4301, DOI 10.1113/JP273895
   Drey M, 2013, EXP GERONTOL, V48, P76, DOI 10.1016/j.exger.2012.05.021
   Dube M, 2018, J VIROL, V92, DOI 10.1128/JVI.00404-18
   Gutierrezocampo E, 2020, JANUARY 2020 ELSEVIE, V34
   Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004
   Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
   Ichiyama T, 2003, SERUM CYTOKINE CONCE, P734
   Johnston CL, 2011, PHYSIOTHERAPY, V97, P284, DOI 10.1016/j.physio.2010.12.001
   Kansagra SM, 2011, PEDIATR NEUROL, V45, P400, DOI 10.1016/j.pediatrneurol.2011.09.007
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390
   Kwong KCNK, 2020, J CLIN NEUROSCI, V77, P13, DOI 10.1016/j.jocn.2020.04.124
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YC, 2012, VIRUS RES, V163, P628, DOI 10.1016/j.virusres.2011.12.021
   Luo G., 2003, AM J PHYSIOL-REG I, V284, P1249
   Madjid M, 2020, JAMA CARDIOL, V10, P1
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matsuda K, 2004, VET PATHOL, V41, P101, DOI 10.1354/vp.41-2-101
   McNeary L, 2020, PM&R, V12, P512, DOI 10.1002/pmrj.12369
   Mendez-Tellez PA, 2012, NEUROHOSPITALIST, V2, P96, DOI 10.1177/1941874412447631
   Mesquita TM de JC, 2016, REV BRAS SAUDE FUNC, V1, P1
   Min A, 2010, NIH PUBLIC ACCESS, V457, P989
   Min XY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4013685
   Narici M, 2020, EUR J SPORT SCI, DOI 10.1080/17461391.2020.1761076
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Poulsen JB, 2012, DAN MED J, V59
   Radigan KA, 2019, J IMMUNOL, V202, P484, DOI 10.4049/jimmunol.1701433
   Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Sheehy LM, 2020, JMIR PUBLIC HEAL SUR, V6
   Shepherd S, 2017, NEUROHOSPITALIST, V7, P41, DOI 10.1177/1941874416663279
   Shi CS, 2019, CELL DEATH DISCOV, V5
   Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930
   Toscano, 2020, NEW ENGL J MED NEJMC, P17
   Tsai Li-Kai, 2005, Acta Neurol Taiwan, V14, P113
   Woods J, 2020, SPORT SOC, DOI 10.1080/17430437.2019.1710132
   Zhao El M, 2020, CHIN MED J
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou L., 2020, TRAVEL MED INFECT DI, DOI DOI 10.1016/J.TMAID.2020
NR 54
TC 0
Z9 0
U1 2
U2 2
PU SOC BRASILEIRA MED ESPORTE
PI SAO PAULO SP
PA AV BRIGADEIRO LUIS ANTONIO, 278, 6 AND, SAO PAULO SP, 01318 901, BRAZIL
SN 1517-8692
EI 1806-9940
J9 REV BRAS MED ESPORTE
JI Rev. Bras. Med. Esporte
PD JUL-AUG
PY 2020
VL 26
IS 4
BP 285
EP 288
DI 10.1590/1517-869220202604ESP002
PG 4
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA MV6KH
UT WOS:000556463800004
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Qian, S
   An, JH
   Qi, FR
   Ye, L
   Chen, Q
   Liu, XQ
   Xie, LX
   Li, GB
AF Qian, Shen
   An, Jianghong
   Qi, Furong
   Ye, Ling
   Chen, Qiong
   Liu, Xunqi
   Xie, Lixin
   Li, Guobao
TI Tocilizumab exerts anti-inflammatory activity in six critically ill
   COVID-19 patients: a retrospective analysis
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); inflammatory response; interleukin
   6 (IL-6); Tocilizumab
ID IL-6
AB Background: Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic, affecting countries across the globe. With no current vaccine, treatment is still a critical intervention for minimizing morbidity and preventing disease-specific mortality. This study aimed to assess the clinical outcomes of critically ill COVID-19 patients using Tocilizumab treatment to provide recommendations for the treatment of COVID-19 patients with severe disease.
   Methods: This was a retrospective analysis of medical records of six critically ill patients admitted to the Third People's Hospital of Shenzhen, China, from January 11 to February 26, 2020. Patient-related outcomes, including demographic, clinical, and laboratory characteristics before and after the initiation of Tocilizumab, were descriptively analyzed. Four to eight milligrams (mg)/kilogram (kg) of Tocilizumab was prescribed, with Chinese treatment guidelines.
   Results: By the end of the last follow-up, Patient 1 and Patient 2 developed complications and died after using Tocilizumab for three to four days. Patient 4 died of multiple organ failure caused by cerebral infarction after using Tocilizumab for 39 days. Patient 3 and Patient 6 were discharged after 29 days and 33 days on Tocilizumab, respectively. Clinical symptoms, including fever, heart rate, and oxygen levels, improved after Tocilizumab use. Two patients appeared transient abnormal of liver or renal function indicator, and they can gradually recover. All elevated serum levels of inflammatory factors gradually decreased, except in Patient 2. Patient 3 and Patient 6's inflammatory lesions also significantly improved after initiating Tocilizumab.
   Conclusions: Anti-inflammatory treatment with Tocilizumab was found to improve inflammatory responses in critically ill COVID-19 patients. Although some side reactions will occur, patients can gradually recover without affecting the efficacy of the therapy. However, the proper timing to start patients on Tocilizumab patients should be explored. Further prospective, randomized controlled clinical trials are called for.
C1 [Qian, Shen; Xie, Lixin] Chinese Peoples Liberat Army Gen Hosp, Coll Pulm & Crit Care Med, Beijing, Peoples R China.
   [Qian, Shen; Qi, Furong; Li, Guobao] Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Dept Pulm Dis 3, Shenzhen, Peoples R China.
   [An, Jianghong; Chen, Qiong; Liu, Xunqi] Third Peoples Hosp Shenzhen, Dept Oncol & Hematol, Shenzhen, Peoples R China.
   [Ye, Ling] Ji Nan Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China.
RP Xie, LX (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Coll Pulm & Crit Care Med, Beijing, Peoples R China.; Li, GB (corresponding author), Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Shenzhen, Peoples R China.
EM xielx301@126.com; feisanke-01@szsy.sustech.edu.cn
FU Medical and Health Three Famous Projects in Shenzhen; Major Emerging
   Infectious Diseases Diagnosis and Research Team [SZSM201612025]; 2020
   Guangdong Province Special Project on Emergency Research on Prevention
   and Control of New Coronavirus Infection Technology [2020B1111340030];
   China National Key Research Program [2018ZX09201013]; China PLA Key
   Research Program [A3704041902-03]; Research Foundation of Medical
   Science and Technology of Guangdong Province [B2019132]; Ji Nan
   University Central University Basic Research Fund [21619359]
FX This research was funded by the Medical and Health Three Famous Projects
   in Shenzhen and awarded to Professor Liu You-Ning, General Hospital of
   the Chinese People's Liberation Army, Respiratory System Critical
   Illness, and Major Emerging Infectious Diseases Diagnosis and Research
   Team (SZSM201612025). This research was funded by the 2020 Guangdong
   Province Special Project on Emergency Research on Prevention and Control
   of New Coronavirus Infection Technology (2020B1111340030). China
   National Key Research Program (2018ZX09201013); China PLA Key Research
   Program (A3704041902-03); Research Foundation of Medical Science and
   Technology of Guangdong Province (No. B2019132); Ji Nan University
   Central University Basic Research Fund (No. 21619359).
CR Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   COOMES EA, 2020, MEDRXIV, DOI DOI 10.1101/2020.03.3020048058
   Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   LIU J, 2020, LONGITUDINAL CHARACT, DOI DOI 10.1101/2020.02.1620023671
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Ou XT, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101672
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   World Health Organization, CLINICAL MANAGEMENT
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Xu G, 2020, J LEUKOCYTE BIOL, V107, P613, DOI 10.1002/JLB.5MR1019-179R
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 20
TC 0
Z9 0
U1 2
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUL
PY 2020
VL 8
IS 14
AR 881
DI 10.21037/atm-20-5080
PG 11
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA MS7ZT
UT WOS:000554494600011
PM 32793725
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Meloni, M
   Izzo, V
   Giurato, L
   Gandini, R
   Uccioli, L
AF Meloni, Marco
   Izzo, Valentina
   Giurato, Laura
   Gandini, Roberto
   Uccioli, Luigi
TI Management of diabetic persons with foot ulceration during COVID-19
   health care emergency: Effectiveness of a new triage pathway
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetes; Diabetic foot ulcers; COVID-19; Amputation; Mortality
ID PERIPHERAL ARTERIAL-DISEASE
AB Aim: To define the outcomes of persons with diabetes and foot ulcers (DFUs) managed through a specific triage pathway during the COVID-19 crisis.
   Methods: Patients who had an active DFU during the COVID-19 emergency were included. All participants were managed using a specific triage system driven both by ulcer'severity and concomitant co-diseases. Subjects with severely complicated DFUs were urgently referred to hospital regardless of the concomitant comorbidities. Subjects with complicated DFUs received outpatient evaluation (within 48-72 h) and were admitted to hospital if required (revascularization, surgical intervention, intravenous antibiotic therapy); after the first outpatient visit or hospitalization, patients were followed according to the number of comorbidities (in the case of 3 or more comorbidities patients were followed up by telemedicine). Patients with uncomplicated DFUs were managed by telemedicine after outpatient evaluation. Healing, major amputation, death and rate of COVID-19 infection were evaluated. The minimum follow-up was 1 month.
   Results: The study group included 151 patients. The mean age was 69.9 +/- 14.2 years, 58.9% were male and 91.4% had type 2 diabetes; 58.7% had severely complicated, 21% complicated and 20.3% uncomplicated DFUs. Among those, 78.8% presented with 3 or more comorbidities. One hundred and six patients had regular clinical follow-ups, while 45 were managed through telemedicine. Forty-one (27.1%) patients healed, 3 (1.9%) had major amputations and 3 (1.9%) died. One patient (0.6%) reported COVID-19 positivity due to infection acquired at home.
   Conclusion: The triage pathway adopted during the COVID-19 pandemic showed adequate management of DFUs and no cases of hospital virus exposure. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Meloni, Marco; Izzo, Valentina; Giurato, Laura; Gandini, Roberto; Uccioli, Luigi] Univ Tor Vergata, Diabet Foot Unit, Rome, Italy.
RP Meloni, M (corresponding author), Univ Tor Vergata, Diabet Foot Unit, Rome, Italy.
EM meloni.marco@libero.it
CR Bus SA, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3267
   Faglia Ezio, 2006, J Foot Ankle Surg, V45, P220, DOI 10.1053/j.jfas.2006.04.002
   Meloni M, 2019, DIAB FOOT J, V22
   Meloni M, FRONT DIAB, V26
   Norgren L, 2007, EUR J VASC ENDOVASC, V33, pS5, DOI [10.1016/j.ejvs.2006.09.024, 10.1016/j.jvs.2006.12.037]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Prompers L, 2008, DIABETOLOGIA, V51, P747, DOI 10.1007/s00125-008-0940-0
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rogers Lee C, 2020, J Am Podiatr Med Assoc, DOI 10.7547/20-051
   van Battum P, 2011, DIABETIC MED, V28, P199, DOI 10.1111/j.1464-5491.2010.03192.x
   Vas PRJ, 2018, INT J LOW EXTR WOUND, V17, P7, DOI 10.1177/1534734618755582
NR 12
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD JUL
PY 2020
VL 165
AR 108245
DI 10.1016/j.diabres.2020.108245
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MT4EL
UT WOS:000554922700024
PM 32497745
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, Y
   Cui, YH
   Shen, MX
   Zhang, JC
   Liu, B
   Dai, MH
   Chen, LL
   Han, DD
   Fan, YF
   Zeng, YJ
   Li, W
   Lin, FY
   Li, S
   Chen, X
   Pan, PH
AF Zhang, Yan
   Cui, Yanhui
   Shen, Minxue
   Zhang, Jianchu
   Liu, Ben
   Dai, Minhui
   Chen, Lingli
   Han, Duoduo
   Fan, Yifei
   Zeng, Yanjun
   Li, Wen
   Lin, Fengyu
   Li, Sha
   Chen, Xiang
   Pan, Pinhua
CA Xiangya Hosp Support Hubei China
TI Association of diabetes mellitus with disease severity and prognosis in
   COVID-19: A retrospective cohort study
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Diabetes mellitus; COVID-19; SARS-CoV-2; Prognosis
ID INTENSIVE INSULIN THERAPY; GLUCOSE CONTROL; CRITICALLY-ILL; MORTALITY;
   CHINA
AB Aims: The 2019 novel coronavirus disease (COVID-19) emerged in Wuhan, China, and was characterized as a pandemic by the World Health Organization. Diabetes is an established risk associated with poor clinical outcomes, but the association of diabetes with COVID-19 has not been reported yet.
   Methods: In this cohort study, we retrospectively reviewed 258 consecutive hospitalized COVID-19 patients with or without diabetes at the West Court of Union Hospital in Wuhan, China, recruited from January 29 to February 12, 2020. The clinical features, treatment strategies and prognosis data were collected and analyzed. Prognosis was followed up until March 12, 2020.
   Results: Of the 258 hospitalized patients (63 with diabetes) with COVID-19, the median age was 64 years (range 23-91), and 138 (53.5%) were male. Common symptoms included fever (82.2%), dry cough (67.1%), polypnea (48.1%), and fatigue (38%). Patients with diabetes had significantly higher leucocyte and neutrophil counts, and higher levels of fasting blood glucose, serum creatinine, urea nitrogen and creatine kinase isoenzyme MB at admission compared with those without diabetes. COVID-19 patients with diabetes were more likely to develop severe or critical disease conditions with more complications, and had higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%). Cox proportional hazard model showed that diabetes (adjusted hazard ratio [aHR] = 3.64; 95% confidence interval [CI]: 1.09, 12.21) and fasting blood glucose (aHR = 1.19; 95% CI: 1.08, 1.31) were associated with the fatality due to COVID-19, adjusting for potential confounders.
   Conclusions: Diabetes mellitus is associated with increased disease severity and a higher risk of mortality in patients with COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Zhang, Yan; Cui, Yanhui; Dai, Minhui; Chen, Lingli; Han, Duoduo; Fan, Yifei; Zeng, Yanjun; Li, Wen; Lin, Fengyu; Pan, Pinhua] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha 410008, Hunan, Peoples R China.
   [Shen, Minxue; Chen, Xiang] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha 410008, Hunan, Peoples R China.
   [Shen, Minxue] Cent South Univ, Xiangya Sch Publ Hlth, Dept Social Med & Hlth Management, Changsha 410008, Hunan, Peoples R China.
   [Zhang, Jianchu] Huazhong Univ Sci & Technol, Union Hosp, Dept Resp Med, Wuhan 430022, Hubei, Peoples R China.
   [Liu, Ben] Cent South Univ, Xiangya Hosp, Dept Emergency, Changsha 410008, Hunan, Peoples R China.
   [Li, Sha] Cent South Univ, Xiangya Hosp, Dept Radiol, Changsha 410008, Hunan, Peoples R China.
RP Pan, PH (corresponding author), Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha 410008, Hunan, Peoples R China.; Chen, X (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha 410008, Hunan, Peoples R China.
EM chenxiangck@126.com; pinhuapan668@csu.edu.cn
OI Liu, Ben/0000-0001-9486-4966
FU Emergency Project of Prevention and Control for COVID-19 of Central
   South University [160260004]; Project of Special Program on COVID-19 of
   Changsha Technology Hall [kq2001049]; Science and technology innovation
   project of Hunan Province [S2018SFYLJS0108]; National Key R&D Program of
   China [2016YFC1304204]
FX This study was supported by Emergency Project of Prevention and Control
   for COVID-19 of Central South University (No. 160260004); Project of
   Special Program on COVID-19 of Changsha Technology Hall (No. kq2001049);
   Science and technology innovation project of Hunan Province (No.
   S2018SFYLJS0108); National Key R&D Program of China (No.
   2016YFC1304204).
CR Banik GR, 2016, VIROL SIN, V31, P81, DOI 10.1007/s12250-015-3679-z
   Chen Cheng-Yu, 2005, J Chin Med Assoc, V68, P4, DOI 10.1016/S1726-4901(09)70124-8
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Duan LP, 2020, ENERGY TECHNOL-GER, V8, DOI 10.1002/ente.201901401
   Guan W, 2020, CLIN CHARACTERISTICS
   Hodgson K, 2015, IMMUNOLOGY, V144, P171, DOI 10.1111/imm.12394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group, 2012, KDIGO CLIN PRACTICE
   Klekotka Renata Barbara, 2015, Pneumonol Alergol Pol, V83, P401, DOI 10.5603/PiAP.2015.0065
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Liu J., 2020, NEUTROPHIL TO LYMPHO
   Liu YJ, 2020, ARTECH HSE MOB COMM, P1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Reaven PD, 2019, NEW ENGL J MED, V380, P2215, DOI 10.1056/NEJMoa1806802
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   THOMAS ML, 2018, CHIN J DIABETES MELL, V10, DOI DOI 10.3390/CANCERS10040101
   Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978
   Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   WHO, 2019, MIDDL E RESP SYNDR C
   WHO, 2020, CLIN MAN SEV AC RESP
   Xia C, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/6494795
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 29
TC 12
Z9 12
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD JUL
PY 2020
VL 165
AR 108227
DI 10.1016/j.diabres.2020.108227
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MT4EL
UT WOS:000554922700010
PM 32446795
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, NR
   Li, CQ
   Hu, Y
   Li, KC
   Liang, JT
   Wang, LL
   Du, LY
   Jiang, SB
AF Zhang, Naru
   Li, Chaoqun
   Hu, Yue
   Li, Kangchen
   Liang, Jintian
   Wang, Lili
   Du, Lanying
   Jiang, Shibo
TI Current development of COVID-19 diagnostics, vaccines and therapeutics
SO MICROBES AND INFECTION
LA English
DT Article
DE SARS-CoV-2; Diagnostic approaches; Vaccines; Therapeutics
ID SPIKE PROTEIN; PNEUMONIA OUTBREAK; CORONAVIRUS; CHLOROQUINE; SARS-COV-2;
   WUHAN; COV; INFECTIONS; TARGET; CHINA
AB A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection. (c) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Zhang, Naru; Li, Chaoqun; Hu, Yue; Li, Kangchen; Liang, Jintian] Zhejiang Univ City Coll, Sch Med, Dept Clin Med, Hangzhou, Peoples R China.
   [Wang, Lili] Hebei Agr Univ, Res Ctr Chinese Jujube, Baoding, Peoples R China.
   [Du, Lanying; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
   [Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE, NHC,CAMS, Shanghai, Peoples R China.
RP Du, LY; Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
EM ldu@nybc.org; shibojiang@fudan.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041025, 81630090]
FX This work was supported by the National Natural Science Foundation of
   China (82041025 and 81630090 to S.J.).
CR Agrawal S, 2020, MONALDI ARCH CHEST D, V90
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Cheung E., S CHINA MORNING POST
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Clover Biopharmaceuticals, 2020, CLOV IN DEV REC SUB
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   J Wang, 2020, SCIENCE, V367
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Kaiser Permanente Washington Health Research Institute, 2020, KAIS PERM LAUNCH 1 C
   KK To, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa149.pii:ciaa149, DOI 10.1093/CID/CIAA149.PII:CIAA149]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luke T, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1061
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shieber J., TECH CRUNCH
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2019, CLIN MICROBIOL INFEC, V25, P1539, DOI 10.1016/j.cmi.2019.04.012
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   WHO, MIDDL E RESP SYNDR C
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 58
TC 6
Z9 6
U1 2
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUL-AUG
PY 2020
VL 22
IS 6-7
BP 231
EP 235
DI 10.1016/j.micinf.2020.05.001
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MX0SH
UT WOS:000557438000001
PM 32387332
OA Green Published
DA 2021-01-01
ER

PT J
AU Ma, CQ
   Su, S
   Wang, JC
   Wei, L
   Du, LY
   Jiang, SB
AF Ma, Cuiqing
   Su, Shan
   Wang, Jiachao
   Wei, Lin
   Du, Lanying
   Jiang, Shibo
TI From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for
   coronavirus vaccine development
SO MICROBES AND INFECTION
LA English
DT Article
DE 2019-nCoV; SARS-CoV-2; HCoV-19; SARS-CoV; Vaccine; Cross-protection
ID ACUTE-RESPIRATORY-SYNDROME; RECEPTOR-BINDING DOMAIN; CELLULAR
   IMMUNE-RESPONSES; SPIKE PROTEIN; S-PROTEIN; NEUTRALIZING ANTIBODIES;
   PNEUMONIA OUTBREAK; DEPENDENT ENTRY; PALM CIVET; L-SIGN
AB The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics. (C) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Ma, Cuiqing; Wang, Jiachao; Wei, Lin] Hebei Med Univ, Key Lab Immune Mech & Intervent Serious Dis Hebei, Dept Immunol, Shijiazhuang 050017, Hebei, Peoples R China.
   [Su, Shan; Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, Key Lab Med Mol Virol MOE,NHC,CAMS, Shanghai, Peoples R China.
   [Du, Lanying; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
RP Jiang, SB (corresponding author), Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, Key Lab Med Mol Virol MOE,NHC,CAMS, Shanghai, Peoples R China.
EM shibojiang@fudan.edu.cn
OI Su, Shan/0000-0003-0593-9968
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81971474]; Scientific and Technological
   Research Projects of Colleges and Universities in Hebei Province
   [ZD2018001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81971474), and Scientific and Technological
   Research Projects of Colleges and Universities in Hebei Province
   (ZD2018001).
CR Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306
   Basso LGM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37131
   Bauch CT, 2005, EPIDEMIOLOGY, V16, P791, DOI 10.1097/01.ede.0000181633.80269.4c
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YZ, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.18
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cyranoski D, 2003, NATURE, V423, P467, DOI 10.1038/423467a
   Deng YQ, 2006, STRUCTURE, V14, P889, DOI 10.1016/j.str.2006.03.007
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Du LY, 2008, VACCINE, V26, P1644, DOI 10.1016/j.vaccine.2008.01.025
   Du LY, 2008, DRUG TODAY, V44, P63, DOI 10.1358/dot.2008.44.1.1131830
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2006, VIROLOGY, V353, P6, DOI 10.1016/j.virol.2006.03.049
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Du LY, 2009, BIOCHEM BIOPH RES CO, V384, P486, DOI 10.1016/j.bbrc.2009.05.003
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0175-7
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guo YJ, 2005, DNA CELL BIOL, V24, P510, DOI 10.1089/dna.2005.24.510
   Han DP, 2007, J VIROL, V81, P12029, DOI 10.1128/JVI.00315-07
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   He YX, 2006, BIOCHEM BIOPH RES CO, V344, P106, DOI 10.1016/j.bbrc.2006.03.139
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Jiang SB, 2020, VIROL SIN, V35, P263, DOI 10.1007/s12250-020-00206-5
   Jiang SB, 2020, CELL MOL IMMUNOL, V17, P554, DOI 10.1038/s41423-020-0372-4
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu RY, 2005, VIRUS RES, V112, P24, DOI 10.1016/j.virusres.2005.02.009
   Liu T, 2020, TIME VARYING TRANSMI, DOI [10.1101/2020.01.25.919787, DOI 10.1101/2020.01.25.919787]
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Messonnier NE, CDC ADVISES TRAVELER
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Planas O, 2020, SCIENCE, V367, DOI 10.1126/science.abb2416
   Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Shen M, 2020, MODELLING EPIDEMIC T, DOI [10.1101/2020.01.23.916726, DOI 10.1101/2020.01.23.916726, 10.1101/2020.01.23.916726.]
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Taguchi F, 2000, J GEN VIROL, V81, P2867, DOI 10.1099/0022-1317-81-12-2867
   Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143
   Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tseng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053096
   Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DN, 2004, PHYSIOL GENOMICS, V18, P245, DOI 10.1152/physiolgenomics.00102.2004
   Wang L., 2015, TRANSBOUND EMERG DIS, V6, P1, DOI DOI 10.1038/NC0MMS8712
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   World Health Organization, COR
   Wu GF, 2001, ADV EXP MED BIOL, V494, P341
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xiong S, 2004, IMMUNOL LETT, V95, P139, DOI 10.1016/j.imlet.2004.06.014
   Yan Z, 2009, ADV EXP MED BIOL, V611, P153, DOI 10.1007/978-0-387-73657-0_69
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zeng FY, 2006, FEBS LETT, V580, P5612, DOI 10.1016/j.febslet.2006.08.085
   Zeng FY, 2004, BIOCHEM BIOPH RES CO, V315, P1134, DOI 10.1016/j.bbrc.2004.01.166
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03
   Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134
   Zhang Y, 2005, COMPUT BIOL CHEM, V29, P254, DOI 10.1016/j.compbiolchem.2005.04.008
   Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 121
TC 7
Z9 7
U1 8
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUL-AUG
PY 2020
VL 22
IS 6-7
BP 245
EP 253
DI 10.1016/j.micinf.2020.05.004
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MX0SH
UT WOS:000557438000003
PM 32437926
OA Green Published
DA 2021-01-01
ER

PT J
AU Yue, HM
   Bai, X
   Wang, JT
   Yu, Q
   Liu, WY
   Pu, JY
   Wang, XY
   Hu, JM
   Xu, D
   Li, XG
   Kang, N
   Li, L
   Lu, WQ
   Feng, T
   Ding, LH
   Li, X
   Qi, XL
AF Yue, Hongmei
   Bai, Xue
   Wang, Jitao
   Yu, Qin
   Liu, Weiying
   Pu, Jiayuan
   Wang, Xiaoya
   Hu, Jianming
   Xu, Dan
   Li, Xiaoguo
   Kang, Ning
   Li, Long
   Lu, Wenqiang
   Feng, Tao
   Ding, Lihui
   Li, Xun
   Qi, Xiaolong
TI Clinical characteristics of coronavirus disease 2019 in Gansu province,
   China
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); Gansu province
AB Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has outbreak in the world. Little is known about the clinical characteristics of patients with SARS-CoV-2 infection in the high-altitude region of China. We reported the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) in Gansu province, China.
   Methods: In this retrospective study, patients with laboratory-confirmed SARS-CoV-2 infection were consecutively enrolled from January 21, 2020 to February 11, 2020. The information on the epidemiological, clinical characteristics, laboratory tests, radiological features on admission, treatment and outcome were obtained with the final follow-up of March 13, 2020. On the basis of the median length of hospital stay, patients were further analyzed in two groups (long-vs. short-hospital stay).
   Results: Of the 86 patients of COVID-19 in 11 cities of Gansu Province, the median hospital stay was 14.0 days (interquartile rang, 11.0-19.0 days). In the overall cohort, the median age was 41.0 years (interquartile rang, 31.0-54.3 years), and 48 (55.8%) patients were female. Forty (46.5%) had a history of exposure to epidemic regions, but none exposed to the Huanan seafood market in Wuhan. Common symptoms included fever (41, 47.7%), and cough (38, 44.2%). On admission, 30 (34.9%) and 58 (67.4%) patients had leukopenia and lymphopenia. According to chest CT scans, 53 (66.3%) of 80 patients showed bilateral pneumonia, and 19 (23.8%) of 80 patients showed unilateral pneumonia. Of the 15 asymptomatic cases, 10 (66.6%) cases were found CT findings of pneumonia. Besides, there were 65 (75.6%) patients with mild and moderate type of COVID-19. All 86 patients received antiviral and traditional Chinese medicine therapy, 53 (61.6%) received antibacterial therapy, and 3 (3.5%) patients received invasive ventilator mechanical ventilation. The proportion of patients received antibiotic treatment in long-hospital stay group was significantly higher than that in the short-hospital stay group (P=0.045). As of March 13, 2020, 84 (97.7%) patients were discharged, and two (2.3%) cases died.
   Conclusions: In the Gansu province cohort of 86 patients of COVID-19, most patients were with mild or moderate type, and most asymptomatic cases showed CT imaging findings of SARS-CoV-2 related pneumonia.
C1 [Yue, Hongmei; Bai, Xue; Yu, Qin; Liu, Weiying; Pu, Jiayuan; Wang, Xiaoya; Hu, Jianming; Li, Long; Lu, Wenqiang; Feng, Tao; Ding, Lihui] Lanzhou Univ, Dept Resp Med, Dept Pulm & Crit Care Med, Hosp 1, Lanzhou, Peoples R China.
   [Yue, Hongmei; Wang, Jitao; Xu, Dan; Li, Xiaoguo; Kang, Ning; Li, Xun; Qi, Xiaolong] Lanzhou Univ, Hosp 1, CHESS Ctr, Lanzhou, Peoples R China.
RP Yue, HM (corresponding author), Lanzhou Univ, Dept Resp Med, Dept Pulm & Crit Care Med, Hosp 1, Lanzhou, Peoples R China.; Qi, XL (corresponding author), Lanzhou Univ, Hosp 1, CHESS Ctr, Lanzhou, Peoples R China.
EM yuehongmei18@sina.com; qixiaolong@vip.163.com
FU Gansu Provincial COVID-19 Science and Technology Major Project
FX This study was supported by Gansu Provincial COVID-19 Science and
   Technology Major Project.
CR Cai J, 2020, EMERGING INFECT DIS
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, 51 WHO
   Wu JY, 2020, INFECT DIS THER, V9, P17, DOI 10.1007/s40121-020-00286-6
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 15
TC 0
Z9 0
U1 3
U2 3
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL
PY 2020
VL 9
IS 4
BP 1404
EP 1412
DI 10.21037/apm-20-887
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA MT5WK
UT WOS:000555045100009
PM 32692208
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chen, YH
   Zhang, K
   Zhu, GJ
   Liu, LX
   Yan, XX
   Cai, ZG
   Zhang, ZH
   Zhi, HJ
   Hu, ZJ
AF Chen, Yuhong
   Zhang, Kun
   Zhu, Guijun
   Liu, Lixia
   Yan, Xixin
   Cai, Zhigang
   Zhang, Zhongheng
   Zhi, Haijun
   Hu, Zhenjie
TI Clinical characteristics and treatment of critically ill patients with
   COVID-19 in Hebei
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE 2019 novel coronavirus; novel coronavirus disease 2019 (COVID-19);
   SARS-CoV-2; 2019-nCoV; critically ill
ID RESPIRATORY-DISTRESS-SYNDROME; CORTICOSTEROIDS; SEPSIS
AB Background: In December, 2019, a novel coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. We aimed to clarify the epidemiology, laboratory examinations, imaging findings, and treatment of critically ill patients with COVID-19 in Hebei province, China.
   Methods: In this retrospective study, the demographic, laboratory and imaging, and treatment data of patients with severe COVID-19 treated in 13 designated hospitals in Hebei were collected and analyzed.
   Results: A total of 319 severe COVID-19 patients were treated at the 13 designated hospitals between 22 January, 2020 and 25 March, 2020. Eventually, 51 critically ill (31 severe cases and 20 critically severe cases) patients were included in the analysis. The patients had an average age of 58.9 +/- 13.7 years, and 27 (52.9%) were men. Twenty-one (41.2%) were familial cluster, and 33 (64.7%) had chronic illnesses. The patients in critically severe group had longer duration from symptom to confirmation, more severe infections, more severe lung injury, and a lower percentage of lymphocytes. All 51 patients received antiviral drugs, 47 (92.2%) received antibacterial agents, 49 ( 96.1%) received traditional Chinese drugs, and 46 (90.2%) received methylprednisolone. The critically severe patients received more fluid and more diuretic treatment; 14 (70.0%) required invasive mechanical ventilation, and 13 (65.0%) developed extrapulmonary complications.
   Conclusions: COVID-19 patients who had underlying diseases and longer confirmation times were more likely to progress to critically severe COVID-19. These patients also presented with a higher risk of respiratory depression, circulatory collapse, extrapulmonary complications, and infection.
C1 [Chen, Yuhong; Zhang, Kun; Zhu, Guijun; Liu, Lixia; Hu, Zhenjie] Hebei Med Univ, Affiliated Hosp 4, Dept Intens Care Unit, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China.
   [Chen, Yuhong; Zhang, Kun; Zhu, Guijun; Liu, Lixia; Hu, Zhenjie] Hebei Prov Tumor Hosp, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China.
   [Yan, Xixin; Cai, Zhigang] Hebei Med Univ, Affiliated Hosp 2, Dept Respirat, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Zhongheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Emergency Med, Hangzhou, Peoples R China.
   [Zhi, Haijun] Cangzhou Cent Hosp, Emergency Dept, Cangzhou, Peoples R China.
RP Chen, YH; Hu, ZJ (corresponding author), Hebei Med Univ, Affiliated Hosp 4, Dept Intens Care Unit, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China.; Chen, YH; Hu, ZJ (corresponding author), Hebei Prov Tumor Hosp, 12 Jiankang Rd, Shijiazhuang, Hebei, Peoples R China.
EM yuhong_apple@126.com; syicu@vip.sina.com
RI Zhang, Zhongheng/E-1282-2011
OI Zhang, Zhongheng/0000-0002-2336-5323
FU Department of Science and Technology of Hebei Province of China
   [20277707D]
FX This study was supported by the Department of Science and Technology of
   Hebei Province of China (20277707D).
CR [Anonymous], 2020, DIAGNOSIS TREATMENT
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   BIFFL WL, 1995, AM J SURG, V170, P591, DOI 10.1016/S0002-9610(99)80022-1
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Lau Arthur Chun-Wing, 2004, Int J Med Sci, V1, P1
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Marik PE, 2018, J THORAC DIS, V10, pS1070, DOI 10.21037/jtd.2018.04.35
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Pan YY, 2020, EUR RADIOL, V30, P3612, DOI 10.1007/s00330-020-06713-z
   Qiu H B, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P273, DOI 10.3760/cma.j.cn112147-20200222-00151
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YT, 2017, BIOMED PHARMACOTHER, V91, P393, DOI 10.1016/j.biopha.2017.04.091
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Warren MA, 2018, THORAX, V73, P840, DOI 10.1136/thoraxjnl-2017-211280
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.02.11
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 29
TC 0
Z9 0
U1 2
U2 2
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL
PY 2020
VL 9
IS 4
BP 2118
EP 2130
DI 10.21037/apm-20-1273
PG 13
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA MT5WK
UT WOS:000555045100086
PM 32692230
OA Other Gold
DA 2021-01-01
ER

PT J
AU Pan, WY
   Li, JJ
   Ou, YF
   Wu, YT
   Cai, SN
   Zhang, YX
   Wang, CL
AF Pan, Wenyan
   Li, Jingjing
   Ou, Yufeng
   Wu, Yitao
   Cai, Shining
   Zhang, Yuxia
   Wang, Chunling
TI Clinical outcome of standardized oxygen therapy nursing strategy in
   COVID-19
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Oxygen therapy; nursing; novel coronavirus pneumonia (COVID-19)
ID NASAL
AB Background: Novel coronavirus pneumonia (COVID-19) has become a global pandemic. However, a technical standard for oxygen therapy nursing, as well as how this would improve clinical outcomes and symptoms, is yet to be explored.
   Methods: From February 9, 2020, to March 31, 2020, 58 patients of confirmed COVID-19 were admitted to the 20th ward of the Eastern Branch, Renmin Hospital of Wuhan University. Fifteen patients who did not receive oxygen therapy and 13 patients who were transferred from other hospitals were excluded. The rest of the 30 patients that received standardized oxygen therapy in our unit were included in the study. Baseline characteristics, symptoms, and finger pulse oxygen saturation were collected during hospitalization.
   Results: Clinical outcomes of the 30 patients were as follows: 27 patients (90.00%) were cured and discharged; 3 patients (10.00%) who continued to stay in hospital were stabilized with symptoms relieved. The fingertip oxygen saturation was 94.80%+/- 3.49% at ICU admission and 97.8%+/- 1.27% when transferred out of ICU after standardized oxygen therapy (P<0.005). The symptoms of dyspnea, fatigue, and muscle aches of the patients were improved when transferred out of ICU, compared with their condition when admitted to ICU (P<0.05).
   Conclusions: The standardized oxygen therapy nursing strategy for patients with COVID-19 emphasizes the nursing measurement, which focuses on the patient's oxygenation. It is led by nurses and starts oxygen therapy at an earlier stage. It not only improves the clinical outcomes of critical patients but also effectively reduces the infection risk of medical staff while emphasizing nursing quality management.
C1 [Pan, Wenyan; Zhang, Yuxia; Wang, Chunling] Fudan Univ, Zhongshan Hosp, Dept Nursing, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Li, Jingjing; Wu, Yitao; Cai, Shining] Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
   [Ou, Yufeng] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China.
RP Zhang, YX; Wang, CL (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Nursing, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM zhang.yuxia@zs-hospital.sh.cn; wang.chunling@zs-hospital.sh.cn
OI Cai, Shining/0000-0002-6275-0494
FU Fudan University for the "Double First-Class Key Discipline
   Construction" [2018-40-22]
FX Fudan University for the "Double First-Class Key Discipline
   Construction" (2018-40-22).
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Research Hospital Association of Critical Care Medicine Youth Committee of Chinese Research Hospital Association of Critical Care Medicine, 2019, CHIN CRIT CARE MED, V32, P269
   [高钰琪 Gao Yuqi], 2020, [中国病理生理杂志, Chinese Journal of Pathophysiology], V36, P568
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kang BJ, 2015, INTENS CARE MED, V41, P623, DOI 10.1007/s00134-015-3693-5
   Mai A, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3808-3
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Ozyilmaz E, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-19
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   SHEPARD JW, 1990, AM REV RESPIR DIS, V142, P1288, DOI 10.1164/ajrccm/142.6_Pt_1.1288
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, NOV COR COVID 19 SIT
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 15
TC 0
Z9 0
U1 4
U2 4
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL
PY 2020
VL 9
IS 4
BP 2171
EP 2177
DI 10.21037/apm-20-1257
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA MT5WK
UT WOS:000555045100091
PM 32692228
OA Other Gold
DA 2021-01-01
ER

PT J
AU Papagiannis, D
   Malli, F
   Raptis, DG
   Papathanasiou, IV
   Fradelos, EC
   Daniil, Z
   Rachiotis, G
   Gourgoulianis, KI
AF Papagiannis, Dimitrios
   Malli, Foteini
   Raptis, Dimitrios G.
   Papathanasiou, Ioanna V.
   Fradelos, Evangelos C.
   Daniil, Zoe
   Rachiotis, Georgios
   Gourgoulianis, Konstantinos I.
TI Assessment of Knowledge, Attitudes, and Practices towards New
   Coronavirus (SARS-CoV-2) of Health Care Professionals in Greece before
   the Outbreak Period
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE SARS-CoV-2; health care professionals; knowledge; attitudes and
   practices; Greece; COVID-19
AB Introduction: The ongoing severe acute respiratory syndrome (SARS)-CoV-2 pandemic has expanded globally. The aim of the current study is to investigate the knowledge, attitudes, and practices (KAP) of health care professionals in Greece towards SARS-CoV-2. Methods: From 10-25 February 2020, 500 health care workers were approached. Knowledge, attitudes, and practices towards SARS-CoV-2 were assessed via a personal interview questionnaire. For knowledge, each correct answer was given 1 point; attitudes, or concerns aimed at prevention of SARS-CoV-2 infection, and practices, or behaviors towards performing preventive practices, were assigned 1 point each. Points were summed and a score for each category was calculated. Results: A total of 461 health care workers returned the questionnaire and were included in the analysis (mean age +/- SD: 44.2 +/- 10.78 years, 74% females). The majority were nurses (47.5%), followed by physicians (30.5%) and paramedics (19%). The majority of subjects (88.28%) had a good level of knowledge (knowledge score equal to 4, or more). The majority of participants (71%) agreed with the temporary traveling restrictions ban. The uptake of a future vaccine against SARS-CoV-2 was estimated at 43%. Knowledge score was significantly associated with both attitudes score (p= 0.011) and practices score (p< 0.001), indicating that subjects with a high knowledge score demonstrated a more positive perception on preventive measures and would practice more preventive measures. Attitudes score was significantly associated with practices score (p= 0.009) indicating that subjects with a higher attitudes score are more likely to perform practices towards the prevention of SARS-CoV-2 transmission. Conclusion: There is a high level of knowledge concerning SARS-CoV-2 pandemic among Greek health care workers and this is significantly associated with positive attitudes and practices towards preventive health measures. The high level of knowledge of health professionals about SARS-CoV-2 may have contributed considerably to the successful management of the pandemic in Greece. Tailored educational campaigns aiming to increase the proportion of health care workers willing to accept a potential SARS-CoV-2 vaccine could be of paramount importance in future proactive vaccine educational campaigns.
C1 [Papagiannis, Dimitrios; Malli, Foteini; Papathanasiou, Ioanna V.; Fradelos, Evangelos C.] Univ Thessaly, Fac Nursing, Larisa 41500, Greece.
   [Malli, Foteini; Raptis, Dimitrios G.; Daniil, Zoe; Gourgoulianis, Konstantinos I.] Univ Thessaly, Dept Resp Med, Fac Med, Larisa 41100, Greece.
   [Rachiotis, Georgios] Univ Thessaly, Sch Hlth Sci, Fac Med, Dept Hyg & Epidemiol, Larisa 41100, Greece.
RP Malli, F (corresponding author), Univ Thessaly, Fac Nursing, Larisa 41500, Greece.; Malli, F (corresponding author), Univ Thessaly, Dept Resp Med, Fac Med, Larisa 41100, Greece.
EM dpapajon@gmail.com; mallifoteini@yahoo.gr; raptisdmed@gmail.com;
   iopapathanasiou@yahoo.gr; evagelosfradelos@hotmail.com;
   zdaniil@med.uth.gr; grachiotis@gmail.com; kgourg@med.uth.gr
OI Malli, Foteini/0000-0002-7595-6715; Fradelos C.,
   Evangelos/0000-0003-0244-9760; Papathanasiou, Ioanna
   V./0000-0002-8874-8085
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 2020, DRAFT LANDSC COVID 1
   CDC, CLEAN HANDS COUNT SA
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Oladimeji AM, 2015, TROP MED INT HEALTH, V20, P1162, DOI 10.1111/tmi.12528
   Rachiotis G, 2010, EUROSURVEILLANCE, V15, P8
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
   ul Haq N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-692
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, COR DIS COVID 19 ADV
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, PROT HLTH WORK NOW
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 3
Z9 3
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 14
AR 4925
DI 10.3390/ijerph17144925
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MV6TG
UT WOS:000556487100001
PM 32650614
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Campos, DMO
   Oliveira, CBS
   Andrade, JMA
   Oliveira, JIN
AF Campos, D. M. O.
   Oliveira, C. B. S.
   Andrade, J. M. A.
   Oliveira, J. I. N.
TI Fighting COVID-19
SO BRAZILIAN JOURNAL OF BIOLOGY
LA English
DT Letter
DE virology; SARS-CoV2; COVID-19; infectious diseases
ID LOPINAVIR/RITONAVIR; EFFICACY
AB The current COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and severe forms of respiratory infection. The lack of vaccines and antivirals prevents clinical strategies against the disease, creating an emerging need for the development of safe and effective treatments. Strategies for vaccine development include complete vaccines against viruses, subunits, and nucleic acids, but are still in their early stages. Studies carried out to date on possible SARS-CoV2 drug targets highlight glycoprotein S, Mpro (main protease or protease type 3C), and a member of the transmembrane serine protease II families (TMPRSS2). However, due to the pandemic state, priority is given to marketed drugs. These include chloroquine (CQ), hydroxychloroquine (HCQ), nitazoxanide, remdesivir, Lopinavir/ritonavir (LPV / r), in addition to treatment with convalescent plasma. But, therapeutic specific effects against SARS-CoV2 have not yet been verified. Most of the information obtained about treatment is based on preliminary and limited studies. We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.
C1 [Campos, D. M. O.; Oliveira, J. I. N.] Univ Fed Rio Grande Norte UFRN, Dept Biofis & Farmacol, Natal, RN, Brazil.
   [Oliveira, C. B. S.] Hosp Pediat Maria Alice Fernandes, Natal, RN, Brazil.
   [Andrade, J. M. A.] Hemoctr Dalton Cunha, Natal, RN, Brazil.
RP Oliveira, CBS (corresponding author), Hosp Pediat Maria Alice Fernandes, Natal, RN, Brazil.
EM bruno_biomedico@yahoo.com.br
OI ANDRADE, JOELMA/0000-0001-7017-2420; Campos, Daniel/0000-0003-4016-3018
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen J., 2020, CHINESE J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fisher D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01533-w
   Gamino-Arroyo AE, 2019, CLIN INFECT DIS, V69, P1903, DOI 10.1093/cid/ciz100
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GREIN J., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007016, DOI 10.1056/NEJMOA200701]
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   LENZER J., 2020, BMJ-BRIT MED J, V369, P369
   Liu J, 2020, URBAN RAIL TRANSIT, V6, P1, DOI 10.1007/s40864-019-00117-z
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 25
TC 0
Z9 0
U1 5
U2 5
PU INT INST ECOLOGY
PI SAO CARLOS
PA RUA BENTO CARLOS, 750 - CENTRO, SAO CARLOS, SP 00000, BRAZIL
SN 1519-6984
EI 1678-4375
J9 BRAZ J BIOL
JI Braz. J. Biol.
PD JUL-SEP
PY 2020
VL 80
IS 3
BP 698
EP 701
DI 10.1590/1519-6984.238155
PG 4
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA MU2NC
UT WOS:000555509500032
PM 32555974
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Isenmann, A
   Isenmann, S
AF Isenmann, Anna
   Isenmann, Stefan
TI COVID-19: Variable symptoms in mild course: olfactory loss and increased
   resting heart rate
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE SARS-CoV-2; COVID-19; anosmia; resting heart rate; epidemiology
AB History A 56-year-old, previously healthy male and long distance runner noticed short episodes of parosmia, followed by anosmia. Few days later, he monitored an increase in his resting heart rate. This was followed by a dry cough, fatigue, and myalgia. At the same time, symptoms occurred in all four family members.
   Clinical findings The patient had a dry cough. The medical examination was normal. Heart rate was 60/min, sinus rhythm, body temperature 36.6 degrees C. Complete anosmia was present. The RT-PCR for SARS-CoV-2 from a deep pharyngeal swab was positive in all five family members.
   Therapy and course Symptoms were present for almost two weeks. All family members had anosmia, that started earlier and lasted longer than the other symptoms, and myalgia. Reduced taste sensation, fatigue, dry cough and sore throat were present in four of five persons. Shortness of breath at rest or gastrointestinal symptoms were absent. Four affected persons had sleep disturbances in the later course of the disease. None of the affected persons had raised temperature at any time during the disease. Specific medical or drug treatment was not necessary. All patients made full recoveries without signs of organ dysfunction, and with full restitution of physical strength.
   Discussion We describe a family of 5 previously healthy persons with a mild course of COVID-19 disease. The symptoms and course are described in detail. Anosmia can precede other symptoms by several days and can indicate an early phase of infection. An increase in resting heart rate can occur in the absence of raised temperature or fever. The symptoms and course are discussed in the context of the ongoing pandemic, and efforts to control infection chains.
C1 [Isenmann, Anna] Univ Southampton, Kassel Sch Med, Southampton, Hants, England.
   [Isenmann, Stefan] St Josef Krankenhaus GmbH Moers, Klin Neurol & Klin Neurophysiol, Asberger Str 4, D-47441 Moers, Germany.
RP Isenmann, S (corresponding author), St Josef Krankenhaus GmbH Moers, Klin Neurol & Klin Neurophysiol, Asberger Str 4, D-47441 Moers, Germany.
EM stefan.isenmann@st-josef-moers.de
CR Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Muller O, 2020, DEUT MED WOCHENSCHR, V145, P670, DOI 10.1055/a-1162-1987
   Robert-Koch-Institut RKI, 2020, COR SARS COV 2
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Streeck H, INFECT FATALITY RATE
   Vetter P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1470
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yan CRH, 2020, INT FORUM ALLERGY RH, V10, P821, DOI 10.1002/alr.22592
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 4
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD JUL
PY 2020
VL 145
IS 15
BP 1095
EP 1099
DI 10.1055/a-1190-0247
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR8BR
UT WOS:000553816500026
PM 32599633
DA 2021-01-01
ER

PT J
AU Fistera, D
   Risse, J
   Manegold, R
   Pabst, D
   Konik, M
   Dolff, S
   Witzke, O
   Schaarschmidt, BM
   Taube, C
   Kill, C
   Holzner, C
AF Fistera, David
   Risse, Joachim
   Manegold, Randi
   Pabst, Dirk
   Konik, Margarete
   Dolff, Sebastian
   Witzke, Oliver
   Schaarschmidt, Benedikt Michael
   Taube, Christian
   Kill, Clemens
   Holzner, Carola
TI COVID-19 Triage: Who is an inpatient? The Essen triage model
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE triage; COVID19; SARS-Cov2; emergency department
AB Introduction Data about optimal initial assessment in patients with suspicion for COVID19-infection or already confirmed infection are sparse. Especially, in preparation for expected mass casualty incident it is necessary to distinguish early and efficiently between outpatient and inpatient treatment including the need for intensive care therapy.
   Methods We present a model for a safe and efficient triage, which is established and used in the university hospital of Essen, Germany. It is intended for a non-disaster situation. This model is a combination of clinical assessment by using vital parameters and Manchester triage scale (MTS). Possible additional parameters are POCT (point-of-care-testing) values, electrocardiogram, CT pulmonary angiography, SARS-Cov2-PCR as well as detailed diagnostic of laboratory values. The model was validated by 100 consecutive patients. We demonstrate three patients to illustrate this model.
   Results During the first two weeks after implementing this model in our normal operation at the emergency department, we had an efficient selectivity between need for inpatient and outpatient treatment. 16 patients were classified as "inpatients" according to initial assessment. Among 84 patients who were initially classified as "outpatients", 7 patients returned to our emergency department within 14 days. Three of these patients returned due to complaints other than COVID19. One female patient had to be admitted due to progressive dyspnea.
   Conclusions This introduced triage-model seems to be an efficient concept. Adjustment might be necessary after further experience and after a growing number of patients.
C1 [Fistera, David; Risse, Joachim; Manegold, Randi; Pabst, Dirk; Kill, Clemens; Holzner, Carola] Univ Med Essen, Zentrum Notfallmed, Hufelandstr 55, D-45147 Essen, Germany.
   [Fistera, David; Taube, Christian] Univ Med Essen, Westdeutsch Lungenzentrum, Essen, Germany.
   [Konik, Margarete; Dolff, Sebastian; Witzke, Oliver] Univ Med Essen, Klin Infektiol, Westdeutsch Zentrum Infektiol WZI, Essen, Germany.
   [Schaarschmidt, Benedikt Michael] Univ Med Essen, Inst Diagnost & Intervent Radiol & Neuroradiol, Essen, Germany.
RP Fistera, D (corresponding author), Univ Med Essen, Zentrum Notfallmed, Hufelandstr 55, D-45147 Essen, Germany.
EM David.fistera@uk-essen.de
OI Taube, Christian/0000-0002-3546-1398
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.20021675]
NR 8
TC 1
Z9 1
U1 2
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD JUL
PY 2020
VL 145
IS 15
BP E87
EP E92
DI 10.1055/a-1167-7596
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA MR8BR
UT WOS:000553816500001
PM 32422662
OA Other Gold
DA 2021-01-01
ER

PT J
AU Poblador-Plou, B
   Carmona-Pirez, J
   Ioakeim-Skoufa, I
   Poncel-Falco, A
   Bliek-Bueno, K
   Cano-del Pozo, M
   Gimeno-Feliu, LA
   Gonzalez-Rubio, F
   Aza-Pascual-Salcedo, M
   Bandres-Liso, AC
   Diez-Manglano, J
   Marta-Moreno, J
   Mucherino, S
   Gimeno-Miguel, A
   Prados-Torres, A
AF Poblador-Plou, Beatriz
   Carmona-Pirez, Jonas
   Ioakeim-Skoufa, Ignatios
   Poncel-Falco, Antonio
   Bliek-Bueno, Kevin
   Cano-del Pozo, Mabel
   Andres Gimeno-Feliu, Luis
   Gonzalez-Rubio, Francisca
   Aza-Pascual-Salcedo, Mercedes
   Cristina Bandres-Liso, Ana
   Diez-Manglano, Jesus
   Marta-Moreno, Javier
   Mucherino, Sara
   Gimeno-Miguel, Antonio
   Prados-Torres, Alexandra
CA EpiChron Grp
TI Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed
   COVID-19 Cases: Results from the PRECOVID Study in Spain
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE chronic diseases; cohort; comorbidity; COVID-19; drugs; gender;
   mortality; multimorbidity; Spain
ID ANTICHOLINERGIC BURDEN; RISK; ETHNICITY; DISEASE; WUHAN; CHINA
AB We aimed to analyze baseline socio-demographic and clinical factors associated with an increased likelihood of mortality in men and women with coronavirus disease (COVID-19). We conducted a retrospective cohort study (PRECOVID Study) on all 4412 individuals with laboratory-confirmed COVID-19 in Aragon, Spain, and followed them for at least 30 days from cohort entry. We described the socio-demographic and clinical characteristics of all patients of the cohort. Age-adjusted logistic regressions models were performed to analyze the likelihood of mortality based on demographic and clinical variables. All analyses were stratified by sex. Old age, specific diseases such as diabetes, acute myocardial infarction, or congestive heart failure, and dispensation of drugs like vasodilators, antipsychotics, and potassium-sparing agents were associated with an increased likelihood of mortality. Our findings suggest that specific comorbidities, mainly of cardiovascular nature, and medications at the time of infection could explain around one quarter of the mortality in COVID-19 disease, and that women and men probably share similar but not identical risk factors. Nonetheless, the great part of mortality seems to be explained by other patient- and/or health-system-related factors. More research is needed in this field to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.
C1 [Poblador-Plou, Beatriz; Carmona-Pirez, Jonas; Ioakeim-Skoufa, Ignatios; Poncel-Falco, Antonio; Bliek-Bueno, Kevin; Cano-del Pozo, Mabel; Andres Gimeno-Feliu, Luis; Gonzalez-Rubio, Francisca; Aza-Pascual-Salcedo, Mercedes; Cristina Bandres-Liso, Ana; Diez-Manglano, Jesus; Marta-Moreno, Javier; Gimeno-Miguel, Antonio; Prados-Torres, Alexandra] Miguel Servet Univ Hosp, Aragon Hlth Sci Inst IACS, IIS Aragon, EpiChron Res Grp, Zaragoza 50009, Spain.
   [Poblador-Plou, Beatriz; Carmona-Pirez, Jonas; Poncel-Falco, Antonio; Andres Gimeno-Feliu, Luis; Gonzalez-Rubio, Francisca; Aza-Pascual-Salcedo, Mercedes; Cristina Bandres-Liso, Ana; Marta-Moreno, Javier; Gimeno-Miguel, Antonio; Prados-Torres, Alexandra] ISCIII, Hlth Serv Res Chron Patients Network REDISSEC, Madrid 28222, Spain.
   [Carmona-Pirez, Jonas; Gonzalez-Rubio, Francisca] Aragon Hlth Serv SALUD, Delicias Sur Primary Care Hlth Ctr, Zaragoza 50009, Spain.
   [Poncel-Falco, Antonio; Cristina Bandres-Liso, Ana] Aragon Hlth Serv SALUD, Zaragoza 50017, Spain.
   [Bliek-Bueno, Kevin] Miguel Servet Univ Hosp, Teaching Unit Prevent Med & Publ Hlth, Zaragoza 50009, Spain.
   [Cano-del Pozo, Mabel] Govt Aragon, Dept Hlth, Gen Directorate Hlth Care, Zaragoza 50017, Spain.
   [Andres Gimeno-Feliu, Luis] Univ Zaragoza, San Pablo Primary Care Hlth Ctr, Aragon Hlth Serv SALUD, Zaragoza 50003, Spain.
   [Aza-Pascual-Salcedo, Mercedes] Aragon Hlth Serv SALUD, Primary Care Pharm Serv Zaragoza III, Zaragoza 50017, Spain.
   [Diez-Manglano, Jesus] Aragon Hlth Serv SALUD, Serv Internal Med, Royo Villanova Hosp, Zaragoza 50015, Spain.
   [Marta-Moreno, Javier] Aragon Hlth Serv SALUD, Serv Neurol, Miguel Servet Univ Hosp, Zaragoza 50009, Spain.
   [Mucherino, Sara] Univ Naples Federico II, Ctr Pharmacoecon, Dept Pharm, CIRFF, I-80138 Naples, Italy.
RP Bliek-Bueno, K; Gimeno-Miguel, A (corresponding author), Miguel Servet Univ Hosp, Aragon Hlth Sci Inst IACS, IIS Aragon, EpiChron Res Grp, Zaragoza 50009, Spain.; Gimeno-Miguel, A (corresponding author), ISCIII, Hlth Serv Res Chron Patients Network REDISSEC, Madrid 28222, Spain.; Bliek-Bueno, K (corresponding author), Miguel Servet Univ Hosp, Teaching Unit Prevent Med & Publ Hlth, Zaragoza 50009, Spain.
EM bpoblador.iacs@aragon.es; jcarmona@iisaragon.es;
   ignacio.ioakim@hotmail.es; aponcel@salud.aragon.es;
   kbliek@salud.aragon.es; micano@aragon.es; lugifel@gmail.com;
   franciscagonzalezrubio@gmail.com; maza@salud.aragon.es;
   acbandres@salud.aragon.es; jdiez@aragon.es; jmartam@gmail.com;
   sara.mucherino@unina.it; agimenomi.iacs@aragon.es;
   sprados.iacs@aragon.es
RI Prados-Torres, Alexandra/P-5818-2017; Rubio, Francisca
   Gonzalez/ABD-1444-2020; Diez-Manglano, J/AAC-3198-2020; Gimeno-Miguel,
   Antonio/AAC-9611-2019; Poblador-Plou, Beatriz/ABC-7915-2020;
   Ioakeim-Skoufa, Ignatios/AAX-4807-2020; Gimeno-Feliu, Luis
   Andres/E-5390-2016
OI Prados-Torres, Alexandra/0000-0002-5704-6056; Rubio, Francisca
   Gonzalez/0000-0001-5939-4436; Diez-Manglano, J/0000-0002-3132-2171;
   Gimeno-Miguel, Antonio/0000-0002-5440-1710; Poblador-Plou,
   Beatriz/0000-0002-5119-5093; Ioakeim-Skoufa,
   Ignatios/0000-0002-6518-749X; Gimeno-Feliu, Luis
   Andres/0000-0003-2928-6623; Mucherino, Sara/0000-0003-3357-5655
FU Gobierno de AragonGobierno de Aragon [B01_20R, PI20/226]; European
   Regional Development Fund "Construyendo Europa desde Aragon"; Instituto
   de Salud Carlos IIIInstituto de Salud Carlos III; IIS Aragon
   [CM19/00164]
FX This research was funded by Gobierno de Aragon (Grant numbers B01_20R
   and PI20/226) and the European Regional Development Fund "Construyendo
   Europa desde Aragon". J.C.-P. was awarded a Rio Hortega research grant
   from Instituto de Salud Carlos III and IIS Aragon (Grant number
   CM19/00164).
CR Amer Geriatrics Soc, 2020, J AM GERIATR SOC, V68, P908, DOI 10.1111/jgs.16477
   Ancin Ducay J.M., 2014, CORRELACION CODIGOS
   [Anonymous], COR DIS COVID 19 DAS
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Carnahan RM, 2006, J CLIN PHARMACOL, V46, P1481, DOI 10.1177/0091270006292126
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dea MLC, 2018, REV ESP SALUD PUBLIC, V92
   D'Adamo H, 2020, J AM GERIATR SOC, V68, P912, DOI 10.1111/jgs.16445
   Elixhauser A., 2009, CLIN CLASSIFICATIONS
   Eum S, 2017, SCHIZOPHR RES, V190, P129, DOI 10.1016/j.schres.2017.03.034
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gamble DT, 2018, INT J EPIDEMIOL, V47, P625, DOI 10.1093/ije/dyx265
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XX, 2020, CLIN CARDIOL, V43, P963, DOI 10.1002/clc.23390
   Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Salahudeen MS, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0029-9
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Singh S, 2008, JAMA-J AM MED ASSOC, V300, P1439, DOI 10.1001/jama.300.12.1439
   Sun HY, 2020, J AM GERIATR SOC, V68, pE19, DOI 10.1111/jgs.16533
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhao H, 2015, EPIDEMIOL INFECT, V143, P3375, DOI 10.1017/S0950268815000576
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
NR 32
TC 3
Z9 3
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 14
AR 5171
DI 10.3390/ijerph17145171
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MS5AC
UT WOS:000554287700001
PM 32709002
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cavagna, L
   Seminari, E
   Zanframundo, G
   Gregorini, M
   Di Matteo, A
   Rampino, T
   Montecucco, C
   Pelenghi, S
   Cattadori, B
   Pattonieri, EF
   Vitulo, P
   Bertani, A
   Sambataro, G
   Vancheri, C
   Biglia, A
   Bozzalla-Cassione, E
   Bonetto, V
   Monti, MC
   Ticozzelli, E
   Turco, A
   Oggionni, T
   Corsico, A
   Bertuccio, F
   Zuccaro, V
   Codullo, V
   Morosini, M
   Marena, C
   Gnecchi, M
   Pellegrini, C
   Meloni, F
AF Cavagna, Lorenzo
   Seminari, Elena
   Zanframundo, Giovanni
   Gregorini, Marilena
   Di Matteo, Angela
   Rampino, Teresa
   Montecucco, Carlomaurizio
   Pelenghi, Stefano
   Cattadori, Barbara
   Pattonieri, Eleonora Francesca
   Vitulo, Patrizio
   Bertani, Alessandro
   Sambataro, Gianluca
   Vancheri, Carlo
   Biglia, Alessandro
   Bozzalla-Cassione, Emanuele
   Bonetto, Valentina
   Monti, Maria Cristina
   Ticozzelli, Elena
   Turco, Annalisa
   Oggionni, Tiberio
   Corsico, Angelo
   Bertuccio, Francesco
   Zuccaro, Valentina
   Codullo, Veronica
   Morosini, Monica
   Marena, Carlo
   Gnecchi, Massimiliano
   Pellegrini, Carlo
   Meloni, Federica
TI Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from
   a Multidisciplinary Cohort of Patients in Northern Italy
SO MICROORGANISMS
LA English
DT Article
DE COVID-19; calcineurin inhibitors; solid organ transplantation; rheumatic
   diseases
ID CYCLOSPORINE; CORONAVIRUSES; REPLICATION; SARS
AB The role of immunosuppression in SARS-CoV-2-related disease (COVID-19) is a matter of debate. We here describe the course and the outcome of COVID-19 in a cohort of patients undergoing treatment with calcineurin inhibitors. In this monocentric cohort study, data were collected from the COVID-19 outbreak in Italy up to 28 April 2020. Patients were followed at our hospital for solid organ transplantation or systemic rheumatic disorders (RMDs) and were on calcineurin inhibitor (CNI)-based therapy. Selected patients were referred from the North of Italy. The aim of our study was to evaluate the clinical course of COVID-19 in this setting. We evaluated 385 consecutive patients (220 males, 57%; median age 61 years, IQR 48-69); 331 (86%) received solid organ transplantation and 54 (14%) had a RMD. CNIs were the only immunosuppressant administered in 47 patients (12%). We identified 14 (4%) COVID-19 patients, all transplanted, mainly presenting with fever (86%) and diarrhea (71%). Twelve patients were hospitalized and two of them died, both with severe comorbidities. No patients developed acute respiratory distress syndrome or infectious complications. The surviving 10 patients are now fully recovered. The clinical course of COVID-19 patients on CNIs is generally mild, and the risk of superinfection seems low.
C1 [Cavagna, Lorenzo; Zanframundo, Giovanni; Montecucco, Carlomaurizio; Biglia, Alessandro; Bozzalla-Cassione, Emanuele; Codullo, Veronica] Univ Pavia, Rheumatol Div, I-27100 Pavia, Italy.
   [Cavagna, Lorenzo; Seminari, Elena; Zanframundo, Giovanni; Gregorini, Marilena; Di Matteo, Angela; Rampino, Teresa; Montecucco, Carlomaurizio; Pattonieri, Eleonora Francesca; Biglia, Alessandro; Bozzalla-Cassione, Emanuele; Oggionni, Tiberio; Corsico, Angelo; Bertuccio, Francesco; Zuccaro, Valentina; Codullo, Veronica; Morosini, Monica; Meloni, Federica] IRCCS Policlin S Matteo Fdn Pavia, I-27100 Pavia, Italy.
   [Seminari, Elena; Di Matteo, Angela; Zuccaro, Valentina] Univ Pavia, Infect Dis Clin, I-27100 Pavia, Italy.
   [Gregorini, Marilena; Rampino, Teresa; Pattonieri, Eleonora Francesca] Univ Pavia, Nephrol Dialysis & Transplantat Unit, I-27100 Pavia, Italy.
   [Pelenghi, Stefano; Cattadori, Barbara; Pellegrini, Carlo] IRCCS Policlin S Matteo Fdn Pavia, Div Cardiac Surg, I-27100 Pavia, Italy.
   [Vitulo, Patrizio] IRCCS Ist Mediterraneo Trapianti & Terapie Ad Alt, Pulmonol Unit, I-90100 Palermo, Italy.
   [Bertani, Alessandro] IRCCS Ist Mediterraneo Trapianti & Terapie Ad Alt, Thorac Surg Unit, I-90100 Palermo, Italy.
   [Sambataro, Gianluca; Vancheri, Carlo] Univ Catania, Reg Referral Ctr Rare Lung Dis, AOU Policlin Vittorio Emanuele Dept Clin & Expt M, I-95125 Catania, Italy.
   [Bonetto, Valentina] Ist Ric Farmacol Mario Negri IRCCS, Dept Biochem & Mol Pharmacol, I-20156 Milan, Italy.
   [Monti, Maria Cristina] Univ Pavia, Dept Publ Hlth, Unit Biostat & Clin Epidemiol, I-27100 Pavia, Italy.
   [Ticozzelli, Elena] IRCCS Policlin S Matteo Fdn Pavia, Gen Surg Unit, I-27100 Pavia, Italy.
   [Turco, Annalisa] IRCCS Policlin S Matteo Fdn Pavia, Cardiol Dept, I-27100 Pavia, Italy.
   [Oggionni, Tiberio; Corsico, Angelo; Bertuccio, Francesco; Morosini, Monica; Meloni, Federica] Univ Pavia, Dept Resp Dis, I-27100 Pavia, Italy.
   [Marena, Carlo] IRCCS Policlin S Matteo Fdn Pavia, SC Direz Med Presidio, I-27100 Pavia, Italy.
   [Gnecchi, Massimiliano] IRCCS Policlin S Matteo Fdn Pavia, Dept Med Sci & Infect Dis, Coronary Care Unit, I-27100 Pavia, Italy.
   [Gnecchi, Massimiliano] IRCCS Policlin S Matteo Fdn Pavia, Dept Med Sci & Infect Dis, Lab Clin & Expt Cardiol, I-27100 Pavia, Italy.
   [Gnecchi, Massimiliano] Univ Pavia, Dept Mol Med, Cardiol Unit, I-27100 Pavia, Italy.
   [Cavagna, Lorenzo] IRCCS Policlin San Matteo, Segreteria Reumatol, Reparti Speciali 4 Piano,Viale Golgi 12, I-27100 Pavia, Italy.
RP Cavagna, L (corresponding author), Univ Pavia, Rheumatol Div, I-27100 Pavia, Italy.; Cavagna, L (corresponding author), IRCCS Policlin S Matteo Fdn Pavia, I-27100 Pavia, Italy.
EM lorenzo.cavagna@unipv.it; e.seminari@smatteo.pv.it;
   gio.zanframundo@gmail.com; mgregorini@hotmail.com;
   a.dimatteo@smatteo.pv.it; T.Rampino@smatteo.pv.it;
   c.montecucco@smatteo.pv.it; s.pelenghi@smatteo.pv.it;
   b.cattadori@smatteo.pv.it; ef.pattonieri@gmail.com; pvitulo@ismett.edu;
   abertani@ismett.edu; dottorsambataro@gmail.com; vancheri@unict.it;
   alessandro.biglia@libero.it; emanuele.bozzalla@gmail.com;
   valentina.bonetto@marionegri.it; cristina.monti@unipv.it;
   e.ticozzelli@smatteo.pv.it; A.Turco@smatteo.pv.it;
   t.oggionni@smatteo.pv.it; corsico@unipv.it;
   francesco.bertuccio01@gmail.com; v.zuccaro@smatteo.pv.it;
   veronicacodullo@yahoo.it; M.Morosini@smatteo.pv.it;
   c.marena@smatteo.pv.it; massimiliano.gnecchi@unipv.it;
   C.Pellegrini@smatteo.pv.it; f.meloni@smatteo.pv.it
RI Gnecchi, Massimiliano/X-7095-2019; Sambataro, Gianluca/K-9528-2016;
   Bonetto, Valentina/ABB-6383-2020; Morosini, Monica/E-2408-2016
OI Gnecchi, Massimiliano/0000-0001-7435-4328; Sambataro,
   Gianluca/0000-0001-9933-1202; Bonetto, Valentina/0000-0003-0456-2054;
   Monti, Maria Cristina/0000-0003-1586-527X; Corsico, Angelo
   Guido/0000-0002-8716-4694; Biglia, Alessandro/0000-0001-6006-678X;
   Cavagna, Lorenzo/0000-0003-3292-1528; Zanframundo,
   Giovanni/0000-0001-5042-1282; Morosini, Monica/0000-0001-6516-1751
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Arpali E, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13296
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Cavagna L, 2013, J RHEUMATOL, V40, P484, DOI 10.3899/jrheum.121026
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hsu JJ, 2020, AM J TRANSPLANT, V20, P1911, DOI 10.1111/ajt.15936
   Huang W, 2019, CLIN EXP RHEUMATOL, V37, P803
   Kim Y, 2020, AM J TRANSPLANT, V20, P2269, DOI 10.1111/ajt.15947
   Kuypers DRJ, 2020, CLIN PHARMACOL THER, V107, P347, DOI 10.1002/cpt.1618
   Ma-Lauer Y, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104620
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 28
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD JUL
PY 2020
VL 8
IS 7
AR 977
DI 10.3390/microorganisms8070977
PG 10
WC Microbiology
SC Microbiology
GA MW7AW
UT WOS:000557185700001
PM 32629788
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marco-Franco, JE
   Guadalajara-Olmeda, N
   Gonzalez-de Julian, S
   Vivas-Consuelo, D
AF Emilio Marco-Franco, Julio
   Guadalajara-Olmeda, Natividad
   Gonzalez-de Julian, Silvia
   Vivas-Consuelo, David
TI COVID-19 Healthcare Planning: Predicting Mortality and the Role of the
   Herd Immunity Barrier in the General Population
SO SUSTAINABILITY
LA English
DT Article
DE healthcare planning; health economy; herd immunity; mathematical
   epidemiology; COVID-19; case fatality rate; infectious fatality rate;
   relative risk ratio; predictive modeling
AB Using a mathematical model for COVID-19 incorporating data on excess of mortality compared to the corresponding period of the previous year obtained from the daily monitoring of mortality in Spain (MoMo), the prediction of total number of casualties in Spain for the first outbreak has been computed. From this figure, and following a stepwise meta-analysis of available reports, the case fatality rate (CFR) and the infectious case fatality rate (IFR) for the outbreak have been estimated. As the impact of age on these rates is notable, it is proposed to include an age-related adjusted fatality ratio in future comparative analyses between studies, calculated by adjusting the results by risk ratio to a reference age band (e.g., 60-69). From the casualty figures, and the corresponding CFR and IFR ratios, the forecast of serologically positive cases in the general Spanish population has been estimated at approximately 1% (0.87-1.3%) of the samples. If the data are confirmed by the ongoing study of the Carlos III Institute, until a vaccine is found, the immunity acquired in the general population after the infectious outbreak is far from the 65-70% herd immunity required as a barrier for COVID-19.
C1 [Emilio Marco-Franco, Julio; Guadalajara-Olmeda, Natividad; Gonzalez-de Julian, Silvia] Univ Politecn Valencia, Res Ctr Econ Engn, Valencia 46022, Spain.
   [Vivas-Consuelo, David] Univ Politecn Valencia, Res Unit Hlth Econ & Management, Valencia 46022, Spain.
RP Marco-Franco, JE (corresponding author), Univ Politecn Valencia, Res Ctr Econ Engn, Valencia 46022, Spain.
EM julio.marco@uib.es; nguadala@omp.upv.es; silgonde@upv.es; dvivas@upv.es
RI ; Vivas-Consuelo, David/E-5479-2011; Guadalajara, Natividad/B-4346-2009
OI Marco-Franco, Julio Emilio/0000-0003-1350-2539; Vivas-Consuelo,
   David/0000-0003-2945-7525; Gonzalez de Julian,
   Silvia/0000-0003-0274-6060; Guadalajara, Natividad/0000-0002-5992-3446
CR [Anonymous], 2020, EP COVID 19
   Baker T., 2020, MATH MODELING DRAWS
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]
   Boseley S., 2020, GUARDIAN
   Camara-Larrauri A., 2010, REV ESP SALUD PUBLIC, V24, P569
   Centro de coordinacion de alertas y emergencias sanitarias R98-[Spanish centre of health alerts and emergencies. R98], 2020, ACT NO 98 ENF COR CO
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Flaxman S, 2020, ESTIMATING NUMBER IN, DOI [10.25561/77731, DOI 10.25561/77731]
   Holmes E.C., 2010, EVOLUTION EMERGENCE, V16
   Instituto Nacional de Estadistica (INE) [National Institute of Statistics of Spain], 2019, DEF SEG CAUS MUERT A
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   London Business School, 2020, FORBES
   Meyerowitz-Katz G, 2020, HERES WHY HERD IMMUN
   Ministerio de Justicia [Spanish Ministry of Justice], 2020, MOMO VIG EXC MORT TO
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Oke J., 2020, GLOBAL COVID 19 CASE
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Red Nacional de Vigilancia Epidemiologica-[Spanish epidemiological surveillance network], 2020, INF SIT COVID 19 ESP
   Regalado A., 2020, MIT TECHNOLOGY  0409
   Riou J, 2020, ADJUSTED AGE SPECIFI, P2020, DOI [10.1101/2020.03.04.20031104, DOI 10.1101/2020.03.04.20031104]
   Russell T.W, 2020, EUROSURVEILLANCE, V25, P6, DOI [10.2807/1560-7917.ES.2020.25.12.2000256, DOI 10.2807/1560-7917.ES.2020.25.12.200025632234121]
   Salje H., 2020, ESTIMATING BURDEN SA
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Streeck H, 2020, VORLAUFIGES ERGEBNIS
   Verity R, 2020, ESTIMATES SEVERITY C, DOI [10.1101/2020.03.09.20033357, DOI 10.1101/2020.03.09.2003335]
   Wang X, 2020, ESTIMATING CASE FATA, DOI [10.1101/2020.02.17.20023630, DOI 10.1101/2020.02.17.20023630]
   Weaver M., GUARDIAN
   Wong JY, 2013, EPIDEMIOLOGY, V24, P830, DOI 10.1097/EDE.0b013e3182a67448
   World Health Organization, 2003, CONS DOC EP SEV AC R, P1
   World Health Organization (WHO), 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Wu J., CORONAVIRUS MISSING
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 35
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD JUL
PY 2020
VL 12
IS 13
AR 5228
DI 10.3390/su12135228
PG 10
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA MT5YX
UT WOS:000555051600001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Sallam, M
   Dababseh, D
   Yaseen, A
   Al-Haidar, A
   Ababneh, NA
   Bakri, FG
   Mahafzah, A
AF Sallam, Malik
   Dababseh, Deema
   Yaseen, Alaa
   Al-Haidar, Ayat
   Ababneh, Nidaa A.
   Bakri, Faris G.
   Mahafzah, Azmi
TI Conspiracy Beliefs Are Associated with Lower Knowledge and Higher
   Anxiety Levels Regarding COVID-19 among Students at the University of
   Jordan
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE novel coronavirus; SARS-CoV-2; Middle East; Facebook; Instagram;
   Twitter; WhatsApp; TV; news
ID EBOLA
AB The world has been afflicted heavily by the burden of coronavirus disease 2019 (COVID-19) that overwhelmed health care systems and caused severe economic and educational deficits, in addition to anxiety among the public. The main aim of this study was to evaluate the mutual effects of belief that the pandemic was the result of a conspiracy on knowledge and anxiety levels among students at the University of Jordan (UJ). An electronic-based survey was conducted between 29 March, 2020 and 31 March, 2020. The targeted population involved all undergraduate and postgraduate students from the health, scientific and humanities schools at UJ. Survey sections included 26 items on: socio-demographic information, knowledge and sources of information about the disease, attitude towards the false notion that COVID-19 stemmed from a conspiracy and items to assess the anxiety level among students during the quarantine period. The total number of participants was 1540 students. The mean age of study participants was 22 years and females predominated the study population (n = 1145, 74.4%). The majority of participants perceived the disease as moderately dangerous (n = 1079, 70.1%). Males, Jordanians and participants with lower income were more inclined to feel that COVID-19 is very dangerous. A lower level of knowledge and a higher level of anxiety about COVID-19 were associated with the belief that the disease is part of a conspiracy. Females and participants with lower income were more likely to believe that the disease is related to conspiracy. Belief in conspiracy regarding the origin of COVID-19 was associated with misinformation about the availability of a vaccine and the therapeutic use of antibiotics for COVID-19 treatment. The Ministry of Health in Jordan was the most common source of information about COVID-19 reported by the participants (n = 1018). The false belief that COVID-19 was the result of a global conspiracy could be the consequence of a lower level of knowledge about the virus and could lead to a higher level of anxiety, which should be considered in the awareness tools of various media platforms about the current pandemic.
C1 [Sallam, Malik; Yaseen, Alaa; Mahafzah, Azmi] Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.
   [Sallam, Malik; Mahafzah, Azmi] Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.
   [Sallam, Malik] Lund Univ, Fac Med, Dept Translat Med, S-22184 Malmo, Sweden.
   [Dababseh, Deema; Al-Haidar, Ayat] Univ Jordan, Sch Dent, Amman 11942, Jordan.
   [Ababneh, Nidaa A.] Univ Jordan, Cell Therapy Ctr CTC, Amman 11942, Jordan.
   [Bakri, Faris G.] Univ Jordan, Sch Med, Dept Internal Med, Amman 11942, Jordan.
   [Bakri, Faris G.] Jordan Univ Hosp, Dept Internal Med, Amman 11942, Jordan.
   [Bakri, Faris G.] Univ Jordan, Infect Dis & Vaccine Ctr, Amman 11942, Jordan.
RP Sallam, M (corresponding author), Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.; Sallam, M (corresponding author), Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.; Sallam, M (corresponding author), Lund Univ, Fac Med, Dept Translat Med, S-22184 Malmo, Sweden.
EM malik.sallam@ju.edu.jo; deemahameddababseh@gmail.com;
   alaa_mohamad1990@yahoo.com; ayat_alhaidar@yahoo.com;
   nidaaanwar@gmail.com; fbakri@yahoo.com; mahafzaa@gmail.com
RI Sallam, Malik/O-5021-2014
OI Sallam, Malik/0000-0002-0165-9670; Ababneh, Nidaa A/0000-0002-2155-3013
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   American Association of Blood Banks (AABB), MESS BLOOD DON COVID
   Atlani-Duault L, 2020, LANCET PUBLIC HEALTH, V5, pE137, DOI 10.1016/S2468-2667(20)30033-5
   Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949
   Benvenuto D, 2020, PATHOG GLOB HEALTH, V114, P64, DOI 10.1080/20477724.2020.1725339
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   CDC, COVID 19 SPREADS
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261
   Graham BS, 2018, NAT IMMUNOL, V19, P20, DOI 10.1038/s41590-017-0007-9
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Hu T, 2019, VIROL SIN, V34, P1, DOI 10.1007/s12250-018-0078-2
   Hua JL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072309
   Johnson SU, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01713
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   Laranjo L, 2015, J AM MED INFORM ASSN, V22, P243, DOI 10.1136/amiajnl-2014-002841
   Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093
   Lowe Derek, HYDROXYCHLOROQUINE
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   Ministry of Health (MoH), 2019, J COR DIS
   Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pybus OG, 2009, NAT REV GENET, V10, P540, DOI 10.1038/nrg2583
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rozenblum R, 2013, BMJ QUAL SAF, V22, P183, DOI 10.1136/bmjqs-2012-001744
   Saez AM, 2015, EMBO MOL MED, V7, P17, DOI 10.15252/emmm.201404792
   Sejvar James J, 2003, Ochsner J, V5, P6
   Simelela N, 2015, CURR HIV-AIDS REP, V12, P256, DOI 10.1007/s11904-015-0259-7
   Swami V, 2014, COGNITION, V133, P572, DOI 10.1016/j.cognition.2014.08.006
   Tucci V, 2017, J GLOB INFECT DIS, V9, P151, DOI 10.4103/jgid.jgid_66_17
   van Prooijen JW, 2018, PERSPECT PSYCHOL SCI, V13, P770, DOI 10.1177/1745691618774270
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Weisberg YJ, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00178
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wilson ME, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa015
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   World Health Organization, WHO COR DIS COVID 19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Ye F, 2020, INT J INFECT DIS, V94, P133, DOI 10.1016/j.ijid.2020.03.042
   Ye Q, 2020, J MED VIROL, V92, P755, DOI 10.1002/jmv.25813
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 48
TC 6
Z9 6
U1 13
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 14
AR 4915
DI 10.3390/ijerph17144915
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MS2CO
UT WOS:000554091300001
PM 32650409
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guo, T
   Fan, YZ
   Chen, M
   Wu, XY
   Zhang, L
   He, T
   Wang, HR
   Wan, J
   Wang, XH
   Lu, ZB
AF Guo, Tao
   Fan, Yongzhen
   Chen, Ming
   Wu, Xiaoyan
   Zhang, Lin
   He, Tao
   Wang, Hairong
   Wan, Jing
   Wang, Xinghuan
   Lu, Zhibing
TI Cardiovascular Implications of Fatal Outcomes of Patients With
   Coronavirus Disease 2019 (COVID-19)
SO JAMA CARDIOLOGY
LA English
DT Article
ID ACE2
AB Importance Increasing numbers of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) are occurring in several countries and continents. Information regarding the impact of cardiovascular complication on fatal outcome is scarce. Objective To evaluate the association of underlying cardiovascular disease (CVD) and myocardial injury with fatal outcomes in patients with COVID-19. Design, Setting, and Participants This retrospective single-center case series analyzed patients with COVID-19 at the Seventh Hospital of Wuhan City, China, from January 23, 2020, to February 23, 2020. Analysis began February 25, 2020. Main Outcomes and Measures Demographic data, laboratory findings, comorbidities, and treatments were collected and analyzed in patients with and without elevation of troponin T (TnT) levels. Results Among 187 patients with confirmed COVID-19, 144 patients (77%) were discharged and 43 patients (23%) died. The mean (SD) age was 58.50 (14.66) years. Overall, 66 (35.3%) had underlying CVD including hypertension, coronary heart disease, and cardiomyopathy, and 52 (27.8%) exhibited myocardial injury as indicated by elevated TnT levels. The mortality during hospitalization was 7.62% (8 of 105) for patients without underlying CVD and normal TnT levels, 13.33% (4 of 30) for those with underlying CVD and normal TnT levels, 37.50% (6 of 16) for those without underlying CVD but elevated TnT levels, and 69.44% (25 of 36) for those with underlying CVD and elevated TnTs. Patients with underlying CVD were more likely to exhibit elevation of TnT levels compared with the patients without CVD (36 [54.5%] vs 16 [13.2%]). Plasma TnT levels demonstrated a high and significantly positive linear correlation with plasma high-sensitivity C-reactive protein levels (beta = 0.530, P < .001) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (beta = 0.613, P < .001). Plasma TnT and NT-proBNP levels during hospitalization (median [interquartile range (IQR)], 0.307 [0.094-0.600]; 1902.00 [728.35-8100.00]) and impending death (median [IQR], 0.141 [0.058-0.860]; 5375 [1179.50-25695.25]) increased significantly compared with admission values (median [IQR], 0.0355 [0.015-0.102]; 796.90 [401.93-1742.25]) in patients who died (P = .001; P < .001), while no significant dynamic changes of TnT (median [IQR], 0.010 [0.007-0.019]; 0.013 [0.007-0.022]; 0.011 [0.007-0.016]) and NT-proBNP (median [IQR], 352.20 [174.70-636.70]; 433.80 [155.80-1272.60]; 145.40 [63.4-526.50]) was observed in survivors (P = .96; P = .16). During hospitalization, patients with elevated TnT levels had more frequent malignant arrhythmias, and the use of glucocorticoid therapy (37 [71.2%] vs 69 [51.1%]) and mechanical ventilation (31 [59.6%] vs 14 [10.4%]) were higher compared with patients with normal TnT levels. The mortality rates of patients with and without use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers was 36.8% (7 of 19) and 21.4% (36 of 168) (P = .13). Conclusions and Relevance Myocardial injury is significantly associated with fatal outcome of COVID-19, while the prognosis of patients with underlying CVD but without myocardial injury is relatively favorable. Myocardial injury is associated with cardiac dysfunction and arrhythmias. Inflammation may be a potential mechanism for myocardial injury. Aggressive treatment may be considered for patients at high risk of myocardial injury.
   Question What is the impact of underlying cardiovascular disease (CVD) and myocardial injury on fatal outcomes in patients with coronavirus disease 2019 (COVID-19)? Findings In this case series study of 187 patients with COVID-19, 27.8% of patients had myocardial injury, which resulted in cardiac dysfunction and arrhythmias. Myocardial injury has a significant association with fatal outcome of COVID-19, while the prognosis of patients with underlying CVD but without myocardial injury were relatively favorable. Meaning It is reasonable to triage patients with COVID-19 according to the presence of underlying CVD and evidence of myocardial injury for prioritized treatment and even more aggressive strategies.
   This case series study evaluates the association of underlying cardiovascular disease and myocardial injury on fatal outcomes in patients with coronavirus disease 2019 (COVID-19).
C1 [Guo, Tao; Fan, Yongzhen; Chen, Ming; Wu, Xiaoyan; Zhang, Lin; He, Tao; Wang, Hairong; Wan, Jing; Lu, Zhibing] Wuhan Univ, Dept Cardiol, Zhongnan Hosp, 169 East Lake Rd, Wuhan 430071, Hubei, Peoples R China.
   [Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, 169 East Lake Rd, Wuhan 430071, Hubei, Peoples R China.
RP Lu, ZB (corresponding author), Wuhan Univ, Dept Cardiol, Zhongnan Hosp, 169 East Lake Rd, Wuhan 430071, Hubei, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, 169 East Lake Rd, Wuhan 430071, Hubei, Peoples R China.
EM wangxinghuan@whu.edu.cn; luzhibing222@163.com
RI ; Wang, Xinghuan/U-5388-2017
OI , Yongzhen/0000-0003-1569-3682; Wang, Xinghuan/0000-0003-3497-0024
FU Special Project for Significant New Drug Research and Development in the
   Major National Science and Technology Projects of China [2020ZX09201007]
FX This work was supported by the Special Project for Significant New Drug
   Research and Development in the Major National Science and Technology
   Projects of China (project 2020ZX09201007).
CR Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wuhan Municipal Health Commission, 2019, REP CLUST PNEUM UNKN
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 603
Z9 616
U1 10
U2 26
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD JUL
PY 2020
VL 5
IS 7
BP 811
EP 818
DI 10.1001/jamacardio.2020.1017
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MQ8PA
UT WOS:000553153600013
PM 32219356
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Inciardi, RM
   Lupi, L
   Zaccone, G
   Italia, L
   Raffo, M
   Tomasoni, D
   Cani, DS
   Cerini, M
   Farina, D
   Gavazzi, E
   Maroldi, R
   Adamo, M
   Ammirati, E
   Sinagra, G
   Lombardi, CM
   Metra, M
AF Inciardi, Riccardo M.
   Lupi, Laura
   Zaccone, Gregorio
   Italia, Leonardo
   Raffo, Michela
   Tomasoni, Daniela
   Cani, Dario S.
   Cerini, Manuel
   Farina, Davide
   Gavazzi, Emanuele
   Maroldi, Roberto
   Adamo, Marianna
   Ammirati, Enrico
   Sinagra, Gianfranco
   Lombardi, Carlo M.
   Metra, Marco
TI Cardiac Involvement in a Patient With Coronavirus Disease 2019
   (COVID-19)
SO JAMA CARDIOLOGY
LA English
DT Article
AB Question What are the cardiac complications associated with the emerging outbreak of coronavirus disease 2019 (COVID-19)? Findings In this case report, an otherwise healthy 53-year-old patient developed acute myopericarditis with systolic dysfunction confirmed on cardiac magnetic resonance imaging a week after onset of fever and dry cough due to COVID-19. The patient was treated with inotropic support, antiviral drugs, corticosteroids, and chloroquine, with progressive stabilization of the clinical course. Meaning The emerging outbreak of COVID-19 can be associated with cardiac involvement, even after the resolution of the upper respiratory tract infection.
   This case report describes the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms.
   Importance Virus infection has been widely described as one of the most common causes of myocarditis. However, less is known about the cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective To describe the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from the influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms. Design, Setting, and Participant This case report describes an otherwise healthy 53-year-old woman who tested positive for COVID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. The patient did not show any respiratory involvement during the clinical course. Exposure Cardiac involvement with COVID-19. Main Outcomes and Measures Detection of cardiac involvement with an increase in levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T, echocardiography changes, and diffuse biventricular myocardial edema and late gadolinium enhancement on cardiac magnetic resonance imaging. Results An otherwise healthy 53-year-old white woman presented to the emergency department with severe fatigue. She described fever and dry cough the week before. She was afebrile but hypotensive; electrocardiography showed diffuse ST elevation, and elevated high-sensitivity troponin T and NT-proBNP levels were detected. Findings on chest radiography were normal. There was no evidence of obstructive coronary disease on coronary angiography. Based on the COVID-19 outbreak, a nasopharyngeal swab was performed, with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Cardiac magnetic resonance imaging showed increased wall thickness with diffuse biventricular hypokinesis, especially in the apical segments, and severe left ventricular dysfunction (left ventricular ejection fraction of 35%). Short tau inversion recovery and T2-mapping sequences showed marked biventricular myocardial interstitial edema, and there was also diffuse late gadolinium enhancement involving the entire biventricular wall. There was a circumferential pericardial effusion that was most notable around the right cardiac chambers. These findings were all consistent with acute myopericarditis. She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization. Conclusions and Relevance This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia.
C1 [Inciardi, Riccardo M.; Lupi, Laura; Zaccone, Gregorio; Italia, Leonardo; Raffo, Michela; Tomasoni, Daniela; Cani, Dario S.; Cerini, Manuel; Adamo, Marianna; Lombardi, Carlo M.; Metra, Marco] Univ Brescia, Inst Cardiol, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Farina, Davide; Gavazzi, Emanuele; Maroldi, Roberto] Univ Brescia, Inst Radiol, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Ammirati, Enrico] Osped Niguarda Ca Granda, De Gasperis Cardio Ctr, Milan, Italy.
   [Ammirati, Enrico] Osped Niguarda Ca Granda, Transplant Ctr, Milan, Italy.
   [Sinagra, Gianfranco] Osped Riuniti, Cardiovasc Dept, Trieste, Italy.
   [Sinagra, Gianfranco] Univ Trieste, Trieste, Italy.
RP Metra, M (corresponding author), Spedali Civili, Inst Cardiol, Piazzale Spedali Civili 1, I-25123 Bresda, BS, Italy.
EM metramarco@libero.it
RI ADAMO, MARIANNA/B-1658-2019; Farina, Davide/M-8997-2019
OI ADAMO, MARIANNA/0000-0002-3855-1815; Farina, Davide/0000-0003-4075-0001;
   inciardi, Riccardo Maria/0000-0003-4846-8529
CR Esfandiarei M, 2008, ANNU REV PATHOL-MECH, V3, P127, DOI 10.1146/annurev.pathmechdis.3.121806.151534
   Friedrich MG, 2009, J AM COLL CARDIOL, V53, P1475, DOI 10.1016/j.jacc.2009.02.007
   Fung G, 2016, CIRC RES, V118, P496, DOI 10.1161/CIRCRESAHA.115.306573
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu PP, 2001, CIRCULATION, V104, P1076, DOI 10.1161/hc3401.095198
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Rahman JE, 2004, J AM COLL CARDIOL, V43, P410, DOI 10.1016/j.jacc.2003.08.043
   WHO, NOV COR CHIN
   World Health Organization, PNEUM UNKN CAUS CHIN
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yu CM, 2006, POSTGRAD MED J, V82, P140, DOI 10.1136/pgmj.2005.037515
NR 15
TC 314
Z9 320
U1 9
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD JUL
PY 2020
VL 5
IS 7
BP 819
EP 824
DI 10.1001/jamacardio.2020.1096
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MQ8PA
UT WOS:000553153600014
PM 32219357
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Li, JY
   Wang, XF
   Chen, J
   Zhang, HM
   Deng, AP
AF Li, Juyi
   Wang, Xiufang
   Chen, Jian
   Zhang, Hongmei
   Deng, Aiping
TI Association of Renin-Angiotensin System Inhibitors With Severity or Risk
   of Death in Patients With Hypertension Hospitalized for Coronavirus
   Disease 2019 (COVID-19) Infection in Wuhan, China
SO JAMA CARDIOLOGY
LA English
DT Article
ID RECEPTOR; ACE2
AB Question Among patients with hypertension, do those taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have greater illness severity or increased risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19) infection? Findings In this single-center case series involving 362 patients with hypertension hospitalized with COVID-19 infection, there was no difference in severity of the disease, complications, and risk of death in those who were taking ACEIs/ARBs compared with those not treated with these medications. Meaning In this single-center study, ACEI/ARB was not associated with severity and outcomes of COVID-19 infection in hospitalized patients with hypertension. These results support current guidelines and societal recommendations for treating hypertension.
   This cohort study examines the association between angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.
   Importance Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19). Objective To investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection. Design, Setting, and Participants Retrospective, single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020. Main Outcomes and Measures COVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors. Results Of the 1178 patients with COVID-19, the median age was 55.5 years (interquartile range, 38-67 years) and 545 (46.3%) were men. The overall in-hospital mortality was 11.0%. There were 362 patients with hypertension (30.7% of the total group; median age, 66.0 years [interquartile range, 59-73 years]; 189 [52.2%] were men), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P = .65) nor did it differ between nonsurvivors and survivors (27.3% vs 33.0%; P = .34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs. Conclusions and Relevance This study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19 infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.
C1 [Li, Juyi; Deng, Aiping] Huazhong Univ Sci & Technol, Key Lab Mol Diag Hubei Prov, Tongji Med Coll, Dept Pharm,Cent Hosp Wuhan, Wuhan, Hubei, Peoples R China.
   [Wang, Xiufang] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Pain, Wuhan, Hubei, Peoples R China.
   [Chen, Jian] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Informat, Wuhan, Hubei, Peoples R China.
   [Zhang, Hongmei] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Endocrinol, Wuhan, Hubei, Peoples R China.
RP Zhang, HM (corresponding author), Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Endocrinol, Wuhan, Hubei, Peoples R China.; Zhang, HM; Deng, AP (corresponding author), Cent Hosp Wuhan, 21 Shengli Rd, Wuhan 430021, Peoples R China.
EM zhm7001@163.com; dapyxb@163.com
OI li, juyi/0000-0002-5141-4655
FU Health and Family Planning Commission of Wuhan City, China [WX18M02,
   WX18C25]
FX This study was supported by the Health and Family Planning Commission of
   Wuhan City, China (grants WX18M02 and WX18C25).
CR American Heart Association, HFSA ACC AHA STAT AD
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 15
TC 89
Z9 94
U1 4
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD JUL
PY 2020
VL 5
IS 7
BP 825
EP 830
DI 10.1001/jamacardio.2020.1624
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MQ8PA
UT WOS:000553153600015
PM 32324209
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Marinaki, S
   Tsiakas, S
   Skalioti, C
   Lourida, P
   Argyraki, A
   Grigorakos, K
   Boletis, I
AF Marinaki, Smaragdi
   Tsiakas, Stathis
   Skalioti, Chrysanthi
   Lourida, Panayiota
   Argyraki, Aikaterini
   Grigorakos, Konstantinos
   Boletis, Ioannis
TI A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who
   Survived COVID-19 Disease: Case Presentation and Current Data of
   COVID-19 Infection in Dialysis and Transplanted Patients in Greece
SO MEDICINA-LITHUANIA
LA English
DT Article
DE COVID-19; pneumonia; glomerulonephritis; immunosuppression;
   transplantation; Renal Replacement Therapy (RRT)
AB The evolving pandemic of Coronavirus Disease 2019 has posed a substantial health risk worldwide. However, there is a paucity of data regarding the clinical course and the therapeutic management of patients with chronic kidney disease and COVID-19 infection. To date, most evidence has come from renal transplantation, with about 45 patients reported thus far, and the current data from the ERA-EDTA (ERACODA) registry for transplanted patients and patients on Renal Replacement Therapy (RRT); as for those with glomerular diseases, data are lacking. Herein, we report the case of a 62-year-old patient with severe membranoproliferative glomerulonephritis who had been receiving a high burden of immunosuppression until four months before the COVID-19 infection. He developed severe disease with acute respiratory failure requiring mechanical ventilation. After treatment with hydroxychloroquine and azithromycin, despite his low chances, he gradually recovered and survived. To the best of our knowledge, this is one of the few reported patients with glomerulonephritis who had COVID-19 Besides our single case with glomerulonephritis early during the disease outbreak, the very low prevalence of COVID-19 infection in the country's transplant recipients (0.038%) and dialysis patients (0.24%) reflects the impact of the rapid implementation of social distancing rules as well as of preventive measures for disease control in the hospitals and dialysis units in our country.
C1 [Marinaki, Smaragdi; Tsiakas, Stathis; Skalioti, Chrysanthi; Boletis, Ioannis] Natl & Kapodistrian Univ Athens, Laiko Hosp, Med Sch, Clin Nephrol & Renal Transplantat, Athens 11527, Greece.
   [Lourida, Panayiota; Argyraki, Aikaterini] Sotiria Chest Dis Hosp, Infect Dis Clin A, Athens 11527, Greece.
   [Grigorakos, Konstantinos] 12 Protopappa Ave, Athens 16345, Greece.
RP Skalioti, C (corresponding author), Natl & Kapodistrian Univ Athens, Laiko Hosp, Med Sch, Clin Nephrol & Renal Transplantat, Athens 11527, Greece.
EM smaragdimarinaki@yahoo.com; stathis.tsiakas@gmail.com;
   c_skalioti@yahoo.com; giotalourida@gmail.com; katrin.argyraki@gmail.com;
   gk_pediatr@yahoo.gr; laikneph@laiko.gr
CR Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bomback AS, 2020, CLIN J AM SOC NEPHRO, V15, P876, DOI 10.2215/CJN.04530420
   Greek Ministry of Health, 2020, NAT REG PAT ENG STAG
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Juni P, 2020, CAN MED ASSOC J, V192, pE566, DOI 10.1503/cmaj.200920
   Nacif LS, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1983
   NPHO, CURR STAT COVID 19 O
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Thiel J, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1306-0
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
NR 14
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JUL
PY 2020
VL 56
IS 7
AR 355
DI 10.3390/medicina56070355
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MS2UL
UT WOS:000554137800001
PM 32708858
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tchelebi, LT
   Haustermans, K
   Scorsetti, M
   Hosni, A
   Huguet, F
   Hawkins, MA
   Dawson, LA
   Goodman, KA
AF Tchelebi, Leila T.
   Haustermans, Karin
   Scorsetti, Marta
   Hosni, Ali
   Huguet, Florence
   Hawkins, Maria A.
   Dawson, Laura A.
   Goodman, Karyn A.
TI Recommendations for the use of radiation therapy in managing patients
   with gastrointestinal malignancies in the era of COVID-19
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Radiation oncology; Gastrointestinal neoplasms; COVID-19; Pandemic
ID STEREOTACTIC BODY RADIOTHERAPY; CLINICAL-PRACTICE GUIDELINES; INOPERABLE
   HEPATOCELLULAR-CARCINOMA; PHASE-III TRIAL; ESOPHAGEAL CANCER;
   RECTAL-CANCER; CHEMORADIOTHERAPY; CHEMOTHERAPY; SURGERY; CHEMORADIATION
AB As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these numbers rise exponentially by the day [1]. According to the Centers for Disease Control (CDC), the most effective means of minimizing the spread of the virus is through reducing interactions between individuals [2]. We performed a review of the literature, as well as national and international treatment guidelines, seeking data in support of the RADS principle (Remote visits, Avoid radiation, Defer radiation, Shorten radiation) [3] as it applies to gastrointestinal cancers. The purpose of the present work is to guide radiation oncologists managing patients with gastrointestinal cancers during the COVID-19 crisis in order to maintain the safety of our patients, while minimizing the impact of the pandemic on cancer outcomes. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Tchelebi, Leila T.] Penn State Coll Med, Dept Radiat Oncol, Hershey, PA USA.
   [Haustermans, Karin] Particle Therapy Interuniv Ctr Leuven, Dept Radiat Oncol, Leuven, Belgium.
   [Scorsetti, Marta] Humanitas Clin & Res Ctr IRCCS, Dept Radiotherapy & Radiosurg, Milan, Italy.
   [Scorsetti, Marta; Dawson, Laura A.] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Hosni, Ali] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada.
   [Huguet, Florence] Sorbonne Univ, Dept Radiat Oncol, Hop Tenon, AP HP, Paris, France.
   [Hawkins, Maria A.] UCL, Univ Coll London Hosp NHS Fdn Trust, Med Phys & Biomed Engn, London, England.
   [Goodman, Karyn A.] Mt Sinai Hosp, Dept Radiat Oncol, New York, NY 10029 USA.
RP Tchelebi, LT (corresponding author), Penn State Canc Inst, Dept Radiat Oncol, 500 Univ Dr, Hershey, PA 17033 USA.
EM ltchelebi@pennstatehealth.psu.edu
RI Hawkins, Maria Andreia/A-9404-2013
OI Hawkins, Maria Andreia/0000-0002-6669-0628; , Leila/0000-0002-4789-449X;
   Haustermans, Karin/0000-0003-0364-682X
FU NIHR Biomedical Research Centre at University College London Hospitals
   NHS Foundation Trust
FX MAH is supported by funding from the NIHR Biomedical Research Centre at
   University College London Hospitals NHS Foundation Trust.
CR Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1
   AlSarraf M, 1997, J CLIN ONCOL, V15, P277, DOI 10.1200/JCO.1997.15.1.277
   Balaban EP, 2016, J CLIN ONCOL, V34, P2654, DOI 10.1200/JCO.2016.67.5561
   Bezjak A, 2002, INT J RADIAT ONCOL, V54, P719, DOI 10.1016/S0360-3016(02)02989-9
   BRIERLEY JD, 1995, INT J RADIAT ONCOL, V31, P255, DOI 10.1016/0360-3016(94)E0102-P
   Bujko K, 2016, ANN ONCOL, V27, P834, DOI 10.1093/annonc/mdw062
   Bujold A, 2013, J CLIN ONCOL, V31, P1631, DOI 10.1200/JCO.2012.44.1659
   Cats A, 2018, LANCET ONCOL, V19, P616, DOI 10.1016/S1470-2045(18)30132-3
   Chan I, 2006, J CLIN ONCOL, V24, P668, DOI 10.1200/JCO.2005.04.4875
   Chaw CL, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.384
   Conroy T, 2014, LANCET ONCOL, V15, P305, DOI 10.1016/S1470-2045(14)70028-2
   CUMMINGS BJ, 1991, INT J RADIAT ONCOL, V21, P1115, DOI 10.1016/0360-3016(91)90265-6
   Dawson LA, 2006, ACTA ONCOL, V45, P856, DOI 10.1080/02841860600936369
   Erlandsson J, 2017, LANCET ONCOL, V18, P336, DOI 10.1016/S1470-2045(17)30086-4
   Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634
   Fernandez-Martos C, 2015, ANN ONCOL, V26, P1722, DOI 10.1093/annonc/mdv223
   Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI [10.1093/annonc/mdx224, 10.1093/annonc/mdx261.355]
   Goodman KA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.1
   Goodman KA, 2010, INT J RADIAT ONCOL, V78, P486, DOI 10.1016/j.ijrobp.2009.08.020
   Hammel P, 2016, JAMA-J AM MED ASSOC, V315, P1844, DOI 10.1001/jama.2016.4324
   Hammer L, 2018, INT J RADIAT ONCOL, V102, pS38, DOI 10.1016/j.ijrobp.2018.06.074
   Herman JM, 2015, CANCER-AM CANCER SOC, V121, P1128, DOI 10.1002/cncr.29161
   HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403
   Hong TS, 2016, J CLIN ONCOL, V34, P460, DOI 10.1200/JCO.2015.64.2710
   Horgan AM, 2012, J CLIN ONCOL, V30, P1934, DOI 10.1200/JCO.2011.40.5381
   Hosni Ali, 2018, Oncotarget, V9, P20439, DOI 10.18632/oncotarget.24926
   Hoyer M, 2005, RADIOTHER ONCOL, V76, P48, DOI 10.1016/j.radonc.2004.12.022
   Hulshof MCCM, 2020, J CLIN ONCOL, V38
   Jones CM, 2019, CLIN ONCOL-UK, V31, P356, DOI 10.1016/j.clon.2019.01.010
   Kachnic LA, 2013, INT J RADIAT ONCOL, V86, P27, DOI 10.1016/j.ijrobp.2012.09.023
   Kang JK, 2012, CANCER-AM CANCER SOC, V118, P5424, DOI 10.1002/cncr.27533
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lordick F, 2016, ANN ONCOL, V27, pv50, DOI 10.1093/annonc/mdw329
   Marijnen C, 2017, RADIOTHER ONCOL, V123, pS227, DOI 10.1016/S0167-8140(17)30871-X
   Marijnen CAM, 2020, RADIOTHER ONCOL, V148, P213, DOI 10.1016/j.radonc.2020.03.039
   Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Murphy JE, 2018, JAMA ONCOL, V4, P963, DOI 10.1001/jamaoncol.2018.0329
   NCCN, NCCN CLIN PRACTICE G
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Park SH, 2015, J CLIN ONCOL, V33, P3130, DOI 10.1200/JCO.2014.58.3930
   Pasini F, 2013, CANCER-AM CANCER SOC, V119, P939, DOI 10.1002/cncr.27822
   Primrose JN, 2019, LANCET ONCOL, V20, P663, DOI 10.1016/S1470-2045(18)30915-X
   Ruhstaller T, 2018, ANN ONCOL, V29, P1386, DOI 10.1093/annonc/mdy105
   Scorsetti M, 2015, J CANCER RES CLIN, V141, P1301, DOI 10.1007/s00432-015-1929-y
   Senkus-Konefka E, 2005, BRIT J CANCER, V92, P1038, DOI 10.1038/sj.bjc.6602477
   Seufferlein T, 2012, ANN ONCOL, V23, P33, DOI 10.1093/annonc/mds224
   Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350
   Stahl M, 2009, J CLIN ONCOL, V27, P851, DOI 10.1200/JCO.2008.17.0506
   Swisher SG, 2003, INT J RADIAT ONCOL, V57, P120, DOI 10.1016/S0360-3016(03)00522-4
   Tchelebi LT, 2020, CANCER-AM CANCER SOC, V126, P2120, DOI 10.1002/cncr.32756
   Tey J, 2017, ONCOTARGET, V8, P25797, DOI 10.18632/oncotarget.15554
   Tse RV, 2008, J CLIN ONCOL, V26, P657, DOI 10.1200/JCO.2007.14.3529
   UNNO M, 2019, J CLIN ONCOL S, V37
   van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
   Versteijne E, 2020, J CLIN ONCOL, V38, P1763, DOI 10.1200/JCO.19.02274
   Vogel A, 2018, ANN ONCOL, V29, P238, DOI 10.1093/annonc/mdy308
   von Dobeln GA, 2019, DIS ESOPHAGUS, V32, DOI 10.1093/dote/doy078
   Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702
   Yoon SM, 2018, JAMA ONCOL, V4, P661, DOI 10.1001/jamaoncol.2017.5847
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
NR 62
TC 10
Z9 11
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUL
PY 2020
VL 148
BP 194
EP 200
DI 10.1016/j.radonc.2020.04.010
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MR0OX
UT WOS:000553294100028
PM 32342878
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ippolito, E
   Fiore, M
   Greco, C
   D'Angelillo, RM
   Ramella, S
AF Ippolito, Edy
   Fiore, Michele
   Greco, Carlo
   D'Angelillo, Rolando Maria
   Ramella, Sara
TI COVID-19 and radiation induced pneumonitis: Overlapping clinical
   features of different diseases
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Letter
ID LUNG-CANCER; THERAPY
C1 [Ippolito, Edy; Fiore, Michele; Greco, Carlo; Ramella, Sara] Campus Biomed Univ, Radiat Oncol, Via Alvaro Portillo 200, I-00128 Rome, Italy.
   [D'Angelillo, Rolando Maria] Tor Vergata Univ, Radiat Oncol, Rome, Italy.
RP Greco, C (corresponding author), Campus Biomed Univ, Radiat Oncol, Via Alvaro Portillo 200, I-00128 Rome, Italy.
EM c.greco@unicampus.it
OI ippolito, edy/0000-0003-1775-2009
CR Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937
   Campian JL, 2013, CANCER INVEST, V31, P183, DOI 10.3109/07357907.2013.767342
   Choi YW, 2004, RADIOGRAPHICS, V24, P985, DOI 10.1148/rg.244035160
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hanania AN, 2019, CHEST, V156, P150, DOI 10.1016/j.chest.2019.03.033
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Palma DA, 2013, INT J RADIAT ONCOL, V85, P444, DOI 10.1016/j.ijrobp.2012.04.043
   Ramella S, 2014, CANCER INVEST, V32, P110, DOI 10.3109/07357907.2014.883525
   World Health Organization, 2020, 74 WHO
   Ye Z, 2020, EUR RADIOL, V30, P4381, DOI 10.1007/s00330-020-06801-0
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUL
PY 2020
VL 148
BP 201
EP 202
DI 10.1016/j.radonc.2020.04.009
PG 2
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MR0OX
UT WOS:000553294100029
PM 32342879
OA Green Published
DA 2021-01-01
ER

PT J
AU Khan, R
   Darafsheh, A
   Goharian, M
   Cilla, S
   Villarreal-Barajas, JE
AF Khan, Rao
   Darafsheh, Arash
   Goharian, Mehran
   Cilla, Savino
   Villarreal-Barajas, J. Eduardo
TI Evolution of clinical radiotherapy physics practice under COVID-19
   constraints
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE COVID-19; Pandemic; Contingency plan; Coronavirus; Medical physic;
   Clinical physic
ID RADIATION ONCOLOGY; CANCER-PATIENTS; RECOMMENDATIONS; STATEMENT;
   OUTBREAK; THERAPY; IMPACT; WUHAN
AB As the COVID-19 spread continues to challenge the societal and professional norms, radiotherapy around the globe is pushed into an unprecedented transformation. We will discuss how clinical physics has transformed to ascertain safety and quality standards across four facilities around the world through diversity of action, innovation, and scientific flexibility. Crown Copyright (C) 2020 Published by Elsevier B.V. All rights reserved.
C1 [Khan, Rao; Darafsheh, Arash] Washington Univ, Sch Med, Dept Radiat Oncol, 4921 Parkview Pl,Campus Box 8224, St Louis, MO 63110 USA.
   [Goharian, Mehran] BC Canc Agcy, Dept Med Phys, Victoria, BC, Canada.
   [Cilla, Savino] Gemelli Molise Hosp, Med Phys Unit, Campobasso, Italy.
   [Villarreal-Barajas, J. Eduardo] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England.
RP Darafsheh, A (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, 4921 Parkview Pl,Campus Box 8224, St Louis, MO 63110 USA.
EM arash.darafsheh@wustl.edu
RI Cilla, Savino/O-7265-2019
OI Cilla, Savino/0000-0001-6711-350X
CR Akbarzadeh MA, 2020, RADIOTHER ONCOL, V148, P211, DOI 10.1016/j.radonc.2020.04.041
   Boldrini L, 2020, RADIOTHER ONCOL, V148, P223, DOI 10.1016/j.radonc.2020.04.036
   Braunstein LZ, 2020, ADV RADIAT ONCOL, V5, P582, DOI 10.1016/j.adro.2020.03.013
   Caruana CJ, 2018, PHYS MEDICA, V48, P162, DOI 10.1016/j.ejmp.2018.03.001
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen W, 2020, ADV RADIAT ONCOL, V5, P560, DOI 10.1016/j.adro.2020.03.008
   Clements JB, 2018, J APPL CLIN MED PHYS, V19, P11, DOI 10.1002/acm2.12469
   De Felice F, 2020, RADIOTHER ONCOL, V147, P84, DOI 10.1016/j.radonc.2020.03.020
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Filippi AR, 2020, INT J RADIAT ONCOL, V107, P597, DOI 10.1016/j.ijrobp.2020.03.007
   Gemici C, 2020, RADIOTHER ONCOL, V149, P107, DOI 10.1016/j.radonc.2020.03.044
   Gregucci F, 2020, RADIOTHER ONCOL, V149, P109, DOI 10.1016/j.radonc.2020.04.002
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Huq MS, 2016, MED PHYS, V43, P4209, DOI 10.1118/1.4947547
   Ismaili N, 2020, RADIOTHER ONCOL, V148, P227, DOI 10.1016/j.radonc.2020.04.029
   Janssens GO, 2020, RADIOTHER ONCOL, V148, P216, DOI 10.1016/j.radonc.2020.04.035
   Lincoln H, 2020, MED PHYS, V47, P2045, DOI 10.1002/mp.14203
   Marijnen CAM, 2020, RADIOTHER ONCOL, V148, P213, DOI 10.1016/j.radonc.2020.03.039
   Papachristofilou A, 2020, ADV RADIAT ONCOL, V5, P577, DOI 10.1016/j.adro.2020.03.012
   Rathod S, 2020, RADIOTHER ONCOL, V149, P124, DOI 10.1016/j.radonc.2020.03.045
   Tchelebi LT, 2020, RADIOTHER ONCOL, V148, P194, DOI 10.1016/j.radonc.2020.04.010
   Tey J, 2020, RADIOTHER ONCOL, V148, P189, DOI 10.1016/j.radonc.2020.03.030
   The Italian Association of Medical Physics (AIFM), POS AIFM OPT MED HLT
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wei W, 2020, RADIOTHER ONCOL, V148, P203, DOI 10.1016/j.radonc.2020.03.029
   Wei W, 2020, RADIOTHER ONCOL, V147, P100, DOI 10.1016/j.radonc.2020.03.016
   Whitaker M, 2020, PHYS ENG SCI MED, V43, P473, DOI 10.1007/s13246-020-00869-0
   Wright JL, 2020, ADV RADIAT ONCOL, V5, P666, DOI 10.1016/j.adro.2020.03.014
   Yerramilli D, 2020, ADV RADIAT ONCOL, V5, P589, DOI 10.1016/j.adro.2020.04.001
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
   Zhang L, 2020, RADIOTHER ONCOL, V149, P104, DOI 10.1016/j.radonc.2020.04.011
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-8140
EI 1879-0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUL
PY 2020
VL 148
BP 274
EP 278
DI 10.1016/j.radonc.2020.05.034
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MR0OX
UT WOS:000553294100045
PM 32474126
OA Bronze, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Wang, CF
   Xie, J
   Zhao, L
   Fei, XC
   Zhang, H
   Tan, Y
   Nie, X
   Zhou, LT
   Liu, ZH
   Ren, Y
   Yuan, L
   Zhang, Y
   Zhang, JS
   Liang, LW
   Chen, XW
   Liu, X
   Wang, P
   Han, X
   Weng, XQ
   Chen, Y
   Yu, T
   Zhang, XX
   Cai, J
   Chen, R
   Shi, ZL
   Bian, XW
AF Wang, Chaofu
   Xie, Jing
   Zhao, Lei
   Fei, Xiaochun
   Zhang, Heng
   Tan, Yun
   Nie, Xiu
   Zhou, Luting
   Liu, Zhenhua
   Ren, Yong
   Yuan, Ling
   Zhang, Yu
   Zhang, Jinsheng
   Liang, Liwei
   Chen, Xinwei
   Liu, Xin
   Wang, Peng
   Han, Xiao
   Weng, Xiangqin
   Chen, Ying
   Yu, Ting
   Zhang, Xinxin
   Cai, Jun
   Chen, Rong
   Shi, Zheng-Li
   Bian, Xiu-Wu
TI Alveolar macrophage dysfunction and cytokine storm in the pathogenesis
   of two severe COVID-19 patients
SO EBIOMEDICINE
LA English
DT Article
DE SARS-CoV-2, COVID-19; Pathology; Alveolar macrophage; Cytokine storm
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; PNEUMONIA; OUTBREAK;
   IDENTIFICATION; PATHOLOGY; SARS
AB Background: The novel coronavirus pneumonia COVID-19 caused by SARS-CoV-2 infection could lead to a series of clinical symptoms and severe illnesses, including acute respiratory distress syndrome (ARDS) and fatal organ failure. We report the fundamental pathological investigation in the lungs and other organs of fatal cases for the mechanistic understanding of severe COVID-19 and the development of specific therapy in these cases.
   Methods: The autopsy and pathological investigations of specimens were performed on bodies of two deceased cases with COVID-19. Gross anatomy and histological investigation by Hematoxylin and eosin (HE) stained were reviewed on each patient. Alcian blue/periodic acid-Schiff (AB-PAS) staining and Masson staining were performed for the examinations of mucus, fibrin and collagen fiber in lung tissues. Immunohistochemical staining was performed on the slides of lung tissues from two patients. Real-time PCR was performed to detect the infection of SARS-CoV-2. Flow cytometry analyses were performed to detect the direct binding of S protein and the expression of ACE2 on the cell surface of macrophages.
   Findings: The main pathological features in lungs included extensive impairment of type I alveolar epithelial cells and atypical hyperplasia of type II alveolar cells, with formation of hyaline membrane, focal hemorrhage, exudation and pulmonary edema, and pulmonary consolidation. The mucous plug with fibrinous exudate in the alveoli and the dysfunction of alveolar macrophages were characteristic abnormalities. The type II alveolar epithelial cells and macrophages in alveoli and pulmonary hilum lymphoid tissue were infected by SARS-CoV-2. S protein of SARS-CoV-2 directly bound to the macrophage via the S-protein-ACE2 interaction.
   Interpretation: Infection of alveolar macrophage by SARS-CoV-2 might be drivers of the "cytokine storm", which might result in damages in pulmonary tissues, heart and lung, and lead to the failure of multiple organs
C1 [Wang, Chaofu; Xie, Jing; Fei, Xiaochun; Zhang, Heng; Zhou, Luting] Shanghai Jiao Tong Univ, Sch Med, Dept Pathol, Ruijin Hosp, Shanghai, Peoples R China.
   [Zhao, Lei; Cai, Jun] Shanghai Jiao Tong Univ, Sch Med, Dept Pathol, Shanghai, Peoples R China.
   [Tan, Yun; Weng, Xiangqin] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Res Shanghai, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai, Peoples R China.
   [Nie, Xiu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China.
   [Liu, Zhenhua] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Ultrasound, Shanghai, Peoples R China.
   [Ren, Yong; Yuan, Ling; Zhang, Yu; Zhang, Jinsheng; Liang, Liwei; Chen, Xinwei; Liu, Xin; Wang, Peng; Han, Xiao] PLA, Gen Hosp Cent Theater Command, Beijing, Peoples R China.
   [Chen, Ying; Shi, Zheng-Li] Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China.
   [Yu, Ting; Chen, Rong] Jin Yin Tan Hosp, Dept Pathol, Wuhan, Peoples R China.
   [Zhang, Xinxin] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Res Lab Clin Virol, Shanghai, Peoples R China.
   [Zhang, Xinxin] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Shanghai, Peoples R China.
   [Bian, Xiu-Wu] Army Med Univ, Third Mil Med Univ, Southwest Hosp, Inst Pathol,Key Lab,Minist Educ, Chongqing, Peoples R China.
   [Bian, Xiu-Wu] Army Med Univ, Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr,Key Lab,Minist Educ, Chongqing, Peoples R China.
RP Wang, CF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Pathol, Ruijin Hosp, Shanghai, Peoples R China.; Cai, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Pathol, Shanghai, Peoples R China.; Shi, ZL (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China.; Chen, R (corresponding author), Jin Yin Tan Hosp, Dept Pathol, Wuhan, Peoples R China.; Bian, XW (corresponding author), Army Med Univ, Third Mil Med Univ, Southwest Hosp, Inst Pathol,Key Lab,Minist Educ, Chongqing, Peoples R China.; Bian, XW (corresponding author), Army Med Univ, Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr,Key Lab,Minist Educ, Chongqing, Peoples R China.
EM wangchaofu@126.com; caijun@shsmu.edu.cn; crjudy@126.com;
   zlshi@wh.iov.cn; bianxiuwu@263.net
RI Bian, Xiu-Wu/D-4736-2017
OI Bian, Xiu-Wu/0000-0003-4383-0197; Tan, Yun/0000-0001-8450-0392
FU Shanghai Guangci Translational Medical Research Development Foundation,
   Shanghai, China
FX This work was supported by the Shanghai Guangci Translational Medical
   Research Development Foundation, Shanghai, China
CR Billiau AD, 2005, BLOOD, V105, P1648, DOI 10.1182/blood-2004-08-2997
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Duan K, 2020, P NATL ACAD SCI US
   Guan WJ, 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kunisch E, 2004, ANN RHEUM DIS, V63, P774, DOI 10.1136/ard.2003.013029
   Lax SF, 2020, ANN INTERN MED, DOI 107326/M20-2566
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Magro C, 2020, TRANSL RES
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Tian S, 2020, J THORAC ONCOL
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wichmann D, 2020, ANN INTERN MED
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan L., 2020, ARCH PATHOL LAB MED
   Zeng Z, 2020, HISTOPATHOLOGY
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 24
TC 24
Z9 25
U1 6
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD JUL
PY 2020
VL 57
AR 102833
DI 10.1016/j.ebiom.2020.102833
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA MP6IO
UT WOS:000552306700010
PM 32574956
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sahi, PK
   Mishra, D
   Singh, T
AF Sahi, Puneet Kaur
   Mishra, Devendra
   Singh, Tejinder
TI Medical Education Amid the COVID-19 Pandemic
SO INDIAN PEDIATRICS
LA English
DT Article
DE Coronavirus; e-Learning; Medical student; Pedagogy
ID SARS
AB The coronavirus pandemic has shaken the mankind to its core. Social distancing is the most important preventive strategy for the spread of this contagion, short of a vaccine. Implementation of the same has forced many countries in to a complete lock-down. Closure of schools and universities has made education uncertain at all levels. Medical education is no exception. In this pandemic, the need for uninterrupted generation of future doctors is felt more than ever in our living memory. Continuity of medical education is thus imperative. While "Live" patient contact is an irreplaceable tenet of clinical teaching, these extraordinary times demand exceptional measures. Pedagogical innovations involving technology and simulation based teaching (Online lectures, video case vignettes, virtual simulators, webcasting, online chat-rooms) need to be brought to the forefront. Since the medical educators have been pushed inevitably to rely on technology-based learning, they should not only embrace it but also develop and evaluate its sustainability and application in preclinical and clinical setting. Meanwhile, the students, whose medical education is stuck in this pandemic time, should realize that there is no better teacher than a first-hand experience, and they are eyewitnesses to the making of history.
C1 [Sahi, Puneet Kaur; Mishra, Devendra] Maulana Azad Med Coll, Dept Pediat, New Delhi 110002, India.
   [Mishra, Devendra] Maulana Azad Med Coll, Dept Med Educ, New Delhi, India.
   [Singh, Tejinder] SGRD Inst Med Sci & Res, Dept Pediat, Amritsar, Punjab, India.
   [Singh, Tejinder] SGRD Inst Med Sci & Res, Dept Med Educ, Amritsar, Punjab, India.
RP Sahi, PK (corresponding author), Maulana Azad Med Coll, Dept Pediat, New Delhi 110002, India.; Sahi, PK (corresponding author), Lok Nayak Hosp, New Delhi 110002, India.
EM puneetksahi@gmail.com
RI Mishra, Devendra/C-4881-2014; Singh, Tejinder/AAX-1694-2020
OI Mishra, Devendra/0000-0002-6810-3095; 
CR Abrahamson SD, 2006, CRIT CARE, V10, DOI 10.1186/cc3916
   Del Rio C, 2020, JAMA
   Dhir SK, 2017, INDIAN PEDIATR, V54, P871, DOI 10.1007/s13312-017-1152-9
   Gillett B, 2008, ACAD EMERG MED, V15, P1144, DOI 10.1111/j.1553-2712.2008.00198.x
   Irby DM, 2010, ACAD MED, V85, P220, DOI 10.1097/ACM.0b013e3181c88449
   Kapoor A, 2019, INDIAN PEDIATR, V56, P967, DOI 10.1007/s13312-019-1664-6
   Liaison Committee on Medical Education, COVID 19 UPD RES
   Lim ECH, 2009, ANN ACAD MED SINGAP, V38, P724
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   Medical Council of India, 2019, IMPL IP BAS CCTV SOL
   Medical Council of India, 2020, ADV REG UG CLASS VIE
   Medical Schools Council, INF MED STUD
   Murphy B, 2020, PUBLIC HLTH
   O'Doherty D, 2018, BMC MED EDUC, V18, DOI 10.1186/s12909-018-1240-0
   Patil NG, 2003, MED EDUC, V37, P1127, DOI 10.1046/j.1365-2923.2003.01723.x
   Raiman L, 2017, BMC MED EDUC, V17, DOI 10.1186/s12909-017-0855-x
   Rose S., 2020, JAMA
   Skochelak SE, 2017, ACAD MED, V92, P16, DOI 10.1097/ACM.0000000000001160
NR 18
TC 3
Z9 4
U1 6
U2 6
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD JUL
PY 2020
VL 57
IS 7
BP 652
EP 657
DI 10.1007/s13312-020-1894-7
PG 6
WC Pediatrics
SC Pediatrics
GA MQ6TQ
UT WOS:000553026200010
PM 32412913
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gautret, P
   Lagier, JC
   Parola, P
   Hoang, V
   Meddeb, L
   Mailhe, M
   Doudier, B
   Courjon, J
   Giordanengo, V
   Vieira, VE
   Dupont, HT
   Honore, S
   Colson, P
   Chabriere, E
   La Scola, B
   Rolain, JM
   Brouqui, P
   Raoult, D
AF Gautret, Philippe
   Lagier, Jean-Christophe
   Parola, Philippe
   Van Thuan Hoang
   Meddeb, Line
   Mailhe, Morgane
   Doudier, Barbara
   Courjon, Johan
   Giordanengo, Valerie
   Vieira, Vera Esteves
   Dupont, Herve Tissot
   Honore, Stephane
   Colson, Philippe
   Chabriere, Eric
   La Scola, Bernard
   Rolain, Jean-Marc
   Brouqui, Philippe
   Raoult, Didier
TI Hydroxychloroquine and azithromycin as a treatment of COVID-19: results
   of an open-label non-randomized clinical trial
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE 2019-nCoV; SARS-CoV-2; COVID-19; Hydroxychloroquine; Azithromycin;
   Clinical trial
ID Q-FEVER; CHLOROQUINE
AB Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads.
   Patients and methods: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.
   Results: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.
   Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported in the litterature for untreated patients. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.
   Conclusion: Despite its small sample size, our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin. (C) 2020 Published by Elsevier B.V.
C1 [Gautret, Philippe; Lagier, Jean-Christophe; Parola, Philippe; Van Thuan Hoang; Meddeb, Line; Mailhe, Morgane; Doudier, Barbara; Vieira, Vera Esteves; Dupont, Herve Tissot; Colson, Philippe; Chabriere, Eric; La Scola, Bernard; Rolain, Jean-Marc; Brouqui, Philippe; Raoult, Didier] IHU Mediterranee Infect, Marseille, France.
   [Gautret, Philippe; Parola, Philippe; Van Thuan Hoang] Aix Marseille Univ, VITROME, SSA, AP HM,IRD, Marseille, France.
   [Lagier, Jean-Christophe; Dupont, Herve Tissot; Colson, Philippe; Chabriere, Eric; La Scola, Bernard; Rolain, Jean-Marc; Brouqui, Philippe; Raoult, Didier] Aix Marseille Univ, MEPHI, AP HM, IRD, Marseille, France.
   [Van Thuan Hoang] Thai Binh Univ Med & Pharm, Thai Binh, Vietnam.
   [Courjon, Johan] CHU Nice, Hop Archet, Infectiol, Nice, France.
   [Courjon, Johan] Univ Cote dAzur, Nice, France.
   [Courjon, Johan] Ctr Mediterraneen Med Mol, INSERM, Virulence Microbienne & Signalisat Inflammatoire, C3M,U1065, Nice, France.
   [Giordanengo, Valerie] CHU Nice, Biol & Pathol Ctr, Dept Virol, F-06200 Nice, France.
   [Honore, Stephane] Hop La Timone, AP HM, Serv Pharm, Marseille, France.
   [Honore, Stephane] Aix Marseille Univ, Lab Pharm Clin, Marseille, France.
RP Raoult, D (corresponding author), IHU Mediterranee Infect, Marseille, France.; Raoult, D (corresponding author), Aix Marseille Univ, MEPHI, AP HM, IRD, Marseille, France.
EM Didier.raoult@gmail.com
RI Rolain, Jean-Marc/Y-3788-2019
OI Rolain, Jean-Marc/0000-0002-2402-4467
FU French Government under the "Investissements d'avenir" (Investments for
   the Future) programFrench National Research Agency (ANR) [10-IAHU-03]
FX This work was supported by the French Government under the
   "Investissements d'avenir" (Investments for the Future) program managed
   by the Agence Nationale de la Recherche (ANR, fr: National Agency for
   Research), (reference: Mediterranee Infection 10-IAHU-03).
CR Amrane S, 2020, TRAVEL MED INFECT DI
   Armstrong N, 2017, J CHROMATOGR B, V1060, P166, DOI 10.1016/j.jchromb.2017.06.011
   Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Colson P, 2020, INT J ANTIMICROB AGE
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Lagier JC, 2018, ZHONGHUA JIE HE HE H, V31, P463, DOI [10.3760/cma.j.issn.1001- 0939.2020.03.009, DOI 10.3760/CMA.J.ISSN.1001-0939.2020.03.009]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Raoult D, 1999, ARCH INTERN MED, V159, P167, DOI 10.1001/archinte.159.2.167
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang M, 2020, SOL RRL, V4, DOI 10.1002/solr.202000013
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 1406
Z9 1429
U1 218
U2 218
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD JUL
PY 2020
VL 56
IS 1
AR 105949
DI 10.1016/j.ijantimicag.2020.105949
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA MQ0UY
UT WOS:000552613500015
PM 32205204
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Marais, BJ
   Sorrell, TC
AF Marais, B. J.
   Sorrell, T. C.
TI Pathways to COVID-19 'community protection'
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS Cov-2; Community protection; Herd immunity; Controlled
   infection
ID RESPIRATORS; MASKS
AB To date, no country has reached a natural COVID-19 epidemic peak and observed peaks essentially reflect the effectiveness of 'lockdown' measures. The major challenge is finding a responsible way out of 'lockdown', given that SARS-CoV-2 is now an established global pathogen. Acknowledging limitations in our knowledge regarding the sufficiency and durability of immune responses following natural SARS Cov-2 infection, we discuss three pathways to 'community protection'. Uncontrolled epidemic spread (route 1; R-0 > 2) has been associated with overwhelmed health care systems and high death rates, especially in the vulnerable. Controlled epidemic spread (route 2; effective R-0 1-2) can be achieved with limited or strict control of social mixing; strict control will be necessary to ensure that only low-risk individuals become infected, without spill-over to vulnerable groups during their period of infectiousness. It has been demonstrated that local epidemic elimination (route 3; effective R-0 < 1) can be achieved through prolonged 'lock down', supplemented by early active case finding with quarantine of close contacts to ensure rapid termination of transmission chains within the community. Although universal availability of a safe and effective vaccine remains the preferred 'exit strategy', this may be hard to achieve and alternative options must be considered with careful consideration of all adverse outcomes - including health, social and economic consequences. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Marais, B. J.; Sorrell, T. C.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia.
RP Marais, BJ (corresponding author), Childrens Hosp, Westmead Clin Sch, Locked Bag 4001, Westmead, NSW, Australia.
EM ben.marais@health.nsw.gov.au
CR Atkinson B, 2020, LANCET, V395, P1339, DOI 10.1016/S0140-6736(20)30868-0
   Callaway Ewen, 2020, Nature, DOI 10.1038/d41586-020-01179-x
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Hart V, 2020, OUTPACING VIRUS DIGI
   Hill-Cawthorne G, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001283
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   Offeddu V, 2017, CLIN INFECT DIS, V65, P1934, DOI 10.1093/cid/cix681
   Richard AN, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20224
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   WHO, 2020, KEY CRIT ETH ACC COV
NR 15
TC 2
Z9 2
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 496
EP 499
DI 10.1016/j.ijid.2020.05.058
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MR2SL
UT WOS:000553440200002
PM 32425642
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jang, S
   Rhee, JY
AF Jang, Sukbin
   Rhee, Ji-Young
TI Three cases of treatment with nafamostat in elderly patients with
   COVID-19 pneumonia who need oxygen therapy
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Nafamostat; Pneumonia; Oxygen treatment
AB No effective treatment for COVID-19 has been well established yet. Nafamostat, known as anticoagulant, has potential anti-inflammatory and anti-viral activities against COVID-19. We report three cases of COVID-19 pneumonia who progressed while using antiviral drugs and needed supplementary oxygen therapy, improved after treatment with nafamostat. These preliminary findings show the possibility that Nafamostat can be considered to be used in elderly patients with COVID-19 pneumonia who need oxygen therapy. The effectiveness of nafamostat should be evaluated in further studies. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Jang, Sukbin; Rhee, Ji-Young] Dankook Univ, Coll Med, Dept Med, Div Infect Dis,Dankook Univ Hosp, 201 Manghang Ro, Chungcheongnam Do, South Korea.
RP Rhee, JY (corresponding author), Dankook Univ, Coll Med, Dept Med, Div Infect Dis,Dankook Univ Hosp, 201 Manghang Ro, Chungcheongnam Do, South Korea.
EM pluripotent@naver.com
OI , Ji-Young/0000-0003-4664-7048; Jang, Sukbin/0000-0003-4783-8110
CR [Anonymous], 2020, NAF
   Gao T., 2020, HIGHLY PATHOGENIC CO
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hoffmann M, 2020, CELL
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
NR 8
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 500
EP 502
DI 10.1016/j.ijid.2020.05.072
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MR2SL
UT WOS:000553440200003
PM 32470602
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ding, J
   Tuan, WJ
   Temte, JL
AF Ding, Jing
   Tuan, Wen-Jan
   Temte, Jonathan L.
TI Managing Close Contacts of COVID-19 Confirmed Cases in Metropolitan
   Areas in China
SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE
LA English
DT Article
DE close-contact management; COVID-19
ID STATES
AB The novel coronavirus (COVID-19) outbreak has rapidly spread across the world. As medical systems continue to develop vaccines and treatments, it is crucial for the public health community to establish nonpharmaceutical interventions (NPIs) that can effectively mitigate the rate of SARS-Coronavirus-2 (SARS-CoV-2) spread across highly populated residential areas, especially among individuals who have close contact with confirmed cases. A community-driven preparedness strategy has been implemented in metropolitan areas in China. The Chinese Center for Disease Control and Prevention (CCDC) has required that all COVID-19 confirmed cases be recorded and documented in a national notifiable disease surveillance system (NDSS). After receiving reports of newly confirmed cases, an epidemiological services team at the CCDC or trained medical professionals at local clinical facilities start a case-contact investigation. A task force performs home visits to infected individuals. Persons under investigation (PUIs) can stay in designated quarantine facilities for 14 days or in special circumstances can be quarantined at home. This community-based approach involved all stakeholders including local public health departments, public safety authorities, neighborhood councils, and community health centers.
C1 [Ding, Jing] Capital Med Univ, Fu Xing Hosp, Yuetan Community Hlth Serv Ctr, Bldg 7, Beijing 100045, Peoples R China.
   [Tuan, Wen-Jan; Temte, Jonathan L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, Madison, WI USA.
RP Ding, J (corresponding author), Capital Med Univ, Fu Xing Hosp, Yuetan Community Hlth Serv Ctr, Bldg 7, Beijing 100045, Peoples R China.
EM xiaoxiaodingj@126.com
CR Bajema KL, 2020, MMWR-MORBID MORTAL W, V69, P166, DOI 10.15585/mmwr.mm6906e1
   Burke RM, 2020, MMWR-MORBID MORTAL W, V69, P245, DOI 10.15585/mmwr.mm6909e1
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Chen Yi WA, 2020, ZHONGHUA LIU XING BI, V41, DOI [10.3760/cma.j.cn112338-20200304-00251, DOI 10.3760/CMA.J.CN112338-20200304-00251]
   Chinese Thoracic Society Chinese Society of General Practice Chinese Association of Chest Physician, 2020, CHIN J GEN PRACT, V19, DOI [10.3760/cma.j.issn.1671-7368.2020.00, DOI 10.3760/CMA.J.ISSN.1671-7368.2020.00]
   Executive Committee of the National People's Congress of the People's Republic of China, LAW PEOPL REP CHIN P
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   National Health Commission of the People's Republic of China, 2020, DAIL BRIEF NOV COR C
   Ratzan S., 2020, NAM PERSPECTIVES, DOI [10.31478/202003a, DOI 10.31478/202003A]
   Swerdlow DL, 2020, JAMA-J AM MED ASSOC, V323, P1129, DOI 10.1001/jama.2020.1960
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   [张欣炜 Zhang Xinwei], 2015, [地理科学, Scientia Geographica Sinica], V35, P665
NR 15
TC 1
Z9 1
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-4659
EI 1550-5022
J9 J PUBLIC HEALTH MAN
JI J. Public Health Manag. Pract.
PD JUL-AUG
PY 2020
VL 26
IS 4
SI SI
BP 345
EP 348
DI 10.1097/PHH.0000000000001189
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MP8BG
UT WOS:000552424400017
PM 32332481
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Crick, JM
   Crick, D
AF Crick, James M.
   Crick, Dave
TI Coopetition and COVID-19: Collaborative business-to-business marketing
   strategies in a pandemic crisis
SO INDUSTRIAL MARKETING MANAGEMENT
LA English
DT Article
DE Coopetition; Coronavirus; COVID-19; Business-to-business marketing
ID CLUSTERS INSIGHTS; FIRM GROWTH; COOPERATION; COMPETITION; INNOVATION;
   VIEW; ALLIANCES; PARADOX; IMPACT; PERSPECTIVE
AB Although coopetition (simultaneous cooperation and competition) should positively affect company performance, it is unclear how implementation of these business-to-business marketing strategies can take place during large-scale emergencies. Therefore, guided by resource-based theory and the relational view, this investigation examines how organisations have used coopetition to cope with the novel Coronavirus (COVID-19) pandemic. Key examples include retailers sharing information about stock levels, pharmaceutical organisations working together to develop a vaccine, technological giants collaborating for the greater good, and charities forming alliances for a joint cause. This paper strengthens the extant literature by highlighting the heterogeneity of coopetition strategies that firms can use within a global crisis. Practitioners must balance the risks and rewards of coopetition activities. In turn, they should decide whether to continue to cooperate with their competitors once the pandemic has ended, or resume operating under individualistic business models. This article ends with some future research directions.
C1 [Crick, James M.; Crick, Dave] Univ Ottawa, Telfer Sch Management, Ottawa, ON K1N 6N5, Canada.
RP Crick, D (corresponding author), Univ Ottawa, Telfer Sch Management, Ottawa, ON K1N 6N5, Canada.
EM dcrick@uottawa.ca
CR Akpinar M, 2016, IND MARKET MANAG, V57, P53, DOI 10.1016/j.indmarman.2016.05.006
   Andersson P., 1998, J BUSINESS TO BUSINE, V4, P43
   Ang SH, 2008, STRATEGIC MANAGE J, V29, P1057, DOI 10.1002/smj.695
   [Anonymous], 2020, DAILY MAIL
   [Anonymous], 2020, GUARDIAN
   [Anonymous], 2020, WASHINGTON POST
   [Anonymous], 2020, NATL POST
   [Anonymous], 2020, NY TIMES
   BARNEY J, 1991, J MANAGE, V17, P99, DOI 10.1177/014920639101700108
   Barney JB, 2018, STRATEGIC MANAGE J, V39, P3305, DOI 10.1002/smj.2949
   Bengtsson M, 1999, J BUS IND MARK, V14, P178, DOI 10.1108/08858629910272184
   Bengtsson M, 2000, IND MARKET MANAG, V29, P411, DOI 10.1016/S0019-8501(99)00067-X
   Bengtsson M, 2016, IND MARKET MANAG, V57, P23, DOI 10.1016/j.indmarman.2016.05.003
   Bengtsson M, 2016, IND MARKET MANAG, V53, P19, DOI 10.1016/j.indmarman.2015.11.008
   Bengtsson M, 2014, IND MARKET MANAG, V43, P180, DOI 10.1016/j.indmarman.2014.02.015
   Bouncken RB, 2018, BRIT J MANAGE, V29, P391, DOI 10.1111/1467-8551.12213
   Bouncken RB, 2013, J BUS RES, V66, P2060, DOI 10.1016/j.jbusres.2013.02.032
   Brandenburger A.M., 1996, COOPETITION
   Chesbrough H., 2020, IND MARKETING MANAGE
   Clark T., 1988, J ACAD MARKET SCI, V16, P43
   CNN, 2020, CNN
   Cortez R. M., 2020, IND MARKETING MANAGE
   Crick J. M., 2020, J STRATEGIC MARKETIN
   Crick JM, 2020, INT MARKET REV, DOI 10.1108/IMR-01-2019-0018
   Crick JM, 2019, J BUS IND MARK, V34, P665, DOI 10.1108/JBIM-07-2018-0217
   Crick JM, 2019, J BUS IND MARK, V34, P518, DOI 10.1108/JBIM-03-2018-0102
   Cui V, 2018, STRATEGIC MANAGE J, V39, P3116, DOI 10.1002/smj.2746
   Czakon W., 2020, LONG RANGE PLANNING
   Czakon W, 2016, IND MARKET MANAG, V57, P64, DOI 10.1016/j.indmarman.2016.05.010
   Dahl J, 2014, IND MARKET MANAG, V43, P272, DOI 10.1016/j.indmarman.2013.12.002
   Day GS, 2014, J ACAD MARKET SCI, V42, P27, DOI 10.1007/s11747-013-0348-3
   Di Benedetto CA, 2019, IND MARKET MANAG, V82, P1, DOI 10.1016/j.indmarman.2019.08.001
   Dyer JH, 2018, STRATEGIC MANAGE J, V39, P3140, DOI 10.1002/smj.2785
   Dyer JH, 1998, ACAD MANAGE REV, V23, P660, DOI 10.2307/259056
   Felzensztein C, 2018, IND MARKET MANAG, V69, P116, DOI 10.1016/j.indmarman.2018.01.013
   Felzensztein C, 2014, J BUS RES, V67, P837, DOI 10.1016/j.jbusres.2013.07.002
   Felzensztein C, 2013, J BUS IND MARK, V28, P357, DOI 10.1108/08858621311313947
   Fortune, 2020, FORTUNE
   Gao HB, 2015, J MARKETING, V79, P80, DOI 10.1509/jm.14.0273
   Gnyawali DR, 2018, J MANAGE, V44, P2511, DOI 10.1177/0149206318788945
   Gnyawali DR, 2016, IND MARKET MANAG, V53, P7, DOI 10.1016/j.indmarman.2015.11.014
   Gnyawali DR, 2011, RES POLICY, V40, P650, DOI 10.1016/j.respol.2011.01.009
   Grewal R, 2001, J MARKETING, V65, P67, DOI 10.1509/jmkg.65.2.67.18259
   Hannah DP, 2018, STRATEGIC MANAGE J, V39, P3163, DOI 10.1002/smj.2750
   Hoffmann W, 2018, STRATEGIC MANAGE J, V39, P3033, DOI 10.1002/smj.2965
   Independent, 2020, INDEPENDENT
   Kennedy CR, 2004, J PUBLIC POLICY MARK, V23, P128, DOI 10.1509/jppm.23.2.128.51404
   KOTLER P, 1974, J MARKETING, V38, P20, DOI 10.2307/1249846
   Kozlenkova IV, 2014, J ACAD MARKET SCI, V42, P1, DOI 10.1007/s11747-013-0336-7
   Lacoste S, 2012, IND MARKET MANAG, V41, P649, DOI 10.1016/j.indmarman.2011.09.013
   Lascaux A, 2020, IND MARKET MANAG, V84, P2, DOI 10.1016/j.indmarman.2019.05.015
   Lavie D, 2006, ACAD MANAGE REV, V31, P638, DOI 10.5465/AMR.2006.21318922
   Lee N, 2013, J BUS RES, V66, P242, DOI 10.1016/j.jbusres.2012.08.004
   Luo XM, 2006, J MARKETING, V70, P67, DOI 10.1509/jmkg.70.2.67
   Luo XM, 2007, J MARKETING RES, V44, P73, DOI 10.1509/jmkr.44.1.73
   Luo YD, 2007, J WORLD BUS, V42, P129, DOI 10.1016/j.jwb.2006.08.007
   Mattsson LG, 2015, MARKETING THEOR, V15, P347, DOI 10.1177/1470593114564903
   McGrath H, 2019, J BUS IND MARK, V34, P1555, DOI 10.1108/JBIM-10-2018-0287
   Medrano N, 2016, J BUS IND MARK, V31, P404, DOI 10.1108/JBIM-02-2013-0048
   Milne GR, 1996, J PUBLIC POLICY MARK, V15, P203, DOI 10.1177/074391569601500203
   Mu JF, 2018, IND MARKET MANAG, V75, P37, DOI 10.1016/j.indmarman.2018.03.010
   Naidoo V, 2010, IND MARKET MANAG, V39, P1311, DOI 10.1016/j.indmarman.2010.02.005
   Nason RS, 2018, J MANAGE, V44, P32, DOI 10.1177/0149206315610635
   Neuwirth RJ, 2015, J LEGAL MED, V36, P330, DOI 10.1080/01947648.2016.1161570
   O'Shaughnessy N., 1996, EUR J MARKETING, V30, P54, DOI [10.1108/03090569610149791, DOI 10.1108/03090569610149791]
   Pangarkar N, 2007, BRIT J MANAGE, V18, P209, DOI 10.1111/j.1467-8551.2006.00490.x
   Park BJ, 2014, IND MARKET MANAG, V43, P210, DOI 10.1016/j.indmarman.2013.11.003
   Pattinson S, 2018, IND MARKET MANAG, V68, P25, DOI 10.1016/j.indmarman.2017.09.005
   Pedersen C. L., 2020, HARVARD BUSINESS REV
   Priem RL, 2001, ACAD MANAGE REV, V26, P57, DOI 10.2307/259394
   Raza-Ullah T, 2014, IND MARKET MANAG, V43, P189, DOI 10.1016/j.indmarman.2013.11.001
   Rindfleisch A, 2003, J MARKETING RES, V40, P421, DOI 10.1509/jmkr.40.4.421.19388
   Ritala P, 2014, IND MARKET MANAG, V43, P236, DOI 10.1016/j.indmarman.2013.11.005
   Ritala P, 2012, BRIT J MANAGE, V23, P307, DOI 10.1111/j.1467-8551.2011.00741.x
   Ritter T, 2002, J BUS IND MARK, V17, P119, DOI 10.1108/08858620210419763
   Ritter T, 2004, IND MARKET MANAG, V33, P175, DOI 10.1016/j.indmarman.2003.10.016
   Ritter T., 2020, HARVARD BUSINESS REV
   Rusko R, 2011, IND MARKET MANAG, V40, P311, DOI 10.1016/j.indmarman.2010.10.002
   Schiavone F, 2019, J BUS IND MARK, V34, P1606, DOI 10.1108/JBIM-08-2018-0232
   Security, 2020, SECURITY
   Shu CL, 2017, J INT MARKETING, V25, P42, DOI 10.1509/jim.16.0075
   Tidstrom A, 2014, IND MARKET MANAG, V43, P261, DOI 10.1016/j.indmarman.2013.12.001
   United Kingdom Government, 2020, STAYING HOM AW OTH S
   Velu C, 2016, IND MARKET MANAG, V53, P124, DOI 10.1016/j.indmarman.2015.11.007
   Williams C, 2012, J INT MARKETING, V20, P65, DOI 10.1509/jim.12.0078
   WXIN-TV Indianapolis, 2020, MSN
   Wyllie J., 2020, CORONAVIRUS NE CHARI
NR 87
TC 6
Z9 6
U1 23
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0019-8501
EI 1873-2062
J9 IND MARKET MANAG
JI Ind. Mark. Manage.
PD JUL
PY 2020
VL 88
BP 206
EP 213
DI 10.1016/j.indmarman.2020.05.016
PG 8
WC Business; Management
SC Business & Economics
GA MQ2ZP
UT WOS:000552766500020
DA 2021-01-01
ER

PT J
AU Pinato, DJ
   Lee, AJX
   Biello, F
   Segui, E
   Aguilar-Company, J
   Carbo, A
   Bruna, R
   Bower, M
   Rizzo, G
   Benafif, S
   Carmona, C
   Chopra, N
   Cruz, CA
   D'Avanzo, F
   Evans, JS
   Galazi, M
   Garcia-Fructuoso, I
   Dalla Pria, A
   Newsom-Davis, T
   Ottaviani, D
   Patriarca, A
   Reyes, R
   Sharkey, R
   Sng, CCT
   Wong, YNS
   Ferrante, D
   Scotti, L
   Avanzi, GC
   Bellan, M
   Castello, LM
   Marco-Hernandez, J
   Molla, M
   Pirisi, M
   Ruiz-Camps, I
   Sainaghi, PP
   Gaidano, G
   Brunet, J
   Tabernero, J
   Prat, A
   Gennari, A
AF Pinato, David J.
   Lee, Alvin J. X.
   Biello, Federica
   Segui, Elia
   Aguilar-Company, Juan
   Carbo, Anna
   Bruna, Riccardo
   Bower, Mark
   Rizzo, Gianpiero
   Benafif, Sarah
   Carmona, Carme
   Chopra, Neha
   Cruz, Claudia Andrea
   D'Avanzo, Francesca
   Evans, Joanne S.
   Galazi, Myria
   Garcia-Fructuoso, Isabel
   Dalla Pria, Alessia
   Newsom-Davis, Thomas
   Ottaviani, Diego
   Patriarca, Andrea
   Reyes, Roxana
   Sharkey, Rachel
   Sng, Christopher C. T.
   Wong, Yien Ning Sophia
   Ferrante, Daniela
   Scotti, Lorenza
   Avanzi, Gian Carlo
   Bellan, Mattia
   Castello, Luigi Mario
   Marco-Hernandez, Javier
   Molla, Meritxell
   Pirisi, Mario
   Ruiz-Camps, Isabel
   Sainaghi, Pier Paolo
   Gaidano, Gianluca
   Brunet, Joan
   Tabernero, Josep
   Prat, Aleix
   Gennari, Alessandra
TI Presenting Features and Early Mortality from SARS-CoV-2 Infection in
   Cancer Patients during the Initial Stage of the COVID-19 Pandemic in
   Europe
SO CANCERS
LA English
DT Article
DE COVID-19; coronavirus; SARS-CoV-2; cancer; survival; outcomes; mortality
AB We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged >18 (mean = 69) and diagnosed with COVID-19 between 26 February and 1 April 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had >1 co-morbidity. A total of 141 (69%) patients had >1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged >65 (36% vs. 16%), in those with >2 co-morbidities (40% vs. 18%) and developing >1 complication from COVID-19 (38% vs. 4%,p= 0.004). Multi-variable analyses confirmed age > 65 and >2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.
C1 [Pinato, David J.; Evans, Joanne S.] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London W12 0HS, England.
   [Lee, Alvin J. X.; Benafif, Sarah; Chopra, Neha; Galazi, Myria; Ottaviani, Diego; Sng, Christopher C. T.; Wong, Yien Ning Sophia] Univ Coll London Hosp, Dept Oncol, London NW1 2PG, England.
   [Biello, Federica; D'Avanzo, Francesca; Gennari, Alessandra] Univ Piemonte Orientale, Dept Translat Med, Div Oncol, I-28100 Novara, Italy.
   [Biello, Federica; Bruna, Riccardo; D'Avanzo, Francesca; Patriarca, Andrea; Sharkey, Rachel; Scotti, Lorenza; Avanzi, Gian Carlo; Bellan, Mattia; Castello, Luigi Mario; Pirisi, Mario; Sainaghi, Pier Paolo; Gennari, Alessandra] Maggiore Carita Hosp, I-28100 Novara, Italy.
   [Segui, Elia; Cruz, Claudia Andrea; Reyes, Roxana; Prat, Aleix] Hosp Clin Barcelona, Dept Med Oncol, Barcelona 08036, Spain.
   [Aguilar-Company, Juan; Tabernero, Josep] Vall dHebron Univ Hosp & Inst Oncol VHIO, Dept Med Oncol, Barcelona 08035, Spain.
   [Aguilar-Company, Juan; Ruiz-Camps, Isabel] Vall dHebron Univ Hosp, Dept Infect Dis, Barcelona 08035, Spain.
   [Carbo, Anna; Carmona, Carme; Garcia-Fructuoso, Isabel; Brunet, Joan] Univ Hosp Josep Trueta, Catalan Inst Oncol, Dept Med Oncol, Girona 17007, Spain.
   [Bruna, Riccardo; Patriarca, Andrea; Sharkey, Rachel; Gaidano, Gianluca] Univ Piemonte Orientale, Dept Translat Med, Div Haematol, I-28100 Novara, Italy.
   [Bower, Mark; Dalla Pria, Alessia; Newsom-Davis, Thomas] Chelsea & Westminster Hosp, Dept Oncol, London SW109NH, England.
   [Bower, Mark; Dalla Pria, Alessia; Newsom-Davis, Thomas] Chelsea & Westminster Hosp, Natl Ctr HIV Malignancy, London SW109NH, England.
   [Rizzo, Gianpiero] Fdn IRCCS Policlin San Matteo, Dept Med Oncol Unit, I-27100 Pavia, Italy.
   [Ferrante, Daniela] Univ Piemonte Orientale, CPO Piemonte, Unit Canc Epidemiol, Dept Translat Med, I-28100 Novara, Italy.
   [Scotti, Lorenza] Univ Piemonte Orientale, Dept Translat Med, I-28100 Novara, Italy.
   [Avanzi, Gian Carlo; Bellan, Mattia; Castello, Luigi Mario; Pirisi, Mario; Sainaghi, Pier Paolo] Univ Piemonte Orientale, Dept Translat Med, Div Internal, I-28100 Novara, Italy.
   [Avanzi, Gian Carlo; Bellan, Mattia; Castello, Luigi Mario; Pirisi, Mario; Sainaghi, Pier Paolo] Univ Piemonte Orientale, Dept Translat Med, Div Emergency Med, I-28100 Novara, Italy.
   [Marco-Hernandez, Javier] Hosp Clin Barcelona, Dept Internal Med, Barcelona 08035, Spain.
   [Molla, Meritxell] Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona 08035, Spain.
   [Prat, Aleix] IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona 08035, Spain.
RP Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London W12 0HS, England.
EM david.pinato@imperial.ac.uk; a.j.lee@ucl.ac.uk;
   federica.biello@maggioreosp.novara.it; SEGUI@clinic.cat;
   jaguilar@vhio.net; acarbo@iconcologia.net;
   riccardo.bruna@maggioreosp.novara.it; m.bower@imperial.ac.uk;
   g.rizzo@smatteo.pv.it; sarah.benafif@nhs.net; ccarmona@iconcologia.net;
   neha.chopra@nhs.net; CACRUZ@clinic.cat;
   francesca.davanzo@maggioreosp.novara.it; joanne.evans@imperial.ac.uk;
   myria.galazi@nhs.net; igarciaf.girona.ics@gencat.cat;
   a.dalla-pria17@imperial.ac.uk; tom.newsom-davis@chelwest.nhs.uk;
   d.ottaviani@ucl.ac.uk; andrea.patriarca@maggioreosp.novara.it;
   RMREYES@clinic.cat; rachel.sharkey@chelwest.nhs.uk;
   christopher.sng@nhs.net; Sophia.wong@nhs.net;
   daniela.ferrante@uniupo.it; lorenza.scotti@uniupo.it;
   giancarlo.avanzi@uniupo.it; mattia.bellan@med.uniupo.it;
   luigi.castello@med.uniupo.it; JMARCO@clinic.cat; MOLLA@clinic.cat;
   mario.pirisi@med.uniupo.it; iruiz@vhebron.net;
   pierpaolo.sainaghi@med.uniupo.it; gianluca.gaidano@med.uniupo.it;
   jbrunet@iconcologia.net; jtabernero@vhio.net; alprat@clinic.cat;
   alessandra.gennari@med.uniupo
RI Aguilar-Company, Juan/U-1890-2019; Pinato, David James/ABB-3719-2020;
   Lee, Alvin Jun Xing/A-1047-2017; Pirisi, Mario/ABF-2102-2020; Bellan,
   Mattia/AAL-5472-2020; Prat, Aleix/P-8561-2014; Sainaghi, Pier
   Paolo/J-1132-2016; Brunet, Joan/C-5292-2018
OI Aguilar-Company, Juan/0000-0002-9838-1950; Lee, Alvin Jun
   Xing/0000-0002-7427-9142; GAIDANO, Gianluca/0000-0002-4681-0151; Molla,
   Meritxell/0000-0001-6215-2251; Prat, Aleix/0000-0003-2377-540X;
   Sainaghi, Pier Paolo/0000-0001-8322-9158; Brunet,
   Joan/0000-0003-1945-3512; Patriarca, Andrea/0000-0003-4415-2906; Ruiz-
   Camps, Isabel/0000-0003-3743-2379; CASTELLO, Luigi
   Mario/0000-0001-8248-1976; Marco-Hernandez, Javier/0000-0001-8486-5404
FU Wellcome Trust Strategic Fund [PS3416]; Cancer Treatment and Research
   Trust (CTRT); AIRC 5 x 1000, Associazione Italiana per la Ricerca sul
   Cancro Foundation, Milan, ItalyAssociazione Italiana per la Ricerca sul
   Cancro (AIRC) [21198]; AIRC IG, Associazione Italiana per la Ricerca sul
   Cancro Foundation, Milan, ItalyAssociazione Italiana per la Ricerca sul
   Cancro (AIRC) [14230]; UPO Aging Project
FX D.J.P. is supported by grant funding from theWellcome Trust Strategic
   Fund (PS3416) and acknowledges grant support by the Cancer Treatment and
   Research Trust (CTRT) as well as infrastructural support by the Cancer
   Research UK Imperial Centre. GG is supported by the AIRC 5 x 1000 Grant,
   No. 21198, Associazione Italiana per la Ricerca sul Cancro Foundation,
   Milan, Italy. A.G. is supported by the AIRC IG grant, No. 14230,
   Associazione Italiana per la Ricerca sul Cancro Foundation, Milan,
   Italy. A.G., G.G., G.C.A., L.M.C., M.B. (Mattia Bellan), P.P.S., M.P.
   from the University of Piemonte Orientale acknowledge support from the
   UPO Aging Project.
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   NICE, COVID 19 RAP GUID DE
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Sehatzadeh S, 2014, Ont Health Technol Assess Ser, V14, P1
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   WHO, 2020, CLIN MAN SEV AC RESP
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   World Health Organization, NOV COR COVID 19 SIT
   Wu C, 2020, JAMA INTERN MED, V13, DOI [10.1001/jamainternmed.2020.099432167524, DOI 10.1001/JAMAINTERNMED.2020.099432167524]
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 29
TC 5
Z9 5
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2020
VL 12
IS 7
AR 1841
DI 10.3390/cancers12071841
PG 14
WC Oncology
SC Oncology
GA MT3RF
UT WOS:000554884800001
PM 32650523
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khajanchi, S
   Sarkar, K
AF Khajanchi, Subhas
   Sarkar, Kankan
TI Forecasting the daily and cumulative number of cases for the COVID-19
   pandemic in India
SO CHAOS
LA English
DT Article
ID TUBERCULOSIS; MODELS
AB The ongoing novel coronavirus epidemic was announced a pandemic by the World Health Organization on March 11, 2020, and the Government of India declared a nationwide lockdown on March 25, 2020 to prevent community transmission of the coronavirus disease (COVID)-19. Due to the absence of specific antivirals or vaccine, mathematical modeling plays an important role in better understanding the disease dynamics and in designing strategies to control the rapidly spreading infectious disease. In our study, we developed a new compartmental model that explains the transmission dynamics of COVID-19. We calibrated our proposed model with daily COVID-19 data for four Indian states, namely, Jharkhand, Gujarat, Andhra Pradesh, and Chandigarh. We study the qualitative properties of the model, including feasible equilibria and their stability with respect to the basic reproduction number
   R 0. The disease-free equilibrium becomes stable and the endemic equilibrium becomes unstable when the recovery rate of infected individuals increases, but if the disease transmission rate remains higher, then the endemic equilibrium always remains stable. For the estimated model parameters,
   R 0 > 1 for all four states, which suggests the significant outbreak of COVID-19. Short-time prediction shows the increasing trend of daily and cumulative cases of COVID-19 for the four states of India.
C1 [Khajanchi, Subhas] Presidency Univ, Dept Math, 86-1 Coll St, Kolkata 700073, India.
   [Sarkar, Kankan] Malda Coll, Dept Math, Malda 732101, W Bengal, India.
RP Sarkar, K (corresponding author), Malda Coll, Dept Math, Malda 732101, W Bengal, India.
EM subhas.maths@presiuniv.ac.in; kankan.math@gmail.com
OI Khajanchi, Subhas/0000-0002-6533-1121; Sarkar,
   Kankan/0000-0002-2777-9611
FU Science and Engineering Research Board (SERB) [ECR/2017/000234];
   Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India)
FX This study was supported by the Science and Engineering Research Board
   (SERB) (File No. ECR/2017/000234), Department of Science and Technology,
   Government of India. The authors are thankful to the anonymous reviewers
   for their careful reading and constructive suggestions/comments, which
   helped in better exposition of the article. The authors declare that
   they have no conflict of interest.
CR Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   ANDERSON R M, 1991
   [Anonymous], BBC NEWS
   [Anonymous], 2020, OBSTET GYNECOL, V135, pe1, DOI DOI 10.1016/J.CHAOS.2020.109846
   [Anonymous], INDIA TODAY
   Banerjee S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123611
   Castillo-Chavez C, 2004, MATH BIOSCI ENG, V1, P361, DOI 10.3934/mbe.2004.1.361
   Chakraborty T, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109850
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Dehning J, 2020, SCIENCE, V369, P160, DOI 10.1126/science.abb9789
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Diekmann O., 2000, MATH EPIDEMIOLOGY IN
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7
   Gumel AB, 2004, P ROY SOC B-BIOL SCI, V271, P2223, DOI 10.1098/rspb.2004.2800
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang XL, 2020, J INFECT DIS, V221, P1948, DOI 10.1093/infdis/jiaa206
   Keeling M. J., 2008, MODELING INFECT DIS
   Khajanchi S., 2020, ARXIV200506286
   Khajanchi S, 2018, PHYSICA A, V497, P52, DOI 10.1016/j.physa.2018.01.014
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Liu ZH, 2020, MATH BIOSCI ENG, V17, P3040, DOI 10.3934/mbe.2020172
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mena R. H., 2020, ARXIV200502294
   Pulla P., 2020, BMJ-BRIT MED J, V368, P1
   Sarkar K., 2020, ARXIV200507071
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Wong G. N., 2020, ARXIV200602036
   World Health Organization, 2020, 129 WHO, P129
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 37
TC 6
Z9 6
U1 6
U2 6
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1054-1500
EI 1089-7682
J9 CHAOS
JI Chaos
PD JUL
PY 2020
VL 30
IS 7
AR 071101
DI 10.1063/5.0016240
PG 16
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA MO9YS
UT WOS:000551872100001
PM 32752627
OA Green Published
DA 2021-01-01
ER

PT J
AU Baay, M
   Lina, B
   Fontanet, A
   Marchant, A
   Saville, M
   Sabot, P
   Duclos, P
   Vandeputte, J
   Neels, P
AF Baay, Marc
   Lina, Bruno
   Fontanet, Arnaud
   Marchant, Arnaud
   Saville, Melanie
   Sabot, Philippe
   Duclos, Philippe
   Vandeputte, Joris
   Neels, Pieter
TI SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
SO BIOLOGICALS
LA English
DT Article
DE SARS-CoV-2; Virology; Epidemiology; Immunology; Vaccine development
ID WAVE
AB This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2.
C1 [Baay, Marc] P95 Epidemiol & Pharmacovigilance, Leuven, Belgium.
   [Lina, Bruno] Univ Claude Bernard Lyon, VirPath Res Lab, Lyon, France.
   [Fontanet, Arnaud] Inst Pasteur, Dept Global Hlth, Emerging Dis Epidemiol Unit, Paris, France.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Brussels, Belgium.
   [Saville, Melanie] CEPI Vaccines, Vaccine R&D, London, England.
   [Sabot, Philippe; Vandeputte, Joris; Neels, Pieter] Int Alliance Biol Standardizat IABS, Geneva, Switzerland.
   [Duclos, Philippe] Univ Geneva, ADVAC, Geneva, Switzerland.
RP Neels, P (corresponding author), Int Alliance Biol Standardizat IABS, Geneva, Switzerland.
EM marc.baay@p-95.com; bruno.lina@univ-lyon1.fr;
   arnaud.fontanet@pasteur.fr; arnaud.marchant@ulb.be;
   melanie.saville@cepi.net; philippe.sabot@iabs.org;
   Philippe.Duclos@unige.ch; joris.vandeputte@iabs.org;
   Pieter.neels@vaccine-advice.be
OI lina, bruno/0000-0002-8959-2123
FU Wellcome TrustWellcome Trust
FX The authors are grateful for the support by a grant of Wellcome Trust to
   organize the webinar; and would like to thank Madinina Cox and Abigail
   Charlet (International Alliance for Biological Standardization) for
   logistic management.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Andreasen V, 2008, J INFECT DIS, V197, P270, DOI 10.1086/524065
   Baay MFD, 2019, BIOLOGICALS, V61, P85, DOI 10.1016/j.biologicals.2018.02.002
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Dorigatti I, 2013, P NATL ACAD SCI USA, V110, P13422, DOI 10.1073/pnas.1303117110
   Etievant S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061871
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Merad M, 2020, NAT REV IMMUNOL, P1
   Miller A, 2020, CORRELATION UNIVERSA
   Monto AS, 2020, J INFECT DIS, V222, P9, DOI 10.1093/infdis/jiaa161
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029
   Vabret N, 2020, IMMUNITY
   Viboud C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102429
   WHO, MIDDL E RESP SYNDR C
   WHO Working Group for Guidance on Human Challenge Studies in COVID-19, KEY CRIT ETH ACC COV
   World Health Organization, EP CURV SEV AC RESP
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 3
Z9 3
U1 3
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
EI 1095-8320
J9 BIOLOGICALS
JI Biologicals
PD JUL
PY 2020
VL 66
BP 35
EP 40
DI 10.1016/j.biologicals.2020.06.005
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA MO6KF
UT WOS:000551631600006
PM 32600951
OA Green Published
DA 2021-01-01
ER

PT J
AU Ciorba, A
   Corazzi, V
   Skarzynski, PH
   Skarzynska, MB
   Bianchini, C
   Pelucchi, S
   Hatzopoulos, S
AF Ciorba, Andrea
   Corazzi, Virginia
   Skarzynski, Piotr Henryk
   Skarzynska, Magdalena B.
   Bianchini, Chiara
   Pelucchi, Stefano
   Hatzopoulos, Stavros
TI Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Letter
DE chloroquine; favipiravir; hydroxychloroquine; lopinavir; ototoxicity;
   remdesivir; SARS-CoV-2 (Covid-19) pandemic
ID HEARING-LOSS
AB Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.
C1 [Ciorba, Andrea; Corazzi, Virginia; Bianchini, Chiara; Pelucchi, Stefano; Hatzopoulos, Stavros] Univ Hosp Ferrara, ENT & Audiol Dept, Via A Moro 8, I-44124 Ferrara, Italy.
   [Skarzynski, Piotr Henryk; Skarzynska, Magdalena B.] Inst Physiol & Pathol Hearing, Warsaw, Poland.
   [Skarzynski, Piotr Henryk] Med Univ Warsaw, Dept Heart Failure & Cardiac Rehabil, Warsaw, Poland.
   [Skarzynski, Piotr Henryk; Skarzynska, Magdalena B.] Inst Sensory Organs, Kajetany, Poland.
RP Ciorba, A (corresponding author), Univ Hosp Ferrara, ENT & Audiol Dept, Via A Moro 8, I-44124 Ferrara, Italy.
EM andrea.ciorba@unife.it
RI Corazzi, Virginia/ABC-4469-2020; Skarzynski, Piotr H./A-9642-2012
OI Corazzi, Virginia/0000-0002-3189-6247; Skarzynski, Piotr
   H./0000-0002-4978-1915; Skarzynska, Magdalena/0000-0003-3340-1698
CR Aimoni C, 2010, AUDIOL NEURO-OTOL, V15, P111, DOI 10.1159/000231636
   Bortoli R, 2007, CLIN RHEUMATOL, V26, P1809, DOI 10.1007/s10067-007-0662-6
   Cianfrone G, 2011, EUR REV MED PHARMACO, V15, P601
   Cohen BE, 2014, TRENDS HEAR, V18, DOI 10.1177/2331216514541361
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1
   Elfiky AA, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117715
   Formann E, 2004, AM J GASTROENTEROL, V99, P873, DOI 10.1111/j.1572-0241.2004.30372.x
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Mustafa MWM, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102483
   Pearson SE, 2019, INT J AUDIOL, V58, P685, DOI 10.1080/14992027.2019.1660918
   Sriwijitalai W, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102473
   Thein P, 2014, HEARING RES, V310, P27, DOI 10.1016/j.heares.2014.01.005
   Williams B, 2001, CLIN INFECT DIS, V33, P2100, DOI 10.1086/324361
NR 14
TC 2
Z9 2
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394-6320
EI 2058-7384
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD JUL
PY 2020
VL 34
AR 2058738420941754
DI 10.1177/2058738420941754
PG 3
WC Immunology; Pathology; Pharmacology & Pharmacy
SC Immunology; Pathology; Pharmacology & Pharmacy
GA MQ1EC
UT WOS:000552638700001
PM 32649262
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Valero-Lopez, G
   Carreon-Guarnizo, E
   Hernandez-Clares, R
   Iniesta-Martinez, F
   Jimenez-Veiga, J
   Moreno-Docon, A
   Iborra-Bendicho, MA
   Aznar-Robles, E
   Hellin-Gil, MF
   Morales-Ortiz, A
   Meca-Lallana, JE
AF Valero-Lopez, G.
   Carreon-Guarnizo, E.
   Hernandez-Clares, R.
   Iniesta-Martinez, F.
   Jimenez-Veiga, J.
   Moreno-Docon, A.
   Iborra-Bendicho, M. A.
   Aznar-Robles, E.
   Hellin-Gil, M. F.
   Morales-Ortiz, A.
   Meca-Lallana, J. E.
TI Pulse immunosuppressive therapy for multiple sclerosis during the
   SARS-CoV-2 lockdown de-escalation plan: Safety algorithm
SO NEUROLOGIA
LA Spanish
DT Article
DE SARS-CoV-2; Multiple sclerosis; COVID-19; Immunosuppressants; PCR
AB Introduction: The COVID-19 pandemic is changing approaches to diagnosis, treatment, and care provision in multiple sclerosis (MS). During both the initial and peak phases of the epidemic, the administration of disease-modifying drugs, typically immunosuppressants administered in pulses, was suspended due to the uncertainty about their impact on SARS-CoV-2 infection, mainly in contagious asymptomatic/presymptomatic patients. The purpose of this study is to present a safety algorithm enabling patients to resume pulse immunosuppressive therapy (PIT) during the easing of lockdown measures.
   Methods: We developed a safety algorithm based on our clinical experience with MS and the available published evidence; the algorithm assists in the detection of contagious asymptomatic/presymptomatic cases and of patients with mild symptoms of SARS-CoV-2 infection with a view to withdrawing PIT in these patients and preventing new infections at day hospitals.
   Results: We developed a clinical/microbiological screening algorithm consisting of a symptom checklist, applied during a teleconsultation 48 hours before the scheduled session of PIT, and PCR testing for SARS-CoV-2 in nasopharyngeal exudate 24 hours before the procedure.
   Conclusion: The application of our safety algorithm presents a favourable risk-benefit ratio despite the fact that the actual proportion of asymptomatic and presymptomatic individuals is unknown. Systematic PCR testing, which provides the highest sensitivity for detecting presymptomatic cases, combined with early detection of symptoms of SARS-CoV-2 infection may reduce infections and improve detection of high-risk patients before they receive PIT. (C) 2020 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U.
C1 [Valero-Lopez, G.; Carreon-Guarnizo, E.; Hernandez-Clares, R.; Jimenez-Veiga, J.; Aznar-Robles, E.; Hellin-Gil, M. F.; Morales-Ortiz, A.; Meca-Lallana, J. E.] Hosp Clin Univ Virgen Arrixaca, Serv Neurol, IMIB Arrixaca, Murcia, Spain.
   [Valero-Lopez, G.; Carreon-Guarnizo, E.; Hernandez-Clares, R.; Iniesta-Martinez, F.; Jimenez-Veiga, J.; Aznar-Robles, E.; Hellin-Gil, M. F.; Meca-Lallana, J. E.] Hosp Clin Univ Virgen Arrixaca, Serv Neurol, IMIB Arrixaca, CSUR Esclerosis Multiple & Unidad Neuroinmunol Cl, Murcia, Spain.
   [Carreon-Guarnizo, E.; Hernandez-Clares, R.; Iniesta-Martinez, F.; Jimenez-Veiga, J.; Meca-Lallana, J. E.] Univ Catolica San Antonio, UCAM, Catedra Neuroinmunol Clin & Esclerosis Multiple, Murcia, Spain.
   [Moreno-Docon, A.; Iborra-Bendicho, M. A.] Hosp Clin Univ Virgen Arrixaca, Serv Microbiol, IMIB Arrixaca, Unidad Virol, Murcia, Spain.
RP Meca-Lallana, JE (corresponding author), Hosp Clin Univ Virgen Arrixaca, Serv Neurol, IMIB Arrixaca, Murcia, Spain.; Meca-Lallana, JE (corresponding author), Hosp Clin Univ Virgen Arrixaca, Serv Neurol, IMIB Arrixaca, CSUR Esclerosis Multiple & Unidad Neuroinmunol Cl, Murcia, Spain.; Meca-Lallana, JE (corresponding author), Univ Catolica San Antonio, UCAM, Catedra Neuroinmunol Clin & Esclerosis Multiple, Murcia, Spain.
EM pmecal@gmail.com
CR [Anonymous], 2020, RECOMENDACIONES TRAT
   [Anonymous], GUIA UT TEST RAP ANT
   Barry B, 2019, NEUROL THER, V8, P241, DOI 10.1007/s40120-019-00160-9
   Bonavita S, 2020, NEUROL SCI, V41, P1007, DOI 10.1007/s10072-020-04391-9
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Callaway E, 2020, NATURE, V577, P458, DOI 10.1038/d41586-020-00117-1
   Centro de coordination de alertas y emergencias sanitarias, ENF COR COVID 19 AP
   Costa-Frossard I, 2020, REV NEUROL, V70, P329, DOI [10.33588/rn.7009.2020155, DOI 10.33588/RN.7009.2020155]
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   EMA, 2020, GUID MAN CLIN TRIALS
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Grupo de investigacion espanol en cancer de mama (GEICAM), DOC GEIC MAN PAC CON
   Gueguen A, 2014, J NEUROL NEUROSUR PS, V85, P1038, DOI 10.1136/jnnp-2014-307591
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Kim SH, 2011, ARCH NEUROL-CHICAGO, V68, P1412, DOI 10.1001/archneurol.2011.154
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Song JY, 2020, NEW ENGL J MED, V382, P1858, DOI 10.1056/NEJMc2001801
   Sorensen PS, 2014, J NEUROL, V261, P1170, DOI 10.1007/s00415-014-7325-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WOLFEL R, 2020, NATURE, DOI DOI 10.1038/541586-020-2196-X
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0213-4853
EI 1578-1968
J9 NEUROLOGIA
JI Neurologia
PD JUL-AUG
PY 2020
VL 35
IS 6
BP 357
EP 362
DI 10.1016/j.nrl.2020.06.001
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA MO4ME
UT WOS:000551501200001
PM 32591152
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU La Vignera, S
   Cannarella, R
   Condorelli, RA
   Torre, F
   Aversa, A
   Calogero, AE
AF La Vignera, Sandro
   Cannarella, Rossella
   Condorelli, Rosita A.
   Torre, Francesco
   Aversa, Antonio
   Calogero, Aldo E.
TI SARS-CoV-2: the endocrinological protective clinical model derived from
   patients with prostate cancer
SO THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
LA English
DT Letter
DE SARS-CoV2; COVID-19; prostate cancer; androgen deprivation therapy
C1 [La Vignera, Sandro; Cannarella, Rossella; Condorelli, Rosita A.; Torre, Francesco; Calogero, Aldo E.] Univ Catania, Dept Clin & Expt Med, Via S Sofia 78, I-95123 Catania, Italy.
   [Aversa, Antonio] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy.
RP La Vignera, S (corresponding author), Univ Catania, Dept Clin & Expt Med, Via S Sofia 78, I-95123 Catania, Italy.
EM sandrolavignera@unict.it
OI La Vignera, Sandro/0000-0002-7113-2372
CR Dalpiaz PLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127515
   La Vignera S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082948
   Lin CW, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820916430
   Ling MA, 2020, EFFECT SARS COV 2 IN
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Tajar A, 2012, J CLIN ENDOCR METAB, V97, P1508, DOI 10.1210/jc.2011-2513
NR 6
TC 2
Z9 2
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2042-0188
EI 2042-0196
J9 THER ADV ENDOCRINOL
JI Ther. Adv. Endocrinol. Metab.
PD JUL
PY 2020
VL 11
AR 2042018820942385
DI 10.1177/2042018820942385
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MQ0OD
UT WOS:000552595600001
PM 32699587
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lingappan, K
   Karmouty-Quintana, H
   Davies, J
   Akkanti, B
   Harting, MT
AF Lingappan, K.
   Karmouty-Quintana, H.
   Davies, J.
   Akkanti, B.
   Harting, M. T.
TI Understanding the age divide in COVID-19: why are children
   overwhelmingly spared?
SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
LA English
DT Article
DE age-based susceptibility; children; coronavirus; COVID-19; pediatric
   lung; SARS-CoV-2
ID KAPPA-B ACTIVATION; IMMUNE-RESPONSES; LIPOPOLYSACCHARIDE; INFLAMMATION;
   DISEASE; BARRIER
AB The rapid emergence and subsequent global dissemination of SARS-CoV-2 disease (COVID-19) has resulted in over 4 million cases worldwide. The disease has a marked predilection for adults, and children are relatively spared. Understanding the age-based differences in pathophysiological pathways and processes relevant to the onset and progression of disease both in the clinical course and in experimental disease models may bold the key to the identification of therapeutic targets. The differences in the clinical course are highlighted by the lack of progression of the SARS-CoV-2 infection beyond mild symptoms in a majority of children, whereas in adults the disease progresses to acute lung injury and an acute respiratory distress syndrome (ARDS)-like phenotype with high mortality. The pathophysiological mechanisms leading to decreased lung injury in children may involve the decreased expression of the mediators necessary for viral entry into the respiratory epithelium and differences in the immune system responses in children. Specifically, decreased expression of proteins, including angiotensin-converting enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in the airway epithelium in children may prevent viral entry. The immune system differences may include a relative preponderance of CD4(+) T cells, decreased neutrophil infiltration, decreased production of proinflammatory cytokines, and increased production of immunomodulatory cytokines in children compared with adults. Notably. the developing lung in children may have a greater capacity to recover and repair after viral infection. Understanding the relative contributions of the above processes to the protective phenotype in the developing lung can guide the trial of the appropriate therapies in adults.
C1 [Lingappan, K.; Davies, J.] Baylor Coll Med, Dept Pediat, Div Neonatol, Houston, TX 77030 USA.
   [Karmouty-Quintana, H.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Akkanti, B.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Pulm Crit Care Sleep Med, Houston, TX 77030 USA.
   [Harting, M. T.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat Surg, Houston, TX 77030 USA.
RP Lingappan, K (corresponding author), Baylor Coll Med, Dept Pediat, Div Neonatol, Houston, TX 77030 USA.
EM lingappa@bcm.edu
RI Karmouty-Quintana, Harry/ABC-9144-2020
OI Karmouty-Quintana, Harry/0000-0003-4753-9823
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL144775, R01HL146395]
FX This work was supported in part by National Heart, Lung, and Blood
   Institute Grants R01HL144775 and R01HL146395 to K.L.
CR Aghdam MK, 2020, INFECT DIS-NOR, V52, P427, DOI 10.1080/23744235.2020.1747634
   Alvira CM, 2007, AM J RESP CRIT CARE, V175, P805, DOI 10.1164/rccm.200608-1162OC
   [Anonymous], 2020, BIORXIV 2020 04 19 0, DOI [10. 1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254]
   Baas T, 2008, J VIROL, V82, P9465, DOI 10.1128/JVI.00489-08
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Dagdeviren S, 2017, FASEB J, V31, P701, DOI 10.1096/fj.201600832R
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   GBD 2015 LRI Collaborators, 2015, LANCET INFECT DIS, V2017, P1133, DOI DOI 10.1016/S1473-3099(17)30396-1
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Im D, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00028
   Kling KM, 2017, AM J PHYSIOL-LUNG C, V312, pL1, DOI 10.1152/ajplung.00347.2016
   Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014
   Lawrence SM, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00023
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Nagata N, 2008, AM J PATHOL, V172, P1625, DOI 10.2353/ajpath.2008.071060
   Paret Michal, 2020, Clin Infect Dis, V71, P2243, DOI 10.1093/cid/ciaa452
   Quasney MW, 2015, PEDIATR CRIT CARE ME, V16, pS118, DOI 10.1097/PCC.0000000000000438
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Prestes TRR, 2017, CURR DRUG TARGETS, V18, P1301, DOI 10.2174/1389450117666160727142401
   Schouten LR, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0529-4
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Smith LS, 2010, AM J RESP CELL MOL, V43, P475, DOI 10.1165/rcmb.2009-0039OC
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang A, 2020, BIORXIV 2020 04 12 3, DOI [10.1101/2020.04.12.037580, DOI 10.1101/2020.04.12.037580]
   WANG Y, 2020, J AUTOIMMUN, DOI DOI 10.1016/J.JAUT.2020.102463
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang G, 2004, J CLIN INVEST, V114, P669, DOI 10.1172/JCI200419300
   Ying LH, 2018, AM J PHYSIOL-LUNG C, V315, pL66, DOI 10.1152/ajplung.00363.2017
   Zhang XM, 2017, NAT REV IMMUNOL, V17, P495, DOI 10.1038/nri.2017.54
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
NR 44
TC 8
Z9 8
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1040-0605
EI 1522-1504
J9 AM J PHYSIOL-LUNG C
JI Am. J. Physiol.-Lung Cell. Mol. Physiol.
PD JUL
PY 2020
VL 319
IS 1
BP L39
EP L44
DI 10.1152/ajplung.00183.2020
PG 6
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA MP0WT
UT WOS:000551934600006
PM 32491949
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dragonetti, D
   Guarini, G
   Pizzuti, M
AF Dragonetti, Daniela
   Guarini, Giuseppe
   Pizzuti, Michele
TI Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on
   heparin therapy
SO BLOOD TRANSFUSION
LA English
DT Letter
C1 [Dragonetti, Daniela] San Carlo Reg Hosp, Dept Clin Lab, Potenza, Italy.
   [Guarini, Giuseppe] San Carlo Reg Hosp, COVID Intens Care, Potenza, Italy.
   [Pizzuti, Michele] San Carlo Reg Hosp, Dept Hematol, Potenza, Italy.
RP Pizzuti, M (corresponding author), San Carlo Reg Hosp, Dept Hematol, Potenza, Italy.
EM pizzuti.m@tiscali.it
CR Cattaneo M, 2020, THROMB HAEMOSTASIS, DOI [10.1055/s- 0040-171209, DOI 10.1055/S-0040-171209]
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SIMTIPRO SRL
PI MILAN
PA VIA DESIDERIO 21, MILAN, 20131, ITALY
SN 1723-2007
J9 BLOOD TRANSFUS-ITALY
JI Blood Transf.
PD JUL-AUG
PY 2020
VL 18
IS 4
BP 328
EP 328
DI 10.2450/2020.0164-20
PG 1
WC Hematology
SC Hematology
GA MO2ES
UT WOS:000551346600013
PM 32697931
DA 2021-01-01
ER

PT J
AU Okba, NMA
   Muller, MA
   Li, WT
   Wang, CY
   GeurtsvanKessel, CH
   Corman, VM
   Lamers, MM
   Sikkema, RS
   de Bruin, E
   Chandler, FD
   Yazdanpanah, Y
   Le Hingrat, Q
   Descamps, D
   Houhou-Fidouh, N
   Reusken, CBEM
   Bosch, BJ
   Drosten, C
   Koopmans, MPG
   Haagmans, BL
AF Okba, Nisreen M. A.
   Mueller, Marcel A.
   Li, Wentao
   Wang, Chunyan
   GeurtsvanKessel, Corine H.
   Corman, Victor M.
   Lamers, Mart M.
   Sikkema, Reina S.
   de Bruin, Erwin
   Chandler, Felicity D.
   Yazdanpanah, Yazdan
   Le Hingrat, Quentin
   Descamps, Diane
   Houhou-Fidouh, Nadhira
   Reusken, Chantal B. E. M.
   Bosch, Berend-Jan
   Drosten, Christian
   Koopmans, Marion P. G.
   Haagmans, Bart L.
TI Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody
   Responses in Coronavirus Disease Patients
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID MERS-COV; TRANSMISSION
AB A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.
C1 [Okba, Nisreen M. A.; GeurtsvanKessel, Corine H.; Lamers, Mart M.; Sikkema, Reina S.; de Bruin, Erwin; Chandler, Felicity D.; Reusken, Chantal B. E. M.; Koopmans, Marion P. G.; Haagmans, Bart L.] Erasmus MC, Rotterdam, Netherlands.
   [Mueller, Marcel A.; Corman, Victor M.; Drosten, Christian] Charite Univ Med Berlin, Berlin, Germany.
   [Mueller, Marcel A.; Corman, Victor M.; Drosten, Christian] German Ctr Infect Res, Berlin, Germany.
   [Li, Wentao; Wang, Chunyan; Bosch, Berend-Jan] Univ Utrecht, Utrecht, Netherlands.
   [Yazdanpanah, Yazdan; Le Hingrat, Quentin; Descamps, Diane] Univ Paris, Paris, France.
   [Yazdanpanah, Yazdan; Le Hingrat, Quentin; Descamps, Diane; Houhou-Fidouh, Nadhira] Hop Bichat Claude Bernard, Paris, France.
   [Reusken, Chantal B. E. M.] RIVM, Bilthoven, Netherlands.
RP Okba, NMA; Haagmans, BL (corresponding author), Erasmus MC, Dept Virosci, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM n.okba@erasmusmc.nl; b.haagmans@erasmusmc.nl
RI Li, Wentao/F-9712-2018; Corman, Victor Max/K-1319-2019; Okba, Nisreen
   MA/K-9984-2017; Mueller, Marcel/O-2425-2019
OI Li, Wentao/0000-0002-7114-762X; Corman, Victor Max/0000-0002-3605-0136;
   Okba, Nisreen MA/0000-0002-2394-1079; Mueller,
   Marcel/0000-0003-2242-5117; Haagmans, Bart/0000-0001-6221-2015
FU Zoonoses Anticipation and Preparedness Initiative (project Innovative
   Medicines Initiative grant) [115760]; Innovative Medicines Initiative;
   European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre; European Federation of Pharmaceutical Industries and
   Associations
FX This study was supported by the Zoonoses Anticipation and Preparedness
   Initiative (project Innovative Medicines Initiative grant no. 115760),
   the Innovative Medicines Initiative; the European Commission, and
   partners of the European Federation of Pharmaceutical Industries and
   Associations.
CR Alshukairi AN, 2016, EMERG INFECT DIS, V22, P1113, DOI 10.3201/eid2206.160010
   Choe PG, 2017, EMERG INFECT DIS, V23, P1079, DOI 10.3201/eid2307.170310
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020, NAT MICROBIOL
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   Harvey R, 2019, EMERG INFECT DIS, V25, P1878, DOI 10.3201/eid2510.190497
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rampling T, 2019, EMERG INFECT DIS, V25, P205, DOI 10.3201/eid2502.180798
   Rodon J, 2019, EMERG MICROBES INFEC, V8, P1593, DOI 10.1080/22221751.2019.1685912
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   World Health Organization, COR DIS COVID 2019 S
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 16
TC 265
Z9 263
U1 20
U2 20
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2020
VL 26
IS 7
BP 1478
EP 1488
DI 10.3201/eid2607.200841
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA MO0MP
UT WOS:000551231700015
PM 32267220
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Hsieh, CC
   Lin, CH
   Wang, WYC
   Pauleen, DJ
   Chen, JV
AF Hsieh, Chih-Chia
   Lin, Chih-Hao
   Wang, William Yu Chung
   Pauleen, David J.
   Chen, Jengchung Victor
TI The Outcome and Implications of Public Precautionary Measures in
   Taiwan-Declining Respiratory Disease Cases in the COVID-19 Pandemic
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; public precautionary measures; universal hygiene; mass making
ID INFLUENZA; MASK
AB With the rapid development of the COVID-19 pandemic, countries are trying to cope with increasing medical demands, and, at the same time, to reduce the increase of infected numbers by implementing a number of public health measures, namely non-pharmaceutical interventions (NPIs). These public health measures can include social distancing, frequent handwashing, and personal protective equipment (PPE) at the personal level; at the community and the government level, these measures can range from canceling activities, avoiding mass gatherings, closing facilities, and, at the extreme, enacting national or provincial lockdowns. Rather than completely stopping the infectious disease, the major purpose of these NPIs in facing an emerging infectious disease is to reduce the contact rate within the population, and reduce the spread of the virus until the time a vaccine or reliable medications become available. The idea is to avoid a surge of patients with severe symptoms beyond the capacity of the hospitals' medical resources, which would lead to more mortality and morbidity. While many countries have experienced steep curves in new cases, some, including Hong Kong, Vietnam, South Korea, New Zealand, and Taiwan, seem to have controlled or even eliminated the infection locally. From its first case of COVID-19 on the 21 January until the 12 May, Taiwan had 440 cases, including just 55 local infections, and seven deaths in total, representing 1.85 cases per 100,000 population and a 1.5% death rate (based on the Worldometer 2020 statistics of Taiwan's population of 23.8 million). This paper presents evidence that spread prevention involving mass masking and universal hygiene at the early stage of the COVID-19 pandemic resulted in a 50% decline of infectious respiratory diseases, based on historical data during the influenza season in Taiwan. These outcomes provide potential support for the effectiveness of widely implementing public health precaution measures in controlling COVID-19 without a lockdown policy.
C1 [Hsieh, Chih-Chia; Lin, Chih-Hao] Natl Cheng Kung Univ Hosp, Dept Emergency Med, Tainan 701401, Taiwan.
   [Wang, William Yu Chung] Univ Waikato, Waikato Management Sch, Hamilton 3210, New Zealand.
   [Pauleen, David J.] Massey Univ, Sch Management, Auckland 0745, New Zealand.
   [Chen, Jengchung Victor] Natl Cheng Kung Univ, Inst Int Management, Tainan 701401, Taiwan.
RP Wang, WYC (corresponding author), Univ Waikato, Waikato Management Sch, Hamilton 3210, New Zealand.
EM hsiehchihchia@gmail.com; emergency.lin@gmail.com;
   william.wang@waikato.ac.nz; D.Pauleen@massey.ac.nz;
   victor@mail.ncku.edu.tw
RI ; Chen, Jengchung Victor/T-9177-2018
OI Lin, Chih-Hao/0000-0002-0042-0131; Chen, Jengchung
   Victor/0000-0002-5247-3139
FU Taiwan Ministry of Science and Technology [MOST 109-2364-F-006-023]
FX This research was funded by Taiwan Ministry of Science and Technology,
   grant number MOST 109-2364-F-006-023 and 2020 Waikato University Study
   Leave Research Grant
CR Aiello AE, 2010, J INFECT DIS, V201, P491, DOI 10.1086/650396
   Bowen LE, 2010, APPL BIOSAFETY, V15, P67, DOI DOI 10.1177/153567601001500204
   Cai J, 2020, EMERG INFECT DIS, V26, P1343, DOI 10.3201/eid2606.200412
   CDC, 2007, INT PREP PLANN GUID
   Centers for Disease Control and Prevention, NTR
   Coroneo Minas Theodore, 2020, Ocul Surf, DOI 10.1016/j.jtos.2020.05.011
   Davies A, 2013, DISASTER MED PUBLIC, V7, P413, DOI 10.1017/dmp.2013.43
   Ferguson NM, 2020, REPORT 9 IMPACT NONP, DOI [10.25561/77482, DOI 10.25561/77482]
   Jiang FC, 2020, EMERG INFECT DIS, V26, P2162, DOI 10.3201/eid2609.201435
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Schwartz J, 2020, CLIN INFECT DIS, V71, P858, DOI [10.1093/cid/ciaa255, 10.1080/10409238.2020.1841726]
   Taiwan National Infectious Disease Statistics System, 2014, TAIW NAT INF DIS STA
   Torri E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103666
   van der Sande M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002618
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, BIW INFL SIT UPD W P
   World Health Organization, NTR
   World Health Organization, 1999, WHO REC SURV STAND
   Wu PC, 2020, OPHTHALMOLOGY, V127, P1462, DOI 10.1016/j.ophtha.2020.01.054
   Zhou SS, 2018, J THORAC DIS, V10, P2059, DOI 10.21037/jtd.2018.03.103
NR 22
TC 3
Z9 3
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 13
AR 4877
DI 10.3390/ijerph17134877
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MM7DM
UT WOS:000550313900001
PM 32640752
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mubarak, M
   Tolouian, R
   Kowalewska, J
   Nasri, H
AF Mubarak, Muhammed
   Tolouian, Ramin
   Kowalewska, Jolanta
   Nasri, Hamid
TI Comment: Newly Diagnosed Glomerulonephritis During COVID-19 Infection
   Undergoing Immunosuppression Therapy, a Case Report
SO IRANIAN JOURNAL OF KIDNEY DISEASES
LA English
DT Letter
C1 [Mubarak, Muhammed] SIUT, Dept Histopathol, Karachi, Pakistan.
   [Tolouian, Ramin] Univ Arizona, Div Nephrol, Tucson, AZ USA.
   [Kowalewska, Jolanta] Eastern Virginia Med Sch, Dept Pathol & Anat, Norfolk, VA 23501 USA.
   [Nasri, Hamid] Nickan Res Inst, Dept Nephropathol, Esfahan, Iran.
RP Nasri, H (corresponding author), Nickan Res Inst, Dept Nephropathol, Esfahan, Iran.
EM hamidnasri@yahoo.com
CR Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Kissling S, 2020, KIDNEY INT, V98, P228, DOI 10.1016/j.kint.2020.04.006
   Larsen CP, 2020, KIDNEY INT REP
   Moeinzadeh F, 2020, IRAN J KIDNEY DIS, V14, P239
   Mubarak M, 2020, J NEPHROPATHOL, V9, pe21, DOI [10.34172/jnp.2020.21, DOI 10.34172/JNP.2020.21]
   Mubarak M, 2020, IMMUNOPATHOL PERSA, V6, DOI 10.34172/ipp.2020.18
   Peleg Y, 2020, KIDNEY INT REP, V5, P940, DOI 10.1016/j.ekir.2020.04.017
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   TOLOUIAN R, 2020, J RENAL INJ PREV, V9, pe19, DOI DOI 10.34172/JRIP.2020.19
   Yalameha B, 2020, J NEPHROPHARMACOL, V9, pe22
NR 10
TC 0
Z9 0
U1 0
U2 0
PU IRANIAN SOC NEPHROLGY
PI TEHRAN
PA APT 12, NO 63, SHAHEED TOUSI ST, DR GHARIB ST, KESHAVARZ BLVD, TEHRAN,
   1419783311, IRAN
SN 1735-8582
EI 1735-8604
J9 IRAN J KIDNEY DIS
JI Iran. J. Kidney Dis.
PD JUL
PY 2020
VL 14
IS 4
BP 323
EP 325
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA MN6WK
UT WOS:000550983700013
PM 32655031
DA 2021-01-01
ER

PT J
AU Moradi, H
   Naeimi, A
   Moeinzadeh, F
AF Moradi, Hazhir
   Naeimi, Azar
   Moeinzadeh, Firouzeh
TI Response to Comment on; Newly Diagnosed Glomerulonephritis During
   COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report
SO IRANIAN JOURNAL OF KIDNEY DISEASES
LA English
DT Letter
C1 [Moradi, Hazhir] Isfahan Univ Med Sci, Med Sch, Esfahan, Iran.
   [Naeimi, Azar] Isfahan Univ Med Sci, Dept Pathol, Esfahan, Iran.
   [Moeinzadeh, Firouzeh] Isfahan Kidney Dis Res Ctr, Esfahan, Iran.
   [Moeinzadeh, Firouzeh] Isfahan Univ Med Sci, Dept Internal Med, Esfahan, Iran.
RP Moeinzadeh, F (corresponding author), Alzahra Hosp, Isfahan Kidney Dis Res Ctr, Internal Med Dept, Esfahan, Iran.
EM f_moinzade@med.mui.ac.ir
OI Naimi, Azar/0000-0002-7717-9112
CR Bajema IM, 2018, KIDNEY INT, V93, P789, DOI 10.1016/j.kint.2017.11.023
   Bariety J, 2005, KIDNEY INT, V68, P1109, DOI 10.1111/j.1523-1755.2005.00503.x
   Bomback AS, 2020, CLIN J AM SOC NEPHRO, V15, P876, DOI 10.2215/CJN.04530420
   Cossey LN, 2017, CLIN KIDNEY J, V10, P443, DOI 10.1093/ckj/sfx029
   Han MH, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9375753
   Kronbichler A, 2020, NAT REV NEPHROL, V16, P365, DOI 10.1038/s41581-020-0305-6
   Park MS, 2013, TUBERC RESPIR DIS, V74, P151, DOI 10.4046/trd.2013.74.4.151
   Pachon MDR, 2010, NEFROLOGIA, V30, P360, DOI 10.3265/Nefrologia.pre2010.Mar.10325
   Thorner PS, 2008, J AM SOC NEPHROL, V19, P495, DOI 10.1681/ASN.2006101115
NR 9
TC 0
Z9 0
U1 0
U2 0
PU IRANIAN SOC NEPHROLGY
PI TEHRAN
PA APT 12, NO 63, SHAHEED TOUSI ST, DR GHARIB ST, KESHAVARZ BLVD, TEHRAN,
   1419783311, IRAN
SN 1735-8582
EI 1735-8604
J9 IRAN J KIDNEY DIS
JI Iran. J. Kidney Dis.
PD JUL
PY 2020
VL 14
IS 4
BP 326
EP 328
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA MN6WK
UT WOS:000550983700014
PM 32655032
DA 2021-01-01
ER

PT J
AU Sharma, V
   Shaw, A
   Lowe, M
   Summers, A
   van Dellen, D
   Augustine, T
AF Sharma, Videha
   Shaw, Alex
   Lowe, Marcus
   Summers, Angela
   van Dellen, David
   Augustine, Titus
TI The impact of the COVID-19 pandemic on renal transplantation in the UK
SO CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; kidney transplantation; NHS; renal insufficiency; renal
   replacement therapy
ID MORTALITY; SURVIVAL; COST
AB COVID-19 is impacting provision of renal transplantation in the UK with a reduction in clinical activity. Publicly available Renal Registry and NHS Blood and Transplant reports were analysed to model the number of missed transplant opportunities, waiting list size and change in dialysis population over a six-month period starting 5 March 2020. An estimated 1,670 kidney transplant opportunities may be lost, which will lead to 6,317 active patients on the kidney-alone waiting list, compared to 4,649 based on usual activity estimates. This will result in 1,324 additional patients on dialysis who would otherwise have been transplanted. COVID-19 will lead to a marked loss of transplant opportunities and a significantly larger national waiting list. The existing strain on dialysis capacity will be exacerbated as patients remain on dialysis as the only available form of renal replacement therapy. These findings will help inform policy and service specific strategies.
C1 [Sharma, Videha; Shaw, Alex; Summers, Angela] Manchester Univ Hosp NHS Fdn Trust, Transplantat, Manchester, Lancs, England.
   [Sharma, Videha; Shaw, Alex; Summers, Angela; van Dellen, David; Augustine, Titus] Univ Manchester, Manchester, Lancs, England.
   [Lowe, Marcus; van Dellen, David; Augustine, Titus] Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England.
   [Augustine, Titus] Manchester Univ Hosp NHS Fdn Trust, Clin Transplantat, Manchester, Lancs, England.
RP Sharma, V (corresponding author), Manchester Univ NHS Fdn Trust, Dept Renal & Pancreat Transplantat, Oxford Rd, Manchester M13 9WL, Lancs, England.
EM videha.sharma@mft.nhs.uk
CR Ahn C, 2020, TRANSPLANTATION, V104, P1974, DOI 10.1097/TP.0000000000003258
   Alberici F., 2020, KIDNEY INT
   American Society of Transplantation, 2020, COVID 19 COR FAQS OR
   Aminian A, 2020, ANN SURG, V272, pE27, DOI 10.1097/SLA.0000000000003925
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bray BD, 2014, NEPHROL DIAL TRANSPL, V29, P681, DOI 10.1093/ndt/gft197
   Browning RB, 2016, J AM PHARM ASSOC, V56, P450, DOI 10.1016/j.japh.2016.03.017
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Department of Health and Social Care, 2019, OPT OUT ORG DON MAX
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Kerr M, 2012, NEPHROL DIAL TRANSPL, V27, P73, DOI 10.1093/ndt/gfs269
   Kotton CN, 2005, J AM SOC NEPHROL, V16, P1758, DOI 10.1681/ASN.2004121113
   Kumar D, 2020, AM J TRANSPLANT, V20, P1773, DOI 10.1111/ajt.15876
   Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307
   LEI Z, 2020, ECLINICAL MED, V21, DOI DOI 10.3390/IJMS21010320
   Li YK, 2020, CURR MED SCI, V40, P295, DOI 10.1007/s11596-020-2176-2
   Lowe M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028786
   Marsh S, 2020, GUARDIAN
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meier-Kriesche HU, 2002, TRANSPLANTATION, V74, P1377, DOI 10.1097/00007890-200211270-00005
   NHS Blood and Transplant, 2020, NHS BLOOD TRANSPL CO, V5
   NHS Blood and Transplant, 2020, ORG DON TRANSPL ACT
   NHS Blood and Transplant, 2019, ANN REP KIDN TRANSPL
   NHS Blood and Transplant, 2020, COV 19 DON SUMM INT
   Oniscu GC, 2005, J AM SOC NEPHROL, V16, P1859, DOI 10.1681/ASN.2004121092
   Schnuelle P, 1998, J AM SOC NEPHROL, V9, P2135
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   UK Renal Registry, 2019, UK REN REG 21 ANN RE
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zanetti-Yabur A, 2017, AM J SURG, V214, P743, DOI 10.1016/j.amjsurg.2017.01.026
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 2
Z9 2
U1 1
U2 1
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD JUL
PY 2020
VL 20
IS 4
BP E82
EP E86
DI 10.7861/clinmed.2020-0183
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM9LD
UT WOS:000550469200009
PM 32457133
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tung-Chen, Y
AF Tung-Chen, Yale
TI Lung ultrasound in the monitoring of COVID-19 infection
SO CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; lung ultrasound; SARS-CoV-2
ID OF-CARE ULTRASOUND; POINT
AB Introduction
   Coronavirus disease 2019 (COVID-19) is a highly contagious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pneumonia and acute respiratory distress syndrome (ARDS) are the most common severe complications. There is growing evidence regarding the imaging findings of COVID-19 in chest X-rays and computed tomography (CT); however, their availability to clinical staff in this pandemic outbreak might be compromised. At this moment, the role of lung ultrasound (LUS) has yet to be explored. The purpose of this case report is to describe the natural course of the disease in mild infection managed at home.
   Case report
   We report a 35-year-old man with recently diagnosed COVID-19 infection. Clinical examination was unremarkable. The diagnosis of mild disease was made clinically which was later reaffirmed by LUS after identifying a bilateral small pleural effusion and a thickened pleural line. During follow up, subpleural consolidations appeared before symptoms slightly aggravated (cough, tiredness and fever). The patient's condition improved after adjustment of therapy at home.
   Conclusion
   LUS is an excellent tool in the characterisation of COVID-19 infection and is more available than CT or X- ray. We emphasise the utility and the opportunity that LUS presents in some clinical scenarios, like this COVID-19 pandemic, and how it may serve as a monitoring and therapy guide.
C1 [Tung-Chen, Yale] Hosp Univ La Paz, Emergency Ultrasound Div Unit, Madrid, Spain.
   [Tung-Chen, Yale] Univ Alfonso X El Sabio, Madrid, Spain.
RP Tung-Chen, Y (corresponding author), Hosp Univ La Paz, Serv Urgencias, Paseo Castellana 261, Madrid 28046, Spain.
EM yale.tung@salud.madrid.org
OI Tung Chen, Yale/0000-0002-5613-3609
CR [Anonymous], 2017, Ann Emerg Med, V69, pe27, DOI 10.1016/j.annemergmed.2016.08.457
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang Y, 2020, PRELIMINARY STUDY UL
   Kruser JM, 2020, CHEST, V157, P498, DOI 10.1016/j.chest.2019.10.037
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Testa A, 2012, CRIT CARE, V16, DOI 10.1186/cc11201
   Tierney DM, 2020, CRIT CARE MED, V48, P151, DOI 10.1097/CCM.0000000000004124
   Tsung JW, 2012, CRIT ULTRASOUND J, V4, DOI 10.1186/2036-7902-4-16
   Volpicelli G, 2006, AM J EMERG MED, V24, P689, DOI 10.1016/j.ajem.2006.02.013
   Volpicelli G, 2012, INTENS CARE MED, V38, P577, DOI 10.1007/s00134-012-2513-4
   Walter JM, 2020, CHEST, V157, P496, DOI 10.1016/j.chest.2019.10.041
   WHO, 2020, PNEUM UNKN CAUS CHIN
   World Health Organization, 2019, ROLL UPD COR COVID 1
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
NR 16
TC 2
Z9 2
U1 2
U2 3
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD JUL
PY 2020
VL 20
IS 4
BP E62
EP E65
DI 10.7861/clinmed.2020-0123
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM9LD
UT WOS:000550469200005
PM 32398268
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ho, VD
   Tee, C
   See, KC
AF Ho, Vanda
   Tee, Caroline
   See, Kay Choong
TI Drug interactions with potential antivirals used for COVID-19 in older
   persons
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Letter
C1 [Ho, Vanda] Natl Univ Singapore Hosp, Dept Med, Div Geriatr Med, Singapore, Singapore.
   [Tee, Caroline] Natl Univ Singapore Hosp, Dept Pharm, Singapore, Singapore.
   [See, Kay Choong] Natl Univ Singapore Hosp, Dept Med, Div Resp & Crit Care Med, Singapore, Singapore.
RP Ho, VD (corresponding author), Natl Univ Singapore Hosp, Dept Med, Div Geriatr Med, Singapore, Singapore.
EM vanda_wt_ho@nuhs.edu.sg
CR Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Fried L, 1998, PRINCIPLES GERIATRIC, P1387
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Liverpool Drug Interaction Group, PRESCR RES
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Wolters Kluwer Health Inc, LEX DRUGS
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD JUL
PY 2020
VL 20
IS 7
BP 737
EP 739
DI 10.1111/ggi.13970
PG 3
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA MM6SW
UT WOS:000550285700019
PM 32691927
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Salawu, A
   Green, A
   Crooks, MG
   Brixey, N
   Ross, DH
   Sivan, M
AF Salawu, Abayomi
   Green, Angela
   Crooks, Michael G.
   Brixey, Nina
   Ross, Denise H.
   Sivan, Manoj
TI A Proposal for Multidisciplinary Tele-Rehabilitation in the Assessment
   and Rehabilitation of COVID-19 Survivors
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; multi-disciplinary tele-rehabilitation; pulmonary
   rehabilitation
ID HOME-BASED TELEREHABILITATION; PULMONARY REHABILITATION; STROKE; COPD;
   BENEFITS; PROGRAM
AB A global pandemic of a new highly contagious disease called COVID-19 resulting from coronavirus (severe acute respiratory syndrome (SARS)-Cov-2) infection was declared in February 2020. Though primarily transmitted through the respiratory system, other organ systems in the body can be affected. Twenty percent of those affected require hospitalization with mechanical ventilation in severe cases. About half of the disease survivors have residual functional deficits that require multidisciplinary specialist rehabilitation. The workforce to deliver the required rehabilitation input is beyond the capacity of existing community services. Strict medical follow-up guidelines to monitor these patients mandate scheduled reviews within 12 weeks post discharge. Due to the restricted timeframe for these events to occur, existing care pathway are unlikely to be able to meet the demand. An innovative integrated post-discharge care pathway to facilitate follow up by acute medical teams (respiratory and intensive care) and a specialist multidisciplinary rehabilitation team is hereby proposed. Such a pathway will enable the monitoring and provision of comprehensive medical assessments and multidisciplinary rehabilitation. This paper proposes that a model of tele-rehabilitation is integrated within the pathway by using digital communication technology to offer quick remote assessment and efficient therapy delivery to these patients. Tele-rehabilitation offers a quick and effective option to respond to the specialist rehabilitation needs of COVID-19 survivors following hospital discharge.
C1 [Salawu, Abayomi; Green, Angela; Crooks, Michael G.; Brixey, Nina] Hull Univ Teaching Hosp Natl Hlth Serv NHS Trust, Kingston Upon Hull HU16 5JQ, N Humberside, England.
   [Salawu, Abayomi; Crooks, Michael G.] Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England.
   [Salawu, Abayomi] Univ Hull, Dept Sport Hlth & Exercise Sci, Kingston Upon Hull HU6 7RX, N Humberside, England.
   [Ross, Denise H.; Sivan, Manoj] Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England.
   [Sivan, Manoj] Univ Leeds, Acad Dept Rehabil Med, Leeds LS1 3EX, W Yorkshire, England.
RP Salawu, A (corresponding author), Hull Univ Teaching Hosp Natl Hlth Serv NHS Trust, Kingston Upon Hull HU16 5JQ, N Humberside, England.; Salawu, A (corresponding author), Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England.; Salawu, A (corresponding author), Univ Hull, Dept Sport Hlth & Exercise Sci, Kingston Upon Hull HU6 7RX, N Humberside, England.
EM abayomi.salawu@hey.nhs.uk; angela.green@hey.nhs.uk;
   michael.crooks@hey.nhs.uk; nina.brixey@hey.nhs.uk; Denise.Ross@nhs.net;
   M.Sivan@leeds.ac.uk
OI Salawu, Abayomi/0000-0003-2496-0826; Sivan, Manoj/0000-0002-0334-2968
CR [Anonymous], 2020, NHS ENGLAND CLIN GUI
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Bolton CE, 2013, THORAX, V68, pii1, DOI 10.1136/thoraxjnl-2013-203808
   Boseley S., 2020, WHO DECLARES CORONAV
   BSRM, 2015, SPEC NEUR SERV STAND
   Cascella M, 2020, FEATURES EVALUATION
   Chan C, 2016, PHYSIOTHER CAN, V68, P242, DOI 10.3138/ptc.2015-33
   Chaplin E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013682
   Chen J, 2015, J STROKE CEREBROVASC, V24, P2660, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.014
   Docherty A.B., 2020, FEATURES 16749 HOSP, DOI [10.1101/2020.04.23.20076042thisversion, DOI 10.1101/2020.04.23.20076042]
   Gallagher James, 2020, BBC
   Gregory P, 2010, TOP STROKE REHABIL, V17, P394, DOI 10.1310/tsr1705-394
   HM Government NHS, 2020, COVID 19 HOSP DISCH
   Hwang R, 2017, J PHYSIOTHER, V63, P101, DOI 10.1016/j.jphys.2017.02.017
   Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553
   Karla M.E., 2018, TRENDS TELEMEDICINE, V1, P1
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550
   Lan CC, 2013, RESP CARE, V58, P1482, DOI 10.4187/respcare.02051
   LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9
   Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3
   Li Thomas St, 2006, Crit Care Resusc, V8, P302
   Lintern S., 2020, INDEPENDENT
   Marquis N, 2015, TELEMED E-HEALTH, V21, P870, DOI 10.1089/tmj.2014.0198
   Mitchell KE, 2014, EUR RESPIR J, V44, P1538, DOI 10.1183/09031936.00047814
   Moss P, 2020, LANCET, V395, pE46, DOI 10.1016/S0140-6736(20)30463-3
   National Health Service Providers, 2020, ACC DIG
   NICE, 2017, REH CRIT ILLN AD QUA
   Nolan CM, 2019, THORAX, V74, P996, DOI 10.1136/thoraxjnl-2018-212765
   Office of National Statistics, 2019, INT ACC HOUS IND
   Paneroni M, 2015, COPD, V12, P217, DOI 10.3109/15412555.2014.933794
   Razaq A., 2020, CEBM
   Ricks E, 2007, PHYSIOTHERAPY, V93, P151, DOI 10.1016/j.physio.2006.09.005
   Rochester CL, 2017, AM J RESP CRIT CARE, V195, P548, DOI 10.1164/rccm.201609-1925ED
   Russell TG, 2007, J TELEMED TELECARE, V13, P217, DOI 10.1258/135763307781458886
   Schnur M.B., 2020, COVID 19 WHO US IS G
   Sivan M., 2020, ADV CLIN NEUROSCI RE
   Stickland MK, 2011, CAN RESPIR J, V18, P216, DOI 10.1155/2011/640865
   Tsai LLY, 2017, RESPIROLOGY, V22, P699, DOI 10.1111/resp.12966
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vlake JH, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-019-0422-0
   World Health Organization, 2017, INT CLASS FUNCT DIS
   World Health Organization (WHO), 2020, NOV COR 2019
   Worldometer, 2020, COVID 19 COR PAND 20
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zbinden-Foncea H, 2020, OBESITY, V28, P1378, DOI 10.1002/oby.22849
   Zhao HM, 2020, CHINESE MED J-PEKING, V133, P1595, DOI 10.1097/CM9.0000000000000848
NR 47
TC 2
Z9 2
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 13
AR 4890
DI 10.3390/ijerph17134890
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MM7KY
UT WOS:000550333500001
PM 32645876
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rad, SMAH
   McLellan, AD
AF Hosseini Rad S M, Ali
   McLellan, Alexander D.
TI Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host
   microRNA Targeting
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE SARS-CoV-2; RNA secondary structure; conserved mutation; miRNA
ID MESSENGER-RNA; SECONDARY STRUCTURE; VIRUS; EXPRESSION; SEQUENCES;
   REPLICATION; PREDICTION; INFECTION; PEPTIDES; STRATEGY
AB The SARS-CoV-2 virus is a recently-emerged zoonotic pathogen already well adapted to transmission and replication in humans. Although the mutation rate is limited, recently introduced mutations in SARS-CoV-2 have the potential to alter viral fitness. In addition to amino acid changes, mutations could affect RNA secondary structure critical to viral life cycle, or interfere with sequences targeted by host miRNAs. We have analysed subsets of genomes from SARS-CoV-2 isolates from around the globe and show that several mutations introduce changes in Watson-Crick pairing, with resultant changes in predicted secondary structure. Filtering to targets matching miRNAs expressed in SARS-CoV-2-permissive host cells, we identified ten separate target sequences in the SARS-CoV-2 genome; three of these targets have been lost through conserved mutations. A genomic site targeted by the highly abundant miR-197-5p, overexpressed in patients with cardiovascular disease, is lost by a conserved mutation. Our results are compatible with a model that SARS-CoV-2 replication within the human host is constrained by host miRNA defences. The impact of these and further mutations on secondary structures, miRNA targets or potential splice sites offers a new context in which to view future SARS-CoV-2 evolution, and a potential platform for engineering conditional attenuation to vaccine development, as well as providing a better understanding of viral tropism and pathogenesis.
C1 [Hosseini Rad S M, Ali; McLellan, Alexander D.] Univ Otago, Dept Microbiol & Immunol, Dunedin 9010, Otago, New Zealand.
RP Rad, SMAH; McLellan, AD (corresponding author), Univ Otago, Dept Microbiol & Immunol, Dunedin 9010, Otago, New Zealand.
EM a.hosseini.rad@postgrad.otago.ac.nz; alex.mclellan@otago.ac.nz
OI Hosseini Rad S.M, Ali/0000-0002-7107-3528
CR Andrews Ryan J, 2020, bioRxiv, DOI 10.1101/2020.04.17.045161
   Apcher S, 2011, P NATL ACAD SCI USA, V108, P11572, DOI 10.1073/pnas.1104104108
   Arslan S, 2019, J CELL BIOCHEM, V120, P15506, DOI 10.1002/jcb.28817
   Barnes D, 2008, CELL HOST MICROBE, V4, P239, DOI 10.1016/j.chom.2008.08.003
   Bernhart SH, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-3
   Bernhart SH, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-474
   Broughton JP, 2016, MOL CELL, V64, P320, DOI 10.1016/j.molcel.2016.09.004
   Carmel I, 2012, RNA, V18, P1947, DOI 10.1261/rna.032185.111
   Chang TH, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S2-S4
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Chen L, 2013, GUT LIVER, V7, P335, DOI 10.5009/gnl.2013.7.3.335
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Condorelli G, 2010, EUR HEART J, V31, P649, DOI 10.1093/eurheartj/ehp573
   Cullen BR, 2006, NAT GENET, V38, pS25, DOI 10.1038/ng1793
   Cullen BR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000787
   Demirci MDS, 2020, PEERJ, V8, DOI 10.7717/peerj.9369
   Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215
   Ding Y, 2005, RNA, V11, P1157, DOI 10.1261/rna.2500605
   Dong DL, 2011, ACTA PHARM SIN B, V1, P1, DOI 10.1016/j.apsb.2011.04.010
   Dubois J, 2014, MBIO, V5, DOI 10.1128/mBio.00070-14
   Duy J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24496
   Farkas C, 2020, PEERJ, V8, DOI 10.7717/peerj.9255
   Faure G, 2016, NUCLEIC ACIDS RES, V44, P10898, DOI 10.1093/nar/gkw671
   Fu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043204
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Granados DP, 2012, BLOOD, V119, pE181, DOI 10.1182/blood-2012-02-412593
   Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363
   Ha M, 2008, BBA-GENE REGUL MECH, V1779, P735, DOI 10.1016/j.bbagrm.2008.03.004
   HARDY WR, 1994, J VIROL, V68, P7790, DOI 10.1128/JVI.68.12.7790-7799.1994
   Hasan M., 2016, J BIOTERROR BIODEF, V7, P2, DOI [10.4172/2157-2526.1000140, DOI 10.4172/2157-2526.1000140]
   Hiller M, 2007, PLOS GENET, V3, P2147, DOI 10.1371/journal.pgen.0030204
   Ivashchenko A., 2020, PREPRINT, DOI [10.21203/rs.3.rs-16264/v1, DOI 10.21203/RS.3.RS-16264/V1]
   Kelly EJ, 2008, NAT MED, V14, P1278, DOI 10.1038/nm.1776
   Khan M.A.-A.-K., 2020, SARS COV 2 PROTEINS, DOI [10.1101/2020.05.06.050260, DOI 10.1101/2020.05.06.050260]
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109
   Kleinman CL, 2012, RNA, V18, P1586, DOI 10.1261/rna.033233.112
   Korber B., 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Lai FW, 2014, J VIROL, V88, P54, DOI 10.1128/JVI.02678-13
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   Lange SJ, 2012, NUCLEIC ACIDS RES, V40, P5215, DOI 10.1093/nar/gks181
   Langlois RA, 2013, NAT BIOTECHNOL, V31, P844, DOI 10.1038/nbt.2666
   Leon-Icaza S.A., 2019, EXRNA, V1, P1, DOI [10.1186/s41544-018-0004-7, DOI 10.1186/S41544-018-0004-7]
   Li LC, 2008, J MOL BIOL, V377, P790, DOI 10.1016/j.jmb.2008.01.068
   Li P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066782
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Liang YC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.325
   Lim J, 2019, ACS OMEGA, V4, P14560, DOI 10.1021/acsomega.9b01790
   Linsen SEV, 2008, CELL RES, V18, P1157, DOI 10.1038/cr.2008.311
   Liu W, 2018, CARDIOLOGY, V141, P212, DOI 10.1159/000493419
   Liu YC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004199
   Liu Z., 2020, ARXIV200404874
   Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116
   Luo P, 2017, INT J CLIN EXP MED, V10, P6742
   MacLean Oscar A, 2020, bioRxiv, DOI 10.1101/2020.05.28.122366
   MacLean OA, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa034
   Mahajan VS, 2009, TRENDS IMMUNOL, V30, P1, DOI 10.1016/j.it.2008.08.009
   Mallick B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007837
   Mann M, 2017, NUCLEIC ACIDS RES, V45, pW435, DOI 10.1093/nar/gkx279
   Morales L, 2017, CELL HOST MICROBE, V21, P344, DOI 10.1016/j.chom.2017.01.015
   Muus C, 2020, BIORXIV, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254]
   Nishikura K, 2010, ANNU REV BIOCHEM, V79, P321, DOI 10.1146/annurev-biochem-060208-105251
   O'Shea TJ, 2014, EMERG INFECT DIS, V20, P741, DOI 10.3201/eid2005.130539
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Palmieri V, 2018, NUCLEIC ACIDS RES, V46, pD770, DOI 10.1093/nar/gkx701
   Peeri M, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-01971-y
   Peng F., 2017, VIROL REP, V7, P1, DOI DOI 10.1016/J.VIREP.2016.11.001
   Perez JT, 2009, NAT BIOTECHNOL, V27, P572, DOI 10.1038/nbt.1542
   Pfeffer S, 2006, ONCOGENE, V25, P6211, DOI 10.1038/sj.onc.1209915
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993
   Raden M, 2018, NUCLEIC ACIDS RES, V46, pW25, DOI 10.1093/nar/gky329
   Rakhmetullina A., 2020, PREPRINT, DOI [10.21203/rs.3.rs-20476/v2, DOI 10.21203/RS.3.RS-20476/V2]
   Rangan R., 2020, DE NOVO 3D MODELS SA, P1, DOI [10.1101/2020.04.14.041962, DOI 10.1101/2020.04.14.041962]
   Rangan Ramya, 2020, bioRxiv, DOI 10.1101/2020.03.27.012906
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rolle K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151246
   Sabarinathan R, 2013, HUM MUTAT, V34, P546, DOI 10.1002/humu.22273
   Santos A, 2015, PEERJ, V3, DOI 10.7717/peerj.1054
   SCHNEIDER PA, 1994, J VIROL, V68, P5007, DOI 10.1128/JVI.68.8.5007-5012.1994
   Schulte C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145930
   Sharma Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10489-2
   Sironi M, 2004, NUCLEIC ACIDS RES, V32, P1783, DOI 10.1093/nar/gkh341
   Tang WF, 2016, J VIROL, V90, P1424, DOI 10.1128/JVI.02143-15
   Tijsen AJ, 2010, CIRC RES, V106, P1035, DOI 10.1161/CIRCRESAHA.110.218297
   Tort FL, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197976
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   van Dorp L., 2020, NO EVIDENCE INCREASE
   Victorovich K. V., 2020, TRANSLATION ASS MUTA, DOI [https://doi.org/10.1101/2020.05.05.078238, DOI 10.1101/2020.05.05.078238]
   Wang HM, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1031440
   Wang XW, 2014, BIOINFORMATICS, V30, P1377, DOI 10.1093/bioinformatics/btu045
   Wei JJ, 2019, VIROL SIN, V34, P162, DOI 10.1007/s12250-018-0061-y
   Winther TN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058236
   Xia XH, 2020, MOL BIOL EVOL, V37, P2699, DOI 10.1093/molbev/msaa094
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yang Z, 2019, CANCER BIOL MED, V16, P276, DOI 10.20892/j.issn.2095-3941.2018.0283
   Yu KK, 2015, ANN HEPATOL, V14, P450, DOI 10.1016/S1665-2681(19)31165-2
   Zhang K, 2018, NAT STRUCT MOL BIOL, V25, P1019, DOI 10.1038/s41594-018-0136-3
   Zhang LY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23226
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhu Z, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4302470
   ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133
NR 105
TC 2
Z9 2
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 13
AR 4807
DI 10.3390/ijms21134807
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MM5OJ
UT WOS:000550205600001
PM 32645951
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cafarotti, S
AF Cafarotti, Stefano
TI Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients
   With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Letter
DE COVID-19; Lung cancer; IL-17 target therapy; Monoclonal antibody
ID IL-17A PROMOTES; CELLS
AB The coronavirus disease 2019 outbreak is evolving rapidly worldwide. The lungs are the target of the primary infection and patients with lung cancer seem to have a poor prognosis. To our knowledge, this is the first reported investigation of a possible role of interleukin-17 target therapy in patients with lung cancer and concomitant severe acute respiratory syndrome-coronavirus-2 infection. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
C1 [Cafarotti, Stefano] Univ Svizzera Italiana, Ist Oncol Svizzera Italiana, Bellinzona, Switzerland.
RP Cafarotti, S (corresponding author), Univ Svizzera Italiana, Ist Oncol Svizzera Italiana, Bellinzona, Switzerland.
EM stefano.cafarotti@eoc.ch
CR Abdel-Moneim A, 2018, BIOMED PHARMACOTHER, V101, P287, DOI 10.1016/j.biopha.2018.02.103
   Camargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835
   Mora-Ruiz MD, 2019, MOL IMMUNOL, V107, P71, DOI 10.1016/j.molimm.2019.01.008
   Ding PW, 2018, INT IMMUNOPHARMACOL, V57, P132, DOI 10.1016/j.intimp.2018.02.006
   Du SY, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12840
   Fabre J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091433
   Hou WQ, 2014, J VIROL, V88, P8479, DOI 10.1128/JVI.00724-14
   Legato M., 2010, PRINCIPES GENDER SPE
   Li CG, 2012, CELL RES, V22, P528, DOI 10.1038/cr.2011.165
   Li JT, 2015, J IMMUNOL, V195, P87, DOI 10.4049/jimmunol.1500054
   Mi S, 2011, J IMMUNOL, V187, P3003, DOI 10.4049/jimmunol.1004081
   Montalbano AM, 2015, CYTOKINE, V76, P391, DOI 10.1016/j.cyto.2015.07.013
   Pan B, 2015, SCI REP-UK, V5, DOI 10.1038/srep16053
   Pan B, 2015, BIOMARKERS, V20, P232, DOI 10.3109/1354750X.2015.1068853
   Patera AC, 2002, VIROLOGY, V299, P56, DOI 10.1006/viro.2002.1400
   Righetti RF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01021
   Ryzhakov G, 2011, J IMMUNOL, V187, P5357, DOI 10.4049/jimmunol.1100917
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Stout-Delgado HW, 2009, CELL HOST MICROBE, V6, P446, DOI 10.1016/j.chom.2009.09.011
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 21
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUL
PY 2020
VL 15
IS 7
BP E101
EP E103
DI 10.1016/j.jtho.2020.04.015
PG 3
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA MM6QP
UT WOS:000550279700001
PM 32353597
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nguyen, A
   David, JK
   Maden, SK
   Wood, MA
   Weeder, BR
   Nellore, A
   Thompson, RF
AF Nguyen, Austin
   David, Julianne K.
   Maden, Sean K.
   Wood, Mary A.
   Weeder, Benjamin R.
   Nellore, Abhinav
   Thompson, Reid F.
TI Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory
   Syndrome Coronavirus 2
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE COVID-19; HLA; MHC class I; SARS-CoV-2; coronavirus
ID DENGUE VIRUS; IMMUNE-RESPONSES; SIN; SARS; INFECTIONS; COVID-19;
   EPITOPES
AB Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen A [HLA-A], -B, and -C genes) may affect susceptibility to and severity of the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We performed a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA-A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explored the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome was successfully sampled and was represented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting that individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (M. Lin, H.-T. Tseng, J. A. Trejaut, H.-L. Lee, et al., BMC Med Genet 4:9, 2003, https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-4-9). Conversely, we found that HLAB*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting that it could enable cross-protective T-cell-based immunity. Finally, we reported global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.
   IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of severity of viral disease in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.
C1 [Nguyen, Austin; David, Julianne K.; Maden, Sean K.; Wood, Mary A.; Weeder, Benjamin R.; Nellore, Abhinav; Thompson, Reid F.] Oregon Hlth & Sci Univ, Computat Biol Program, Portland, OR 97201 USA.
   [Nguyen, Austin; David, Julianne K.; Maden, Sean K.; Weeder, Benjamin R.; Nellore, Abhinav; Thompson, Reid F.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
   [Wood, Mary A.] Portland VA Res Fdn, Portland, OR USA.
   [Nellore, Abhinav] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
   [Thompson, Reid F.] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA.
   [Thompson, Reid F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
   [Thompson, Reid F.] VA Portland Healthcare Syst, Div Hosp & Specialty Med, Portland, OR 97239 USA.
RP Nellore, A; Thompson, RF (corresponding author), Oregon Hlth & Sci Univ, Computat Biol Program, Portland, OR 97201 USA.; Nellore, A; Thompson, RF (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.; Nellore, A (corresponding author), Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.; Thompson, RF (corresponding author), Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97201 USA.; Thompson, RF (corresponding author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.; Thompson, RF (corresponding author), VA Portland Healthcare Syst, Div Hosp & Specialty Med, Portland, OR 97239 USA.
EM nellore@ohsu.edu; thompsre@ohsu.edu
OI Nguyen, Austin/0000-0001-7940-4830; Weeder,
   Benjamin/0000-0002-4128-5861; David, Julianne/0000-0003-2690-8239;
   Maden, Sean/0000-0002-2212-4894
FU U.S. Department of Veterans AffairsUS Department of Veterans Affairs
   [1IK2CX002049-01]; Sunlin & Priscilla Chou Foundation
FX R.F.T. was supported by the U.S. Department of Veterans Affairs under
   award number 1IK2CX002049-01 and by the Sunlin & Priscilla Chou
   Foundation.
CR Abdelmageed MI, 2020, DESIGN MULTIEPITOPE, DOI [10.1101/2020.02.04.934232, DOI 10.1101/2020.02.04.934232]
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Al-Tawfiq Jaffar A, 2016, World J Clin Pediatr, V5, P391
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI [10.1101/2020.03.03.20028423, DOI 10.1101/2020.03.03.20028423]
   Campbell Katie M, 2020, bioRxiv, DOI 10.1101/2020.03.30.016931
   Cao Q, 2020, J FORMOS MED ASSOC, V119, P670, DOI 10.1016/j.jfma.2020.02.009
   Caramelo F, 2020, ESTIMATION RISK FACT, V19, DOI [10.1101/2020.02.24.20027268, DOI 10.1101/2020.02.24.20027268]
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Denison Mark R, 2004, Pediatr Infect Dis J, V23, pS207, DOI 10.1097/01.inf.0000144666.95284.05
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dong C., 2020, CHARACTERIZATION ANT, DOI [10.1101/2020.03.17.20036640, DOI 10.1101/2020.03.17.20036640]
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   Galvez J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00349
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guan WJ, 2020, COMORBIDITY ITS IMPA, DOI [10.1101/2020.02.25.20027664, DOI 10.1101/2020.02.25.20027664]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jain V, 2020, SYSTEMATIC REV METAA, DOI [DOI 10.1101/2020.03.15.20035360, 10.1101/2020.03.15.20035360]
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Klenerman P, 1998, NATURE, V394, P482
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216
   Lau JTF, 2004, EMERG INFECT DIS, V10, P235
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Lv Huibin, 2020, bioRxiv, DOI 10.1101/2020.03.15.993097
   MacDonald KS, 2000, J INFECT DIS, V181, P1581, DOI 10.1086/315472
   Nielsen M, 2005, IMMUNOGENETICS, V57, P33, DOI 10.1007/s00251-005-0781-7
   O'Donnell TJ, 2018, CELL SYST, V7, P129, DOI 10.1016/j.cels.2018.05.014
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Park MS, 2016, IMMUNE NETW, V16, P261, DOI 10.4110/in.2016.16.5.261
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Roser M, 2020, CORONAVIRUS DIS COVI
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sette A, 2009, VACCINE, V27, pG21, DOI 10.1016/j.vaccine.2009.10.011
   Shao XM, 2020, CANCER IMMUNOL RES, V8, P396, DOI 10.1158/2326-6066.CIR-19-0464
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Si YJ, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13322
   Sibener LV, 2018, CELL, V174, P672, DOI 10.1016/j.cell.2018.06.017
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Singh RAK, 2002, J IMMUNOL, V169, P6779, DOI 10.4049/jimmunol.169.12.6779
   South A, 2011, R J, V3, P35
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   Taiaroa G, 2020, BIORXIV, DOI [10.1101/2020.03.05.976167, DOI 10.1101/2020.03.05.976167]
   Tan Yongjun, 2020, bioRxiv, DOI 10.1101/2020.03.04.977736
   Tang A, 2020, RETROSPECTIVE STUDY, DOI [10.1101/2020.03.08.20029710., DOI 10.1101/2020.03.08.20029710, 10.1101/2020.03.08.20029710]
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thabet F, 2015, SAUDI MED J, V36, P484, DOI 10.15537/smj.2015.4.10243
   Thevarajan I, 2020, BREADTH CONCOMITANT, DOI [10.1101/2020.02.20.20025841, DOI 10.1101/2020.02.20.20025841]
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   Vatti A, 2017, J AUTOIMMUN, V83, P12, DOI 10.1016/j.jaut.2017.04.008
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wood MA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4325-6
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657
   Zheng Z., 2020, BIORXIV, DOI [10.110 1/2020.03.06.980037, DOI 10.1101/2020.03.06.980037, 10.1101/2020.03.06.980037]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu J, 2020, PROFILING IMMUNE VUL, DOI [10.1101/2020.02.08.939553, DOI 10.1101/2020.02.08.939553, 10.1101/2020.02.08.939553.]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 78
TC 68
Z9 67
U1 5
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2020
VL 94
IS 13
AR e00510-20
DI 10.1128/JVI.00510-20
PG 12
WC Virology
SC Virology
GA MM4XP
UT WOS:000550161700008
PM 32303592
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Williams, VM
   Kahn, JM
   Harkenrider, MM
   Chino, J
   Chen, J
   Fang, LC
   Dunn, EF
   Fields, E
   Mayadev, JS
   Rengan, R
   Petereit, D
   Dyer, BA
AF Williams, Vonetta M.
   Kahn, Jenna M.
   Harkenrider, Matthew M.
   Chino, Junzo
   Chen, Jonathan
   Fang, L. Christine
   Dunn, Emily F.
   Fields, Emma
   Mayadev, Jyoti S.
   Rengan, Ramesh
   Petereit, Daniel
   Dyer, Brandon A.
TI COVID-19 impact on timing of brachytherapy treatment and strategies for
   risk mitigation
SO BRACHYTHERAPY
LA English
DT Article
DE Coronavirus; COVID19; COVID-19; Cervical cancer; Uterine cancer; Breast
   cancer; Prostate cancer; Brachytherapy; Radiotherapy; Radiation oncology
ID DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; SOCIETY CONSENSUS
   GUIDELINES; PARTIAL BREAST IRRADIATION; PELVIC RADIATION-THERAPY;
   ADJUVANT VAGINAL BRACHYTHERAPY; IMAGE-GUIDED BRACHYTHERAPY; LOCALIZED
   PROSTATE-CANCER; STAGE ENDOMETRIAL CANCER; ADVANCED CERVICAL-CANCER
AB PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic.
   METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided.
   RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources.
   CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve. (C) 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
C1 [Williams, Vonetta M.; Chen, Jonathan; Fang, L. Christine; Rengan, Ramesh; Dyer, Brandon A.] Univ Washington, Dept Radiat Oncol, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [Kahn, Jenna M.] Oregon Hlth & Sci Univ, Dept Radiat Oncol, Portland, OR 97201 USA.
   [Harkenrider, Matthew M.] Loyola Univ Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA.
   [Chino, Junzo] Duke Univ, Dept Radiat Oncol, Durham, VA USA.
   [Dunn, Emily F.] Willamette Valley Canc Inst & Res Ctr, Dept Radiat Oncol, Eugene, OR USA.
   [Fields, Emma] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA.
   [Mayadev, Jyoti S.] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA.
   [Petereit, Daniel] Monument Hlth Canc Care Inst, Dept Radiat Oncol, Rapid City, SD USA.
RP Dyer, BA (corresponding author), Univ Washington, Dept Radiat Oncol, 1959 NE Pacific St, Seattle, WA 98195 USA.
EM badyer@uw.edu
CR AHMAD NR, 1995, INT J RADIAT ONCOL, V33, P837, DOI 10.1016/0360-3016(95)00197-0
   Albuquerque K, 2019, BRACHYTHERAPY, V18, P429, DOI 10.1016/j.brachy.2019.02.008
   ALLAM A, 1995, INT J RADIAT ONCOL, V32, P105, DOI 10.1016/0360-3016(95)00511-V
   Andrews SF, 2005, CANCER-AM CANCER SOC, V104, P299, DOI 10.1002/cncr.21184
   Beriwal S, 2012, BRACHYTHERAPY, V11, P68, DOI 10.1016/j.brachy.2011.06.008
   Boorjian SA, 2005, BJU INT, V96, P773, DOI 10.1111/j.1464-410X.2005.05763.x
   Cattaneo R, 2014, INT J RADIAT ONCOL, V88, P866, DOI 10.1016/j.ijrobp.2013.11.247
   Cefaro GA, 2007, BREAST J, V13, P575, DOI 10.1111/j.1524-4741.2007.00511.x
   Cepeda MS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006581.pub2
   Charra-Brunaud C, 2012, RADIOTHER ONCOL, V103, P305, DOI 10.1016/j.radonc.2012.04.007
   Chrousos G.P., 1986, Advances in Experimental Medicine and Biology, V196, P317
   Correa C, 2017, PRACT RADIAT ONCOL, V7, P73, DOI 10.1016/j.prro.2016.09.007
   Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5
   Dyer B, 2017, HDB IMAGE GUIDED BRA, P119
   Dyer BA, 2019, BRACHYTHERAPY, V18, P378, DOI 10.1016/j.brachy.2019.01.001
   Fabrini MG, 2012, ANTICANCER RES, V32, P169
   Finsen V, 2017, TIDSSKR NORSKE LAEGE, V137, P629, DOI 10.4045/tidsskr.16.0515
   Frank SJ, 2005, INT J RADIAT ONCOL, V62, P138, DOI 10.1016/j.ijrobp.2004.09.032
   Frank SJ, 2018, INT J RADIAT ONCOL, V100, P374, DOI 10.1016/j.ijrobp.2017.09.050
   Freedland SJ, 2006, J UROLOGY, V175, P1298, DOI 10.1016/S0022-5347(05)00646-4
   Froud PJ, 2000, INT J RADIAT ONCOL, V46, P363, DOI 10.1016/S0360-3016(99)00412-5
   FYLES A, 1992, RADIOTHER ONCOL, V25, P273, DOI 10.1016/0167-8140(92)90247-R
   Ghanem AI, 2017, INT J RADIAT ONCOL, V99, pE292, DOI 10.1016/j.ijrobp.2017.06.1299
   GIRINSKY T, 1993, INT J RADIAT ONCOL, V27, P1051, DOI 10.1016/0360-3016(93)90522-W
   Grimm P, 2012, BJU INT, V109, P22, DOI 10.1111/j.1464-410X.2011.10827.x
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gunderson CC, 2012, GYNECOL ONCOL, V125, P477, DOI 10.1016/j.ygyno.2012.01.003
   Harkenrider MM, 2018, BRACHYTHERAPY, V17, P187, DOI 10.1016/j.brachy.2017.09.010
   Harkenrider MM, 2017, BRACHYTHERAPY, V16, P95, DOI 10.1016/j.brachy.2016.04.005
   Hendry J, 2017, INT J RADIAT ONCOL, V99, P1313
   Huang J, 2003, J CLIN ONCOL, V21, P555, DOI 10.1200/JCO.2003.04.171
   Hughes KS, 2013, J CLIN ONCOL, V31, P2382, DOI 10.1200/JCO.2012.45.2615
   Jhingran A, 2012, INT J RADIAT ONCOL, V84, pE23, DOI 10.1016/j.ijrobp.2012.02.044
   Jolly S, 2005, GYNECOL ONCOL, V97, P887, DOI 10.1016/j.ygyno.2005.02.021
   Kamrava M, 2017, BRACHYTHERAPY, V16, P1129, DOI 10.1016/j.brachy.2017.07.012
   Karlsson P, 2011, INT J RADIAT ONCOL, V80, P398, DOI 10.1016/j.ijrobp.2010.02.042
   Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048
   Khan AJ, 2019, INT J RADIAT ONCOL, V104, P67, DOI 10.1016/j.ijrobp.2018.12.050
   Khan MA, 2004, J UROLOGY, V172, P1835, DOI 10.1097/01.ju.0000140277.08623.13
   Kim MK, 2011, INT J GYNECOL CANCER, V21, P673, DOI 10.1111/IGC.0b013e3181fd9a06
   Kirchheiner K, 2016, RADIOTHER ONCOL, V118, P160, DOI 10.1016/j.radonc.2015.12.025
   Laliscia C, 2017, ONCOL RES TREAT, V40, P697, DOI 10.1159/000480350
   LANCIANO RM, 1993, INT J RADIAT ONCOL, V25, P391, DOI 10.1016/0360-3016(93)90058-4
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lipsett M B, 1986, Adv Exp Med Biol, V196, P97
   MacLeod C, 1998, INT J RADIAT ONCOL, V42, P1033, DOI 10.1016/S0360-3016(98)00292-2
   Malone S, 2020, J CLIN ONCOL, V38, P593, DOI 10.1200/JCO.19.01904
   Martell K, 2019, RADIOTHER ONCOL, V141, P149, DOI 10.1016/j.radonc.2019.08.017
   Martinez-Moreno M, 2018, CUREUS, V10, DOI 10.7759/cureus.2170
   MCKAY W, 1987, ANESTH ANALG, V66, P572
   Merrick GS, 2016, BRACHYTHERAPY, V15, P79, DOI 10.1016/j.brachy.2015.09.011
   Merrick GS, 2015, BRACHYTHERAPY, V14, P677, DOI 10.1016/j.brachy.2015.05.001
   MORRIS RW, 1984, ANAESTH INTENS CARE, V12, P113, DOI 10.1177/0310057X8401200204
   Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026
   Morrow M, 2016, ANN SURG ONCOL, V23, P3801, DOI 10.1245/s10434-016-5449-z
   Morton G, 2020, RADIOTHER ONCOL, V146, P90, DOI 10.1016/j.radonc.2020.02.009
   Nam Robert K, 2003, Can J Urol, V10, P1891
   NCCN, 2020, CLIN PRACT GUID ONC
   Nguyen PL, 2005, CANCER-AM CANCER SOC, V103, P2053, DOI 10.1002/cncr.21050
   Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2
   Olivotto IA, 2009, J CLIN ONCOL, V27, P16, DOI 10.1200/JCO.2008.18.1891
   PETEREIT DG, 1995, INT J RADIAT ONCOL, V32, P1301, DOI 10.1016/0360-3016(94)00635-X
   Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606
   Phan T, 2015, CURR ONCOL, V22, P356, DOI 10.3747/co.22.2562
   Potter R, 2016, INT J RADIAT ONCOL, V94, P588, DOI 10.1016/j.ijrobp.2015.09.023
   Potter R, 2011, RADIOTHER ONCOL, V100, P116, DOI 10.1016/j.radonc.2011.07.012
   Potters L., LEADING STORM LESSON
   Rao BS, 2017, J CLIN DIAGN RES, V11, pXC6, DOI 10.7860/JCDR/2017/22489.9607
   Schwarz JK, 2015, BRACHYTHERAPY, V14, P587, DOI 10.1016/j.brachy.2015.06.002
   Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387
   Shah C, 2013, BRACHYTHERAPY, V12, P267, DOI 10.1016/j.brachy.2013.02.001
   Shurell E, 2018, CANCER-AM CANCER SOC, V124, P46, DOI 10.1002/cncr.30972
   Small W, 2012, BRACHYTHERAPY, V11, P58, DOI 10.1016/j.brachy.2011.08.005
   Song SS, 2013, CANCER-AM CANCER SOC, V119, P325, DOI 10.1002/cncr.27652
   Sood BM, 2002, INT J RADIAT ONCOL, V53, P702, DOI 10.1016/S0360-3016(02)02745-1
   Souhami L, 2005, GYNECOL ONCOL, V97, P508, DOI 10.1016/j.ygyno.2005.02.015
   Strnad V, 2016, LANCET, V387, P229, DOI 10.1016/S0140-6736(15)00471-7
   Tait LM, 2016, BRACHYTHERAPY, V15, P333, DOI 10.1016/j.brachy.2016.01.002
   Tanderup K, 2016, RADIOTHER ONCOL, V120, P441, DOI 10.1016/j.radonc.2016.05.014
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Townamchai K, 2012, GYNECOL ONCOL, V127, P351, DOI 10.1016/j.ygyno.2012.07.111
   Trifiletti DM, 2015, BRACHYTHERAPY, V14, P905, DOI 10.1016/j.brachy.2015.07.005
   Tsoutsou PG, 2009, CRIT REV ONCOL HEMAT, V71, P102, DOI 10.1016/j.critrevonc.2008.09.002
   Ushijima K, 2007, J CLIN ONCOL, V25, P2798, DOI 10.1200/JCO.2006.08.8344
   van den Bergh RCN, 2013, EUR UROL, V64, P204, DOI 10.1016/j.eururo.2013.02.024
   Viswanathan AN, 2007, INT J RADIAT ONCOL, V68, P491, DOI 10.1016/j.ijrobp.2006.12.021
   Viswanathan AN, 2015, CANCER-AM CANCER SOC, V121, P2156, DOI 10.1002/cncr.29337
   Viswanathan AN, 2012, BRACHYTHERAPY, V11, P47, DOI 10.1016/j.brachy.2011.07.002
   Wachter-Gerstner N, 2003, RADIOTHER ONCOL, V68, P51, DOI 10.1016/S0167-8140(03)00083-5
   White J, 2016, INT J RADIAT ONCOL, V95, P1460, DOI 10.1016/j.ijrobp.2016.03.037
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yuk JS, 2017, ANN SURG ONCOL, V24, P1322, DOI 10.1245/s10434-016-5699-9
NR 92
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1538-4721
EI 1873-1449
J9 BRACHYTHERAPY
JI Brachytherapy
PD JUL-AUG
PY 2020
VL 19
IS 4
BP 401
EP 411
DI 10.1016/j.brachy.2020.04.005
PG 11
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA MN0YQ
UT WOS:000550573500003
PM 32359937
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gualtieri, P
   Falcone, C
   Romano, L
   Macheda, S
   Correale, P
   Arciello, P
   Polimeni, N
   De Lorenzo, A
AF Gualtieri, Paola
   Falcone, Carmela
   Romano, Lorenzo
   Macheda, Sebastiano
   Correale, Pierpaolo
   Arciello, Pietro
   Polimeni, Nicola
   De Lorenzo, Antonino
TI Body Composition Findings by Computed Tomography in SARS-CoV-2 Patients:
   Increased Risk of Muscle Wasting in Obesity
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE diagnostic imaging; CT scan; body composition; fat; lean; liver
   attenuation; inflammation; muscle wasting; obesity
ID SKELETAL-MUSCLE; CRITICAL ILLNESS; FAT MASS; LIVER; METABOLISM;
   NUTRITION; LIGASES; STRESS; INDEX
AB Obesity is a characteristic of COVID-19 patients and the risk of malnutrition can be underestimated due to excess of fat: a paradoxical danger. Long ICU hospitalization exposes patients to a high risk of wasting and loss of lean body mass. The complex management precludes the detection of anthropometric parameters for the definition and monitoring of the nutritional status. The use of imaging diagnostics for body composition could help to recognize and treat patients at increased risk of wasting with targeted pathways. COVID-19 patients admitted to the ICU underwent computed tomography within 24 h and about 20 days later, to evaluate the parameters of the body and liver composition. The main results were the loss of the lean mass index and a greater increase in liver attenuation in obese subjects. These could be co-caused by COVID-19, prolonged bed rest, the complex medical nutritional therapy, and the starting condition of low-grade inflammation of the obese. The assessment of nutritional status, with body composition applied to imaging diagnostics and metabolic profiles in COVID-19, will assist in prescribing appropriate medical nutritional therapy. This will reduce recovery times and complications caused by frailty.
C1 [Gualtieri, Paola; De Lorenzo, Antonino] Univ Roma Tor Vergata, Sect Clin Nutr & Nutrigen, Dept Biomed & Prevent, I-0133 Rome, Italy.
   [Falcone, Carmela; Arciello, Pietro] Grande Osped Metropolitano Bianchi Melacrino More, Radiol Unit, I-89124 Reggio Di Calabria, Italy.
   [Romano, Lorenzo] Univ Roma Tor Vergata, Sch Specializat Food Sci, I-00133 Rome, Italy.
   [Macheda, Sebastiano; Polimeni, Nicola] Grande Osped Metropolitano Bianchi Melacrino More, Unit Intens Care Med & Anesthesia, I-89124 Reggio Di Calabria, Italy.
   [Correale, Pierpaolo] Grande Osped Metropolitano Bianchi Melacrino More, Med Oncol Unit, I-89124 Reggio Di Calabria, Italy.
RP Romano, L (corresponding author), Univ Roma Tor Vergata, Sch Specializat Food Sci, I-00133 Rome, Italy.
EM paola.gualtieri@uniroma2.it; milafalcone@gmail.com;
   lorenzo.romano@alumni.uniroma2.eu; nucciomacheda58@gmail.com;
   correalep@yahoo.it; pietroarciello@tin.it; nicopolimeni@hotmail.it;
   delorenzo@uniroma2.it
RI Correale, Pierpaolo/K-1640-2016
OI Correale, Pierpaolo/0000-0003-2154-6734; Romano,
   Lorenzo/0000-0001-7574-2592
CR Aubertin-Leheudre M, 2020, J AM MED DIR ASSOC, V21, P973, DOI 10.1016/j.jamda.2020.04.022
   Avolio E, 2020, CURR MED CHEM, V27, P216, DOI 10.2174/0929867326666190326113607
   Biolo G, 2002, INTENS CARE MED, V28, P1512, DOI 10.1007/s00134-002-1512-2
   Bloch S, 2012, EUR RESPIR J, V39, P1000, DOI 10.1183/09031936.00090011
   Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874
   Brealey David, 2009, J Diabetes Sci Technol, V3, P1250
   Claycombe K, 2008, P NATL ACAD SCI USA, V105, P2017, DOI 10.1073/pnas.0712053105
   De Lorenzo A, 2019, EUR REV MED PHARMACO, V23, P2513, DOI 10.26355/eurrev_201903_17399
   De Lorenzo A, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1919-y
   De Lorenzo A, 2016, WORLD J GASTROENTERO, V22, P681, DOI 10.3748/wjg.v22.i2.681
   De Lorenzo A, 2020, NUTRITION, V71, DOI 10.1016/j.nut.2019.110615
   Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   Epstein Danny, 2020, Eur J Case Rep Intern Med, V7, P001651, DOI 10.12890/2020_001651
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fredriksson K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003686
   Friedrich O, 2006, CURR OPIN CLIN NUTR, V9, P403, DOI 10.1097/01.mco.0000232900.59168.a0
   Gardner EM, 2011, ANNU REV NUTR, V31, P353, DOI 10.1146/annurev-nutr-081810-160812
   Handu Deepa, 2020, J Acad Nutr Diet, DOI 10.1016/j.jand.2020.05.012
   Hruschka DJ, 2016, OBES REV, V17, P1030, DOI 10.1111/obr.12449
   Kiekens C, 2020, EUR J PHYS REHAB MED, V56, P323, DOI 10.23736/S1973-9087.20.06305-4
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Krukowski RA, 2020, OBESITY, V28, P1182, DOI 10.1002/oby.22851
   Kyle UG, 2001, EUR J CLIN NUTR, V55, P663, DOI 10.1038/sj.ejcn.1601198
   Leander P, 2000, ACTA RADIOL, V41, P151, DOI 10.1080/028418500127345172
   Lecker SH, 2003, CURR OPIN CLIN NUTR, V6, P271, DOI 10.1097/01.mco.0000068963.34812.e5
   Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165
   LIAW KY, 1985, J TRAUMA, V25, P628, DOI 10.1097/00005373-198507000-00009
   Narici M, 2020, EUR J SPORT SCI, DOI 10.1080/17461391.2020.1761076
   ORPHANIDOU C, 1994, J AM DIET ASSOC, V94, P855, DOI 10.1016/0002-8223(94)92363-9
   Preiser JC, 2014, BRIT J ANAESTH, V113, P945, DOI 10.1093/bja/aeu187
   Rocha R, 2005, J HUM NUTR DIET, V18, P365, DOI 10.1111/j.1365-277X.2005.00634.x
   Romano L, 2020, Eur Rev Med Pharmacol Sci, V24, P4035, DOI 10.26355/eurrev_202004_20874
   Romano L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071526
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Scimeca M, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1143-6
   Sharma Kavita, 2019, Curr Nutr Rep, V8, P317, DOI 10.1007/s13668-019-00288-y
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   SIRI WE, 1993, NUTRITION, V9, P481
   Stofkova A, 2009, Endocr Regul, V43, P157
   Tanimura K, 2016, ANN AM THORAC SOC, V13, P334, DOI 10.1513/AnnalsATS.201507-446OC
   Tappy L, 1998, CRIT CARE MED, V26, P860, DOI 10.1097/00003246-199805000-00018
   Tobert CM, 2018, J ACAD NUTR DIET, V118, P125, DOI 10.1016/j.jand.2016.12.019
   Wells MM, 2016, CAN J GASTROENTEROL, V2016, DOI 10.1155/2016/4930987
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zheng KI, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154244
NR 46
TC 5
Z9 5
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 13
AR 4670
DI 10.3390/ijms21134670
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA MM6EP
UT WOS:000550247800001
PM 32630032
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Monrad, JT
AF Monrad, Joshua Teperowski
TI Ethical considerations for epidemic vaccine trials
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE ethics; clinical trials
ID VULNERABILITY; EFFICACY
AB Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines.
C1 [Monrad, Joshua Teperowski] Yale Univ, Program Eth Polit & Econ, New Haven, CT 06520 USA.
RP Monrad, JT (corresponding author), Yale Univ, Program Eth Polit & Econ, New Haven, CT 06520 USA.
EM joshua.monrad@yale.edu
CR Adebamowo C, 2014, LANCET, V384, P1423, DOI 10.1016/S0140-6736(14)61734-7
   Beauchamp T.L., 2012, PRINCIPLES BIOMEDICA
   Beckstead N., 2013, THESIS
   Benatar SR, 2000, BMJ-BRIT MED J, V321, P824, DOI 10.1136/bmj.321.7264.824
   Branswell H, 2019, DEBATE WHETHER TEST
   Branswell H, 2019, SPOT GOOD NEWS EBOLA
   CEPI, 2019, GLOB CONS WORK DRC G
   CIOMS, 2016, INT ETH GUID BIOM RE
   Doshi P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m734
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Hollis A, 2008, PUBLIC HEALTH ETH-UK, V1, P124, DOI 10.1093/phe/phn016
   Hurst SA, 2008, BIOETHICS, V22, P191, DOI 10.1111/j.1467-8519.2008.00631.x
   Kupferschmidt K, 2019, SCIENCE, V364, P1221, DOI 10.1126/science.364.6447.1221
   London AJ, 2019, BIOETHICS, V33, P326, DOI 10.1111/bioe.12467
   Luseno WK, 2019, AIDS BEHAV, V23, P3460, DOI 10.1007/s10461-019-02620-7
   Mahamba F, 2019, REUTERS
   Metzger WG, 2018, LANCET, V391, P1021, DOI 10.1016/S0140-6736(18)30560-9
   Millett P, 2017, HEALTH SECUR, V15, P335, DOI 10.1089/hs.2017.0044
   Molyneux M, 2017, HUM VACC IMMUNOTHER, V13, P2160, DOI 10.1080/21645515.2016.1272744
   National Academies of Sciences Engineering and Medicine Health and Medicine Division; Board on Health Sciences Policy Board on Global Health, 2017, INT CLIN RES EP RESP
   National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH PRINC G
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Reverby SM, 2012, PUBLIC HEALTH REV, V34, DOI 10.1007/BF03391665
   Schroeder D, 2009, CAMB Q HEALTHC ETHIC, V18, P113, DOI 10.1017/S0963180109090203
   Schwartz JL, 2018, AM J PUBLIC HEALTH, V108, P1455, DOI 10.2105/AJPH.2018.304581
   SFRC Subcommittee on Africa and Global Health, 2019, EB HEAR
   Snyder CM, 2011, HEALTH AFFAIR, V30, P1508, DOI 10.1377/hlthaff.2011.0403
   Washington HA, 2011, DEADLY MONOPOLIES SH
   Winslow RL, 2017, JAMA-J AM MED ASSOC, V317, P1074, DOI 10.1001/jama.2016.20644
   World Health Organisation, 2019, PREL RES EFF RVSV ZE
NR 34
TC 3
Z9 3
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD JUL
PY 2020
VL 46
IS 7
BP 465
EP 469
DI 10.1136/medethics-2020-106235
PG 5
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
   Biomedical Social Sciences
GA MM3GJ
UT WOS:000550043000011
PM 32414757
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Milewska, A
   Kula-Pacurar, A
   Wadas, J
   Suder, A
   Szczepanski, A
   Dabrowska, A
   Owczarek, K
   Marcello, A
   Ochman, M
   Stacel, T
   Rajfur, Z
   Sanak, M
   Labaj, P
   Branicki, W
   Pyrc, GK
AF Milewska, Aleksandra
   Kula-Pacurar, Anna
   Wadas, Jakub
   Suder, Agnieszka
   Szczepanski, Artur
   Dabrowska, Agnieszka
   Owczarek, Katarzyna
   Marcello, Alessandro
   Ochman, Marek
   Stacel, Tomasz
   Rajfur, Zenon
   Sanak, Marek
   Labaj, Pawel
   Branicki, Wojciech
   Pyrc, G. Krzysztof
TI Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human
   Respiratory Epithelium
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE COVID-19; Coronaviridae; FISH; HAE; NCoV-2019; SARS; SARS-CoV-2;
   coronavirus; human airway epithelium; model
ID AIRWAY
AB Currently, there are four seasonal coronaviruses associated with relatively mild respiratory tract disease in humans. However, there is also a plethora of animal coronaviruses which have the potential to cross the species border. This regularly results in the emergence of new viruses in humans. In 2002, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged and rapidly disappeared in May 2003. In 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) was identified as a possible threat to humans, but its pandemic potential so far is minimal, as human-to-human transmission is ineffective. The end of 2019 brought us information about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emergence, and the virus rapidly spread in 2020, causing an unprecedented pandemic. At present, studies on the virus are carried out using a surrogate system based on the immortalized simian Vero E6 cell line. This model is convenient for diagnostics, but it has serious limitations and does not allow for understanding of the biology and evolution of the virus. Here, we show that fully differentiated human airway epithelium cultures constitute an excellent model to study infection with the novel human coronavirus SARS-CoV-2. We observed efficient replication of the virus in the tissue, with maximal replication at 2 days postinfection. The virus replicated in ciliated cells and was released apically.
   IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged by the end of 2019 and rapidly spread in 2020. At present, it is of utmost importance to understand the biology of the virus, rapidly assess the treatment potential of existing drugs, and develop new active compounds. While some animal models for such studies are under development, most of the research is carried out in Vero E6 cells. Here, we propose fully differentiated human airway epithelium cultures as a model for studies on SARS-CoV-2.
C1 [Milewska, Aleksandra; Kula-Pacurar, Anna; Suder, Agnieszka; Szczepanski, Artur; Dabrowska, Agnieszka; Owczarek, Katarzyna; Labaj, Pawel; Branicki, Wojciech; Pyrc, G. Krzysztof] Jagiellonian Univ, Malopolska Ctr Biotechnol, Krakow, Poland.
   [Milewska, Aleksandra; Wadas, Jakub; Szczepanski, Artur; Dabrowska, Agnieszka] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Microbiol Dept, Krakow, Poland.
   [Marcello, Alessandro] Int Ctr Genet Engn & Biotechnol ICGEB, Lab Mol Virol, Trieste, Italy.
   [Ochman, Marek; Stacel, Tomasz] Med Univ Silesia, Silesian Ctr Heart Dis, Dept Cardiac Vasc & Endovasc Surg & Transplantol, Zabrze, Poland.
   [Rajfur, Zenon] Jagiellonian Univ, Fac Phys Astron & Appl Comp Sci, Inst Phys, Krakow, Poland.
   [Sanak, Marek] Jagiellonian Univ Med Coll, Dept Internal Med 2, Fac Med, Krakow, Poland.
RP Pyrc, GK (corresponding author), Jagiellonian Univ, Malopolska Ctr Biotechnol, Krakow, Poland.
EM k.a.pyrc@uj.edu.pl
RI Kula-Pacurar, Anna/AAX-1746-2020
OI Szczepanski, Artur/0000-0003-0421-9520; Branicki,
   Wojciech/0000-0002-7412-5733; Marcello, Alessandro/0000-0002-8903-8202;
   Labaj, Pawel/0000-0002-4994-0234; Kula-Pacurar, Anna/0000-0001-8404-2176
FU Ministry of Science and Higher EducationMinistry of Science and Higher
   Education, Poland [SARS-CoV-2]; National Science CenterNational Science
   Center, PolandNational Science Centre, Poland [UMO-2017/27/B/NZ6/02488,
   UMO-2018/30/E/NZ1/00874]
FX This work was supported by funds provided by the Ministry of Science and
   Higher Education for research on SARS-CoV-2 and grants from the National
   Science Center (grants UMO-2017/27/B/NZ6/02488 to K.P. and
   UMO-2018/30/E/NZ1/00874 to A.K.-P.).
CR Chen S, 2019, REPROD DOMEST ANIM, V54, P38, DOI 10.1111/rda.13481
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Jonsdottir HR, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0479-5
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Milewska A., 2020, BIORXIV, DOI [10.1101/2020.03.01.971499, DOI 10.1101/2020.03.01.971499]
   Milewska A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24448-2
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106
   NASKALSKA A, 2018, PLOS ONE, V13
   Pyrc K, 2006, J MOL BIOL, V364, P964, DOI 10.1016/j.jmb.2006.09.074
   Pyrc K, 2010, J VIROL, V84, P11255, DOI 10.1128/JVI.00947-10
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sharif-Yakan A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004457
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
NR 21
TC 4
Z9 4
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2020
VL 94
IS 15
AR e00957-20
DI 10.1128/JVI.00957-20
PG 7
WC Virology
SC Virology
GA MM5CK
UT WOS:000550174300001
PM 32434888
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lew, HL
   Oh-Park, M
   Cifu, DX
AF Lew, Henry L.
   Oh-Park, Mooyeon
   Cifu, David X.
TI The War on COVID-19 Pandemic Role of Rehabilitation Professionals and
   Hospitals
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE COVID-19; Pandemic; Rehabilitation
AB The global outbreak of coronavirus disease 2019 has created an unprecedented challenge to the society. Currently, the United States stands as the most affected country, and the entire healthcare system is affected, from emergency department, intensive care unit, postacute care, outpatient, to home care. Considering the debility, neurological, pulmonary, neuromuscular, and cognitive complications, rehabilitation professionals can play an important role in the recovery process for individuals with coronavirus disease 2019. Clinicians across the nation's rehabilitation system have already begun working to initiate intensive care unit-based rehabilitation care and develop programs, settings, and specialized care to meet the short- and long-term needs of these individuals. We describe the anticipated rehabilitation demands and the strategies to meet the needs of this population. The complications from coronavirus disease 2019 can be reduced by (1) delivering interdisciplinary rehabilitation that is initiated early and continued throughout the acute hospital stay, (2) providing patient/family education for self-care after discharge from inpatient rehabilitation at either acute or subacute settings, and (3) continuing rehabilitation care in the outpatient setting and at home through ongoing therapy either in-person or via telehealth.
C1 [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Commun Sci & Disorders, Speech & Hearing Clin, Honolulu, HI 96822 USA.
   [Lew, Henry L.; Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA.
   [Oh-Park, Mooyeon] Burke Rehabil Hosp, 785 Mamaroneck Ave, White Plains, NY 10605 USA.
   [Oh-Park, Mooyeon] Montefiore Hlth Syst, Albert Einstein Coll Med, Arthur S Abramson Dept Rehabil Med, Bronx, NY USA.
   [Cifu, David X.] US Dept Vet Affairs, Montrose, VA USA.
   [Cifu, David X.] Chron Effects Neurotrauma Consortium LIMBIC CENC, Long Term Impact Mil Relevant Brain Injury Consor, Richmond, VA USA.
RP Oh-Park, M (corresponding author), Burke Rehabil Hosp, 785 Mamaroneck Ave, White Plains, NY 10605 USA.
CR ACGME, STAG 3 PAND EM STAT
   [Anonymous], 2020, SEVERE OUTCOMES PATI
   Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
NR 5
TC 3
Z9 3
U1 6
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JUL
PY 2020
VL 99
IS 7
BP 571
EP 572
DI 10.1097/PHM.0000000000001460
PG 2
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA MM1OZ
UT WOS:000549929300002
PM 32371624
OA Green Published
DA 2021-01-01
ER

PT J
AU Yu, YT
   Li, YJ
   Zhang, ZH
   Gu, ZC
   Zhong, H
   Zha, QF
   Yang, LY
   Zhu, C
   Chen, EZ
AF Yu, Yuetian
   Li, Yujie
   Zhang, Zhongheng
   Gu, Zhichun
   Zhong, Han
   Zha, Qiongfang
   Yang, Luyu
   Zhu, Cheng
   Chen, Erzhen
TI A bibliometric analysis using VOSviewer of publications on COVID-19
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Bibliometric analysis; novel coronavirus; coronavirus disease 2019
   (COVID-19); SARS-CoV-2; trends
AB Background: As a global pandemic, COVID-19 has aroused great concern in the last few months and a growing number of related researches have been published. Therefore, a bibliometric analysis of these publications may provide a direction of hot topics and future research trends.
   Methods: The global literatures about COVID-19 published between 2019 and 2020 were scanned in the Web of Science collection database. "COVID-19" "Novel Coronavirus" "2019-nCoV" and "SARS-CoV-2" were used as the keywords to reach the relevant publications. VOSviewer was applied to perform the bibliometric analysis of these articles.
   Results: Totally 3,626 publications on the topic of COVID-19 were identified and "COVID-19" with a total link strength of 2,649 appeared as the most frequent keyword, which had a strong link to "pneumonia" and "epidemiology". The mean citation count of the top 100 most cited articles was 96 (range, 26-883). Most of them were descriptive studies and concentrated on the clinical features. The highest-ranking journal was British medical journal with 211 publications and the most cited journal was Lancet with 2,485 citation counts. Eleven articles written by Christian Drosten from Berlin Institute of Virology have been cited for 389 times and 40 articles from Chinese Academy of Sciences have been cited for 1,597 times which are the most cited author and organization. The number of collaborators with China is 44 and the total link strength is 487. The main partners of China are USA, England and Germany. The published literatures have focused on three topics: disease management, clinical features and pathogenesis.
   Conclusions: The current growth trends predict a large increase in the number of global publications on COVID-19. China made the most outstanding contribution within this important field. Disease treatment, spike protein and vaccine may be hotspots in the future.
C1 [Yu, Yuetian; Li, Yujie] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Crit Care Med, Shanghai, Peoples R China.
   [Zhang, Zhongheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Emergency Med, Hangzhou, Peoples R China.
   [Gu, Zhichun; Zhong, Han] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Pharm, Shanghai, Peoples R China.
   [Zha, Qiongfang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Yang, Luyu] Wuhan Univ, Wuhan Hosp 3, Dept Intens Care Unit, Wuhan 430060, Peoples R China.
   [Zhu, Cheng; Chen, Erzhen] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Dept Emergency Med, Shanghai 200025, Peoples R China.
RP Yang, LY (corresponding author), Wuhan Univ, Wuhan Hosp 3, Dept Intens Care Unit, Wuhan 430060, Peoples R China.; Zhu, C; Chen, EZ (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Dept Emergency Med, Shanghai 200025, Peoples R China.
EM yangluyu_114@164.com; zhucheng1203@163.com; erzhenchen1963@sina.com
RI Zhang, Zhongheng/E-1282-2011
OI Zhang, Zhongheng/0000-0002-2336-5323
CR Brown A, 2020, LANCET, V395, P1099, DOI 10.1016/S0140-6736(20)30742-X
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen CM, 2014, EXPERT OPIN BIOL TH, V14, P1295, DOI 10.1517/14712598.2014.920813
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Mukherjee R, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00040-7
   Stephan P, 2017, NATURE, V544, P411, DOI 10.1038/544411a
   Vanden Eynde JJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13040065
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Yousefi B, 2020, J CELL PHYSIOL, V235, P9133, DOI 10.1002/jcp.29785
   Zhong H, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104872
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 15
U2 15
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUL
PY 2020
VL 8
IS 13
AR 816
DI 10.21037/atm-20-4235
PG 12
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA MM3DZ
UT WOS:000550036800009
PM 32793661
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Melgaco, JG
   Azamor, T
   Bom, APDA
AF Melgaco, Juliana Gil
   Azamor, Tamiris
   Bom, Ana Paula Dinis Ano
TI Protective immunity after COVID-19 has been questioned: What can we do
   without SARS-CoV-2-IgG detection?
SO CELLULAR IMMUNOLOGY
LA English
DT Letter
ID T-CELL; MEMORY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps.
C1 [Melgaco, Juliana Gil; Azamor, Tamiris; Bom, Ana Paula Dinis Ano] Fiocruz MS, Oswaldo Cruz Fdn, Lab Immunol Technol, Immunobiol Technol Inst,Biomanguinhos, Ave Brasil 4365,Rocha Lima Bldg,4th Floor, BR-21040900 Rio De Janeiro, Brazil.
RP Melgaco, JG (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, Lab Immunol Technol, Immunobiol Technol Inst,Biomanguinhos, Ave Brasil 4365,Rocha Lima Bldg,4th Floor, BR-21040900 Rio De Janeiro, Brazil.
EM juliana.melgaco@bio.fiocruz.br
CR Bauer T, 2006, VACCINE, V24, P572, DOI 10.1016/j.vaccine.2005.08.058
   Grant EJ, 2016, CURR OPIN VIROL, V19, P99, DOI 10.1016/j.coviro.2016.08.015
   Huang A.T., 2020, INFECT DIS EXCEPT HI, DOI 10.1101/2020.04.14.20065771
   Melgaco JG, 2015, VACCINE, V33, P3813, DOI 10.1016/j.vaccine.2015.06.099
   Pizzolla A, 2019, J IMMUNOL, V202, P374, DOI 10.4049/jimmunol.1800979
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Thevarajan I, 2020, BREADTH CONCOMITANT, DOI [10.1101/2020.02.20.20025841, DOI 10.1101/2020.02.20.20025841]
   Weiskopf D, 2020, PHENOTYPE SARS COV 2, DOI [10.1101/2020.04.11.20062349, DOI 10.1101/2020.04.11.20062349]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
NR 10
TC 8
Z9 9
U1 3
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PD JUL
PY 2020
VL 353
AR 104114
DI 10.1016/j.cellimm.2020.104114
PG 2
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA MM0IB
UT WOS:000549842900003
PM 32361409
OA Green Published
DA 2021-01-01
ER

PT J
AU Di Altobrando, A
   Patrizi, A
   Bardazzi, F
AF Di Altobrando, A.
   Patrizi, A.
   Bardazzi, F.
TI Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune
   blistering diseases?
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter
C1 [Di Altobrando, A.; Patrizi, A.; Bardazzi, F.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Div Dermatol, Bologna, Italy.
RP Patrizi, A (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Div Dermatol, Bologna, Italy.
EM annalisa.patrizi@unibo.it
OI Annalisa, Patrizi/0000-0002-8398-0483; Di Altobrando,
   Ambra/0000-0003-3236-8822
CR American Academy of Dermatology Association, GUID US BIOL AG COVI
   Baroero L, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0813-0
   Bilgic A, 2019, EXPERT REV CLIN PHAR, V12, P973, DOI 10.1080/17512433.2019.1670059
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Miyamoto D, 2019, AN BRAS DERMATOL, V94, P133, DOI 10.1590/abd1806-4841.20199007
   Ruocco E, 2014, DERMATOLOGY, V229, P310, DOI 10.1159/000365845
NR 6
TC 8
Z9 8
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD JUL
PY 2020
VL 34
IS 7
BP E295
EP E297
DI 10.1111/jdv.16491
PG 3
WC Dermatology
SC Dermatology
GA ML5FY
UT WOS:000549493000004
PM 32302437
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Naeem, S
   Ikram, R
   Shareef, H
   Ali, H
   Khan, SS
AF Naeem, Sadaf
   Ikram, Rahila
   Shareef, Huma
   Ali, Huma
   Khan, Saira Saeed
TI Herbs, Immunity and nCOVID-19: Old performers in new Pandemic
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Novel coronavirus (nCOVID-19); pandemic; pathogenesis; immunity; herbs
ID ANTIVIRAL ACTIVITY; CHINESE MEDICINE; CORONAVIRUS; SARS; PATHOGENESIS;
   SARS-COV-2; PNEUMONIA; GINGER; VIRUS
AB The novel coronavirus (nCOVID-19) has spread to endless nations and turn out to be a pandemic around the globe. Because of the developing number of affirmed cases and open public hazard owing to its high risk of infection rate, it has expected a lot of consideration from world health organizations and national health regulatory and monitoring agencies. The world is in surge to explore or discover novel treatment options and vaccine that can lead to cure. There is no proven effective treatment for nCOVID-19 however along with available antiviral therapy Chinese researchers recommended herbal treatments as effective and alternative treatments options to treat this pandemic. Herbal products are wealthy in dynamic phytochemicals, such as the terpenoids, various collection of flavonoids, sulfides, lignans constiuents, coumarins concentrates, saponins moities, polyphenolics composite, numerous alkaloids, polyines, furyl mixtures, proteins and related compounds, thiophenes and peptides groups. In this review we discussed pathogeneis, immunity and current herbal treatment strategies of nCOVID-19 to cure this world wide pandemic.
C1 [Naeem, Sadaf; Shareef, Huma; Ali, Huma] Jinnah Sindh Med Univ, Inst Pharmaceut Sci, Karachi, Pakistan.
   [Ikram, Rahila; Khan, Saira Saeed] Univ Karachi, Fac Pharm & Pharmaceut Sci, Dept Pharmacol, Karachi, Pakistan.
RP Naeem, S (corresponding author), Jinnah Sindh Med Univ, Inst Pharmaceut Sci, Karachi, Pakistan.
EM ssadafnaeem@gmail.com
CR Akinyemi AJ, 2016, J APPL BIOMED, V14, P59, DOI 10.1016/j.jab.2015.06.001
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   [Anonymous], 2020, NAT PLANTS, V6, P177, DOI 10.1038/s41477-020-0628-0
   Aqil K, 2018, PAK J ZOOL, V50, P2223, DOI 10.17582/journal.pjz/2018.50.6.2223.2228
   Arashiro T, 2020, EMERG INFECT DIS, V26, P6
   Beutler B, 2007, NAT REV IMMUNOL, V7, P753, DOI 10.1038/nri2174
   Bouchentouf S, 2020, IDENTIFICATION COMPO
   Burki TK, 2020, LANCET RESP MED, V8, P238, DOI 10.1016/S2213-2600(20)30056-4
   Catanzaro N, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197820
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chandel V., 2020, CHEM BIOL LETT, V7, P166, DOI DOI 10.20944/PREPRINTS202003.0349.V1
   Chang JS, 2013, J ETHNOPHARMACOL, V145, P146, DOI 10.1016/j.jep.2012.10.043
   Chen N, LANCET, V395, P507
   Chiesa MA, 2019, MOL PLANT PATHOL, V20, P254, DOI 10.1111/mpp.12752
   Conti P, 2020, J BIOL REGUL HOMEOST, V34, P2, DOI DOI 10.23812/EDIT0RIAL-C0NTI-2
   Dao TT, 2011, BIOORG MED CHEM LETT, V21, P294, DOI 10.1016/j.bmcl.2010.11.016
   Delano MJ, 2016, IMMUNOL REV, V274, P330, DOI 10.1111/imr.12499
   Dhawan BN, 2012, P NATL A SCI INDIA B, V82, P209, DOI 10.1007/s40011-011-0016-7
   Diao B, 2020, REDUCTION FUNCTIONAL
   Dibakar Goswami, 2020, NATURAL PRODUCT COMP
   Ding WX, 2014, J ETHNOPHARMACOL, V155, P589, DOI 10.1016/j.jep.2014.05.066
   Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Haider Z., 2020, SILICO DISCOVERY NOV
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   LI GD, 2020, HYPERTENS RES, P1, DOI DOI 10.14232/EJQTDE.2020.1.30
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li T, 2013, ANTIVIR RES, V97, P1, DOI 10.1016/j.antiviral.2012.10.006
   Lillehoj H, 2018, VET RES, V49, DOI 10.1186/s13567-018-0562-6
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Makni M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6251546
   McDermott J H, 2000, J Am Pharm Assoc (Wash), V40, P785
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542
   Qamar MT, 2020, J PHARM ANAL, V9, P22
   Qamar MT, 2020, STRUCTURAL BASIS SAR
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shidfar Farzad, 2015, J Complement Integr Med, V12, P165, DOI 10.1515/jcim-2014-0021
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x
   Tan BKH, 2004, CURR MED CHEM, V11, P1423, DOI 10.2174/0929867043365161
   Tariq S, 2019, MICROB PATHOGENESIS, V134, DOI 10.1016/j.micpath.2019.103580
   Tinku Gupta M. M., 2018, AJPER, V7
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Ulasli M, 2014, MOL BIOL REP, V41, P1703, DOI 10.1007/s11033-014-3019-7
   Utomo R. Y., 2020, REVEALING POTENCY CI, DOI [10.20944/preprints202003.0214.v1, DOI 10.20944/PREPRINTS202003.0214.V1, 10.20944/preprints202003.0214.v1.]
   Verity R, 2020, LANCET INFECT DIS, p[S1473, 30243]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   World Health Organization (WHO), WHO B, P1
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang N.S., 1999, J CHINESE MED, V10, P179
   Yang XW, 1999, J NAT PROD, V62, P1510, DOI 10.1021/np990180u
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yousaf T, 2018, MICROB PATHOGENESIS, V118, P154, DOI 10.1016/j.micpath.2018.03.030
   Zhavoronkov A, 2020, CHEMRXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhuang SR, 2012, BRIT J NUTR, V107, P712, DOI 10.1017/S000711451100345X
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 72
TC 0
Z9 0
U1 5
U2 5
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD JUL
PY 2020
VL 33
IS 4
BP 1747
EP 1753
DI 10.36721/PJPS.2020.33.4.REG.1747-1753.1
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ML4FH
UT WOS:000549423400040
DA 2021-01-01
ER

PT J
AU Liu, HL
   He, X
   Wang, YD
   Zhou, SN
   Zhang, DL
   Zhu, JY
   He, Q
   Zhu, ZJ
   Li, GM
   Sun, LB
   Wang, JL
   Cheng, G
   Liu, ZW
   Lau, G
AF Liu, Hongling
   He, Xi
   Wang, Yudong
   Zhou, Shuangnan
   Zhang, Dali
   Zhu, Jiye
   He, Qiang
   Zhu, Zhijun
   Li, Guangming
   Sun, Libo
   Wang, Jianli
   Cheng, Gregory
   Liu, Zhenwen
   Lau, George
TI Management of COVID-19 in patients after liver transplantation: Beijing
   working party for liver transplantation
SO HEPATOLOGY INTERNATIONAL
LA English
DT Article
DE 2019-nCoV; COVID-19; Liver transplantation; Management
ID ACUTE RESPIRATORY SYNDROME
AB Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.
C1 [Liu, Hongling; He, Xi; Zhou, Shuangnan; Zhang, Dali; Liu, Zhenwen; Lau, George] Chinese Peoples Liberat Army Gen Hosp, Liver Transplantat Ctr, Med Ctr 5, 100 West 4th Ring Middle Rd, Beijing 100039, Peoples R China.
   [Wang, Yudong; Cheng, Gregory; Lau, George] Humanity & Hlth Clin Trial Ctr, Humanity & Hlth Med Grp, Unit 2101,21F,9 Queens Rd, Hong Kong, Peoples R China.
   [Zhu, Jiye] Beijing Med Univ, Peoples Hosp, Dept Surg, Beijing 100044, Peoples R China.
   [He, Qiang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hepatobiliary & Pancreaticosplen Surg, Beijing 100020, Peoples R China.
   [Zhu, Zhijun] Capital Med Univ, Beijing Friendship Hosp, Clin Ctr Pediat Liver Transplantat, Beijing 100050, Peoples R China.
   [Li, Guangming; Sun, Libo] Capital Med Univ, Beijing Youan Hosp, Dept Gen Surg, Beijing 100069, Peoples R China.
   [Li, Guangming; Sun, Libo] Capital Med Univ, Beijing Youan Hosp, Liver Transplant Ctr, Beijing 100069, Peoples R China.
   [Wang, Jianli] Chinese Peoples Liberat Army Gen Hosp, Dept Liver Transplantat, Med Ctr 3, Beijing 100039, Peoples R China.
RP Liu, ZW; Lau, G (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Liver Transplantat Ctr, Med Ctr 5, 100 West 4th Ring Middle Rd, Beijing 100039, Peoples R China.; Lau, G (corresponding author), Humanity & Hlth Clin Trial Ctr, Humanity & Hlth Med Grp, Unit 2101,21F,9 Queens Rd, Hong Kong, Peoples R China.
EM liuzhenwen@medmail.com.cn; gkklau@hnhmgl.com
CR Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen S, 2019, GUIDANCE CLIN DIAGNO, DOI [10.3760/cma.j.issn.0254, DOI 10.3760/CMA.J.ISSN.0254.HTTP://RS.YIGLE.C0M/M/YUFABIA0/1181145.HTM]
   China National Health Commission, NAT HLTH HLTH COMM P
   Chui AKK, 2004, TRANSPL P, V36, P2277, DOI 10.1016/j.transproceed.2004.08.036
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Shi HS, 2020, J CLIN RADIOL, DOI DOI 10.13437/J.CNKI.JCR.20200206.002
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 13
TC 17
Z9 18
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1936-0533
EI 1936-0541
J9 HEPATOL INT
JI Hepatol. Int.
PD JUL
PY 2020
VL 14
IS 4
BP 432
EP 436
DI 10.1007/s12072-020-10043-z
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ML6VR
UT WOS:000549601600003
PM 32277387
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lee, KCH
   Sewa, DW
   Phua, GC
AF Lee, Ken Cheah Hooi
   Sewa, Duu Wen
   Phua, Ghee Chee
TI Potential role of statins in COVID-19
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RANDOMIZED-TRIAL; INFLUENZA; THERAPY
AB Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Lee, Ken Cheah Hooi; Sewa, Duu Wen; Phua, Ghee Chee] Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore.
RP Lee, KCH (corresponding author), Dept Resp & Crit Care Med, 20 Coll Rd, Singapore 169856, Singapore.
EM ken.lee.c.h@singhealth.com.sg
CR Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   [Anonymous], 2020, ESC GUIDANCE DIAGNOS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arslan F, 2008, CIRC RES, V103, P334, DOI 10.1161/CIRCRESAHA.108.182220
   Biere-Rafi S, 2013, EUR HEART J, V34, P1800, DOI 10.1093/eurheartj/eht046
   Bozkurt B, 2020, HFSA ACC AHA STATEME
   Chansrichavala P, 2009, ASIAN PAC J ALLERGY, V27, P49
   de Simone G, 2020, J HUM HYPERTENS, V34, P547, DOI 10.1038/s41371-020-0366-9
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Fedson DS, 2018, J PUBLIC HEALTH POL, V39, P268, DOI 10.1057/s41271-018-0138-8
   Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   Fedson DS, 2015, INT J INFECT DIS, V36, P80, DOI 10.1016/j.ijid.2015.04.019
   Fedson DS, 2013, ANTIVIR RES, V99, P417, DOI 10.1016/j.antiviral.2013.06.018
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Gavriilaki E, 2020, BRIT J HAEMATOL, V189, pE227, DOI 10.1111/bjh.16783
   Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241
   Grimaldi D, 2016, MINERVA ANESTESIOL, V82, P1230
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kruger P, 2013, AM J RESP CRIT CARE, V187, P743, DOI 10.1164/rccm.201209-1718OC
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Laidler MR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv028
   Li J, 2020, J CLIN TRANSL HEPATO, V8, P13, DOI 10.14218/JCTH.2020.00019
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Poor HD, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.44
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 36
TC 6
Z9 6
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 615
EP 617
DI 10.1016/j.ijid.2020.05.115
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MM0DS
UT WOS:000549831500031
PM 32502659
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU MacIntyre, CR
   Chughtai, AA
   Seale, H
   Dwyer, DE
   Wang, QY
AF MacIntyre, C. Raina
   Chughtai, Abrar A.
   Seale, Holly
   Dwyer, Dominic E.
   Quanyi Wang
TI Human coronavirus data from four clinical trials of masks and
   respirators
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID MEDICAL MASKS; N95 RESPIRATORS; INFLUENZA TRANSMISSION; PREVENTING
   INFLUENZA; HAND HYGIENE; VIRUS; INFECTION; EFFICACY
AB There are few published data on the efficacy of masks or respirators against coronavirus infections. This is an important research question to inform the response to the COVID-19 epidemic. The transmission modes of human coronaviruses are similar, thought to be by droplet, contact, and sometimes airborne routes. There are several randomized clinical trials of masks and respirators, but most used clinical endpoints or tested only for influenza. In four trials that we conducted, we tested for human coronaviruses, but only composite viral endpoints were reported in the trials. We reviewed and analyzed the coronavirus data from four of our trials. Laboratory-confirmed coronavirus infections were identified in our community household trial (one case), health worker trials (eight cases), and trial of mask use by sick patients (19 cases). No coronavirus infections were transmitted in households to parents who wore P2 or surgical masks, but one child with coronavirus infection transmitted infection to a parent in the control arm. No transmissions to close contacts occurred when worn by sick patients with coronavirus infections. There was a higher risk of coronavirus infection in HCWs who wore a mask compared to a respirator, but the difference was not statistically significant. These are the only available clinical trial data on coronavirus infections associated with mask or respirator use. More clinical trials are needed to assess the efficacy of respiratory protection against coronavirus infections. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [MacIntyre, C. Raina] Univ New South Wales, Biosecur Program, Kirby Inst, UNSW Med, Sydney, NSW 2052, Australia.
   Univ New South Wales, UNSW Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [Quanyi Wang] Beijing CDC, Inst Infect Dis & Endem Dis Control, Beijing, Peoples R China.
   [Dwyer, Dominic E.] Westmead Hosp, Inst Clin Pathol & Med Reseach, Sydney, NSW, Australia.
RP MacIntyre, CR (corresponding author), Univ New South Wales, Biosecur Program, Kirby Inst, UNSW Med, Sydney, NSW 2052, Australia.
EM rainam@protonmail.com
RI Seale, Holly/D-4200-2011
OI Seale, Holly/0000-0002-1877-5395
CR Aiello AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029744
   Aiello AE, 2010, J INFECT DIS, V201, P491, DOI 10.1086/650396
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142
   Jacobs JL, 2009, AM J INFECT CONTROL, V37, P417, DOI 10.1016/j.ajic.2008.11.002
   Johnson DF, 2009, CLIN INFECT DIS, V49, P275, DOI 10.1086/600041
   Larson EL, 2010, PUBLIC HEALTH REP, V125, P178, DOI 10.1177/003335491012500206
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2017, INFLUENZA OTHER RESP, V11, P511, DOI 10.1111/irv.12474
   MacIntyre CR, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012330
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Maclntyre CR, 2009, EMERG INFECT DIS, V15, P233, DOI 10.3201/eid1502.081167
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Simmerman JM, 2011, INFLUENZA OTHER RESP, V5, P256, DOI 10.1111/j.1750-2659.2011.00205.x
   Suess T, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-26
   US Centers for Disease Control, 2020, GUID WEAR REM PERS P
   US Centers for Disease Control and Prevention, INT INF PREV CONTR R
   van der Hoek L, 2007, ANTIVIR THER, V12, P651
   Wang X, 2020, ASS 2019 NCOV TRANSM, DOI [10.1101/2020.02.18.20021881, DOI 10.1101/2020.02.18.20021881]
   World Health Organization, 2020, RAT US PERS PROT EQ
   Wu Z, 2020, JAMA
NR 23
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 631
EP 633
DI 10.1016/j.ijid.2020.05.092
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MM0DS
UT WOS:000549831500033
PM 32497810
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jacobs, JP
   Stammers, AH
   St Louis, J
   Hayanga, JWA
   Firstenberg, MS
   Mongero, LB
   Tesdahl, EA
   Rajagopal, K
   Cheema, FH
   Coley, T
   Badhwar, V
   Sestokas, AK
   Slepian, MJ
AF Jacobs, Jeffrey P.
   Stammers, Alfred H.
   St Louis, James
   Hayanga, J. W. Awori
   Firstenberg, Michael S.
   Mongero, Linda B.
   Tesdahl, Eric A.
   Rajagopal, Keshava
   Cheema, Faisal H.
   Coley, Tom
   Badhwar, Vinay
   Sestokas, Anthony K.
   Slepian, Marvin J.
TI Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary
   and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32
   Patients
SO ASAIO JOURNAL
LA English
DT Article
DE extracorporeal membrane oxygenation; coronavirus; coronavirus disease
   2019; pulmonary failure; acute respiratory distress syndrome; heart
   failure; outcomes; quality
ID COVID-19 PATIENTS; CYTOKINE STORM; ECMO; PNEUMONIA; SEPSIS
AB As coronavirus disease 2019 (COVID-19) cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO. A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020, when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020. During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at nine different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died before or shortly after decannulation, and five are alive and extubated after removal from ECMO, with one of these five discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: four of five survivors received intravenous steroids, three of five survivors received antiviral medications (Remdesivir), two of five survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and one of five survivors received hydroxychloroquine. Analysis of these 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and acute respiratory distress syndrome (ARDS). These initial data may provide useful information to help define the best strategies to care for these challenging patients and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19.
C1 [Jacobs, Jeffrey P.; Stammers, Alfred H.; Mongero, Linda B.; Tesdahl, Eric A.; Coley, Tom; Sestokas, Anthony K.] SpecialtyCare Inc, Med Dept, Nashville, TN USA.
   [Jacobs, Jeffrey P.; Hayanga, J. W. Awori; Badhwar, Vinay] West Virginia Univ, Dept Cardiovasc & Thorac Surg, Morgantown, WV 26506 USA.
   [St Louis, James] Univ Missouri, Sch Med, Dept Surg, Kansas City, MO 64108 USA.
   [Firstenberg, Michael S.] Med Ctr Aurora, Dept Cardiothorac & Vasc Surg, Aurora, CO USA.
   [Rajagopal, Keshava; Cheema, Faisal H.] Univ Houston, Coll Med, Dept Clin Sci, HCA Houston Healthcare, Houston, TX USA.
   [Cheema, Faisal H.] HCA Res Inst, Nashville, TN USA.
   [Slepian, Marvin J.] Univ Arizona, Sarver Heart Ctr, Dept Med, 1501 North Campbell Ave, Tucson, AZ 85724 USA.
   [Slepian, Marvin J.] Univ Arizona, Sarver Heart Ctr, Dept Biomed Engn, 1501 North Campbell Ave, Tucson, AZ 85724 USA.
RP Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Med, 1501 North Campbell Ave, Tucson, AZ 85724 USA.; Slepian, MJ (corresponding author), Univ Arizona, Sarver Heart Ctr, Dept Biomed Engn, 1501 North Campbell Ave, Tucson, AZ 85724 USA.; Jacobs, JP (corresponding author), 2021 Brightwaters Blvd, St Petersburg, FL 33704 USA.
EM JeffJacobs@msn.com; chairman.syns@gmail.com
RI Slepian, Marvin/ABG-8305-2020
OI Slepian, Marvin/0000-0002-7864-6691
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM104942] Funding Source: Medline
CR Abrams D, 2019, LANCET RESP MED, V7, P108, DOI 10.1016/S2213-2600(18)30506-X
   [Anonymous], 2020, EXTRACORPOREAL LIFE
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Centers for Disease Control and Prevention (CDC) of the United States of America, 2009, H1N1 PAND H1N1PDM09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Field D, 1996, LANCET, V348, P75
   Firstenberg MS, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00243-9
   Fortenberry James D, 2006, Semin Pediatr Infect Dis, V17, P72, DOI 10.1053/j.spid.2006.04.005
   Harm S, 2020, BLOOD PURIFICAT, V49, P33, DOI 10.1159/000502680
   Hartman ME, 2020, ASAIO J, V66, P603, DOI 10.1097/MAT.0000000000001177
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   John Hopkins University Corona Virus Resource Center, 2020, COR COVID 19 GLOB CA
   Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Rajagopal K, 2020, ASAIO J, V66, P588, DOI 10.1097/MAT.0000000000001180
   Risnes I, 2008, PERFUSION-UK, V23, P173, DOI 10.1177/0267659108097882
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shah SM, 2018, CARDIOL YOUNG, V28, P1316, DOI 10.1017/S1047951118001282
   US Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   WHO, 2020, CLIN MAN SEV AC RESP
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 27
TC 36
Z9 36
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD JUL
PY 2020
VL 66
IS 7
BP 722
EP 730
DI 10.1097/MAT.0000000000001185
PG 9
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA MJ2AE
UT WOS:000547893900008
PM 32317557
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Loforte, A
   Dal Checco, E
   Gliozzi, G
   Benedetto, M
   Cavalli, GG
   Mariani, C
   Piccone, G
   Agulli, M
   Pacini, D
   Baiocchi, M
AF Loforte, Antonio
   Dal Checco, Erika
   Gliozzi, Gregorio
   Benedetto, Maria
   Cavalli, Giulio Giovanni
   Mariani, Carlo
   Piccone, Giulia
   Agulli, Marta
   Pacini, Davide
   Baiocchi, Massimo
TI Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19
   Respiratory Distress Syndrome: Initial Experience
SO ASAIO JOURNAL
LA English
DT Article
DE COVID-19; pandemic; ARDS; extracorporeal membrane oxygenation
AB SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.
C1 [Loforte, Antonio; Gliozzi, Gregorio; Cavalli, Giulio Giovanni; Mariani, Carlo; Pacini, Davide] ALMA Mater Studiorum Univ Bologna, S Orsola Hosp, Cardiac Surg Unit, Cardiothorac Vasc Dept, Via Massarenti 9, I-40138 Bologna, Italy.
   [Dal Checco, Erika; Benedetto, Maria; Piccone, Giulia; Agulli, Marta; Baiocchi, Massimo] ALMA Mater Studiorum Univ Bologna, S Orsola Hosp, Anaesthesiol & Intens Care Unit, Cardiothorac Vasc Dept, Bologna, Italy.
RP Loforte, A (corresponding author), ALMA Mater Studiorum Univ Bologna, S Orsola Hosp, Cardiac Surg Unit, Cardiothorac Vasc Dept, Via Massarenti 9, I-40138 Bologna, Italy.
EM antonioloforte@yahoo.it
RI Loforte, Antonio/K-4919-2018
OI Loforte, Antonio/0000-0002-3689-0477; Cavalli, Giulio
   Giovanni/0000-0002-4304-8739
CR Akar AR, 2020, TURK GOGUS KALP DAMA, V28, P229, DOI 10.5606/tgkdc.dergisi.2020.09293
   ELSO, COVID 19 CAS ECMO EL
   Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   World Health Organization, ROLL UPD COR DIS COV
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 8
TC 2
Z9 2
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD JUL
PY 2020
VL 66
IS 7
BP 734
EP 738
DI 10.1097/MAT.0000000000001198
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA MJ2AE
UT WOS:000547893900010
PM 32597627
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Scarano, A
   Inchingolo, F
   Lorusso, F
AF Scarano, Antonio
   Inchingolo, Francesco
   Lorusso, Felice
TI Facial Skin Temperature and Discomfort When Wearing Protective Face
   Masks: Thermal Infrared Imaging Evaluation and Hands Moving the Mask
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE N95 respirators; surgical mask; protective face masks; COVID-19;
   Infection control; Infrared Imaging
ID RANDOMIZED CLINICAL-TRIAL; HEALTH-CARE WORKERS; N95 RESPIRATORS; MEDICAL
   MASKS; HEART-RATE; SENSITIVITY; INFECTION; SURFACE; TIME
AB Individual respiratory protective devices and face masks represent critical tools in protecting health care workers in hospitals and clinics, and play a central role in decreasing the spread of the high-risk pandemic infection of 2019, coronavirus disease (COVID-19). The aim of the present study was to compare the facial skin temperature and the heat flow when wearing medical surgical masks to the same factors when wearing N95 respirators. A total of 20 subjects were recruited and during the evaluation, each subject was invited to wear a surgical mask or respirator for 1 h. The next day in the morning at the same hour, the same subject wore a N95 mask for 1 h with the same protocol. Infrared thermal evaluation was performed to measure the facial temperature of the perioral region and the perception ratings related to the humidity, heat, breathing difficulty, and discomfort were recorded. A significant difference in heat flow and perioral region temperature was recorded between the surgical mask and the N95 respirator (p< 0.05). A statistically significant difference in humidity, heat, breathing difficulty, and discomfort was present between the groups. The study results suggest that N95 respirators are able to induce an increased facial skin temperature, greater discomfort and lower wearing adherence when compared to the medical surgical masks.
C1 [Scarano, Antonio; Lorusso, Felice] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, I-66100 Chieti, Italy.
   [Inchingolo, Francesco] Univ Bari Aldo Moro, Dept Interdisciplinary Med, I-70121 Bari, Italy.
RP Scarano, A (corresponding author), Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, I-66100 Chieti, Italy.
EM ascarano@unich.it; Francesco.inchingolo@uniba.it;
   felice.lorusso@unich.it
RI Lorusso, Felice/ABF-3222-2020; Lorusso, Felice/A-3906-2017; SCARANO,
   Antonio/F-6961-2017
OI Lorusso, Felice/0000-0002-2660-9231; Lorusso,
   Felice/0000-0002-2660-9231; SCARANO, Antonio/0000-0003-1374-6146
CR Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Christensen J, 2012, DENTOMAXILLOFAC RAD, V41, P662, DOI 10.1259/dmfr/55922484
   Cotter JD, 2005, J PHYSIOL-LONDON, V565, P335, DOI 10.1113/jphysiol.2004.081562
   CRAWSHAW LI, 1975, PFLUG ARCH EUR J PHY, V354, P19, DOI 10.1007/BF00584500
   FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869
   Gu J, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1867, DOI 10.1177/1010539512443699
   Hanson MA, 1999, ANN OCCUP HYG, V43, P309, DOI 10.1016/S0003-4878(99)00053-8
   Laird IS, 2002, ANN OCCUP HYG, V46, P143, DOI 10.1093/annhyg/mef015
   Lee VJ, 2020, LANCET INFECT DIS, V20, P17, DOI 10.1016/S1473-3099(19)30674-7
   Lenhardt R, 2006, ANESTHESIOLOGY, V105, P1117, DOI 10.1097/00000542-200612000-00011
   Li Y, 2005, INT ARCH OCC ENV HEA, V78, P501, DOI 10.1007/s00420-004-0584-4
   Luximon Y, 2016, WORK, V54, P825, DOI 10.3233/WOR-162353
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2017, INFLUENZA OTHER RESP, V11, P511, DOI 10.1111/irv.12474
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Marrakchi S, 2007, CONTACT DERMATITIS, V57, P28, DOI 10.1111/j.1600-0536.2007.01138.x
   NADEL ER, 1973, PFLUG ARCH EUR J PHY, V340, P71, DOI 10.1007/BF00592198
   Nakamura M, 2013, EUR J APPL PHYSIOL, V113, P63, DOI 10.1007/s00421-012-2406-9
   Offeddu V, 2017, CLIN INFECT DIS, V65, P1934, DOI 10.1093/cid/cix681
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Scarano A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041019
   Scarano A, 2019, LASER SURG MED, V51, P516, DOI 10.1002/lsm.23054
   Scarano A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061277
   Smith JD, 2016, CAN MED ASSOC J, V188, P567, DOI 10.1503/cmaj.150835
   Stevens JC, 1998, SOMATOSENS MOT RES, V15, P13
   STEVENS JC, 1974, PHYSIOL BEHAV, V13, P825, DOI 10.1016/0031-9384(74)90269-8
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Wang LJ, 2016, PHYSIOL BEHAV, V157, P270, DOI 10.1016/j.physbeh.2016.02.018
   Yip W.L., 2005, HONG KONG J EMERG ME, V12, P23, DOI DOI 10.1177/102490790501200102
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 31
TC 7
Z9 7
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUL
PY 2020
VL 17
IS 13
AR 4624
DI 10.3390/ijerph17134624
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA MM6XS
UT WOS:000550298500001
PM 32605056
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borghesi, A
   Zigliani, A
   Golemi, S
   Carapella, N
   Maculotti, P
   Farina, D
   Maroldi, R
AF Borghesi, Andrea
   Zigliani, Angelo
   Golemi, Salvatore
   Carapella, Nicola
   Maculotti, Patrizia
   Farina, Davide
   Maroldi, Roberto
TI Chest X-ray severity index as a predictor of in-hospital mortality in
   coronavirus disease 2019: A study of 302 patients from Italy
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Chest X-ray; Scoring system
AB Objectives: This study aimed to assess the usefulness of a new chest X-ray scoring system - the Brixia score - to predict the risk of in-hospital mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).
   Methods: Between March 4, 2020 and March 24, 2020, all CXR reports including the Brixia score were retrieved. We enrolled only hospitalized Caucasian patients with COVID-19 for whom the final outcome was available. For each patient, age, sex, underlying comorbidities, immunosuppressive therapies, and the CXR report containing the highest score were considered for analysis. These independent variables were analyzed using a multivariable logistic regression model to extract the predictive factors for inhospital mortality.
   Results: 302 Caucasian patients who were hospitalized for COVID-19 were enrolled. In the multivariable logistic regression model, onlyBrixia score, patient age, and conditions that induced immunosuppression were the significant predictive factors for in-hospital mortality. According to receiver operating characteristic curve analyses, the optimal cutoff values for Brixia score and patient age were 8 points and 71 years, respectively. Three different models that included the Brixia score showed excellent predictive power.
   Conclusions: Patients with a high Brixia score and at least one other predictive factor had the highest risk of in-hospital death. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Borghesi, Andrea; Zigliani, Angelo; Golemi, Salvatore; Carapella, Nicola; Maculotti, Patrizia; Farina, Davide; Maroldi, Roberto] Univ Brescia, Dept Med & Surg Specialties, ASST Spedali Civili Brescia, Radiol Sci & Publ Hlth, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
RP Borghesi, A (corresponding author), Univ Brescia, Dept Med & Surg Specialties, ASST Spedali Civili Brescia, Radiol Sci & Publ Hlth, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
EM andrea.borghesi@unibs.it
RI Borghesi, Andrea/Q-3772-2019
OI BORGHESI, Andrea/0000-0002-4761-2923; FARINA, Davide/0000-0003-4075-0001
CR Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Borghesi A, 2020, RADIOL MED, V125, P509, DOI 10.1007/s11547-020-01200-3
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   World Health Organization (WHO), 81 WHO
   Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548
   Zhou F, 2020, LANCET, V6736, P1, DOI DOI 10.1016/S0140-6736(20)30566-3
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 11
TC 10
Z9 10
U1 6
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 291
EP 293
DI 10.1016/j.ijid.2020.05.021
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA MJ8EQ
UT WOS:000548321500013
PM 32437939
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Putra, BE
   Adiarto, S
   Dewayanti, SR
   Juzar, DA
AF Putra, Bayushi Eka
   Adiarto, Suko
   Dewayanti, Santi Rahayu
   Juzar, Dafsah Arifa
TI Viral exanthem with "Spins and needles sensation" on extremities of a
   COVID-19 patient: A self-reported case from an Indonesian medical
   frontliner
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Cutaneous manifestation; Pins and needles sensation; Medical
   personnel
AB Cutaneous manifestation is a newly reported clinical manifestation of COVID-19 infection. The clinical description of cutaneous manifestation is still not fully described. Our patient, a medical person, had viral exanthem distributed in the extremities along with a "Spins and needles sensation," which differs from a previously published paper on cutaneous manifestations. The differential diagnosis of drug-induced skin rash and hand-foot-mouth disease was ruled out based on the patient's previous history and course of the disease. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Putra, Bayushi Eka; Adiarto, Suko; Juzar, Dafsah Arifa] Univ Indonesia, Dept Cardiol & Vasc Med, Harapan Kita Natl Cardiovasc Ctr, Fac Med, Jakarta, Indonesia.
   [Dewayanti, Santi Rahayu] Univ Indonesia, Harapan Kita Natl Cardiovasc Ctr, Fac Med, Jakarta, Indonesia.
RP Putra, BE (corresponding author), Univ Indonesia, Dept Cardiol & Vasc Med, Harapan Kita Natl Cardiovasc Ctr, Fac Med, Jakarta, Indonesia.
EM ekaputra_bayushi@yahoo.com
RI Eka Putra, Bayushi/P-2014-2016
OI Eka Putra, Bayushi/0000-0002-3223-1108; Adiarto,
   Suko/0000-0002-2848-0566
FU National Cardiovascular Centre Harapan Kita
FX Publication is supported by National Cardiovascular Centre Harapan Kita.
CR An I, 2017, AUSTRALAS J DERMATOL, V58, pE253, DOI 10.1111/ajd.12563
   Gugus Tugas Percepatan, GUG TUG PERC PEN COV
   Hand-Foot-and-Mouth Disease (HFMD), PRACT ESS BACKGR PAT
   Kenneth McIntosh M, 2020, CORONAVIRUS DIS 2019
   Knopfel N, 2019, CLIN DERMATOL, V37, P213, DOI 10.1016/j.clindermatol.2019.01.009
   Lee CH, 2020, DERMATOL SIN, V38, P1, DOI 10.4103/ds.ds_5_20
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Shah SN, 2014, J CLIN DIAGN RES, V8, pZH01, DOI 10.7860/JCDR/2014/10173.4761
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhao JJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2008-y
NR 10
TC 6
Z9 7
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUL
PY 2020
VL 96
BP 355
EP 358
DI 10.1016/j.ijid.2020.05.020
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA MJ8EQ
UT WOS:000548321500020
PM 32437936
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lund, LC
   Reilev, M
   Hallas, J
   Kristensen, KB
   Thomsen, RW
   Christiansen, CF
   Sorensen, HT
   Johansen, NB
   Brun, NC
   Voldstedlund, M
   Stovring, H
   Thomsen, MK
   Christensen, S
   Pottegard, A
AF Lund, Lars Christian
   Reilev, Mette
   Hallas, Jesper
   Kristensen, Kasper Bruun
   Thomsen, Reimar Wernich
   Christiansen, Christian Fynbo
   Sorensen, Henrik Toft
   Johansen, Nanna Borup
   Brun, Nikolai Constantin
   Voldstedlund, Marianne
   Stovring, Henrik
   Thomsen, Marianne Kragh
   Christensen, Steffen
   Pottegard, Anton
TI Association of Nonsteroidal Anti-inflammatory Drug Use and Adverse
   Outcomes Among Patients Hospitalized With Influenza
SO JAMA NETWORK OPEN
LA English
DT Article
ID MORTALITY; PNEUMONIA; ASPIRIN
AB This cohort study examines the association of nonsteroidal anti-inflammatory drugs (NSAIDs) with adverse outcomes in patients hospitalized with influenza or influenza pneumonia.
   Importance During the ongoing coronavirus disease 2019 pandemic, case reports have suggested that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes. Objective To study the association of NSAID use with adverse outcomes in patients hospitalized with influenza or influenza pneumonia. Design, Setting, and Participants This cohort study used propensity score matching among 7747 individuals aged 40 years or older who were hospitalized with influenza, confirmed by polymerase chain reaction or antigen testing, between 2010 and 2018. Data were collected using Danish nationwide registers. All analyses reported were performed on May 29, 2020. Exposures Prescription fill of an NSAID within 60 days before admission. Main Outcomes and Measures Risk ratio (RR) and risk difference (RD) with 95% CIs for intensive care unit admission and death within 30 days of admission. Results A total of 7747 patients (median [interquartile range] age, 71 [59-80] years, 3980 [51.4%] men) with confirmed influenza were identified. Of these, 520 (6.7%) were exposed to NSAIDs. In the unmatched cohorts, 104 of 520 patients (20.0%) who used NSAIDs and 958 of 7227 patients (13.3%) who did not use NSAIDs were admitted to the intensive care unit. For death within 30 days of admission, we observed 37 events (7.1%) among those who used NSAIDs compared with 563 events (7.8%) among those who did not. Current NSAID use was associated with intensive care unit admission (RR, 1.51; 95% CI, 1.26 to 1.81; RD, 6.7%; 95% CI, 3.2% to 10.3%), while NSAID use was not associated with death (RR, 0.91; 95% CI, 0.66 to 1.26; RD, -0.7%; 95% CI, -3.0% to 1.6%). In the matched cohorts, risks were unchanged for patients who used NSAIDs, while 83 ICU admissions (16.0%) and 36 deaths (6.9%) were observed among matched individuals who did not use NSAIDs. Matched (ie, adjusted) analyses yielded attenuated risk estimates for intensive care unit admission (RR, 1.25; 95% CI, 0.95 to 1.63; RD, 4.0%; 95% CI, -0.6% to 8.7%) and death (RR, 1.03; 95% CI, 0.66 to 1.60; RD, 0.2%; 95% CI, -2.9% to 3.3%). Associations were more pronounced among patients who used NSAIDs for a longer period (eg, for intensive care unit admission: RR, 1.90; 95% CI, 1.19 to 3.06; RD, 13.4%; 95% CI, 4.0% to 22.8%). Conclusions and Relevance In this cohort study of adult patients hospitalized with influenza, the use of NSAIDs was not associated with 30-day intensive care unit admission or death in adjusted analyses. There was an association between long-term use of NSAIDs and intensive care unit admission.
   Question Is exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) associated with increased risk of intensive care unit admission or death among patients hospitalized with influenza? Findings In this Danish nationwide cohort study that included 7747 adults aged 40 years or older, no association of NSAID use with intensive care unit admission or 30-day mortality was found. Meaning The findings of this study suggest that among patients hospitalized with influenza, those who use NSAIDs do not have worse prognosis than those with no NSAID use.
C1 [Lund, Lars Christian; Reilev, Mette; Hallas, Jesper; Kristensen, Kasper Bruun; Stovring, Henrik; Pottegard, Anton] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, JB Winslows Vej 19,2, DK-5000 Odense C, Denmark.
   [Hallas, Jesper] Odense Univ Hosp, Dept Clin Biochem & Clin Pharmacol, Odense, Denmark.
   [Thomsen, Reimar Wernich; Christiansen, Christian Fynbo; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark.
   [Sorensen, Henrik Toft] Stanford Univ, Ctr Populat Hlth & Sci, Stanford, CA 94305 USA.
   [Johansen, Nanna Borup; Brun, Nikolai Constantin] Danish Med Agcy, Dept Med Evaluat & Biostat, Copenhagen, Denmark.
   [Voldstedlund, Marianne] Statens Serum Inst, Copenhagen, Denmark.
   [Stovring, Henrik] Aarhus Univ, Dept Publ Hlth Biostat, Aarhus, Denmark.
   [Thomsen, Marianne Kragh] Aarhus Univ Hosp, Dept Clin Microbiol, Aarhus, Denmark.
   [Christensen, Steffen] Aarhus Univ Hosp, Dept Anaesthesia & Intens Care Med, Aarhus, Denmark.
   [Pottegard, Anton] Odense Univ Hosp, Hosp Pharm Funen, Odense, Denmark.
RP Pottegard, A (corresponding author), Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, JB Winslows Vej 19,2, DK-5000 Odense C, Denmark.
EM apottegaard@health.sdu.dk
RI ; Christiansen, Christian/B-5870-2014
OI Thomsen, Reimar/0000-0001-9135-3474; Kristensen, Kasper
   Bruun/0000-0001-6373-1386; Pottegard, Anton/0000-0001-9314-5679;
   Christiansen, Christian/0000-0002-0727-953X
CR Basille D, 2018, AM J RESP CRIT CARE, V198, P128, DOI 10.1164/rccm.201802-0229LE
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853
   Epperly H, 2016, JPN J INFECT DIS, V69, P248, DOI 10.7883/yoken.JJID.2014.577
   Glynn RJ, 2001, EPIDEMIOLOGY, V12, P682, DOI 10.1097/00001648-200111000-00017
   Gutthann SP, 1996, ARCH INTERN MED, V156, P2433, DOI 10.1001/archinte.1996.00440200041005
   Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   LITTLE P, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F6041
   Meganathan P, 2019, INDIAN J PEDIATR, V86, P140, DOI 10.1007/s12098-018-2769-y
   Messika J, 2014, J CRIT CARE, V29, P733, DOI 10.1016/j.jcrc.2014.05.021
   Pottegard A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213
   Rassen JA, 2012, PHARMACOEPIDEM DR S, V21, P69, DOI 10.1002/pds.3263
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Schmidt M, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3426
   Schmidt M, 2016, INT J EPIDEMIOL, V45, P1401, DOI 10.1093/ije/dyw116
   Schmidt M, 2016, EUR HEART J-CARD PHA, V2, P108, DOI 10.1093/ehjcvp/pvv054
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3
   Schmidt M, 2014, CLIN EPIDEMIOL, V6, P155, DOI 10.2147/CLEP.S59156
   Stovring H, 2016, PHARMACOEPIDEM DR S, V25, P1451, DOI 10.1002/pds.4114
   Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198
   Thomsen RW, 2006, J INTERN MED, V259, P410, DOI 10.1111/j.1365-2796.2006.01629.x
   Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   Voiriot G, 2011, CHEST, V139, P387, DOI 10.1378/chest.09-3102
   Voldstedlund M, 2014, EUROSURVEILLANCE, V19, P29, DOI 10.2807/1560-7917.ES2014.19.1.20667
NR 28
TC 2
Z9 2
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD JUL 1
PY 2020
VL 3
IS 7
AR e2013880
DI 10.1001/jamanetworkopen.2020.13880
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK6RG
UT WOS:000548912600004
PM 32609352
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lancaster, K
   Rhodes, T
AF Lancaster, Kari
   Rhodes, Tim
TI Wastewater monitoring of SARS-CoV-2: lessons from illicit drug policy
SO LANCET GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Letter
C1 [Lancaster, Kari; Rhodes, Tim] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW 2052, Australia.
   [Rhodes, Tim] London Sch Hyg & Trop Med, London, England.
RP Lancaster, K (corresponding author), Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW 2052, Australia.
EM k.lancaster@unsw.edu.au
CR Johnson GA, 2017, SOC SCI MED, V189, P63, DOI 10.1016/j.socscimed.2017.07.029
   Lancaster Kari, 2019, Current Opinion in Environmental Science & Health, V9, P85, DOI 10.1016/j.coesh.2019.06.006
   Lancaster K, 2019, INT J DRUG POLICY, V63, P47, DOI 10.1016/j.drugpo.2018.10.011
   Lodder W, 2020, LANCET GASTROENTEROL, V5, P533, DOI 10.1016/S2468-1253(20)30087-X
   Mallapaty S, 2020, NATURE, V580, P176, DOI 10.1038/d41586-020-00965-x
NR 5
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
EI 2468-1253
J9 LANCET GASTROENTEROL
JI Lancet Gastroenterol. Hepatol.
PD JUL
PY 2020
VL 5
IS 7
BP 641
EP 642
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA MI6YL
UT WOS:000547550500012
PM 32553143
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lopes, BCD
   Jaspal, R
AF da Silva Lopes, Barbara Cristina
   Jaspal, Rusi
TI Understanding the Mental Health Burden of COVID-19 in the United Kingdom
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE COVID-19; social isolation; religious/ethnic minorities; depression;
   paranoia
ID PSYCHOSIS; PARANOIA; THERAPY; DEPRESSION; ANXIETY; PREDISPOSITION;
   METAANALYSIS; LONELINESS; INCOME; WORRY
AB This article outlines the mental health burden of COVID-19 in the United Kingdom population, and presents preliminary evidence of less common psychiatric issues, such as paranoia and hallucinations, to which vulnerable groups in the U.K. population may be more vulnerable. It is argued that cognitive-behavioral therapy, with components of mindfulness, should be part of the therapeutic response.
C1 [da Silva Lopes, Barbara Cristina] Univ Coimbra, Fac Psychol & Educ Sci, Ctr Res Neuropsychol & Copit & Behav Intervent CI, Rua Colegio Novo, P-3000115 Coimbra, Portugal.
   [Jaspal, Rusi] Nottingham Trent Univ, Sch Social Sci, Dept Psychol, Nottingham, England.
RP Lopes, BCD (corresponding author), Univ Coimbra, Fac Psychol & Educ Sci, Ctr Res Neuropsychol & Copit & Behav Intervent CI, Rua Colegio Novo, P-3000115 Coimbra, Portugal.
EM barbaracslopes@gmail.com
OI Jaspal, Rusi/0000-0002-8463-9519; Lopes, Barbara/0000-0002-1400-020X
FU Nottingham Trent University-School of Social Sciences in the United
   Kingdom
FX The research has been funded by Nottingham Trent University-School of
   Social Sciences in the United Kingdom.
CR Braehler C, 2013, BRIT J CLIN PSYCHOL, V52, P199, DOI 10.1111/bjc.12009
   Chadwick P, 2016, SCHIZOPHR RES, V175, P168, DOI 10.1016/j.schres.2016.04.001
   da Rocha BM, 2018, SCHIZOPHRENIA BULL, V44, P114, DOI 10.1093/schbul/sbx036
   Ellett L, 2003, J NERV MENT DIS, V191, P425, DOI 10.1097/01.NMD.0000081646.33030.EF
   FITZPATRICK KM, 1993, J CONSULT CLIN PSYCH, V61, P528, DOI 10.1037/0022-006X.61.3.528
   Freeman D, 2011, PSYCHOL MED, V41, P923, DOI 10.1017/S0033291710001546
   Freeman D, 2005, BRIT J PSYCHIAT, V186, P427, DOI 10.1192/bjp.186.5.427
   Freeman D, 2015, LANCET PSYCHIAT, V2, P305, DOI 10.1016/S2215-0366(15)00039-5
   Freeman Daniel J., 2008, PARANOIA 21 CENTURY
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Hyland P., 2020, ANXIETY DEPRESSION R, DOI [10.31234/osf.io/8yqxr, DOI 10.31234/OSF.IO/8YQXR]
   Jaspal R., 2020, PREDICTING SOC UNPUB
   Jaspal R., 2020, FEAR SOCIAL IS UNPUB
   Kanter J., 2020, COVID 19 COULD LEAD
   Katshu Mohammad Zia Ul Haq, 2019, BMJ Case Rep, V12, DOI 10.1136/bcr-2019-232363
   Key FA, 2003, BEHAV THER, V34, P97, DOI 10.1016/S0005-7894(03)80024-2
   Kompus K, 2018, LANCET PSYCHIAT, V5, P189, DOI 10.1016/S2215-0366(18)30063-4
   Lincoln TM, 2009, PSYCHOL MED, V39, P1129, DOI 10.1017/S0033291708004613
   Lopes B., 2020, PARANOIA HALLU UNPUB
   Lopes B., 2020, IMPACT COVID 1 UNPUB
   Lopes B, 2013, BEHAV COGN PSYCHOTH, V41, P221, DOI 10.1017/S1352465812000483
   Madiha S., 2016, PSYCHIAT RES, V241, P309
   Morrison AP, 2000, BRIT J CLIN PSYCHOL, V39, P67, DOI 10.1348/014466500163112
   Patel V, 2018, WORLD PSYCHIATRY, V17, P76, DOI 10.1002/wps.20492
   Qassem T, 2015, SOC PSYCH PSYCH EPID, V50, P1057, DOI 10.1007/s00127-014-0960-7
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rippy AE, 2006, J MUSLIM MENT HEALTH, V1, P5, DOI 10.1080/15564900600654351
   Santini ZI, 2020, LANCET PUBLIC HEALTH, V5, pE62, DOI 10.1016/S2468-2667(19)30230-0
   Shevlin M., 2020, ANXIETY DEPRESSION T, DOI [10.31234/ osf.io/hb6nq, DOI 10.31234/OSF.IO/HB6NQ, 10.31234/osf.io/hb6nq]
   Thompson RR, 2017, CLIN PSYCHOL SCI, V5, P513, DOI 10.1177/2167702617692030
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814
   Wickham S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105140
NR 34
TC 6
Z9 6
U1 12
U2 13
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD JUL
PY 2020
VL 12
IS 5
BP 465
EP 467
DI 10.1037/tra0000632
PG 3
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MK2EG
UT WOS:000548598100010
PM 32478547
OA Green Accepted
DA 2021-01-01
ER

PT J
AU van den Berg, K
   Vermeulen, M
   Glatt, TN
   Wasserman, S
   Barrett, CL
   Peter, J
   Brittain, D
   Louw, VJ
AF van den Berg, Karin
   Vermeulen, Marion
   Glatt, Tanya Nadia
   Wasserman, Sean
   Barrett, Claire L.
   Peter, Jonny
   Brittain, David
   Louw, Vernon J.
TI COVID-19: Convalescent plasma as a potential therapy
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Letter
ID EBOLA-VIRUS DISEASE
C1 [van den Berg, Karin] South African Natl Blood Serv, Med Div, Translat Res, Roodepoort, South Africa.
   [van den Berg, Karin; Louw, Vernon J.] Univ Cape Town, Fac Hlth Sci, Dept Med, Div Clin Haematol, Rondebosch, South Africa.
   [Vermeulen, Marion] South African Natl Blood Serv, Operat Div, Operat Testing, Roodepoort, South Africa.
   [Glatt, Tanya Nadia] South African Natl Blood Serv, Cellular Therapy Lab, Roodepoort, South Africa.
   [Wasserman, Sean] Univ Cape Town, Fac Hlth Sci, Dept Med, Div Infect Dis & HIV Med, Rondebosch, South Africa.
   [Wasserman, Sean] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa, Rondebosch, South Africa.
   [Barrett, Claire L.] Univ Free State, Fac Hlth Sci, Sch Clin Med, Bloemfontein, South Africa.
   [Peter, Jonny] Univ Cape Town, Fac Hlth Sci, Dept Med, Div Allergy & Clin Immunol, Rondebosch, South Africa.
   [Peter, Jonny] Univ Cape Town, Lung Inst, Allergy & Immunol Unit, Rondebosch, South Africa.
   [Brittain, David] Netcare Pretoria East Hosp, Alberts Cellular Therapy, Pretoria, South Africa.
RP van den Berg, K (corresponding author), South African Natl Blood Serv, Med Div, Translat Res, Roodepoort, South Africa.; van den Berg, K (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Med, Div Clin Haematol, Rondebosch, South Africa.
EM karin.vandenberg@sanbs.org.za
RI Louw, Vernon/ABA-1753-2020
OI Louw, Vernon/0000-0002-2885-3342
CR [Anonymous], 2020, TREATMENT GUIDE COVI
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao Bin, 2020, N Engl J Med, V382, pe68, DOI 10.1056/NEJMc2008043
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   CASADEVALL A, 1995, CLIN INFECT DIS, V21, P150, DOI 10.1093/clinids/21.1.150
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Joyner Michael, 2020, medRxiv, DOI 10.1101/2020.05.12.20099879
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Nie QH, 2003, WORLD J GASTROENTERO, V9, P1139, DOI 10.3748/wjg.v9.i6.1139
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Sahr F, 2017, J INFECTION, V74, P302, DOI 10.1016/j.jinf.2016.11.009
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Wong V. W. S., 2003, Hong Kong Medical Journal, V9, P199
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xinhua, CHIN PUTS 245 COVID
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou Xian-zhi, 2003, Zhonghua Yi Xue Za Zhi, V83, P1018
NR 35
TC 0
Z9 0
U1 1
U2 1
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD JUL
PY 2020
VL 110
IS 7
BP 562
EP 563
DI 10.7196/SAMJ.2020.v110i7.14983
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK1FH
UT WOS:000548531600003
PM 32880317
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ntshalintshali, SD
   Mnqwazi, C
AF Ntshalintshali, S. D.
   Mnqwazi, C.
TI Affordable digital innovation to reduce SARS-CoV-2 transmission among
   healthcare workers
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
ID SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; CAPE-TOWN; MORTALITY; RISK; TB
AB In the South African public healthcare sector, patient medical records are still written on paper and stored in filing rooms. There has been an attempt to move towards a paperless electronic system in many public healthcare facilities, but owing to lack of funding, this has been a challenge to achieve. During the current COVID-19 pandemic, the virus could be transmitted through the physical manipulation of patient records by various categories of staff who handle the records with or without gloves for protection. We discuss a digital option that has been partially used at Tygerberg Hospital (TBH), Cape Town, to avoid SARS-CoV-2 patient hard-copy record manipulation. It includes assignment of a QR code to every patient admitted as a person under investigation or confirmed COVID-19 case. The QR code is synced to one of the many free online medical notes smartphone applications (apps), which are password-protected with patient information privacy regulations (Trello is used at TBH), for daily medical notes review and editing. Upon discharge, all notes made during the patient's hospital stay, together with the discharge summary, are printed to generate a hard copy of notes for filing to avoid violation of the current national and provincial patient records policy. Doing this means that a patient will have a virtual online file through the designated app until discharge, when a physical file will be made for storage and safekeeping. It will keep physical manipulation of patient records to the minimum, and potentially assist in reducing transmission of the SARS-CoV-2 virus among healthcare workers.
C1 [Ntshalintshali, S. D.] Stellenbosch Univ, Tygerberg Hosp, Dept Internal Med, Div Rheumatol, Cape Town, South Africa.
   [Ntshalintshali, S. D.; Mnqwazi, C.] Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South Africa.
   [Mnqwazi, C.] Stellenbosch Univ, Tygerberg Hosp, Dept Internal Med, Cape Town, South Africa.
RP Ntshalintshali, SD (corresponding author), Stellenbosch Univ, Tygerberg Hosp, Dept Internal Med, Div Rheumatol, Cape Town, South Africa.; Ntshalintshali, SD (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South Africa.
EM sipho.duncan@gmail.com
OI Ntshalintshali, Sipho Duncan/0000-0002-7812-4447
FU South African Medical Research Council (SAMRC) through its Division of
   Research Capacity Development under the Bongani Mayosi National Health
   Scholars Program from Public Health Enhancement Fund/SA National
   Department of Health; South African National Research Foundation through
   Centre of Excellence in Epidemiological Modelling and Analysis; SAMRC;
   SA National Research Foundation (NRF); United Way Worldwide grant by the
   Lilly Foundation; NRF South African Research Chairs Initiative; NRF
FX The work reported herein was made possible through funding by the South
   African Medical Research Council (SAMRC) through its Division of
   Research Capacity Development under the Bongani Mayosi National Health
   Scholars Program from funding received from the Public Health
   Enhancement Fund/SA National Department of Health to MO. The contents of
   any publications emanating from MO's PhD studies are solely the
   responsibility of the author and do not necessarily represent the
   official views of the SAMRC or the funders. AW is supported financially
   by a grant from the South African National Research Foundation through
   its funding of the Centre of Excellence in Epidemiological Modelling and
   Analysis. ML is financially supported by the SAMRC, the SA National
   Research Foundation (NRF), and a United Way Worldwide grant made
   possible by the Lilly Foundation on behalf of the Lilly MDRTB
   Partnership. ACH is financially supported by the NRF South African
   Research Chairs Initiative. The financial assistance of the NRF towards
   this research is hereby acknowledged. Opinions expressed, and
   conclusions arrived at, are those of the authors and are not necessarily
   to be attributed to the NRF.
CR Burger EH, 2012, J CLIN EPIDEMIOL, V65, P309, DOI 10.1016/j.jclinepi.2011.08.007
   Druyts E, 2013, AIDS, V27, P417, DOI 10.1097/QAD.0b013e328359b89b
   Glaziou P, 2019, METHODS USED WHO EST
   Herbst AJ, 2009, B WORLD HEALTH ORGAN, V87, P754, DOI 10.2471/BLT.08.058982
   Johnson LF, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002468
   Johnson LF, 2012, S AFR J HIV MED, P22
   Kaplan R, 2014, JAIDS-J ACQ IMM DEF, V66, P487, DOI 10.1097/QAI.0000000000000201
   Larson E, 2014, INT J STD AIDS, V25, P636, DOI 10.1177/0956462413515639
   Lawn SD, 2009, CURR OPIN HIV AIDS, V4, P325, DOI 10.1097/COH.0b013e32832c7d61
   Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f
   Loveday M, 2019, SAMJ S AFR MED J, V109, P728, DOI [10.7196/SAMJ.2019.v109i10.14073, 10.7196/samj.2019.v109i10.14073]
   Makgoba MW, 2000, SCIENCE, V288, P1171, DOI 10.1126/science.288.5469.1171
   Nojilana B, 2009, SAMJ S AFR MED J, V99, P648
   Omar T, 2015, INT J TUBERC LUNG D, V19, P1320, DOI 10.5588/ijtld.15.0222
   Osman M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1914-z
   Simelela NP, 2014, SAMJ S AFR MED J, V104, P249, DOI [10.7196/SAMJ.7700, 10.7196/samj.7700]
   Statistics SA, 2018, MORT CAUS DEATH S AF
   Statistics South Africa, 2014, MORT CAUS DEATH S AF
   Statistics South Africa, 2012, CAUS DEATH CERT GUID
   WHO, 2019, GLOB TUB REP 2019
   World Health Organization, 2019, TUB DAT WHOS GLOB TB
   Yan I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160481
NR 22
TC 0
Z9 0
U1 0
U2 0
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD JUL
PY 2020
VL 110
IS 7
BP 605
EP 609
DI 10.7196/SAMJ.2020.v110i7.14879
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MK1FH
UT WOS:000548531600019
PM 32880330
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Li, XJ
   Giorgi, EE
   Marichann, MH
   Foley, B
   Xiao, C
   Kong, XP
   Chen, Y
   Korber, B
   Gao, F
   Gnanakaran, S
AF Li, Xiaojun
   Giorgi, Elena E.
   Marichann, Manukumar Honnayakanahalli
   Foley, Brian
   Xiao, Chuan
   Kong, Xiang-Peng
   Chen, Yue
   Korber, Bette
   Gao, Feng
   Gnanakaran, S.
TI Emergence of SARS-CoV-2 through recombination and strong purifying
   selection
SO SCIENCE ADVANCES
LA English
DT Article
ID SARS-RELATED CORONAVIRUS; SPIKE; PNEUMONIA; PROTEIN; BATS
AB COVID-19 has become a global pandemic caused by the novel coronavirus SARS-CoV-2. Understanding the origins of SARS-CoV-2 is critical for deterring future zoonosis, discovering new drugs, and developing a vaccine. We show evidence of strong purifying selection around the receptor binding motif (RBM) in the spike and other genes among bat, pangolin, and human coronaviruses, suggesting similar evolutionary constraints in different host species. We also demonstrate that SARS-CoV-2's entire RBM was introduced through recombination with coronaviruses from pangolins, possibly a critical step in the evolution of SARS-CoV-2's ability to infect humans. Similar purifying selection in different host species, together with frequent recombination among coronaviruses, suggests a common evolutionary mechanism that could lead to new emerging human coronaviruses.
C1 [Li, Xiaojun; Marichann, Manukumar Honnayakanahalli; Chen, Yue; Gao, Feng] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Giorgi, Elena E.; Foley, Brian; Korber, Bette; Gnanakaran, S.] Los Alamos Natl Lab, Theoret Biol & Biophys, Los Alamos, NM 87544 USA.
   [Xiao, Chuan] Univ Texas El Paso, Dept Chem & Biochem, El Paso, TX 79968 USA.
   [Kong, Xiang-Peng] NYU, Grossman Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
   [Korber, Bette] New Mexico Consortium, Los Alamos, NM 87545 USA.
   [Gao, Feng] Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun 130012, Peoples R China.
RP Gao, F (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.; Gao, F (corresponding author), Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun 130012, Peoples R China.
EM fgao@duke.edu
RI Xiao, Chuan/B-2130-2010; H.M, Manukumar/H-4266-2018
OI Xiao, Chuan/0000-0001-6599-8762; Li, Xiaojun/0000-0002-5780-0880; H.M,
   Manukumar/0000-0002-6488-7136
FU Laboratory Directed Research and Development program of Los Alamos
   National Laboratory [20200554ECR]
FX E.E.G., B.K., S.G., and B.F. acknowledge support by the Laboratory
   Directed Research and Development program of Los Alamos National
   Laboratory under project number 20200554ECR.
CR ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Brufsky A, 2020, J MED VIROL, V92, P1386, DOI 10.1002/jmv.25902
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Foley B., 2018, 1825673 LAUR LOS AL
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hon CC, 2008, J VIROL, V82, P1819, DOI 10.1128/JVI.01926-07
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Korber B., 2000, COMPUTATIONAL ANAL H, P55, DOI DOI 10.1007/B112102
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin XD, 2017, VIROLOGY, V507, P1, DOI 10.1016/j.virol.2017.03.019
   Liu P, 2020, ARE PANGOLINS INTERM, DOI [10.1101/2020.02.18.954628, DOI 10.1101/2020.02.18.954628]
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   SIEPEL AC, 1995, AIDS RES HUM RETROV, V11, P1413, DOI 10.1089/aid.1995.11.1413
   Walls A. C., 2020, CELL, V180
   Wang N., 2020, BIORXIV
   Wang N, 2018, VIROL SIN, V33, P104, DOI 10.1007/s12250-018-0012-7
   WHO, 2020, NOV COR COVID 19 SIT
   Wong Mc CS, 2020, BIORXIV
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xiao C, 2020, EMERG MICROBES INFEC, V9, P378, DOI 10.1080/22221751.2020.1727299
   Yang Jianyi, 2015, Curr Protoc Bioinformatics, V52, DOI 10.1002/0471250953.bi0508s52
   Zhou H., 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 34
Z9 33
U1 2
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUL
PY 2020
VL 6
IS 27
AR eabb9153
DI 10.1126/sciadv.abb9153
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK4DR
UT WOS:000548735500039
PM 32937441
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Panda, PK
   Arul, MN
   Patel, P
   Verma, SK
   Luo, W
   Rubahn, HG
   Mishra, YK
   Suar, M
   Ahuja, R
AF Panda, Pritam Kumar
   Arul, Murugan Natarajan
   Patel, Paritosh
   Verma, Suresh K.
   Luo, Wei
   Rubahn, Horst-Gunter
   Mishra, Yogendra Kumar
   Suar, Mrutyunjay
   Ahuja, Rajeev
TI Structure-based drug designing and immunoinformatics approach for
   SARS-CoV-2
SO SCIENCE ADVANCES
LA English
DT Article
ID SPIKE; BINDING; GROMACS
AB The prevalence of respiratory illness caused by the novel SARS-CoV-2 virus associated with multiple organ failures is spreading rapidly because of its contagious human-to-human transmission and inadequate globalhealth care systems. Pharmaceutical repurposing, an effective drug development technique using existing drugs, could shorten development time and reduce costs compared to those of de novo drug discovery. We carried out virtual screening of antiviral compounds targeting the spike glycoprotein (S), main protease (M-pro), and the SARS-CoV-2 receptor binding domain (RBD)-angiotensin-converting enzyme 2 (ACE2) complex of SARS-CoV-2. PC786, an antiviral polymerase inhibitor, showed enhanced binding affinity to all the targets. Furthermore, the postfusion conformation of the trimeric S protein RBD with ACE2 revealed conformational changes associated with PC786 drug binding. Exploiting immunoinformatics to identify T cell and B cell epitopes could guide future experimental studies with a higher probability of discovering appropriate vaccine candidates with fewer experiments and higher reliability.
C1 [Panda, Pritam Kumar; Luo, Wei; Ahuja, Rajeev] Uppsala Univ, Dept Phys & Astron, Mat Theory Div, Condensed Matter Theory Grp, Box 516, SE-75120 Uppsala, Sweden.
   [Arul, Murugan Natarajan] Alballova Univ Ctr, Royal Inst Technol KTH, Dept Theoret Chem & Biol, S-10691 Stockholm, Sweden.
   [Patel, Paritosh; Verma, Suresh K.; Suar, Mrutyunjay] KIIT Univ, Sch Biotechnol, Bhubaneswar 751024, India.
   [Rubahn, Horst-Gunter] Syddansk Univ, Als 2, DK-6400 Sonderborg, Denmark.
   [Mishra, Yogendra Kumar] Univ Southern Denmark, NanoSYD, Mads Clausen, Als 2, DK-6400 Sonderborg, Denmark.
   [Ahuja, Rajeev] Royal Inst Technol KTH, Dept Mat Sci & Engn, Appl Mat Phys, SE-10044 Stockholm, Sweden.
RP Panda, PK; Ahuja, R (corresponding author), Uppsala Univ, Dept Phys & Astron, Mat Theory Div, Condensed Matter Theory Grp, Box 516, SE-75120 Uppsala, Sweden.; Ahuja, R (corresponding author), Royal Inst Technol KTH, Dept Mat Sci & Engn, Appl Mat Phys, SE-10044 Stockholm, Sweden.
EM pritam.panda@physics.uu.se; rajeev.ahuja@physics.uu.se
RI Mishra, Yogendra Kumar/G-6241-2010; Verma, Suresh K/G-6701-2018; Panda,
   Pritam Kumar/E-8002-2015
OI Mishra, Yogendra Kumar/0000-0002-8786-9379; Verma, Suresh
   K/0000-0003-1029-9766; Natarajan Arul, Murugan/0000-0003-0185-5724;
   Panda, Pritam Kumar/0000-0003-4879-2302; Ahuja,
   Rajeev/0000-0003-1231-9994
FU Swedish Research Council (VR grant)Swedish Research Council [2016-06014]
FX The authors acknowledge the financial support from the Swedish Research
   Council (VR grant no. 2016-06014).
CR Biovia D. S., 2000, J CHEM PHYS
   Brookes DW, 2018, BRIT J PHARMACOL, V175, P2520, DOI 10.1111/bph.14221
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cohen J., 2020, SCIENCE
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   El-Manzalawy Yasser, 2010, Immunome Res, V6 Suppl 2, pS2, DOI 10.1186/1745-7580-6-S2-S2
   Fehr A.R., 2015, CORONAVIRUSES METHOD
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kirchmair Johannes, 2011, Infectious Disorders - Drug Targets, V11, P64
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Maupetit J, 2009, NUCLEIC ACIDS RES, V37, pW498, DOI 10.1093/nar/gkp323
   PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Potocnakova L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6760830
   Qamar M. T. U., 2019, J TRANSL MED
   Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trott O., 2010, J COMPUT CHEM, V32, P174
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 38
TC 13
Z9 13
U1 7
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JUL
PY 2020
VL 6
IS 28
AR eabb8097
DI 10.1126/sciadv.abb8097
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK4DS
UT WOS:000548735600037
PM 32691011
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shereen, MA
   Khan, S
   Kazmi, A
   Bashir, N
   Siddique, R
AF Shereen, Muhammad Adnan
   Khan, Suliman
   Kazmi, Abeer
   Bashir, Nadia
   Siddique, Rabeea
TI COVID-19 infection: Origin, transmission, and characteristics of human
   coronaviruses
SO JOURNAL OF ADVANCED RESEARCH
LA English
DT Article
DE Coronaviruses; COVID-19; Origin; Outbreak; Spread
ID ACUTE RESPIRATORY SYNDROME; DIPEPTIDYL PEPTIDASE 4; SARS CORONAVIRUS;
   SPIKE PROTEIN; FUNCTIONAL RECEPTOR; PROTECTIVE IMMUNITY; VIRUS; VACCINE;
   COV; IMMUNIZATION
AB The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir. The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery. In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Shereen, Muhammad Adnan; Khan, Suliman; Bashir, Nadia; Siddique, Rabeea] Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Shereen, Muhammad Adnan] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan, Peoples R China.
   [Kazmi, Abeer] Wuhan Univ, Coll Life Sci, Wuhan, Peoples R China.
RP Khan, S (corresponding author), Zhengzhou Univ, Dept Cerebrovasc Dis, Affiliated Hosp 2, Zhengzhou, Peoples R China.
EM suliman.khan18@mails.ucas.ac.cn
OI Shereen, Muhammad Adnan/0000-0002-0914-0697; Khan,
   Suliman/0000-0003-4954-0748
FU Second Affiliated Hospital of Zhengzhou University
FX The authors acknowledge the Postdoctoral grant from The Second
   Affiliated Hospital of Zhengzhou University (for S.K).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   [Anonymous], S CHINA MORNING POST
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JF-W, 2020, LANCET
   Chen Y, 2020, J MED VIROL
   Clover B., CLOV IN DEV REC SUB
   Cockrell AS, 2014, J VIROL, V88, P5195, DOI 10.1128/JVI.03764-13
   Corman VM, 2014, J VIROL, V88, P11297, DOI 10.1128/JVI.01498-14
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Derebail VK, 2020, MASS MED SOC
   Dong N., 2020, BIORXIV
   Geo-Vax, GEOVAX
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]
   Huang C, 2020, LANCET
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Inovio IP, IN SEL CEP DEV VACC
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Kan B, 2005, J VIROL, V79, P11892, DOI 10.1128/JVI.79.18.11892-11900.2005
   Kapadia SU, 2005, VIROLOGY, V340, P174, DOI 10.1016/j.virol.2005.06.016
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Li B, 2020, MSPHERE, V5, DOI [10.1128/mSphere.00170-20, 10.1128/mSphere.00807-19]
   Lu R, 2020, LANCET
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McKay BLP, DRUGMAKERS RUSH DEV
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Nagata N, 2007, J VIROL, V81, P1848, DOI 10.1128/JVI.01967-06
   Ng CS, 2020, CELL DEATH DIFFER, V27, P2363, DOI 10.1038/s41418-020-0509-0
   Paden CR, 2018, ZOONOSES PUBLIC HLTH, V65, P322, DOI 10.1111/zph.12435
   Parker CG, 2020, GEN COMP ENDOCR, V292, DOI 10.1016/j.ygcen.2020.113467
   Parry J., 2020, CHINA CORONAVIRUS CA
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perlman S., 2020, ANOTHER DECADE ANOTH
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Phan LT, 2020, N ENGL J MED
   Pyrc K, 2007, EXPERT REV ANTI-INFE, V5, P245, DOI 10.1586/14787210.5.2.245
   Qin E, 2006, VACCINE, V24, P1028, DOI 10.1016/j.vaccine.2005.06.038
   Qu D, 2005, VACCINE, V23, P924, DOI 10.1016/j.vaccine.2004.07.031
   Rahman A, 2019, AM J PUBLIC HEALTH, V109, P1288, DOI [10.21, 10.2105/AJPH.2019.305186]
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Richardson P, 2020, LANCET
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi GY, 2004, ICIA 2004: PROCEEDINGS OF 2004 INTERNATIONAL CONFERENCE ON INFORMATION ACQUISITION, P116
   Shi YL, 2003, J CLIN MICROBIOL, V41, P5781, DOI 10.1128/JCM.41.12.5781-5782.2003
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   Spruth M, 2006, VACCINE, V24, P652, DOI 10.1016/j.vaccine.2005.08.055
   Stadler K, 2005, EMERG INFECT DIS, V11, P1312, DOI 10.3201/eid1108.041003
   Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143
   Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272
   Tian X, 2020, BIORXIV
   Uyeki TM, 2020, NEW ENGL J MED, V382
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Vara V., 2020, CORONAVIRUS OUTBREAK
   Wan Y., 2020, J VIROL
   Wang BX, 2019, SEMINARS IMMUNOLOGY
   Wang Chen, 2020, LANCET
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang Z, 2020, BIOSCIENCE TRENDS
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   World Health Organization, 2020, LAB TEST COR DIS 201
   Wu A, 2020, CELL HOST MICROBE
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xinhua, CHIN FAST TRACKS NOV
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang T, 2020, J MT SCI-ENGL, V17, P2108, DOI 10.1007/s11629-019-5772-5
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zheng BJ, 2004, EMERG INFECT DIS, V10, P176, DOI 10.3201/eid1002.030533
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou J, 2005, VACCINE, V23, P3202, DOI 10.1016/j.vaccine.2004.11.075
   Zhou P, 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 85
TC 330
Z9 338
U1 27
U2 166
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2090-1232
EI 2090-1224
J9 J ADV RES
JI J. Adv. Res.
PD JUL
PY 2020
VL 24
BP 91
EP 98
DI 10.1016/j.jare.2020.03.005
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MM5HS
UT WOS:000550188100008
PM 32257431
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Canfield, GS
   Schultz, JS
   Windham, S
   Scherger, S
   Henao-Martinez, AF
   Shapiro, L
   Franco-Paredes, C
   Chastain, DB
   Wand, T
   Krsak, M
AF Canfield, Gregory S.
   Schultz, Jonathan S.
   Windham, Sam
   Scherger, Sias
   Henao-Martinez, Andres F.
   Shapiro, Leland
   Franco-Paredes, Carlos
   Chastain, Daniel B.
   Wand, Taylor
   Krsak, Martin
TI Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons
   of History
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
C1 [Canfield, Gregory S.; Schultz, Jonathan S.; Windham, Sam; Scherger, Sias; Henao-Martinez, Andres F.; Shapiro, Leland; Franco-Paredes, Carlos; Wand, Taylor; Krsak, Martin] Univ Colorado, Anschutz Med Ctr, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.
   [Shapiro, Leland] Rocky Mt Reg Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Aurora, CO USA.
   [Franco-Paredes, Carlos] Federico Gomez, Hosp Infantil Mexico, Inst Nacl Salud, Mexico City, DF, Mexico.
   [Chastain, Daniel B.] Univ Georgia, Dept Clin & Adm Pharm, Coll Pharm, Albany, GA USA.
RP Franco-Paredes, C (corresponding author), Univ Colorado, Anschutz Med Ctr, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.; Franco-Paredes, C (corresponding author), Federico Gomez, Hosp Infantil Mexico, Inst Nacl Salud, Mexico City, DF, Mexico.
EM carlos.franco-paredes@cuanschutz.edu
RI Krsak, Martin/ABB-2416-2020; Henao, Andres/AAD-6680-2020;
   Henao-Martinez, Andres F./E-1488-2012
OI Krsak, Martin/0000-0002-1746-7462; Henao-Martinez, Andres
   F./0000-0001-7363-8652; Canfield, Gregory/0000-0003-3671-311X; Windham,
   Samuel/0000-0002-3572-8291
FU Emily Foundation
FX Dr Shapiro is supported by The Emily Foundation, Boston, Massachusetts.
   For all other authors, no financial support was declared.
CR ABRAHAM J. JOHNSTON, 1948, BRIT JOUR VENEREAL DIS, V24, P153
   Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Boikos C, 2017, J ANTIMICROB CHEMOTH, V72, P1556, DOI 10.1093/jac/dkx013
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Frierson J. Gordon, 2010, Yale Journal of Biology and Medicine, V83, P77
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gradmann C., 2009, LAB DIS R KOCHS MED
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Grober ED, 2005, CAN J SURG, V48, P39
   Kahneman D., 2011, THINKING FAST SLOW
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Offit PA, 2005, NEW ENGL J MED, V352, P1411, DOI 10.1056/NEJMp048180
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   Schofield AT, 1894, LANCET, V143, P372, DOI [10.1016/S0140-6736(01)66349-9, DOI 10.1016/S0140-6736(01)66349-9]
   Sencer DJ, 2006, EMERG INFECT DIS, V12, P29
   Steverding D, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-3
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 19
TC 0
Z9 0
U1 0
U2 0
PU FRONTLINE MEDICAL COMMUNICATIONS
PI THE WOODLANDS
PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386
   USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD JUL
PY 2020
VL 15
IS 7
BP 434
EP 436
DI 10.12788/jhm.3469
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MJ8JD
UT WOS:000548333400012
PM 32584243
OA Bronze
DA 2021-01-01
ER

PT J
AU Obi, AT
   Barnes, GD
   Wakefield, TW
   Brown, S
   Eliason, JL
   Arndt, E
   Henke, PK
AF Obi, Andrea T.
   Barnes, Geoff D.
   Wakefield, Thomas W.
   Brown, Sandra
   Eliason, Jonathon L.
   Arndt, Erika
   Henke, Peter K.
TI Practical diagnosis and treatment of suspected venous thromboembolism
   during COVID-19 pandemic
SO JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS
LA English
DT Article
DE Anticoagulant; Deep venous thrombosis; Duplex ultrasonography; Pulmonary
   embolism; Venous thromboembolism
ID DEEP-VEIN THROMBOSIS; WELLS SCORE; PREVENTION
AB A markedly increased demand for vascular ultrasound laboratory and other imaging studies in COVID-19-positive patients has occurred, due to most of these patients having a markedly elevated D-dimer and a presumed prothrombotic state in many of the very ill patients. In the present report, we have summarized a broad institutional consensus focusing on evaluation and recommended empirical therapy for COVID-19-positive patients. We recommend following the algorithms with the idea that as more data becomes available these algorithmsmay well change.
C1 [Obi, Andrea T.; Wakefield, Thomas W.; Brown, Sandra; Eliason, Jonathon L.; Arndt, Erika; Henke, Peter K.] Univ Michigan Hlth Syst, Dept Surg, Vasc Surg Sect, Ann Arbor, MI USA.
   [Barnes, Geoff D.] Univ Michigan Hlth Syst, Dept Cardiol, Sect Vasc Med, Ann Arbor, MI USA.
RP Henke, PK (corresponding author), Univ Michigan Hlth Syst, Vasc Surg Sect, Dept Surg, Frankel Cardiovasc Ctr, SPC 5463,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM henke@umich.edu
FU Vascular Cures Wiley Foundation
FX Dr Obi was supported by a Vascular Cures Wiley Foundation grant.
CR Bahia A, 2011, J HOSP MED, V6, P190, DOI 10.1002/jhm.827
   Bartlett MA, 2015, VASC HEALTH RISK MAN, V11, P461, DOI 10.2147/VHRM.S73799
   Chen J, 2020, LANCET
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301
   KILLEWICH LA, 1993, J VASC SURG, V17, P934, DOI 10.1016/0741-5214(93)90043-L
   LI XD, 2020, ZHONGHUA JIE HE HE H, V26, P151
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   Pannucci CJ, 2017, ANN SURG, V265, P1094, DOI 10.1097/SLA.0000000000002126
   Silveira PC, 2015, JAMA INTERN MED, V175, P1112, DOI 10.1001/jamainternmed.2015.1687
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Underhill J, 2017, J VASC SURG-VENOUS L, V5, P630, DOI 10.1016/j.jvsv.2017.03.018
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 16
Z9 16
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-333X
J9 J VASC SURG-VENOUS L
JI J. Vasc. Surg.-Venous Lymphat. Dis.
PD JUL
PY 2020
VL 8
IS 4
BP 526
EP 534
DI 10.1016/j.jvsv.2020.04.009
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA ML5QJ
UT WOS:000549520200006
PM 32305585
OA Green Published
DA 2021-01-01
ER

PT J
AU Winck, JC
   Ambrosino, N
AF Winck, J. C.
   Ambrosino, N.
TI COVID-19 pandemic and non invasive respiratory management: Every Goliath
   needs a David. An evidence based evaluation of problems
SO PULMONOLOGY
LA English
DT Article
DE Non invasive ventilation; High flow nasal cannula; Pronation; Chest
   physiotherapy; Health care workers; Acute respiratory failure
ID FLOW NASAL CANNULA; EXHALED AIR DISPERSION; POSITIVE-PRESSURE
   VENTILATION; NONINVASIVE VENTILATION; OXYGEN-THERAPY; FAILURE;
   INFLUENZA; INFECTION; SUPPORT; COHORT
AB Background and aim: The war against Covid-19 is far from won. This narrative review attempts to describe some problems with the management of Covid-19 induced acute respiratory failure (ARF) by pulmonologists. Methods: We searched the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and reviewed the references of retrieved articles for additional studies. The search was limited to the terms: Covid-19 AND : acute respiratory distress syndrome (ARDS), SARS, MERS, non invasive ventilation (NIV), high flow nasal cannula (HFNC), pronation (PP), health care workers (HCW). Results: Protection of Health care workers should be paramount, so full Personal Protective Equipment and Negative pressure rooms are warranted. HFNC alone or with PP could be offered for mild cases (PaO2/FiO2 between 200 - 300); NIV alone or with PP may work in moderate cases (PaO2/FiO2 between 100 - 200). Rotation and coupled (HFNC/NIV) strategy can be beneficial. A window of opportunity of 1--2 h is advised. If PaO2/FIO2 significantly increases, Respiratory Rate decreases with a relatively low Exhaled Tidal Volume, the non-invasive strategy could be working and intubation delayed. Conclusion: Although there is a role for non-invasive respiratory therapies in the context of COVID-19 ARF, more research is still needed to define the balance of benefits and risks to patients and HCW. Indirectly, non invasive respiratory therapies may be of particular benefit in reducing the risks to healthcare workers by obviating the need for intubation, a potentially highly infectious procedure. (c) 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espan similar to a, S.L.U. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/).
C1 [Winck, J. C.] Univ Porto, Fac Med, Porto, Portugal.
   [Ambrosino, N.] Ist Montescano, Ist Clin Sci Maugeri IRCCS, Montescano, Italy.
RP Winck, JC (corresponding author), Univ Porto, Fac Med, Porto, Portugal.
EM jcwinck@mail.telepac
RI Ambrosino, Nicolino/AAC-2005-2020
OI Ambrosino, Nicolino/0000-0002-5331-1393
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Australian and New Zealand Intensive Care Society, 2020, ANZICS COVID 19 GUID
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Cao JL, 2020, INTENS CARE MED, V46, P851, DOI 10.1007/s00134-020-05987-7
   Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Cheung TMT, 2004, CHEST, V126, P845, DOI 10.1378/chest.126.3.845
   ClinicalTrials gov, 2020, PRON POS HIGH FLOW O
   Cortegiani A, 2020, Pulmonology, DOI 10.1016/j.pulmoe.2020.02.001
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020
   Frat JP, 2019, RESPIROLOGY, V24, P724, DOI 10.1111/resp.13435
   Frat JP, 2015, RESP CARE, V60, P170, DOI 10.4187/respcare.03075
   Gattinoni L, 2020, INTENSIVE CARE MED
   Goligher EC, 2017, AM J RESP CRIT CARE, V195, P1128, DOI 10.1164/rccm.201701-0006ED
   Gomez CC, 2020, ARCH BRONCONEUMOL
   Grasselli G, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2.020.5394, DOI 10.1001/JAMA.2.020.5394]
   Grieco DL, 2020, AM J RESP CRIT CARE, V201, P303, DOI 10.1164/rccm.201904-0841OC
   Guan WJ, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa7007032, DOI 10.1056/NEJMOA7007032]
   Harari SA, 2020, MANAGING RESP CARE P
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2007, CHEST, V132, P540, DOI 10.1378/chest.07-0636
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Hui DS, 2015, CHEST, V147, P1336, DOI 10.1378/chest.14-1934
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Kotoda M, 2020, J HOSP INFECT, V104, P534, DOI 10.1016/j.jhin.2019.11.010
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Leonard S, 2020, INC SCI INNOVATION, V2020
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Ling Yun, 2015, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V27, P630, DOI 10.3760/cma.j.issn.2095-4352.2015.08.002
   Loh NHW, 2020, CAN J ANESTH, V67, P893, DOI 10.1007/s12630-020-01634-3
   Luo Yufeng, 2015, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V27, P841
   Mauri T, 2017, INTENS CARE MED, V43, P1453, DOI 10.1007/s00134-017-4890-1
   Mazzoleni S, 2020, PULMONOLOGY, V26, P117, DOI 10.1016/j.pulmoe.2020.03.002
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   NHS, 2020, GUID ROL US NON RESP
   Niederman MS, 2020, AM J RESP CRIT CARE, DOI [10.1164/rccm.202003-0741ED, DOI 10.1164/RCCM,202003-0741ED]
   Onodera M, 2019, RESP CARE, V64, P545, DOI 10.4187/respcare.06299
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Perez-Nieto Orlando R, 2020, Crit Care, V24, P114, DOI 10.1186/s13054-020-2821-y
   Pisani L, 2019, PULMONOLOGY, V25, P348, DOI 10.1016/j.pulmoe.2019.08.001
   Rello J, 2012, J CRIT CARE, V27, P434, DOI 10.1016/j.jcrc.2012.04.006
   Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044
   Respiratory care committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V17, pE020, DOI 10.3760/cma.j.issn.1001-0939.2020.0020
   Riera J, 2013, RESP CARE, V58, P589, DOI 10.4187/respcare.02086
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Scaravilli V, 2015, J CRIT CARE, V30, P1390, DOI 10.1016/j.jcrc.2015.07.008
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   Societade Portuguesa de Pneumologia, TER RESP NAO INV CON
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z
   Wang Y, 2020, AM J RESP CRIT CARE, DOI [10.1164/rccm.707003-0736LE, DOI 10.1164/RCCM.707003-0736LE]
   Wax RS, 2020, CAN J ANAESTH, DOI [10.1007/s12630-070-01591-x, DOI 10.1007/S12630-070-01591-X]
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu C, 2020, JAMA INTERN MED, DOI [10.1001/jamainternmed.7070.0994, DOI 10.1001/JAMAINTERNMED.7070.0994]
   Wu Z, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.7070.2648, DOI 10.1001/JAMA.7070.2648]
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 70
TC 17
Z9 17
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2531-0437
J9 PULMONOLOGY
JI Pulmonology
PD JUL-AUG
PY 2020
VL 26
IS 4
BP 213
EP 220
DI 10.1016/j.pulmoe.2020.04.013
PG 8
WC Respiratory System
SC Respiratory System
GA MI7SX
UT WOS:000547603700007
PM 32362507
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Motta, I
   Centis, R
   D'Ambrosio, L
   Garcia-Garcia, JM
   Goletti, D
   Gualano, G
   Lipani, F
   Palmieri, F
   Sanchez-Montalva, A
   Pontali, E
   Sotgiu, G
   Spanevello, A
   Stochino, C
   Tabernero, E
   Tadolini, M
   van den Boom, MV
   Villa, S
   Visca, D
   Migliori, GB
AF Motta, I.
   Centis, R.
   D'Ambrosio, L.
   Garcia-Garcia, J. -M.
   Goletti, D.
   Gualano, G.
   Lipani, F.
   Palmieri, F.
   Sanchez-Montalva, A.
   Pontali, E.
   Sotgiu, G.
   Spanevello, A.
   Stochino, C.
   Tabernero, E.
   Tadolini, M.
   van den Boom, M.
   Villa, S.
   Visca, D.
   Migliori, G. B.
TI Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths
   occurring in 69 patients from two cohorts
SO PULMONOLOGY
LA English
DT Article
DE TB; COVID-19; Mortality; Migrants; Sequelae; Infection contra
AB Little is known about the relationship between the COVID-19 and tuberculosis (TB). The aim of this study is to describe a group of patients who died with TB (active disease or sequelae) and COVID-19 in two cohorts.
   Data from 49 consecutive cases in 8 countries (cohort A) and 20 hospitalised patients with TB and COVID-19 (cohort B) were analysed and patients who died were described. Demographic and clinical variables were retrospectively collected, including co-morbidities and risk factors for TB and COVID-19 mortality. Overall, 8 out of 69 (11.6%) patients died, 7 from cohort A (14.3%) and one from cohort B (5%). Out of 69 patients 43 were migrants, 26/49 (53.1%) in cohort A and 17/20 (85.0%) in cohort B. Migrants: (1) were younger than natives; in cohort A the median (IQR) age was 40 (27-49) VS. 66 (46-70) years, whereas in cohort B 37 (27-46) VS. 48 (47-60) years; (2) had a lower mortality rate than natives (1/43, 2.3% versus 7/26, 26.9%; p-value: 0.002); (3) had fewer co-morbidities than natives (23/43, 53.5% versus 5/26-19.2%) natives; p-value: 0.005). The study findings show that: (1) mortality is likely to occur in elderly patients with co morbidities; (2) TB might not be a major determinant of mortality and (3) migrants had lower mortality, probably because of their younger age and lower number of co-morbidities. However, in settings where advanced forms of TB frequently occur and are caused by drug-resistant strains of M. tuberculosis, higher mortality rates can be expected in young individuals. (C) 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ticenses/bync-nd/4.0/).
C1 [Motta, I.; Lipani, F.] Osped Amedeo Savoia, Clin Univ Malattie Infett, Dipartimento Sci Med, Turin, Italy.
   [Centis, R.; Migliori, G. B.] Ist Clin Sci Maugeri IRCCS, Serv Epidemiol Clin Malattie Resp, Tradate, Italy.
   [D'Ambrosio, L.] Publ Hlth Consulting Grp, Lugano, Switzerland.
   [Garcia-Garcia, J. -M.] SEPAR, TB Res Programme PII TB, Barcelona, Spain.
   [Goletti, D.] IRCCS, Natl Inst Infect Dis L Spallanzani, Translat Res Unit, Rome, Italy.
   [Gualano, G.; Palmieri, F.] IRCCS, Natl Inst Infect Dis L Spallanzani, Resp Infect Dis Unit, Rome, Italy.
   [Sanchez-Montalva, A.] Vali dHebron Univ Hosp, Infect Dis Dept, Int Hlth & TB Unit, Barcelona, Spain.
   [Sanchez-Montalva, A.] Vali dHebron Inst Res VHIR, Barcelona, Spain.
   [Sanchez-Montalva, A.] Spanish Soc Infect Dis SEIMC, Grp Estudio Infecc Micobacterias GEIM, Barcelona, Spain.
   [Pontali, E.] Galliera Hosp, Dept Infect Dis, Genoa, Italy.
   [Sotgiu, G.] Univ Sassari, Dept Med Surg & Expt Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
   [Spanevello, A.; Visca, D.] IRCCS, Div Pulm Rehabil, Ist Clin Sci Maugeri, Tradate, Italy.
   [Spanevello, A.; Visca, D.] Univ Insubria, Dept Med & Surg, Resp Dis, Tradate, Varese Como, Italy.
   [Stochino, C.] E Morelli Sondalo Hosp, Phthisiol Unit, ASST Valtellina & Alto Lario, Sondrio, Italy.
   [Tabernero, E.] Hosp Cruces, Serv Neumol, Bilbao, Spain.
   [Tadolini, M.] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Unit Infect Dis, Bologna, Italy.
   [van den Boom, M.] World Hlth Org Reg Off Europe, Copenhagen, Denmark.
   [Villa, S.] Univ Milan, Ctr Multidisciplinary Res Hlth Sci, Milan, Italy.
RP Migliori, GB (corresponding author), Ist Clin Sci Maugeri IRCCS, Serv Epidemiol Clin Malattie Resp, Tradate, Italy.
EM giovannibattista.migliori@icsmaugeri.it
OI Garcia-Garcia, Jose-Maria/0000-0002-2809-6230; Pontali,
   Emanuele/0000-0002-1085-0442
CR Akkerman O, 2019, INT J INFECT DIS, V83, P72, DOI 10.1016/j.ijid.2019.03.036
   Borisov S, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01522-2019
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Esposito S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01260-2020
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Leung CC, 2020, INT J TUBERC LUNG D, V24, P364, DOI 10.5588/ijtld.20.0124
   Tadolini M, 2020, EUR RESP J
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 11
TC 26
Z9 26
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2531-0437
J9 PULMONOLOGY
JI Pulmonology
PD JUL-AUG
PY 2020
VL 26
IS 4
BP 233
EP 240
DI 10.1016/j.pulmoe.2020.05.002
PG 8
WC Respiratory System
SC Respiratory System
GA MI7SX
UT WOS:000547603700009
PM 32411943
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Aysha, AA
   Rentsch, C
   Prentice, R
   Johnson, D
   Bryant, RV
   Ward, MG
   Costello, SP
   Lewindon, P
   Ghaly, S
   Connor, SJ
   Begun, J
   Christensen, B
AF Aysha, Al-Ani
   Rentsch, Clarissa
   Prentice, Ralley
   Johnson, Doug
   Bryant, Robert V.
   Ward, Mark G.
   Costello, Samuel P.
   Lewindon, Peter
   Ghaly, Simon
   Connor, Susan J.
   Begun, Jakob
   Christensen, Britt
TI Practical management of inflammatory bowel disease patients during the
   COVID-19 pandemic: expert commentary from the Gastroenterological
   Society of Australia Inflammatory Bowel Disease faculty
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; inflammatory bowel disease; Crohn disease;
   ulcerative colitis; immunosuppression
AB The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there are insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID-19 pandemic in the Australasian setting.
C1 [Aysha, Al-Ani; Rentsch, Clarissa; Prentice, Ralley; Christensen, Britt] Royal Melbourne Hosp, Dept Gastroenterol, 300 Grattan St, Parkville, Vic 3052, Australia.
   [Johnson, Doug] Royal Melbourne Hosp, Victorian Infect Dis Unit, Parkville, Vic, Australia.
   [Ward, Mark G.; Christensen, Britt] Monash Univ, Dept Gastroenterol, Clayton, Vic, Australia.
   [Ward, Mark G.] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia.
   [Bryant, Robert V.; Costello, Samuel P.] Queen Elizabeth Hosp, Dept Gastroenterol, Woodville, SA, Australia.
   [Bryant, Robert V.; Costello, Samuel P.] Univ Adelaide, Fac Hlth Sci, Sch Med, Adelaide, SA, Australia.
   [Lewindon, Peter] Queensland Childrens Hosp, Dept Gastroenterol, South Brisbane, Qld, Australia.
   [Begun, Jakob] Mater Hosp, Dept Gastroenterol, Brisbane, Qld, Australia.
   [Begun, Jakob] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia.
   [Ghaly, Simon] St Vincents Hosp, Dept Gastroenterol, Darlinghurst, NSW, Australia.
   [Connor, Susan J.] Liverpool Hosp, Dept Gastroenterol, Liverpool, NSW, Australia.
   [Connor, Susan J.] Univ NSW, South Western Sydney Clin Sch, Sydney, NSW, Australia.
   [Connor, Susan J.] Ingham Inst Appl Med Res, Dept Gastroenterol, Sydney, NSW, Australia.
RP Christensen, B (corresponding author), Royal Melbourne Hosp, Dept Gastroenterol, 300 Grattan St, Parkville, Vic 3052, Australia.
EM britt_christensen@hotmail.com
RI Connor, Susan/ABF-5155-2020; Begun, Jakob/J-6793-2014
OI Connor, Susan/0000-0001-5606-0270; Costello, Samuel/0000-0002-2857-1812;
   Begun, Jakob/0000-0001-5256-7672
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   Al-Ani AH, 2020, ALIMENT PHARM THER, V52, P54, DOI 10.1111/apt.15779
   An P, 2020, LANCET
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   BAPEN's Nasogastric Tube Safety Special Interest Group, 2020, BAPEN STAT COV 19 EN
   Brenner EJ, 2020, SECURE IBD DATABASE
   Chapple L-A, 2020, NUTR MANAGEMENT CRIT
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Colombel JF, 2017, GUT, V66, P839, DOI 10.1136/gutjnl-2015-311079
   European Centre for Disease Prevention and Control, 2020, TECHN REP GUID DISCH
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Nasogastric (NGT)/nasojejunal tube (NJT) placement and aerosol generation (AGP), 2020, 7 ELMS
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Ransford RAJ, 2002, GUT, V51, P536, DOI 10.1136/gut.51.4.536
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Singh S, 2020, CLIN GASTROENTEROL H, V18, P69, DOI 10.1016/j.cgh.2019.02.044
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012
   Weisshof R, 2019, DIGEST DIS SCI, V64, P1945, DOI 10.1007/s10620-019-05492-y
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
NR 26
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-0903
EI 1445-5994
J9 INTERN MED J
JI Intern. Med. J.
PD JUL
PY 2020
VL 50
IS 7
BP 798
EP 804
DI 10.1111/imj.14889
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MI3WL
UT WOS:000547341700005
PM 32656985
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Drew, ED
   Janes, RW
AF Drew, Elliot D.
   Janes, Robert W.
TI Identification of a druggable binding pocket in the spike protein
   reveals a key site for existing drugs potentially capable of combating
   Covid-19 infectivity
SO BMC MOLECULAR AND CELL BIOLOGY
LA English
DT Article
ID SERVER
AB Background: Following the recent outbreak of the new coronavirus pandemic (Covid-19), the rapid determination of the structure of the homo-trimeric spike glycoprotein has prompted the study reported here. The aims were to identify potential "druggable" binding pockets in the protein and, if located, to virtual screen pharmaceutical agents currently in use for predicted affinity to these pockets which might be useful to restrict, reduce, or inhibit the infectivity of the virion.
   Results: Our analyses of this structure have revealed a key potentially druggable pocket where it might be viable to bind pharmaceutical agents to inhibit its ability to infect human cells. This pocket is found at the inter-chain interface that exists between two domains prior to the virion binding to human Angiotensin Converting Enzyme 2 (ACE2) protein. One of these domains is the highly mobile receptor binding domain, which must move into position to interact with ACE2, which is an essential feature for viral entry to the host cell. Virtual screening with a library of purchasable drug molecules has identified pharmaceuticals currently in use as prescription and over the counter medications that, in silico, readily bind into this pocket.
   Conclusions: This study highlights possible drugs already in use as pharmaceuticals that may act as agents to interfere with the movements of the domains within this protein essential for the infectivity processes and hence might slow, or even halt, the infection of host cells by this new coronavirus. As these are existing pharmaceuticals already approved for use in humans, this knowledge could accelerate their roll-out, through repurposing, for affected individuals and help guide the efforts of other researchers in finding effective treatments for the disease.
C1 [Drew, Elliot D.; Janes, Robert W.] Queen Mary Univ London, Sch Biol & Chem Sci, Mile End Rd, London E1 4NS, England.
RP Janes, RW (corresponding author), Queen Mary Univ London, Sch Biol & Chem Sci, Mile End Rd, London E1 4NS, England.
EM r.w.janes@qmul.ac.uk
FU Biotechnology and Biological Sciences Research Council (BBSRC),
   UKBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/P024106]; UKRI through BBSRC [BB/P024106]
FX This research was supported by grants from the Biotechnology and
   Biological Sciences Research Council (BBSRC), UK, [BB/P024106 to R.W.J.]
   and open access funding from UKRI through BBSRC [BB/P024106]. The
   funding bodies played no role in the design of the study and collection,
   analysis, and interpretation of data and in writing the manuscript.
CR Backman TWH, 2011, NUCLEIC ACIDS RES, V39, pW486, DOI 10.1093/nar/gkr320
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Djoumbou Feunang Yannick, 2016, J Cheminform, V8, P61
   Drew ED, 2019, NUCLEIC ACIDS RES, V47, pW477, DOI 10.1093/nar/gkz456
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Jia FJ, 2020, PROTEIN CELL, V11, P624, DOI 10.1007/s13238-020-00708-8
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Labbe CM, 2015, NUCLEIC ACIDS RES, V43, pW448, DOI 10.1093/nar/gkv306
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Siramshetty VB, 2018, NUCLEIC ACIDS RES, V46, pD1137, DOI 10.1093/nar/gkx1088
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ursu O, 2017, NUCLEIC ACIDS RES, V45, pD932, DOI 10.1093/nar/gkw993
   Volkamer A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/ci200454v
   Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Willman M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121119
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342
   Zhang N, 2016, BIOORG MED CHEM LETT, V26, P3594, DOI 10.1016/j.bmcl.2016.06.013
NR 24
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2661-8850
J9 BMC MOL CELL BIOL
JI BMC Mol. Cell Biol.
PD JUL 1
PY 2020
VL 21
IS 1
AR 49
DI 10.1186/s12860-020-00294-x
PG 13
WC Cell Biology
SC Cell Biology
GA MH9QY
UT WOS:000547055800001
PM 32611313
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crighton, AJ
   McCann, CT
   Todd, EJ
   Brown, AJ
AF Crighton, Alexander J.
   McCann, Catherine T.
   Todd, Elizabeth J.
   Brown, Alyson J.
TI Safe use of paracetamol and high-dose NSAID analgesia in dentistry
   during the COVID-19 pandemic
SO BRITISH DENTAL JOURNAL
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ASPIRIN; RISK
AB With dental services currently altered, dentists are being asked to provide advice, analgesia and antibiotics in situations where they would normally be offering operative care. Dentists are familiar with using analgesia for short courses for their patients, but using higher-dose regimes and for periods of over two weeks brings special challenges. This paper reviews the areas where special precautions are needed when using analgesia in the current situation.
C1 [Crighton, Alexander J.; Todd, Elizabeth J.; Brown, Alyson J.] Glasgow Dent Hosp & Sch, NHS Greater Glasgow & Clyde, Dept Oral Med, 378 Sauchiehall St, Glasgow, Lanark, Scotland.
   [McCann, Catherine T.] Glasgow Dent Hosp & Sch, NHS Greater Glasgow & Clyde, Dept Paediat Dent, 378 Sauchiehall St, Glasgow, Lanark, Scotland.
RP Crighton, AJ (corresponding author), Glasgow Dent Hosp & Sch, NHS Greater Glasgow & Clyde, Dept Oral Med, 378 Sauchiehall St, Glasgow, Lanark, Scotland.
EM alexander.crighton@glasgow.ac.uk
CR AAPD, 2018, PAIN MAN INF CHILDR
   Arfe A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4857
   Black E, 2019, PAIN PRACT, V19, P875, DOI 10.1111/papr.12814
   Dwyer JP, 2014, J GASTROEN HEPATOL, V29, P1356, DOI 10.1111/jgh.12560
   Friedman RJ, 2012, THROMB HAEMOSTASIS, V108, P183, DOI 10.1160/TH11-08-0589
   Gatoulis SC, 2012, CLIN THER, V34, P138, DOI 10.1016/j.clinthera.2011.11.018
   Goldstein JL, 2004, CLIN THER, V26, P1637, DOI 10.1016/j.clinthera.2004.10.002
   Gurbel P, 2019, J THROMB THROMBOLYS, V47, P16, DOI 10.1007/s11239-018-1764-5
   Hwang AY, 2018, AM J HYPERTENS, V31, P1324, DOI 10.1093/ajh/hpy118
   Moore PA, 2018, J AM DENT ASSOC, V149, P256, DOI 10.1016/j.adaj.2018.02.012
   NICE, 2019, NSAIDS PRESCR ISS
   NICE, 2019, 1 4 ID CAUS AC KIDN
   NICE, 2014, 1 4 ASS STROK BLEED
   Schuijt MP, 2009, BRIT J PHARMACOL, V157, P931, DOI 10.1111/j.1476-5381.2009.00243.x
   SDCEP, 2015, MAN DENT PAT TAK ANT
   SDCEP, 2020, MAN AC DENT PROBL DU
   Siddique I, 2015, BRIT DENT J, V219, DOI 10.1038/sj.bdj.2015.706
   Specialist Pharmacy Service, 2018, NSAID SAF AUD 2018 1
NR 18
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0610
EI 1476-5373
J9 BRIT DENT J
JI Br. Dent. J.
PD JUL
PY 2020
VL 229
IS 1
BP 15
EP 18
DI 10.1038/s41415-020-1784-3
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA MH7YS
UT WOS:000546940200002
PM 32651512
OA Green Published
DA 2021-01-01
ER

PT J
AU Odhiambo, F
   Mulwa, E
   Ayieko, J
   Kulzer, J
   Aluda, M
   Chatterjee, P
   Onyango, R
   Nyanaro, G
   Bukusi, EA
   Cohen, CR
AF Odhiambo, Francesca
   Mulwa, Edwin
   Ayieko, James
   Kulzer, Jayne
   Aluda, Maurice
   Chatterjee, Purba
   Onyango, Raphael
   Nyanaro, George
   Bukusi, Elizabeth A.
   Cohen, Craig R.
TI Implementation of HIV care in Western Kenya during corona virus disease
   2019 response
SO AIDS
LA English
DT Article
DE antiretroviral therapy; corona virus disease 2019; HIV; Kenya
AB To ensure the continuity of high-quality HIV care in Kisumu County, Kenya during the corona virus disease 2019 pandemic, the Ministry of Health implemented a strategy to promote physical distancing and corona virus disease 2019 case detection. A total of 23 262 (84.2%) of the 27 641 patients eligible for early refill received an extra 3-month supply of antiretrovirals. Across 60 Ministry of Health clinics, average attendance decreased from 1298 to 640 patients per day postintervention, representing a 50.7% reduction.
C1 [Odhiambo, Francesca; Mulwa, Edwin; Ayieko, James; Aluda, Maurice; Onyango, Raphael; Nyanaro, George; Bukusi, Elizabeth A.] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya.
   [Kulzer, Jayne; Chatterjee, Purba; Cohen, Craig R.] Univ Calif San Francisco, Bixby Ctr Global Reprod Hlth, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
RP Odhiambo, F (corresponding author), Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya.
EM fodhiambo@kemri-ucsf.org
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [GH001947]
FX The publication was supported by the Cooperative Agreement (GH001947)
   funded by the Centers for Disease Control and Prevention. Its contents
   are solely the responsibility of the authors and do not necessarily
   represent the official views of the Centers for Disease Control and
   Prevention or the Department of Health and Human. We gratefully
   acknowledge the Director of KEMRI, the Director of KEMRI's Centre for
   Microbiology Research and the Kisumu County Ministry ofHealth.
CR Lewis Kulzer Jayne, 2012, J Int AIDS Soc, V15, P8, DOI 10.1186/1758-2652-15-8
   National AIDS and STI Control Programme (NASCOP), 2020, PREL KENPHIA 2018 RE
   World Health Organization, INF PREV CONTR COVID
   World Health Organization, 2020, COR DIS COVID 19 ADV
NR 4
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUL 1
PY 2020
VL 34
IS 8
BP F1
EP F2
DI 10.1097/QAD.0000000000002576
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MH5VK
UT WOS:000546796300001
PM 32501845
DA 2021-01-01
ER

PT J
AU Gray, DJ
   Kurscheid, J
   Mationg, ML
   Williams, GM
   Gordon, C
   Kelly, M
   Wangdi, K
   McManus, DP
AF Gray, Darren J.
   Kurscheid, Johanna
   Mationg, Mary Lorraine
   Williams, Gail M.
   Gordon, Catherine
   Kelly, Matthew
   Wangdi, Kinley
   McManus, Donald P.
TI Health-education to prevent COVID-19 in schoolchildren: a call to action
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE COVID-19; Children; Health education; Health promotion; Prevention
AB Background There is currently considerable international debate around school closures/openings and the role of children in the transmission of coronavirus disease 2019 (COVID-19). Whilst evidence suggests that children are not impacted by COVID-19 as severely as adults, little is still known about their transmission potential, and with a lot of asymptomatic cases they may be silent transmitters (i.e. infectious without showing clinical signs of disease), albeit at a lower level than adults. In relation to this, it is somewhat concerning that in many countries children are cared for, or are often in close contact with, older individuals such as grandparents - the age group most at risk of acquiring serious respiratory complications resulting in death. Main text We emphasise that in the absence of a vaccine or an effective therapeutic drug, preventive measures such as good hygiene practices - hand washing, cough etiquette, disinfection of surfaces and social distancing represent the major (in fact only) weapons that we have against COVID-19. Accordingly, we stress that there is a pressing need to develop specific COVID-19 prevention messages for schoolchildren. Conclusion An entertainment education intervention for schoolchildren systematically implemented in schools would be highly effective and fill this need. With such measures in place there would be greater confidence around the opening of schools.
C1 [Gray, Darren J.; Kurscheid, Johanna; Mationg, Mary Lorraine; Kelly, Matthew; Wangdi, Kinley] Australian Natl Univ, Res Sch Populat Hlth, Dept Global Hlth, Canberra, ACT, Australia.
   [Williams, Gail M.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia.
   [Gordon, Catherine; McManus, Donald P.] QIMR Berghofer Med Res Inst, Div Infect Dis, Brisbane, Qld, Australia.
RP Gray, DJ (corresponding author), Australian Natl Univ, Res Sch Populat Hlth, Dept Global Hlth, Canberra, ACT, Australia.; McManus, DP (corresponding author), QIMR Berghofer Med Res Inst, Div Infect Dis, Brisbane, Qld, Australia.
EM darren.gray@anu.edu.au; Don.McManus@qimrberghofer.edu.au
RI Kelly, Matthew/ABC-1069-2020
OI Kelly, Matthew/0000-0001-7963-2139; Wangdi, Kinley/0000-0002-8857-2665
FU National Health & Medical Research Council (Australia)National Health
   and Medical Research Council of Australia; Australian Infectious Disease
   Research Centre; College of Health & Medicine, Australian National
   University; UBS Optimus Foundation
FX \UBS Optimus Foundation. National Health & Medical Research Council
   (Australia). Australian Infectious Disease Research Centre. College of
   Health & Medicine, Australian National University.
CR Bieri FA, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-29
   Bieri FA, 2013, NEW ENGL J MED, V368, P1603, DOI 10.1056/NEJMoa1204885
   Bieri FA, 2012, AM J TROP MED HYG, V87, P972, DOI 10.4269/ajtmh.2012.12-0375
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   The United Nations Department of Global Communications (DGC), UN TACKL INF MIS CYB
   Worby CJ, 2015, EPIDEMICS-NETH, V13, P10, DOI 10.1016/j.epidem.2015.04.003
   World Health Organization, COR
   World Health Organization, ED HLTH MAN HLTH ED
NR 8
TC 1
Z9 1
U1 8
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD JUL 1
PY 2020
VL 9
IS 1
AR 81
DI 10.1186/s40249-020-00695-2
PG 3
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA MH8PI
UT WOS:000546983800001
PM 32611385
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ronco, C
   Reis, T
   Husain-Syed, F
AF Ronco, Claudio
   Reis, Thiago
   Husain-Syed, Faeq
TI Management of acute kidney injury in patients with COVID-19
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
AB The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management.
C1 [Ronco, Claudio] Univ Padua, Dept Med, Padua, Italy.
   [Ronco, Claudio] San Bortolo Hosp, Dept Nephrol Dialysis & Kidney Transplantat, Viale Rodolfi 37, I-36100 Vicenza, Italy.
   [Ronco, Claudio; Reis, Thiago; Husain-Syed, Faeq] Int Renal Res Inst Vicenza, Vicenza, Italy.
   [Reis, Thiago] Clin Doencas Renais Brasilia, Dept Nephrol, Brasilia, DF, Brazil.
   [Husain-Syed, Faeq] Univ Hosp Giessen & Marburg, Dept Internal Med 2, Div Nephrol Pulmonol & Crit Care Med, German Ctr Lung Res, Giessen, Germany.
RP Ronco, C (corresponding author), San Bortolo Hosp, Dept Nephrol Dialysis & Kidney Transplantat, Viale Rodolfi 37, I-36100 Vicenza, Italy.
EM cronco@goldnet.it
OI Reis, Thiago/0000-0002-7071-117X; Ronco, Claudio/0000-0002-6697-4065
CR Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   De Rosa S, 2020, BLOOD PURIFICAT, V49, P502, DOI 10.1159/000505146
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fanelli V, 2018, AM J RESP CRIT CARE, V198, P687, DOI 10.1164/rccm.201712-2575LE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0530-y
   Husain-Syed F, 2018, INTENS CARE MED, V44, P1447, DOI 10.1007/s00134-018-5329-z
   Joannidis M, 2007, INTENS CARE MED, V33, P1571, DOI 10.1007/s00134-007-0719-7
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Klein DJ, 2018, INTENS CARE MED, V44, P2205, DOI 10.1007/s00134-018-5463-7
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Ronco C, 2020, LANCET RESP MED, V8, P240, DOI 10.1016/S2213-2600(20)30060-6
   Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 66
Z9 65
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD JUL
PY 2020
VL 8
IS 7
BP 738
EP 742
DI 10.1016/S2213-2600(20)30229-0
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MI3QZ
UT WOS:000547326600026
PM 32416769
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ueffing, M
   Bayyoud, T
   Schindler, M
   Ziemssen, F
AF Ueffing, Marius
   Bayyoud, Tarek
   Schindler, Michael
   Ziemssen, Focke
TI Basic principles of replication and immunology of SARS-CoV-2
SO OPHTHALMOLOGE
LA German
DT Article
DE Binding affinity; Immune response; SARS-CoV-2; Seroconversion; Viral
   replication
ID SARS CORONAVIRUS
AB Coronaviruses are a genetically highly variable family of viruses that infect vertebrates and have succeeded in infecting humans many times by overcoming the species barrier. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which initially appeared in China at the end of 2019, exhibits a high infectivity and pathogenicity compared to other coronaviruses. As the viral coat and other viral components are recognized as being foreign by the immune system, this can lead to initial symptoms, which are induced by the very efficiently working immune defense system via the respiratory epithelium. During severe courses a systemically expressed proinflammatory cytokine storm and subsequent changes in the coagulation and complement systems can occur. Virus-specific antibodies, the long-term expression of which is ensured by the formation of B memory cell clones, generate a specific immune response that is also detectable in blood (seroconversion). Specifically effective cytotoxic CD8+ T-cell populations are also formed, which recognize viral epitopes as pathogen-specific patterns in combination with MHC presentation on the cell surface of virus-infected cells and destroy these cells. At the current point in time it is unclear how regular, robust and durable this immune status is constructed. Experiences with other coronavirus infections (SARS and Middle East respiratory syndrome, MERS) indicate that the immunity could persist for several years. Based on animal experiments, already acquired data on other coronavirus types and plausibility assumptions, it can be assumed that seroconverted patients have an immunity of limited duration and only a very low risk of reinfection. Knowledge of the molecular mechanisms of viral cycles and immunity is an important prerequisite for the development of vaccination strategies and development of effective drugs.
C1 [Ueffing, Marius; Bayyoud, Tarek; Ziemssen, Focke] Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Dept Augenheilkunde, Forschungsinst Augenheilkunde, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Ueffing, Marius; Bayyoud, Tarek; Ziemssen, Focke] Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Dept Augenheilkunde, Augenklin, Tubingen, Germany.
   [Schindler, Michael] Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Sekt Mol Virol, Inst Med Virol & Epidemiol, Tubingen, Germany.
RP Ueffing, M (corresponding author), Eberhardt Karls Univ Tubingen, Univ Klinikum Tubingen, Dept Augenheilkunde, Forschungsinst Augenheilkunde, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
EM mue@klinikum.uni-tuebingen.de
CR Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Miesbach WA, 2020, DTSCH ARZTEBL, V117, pA
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Robert-Koch-Institut, 2020, SARS COV 2 STECKBR C
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Sit THC, 2020, NATURE, DOI 10.1038/s41586-020-2334-5
   Song WC, 2020, J CLIN INVEST, V130, P3950, DOI 10.1172/JCI140183
   Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263
   Stein RA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13512
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2020, NAT MED, V26, P1077, DOI 10.1038/s41591-020-0912-6
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 41
TC 2
Z9 1
U1 13
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
PD JUL
PY 2020
VL 117
IS 7
SI SI
BP 609
EP 614
DI 10.1007/s00347-020-01155-w
PG 6
WC Ophthalmology
SC Ophthalmology
GA MH4QK
UT WOS:000546715500005
PM 32613257
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rokohl, AC
   Loreck, N
   Matos, PAW
   Mor, JM
   Zwingelberg, S
   Grajewski, RS
   Cursiefen, C
   Heindl, LM
AF Rokohl, Alexander C.
   Loreck, Niklas
   Matos, Philomena A. Wawer
   Mor, Joel M.
   Zwingelberg, Sarah
   Grajewski, Rafael S.
   Cursiefen, Claus
   Heindl, Ludwig M.
TI The role of ophthalmology in the COVID-19 pandemic
SO OPHTHALMOLOGE
LA German
DT Article
DE SARS-CoV-2; Ophthalmology; Coronavirus; Corona-Virus-Disease-19;
   Conjunctivitis
ID DISEASE 2019 COVID-19
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 19 (COVID-19) has led to a worldwide pandemic. This pandemic presents a huge challenge for the healthcare system and also for ophthalmologists. Previous studies and case reports indicated that SARS-CoV-2 also infects the conjunctiva resulting in conjunctivitis. In addition, infectious virus particles in the tear fluid can be potential sources of infection; however, the detection of SARS-CoV-2 RNA in the tear fluid has rarely been successful. Although isolated conjunctival involvement is highly unlikely, at the current point in time of the COVID-19 pandemic, practically every patient examined by an ophthalmologist could be infected with SARS-CoV-2. Therefore, protective and hygiene measures should currently be consistently followed to minimize the risk of spreading the virus. Currently, there are no treatment recommendations for conjunctivitis associated with COVID-19. Tear substitutes might be helpful for symptom relief but there is no evidence for a topical antiviral therapy. In the future ophthalmologists could play a decisive role in the screening of maculopathies that might occur during COVID-19 treatment using chloroquine or hydroxychloroquine.
C1 [Rokohl, Alexander C.] Univ Cologne, Med Fak, Zentrum Augenheilkunde, Kerpener Str 62, D-50924 Cologne, Germany.
   [Rokohl, Alexander C.] Uniklin Koln, Kerpener Str 62, D-50924 Cologne, Germany.
RP Rokohl, AC (corresponding author), Univ Cologne, Med Fak, Zentrum Augenheilkunde, Kerpener Str 62, D-50924 Cologne, Germany.; Rokohl, AC (corresponding author), Uniklin Koln, Kerpener Str 62, D-50924 Cologne, Germany.
EM alexander.rokohl@uk-koeln.de
RI Cursiefen, Claus/ABE-5284-2020; Rokohl, Alexander/K-6191-2019
OI Rokohl, Alexander/0000-0002-0224-3597
CR BERNSTEIN HN, 1983, AM J MED, V75, P25, DOI 10.1016/0002-9343(83)91267-6
   Cheema M, 2020, CAN J OPHTHALMOL, V55, pE125, DOI 10.1016/j.jcjo.2020.03.003
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hagmann SHF, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101649
   Holz FG, 2020, OPHTHALMOLOGE, V117, P295, DOI 10.1007/s00347-020-01097-3
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Liang L, 2020, ACTA OPHTHALMOL, V98, P223, DOI 10.1111/aos.14413
   Liu XP, 2020, INFLUENZA OTHER RESP, V14, P472, DOI 10.1111/irv.12740
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Luers JC, 2020, LARYNGO RHINO OTOL, V99, P287, DOI 10.1055/a-1095-2344
   Luers Jan C, 2020, Clin Infect Dis, V71, P2262, DOI 10.1093/cid/ciaa525
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Parrish RK, 2020, AM J OPHTHALMOL, V213, pA1, DOI 10.1016/j.ajo.2020.02.014
   Peng YZ, 2020, J MED VIROL, DOI 10.1002/jmv.25753
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Seah IYJ, 2020, OPHTHALMOLOGY, V127, P977, DOI 10.1016/j.ophtha.2020.03.026
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Yu AY, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00187-2
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang X, 2020, OCUL SURF, V18, P360, DOI 10.1016/j.jtos.2020.03.010
NR 26
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
PD JUL
PY 2020
VL 117
IS 7
SI SI
BP 642
EP 647
DI 10.1007/s00347-020-01148-9
PG 6
WC Ophthalmology
SC Ophthalmology
GA MH4QK
UT WOS:000546715500014
PM 32519117
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tsay, C
   Lejarza, F
   Stadtherr, MA
   Baldea, M
AF Tsay, Calvin
   Lejarza, Fernando
   Stadtherr, Mark A.
   Baldea, Michael
TI Modeling, state estimation, and optimal control for the US COVID-19
   outbreak
SO SCIENTIFIC REPORTS
LA English
DT Article
AB The novel coronavirus SARS-CoV-2 and resulting COVID-19 disease have had an unprecedented spread and continue to cause an increasing number of fatalities worldwide. While vaccines are still under development, social distancing, extensive testing, and quarantining of confirmed infected subjects remain the most effective measures to contain the pandemic. These measures carry a significant socioeconomic cost. In this work, we introduce a novel optimization-based decision-making framework for managing the COVID-19 outbreak in the US. This includes modeling the dynamics of affected populations, estimating the model parameters and hidden states from data, and an optimal control strategy for sequencing social distancing and testing events such that the number of infections is minimized. The analysis of our extensive computational efforts reveals that social distancing and quarantining are most effective when implemented early, with quarantining of confirmed infected subjects having a much higher impact. Further, we find that "on-off" policies alternating between strict social distancing and relaxing such restrictions can be effective at "flattening" the curve while likely minimizing social and economic cost.
C1 [Tsay, Calvin; Lejarza, Fernando; Stadtherr, Mark A.; Baldea, Michael] Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA.
   [Baldea, Michael] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA.
RP Baldea, M (corresponding author), Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA.; Baldea, M (corresponding author), Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA.
EM mbaldea@che.utexas.edu
FU National Science Foundation (NSF)National Science Foundation (NSF)
   [1454433]
FX Partial financial support from the National Science Foundation (NSF)
   through CAREER Award 1454433 is acknowledged with gratitude. The authors
   also thank Dr. Richard Pattison (Apeel Sciences) for his insightful
   comments throughout this study.
CR Anastassopoulou C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230405
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bendavid E, 2020, COVID 19 ANTIBODY SE
   Biegler LT, 2007, CHEM ENG PROCESS, V46, P1043, DOI 10.1016/j.cep.2006.06.021
   Biswas MHA, 2014, MATH BIOSCI ENG, V11, P761, DOI 10.3934/mbe.2014.11.761
   Djidjou-Demasse Ramses, 2020, OPTIMAL COVID 19 EPI
   Ferguson N, 2020, TECH REP
   Floudas CA, 2013, DETERMINISTIC GLOBAL
   Gostic K, 2020, ELIFE, V9, DOI 10.7554/eLife.55570
   Hart W.E., 2017, PYOMO OPTIMIZATION M
   Keeling M. J., 2011, MODELING INFECT DIS
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lenhart S., 2007, OPTIMAL CONTROL APPL
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Liu Z., 2020, ARXIV200212298
   Magal P., 2020, PREDICTING NUMBER RE
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Moore S. E., 2020, ARXIV200400443
   Neilan RM, 2010, DIMACS SER DISCRET M, V75, P67
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Pan JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1133-9
   Park S. W., 2020, TIME SCALE ASYMPTOMA
   Paterlini Marta, 2020, Nature, DOI 10.1038/d41586-020-01001-8
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Peng L, 2020, ARXIV200206563
   Process Systems Enterprise, 1997, GEN PROC MOD SYST GP
   Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa030
   Sameni R, 2020, ARXIV200311371
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tawarmalani M, 2005, MATH PROGRAM, V103, P225, DOI 10.1007/s10107-005-0581-8
   Tobias A, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138539
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Wan EA, 2000, IEEE 2000 ADAPTIVE SYSTEMS FOR SIGNAL PROCESSING, COMMUNICATIONS, AND CONTROL SYMPOSIUM - PROCEEDINGS, P153, DOI 10.1109/ASSPCC.2000.882463
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 37
TC 4
Z9 4
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 1
PY 2020
VL 10
IS 1
AR 10711
DI 10.1038/s41598-020-67459-8
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MH2GR
UT WOS:000546550700025
PM 32612204
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Angus, DC
   Berry, S
   Lewis, RJ
   Al-Beidh, F
   Arabi, Y
   van Bentum-Puijk, W
   Bhimani, Z
   Bonten, M
   Broglio, K
   Brunkhorst, F
   Cheng, AC
   Chiche, JD
   De Jong, M
   Detry, M
   Goossens, H
   Gordon, A
   Green, C
   Higgins, AM
   Hullegie, SJ
   Kruger, P
   Lamontagne, F
   Litton, E
   Marshall, J
   McGlothlin, A
   McGuinness, S
   Mouncey, P
   Murthy, S
   Nichol, A
   O'Neill, GK
   Parke, R
   Parker, J
   Rohde, G
   Rowan, K
   Turner, A
   Young, P
   Derde, L
   McArthur, C
   Webb, SA
AF Angus, Derek C.
   Berry, Scott
   Lewis, Roger J.
   Al-Beidh, Farah
   Arabi, Yaseen
   van Bentum-Puijk, Wilma
   Bhimani, Zahra
   Bonten, Marc
   Broglio, Kristine
   Brunkhorst, Frank
   Cheng, Allen C.
   Chiche, Jean-Daniel
   De Jong, Menno
   Detry, Michelle
   Goossens, Herman
   Gordon, Anthony
   Green, Cameron
   Higgins, Alisa M.
   Hullegie, Sebastiaan J.
   Kruger, Peter
   Lamontagne, Francois
   Litton, Edward
   Marshall, John
   McGlothlin, Anna
   McGuinness, Shay
   Mouncey, Paul
   Murthy, Srinivas
   Nichol, Alistair
   O'Neill, Genevieve K.
   Parke, Rachael
   Parker, Jane
   Rohde, Gernot
   Rowan, Kathryn
   Turner, Anne
   Young, Paul
   Derde, Lennie
   McArthur, Colin
   Webb, Steven A.
TI The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for
   Community-acquired Pneumonia) Study Rationale and Design
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE randomized clinical trial; Bayesian adaptive platform trial; master
   protocol; community-acquired pneumonia; coronavirus disease 2019
ID INTENSIVE-CARE-UNIT; CONSERVATIVE OXYGEN-THERAPY; SEPTIC SHOCK;
   MECHANICAL VENTILATION; FLUID RESUSCITATION; TRIAL; MORTALITY;
   GUIDELINES; ADULTS; CORTICOSTEROIDS
AB There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features: 1) randomization, allowing robust causal inference; 2) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; 3) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; 4) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and 5) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.
C1 [Angus, Derek C.] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Dept Crit Care Med, Pittsburgh, PA USA.
   [Berry, Scott; Lewis, Roger J.; Broglio, Kristine; Detry, Michelle; McGlothlin, Anna] Berry Consultants LLC, Austin, TX USA.
   [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA.
   [Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Emergency Med, Los Angeles, CA 90095 USA.
   [Al-Beidh, Farah; Gordon, Anthony] Imperial Coll London, Dept Surg & Canc, Div Anaesthet Pain Med & Intens Care Med, London, England.
   [Al-Beidh, Farah; Gordon, Anthony] Imperial Coll, Healthcare Natl Hlth Serv Trust, London, England.
   [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Coll Med, Dept Intens Care, Riyadh, Saudi Arabia.
   [van Bentum-Puijk, Wilma; Bonten, Marc; Hullegie, Sebastiaan J.; Derde, Lennie] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Bonten, Marc] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
   [Derde, Lennie] Univ Med Ctr Utrecht, Intens Care Ctr, Utrecht, Netherlands.
   [Bhimani, Zahra; Marshall, John] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Brunkhorst, Frank] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Ctr Clin Studies, Jena, Germany.
   [Brunkhorst, Frank] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Ctr Sepsis Control & Care, Jena, Germany.
   [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic, Australia.
   [Cheng, Allen C.; Green, Cameron; Higgins, Alisa M.; McGuinness, Shay; Nichol, Alistair; O'Neill, Genevieve K.; Parker, Jane; Webb, Steven A.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Epidemiol & Prevent Med, Melbourne, Vic, Australia.
   [Chiche, Jean-Daniel] Paris Descartes Univ, Hop Cochin, Med Intens Care Unit, Paris, France.
   [De Jong, Menno] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands.
   [Goossens, Herman] Antwerp Univ Hosp, Dept Microbiol, Antwerp, Belgium.
   [Kruger, Peter] Princess Alexandra Hosp, Intens Care Unit, Brisbane, Qld, Australia.
   [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada.
   [Litton, Edward; Webb, Steven A.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia.
   [Marshall, John] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.
   [McGuinness, Shay; Parke, Rachael] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand.
   [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand.
   [McGuinness, Shay; Parke, Rachael; Turner, Anne; Young, Paul; McArthur, Colin] Med Res Inst New Zealand, Wellington, New Zealand.
   [Mouncey, Paul; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, Clin Trials Unit, London, England.
   [Murthy, Srinivas] Univ British Columbia, Sch Med, Vancouver, BC, Canada.
   [Nichol, Alistair] St Vincents Univ Hosp, Dept Anesthesia & Intens Care, Dublin, Ireland.
   [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland.
   [Parke, Rachael] Univ Auckland, Sch Nursing, Auckland, New Zealand.
   [Rohde, Gernot] Univ Hosp Frankfurt, Dept Resp Med, Frankfurt, Germany.
   [Rohde, Gernot] CAPNETZ Fdn, Hannover, Germany.
   [Young, Paul] Wellington Hosp, Intens Care Unit, Wellington, New Zealand.
   [Webb, Steven A.] St John God Hosp, Subiaco, WA, Australia.
RP Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA.
EM angusdc@upmc.edu
RI Gordon, Anthony/A-3472-2012; Arabi, Yaseen/ABF-3316-2020; Chiche,
   Jean-Daniel/P-5220-2017
OI Gordon, Anthony/0000-0002-0419-547X; Arabi, Yaseen/0000-0001-5735-6241;
   Derde, Lennie/0000-0002-3577-5629; Young, Paul/0000-0002-3428-3083;
   Angus, Derek/0000-0002-7026-5181; Chiche,
   Jean-Daniel/0000-0002-6433-6254; Murthy, Srinivas/0000-0002-9476-839X;
   Nichol, Alistair/0000-0002-4689-1238
FU European UnionEuropean Union (EU) [602525]; Australian National Health
   and Medical Research CouncilNational Health and Medical Research Council
   of Australia [APP1101719]; New Zealand Health Research CouncilHealth
   Research Council of New Zealand [16/631]; Canadian Institute of Health
   Research Strategy for Patient-Oriented Research Innovative Clinical
   Trials ProgramCanadian Institutes of Health Research (CIHR) [158584];
   British Embassy
FX Supported by the European Union, FP7-HEALTH-2013-INNOVATION-1 grant
   602525 to the PREPARE (Platform for European Preparedness Against [Re-]
   emerging Epidemics) Consortium, Australian National Health and Medical
   Research Council grant APP1101719, New Zealand Health Research Council
   grant 16/631, and Canadian Institute of Health Research Strategy for
   Patient-Oriented Research Innovative Clinical Trials Program Grant
   158584; the original design was supported by a development grant from
   the British Embassy.
CR Adaptive Platform Trials Coalition, 2019, Nat Rev Drug Discov, V18, P797, DOI 10.1038/s41573-019-0034-3
   ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336
   Alvarez-Lerma Francisco, 2004, Curr Opin Crit Care, V10, P369
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Angus DC, 2020, NEW ENGL J MED, V382, P1054, DOI 10.1056/NEJMe2000800
   Angus DC, 2015, JAMA-J AM MED ASSOC, V314, P767, DOI 10.1001/jama.2015.7762
   Annane D, 2018, NEW ENGL J MED, V378, P809, DOI 10.1056/NEJMoa1705716
   Annane D, 2004, BRIT MED J, V329, P480, DOI 10.1136/bmj.38181.482222.55
   Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927
   Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316
   Bjerre LM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002109.pub3
   Blum CA, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-257
   Bodi M, 2005, CLIN INFECT DIS, V41, P1709, DOI 10.1086/498119
   Briegel J, 2001, J AM SOC NEPHROL, V12, pS70
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Butler CC, 2020, LANCET, V395, P42, DOI 10.1016/S0140-6736(19)32982-4
   Chen YJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007720.pub2
   Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3
   Cochrane AL, 1972, EFFECTIVENESS EFFICI
   De Pascale G, 2011, MINERVA ANESTESIOL, V77, P902
   Dobson J, 2015, LANCET, V385, P1728
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Dodd LE, 2016, J INFECT DIS, V213, P1906, DOI 10.1093/infdis/jiw061
   Ebell MH, 2017, BMJ-BRIT MED J, V358, P3266
   Eccles S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6722
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Finfer S, 2004, NEW ENGL J MED, V350, P2247
   Fiore LD, 2011, CLIN TRIALS, V8, P183, DOI [10.1177/1740774511398368, 10.1177/1740774510395635]
   Frei CR, 2010, CLIN THER, V32, P293, DOI 10.1016/j.clinthera.2010.02.006
   Girardis M, 2017, JAMA-J AM MED ASSOC, V317, P647, DOI 10.1001/jama.2016.20829
   Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Goodman S, 2010, JAMA-J AM MED ASSOC, V304, P157, DOI [10.1001/jama.2010.931, 10.1001/jama.2010.933]
   Gorman SK, 2007, ANN PHARMACOTHER, V41, P1233, DOI 10.1345/aph.1H660
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Jantz MA, 1999, AM J RESP CRIT CARE, V160, P1079, DOI 10.1164/ajrccm.160.4.9901075
   Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09
   Kapur J, 2019, NEW ENGL J MED, V381, P2103, DOI 10.1056/NEJMoa1905795
   Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC
   Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707
   Lamontagne F, 2010, J CRIT CARE, V25, P420, DOI 10.1016/j.jcrc.2009.08.009
   LaVange LM, 2020, STAT CONSIDERATIONS
   LEROY O, 1995, INTENS CARE MED, V21, P24, DOI 10.1007/BF02425150
   Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434
   Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   McCabe C, 2009, ARCH INTERN MED, V169, P1525, DOI 10.1001/archinternmed.2009.259
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Mortensen EM, 2004, AM J MED, V117, P726, DOI 10.1016/j.amjmed.2004.06.028
   Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885
   Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759
   Park JW, 2016, NEW ENGL J MED, V375, P11, DOI 10.1056/NEJMoa1513750
   Povoa P, 2012, CURR OPIN INFECT DIS, V25, P199, DOI 10.1097/QCO.0b013e32834f44c7
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rubin BK, 1997, AM J RESP CRIT CARE, V155, P2018, DOI 10.1164/ajrccm.155.6.9196110
   Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749
   Salluh JIF, 2011, J CRIT CARE, V26, P193, DOI 10.1016/j.jcrc.2010.07.014
   Shorr AF, 2006, CHEST, V130, P93, DOI [10.1378/chest.130.1.93, 10.1016/S0012-3692(15)50958-6]
   Singanayagam A, 2009, QJM-INT J MED, V102, P379, DOI 10.1093/qjmed/hcp027
   Sligl WI, 2013, CRIT CARE CLIN, V29, P563, DOI 10.1016/j.ccc.2013.03.009
   TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001
   Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88
   U.S. Department of Health and Human Services FaDA, 2020, AD DES MED DEV CLIN
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Viele K, 2020, CLIN TRIALS, V17, P52, DOI 10.1177/1740774519877836
   Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481
   Wiersinga WJ, 2012, NETH J MED, V70, P90
   WILCOX RG, 1988, LANCET, V2, P525
   Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x
   Young P, 2020, INTENS CARE MED, V46, P17, DOI 10.1007/s00134-019-05857-x
NR 77
TC 12
Z9 12
U1 5
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD JUL
PY 2020
VL 17
IS 7
BP 879
EP 891
DI 10.1513/AnnalsATS.202003-192SD
PG 13
WC Respiratory System
SC Respiratory System
GA MH3GU
UT WOS:000546620500017
PM 32267771
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shyh, GI
   Nawarskas, JJ
   Cheng-Lai, A
AF Shyh, Grace I.
   Nawarskas, James J.
   Cheng-Lai, Angela
TI Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor
   Blockers in Patients With Coronavirus Disease 2019 Friend or Foe?
SO CARDIOLOGY IN REVIEW
LA English
DT Article
DE coronavirus disease 2019; renin-angiotensin-aldosterone system;
   angiotensin-converting enzyme 2
ID SARS CORONAVIRUS; FUNCTIONAL RECEPTOR; ACE2; PROTEIN
AB When the coronavirus disease 2019 (COVID-19) wreaked an unprecedented havoc of an escalating number of deaths and hospitalization in the United States, clinicians were faced with a myriad of unanswered questions, one of the them being the implication of the renin-angiotensin-aldosterone system in patients with COVID-19. Animal data and human studies have shown that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the expression of ACE2. ACE2 is an enzyme found in the heart, kidney, gastrointestinal tract, and lung and is a coreceptor for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV2), the virus responsible for COVID-19. Therefore, one can speculate that discontinuing ACE inhibitor or ARB therapy may lead to decreased ACE2 expression, thereby attenuating the infectivity of SARS-CoV-2, and mitigating the disease progression of COVID-19. However, several studies have also shown that ACE2 exhibits reno- and cardioprotection and preserves lung function in acute respiratory distress syndrome, which would favor ACE inhibitor or ARB therapy. This article is to examine and summarize the 2 opposing viewpoints and provide guideline recommendations to support the use or discontinuation of ACE inhibitors and ARBs in patients with COVID-19.
C1 [Shyh, Grace I.] NewYork Presbyterian Hosp, Dept Pharm, 170 William St, New York, NY 10038 USA.
   [Nawarskas, James J.] Univ New Mexico, Coll Pharm, Dept Pharm Practice & Adm Sci, Albuquerque, NM 87131 USA.
   [Cheng-Lai, Angela] Montefiore Med Ctr, Dept Pharm, 111 E 210th St, Bronx, NY 10467 USA.
RP Shyh, GI (corresponding author), NewYork Presbyterian Hosp, Dept Pharm, 170 William St, New York, NY 10038 USA.
EM gis9029@nyp.org
CR Averill DB, 2003, CIRCULATION, V108, P2141, DOI 10.1161/01.CIR.0000092888.63239.54
   Brosnihan KB, 2005, HYPERTENSION, V46, P1097, DOI 10.1161/01.HYP.0000185149.56516.0a
   Chappell MC, 1998, HYPERTENSION, V31, P362, DOI 10.1161/01.HYP.31.1.362
   Deddish PA, 1998, HYPERTENSION, V31, P912, DOI 10.1161/01.HYP.31.4.912
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Ferreira AJ, 2001, HYPERTENSION, V38, P665, DOI 10.1161/01.HYP.38.3.665
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Loot AE, 2002, CIRCULATION, V105, P1548, DOI 10.1161/01.CIR.0000013847.07035.B9
   Nadarajah R, 2012, KIDNEY INT, V82, P292, DOI 10.1038/ki.2012.83
   Saseen JJ, 2008, PHARMACOTHERAPY PATH, P139
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 25
TC 5
Z9 5
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1061-5377
EI 1538-4683
J9 CARDIOL REV
JI Cardiol. Rev.
PD JUL-AUG
PY 2020
VL 28
IS 4
BP 213
EP 216
DI 10.1097/CRD.0000000000000319
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MG3DH
UT WOS:000545914300008
PM 32496364
DA 2021-01-01
ER

PT J
AU Tan, AC
   Ashley, DM
   Khasraw, M
AF Tan, Aaron C.
   Ashley, David M.
   Khasraw, Mustafa
TI Adapting to a Pandemic - Conducting Oncology Trials during the
   SARS-CoV-2 Pandemic
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID REAL-WORLD EVIDENCE
AB The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has necessitated changes in cancer care delivery as resources are reallocated. Clinical trials and other research activities are inevitably impacted. Start-up activities for new trials may be deferred and recruitment suspended. For patients already enrolled however, there are challenges in continuing treatment on trial. Regulatory bodies have issued guidance on managing dinical trials during the pandemic, including contingency measures for remote study visits, delivery of investigational product, and site monitoring visits. New cancer dinical trial practices during the SARS-CoV-2 pandemic indude new risk assessment strategies, decentralized and remote trial coordination, data collection, and delegation of specific therapeutic activities. This experience could provide evidence of more feasible and cost-effective methods for future clinical trial conduct.
C1 [Tan, Aaron C.] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
   [Ashley, David M.; Khasraw, Mustafa] Duke Univ, Med Ctr, Durham, NC USA.
RP Khasraw, M (corresponding author), Duke Univ, Duke Canc Inst, Durham, NC 27708 USA.
EM mustafa.khasraw@duke.edu
RI Khasraw, Mustafa/ABH-5962-2020
OI Khasraw, Mustafa/0000-0003-3249-9849; Tan, Aaron/0000-0001-7292-1114
CR Ashley D, 2015, LANCET ONCOL, V16, pE190, DOI 10.1016/S1470-2045(14)71153-2
   Burki TK, 2020, LANCET ONCOL, DOI 10.1016/S1470-2045(70)30096-6
   Coravos Andrea, 2019, Digit Biomark, V3, P31, DOI 10.1159/000500413
   DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Health Sciences Authority, 2020, GUID COND CLIN TRIAL
   Khozin S, 2019, CLIN PHARMACOL THER, V106, P25, DOI 10.1002/cpt.1441
   Khozin S, 2018, NAT REV DRUG DISCOV, V17, P529, DOI 10.1038/nrd.2018.34
   Li XW, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041201
   Medicines and Healthcare products Regulatory Agency, 2020, MAN CLIN TRIALS COR
   National University Cancer Institute of Singapore (NCIS) Workflow Team, 2020, ANN ONCOL
   Pietrantonio F, 2020, JAMA ONCOL, V11
   Pung R, 2020, LANCET, V395, P1039, DOI 10.1016/S0140-6736(20)30528-6
   Sabesan S, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12587
   Sabesan S, 2017, ACCESS CLIN TRIALS C
   Senft D, 2017, TRENDS MOL MED, V23, P874, DOI 10.1016/j.molmed.2017.08.003
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141
   The Lancet Oncology, 2020, Lancet Oncol, V21, P467, DOI 10.1016/S1470-2045(20)30175-3
   Unger Joseph M, 2016, Am Soc Clin Oncol Educ Book, P185, DOI [10.14694/EDBK_156686, 10.1200/EDBK_156686]
   Wong JEL, 2020, JAMA
   World Health Organization, 2020, COR DIS COVI 19 PAND
NR 23
TC 6
Z9 6
U1 3
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL
PY 2020
VL 26
IS 13
BP 3100
EP 3103
DI 10.1158/1078-0432.CCR-20-1364
PG 4
WC Oncology
SC Oncology
GA MG4PX
UT WOS:000546016400004
PM 32312892
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Iftikhar, H
   Ali, HN
   Farooq, S
   Naveed, H
   Shahzad-ul-Hussan, S
AF Iftikhar, Hafsa
   Ali, Hafiza Nayyer
   Farooq, Sadia
   Naveed, Hammad
   Shahzad-ul-Hussan, Syed
TI Identification of potential inhibitors of three key enzymes of SARS-CoV2
   using computational approach
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Drug repurposing; SARS-CoV-2; RdRp; Helicase; Rimantadine; Grazoprevir
ID SARS-CORONAVIRUS; DRUG; DISCOVERY
AB The recent outbreak of coronavirus disease-19 (COVID-19) continues to drastically affect healthcare throughout the world. To date, no approved treatment regimen or vaccine is available to effectively attenuate or prevent the infection. Therefore, collective and multidisciplinary efforts are needed to identify new therapeutics or to explore effectiveness of existing drugs and drug-like small molecules against SARS-CoV-2 for lead identification and repurposing prospects. This study addresses the identification of small molecules that specifically bind to any of the three essential proteins (RdRp, 3CL-protease and helicase) of SARS-CoV-2. By applying computational approaches we screened a library of 4574 compounds also containing FDA-approved drugs against these viral proteins. Shortlisted hits from initial screening were subjected to iterative docking with the respective proteins. Ranking score on the basis of binding energy, clustering score, shape complementarity and functional significance of the binding pocket was applied to identify the binding compounds. Finally, to minimize chances of false positives, we performed docking of the identified molecules with 100 irrelevant proteins of diverse classes thereby ruling out the non-specific binding. Three FDA-approved drugs showed binding to 3CL-protease either at the catalytic pocket or at an allosteric site related to functionally important dimer formation. A drug-like molecule showed binding to RdRp in its catalytic pocket blocking the key catalytic residues. Two other druglike molecules showed specific interactions with helicase at a key domain involved in catalysis. This study provides lead drugs or drug-like molecules for further in vitro and clinical investigation for drug repurposing and new drug development prospects.
C1 [Iftikhar, Hafsa; Ali, Hafiza Nayyer; Shahzad-ul-Hussan, Syed] Lahore Univ Management Sci, Syed Babar Ali Sch Sci & Engn, Dept Biol, Lahore, Pakistan.
   [Farooq, Sadia; Naveed, Hammad] Natl Univ Comp & Emerging Sci, Dept Comp Sci, Islamabad, Pakistan.
RP Shahzad-ul-Hussan, S (corresponding author), Lahore Univ Management Sci, Syed Babar Ali Sch Sci & Engn, Dept Biol, Lahore, Pakistan.; Naveed, H (corresponding author), Natl Univ Comp & Emerging Sci, Dept Comp Sci, Islamabad, Pakistan.
EM hammad.naveed@nu.edu.pk; shahzad.hussan@lums.edu.pk
FU Lahore University of Management Sciences; Higher Education Commission of
   PakistanHigher Education Commission of Pakistan
FX This study was supported by an internal funding from Lahore University
   of Management Sciences. One of the authors, Hafsa Iftikhar was supported
   by the Higher Education Commission of Pakistan in the form of PhD
   stipend.
CR Alric L, 2016, EXPERT OPIN PHARMACO, V17, P735, DOI 10.1517/14656566.2016.1161028
   [Anonymous], 1985, Bull World Health Organ, V63, P51
   [Anonymous], 2020, ONLINE SMILES TRANSL
   Ashraf MU, 2019, MED RES REV, V39, P1091, DOI 10.1002/med.21554
   Bayham J, 2020, LANCET PUBLIC HEALTH, V5, pE271, DOI 10.1016/S2468-2667(20)30082-7
   Burkle FM, 2020, PREHOSP DISASTER MED, V35, P426, DOI 10.1017/S1049023X20000515
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Galvao M.G. Alves, 2012, COCHRANE DB SYST REV, V1
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huppertz LM, 2015, FORENSIC TOXICOL, V33, P388, DOI 10.1007/s11419-015-0277-6
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johnson DK, 2017, CURR TOP MED CHEM, V17, P2703, DOI 10.2174/1568026617666170508153904
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   KUNKEL L, 1956, Medizinische, V10, P1820
   Labbe CM, 2015, NUCLEIC ACIDS RES, V43, pW448, DOI 10.1093/nar/gkv306
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mirza M. U., 2020, STRUCTURAL ELUCIDATI, DOI [10.20944/preprints202003.0085.v1, DOI 10.20944/PREPRINTS202003.0085.V1]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Naveed H, 2015, BIOINFORMATICS, V31, P3922, DOI 10.1093/bioinformatics/btv477
   NITZ RE, 1955, ARZNEIMITTEL-FORSCH, V5, P357
   Par A, 2018, ORVOSI HETILAP, V159, P455, DOI 10.1556/650.2018.30997
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Qadir A, 2018, EUR J MED CHEM, V156, P444, DOI 10.1016/j.ejmech.2018.07.014
   Romano KP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002832
   Ruhlmann Christina, 2009, Ther Clin Risk Manag, V5, P375
   Seidel T, 2019, PROG CHEM ORG NAT PR, V110, P99, DOI 10.1007/978-3-030-14632-0_4
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Soumana DI, 2016, ACS CHEM BIOL, V11, P900, DOI 10.1021/acschembio.5b00647
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weston S., 2020, BROAD ANTICORONAVIRA, DOI [10.1101/2020.03.25.008482, DOI 10.1101/2020.03.25.008482]
   WHO, 2020, 84 WHO
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zheng YX, 2020, J GASTROEN HEPATOL, V35, P1477, DOI 10.1111/jgh.15051
NR 53
TC 4
Z9 4
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD JUL
PY 2020
VL 122
AR 103848
DI 10.1016/j.compbiomed.2020.103848
PG 8
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA MG9BB
UT WOS:000546326800017
PM 32658735
OA Green Published
DA 2021-01-01
ER

PT J
AU Rizk, HG
   Strange, C
   Atallah, S
   Massingale, S
   Clendaniel, R
AF Rizk, Habib G.
   Strange, Christine
   Atallah, Stephanie
   Massingale, Shelly
   Clendaniel, Richard
TI Coronavirus Disease 2019 Return to Work Guidance and Recommendations for
   Vestibular Clinicians
SO EAR AND HEARING
LA English
DT Article
DE COVID-19; Decontamination; Safety; Physical therapy; Vestibular
ID N95 RESPIRATORS; COVID-19; MASKS
AB As states begin issuing progressive deconfinement guidelines, hospitals and institutions are starting to reopen for elective procedures and consultations. Vestibular clinicians are opening their practices to evaluate, test, or treat patients with dizziness and balance problems. The following document, requested by the American Balance Society, collates the current information about the virus, including transmission from asymptomatic carriers, decontamination, and other safety protocols, and provides a return to work guidance for clinicians caring for this population of patients, promoting provider, patient, and staff safety.
C1 [Rizk, Habib G.; Strange, Christine] Med Univ South Carolina, Dept Otolaryngol Head Neck Surg, Charleston, SC 29425 USA.
   [Atallah, Stephanie] Sahlgrens Univ Hosp, Dept Infect Dis, Gothenburg, Sweden.
   [Massingale, Shelly] Banner Sports Med & Concuss Ctr, Phoenix, AZ USA.
   [Clendaniel, Richard] Duke Univ, Med Ctr, Phys Therapy Div, Durham, NC USA.
RP Rizk, HG (corresponding author), Med Univ South Carolina, Head Neck Surg, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM rizkh@musc.edu
CR Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   Centers for Disease Control and Prevention, 2020, SYMPT COR
   Centers for Disease Control and Prevention, 2020, PROT YOURS OTH
   Centers for Disease Control and Prevention, 2020, CLIN QUEST COVID 19
   Centers for Disease Control and Prevention (CDC), 2020, REOP GUID CLEAN DIS
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   He DH, 2020, INT J INFECT DIS, V94, P145, DOI 10.1016/j.ijid.2020.04.034
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Lee SA, 2016, J HEALTHC ENG, V2016, DOI 10.1155/2016/8572493
   Li JPO, 2020, BRIT J OPHTHALMOL, V104, P297, DOI 10.1136/bjophthalmol-2020-315994
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Rahimi F, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101677
   Smith JD, 2016, CAN MED ASSOC J, V188, P567, DOI 10.1503/cmaj.150835
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
NR 16
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-0202
EI 1538-4667
J9 EAR HEARING
JI Ear Hear.
PD JUL-AUG
PY 2020
VL 41
IS 4
BP 693
EP 696
DI 10.1097/AUD.0000000000000903
PG 4
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA MG4XD
UT WOS:000546035600001
PM 32427744
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhu, PT
   Zheng, YH
AF Zhu, Peitao
   Zheng, Yinghe
TI Constructivist Retelling of the Epic of Gilgamesh: Implications for the
   COVID-19 Pandemic
SO JOURNAL OF CONSTRUCTIVIST PSYCHOLOGY
LA English
DT Article; Early Access
ID INNOVATIVE MOMENTS; MEANING RECONSTRUCTION; THERAPY; GRIEF
AB Storytelling meets a fundamental human need, as narratives bring continuity, identity, and agency to an otherwise meaningless human experience. The retelling of stories not only facilitates connections but also allows new perspectives to emerge. Through a constructivist lens, we illustrate thatThe Epic of Gilgamesh,the oldest written story known in human history, has a great deal of relevance to present times, where the COVID-19 pandemic presents itself as a once-in-a century challenge to human societies across the globe. Using a narrative framework, we accentuate the necessary elements that facilitate the narrative reconstructions in face of grief and loss stemming from the pandemic, as informed by the heroic story. We discuss the implications pertinent to mental health practitioners as well as at the broader societal level.
C1 [Zhu, Peitao] Northern Illinois Univ, Dept Counseling & Higher Educ, Gabel Hall 200, De Kalb, IL 60115 USA.
RP Zhu, PT (corresponding author), Northern Illinois Univ, Dept Counseling & Higher Educ, Gabel Hall 200, De Kalb, IL 60115 USA.
EM pzhu@niu.edu
OI Zhu, Peitao/0000-0001-5884-0254
CR Alves D, 2014, PSYCHOTHERAPY, V51, P308, DOI 10.1037/a0031151
   Arciero G., 2000, CONSTRUCTIONS DISORD, P89
   Atlani-Duault L, 2020, LANCET PUBLIC HEALTH, V5, pE137, DOI 10.1016/S2468-2667(20)30033-5
   Campbell Joseph, 2008, HERO 1000 FACES, V17
   Cassino D, 2020, MENS MISPLACED SENSE
   Chen H. A., 2020, AM J SURG, DOI [https://doi.org/10.1016/j.amjsurg.2020.05.02, 10.1016/j.amjsurg.2020.05.02, DOI 10.1016/J.AMJSURG.2020.05.02]
   Davis DA, 2011, SOUTHERN LIT J, V43, P55, DOI 10.1353/slj.2011.0007
   Devakumar D, 2020, LANCET, V395, P1194, DOI 10.1016/S0140-6736(20)30792-3
   Gillies J, 2006, J CONSTR PSYCHOL, V19, P31, DOI 10.1080/10720530500311182
   Goncalves M, 2009, J CONSTR PSYCHOL, V22, P1, DOI 10.1080/10720530802500748
   HARPER CA, 2020, INT J MENT HEAL 0427, DOI DOI https://doi.org/10.1007/s11469-020-00281-5
   Hoffman S., 2004, HUMAN PSYCHOL, V32, P379, DOI [https://doi.org/10.1080/08873267.2004.9961761, DOI 10.1080/08873267.2004.9961761]
   Janoff-Bulman R., 1992, SHATTERED ASSUMPTION
   JANOFFBULMAN R, 1989, SOC COGNITION, V7, P113, DOI 10.1521/soco.1989.7.2.113
   Jones DS, 2020, NEW ENGL J MED, V382, P1681, DOI 10.1056/NEJMp2004361
   Leahy RL, 2016, AUST PSYCHOL, V51, P82, DOI 10.1111/ap.12142
   Mamzer H, 2020, SOC REGISTER, V4, P7, DOI DOI https://doi.org/10.14746/sr.2020.4.2.01
   Matos M, 2009, PSYCHOTHER RES, V19, P68, DOI 10.1080/10503300802430657
   Milman E, 2020, DEATH STUD, DOI 10.1080/07481187.2020.1775362
   Mitchell S., 2004, GILGAMESH NEW ENGLIS
   Neimeyer RA, 2010, J CONTEMP PSYCHOTHER, V40, P73, DOI 10.1007/s10879-009-9135-3
   Neimeyer RA, 2005, OMEGA-J DEATH DYING, V52, P37
   Neimeyer RA, 2019, DEATH STUD, V43, P79, DOI 10.1080/07481187.2018.1456620
   Ortiz M., 2020, NY TIMES
   Piazza-Bonin E, 2016, J CONSTR PSYCHOL, V29, P269, DOI 10.1080/10720537.2015.1118712
   Raskin JD, 2020, J HUMANIST PSYCHOL, DOI 10.1177/0022167820937509
   Ribeiro AP, 2011, INTEGR PSYCHOL BEHAV, V45, P281, DOI 10.1007/s12124-010-9149-0
   Smith A., 2020, NBCNEWS         0503
   White M, 1990, NARRATIVE MEANS THER
   Yalom I., 1980, EXISTENTIAL THERAPY
NR 30
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1072-0537
EI 1521-0650
J9 J CONSTR PSYCHOL
JI J. Constr. Psychol.
DI 10.1080/10720537.2020.1786867
EA JUL 2020
PG 9
WC Psychology, Clinical
SC Psychology
GA MG8MJ
UT WOS:000546285200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Thachil, J
   Tang, N
   Gando, S
   Falanga, A
   Cattaneo, M
   Levi, M
   Clark, C
   Iba, T
AF Thachil, Jecko
   Tang, Ning
   Gando, Satoshi
   Falanga, Anna
   Cattaneo, Marco
   Levi, Marcel
   Clark, Cary
   Iba, Toshiaki
TI DOACs and "newer" hemophilia therapies in COVID-19: Reply
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
DE anticoagulant; COVID-19; thrombosis
C1 [Thachil, Jecko] Manchester Univ Hosp, Dept Haematol, Manchester, Lancs, England.
   [Tang, Ning] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Peoples R China.
   [Gando, Satoshi] Sapporo Higashi Tokushukai Hosp, Dept Acute & Crit Care Med, Sapporo, Hokkaido, Japan.
   [Falanga, Anna] Hosp Papa Giovanni XXIII, Dept Transfus Med & Hematol, Bergamo, Italy.
   [Falanga, Anna] Univ Milano Bicocca, Bergamo, Italy.
   [Cattaneo, Marco] Univ Milan, Dipartimento Sci Salute, ASST Santi Paolo & Carlo, Milan, Italy.
   [Levi, Marcel] Univ Coll London Hosp NHS Fdn Trust, Dept Med, London, England.
   [Levi, Marcel] Univ Coll London Hosp NHS Fdn Trust, Cardiometab Programme NIHR UCLH UCL BRC, London, England.
   [Clark, Cary] Int Soc Thrombosis & Haemostasis, Programs & Educ, Carrboro, NC USA.
   [Iba, Toshiaki] Juntendo Univ, Grad Sch Med, Dept Emergency & Disaster Med, Tokyo, Japan.
RP Thachil, J (corresponding author), Manchester Royal Infirm, Dept Haematol, Oxford Rd, Manchester M13 9WL, Lancs, England.
EM jecko.thachil@mft.nhs.uk
RI Levi, Marcel/AAZ-8559-2020
CR Agnelli G, 2020, NEW ENGL J MED, V382, P1599, DOI 10.1056/NEJMoa1915103
   Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461
   Lurkin A, 2019, CEREBROVASC DIS, V48, P32, DOI 10.1159/000502454
   Naymagon L, 2020, BLOOD ADV, V4, P655, DOI 10.1182/bloodadvances.2019001310
   Raskob GE, 2018, NEW ENGL J MED, V378, P615, DOI 10.1056/NEJMoa1711948
   Young AM, 2018, J CLIN ONCOL, V36, P2017, DOI 10.1200/JCO.2018.78.8034
NR 6
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2020
VL 18
IS 7
BP 1795
EP 1796
DI 10.1111/jth.14841
PG 2
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA MG6WK
UT WOS:000546169500035
PM 32282993
OA Bronze
DA 2021-01-01
ER

PT J
AU Hewlett, MJ
AF Hewlett, Martinez J.
TI Love Thy Neighbor as Thyself: Vaccination in the Age of COVID-19
SO THEOLOGY AND SCIENCE
LA English
DT Article
DE SARS-CoV-2; COVID-19; vaccination; vaccine hesitance; herd immunity
AB SARS-CoV-2, the causative agent of COVID-19, represents that latest challenge in the long history of vaccine development and deployment. The pathway out of the current pandemic due to this virus requires a sufficient number of the population developing immune resistance such that herd immunity results. Finding a safe and efficacious vaccine is the most compassionate route of exit, compared to natural infection leading to unwanted fatalities of the most susceptible. As a result, vaccine acceptance might be looked on as one form of obeying the Second Great Commandment: Love thy neighbor as thyself.
C1 [Hewlett, Martinez J.] Univ Arizona, Dept Cellular & Mol Biol, Tucson, AZ 85721 USA.
   [Hewlett, Martinez J.] Univ New Mexico, Taos, NM 87557 USA.
RP Hewlett, MJ (corresponding author), Univ Arizona, Dept Cellular & Mol Biol, Tucson, AZ 85721 USA.; Hewlett, MJ (corresponding author), Univ New Mexico, Taos, NM 87557 USA.
CR Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z
   Barquet N, 1997, ANN INTERN MED, V127, P635, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00010
   Deer Brian, 2011, BMJ, V342, pc5347, DOI 10.1136/bmj.c5347
   Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1
   Murch SH, 2004, LANCET, V363, P750, DOI 10.1016/S0140-6736(04)15715-2
   Sanche S, 2020, NOVEL CORONAVIRUS 20, DOI DOI 10.1101/2020.02.07.20021154V1
NR 6
TC 0
Z9 0
U1 4
U2 4
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1474-6700
EI 1474-6719
J9 THEOL SCI
JI Theol. Sci.
PD JUL 2
PY 2020
VL 18
IS 3
BP 349
EP 351
DI 10.1080/14746700.2020.1786212
EA JUL 2020
PG 3
WC History & Philosophy Of Science; Religion
SC History & Philosophy of Science; Religion
GA ND8NI
UT WOS:000547085200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Joshi, AY
   Mullakary, RM
   Iyer, VN
AF Joshi, Avni Y.
   Mullakary, Roshini M.
   Iyer, Vivek N.
TI Successful treatment of coronavirus disease 2019 in a patient with
   asthma
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article
ID CLINICAL CHARACTERISTICS
AB Underlying lung disease, especially asthma, has recently been found to be associated with a higher risk of hospitalization with coronavirus disease 2019 (COVID-19) infection. Inhaled corticosteroids (ICS) are the most commonly used controller medications in patients with asthma. It is unclear whether ICS use increases the risk for severe COVID-19 infection. At the current time, asthma organizations are still recommending the continued use of ICS and other asthma medications to minimize the risk of uncontrolled asthma. However, for patients with asthma and who have recovered from COVID-19 infection, the timing of resumption of asthma therapy is equally uncertain. Pulmonary function testing and exhaled oral nitric oxide testing are aerosol-generating procedures and are currently being severely restricted at most health-care facilities. We presented a case of a patient with cough-variant asthma who developed severe COVID-19 associated acute respiratory distress syndrome with the need for intubation and prolonged mechanical ventilation. We highlighted the potential utility of using COVID-19 RNA detection as well as immunoglobulin G antibody testing to help guide the timing of resumption of asthma therapy.
C1 [Joshi, Avni Y.; Mullakary, Roshini M.] Mayo Clin, Div Allerg Dis, 200 First St SW, Rochester, MN 55905 USA.
   [Iyer, Vivek N.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA.
RP Joshi, AY (corresponding author), Mayo Clin, Div Allerg Dis, 200 First St SW, Rochester, MN 55905 USA.
EM Joshi.avni@mayo.edu
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316
NR 14
TC 1
Z9 1
U1 6
U2 6
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD JUL 1
PY 2020
VL 41
IS 4
BP 296
EP 300
DI 10.2500/aap.2020.41.200044
PG 5
WC Allergy
SC Allergy
GA MG8YW
UT WOS:000546320600012
PM 32605700
DA 2021-01-01
ER

PT J
AU Senkal, N
   Meral, R
   Medetalibeyoglu, A
   Konyaoglu, H
   Kose, M
   Tukek, T
AF Senkal, Naci
   Meral, Rasimcan
   Medetalibeyoglu, Alpay
   Konyaoglu, Hilal
   Kose, Murat
   Tukek, Tufan
TI Association between chronic ACE inhibitor exposure and decreased odds of
   severe disease in patients with COVID-19
SO ANATOLIAN JOURNAL OF CARDIOLOGY
LA English
DT Article
DE coronavirus disease 2019; angiotensin-converting enzyme 2; angiotensin
   II receptor type 1 blockers; angiotensin-converting enzyme inhibitors
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS-CORONAVIRUS; FUNCTIONAL RECEPTOR
AB Objective: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Renin-angiotensin-aldosterone-system (RAAS) inhibitors may increase the expression of angiotensin-converting enzyme 2, which is the receptor for SARSCoV-2 Spike protein. The consequences of using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the COVID-19 pandemic are unknown.
   Methods: A retrospective cohort study aiming to identify the odds of severe disease (defined as either hospitalization of >= 14 days, admission to the intensive care unit, or death) associated with exposure to ACEi or ARB was conducted. Adult patients (age >= 18 years) with COVID-19 admitted to the Istanbul Faculty of Medicine Corona Center between March 9 and May 11, 2020, were included. Chronic users of ACEi, ARB, or other antihypertensive drugs were matched according to age, sex, sick days before hospitalization, comorbidities, smoking, number of antihypertensive regimens, doxazosin use, furosemide use, and serum creatinine level. Odds ratios (OR) of having severe disease were calculated.
   Results: In total, 611 patients were admitted with COVID-19, confirmed by either reverse-transcriptase polymerase chain reaction or computed tomography (CT). There were 363 males, and the age ranged from 18 to 98 years, with an average age of 57 +/- 15 years. Of these, 165 participants had severe disease (53 deaths, case fatality rate: 8.7%). Among those with hypertension (n=249), ARB exposure was compatible with decreased odds (OR=0.60, 95% CI: 0.27-1.36, p=0.31) of severe disease though not statistically significant, while ACEi exposure significantly reduced the risk of severe disease (OR=0.37, 95% CI: 0.15-0.87, p=0.03). ACEi exposure was associated with milder infiltrations seen on baseline CT, lower C-reactive protein and ferritin, higher monocytes, shorter hospitalization, and less requirement for specific empirical treatments (favipiravir and meropenem).
   Conclusion: Our data suggest that exposure to ACEi drugs may have favorable effects in the context of COVID-19 pneumonia.
C1 [Senkal, Naci; Medetalibeyoglu, Alpay; Konyaoglu, Hilal; Kose, Murat; Tukek, Tufan] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Istanbul, Turkey.
   [Meral, Rasimcan] Istanbul Univ, Istanbul Fac Med, Dept Gen Surg & Med Biol, Istanbul, Turkey.
RP Meral, R (corresponding author), Istanbul Univ, Istanbul Tip Fak, Genel Cerrahi Anabilim Dali, Tibbi Biyol Anabilim Dali, Istanbul, Turkey.
EM rasimcanmeral@istanbul.edu.tr
RI Kose, Murat/AAY-9981-2020
CR [Anonymous], 2020, COVID 19 ERISKIN TED
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   GOWER JC, 1971, BIOMETRICS, V27, P857, DOI 10.2307/2528823
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kaufman L, 2009, FINDING GROUPS DATA
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lubel J, 2020, NEW ENGL J MED, V382, pe92, DOI DOI 10.1056/NEJMC2013707
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Marty FM, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMvcm2010260
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Nicholls J, 2005, NAT MED, V11, P821, DOI 10.1038/nm0805-821
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Rubin EJ, 2020, NEW ENGL J MED, V382, P2464, DOI 10.1056/NEJMe2020822
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Tan KW, 1999, BRIT J CLIN PHARMACO, V48, P628
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, COR COVID 19 GLOB CA
   Tignanelli CJ, 2020, LANCET RESP MED, V8, pE30, DOI 10.1016/S2213-2600(20)30153-3
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Watkins J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m810
   Watson JA, ZENODO, DOI [10.5281, DOI 10.5281/ZENODO.3873178]
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 6
Z9 6
U1 1
U2 1
PU TURKISH SOC CARDIOLOGY
PI BAHCELIEVLER
PA COBANCESME SANAYI CAD NO 11, NISH ISTANBUL A BLOK KAT 8 NO 47-48,
   YENIBOSNA, BAHCELIEVLER, ISTANBUL 34196, TURKEY
SN 2149-2263
EI 2149-2271
J9 ANATOL J CARDIOL
JI Anat. J. Cardiol.
PD JUL
PY 2020
VL 24
IS 1
BP 21
EP 29
DI 10.14744/AnatolJCardiol.2020.57431
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MH7UB
UT WOS:000546928100009
PM 32628137
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sablerolles, RSG
   Hogenhuis, FEF
   Lafeber, M
   van de Loo, BPA
   Borgsteede, SD
   Boersma, E
   Versmissen, J
   van der Kuy, HM
AF Sablerolles, Roos S. G.
   Hogenhuis, Freija E. F.
   Lafeber, Melvin
   van de Loo, Bob P. A.
   Borgsteede, Sander D.
   Boersma, Eric
   Versmissen, Jorie
   van der Kuy, Hugo M.
CA COMET Res Team
TI COvid MEdicaTion (COMET) study: protocol for a cohort study
SO EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE
LA English
DT Article
DE hypertension; virology; clinical pharmacy; adverse effects; vascular
   medicine
ID ANGIOTENSIN-CONVERTING ENZYME-2; RECEPTOR BLOCKERS; INHIBITION; SYSTEM;
   ACE2
AB Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
C1 [Sablerolles, Roos S. G.; Lafeber, Melvin; Versmissen, Jorie] Erasmus MC, Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
   [Hogenhuis, Freija E. F.; Versmissen, Jorie; van der Kuy, Hugo M.] Erasmus MC, Univ Med Ctr, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands.
   [van de Loo, Bob P. A.] Digitalis Rx BV, Amsterdam, Netherlands.
   [Borgsteede, Sander D.] Hlth Base Fdn, Dept Clin Decis Support, Utrecht, Netherlands.
   [Boersma, Eric] Erasmus MC, Dept Cardiol, Univ Med Ctr, Rotterdam, Netherlands.
RP van der Kuy, HM (corresponding author), Erasmus MC, Univ Med Ctr, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands.
EM h.vanderkuy@erasmusmc.nl
RI van der Kuy, Hugo/AAU-1973-2020; Van der Linden, Lorenz/G-5313-2018
OI van der Kuy, Hugo/0000-0002-7128-8801; Slob, Elise Margaretha
   Adriana/0000-0002-8411-7825; fleming, glenda/0000-0001-7321-8092; Van
   der Linden, Lorenz/0000-0001-5195-1891; Scott,
   Michael/0000-0003-4048-0937
CR Arendse LB, 2019, PHARMACOL REV, V71, P539, DOI 10.1124/pr.118.017129
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, KIDNEY INT, V68, P2189, DOI 10.1111/j.1523-1755.2005.00675.x
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Netea M, 2020, KININS CYTOKINES COV
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Silva ACSE, 2016, PHARMACOL RES, V107, P154, DOI 10.1016/j.phrs.2016.03.018
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Versmissen J, 2020, J HYPERTENS, V38, P1196, DOI 10.1097/HJH.0000000000002472
   Wang XX, 2016, J MOL CELL CARDIOL, V97, P180, DOI 10.1016/j.yjmcc.2016.05.012
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2047-9956
EI 2047-9964
J9 EUR J HOSP PHARM-S P
JI Eur. J. Hosp. Pharm.-Sci. Pract.
PD JUL
PY 2020
VL 27
IS 4
BP 191
EP 193
DI 10.1136/ejhpharm-2020-002329
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG0LK
UT WOS:000545726600003
PM 32587077
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ilona, B
   Laszlo, G
   Marienn, R
   Gabriella, B
   Lilla, H
   Botond, L
   Eszter, M
   Sandor, N
   Peter, R
   Gabriella, S
   Janos, S
   Janos, S
   Miklos, S
   Istvan, VN
AF Ilona, Bobek
   Laszlo, Gopcsa
   Marienn, Reti
   Gabriella, Beko
   Lilla, Hancz
   Botond, Lakatos
   Eszter, Molnar
   Sandor, Nagy
   Peter, Remenyi
   Gabriella, Sebestyen
   Janos, Sinko
   Janos, Szlavik
   Miklos, Szolnoky
   Istvan, Valyi-Nagy
TI Successful administration of convalescent plasma in critically ill
   COVID-19 patients in Hungary: the first two cases
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE COVID-19; SARS-CoV-2; convalescent plasma; interleukin-6
AB Introduction: At present, neither specific curative treatment nor vaccines for novel coronavirus 2019 (COVID-19) are available. There is an urgent need to look for alternative strategies for COVID-19 treatment especially in the case of severe and/or critically ill patients with cytokine release syndrome (CRS).
   Aim: Convalescent plasma proved to increase survival rates in other severe viral infections. Therefore, convalescent plasma could be a promising treatment option for severe COVID-19 patients.
   Method: In our article, we present the first two critically ill Hungarian patients with COVID-19 infection treated with convalescent fresh frozen plasma.
   Results: At the time of plasma therapy both patients were on mechanical ventilation and received antiviral agents and a full scale of supportive care. Each patient received 3 x 200 mL of convalescent plasma of recently recovered donors with sufficient novel anti-coronavirus IgG titers. Subsequent to convalescent plasma infusion, oxygenization improved and inflammatory markers decreased in both individuals. As compared to pretransfusion, lymphocyte counts increased and interleukin-6 level lessened. Both patients were weaned from mechanical ventilation within 2 weeks of treatment. No severe adverse effects were observed.
   Conclusions: Our experience indicates that convalescent plasma therapy is well tolerated and could potentially improve clinical outcomes. Optimal dose and timing as well as precise assessment of clinical benefit of convalescent plasma therapy will need further investigation in larger, well-controlled trials. This is the first report of the successful use of convalescent plasma in the treatment of critically ill patients with COVID-19 infection in Hungary.
C1 [Ilona, Bobek; Lilla, Hancz; Eszter, Molnar; Gabriella, Sebestyen; Istvan, Valyi-Nagy] Del Pesti Centrumkorhaz, Orszagos Hematologiai & Infektologiai Int, Intenz Terapias Osztaly, Budapest, Hungary.
   [Laszlo, Gopcsa; Peter, Remenyi; Janos, Sinko] Del Pesti Centrumkorhaz, Orszagos Hematologiai & Infektologiai Int, Hematologiai & Ossejt Transzplantacios Osztaly, Budapest, Hungary.
   [Marienn, Reti] Del Pesti Centrumkorhaz, Orszagos Hematologiai & Infektologiai Int, Hematologiai & Ossejt Transzplantacios Osztaly, Apheresis & Ossejt Feldolgozo Reszleg, Budapest, Hungary.
   [Gabriella, Beko] Del Pesti Centrumkorhaz, Orszagos Hematologiai & Infektologiai Int, Kozponti Lab, Budapest, Hungary.
   [Botond, Lakatos; Janos, Szlavik; Istvan, Valyi-Nagy] Del Pesti Centrumkorhaz, Orszagos Hematologiai & Infektologiai Int, Infektologiai Osztaly, Budapest, Hungary.
   [Sandor, Nagy] Orszagos Verellato Szolgalat, Budapest, Hungary.
   [Miklos, Szolnoky] Biotest Hungaria Kft, Torokbalint, Hungary.
RP Laszlo, G (corresponding author), Albert Florian Ut 5-7, H-1097 Budapest, Hungary.
EM laszlogopcsa@yahoo.com
CR Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Andras V, 2020, ORVOSI HETILAP, V161, P644, DOI 10.1556/650.2020.31830
   Bela F, 2020, ORVOSI HETILAP, V161, P652, DOI 10.1556/650.2020.31808
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fleming AB, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104388
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Lakatos B, 2020, ORVOSI HETILAP, V161, P1071
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 16
TC 3
Z9 3
U1 1
U2 1
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD JUL
PY 2020
VL 161
IS 27
BP 1111
EP 1121
DI 10.1556/650.2020.31901
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA MG9TM
UT WOS:000546375100001
PM 32564002
OA Other Gold
DA 2021-01-01
ER

PT J
AU Piantoni, S
   Patroni, A
   Toniati, P
   Furloni, R
   Franceschini, F
   Andreoli, L
   Scarsi, M
AF Piantoni, Silvia
   Patroni, Andrea
   Toniati, Paola
   Furloni, Roberto
   Franceschini, Franco
   Andreoli, Laura
   Scarsi, Mirko
TI Why not to use colchicine in COVID-19? An old anti-inflammatory drug for
   a novel auto-inflammatory disease
SO RHEUMATOLOGY
LA English
DT Letter
C1 [Piantoni, Silvia; Toniati, Paola; Franceschini, Franco; Andreoli, Laura] ASST Spedali Civili, Dept Clin & Expt Sci, Rheumatol & Clin Immunol Unit, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
   [Piantoni, Silvia; Toniati, Paola; Franceschini, Franco; Andreoli, Laura] Univ Brescia, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
   [Patroni, Andrea] Hosp Infect Comm CIO, Brescia, Italy.
   [Furloni, Roberto; Scarsi, Mirko] ASST Valcamon, Internal Med Unit, Brescia, Italy.
RP Piantoni, S (corresponding author), ASST Spedali Civili, Dept Clin & Expt Sci, Rheumatol & Clin Immunol Unit, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.; Piantoni, S (corresponding author), Univ Brescia, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
EM slv.piantoni@gmail.com
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Gultekin N, 2014, J PAK MED ASSOC, V64, P1420
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Lucchino B, 2020, RHEUMATOL
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Pereira EG, 2016, AN BRAS DERMATOL, V91, P231, DOI 10.1590/abd1806-4841.20164029
   Spoto S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-018-3606-7
NR 8
TC 5
Z9 5
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUL
PY 2020
VL 59
IS 7
BP 1769
EP 1770
DI 10.1093/rheumatology/keaa217
PG 2
WC Rheumatology
SC Rheumatology
GA MG8EH
UT WOS:000546263000046
PM 32472681
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ravichandran, S
   Coyle, EM
   Klenow, L
   Tang, JJ
   Grubbs, G
   Liu, SF
   Wang, T
   Golding, H
   Khurana, S
AF Ravichandran, Supriya
   Coyle, Elizabeth M.
   Klenow, Laura
   Tang, Juanjie
   Grubbs, Gabrielle
   Liu, Shufeng
   Wang, Tony
   Golding, Hana
   Khurana, Surender
TI Antibody signature induced by SARS-CoV-2 spike protein immunogens in
   rabbits
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID REPERTOIRE; RESPONSES; TARGETS; VACCINE
AB Multiple vaccine candidates against SARS-CoV-2 based on viral spike protein are under development. However, there is limited information on the quality of antibody responses generated with these vaccine modalities. To better understand antibody responses induced by spike protein-based vaccines, we performed a qualitative study by immunizing rabbits with various SARS-CoV-2 spike protein antigens: S ectodomain (S1+S2; amino acids 16 to 1213), which lacks the cytoplasmic and transmembrane domains (CT-TM), the S1 domain (amino acids 16 to 685), the receptor binding domain (RBD) (amino acids 319 to 541), and the S2 domain (amino acids 686 to 1213, lacking the RBD, as control). Resulting antibody quality and function were analyzed by enzyme-linked immunosorbent assay (ELISA), RBD competition assay, surface plasmon resonance (SPR) against different spike proteins in native conformation, and neutralization assays. All three antigens (S1+S2 ectodomain, S1 domain, and RBD), but not S2, generated strong neutralizing antibodies against SARS-CoV-2. Vaccination-induced antibody repertoire was analyzed by SARS-CoV-2 spike genome fragment phage display libraries (SARS-CoV-2 GFPDL), which identified immunodominant epitopes in the S1, S1-RBD, and S2 domains. Furthermore, these analyses demonstrated that the RBD immunogen elicited a higher antibody titer with five-fold higher affinity antibodies to native spike antigens compared with other spike antigens, and antibody affinity correlated strongly with neutralization titers. These findings may help guide rational vaccine design and facilitate development and evaluation of effective therapeutics and vaccines against COVID-19 disease.
C1 [Ravichandran, Supriya; Coyle, Elizabeth M.; Klenow, Laura; Tang, Juanjie; Grubbs, Gabrielle; Liu, Shufeng; Wang, Tony; Golding, Hana; Khurana, Surender] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20871 USA.
RP Khurana, S (corresponding author), US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20871 USA.
EM surender.khurana@fda.hhs.gov
OI Khurana, Surender/0000-0002-0593-7965
FU FDA intramural grant funds
FX The antibody characterization work described in this manuscript was
   supported by FDA intramural grant funds. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   Fuentes S, 2020, J INFECT DIS, V221, P636, DOI 10.1093/infdis/jiz608
   Fuentes S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005554
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Halliley JL, 2015, J INFECT DIS, V212, P1270, DOI 10.1093/infdis/jiv210
   Khurana S, 2020, CELL HOST MICROBE, V27, P262, DOI 10.1016/j.chom.2020.01.001
   Khurana S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0076-2
   Khurana S, 2016, NAT MED, V22, P1439, DOI 10.1038/nm.4201
   Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336
   Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624
   Khurana S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000049
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 18
TC 10
Z9 10
U1 7
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUL 1
PY 2020
VL 12
IS 550
AR eabc3539
DI 10.1126/scitranslmed.abc3539
PG 7
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA MG9RI
UT WOS:000546369500005
PM 32513867
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jeon, S
   Ko, M
   Lee, J
   Choi, I
   Byun, SY
   Park, S
   Shum, D
   Kim, S
AF Jeon, Sangeun
   Ko, Meehyun
   Lee, Jihye
   Choi, Inhee
   Byun, Soo Young
   Park, Soonju
   Shum, David
   Kim, Seungtaek
TI Identification of Antiviral Drug Candidates against SARS-CoV-2 from
   FDA-Approved Drugs
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; FDA-approved drug; SARS-CoV-2
ID CORONAVIRUS; CICLESONIDE
AB Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.
C1 [Jeon, Sangeun; Ko, Meehyun; Lee, Jihye; Kim, Seungtaek] Inst Pasteur Korea, Zoonot Virus Lab, Seongnam, South Korea.
   [Choi, Inhee] Inst Pasteur Korea, Med Chem, Seongnam, South Korea.
   [Byun, Soo Young; Park, Soonju; Shum, David] Inst Pasteur Korea, Screening Discovery Platform, Seongnam, South Korea.
RP Kim, S (corresponding author), Inst Pasteur Korea, Zoonot Virus Lab, Seongnam, South Korea.
EM seungtaek.kim@ip-korea.org
OI Jeon, Sangeun/0000-0003-3695-6357
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [NRF-2017M3A9G6068245, NRF-2020M3E9A1041756]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIT) (NRF-2017M3A9G6068245 and
   NRF-2020M3E9A1041756).
CR Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Iwabuchi K, 2020, J INFECT CHEMOTHER, V26, P625, DOI 10.1016/j.jiac.2020.04.007
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Mao LJ, 2020, BMC INFECT DIS, V20, DOI [10.1186/s12879-020-05056-w, 10.1186/s12879-020-05072-w]
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Maxmen A, 2020, NATURE, V578, P350, DOI 10.1038/d41586-020-00454-1
   Mizumoto K, 2020, ESTIMATING RISK 2019, DOI [10.1101/2020.02.19.20025163, DOI 10.1101/2020.02.19.20025163]
   Schaffner TJ, 2009, J ASTHMA ALLERGY, V2, P25
   SMITH TC, 1976, CLIN PHARMACOL THER, V19, P802
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 14
TC 54
Z9 54
U1 4
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUL
PY 2020
VL 64
IS 7
AR e00819-20
DI 10.1128/AAC.00819-20
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA MG1EG
UT WOS:000545775600008
PM 32366720
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Wall, C
   Johnson, T
   de Steiger, R
AF Wall, Chris
   Johnson, Theresa
   de Steiger, Richard
TI Symptom management for patients awaiting joint replacement surgery
SO AUSTRALIAN JOURNAL OF GENERAL PRACTICE
LA English
DT Article
ID KNEE OSTEOARTHRITIS; CHONDROITIN SULFATE; HIP; COMBINATION; GLUCOSAMINE;
   WEIGHT; RISK; PAIN
AB Background
   Joint replacement surgery is a highly effective treatment option for patients with severe osteoarthritis (OA) of the hip and knee when other treatments have failed. Unfortunately, as a result of the COVID-19 pandemic, a temporary suspension of non-urgent elective surgery was implemented. Thousands of patients currently awaiting hip and knee replacements have been affected. Many of these patients will present to their general practitioners for symptom management during this interim period.
   Objective
   The purpose of this article is to summarise current recommendations for the non-operative management of patients with symptomatic OA.
   Discussion
   Non-operative treatment modalities for OA include education, lifestyle modification and exercise, mass reduction, physiotherapy, orthoses, psychology, pharmaceuticals and injections. Multimodal therapy is required for patients with severe symptoms. A number of useful online resources are presented, as access to public allied health services may be limited because of the COVID-19 pandemic.
C1 [Wall, Chris] Toowoomba Hosp, Dept Orthopaed, Toowoomba, Qld, Australia.
   [Wall, Chris] Univ Queensland, Rural Clin Sch, Sch Med, Brisbane, Qld, Australia.
   [Johnson, Theresa] Darling Downs Hosp & Hlth Serv, Toowoomba, Qld, Australia.
   [de Steiger, Richard] Univ Melbourne, Surg, Melbourne, Vic, Australia.
   [de Steiger, Richard] Australian Orthopaed Assoc Natl Joint Replacement, Adelaide, SA, Australia.
RP Wall, C (corresponding author), Toowoomba Hosp, Dept Orthopaed, Toowoomba, Qld, Australia.; Wall, C (corresponding author), Univ Queensland, Rural Clin Sch, Sch Med, Brisbane, Qld, Australia.
EM Chris.Wall@health.qld.gov.au
RI Wall, Chris/AAT-3914-2020
OI Wall, Chris/0000-0002-2446-5326
CR Ackerman IN, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2411-9
   Australian Commission on Safety and Quality in Health Care, 2017, OST KNEE CLIN CAR ST
   Australian Health Ministers' Advisory Council, 2015, NAT EL SURG URG CAT
   Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), 2019, HIP KNEE SHOULD ANTH
   Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), 2019, AN STAT TERR HLTH DA
   Christensen R, 2007, ANN RHEUM DIS, V66, P433, DOI 10.1136/ard.2006.065904
   Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763
   Daigle ME, 2012, BEST PRACT RES CL RH, V26, P649, DOI 10.1016/j.berh.2012.07.013
   Duivenvoorden T, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004020.pub3
   Fransen M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-095424
   Jones A, 2012, ANN RHEUM DIS, V71, P172, DOI 10.1136/ard.2010.140178
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140-6736(07)60457-7
   Persson MSM, 2018, OSTEOARTHR CARTILAGE, V26, P1575, DOI 10.1016/j.joca.2018.08.008
   Quicke JG, 2015, OSTEOARTHR CARTILAGE, V23, P1445, DOI 10.1016/j.joca.2015.05.002
   Richardson SS, 2019, J BONE JOINT SURG AM, V101, P112, DOI 10.2106/JBJS.18.00454
   Sawitzke AD, 2010, ANN RHEUM DIS, V69, P1459, DOI 10.1136/ard.2009.120469
   Stubbs B, 2016, AGE AGEING, V45, P228, DOI 10.1093/ageing/afw001
   The Royal Australian College of General Practitioners, 2018, GUID MAN KNEE HIP OS
   Victorian Musculoskeletal Clinical Leadership Group, 2018, VICT MOD CAR OST HIP
   Wang YY, 2013, RHEUMATOLOGY, V52, P1033, DOI 10.1093/rheumatology/kes419
   Werner BC, 2016, J ARTHROPLASTY, V31, P820, DOI 10.1016/j.arth.2015.08.032
   Zeng C, 2018, BRIT J SPORT MED, V52, P642, DOI 10.1136/bjsports-2017-098043
NR 23
TC 0
Z9 0
U1 4
U2 4
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 2208-794X
EI 2208-7958
J9 AUST J GEN PRACT
JI Aust. J. Gen. Pract.
PD JUL
PY 2020
VL 49
IS 7
BP 444
EP 446
DI 10.31128/ajgp-03-20-5286
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MG8PU
UT WOS:000546295000007
PM 32600002
OA Bronze
DA 2021-01-01
ER

PT J
AU Gao, LQ
   Xu, J
   Chen, SD
AF Gao, Liang-qin
   Xu, Jing
   Chen, Shao-dong
TI In SilicoScreening of Potential Chinese Herbal Medicine Against COVID-19
   by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II
   Using Molecular Docking
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE molecular docking; COVID-19; SARS-CoV-2 3CL hydrolytic enzyme;
   angiotensin converting enzyme II; Chinese medicine
AB Objective To seek potential Chinese herbal medicine (CHM) for the treatment of coronavirus disease 2019 (COVID-19) through the molecular docking of the medicine with SARS-CoV-2 3CL hydrolytic enzyme and the angiotensin converting enzyme II(ACE2) as receptors, using computer virtual screening technique, so as to provide a basis for combination forecasting. Methods The molecular docking of CHM with the SARS-Cov-2 3CL hydrolase and the ACE2 converting enzyme, which were taken as the targets, was achieved by the Autodock Vina software. The CHM monomers acting on 3CLpro and ACE2 receptors were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, the active ingredients were selected, and the key CHMs and compounds were speculated. Based on the perspective of network pharmacology, the chemical-target network was constructed, and the functional enrichment analysis of gene ontology and the pathway enrichment analysis of Kyoto encyclopedia of genes and genomes were carried out by DAVID to speculate about the mechanism of action of the core drug pairs. Results There are 6 small molecule compounds that have the optimal binding energy with the two target proteins. Among 238 potential anti-COVID-19 herbs screened in total, 16 kinds of CHM containing the most active ingredients, and 5 candidate anti-COVID-19 herbs that had been used in high frequency, as well as a core drug pair, namely,Forsythiae Fructus-Lonicerae Japonicae Floswere selected. Conclusion The core drug pair ofForsythiae Fructus-Lonicerae Japonicae Floscontaining multiple components and targets is easy to combine with 3CLpro and ACE2, and exerts an anti-COVID-19 pneumonia effect through multi-component and multi-target, and plays the role of anti-COVID-19 pneumonia in multi-pathway.
C1 [Gao, Liang-qin] Xiamen Univ, Xiamen Univ Hosp, Dept Tradit Chinese Med, Xiamen 361005, Fujian, Peoples R China.
   [Xu, Jing] Xiamen Univ, Coll Ocean & Earth Sci, Xiamen 361102, Fujian, Peoples R China.
   [Chen, Shao-dong] Xiamen Univ, Sch Med, Dept Tradit Chinese Med, Xiamen 361002, Fujian, Peoples R China.
RP Chen, SD (corresponding author), Xiamen Univ, Sch Med, Dept Tradit Chinese Med, Xiamen 361002, Fujian, Peoples R China.
EM adong@xmu.edu.cn
CR Chenoweth JA, 2020, CLIN TOXICOL, V58, P1067, DOI 10.1080/15563650.2020.1732404
   Cui XY, 2011, CHIN PHARM, V20, P8
   DING XY, 2019, SHANDONG SCI, V32, P36
   Duan H., 2009, MOD J INTEGR TRADIT, V18, P1214
   Hirayama N, 2017, DRUG METAB PHARMACOK, V32, P31, DOI 10.1016/j.dmpk.2016.10.002
   Li JS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15290
   [梁静静 Liang Jingjing], 2016, [生命科学, Chinese Bulletin of Life Sciences], V28, P153
   National Health Commission of the People's Republic of China National Administration of Traditional Chinese Medicine, DIAGN TREATM PLAN PN
   Ran J, 2020, J EMERG TRADIT CHIN, P1
   Ruan HP, 2020, IEEJ T ELECTR ELECTR, V15, P881, DOI 10.1002/tee.23130
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   [于明坤 Yu Mingkun], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P383
   [宗阳 Zong Yang], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P836
NR 13
TC 2
Z9 2
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JUL
PY 2020
VL 26
IS 7
BP 527
EP 532
DI 10.1007/s11655-020-3476-x
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA MF9FN
UT WOS:000545643400008
PM 32632717
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Boelaert, K
   Visser, WE
   Taylor, PN
   Moran, C
   Leger, J
   Persani, L
AF Boelaert, Kristien
   Visser, W. Edward
   Taylor, Peter Nicholas
   Moran, Carla
   Leger, Juliane
   Persani, Luca
TI ENDOCRINOLOGY IN THE TIME OF COVID-19 Management of hyperthyroidism and
   hypothyroidism
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID AMERICAN THYROID ASSOCIATION; DIAGNOSIS; GUIDELINES; PREGNANCY; THERAPY;
   DISEASE
AB This manuscript provides guidance on the management of thyroid dysfunction during the COVID-19 pandemic. Autoimmune thyroid diseases are not linked to increased risks of COVID-19. Uncontrolled thyrotoxicosis may result in more severe complications from SARS-CoV-2 infection, including thyroid storm. The management of patients with a new diagnosis of hyperthyroidism is best undertaken with a block-and-replace regimen due to limited biochemical testing availability. Antithyroid drug (ATD)-induced neutropenia may favour the progression of COVID-19 and symptoms of infection may be confused with SARS-CoV-2 infection. The withdrawal of ATDs and urgent measurement of neutrophils should be considered in case of flu-like manifestations occurring in the initial months of treatment. Urgent surgery or 131-I may be undertaken in selected cases of uncontrolled thyrotoxicosis. Patients with COVID-19 infection may present with conjunctivitis, which could cause diagnostic difficulties in patients with new or existing Graves' ophthalmopathy. Patients who are on replacement treatment with thyroid hormones should ensure they have sufficient supply of medication. The usual advice to increase dosage of levothyroxine during pregnancy should be adhered to. Many newly presenting and previously diagnosed patients with thyroid dysfunction can be managed through virtual telephone or video clinics supported by a dedicated nurse-led service, depending on available facilities.
C1 [Boelaert, Kristien] Univ Birmingham, Inst Appl Hlth Res, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Visser, W. Edward] Erasmus MC, Dept Internal Med, Acad Ctr Thyroid Dis, Rotterdam, Netherlands.
   [Taylor, Peter Nicholas] Cardiff Univ, Univ Wales Hosp, Sch Med, Thyroid Res Grp, Heath Pk, Cardiff, Wales.
   [Moran, Carla] Beacon Hosp, Dublin, Ireland.
   [Leger, Juliane] Univ Paris, Hop Robert Debre, Reference Ctr Growth & Dev Endocrine Dis, Pediat Endocrinol Diabetol Dept, Paris, France.
   [Persani, Luca] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Persani, Luca] Univ Milan, Postgrad Sch Endocrinol & Metab Dis, Milan, Italy.
   [Persani, Luca] San Luca Hosp, Dept Endocrine & Metab Dis, IRCCS Ist Auxol Italiano, Milan, Italy.
RP Boelaert, K (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Coll Med & Dent Sci, Birmingham, W Midlands, England.
EM k.boelaert@bham.ac.uk
RI Persani, Luca/B-6543-2008
OI Persani, Luca/0000-0003-2068-9581
CR Abraham P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003420.pub4
   Alexander EK, 2017, THYROID, V27, P315, DOI 10.1089/thy.2016.0457
   Antonelli A, 2020, BEST PRACT RES CL EN, V34, DOI 10.1016/j.beem.2020.101387
   Burch HB, 2018, EUR J ENDOCRINOL, V179, pR261, DOI 10.1530/EJE-18-0678
   Chaker L, 2017, LANCET, V390, P1550, DOI 10.1016/S0140-6736(17)30703-1
   De Leo S, 2016, LANCET, V388, P906, DOI 10.1016/S0140-6736(16)00278-6
   Deprest J, 2020, FETAL DIAGN THER, V47, P689, DOI 10.1159/000508254
   Fliers E, 2015, LANCET DIABETES ENDO, V3, P816, DOI 10.1016/S2213-8587(15)00225-9
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Kahaly GJ, 2018, EUR THYROID J, V7, P167, DOI 10.1159/000490384
   Korevaar TIM, 2017, NAT REV ENDOCRINOL, V13, P610, DOI 10.1038/nrendo.2017.93
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Leger J, 2014, J CLIN ENDOCR METAB, V99, P363, DOI 10.1210/jc.2013-1891
   Ross DS, 2016, THYROID, V26, P1343, DOI 10.1089/thy.2016.0229
   Taylor PN, 2020, NAT REV ENDOCRINOL, V16, P104, DOI 10.1038/s41574-019-0305-4
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Wei L, 2010, BIOCHEM CELL BIOL, V88, P723, DOI 10.1139/O10-022
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 3
Z9 3
U1 2
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD JUL
PY 2020
VL 183
IS 1
BP G33
EP G39
DI 10.1530/EJE-20-0445
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MG8RO
UT WOS:000546300200013
PM 32438340
OA Bronze
DA 2021-01-01
ER

PT J
AU Vrachimis, A
   Iakovou, I
   Giannoula, E
   Giovanella, L
AF Vrachimis, Alexis
   Iakovou, Ioannis
   Giannoula, Evanthia
   Giovanella, Luca
TI ENDOCRINOLOGY IN THE TIME OF COVID-19 Management of thyroid nodules and
   cancer
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID ASSOCIATION GUIDELINES; TASK-FORCE; DIAGNOSIS
AB Most patients with thyroid nodules and thyroid cancer (TC) referred for diagnostic work-up and treatment are not considered at higher risk of infection from SARS-CoV-2 compared to the general population. On the other hand, healthcare resources should be spared to the maximum extent possible during a pandemic. Indeed, while thyroid nodules are very common, only a small percentage are cancerous and, in turn, most thyroid cancers are indolent in nature. Accordingly, diagnostic work-up of thyroid nodules, thyroid surgery for either benign or malignant thyroid nodules and radioiodine treatment for differentiated thyroid cancers may be safely postponed during SARS-CoV-2 pandemic. Appropriate patient counselling, however, is mandatory and red flags should be carefully identified prompting immediate evaluation and treatment as appropriate. For these selected cases diagnostic work-up (e.g. ultrasound, scintigraphy, fine-needle aspiration), surgery and radioiodine therapy may proceed despite the threat of SARS-CoV-2 infection and COVID-19, after an individual risk-benefit analysis.
C1 [Vrachimis, Alexis] European Univ, German Oncol Ctr, Dept Nucl Med, Univ Hosp, Limassol, Cyprus.
   [Iakovou, Ioannis; Giannoula, Evanthia] Univ Hosp AHEPA, Acad Dept Nucl Med, Sch Med, Thessaloniki, Greece.
   [Iakovou, Ioannis] Gen Hosp Papageorgiou, Acad Dept Nucl Med, Thessaloniki, Greece.
   [Giovanella, Luca] Imaging Inst Southern Switzerland, Clin Nucl Med, Bellinzona, Switzerland.
   [Giovanella, Luca] Imaging Inst Southern Switzerland, Competence Ctr Thyroid Dis, Bellinzona, Switzerland.
   [Giovanella, Luca] Zurich Univ Hosp, Clin Nucl Med, Zurich, Switzerland.
RP Vrachimis, A (corresponding author), European Univ, German Oncol Ctr, Dept Nucl Med, Univ Hosp, Limassol, Cyprus.
EM alexis.vrachimis@goc.com.cy
OI IAKOVOU, IOANNIS/0000-0003-2101-3954
CR American Thyroid Association, NOV COR COVID 19 THY
   Ancker OV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010010
   [Anonymous], STAT REG COR COVID 1
   [Anonymous], 2020, COR COVID 19 PEOPL T
   Bartalena L, 2016, EUR THYROID J, V5, P9, DOI 10.1159/000443828
   Bibbins-Domingo K, 2017, JAMA-J AM MED ASSOC, V317, P1882, DOI 10.1001/jama.2017.4011
   British Association of Endocrine and Thyroid Surgeons, BAETS STAT COVID 19
   British Thyroid Foundation (BTF), THYR DIS COR COVID 1
   British Thyroid Foundation (BTF) and Thyroid Cancer Forum-UK (TCF-UK), BTA SFE ADV PAT THYR
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Durante C, 2018, JAMA-J AM MED ASSOC, V319, P914, DOI 10.1001/jama.2018.0898
   Elisei R, 2004, J CLIN ENDOCR METAB, V89, P163, DOI 10.1210/jc.2003-030550
   ETA Public Health Board Statement, 2020, COVID 19 INF REC PAT
   European Commission, GUID APPS SUPP FIGHT
   Giovanella L, 2019, EUR J NUCL MED MOL I, V46, P2514, DOI 10.1007/s00259-019-04472-8
   Giovanella L, 2014, BEST PRACT RES CL EN, V28, P507, DOI 10.1016/j.beem.2014.01.008
   Giovanella L, 2010, HEAD NECK-J SCI SPEC, V32, P607, DOI 10.1002/hed.21229
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Huang HL, 2020, NUCL MED COMMUN, V41, P297, DOI 10.1097/MNM.0000000000001183
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Li M, 2020, CLIN THYROIDOL, V32, P156, DOI DOI 10.1089/CT.2020;32.156-158)
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Maier TM, 2015, J NUCL MED, V56, P190, DOI 10.2967/jnumed.114.150284
   Public Health England, GUID SHIELD PROT PEO
   Romesser PB, 2016, RADIOTHER ONCOL, V118, P286, DOI 10.1016/j.radonc.2015.12.008
   Ross DS, 2016, THYROID, V26, P1343, DOI 10.1089/thy.2016.0229
   Society for Endocrinology, 2020, COVID 19 RES MAN END
   Spitzweg C, 2017, INTERNIST, V58, P1011, DOI 10.1007/s00108-017-0306-0
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tessler FN, 2017, J AM COLL RADIOL, V14, P587, DOI 10.1016/j.jacr.2017.01.046
   THYROIDPATIENTSCA, QUEST THYR COVID 19
   Tuttle RM, 2019, THYROID, V29, P461, DOI 10.1089/thy.2018.0597
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 35
TC 6
Z9 7
U1 1
U2 1
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD JUL
PY 2020
VL 183
IS 1
BP G41
EP G48
DI 10.1530/EJE-20-0269
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MG8RO
UT WOS:000546300200014
PM 32438345
OA Bronze
DA 2021-01-01
ER

PT J
AU Kuroda, N
AF Kuroda, Naoto
TI Demand for BCG Vaccine Due to Unproven Claims of its Role in Preventing
   COVID-19 Is Causing Shortages of Vaccines for Infants in Japan
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 [Kuroda, Naoto] Wayne State Univ, Dept Pediat, Childrens Hosp Michigan, Detroit, MI 48202 USA.
RP Kuroda, N (corresponding author), Wayne State Univ, Dept Pediat, Childrens Hosp Michigan, Detroit, MI 48202 USA.
CR de Vrieze J., 2020, SCIENCE
   Hill SB, 2005, B WORLD HEALTH ORGAN, V83, P796
   Kaufmann SHE, 2020, IMMUNE BOOST CORONA
   Miller A, 2020, CORRELATION UNIVERSA, DOI 10.1101/2020.03.24.20042937
   Vaccinology, 2020, OP EFF BCG VACC COVI
NR 5
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUL
PY 2020
VL 39
IS 7
BP E159
EP E160
DI 10.1097/INF.0000000000002724
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA MG3ZJ
UT WOS:000545971700024
PM 32379194
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Alshammari, TM
   Altebainawi, AF
   Alenzi, KA
AF Alshammari, Thamir M.
   Altebainawi, Ali F.
   Alenzi, Khalidah A.
TI Importance of early precautionary actions in avoiding the spread of
   COVID-19: Saudi Arabia as an Example
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE COVID-19; Early precautions; SARS-CoV-2; Coronavirus; Saudi Arabia
AB Late in 2019, several cases of infection with a new strain of coronavirus were reported in China. This new strain was later officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organization (WHO). This new virus (SARS-CoV2-) mainly affects the respiratory system and causes coronavirus disease 2019 (COVID-19). The first case of COVID-19 was reported to the WHO on December 31st, 2019, and the virus has spread dramatically in many countries worldwide. On March 11th, 2020, the WHO declared that COVID-19 had affected most of the world, and many deaths were linked to COVID-19. Unfortunately, there is no available treatment for COVID-19, and there is no available vaccine against SARS-CoV-2. Thus, preventive methods are the only way to limit the spread of the virus. Preventive actions have been taken by many countries, such as travel bans, closing borders and working from home. Saudi Arabia was one of the countries that took very early precautionary actions in the belief that these actions are the best way to fight the virus. Therefore, we present the actions that were taken by the Kingdom of Saudi Arabia to fight the new viral pandemic. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Alshammari, Thamir M.] Saudi Food & Drug Author, Riyadh, Saudi Arabia.
   [Alshammari, Thamir M.; Altebainawi, Ali F.] King Saud Univ, Medicat Safety Res Chair, Riyadh, Saudi Arabia.
   [Altebainawi, Ali F.] Minist Hlth, King Khalid Hosp, Pharmaceut Care Serv, Hail, Saudi Arabia.
   [Alenzi, Khalidah A.] Minist Hlth, Reg Drug Informat & Pharmacovigilance Ctr, Tabuk, Saudi Arabia.
   [Altebainawi, Ali F.] AJA Pharmaceut Ind Co Ltd, Dept Pharmacovigilance, Hail, Saudi Arabia.
RP Alshammari, TM (corresponding author), Saudi Food & Drug Author, Riyadh, Saudi Arabia.; Alshammari, TM (corresponding author), King Saud Univ, Medicat Safety Res Chair, Riyadh, Saudi Arabia.
EM tmshammari.c@sfda.gov.sa
RI Altebainawi, Ali Faris/R-3042-2018
OI Altebainawi, Ali Faris/0000-0002-7862-5778
CR Airlines S., 2020, UPDATES OUR RESPONSE
   Al-Tawfiq JA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105968
   AL-THAQAFI T, 2020, SAUD AR GETS GRIPS C
   [Anonymous], 2020, NEWS UAQ
   [Anonymous], 2020, CORONAVIRUS SAUDI AR
   [Anonymous], 2020, NEWS ARAB
   [Anonymous], 2020, FRANCE 24
   [Anonymous], 2020, SAUDI ARABIA SUSPEND
   Cascella M, 2020, FEATURES EVALUATION
   Khalid T., 2020, CORONAVIRUS SAUDI AR
   MOH, 2020, COVID 19 MON COMM HO
   MOH, 2020, AL RAB COVID 19 CAS
   MOH, 2020, AL RAB ORD KING ALL
   MOH, 2020, COVID 19 FOLL UP COM
   National T, 2020, BANK SAUD AR TOLD WO
   News A.J.E.L., 2020, NEWS AJEL
   Saudi Ministry of Health (MOH), 2020, MOH CONT ACT SURV CO
   Shariff AI, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-1291-6
   SPA, 2020, MIN HLTH ANN 1 CAS N
   SPA, 2020, EXTR G20 LEAD SUMM C
   SPA, 2020, OFF SOURC MIN INT SU
   SPA, 2020, MIN INT SUSP ENTR EX
   SPA, 2020, MOR SAR 120 BN GOV S
   SPA, 2020, CUST 2 HOL MOSQ DEL
   SPA, 2020, SAUD AR IMP 24 HOUS
   SPA, 2020, OFF SPOK MIN HLTH KI
   SPA, 2020, MIN HLTH SICK LEAV T
   SPA, 2020, KINGD GOV SETS PREV
   SPA, 2020, BAHR BANS TRAV IR
   SPA, 2020, CUST 2 HOL MOSQ ISS
   SPA, 2020, MIN HLTH BROADC MOR
   SPA, 2020, MIN TOUR TEMP SUSP I
   SPA, 2020, OFF SOURC INT MIN CI
   SPA, 2020, SAUD CUST EXP MED PH
   SPA, 2020, MIN INT CURF ALL MAK
   SPA, 2020, OFF SOURC DEN IR IRR
   SPA, 2020, OFF SOURC MIN INT CI
   SPA, 2020, NOV COR COVID 19 FOL
   SPA, 2020, MAD PRINC APPL PREC
   SPA, 2020, OFF SOURC MIN INT KI
   SPA, 2020, IM GRAND MOSQ PROPH
   SPA, 2020, MIN SPORTS SUSP ALL
   SPA, 2020, KINGD GOV DEC SUSP A
   SPA, 2020, MIN ED WE AB SERV 60
   SPA, 2020, SAUD AR SIGNS SR9550
   Times TS, 2020, TIMES TS
   World Health Organization, 2020, COR COVID 19
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Yan YX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072323
NR 49
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-0164
EI 2213-7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD JUL
PY 2020
VL 28
IS 7
BP 898
EP 902
DI 10.1016/j.jsps.2020.05.005
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MG5IW
UT WOS:000546066700014
PM 32641902
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gomez, CC
   Rodriguez, OP
   Torne, ML
   Santaolalla, CE
   Jimenez, JFM
   Fernandez, JG
   Perales, JMC
   Heili-Frades, SB
   Monreal, MF
   Nilsson, JMD
   Arias, EL
   Rocamora, JLS
   Garrote, JI
   Serrano, MJZ
   Martinez, MG
   Munoz, EF
   Andres, OMS
   Cervera, GR
   Serra, AM
   Martinez, GH
   Lopez, CD
   Gas, OR
   Roca, RF
   Berrocal, AR
   Ortola, CF
AF Cinesi Gomez, Cesar
   Penuelas Rodriguez, Oscar
   Lujan Torne, Manel
   Egea Santaolalla, Carlos
   Masa Jimenez, Juan Fernando
   Fernandez, Javier Garcia
   Carratala Perales, Jose Manuel
   Beatrice Heili-Frades, Sarah
   Ferrer Monreal, Miquel
   de Andres Nilsson, Jose M.
   Lista Arias, Eva
   Sanchez Rocamora, Juan Luis
   Ignacio Garrote, Jose
   Zamorano Serrano, Miguel J.
   Gonzalez Martinez, Monica
   Munoz, Eva Farrero
   San Andres, Olga Mediano
   Rialp Cervera, Gemma
   Mas Serra, Arantxa
   Hernandez Martinez, Gonzalo
   de Haro Lopez, Candelaria
   Roca Gas, Oriol
   Ferrer Roca, Ricard
   Romero Berrocal, Antonio
   Ferrando Ortola, Carlos
TI Clinical Consensus Recommendations Regarding Non-Invasive Respiratory
   Support in the Adult Patient with Acute Respiratory Failure Secondary to
   SARSCoV-2 infection
SO ARCHIVOS DE BRONCONEUMOLOGIA
LA Spanish
DT Article
DE Non-invasive mechanical ventilation; High-flow nasal therapy;
   Aerosol-generating procedures; Infection control
ID POSITIVE-PRESSURE VENTILATION; NASAL CANNULA; OXYGEN; AIR
AB Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coro- navirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence -informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies ( Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emer- gency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sep- sis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best pos- sible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials. (c) 2020 Published by Elsevier Espana, S.L.U. on behalf of SEPAR.
C1 [Cinesi Gomez, Cesar] Serv Murciano Salud, Direcc Gen Asistencia Sanit, Murcia, Spain.
   [Cinesi Gomez, Cesar] Oficial Med Urgencias & Emergencias, Murcia, Spain.
   [Penuelas Rodriguez, Oscar] CIBERES, CIBER Enfermedades Resp, Hosp Univ Getafe, Serv Med Intens & Grandes Quemados, Madrid, Spain.
   [Lujan Torne, Manel] Univ Autonoma Barcelona, Ctr Invest Biomed Red CIBERES, Corp Parc Tauli, Serv Neumol,Hosp Sabadell, Barcelona, Spain.
   [Egea Santaolalla, Carlos] Hosp Univ ARaba, OSI Araba, Unidad Func Sueno, Vitoria, Spain.
   [Masa Jimenez, Juan Fernando] Inst Univ Invest Biosanit Extremadura INUBE, CIBER Enfermedades Resp CIBERES, Hosp San Pedro Alcantara, Serv Neumol, Caceres, Spain.
   [Fernandez, Javier Garcia] Hosp Univ Puerta Hierro, Serv Anestesia Cuidados Crit Quirurg & Dolor, Madrid, Spain.
   [Carratala Perales, Jose Manuel] Fdn FISABIO, Inst Invest Sanit Biomed Alicante ISABIAL, Hosp Gen Alicante, Serv Urgencias,Unidad Corta Estancia & Hospitaliz, Alicante, Spain.
   [Beatrice Heili-Frades, Sarah] Hosp Univ Fdn Jimenez Diaz, CIBERES, Responsable UCIR, Jefe Asociado Neumol,REVA,EMDOS, Madrid, Spain.
   [Ferrer Monreal, Miquel] Univ Barcelona, Hosp Clin Barcelona, Inst Clin Resp, Servei Pneumol,IDIBAPS,CibeRes CB06-06-0028, Barcelona, Spain.
   [de Andres Nilsson, Jose M.] Hosp Royo Villanova, Serv Urgencias, Zaragoza, Spain.
   [Lista Arias, Eva] Parc Tauli Hosp Univ, Serv Urgencias, Barcelona, Spain.
   [Sanchez Rocamora, Juan Luis] Hosp Gen Villarrobledo, Serv Urgencias, Albacete, Spain.
   [Ignacio Garrote, Jose] SESCAM, GUETS, Med Emergencias, Toledo, Spain.
   [Zamorano Serrano, Miguel J.] Hosp Ramon & Cajal, Med Adjunto Urgencias, Madrid, Spain.
   [Gonzalez Martinez, Monica] Univ Cantabria, IDIVAL, Hosp Univ Marques Valdecilla, Unidad Sueno & Ventilac,Neumol, Santander, Spain.
   [Munoz, Eva Farrero] Hosp Univ Bellvitge, Servei Pneumol, Barcelona, Spain.
   [San Andres, Olga Mediano] Hosp Univ Guadalajara, Neumol, Unidad Sueno, Guadalajara, Spain.
   [Rialp Cervera, Gemma] Hosp Univ Son Liatzer, Serv Med Inten, Palma De Mallorca, Spain.
   [Mas Serra, Arantxa] Hosp Gen Hosp, Hosp St Joan Despi Moises Broggi, Servei Med Intens, Barcelona, Spain.
   [Hernandez Martinez, Gonzalo] Hosp Univ Virgen Salud, Serv Med Intens, Toledo, Spain.
   [de Haro Lopez, Candelaria] Inst Salud Carlos III, Area Crit, Corp Sanit & Univ Parc Tauli, CIBER Enfermedades Resp CIBERES, Barcelona, Spain.
   [Roca Gas, Oriol] Inst Salud Carlos III, Area Crit, Barcelona, Spain.
   [Ferrer Roca, Ricard] Univ Autonoma Barcelona, Inst Salud Carlos III, Hosp Univ Vall Hebron, Serv Med Intens,Inst Recerca Vall Hebron,Ciber En, Barcelona, Spain.
   [Romero Berrocal, Antonio] Hosp Univ Vall Hebron, Shock Organ Dysfunct & Resuscitat Res Grp, Vall Hebron Inst Recerca, CIBER Enfermedades Resp,CIBERES,Serv Med Intens, Barcelona, Spain.
   [Ferrando Ortola, Carlos] Hosp Univ Puerta Hierro, Serv Anestesia & Reanimac, Madrid, Spain.
   [Ferrando Ortola, Carlos] Hosp Clin Barcelona, Serv Anestesia & Cuidados Intens, Jefe Secc, Area Cuidados Intens Quirurg, Barcelona, Spain.
RP Torne, ML (corresponding author), Univ Autonoma Barcelona, Ctr Invest Biomed Red CIBERES, Corp Parc Tauli, Serv Neumol,Hosp Sabadell, Barcelona, Spain.
EM mlujan@tauli.cat
RI Lujan, Manel/AAZ-2769-2020; Gomez, Cesar/AAY-7682-2020
OI Gonzalez, Monica/0000-0003-1516-0181; HEILI-FRADES,
   SARAH/0000-0003-4901-6487; Lujan, Manel/0000-0001-9033-7712; Romero
   Berrocal, Antonio/0000-0003-4003-0709
CR Belenguer-Muncharaz A, 2011, MED INTENSIVA, V35, P470, DOI 10.1016/j.medin.2011.04.001
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   CDC, 2020, COR DIS 2019 COVID 1
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Cheung TMT, 2004, CHEST, V126, P845, DOI 10.1378/chest.126.3.845
   Cortegiani A, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3514-1
   Davidson C, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000133
   Duan J, 2017, INTENS CARE MED, V43, P192, DOI 10.1007/s00134-016-4601-3
   Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/201001-0037OC, 10.1164/rccm.201001-0037OC]
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Guan VV, 2020, NEW ENGL J MED, DOI [10.1056/NEJM0a2002012, DOI 10.1056/NEJMOA2002012]
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Lellouche F, 2014, INTENS CARE MED, V40, P211, DOI 10.1007/s00134-013-3145-z
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Malave A, 2010, VIRTUAL MENTOR, V12, P719
   Masclans JR, 2013, CLIN MICROBIOL INFEC, V19, P249, DOI 10.1111/j.1469-0691.2012.03797.x
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Ministerio de Sanidad, MAN CLIN PAC CON ENF
   Ministerio de Sanidad, PREV CONTR INF MAN P
   Ministerio de Sanidad. Gobierno de Espana, PROC ACT FRENT CAS I
   Nin N, 2011, J CRIT CARE, V26, P186, DOI 10.1016/j.jcrc.2010.05.031
   Park JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5484-8
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Pisani L, 2014, CRIT CARE MED, V35, P501
   Respiratory care committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V17, pE020, DOI 10.3760/cma.j.issn.1001-0939.2020.0020
   Ricard JD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022983
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Roca O, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1263-z
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rodriguez A, 2017, RESP CARE, V62, P1307, DOI 10.4187/respcare.05481
   Scala R, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0008-2018
   Scala R, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0310-5
   Sun JY, 2019, INT J CHRONIC OBSTR, V14, P1229, DOI 10.2147/COPD.S206567
   Tonetti T, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.07.08
   Tramm R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010381.pub2
   Tran K, 2011, AEROSOL GENERATING P
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, RAT US PERS PROT EQ
   Wright BJ, 2014, EMERG MED CLIN N AM, V32, P871, DOI 10.1016/j.emc.2014.07.012
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yuste Maria Eugenia, 2019, Rev. bras. ter. intensiva, V31, P156, DOI [10.5935/0103-507X.20190026, 10.5935/0103-507x.20190026]
   Zhao HY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1760-8
NR 48
TC 7
Z9 8
U1 5
U2 5
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0300-2896
EI 1579-2129
J9 ARCH BRONCONEUMOL
JI Arch. Bronconeumol.
PD JUL
PY 2020
VL 56
SU 2
BP 11
EP 18
DI 10.1016/j.arbres.2020.03.005
PG 8
WC Respiratory System
SC Respiratory System
GA MG5FY
UT WOS:000546058900006
PM 32336563
OA Green Published
DA 2021-01-01
ER

PT J
AU Chen, RC
   Liang, WH
   Jiang, M
   Guan, WJ
   Zhan, C
   Wang, T
   Tang, CL
   Sang, L
   Liu, JX
   Ni, ZY
   Hu, Y
   Liu, L
   Shan, H
   Lei, CL
   Peng, YX
   Wei, L
   Liu, Y
   Hu, YH
   Peng, P
   Wang, JM
   Liu, JY
   Chen, Z
   Li, G
   Zheng, ZJ
   Qiu, SQ
   Luo, J
   Ye, CJ
   Zhu, SY
   Liu, XQ
   Chang, LL
   Ye, F
   Zheng, JP
   Zhang, NF
   Li, YM
   He, JX
   Li, SY
   Zhong, NS
AF Chen, Ruchong
   Liang, Wenhua
   Jiang, Mei
   Guan, Weijie
   Zhan, Chen
   Wang, Tao
   Tang, Chunli
   Sang, Ling
   Liu, Jiaxing
   Ni, Zhengyi
   Hu, Yu
   Liu, Lei
   Shan, Hong
   Lei, Chunliang
   Peng, Yixiang
   Wei, Li
   Liu, Yong
   Hu, Yahua
   Peng, Peng
   Wang, Jianming
   Liu, Jiyang
   Chen, Zhong
   Li, Gang
   Zheng, Zhijian
   Qiu, Shaoqin
   Luo, Jie
   Ye, Changjiang
   Zhu, Shaoyong
   Liu, Xiaoqing
   Chang, Linling
   Ye, Feng
   Zheng, Jinping
   Zhang, Nuofu
   Li, Yimin
   He, Jianxing
   Li, Shiyue
   Zhong, Nanshan
CA Med Treatment Expert Grp COVID-19
TI Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus
   Disease 2019 From a Nationwide Analysis in China
SO CHEST
LA English
DT Article
DE COVID-19; fatal outcome; nomogram; risk factors
ID RESPIRATORY-DISTRESS-SYNDROME; PNEUMONIA
AB BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has become a global health emergency. The cumulative number of new confirmed cases and deaths are still increasing out of China. Independent predicted factors associated with fatal outcomes remain uncertain.
   RESEARCH QUESTION: The goal of the current study was to investigate the potential risk factors associated with fatal outcomes from COVID-19 through a multivariate Cox regression analysis and a nomogram model.
   STUDY DESIGN AND METHODS: A retrospective cohort of 1,590 hospitalized patients with COVID-19 throughout China was established. The prognostic effects of variables, including clinical features and laboratory findings, were analyzed by using Kaplan-Meier methods and a Cox proportional hazards model. A prognostic nomogram was formulated to predict the survival of patients with COVID-19.
   RESULTS: In this nationwide cohort, nonsurvivors included a higher incidence of elderly people and subjects with coexisting chronic illness, dyspnea, and laboratory abnormalities on admission compared with survivors. Multivariate Cox regression analysis showed that age >= 75 years (hazard ratio [HR], 7.86; 95% CI, 2.44-25.35), age between 65 and 74 years (HR, 3.43; 95% CI, 1.24-9.5), coronary heart disease (HR, 4.28; 95% CI, 1.14-16.13), cerebrovascular disease (HR, 3.1; 95% CI, 1.07-8.94), dyspnea (HR, 3.96; 95% CI, 1.42-11), procalcitonin level > 0.5 ng/mL (HR, 8.72; 95% CI, 3.42-22.28), and aspartate aminotransferase level > 40 U/L (HR, 2.2; 95% CI, 1.1-6.73) were independent risk factors associated with fatal outcome. A nomogram was established based on the results of multivariate analysis. The internal bootstrap resampling approach suggested the nomogram has sufficient discriminatory power with a C-index of 0.91 (95% CI, 0.85-0.97). The calibration plots also showed good consistency between the prediction and the observation.
   INTERPRETATION: The proposed nomogram accurately predicted clinical outcomes of patients with COVID-19 based on individual characteristics. Earlier identification, more intensive surveillance, and appropriate therapy should be considered in patients at high risk.
C1 [Chen, Ruchong; Liang, Wenhua; Jiang, Mei; Guan, Weijie; Zhan, Chen; Wang, Tao; Tang, Chunli; Sang, Ling; Liu, Jiaxing; Liu, Xiaoqing; Ye, Feng; Zheng, Jinping; Zhang, Nuofu; Li, Yimin; He, Jianxing; Li, Shiyue; Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Res Dis, State Key Lab Resp Dis,Guangzhou Inst Resp Hlth, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [Ni, Zhengyi] Wuhan Jin Yin Tan Hosp, Wuhan, Hubei, Peoples R China.
   [Hu, Yu] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China.
   [Liu, Lei] Shenzhen Third Peoples Hosp, Shenzhen, Peoples R China.
   [Liu, Lei] Southern Univ Sci & Technol, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.
   [Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Zhuhai, Guangdong, Peoples R China.
   [Lei, Chunliang] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.
   [Peng, Yixiang] Cent Hosp Wuhan, Wuhan, Hubei, Peoples R China.
   [Wei, Li] Wuhan Hosp Tradit Chinese & Western Med, Wuhan Hosp 1, Wuhan, Hubei, Peoples R China.
   [Liu, Yong] Chengdu Publ Hlth Clin Med Ctr, Chengdu, Sichuan, Peoples R China.
   [Hu, Yahua] Hubei Polytech Univ, Affiliated Hosp, Huangshi Cent Hosp, Edong Healthcare Grp, Huangshi, Hubei, Peoples R China.
   [Peng, Peng] Wuhan Pulm Hosp, Wuhan, Hubei, Peoples R China.
   [Wang, Jianming] Wuhan Univ Sci & Technol, Tianyou Hosp, Wuhan, Hubei, Peoples R China.
   [Liu, Jiyang] First Hosp Changsha, Changsha, Hunan, Peoples R China.
   [Chen, Zhong] Third Peoples Hosp Hainan Prov, Sanya, Hainan, Peoples R China.
   [Li, Gang] Huanggang Cent Hosp, Huanggang, Hubei, Peoples R China.
   [Zheng, Zhijian] Wenling First Peoples Hosp, Wenling, Zhejiang, Peoples R China.
   [Qiu, Shaoqin] Third Peoples Hosp Yichang, Yichang, Hubei, Peoples R China.
   [Luo, Jie] Hubei Univ Med, Affiliated Taihe Hosp, Shiyan, Peoples R China.
   [Ye, Changjiang] Xiantao First Peoples Hosp, Xiantao, Peoples R China.
   [Zhu, Shaoyong] Peoples Hosp Huangpi Dist, Wuhan, Peoples R China.
RP Li, SY (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Res Dis, State Key Lab Resp Dis,Guangzhou Inst Resp Hlth, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM lishiyue@188.com
OI li, yimin/0000-0003-0810-5256; Wenhua, Liang/0000-0002-1391-8238
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Jong E, 2016, LANCET INFECT DIS, V16, P819, DOI 10.1016/S1473-3099(16)00053-0
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Kattan MW, 2003, J NATL CANCER I, V95, P634, DOI 10.1093/jnci/95.9.634
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Ruan Q, 2020, INTENS CARE MED, V368, pm641
   Schuetz P, 2019, CLIN CHEM LAB MED, V57, P1308, DOI 10.1515/cclm-2018-1181
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   WHO, 2020, CLIN MAN SEV AC RESP
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   World Health Organization, COR DIS 2019 COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, pE26
   Yang X, 2020, LANCET RESP MED, V8, pE26
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 25
TC 82
Z9 83
U1 15
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD JUL
PY 2020
VL 158
IS 1
BP 97
EP 105
DI 10.1016/j.chest.2020.04.010
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MF9LR
UT WOS:000545659700037
PM 32304772
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Tang, X
   Du, RH
   Wang, R
   Cao, TZ
   Guan, LL
   Yang, CQ
   Zhu, Q
   Hu, M
   Li, XY
   Li, Y
   Liang, LR
   Tong, ZH
   Sun, B
   Peng, P
   Shi, HZ
AF Tang, Xiao
   Du, Rong-Hui
   Wang, Rui
   Cao, Tan-Ze
   Guan, Lu-Lu
   Yang, Cheng-Qing
   Zhu, Qi
   Hu, Ming
   Li, Xu-Yan
   Li, Ying
   Liang, Li-Rong
   Tong, Zhao-Hui
   Sun, Bing
   Peng, Peng
   Shi, Huan-Zhong
TI Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and
   H1N1
SO CHEST
LA English
DT Article
DE ARDS; COVID-19; H1N1; influenza A; mortality
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; RADIOLOGICAL FINDINGS; INFLUENZA;
   PNEUMONIA; INFECTION
AB BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases such as influenza viruses.
   RESEARCH QUESTION: The aim of this study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with ARDS.
   STUDY DESIGN AND METHODS: This analysis was a retrospective case-control study. Two independent cohorts of patients with ARDS infected with either COVID-19 (n = 73) or H1N1 (n = 75) were compared. Their clinical manifestations, imaging characteristics, treatments, and prognosis were analyzed and compared.
   RESULTS: The median age of patients with COVID-19 was higher than that of patients with H1N1, and there was a higher proportion of male subjects among the H1N1 cohort (P <.05). Patients with COVID-19 exhibited higher proportions of nonproductive coughs, fatigue, and GI symptoms than those of patients with H1N1 (P <.05). Patients with H1N1 had higher Sequential Organ Failure Assessment (SOFA) scores than patients with COVID-19 (P <.05). The PaO2/FIO2 of 198.5 mm Hg in the COVID-19 cohort was significantly higher than the PaO2/FIO2 of 107.0 mm Hg in the H1N1 cohort (P <.001). Ground-glass opacities was more common in patients with COVID-19 than in patients with H1N1 (P <.001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of patients with COVID-19 was 28.8%, whereas that of patients with H1N1 was 34.7% (P =.483). SOFA score-adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients, with a rate ratio of 2.009 (95% CI, 1.563-2.583; P <.001).
   INTERPRETATION: There were many differences in clinical presentations between patients with ARDS infected with either COVID-19 or H1N1. Compared with H1N1 patients, patients with COVID-19-induced ARDS had lower severity of illness scores at presentation and lower SOFA score-adjusted mortality.
C1 [Tang, Xiao; Wang, Rui; Li, Xu-Yan; Li, Ying; Liang, Li-Rong; Tong, Zhao-Hui; Sun, Bing; Shi, Huan-Zhong] Capital Med Univ, Beijing Engn Res Ctr Diag & Treatment Resp & Crit, Beijing Key Lab Resp & Pulm Circulat Disorders, Beijing Chao Yang Hosp,Beijing Inst Resp Med,Dept, Beijing, Peoples R China.
   [Du, Rong-Hui; Cao, Tan-Ze; Guan, Lu-Lu; Yang, Cheng-Qing; Zhu, Qi; Hu, Ming; Peng, Peng] Wuhan Pulm Hosp, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
RP Sun, B (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Resp & Crit Care Med, 8 Gongtinan Rd, Beijing 100020, Peoples R China.
EM ricusunbing@126.com
RI Tang, Xiao/ABC-4723-2020
FU Beijing Municipal Administration of Hospitals' Mission Plan
   [SML20150301]; 1351 Talents Program of Beijing Chao-Yang Hospital
   [WXZXZ-2017-01]; Novel Coronavirus Pneumonia Key Technology Research and
   Development Funding of the Beijing Hospital Authority [Covid-19-BHA03]
FX This work was supported by the Beijing Municipal Administration of
   Hospitals' Mission Plan [SML20150301], the 1351 Talents Program of
   Beijing Chao-Yang Hospital [WXZXZ-2017-01], and Novel Coronavirus
   Pneumonia Key Technology Research and Development Funding of the Beijing
   Hospital Authority [Covid-19-BHA03].
CR Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612
   Center for Disease Control and Prevention, WEEKL US INFL SURV R
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Marchiori E, 2011, EUR J RADIOL, V80, pE500, DOI 10.1016/j.ejrad.2010.10.003
   Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rohani P, 2016, J INTENSIVE CARE MED, V31, P51, DOI 10.1177/0885066614538753
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wenjie T., 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/CCDCW2020.017
   World Health Organization, COR DIS COVID 2019 S
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2009, SCIENCE, V326, P729, DOI 10.1126/science.1177373
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
NR 24
TC 46
Z9 46
U1 2
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD JUL
PY 2020
VL 158
IS 1
BP 195
EP 205
DI 10.1016/j.chest.2020.03.032
PG 11
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MF9LR
UT WOS:000545659700047
PM 32224074
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Radbel, J
   Narayanan, N
   Bhatt, PJ
AF Radbel, Jared
   Narayanan, Navaneeth
   Bhatt, Pinki J.
TI Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome A
   Cautionary Case Report
SO CHEST
LA English
DT Article
DE COVID-19; critical care; cytokines; viral disease
AB Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 4.1 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.
C1 [Radbel, Jared] Rutgers Robert Wood Johnson Med Sch, Div Pulm & Crit Care Med, Dept Med, New Brunswick, NJ USA.
   [Narayanan, Navaneeth] Rutgers Ernest Mario Sch Pharm, Dept Pharm Practice & Adm, New Brunswick, NJ USA.
   [Bhatt, Pinki J.] Rutgers Robert Wood Johnson Med Sch, Div Infect Dis, Dept Med, New Brunswick, NJ USA.
RP Radbel, J (corresponding author), Rutgers Robert Wood Johnson Med Sch, 1 Robert Wood Johnson Pl,MEB 568, New Brunswick, NJ 08901 USA.
EM jr1106@rwjms.rutgers.edu
OI Radbel, Jared/0000-0002-3013-6270
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756
   Huang C, LANCET
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Johns Hopkins Coronavirus Resource Center, COVID 19 DASHB CTR S
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Ramos-Casals M, 2014, LANCET, V383, P1503, DOI 10.1016/S0140-6736(13)61048-X
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 41
Z9 42
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD JUL
PY 2020
VL 158
IS 1
BP E15
EP E19
DI 10.1016/j.chest.2020.04.024
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MF9LR
UT WOS:000545659700011
PM 32343968
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, B
   Liu, SY
   Tan, T
   Huang, WH
   Dong, YH
   Chen, LY
   Chen, QY
   Zhang, L
   Zhong, QY
   Zhang, XP
   Zou, YJ
   Zhang, SX
AF Zhang, Bin
   Liu, Shuyi
   Tan, Tan
   Huang, Wenhui
   Dong, Yuhao
   Chen, Luyan
   Chen, Qiuying
   Zhang, Lu
   Zhong, Qingyang
   Zhang, Xiaoping
   Zou, Yujian
   Zhang, Shuixing
TI Treatment With Convalescent Plasma for Critically Ill Patients With
   Severe Acute Respiratory Syndrome Coronavirus 2 Infection
SO CHEST
LA English
DT Article
DE convalescent plasma; critical illness; SARS-CoV-2
ID PNEUMONIA; THERAPY
AB As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
C1 [Zhang, Bin; Liu, Shuyi; Huang, Wenhui; Chen, Luyan; Chen, Qiuying; Zhang, Lu; Zhang, Shuixing] Jinan Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Tan, Tan] Xiangtan Cent Hosp, Xiangtan, Hunan, Peoples R China.
   [Dong, Yuhao] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China.
   [Zhong, Qingyang] Dongguan Ninth Peoples Hosp, Dongguan, Guangdong, Peoples R China.
   [Zhang, Xiaoping] Second Peoples Hosp Zhongshan, Zhongshan, Guangdong, Peoples R China.
   [Zou, Yujian] Dongguan Peoples Hosp, Dongguan, Guangdong, Peoples R China.
RP Zhang, SX (corresponding author), 613 Huangpu West R, Guangzhou 510627, Guangdong, Peoples R China.
EM shui7515@126.com
RI Zhang, Bin/M-3689-2014
OI Zhang, Bin/0000-0001-7313-9300
CR Bao L., 2020, BIORXIV, DOI [10.1101/2020.03.13, DOI 10.1101/2020.03.13]
   Cao B, NEW ENGL J MED, DOI [10.1056/NEJMe2, DOI 10.1056/NEJME2]
   Chen JB, 2020, J INFECTION, V80, P310, DOI 10.1016/j.jinf.2019.11.024
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   De Backer D, 2017, JAMA-J AM MED ASSOC, V317, P807, DOI 10.1001/jama.2017.0059
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 92
Z9 93
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD JUL
PY 2020
VL 158
IS 1
BP E9
EP E13
DI 10.1016/j.chest.2020.03.039
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA MF9LR
UT WOS:000545659700008
PM 32243945
OA Other Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Lysaker, PH
   Hillis, JD
   Zalzala, AB
   Gagen, EC
AF Lysaker, Paul H.
   Hillis, Jaclyn D.
   Zalzala, Aieyat B.
   Gagen, Emily C.
TI Reflection and Recovery from Psychosis during the Time of COVID-19:
   Adaptation in Psychotherapy in the United States
SO CLINICA Y SALUD
LA English
DT Article
DE COVID-19; Pandemic; Psychosis; Recovery; Psychotherapy; Metacognition;
   Intersubjectivity
ID SCHIZOPHRENIA; INSIGHT; ILLNESS; MODEL
AB In response to the coronavirus (COVID-19) pandemic several adaptations have allowed us to continue to provide one form of recovery-oriented psychotherapy to persons with psychosis: Metacognitive Insight and Reflection Therapy (MERIT). These successful adaptations have included the incorporation of patients' experience of the pandemic and the exploration of challenges from temporary changes in therapy platforms to deepen reflections about patients' self-experience, their experience of intersubjectivity and their own agentic responses to psychosocial challenges.
C1 [Lysaker, Paul H.] Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.
   [Hillis, Jaclyn D.] Chillicothe VA Med Ctr, Chillicothe, VA USA.
   [Zalzala, Aieyat B.] Hartford Hosp, Inst Living, Hartford, CT 06115 USA.
   [Gagen, Emily C.] Providence VA Med Ctr, Providence, RI USA.
RP Lysaker, PH (corresponding author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.
EM plysaker@iupui.edu
CR Frankl V. E., 1992, MANS SEARCH MEANING
   Hamm JA, 2016, CLIN SUPERV, V35, P42, DOI 10.1080/07325223.2016.1140102
   Hasson-Ohayon I, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00567
   Hasson-Ohayon I, 2017, CLIN PSYCHOL PSYCHOT, V24, P428, DOI 10.1002/cpp.2012
   Korsbek L, 2013, PSYCHIATR REHABIL J, V36, P222, DOI 10.1037/prj0000018
   Leonhardt BL, 2017, EXPERT REV NEUROTHER, V17, P1117, DOI 10.1080/14737175.2017.1378099
   Leonhardt BL, 2015, AM J PSYCHOTHER, V69, P35, DOI 10.1176/appi.psychotherapy.2015.69.1.35
   Lysaker P. H., 2017, RECOVERY MEANING MAK
   Lysaker P. H., 2008, SCHIZOPHRENIA FATE S
   Lysaker PH, 2020, PSYCHOL RES BEHAV MA, V13, P331, DOI 10.2147/PRBM.S198628
   Lysaker Paul H, 2020, Schizophr Res Cogn, V19, P100142, DOI 10.1016/j.scog.2019.100142
   Lysaker PH, 2011, PSYCHOL PSYCHOTHER-T, V84, P58, DOI 10.1348/147608310X520436
   Maslow A, 1954, MOTIVATION PERSONALI
   Semerari A, 2003, CLIN PSYCHOL PSYCHOT, V10, P238, DOI 10.1002/cpp.362
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
NR 15
TC 0
Z9 0
U1 0
U2 0
PU COLEGIO OFICIAL PSICOLOGOS MADRID
PI MADRID
PA C/CUESTA SAN VICENTE, NO 4, 6 PLANTA, MADRID, 28008, SPAIN
SN 1130-5274
EI 2174-0550
J9 CLIN SALUD
JI Clin. Salud
PD JUL
PY 2020
VL 31
IS 2
BP 99
EP 103
DI 10.5093/clysa2020a16
PG 5
WC Psychology, Clinical
SC Psychology
GA MF4WF
UT WOS:000545343800005
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gabriella, D
   Cristina, S
   Concetta, R
   Francesco, R
   Annalisa, C
AF Gabriella, Di Mauro
   Cristina, Scavone
   Concetta, Rafaniello
   Francesco, Rossi
   Annalisa, Capuano
TI SARS-Cov-2 infection: Response of human immune system and possible
   implications for the rapid test and treatment
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE SARS-Cov-2 infection; Human immune system; Rapid test; Pharmacological
   treatments; Outbreak
ID CORONAVIRUS; SARS; MERS
AB The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of beta-coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004.
   Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infection as well as the role of virus-specific T cells and by B-lymphocytes. Moreover, specific data on the production of IgG and IgM is crucial to allow the rapid identification of the infection. In this paper we also described the importance of sensitive and specific rapid test for SARS-CoV-2. Indeed, this test represents an important immunological tool aimed at identifying the precise phase of the infection in order to undertake a more appropriate pharmacological treatment. Lastly, we provided an overview of pharmacological treatments aimed to reduce inflammatory processes underlying the infection and the need for the discovery of a new vaccine against SARS-CoV-2.
C1 [Gabriella, Di Mauro; Cristina, Scavone; Concetta, Rafaniello; Francesco, Rossi; Annalisa, Capuano] Univ Campania Luigi Vanvitelli, Dept Expt Med, Reg Ctr Pharmacovigilance, Naples, Campania Region, Italy.
RP Gabriella, D (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Reg Ctr Pharmacovigilance, Naples, Campania Region, Italy.
EM gabriella.dimauro@unicampania.it
CR Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Howard JH, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13347
   Li Z., 2020, J MED VIROL, V27
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Prompetchara Eakachai, 2020, ASIAN PAC J ALLERGY
   Qin C, 2020, CLIN INFECT DIS, V12
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 11
TC 21
Z9 22
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2020
VL 84
AR 106519
DI 10.1016/j.intimp.2020.106519
PG 3
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA LY3SB
UT WOS:000540446500087
PM 32311668
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Denadai, R
   Lo, LJ
AF Denadai, Rafael
   Lo, Lun-Jou
TI Teleconsultation-mediated nasoalveolar molding therapy for babies with
   cleft lip/palate during the COVID-19 outbreak: Implementing change at
   pandemic speed
SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY
LA English
DT Letter
C1 [Denadai, Rafael] SOBRAPAR Hosp, Inst Plast & Craniofacial Surg, Av Adolpho Lutz 100, BR-13084880 Campinas, SP, Brazil.
   [Lo, Lun-Jou] Chang Gung Univ, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, 5 Fu Shin St, Taoyuan 333, Taiwan.
   [Lo, Lun-Jou] Chang Gung Univ, Chang Gung Mem Hosp, Craniofacial Res Ctr, 5 Fu Shin St, Taoyuan 333, Taiwan.
RP Denadai, R (corresponding author), SOBRAPAR Hosp, Inst Plast & Craniofacial Surg, Av Adolpho Lutz 100, BR-13084880 Campinas, SP, Brazil.
EM denadai.rafael@hotmail.com
RI Denadai, Rafael/A-8038-2013
OI Denadai, Rafael/0000-0003-0525-3480
CR Armstrong A, 2020, J PLAST RECONSTR AES, V73, P1174, DOI 10.1016/j.bjps.2020.03.027
   Esenlik E, 2020, CLEFT PALATE-CRAN J, V57, P529, DOI 10.1177/1055665619899752
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1090
NR 5
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1748-6815
EI 1878-0539
J9 J PLAST RECONSTR AES
JI J. Plast. Reconstr. Aesthet. Surg.
PD JUL
PY 2020
VL 73
IS 7
BP 1360
EP 1361
DI 10.1016/j.bjps.2020.05.005
PG 2
WC Surgery
SC Surgery
GA MF4EU
UT WOS:000545298500023
PM 32426028
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ramachandran, R
   Jha, V
AF Ramachandran, Raja
   Jha, Vivekanand
TI Adding insult to injury: kidney replacement therapy during COVID-19 in
   India
SO KIDNEY INTERNATIONAL
LA English
DT Letter
C1 [Ramachandran, Raja] Post Grad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India.
   [Jha, Vivekanand] Univ South Wales, George Inst Global Hlth, New Delhi, India.
   [Jha, Vivekanand] Manipal Acad Higher Educ, Manipal, Karnataka, India.
   [Jha, Vivekanand] Univ Oxford, Oxford, England.
RP Jha, V (corresponding author), George Inst Global Hlth, 310-11 Splendor Forum, New Delhi 110025, India.
EM vjha@pginephro.org
OI Jha, Vivekanand/0000-0002-8015-9470
CR Chakravarty I., SCROLL
   Dare AJ, 2017, LANCET GLOB HEALTH, V5, pE89, DOI 10.1016/S2214-109X(16)30308-4
   Dhaliwal T., HINDUSTANTIMES
   Jaiswal PB, WEEK
   Mampatta S., BUSINESS STANDARD
   Marpakwar C, MUMBAIMIRROR
   Salaria S., TIMES INDIA
NR 7
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2020
VL 98
IS 1
BP 238
EP 239
DI 10.1016/j.kint.2020.04.019
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA MF7NY
UT WOS:000545526100010
PM 32471634
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tian, JB
   Yuan, XL
   Xiao, J
   Zhong, Q
   Yang, CG
   Liu, B
   Cai, YM
   Lu, ZQ
   Wang, J
   Wang, YN
   Liu, SL
   Cheng, B
   Wang, J
   Zhang, M
   Wang, L
   Niu, SY
   Yao, Z
   Deng, XB
   Zhou, F
   Wei, W
   Li, QL
   Chen, X
   Chen, WQ
   Yang, Q
   Wu, SJ
   Fan, JQ
   Shu, B
   Hu, ZQ
   Wang, SG
   Yang, XP
   Liu, WH
   Miao, XP
   Wang, ZH
AF Tian, Jianbo
   Yuan, Xianglin
   Xiao, Jun
   Zhong, Qiang
   Yang, Chunguang
   Liu, Bo
   Cai, Yimin
   Lu, Zequn
   Wang, Jing
   Wang, Yanan
   Liu, Shuanglin
   Cheng, Biao
   Wang, Jin
   Zhang, Ming
   Wang, Lu
   Niu, Siyuan
   Yao, Zhi
   Deng, Xiongbo
   Zhou, Fan
   Wei, Wei
   Li, Qinglin
   Chen, Xin
   Chen, Wenqiong
   Yang, Qin
   Wu, Shiji
   Fan, Jiquan
   Shu, Bo
   Hu, Zhiquan
   Wang, Shaogang
   Yang, Xiang-Ping
   Liu, Wenhua
   Miao, Xiaoping
   Wang, Zhihua
TI Clinical characteristics and risk factors associated with COVID-19
   disease severity in patients with cancer in Wuhan, China: a multicentre,
   retrospective, cohort study
SO LANCET ONCOLOGY
LA English
DT Article
ID RESPIRATORY SYNDROME; CYTOKINE STORM; TNF-ALPHA
AB Background COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has been reported in patients with cancer. We aimed to systematically characterise clinical features and determine risk factors of COVID-19 disease severity for patients with cancer and COVID-19.
   Methods In this multicentre, retrospective, cohort study, we included all adult patients (aged >= 18 years) with any type of malignant solid tumours and haematological malignancy who were admitted to nine hospitals in Wuhan, China, with laboratory-confirmed COVID-19 between Jan 13 and March 18,2020. Enrolled patients were statistically matched (2:1) with patients admitted with COVID-19 who did not have cancer with propensity score on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, illness severity, and clinical interventions were compared between patients with COVID-19 with or without cancer as well as between patients with cancer with non-severe or severe COVID-19. COVID-19 disease severity was defined on admission on the basis of the WHO guidelines. Univariable and multivariable logistic regression, adjusted for age, sex, comorbidities, cancer type, tumour stage, and antitumour treatments, were used to explore risk factors associated with COVID-19 disease severity. This study was registered in the Chinese Clinical Trial Register, ChiCTR2000030807.
   Findings Between Jan 13 and March 18,2020,13 077 patients with COVID-19 were admitted to the nine hospitals in Wuhan and 232 patients with cancer and 519 statistically matched patients without cancer were enrolled. Median follow-up was 29 days (IQR 22-38) in patients with cancer and 27 days (20-35) in patients without cancer. Patients with cancer were more likely to have severe COVID-19 than patients without cancer (148 [64%] of 232 vs 166 [32%] of 519; odds ratio [OR] 3.61 [95% CI 2.59-5.04]; p<0.0001). Risk factors previously reported in patients without cancer, such as older age; elevated interleukin 6, procalcitonin, and D-dimer; and reduced lymphocytes were validated in patients with cancer. We also identified advanced tumour stage (OR 2.60, 95% CI 1.05-6.43; p=0.039), elevated tumour necrosis factor a (1.22, 1.01-1.47; 13=0.037), elevated N-terminal pro-B-type natriuretic peptide (1.65, 1.03-2.78; p=0.032), reduced CD4+ T cells (0.84,0.71-0.98; p=0.031), and reduced albumin-globulin ratio (0.12, 0.02-0.77; p=0.024) as risk factors of COVID-19 severity in patients with cancer.
   Interpretation Patients with cancer and COVID-19 were more likely to deteriorate into severe illness than those without cancer. The risk factors identified here could be helpful for early clinical surveillance of disease progression in patients with cancer who present with COVID-19. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tian, Jianbo; Cai, Yimin; Lu, Zequn; Zhang, Ming; Wang, Lu; Niu, Siyuan; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat,Key Lab Environm & Hlth, Wuhan, Peoples R China.
   [Yang, Xiang-Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China.
   [Yuan, Xianglin; Liu, Bo; Chen, Xin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China.
   [Xiao, Jun; Yang, Chunguang; Wang, Jing; Wang, Yanan; Wang, Jin; Chen, Wenqiong; Hu, Zhiquan; Wang, Shaogang; Wang, Zhihua] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430030, Peoples R China.
   [Zhong, Qiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Crit Care Med, Wuhan, Peoples R China.
   [Yang, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Pathol, Wuhan, Peoples R China.
   [Wu, Shiji] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Lab Med, Wuhan, Peoples R China.
   [Liu, Wenhua] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Clin Res Ctr, Wuhan, Peoples R China.
   [Liu, Shuanglin] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Hosp 1, Dept Urol, Wuhan, Peoples R China.
   [Cheng, Biao] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Pharm, Wuhan, Peoples R China.
   [Shu, Bo] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Urol, Wuhan, Peoples R China.
   [Fan, Jiquan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Oncol, Wuhan, Peoples R China.
   [Yao, Zhi] Wuhan Pulm Hosp, Dept Respirol & TB Specialty, Wuhan, Peoples R China.
   [Deng, Xiongbo] Wuhan Jinyintan Hosp, Dept Radiol, Wuhan, Peoples R China.
   [Zhou, Fan] Huazhong Univ Sci & Technol, Puai Hosp, Tongji Med Coll, Dept Urol,Wuhan Hosp 4, Wuhan, Peoples R China.
   [Wei, Wei] Fifth Hosp Wuhan, Dept Urol, Wuhan, Peoples R China.
   [Li, Qinglin] Wuhan Hankou Hosp, Dept Resp Med, Wuhan, Peoples R China.
RP Wang, ZH (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430030, Peoples R China.
EM zhwang_hust@hotmail.com
RI miao, xiaoping/C-4336-2011; Liu, Wenhua/ABB-7509-2020
OI miao, xiaoping/0000-0002-6818-9722; liu, bo/0000-0001-5118-1890; Chen,
   Xin/0000-0002-0566-7678; Yang, Xiang-Ping/0000-0001-9003-1772
FU China National Natural Science FoundationNational Natural Science
   Foundation of China (NSFC) [81974400]
FX China National Natural Science Foundation.; This work is supported by
   the China National Natural Science Foundation (grant number 81974400).
   We thank all patients and their families involved in the study and all
   health-care workers who are working against COVID-19. We also thank
   David Horne (City of Hope, CA, USA), Hui Zhu (Cleveland Clinic
   Foundation, OH, USA), Gonghong Wei (University of Oulu, Finland), and
   Jiping Wang (Northwestern University, IL, USA) for their assistance.
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Josephs SF, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1611-7
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Ma Xiaomei, 2006, Yale J Biol Med, V79, P85
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Nie ZY, 2011, BRIT J PHARMACOL, V164, P444, DOI 10.1111/j.1476-5381.2011.01393.x
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Prescott RJ, 2019, STAT MED, V38, P4264, DOI 10.1002/sim.8294
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Saito LB, 2018, J GEN VIROL, V99, P464, DOI 10.1099/jgv.0.001015
   Veselka J, 2019, EUR HEART J, V40, P1681, DOI 10.1093/eurheartj/ehz110
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang YZ, 2020, NEURORADIOLOGY, V62, P1141, DOI 10.1007/s00234-020-02455-3
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2016, CONS GUID US ANT DRU
   World Health Organization, ROLL UPD COR DIS COV
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
NR 30
TC 54
Z9 54
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD JUL
PY 2020
VL 21
IS 7
BP 893
EP 903
DI 10.1016/S1470-2045(20)30309-0
PG 11
WC Oncology
SC Oncology
GA MF4QM
UT WOS:000545328900027
PM 32479790
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yang, KY
   Sheng, YH
   Huang, CL
   Jin, Y
   Xiong, N
   Jiang, K
   Lu, HD
   Liu, J
   Yang, JY
   Dong, YH
   Pan, DF
   Shu, CR
   Li, J
   Wei, JL
   Huang, Y
   Peng, L
   Wu, MJ
   Zhang, RG
   Wu, B
   Li, YH
   Cai, LQ
   Li, GL
   Zhang, T
   Wu, G
AF Yang, Kunyu
   Sheng, Yuhan
   Huang, Chaolin
   Jin, Yang
   Xiong, Nian
   Jiang, Ke
   Lu, Hongda
   Liu, Jing
   Yang, Jiyuan
   Dong, Youhong
   Pan, Dongfeng
   Shu, Chengrong
   Li, Jun
   Wei, Jielin
   Huang, Yu
   Peng, Ling
   Wu, Mengjiao
   Zhang, Ruiguang
   Wu, Bian
   Li, Yuhui
   Cai, Liqiong
   Li, Guiling
   Zhang, Tao
   Wu, Gang
TI Clinical characteristics, outcomes, and risk factors for mortality in
   patients with cancer and COVID-19 in Hubei, China: a multicentre,
   retrospective, cohort study
SO LANCET ONCOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; CORONAVIRUS; PNEUMONIA; SEX
AB Background Patients with cancer are a high-risk population in the COVID-19 pandemic. We aimed to describe clinical characteristics and outcomes of patients with cancer and COVID-19, and examined risk factors for mortality in this population.
   Methods We did a retrospective, multicentre, cohort study of 205 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and with a pathological diagnosis of a malignant tumour in nine hospitals within Hubei, China, from Jan 13 to March 18, 2020. All patients were either discharged from hospitals or had died by April 20, 2020. Clinical characteristics, laboratory data, and cancer histories were compared between survivors and non-survivors by use of chi(2) test. Risk factors for mortality were identified by univariable and multivariable logistic regression models.
   Findings Between Jan 13 and Mar 18, 2020, 205 patients with cancer and laboratory-confirmed SARS-CoV-2 infection were enrolled (median age 63 years [IQR 56-70; range 14-96]; 109 [53%] women). 183 (89%) had solid tumours and 22 (11%) had haematological malignancies. The median duration of follow-up was 68 days (IQR 59-78). The most common solid tumour types were breast (40 [20%] patients), colorectal (28 [14%]), and lung cancer (24 [12%]). 54 (30%) of 182 patients received antitumour therapies within 4 weeks before symptom onset. 30 (15%) of 205 patients were transferred to an intensive care unit and 40 (20%) died during hospital admission. Patients with haematological malignancies had poorer prognoses than did those with solid tumours: nine (41%) of 22 patients with haematological malignancies died versus 31 (17%) of 183 patients with solid tumours (hazard ratio for death 3.28 [95% CI 1. 56-6 91]; log rank p=0.0009). Multivariable regression analysis showed that receiving chemotherapy within 4 weeks before symptom onset (odds ratio [OR] 3.51 [95% CI 1.16-10.59]; p=0.026) and male sex (OR 3.86 [95% CI 1.57-9.50]; p=0.0033) were risk factors for death during admission to hospital.
   Interpretation Patients with cancer and COVID-19 who were admitted to hospital had a high case-fatality rate. Unfavourable prognostic factors, including receiving chemotherapy within 4 weeks before symptom onset and male sex, might help clinicians to identify patients at high risk of fatal outcomes. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yang, Kunyu; Sheng, Yuhan; Wei, Jielin; Huang, Yu; Peng, Ling; Wu, Mengjiao; Zhang, Ruiguang; Wu, Bian; Li, Guiling; Zhang, Tao; Wu, Gang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.
   [Jin, Yang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med,NHC Key Lab Pulm Dis, Wuhan, Peoples R China.
   [Xiong, Nian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China.
   [Jiang, Ke] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China.
   [Cai, Liqiong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan, Peoples R China.
   [Huang, Chaolin] Jin Yin Tan Hosp, Wuhan, Peoples R China.
   [Xiong, Nian] Wuhan Red Cross Hosp, Wuhan, Peoples R China.
   [Lu, Hongda; Li, Yuhui] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China.
   [Liu, Jing] Huanggang Cent Hosp, Dept Oncol, Huanggang, Peoples R China.
   [Yang, Jiyuan] Yangtze Univ, Peoples Hosp 1, Dept Oncol, Jingzhou, Peoples R China.
   [Dong, Youhong] Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Oncol, Xiangyang, Peoples R China.
   [Pan, Dongfeng] Hubei Univ Med, Suizhou Cent Hosp, Dept Oncol, Suizhou, Peoples R China.
   [Shu, Chengrong] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Canc Ctr, Xianning, Peoples R China.
   [Li, Jun] Cent Hosp Xiaogan, Dept Oncol, Xiaogan, Peoples R China.
RP Wu, G (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.
EM xhzlwg@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC 81874218, NSFC 81672978]
FX National Natural Science Foundation of China.; This work was supported
   by the National Natural Science Foundation of China (NSFC 81874218, NSFC
   81672978). We thank all front-line healthcare workers for their efforts
   during the COVID-19 pandemic.
CR Azoulay E, 2014, INTENS CARE MED, V40, P1106, DOI 10.1007/s00134-014-3354-0
   Azoulay E, 2010, AM J RESP CRIT CARE, V182, P1038, DOI 10.1164/rccm.201001-0018OC
   Bow EJ, 2013, J ANTIMICROB CHEMOTH, V68, P492, DOI 10.1093/jac/dks512
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2015, LANCET, V386, P1447, DOI 10.1016/S0140-6736(15)00340-2
   Chinese Center for Disease Control and Prevention, 2020, EP SIT COVID 19
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   LIU X, 2016, MEDIAT INFLAMM, V2016, DOI DOI 10.1155/2016/8191254
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Morrison VA, 2009, CLIN LYMPHOMA MYELOM, V9, P365, DOI 10.3816/CLM.2009.n.071
   Ogimi C, 2017, CLIN INFECT DIS, V64, P1532, DOI 10.1093/cid/cix160
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, CLIN MAN SEV AC RESP
   WU F, 2020, JAMA ONCOL
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zheng R S, 2019, Zhonghua Zhong Liu Za Zhi, V41, P19, DOI 10.3760/cma.j.issn.0253-3766.2019.01.005
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 57
Z9 59
U1 12
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD JUL
PY 2020
VL 21
IS 7
BP 904
EP 913
DI 10.1016/S1470-2045(20)30310-7
PG 10
WC Oncology
SC Oncology
GA MF4QM
UT WOS:000545328900028
PM 32479787
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Garassino, MC
   Whisenant, JG
   Huang, LC
   Trama, A
   Torri, V
   Agustoni, F
   Baena, J
   Banna, G
   Berardi, R
   Bettini, AC
   Bria, E
   Brighenti, M
   Cadranel, J
   De Toma, A
   Chini, C
   Cortellini, A
   Felip, E
   Finocchiaro, G
   Garrido, P
   Genova, C
   Giusti, R
   Gregorc, V
   Grossi, F
   Grosso, F
   Intagliata, S
   La Verde, N
   Liu, SV
   Mazieres, J
   Mercadante, E
   Michielin, O
   Minuti, G
   Moro-Sibilot, D
   Pasello, G
   Passaro, A
   Scotti, V
   Solli, P
   Stroppa, E
   Tiseo, M
   Viscardi, G
   Voltolini, L
   Wu, YL
   Zai, S
   Pancaldi, V
   Dingemans, AM
   Van Meerbeeck, J
   Barlesi, F
   Wakelee, H
   Peters, S
   Horn, L
AF Garassino, Marina Chiara
   Whisenant, Jennifer G.
   Huang, Li-Ching
   Trama, Annalisa
   Torri, Valter
   Agustoni, Francesco
   Baena, Javier
   Banna, Giuseppe
   Berardi, Rossana
   Bettini, Anna Cecilia
   Bria, Emilio
   Brighenti, Matteo
   Cadranel, Jacques
   De Toma, Alessandro
   Chini, Claudio
   Cortellini, Alessio
   Felip, Enriqueta
   Finocchiaro, Giovanna
   Garrido, Pilar
   Genova, Carlo
   Giusti, Raffaele
   Gregorc, Vanesa
   Grossi, Francesco
   Grosso, Federica
   Intagliata, Salvatore
   La Verde, Nicla
   Liu, Stephen, V
   Mazieres, Julien
   Mercadante, Edoardo
   Michielin, Olivier
   Minuti, Gabriele
   Moro-Sibilot, Denis
   Pasello, Giulia
   Passaro, Antonio
   Scotti, Vieri
   Solli, Piergiorgio
   Stroppa, Elisa
   Tiseo, Marcello
   Viscardi, Giuseppe
   Voltolini, Luca
   Wu, Yi-Long
   Zai, Silvia
   Pancaldi, Vera
   Dingemans, Anne-Marie
   Van Meerbeeck, Jan
   Barlesi, Fabrice
   Wakelee, Heather
   Peters, Solange
   Horn, Leora
CA TERAVOLT Investigators
TI COVID-19 in patients with thoracic malignancies (TERAVOLT): first
   results of an international, registry-based, cohort study
SO LANCET ONCOLOGY
LA English
DT Article
AB Background Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies.
   Methods The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1,2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data.
   Findings Between March 26 and April 12,2020,200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68.0 years (61.8-75.0) and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1.88, 95% 1.00-3.62), being a current or former smoker (4.24, 1.70-12.95), receiving treatment with chemotherapy alone (2.54, 1.09-6 41), and the presence of any comorbidities (2.65, 1.09-7.46) were associated with increased risk of death. However, in multivariable analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associated with increased risk of death.
   Interpretation With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in a multidisciplinary setting based on cancer specific mortality and patients' preference. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Garassino, Marina Chiara; De Toma, Alessandro; Viscardi, Giuseppe] Fdn IRCCS Ist Nazl Tumori, Thorac Unit, Med Oncol Dept, Milan, Italy.
   [Trama, Annalisa] Fdn IRCCS Ist Nazl Tumori, Evaluat Epidemiol, Dept Res, Milan, Italy.
   [Whisenant, Jennifer G.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Huang, Li-Ching] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA.
   [Torri, Valter] Mario Negri Inst Pharmacol Res IRCCS, Lab Clin Res Methodol, Oncol Dept, Milan, Italy.
   [Agustoni, Francesco] Fdn IRCCS Policlin San Matteo, Med Oncol Dept, Pavia, Italy.
   [Baena, Javier] Hosp Univ 12 Octubre, Med Oncol Dept, Thorac Canc & Early Drug Dev Unit, Madrid, Spain.
   [Banna, Giuseppe] Portsmouth Hosp NHS Trust, Dept Oncol, Portsmouth, Hants, England.
   [Berardi, Rossana] Univ Politecn Marche, Med Oncol Dept, AOU Osped Riuniti Ancona, Ancona, Italy.
   [Bettini, Anna Cecilia] ASST Papa Giovanni XXIII, Oncol Unit, Bergamo, Italy.
   [Bria, Emilio] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy.
   [Brighenti, Matteo] ASST Cremona, Med Oncol Dept, Cremona, Italy.
   [Cadranel, Jacques] Hop Tenon, Paris, France.
   [Chini, Claudio] ASST Sette Laghi, Oncol Unit, Varese, Italy.
   [Cortellini, Alessio] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
   [Felip, Enriqueta] Vall dHebron Univ Hosp, Vali dHebron Inst Oncol, Barcelona, Spain.
   [Finocchiaro, Giovanna] Umanitas Clin & Res Ctr IRCCS, Rozzano, Italy.
   [Garrido, Pilar] Univ Alcala De Henares, Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain.
   [Genova, Carlo] IRCCS Osped Policlin San Martino, Genoa, Italy.
   [Giusti, Raffaele] St Andrea Hosp, Med Oncol Unit, Rome, Italy.
   [Gregorc, Vanesa] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy.
   [Grossi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Dept, Milan, Italy.
   [Grosso, Federica] Azienda Osped Nazl Santi Antonio & Biagio & Cesar, Mesothelioma Unit, Alessandria, Italy.
   [Zai, Silvia] Azienda Osped Nazl Santi Antonio & Biagio & Cesar, Med Oncol Dept, Alessandria, Italy.
   [Intagliata, Salvatore] ASST Spedali Civili Brescia, Med Oncol Dept, Brescia, Italy.
   [La Verde, Nicla] ASST Fatebenefratelli Sacco, Med Oncol Dept, Milan, Italy.
   [Liu, Stephen, V] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
   [Mazieres, Julien] CHU, Inst Univ Canc, Toulouse, France.
   [Mercadante, Edoardo] IRCCS Regina Elena NCI, Thorac Surge Unit, Expt Clin Oncol Dept, Rome, Italy.
   [Michielin, Olivier; Peters, Solange] Lausanne Univ, Lausanne Univ Hosp, Oncol Dept, Lausanne, Switzerland.
   [Minuti, Gabriele] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy.
   [Moro-Sibilot, Denis] CHU Grenoble Alpes, Serv Hosp Univ Pneumol Physiol, Grenoble, France.
   [Pasello, Giulia] Ist Oncol Veneto IRCCS, Padua, Italy.
   [Passaro, Antonio] European Inst Oncol IRCCS, European Inst Oncol, Milan, Italy.
   [Scotti, Vieri; Voltolini, Luca] Azienda Osped Univ Careggi, Radiotherapy Unit Scotti 5, Thorac Surg Unit LVoltol, Florence, Italy.
   [Solli, Piergiorgio] Alma Mater Studiorum Univ, Thorac Surg, Policlin S Orsola, Bologna, Italy.
   [Stroppa, Elisa] Osped Guglielmo Saliceto, Med Oncol Unit, Piacenza, Italy.
   [Tiseo, Marcello] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Parma, Italy.
   [Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Dept, Guangzhou, Peoples R China.
   [Pancaldi, Vera] Ctr Rech Cancerol Toulouse, Toulouse, France.
   [Dingemans, Anne-Marie] Univ Maastricht, Erasmus Univ Med Ctr, Dept Pulmonol, Rotterdam, Netherlands.
   [Van Meerbeeck, Jan] Antwerp Univ Hosp, Dept Pulmonol & Thorac Oncol, Edegem, Belgium.
   [Barlesi, Fabrice] Aix Marseille Univ, Gustave Roussy Inst, Villejuif, CNRS,INSERM,CRCM, Marseille, France.
   [Wakelee, Heather] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Horn, Leora] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
RP Garassino, MC (corresponding author), Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Thorac Oncol Unit, I-20126 Milan, Italy.
EM marina.garassino@istitutotumori.mi.it
RI van Meerbeeck, Jan/ABA-5109-2020; Torri, Valter/AAH-5705-2019; la verde,
   nicla/AAW-9398-2020; Mercadante, Edoardo/ABH-9867-2020; Michielin,
   Olivier/ABE-7924-2020; GARRIDO, PILAR/D-5187-2017; peters,
   solange/ABF-2187-2020; Wu, Yi-Long/C-3396-2008; Passaro,
   Antonio/M-1888-2016; Wu, Yi-Long/AAW-9832-2020; MAZIERES,
   JULIEN/M-3986-2014; Pancaldi, Vera/I-2555-2015
OI Torri, Valter/0000-0001-9541-9354; la verde, nicla/0000-0002-2884-1632;
   Mercadante, Edoardo/0000-0003-2101-1254; GARRIDO,
   PILAR/0000-0002-5899-6125; Wu, Yi-Long/0000-0002-3611-0258; Passaro,
   Antonio/0000-0002-7575-3870; Wu, Yi-Long/0000-0002-3611-0258; Banna,
   Giuseppe Luigi/0000-0003-0764-3650; Pancaldi, Vera/0000-0002-7433-624X;
   Wu, Yi-Long/0000-0001-8734-2131; MORO-SIBILOT, Denis/0000-0001-6776-8610
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Bailo L, 2019, PATIENT PREFER ADHER, V13, P2225, DOI 10.2147/PPA.S205819
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Calabro L, 2020, LANCET RESP MED, V8, P542, DOI 10.1016/S2213-2600(20)30170-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Epic Health Research Network, 2020, DEL CANC SCREEN
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johns Hopkins University of Medicine, COVID 19 CAS TRACK
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Robilotti EV, 2020, DETERMINANTS SEVERIT, DOI [10.1101/2020.05.04.20086322, DOI 10.1101/2020.05.04.20086322]
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Whisenant JG, 2020, CANCER CELL, V37, P742, DOI 10.1016/j.ccell.2020.05.008
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu WB, 2020, J MED VIROL, V92, P1525, DOI 10.1002/jmv.25763
NR 26
TC 78
Z9 77
U1 11
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470-2045
EI 1474-5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD JUL
PY 2020
VL 21
IS 7
BP 914
EP 922
DI 10.1016/S1470-2045(20)30314-4
PG 9
WC Oncology
SC Oncology
GA MF4QM
UT WOS:000545328900029
PM 32539942
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU de Sanctis, V
   Canatan, D
   Corrons, JLV
   Karimi, M
   Daar, S
   Kattamis, C
   Soliman, AT
   Wali, Y
   Alkindi, S
   Huseynov, V
   Nasibova, A
   Tiryaki, TO
   Evim, MS
   Gunes, AM
   Karakas, Z
   Christou, S
   Campisi, S
   Zarei, T
   Khater, D
   Oymak, Y
   Kaleva, V
   Stoyanova, D
   Banchev, A
   Galati, MC
   Yassin, MA
   Kakar, S
   Skafida, M
   Kilinc, Y
   Alyaarubi, S
   Verdiyevas, N
   Stoeva, I
   Raiola, G
   Mariannis, D
   Ruggiero, L
   Di Maio, S
AF de Sanctis, Vincenzo
   Canatan, Duran
   Vives Corrons, Joan Lluis
   Karimi, Mehran
   Daar, Shahina
   Kattamis, Christos
   Soliman, Ashraf T.
   Wali, Yasser
   Alkindi, Salam
   Huseynov, Valeh
   Nasibova, Afag
   Tiryaki, Tarik Onur
   Evim, Melike Sezgin
   Gunes, Adalet Meral
   Karakas, Zeynep
   Christou, Soteroula
   Campisi, Saveria
   Zarei, Tahereh
   Khater, Doaa
   Oymak, Yesim
   Kaleva, Valeriya
   Stoyanova, Denka
   Banchev, Atanas
   Galati, Maria Concetta
   Yassin, Mohamed A.
   Kakar, Shruti
   Skafida, Myrto
   Kilinc, Yurdanur
   Alyaarubi, Saif
   Verdiyevas, Narmin
   Stoeva, Iva
   Raiola, Giuseppe
   Mariannis, Demetris
   Ruggiero, Leopoldo
   Di Maio, Salvatore
TI Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A
   Multicentre ICET-A Study
SO MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; beta-thalassemia; Sickle cell disease; Patients'
   characteristics; Clinical course; Risk factors
ID BETA
AB Objectives: This study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent beta thalassemia major (TM), beta-thalassemia intermedia (TI) and sickle cell disease (SCD).
   Design: A total of 17 Centers, from 10 countries, following 9,499 patients with hemoglobinopathies, participated in the survey.
   Main outcome data: Clinical, laboratory, and radiologic findings and outcomes of patients with COVID-19 were collected from medical records and summarized.
   Results: A total of 13 patients, 7 with TM, 3 with TI, and 3 with SCD, with confirmed COVID-19, were identified in 6 Centers from different countries. The overall mean age of patients was 33.7 +/- 12.3 years (range:13-66); 9/13 (69.2%) patients were females. Six patients had pneumonia, and 4 needed oxygen therapy. Increased C-reactive protein (6/10), high serum lactate dehydrogenase (LDH; 6/10), and erythrocyte sedimentation rate (ESR; 6/10) were the most common laboratory findings. 6/10 patients had an exacerbation of anemia (2 with SCD). In the majority of patients, the course of COVID-19 was moderate (6/10) and severe in 3/10 patients. A 30-year-old female with TM, developed a critical SARS-CoV-2 infection, followed by death in an Intensive Care Unit. In one Center (Oman), the majority of suspected cases were observed in patients with SCD between the age of 21 and 40 years. A rapid clinical improvement of tachypnea/dyspnea and oxygen saturation was observed, after red blood cell exchange transfusion, in a young girl with SCD and worsening of anemia (Hb level from 9.2 g/dl to 6.1g/dl).
   Conclusions: The data presented in this survey permit an early assessment of the clinical characteristics of COVID 19 in different countries. 70% of symptomatic patients with COVID-19 required hospitalization. The presence of associated co-morbidities can aggravate the severity of COVID-19, leading to a poorer prognosis irrespective of age.
C1 [de Sanctis, Vincenzo] Quisisana Hosp, Pediat & Adolescent Outpatient Clin, I-44121 Ferrara, Italy.
   [Canatan, Duran] Antalya Genet Dis Diagnost Ctr, Antalya, Turkey.
   [Vives Corrons, Joan Lluis] Inst Leukaemia Res Josep Carreras IJC, Red Blood Cell & Haematopoiet Disorders Unit, Catalonia, Spain.
   [Vives Corrons, Joan Lluis] Univ Barcelona, Catalonia, Spain.
   [Karimi, Mehran; Zarei, Tahereh] Shiraz Univ Med Sci, Hematol Res Ctr, Shiraz, Iran.
   [Daar, Shahina; Alkindi, Salam] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Haematol, Muscat, Oman.
   [Kattamis, Christos; Skafida, Myrto] Natl Kapodistrian Univ Athens, Dept Paediat 1, Athens, Greece.
   [Soliman, Ashraf T.] Hamad Med Ctr, Dept Pediat, Pediat & Endocrinol, Doha, Qatar.
   [Soliman, Ashraf T.] Alexandria Univ, Dept Pediat, Alexandria, Egypt.
   [Wali, Yasser] Sultan Qaboos Univ, Coll Med, Dept Child Hlth, Paediat Hematol Unit, Muscat, Oman.
   [Wali, Yasser] Alexandria Univ, Fac Med, Dept Paediat, Alexandria, Egypt.
   [Huseynov, Valeh; Nasibova, Afag; Verdiyevas, Narmin] Ctr Thalassemia, Baku, Azerbaijan.
   [Tiryaki, Tarik Onur] Istanbul Univ, Fac Med, Dept Hematol, Istanbul, Turkey.
   [Evim, Melike Sezgin; Gunes, Adalet Meral] Uludag Univ, Fac Med, Dept Pediat Hematol, Bursa, Turkey.
   [Karakas, Zeynep] Istanbul Univ, Istanbul Fac Med, Pediat Hematol Oncol, Istanbul, Turkey.
   [Christou, Soteroula] Archibishop Makarios III Hosp, Thalassaemia Clin, Nicosia, Cyprus.
   [Campisi, Saveria] Umberto I Hosp, UOSD Thalassemia, Siracusa, Italy.
   [Khater, Doaa] Alexandria Univ, Dept Pediat Endocrinol, Alexandria, Egypt.
   [Khater, Doaa] Sultan Qaboos Univ, Dept Pediat, Muscat, Oman.
   [Oymak, Yesim] Dr Behcet Uz Childrens Hosp, Izmir, Turkey.
   [Kaleva, Valeriya] Expert Ctr Coagulopathies & Rare Anemias, Varna, Bulgaria.
   [Stoyanova, Denka; Banchev, Atanas] Univ Hosp Tzaritza Giovanna ISUL, Pediat Hematoncol, Sofia, Bulgaria.
   [Galati, Maria Concetta] Pugliese Ciaccio Hosp, Pediat Haematoncol, Catanzaro, Italy.
   [Yassin, Mohamed A.] Hamad Med Corp HMC, Natl Ctr Canc Care & Res, Hematol Sect, Doha, Qatar.
   [Kakar, Shruti] Dayanand Med Coll & Hosp, Dept Pediat, Pediat Hematol Oncol, Ludhiana, Punjab, India.
   [Kilinc, Yurdanur] Cukurova Univ, Dept Pediat Hematol, Adana, Turkey.
   [Alyaarubi, Saif] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Child Hlth, Pediat Endocrinol Unit, Muscat, Oman.
   [Stoeva, Iva] Univ Paediat Hosp, Screening & Funct Endocrine Diagnost, Sofia, Bulgaria.
   [Raiola, Giuseppe] Pugliese Ciaccio Hosp, Dept Paediat, Catanzaro, Italy.
   [Mariannis, Demetris] Royal Lancaster Infirm, Lancaster, England.
   [Di Maio, Salvatore] Santobono Pausilipon Childrens Hosp, Pediat, Naples, Italy.
RP de Sanctis, V (corresponding author), Quisisana Hosp, Pediat & Adolescent Outpatient Clin, I-44121 Ferrara, Italy.
EM vdesanctis@libero.it
RI Karimi, Mehran/P-3530-2017
OI Karimi, Mehran/0000-0001-8555-1001
CR [Anonymous], 2020, HAEM HCCS ADV COVID
   do Nascimento IB, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040941
   Cereda D., 2020, EARLY PHASE COVID 19
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Heilbronner C, 2020, BRIT J HAEMATOL, V190, pE21, DOI 10.1111/bjh.16802
   Hussain FA, 2020, BRIT J HAEMATOL, V189, P851, DOI 10.1111/bjh.16734
   Jaillon S, 2019, CLIN REV ALLERG IMMU, V56, P308, DOI 10.1007/s12016-017-8648-x
   Karimi M, 2020, BRIT J HAEMATOL, V190, pE137, DOI 10.1111/bjh.16911
   Karimi Mehran, 2020, Acta Biomed, V91, P50, DOI 10.23750/abm.v91i2.9592
   Karimi M, 2014, PEDIATR HEMAT ONCOL, V31, P583, DOI 10.3109/08880018.2014.937884
   KATTAMIS C, 1982, EUR J PEDIATR, V139, P135, DOI 10.1007/BF00441497
   Ki M, 2019, EPIDEMIOL HEALTH, V41, DOI 10.4178/epih.e2019038
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Leone G, 2015, MEDITERR J HEMATOL I, V7, DOI 10.4084/MJHID.2015.057
   McCloskey KA, 2020, BRIT J HAEMATOL, V190, pE57, DOI 10.1111/bjh.16779
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Motta I, 2020, AM J HEMATOL, V95, pE198, DOI 10.1002/ajh.25840
   National Health Commission of the People's Republic of China, 2020, NAT REC DIAGN TREATM
   Nur E, 2020, AM J HEMATOL, V95, P725, DOI 10.1002/ajh.25821
   Odievre MH, 2020, AM J HEMATOL, V95, pE192, DOI 10.1002/ajh.25855
   Quinn CT, 2016, EXP BIOL MED, V241, P679, DOI 10.1177/1535370216640385
   Sun KY, 2020, LANCET DIGIT HEALTH, V2, pE201, DOI 10.1016/S2589-7500(20)30026-1
   Taher AT, 2020, AM J HEMATOL, V95, pE208, DOI 10.1002/ajh.25857
   Vives Corrons Joan-Lluis, 2020, Acta Biomed, V91, P216, DOI 10.23750/abm.v91i2.9532
   WHO, 2020, CLIN MAN SEV AC RESP
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhao J, 2020, RELATIONSHIP ABO BLO, DOI 10.1101/2020.03.11.20031096
NR 29
TC 3
Z9 3
U1 1
U2 1
PU MATTIOLI 1885
PI FIDENZA
PA VIA DELLA LODESANA 649-SX, FIDENZA, 43046 PR, ITALY
EI 2035-3006
J9 MEDITERR J HEMATOL I
JI Med. J. Hematol. Infect. Dis.
PD JUL 1
PY 2020
VL 12
AR e2020046
DI 10.4084/MJHID.2020.046
PG 9
WC Hematology; Infectious Diseases
SC Hematology; Infectious Diseases
GA MH3PE
UT WOS:000546644500001
PM 32670524
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Goyal, M
   Ospel, JM
AF Goyal, Mayank
   Ospel, Johanna M.
TI Stroke Systems of Care Current State of Affairs and Future Directions
SO STROKE
LA English
DT Article
DE COVID-19; pandemics; reperfusion; triage; workflow
ID MULTIPHASE CT ANGIOGRAPHY; LARGE VESSEL OCCLUSION; ACUTE
   ISCHEMIC-STROKE; ENDOVASCULAR THROMBECTOMY; TIME; METAANALYSIS;
   MANAGEMENT; EFFICACY; OUTCOMES; THERAPY
C1 [Goyal, Mayank; Ospel, Johanna M.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
   [Goyal, Mayank] Univ Calgary, Dept Radiol, Calgary, AB, Canada.
   [Ospel, Johanna M.] Univ Hosp Basel, Dept Neuroradiol, Basel, Switzerland.
RP Goyal, M (corresponding author), Univ Calgary, Foothills Med Ctr, Dept Radiol, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.; Goyal, M (corresponding author), Univ Calgary, Foothills Med Ctr, Dept Clin Neurosci, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.
EM mgoyal@ucalgary.ca
OI goyal, mayank/0000-0001-9060-2109
FU University of Basel Research Foundation; Julia Bangerter Rhyner
   Foundation; Freiwillige Akademische Gesellschaft Basel
FX Dr Goyal is a consultant for Medtronic, Stryker, Microvention, GE
   Healthcare, Mentice. Dr Ospel is supported by the University of Basel
   Research Foundation, Julia Bangerter Rhyner Foundation and Freiwillige
   Akademische Gesellschaft Basel.
CR Ajmi SC, 2019, BMJ QUAL SAF, V28, P939, DOI 10.1136/bmjqs-2018-009117
   BCV C, 2020, STROKE
   Chowdhury S, 2019, NEW ENGL J MED, V381, P1501, DOI 10.1056/NEJMp1907988
   Dehkharghani S, 2015, AM J NEURORADIOL, V36, P1419, DOI 10.3174/ajnr.A4363
   Forestdevices, 2020, FORESTDEVICES FOREST, P2020
   Goyal M, 2014, AM J NEURORADIOL, V35, P616, DOI 10.3174/ajnr.A3770
   Goyal M, 2020, LANCET NEUROL, V19, P210, DOI [10.1016/S1474-4422(20)30005-3, 10.1161/STR.0000000000000211]
   Goyal M, 2019, NEURORADIOLOGY, V61, P3, DOI 10.1007/s00234-018-2117-y
   Goyal M, 2017, J NEUROINTERV SURG, V9, P915, DOI 10.1136/neurintsurg-2016-012486
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Hill MD, 2020, LANCET, V395, P878, DOI 10.1016/S0140-6736(20)30258-0
   Holodinsky JK, 2018, JAMA NEUROL, V75, P1477, DOI 10.1001/jamaneurol.2018.2424
   Kurz MW, 2020, STROKE, V51, P1978, DOI 10.1161/STROKEAHA.119.026732
   Liebeskind DS, 2019, J NEUROINTERV SURG, V11, P433, DOI 10.1136/neurintsurg-2018-014127
   McTaggart RA, 2020, STROKE, V51, P1951, DOI 10.1161/STROKEAHA.119.026735
   McTaggart RA, 2020, STROKE, V51, P1961, DOI 10.1161/STROKEAHA.119.026736
   Menon BK, 2019, J NEUROINTERV SURG, V11, P1065, DOI 10.1136/neurintsurg-2018-014678
   Menon BK, 2015, RADIOLOGY, V275, P510, DOI 10.1148/radiol.15142256
   Noorian AR, 2018, STROKE, V49, P565, DOI 10.1161/STROKEAHA.117.019228
   Ospel JM, 2020, AM J NEURORADIOL, V41, P200, DOI 10.3174/ajnr.A6376
   Ospel JM, 2019, EXPERT REV MED DEVIC, V16, P955, DOI 10.1080/17434440.2019.1684263
   Ospel JM, 2020, INTERV NEURORADIOL, V26, P420, DOI 10.1177/1591019920908131
   de la Ossa NP, 2016, STROKE, V47, P2877, DOI 10.1161/STROKEAHA.116.014911
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Roman LS, 2018, LANCET NEUROL, V17, P895, DOI 10.1016/S1474-4422(18)30242-4
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Shah S, 2019, CIRCULATION, V139, P1568, DOI 10.1161/CIRCULATIONAHA.118.036509
   Srivastava MVP, 2020, STROKE, V51, P1969, DOI 10.1161/STROKEAHA.119.026733
   Tahtali D, 2016, NERVENARZT, V87, P1322, DOI 10.1007/s00115-016-0162-5
   Wiegers E CK, 2020, PATH RES FORMAL IMPL, V51, P1941
NR 30
TC 0
Z9 0
U1 6
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUL
PY 2020
VL 51
IS 7
BP 1928
EP 1931
DI 10.1161/STROKEAHA.120.030288
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA ME9MV
UT WOS:000544979200018
PM 32568659
DA 2021-01-01
ER

PT J
AU Hoyer, C
   Ebert, A
   Huttner, HB
   Puetz, V
   Kallmunzer, B
   Barlinn, K
   Haverkamp, C
   Harloff, A
   Brich, J
   Platten, M
   Szabo, K
AF Hoyer, Carolin
   Ebert, Anne
   Huttner, Hagen B.
   Puetz, Volker
   Kallmuenzer, Bernd
   Barlinn, Kristian
   Haverkamp, Christian
   Harloff, Andreas
   Brich, Jochen
   Platten, Michael
   Szabo, Kristina
TI Acute Stroke in Times of the COVID-19 Pandemic A Multicenter Study
SO STROKE
LA English
DT Article
DE brain ischemia; pandemics; reperfusion; stroke; thrombectomy
AB Background and Purpose: This study aims to assess the number of patients with acute ischemic cerebrovascular events seeking in-patient medical emergency care since the implementation of social distancing measures in the coronavirus disease 2019 (COVID-19) pandemic. Methods: In this retrospective multicenter study, data on the number of hospital admissions due to acute ischemic stroke or transient ischemic attack and numbers of reperfusion therapies performed in weeks 1 to 15 of 2020 and 2019 were collected in 4 German academic stroke centers. Poisson regression was used to test for a change in admission rates before and after the implementation of extensive social distancing measures in week 12 of 2020. The analysis of anonymized regional mobility data allowed for correlations between changes in public mobility as measured by the number and length of trips taken and hospital admission for stroke/transient ischemic attack. Results: Only little variation of admission rates was observed before and after week 11 in 2019 and between the weeks 1 and 11 of 2019 and 2020. However, reflecting the impact of the COVID-19 pandemic, a significant decrease in the number of admissions for transient ischemic attack was observed (-85%, -46%, -42%) in 3 of 4 centers, while in 2 of 4 centers, stroke admission rates decreased significantly by 40% and 46% after week 12 in 2020. A relevant effect on reperfusion therapies was found for 1 center only (thrombolysis, -60%; thrombectomy, -61%). Positive correlations between number of ischemic events and mobility measures in the corresponding cities were identified for 3 of 4 centers. Conclusions: These data demonstrate and quantify decreasing hospital admissions due to ischemic cerebrovascular events and suggest that this may be a consequence of social distancing measures, in particular because hospital resources for acute stroke care were not limited during this period. Hence, raising public awareness is necessary to avoid serious healthcare and economic consequences of undiagnosed and untreated strokes and transient ischemic attacks.
C1 [Hoyer, Carolin; Ebert, Anne; Platten, Michael; Szabo, Kristina] Heidelberg Univ, Med Fac Mannheim, Dept Neurol, Mannheim, Germany.
   [Huttner, Hagen B.; Kallmuenzer, Bernd] Univ Hosp Erlangen, Dept Neurol, Erlangen, Germany.
   [Puetz, Volker; Barlinn, Kristian] Tech Univ Dresen, Carl Gustav Carus Univ Hosp, Dept Neurol, Dresden Neurovasc Ctr, Dresden, Germany.
   [Harloff, Andreas; Brich, Jochen] Univ Freiburg, Fac Med, Dept Neurol & Clin Neurosci, Freiburg, Germany.
   [Haverkamp, Christian] Univ Freiburg, Inst Digitalizat Med, Fac Med, Freiburg, Germany.
RP Hoyer, C (corresponding author), Univ Med Mannheim, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM carolin.hoyer@umm.de
RI Platten, Michael/F-2902-2013
OI Platten, Michael/0000-0002-4746-887X
FU Heidelberg University
FX Dr Hoyer receives a grant for postdoctoral lecture qualification within
   the Olympia Morata Program of Heidelberg University.
CR [Anonymous], DASHB COVID 19 FALL
   Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508
   Dhand A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09073-5
   Katan M, 2018, SEMIN NEUROL, V38, P208, DOI 10.1055/s-0038-1649503
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
NR 5
TC 13
Z9 13
U1 5
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUL
PY 2020
VL 51
IS 7
BP 2224
EP 2227
DI 10.1161/STROKEAHA.120.030395
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA ME9MV
UT WOS:000544979200054
PM 32516064
DA 2021-01-01
ER

PT J
AU Yao, WL
   Wang, TT
   Jiang, BL
   Gao, F
   Wang, L
   Zheng, HB
   Xiao, WM
   Yao, SL
   Mei, W
   Chen, XD
   Luo, AL
   Sun, L
   Cooks, T
   Behringer, E
   Huitink, JM
   Wong, DT
   Lane-Falls, M
   McNarry, AF
   McGuire, B
   Higgs, A
   Shah, A
   Patel, A
   Zuo, MZ
   Ma, WH
   Xue, ZG
   Zhang, LM
   Li, WX
   Wang, Y
   Hagberg, C
   O'Sullivan, EP
   Fleishers, LA
   Wei, HF
AF Yao, Wenlong
   Wang, Tingting
   Jiang, Bailing
   Gao, Feng
   Wang, Li
   Zheng, Hongbo
   Xiao, Weimin
   Yao, Shanglong
   Mei, Wei
   Chen, Xiangdong
   Luo, Ailin
   Sun, Liang
   Cooks, Tim
   Behringer, Elizabeth
   Huitink, Johannes M.
   Wong, David T.
   Lane-Falls, Meghan
   McNarry, Alistair F.
   McGuire, Barry
   Higgs, Andrew
   Shah, Amit
   Patel, Anil
   Zuo, Mingzhang
   Ma, Wuhua
   Xue, Zhanggang
   Zhang, Li-Ming
   Li, Wenxian
   Wang, Yong
   Hagberg, Carin
   O'Sullivan, Ellen P.
   Fleishers, Lee A.
   Wei, Huafeng
TI Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan,
   China: lessons learnt and international expert recommendations
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE airway management; ARDS; consensus recommendations; COVID-19; critical
   care; infection prevention and control; pneumonia; respiratory failure;
   tracheal intubation
ID FLOW OXYGEN-THERAPY; CRITICALLY-ILL; VENTILATION; MANAGEMENT; ETOMIDATE;
   MORTALITY; SARS
AB Tracheal intubation in coronavirus disease 2019 (COVID-19) patients creates a risk to physiologically compromised patients and to attending healthcare providers. Clinical information on airway management and expert recommendations in these patients are urgently needed. By analysing a two-centre retrospective observational case series from Wuhan, China, a panel of international airway management experts discussed the results and formulated consensus recommendations for the management of tracheal intubation in COVID-19 patients. Of 202 COVID-19 patients undergoing emergency tracheal intubation, most were males (n=136; 67.3%) and aged 65 yr or more (n=128; 63.4%). Most patients (n=152; 75.2%) were hypoxaemic (SaO(2) <90%) before intubation. Personal protective equipment was worn by all intubating healthcare workers. Rapid sequence induction (RSI) or modified RSI was used with an intubation success rate of 89.1% on the first attempt and 100% overall. Hypoxaemia (SaO(2) <90%) was common during intubation (n=148; 73.3%). Hypotension (arterial pressure <90/60mmHg) occurred in 36 (17.8%) patients during and 45 (22.3%) after intubation with cardiac arrest in four (2.0%). Pneumothorax occurred in 12 (5.9%) patients and death within 24 h in 21 (10.4%). Up to 14 days post-procedure, there was no evidence of cross infection in the anaesthesiologists who intubated the COVID-19 patients. Based on clinical information and expert recommendation, we propose detailed planning, strategy, and methods for tracheal intubation in COVID-19 patients.
C1 [Yao, Wenlong; Gao, Feng; Zheng, Hongbo; Mei, Wei; Luo, Ailin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.
   [Wang, Tingting; Wang, Li; Xiao, Weimin; Yao, Shanglong; Chen, Xiangdong] Huazhong Univ Sci & Technol, Union Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.
   [Jiang, Bailing; Sun, Liang; Lane-Falls, Meghan; Fleishers, Lee A.; Wei, Huafeng] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
   [Jiang, Bailing; Sun, Liang] Peking Univ Peoples Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Cooks, Tim] Royal United Hosp, Dept Anaesthesia & Intens Care Med, Bath, Avon, England.
   [Behringer, Elizabeth] Kaiser Perrnanente Los Angeles Med Ctr, Div Cardiovasc Surg & Crit Care, Los Angeles, CA USA.
   [Huitink, Johannes M.] Airway Management Acad, Amsterdam, Netherlands.
   [Wong, David T.] Univ Toronto, Univ Hlth Network, Toronto Western Hosp, Dept Anaesthesia, Toronto, ON, Canada.
   [McNarry, Alistair F.] Western Gen Hosp, Dept Anaesthesia, Edinburgh, Midlothian, Scotland.
   [McGuire, Barry] Ninewells Hosp, Dept Anaesthesia, Dundee, Scotland.
   [Higgs, Andrew] Warrington Hosp, Depat Anaesthesia & Intens Care Med, Warrington, Cheshire, England.
   [Higgs, Andrew] Halton Hosp, Depat Anaesthesia & Intens Care Med, Warrington, Cheshire, England.
   [Shah, Amit] Kailash Canc Hosp & Res Ctr, Dept Anesthesiol, Muni Seva Ashram, Goraj, India.
   [Patel, Anil] Royal Natl Throat Nose & Ear Hosp, Dept Anaesthesiol, London, England.
   [Zuo, Mingzhang] Chinese Acad Med Sci, Dept Anesthesiol, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med, Beijing, Peoples R China.
   [Ma, Wuhua; Wang, Yong] Guangzhou Univ Tradit Chinese Med, Dept Anesthesiol, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Xue, Zhanggang] Fudan Univ, Dept Anesthesiol, Zhongshan Hosp, Shanghai, Peoples R China.
   [Zhang, Li-Ming] Univ Pittsburgh, Med Ctr, Dept Anesthesiol & Perioperat Med, Pittsburgh, PA USA.
   [Zhang, Li-Ming] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Li, Wenxian] Fudan Univ, Dept Anesthesiol, Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China.
   [Hagberg, Carin] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA.
   [O'Sullivan, Ellen P.] St James Hosp, Dept Anaesthesia & Intens Care Med, Dublin, Ireland.
RP Luo, AL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.; Chen, XD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.; Wei, HF (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
EM Xiangdongchen2013@163.com; alluo@tjh.tjmu.edu.cn;
   huafeng.wee@penumedicine.upenn.edu
RI Jiang, Bailin/Y-8865-2018; McNarry, Alistair/ABC-5143-2020; Lane-Fall,
   Meghan/L-9854-2013
OI Jiang, Bailin/0000-0002-9012-7472; Lane-Fall,
   Meghan/0000-0001-7050-0017; Hagberg, Carin/0000-0002-4336-8820
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Bajwa Abubakr A, 2010, J Intensive Care Med, V25, P121, DOI 10.1177/0885066609356050
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Brewster DJ, 2020, MED J AUSTRALIA, V212, P472, DOI 10.5694/mja2.50598
   Cai SJ, 2020, ZHONGHUA JIE HE HE H, V43, pE033
   Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6
   Chen XD, 2020, ANESTHESIOLOGY, V132, P1307, DOI 10.1097/ALN.0000000000003301
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x
   De Jong A, 2018, CRIT CARE MED, V46, P532, DOI 10.1097/CCM.0000000000002925
   Ensinger H, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P132, DOI 10.1055/s-2007-995889
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   European Centre for Disease Prevention and Control, 2020, INF PREV CONTR COVID
   Gu WJ, 2015, CHEST, V147, P335, DOI 10.1378/chest.14-1012
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta S, 2020, INDIAN J ANAESTH, V64, P11, DOI 10.4103/ija.IJA_597_19
   Hall D, 2020, ANAESTHESIA, V75, P822, DOI 10.1111/anae.15047
   HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang HB, 2018, J CRIT CARE, V43, P300, DOI 10.1016/j.jcrc.2017.09.176
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Khandelwal N, 2016, ANESTH ANALG, V122, P1101, DOI 10.1213/ANE.0000000000001184
   Koga Y, 2020, ACUTE MED SURG, V7, DOI 10.1002/ams2.461
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Levy SD, 2016, LANCET, V387, P1867, DOI 10.1016/S0140-6736(16)30245-8
   Lewis SR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011136.pub2
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Mosier JM, 2015, WEST J EMERG MED, V16, P1109, DOI 10.5811/westjem.2015.8.27467
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Nicolle L, 2003, CAN J ANAESTH, V50, P983, DOI 10.1007/BF03018360
   Nolan JP, 2011, ANAESTHESIA, V66, P81, DOI 10.1111/j.1365-2044.2011.06937.x
   Patel A, 2015, ANAESTHESIA, V70, P323, DOI 10.1111/anae.12923
   Public Health England, 2020, COVID 19 INF PREV CO
   Respiratory care committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V17, pE020, DOI 10.3760/cma.j.issn.1001-0939.2020.0020
   Smischney NJ, 2018, J CRIT CARE, V44, P179, DOI 10.1016/j.jcrc.2017.10.018
   Smischney NJ, 2016, MED SCI MONITOR, V22, P346, DOI 10.12659/MSM.895919
   TEASDALE G, 1974, LANCET, V2, P81
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tsan SEH, 2020, ANESTH ANALG, V131, P210, DOI 10.1213/ANE.0000000000004349
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verbeek T, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.100340
   Vinclair M, 2008, INTENS CARE MED, V34, P714, DOI 10.1007/s00134-007-0970-y
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Weingart SD, 2012, ANN EMERG MED, V59, P165, DOI 10.1016/j.annemergmed.2011.10.002
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2019, 81 WHO
   Wu CN, 2020, BRIT J ANAESTH, V125, pE166, DOI [10.1016/j.bja.2020.02.020, 10.1016/j.bja.2020.04.004]
   Wu CN, 2017, INTERN EMERG MED, V12, P667, DOI 10.1007/s11739-016-1531-6
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49, P1, DOI DOI 10.3785/J.ISSN.1008-9292.2020.02.02.0E0
   Yam LYC, 2003, RESPIROLOGY, V8, pS31, DOI 10.1046/j.1440-1843.2003.00521.x
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zuo Mingzhang, 2020, Chinese Medical Sciences Journal, V35, P105, DOI 10.24920/003724
NR 58
TC 54
Z9 55
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2020
VL 125
IS 1
BP E28
EP E37
DI 10.1016/j.bja.2020.03.026
PG 10
WC Anesthesiology
SC Anesthesiology
GA MD9XJ
UT WOS:000544318800009
PM 32312571
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bassetti, M
   Giacobbe, DR
   Aliberti, S
   Barisione, E
   Centanni, S
   De Rosa, FG
   Di Marco, F
   Gori, A
   Granata, G
   Mikulska, M
   Petrosillo, N
   Richeldi, L
   Santus, P
   Tascini, C
   Vena, A
   Viale, P
   Blasi, F
AF Bassetti, M.
   Giacobbe, D. R.
   Aliberti, S.
   Barisione, E.
   Centanni, S.
   De Rosa, F. G.
   Di Marco, F.
   Gori, A.
   Granata, G.
   Mikulska, M.
   Petrosillo, N.
   Richeldi, L.
   Santus, P.
   Tascini, C.
   Vena, A.
   Viale, P.
   Blasi, F.
CA Italian Soc Anti-Infect Therapy SI
   Italian Soc Pulmonology SIP
TI paper Balancing evidence and frontline experience in the early phases of
   the COVID-19 pandemic: current position of the Italian Society of
   Anti-infective Therapy (SITA) and the Italian Society of Pulmonology
   (SIP)
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Coronavirus; COVID-19; Pneumonia; SARS-CoV-2; Therapy
ID RESPIRATORY-DISTRESS-SYNDROME; COMMUNITY-ACQUIRED PNEUMONIA;
   CRITICALLY-ILL PATIENTS; NEURAMINIDASE INHIBITORS; CORTICOSTEROID
   TREATMENT; IN-VITRO; CORONAVIRUS; INFECTION; SARS; REMDESIVIR
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure. At the present time the absolute number of severe cases requiring ventilator support is reaching or even surpassing the intensive care unit bed capacity in the most affected regions and countries. Objectives: To narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and frontline opinions and to provide balanced answers to pressing clinical questions. Sources: Inductive PubMed search for publications relevant to the topic. Content: The available literature and the authors' frontline-based opinion are summarized in brief narrative answers to selected clinical questions, with a conclusive statement provided for each answer. Implications: Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to welldesigned randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients. M. Bassetti, Clin Microbiol Infect 2020;26:880 (c) 2020 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Bassetti, M.; Giacobbe, D. R.; Mikulska, M.; Vena, A.] Osped Policlin San Martino IRCCS, Infect Dis Unit, Genoa, Italy.
   [Bassetti, M.; Giacobbe, D. R.; Mikulska, M.] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy.
   [Aliberti, S.; Blasi, F.] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Aliberti, S.; Blasi, F.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit & Cyst Fibrosis Adult Ctr, Internal Med Dept, Milan, Italy.
   [Barisione, E.] Osped Policlin San Martino IRCCS, Intervent Pulmonol, Genoa, Italy.
   [Centanni, S.] Univ Milan, Dept Hlth Sci, Resp Unit, ASST Santi Paolo & Carlo, Milan, Italy.
   [De Rosa, F. G.] Univ Turin, Dept Med Sci, Infect Dis, Turin, Italy.
   [Di Marco, F.] Univ Milan, ASST Papa Giovanni XXIII Hosp, Dept Hlth Sci, Resp Unit, Bergamo, Italy.
   [Gori, A.] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Infect Dis Unit, Milan, Italy.
   [Granata, G.; Petrosillo, N.] IRCCS, Clin & Res Dept Infect Dis, Severe & Immunedepress Associated Infect Unit, Natl Inst Infect Dis L Spallanzani, Rome, Italy.
   [Richeldi, L.] Fdn Policlin Univ A Gemelli IRCCS, UOC Pneumol, Dipartimento Sci Gastroenterol Endocrinometab & N, Rome, Italy.
   [Richeldi, L.] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Santus, P.] Univ Milan, Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci DIBIC, Div Resp Dis, Milan, Italy.
   [Tascini, C.] Santa Maria Misericordia Hosp, Infect Dis Clin, Udine, Italy.
   [Viale, P.] Univ Bologna, Dept Med & Surg Sci, Infect Dis Unit, Alma Mater Studiorum, Bologna, Italy.
RP Bassetti, M (corresponding author), Univ Genoa, Infect Dis Unit, Osped Policlin San Martino IRCCS, Lgo R Benzi 10, I-16132 Genoa, Italy.
EM matteo.bassetti@unige.it
RI Richeldi, Luca/ABF-2486-2020; Granata, Guido/AAI-1821-2019; Giacobbe,
   Daniele Roberto/K-2777-2018; Richeldi, Luca/B-6243-2019
OI Richeldi, Luca/0000-0001-8594-1448; Granata, Guido/0000-0001-5796-0545;
   Giacobbe, Daniele Roberto/0000-0003-2385-1759; CENTANNI,
   STEFANO/0000-0001-9923-535X; Barisione, Emanuela/0000-0001-5365-134X; DE
   ROSA, Francesco Giuseppe/0000-0001-8338-0130; di marco,
   fabiano/0000-0002-1743-0504
CR Agostini M.L., 2018, MBIO, P9
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Bassetti M, 2019, EXPERT REV CLIN PHAR, V12, P1037, DOI 10.1080/17512433.2019.1680283
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Brunner HI, 2015, ANN RHEUM DIS, V74, P1110, DOI 10.1136/annrheumdis-2014-205351
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Chen X., 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.20029520, DOI 10.1101/2020.02.29.20029520]
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dysart K, 2009, RESP MED, V103, P1400, DOI 10.1016/j.rmed.2009.04.007
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Hageman JC, 2006, EMERG INFECT DIS, V12, P894, DOI 10.3201/eid1206.051141
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jean C, 2010, CLIN INFECT DIS, V50, pE59, DOI 10.1086/652291
   Katzen J, 2019, CLIN INFECT DIS, V69, P52, DOI 10.1093/cid/ciy860
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Louie JK, 2012, CLIN INFECT DIS, V55, P1198, DOI 10.1093/cid/cis636
   MEDURI GU, 1995, CHEST, V108, P1315, DOI 10.1378/chest.108.5.1315
   Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Metersky ML, 2012, INT J INFECT DIS, V16, pE321, DOI 10.1016/j.ijid.2012.01.003
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Mizumoto K, 2020, ESTIMATING ASYMPTOMA, DOI [10.2807/1560-7917.ES.2020.25.10.2000180, DOI 10.2807/1560-7917.ES.2020.25.10.2000180]
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   National Health Commission (NHC) of the People's Republic of China, 2020, DIAGN TREATM GUID CO
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nicastri E, 2020, INFECT DIS REP
   Olsen SJ, 2020, EMERG INFECT DIS, V26, P1567, DOI 10.3201/eid2607.200359
   Paddock CD, 2012, J INFECT DIS, V205, P895, DOI 10.1093/infdis/jir861
   Paul M, 2018, J INFECT DIS, V217, P508, DOI 10.1093/infdis/jix536
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Seam N, 2012, CRIT CARE MED, V40, P495, DOI 10.1097/CCM.0b013e318232da5e
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Tang BMP, 2009, CRIT CARE MED, V37, P1594, DOI 10.1097/CCM.0b013e31819fb507
   Umberto Meduri Gianfranco, 2011, Presse Med, V40, pe543, DOI 10.1016/j.lpm.2011.04.023
   US Centers for Disease Control and Prevention, THER OPT PAT COVID 1
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu X, PREPRINT
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 87
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD JUL
PY 2020
VL 26
IS 7
BP 880
EP 894
DI 10.1016/j.cmi.2020.04.031
PG 15
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA MD9FW
UT WOS:000544273300015
PM 32360444
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lian, N
   Xie, H
   Lin, S
   Huang, J
   Zhao, J
   Lin, Q
AF Lian, N.
   Xie, H.
   Lin, S.
   Huang, J.
   Zhao, J.
   Lin, Q.
TI Umifenovir treatment is not associated with improved outcomes in
   patients with coronavirus disease 2019: a retrospective study
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Antiviral intervention; Corona virus disease 2019; Umifenovir; Arbidol;
   Effectiveness
ID ACUTE RESPIRATORY SYNDROME
AB Objectives: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Umifenovir (Arbidol ?) is an antiviral drug being used to treat in fluenza in Russia and China. This study aimed to investigate the effectiveness and safety of umifenovir for COVID- 19. Methods: A retrospective study was performed in a non -intensive care unit (ICU) ward in Jinyintan Hospital from 2 February 2020 to 20 March 2020. COVID-19 was con firmed by real-time reverse-tran- scriptase polymerase chain reaction (RT-PCR) assay of pharyngeal swab specimens. The con firmed pa- tients were divided into the umifenovir group and the control group according to the use of umifenovir. The main outcomes were the rate of negative pharyngeal swab tests for SARS-CoV-2 within 1 week after admission and the time for the virus to turn negative. The negativity time of SARS-CoV-2 was de fined as the first day of a negative test if the nucleic acid of SARS-CoV-2 was negative for two consecutive tests. Results: A total of 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline clinical and laboratory characteristics were comparable between the two groups. Thirty-three out of 45 (73%) patients in the umifenovir group tested negative for SARS-CoV-2 within 7 days after admission, the number was 28/36 (78%) in the control group (p 0.19). The median time from onset of symptoms to SARS-CoV-2 turning negative was 18 days (interquartile range (IQR) 12-21) in the umifenovir group and 16 days (IQR 11-21) in the control group (p 0.42). Patients in the umifenovir group had a longer hospital stay than patients in the control group (13 days (IQR 9-17) vs 11 days (IQR 9-14), p 0.04). No deaths or severe adverse reactions were found in both groups. Discussion: Umifenovir might not improve the prognosis or accelerate SARS-CoV-2 clearance in non -ICU patients. A randomized control clinical trial is needed to assess the ef ficacy of umifenovir. (c) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Lian, N.; Xie, H.; Huang, J.; Zhao, J.; Lin, Q.] Fujian Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.
   [Lin, S.] Fujian Med Univ, Liver Res Ctr, Affiliated Hosp 1, Fuzhou, Peoples R China.
RP Lin, Q (corresponding author), Fujian Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.
EM linqc_fy@126.com
FU Natural Science Foundation of Fujian Province, ChinaNatural Science
   Foundation of Fujian Province [2019J01440]; Startup Fund for Scientific
   Research, Fujian Medical University, China [2017XQ1080]
FX The authors disclose no conflicts of interest. This work was supported
   by the Natural Science Foundation of Fujian Province, China (No.
   2019J01440) and Startup Fund for Scientific Research, Fujian Medical
   University, China (NO.2017XQ1080).
CR [Anonymous], 2020, NOVEL CORONAVIRUS PN
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Behzadi MA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01327
   Chang YC, 2005, RADIOLOGY, V236, P1067, DOI 10.1148/radiol.2363040958
   [陈军 Chen Jun], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P86
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   El Zowalaty ME, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100124
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Proskurnina EV, 2020, MOLECULES, V25, DOI 10.3390/molecules25071577
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
NR 15
TC 40
Z9 40
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD JUL
PY 2020
VL 26
IS 7
BP 917
EP 921
DI 10.1016/j.cmi.2020.04.026
PG 5
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA MD9FW
UT WOS:000544273300020
PM 32344167
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Almutairi, N
   Schwartz, RA
AF Almutairi, Nawaf
   Schwartz, Robert A.
TI COVID-19 with dermatologic manifestations and implications: An unfolding
   conundrum
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE urticaria; skin signs of systemic disease; infection-bacterial; fungal;
   viral; drug reaction; therapy-topical; inflammatory disorders
ID CORONAVIRUS
AB The novel coronavirus SARS-CoV-2 has caused Coronavirus Disease 2019, widely known as COVID-19, now a pandemic with extraordinary infectivity, mortality, and fomite adhesiveness. We delineate cutaneous manifestations of COVID-19, some of which may represent adverse cutaneous drug reactions, and skin changes associated with COVID-19 lifestyle alterations in patients and health care workers. We review COVID-19 from both a dermatologic and public health perspective.
C1 Kuwait Univ, Fac Med, Safat, Kuwait.
   Rutgers New Jersey Med Sch, Newark, NJ USA.
RP Schwartz, RA (corresponding author), Rutgers New Jersey Med Sch, Dermatol, 185 South Orange Ave, Newark, NJ 07103 USA.
EM roschwar@cal.berkeley.edu
OI Schwartz, Robert/0000-0003-3036-3825
CR Adadias-Granado I, GEN PUSTULAR F UNPUB
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, WHAT HEALTHC PERS SH
   Bailey Heather E, 2020, Neurodiagn J, V60, P41, DOI 10.1080/21646821.2020.1725864
   Beun R, 2020, INT J LAB HEMATOL, V42, P19, DOI 10.1111/ijlh.13230
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Elston DM, 2020, J AM ACAD DERMATOL, V82, P1085, DOI 10.1016/j.jaad.2020.03.012
   Elston DM, 2020, J AM ACAD DERMATOL, V82, P819, DOI 10.1016/j.jaad.2020.02.031
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   Foo CCI, 2006, CONTACT DERMATITIS, V55, P291, DOI 10.1111/j.1600-0536.2006.00953.x
   Glauser W, 2020, CAN MED ASSOC J, V192, pE264, DOI 10.1503/cmaj.1095852
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   HuiDS IAE, 2020, INT J INFECT DIS, V91, P264, DOI [10.1016/j.ijid.2020.01.009, DOI 10.1016/J.IJID.2020.01.009]
   Ippolito G, 2020, LANCET RESP MED, V8, P230, DOI 10.1016/S2213-2600(20)30070-9
   Jewell NP, 2020, ANN INTERN MED, V173, P226, DOI 10.7326/M20-1565
   Johanigman J, 2020, GLOBAL POLICY, V11
   Joob B, 2020, J HOSP INFECT, V104, P453, DOI 10.1016/j.jhin.2020.02.016
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Joob B, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620918308
   Kanitakis J, 2020, J AM ACAD DERMATOL, V83, P870, DOI 10.1016/j.jaad.2020.05.145
   KAPILA CC, 1958, BMJ-BRIT MED J, V2, P1311, DOI 10.1136/bmj.2.5108.1311
   Kapila R, INDIAN J MED SCI
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lan JJ, 2020, J AM ACAD DERMATOL, V82, P1215, DOI 10.1016/j.jaad.2020.03.014
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020
   Lin P, 2020, BRIT J DERMATOL, V183, P190, DOI 10.1111/bjd.19089
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Manalo IF, 2020, J AM ACAD DERMATOL, V83, pE157, DOI [10.1016/j.jaad.2020.04.018, 10.1016/j.jaad.2020.05.001]
   Marzano AV, 2020, J AM ACAD DERMATOL, V83, P280, DOI 10.1016/j.jaad.2020.04.044
   Moein ST, 2020, INT FORUM ALLERGY RH, V10, P944, DOI 10.1002/alr.22587
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13481
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13380
   Schwartz RA, 2020, INDIAN J DERMATOL, V65, P1, DOI 10.4103/ijd.IJD_277_19
   Soria A, 2015, DERMATOLOGY, V231, P353, DOI 10.1159/000438787
   Su CJ, 2020, J EUR ACAD DERMATOL, V34, pE251, DOI 10.1111/jdv.16469
   Troyer EA, 2020, BRAIN BEHAV IMMUN, V87, P34, DOI 10.1016/j.bbi.2020.04.027
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   von Economo C., 1917, WIEN KLIN WOCHENSCHR, V30, P581
   Wang C, 2020, AUSTRALAS J DERMATOL, V61, P210, DOI 10.1111/ajd.13313
   WHO, 2005, 2 M INT HLTH REG
   Wollenberg A, 2020, J EUR ACAD DERMATOL, V34, pE241, DOI 10.1111/jdv.16411
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yao X, 2020, CHINESE J PATHOL, V49, pE009
   Yen MY, 2020, J MICROBIOL IMMUNOL, V53, P377, DOI 10.1016/j.jmii.2020.03.011
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 60
TC 9
Z9 9
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD SEP
PY 2020
VL 33
IS 5
SI SI
AR e13544
DI 10.1111/dth.13544
EA JUL 2020
PG 8
WC Dermatology
SC Dermatology
GA OB4SO
UT WOS:000544553300001
PM 32385869
OA Green Published, Bronze, Green Accepted
DA 2021-01-01
ER

PT J
AU Levesque, V
   Millaire, E
   Corsilli, D
   Rioux-Masse, B
   Carrier, FM
AF Levesque, Valerie
   Millaire, Emilie
   Corsilli, Daniel
   Rioux-Masse, Benjamin
   Carrier, Francois-Martin
TI Severe immune thrombocytopenic purpura in critical COVID-19
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE COVID-19; Thrombocytopenia; Bleeding; Immunoglobulin; Corticosteroids
AB COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 x 10(9)/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high-dose dexamethasone to observe an increase in platelet count. COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.
C1 [Levesque, Valerie; Millaire, Emilie] Univ Montreal, Dept Med, Montreal, PQ, Canada.
   [Corsilli, Daniel; Carrier, Francois-Martin] CHU Montreal, Dept Med, Crit Care Div, Montreal, PQ, Canada.
   [Rioux-Masse, Benjamin; Carrier, Francois-Martin] CHU Montreal, Dept Med, Hematol Div, Montreal, PQ, Canada.
   [Carrier, Francois-Martin] CHU Montreal, Dept Anesthesiol, Montreal, PQ, Canada.
   [Carrier, Francois-Martin] Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Carrefour Innovat, 900 Rue St Denis,Porte S03-434, Montreal, PQ H2X 0A9, Canada.
RP Carrier, FM (corresponding author), CHU Montreal, Dept Med, Crit Care Div, Montreal, PQ, Canada.; Carrier, FM (corresponding author), CHU Montreal, Dept Med, Hematol Div, Montreal, PQ, Canada.; Carrier, FM (corresponding author), CHU Montreal, Dept Anesthesiol, Montreal, PQ, Canada.; Carrier, FM (corresponding author), Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Carrefour Innovat, 900 Rue St Denis,Porte S03-434, Montreal, PQ H2X 0A9, Canada.
EM francois.martin.carrier@umontreal.ca
OI Carrier, Francois Martin/0000-0003-0310-0616
FU Fonds de Recherche du Quebec - SanteFonds de la Recherche en Sante du
   Quebec
FX FMC is a recipient of a Career Award from the Fonds de Recherche du
   Quebec - Sante.
CR Arnold DM, 2013, J THROMB HAEMOST, V11, P169, DOI 10.1111/jth.12052
   Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Chen WX, 2020, BRIT J HAEMATOL, V190, P179, DOI 10.1111/bjh.16885
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Liebman Howard A, 2008, Hematology Am Soc Hematol Educ Program, P212, DOI 10.1182/asheducation-2008.1.212
   Neunert C, 2015, J THROMB HAEMOST, V13, P457, DOI 10.1111/jth.12813
   Neunert C, 2019, BLOOD ADV, V3, P3829, DOI 10.1182/bloodadvances.2019000966
   Pavord S, 2020, BRIT J HAEMATOL, V189, P1038, DOI 10.1111/bjh.16775
   Samson M, 2019, CUREUS, V11, DOI 10.7759/cureus.5849
   Wang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094124
   Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 13
TC 3
Z9 3
U1 2
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD NOV
PY 2020
VL 112
IS 5
BP 746
EP 750
DI 10.1007/s12185-020-02931-9
EA JUL 2020
PG 5
WC Hematology
SC Hematology
GA OB5QH
UT WOS:000544832000002
PM 32613314
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zeng, QL
   Yu, ZJ
   Gou, JJ
   Li, GM
   Ma, SH
   Zhang, GF
   Xu, JH
   Lin, WB
   Cui, GL
   Zhang, MM
   Li, C
   Wang, ZS
   Zhang, ZH
   Liu, ZS
AF Zeng, Qing-Lei
   Yu, Zu-Jiang
   Gou, Jian-Jun
   Li, Guang-Ming
   Ma, Shu-Huan
   Zhang, Guo-Fan
   Xu, Jiang-Hai
   Lin, Wan-Bao
   Cui, Guang-Lin
   Zhang, Min-Min
   Li, Cheng
   Wang, Ze-Shuai
   Zhang, Zhi-Hao
   Liu, Zhang-Suo
TI Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in
   Patients With Coronavirus Disease 2019
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19);
   Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
   Survival rate; Viral shedding
ID OUTBREAK
AB Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.
C1 [Zeng, Qing-Lei; Yu, Zu-Jiang; Gou, Jian-Jun; Zhang, Zhi-Hao; Liu, Zhang-Suo] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Li, Guang-Ming; Ma, Shu-Huan; Zhang, Min-Min; Li, Cheng] Sixth Peoples Hosp Zhengzhou City, Dept Infect Dis, Zhengzhou, Peoples R China.
   [Zhang, Guo-Fan] Nanyang Med Coll, Affiliated Hosp 1, Dept Infect Dis, Nanyang City, Peoples R China.
   [Xu, Jiang-Hai] Fifth Peoples Hosp Anyang City, Dept Infect Dis, Anyang, Peoples R China.
   [Lin, Wan-Bao] Xinyang Cent Hosp, Dept Infect Dis, Xinyang City, Peoples R China.
   [Cui, Guang-Lin] Zhengzhou Univ, Dept Clin Lab, Affiliated Hosp 1, Zhengzhou, Peoples R China.
   [Wang, Ze-Shuai] Zhengzhou Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Zhengzhou, Peoples R China.
RP Liu, ZS (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Eastern Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM zhangsuoliu@zzu.edu.cn
RI Zeng, Qing-Lei/ABD-6706-2020; Zeng, Qing-Lei/ABG-3295-2020
OI Zeng, Qing-Lei/0000-0002-2094-4784; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970517]; Zhongyuan (Henan) Thousands
   Outstanding Talents Plan [ZYQR201912179]; Foundation for Distinguished
   Young Talents of Zhengzhou University Medical School [2020ZQLMS]; Key
   Scientific Research Project of Henan Higher Education Institutions of
   China [20B320028]
FX This study was supported by The National Natural Science Foundation of
   China (grant 81970517), Zhongyuan (Henan) Thousands Outstanding Talents
   Plan (grant ZYQR201912179), the Foundation for Distinguished Young
   Talents of Zhengzhou University Medical School (grant 2020ZQLMS), and
   the Key Scientific Research Project of Henan Higher Education
   Institutions of China (grant 20B320028).
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 94 WHO
   World Health Organization, 2020, 55 WHO
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 69
Z9 69
U1 3
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2020
VL 222
IS 1
BP 38
EP 43
DI 10.1093/infdis/jiaa228
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MD8AI
UT WOS:000544190800008
PM 32348485
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Cioffi, A
AF Cioffi, Andrea
TI Coronavirus Disease 2019: Is Everything Lawful to Create an Effective
   Vaccine?
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Cioffi, Andrea] Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy.
RP Cioffi, A (corresponding author), Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy.
EM an.cioffi19@gmail.com
OI Cioffi, Andrea/0000-0001-5163-9558
CR Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2020
VL 222
IS 1
BP 169
EP 169
DI 10.1093/infdis/jiaa216
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MD8AI
UT WOS:000544190800022
PM 32348489
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Eyal, N
   Lipsitch, M
   Smith, PG
AF Eyal, Nir
   Lipsitch, Marc
   Smith, Peter G.
TI Coronavirus Disease 2019: Is Everything Lawful to Create an Effective
   Vaccine? Response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Letter
C1 [Eyal, Nir] Rutgers State Univ, Ctr Populat Level Bioeth, Rm 400,112 Paterson St, New Brunswick, NJ 08901 USA.
   [Eyal, Nir] Rutgers State Univ, Dept Philosophy, New Brunswick, NJ USA.
   [Eyal, Nir] Rutgers Sch Publ Hlth, Dept Hlth Behav Soc & Policy, Piscataway, NJ USA.
   [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Ctr Communicable Dis Dynam, Boston, MA USA.
   [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
   [Smith, Peter G.] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England.
RP Eyal, N (corresponding author), Rutgers State Univ, Ctr Populat Level Bioeth, Rm 400,112 Paterson St, New Brunswick, NJ 08901 USA.
EM nir.eyal@rutgers.edu; nir.eyal@rutgers.edu; nir.eyal@rutgers.edu
RI smith, peter/ABH-9627-2020
OI smith, peter/0000-0003-0080-7560; Lipsitch, Marc/0000-0003-1504-9213
CR Lentine KL, 2012, ADV CHRONIC KIDNEY D, V19, P220, DOI 10.1053/j.ackd.2011.09.005
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
NR 2
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2020
VL 222
IS 1
BP 169
EP 170
DI 10.1093/infdis/jiaa217
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA MD8AI
UT WOS:000544190800023
PM 32348499
OA Bronze
DA 2021-01-01
ER

PT J
AU Rai, AT
   Frei, D
AF Rai, Ansaar T.
   Frei, Donald
TI A rationale and framework for seeking remote electronic or phone consent
   approval in endovascular stroke trials - special relevance in the
   COVID-19 environment and beyond
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE stroke; thrombectomy
ID EXPLICIT INFORMED-CONSENT; ELICITATION; THERAPY; FIELD
AB Background Enrollment in time-sensitive endovascular stroke trials can be challenging because of an inability to consent a debilitated patient. Often the legally authorized representative is not on site. Remote consent procedures in the US are inconsistent with the majority of sites shunning these approaches. The current pandemic with visitor restrictions highlights the need for enhancing these options. Methods Remote electronic and phone consent procedures specifically for endovascular stroke trials from two comprehensive stroke centers (CSC) are presented. An overview of the genesis of informed consent procedures in the US is also included. Results The two CSCs identified as Institution-1 and Institution-2 are large tertiary systems. Institution-1 is a non-profit university-affiliated academic medical center in rural geography. Institution-2 is an HCA hospital in an urban environment. Both serve patients through a spoke-and-hub network, have participated in multiple randomized endovascular stroke trials, and have successfully used these remote options for enrollment. A tiered approach is employed at both institutions with an emphasis on obtaining informed consent in person and resorting to alternatives methods when efforts to that are unsuccessful. A rationale for electronic and phone consent is included, followed by step-by-step illustration of the process at each institution. Conclusion Two examples of remote electronic or phone consent procedures from institutions in different geographic environments and organization structures demonstrate that these options can be successfully used for enrollment in stroke trials. The current pandemic highlights the need to enhance these approaches while maintaining appropriate adherence to ethical and legal frameworks.
C1 [Rai, Ansaar T.] West Virginia Univ, Rockefeller Neurosci Inst, Robert C Byrd Hlth Sci Ctr, Neuroradiol, Morgantown, WV 26505 USA.
   [Frei, Donald] Radiol Imaging Associates, Intervent Neuroradiol, Englewood, CO USA.
RP Rai, AT (corresponding author), West Virginia Univ, Rockefeller Neurosci Inst, Robert C Byrd Hlth Sci Ctr, Neuroradiol, Morgantown, WV 26505 USA.
EM ansaar.rai@gmail.com
OI Frei, Donald/0000-0002-7811-5030
CR [Anonymous], 1979, Fed Regist, V44, P23191
   [Anonymous], 1996, Fed Regist, V61, P51498
   [Anonymous], 2017, CANC DISCOVERY, V7, pOF12
   Aron AW, 2015, J STROKE CEREBROVASC, V24, P492, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.024
   Bobb MR, 2016, ACAD EMERG MED, V23, P759, DOI 10.1111/acem.12966
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Ernst AA, 2005, ACAD EMERG MED, V12, P1050, DOI 10.1197/j.aem.2005.06.015
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Haussen DC, 2020, J NEUROINTERV SURG, V12, P483, DOI 10.1136/neurintsurg-2019-015283
   Haussen DC, 2017, STROKE, V48, P3156, DOI 10.1161/STROKEAHA.117.018380
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Perrenoud Beatrice, 2015, JBI Database System Rev Implement Rep, V13, P82, DOI 10.11124/jbisrir-2015-2304
   Reeves JJ, 2020, J AM MED INFORM ASSN, V27, P853, DOI 10.1093/jamia/ocaa037
   Sanossian N, 2009, CEREBROVASC DIS, V28, P539, DOI 10.1159/000247596
   Saver JL, 2006, PREHOSP EMERG CARE, V10, P182, DOI 10.1080/10903120500541035
   Saver JL, 2014, INT J STROKE, V9, P220, DOI 10.1111/ijs.12242
NR 17
TC 3
Z9 3
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUL
PY 2020
VL 12
IS 7
BP 654
EP 657
DI 10.1136/neurintsurg-2020-016221
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA MD6JR
UT WOS:000544078400006
PM 32381522
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Foerch, C
   Friedauer, L
   Bauer, B
   Wolf, T
   Adam, EH
AF Foerch, Christian
   Friedauer, Lucie
   Bauer, Boris
   Wolf, Timo
   Adam, Elisabeth H.
TI Severe COVID-19 infection in a patient with multiple sclerosis treated
   with fi ngolimod
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE Critical care; Multiple sclerosis; Fingolimod; Viral infection; COVID-19
ID FINGOLIMOD
AB Background: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. Methods and results: We report a 57 -year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [re- ference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground -glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation im- proved, and the patient was transferred to a normal ward five days after admission. Conclusion: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients.
C1 [Foerch, Christian; Friedauer, Lucie] Goethe Univ, Univ Hosp, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.
   [Bauer, Boris] Radiol Sachsenhausen GmbH, Frankfurt, Germany.
   [Wolf, Timo] Goethe Univ, Dept Internal Med, Univ Hosp, Frankfurt, Germany.
   [Adam, Elisabeth H.] Goethe Univ, Univ Hosp, Dept Anesthesiol Intens Care & Pain Therapy, Frankfurt, Germany.
RP Foerch, C (corresponding author), Goethe Univ, Univ Hosp, Dept Neurol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.
EM foerch@em.uni-frankfurt.de
CR Arvin AM, 2015, JAMA NEUROL, V72, P31, DOI 10.1001/jamaneurol.2014.3065
   Guan WJ, 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494
   Natarajan V, 2013, AM J RESP CELL MOL, V49, P6, DOI 10.1165/rcmb.2012-0411TR
   Pinschewer DD, 2011, NEUROLOGY, V76, pS15, DOI 10.1212/WNL.0b013e31820d9596
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 7
TC 16
Z9 16
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD JUL
PY 2020
VL 42
AR 102180
DI 10.1016/j.msard.2020.102180
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA MD6FC
UT WOS:000544066300029
PM 32408155
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rejdak, K
   Grieb, P
AF Rejdak, Konrad
   Grieb, Pawel
TI Adamantanes might be protective from COVID-19 in patients with
   neurological diseases: multiple sclerosis, parkinsonism and cognitive
   impairment
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE Adamantanes; Amantadine; Memantine; Multiple sclerosis; PD; Cognitive
   impairment; SARS-CoV-2; COVID-19; Protection
AB Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find pro- tective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evi- dence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire -based study performed to assess severity of COVID-19 in patients suf- fering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.
C1 [Rejdak, Konrad] Med Univ Lublin, Dept Neurol, 8 Jaczewskiego Str, PL-20954 Lublin, Poland.
   [Grieb, Pawel] Polish Acad Sci, Dept Expt Pharmacol, Med Res Ctr, Warsaw, Poland.
RP Rejdak, K (corresponding author), Med Univ Lublin, Dept Neurol, 8 Jaczewskiego Str, PL-20954 Lublin, Poland.
EM k.rejdak@umlub.pl; pgrieb@imdik.pan
OI Rejdak, Konrad/0000-0002-7019-6681
CR Cimolai N, 2020, J MED VIROL, V92, P531, DOI 10.1002/jmv.25752
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Smieszek S., 2020, AMANTADINE DISRUPTS, DOI [10.1101/2020.04.05.026187, DOI 10.1101/2020.04.05.026187]
   Tipton PW, 2020, NEUROL NEUROCHIR POL, V54, P204, DOI 10.5603/PJNNS.a2020.0039
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
NR 5
TC 12
Z9 12
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD JUL
PY 2020
VL 42
AR 102163
DI 10.1016/j.msard.2020.102163
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA MD6FC
UT WOS:000544066300021
PM 32388458
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hensel, A
   Bauer, R
   Heinrich, M
   Spiegler, V
   Kayser, O
   Hempel, G
   Kraft, K
AF Hensel, Andreas
   Bauer, Rudolf
   Heinrich, Michael
   Spiegler, Verena
   Kayser, Oliver
   Hempel, Georg
   Kraft, Karin
TI Challenges at the Time of COVID-19: Opportunities and Innovations in
   Antivirals from Nature
SO PLANTA MEDICA
LA English
DT Article
DE COVID; Coronaviridae; Echinacea; Asteraceae; virus; tannins; lignans;
   anti-adhesion; immune system; phytotherapy
ID HEPATITIS-B; CHINESE MEDICINE; IN-VITRO; STANDARDIZED ECHINACEA;
   INFLUENZA-VIRUS; ESSENTIAL OILS; BICYCLOL; REPLICATION; EFFICACY;
   LIGNANS
AB As viral infections are an increasing threat to human societies, the need for new therapeutic strategies is becoming even more obvious. As no vaccine is available for COVID-19, the development of directly acting antiviral agents and preventive strategies have to be considered. Nature provides a huge reservoir of anti-infectious compounds, from which we can deduce innovative ideas, therapies, and products. Anti-adhesive natural products interact with the receptor-mediated recognition and early interaction of viruses with the host cells, leading to a reduced internalisation of the virus and reduced infections (e.g., procyanidin-B-2-di-O-gallate against influenza and herpes virus). Lignans like podophyllotoxin and bicyclol show strong antiviral activities against different viruses, and essential oils can directly interact with viral membranes and reduce the host's inflammatory responses (e.g., 1,8-cineol). Echinacea extracts stimulate the immune system, and bioavailable alkamides are key players by interacting with immunomodulating cannabinoid receptors. COVID-19 and SARS-CoV-2 infections have, in part, successfully been treated in China by preparations from traditional Chinese medicine and, while it is too early to draw conclusions, some promising data are available. There is huge potential, but intensified research is needed to develop evidence-based medicines with a clearly defined chemical profile. Intensified research and development, and therefore funding, are needed for exploiting nature's reservoir against viral infections. Combined action for basic research, chemistry, pharmacognosy, virology, and clinical studies, but also supply chain, sustainable sourcing, and economic aspects have to be considered. This review calls for intensified innovative science on natural products for the patients and for a healthier world!
C1 [Hensel, Andreas; Spiegler, Verena] Univ Munster, Inst Pharmaceut Biol & Phytochem, Corrensstr 48, D-48149 Munster, Germany.
   [Bauer, Rudolf] Karl Franzens Univ Graz, Inst Pharmaceut Sci, Graz, Austria.
   [Heinrich, Michael] UCL Sch Pharm, Pharmacognosy & Phytotherapy, London, England.
   [Kayser, Oliver] TU Dortmund Univ, Tech Biochem, Dortmund, Germany.
   [Hempel, Georg] Univ Munster, Inst Pharmaceut & Med Chem, Clin Pharm, Munster, Germany.
   [Kraft, Karin] Univ Med Rostock, Chair Complementary Med, Rostock, Germany.
RP Hensel, A (corresponding author), Univ Munster, Inst Pharmaceut Biol & Phytochem, Corrensstr 48, D-48149 Munster, Germany.
EM ahensel@uni-muenster.de
CR Ang L, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100407
   Bahr I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00245
   Bao XQ, 2008, CELL STRESS CHAPERON, V13, P347, DOI 10.1007/s12192-008-0034-4
   Chen M, 2006, J NAT PROD, V69, P1697, DOI 10.1021/np060239e
   Derksen A, 2016, J ETHNOPHARMACOL, V188, P144, DOI 10.1016/j.jep.2016.05.016
   Derksen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110089
   Eich E, 1996, J MED CHEM, V39, P86, DOI 10.1021/jm950387u
   Ezzat K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10192-2
   Gescher K, 2011, J ETHNOPHARMACOL, V134, P468, DOI 10.1016/j.jep.2010.12.038
   Gescher K, 2011, FITOTERAPIA, V82, P408, DOI 10.1016/j.fitote.2010.11.022
   Gescher K, 2011, ANTIVIR RES, V89, P9, DOI 10.1016/j.antiviral.2010.10.007
   Goel V, 2004, J CLIN PHARM THER, V29, P75, DOI 10.1111/j.1365-2710.2003.00542.x
   Gyurova IE, 2020, VIRAL IMMUNOL, V33, P334, DOI 10.1089/vim.2019.0129
   Hsu ACY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00743
   Huang MH, 2019, ACTA PHARMACOL SIN B, V9, P769, DOI 10.1016/j.apsb.2019.01.013
   Huang RL, 2003, PHYTOTHER RES, V17, P449, DOI 10.1002/ptr.1167
   Hudson JB, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/769896
   Hui DS, 2018, ANTIVIR RES, V150, P202, DOI 10.1016/j.antiviral.2018.01.002
   Kaplan I., 1942, NEW ORL MED SURG J, V94, P388
   Kim SJ, 2019, MOL MED REP, V19, P3330, DOI 10.3892/mmr.2019.9967
   Kuo YC, 2006, ANTIVIR RES, V70, P112, DOI 10.1016/j.antiviral.2006.01.011
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Li J, 2013, BIOORG MED CHEM LETT, V23, P2238, DOI 10.1016/j.bmcl.2013.01.046
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li Y, 2016, INFLAMMATION, V39, P1582, DOI 10.1007/s10753-016-0394-3
   Liu GT, 2009, MED CHEM, V5, P29, DOI 10.2174/157340609787049316
   Liu S, 2014, J ETHNOPHARMACOL, V155, P1061, DOI 10.1016/j.jep.2014.05.064
   Loizzo MR, 2008, CHEM BIODIVERS, V5, P461, DOI 10.1002/cbdv.200890045
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Maginnis MS, 2018, J MOL BIOL, V430, P2590, DOI 10.1016/j.jmb.2018.06.024
   Martinez-Lopez A, 2019, EBIOMEDICINE, V47, P269, DOI 10.1016/j.ebiom.2019.08.060
   Merino-Ramos T, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00376-17, 10.1128/aac.00376-17]
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Nussing S, 2018, FRONT MED-PRC, V12, P34, DOI 10.1007/s11684-017-0606-8
   Park S, 2018, J MED FOOD, V21, P261, DOI 10.1089/jmf.2017.4073
   Pleschka S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-197
   Raduner S, 2006, J BIOL CHEM, V281, P14192, DOI 10.1074/jbc.M601074200
   Reichling J, 2009, FORSCH KOMPLEMENTMED, V16, P79, DOI 10.1159/000207196
   Schmidt Stanislaw, 2018, Oncotarget, V9, P20891, DOI 10.18632/oncotarget.25058
   Schoop R, 2006, CLIN THER, V28, P174, DOI 10.1016/j.clinthera.2006.02.001
   SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215
   Sharma M, 2009, ANTIVIR RES, V83, P165, DOI 10.1016/j.antiviral.2009.04.009
   Soares S, 2019, J AGR FOOD CHEM, V67, P9579, DOI 10.1021/acs.jafc.9b02574
   Soto-Acosta R, 2014, ANTIVIR RES, V109, P132, DOI 10.1016/j.antiviral.2014.07.002
   Spelman K, 2006, ALTERN MED REV, V11, P128
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Wang K, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/7862782
   Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   WHO, 2019, WHO GLOB REP TRAD CO
   Wisskirchen K, 2014, TRENDS PHARMACOL SCI, V35, P470, DOI 10.1016/j.tips.2014.06.004
   Woelkart K, 2008, PLANTA MED, V74, P633, DOI 10.1055/s-2007-993766
   Woelkart K, 2007, PLANTA MED, V73, P615, DOI 10.1055/s-2007-981531
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zalesak F, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104284
   Zhang HJ, 2017, PHYTOCHEMISTRY, V136, P94, DOI 10.1016/j.phytochem.2017.01.005
NR 57
TC 6
Z9 6
U1 8
U2 8
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD JUL
PY 2020
VL 86
IS 10
BP 659
EP 664
DI 10.1055/a-1177-4396
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA ME4TN
UT WOS:000544649200001
PM 32434254
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Loinaz, C
   Marcacuzco, A
   Fernandez-Ruiz, M
   Caso, O
   Cambra, F
   San Juan, R
   Justo, I
   Calvo, J
   Garcia-Sesma, A
   Manrique, A
   Asin, MAPJ
   Folgueira, MD
   Aguado, JM
   Lumbreras, C
AF Loinaz, Carmelo
   Marcacuzco, Alberto
   Fernandez-Ruiz, Mario
   Caso, Oscar
   Cambra, Felix
   San Juan, Rafael
   Justo, Iago
   Calvo, Jorge
   Garcia-Sesma, Alvaro
   Manrique, Alejandro
   Perez-Jacoiste Asin, Maria Asuncion
   Dolores Folgueira, Maria
   Maria Aguado, Jose
   Lumbreras, Carlos
TI Varied clinical presentation and outcome of SARS-CoV-2 infection in
   liver transplant recipients: Initial experience at a single center in
   Madrid, Spain
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE COVID-19; immunosuppression; liver transplant; prognosis; SARS-CoV2
AB Background Which are the consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant (LT) recipients? Methods We attempted to address this question by reviewing our single-center experience during the first 2 months of the pandemics at a high incidence area. Results Nineteen adult patients (5 females) were diagnosed by May 5, 2020. Median age was 58 (range 55-72), and median follow-up since transplantation was 83 (range 20-183) months. Cough (84.2%), fever (57.9%), and dyspnea (47.4%) were the most common symptoms. Thirteen patients (68.4%) had pneumonia in x-ray/CT scan. Hydroxychloroquine was administered in 11 patients, associated with lopinavir/ritonavir and interferon beta in 2 cases each. Immunomodulatory therapy with tocilizumab was used in 2 patients. Immunosuppression (IS) was halted in one patient and modified in only other two due to potential drug interactions. Five (26.3%) patients were managed as outpatient. Two patients (10.5%) died, 10 (52.6%) were discharged home, and 2 (10.5%) were still hospitalized after a median follow-up of 41 days from the onset of symptoms. Baseline IS regimen remained unchanged in all surviving recipients, with good liver function. Conclusions Our preliminary experience shows a broad spectrum of disease severity in LT patients with COVID-19, with a favorable outcome in most of them without needing to modify baseline IS.
C1 [Loinaz, Carmelo; Marcacuzco, Alberto; Caso, Oscar; Cambra, Felix; Justo, Iago; Calvo, Jorge; Garcia-Sesma, Alvaro; Manrique, Alejandro] Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp, HBP & Transplant Surg Unit,Dept Gen Surg Digest T, Madrid, Spain.
   [Fernandez-Ruiz, Mario; San Juan, Rafael; Maria Aguado, Jose] Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp, Unit Infect Dis, Madrid, Spain.
   [Dolores Folgueira, Maria] Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp, Dept Microbiol, Madrid, Spain.
   [Perez-Jacoiste Asin, Maria Asuncion; Lumbreras, Carlos] Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp, Dept Internal Med, Madrid, Spain.
RP Loinaz, C (corresponding author), Hosp Univ 12 Octubre, Ctr Actividades Ambulatorias, HBP & Transplant Surg Unit, 6a Planta,Bloque A,Avda Cordoba S-N, Madrid 28041, Spain.
EM cloinaz@yahoo.es
OI Lumbreras, Carlos/0000-0003-4748-8288; LOINAZ,
   CARMELO/0000-0002-1873-0568; Fernandez-Ruiz, Mario/0000-0002-0315-8001
FU Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
   IIIInstituto de Salud Carlos IIISpanish Government [18/00073]
FX Spanish Ministry of Science and Innovation, Instituto de Salud Carlos
   III, Grant/Award Number: 18/00073
CR Agnes S, 2020, LIVER TRANSPL
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2017, AM J TRANSPLANT, V17, P856, DOI 10.1111/ajt.14208
   Gori A, 2020, AM J TRANSPLANT, V20, P1939, DOI 10.1111/ajt.15853
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halazun KJ, 2020, AM J TRANSPLANT, V20, P1785, DOI 10.1111/ajt.15888
   Hammami MB, 2020, AM J TRANSPLANT, V20, P2254, DOI 10.1111/ajt.15985
   Huang JF, 2020, AM J TRANSPLANT, V20, P1907, DOI 10.1111/ajt.15909
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Instituto de Salud Carlos III  Centro Nacional de Epidemiologia, INF SIT COVID 19 ESP
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Lagana SM, 2020, ARCH PATHOL LAB MED
   Li F, 2012, DRUG METAB DISPOS, V40, P18, DOI 10.1124/dmd.111.041400
   Liu B, 2020, AM J TRANSPLANT, V20, P1891, DOI 10.1111/ajt.15901
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Qin J, 2020, HEPATOLOGY
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2020
VL 22
IS 5
AR e13372
DI 10.1111/tid.13372
EA JUL 2020
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA OR6XJ
UT WOS:000544398900001
PM 32562561
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chen, S
   Yin, Q
   Shi, HB
   Du, DF
   Chang, S
   Ni, L
   Qiu, HF
   Chen, ZS
   Zhang, JX
   Zhang, WJ
AF Chen, Song
   Yin, Qin
   Shi, Huibo
   Du, Dunfeng
   Chang, Sheng
   Ni, Li
   Qiu, Haifang
   Chen, Zhishui
   Zhang, Jixian
   Zhang, Weijie
TI A familial cluster, including a kidney transplant recipient, of
   Coronavirus Disease 2019 (COVID-19) in Wuhan, China
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE COVID-19; kidney; novel coronavirus; pneumonia; transplantation;
   treatment
AB In December 2019, an outbreak of COVID-19 occurred in Wuhan, China, and spread to the whole of China and to multiple countries worldwide. Unlike SARS and MERS, where secondary transmission mostly occurred in hospital settings, COVID-19 transmission occurs in large numbers within families. Herein we report three cases of a familial cluster with one family member being a kidney transplant recipient. The initial clinical symptoms of COVID-19 in these three patients were the same, but their progression was different. Based on the severity of clinical symptoms, chest computer tomography findings and SARS-Cov-2 RNA test results, we admitted the husband to the respiratory intensive care unit (RICU) and used a treatment consisting of immunosuppressant reduction/cessation and low dose methylprednisolone-based therapy, and his wife to the respiratory isolation ward. In contrast, the son received in-home isolation and home-based care. All three family members made a full recovery.
C1 [Chen, Song; Shi, Huibo; Du, Dunfeng; Chang, Sheng; Chen, Zhishui; Zhang, Weijie] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Chen, Song; Shi, Huibo; Du, Dunfeng; Chang, Sheng; Chen, Zhishui; Zhang, Weijie] Chinese Acad Med Sci, Key Lab Organ Transplantat, Minist Educ, Natl Hlth Commiss, Wuhan, Peoples R China.
   [Yin, Qin; Qiu, Haifang; Zhang, Jixian] Hubei Prov Hosp Integrated Chinese & Western Med, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
   [Ni, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Div Cardiol, Tongji Med Coll,Dept Internal Med, Wuhan, Peoples R China.
   [Ni, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Tongji Med Coll, Wuhan, Peoples R China.
RP Zhang, WJ (corresponding author), Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.; Zhang, WJ (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, Minist Educ, Natl Hlth Commiss, Wuhan, Peoples R China.; Zhang, JX (corresponding author), Hubei Prov Hosp Integrated Chinese & Western Med, Dept Resp & Crit Care Med, Wuhan, Peoples R China.
EM wjzhangtj@126.com; wjzhangtj@126.com
FU Health and Family Planning Commission of Hubei Province [WJ2019Z006]
   Funding Source: Medline
CR Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   National Health Commission of the People's Republic of China, MARCH 21 DAIL BRIEF
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 6
TC 22
Z9 22
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1869
EP 1874
DI 10.1111/ajt.15903
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000543732500019
PM 32243690
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Huang, JF
   Lin, H
   Wu, YL
   Fang, YY
   Kumar, R
   Chen, GP
   Lin, S
AF Huang, Jiaofeng
   Lin, Heng
   Wu, Yinlian
   Fang, Yingying
   Kumar, Rahul
   Chen, Gongping
   Lin, Su
TI COVID-19 in posttransplant patients-report of 2 cases
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Coronavirus; COVID-19; transplantation
ID MYCOPHENOLATE-MOFETIL
AB Coronavirus Disease 2019 (COVID-19) has become a pandemic since March 2020. We describe here 2 cases of COVID-19 infection in a posttransplant setting. First one is a 59-year-old renal transplant recipient; the second is a 51-year-old allogeneic bone marrow transplant recipient. Both patients were on immunosuppressant therapy and had stable graft function before COVID-19 infection. After the diagnosis of COVID-19, immunosuppressive agents were discontinued and methylprednisolone with prophylactic antibiotics were initiated, however, the lung injury progressed. The T cells were extremely low in both patients after infection. Both patients died despite the maximal mechanical ventilatory support. Therefore, the prognosis of COVID-19 pneumonia following transplantation is not optimistic and remains guarded. Lower T cell count may be a surrogate for poor outcome.
C1 [Huang, Jiaofeng; Wu, Yinlian; Lin, Su] Fujian Med Univ, Affiliated Hosp 1, Dept Liver Res Ctr, Fuzhou, Peoples R China.
   [Lin, Heng] Fuzhou Pulm Hosp, Dept Oncol, Fuzhou, Peoples R China.
   [Fang, Yingying] Third Peoples Hosp Yichang City, Dept TB, Yichang, Peoples R China.
   [Kumar, Rahul] Changi Gen Hosp, Dept Gastroenterol & Hepatol, Singapore, Singapore.
   [Chen, Gongping] Fujian Med Univ, Affiliated Hosp 1, Dept Resp, Fuzhou, Peoples R China.
RP Lin, S (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Dept Liver Res Ctr, Fuzhou, Peoples R China.
EM sumer5129@fjmu.edu.cn
RI Kumar, Rahul/AAW-7405-2020
OI Kumar, Rahul/0000-0002-5092-4821; Lin, Heng/0000-0001-8812-9842
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Knight SR, 2008, TRANSPLANTATION, V85, P1675, DOI 10.1097/TP.0b013e3181744199
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2
   McMurray RW, 2002, AM J MED SCI, V323, P194, DOI 10.1097/00000441-200204000-00005
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   World Health Organization, 2020, COR DIS SIT REP
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 7
TC 47
Z9 48
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1879
EP 1881
DI 10.1111/ajt.15896
PG 3
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000543732500021
PM 32243697
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Romanelli, A
   Mascolo, S
AF Romanelli, Antonio
   Mascolo, Silvia
TI Immunosuppression drug-related and clinical manifestation of Coronavirus
   disease 2019: A therapeutical hypothesis
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Letter
DE calcineurin inhibitor; HIV; lung injury; severe acute respiratory
   syndrome coronavirus 2
ID COVID-19
C1 [Romanelli, Antonio] AOR San Carlo, San Carlo Hosp, Dept Anaesthesia & Intens Care, Potenza, Italy.
   [Mascolo, Silvia] AORN Colli, Cotugno Hosp, Dept Infect Dis, Naples, Italy.
RP Romanelli, A (corresponding author), AOR San Carlo, San Carlo Hosp, Dept Anaesthesia & Intens Care, Potenza, Italy.
EM antonioromanelli86@gmail.com
RI Romanelli, Antonio/A-4792-2017; Mascolo, Silvia/AAL-3975-2020
OI Romanelli, Antonio/0000-0002-6895-6485; Mascolo,
   Silvia/0000-0003-1696-1474
CR Abadja F, 2011, TRANSPLANTATION, V92, P396, DOI 10.1097/TP.0b013e3182247b5f
   Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 5
TC 23
Z9 23
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1947
EP 1948
DI 10.1111/ajt.15905
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000543732500039
PM 32243698
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aghamohammadi, M
   Alizargar, J
   Hsieh, NC
   Wu, SFV
AF Aghamohammadi, Mehdi
   Alizargar, Javad
   Hsieh, Nan-Chen
   Wu, Shu-Fang Vivienne
TI Prophylactic anticoagulant therapy for reducing the risk of stroke and
   other thrombotic events in COVID-19 patients
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Aghamohammadi, Mehdi] Zanjan Univ Med Sci, Sch Med, Vali e Asr Hosp, Dept Internal Med, Zanjan, Iran.
   [Alizargar, Javad] Natl Taipei Univ Nursing & Hlth Sci, Res Ctr Healthcare Ind Innovat, Taipei 112, Taiwan.
   [Hsieh, Nan-Chen] Natl Taipei Univ Nursing & Hlth Sci, Dept Informat Management, Taipei 112, Taiwan.
   [Wu, Shu-Fang Vivienne] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Coll Nursing, Taipei 112, Taiwan.
RP Alizargar, J (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Res Ctr Healthcare Ind Innovat, Taipei 112, Taiwan.
EM jaz.tmu@gmail.com
RI aghamohammadi, mehdi/ABI-3373-2020
OI Alizargar, Javad/0000-0003-2966-1315
CR Cheng SC, 2020, J FORMOS MED ASSOC, V119, P747, DOI 10.1016/j.jfma.2020.02.007
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Ministry of Health and Medical Education of Iran, FLOWCH DIAGN TREATM, P6
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Wang H-Y, 2020, THER ADV NEUROL DISO, P13
NR 5
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD JUL
PY 2020
VL 119
IS 7
BP 1230
EP 1231
DI 10.1016/j.jfma.2020.05.005
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA ME8HU
UT WOS:000544894700012
PM 32402522
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, DH
   Li, L
   Wu, X
   Zheng, DD
   Wang, JZ
   Yang, L
   Zheng, CS
AF Liu, Dehan
   Li, Lin
   Wu, Xin
   Zheng, Dandan
   Wang, Jiazheng
   Yang, Lian
   Zheng, Chuansheng
TI Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease
   (COVID-19) Pneumonia: A Preliminary Analysis
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE coronavirus disease; COVID-19; CT; ground-glass opacity (GGO);
   pregnantwomen with COVID-19 pneumonia; reverse transcription-polymerase
   chain reaction (RT-PCR)
ID RESPIRATORY SYNDROME; CT
AB OBJECTIVE. The purpose of this study was to describe the clinical manifestations and CT features of coronavirus disease (COVID-19) pneumonia in 15 pregnant women and to provide some initial evidence that can be used for guiding treatment of pregnant women with COVID-19 pneumonia.
   MATERIALS AND METHODS. We reviewed the clinical data and CT examinations of 15 consecutive pregnant women with COVID-19 pneumonia in our hospital from January 20, 2020, to February 10, 2020. A semiquantitative CT scoring system was used to estimate pulmonary involvement and the time course of changes on chest CT. Symptoms and laboratory results were analyzed, treatment experiences were summarized, and clinical outcomes were tracked.
   RESULTS. Eleven patients had successful delivery (10 cesarean deliveries and one vaginal delivery) during the study period, and four patients were still pregnant (three in the second trimester and one in the third trimester) at the end of the study period. No cases of neonatal asphyxia, neonatal death, stillbirth, or abortion were reported. The most common early finding on chest CT was ground-glass opacity (GGO). With disease progression, crazy paving pattern and consolidations were seen on Cr. The abnormalities showed absorptive changes at the end of the study period for all patients. The most common onset symptoms of COVID-19 pneumonia in pregnant women were fever (13/15 patients) and cough (9/15 patients). The most common abnormal laboratory finding was lymphocytopenia (12/15 patients). CT images obtained before and after delivery showed no signs of pneumonia aggravation after delivery. The four patients who were still pregnant at the end of the study period were not treated with antiviral drugs but had achieved good recovery.
   CONCLUSION. Pregnancy and childbirth did not aggravate the course of symptoms or CT features of COVID-19 pneumonia All the cases of COVID-19 pneumonia in the pregnant women in our study were the mild type. All the women in this study-some of whom did not receive antiviral drugs-achieved good recovery from COVID-19 pneumonia.
C1 [Liu, Dehan; Li, Lin; Wu, Xin; Yang, Lian; Zheng, Chuansheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Jiefang Ave 1277, Wuhan 430022, Peoples R China.
   [Liu, Dehan; Li, Lin; Wu, Xin; Yang, Lian; Zheng, Chuansheng] Hubei Prov Key Lab Mol Imaging, Wuhan, Peoples R China.
   [Zheng, Dandan; Wang, Jiazheng] Philips Healthcare, MSC Clin & Tech Solut, Beijing, Peoples R China.
RP Yang, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Jiefang Ave 1277, Wuhan 430022, Peoples R China.; Yang, L (corresponding author), Hubei Prov Key Lab Mol Imaging, Wuhan, Peoples R China.
EM yanglian@hust.edu.cn
OI WANG, JIAZHENG/0000-0003-1182-442X
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang YC, 2005, RADIOLOGY, V236, P1067, DOI 10.1148/radiol.2363040958
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Das KM, 2015, AM J ROENTGENOL, V204, P736, DOI 10.2214/AJR.14.13671
   Fang Y., 2020, RADIOLOGY
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Johkoh T, 1999, RADIOLOGY, V211, P155, DOI 10.1148/radiology.211.1.r99ap10155
   McCollough CH, 2007, RADIOGRAPHICS, V27, P909, DOI 10.1148/rg.274065149
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM PROT PN
   Pan F, 2019, J ALGORITHMS COMPUT, V13, DOI 10.1177/1748302619891611
   Pan Y, 2020, EUR RADIOL
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   World Health Organization website, 2020, CLIN MAN SEV AC RESP
   Wrapp D., 2020, SCIENCE
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 107
Z9 115
U1 22
U2 32
PU AMER ROENTGEN RAY SOC
PI LEESBURG
PA 44211 SLATESTONE CT, LEESBURG, VA USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUL
PY 2020
VL 215
IS 1
BP 127
EP 132
DI 10.2214/AJR.20.23072
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA MC5EX
UT WOS:000543311000035
PM 32186894
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Fadini, GP
   Morieri, ML
   Longato, E
   Bonora, BM
   Pinelli, S
   Selmin, E
   Voltan, G
   Falaguasta, D
   Tresso, S
   Costantini, G
   Sparacino, G
   Di Camillo, B
   Tramontan, L
   Cattelan, AM
   Vianello, A
   Fioretto, P
   Vettor, R
   Avogaro, A
AF Fadini, Gian Paolo
   Morieri, Mario Luca
   Longato, Enrico
   Bonora, Benedetta Maria
   Pinelli, Silvia
   Selmin, Elisa
   Voltan, Giacomo
   Falaguasta, Daniele
   Tresso, Silvia
   Costantini, Giorgia
   Sparacino, Giovanni
   Di Camillo, Barbara
   Tramontan, Lara
   Cattelan, Anna Maria
   Vianello, Andrea
   Fioretto, Paola
   Vettor, Roberto
   Avogaro, Angelo
TI Exposure to dipeptidyl-peptidase-4 inhibitors andCOVID-19 among people
   with type 2 diabetes: A case-control study
SO DIABETES OBESITY & METABOLISM
LA English
DT Article
DE antidiabetic drug; database research; DPP-4 inhibitor;
   pharmacoepidemiology
AB Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19.
C1 [Fadini, Gian Paolo; Morieri, Mario Luca; Bonora, Benedetta Maria; Pinelli, Silvia; Selmin, Elisa; Voltan, Giacomo; Falaguasta, Daniele; Tresso, Silvia; Costantini, Giorgia; Fioretto, Paola; Vettor, Roberto; Avogaro, Angelo] Univ Padua, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy.
   [Longato, Enrico; Sparacino, Giovanni; Di Camillo, Barbara] Univ Padua, Dept Informat Engn, Padua, Italy.
   [Tramontan, Lara] Arsenal IT, Treviso, Veneto Region, Italy.
   [Cattelan, Anna Maria] Univ Hosp Padova, Unit Infect Dis, Padua, Italy.
   [Vianello, Andrea] Univ Padua, Dept Cardiothorac Vasc Sci & Publ Hlth, Padua, Italy.
RP Fadini, GP (corresponding author), Univ Padua, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy.
EM gianpaolo.fadini@unipd.it
RI Morieri, Mario Luca/K-3238-2018
OI Morieri, Mario Luca/0000-0001-6864-0547; Voltan,
   Giacomo/0000-0002-3628-0492; Costantini, Giorgia/0000-0003-1022-9338;
   FADINI, GIAN PAOLO/0000-0002-6510-2097; Vianello,
   Andrea/0000-0002-8790-6029
FU Universita degli Studi di Padova
FX Universita degli Studi di Padova
CR Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004
   Fadini GP, 2020, J ENDOCRINOL INVEST, V43, P867, DOI 10.1007/s40618-020-01236-2
   Fadini GP, 2012, DIABETES OBES METAB, V14, P518, DOI 10.1111/j.1463-1326.2011.01550.x
   Fadini GP, 2011, VASC PHARMACOL, V55, P10, DOI 10.1016/j.vph.2011.05.001
   Goossen K, 2012, DIABETES OBES METAB, V14, P1061, DOI 10.1111/j.1463-1326.2012.01610.x
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Schott G, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0571-8
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Yuan Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01387-19
NR 14
TC 15
Z9 15
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8902
EI 1463-1326
J9 DIABETES OBES METAB
JI Diabetes Obes. Metab.
PD OCT
PY 2020
VL 22
IS 10
BP 1946
EP 1950
DI 10.1111/dom.14097
EA JUL 2020
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NK1QY
UT WOS:000544345600001
PM 32463179
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Fusi-Schmidhauser, T
   Preston, NJ
   Keller, N
   Gamondi, C
AF Fusi-Schmidhauser, Tanja
   Preston, Nancy J.
   Keller, Nikola
   Gamondi, Claudia
TI Conservative Management of COVID-19 Patients-Emergency Palliative Care
   in Action
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE COVID-19; palliative; symptoms; emergency
AB Context. The COVID-19 pandemic is spreading across the world. Many patients will not be suitable for mechanical ventilation owing to the underlying health conditions, and they will require a conservative approach including palliative care management for their important symptom burden.
   Objectives. To develop a management plan for patients who are not suitable for mechanical ventilation that is tailored to the stage their COVID-19 disease.
   Methods. Patients were identified as being stable, unstable, or at the end of life using the early warning parameters for COVID-19. Furthermore, a COVID-19especific assessment tool was developed locally, focusing on key symptoms observed in this population which assess dyspnoea, distress, and discomfort. This tool helped to guide the palliative care management as per patients' disease stage.
   Results. A management plan for all patients' (stable, unstable, end of life) was created and implemented in acute hospitals. Medication guidelines were based on the limitations in resources and availability of drugs. Staff members who were unfamiliar with palliative care required simple, clear instructions to follow including medications for key symptoms such as dyspnoea, distress, fever, and discomfort. Nursing interventions and family involvement were adapted as per patients' disease stage and infection control requirements.
   Conclusion. Palliative care during the COVID-19 pandemic needs to adapt to an emergency style of palliative care as patients can deteriorate rapidly and require quick decisions and clear treatment plans. These need to be easily followed up by generalist staff members caring for these patients. Furthermore, palliative care should be at the forefront to help make the best decisions, give care to families, and offer spiritual support. (C) 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Fusi-Schmidhauser, Tanja; Keller, Nikola; Gamondi, Claudia] Inst Oncol Southern Switzerland, Palliat & Support Care Clin, Bellinzona, Switzerland.
   [Fusi-Schmidhauser, Tanja; Keller, Nikola; Gamondi, Claudia] Ente Osped Cantonale, Bellinzona, Switzerland.
   [Preston, Nancy J.] Univ Lancaster, Int Observ End Life Care, Lancaster, England.
RP Preston, NJ (corresponding author), Inst Oncol Southern Switzerland, Lancaster LA1 4YG, England.; Preston, NJ (corresponding author), Ente Osped Cantonale, Lancaster LA1 4YG, England.
EM n.j.preston@lancaster.ac.uk
OI Preston, Nancy/0000-0003-2659-2342
CR Clemens KE, 2008, SUPPORT CARE CANCER, V17, P367
   Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3
   OLIVER D, 2019, BMJ-BRIT MED J, V367, DOI DOI 10.1136/BMJ.L5917
   Royal College of Physicians, 2017, NAT EARL WARN SCOR N
   Sun Q, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00650-2
   WHO, 2020, CLIN MAN SEV RESP IN
NR 6
TC 12
Z9 13
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL
PY 2020
VL 60
IS 1
BP E27
EP E30
DI 10.1016/j.jpainsymman.2020.03.030
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA MB4HZ
UT WOS:000542565600009
PM 32276101
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Hirsch, JS
   Ng, JH
   Ross, DW
   Sharma, P
   Shah, HH
   Barnett, RL
   Hazzan, AD
   Fishbane, S
   Jhaveri, KD
AF Hirsch, Jamie S.
   Ng, Jia H.
   Ross, Daniel W.
   Sharma, Purva
   Shah, Hitesh H.
   Barnett, Richard L.
   Hazzan, Azzour D.
   Fishbane, Steven
   Jhaveri, Kenar D.
CA Northwell COVID-19 Res Consortium
   Northwell Nephrology COVID-19 Res
TI Acute kidney injury in patients hospitalized with COVID-19
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE AKI; continuous RRT; COVID-19; dialysis; renal failure
AB The rate of acute kidney injury (AKI) associated with patients hospitalized with Covid-19, and associated outcomes are not well understood. This study describes the presentation, risk factors and outcomes of AKI in patients hospitalized with Covid-19. We reviewed the health records for all patients hospitalized with Covid-19 between March 1, and April 5, 2020, at 13 academic and community hospitals in metropolitan New York. Patients younger than 18 years of age, with end stage kidney disease or with a kidney transplant were excluded. AKI was de fined according to KDIGO criteria. Of 5,449 patients admitted with Covid-19, AKI developed in 1,993 (36.6%). The peak stages of AKI were stage 1 in 46.5%, stage 2 in 22.4% and stage 3 in 31.1%. Of these, 14.3% required renal replacement therapy (RRT). AKI was primarily seen in Covid-19 patients with respiratory failure, with 89.7% of patients on mechanical ventilation developing AKI compared to 21.7% of non -ventilated patients. 276/285 (96.8%) of patients requiring RRT were on ventilators. Of patients who required ventilation and developed AKI, 52.2% had the onset of AKI within 24 hours of intubation. Risk factors for AKI included older age, diabetes mellitus, cardiovascular disease, black race, hypertension and need for ventilation and vasopressor medications. Among patients with AKI, 694 died (35%), 519 (26%) were discharged and 780 (39%) were still hospitalized. AKI occurs frequently among patients with Covid-19 disease. It occurs early and in temporal association with respiratory failure and is associated with a poor prognosis.
C1 [Hirsch, Jamie S.; Ng, Jia H.; Ross, Daniel W.; Sharma, Purva; Shah, Hitesh H.; Barnett, Richard L.; Hazzan, Azzour D.; Fishbane, Steven; Jhaveri, Kenar D.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, Div Kidney Dis & Hypertens, Great Neck, NY USA.
   [Hirsch, Jamie S.] Feinstein Inst Med Res, Inst Hlth Innovat & Outcomes Res, Manhasset, NY USA.
   [Hirsch, Jamie S.] Northwell Hlth, Dept Informat Serv, N Hyde Park, NY USA.
RP Jhaveri, KD (corresponding author), 100 Community Dr, Great Neck, NY 11021 USA.
EM kjhaveri@northwell.edu
CR Abelson R, 2020, NY TIMES
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Benchimol EI, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001885, 10.1016/j.zefq.2016.07.010]
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   EQUATOR Network, REP STUD COND US OBS
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jalal K, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1429-4
   Johns Hopkins Coronavirus Resource Center, RAC DAT TRANSP STAT
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Levey AS, 2010, AM J KIDNEY DIS, V55, P622, DOI 10.1053/j.ajkd.2010.02.337
   New York State Department of Health, FAT
   NHS England, AC KIDN INJ AKI ALG
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization (WHO), 2020, NOV COR CHIN
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 125
Z9 127
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2020
VL 98
IS 1
BP 209
EP 218
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA MB9PK
UT WOS:000542929400027
PM 32416116
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Su, H
   Yang, M
   Wan, C
   Yi, LX
   Tang, F
   Zhu, HY
   Yi, F
   Yang, HC
   Fogo, AB
   Nie, X
   Zhang, C
AF Su, Hua
   Yang, Ming
   Wan, Cheng
   Yi, Li-Xia
   Tang, Fang
   Zhu, Hong-Yan
   Yi, Fan
   Yang, Hai-Chun
   Fogo, Agnes B.
   Nie, Xiu
   Zhang, Chun
TI Renal histopathological analysis of 26 postmortem fi ndings of patients
   with COVID-19 in China
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE KEYWORDS; acute kidney injury; COVID-19; proteinuria; renal pathology;
   SARS-CoV-2
ID CORONAVIRUS REPLICATION
AB Although the respiratory and immune systems are the major targets of Coronavirus Disease 2019 (COVID-19), acute kidney injury and proteinuria have also been observed. Currently, detailed pathologic examination of kidney damage in critically ill patients with COVID-19 has been lacking. To help de fine this we analyzed kidney abnormalities in 26 autopsies of patients with COVID-19 by light microscopy, ultrastructural observation and immunostaining. Patients were on average 69 years (19 male and 7 female) with respiratory failure associated with multiple organ dysfunction syndrome as the cause of death. Nine of the 26 showed clinical signs of kidney injury that included increased serum creatinine and/or new -onset proteinuria. By light microscopy, diffuse proximal tubule injury with the loss of brush border, non -isometric vacuolar degeneration, and even frank necrosis was observed. Occasional hemosiderin granules and pigmented casts were identi fied. There were prominent erythrocyte aggregates obstructing the lumen of capillaries without platelet or fibrinoid material. Evidence of vasculitis, interstitial in flammation or hemorrhage was absent. Electron microscopic examination showed clusters of coronavirus-like particles with distinctive spikes in the tubular epithelium and podocytes. Furthermore, the receptor of SARS-CoV-2, ACE2 was found to be upregulated in patients with COVID-19, and immunostaining with SARS-CoV nucleoprotein antibody was positive in tubules. In addition to the direct virulence of SARS-CoV-2, factors contributing to acute kidney injury included systemic hypoxia, abnormal coagulation, and possible drug or hyperventilation -relevant rhabdomyolysis. Thus, our studies provide direct evidence of the invasion of SARSCoV-2 into kidney tissue. These findings will greatly add to the current understanding of SARS-CoV-2 infection.
C1 [Su, Hua; Wan, Cheng; Yi, Li-Xia; Tang, Fang; Zhu, Hong-Yan; Zhang, Chun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nephrol, 1277 Jie Fang Ave, Wuhan 430022, Hubei, Peoples R China.
   [Yang, Ming; Nie, Xiu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 7277 Jie Fang Ave, Wuhan 430022, Peoples R China.
   [Yi, Fan] Shandong Univ, Sch Basic Med Sci, Dept Pharmacol, Key Lab Infect & Immun Shandong Prov, Jinan, Peoples R China.
   [Yang, Hai-Chun; Fogo, Agnes B.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.
RP Zhang, C (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nephrol, 1277 Jie Fang Ave, Wuhan 430022, Hubei, Peoples R China.; Nie, X (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 7277 Jie Fang Ave, Wuhan 430022, Peoples R China.
EM niexiuyishi@126.com; drzhangchun@hust.edu.cn
FU International (Regional) Cooperation and Exchange Project [81961138007];
   Key Special Project of Ministry of Science and Technology, China
   [2020YFC0845700, 2020YFC0845800]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81873602,
   81570671, 81770711, 81974096]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [2020kfyXGYJ101]; Program for HUST Academic Frontier Youth
   Team [2017QYTD20]; Hubei Provincial Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [2017CKB899]
FX This work was financially supported by the International (Regional)
   Cooperation and Exchange Project (81961138007), the Key Special Project
   of Ministry of Science and Technology, China (grants 2020YFC0845700 and
   2020YFC0845800), the National Natural Science Foundation of China
   (grants 81873602, 81570671, 81770711, and 81974096), the Fundamental
   Research Funds for the Central Universities (grant 2020kfyXGYJ101),
   Program for HUST Academic Frontier Youth Team (grant 2017QYTD20), and
   Hubei Provincial Natural Science Foundation of China (grant 2017CKB899).
CR Alsaad KO, 2018, HISTOPATHOLOGY, V72, P516, DOI 10.1111/his.13379
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Falk RJ, 1997, J AM SOC NEPHROL, V8, P314
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lee SH, 2019, AM J PHYSIOL-RENAL, V317, pE670, DOI 10.1152/ajprenal.00451.2018
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Mizuiri Sonoo, 2015, World J Nephrol, V4, P74, DOI 10.5527/wjn.v4.i1.74
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Tietavainen J, 2019, KIDNEY INT REP, V4, P1296, DOI 10.1016/j.ekir.2019.05.770
   WANG K, BIORXIV, DOI DOI 10.1101/2020.03.14
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 14
TC 251
Z9 253
U1 8
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2020
VL 98
IS 1
BP 219
EP 227
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA MB9PK
UT WOS:000542929400028
PM 32327202
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Lightner, AL
   Garcia-Olmo, D
AF Lightner, Amy L.
   Garcia-Olmo, Damian
TI Mesenchymal Stem Cell Therapy Can Transcend Perianal Crohn's Disease:
   How Colorectal Surgeons Can Help in the Coronavirus Disease 2019 Crisis
SO DISEASES OF THE COLON & RECTUM
LA English
DT Article
ID ADIPOSE-TISSUE; STROMAL CELLS; CLINICAL-TRIAL; FISTULA
C1 [Lightner, Amy L.] Cleveland Clin, Lerner Res Inst, Digest Dis & Surg Inst, Cleveland, OH 44195 USA.
   [Garcia-Olmo, Damian] Univ Autonoma Madrid, Fdn Jimenez Diaz Univ Hosp, Madrid, Spain.
RP Lightner, AL (corresponding author), Cleveland Clin, Digest Dis Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM Lightna@ccf.org
OI Garcia Olmo, Damian/0000-0002-9369-2338
CR Barrio L, 2014, CYTOTHERAPY, V16, P1692, DOI 10.1016/j.jcyt.2014.07.012
   Cho YB, 2015, STEM CELL TRANSL MED, V4, P532, DOI 10.5966/sctm.2014-0199
   Cho YB, 2013, CELL TRANSPLANT, V22, P279, DOI 10.3727/096368912X656045
   Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841
   de la Portilla F, 2013, INT J COLORECTAL DIS, V28, P313, DOI 10.1007/s00384-012-1581-9
   DelaRosa O, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/865601
   Dietz AB, 2017, GASTROENTEROLOGY, V153, P59, DOI 10.1053/j.gastro.2017.04.001
   Eggenhofer E, 2012, TRANSPLANT RES, V1, DOI 10.1186/2047-1440-1-12
   Franquesa M, 2015, STEM CELLS, V33, P880, DOI 10.1002/stem.1881
   Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-005-0052-6
   Garcia-Olmo D, 2009, DIS COLON RECTUM, V52, P79, DOI 10.1007/DCR.0b013e3181973487
   Gonzalez-Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534
   Herreros MD, 2012, DIS COLON RECTUM, V55, P762, DOI 10.1097/DCR.0b013e318255364a
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liang B, CLIN REMISSION CRITI
   Liu K, 2020, CHIN MED J
   Lombardo E, 2015, WORLD J STEM CELLS, V7, P368, DOI 10.4252/wjsc.v7.i2.368
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Matthay MA, 2017, STEM CELLS, V35, P316, DOI 10.1002/stem.2551
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Molendijk I, 2015, GASTROENTEROLOGY, V149, P918, DOI 10.1053/j.gastro.2015.06.014
   Panes J, 2016, LANCET, V388, P1281, DOI 10.1016/S0140-6736(16)31203-X
   Pedrazza L, 2014, INFLAMM RES, V63, P719, DOI 10.1007/s00011-014-0745-1
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shin S, 2013, INT J MED SCI, V10, P8, DOI 10.7150/ijms.5385
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   US Food and Drug Administration, FAST TRACK DES REQ
NR 30
TC 2
Z9 3
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0012-3706
EI 1530-0358
J9 DIS COLON RECTUM
JI Dis. Colon Rectum
PD JUL
PY 2020
VL 63
IS 7
BP 874
EP 878
DI 10.1097/DCR.0000000000001700
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA LY8XA
UT WOS:000540811600005
PM 32251143
DA 2021-01-01
ER

PT J
AU Pothuri, B
   Secord, AA
   Armstrong, DK
   Chan, J
   Fader, AN
   Huh, W
   Kesterson, J
   Liu, JF
   Moore, K
   Westin, SN
   Naumann, RW
AF Pothuri, Bhavana
   Secord, Angeles Alvarez
   Armstrong, Deborah K.
   Chan, John
   Fader, Amanda N.
   Huh, Warner
   Kesterson, Joshua
   Liu, Joyce F.
   Moore, Kathleen
   Westin, Shannon N.
   Naumann, R. Wendel
TI Anti-cancer therapy and clinical trial considerations for gynecologic
   oncology patients during the COVID-19 pandemic crisis
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
ID PHASE-III TRIAL; GESTATIONAL TROPHOBLASTIC TUMORS; RECURRENT ENDOMETRIAL
   CARCINOMA; GEMCITABINE PLUS DOCETAXEL; RELAPSED OVARIAN-CANCER;
   MAINTENANCE THERAPY; DOUBLE-BLIND; OPEN-LABEL; UTERINE LEIOMYOSARCOMA;
   EUROPEAN ORGANIZATION
AB Objectives. The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patientswith cancermay have factorswhich place themat high risk for COVID 19morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity.
   Methods. An expert panel convened to develop initial consensus guidelines regarding anti-neoplastic therapy during the COVID-19 pandemic with respect to gynecologic cancer care and clinical trials.
   Results. COVID-19 poses special risks to patients who are older, have medical co-morbidities, and cancer. In addition, this pandemicwill likely strain resources, making delivery of cancer care or conduct of clinical trials unpredictable. Recommendations are to limit visits and contact with health care facilities by using telemedicine when appropriate, and choosing regimenswhich require less frequent visits and which are less immunosuppressive. Deviations will occur in clinical trials as a result of limited resources, and it is important to understand regulatory obligations to trial sponsors as well as to the IRB to ensure that clinical trial and patient safety oversight are maintained.
   Conclusions. The ongoing crisiswill strain resources needed to deliver cancer care. When alterations to the delivery of care are mandated, efforts should be taken to minimize risks and maximize safety while approximating standard practice. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Pothuri, Bhavana] NYU, Perlmutter Canc Ctr, NYU Langone Hlth, Sch Med, New York, NY 10016 USA.
   [Secord, Angeles Alvarez] Duke Univ Hlth Syst, Duke Canc Inst, Durham, NC USA.
   [Armstrong, Deborah K.; Fader, Amanda N.] Johns Hopkins Sch Med, Dept Gynecol & Obstet, Kelly Gynecol Oncol Serv, Baltimore, MD USA.
   [Chan, John] Calif Pacific Palo Alto Med Fdn, Sutter Res Inst, San Francisco, CA USA.
   [Huh, Warner] Univ Alabama Birmingham, Birmingham, AL USA.
   [Kesterson, Joshua] Penn State Hershey Med Ctr, Hershey, PA USA.
   [Liu, Joyce F.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Moore, Kathleen] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA.
   [Westin, Shannon N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Naumann, R. Wendel] Atrium Hlth, Levine Canc Ctr, Charlotte, NC USA.
RP Pothuri, B (corresponding author), NYU, Langone Med Ctr, Dept Obstet & Gynecol, Perlmutter Canc Ctr, 240 East 38th St,19th Floor, New York, NY 10016 USA.
EM Bhavana.Pothuri@nyulangone.org
OI Pothuri, Bhavana/0000-0003-4578-2061
CR Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505
   BAGSHAWE KD, 1989, BRIT J OBSTET GYNAEC, V96, P795, DOI 10.1111/j.1471-0528.1989.tb03318.x
   BARTER JF, 1987, AM J OBSTET GYNECOL, V157, P1166, DOI 10.1016/S0002-9378(87)80285-5
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Bell J, 2006, GYNECOL ONCOL, V102, P432, DOI 10.1016/j.ygyno.2006.06.013
   Benson C, 2016, GYNECOL ONCOL, V142, P89, DOI 10.1016/j.ygyno.2016.03.024
   Bower M, 1997, J CLIN ONCOL, V15, P2636, DOI 10.1200/JCO.1997.15.7.2636
   Brown J, 2017, GYNECOL ONCOL, V144, P200, DOI 10.1016/j.ygyno.2016.08.330
   Brown J, 2014, INT J GYNECOL CANCER, V24, pS48, DOI 10.1097/IGC.0000000000000223
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   CARG, CARG PRED TOOL
   CDC, INT CLIN GUID MAN PA
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Chung HC, 2019, J CLIN ONCOL, V37, P1470, DOI 10.1200/JCO.18.01265
   Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140-6736(17)32440-6
   Coleman RL, 2017, LANCET ONCOL, V18, P779, DOI 10.1016/S1470-2045(17)30279-6
   Corzo C, 2018, J MINIM INVAS GYN, V25, P308, DOI 10.1016/j.jmig.2017.07.022
   deWit R, 1997, J CLIN ONCOL, V15, P1837, DOI 10.1200/JCO.1997.15.5.1837
   Diehl A, 2017, ONCOTARGET, V8, P114268, DOI 10.18632/oncotarget.23217
   EIFEL PJ, 1991, GYNECOL ONCOL, V41, P199, DOI 10.1016/0090-8258(91)90308-R
   Fader AN, 2017, GYNECOL ONCOL, V147, P85, DOI 10.1016/j.ygyno.2017.07.127
   Fan XX, 2019, J INVEST SURG, DOI 10.1080/08941939.2019.1698679
   Fiorica JV, 2004, GYNECOL ONCOL, V92, P10, DOI 10.1016/j.ygyno.2003.11.008
   Food and Drug Administration, FDA GUID COND CLIN T
   Garcia AA, 2008, J CLIN ONCOL, V26, P76, DOI 10.1200/JCO.2007.12.1939
   George S, 2014, CANCER-AM CANCER SOC, V120, P738, DOI 10.1002/cncr.28476
   Gershenson DM, 2017, J CLIN ONCOL, V35, P1103, DOI 10.1200/JCO.2016.71.0632
   Gonzalez-Martin A, 2019, NEW ENGL J MED, V381, P2391, DOI 10.1056/NEJMoa1910962
   Hensley ML, 2008, GYNECOL ONCOL, V109, P323, DOI 10.1016/j.ygyno.2008.02.024
   Hensley ML, 2017, GYNECOL ONCOL, V147, P1, DOI 10.1016/j.ygyno.2017.09.004
   Hensley ML, 2009, GYNECOL ONCOL, V112, P563, DOI 10.1016/j.ygyno.2008.11.027
   Hensley ML, 2002, J CLIN ONCOL, V20, P2824, DOI 10.1200/JCO.2002.11.050
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kamelle SA, 2004, GYNECOL ONCOL, V94, P249, DOI 10.1016/j.ygyno.2004.05.038
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6
   Kern WV, 2013, J CLIN ONCOL, V31, P1149, DOI 10.1200/JCO.2012.45.8109
   Kitagawa R, 2015, J CLIN ONCOL, V33, P2129, DOI 10.1200/JCO.2014.58.4391
   Lala M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3062
   Lanciano R, 2005, J CLIN ONCOL, V23, P8289, DOI 10.1200/JCO.2004.00.0497
   Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535
   Lentz SS, 1996, J CLIN ONCOL, V14, P357, DOI 10.1200/JCO.1996.14.2.357
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   LURAIN JR, 1995, AM J OBSTET GYNECOL, V172, P574, DOI 10.1016/0002-9378(95)90575-8
   Makker V, 2020, J CLIN ONCOL, V38
   Marina N, 2006, J CLIN ONCOL, V24, P2544, DOI 10.1200/JCO.2005.04.1251
   Miller D, 2012, GYNECOL ONCOL, V125, P771, DOI 10.1016/j.ygyno.2012.03.034
   Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310
   Moore DH, 1998, INT J RADIAT ONCOL, V42, P79, DOI 10.1016/S0360-3016(98)00193-X
   Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858
   Moore KN, 2019, LANCET ONCOL, V20, P636, DOI 10.1016/S1470-2045(19)30029-4
   Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   National Comprehensive Cancer Network (NCCN), UT NEOPL VERS 1 2020
   National Institutes of Health, GUID NIH FUND CLIN T
   Newlands ES, 2000, J CLIN ONCOL, V18, P854, DOI 10.1200/JCO.2000.18.4.854
   NIH, GUID MEM NRG LEAD UP
   Osborne RJ, 2016, OBSTET GYNECOL, V128, P535, DOI 10.1097/AOG.0000000000001554
   Osborne RJ, 2011, J CLIN ONCOL, V29, P825, DOI 10.1200/JCO.2010.30.4386
   Otsuki A, 2015, INT J GYNECOL CANCER, V25, P92, DOI 10.1097/IGC.0000000000000302
   Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153
   Pal N, 2018, OBSTET GYNECOL, V131, P109, DOI 10.1097/AOG.0000000000002390
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Petit-Moneger A, 2016, J GERIATR ONCOL, V7, P99, DOI 10.1016/j.jgo.2016.01.004
   Pujade-Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470-2045(17)30469-2
   Ray-Coquard I, 2019, NEW ENGL J MED, V381, P2416, DOI 10.1056/NEJMoa1911361
   Rolston KVI, 2010, SUPPORT CARE CANCER, V18, P89, DOI 10.1007/s00520-009-0634-2
   Rose PG, 2006, GYNECOL ONCOL, V102, P236, DOI 10.1016/j.ygyno.2005.12.003
   Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502
   Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8
   Salani R, 2017, GYNECOL ONCOL, V146, P3, DOI 10.1016/j.ygyno.2017.03.022
   Seddon B, 2017, LANCET ONCOL, V18, P1397, DOI 10.1016/S1470-2045(17)30622-8
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Slomovitz BM, 2015, J CLIN ONCOL, V33, P930, DOI 10.1200/JCO.2014.58.3401
   Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748
   Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736
   Vergote I, 2010, GYNECOL ONCOL, V119, P1, DOI 10.1016/j.ygyno.2010.08.011
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Williams SD, 2004, GYNECOL ONCOL, V95, P496, DOI 10.1016/j.ygyno.2004.07.044
   Yu J, 2020, JAMA ONCOL
   Zhang L., 2020, ANN ONCOL
   2020, MMWR MORBID MORTAL W, V69, P343
NR 87
TC 9
Z9 9
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUL
PY 2020
VL 158
IS 1
BP 16
EP 24
DI 10.1016/j.ygyno.2020.04.694
PG 9
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA MC0NH
UT WOS:000542994200044
PM 32386911
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sharma, D
   Rasmussen, M
   Han, RQ
   Whalin, MK
   Davis, M
   Kofke, WA
   Venkatraghvan, L
   Raychev, R
   Fraser, JF
AF Sharma, Deepak
   Rasmussen, Mads
   Han, Ruquan
   Whalin, Matthew K.
   Davis, Melinda
   Kofke, W. Andrew
   Venkatraghvan, Lakshmikumar
   Raychev, Radoslav
   Fraser, Justin F.
TI Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke
   During COVID-19 Pandemic: Consensus Statement From Society for
   Neuroscience in Anesthesiology & Critical Care (SNACC) Endorsed by
   Society of Vascular & Interventional Neurology (SVIN), Society of
   NeuroInterventional Surgery (SNIS), Neurocritical Care Society (NCS),
   European Society of Minimally Invasive Neurological Therapy (ESMINT) and
   American Association of Neurological Surgeons (AANS) and Congress of
   Neurological Surgeons (CNS) Cerebrovascular Section
SO JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY
LA English
DT Article
DE conscious sedation; COVID-19 pandemic; general anesthesia; monitored
   anesthesia care; patient-to-professional transmission; stroke;
   thrombectomy
ID EXHALED AIR DISPERSION; GENERAL-ANESTHESIA; CONSCIOUS SEDATION; OXYGEN
   DELIVERY; OUTCOMES; THROMBECTOMY; VENTILATION; SAFETY; IMPACT
AB The pandemic of coronavirus disease 2019 (COVID-19) has unique implications for the anesthetic management of endovascular therapy for acute ischemic stroke. The Society for Neuroscience in Anesthesiology and Critical Care appointed a task force to provide timely, consensus-based expert recommendations using available evidence for the safe and effective anesthetic management of endovascular therapy for acute ischemic stroke during the COVID-19 pandemic. The goal of this consensus statement is to provide recommendations for anesthetic management considering the following (and they are): (1) optimal neurological outcomes for patients; (2) minimizing the risk for health care professionals, and (3) facilitating judicious use of resources while accounting for existing variability in care. It provides a framework for selecting the optimal anesthetic technique (general anesthesia or monitored anesthesia care) for a given patient and offers suggestions for best practices for anesthesia care during the pandemic. Institutions and health care providers are encouraged to adapt these recommendations to best suit local needs, considering existing practice standards and resource availability to ensure safety of patients and providers.
C1 [Sharma, Deepak] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
   [Sharma, Deepak] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Rasmussen, Mads] Aarhus Univ Hosp, Dept Anesthesia, Aarhus, Denmark.
   [Han, Ruquan] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Whalin, Matthew K.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA.
   [Davis, Melinda] Univ Calgary, Cumming Sch Med, Dept Anesthesiol Pain & Perioperat Med, Calgary, AB, Canada.
   [Venkatraghvan, Lakshmikumar] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada.
   [Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
   [Kofke, W. Andrew] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Raychev, Radoslav] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Neurol Surg, Lexington, KY USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Radiol, Lexington, KY USA.
   [Fraser, Justin F.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
RP Sharma, D (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.; Sharma, D (corresponding author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
EM dsharma@uw.edu
OI Rasmussen, Mads/0000-0002-0416-6767
CR Abou-Chebl A, 2015, STROKE, V46, P2142, DOI 10.1161/STROKEAHA.115.008761
   Anesthesia Patient Safety Foundation, 2020, FAQ AN MACH US PROT
   ASA Committee on Occupational Health, COR RES AN
   Atkinson J, 2009, NATURAL VENTILATION FOR INFECTION CONTROL IN HEALTH-CARE SETTINGS, P1
   Berkhemer OA, 2016, NEUROLOGY, V87, P656, DOI 10.1212/WNL.0000000000002976
   Bonow RO, 2020, JAMA CARDIOL
   Bowdle A, 2020, ANAESTHESIA, V75, P1133, DOI 10.1111/anae.15009
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P525, DOI 10.3174/ajnr.A4159
   Campbell BCV, 2018, LANCET NEUROL, V17, P47, DOI 10.1016/S1474-4422(17)30407-6
   Campbell D, 2019, J NEUROSURG ANESTHES
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Chen X, 2020, ANESTHESIOLOGY
   Cole EC, 1998, AM J INFECT CONTROL, V26, P453, DOI 10.1016/S0196-6553(98)70046-X
   Davis MJ, 2012, ANESTHESIOLOGY, V116, P396, DOI 10.1097/ALN.0b013e318242a5d2
   Del Rio C, 2020, JAMA
   Greenland JR, 2020, ANESTHESIOLOGY
   Guo T, 2020, JAMA CARDIOL
   Henden PL, 2017, STROKE, V48, P1601, DOI 10.1161/STROKEAHA.117.016554
   Hui DS, 2007, CHEST, V132, P540, DOI 10.1378/chest.07-0636
   Hui DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050845
   Hui DS, 2011, RESPIROLOGY, V16, P1005, DOI 10.1111/j.1440-1843.2011.01995.x
   Johns Hopkins Center for Systems Science and Engineering, 2020, COR COVID 19 GLOB CA
   Jumaa MA, 2010, STROKE, V41, P1180, DOI 10.1161/STROKEAHA.109.574194
   Kharasch ED, 2020, ANESTHESIOLOGY
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y, 2020, SSRN ELECT J
   Luo M, 2020, ANESTHESIOLOGY
   Meng L, 2020, ANESTHESIOLOGY
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Rasmussen M, 2017, ACTA ANAESTH SCAND, V61, P885, DOI 10.1111/aas.12934
   Rasmussen M, 2018, STROKE, V49, pE20, DOI 10.1161/STROKEAHA.117.019573
   Rusy DA, 2019, J NEUROSURG ANESTHES
   Schonenberger S, 2019, JAMA-J AM MED ASSOC, V322, P1283, DOI 10.1001/jama.2019.11455
   Schonenberger S, 2016, JAMA-J AM MED ASSOC, V316, P1986, DOI 10.1001/jama.2016.16623
   Shi S, 2020, JAMA CARDIOL
   Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474
   Sivasankar C, 2016, J NEUROINTERV SURG, V8, P1101, DOI 10.1136/neurintsurg-2015-011998
   Talke PO, 2014, J NEUROSURG ANESTH, V26, P95, DOI 10.1097/ANA.0000000000000042
   Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022
   Tang JW, 2009, J R SOC INTERFACE, V6, pS727, DOI 10.1098/rsif.2009.0295.focus
   van den Berg LA, 2015, STROKE, V46, P1257, DOI 10.1161/STROKEAHA.115.008699
   van Doremalen N, 2020, N ENGL J MED
   Wu Z, 2020, JAMA
   Yu IT, 2007, CLIN INFECT DIS, V44, P1017, DOI 10.1086/512819
   Zhang Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011754
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuo M-Z, 2020, CHIN MED SCI J, DOI DOI 10.24920/
NR 48
TC 16
Z9 16
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0898-4921
EI 1537-1921
J9 J NEUROSURG ANESTH
JI J. Neurosurg. Anesthesiol.
PD JUL
PY 2020
VL 32
IS 3
BP 193
EP 201
DI 10.1097/ANA.0000000000000688
PG 9
WC Anesthesiology; Clinical Neurology; Surgery
SC Anesthesiology; Neurosciences & Neurology; Surgery
GA MC3TE
UT WOS:000543212900004
PM 32282614
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Flexman, AM
   Abcejo, AS
   Avitsian, R
   De Sloovere, V
   Highton, D
   Juul, N
   Li, S
   Meng, LZ
   Paisansathan, C
   Rath, GP
   Rozet, I
AF Flexman, Alana M.
   Abcejo, Arnoley S.
   Avitsian, Rafi
   De Sloovere, Veerle
   Highton, David
   Juul, Niels
   Li, Shu
   Meng, Lingzhong
   Paisansathan, Chanannait
   Rath, Girija P.
   Rozet, Irene
TI Neuroanesthesia Practice During the COVID-19 Pandemic: Recommendations
   From Society for Neuroscience in Anesthesiology and Critical Care
   (SNACC)
SO JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY
LA English
DT Article
DE neuroanesthesia; COVID-19; pandemic
ID ACUTE RESPIRATORY SYNDROME; ELECTROCONVULSIVE-THERAPY; AWAKE CRANIOTOMY;
   MANAGEMENT; SURVIVORS; RESECTION; DEATH; LIFE
AB The pandemic of coronavirus disease 2019 (COVID-19) has several implications relevant to neuroanesthesiologists, including neurological manifestations of the disease, impact of anesthesia provision for specific neurosurgical procedures and electroconvulsive therapy, and health care provider wellness. The Society for Neuroscience in Anesthesiology and Critical Care appointed a task force to provide timely, consensus-based expert guidance for neuroanesthesiologists during the COVID-19 pandemic. The aim of this document is to provide a focused overview of COVID-19 disease relevant to neuroanesthesia practice. This consensus statement provides information on the neurological manifestations of COVID-19, advice for neuroanesthesia clinical practice during emergent neurosurgery, interventional radiology (excluding endovascular treatment of acute ischemic stroke), transnasal neurosurgery, awake craniotomy and electroconvulsive therapy, as well as information about health care provider wellness. Institutions and health care providers are encouraged to adapt these recommendations to best suit local needs, considering existing practice standards and resource availability to ensure safety of patients and providers.
C1 [Flexman, Alana M.] Univ British Columbia, Vancouver Gen Hosp, Dept Anesthesiol & Perioperat Care, Vancouver, BC, Canada.
   [Abcejo, Arnoley S.] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, NY USA.
   [Avitsian, Rafi] Cleveland Clin, Dept Gen Anesthesiol, Cleveland, OH 44106 USA.
   [De Sloovere, Veerle] Univ Hosp Leuven, Dept Anesthesiol, Leuven, Belgium.
   [Highton, David] Univ Queensland, Princess Alexandra Hosp, Woolloongabba, Qld, Australia.
   [Juul, Niels] Aarhus Univ Hosp, Dept Anesthesia, Aarhus, Denmark.
   [Li, Shu] Capital Med Univ, Beijing Tian Tan Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Meng, Lingzhong] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
   [Paisansathan, Chanannait] Univ Illinois, Dept Anesthesiol, Chicago, IL USA.
   [Rath, Girija P.] All India Inst Med Sci AIIMS, Neurosci Ctr, Dept Neuroanesthesiol & Crit Care, New Delhi, India.
   [Rozet, Irene] Univ Washington, Dept Anesthesiol & Pain Management, Seattle, WA 98195 USA.
RP Flexman, AM (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Dept Anesthesiol & Perioperat Care, Vancouver, BC, Canada.
EM alana.flexman@vch.ca
RI Meng, Lingzhong/ABG-8186-2020; Highton, David/K-9544-2017
OI Meng, Lingzhong/0000-0002-5168-5084; Highton, David/0000-0002-4608-4081
CR Adams JG, 2020, JAMA
   American Association of Neurological Surgeons, 2020, COVID 19 NEUR
   American College of Surgeons, 2020, COVID 19 EL CAS TRIA
   American Medical Association, 2020, CAR OUR CAR COVID 19
   American Society of Anesthesiologists, 2020, US PERS PROT EQ AN P
   [Anonymous], 2020, GUID ENT SURG COVID
   [Anonymous], 2020, CHIN CLIN GUID COVID
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Blumberger DM, 2017, ACTA PSYCHIAT SCAND, V136, P583, DOI 10.1111/acps.12815
   Bourouiba L., 2020, JAMA
   Chen X, 2020, ANESTHESIOLOGY
   Christensen STJ, 2019, PSYCHIAT RES, V271, P239, DOI 10.1016/j.psychres.2018.11.035
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Dexter F, 2020, CAN J ANESTH, V67, P1104, DOI 10.1007/s12630-020-01655-y
   Draper H, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-192
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Givi B, 2020, JAMA OTOLARYNGOL HEA
   Gomez-Arnau J, 2018, GEN HOSP PSYCHIAT, V50, P54, DOI 10.1016/j.genhosppsych.2017.09.003
   Granados JAT, 2009, P NATL ACAD SCI USA, V106, P17290, DOI 10.1073/pnas.0904491106
   Greenland JR, 2020, ANESTHESIOLOGY
   Guan WJ, 2020, EUR RESP J
   Hansen E, 2013, ACTA NEUROCHIR, V155, P1417, DOI 10.1007/s00701-013-1801-2
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1106
   Jelovac A, 2013, NEUROPSYCHOPHARMACOL, V38, P2467, DOI 10.1038/npp.2013.149
   Kwek SK, 2006, J PSYCHOSOM RES, V60, P513, DOI 10.1016/j.jpsychores.2005.08.020
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lan L, 2020, JAMA
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Li SY, 2016, J CLIN ANESTH, V34, P440, DOI 10.1016/j.jclinane.2016.05.034
   Li Y, 2020, ACUTE CEREBROVASCULA
   Li YC, 2020, J MED VIROL, V92, P707, DOI 10.1002/jmv.25824
   Malm H, 2008, AM J BIOETHICS, V8, P4, DOI 10.1080/15265160802317974
   Mao L, 2020, NEUROLOGICAL MANIFES, DOI DOI 10.1101/2020.02.22.20026500V1
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   Meng L, 2020, ANESTHESIOLOGY
   Meng LZ, 2017, CAN J ANESTH, V64, P517, DOI 10.1007/s12630-017-0840-1
   Meng LZ, 2015, J NEUROSURG ANESTH, V27, P310, DOI 10.1097/ANA.0000000000000179
   Meng LZ, 2015, J CLIN ANESTH, V27, P256, DOI 10.1016/j.jclinane.2015.01.004
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   New South Wales Government, 2020, COVID 19 INT GUID EL
   Orser BA, 2020, CAN J ANESTH, V67, P1066, DOI 10.1007/s12630-020-01657-w
   Patel ZM, 2020, NEUROSURGERY
   Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V101623
   Rozet I, 2018, CURR ANESTHESIOL REP, V8, P290, DOI [10.1007/s40140-018-0283-4, DOI 10.1007/S40140-018-0283-4]
   Sanghani SN, 2018, CURR OPIN PSYCHIATR, V31, P213, DOI 10.1097/YCO.0000000000000418
   Sharma D, 2020, J NEUROSURG ANESTHES
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   Slade EP, 2017, JAMA PSYCHIAT, V74, P798, DOI 10.1001/jamapsychiatry.2017.1378
   Tor PC, 2020, J ECT, DOI 10:1097/YCT0000000000000690.
   Wang W., 2020, JAMA
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   WHO, COR DIS COVID 19 PAN
   Xie XZ, 2020, EUR RADIOL, V30, P4347, DOI 10.1007/s00330-020-06821-w
   Yao Bai Y, 2020, JAMA
   Zhang Z, 2020, J INFECT
   Zhao W, 2020, AJR AM J ROENTGENOL
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zoia C, 2020, ACTA NEUROCHIR, V162, P1221, DOI 10.1007/s00701-020-04305-w
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zuo M-Z, 2020, CHIN MED SCI J, DOI DOI 10.24920/
NR 64
TC 17
Z9 18
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0898-4921
EI 1537-1921
J9 J NEUROSURG ANESTH
JI J. Neurosurg. Anesthesiol.
PD JUL
PY 2020
VL 32
IS 3
BP 202
EP 209
DI 10.1097/ANA.0000000000000691
PG 8
WC Anesthesiology; Clinical Neurology; Surgery
SC Anesthesiology; Neurosciences & Neurology; Surgery
GA MC3TE
UT WOS:000543212900005
PM 32301764
OA Green Published
DA 2021-01-01
ER

PT J
AU Gianfrancesco, M
   Hyrich, KL
   Al-Adely, S
   Carmona, L
   Danila, MI
   Gossec, L
   Izadi, Z
   Jacobsohn, L
   Katz, P
   Lawson-Tovey, S
   Mateus, EF
   Rush, S
   Schmajuk, G
   Simard, J
   Strangfeld, A
   Trupin, L
   Wysham, KD
   Bhana, S
   Costello, W
   Grainger, R
   Hausmann, JS
   Liew, JW
   Sirotich, E
   Sufka, P
   Wallace, ZS
   Yazdany, J
   Machado, PM
   Robinson, PC
AF Gianfrancesco, Milena
   Hyrich, Kimme L.
   Al-Adely, Sarah
   Carmona, Loreto
   Danila, Maria, I
   Gossec, Laure
   Izadi, Zara
   Jacobsohn, Lindsay
   Katz, Patricia
   Lawson-Tovey, Saskia
   Mateus, Elsa F.
   Rush, Stephanie
   Schmajuk, Gabriela
   Simard, Julia
   Strangfeld, Anja
   Trupin, Laura
   Wysham, Katherine D.
   Bhana, Suleman
   Costello, Wendy
   Grainger, Rebecca
   Hausmann, Jonathan S.
   Liew, Jean W.
   Sirotich, Emily
   Sufka, Paul
   Wallace, Zachary S.
   Yazdany, Jinoos
   Machado, Pedro M.
   Robinson, Philip C.
CA COVID-19 Global Rheumatology Allia
TI Characteristics associated with hospitalisation for COVID-19 in people
   with rheumatic disease: data from the COVID-19 Global Rheumatology
   Alliance physician-reported registry
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID CLINICAL-COURSE; HYDROXYCHLOROQUINE; ARTHRITIS; SERIES
AB Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.
   Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.
   Results A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose >= 10 mg/ day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug ( NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.
   Conclusions We found that glucocorticoid exposure of >= 10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.
C1 [Robinson, Philip C.] Univ Queensland, Fac Med, Herston, Qld 4029, Australia.
   [Gianfrancesco, Milena; Izadi, Zara; Jacobsohn, Lindsay; Katz, Patricia; Rush, Stephanie; Schmajuk, Gabriela; Trupin, Laura; Yazdany, Jinoos] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA 94143 USA.
   [Hyrich, Kimme L.; Al-Adely, Sarah] Univ Manchester, Ctr Epidemiol Versus Arthrit, Manchester, Lancs, England.
   [Hyrich, Kimme L.; Al-Adely, Sarah; Lawson-Tovey, Saskia] Manchester Univ NHS Fdn Trust, Natl Inst Hlth Res Manchester Biomed Res Ctr, Manchester, Lancs, England.
   [Carmona, Loreto] Inst Salud Musculoesquelet, Madrid, Spain.
   [Danila, Maria, I] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Gossec, Laure] Sorbonne Univ, INSERM, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France.
   [Gossec, Laure] Hop Univ Pitie Salpetriere, AP HP, Rheumatol Dept, Paris, France.
   [Lawson-Tovey, Saskia] Univ Manchester, Ctr Genet & Genom Versus Arthrit, Manchester, Lancs, England.
   [Mateus, Elsa F.] Portuguese League Rheumat Dis LPCDR, Lisbon, Portugal.
   [Simard, Julia] Stanford Sch Med, Div Epidemiol, Hlth Res & Policy, Stanford, CA 94305 USA.
   [Simard, Julia] Stanford Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
   [Strangfeld, Anja] Deutsch Rheuma Forschungszentrum Berlin, Forschungsbereich Epidemiol, Berlin, Germany.
   [Wysham, Katherine D.; Liew, Jean W.] Univ Washington, Seattle, WA 98195 USA.
   [Bhana, Suleman] Crystal Run Healthcare, Middletown, NY USA.
   [Costello, Wendy] Irish Childrens Arthrit Network iCAN, Tipperary, Ireland.
   [Grainger, Rebecca] Univ Otago, Dept Med, Wellington, New Zealand.
   [Hausmann, Jonathan S.] Boston Childrens Hosp, Boston, MA USA.
   [Hausmann, Jonathan S.; Wallace, Zachary S.] Harvard Med Sch, Boston, MA 02115 USA.
   [Sirotich, Emily] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Sirotich, Emily] Canadian Arthrit Patient Alliance, Toronto, ON, Canada.
   [Sufka, Paul] Healthpartners, St Paul, MN USA.
   [Wallace, Zachary S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Machado, Pedro M.] Univ Coll London UCL, Ctr Rheumatol, London, England.
   [Machado, Pedro M.] Univ Coll London UCL, Dept Neuromuscular Dis, London, England.
   [Machado, Pedro M.] Univ Coll London Hosp UCLH, Natl Inst Hlth Res NIHR, Biomed Res Ctr BRC, London, England.
   [Machado, Pedro M.] London North West Univ Healthcare NHS Trust, Northwick Pk Hosp, Dept Rheumatol, London, England.
   [Robinson, Philip C.] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Herston, Qld, Australia.
RP Robinson, PC (corresponding author), Univ Queensland, Fac Med, Herston, Qld 4029, Australia.
EM philip.robinson@uq.edu.au
RI Wysham, Katherine/AAN-6309-2020; Sparks, Jeffrey/Z-1574-2018; De la
   Torre, Natalia/ABH-4368-2020; Campos, Jose/H-1531-2012; Machado,
   Pedro/C-8621-2013; Robinson, Philip/B-8319-2011
OI Wysham, Katherine/0000-0001-8707-7649; Sparks,
   Jeffrey/0000-0002-5556-4618; Campos, Jose/0000-0003-1744-0910; Machado,
   Pedro/0000-0002-8411-7972; de la Torre Rubio,
   Natalia/0000-0002-0458-4539; Lawson-Tovey, Saskia/0000-0002-8611-162X;
   Sirotich, Emily/0000-0002-7087-8543; Robinson,
   Philip/0000-0002-3156-3418; Gossec, Laure/0000-0002-4528-310X
FU NIAMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [K01 AR075085, P30 AR070155, K24
   AR074534] Funding Source: Medline
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Chen J, 2020, J ZHEJIANG U
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Coletto LA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13415
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Favalli Ennio Giulio, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217615, 10.1136/annrheumdis-2020-217787]
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Gautret P, 2020, TRAVEL MED INFECT DI
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gianfrancesco M, 2020, LANCET RHEUMATOL
   Goyal P, N ENGL J MED OVERSEA
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang C, 2020, LANCET
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim AHJ, 2020, ANN INTERN MED
   Konig MF, 2020, ANN RHEUM DIS, V79, P1386, DOI 10.1136/annrheumdis-2020-217690
   Landewe RBM, 2020, ANN RHEUM DIS, V79, P851, DOI [10.1136/annrheumdis-2020-216999, 10.1136/annrheumdis-2020-217877]
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Liu Y, 2020, ENERGY STORAGE MATER, V26, P1, DOI 10.1016/j.ensm.2019.12.019
   Luo P, 2020, J MED VIROL, V8
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Mahevas M, 2020, NO EVIDENCE CLIN EFF
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robinson PC, NAT REV RHEUMATOL, V39
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Strangfeld A, 2011, ANN RHEUM DIS, V70, P1914, DOI 10.1136/ard.2011.151043
   Wallace ZS, 2020, RHEUMATOLOGY, V59, P1204, DOI 10.1093/rheumatology/keaa191
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 37
TC 81
Z9 80
U1 3
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUL
PY 2020
VL 79
IS 7
BP 859
EP 866
DI 10.1136/annrheumdis-2020-217871
PG 8
WC Rheumatology
SC Rheumatology
GA MB6TM
UT WOS:000542734200014
PM 32606045
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sanchez-Piedra, C
   Diaz-Torne, C
   Manero, J
   Pego-Reigosa, JM
   Rua-Figueroa, I
   Gonzalez-Gay, MA
   Gomez-Reino, J
   Alvaro-Gracia, JM
AF Sanchez-Piedra, Carlos
   Diaz-Torne, Cesar
   Manero, Javier
   Pego-Reigosa, Jose M.
   Rua-Figueroa, Inigo
   Gonzalez-Gay, Miguel A.
   Gomez-Reino, Juan
   Alvaro-Gracia, Jose M.
CA BIOBADASER Study Grp
TI Clinical features and outcomes of COVID-19 in patients with rheumatic
   diseases treated with biological and synthetic targeted therapies
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Letter
C1 [Sanchez-Piedra, Carlos] Soc Espanola Reumatol, Res Unit, Madrid, Spain.
   [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Rheumatol, Barcelona, Spain.
   [Manero, Javier] Hosp Univ Miguel Servet, Rheumatol, Zaragoza, Aragon, Spain.
   [Pego-Reigosa, Jose M.] Complejo Hosp Vigo Hosp Xeral, Rheumatol, Vigo, Galicia, Spain.
   [Rua-Figueroa, Inigo] Hosp Univ Insulsar Gran Canaria Doctor Negrin, Rheumatol, Las Palmas Gran Canaria, Spain.
   [Gonzalez-Gay, Miguel A.] Hosp Univ Marques de Valdecilla Serv Med Interna, Rheumatol, Santander, Cantabria, Spain.
   [Gomez-Reino, Juan] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Galicia, Spain.
   [Alvaro-Gracia, Jose M.] Hosp Gen Univ Gregorio Maranon, Rheumatol, Madrid 28007, Spain.
RP Alvaro-Gracia, JM (corresponding author), Hosp Gen Univ Gregorio Maranon, Rheumatol, Madrid 28007, Spain.
EM jalvarogracia@gmail.com
RI Gomez-Reino, Juan/ABI-2853-2020; Gonzalez-Gay, Miguel/B-2306-2008
OI Cesar, Diaz-Torne/0000-0001-6275-7699; Gonzalez-Gay,
   Miguel/0000-0002-7924-7406
CR (CCAES) CdCdAyES, 2020, ENF POR NUEV COR COV
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Gianfrancesco MA, 2020, LANCET RHEUMATOLOGY
   Haberman R, 2020, N ENGL J MED OVERSEA
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Neurath MF, 2020, GUT, V382
NR 6
TC 6
Z9 6
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUL
PY 2020
VL 79
IS 7
DI 10.1136/annrheumdis-2020-217948
PG 3
WC Rheumatology
SC Rheumatology
GA MB6TM
UT WOS:000542734200032
PM 32503857
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cai, QX
   Chen, FJ
   Wang, T
   Luo, F
   Liu, XH
   Wu, QK
   He, Q
   Wang, ZQ
   Liu, YX
   Liu, L
   Chen, J
   Xu, L
AF Cai, Qingxian
   Chen, Fengjuan
   Wang, Tao
   Luo, Fang
   Liu, Xiaohui
   Wu, Qikai
   He, Qing
   Wang, Zhaoqin
   Liu, Yingxia
   Liu, Lei
   Chen, Jun
   Xu, Lin
TI Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen,
   China
SO DIABETES CARE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; BODY-MASS INDEX; FOLLOW-UP; ADIPOSITY;
   MORTALITY; OUTCOMES
AB OBJECTIVE Patients with obesity are at increased risk of exacerbations from viral respiratory infections. However, the association of obesity with the severity of coronavirus disease 2019 (COVID-19) is unclear. We examined this association using data from the only referral hospital in Shenzhen, China. RESEARCH DESIGN AND METHODS A total of 383 consecutively hospitalized patients with COVID-19 admitted from 11 January 2020 to 16 February 2020 and followed until 26 March 2020 at the Third People's Hospital of Shenzhen were included. Underweight was defined as a BMI <18.5 kg/m(2), normal weight as 18.5-23.9 kg/m(2), overweight as 24.0-27.9 kg/m(2), and obesity as >= 28 kg/m(2). RESULTS Of the 383 patients, 53.1% were normal weight, 4.2% were underweight, 32.0% were overweight, and 10.7% were obese at admission. Obese patients tended to have symptoms of cough (P= 0.03) and fever (P= 0.06) compared with patients who were not obese. Compared with normal weight patients, those who were overweight had 1.84-fold odds of developing severe COVID-19 (odds ratio [OR] 1.84, 95% CI 0.99-3.43,P= 0.05), while those who were obese were at 3.40-fold odds of developing severe disease (OR 3.40, 95% CI 1.40-2.86,P= 0.007), after adjusting for age, sex, epidemiological characteristics, days from disease onset to hospitalization, presence of hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease, liver disease, and cancer, and drug used for treatment. Additionally, after similar adjustment, men who were obese versus those who were normal weight were at increased odds of developing severe COVID-19 (OR 5.66, 95% CI 1.80-17.75,P= 0.003). CONCLUSIONS In this study, obese patients had increased odds of progressing to severe COVID-19. As the severe acute respiratory syndrome coronavirus 2 may continue to spread worldwide, clinicians should pay close attention to obese patients, who should be carefully managed with prompt and aggressive treatment.
C1 [Cai, Qingxian; Luo, Fang; Liu, Xiaohui; Wu, Qikai; He, Qing; Wang, Zhaoqin; Liu, Yingxia; Liu, Lei; Chen, Jun] Southern Univ Sci & Technol, Affiliated Hosp 2, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China.
   [Chen, Fengjuan] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Guangdong, Peoples R China.
   [Wang, Tao; Xu, Lin] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China.
RP Chen, J (corresponding author), Southern Univ Sci & Technol, Affiliated Hosp 2, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China.; Xu, L (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China.
EM drchenjun@163.com; xulin27@mail.sysu.edu.cn
FU Sanming Project of Medicine in Shenzhen [SZSM201412003, SZSM201512005];
   Bill & Melinda Gates FoundationBill & Melinda Gates Foundation; Shenzhen
   Science and Technology Research and Development Project
   [202002073000001]
FX This work was supported by the Sanming Project of Medicine in Shenzhen
   (SZSM201412003, SZSM201512005) and Bill & Melinda Gates Foundation,
   Shenzhen Science and Technology Research and Development Project
   (202002073000001).
CR Akinnusi ME, 2008, CRIT CARE MED, V36, P151, DOI 10.1097/01.CCM.0000297885.60037.6E
   Bahammam AS, 2012, RESPIROLOGY, V17, P759, DOI 10.1111/j.1440-1843.2011.02099.x
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baik I, 2000, ARCH INTERN MED, V160, P3082, DOI 10.1001/archinte.160.20.3082
   Barba C, 2004, LANCET, V363, P157, DOI 10.1016/s0140-6736(03)15268-3
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309
   Chen L, 2020, BRIT J OPHTHALMOL, V104, P748, DOI 10.1136/bjophthalmol-2020-316304
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dixon AE, 2018, EXPERT REV RESP MED, V12, P755, DOI 10.1080/17476348.2018.1506331
   Duarte AG, 2007, CRIT CARE MED, V35, P732, DOI 10.1097/01.CCM.0000256842.39767.41
   Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW
   Ho YC, 2009, J INFECTION, V58, P439, DOI 10.1016/j.jinf.2009.03.007
   Huang T, 2020, INFECT CONT HOSP EP, V41, P978, DOI 10.1017/ice.2020.119
   Jiang CQ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58633-z
   Lin DC, 2020, SCI CHINA LIFE SCI, V63, P606, DOI 10.1007/s11427-020-1668-5
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Morgan OW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009694
   Morris AE, 2007, CHEST, V131, P342, DOI 10.1378/chest.06-1709
   National Health Commission of the People's Republic of China, 2020, HDB PREV TREATM PNEU
   Poirier P, 2009, CIRCULATION, V120, P86, DOI 10.1161/CIRCULATIONAHA.109.192575
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Wang YR, 2020, J INFECT DIS, V221, P1770, DOI 10.1093/infdis/jiaa119
   World Health Organization, CLIN MAN SEV AC RESP
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu L, 2017, DIABETIC MED, V34, P1400, DOI 10.1111/dme.13378
   Xu L, 2017, DIABETOLOGIA, V60, P2210, DOI 10.1007/s00125-017-4396-y
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yuan J, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa398, DOI 10.1093/CID/CIAA398]
   Zammit C, 2010, INT J GEN MED, V3, P335, DOI 10.2147/IJGM.S11926
   Zhao JF, 2020, ELECTRON J DIFFER EQ
NR 39
TC 69
Z9 70
U1 3
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2020
VL 43
IS 7
BP 1392
EP 1398
DI 10.2337/dc20-0576
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MC8MR
UT WOS:000543534300010
PM 32409502
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rao, ST
   Lau, A
   So, HC
AF Rao, Shitao
   Lau, Alexandria
   So, Hon-Cheong
TI Exploring Diseases/Traits and Blood Proteins Causally Related to
   Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian
   Randomization Analysis Highlights Tentative Relevance of
   Diabetes-Related Traits
SO DIABETES CARE
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; RISK-FACTORS; METAANALYSIS; INFECTION;
   PLEIOTROPY; PHENOTYPE; FRAMEWORK; ZINC
AB OBJECTIVE COVID-19 has become a major public health problem. There is good evidence that ACE2 is a receptor for SARS-CoV-2, and high expression ofACE2may increase susceptibility to infection. We aimed to explore risk factors affecting susceptibility to infection and prioritize drug repositioning candidates, based on Mendelian randomization (MR) studies onACE2lung expression. RESEARCH DESIGN AND METHODS We conducted a phenome-wide MR study to prioritize diseases/traits and blood proteins causally linked toACE2lung expression in GTEx. We also explored drug candidates whose targets overlapped with the top-ranked proteins in MR, as these drugs may alterACE2expression and may be clinically relevant. RESULTS The most consistent finding was tentative evidence of an association between diabetes-related traits and increasedACE2expression. Based on one of the largest genome-wide association studies on type 2 diabetes mellitus (T2DM) to date (N= 898,130), T2DM was causally linked to raisedACE2expression (P= 2.91E-03; MR-IVW). Significant associations (at nominal level;P< 0.05) withACE2expression were observed across multiple diabetes data sets and analytic methods for T1DM, T2DM, and related traits including early start of insulin. Other diseases/traits having nominal significant associations with increased expression included inflammatory bowel disease, (estrogen receptor-positive) breast cancer, lung cancer, asthma, smoking, and elevated alanine aminotransferase. We also identified drugs that may target the top-ranked proteins in MR, such as fostamatinib and zinc. CONCLUSIONS Our analysis suggested that diabetes and related traits may increaseACE2expression, which may influence susceptibility to infection (or more severe infection). However, none of these findings withstood rigorous multiple testing corrections (at false discovery rate <0.05). Proteome-wide MR analyses might help uncover mechanisms underlyingACE2expression and guide drug repositioning. Further studies are required to verify our findings.
C1 [Rao, Shitao; Lau, Alexandria; So, Hon-Cheong] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [So, Hon-Cheong] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.
   [So, Hon-Cheong] Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Shatin, Hong Kong, Peoples R China.
   [So, Hon-Cheong] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
   [So, Hon-Cheong] Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong, Peoples R China.
   [So, Hon-Cheong] Chinese Univ Hong Kong, Margaret KL Cheung Res Ctr Management Parkinsonis, Shatin, Hong Kong, Peoples R China.
   [So, Hon-Cheong] Chinese Univ Hong Kong, Brain & Mind Inst, Shatin, Hong Kong, Peoples R China.
RP So, HC (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.; So, HC (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.; So, HC (corresponding author), Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Shatin, Hong Kong, Peoples R China.; So, HC (corresponding author), Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.; So, HC (corresponding author), Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong, Peoples R China.; So, HC (corresponding author), Chinese Univ Hong Kong, Margaret KL Cheung Res Ctr Management Parkinsonis, Shatin, Hong Kong, Peoples R China.; So, HC (corresponding author), Chinese Univ Hong Kong, Brain & Mind Inst, Shatin, Hong Kong, Peoples R China.
EM hcso@cuhk.edu.hk
RI RAO, Shitao/J-1068-2019
OI RAO, Shitao/0000-0002-3604-4684; So, Hon-Cheong/0000-0002-7102-833X
FU Lo Kwee Seong Biomedical Research Fund; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81971706]; Chinese University of Hong Kong Direct GrantChinese
   University of Hong Kong
FX This study was partially supported by the Lo Kwee Seong Biomedical
   Research Fund, a National Natural Science Foundation of China grant
   (81971706), and a Chinese University of Hong Kong Direct Grant.
CR Alqahtani FY, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818002923
   [Anonymous], 2017, DETAILS CONSIDERATIO
   [Anonymous], 2019, ANAL METHODS
   [Anonymous], 2020, RECOMBINANT HUMAN AN
   Banik GR, 2016, VIROL SIN, V31, P81, DOI 10.1007/s12250-015-3679-z
   Bellera C, 2018, STAT METHODS MED RES, V27, P1271, DOI 10.1177/0962280216660127
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bowden J, 2019, RES SYNTH METHODS, V10, P486, DOI 10.1002/jrsm.1346
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S, 2018, EUR J EPIDEMIOL, V33, P947, DOI 10.1007/s10654-018-0424-6
   Burgess S, 2017, EUR J EPIDEMIOL, V32, P377, DOI 10.1007/s10654-017-0255-x
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Colonna L, 2010, J IMMUNOL, V185, P1532, DOI 10.4049/jimmunol.1000983
   Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Ferrario CM, 2010, AM J PHYSIOL-RENAL, V298, pF1297, DOI 10.1152/ajprenal.00110.2010
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Folkersen L, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006706
   Gamazon ER, 2018, NAT GENET, V50, P956, DOI 10.1038/s41588-018-0154-4
   Gordon DE, 2020, SARS COV 2 HUMAN PRO
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Hemani G, 2018, HUM MOL GENET, V27, pR195, DOI 10.1093/hmg/ddy163
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Igase M, 2005, AM J PHYSIOL-HEART C, V289, pH1013, DOI 10.1152/ajpheart.00068.2005
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kang YQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00897
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Langdon RJ, 2019, CANCER EPIDEM BIOMAR, V28, P2070, DOI 10.1158/1055-9965.EPI-19-0036
   Li G, 2020, HYPERTENS RES, V43, P588, DOI 10.1038/s41440-020-0433-1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li X, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002937
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   LINARES A, 2014, FASEB J S, V28
   Lloyd-Jones LR, 2018, GENETICS, V208, P1397, DOI 10.1534/genetics.117.300360
   Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6
   Mahajan A, 2014, NAT GENET, V46, P234, DOI 10.1038/ng.2897
   Meng XR, 2019, INT J EPIDEMIOL, V48, P1425, DOI 10.1093/ije/dyz182
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Pendergrass SA, 2011, GENET EPIDEMIOL, V35, P410, DOI 10.1002/gepi.20589
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rolf MG, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.175
   Roth DE, 2010, INT J EPIDEMIOL, V39, P795, DOI 10.1093/ije/dyp391
   Schmidt AF, 2019, GENETIC DRUG TARGET
   Scott JG, 2015, J AM STAT ASSOC, V110, P459, DOI 10.1080/01621459.2014.990973
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Smith GD, 2007, PLOS MED, V4, P1985, DOI 10.1371/journal.pmed.0040352
   Sommerstein R, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016509
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Thomas NJ, 2018, LANCET DIABETES ENDO, V6, P122, DOI 10.1016/S2213-8587(17)30362-5
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Vuille-Dit-Bille RN, 2015, AMINO ACIDS, V47, P693, DOI 10.1007/s00726-014-1889-6
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wrapp D, 2020, CRYO EM STRUCTURE 20
   Zhao Q, 2018, ARXIV180109652
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02317-2
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 68
TC 18
Z9 18
U1 2
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2020
VL 43
IS 7
BP 1416
EP 1426
DI 10.2337/dc20-0643
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MC8MR
UT WOS:000543534300013
PM 32430459
OA Bronze
DA 2021-01-01
ER

PT J
AU Ceriello, A
   Standl, E
   Catrinoiu, D
   Itzhak, B
   Lalic, NM
   Rahelic, D
   Schnell, O
   Skrha, J
   Valensi, P
AF Ceriello, Antonio
   Standl, Eberhard
   Catrinoiu, Doina
   Itzhak, Baruch
   Lalic, Nebojsa M.
   Rahelic, Dario
   Schnell, Oliver
   Skrha, Jan
   Valensi, Paul
CA Diabet and Cardiovascular Dis
TI Issues of Cardiovascular Risk Management in People With Diabetes in the
   COVID-19 Era
SO DIABETES CARE
LA English
DT Article
ID HYPERGLYCEMIA; INSULIN; ACTIVATION; MELLITUS; GLUCOSE; STRESS
AB People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage induced or aggravated by the disease process of COVID-19 and its implications for the cardiovascular risk management of people with diabetes, especially taking into account potential interactions with mechanisms of cellular intrusion of SARS-CoV-2. Severe infection with SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure. They may evolve along with multiorgan failure directly due to SARS-CoV-2-infected endothelial cells and resulting endotheliitis. This complex pathology may bear challenges for the use of most diabetes medications in terms of emerging contraindications that need close monitoring of all people with diabetes diagnosed with SARS-CoV-2 infection. Whenever possible, continuous glucose monitoring should be implemented to ensure stable metabolic compensation. Patients in the intensive care unit requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. Although not only ACE inhibitors and angiotensin 2 receptor blockers but also SGLT2 inhibitors, GLP-1 receptor agonists, pioglitazone, and probably insulin seem to increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, no evidence presently exists that shows this might be harmful in terms of acquiring or worsening COVID-19. In conclusion, COVID-19 and related cardio-renal-pulmonary damage can profoundly affect cardiovascular risk management of people with diabetes.
C1 [Ceriello, Antonio] IRCCS MultiMed, Milan, Italy.
   [Standl, Eberhard; Schnell, Oliver] Forschergrp Diabet eV, Munich Helmholtz Ctr, Munich, Germany.
   [Catrinoiu, Doina] Ovidius Univ Constanta, Fac Med, Clin Ctr Diabet Nutr & Metab Dis, Constanta, Romania.
   [Itzhak, Baruch] Clalit Hlth Serv, Haifa, Israel.
   [Itzhak, Baruch] Technion Fac Med, Haifa, Israel.
   [Lalic, Nebojsa M.] Univ Belgrade, Fac Med, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia.
   [Rahelic, Dario] Vuk Vrhovac Univ, Merkur Univ Hosp, Clin Diabet Endocrinol & Metab Dis, Zagreb, Croatia.
   [Rahelic, Dario] Univ Zagreb, Sch Med, Zagreb, Croatia.
   [Rahelic, Dario] Univ Osijek, Sch Med, Osijek, Croatia.
   [Skrha, Jan] Charles Univ Prague, Fac Med 1, Dept Internal Med 3, Prague, Czech Republic.
   [Valensi, Paul] Paris 13 Univ, Sorbonne Paris Cite, Jean Verdier Hosp,CRNH IdF, AP HP,Dept Endocrinol,Diabetol,Nutr,CINFO, Bondy, France.
RP Ceriello, A (corresponding author), IRCCS MultiMed, Milan, Italy.
EM antonio.ceriello@hotmail.it
OI Lalic, Nebojsa/0000-0002-8082-6560
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Amin EF, 2020, FUND CLIN PHARMACOL, V34, P548, DOI 10.1111/fcp.12548
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Bornstein SR, 2020, NAT REV ENDOCRINOL, V16, P297, DOI 10.1038/s41574-020-0353-9
   Buse JB, 2020, DIABETES CARE, V43, P487, DOI 10.2337/dci19-0066
   CERIELLO A, 1994, DIABETES, V43, P430, DOI 10.2337/diabetes.43.3.430
   CERIELLO A, 1993, DIABETOLOGIA, V36, P1119, DOI 10.1007/BF00401055
   Ceriello A, 2008, DIABETES-METAB RES, V24, P14, DOI 10.1002/dmrr.790
   Ceriello A, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108151
   Ceriello A, 2019, LANCET DIABETES ENDO, V7, P221, DOI 10.1016/S2213-8587(18)30136-0
   Ceriello A, 2012, DIABETES, V61, P2993, DOI 10.2337/db12-0224
   Ceriello A, 2009, J AM COLL CARDIOL, V53, pS9, DOI 10.1016/j.jacc.2008.09.054
   Chao WC, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-0635-3
   Chase JG, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2110-1
   Cherney DZI, 2014, KIDNEY INT, V86, P1057, DOI 10.1038/ki.2014.246
   Cosentino F, 2020, EUR HEART J, V41, P255, DOI 10.1093/eurheartj/ehz486
   Dandona P, 2009, J AM COLL CARDIOL, V53, pS14, DOI 10.1016/j.jacc.2008.10.038
   Dreher M, 2020, DTSCH ARZTEBL, V117, P271, DOI DOI 10.3238/arztebl.2020.0271
   Duffy EY, 2020, CIRCULATION, V141, P1943, DOI 10.1161/CIRCULATIONAHA.120.047194
   Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5
   European Medicine Agency, EMA ADV CONT US MED
   Fadini GP, 2020, J ENDOCRINOL INVEST, V43, P867, DOI 10.1007/s40618-020-01236-2
   Gentile S, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108137
   Giorda CB, 2011, EUR J CARDIOV PREV R, V18, P415, DOI 10.1177/1741826710389402
   Gong J, 2020, CLIN INFECT DIS, V71, P833, DOI 10.1093/cid/ciaa443
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Iacobellis G, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108185
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Iqbal A, 2019, J CLIN ENDOCR METAB, V104, P1187, DOI 10.1210/jc.2018-01168
   Klonoff David C, 2011, J Diabetes Sci Technol, V5, P755
   Le Y, 2016, J RENIN-ANGIO-ALDO S, V17, DOI 10.1177/1470320316677918
   Levitt David L, 2017, J Diabetes Sci Technol, V11, P1028, DOI 10.1177/1932296817698499
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Muskiet MHA, 2015, LANCET DIABETES ENDO, V3, P928, DOI 10.1016/S2213-8587(15)00424-6
   Pal Rimesh, 2020, Diabetes Res Clin Pract, V162, P108132, DOI 10.1016/j.diabres.2020.108132
   Prattichizzo F, 2020, NAT REV ENDOCRINOL, V16, P15, DOI 10.1038/s41574-019-0294-3
   Prattichizzo F, 2018, AGEING RES REV, V41, P1, DOI 10.1016/j.arr.2017.10.003
   QUATRARO A, 1990, ANN INTERN MED, V112, P678, DOI 10.7326/0003-4819-112-9-678
   Rizzo M, 2018, BBA-MOL BASIS DIS, V1864, P2814, DOI 10.1016/j.bbadis.2018.05.012
   Salem ESB, 2014, AM J PHYSIOL-RENAL, V306, pF629, DOI 10.1152/ajprenal.00516.2013
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shetty S, 2012, ENDOCR PRACT, V18, P363, DOI 10.4158/EP11260.OR
   Tang O, 2020, DIABETES CARE, V43, P1200, DOI 10.2337/dc19-2043
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang AH, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108118
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang J, 2018, AM J RESP CRIT CARE, V198, P509, DOI 10.1164/rccm.201712-2570OC
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang W, 2013, ANN HEPATOL, V12, P892, DOI 10.1016/S1665-2681(19)31294-3
   Zheng RH, 2019, DRUG DES DEV THER, V13, P2745, DOI 10.2147/DDDT.S213910
   Zhou J, 2020, METABOLISM, V107, DOI 10.1016/j.metabol.2020.154216
NR 57
TC 24
Z9 24
U1 8
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2020
VL 43
IS 7
BP 1427
EP 1432
DI 10.2337/dc20-0941
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA MC8MR
UT WOS:000543534300014
PM 32409501
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rizzo, E
AF Rizzo, Emanuele
TI Ivermectin, antiviral properties and COVID-19: a possible new mechanism
   of action
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article
DE Ivermectin; Antiviral; Ionophore; COVID-19; SARS-CoV-2
ID NUCLEAR IMPORT; INHIBITORS; DRUG; TRANSPORT; IONOPHORE; NYSTATIN
AB Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature.
C1 [Rizzo, Emanuele] Local Hlth Author Lecce ASL Lecce, Dept Prevent, Lecce, Italy.
   [Rizzo, Emanuele] Italian Soc Environm Med SIMA, Milan, Italy.
RP Rizzo, E (corresponding author), Local Hlth Author Lecce ASL Lecce, Dept Prevent, Lecce, Italy.; Rizzo, E (corresponding author), Italian Soc Environm Med SIMA, Milan, Italy.
EM emanuele.rizzo@email.com
OI Rizzo, Emanuele/0000-0001-5781-5911
CR ABBOTT BJ, 1979, ANTIMICROB AGENTS CH, V16, P808, DOI 10.1128/AAC.16.6.808
   Ashraf S, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0314-4
   Ashraf S, 2016, VET PARASITOL, V226, P1, DOI 10.1016/j.vetpar.2016.06.015
   Bakker EP, 1979, ANTIBIOTICS, V5, P1
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Caly L, 2012, ANTIVIR RES, V95, P202, DOI 10.1016/j.antiviral.2012.06.008
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Cordova A, 2003, BIOPHYS J, V85, P70, DOI 10.1016/S0006-3495(03)74455-5
   Crump A, 2017, J ANTIBIOT, V70, P495, DOI 10.1038/ja.2017.11
   Freedman J.C., 2012, CELL PHYSL SOURCE BO, P61, DOI [10.1016/B978-0-12-387738-3.00004-4, DOI 10.1016/B978-0-12-387738-3.00004-4]
   Geary TG, 2005, TRENDS PARASITOL, V21, P530, DOI 10.1016/j.pt.2005.08.014
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   IKEHARA T, 1986, J MEMBRANE BIOL, V90, P231
   Intuyod K, 2019, ANTICANCER RES, V39, P4837, DOI 10.21873/anticanres.13669
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001
   Juarez M, 2018, AM J CANCER RES, V8, P317
   Kaushik V, 2018, CANCERS, V10, DOI 10.3390/cancers10100360
   KLOTZ U, 1990, EUR J CLIN PHARMACOL, V39, P607, DOI 10.1007/BF00316107
   Krenn BM, 2009, J VIROL, V83, P58, DOI 10.1128/JVI.01543-08
   Lim LE, 2013, ANTIMICROB AGENTS CH, V57, P1040, DOI 10.1128/AAC.01696-12
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Lv CJ, 2018, ANTIVIR RES, V159, P55, DOI 10.1016/j.antiviral.2018.09.010
   RAMOS H, 1989, BIOCHIM BIOPHYS ACTA, V982, P303, DOI 10.1016/0005-2736(89)90069-2
   Rang PH, 2015, RANG DALES PHARM
   Sandler ZJ, 2020, BIORXIV, DOI [10.1101/2020.01.21.914929, DOI 10.1101/2020.01.21.914929]
   Sigrist CJA, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104759
   Stillwell W., 2016, INTRO BIOL MEMBRANES
   Takahashi Y, 2002, INT J SYST EVOL MICR, V52, P2163, DOI [10.1099/ijs.0.02237-0, 10.1099/00207713-52-6-2163]
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Ventre E, 2017, ALLERGY, V72, P1212, DOI 10.1111/all.13118
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wagstaff KM, 2011, J BIOMOL SCREEN, V16, P192, DOI 10.1177/1087057110390360
   WHO, 2019, WHO MOD LIST ESS MED
   Yamasaki M, 2011, J PARASITOL, V97, P1190, DOI 10.1645/GE-2799.1
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
NR 36
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0028-1298
EI 1432-1912
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PD JUL
PY 2020
VL 393
IS 7
BP 1153
EP 1156
DI 10.1007/s00210-020-01902-5
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MB5SZ
UT WOS:000542663900003
PM 32462282
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Loungani, RS
   Rehorn, MR
   Newby, LK
   Katz, JN
   Klem, I
   Mentz, RJ
   Jones, WS
   Vemulapalli, S
   Kelsey, AM
   Blazing, MA
   Piccini, JP
   Patel, MR
AF Loungani, Rahul S.
   Rehorn, Michael R.
   Newby, L. Kristin
   Katz, Jason N.
   Klem, Igor
   Mentz, Robert J.
   Jones, W. Schuyler
   Vemulapalli, Sreekanth
   Kelsey, Anita M.
   Blazing, Michael A.
   Piccini, Jonathan P.
   Patel, Manesh R.
TI A care pathway for the cardiovascular complications of COVID-19:
   Insights from an institutional response
SO AMERICAN HEART JOURNAL
LA English
DT Article
AB The infection caused by severe acute respiratory syndrome coronavirus-2, or COVID-19, can result in myocardial injury, heart failure, and arrhythmias. In addition to the viral infection itself, investigational therapies for the infection can interact with the cardiovascular system. As cardiologists and cardiovascular service lines will be heavily involved in the care of patients with COVID-19, our division organized an approach to manage these complications, attempting to balance resource utilization and risk to personnel with optimal cardiovascular care. The model presented can provide a framework for other institutions to organize their own approaches and can be adapted to local constraints, resource availability, and emerging knowledge.
C1 Duke Univ, Div Cardiol, Med Ctr, Durham, NC 27710 USA.
   Duke Univ, Duke Heart Ctr, Med Ctr, Durham, NC 27710 USA.
RP Loungani, RS (corresponding author), Duke Univ, Med Ctr, 2301 Erwin Rd,DUMC 3845, Durham, NC 27710 USA.
EM Rahul.loungani@duke.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [U01 HL125511] Funding Source: Medline; NIA NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01 AG045551] Funding Source: Medline
CR Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Chen C, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P567, DOI 10.3760/cma.j.cn112148-20200225-00123
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Januzzi J., 2020, CARDIOLOGY MAGAZINE
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Linde JJ, 2020, J AM COLL CARDIOL, V75, P453, DOI 10.1016/j.jacc.2019.12.012
   Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mahmud E, 2020, J AM COLL CARDIOL, V76, P1375, DOI 10.1016/j.jacc.2020.04.039
   McCreary EK, 2020, COVID 19 TREATMENT R
   Mehra MR, 2020, JACC-HEART FAIL, V1248
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Patel AB, 2020, JAMA
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Walkey AJ, 2011, JAMA-J AM MED ASSOC, V306, P2248, DOI 10.1001/jama.2011.1615
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   YAO B, 2020, ZHONGHUA XIN XUE GUA, V48, DOI DOI 10.1177/0300060520903617
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 40
TC 4
Z9 4
U1 2
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD JUL
PY 2020
VL 225
BP 3
EP 9
DI 10.1016/j.ahj.2020.04.024
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MA2HL
UT WOS:000541737100002
PM 32417526
OA Green Published
DA 2021-01-01
ER

PT J
AU Ludwig, S
   Zarbock, A
AF Ludwig, Stephan
   Zarbock, Alexander
TI Coronaviruses and SARS-CoV-2: A Brief Overview
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IDENTIFICATION; PNEUMONIA; VIRUSES
AB In late December 2019, several cases of pneumonia of unknown origin were reported from China, which in early January 2020 were announced to be caused by a novel coronavirus. The virus was later denominated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined as the causal agent of coronavirus disease 2019 (COVID-19). Despite massive attempts to contain the disease in China, the virus has spread globally, and COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. Here we provide a short background on coronaviruses, and describe in more detail the novel SARS-CoV-2 and attempts to identify effective therapies against COVID-19.
C1 [Ludwig, Stephan] Univ Hosp Munster, Inst Mol Virol IMV, Von Esmarch Str 56, D-48149 Munster, Germany.
   [Zarbock, Alexander] Univ Hosp Munster, Dept Anaesthesiol Intens Care & Pain Med, Munster, Germany.
RP Ludwig, S (corresponding author), Univ Hosp Munster, Inst Mol Virol IMV, Von Esmarch Str 56, D-48149 Munster, Germany.
EM ludwigs@uni-muenster.de
OI Ludwig, Stephan/0000-0003-4490-3052
FU Deutsche Forschungsgemeinschaft (DFG, Clinical Research Unit)German
   Research Foundation (DFG) [CRU342]; Deutsche Forschungsgemeinschaft
   (DFG, Collaborative Research Center "Breaking Barriers")German Research
   Foundation (DFG) [SFB1009]
FX This study was supported by the Deutsche Forschungsgemeinschaft (DFG,
   Clinical Research Unit CRU342 and Collaborative Research Center
   "Breaking Barriers" SFB1009).
CR BEAUDETTE F. R., 1937, Journal of the American Veterinary Medical Association, V90, P51
   Cao B, 2020, NEW ENGL J MED, V382
   Corman VM, 2019, INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gordon CJ, 2020, J BIOL CHEM
   Guan WJ, 2020, N ENGL J MED
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ICTV, 2019, VIR TAX 2018B REL
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Poston J.T, 2020, JAMA
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   Tang X, 2020, NATL SCI REV
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Wu Z, 2020, JAMA
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 12
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUL
PY 2020
VL 131
IS 1
BP 93
EP 96
DI 10.1213/ANE.0000000000004845
PG 4
WC Anesthesiology
SC Anesthesiology
GA MA5ML
UT WOS:000541957000023
PM 32243297
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hao, FY
   Tan, WQ
   Jiang, L
   Zhang, L
   Zhao, XL
   Zou, YR
   Hu, YR
   Luo, X
   Jiang, XJ
   McIntyre, RS
   Tran, B
   Sun, JQ
   Zhang, ZS
   Ho, R
   Ho, C
   Tam, W
AF Hao, Fengyi
   Tan, Wanqiu
   Jiang, Li
   Zhang, Ling
   Zhao, Xinling
   Zou, Yiran
   Hu, Yirong
   Luo, Xi
   Jiang, Xiaojiang
   McIntyre, Roger S.
   Tran, Bach
   Sun, Jiaqian
   Zhang, Zhisong
   Ho, Roger
   Ho, Cyrus
   Tam, Wilson
TI Do psychiatric patients experience more psychiatric symptoms during
   COVID-19 pandemic and lockdown? A case-control study with service and
   research implications for immunopsychiatry
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Anxiety; COVID-19; Coronavirus; Depression; Epidemic; Immunopsychiatry;
   Insomnia; Psychiatric illness; Lockdown; Pandemic; PTSD; Stress; Suicide
ID COGNITIVE-BEHAVIORAL THERAPY; PSYCHOLOGICAL IMPACT; OUTBREAK; CARE
AB This study aimed to assess and compare the immediate stress and psychological impact experienced by people with and without psychiatric illnesses during the peak of 2019 coronavirus disease (COVID-19) epidemic with strict lockdown measures. Seventy-six psychiatric patients and 109 healthy control subjects were recruited from Chongqing, China and completed a survey on demographic data, physical symptoms during the past 14 days and a range of psychiatric symptoms using the Impact of Event Scale-Revised (IES-R), Depression, Anxiety and Stress Scale (DASS-21) and Insomnia Severity Index (ISI). IES-R measures PTSD symptoms in survivorship after an event. DASS-21 is based on tripartite model of psychopathology that comprise a general distress construct with distinct characteristics. The mean IES-R, DASS-21 anxiety, depression and stress subscale and ISI scores were higher in psychiatric patients than healthy controls (p < 0.001). Serious worries about their physical health, anger and impulsivity and intense suicidal ideation were significantly higher in psychiatric patients than healthy controls (p < 0.05). More than one-third of psychiatric patients might fulfil the diagnostic criteria post-traumatic stress disorder (PTSD). More than one-quarter of psychiatric patients suffered from moderately severe to severe insomnia. Respondents who reported no change, poor or worse physical health status and had a psychiatric illness were significantly more likely to have higher mean IES-R, DASS depression, anxiety and stress subscale scores and ISI scores (p < 0.05). This study confirms the severity of negative psychological impact on psychiatric patients during the COVID-19 epidemic with strict lockdown measures. Understanding the psychological impact on psychiatric patients during the COVID-19 pandemic has the potential to provide insight into how to develop a new immunopsychiatry service. Further research is required to compare pro-inflammatory cytokines between psychiatric patients and healthy controls during the pandemic.
C1 [Hao, Fengyi; Jiang, Li; Zhang, Ling; Zhao, Xinling; Zou, Yiran; Hu, Yirong; Luo, Xi] First Peoples Hosp Chongqing Liang Jiang New Area, Chongqing, Peoples R China.
   [Tan, Wanqiu; Ho, Roger] Natl Univ Singapore, Inst Hlth Innovat & Technol iHealthtech, Singapore 119077, Singapore.
   [Tan, Wanqiu] China Singapore Chongqing Demonstrat Initiat Stra, Chongqing 400043, Peoples R China.
   [Jiang, Xiaojiang] Army Med Univ, Daping Hosp, Dept Neurol, Chongqing, Peoples R China.
   [McIntyre, Roger S.] Univ Toronto, Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada.
   [Tran, Bach] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Tran, Bach] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi 100000, Vietnam.
   [Sun, Jiaqian; Ho, Roger] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore 119077, Singapore.
   [Zhang, Zhisong] Huaibei Normal Univ, Fac Educ, Huaibei 235000, Peoples R China.
   [Ho, Cyrus] Natl Univ Hlth Syst, Dept Psychol Med, Singapore, Singapore.
   [Tam, Wilson] Natl Univ Singapore, Alice Lee Ctr Nursing Studies, Singapore, Singapore.
RP Ho, R (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Level 9,NUHS Tower Block,1E Kent Ridge Rd, Singapore 119228, Singapore.
EM pcmrhcm@nus.edu.sg
RI McIntyre, Roger/AAU-1000-2020; Ho, Roger C/H-8714-2014; TAM, Wilson
   W.S./H-5890-2019
OI McIntyre, Roger/0000-0003-4733-2523; Ho, Roger C/0000-0001-9629-4493;
   TAM, Wilson W.S./0000-0003-0641-3060
FU Chongqing Science and Technology Dissemination and Popularization
   Project [cstc2019kpzxkphdA0014]; Vingroup Innovation Foundation (VINIF)
   COVID research grant [VINIF.2020.Covid19.DA07]; National University of
   Singapore iHeathtech Other Operating Expenses [R-722-000-004-731]
FX This work was supported by grants from the Chongqing Science and
   Technology Dissemination and Popularization Project
   (cstc2019kpzxkphdA0014) for Fengyi Hao, Vingroup Innovation Foundation
   (VINIF) COVID research grant (VINIF.2020.Covid19.DA07) for Bach Tran and
   National University of Singapore iHeathtech Other Operating Expenses
   (R-722-000-004-731) for Roger Ho.
CR Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Chew N.W., 2020, BRAIN BEHAV IMMUN
   Chua SE, 2004, CAN J PSYCHIAT, V49, P385
   Colizzi M., 2020, BRAIN BEHAV IMMUN HL, DOI [10.1016/j.bbih.2020.100073, DOI 10.1016/J.BBIH.2020.100073.100073]
   Gautam R, 2020, BRAIN BEHAV IMMUN, V88, P948, DOI 10.1016/j.bbi.2020.04.025
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Ho CSH, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16010163
   Joob B, 2020, BRAIN BEHAV IMMUN, V87, P10, DOI 10.1016/j.bbi.2020.03.020
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   Lee SM, 2018, COMPR PSYCHIAT, V87, P123, DOI 10.1016/j.comppsych.2018.10.003
   Lee Y, 2018, THER ADV PSYCHOPHARM, V8, P337, DOI 10.1177/2045125318791944
   Li ZY, 2020, BRAIN BEHAV IMMUN, V88, P916, DOI 10.1016/j.bbi.2020.03.007
   Lima BB, 2019, BRAIN BEHAV IMMUN, V75, P26, DOI 10.1016/j.bbi.2018.08.015
   Liu Y, 2012, J AFFECT DISORDERS, V139, P230, DOI 10.1016/j.jad.2011.08.003
   Lu YX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186700
   McAlonan GM, 2007, CAN J PSYCHIAT, V52, P241, DOI 10.1177/070674370705200406
   Montemurro N, 2020, BRAIN BEHAV IMMUN, V87, P23, DOI 10.1016/j.bbi.2020.03.032
   Mukhtar S, 2020, BRAIN BEHAV IMMUN, V87, P28, DOI 10.1016/j.bbi.2020.04.012
   Ng A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30487-6
   Osimo EF, 2020, BRAIN BEHAV IMMUN, V87, P901, DOI 10.1016/j.bbi.2020.02.010
   Qiu JY, 2020, BRAIN BEHAV IMMUN, V87, P51, DOI 10.1016/j.bbi.2020.04.032
   Quek TC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071410
   Shi Yudong, 2020, Brain Behav Immun Health, V4, P100064, DOI 10.1016/j.bbih.2020.100064
   Simpson R.J., 2020, BRAIN BEHAV IMMUN, DOI [10.1016/j.bbi.2020.04, DOI 10.1016/J.BBI.2020.04]
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tan W., 2020, BRAIN BEHAV IMMUN
   Tembe M, 2019, DISASTER MED PUBLIC, V13, P211, DOI 10.1017/dmp.2018.20
   Le TA, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0223-4
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Zhang J, 2020, BRAIN BEHAV IMMUN, V87, P49, DOI 10.1016/j.bbi.2020.04.031
   Zhang MWB, 2017, TECHNOL HEALTH CARE, V25, P163, DOI 10.3233/THC-161261
   Zhang MWB, 2015, TECHNOL HEALTH CARE, V23, P737, DOI 10.3233/THC-151026
   Zhang MWB, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.2827
   Zhang ZS, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010280
   Zhu S, 2020, BRAIN BEHAV IMMUN, V87, P56, DOI 10.1016/j.bbi.2020.04.045
NR 36
TC 84
Z9 84
U1 13
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD JUL
PY 2020
VL 87
BP 100
EP 106
DI 10.1016/j.bbi.2020.04.069
PG 7
WC Immunology; Neurosciences; Psychiatry
SC Immunology; Neurosciences & Neurology; Psychiatry
GA MC0CQ
UT WOS:000542965400031
PM 32353518
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sahay, S
   Farber, HW
AF Sahay, Sandeep
   Farber, Harrison W.
TI Management of hospitalized patients with pulmonary arterial hypertension
   and COVID-19 infection
SO PULMONARY CIRCULATION
LA English
DT Letter
ID NITRIC-OXIDE; THERAPY; RISK
C1 [Sahay, Sandeep] Houston Methodist Hosp, Houston Methodist Lung Ctr, Houston, TX 77030 USA.
   [Farber, Harrison W.] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA.
RP Sahay, S (corresponding author), Houston Methodist Hosp, Weill Cornell Med, Houston, TX 77030 USA.
EM ssahay@houstonmethodist.org
OI Sahay, Sandeep/0000-0002-0672-1680
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Benza RL, 2019, CHEST, V156, P323, DOI 10.1016/j.chest.2019.02.004
   Bikdeli B, 2020, J AM COLL CARDIOL, V15
   Chakinala MM, 2017, J HEART LUNG TRANSPL, V36, P193, DOI 10.1016/j.healun.2016.06.019
   Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gordon C, 2010, CURR OPIN ANESTHESIO, V23, P49, DOI 10.1097/ACO.0b013e3283346c51
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gu ZC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16349-7
   Hoeper MM, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01906-2018
   Hoeper MM, 2011, AM J RESP CRIT CARE, V184, P1114, DOI 10.1164/rccm.201104-0662CI
   Hoeper MM, 2002, AM J RESP CRIT CARE, V165, P341, DOI 10.1164/ajrccm.165.3.200109-0130c
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Klose H, 2019, J HEART LUNG TRANSPL, V38, pS490, DOI 10.1016/j.healun.2019.01.1247
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   McLaughlin VV, 2010, J AM COLL CARDIOL, V55, P1915, DOI 10.1016/j.jacc.2010.01.027
   Myles P S, 1994, J Cardiothorac Vasc Anesth, V8, P678, DOI 10.1016/1053-0770(94)90203-8
   Pritts CD, 2010, CURR OPIN ANESTHESIO, V23, P6
   Reyes A, 2019, AM J RESP CRIT CARE, V199
   Sahay S, 2017, SEMIN RESP CRIT CARE, V38, P686, DOI 10.1055/s-0037-1607208
   VIITANEN A, 1990, ANESTHESIOLOGY, V73, P393, DOI 10.1097/00000542-199009000-00005
   VIITANEN A, 1989, CHEST, V95, P773, DOI 10.1378/chest.95.4.773
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wenzel RR, 2001, BRIT J CLIN PHARMACO, V52, P151, DOI 10.1046/j.0306-5251.2001.01422.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD JUL
PY 2020
VL 10
IS 3
AR 2045894020933480
DI 10.1177/2045894020933480
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA MB3YT
UT WOS:000542541600001
PM 32595934
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Davies, M
   Osborne, V
   Lane, S
   Roy, D
   Dhanda, S
   Evans, A
   Shakir, S
AF Davies, Miranda
   Osborne, Vicki
   Lane, Samantha
   Roy, Debabrata
   Dhanda, Sandeep
   Evans, Alison
   Shakir, Saad
TI Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk
   Assessment
SO DRUG SAFETY
LA English
DT Article
ID INHIBIT
AB Introduction There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit-risk assessment was designed and conducted to examine the benefit-risk profile of remdesivir in COVID-19 patients compared with standard of care, placebo or other treatments. A key objective of this study was to provide a platform for a dynamic systematic benefit-risk evaluation, which starts with inevitably limited information (to meet the urgent unmet public health need worldwide), then update the benefit-risk evaluation as more data become available. Methods The Benefit-Risk Action Team (BRAT) framework was used to assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19 compared with standard of care, placebo or other treatments. We searched PubMed, Google Scholar and government agency websites to identify literature reporting clinical outcomes in patients taking remdesivir for COVID-19. A value tree was constructed and key benefits and risks were ranked by two clinicians in order of considered importance. Results Using the BRAT method, several key benefits and risks for use of remdesivir in COVID-19 compared with placebo have been identified. In one trial, the benefit of time to clinical improvement was not statistically significant (21 vs 23 days, HR 1.23, 95% CI 0.87-1.75), although the study was underpowered. In another trial, a shorter time to recovery in patients treated with remdesivir was observed (11 vs 15 days), with non-significant reduced mortality risk (8% vs 12%). Risk data were only available from one trial. This trial reported fewer serious adverse events in patients taking remdesivir (18%) compared with the placebo group (26%); however, more patients in the remdesivir group discontinued treatment as a result of an adverse event compared with those patients receiving placebo (12% vs 5%). Conclusions Preliminary clinical trial results suggest that there may be a favourable benefit-risk profile for remdesivir compared with placebo in severe COVID-19 infection and further data on benefits would strengthen this evaluation. There is limited safety data for remdesivir, which should be obtained in further studies. The current framework summarises the key anticipated benefits and risks for which further data are needed. Ongoing clinical trial data can be incorporated into the framework when available to provide an updated benefit-risk assessment.
C1 [Davies, Miranda; Osborne, Vicki; Lane, Samantha; Roy, Debabrata; Dhanda, Sandeep; Evans, Alison; Shakir, Saad] Drug Safety Res Unit, Bursledon Hall,Blundell Lane, Southampton SO31 1AA, Hants, England.
   [Davies, Miranda; Osborne, Vicki; Lane, Samantha; Roy, Debabrata; Dhanda, Sandeep; Evans, Alison; Shakir, Saad] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England.
RP Davies, M (corresponding author), Drug Safety Res Unit, Bursledon Hall,Blundell Lane, Southampton SO31 1AA, Hants, England.; Davies, M (corresponding author), Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England.
EM miranda.davies@dsru.org
OI Osborne, Vicki/0000-0002-3669-6084
CR Agency EM, 2020, SUMM COMP US REM GIL
   [Anonymous], 2020, GIL ANN RES PHAS 3 T
   Bin Cao P, 2020, PHASE 3 RANDOMIZED D
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Coplan PM, 2011, CLIN PHARMACOL THER, V89, P312, DOI 10.1038/clpt.2010.291
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   FDA, 2020, COR COVID 19 UPD FDA
   Gilead, 2020, STUD EV SAF ANT ACT
   Gilead, 2020, PHAS 3 RAND STUD EV
   Gilead, 2020, EXP ACC TREATM PROT
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Herper M., 2020, INSIDE NIHS CONTROVE
   Holden WL, 2003, PHARMACOEPIDEM DR S, V12, P693, DOI 10.1002/pds.794
   Hospital OU, 2020, NORW NOR SOL MULT TI
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Kumar S, 2020, HEART LUNG CIRC, V29, pE57, DOI 10.1016/j.hlc.2020.04.001
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   National Institute of Allergy and Infectious Diseases, 2020, NIH CLIN TRIAL SHOWS
   Nixon R, 2016, BIOMETRICAL J, V58, P8, DOI 10.1002/bimj.201300248
   Osborne Vicki, 2020, BMJ Evid Based Med, V25, P199, DOI 10.1136/bmjebm-2019-111295
   PROTECT, 2015, PROTECT
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sutton AJ, 2005, J CLIN EPIDEMIOL, V58, P26, DOI 10.1016/j.jclinepi.2004.03.015
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, WHO ANN COVID 19 PAN
   World Health Organization, 2020, NAM COR DIS COVID 19
NR 34
TC 7
Z9 7
U1 2
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD JUL
PY 2020
VL 43
IS 7
BP 645
EP 656
DI 10.1007/s40264-020-00952-1
PG 12
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA LZ5CB
UT WOS:000541240900006
PM 32468196
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Li, Q
   Tang, B
   Bragazzi, NL
   Xiao, YN
   Wu, JH
AF Li, Qian
   Tang, Biao
   Bragazzi, Nicola Luigi
   Xiao, Yanni
   Wu, Jianhong
TI Modeling the impact of mass influenza vaccination and public health
   interventions on COVID-19 epidemics with limited detection capability
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Coronavirus; Pandemic outbreak; Limited resources; Influenza season;
   Influenza vaccination
ID TRANSMISSION
AB The emerging coronavirus SARS-CoV-2 has caused a COVID-19 pandemic. SARS-CoV-2 causes a generally mild, but sometimes severe and even life-threatening infection, known as COVID-19. Currently, there exist no effective vaccines or drugs and, as such, global public authorities have so far relied upon non pharmaceutical interventions (NPIs). Since COVID-19 symptoms are aspecific and may resemble a common cold, if it should come back with a seasonal pattern and coincide with the influenza season, this would be particularly challenging, overwhelming and straining the healthcare systems, particularly in resource-limited contexts, and would increase the likelihood of nosocomial transmission. In the present study, we devised a mathematical model focusing on the treatment of people complaining of influenza-like-illness (ILI) symptoms, potentially at risk of contracting COVID-19 or other emerging/re-emerging respiratory infectious agents during their admission at the health-care setting, who will occupy the detection kits causing a severe shortage of testing resources. The model is used to assess the effect of mass influenza vaccination on the spread of COVID-19 and other respiratory pathogens in the case of a coincidence of the outbreak with the influenza season. Here, we show that increasing influenza vaccine uptake or enhancing the public health interventions would facilitate the management of respiratory outbreaks coinciding with the peak flu season, especially, compensate the shortage of the detection resources. However, how to increase influenza vaccination coverage rate remains challenging. Public health decision- and policy-makers should adopt evidence-informed strategies to improve influenza vaccine uptake.
C1 [Li, Qian; Xiao, Yanni] Xi An Jiao Tong Univ, Dept Appl Math, Xian 710049, Peoples R China.
   [Li, Qian; Tang, Biao; Bragazzi, Nicola Luigi; Wu, Jianhong] York Univ, Dept Math & Stat, Lab Ind & Appl Math, Toronto, ON, Canada.
RP Wu, JH (corresponding author), York Univ, Dept Math & Stat, Lab Ind & Appl Math, Toronto, ON, Canada.
EM wujh@yorku.ca
RI ; Bragazzi, Nicola/G-1672-2011
OI Tang, Biao/0000-0002-0418-5773; Bragazzi, Nicola/0000-0001-8409-868X
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [11631012]; Canadian Institute of
   Health Research (CIHR) 2019 Novel Coronavirus (COVID-19) rapid research
   programCanadian Institutes of Health Research (CIHR)
FX YX was supported by the National Natural Science Foundation of China
   (NSFC, 11631012), JW was supported by the Canadian Institute of Health
   Research (CIHR) 2019 Novel Coronavirus (COVID-19) rapid research
   program.
CR Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   National Health Commission of the People's Republic of China, 2020, NATL HLTH COMMISSION
   Ngonghala C.N., 2020, ARXIV PREPRINT ARXIV
   Sajadi M.M., 2020, TEMPERATURE HUMIDITY, DOI 10.2139/ssrn.3550308
   Schlagenhauf P, 2003, LANCET, V362, P809, DOI 10.1016/S0140-6736(03)14301-2
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Tang B, 2020, INT J INFECT DIS, V95, P288, DOI 10.1016/j.ijid.2020.03.018
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Thomas RE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005188.pub4
   ZHANG X, 2020, GEROSCIENCE 0517, pB8001, DOI DOI 10.1126/SCIENCE.ABB8001
NR 15
TC 16
Z9 16
U1 27
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD JUL
PY 2020
VL 325
AR 108378
DI 10.1016/j.mbs.2020.108378
PG 9
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA LZ5KX
UT WOS:000541263900009
OA Green Published
DA 2021-01-01
ER

PT J
AU Ngonghala, CN
   Iboi, E
   Eikenberry, S
   Scotch, M
   MacIntyre, CR
   Bonds, MH
   Gumel, AB
AF Ngonghala, Calistus N.
   Iboi, Enahoro
   Eikenberry, Steffen
   Scotch, Matthew
   MacIntyre, Chandini Raina
   Bonds, Matthew H.
   Gumel, Abba B.
TI Mathematical assessment of the impact of non-pharmaceutical
   interventions on curtailing the 2019 novel Coronavirus
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Mathematical model; COVID-19; SARS-CoV-2; Social-distancing; Quarantine;
   Isolation; Contact-tracing; Face-mask; Non-pharmaceutical intervention
ID FINAL SIZE; PANDEMIC INFLUENZA; HAND HYGIENE; RISK-FACTORS; MASK USE;
   MODELS; TRANSMISSION; QUARANTINE; SARS; INFECTION
AB A pandemic of a novel Coronavirus emerged in December of 2019 (COVID-19), causing devastating public health impact across the world. In the absence of a safe and effective vaccine or antivirals, strategies for controlling and mitigating the burden of the pandemic are focused on non-pharmaceutical interventions, such as social-distancing, contact-tracing, quarantine, isolation, and the use of face-masks in public. We develop a new mathematical model for assessing the population-level impact of the aforementioned control and mitigation strategies. Rigorous analysis of the model shows that the disease-free equilibrium is locally-asymptotically stable if a certain epidemiological threshold, known as the reproduction number (denoted by R-c), is less than unity. Simulations of the model, using data relevant to COVID-19 transmission dynamics in the US state of New York and the entire US, show that the pandemic burden will peak in mid and late April, respectively. The worst-case scenario projections for cumulative mortality (based on the baseline levels of anti-COVID non-pharmaceutical interventions considered in the study) decrease dramatically by 80% and 64%, respectively, if the strict social-distancing measures implemented are maintained until the end of May or June, 2020. The duration and timing of the relaxation or termination of the strict social-distancing measures are crucially-important in determining the future trajectory of the COVID-19 pandemic. This study shows that early termination of the strict social-distancing measures could trigger a devastating second wave with burden similar to those projected before the onset of the strict social-distancing measures were implemented. The use of efficacious face-masks (such as surgical masks, with estimated efficacy >= 70%) in public could lead to the elimination of the pandemic if at least 70% of the residents of New York state use such masks in public consistently (nationwide, a compliance of at least 80% will be required using such masks). The use of low efficacy masks, such as cloth masks (of estimated efficacy less than 30%), could also lead to significant reduction of COVID-19 burden (albeit, they are not able to lead to elimination). Combining low efficacy masks with improved levels of the other anti-COVID-19 intervention strategies can lead to the elimination of the pandemic. This study emphasizes the important role social-distancing plays in curtailing the burden of COVID19. Increases in the adherence level of social-distancing protocols result in dramatic reduction of the burden of the pandemic, and the timely implementation of social-distancing measures in numerous states of the US may have averted a catastrophic outcome with respect to the burden of COVID-19. Using face-masks in public (including the low efficacy cloth masks) is very useful in minimizing community transmission and burden of COVID-19, provided their coverage level is high. The masks coverage needed to eliminate COVID-19 decreases if the masks-based intervention is combined with the strict social-distancing strategy.
C1 [Ngonghala, Calistus N.] Univ Florida, Dept Math, Gainesville, FL 32611 USA.
   [Iboi, Enahoro; Eikenberry, Steffen; Gumel, Abba B.] Arizona State Univ, Sch Math & Stat Sci, Tempe, AZ 85287 USA.
   [Scotch, Matthew] Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA.
   [MacIntyre, Chandini Raina] Univ New South Wales, Fac Med, Kirby Inst, Sydney, NSW, Australia.
   [Bonds, Matthew H.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
   [MacIntyre, Chandini Raina] Arizona State Univ, Coll Hlth Solut, Tempe, AZ 85287 USA.
   [MacIntyre, Chandini Raina] Arizona State Univ, Coll Publ Affairs & Community Solut, Tempe, AZ 85287 USA.
   [Gumel, Abba B.] Univ Pretoria, Dept Math & Appl Math, ZA-0002 Pretoria, South Africa.
RP Gumel, AB (corresponding author), Arizona State Univ, Sch Math & Stat Sci, Tempe, AZ 85287 USA.; Gumel, AB (corresponding author), Univ Pretoria, Dept Math & Appl Math, ZA-0002 Pretoria, South Africa.
EM agumel@asu.edu
OI MacIntyre, C Raina/0000-0002-3060-0555; Gumel, Abba/0000-0002-8413-1248;
   Iboi, Enahoro/0000-0003-0285-3050
FU Simons Foundation [627346]; National Science FoundationNational Science
   Foundation (NSF) [1917512]
FX One of the authors (ABG) acknowledge the support, in part, of the Simons
   Foundation (Award #585022) and the National Science Foundation (Award
   #1917512). CNN acknowledges the support of the Simons Foundation (Award
   #627346). One of the authors (ABG) acknowledges the useful conversation
   with Dieter Armbruster on some aspects of public mask usage. The authors
   are grateful to the two anonymous reviewers and the Handling Editor for
   their very constructive comments, which have significantly enhanced the
   manuscript.
CR Aiello AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029744
   Aiello AE, 2010, J INFECT DIS, V201, P491, DOI 10.1086/650396
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, SIT UPD WORLDW
   Arino J, 2007, MATH BIOSCI ENG, V4, P159, DOI 10.3934/mbe.2007.4.159
   Begley Sharon, 2020, SOCIAL DISTANCING IS
   Bell D, 2006, EMERG INFECT DIS, V12, P88
   Bi Q, 2020, EPIDEMIOLOGY TRANSMI
   Bootsma MCJ, 2007, P NATL ACAD SCI USA, V104, P7588, DOI 10.1073/pnas.0611071104
   Brauer F, 2019, B MATH BIOL, V81, P869, DOI 10.1007/s11538-018-00549-x
   Brauer Fred, 2017, Infect Dis Model, V2, P12, DOI 10.1016/j.idm.2016.12.001
   Brauer F, 2008, MATH BIOSCI ENG, V5, P681, DOI 10.3934/mbe.2008.5.681
   Bryner J., 2020, LIVE SCI
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226
   Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142
   Davies A, 2013, DISASTER MED PUBLIC, V7, P413, DOI 10.1017/dmp.2013.43
   Day T, 2006, AM J EPIDEMIOL, V163, P479, DOI 10.1093/aje/kwj056
   Del Rio C, 2020, JAMA
   Denes A, 2019, INFECT DIS MODEL, V4, P12, DOI 10.1016/j.idm.2019.01.003
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Dong E, 2020, LANCET INFECT DIS
   E. The National Academies of Sciences, 2020, RAP EXP CONS EFF FAB
   Eikenberry SE, 2020, INFECT DIS MODEL, V5, P293, DOI 10.1016/j.idm.2020.04.001
   Feng Y., 2020, NY DAILY NEWS
   Feng Z, 2007, MATH BIOSCI ENG, V4, P675, DOI 10.3934/mbe.2007.4.675
   Feng ZL, 2007, B MATH BIOL, V69, P1511, DOI 10.1007/s11538-006-9174-9
   Ferguson NM, 2020, IMPACT NONPHARMACEUT, V16
   French Paul, 2020, 1918 FLU PANDEMIC NO
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gudbjartsson DF, 2020, NEW ENGL J MED
   Hellewell Joel, 2020, LANCET GLOBAL HLTH
   Herbst Meghan, 2020, WIRED
   IHME COVID-19 health service utilization forecasting team, 2020, IHME COVID19 HLTH SE
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Kucharski AJ, 2020, LANCET INFECT DIS
   Lai CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062196
   Lau JTF, 2004, EMERG INFECT DIS, V10, P587, DOI 10.3201/eid1004.030628
   Lauer SA, 2020, ANN INT MED
   Layne N., 2020, REUTERS HEATH NEWS
   Levenson E., 2020, CABLE NEWS NETWORK
   Li R, 2020, SCIENCE
   Luckingham B, 1984, J Ariz Hist, V25, P191
   Maclntyre CR, 2009, EMERG INFECT DIS, V15, P233, DOI 10.3201/eid1502.081167
   Mervosh S., 2020, NY TIMES
   Michaud Josh, 2020, IS CONTACT TRACING G
   Mizumoto K., 2020, INFECT DIS MODEL, P2020
   Morens DM, 2009, PUBLIC HEALTH REP, V124, P22, DOI 10.1177/003335490912400105
   Silverstein WK, 2020, LANCET, V395, P734, DOI 10.1016/S0140-6736(20)30370-6
   Stockwell RE, 2018, AM J RESP CRIT CARE, V198, P1339, DOI 10.1164/rccm.201805-0823LE
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Tognotti E, 2009, J INFECT DEV COUNTR, V3, P331, DOI 10.3855/jidc.239
   Uyeki TM, 2020, NEW ENGL J MED, V382
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   van der Sande M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002618
   Vanden Driessche K, 2015, AM J RESP CRIT CARE, V192, P897, DOI 10.1164/rccm.201503-0481LE
   Wang CJ, 2020, JAMA, P2020
   WHO, 2020, COR DIS COVID 19 TEC
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, EM PREP RESP PNEUM U
   World Health Organization, 2020, COR DIS 2019 COVID 1, V46
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu J, 2004, EMERG INFECT DIS, V10, P210, DOI 10.3201/eid1002.030730
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yao Bai Y, 2020, JAMA
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Young BE, 2020, JAMA
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 70
TC 33
Z9 34
U1 18
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD JUL
PY 2020
VL 325
AR 108364
DI 10.1016/j.mbs.2020.108364
PG 15
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA LZ5KX
UT WOS:000541263900004
PM 32360770
OA Green Published
DA 2021-01-01
ER

PT J
AU Tsatsakis, A
   Petrakis, D
   Nikolouzakis, TK
   Docea, AO
   Calina, D
   Vinceti, M
   Goumenou, M
   Kostoff, RN
   Mamoulakis, C
   Aschner, M
   Hernandez, AF
AF Tsatsakis, Aristidis
   Petrakis, Demetrious
   Konstantinos Nikolouzakis, Taxiarchis
   Docea, Anca Oana
   Calina, Daniela
   Vinceti, Marco
   Goumenou, Marina
   Kostoff, Ronald N.
   Mamoulakis, Charalampos
   Aschner, Michael
   Hernandez, Antonio F.
TI COVID-19, an opportunity to reevaluate the correlation between long-term
   effects of anthropogenic pollutants on viral epidemic/pandemic events
   and prevalence
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Xenobiotics; Pollutants; Immune deficiency; COVID-19; Chronic diseases;
   Coronavirus; SARS-CoV-2; Epidemic; Pandemic
ID ARYL-HYDROCARBON RECEPTOR; IMMUNE-SYSTEM; MONOCLONAL-ANTIBODIES;
   HOST-RESISTANCE; EXPOSURE; CORONAVIRUS; PESTICIDES; CANCER; HEALTH;
   MICROBIOME
AB Occupational, residential, dietary and environmental exposures to mixtures of synthetic anthropogenic chemicals after World War II have a strong relationship with the increase of chronic diseases, health cost and environmental pollution. The link between environment and immunity is particularly intriguing as it is known that chemicals and drugs can cause immunotoxicity (e.g., allergies and autoimmune diseases). In this review, we emphasize the relationship between long-term exposure to xenobiotic mixtures and immune deficiency inherent to chronic diseases and epidemics/pandemics. We also address the immunotoxicologic risk of vulnerable groups, taking into account biochemical and biophysical properties of SARS-CoV-2 and its immunopathological implications. We particularly underline the common mechanisms by which xenobiotics and SARS-CoV-2 act at the cellular and molecular level. We discuss how long-term exposure to thousand chemicals in mixtures, mostly fossil fuel derivatives, exposure toparticle matters, metals, ultraviolet (UV)-B radiation, ionizing radiation and lifestyle contribute to immunodeficiency observed in the contemporary pandemic, such as COVID-19, and thus threaten global public health, human prosperity and achievements, and global economy. Finally, we propose metrics which are needed to address the diverse health effects of anthropogenic COVID-19 crisis at present and those required to prevent similar future pandemics.
C1 [Tsatsakis, Aristidis; Petrakis, Demetrious; Konstantinos Nikolouzakis, Taxiarchis; Goumenou, Marina] Univ Crete, Med Sch, Lab Toxicol, Iraklion 71409, Greece.
   [Tsatsakis, Aristidis; Aschner, Michael] Sechenov Univ, Dept Analyt & Forens Med Toxicol, 2-4 Bolshaya Pirogovskaya St, Moscow 119991, Russia.
   [Tsatsakis, Aristidis; Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, New York, NY 10461 USA.
   [Docea, Anca Oana] Univ Med & Pharm Craiova, Dept Toxicol, Craiova 200349, Romania.
   [Calina, Daniela] Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania.
   [Vinceti, Marco] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy.
   [Kostoff, Ronald N.] Georgia Inst Technol, Sch Publ Policy, Gainesville, VA 20155 USA.
   [Mamoulakis, Charalampos] Univ Crete, Univ Gen Hosp Heraklion, Med Sch, Dept Urol, Iraklion 71003, Greece.
   [Hernandez, Antonio F.] Univ Granada, Dept Legal Med & Toxicol, Sch Med, Granada 180016, Spain.
RP Tsatsakis, A (corresponding author), Univ Crete, Med Sch, Lab Toxicol, Iraklion 71409, Greece.; Tsatsakis, A (corresponding author), Sechenov Univ, Dept Analyt & Forens Med Toxicol, 2-4 Bolshaya Pirogovskaya St, Moscow 119991, Russia.; Docea, AO (corresponding author), Univ Med & Pharm, Fac Pharm, Dept Toxicol, Craiova 200349, Romania.
EM tsatsaka@uoc.gr; dimitriospetrakis@hotmail.com; konstan10@hotmail.gr;
   ancadocea@gmail.com; calinadaniela@gmail.com; marco.vinceti@unimore.it;
   rkostoff@gmail.com; mamoulak@uoc.gr; michael.Aschner@einstein.yu.edu;
   ajerez@ugr.es
RI Docea, Anca Oana/P-5807-2019; Calina, Daniela/I-5509-2017; Hernandez,
   Antonio F./G-4994-2010; Tsatsakis, Aristidis M./H-2890-2013; Calina,
   Daniela/M-6679-2019
OI Docea, Anca Oana/0000-0002-8162-5955; Hernandez, Antonio
   F./0000-0003-2983-5418; Tsatsakis, Aristidis M./0000-0003-3824-2462;
   Calina, Daniela/0000-0002-1523-9116
CR Abassi Z, 2020, AM J PHYSIOL-HEART C, V318, pH1080, DOI 10.1152/ajpheart.00215.2020
   Aloizou AM, 2020, TOXICOL LETT, V326, P31, DOI 10.1016/j.toxlet.2020.03.005
   Anthoney N, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156018
   Avery JC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091203
   Bawa AS, 2013, J FOOD SCI TECH MYS, V50, P1035, DOI 10.1007/s13197-012-0899-1
   Beamer CA, 2013, NANOTOXICOLOGY, V7, P1070, DOI 10.3109/17435390.2012.702230
   Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20
   Bermejo-Martin JF, 2009, CRIT CARE, V13, DOI 10.1186/cc8208
   Berzins SP, 2002, TRENDS MOL MED, V8, P469, DOI 10.1016/S1471-4914(02)02415-2
   Bhatt D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00071
   Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7
   Boule LA, 2015, AM J PHYSIOL-LUNG C, V309, pL305, DOI 10.1152/ajplung.00135.2015
   Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998
   BROWN DP, 1992, SCAND J WORK ENV HEA, V18, P155, DOI 10.5271/sjweh.1593
   Cao FJ, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00701
   Cascella M, 2020, STATPEARLS
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Cetkovic-Cvrlje M, 2016, J IMMUNOTOXICOL, V13, P108, DOI 10.3109/1547691X.2015.1017060
   Chen Q, 2014, J CLIN MICROBIOL, V52, P234, DOI 10.1128/JCM.02820-13
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Chiappini F, 2014, TOXICOL LETT, V230, P1, DOI 10.1016/j.toxlet.2014.08.002
   Childs CE, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081933
   Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412
   Cocco P, 1997, ANN NY ACAD SCI, V837, P246, DOI 10.1111/j.1749-6632.1997.tb56878.x
   Condette CJ, 2015, J PEDIATR GASTR NUTR, V61, P30, DOI 10.1097/MPG.0000000000000734
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Crooke SN, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.110632
   Cruz T, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1105-z
   Cruzat V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111564
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Demsia G, 2007, MUTAT RES-GEN TOX EN, V634, P32, DOI 10.1016/j.mrgentox.2007.05.018
   DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dietert RR, 2004, TOXICOL APPL PHARM, V198, P86, DOI 10.1016/j.taap.2003.08.020
   Dimakakou E, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081704
   Dinu M, 2018, EUR J CLIN NUTR, V72, P30, DOI 10.1038/ejcn.2017.58
   Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555
   Donovan SM, 2016, ANN NUTR METAB, V69, P42, DOI 10.1159/000452818
   Eldakroory S, 2017, HUM EXP TOXICOL, V36, P1326, DOI 10.1177/0960327116685887
   Engin AB, 2017, PART FIBRE TOXICOL, V14, DOI 10.1186/s12989-017-0199-z
   Esser C, 2015, PHARMACOL REV, V67, P259, DOI 10.1124/pr.114.009001
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fenga C, 2017, MOL MED REP, V15, P3355, DOI 10.3892/mmr.2017.6381
   Fernadez-Sola J, 2005, MED CLIN-BARCELONA, V124, P451, DOI 10.1157/13073217
   Ffrench-Constant RH, 2013, GENETICS, V194, P807, DOI 10.1534/genetics.112.141895
   FIGATALAMANCA I, 1993, INT J EPIDEMIOL, V22, P674, DOI 10.1093/ije/22.4.674
   Fountoucidou P, 2019, TOXICOL LETT, V317, P24, DOI 10.1016/j.toxlet.2019.09.015
   Zambrano-Zaragoza JF, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/651503
   Frericks M, 2007, TOXICOL APPL PHARM, V220, P320, DOI 10.1016/j.taap.2007.01.014
   Gangemi S, 2016, INT J MOL MED, V38, P1012, DOI 10.3892/ijmm.2016.2728
   Gao D, 2007, TOXICOL APPL PHARM, V222, P69, DOI 10.1016/j.taap.2007.04.001
   Giraldo AMV, 2014, BIOCHEM SOC T, V42, P1460, DOI 10.1042/BST20140145
   Go RE, 2015, TOXICOL APPL PHARM, V289, P48, DOI 10.1016/j.taap.2015.09.001
   Go YM, 2014, REDOX BIOL, V2, P358, DOI 10.1016/j.redox.2013.12.032
   Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118
   Guillette EA, 1998, ENVIRON HEALTH PERSP, V106, P347, DOI 10.2307/3434041
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012
   Hafeez U, 2018, CURR OPIN PHARMACOL, V41, P114, DOI 10.1016/j.coph.2018.05.010
   Hargrove D, 2006, LANCET ONCOL, V7, P241, DOI 10.1016/S1470-2045(06)70615-5
   Hartung T, 2013, ALTEX-ALTERN ANIM EX, V30, P411, DOI 10.14573/altex.2013.4.411
   Head JL, 2009, BIOCHEM PHARMACOL, V77, P642, DOI 10.1016/j.bcp.2008.10.031
   Hernandez AF, 2020, FOOD CHEM TOXICOL, V137, DOI 10.1016/j.fct.2020.111123
   Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holladay SD, 1999, ENVIRON HEALTH PERSP, V107, P687, DOI 10.2307/3434328
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Holtz LR, 2014, VIROLOGY, V468, P556, DOI 10.1016/j.virol.2014.09.012
   Huh Jooryung, 2012, Korean J Hematol, V47, P92, DOI 10.5045/kjh.2012.47.2.92
   Ibs KH, 2003, J NUTR, V133, p1452S, DOI 10.1093/jn/133.5.1452S
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Jin LM, 2008, ASIAN J ANDROL, V10, P6, DOI 10.1111/j.1745-7262.2008.00371.x
   Jin YX, 2017, ENVIRON POLLUT, V222, P1, DOI 10.1016/j.envpol.2016.11.045
   Kalkanidis M, 2006, METHODS, V40, P20, DOI 10.1016/j.ymeth.2006.05.018
   Karzi V, 2018, J APPL TOXICOL, V38, P1144, DOI 10.1002/jat.3627
   Kendall M, 2012, RESPIROLOGY, V17, P743, DOI 10.1111/j.1440-1843.2012.02171.x
   Khazaal AQ, 2018, J RECEPT LIGAND CH R, V10, P13, DOI 10.2147/JRLCR.S133886
   Kidane D, 2014, CRIT REV BIOCHEM MOL, V49, P116, DOI 10.3109/10409238.2013.875514
   Kim D, 2000, BRAIN BEHAV IMMUN, V14, P305, DOI 10.1006/brbi.2000.0609
   Kishikawa H, 1998, J TOXICOL ENV HEAL A, V53, P357
   Koike E, 2018, INT J IMMUNOPATH PH, V32, DOI 10.1177/2058738418774897
   Kostoff R.N., 2020, COMBINING TACTICAL S
   Kostoff R.N., 2017, MICROWAVE EFFECTS DN, DOI [10.1007/978-3-319-50289-2_4, DOI 10.1007/978-3-319-50289-2_4]
   Kostoff R.N., 2019, ADVERSE EFFECTS WIRE
   Kostoff RN, 2020, TOXICOL LETT, V323, P35, DOI 10.1016/j.toxlet.2020.01.020
   Kostoff RN, 2018, TOXICOL REP, V5, P1169, DOI 10.1016/j.toxrep.2018.10.010
   Kreitinger JM, 2016, J IMMUNOL, V196, P3217, DOI 10.4049/jimmunol.1502149
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kwak Eun Soo, 2009, Open Allergy J, V2, P45
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Langer P, 2010, FRONT NEUROENDOCRIN, V31, P497, DOI 10.1016/j.yfrne.2010.08.001
   Lee GY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111614
   Leon ME, 2019, INT J EPIDEMIOL, V48, P1519, DOI 10.1093/ije/dyz017
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li J, 2020, PROTEIN CELL, V11, P235, DOI 10.1007/s13238-020-00693-y
   Li M, 2019, CHEMOSPHERE, V219, P155, DOI 10.1016/j.chemosphere.2018.12.011
   Lim ES, 2015, NAT MED, V21, P1228, DOI 10.1038/nm.3950
   Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14
   Liu FF, 2018, ACTA PHARM SIN B, V8, P552, DOI 10.1016/j.apsb.2018.01.008
   Liu YJ, 2019, INT J EPIDEMIOL, V48, P455, DOI 10.1093/ije/dyz009
   Ma J, 2012, J NEUROIMMUNE PHARM, V7, P750, DOI 10.1007/s11481-012-9367-y
   Maggini S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101531
   Malagoli C, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-16
   Martinez-Valenzuela C, 2017, ENVIRON SCI POLLUT R, V24, P2412, DOI 10.1007/s11356-016-7974-5
   McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922
   McKeen S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020364
   Mesnage R, 2013, TOXICOLOGY, V313, P122, DOI 10.1016/j.tox.2012.09.006
   Miles EA, 2008, ATHEROSCLEROSIS, V196, P298, DOI 10.1016/j.atherosclerosis.2006.11.002
   Minot S, 2013, P NATL ACAD SCI USA, V110, P12450, DOI 10.1073/pnas.1300833110
   Modi SR, 2013, NATURE, V499, P219, DOI 10.1038/nature12212
   Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC
   Moyano DF, 2012, J AM CHEM SOC, V134, P3965, DOI 10.1021/ja2108905
   N'Diaye M, 2006, J BIOL CHEM, V281, P19906, DOI 10.1074/jbc.M601192200
   Nakajima Y, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-8
   Nawaz MA, 2019, FOOD CHEM TOXICOL, V124, P423, DOI 10.1016/j.fct.2018.12.030
   Neagu M, 2017, ARCH TOXICOL, V91, P1031, DOI 10.1007/s00204-016-1797-5
   Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408
   OECD, 2014, OB UPD
   Olofsson S, 2005, LANCET INFECT DIS, V5, P184, DOI 10.1016/S1473-3099(05)01311-3
   Ono Y, 2013, EXP DERMATOL, V22, P349, DOI 10.1111/exd.12148
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Palomaki J, 2011, ACS NANO, V5, P6861, DOI 10.1021/nn200595c
   Peng H, 2016, CHEM-BIOL INTERACT, V243, P82, DOI 10.1016/j.cbi.2015.11.011
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Peterson JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05910-1
   [Петракис Д. Petrakis D.], 2017, [Здравоохранение Российской Федерации, Zdravookhranenie Rossiiskoi Federatsii], V61, P103, DOI 10.18821/0044-197X-2017-61-2-103-112
   Petrakis D, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101282
   Piperigkou Z, 2016, FOOD CHEM TOXICOL, V91, P42, DOI 10.1016/j.fct.2016.03.003
   Plaza-Diaz J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081038
   Polsky JY, 2007, J ANDROL, V28, P28, DOI 10.2164/jandrol.106.000851
   Post CM, 2019, ISCIENCE, V20, P168, DOI 10.1016/j.isci.2019.09.014
   Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011
   Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880
   Quintana FJ, 2013, PHARMACOL REV, V65, P1148, DOI 10.1124/pr.113.007823
   Reyes A, 2012, NAT REV MICROBIOL, V10, P607, DOI 10.1038/nrmicro2853
   Roca M, 2012, PSYCHOL MED, V42, P2445, DOI 10.1017/S0033291712000451
   Roca M, 2013, EUR J CLIN INVEST, V43, P510, DOI 10.1111/eci.12064
   Rogero MM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040432
   Ruszkiewicz JA, 2017, TOXICOL REP, V4, P245, DOI 10.1016/j.toxrep.2017.05.006
   Sakurai S, 2017, J BIOL CHEM, V292, P17609, DOI 10.1074/jbc.M117.812974
   Salanitro AH, 2012, ARCH GERONTOL GERIAT, V54, pE387, DOI 10.1016/j.archger.2012.01.006
   Santiago-Lopez L, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081039
   Sassi F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111656
   Seitz M, 2003, J CLIN IMMUNOL, V23, P477, DOI 10.1023/B:JOCI.0000010424.41475.17
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sherr DH, 2013, SEMIN IMMUNOPATHOL, V35, P705, DOI 10.1007/s00281-013-0390-8
   SILKWORTH JB, 1985, J PHARMACOL EXP THER, V235, P606
   Stanaway IB, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.02149-16
   Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245
   Sunyer J, 2010, EPIDEMIOLOGY, V21, P729, DOI 10.1097/EDE.0b013e3181e5ea96
   Thompson HM, 2014, APIDOLOGIE, V45, P545, DOI 10.1007/s13592-014-0273-6
   Torres-Castro P, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091171
   Totura A.L., 2015, MBIO, V6, DOI [10.1128/mBio.00638-15.e00638-15, DOI 10.1128/MBIO.00638-15.E00638-15]
   Tsatsakis A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091295
   Tsatsakis A, 2019, TOXICOL LETT, V316, P154, DOI 10.1016/j.toxlet.2019.09.004
   Tsatsakis A, 2019, TOXICOL LETT, V309, P33, DOI 10.1016/j.toxlet.2018.12.003
   Tsatsakis AM, 2017, FOOD CHEM TOXICOL, V107, P108, DOI 10.1016/j.fct.2017.06.033
   Tsiaoussis J, 2018, TOXICOLOGY, V409, P137, DOI 10.1016/j.tox.2018.07.018
   Tsiaoussis J, 2019, TOXICOL LETT, V312, P72, DOI 10.1016/j.toxlet.2019.04.014
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Voorhis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082545
   Vardavas CI, 2011, PUBLIC HEALTH, V125, P121, DOI 10.1016/j.puhe.2010.11.012
   Vassilopoulou Loukia, 2017, Adv Exp Med Biol, V960, P81, DOI 10.1007/978-3-319-48382-5_4
   Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881
   Vidya MK, 2018, INT REV IMMUNOL, V37, P20, DOI 10.1080/08830185.2017.1380200
   Vorderstrasse BA, 2003, TOXICOLOGY, V188, P15, DOI 10.1016/S0300-483X(02)00749-7
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang P.H., 2020, INCREASING HOST CELL, V2020
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
   Wang WW, 2015, INFLAMM BOWEL DIS, V21, P1419, DOI 10.1097/MIB.0000000000000344
   Warren T., 2015, OPEN FORUM INFECT S1, V2
   Wheeler MA, 2017, J BIOL CHEM, V292, P12383, DOI 10.1074/jbc.R116.767723
   WHO, 2019, COUNTR AR SPEND MOR
   Williams JN, 2018, LUPUS, V27, P2129, DOI 10.1177/0961203318805844
   Winans B, 2011, REPROD TOXICOL, V31, P327, DOI 10.1016/j.reprotox.2010.09.004
   Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818
   World Health Organization, 2019, GLOB SPEND HLTH WORL
   Yahfoufi N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111618
   Yang ML, 2020, CONTEMP NURSE, V56, P90, DOI [10.1080/10376178.2020.1742178, 10.1080/02713683.2020.1857781]
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zafiropoulos A, 2014, HUM EXP TOXICOL, V33, P1241, DOI 10.1177/0960327114532384
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang C., 2016, FOOD SCI HUM WELL, V5, P116, DOI DOI 10.1016/J.FSHW.2016.04.002
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zinocker MK, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030365
NR 186
TC 20
Z9 21
U1 22
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD JUL
PY 2020
VL 141
AR 111418
DI 10.1016/j.fct.2020.111418
PG 15
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA LZ3EP
UT WOS:000541110800040
PM 32437891
OA Green Published
DA 2021-01-01
ER

PT J
AU Tiwari, M
   Mishra, D
AF Tiwari, Manish
   Mishra, Divya
TI Investigating the genomic landscape of novel coronavirus (2019-nCoV) to
   identify non -synonymous mutations for use in diagnosis and drug design
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
ID MULTIPLE SEQUENCE ALIGNMENT; SPIKE PROTEIN; VIRUS; RESISTANCE; TARGET;
   BATS; TOOL; COV
C1 [Tiwari, Manish] Natl Inst Plant Genome Res, Jawaharlal Nehru Univ Campus,Aruna Asaf Ali Marg, New Delhi 110067, India.
   [Mishra, Divya] Kansas State Univ, Dept Plant Pathol, Manhattan, KS 66506 USA.
RP Mishra, D (corresponding author), Kansas State Univ, Dept Plant Pathol, Manhattan, KS 66506 USA.
EM divyam@ksu.edu
RI Tiwari, Manish/ABH-8986-2020
OI Tiwari, Manish/0000-0002-3994-6181
CR Cote M, 2012, J BIOL CHEM, V287, P7640, DOI 10.1074/jbc.M111.334722
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   FAN NS, 1995, FEBS LETT, V359, P233, DOI 10.1016/0014-5793(95)00051-A
   Glinsky GV, 2010, CELL CYCLE, V9, P958, DOI 10.4161/cc.9.5.10913
   Hong L, 1997, FEBS LETT, V420, P11, DOI 10.1016/S0014-5793(97)01477-4
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Julias JG, 2004, VIROLOGY, V322, P13, DOI 10.1016/j.virol.2004.01.004
   Kurosaki Y, 2018, J GEN VIROL, V99, P181, DOI 10.1099/jgv.0.000999
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Letunic I, 2007, BIOINFORMATICS, V23, P127, DOI 10.1093/bioinformatics/btl529
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Marquez-Jurado S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100547
   Rolling T, 2009, J VIROL, V83, P6673, DOI 10.1128/JVI.00212-09
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Tang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep17155
   Tao Y, 2019, MICROBIOL RESOUR ANN, V8, DOI [10.1128/mra.00548-19, 10.1128/MRA.00548-19]
   Walls A.C., 2020, CELL
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   WOLF DG, 1995, J CLIN INVEST, V95, P257, DOI 10.1172/JCI117648
   Yamada S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001034
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 28
TC 7
Z9 7
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2020
VL 128
PG 7
WC Virology
SC Virology
GA LZ4AA
UT WOS:000541168000043
DA 2021-01-01
ER

PT J
AU Oualha, M
   Bendavid, M
   Berteloot, L
   Corsia, A
   Lesage, F
   Vedrenne, M
   Salvador, E
   Grimaud, M
   Chareyre, J
   de Marcellus, C
   Dupic, L
   de Saint Blanquat, L
   Heilbronner, C
   Drummond, D
   Castelle, M
   Berthaud, R
   Angoulvant, F
   Toubiana, J
   Pinhas, Y
   Frange, P
   Cheron, G
   Fourgeaud, J
   Moulin, F
   Renolleau, S
AF Oualha, M.
   Bendavid, M.
   Berteloot, L.
   Corsia, A.
   Lesage, F.
   Vedrenne, M.
   Salvador, E.
   Grimaud, M.
   Chareyre, J.
   de Marcellus, C.
   Dupic, L.
   de Saint Blanquat, L.
   Heilbronner, C.
   Drummond, D.
   Castelle, M.
   Berthaud, R.
   Angoulvant, F.
   Toubiana, J.
   Pinhas, Y.
   Frange, P.
   Cheron, G.
   Fourgeaud, J.
   Moulin, F.
   Renolleau, S.
TI Severe and fatal forms of COVID-19 in children
SO ARCHIVES DE PEDIATRIE
LA English
DT Article
DE COVID-19; Coronavirus; SARS-Cov-2
AB Objectives: The aim of this study was to describe severe forms of novel coronavirus disease 2019 in children, including patient characteristics, clinical, laboratory, and imaging findings, as well as the disease management and outcomes.
   Methods: This was a retrospective, single-center, observational study conducted in a pediatric intensive and high-dependency care unit (PICU, HDU) in an urban hospital in Paris. All patients, aged from 1 month to 18 years, admitted for confirmed or highly suspected SARS-CoV-2 were included.
   Results: We analyzed the data of 27 children. Comorbidities (n = 19, 70%) were mainly neurological (n = 7), respiratory, (n = 4), or sickle cell disease (n = 4). SARS-CoV-2 PCR results were positive in 24 children (nasopharyngeal swabs). The three remaining children had a chest CT scan consistent with COVID-19. Respiratory involvement was observed in 24 patients (89%). Supportive treatments were invasive mechanical ventilation (n = 9), catecholamine (n = 4), erythropheresis (n = 4), renal replacement therapy (n = 1), and extracorporeal membrane oxygenation (n = 1). Five children died, of whom three were without past medical history.
   Conclusion: This study highlighted the large spectrum of clinical presentation and time course of disease progression as well as the non-negligible occurrence of pediatric life-threatening and fatal cases of COVID-19 mostly in patients with comorbidities. Additional laboratory investigations are needed to further analyze the mechanism underlying the variability of SARS-Cov-2 pathogenicity in children. (C) 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
C1 [Oualha, M.; Bendavid, M.; Corsia, A.; Lesage, F.; Vedrenne, M.; Salvador, E.; Grimaud, M.; Chareyre, J.; de Marcellus, C.; Dupic, L.; de Saint Blanquat, L.; Heilbronner, C.; Moulin, F.; Renolleau, S.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Pediat Intens Care Unit, Paris, France.
   [Berteloot, L.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Pediat Radiol Dept, Paris, France.
   [Berteloot, L.] Univ Paris 05, Inst Imagine, Sorbonne Paris Cite, INSERM U1163, Paris, France.
   [Drummond, D.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Dept Pediat Pneumol & Allergol, Paris, France.
   [Drummond, D.] Univ Paris, INSERM UMR 1138, Paris, France.
   [Castelle, M.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Dept Pediat Immunohematol & Rhumatol, Paris, France.
   [Berthaud, R.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Dept Pediat Nephrol, Paris, France.
   [Angoulvant, F.; Cheron, G.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Pediat Emergency Dept, Paris, France.
   [Angoulvant, F.] Univ Paris, Ctr Rech Cordeliers, UMRS 1138, INSERM, Paris, France.
   [Toubiana, J.; Pinhas, Y.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Dept Gen Paediat & Paediat Infect Dis, Paris, France.
   [Frange, P.] Ctr Univ Paris, Necker Enfants Malades Univ Hosp, APHP, Clin Microbiol Lab, Paris, France.
   [Frange, P.] Univ Paris, Imagine Inst, EHU PACT 7328, Paris, France.
   [Fourgeaud, J.] Univ Paris, Ctr Univ Paris, Necker Enfants Malades Univ Hosp, Virol Lab,APHP,EHU PACT 7328,Imagine Inst, Paris, France.
RP Oualha, M (corresponding author), Univ Paris, Hop Univ Necker, AP HP,Ctr Univ Paris,EA Pharmacol & Evaluat Thera, Serv Reanimat & Surveillance Continue Med Chirurg, Paris, France.
EM mehdi.oualha@aphp.fr
RI Toubiana, Julie/AAZ-8996-2020
OI Toubiana, Julie/0000-0001-9561-669X
CR Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Colombo C, 2020, LANCET RESP MED, V8, pE35, DOI 10.1016/S2213-2600(20)30177-6
   Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Foust AM, 2020, RADIOL CARDIOTHORAC, V2, pe200214, DOI [10.1148/ryct.2020200214, DOI 10.1148/RYCT.2020200214]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leteurtre S, 2013, CRIT CARE MED, V41, P1761, DOI 10.1097/CCM.0b013e31828a2bbd
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ogimi C, 2019, J PEDIAT INF DIS SOC, V8, P21, DOI 10.1093/jpids/pix093
   Ong JSM, 2020, PEDIATR CRIT CARE ME, V21, P662, DOI 10.1097/PCC.0000000000002376
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
NR 17
TC 12
Z9 12
U1 4
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0929-693X
EI 1769-664X
J9 ARCH PEDIATRIE
JI Arch. Pediatr.
PD JUL
PY 2020
VL 27
IS 5
BP 235
EP 238
DI 10.1016/j.arcped.2020.05.010
PG 4
WC Pediatrics
SC Pediatrics
GA LZ3UF
UT WOS:000541152900001
PM 32518045
OA Green Published
DA 2021-01-01
ER

PT J
AU Fang, XW
   Mei, Q
   Yang, TJ
   Li, L
   Wang, YZ
   Tong, F
   Geng, SK
   Pan, AJ
AF Fang, Xiaowei
   Mei, Qing
   Yang, Tianjun
   Li, Lei
   Wang, Yinzhong
   Tong, Fei
   Geng, Shike
   Pan, Aijun
TI Low-dose corticosteroid therapy does not delay viral clearance in
   patients with COVID-19
SO JOURNAL OF INFECTION
LA English
DT Letter
C1 [Fang, Xiaowei; Mei, Qing; Yang, Tianjun; Wang, Yinzhong; Tong, Fei; Pan, Aijun] Univ Sci & Technol China, USTC Anhui Prov Hosp, Div Life Sci & Med, Dept Intens Care Unit,Affiliated Hosp 1, 17 Lu Jiang Rd, Hefei 230001, Anhui, Peoples R China.
   [Li, Lei] Univ Sci & Technol China, USTC Anhui Prov Hosp, Div Life Sci & Med, Dept Infect Dis,Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China.
   [Geng, Shike; Pan, Aijun] Anhui Med Univ, Dept Intens Care Unit, Prov Hosp, Hefei 230001, Anhui, Peoples R China.
RP Pan, AJ (corresponding author), Univ Sci & Technol China, USTC Anhui Prov Hosp, Div Life Sci & Med, Dept Intens Care Unit,Affiliated Hosp 1, 17 Lu Jiang Rd, Hefei 230001, Anhui, Peoples R China.
EM aijunpan868@sina.com
CR Arabi Y.M., 2018, AM J RESP CRIT CARE, V197, P757
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Chen J., 2020, CHINA J INFECT
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   National Health Commission of the People's Republic of China, 2020, 5 TRIAL VERS DIAGN T
   Ni Q., 2020, CHIN J CLIN INFECT D, V13
NR 7
TC 32
Z9 32
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUL
PY 2020
VL 81
IS 1
BP 147
EP 149
DI 10.1016/j.jinf.2020.03.039
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA LY8ZW
UT WOS:000540819000040
PM 32283153
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Azzi, L
   Carcano, G
   Gianfagna, F
   Grossi, P
   Dalla Gasperina, D
   Genoni, A
   Fasano, M
   Sessa, F
   Tettamanti, L
   Carinci, F
   Maurino, V
   Rossi, A
   Tagliabue, A
   Baj, A
AF Azzi, Lorenzo
   Carcano, Giulio
   Gianfagna, Francesco
   Grossi, Paolo
   Dalla Gasperina, Daniela
   Genoni, Angelo
   Fasano, Mauro
   Sessa, Fausto
   Tettamanti, Lucia
   Carinci, Francesco
   Maurino, Vittorio
   Rossi, Agostino
   Tagliabue, Angelo
   Baj, Andreina
TI Saliva is a reliable tool to detect SARS-CoV-2
SO JOURNAL OF INFECTION
LA English
DT Article
DE COVID-19; SARS-CoV-2; Saliva; Coronavirus; nCoV-2019
ID CORONAVIRUS
AB Objectives: This study analyzed salivary samples of COVID-19 patients and compared the results with their clinical and laboratory data.
   Methods: Salivary samples of 25 COVID-19 patients were analyzed by rRT-PCR. The following data were collected: age, sex, comorbidities, drugs. Lactate dehydrogenase (LDH) and ultrasensitive reactive C protein (usRCP) values were registered on the same day when a salivary swab was collected. Prevalence of positivity in saliva and association between clinical data and the cycle threshold as a semiquantitative indicator of viral load were considered.
   Results: Twenty-five subjects were recruited into this study, 17 males and 8 females. The mean age was 61.5 +/- 11.2 years. Cardiovascular and/or dysmetabolic disorders were observed in 65.22% of cases. All the samples tested positive for the presence of SARS-CoV-2, while there was an inverse association between LDH and Ct values. Two patients showed positive salivary results on the same days when their pharyngeal or respiratory swabs showed conversion.
   Conclusions: Saliva is a reliable tool to detect SARS-CoV-2. The role of saliva in COVID-19 diagnosis could not be limited to a qualitative detection of the virus, but it may also provide information about the clinical evolution of the disease. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Azzi, Lorenzo; Tettamanti, Lucia; Maurino, Vittorio; Tagliabue, Angelo] Univ Insubria, Dept Med & Surg, Unit Oral Med & Pathol, ASST Sette Laghi, Varese, Italy.
   [Carcano, Giulio] Univ Insubria, Unit Gen Emergency & Transplant Surg, ASST Sette Laghi, Varese, Italy.
   [Gianfagna, Francesco] Univ Insubria, Res Ctr Epidemiol & Prevent Med EPIMED, Dept Med & Surg, Varese, Italy.
   [Gianfagna, Francesco] Mediterranea Cardioctr, Naples, Italy.
   [Grossi, Paolo; Dalla Gasperina, Daniela] Univ Insubria, Dept Med & Surg, Unit Infect & Trop Dis, ASST Sette Laghi, Varese, Italy.
   [Genoni, Angelo; Rossi, Agostino; Baj, Andreina] Univ Insubria, Dept Med & Surg, Lab Clin Microbiol, ASST Sette Laghi, Varese, Italy.
   [Fasano, Mauro] Univ Insubria, Dept Sci & High Technol, Lab Biochem & Funct Prote, Busto Arsizio, VA, Italy.
   [Sessa, Fausto] Univ Insubria, Dept Med & Surg, Unit Pathol, ASST Sette Laghi, Varese, Italy.
   [Carinci, Francesco] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
RP Azzi, L (corresponding author), Univ Insubria, Unit Oral Med & Pathol, Dept Med & Surg, ASST Sette Laghi,Osped Circolo, I-21100 Varese, Italy.
EM l.azzi@uninsubria.it
RI Baj, Andreina/C-8047-2013; Gianfagna, Francesco/K-4561-2016
OI Gianfagna, Francesco/0000-0003-4615-0816; Fasano,
   Mauro/0000-0003-0628-5871; BAJ, ANDREINA/0000-0003-0088-2712
CR Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P453
   Cassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   China National Health Commission, 2020, CHIN CLIN GUID COVID
   Chojnowska S, 2018, ADV MED SCI-POLAND, V63, P185, DOI 10.1016/j.advms.2017.11.002
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Golatowski C, 2013, CLIN CHIM ACTA, V419, P42, DOI 10.1016/j.cca.2013.01.013
   Guo FZ, 2020, J MED VIROL, V92, P1797, DOI 10.1002/jmv.25916
   Hong KH, 2020, ANN LAB MED
   Khurshid Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072225
   Khurshid Z, 2019, J INFECT PUBLIC HEAL, V12, P601, DOI 10.1016/j.jiph.2019.05.004
   Khurshid Z, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060846
   Lo IL, 2020, INT J BIOL SCI, V16, P1698, DOI 10.7150/ijbs.45357
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Martina E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020466
   Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175
   Niedrig M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3611-x
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   SHI XD, 2020, J MED VIROL, DOI DOI 10.1002/JMV.25776
   Tian H Y, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, P235, DOI 10.3760/cma.j.issn.0253-9624.2020.03.002
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Wang WK, 2004, EMERG INFECT DIS, V10, P1213, DOI 10.3201/eid1007.031113
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2019, 2019 NCOV SIT REP 1
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 32
TC 85
Z9 86
U1 11
U2 16
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUL
PY 2020
VL 81
IS 1
BP E45
EP E50
DI 10.1016/j.jinf.2020.04.005
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA LY8ZW
UT WOS:000540819000009
PM 32298676
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Deng, LS
   Li, CN
   Zeng, Q
   Liu, X
   Li, XH
   Zhang, HT
   Hong, ZS
   Xia, JY
AF Deng, Lisi
   Li, Chunna
   Zeng, Qi
   Liu, Xi
   Li, Xinghua
   Zhang, Haitang
   Hong, Zhongsi
   Xia, Jinyu
TI Arbidol combined with LPV/r versus LPV/r alone against Corona Virus
   Disease 2019: A retrospective cohort study
SO JOURNAL OF INFECTION
LA English
DT Article
DE Corona Virus Disease 2019; Arbidol; Lopinavir/ritonavir; Antiviral
   intervention; Combination therapy
ID ACUTE RESPIRATORY SYNDROME; LOPINAVIR/RITONAVIR; SARS; MANAGEMENT;
   PNEUMONIA; CHINA
AB Background: Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.
   Methods: In this retrospective cohort study, we included adults (age >= 18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7).
   Results: We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 005). After 14 days, 15 (94%) of 16 and 9 (52 9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0 05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0 05).
   Conclusion: In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Deng, Lisi; Li, Chunna; Liu, Xi; Li, Xinghua; Zhang, Haitang; Hong, Zhongsi; Xia, Jinyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, 52 East Meihua Rd, Zhuhai 519000, Guangdong, Peoples R China.
   [Zeng, Qi] Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, Zhuhai, Guangdong, Peoples R China.
RP Hong, ZS; Xia, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, 52 East Meihua Rd, Zhuhai 519000, Guangdong, Peoples R China.
EM hongzhs@mail.sysu.edu.cn; xiajinyu@mail.sysu.edu.cn
OI zeng, qi/0000-0002-8700-6661
CR [Anonymous], CLIN MAN SEV AC RESP
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Barnard DL, 2011, FUTURE VIROL, V6, P615, DOI 10.2217/fvl.11.33
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chung M, 2020, RADIOLOGY
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Mo Y, 2016, J ANTIMICROB CHEMOTH, V71, P3340, DOI 10.1093/jac/dkw338
   Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Public Health England International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), CLIN DEC MAK TOOL TR
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wang D, 2020, JAMA, V2020
   Xu Z, 2020, LANCET RESP MED
   Zhang JJ, 2020, CHINA ALLERGY, V2020
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
NR 26
TC 104
Z9 107
U1 3
U2 17
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUL
PY 2020
VL 81
IS 1
BP E1
EP E5
DI 10.1016/j.jinf.2020.03.002
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA LY8ZW
UT WOS:000540819000001
PM 32171872
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhu, Z
   Lu, ZH
   Xu, TM
   Chen, C
   Yang, G
   Zha, T
   Lu, JC
   Xue, Y
AF Zhu, Zhen
   Lu, Zhaohui
   Xu, Tianmin
   Chen, Cong
   Yang, Gang
   Zha, Tao
   Lu, Jianchun
   Xue, Yuan
TI Arbidol monotherapy is superior to lopinavir/ritonavir in treating
   COVID-19
SO JOURNAL OF INFECTION
LA English
DT Article
DE COVID-19; SARS-CoV2; Ct value; Antiviral therapy; Pneumonia
AB Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame lab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Zhu, Zhen; Lu, Jianchun; Xue, Yuan] Third Peoples Hosp Changzhou, Inst Hepatol, 300 Lanling North Rd, Changzhou 213000, Jiangsu, Peoples R China.
   [Zhu, Zhen] Third Peoples Hosp Changzhou, Clin Lab, Changzhou, Jiangsu, Peoples R China.
   [Lu, Zhaohui; Yang, Gang] Second Peoples Hosp Wuhu, Dept Resp Dis, Wuhu, Anhui, Peoples R China.
   [Xu, Tianmin] Third Peoples Hosp Changzhou, Dept Infect Dis, Changzhou, Jiangsu, Peoples R China.
   [Chen, Cong] Changzhou Ctr Dis Control & Prevent, Changzhou, Jiangsu, Peoples R China.
   [Zha, Tao] Wuhu Ctr Dis Control & Prevent, Wuhu, Anhui, Peoples R China.
   [Lu, Jianchun; Xue, Yuan] Third Peoples Hosp Changzhou, Dept Liver Dis, Changzhou, Jiangsu, Peoples R China.
RP Xue, Y (corresponding author), Third Peoples Hosp Changzhou, Inst Hepatol, 300 Lanling North Rd, Changzhou 213000, Jiangsu, Peoples R China.
EM xueyuan80908@163.com
RI xue, yuan/ABB-7406-2020
FU Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation
   of Jiangsu Province [BK20180183]; Science and Technology Project of
   Changzhou [CJ20179030]
FX This work was supported by the Natural Science Foundation of Jiangsu
   Province [BK20180183] and the Science and Technology Project of
   Changzhou [CJ20179030].
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Deng L, 2020, J INFECTION, DOI [10.1016/j.jinf.2020.1003.1002, DOI 10.1016/J.JINF.2020.1003.1002]
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e88
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia, 2020, ZHONGHUA JIE HE HE H, V43, pE019
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49, P1, DOI DOI 10.3785/J.ISSN.1008-9292.2020.02.02.0E0
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 12
TC 72
Z9 74
U1 2
U2 7
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUL
PY 2020
VL 81
IS 1
BP E21
EP E23
DI 10.1016/j.jinf.2020.03.060
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA LY8ZW
UT WOS:000540819000004
PM 32283143
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sanchez, DP
   Kirsner, RS
   Lev-Tov, H
AF Sanchez, Daniela P.
   Kirsner, Robert S.
   Lev-Tov, Hadar
TI Clinical considerations for managing dermatology patients on systemic
   immunosuppressive or biologic therapy, or both, during the COVID-19
   pandemic
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Sanchez, Daniela P.; Kirsner, Robert S.; Lev-Tov, Hadar] Univ Miami, Miller Sch Med, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA.
   [Sanchez, Daniela P.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Lev-Tov, H (corresponding author), Univ Miami, Miller Sch Med, 1600 NW 10th Ave,RMSB 2023A, Miami, FL 33136 USA.
EM hlevtov@med.miami.edu
CR American College of Rheumatology, MESS ACR COR DIS 201
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 2
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
NR 3
TC 2
Z9 2
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUL
PY 2020
VL 83
IS 1
BP 288
EP 292
DI 10.1016/j.jaad.2020.04.143
PG 6
WC Dermatology
SC Dermatology
GA LY9CV
UT WOS:000540826700110
PM 32380214
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wambier, CG
   Goren, A
AF Wambier, Carlos Gustavo
   Goren, Andy
TI Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
   is likely to be androgen mediated
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE 5-alpha reductase; ACE2; androgen receptor; androgenetic alopecia;
   angiotensin converting enzyme 2; COVID-19; dutasteride; finasteride;
   human skin; retinoids; antiandrogen therapy; SARS-CoV-2; TMPRSS2;
   transmembrane protease serine 2
ID TMPRSS2
C1 [Wambier, Carlos Gustavo] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Goren, Andy] Appl Biol Inc, Irvine, CA USA.
RP Wambier, CG (corresponding author), Rhode Isl Hosp, 593 Eddy St,APC,10th Floor, Providence, RI 02903 USA.
EM carlos_wambier@brown.edu
RI Wambier, Carlos Gustavo/H-4281-2012
OI Wambier, Carlos Gustavo/0000-0002-4636-4489
CR Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   National Institutes of Health, TMPRSS2 TRANSM SER P
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
NR 5
TC 39
Z9 44
U1 4
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUL
PY 2020
VL 83
IS 1
BP 308
EP 309
DI 10.1016/j.jaad.2020.04.032
PG 2
WC Dermatology
SC Dermatology
GA LY9CV
UT WOS:000540826700115
PM 32283245
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abreu, GEA
   Aguilar, MEH
   Covarrubias, DH
   Duran, FR
AF Aranda Abreu, Gonzalo Emiliano
   Hernandez Aguilar, Maria Elena
   Herrera Covarrubias, Deissy
   Rojas Duran, Fausto
TI Amantadine as a drug to mitigate the effects of COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Amantadine; Viroporin; Docking
ID CHANNEL
AB The SARS-CoV-2 virus has spread around the world. At this time, there is no vaccine that can help people prevent the spread of coronavirus.
   We are proposing amantadine as a drug that can be used to mitigate the effects of the virus.
   It is demonstrated by docking models how amantadine can exert its action on Coronavirus viroporin E.
C1 [Aranda Abreu, Gonzalo Emiliano; Hernandez Aguilar, Maria Elena; Herrera Covarrubias, Deissy; Rojas Duran, Fausto] Univ Veracruzana, Ctr Invest Cerebrales, Av Luis Castelazo Ayala S-N,Carr Xalapa Veracruz, Xalapa 91190, Veracruz, Mexico.
RP Abreu, GEA (corresponding author), Univ Veracruzana, Ctr Invest Cerebrales, Av Luis Castelazo Ayala S-N,Carr Xalapa Veracruz, Xalapa 91190, Veracruz, Mexico.
EM garanda@uv.mx; elenahernandez@uv.mx; dherrera@uv.mx; frojas@uv.mx
RI Herrera-Covarrubias, Deissy/K-1418-2017
OI Herrera-Covarrubias, Deissy/0000-0001-5752-4700; Rojas-Duran,
   Fausto/0000-0003-4497-0909
CR EVANS SG, 1993, BIOCHEM PHARMACOL, V45, P1168, DOI 10.1016/0006-2952(93)90264-W
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017
   Tang T, 2019, MOLECULES, V24, DOI 10.3390/molecules24101941
   Thomaston JL, 2018, J AM CHEM SOC, V140, P15219, DOI 10.1021/jacs.8b06741
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993
NR 10
TC 7
Z9 7
U1 6
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109755
DI 10.1016/j.mehy.2020.109755
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800004
PM 32361100
OA Green Published
DA 2021-01-01
ER

PT J
AU Carboni, E
   Carta, AR
   Carboni, E
AF Carboni, Elena
   Carta, Anna R.
   Carboni, Ezio
TI Can pioglitazone be potentially useful therapeutically in treating
   patients with COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; INFLAMMATORY CYTOKINES;
   INSULIN-RESISTANCE; LUNG INJURY; MICE; INFECTION
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths. Despite the immense and ongoing global effort, no efficacious drugs to fight this plague have been identified and patients admitted to the intensive care units (ICU), for respiratory distress, are managed mostly by means of supportive care based on oxygen maintenance. Several authors have reported that the prevalence of hypertension, diabetes, cardiovascular and cerebrovascular diseases comorbidities were indeed frequent among patients with COVID-19, which suggests that these conditions are likely to aggravate and complicate the prognosis. What the aforementioned diseases have in common is a latent chronic inflammatory state that may be associated with the alteration of laboratory parameters that are typical of the metabolic syndrome and insulin resistance. In severe COVID-19 patients laboratory markers of inflammation such as C-reactive protein, IL-6, D-dimer, serum ferritin and lactate dehydrogenase are elevated in many patients; assessed since the 4th-6th day of illness onset, such increases seem to be predictive of an adverse prognosis. Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. TZD are PPAR. agonists that act on nuclear receptors, thereby triggering certain transcription factors. TZD were widely used for type-2 diabetes in the first decade of this century and although concerns have been raised for possible side effects associated with long-term treatment, their use has been recently revaluated for their anti-inflammatory properties in numerous medical conditions.
C1 [Carta, Anna R.; Carboni, Ezio] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy.
   [Carboni, Elena] Magna Graecia Univ Catanzaro, Dept Paediat, Catanzaro, Italy.
RP Carboni, E (corresponding author), Dept Biomed Sci, Bldg A,SP Monserrato Sestu Km 0,7, I-09042 Monserrato, CA, Italy.
EM ecarboni@unica.it
RI Carta, Anna R./AAT-8454-2020
OI Carta, Anna R./0000-0003-3104-9010
CR Agarwal R, 2006, AM J PHYSIOL-RENAL, V290, pF600, DOI 10.1152/ajprenal.00289.2005
   Aoki Y, 2009, RESPIRATION, V77, P311, DOI 10.1159/000168676
   Barbarin V, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-112
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bloomgarden ZT, 2020, J DIABETES, V12, P347, DOI 10.1111/1753-0407.13027
   Carta AR, 2013, CURR DRUG TARGETS, V14, P743, DOI 10.2174/1389450111314070004
   Carta AR, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/689181
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   CHEN GH, 2020, J MED VIROL, DOI DOI 10.1002/JMV.25770
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chinese Clinical Trial Registry, 2020, MULT RAND CONTR TRIA
   Colle R, 2017, PHARMACOPSYCHIATRY, V50, P49, DOI 10.1055/s-0042-120120
   Esser N, 2014, DIABETES RES CLIN PR, V105, P141, DOI 10.1016/j.diabres.2014.04.006
   Forst T, 2008, DIABETES VASC DIS RE, V5, P298, DOI 10.3132/dvdr.2008.043
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Galimberti D, 2017, EXPERT OPIN INV DRUG, V26, P97, DOI 10.1080/13543784.2017.1265504
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kanda Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE278, DOI 10.1152/ajpendo.00388.2009
   King GL, 2016, DIABETES, V65, P1462, DOI 10.2337/db16-0152
   Kutsukake M, 2014, J SURG RES, V189, P295, DOI 10.1016/j.jss.2014.03.007
   Laakso M, 2014, NAT REV ENDOCRINOL, V10, P293, DOI 10.1038/nrendo.2014.29
   Lebovitz HE, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1270-y
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liu CX, 2016, CYTOKINE, V86, P100, DOI 10.1016/j.cyto.2016.06.028
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Mori I, 2018, ACTA VIROL, V62, P28, DOI 10.4149/av_2018_103
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Omeragic A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0957-8
   Patel SP, 2017, EXP NEUROL, V293, P74, DOI 10.1016/j.expneurol.2017.03.021
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Pfutzner Andreas, 2010, J Diabetes Sci Technol, V4, P706
   Qiu D, 2015, INT J CLIN PHARM TH, V53, P746, DOI 10.5414/CP202339
   Sakamoto A, 2012, EUR J PHARMACOL, V682, P131, DOI 10.1016/j.ejphar.2012.02.027
   Shafaroodi H, 2012, BRAIN RES BULL, V87, P544, DOI 10.1016/j.brainresbull.2012.02.001
   Sharma R, 2009, PULM PHARMACOL THER, V22, P183, DOI 10.1016/j.pupt.2008.11.011
   Simon DK, 2015, J PARKINSON DIS, V5, P731, DOI 10.3233/JPD-150666
   Xie X, 2018, INT J OBESITY, V42, P213, DOI 10.1038/ijo.2017.192
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yang J, 2020, INT J INFECT DIS, DOI [10.1016/j.ijid.2020.03., DOI 10.1016/J.IJID.2020.03]
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang WY, 2008, ARTERIOSCL THROM VAS, V28, P2312, DOI 10.1161/ATVBAHA.108.175687
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou L., 2020, TRAVEL MED INFECT DI, DOI DOI 10.1016/J.TMAID.2020
NR 57
TC 19
Z9 19
U1 3
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109776
DI 10.1016/j.mehy.2020.109776
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800011
PM 32344313
OA Green Published
DA 2021-01-01
ER

PT J
AU Geier, MR
   Geier, DA
AF Geier, Mark R.
   Geier, David A.
TI Respiratory conditions in coronavirus disease 2019 (COVID-19): Important
   considerations regarding novel treatment strategies to reduce mortality
SO MEDICAL HYPOTHESES
LA English
DT Article
DE 2019-nCoV; EPO; Pulmonary; SARS-CoV-2
ID BLOOD; ERYTHROPOIETIN; TRANSFUSION; OXYGENATION; TISSUE
AB A novel virus named 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) causes symptoms that are classified as coronavirus disease (COVID-19). Respiratory conditions are extensively described among more serious cases of COVID-19, and the onset of acute respiratory distress syndrome (ARDS) is one of the hallmark features of critical COVID-19 cases. ARDS can be directly life-threatening because it is associated with low blood oxygenation levels and can result in organ failure. There are no generally recognized effective treatments for COVID-19, but treatments are urgently needed. Anti-viral medications and vaccines are in the early developmental stages and may take many months or even years to fully develop. At present, management of COVID-19 with respiratory and ventilator support are standard therapeutic treatments, but unfortunately such treatments are associated with high mortality rates. Therefore, it is imperative to consider novel new therapeutic interventions to treat/ameliorate respiratory conditions associated with COVID-19. Alternate treatment strategies utilizing clinically available treatments such as hyperbaric oxygen therapy (HBOT), packed red blood cell (pRBC) transfusions, or erthropoiesis-stimulating agent (ESA) therapy were hypothesized to increase oxygenation of tissues by alternative means than standard respiratory and ventilator treatments. It was also revealed that alternative treatments currently being considered for COVID-19 such as chloroquine and hydroxychloroquine by increasing hemoglobin production and increasing hemoglobin availability for oxygen binding and acetazolamine (for the treatment of altitude sickness) by causing hyperventilation with associated increasing levels of oxygen and decreasing levels of carbon dioxide in the blood may significantly ameliorate COVID-19 respiratory symptoms. In conclusion, is recommend, given HBOT, pRBC, and ESA therapies are currently available and routinely utilized in the treatment of other conditions, that such therapies be tried among COVID-19 patients with serious respiratory conditions and that future controlled-clinical trials explore the potential usefulness of such treatments among COVID-19 patients with respiratory conditions.
C1 [Geier, Mark R.; Geier, David A.] Inst Chron Illnesses Inc, 14 Redgate Ct, Silver Spring, MD 20905 USA.
RP Geier, MR (corresponding author), Inst Chron Illnesses Inc, 14 Redgate Ct, Silver Spring, MD 20905 USA.
EM mgeier@comcast.net
CR Aktas S, 2019, J PAEDIATR CHILD H, V55, P1209, DOI 10.1111/jpc.14378
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Boerema I, 1960, J CARDIOVASC SURG, V1, P133
   do Nascimento IB, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040941
   Chan YL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091946
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Contaldo C, 2009, SHOCK, V31, P599, DOI 10.1097/SHK.0b013e31818b9cc4
   Elliott S, 2012, BIOL-TARGETS THER, V6, P163, DOI 10.2147/BTT.S32281
   Fabricant L, 2013, J TRAUMA ACUTE CARE, V74, P371, DOI 10.1097/TA.0b013e31827e1d40
   Fantini J, INT J ANTIMICROB AGE
   Gbinigie K, BJGP OPEN
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iyamu E, 2009, BIOCHEM PHARMACOL, V77, P1021, DOI 10.1016/j.bcp.2008.11.016
   Kanne JP, 2020, RADIOLOGY, V295, P16, DOI 10.1148/radiol.2020200241
   KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995
   LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471
   Leaf DE, 2007, J APPL PHYSIOL, V102, P1313, DOI 10.1152/japplphysiol.01572.2005
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lutje S, NUCL MED SARS COV 2
   MITKA M, 2013, JAMA-J AM MED ASSOC, V310, P572, DOI DOI 10.1001/JAMA.2013.192555
   Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b
   Rodgers GM, 2019, ACTA HAEMATOL-BASEL, V142, P13, DOI 10.1159/000496967
   Shaz BH, 2010, ANESTHESIOLOGY, V113, P1012, DOI 10.1097/ALN.0b013e3181f710b8
   Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M, 2020, PRECISION CLIN MED, V3, P14, DOI [10.1093/pcmedi/pbaa002, DOI 10.1093/PCMEDI/PBAA002]
   Windsant ICV, 2012, CRIT CARE, V16, DOI 10.1186/cc11359
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
   World Health Organization, 2020, NA COR DIS COVID 201
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang X, LANCE RESP MED
NR 36
TC 9
Z9 10
U1 5
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109760
DI 10.1016/j.mehy.2020.109760
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800053
PM 32344310
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mishra, PM
   Uversky, VN
   Nandi, CK
AF Mishra, Pushpendra Mani
   Uversky, Vladimir N.
   Nandi, Chayan K.
TI Serum albumin-mediated strategy for the effective targeting of
   SARS-CoV-2
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS CoV-2; Antiviral drug; Treatment strategy
ID VIRUS-INFECTION; CURCUMIN
AB Novel coronavirus (NCoV-19), also known as SARS CoV-2, is a pathogen causing an emerging infection that rapidly increases in incidence and geographic range, is associated with the ever-increasing morbidity and mortality rates, and shows sever economic impact worldwide. The WHO declares the NCoV-19 infection disease (COVID-19) a Public Health Emergency of International Concern on 30 January 2020 and subsequently, on March 11, 2020, declared it a Global Pandemic. Although some people infected with SARS CoV-2 have no symptoms, the spectrum of symptomatic infection ranges from mild to critical, with most COVID-19 infections being not severe. The common mild symptoms include body aches, dry cough, fatigue, low-grade fever, nasal congestion, and sore throat. More severe COVID-19 symptoms are typical of pneumonia, and upon progression, the patient's condition can worsen with severe respiratory and cardiac problems. Currently, there is no drug or vaccine for curing patients. It has been observed that people with challenged immunity are highly prone to SARS CoV-2 infection and least likely to recover. Also, older adults and people of any age with serious underlying medical conditions might be at higher risk for severe forms of COVID-19. We are suggesting here a strategy for the COVID-19 treatment that could be effective in curing the patients in the current scenario when no efficient medicine or Vaccine is currently available, and Clinicians solely depend upon the performing trials with drugs with known antiviral activities. Our proposed strategy is based on the compilation of published scientific research and concepts. The different published research indicates the success of a similar strategy in different physiological conditions, and such a strategy is widely studied at the cellular level and in animal models.
C1 [Mishra, Pushpendra Mani; Nandi, Chayan K.] Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.
   [Mishra, Pushpendra Mani; Nandi, Chayan K.] Indian Inst Technol Mandi, BioX Ctr, Mandi 175005, Himachal Prades, India.
   [Uversky, Vladimir N.] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33620 USA.
   [Uversky, Vladimir N.] Univ S Florida, Morsani Coll Med, Byrd Alzheimers Res Inst, Tampa, FL 33620 USA.
   [Uversky, Vladimir N.] Russian Acad Sci, Inst Biol Instrumentat, Lab New Methods Biol, Fed Res Ctr,Pushchino Sci Ctr Biol Res, Pushchino 142290, Moscow Region, Russia.
RP Nandi, CK (corresponding author), Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.; Uversky, VN (corresponding author), Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33620 USA.; Uversky, VN (corresponding author), Univ S Florida, Morsani Coll Med, Byrd Alzheimers Res Inst, Tampa, FL 33620 USA.
EM vuversky@health.usf.edu; chayan@iitmandi.ac.in
RI NANDI, CHAYAN KANTI/C-6829-2018
OI Mishra, Pushpendra Mani/0000-0001-6674-6196
FU Council of Scientific and Industrial Research (CSIR), IndiaCouncil of
   Scientific & Industrial Research (CSIR) - India
   [09/1058(0013)/2019-EMR-I]; Indian Institute of Technology Mandi,
   Himachal Pradesh, India
FX The authors acknowledge the funding support from the Council of
   Scientific and Industrial Research (CSIR), India. The file no. for the
   same is 09/1058(0013)/2019-EMR-I. The authors also acknowledge the host
   support and facilities provided by the Indian Institute of Technology
   Mandi, Himachal Pradesh, India.
CR [Anonymous], SER ALB IS ASS HIGH
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen DY, 2010, FOOD CHEM, V119, P1346, DOI 10.1016/j.foodchem.2009.09.011
   Chen TZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080816
   Chu CY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5615647
   Chung SS, 2015, ANTICANCER RES, V35, P39
   Cyranoski D, 2020, NATURE, V579, P18, DOI 10.1038/d41586-020-00548-w
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Finicle BT, 2018, NAT REV CANCER, V18, P619, DOI 10.1038/s41568-018-0048-x
   Hewlings SJ, 2017, FOODS, V6, DOI 10.3390/foods6100092
   Jin G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.84
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lai YH, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2316-4
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li JR, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020176
   Mathew D, 2018, J FUNCT FOODS, V40, P692, DOI 10.1016/j.jff.2017.12.017
   Merlot AM, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00299
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Smith T., 2020, COVID 19 DRUG THERAP
   Tanaka R, 2014, THERAPEUTIC IMPACT H, DOI [10.3389/fimmu.2014.00561, DOI 10.3389/FIMMU.2014.00561]
   Wang HW, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0148-0
   Yang J, 2017, SCI REP-UK, V7, P1, DOI 10.1038/s41598-017-09018-2
   Zhou DH, 2013, INT J MOL SCI, V14, P12023, DOI 10.3390/ijms140612023
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 5
Z9 5
U1 8
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109790
DI 10.1016/j.mehy.2020.109790
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800055
PM 32353740
OA Green Published
DA 2021-01-01
ER

PT J
AU Pindiprolu, SKSS
   Pindiprolu, SH
AF Pindiprolu, Sai Kiran S. S.
   Pindiprolu, Sai Harshini
TI Plausible mechanisms of Niclosamide as an antiviral agent against
   COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drug discovery; Repurposing; Niclosamide
ID SARS
AB Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.
C1 [Pindiprolu, Sai Kiran S. S.] JNTUK, Sch Pharmaceut Sci & Technol, Kakinada, India.
   [Pindiprolu, Sai Harshini] Sree Sai Dent Coll & Res Inst, Srikakulam 532001, Andhra Pradesh, India.
RP Pindiprolu, SH (corresponding author), Sree Sai Dent Coll & Res Inst, Srikakulam 532001, Andhra Pradesh, India.
EM drharshini93@gmail.com
RI Pindiprolu, Sai Kiran/R-5901-2019
OI Pindiprolu, Sai Kiran/0000-0002-5400-4491
CR Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4
   Greener M., 2017, PRESCRIBER, V28, P34
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Mao LJ, 2020, BMC INFECT DIS, V20, DOI [10.1186/s12879-020-05056-w, 10.1186/s12879-020-05072-w]
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Pan JX, 2012, CHIN J CANCER, V31, P178, DOI 10.5732/cjc.011.10290
   Pindiprolu SH, 2019, MED HYPOTHESES, V129, DOI 10.1016/j.mehy.2019.109241
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Thomson GA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13519
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Xu Z, 2020, LANCET RESP MED
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
NR 16
TC 7
Z9 7
U1 4
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109765
DI 10.1016/j.mehy.2020.109765
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800048
PM 32361588
OA Green Published
DA 2021-01-01
ER

PT J
AU Salem, ML
   El-Hennawy, D
AF Salem, Mohamed Labib
   El-Hennawy, Dina
TI The possible beneficial adjuvant effect of influenza vaccine to minimize
   the severity of COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Letter
ID VIRUS
C1 [Salem, Mohamed Labib] Tanta Univ, Fac Sci, Dept Zool, Immunol & Biotechnol Unit, Tanta, Egypt.
   [Salem, Mohamed Labib; El-Hennawy, Dina] Tanta Univ, Teaching Hosp, Ctr Excellence Canc Res, Tanta, Egypt.
   [El-Hennawy, Dina] Basyun Cent Hosp, Hlth Off 1, Algharbiya, Egypt.
RP El-Hennawy, D (corresponding author), Tanta Univ, Teaching Hosp, Ctr Excellence Canc Res, Tanta, Egypt.
EM mohamed.labib@science.tanta.edu.eg; Henawy.dt@gmail.com
CR Abdella R, 2020, P NATL ACAD SCI USA, V117, P4931, DOI 10.1073/pnas.1919837117
   Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533
   Horns F, 2020, CELL REP, V30, P905, DOI 10.1016/j.celrep.2019.12.063
   Koutsakos M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8405
   Kumar V, 2017, INDIAN J PEDIATR, V84, P139, DOI 10.1007/s12098-016-2232-x
   Page Jeremy, 2020, WALL STREET J
   Salman S, 2020, MED HYPOTHESES, V140
   Salman S, 2020, INT J CANC BIOMED RE, V5, P11
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105
   Zheng J, 2018, CURR OPIN VIROL, V28, P43, DOI 10.1016/j.coviro.2017.11.002
NR 11
TC 11
Z9 11
U1 5
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109752
DI 10.1016/j.mehy.2020.109752
PG 1
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800061
PM 32361099
OA Green Published
DA 2021-01-01
ER

PT J
AU Silberstein, M
AF Silberstein, Morry
TI Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Letter
ID INTERLEUKIN-6
AB There is anecdotal evidence that tocilizumab, an immunosuppressant drug, may be a potential therapeutic option for patients with severe manifestations of coronavirus disease 2019 (COVID-19). Like tocilizumab, Vitamin D appears to modulate the activity of an interleukin (IL-6), which may explain the seasonal variation in prevalence of influenza. While most cases of COVID-19 have, thus far, occurred in the Northern Hemisphere winter, limiting the ability to assess seasonal variation, there remains substantial variation in the severity of this condition that has yet to be explained. A retrospective comparison of Vitamin D levels in previously obtained blood samples between survivors and confirmed fatalities could establish a rationale for implementation of widespread Vitamin D supplementation. This would be far cheaper and simpler than tocilizumab as a therapeutic option to trial.
C1 [Silberstein, Morry] Curtin Univ, Sch Mol & Life Sci, Perth, WA 6845, Australia.
RP Silberstein, M (corresponding author), Curtin Univ, Sch Mol & Life Sci, Perth, WA 6845, Australia.
EM m.silberstein@curtin.edu.au
CR Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Gianotti G., 2020, IM DOCTOR ITALYS HAR
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HOPESIMPSON RE, 1981, J HYG-CAMBRIDGE, V86, P35, DOI 10.1017/S0022172400068728
   Labudzynskyi D, 2016, EUR REV MED PHARMACO, V20, P2916
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Manion M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175517
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tanaka T, 2014, SEMIN IMMUNOL, V26, P88, DOI 10.1016/j.smim.2014.01.009
   Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094
   Xie ZH, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00539
   Yu HJ, 2016, J CLIN LAB ANAL, V30, P905, DOI 10.1002/jcla.21955
NR 13
TC 12
Z9 12
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109767
DI 10.1016/j.mehy.2020.109767
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800065
PM 32353742
OA Green Published
DA 2021-01-01
ER

PT J
AU Vavougios, GD
AF Vavougios, George D.
TI A data-driven hypothesis on the epigenetic dysregulation of host
   metabolism by SARS coronaviral infection: Potential implications for the
   SARS-CoV-2 modus operandi
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV; SARS-CoV-2; Gene set enrichment analysis; Diabetes;
   Triglycerides; Viruses
AB COVID-19, the disease caused by the novel SARS-CoV-2, a betacoronavirus structurally similar to SARS-CoV. Based on both structural and syndromic similarities with SARS-CoV, a hypothesis is formed on SARS-CoV-2 potential to affect the host's metabolism as part of its lifecycle. This hypothesis is evaluated by (a) exploratory analysis of SARS-CoV/human transcriptomic interaction data and gene set enrichment analysis (b) a confirmatory, focused review of the literature based on the findings by (a). A STRING Viruses (available search for human - SARS-CoV (NCBI taxonomy Id: 9606 vs. NCBI taxonomy Id: 694009) genomic interactions reveals ten human proteins, interacting with SARS-CoV: SGTA, FGL2, SPECC1, STAT3, PHB, BCL2L1, PPP1CA, CAV1, JUN, XPO1. Gene set enrichment analyses (GSEA) with STRING on this network revealed their role as a putative protein - protein interaction network (PPI; Enrichment p-value = 0.0296) mediating, viral parasitism, interleukin as well as insulin signaling, diabetes and triglyceride catabolism. In the literature, SARS-CoV has been known to cause de novo diabetes by ACE2-dependent uptake on pancreatic isle cells, and furthermore dysregulate lipid autophagy in favor of the viral lifecycle. Conversely, currently there are only non-causative, observational evidence of worse outcomes for COVID-19 patients with comorbid diabetes or hyperglycemia. No study has reported on the lipid profiles of COVID-19 patients; however, lipid-targeting molecules have been proposed as agents against SARS-CoV-2. Future studies, reporting on lipid and glucose metabolism of COVID-19 patients could help elucidate the disease's seculae and aid drug design.
C1 [Vavougios, George D.] Athens Naval Hosp, Dept Neurol, Athens, Greece.
   [Vavougios, George D.] Univ Thessaly, Dept Resp Med, Larisa, Greece.
   [Vavougios, George D.] Dept Comp & Elect Engn, Volos, Greece.
RP Vavougios, GD (corresponding author), 70 Deinokratous St, Athens 11125, Greece.
EM dantevavougios@hotmail.com
OI Vavougios, George/0000-0002-0413-4028
CR Baglivo Mirko, 2020, Acta Biomed, V91, P161, DOI 10.23750/abm.v91i1.9402
   Ceccarelli M, 2020, EUR REV MED PHARMACO, V24, P2781, DOI 10.26355/eurrev_202003_20551
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006
   Hoffmann M, 2020, CELL
   Jarajapu YPR, 2013, DIABETES, V62, P1258, DOI 10.2337/db12-0808
   Lu R, 2020, LANCET, DOI [10.1016/j.cell.2020.02.052, DOI 10.1016/J.CELL.2020.02.052]
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   WU J, 2020, JAMA INTERN MED, DOI DOI 10.1001/JAMAINTERNMED.2020.0994
   Wu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09536-z
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang JS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02286
   Zhang XL, 2020, INT J INFECT DIS, V94, P81, DOI 10.1016/j.ijid.2020.03.040
   Zhang ZL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00286
NR 19
TC 5
Z9 5
U1 2
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2020
VL 140
AR 109759
DI 10.1016/j.mehy.2020.109759
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LY7PY
UT WOS:000540720800003
PM 32344305
OA Green Published
DA 2021-01-01
ER

PT J
AU Mantlo, E
   Bukreyeva, N
   Maruyama, J
   Paessler, S
   Huang, C
AF Mantlo, Emily
   Bukreyeva, Natalya
   Maruyama, Junki
   Paessler, Slobodan
   Huang, Cheng
TI Antiviral activities of type I interferons to SARS-CoV-2 infection
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; Interferon; Antiviral therapy; Innate immune
ID HOST GENE-EXPRESSION; CORONAVIRUS; VIRUS; REPLICATION; ANTAGONISM;
   SUPPRESS; DOMAIN; COV
AB There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFN alpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV2 infection, a finding which could inform future treatment options for COVID-19.
C1 [Mantlo, Emily; Bukreyeva, Natalya; Maruyama, Junki; Paessler, Slobodan; Huang, Cheng] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Paessler, Slobodan; Huang, Cheng] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
RP Huang, C (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.
EM chhuang@utmb.edu
RI Maruyama, Junki/M-4735-2019; Huang, Cheng/R-6619-2017
OI Maruyama, Junki/0000-0003-0088-4793; Huang, Cheng/0000-0001-5402-353X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI060549]; Public Health ServiceUnited
   States Public Health Service [RO1AI093445, RO1AI129198]; John. S. Dunn
   Distinguished Chair in Biodefense endowment; UTMB Commitment Fund
   [P84373]; Department of Pathology Pilot Grant; Public Health Service
   awardUnited States Public Health Service [5UC7AI094660]
FX We thank Drs. Kenneth Plante (The World Reference Center for Emerging
   Viruses and Arboviruses, UTMB) and Natalie Thornburg from the CDC for
   providing the SARS-CoV-2 stock virus. E.K.M was supported by NIH T32
   training grant AI060549. Work in the Paessler laboratory was supported
   in parts by Public Health Service grants RO1AI093445 and RO1AI129198 and
   the John. S. Dunn Distinguished Chair in Biodefense endowment. C.H. was
   supported by UTMB Commitment Fund P84373 and Department of Pathology
   Pilot Grant and would like to acknowledge the Galveston National
   Laboratory (supported by the Public Health Service award 5UC7AI094660)
   for support of his research activity.
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Dahl H, 2004, SCAND J INFECT DIS, V36, P829, DOI 10.1080/00365540410021144
   DESMYTER J, 1968, J VIROL, V2, P955, DOI 10.1128/JVI.2.10.955-961.1968
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Freundt EC, 2009, J VIROL, V83, P6631, DOI 10.1128/JVI.00367-09
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009
   Huang C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001659
   Huang P, 2011, INT J SINO-WEST STUD, V1, P7
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kash JC, 2006, J VIROL, V80, P3009, DOI 10.1128/JVI.80.6.3009-3020.2006
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Moriguchi H, 2003, LANCET, V362, P1159, DOI 10.1016/S0140-6736(03)14484-4
   Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227
   Strayer David R., 2014, Infectious Disorders - Drug Targets, V14, P37
   Sun L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030802
   Varshney B, 2011, BIOCHEMISTRY-US, V50, P5419, DOI 10.1021/bi200303r
   Wong HH, 2018, VIROLOGY, V515, P165, DOI 10.1016/j.virol.2017.12.028
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 29
TC 62
Z9 61
U1 8
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUL
PY 2020
VL 179
AR 104811
DI 10.1016/j.antiviral.2020.104811
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IV
UT WOS:000540344700008
PM 32360182
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Tai, WB
   Zhang, XJ
   He, YX
   Jiang, SB
   Du, LY
AF Tai, Wanbo
   Zhang, Xiujuan
   He, Yuxian
   Jiang, Shibo
   Du, Lanying
TI Identification of SARS-CoV RBD-targeting monoclonal antibodies with
   cross-reactive or neutralizing activity against SARS-CoV-2
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; SARS-CoV; Receptor-binding domain; Neutralizing
   monoclonal antibodies; Cross-neutralization
ID RECEPTOR-BINDING DOMAIN; CORONAVIRUS SPIKE PROTEIN; PNEUMONIA OUTBREAK;
   EPITOPES; VACCINE; CHINA
AB SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs.
C1 [Tai, Wanbo; Zhang, Xiujuan; Jiang, Shibo; Du, Lanying] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
   [He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Beijing 100730, Peoples R China.
   [He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Ctr AIDS Res, Beijing 100730, Peoples R China.
   [Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
RP Jiang, SB; Du, LY (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
EM sjiang@nybc.org; ldu@nybc.org
RI Tai, Wanbo/G-3838-2018; Zhang, Xiujuan/AAG-9780-2020
OI Tai, Wanbo/0000-0002-9864-8993; 
FU NIH grants, United StatesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI137472,
   R01AI139092]; New York Blood Center, United States [VIM-NYB616]
FX This work was supported by the NIH grants, United States [R01AI137472
   and R01AI139092] and an intramural fund of the New York Blood Center,
   United States [VIM-NYB616].
CR Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tai WB, 2017, J VIROL, V91, DOI 10.1128/JVI.01651-16
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   World Health Organization [WHO], 2020, 103 WHO
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 14
Z9 14
U1 10
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD JUL
PY 2020
VL 179
AR 104820
DI 10.1016/j.antiviral.2020.104820
PG 6
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA LY2IV
UT WOS:000540344700016
OA Green Published
DA 2021-01-01
ER

PT J
AU Hamadani, M
   Zhang, MJ
   Tang, XY
   Fei, MW
   Brunstein, C
   Chhabra, S
   D'Souza, A
   Milano, F
   Phelan, R
   Saber, W
   Shaw, BE
   Weisdorf, D
   Devine, SM
   Horowitz, MM
AF Hamadani, Mehdi
   Zhang, Mei-Jie
   Tang, Xiao-Ying
   Fei, Mingwei
   Brunstein, Claudio
   Chhabra, Saurabh
   D'Souza, Anita
   Milano, Filippo
   Phelan, Rachel
   Saber, Wael
   Shaw, Bronwen E.
   Weisdorf, Daniel
   Devine, Steven M.
   Horowitz, Mary M.
TI Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic
   Hematopoietic Cell Transplantation Using Post-Transplantation
   Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Cryopreservation; ptCY; Allogeneic hematopoietic stem cell
   transplantation; COVID-19
ID BONE-MARROW-TRANSPLANTATION; DONOR TRANSPLANTATION; ACUTE GVHD; FRESH;
   BLOOD; ENGRAFTMENT; LEUKEMIA; OUTCOMES
AB The COVID-19 pandemic has created significant barriers to timely donor evaluation, cell collection, and graft transport for allogeneic hematopoietic stem cell transplantation (allo-HCT). To ensure availability of donor cells on the scheduled date of infusion, many sites now collect cryopreserved grafts before the start of pretransplantation conditioning. Post-transplantation cyclophosphamide (ptCY) is an increasingly used approach for graft-versus-host disease (GVHD) prophylaxis, but the impact of graft cryopreservation on the outcomes of allo-HCT using ptCY is not known. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared the outcomes of HCT using cryopreserved versus fresh grafts in patients undergoing HCT for hematologic malignancy with ptCY. We analyzed 274 patients with hematologic malignancy undergoing allo-HCT between 2013 and 2018 with cryopreserved grafts and ptCY. Eighteen patients received bone marrow grafts and 256 received peripheral blood stem cell grafts. These patients were matched for age, graft type, disease risk index (DRI), and propensity score with 1080 patients who underwent allo-HCT with fresh grafts. The propensity score, which is an assessment of the likelihood of receiving a fresh graft versus a cryopreserved graft, was calculated using logistic regression to account for the following: disease histology, Karnofsky Performance Score (KPS), HCT Comorbidity Index, conditioning regimen intensity, donor type, and recipient race. The primary endpoint was overall survival (OS). Secondary endpoints included acute and chronic graft-versus-host disease (GVHD), non-relapse mortality (NRM), relapse/progression and disease-free survival (DFS). Because of multiple comparisons, only P values <.01 were considered statistically significant. The 2 cohorts (cryopreserved and fresh) were similar in terms of patient age, KPS, diagnosis, DRI, HCT-CI, donor/graft source, and conditioning intensity. One-year probabilities of OS were 71.1% (95% confidence interval [CI], 68.3% to 73.8%) with fresh grafts and 70.3% (95% CI, 64.6% to 75.7%) with cryopreserved grafts (P=.81). Corresponding probabilities of OS at 2 years were 60.6% (95% CI, 57.3% to 63.8%) and 58.7% (95% CI, 51.9% to 65.4%) (P=.62). In matched-pair regression analysis, graft cryopreservation was not associated with a significantly higher risk of mortality (hazard ratio [HR] for cryopreserved versus fresh, 1.05; 95% CI,.86 to 1.29; P=.60). Similarly, rates of neutrophil recovery (HR,.91; 95% CI,.80 to 1.02; P=.12), platelet recovery (HR,.88; 95% CI,.78 to 1.00; P=.05), grade III-IV acute GVHD (HR,.78; 95% CI,.50 to 1.22; P=.27), NRM (HR, 1.16; 95% CI,.86 to 1.55; P=.32) and relapse/progression (HR, 1.21; 95% CI,.97 to 1.50; P=.09) were similar with cryopreserved grafts versus fresh grafts. There were somewhat lower rates of chronic GVHD (HR, 78; 95% CI,.61 to.99; P=.04) and DFS (HR for treatment failure, 1.19; 95% CI, 1.01 to 1.29; P=.04) with graft cryopreservation that were of marginal statistical significance after adjusting for multiple comparisons. Overall, our data indicate that graft cryopreservation does not significantly delay hematopoietic recovery, increase the risk of acute GVHD or NRM, or decrease OS after allo-HCT using ptCY. (c) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Hamadani, Mehdi; Zhang, Mei-Jie; Tang, Xiao-Ying; Fei, Mingwei; Chhabra, Saurabh; D'Souza, Anita; Phelan, Rachel; Saber, Wael; Shaw, Bronwen E.; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.
   [Hamadani, Mehdi; Chhabra, Saurabh; D'Souza, Anita; Saber, Wael; Shaw, Bronwen E.; Horowitz, Mary M.] Med Coll Wisconsin, BMT & Cellular Therapy Program, Milwaukee, WI 53226 USA.
   [Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.
   [Brunstein, Claudio; Weisdorf, Daniel] Univ Minnesota, Blood & Marrow Transplant & Cellular Therapy Prog, Minneapolis, MN USA.
   [Milano, Filippo] Fred Hutchinson Canc Res Ctr, Div Med Oncol, 1124 Columbia St, Seattle, WA 98104 USA.
   [Phelan, Rachel] Med Coll Wisconsin, Dept Pediat Hematol Oncol Bone Marrow Transplanta, Milwaukee, WI 53226 USA.
   [Devine, Steven M.] Natl Marrow Donor Program Be Match, Minneapolis, MN USA.
RP Hamadani, M (corresponding author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA.
EM mhamadani@mcw.edu
FU National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U24-CA076518]; National Heart, Lung and Blood
   Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); National Institute of Allergy and Infectious
   Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); NHLBIUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [5U10HL069294]; NCIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI); Health Resources
   and Services Administration (HRSA/DHHS)United States Department of
   Health & Human ServicesUnited States Health Resources & Service
   Administration (HRSA) [HHSH250201200016C]; Office of Naval
   ResearchOffice of Naval Research [N00014-13-1-0039, N00014-14-1-0028];
   Allos Therapeutics, Inc.; Actinium Pharmaceuticals; Amgen, Inc.Amgen;
   Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association;
   Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research
   Center; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint
   Venture Ltd.; Genentech, Inc.Roche HoldingGenentech; Gentium SpA;
   Genzyme CorporationGenzyme Corporation; GlaxoSmithKlineGlaxoSmithKline;
   Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics,
   Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis
   Pharma; Leukemia & Lymphoma SocietyLeukemia and Lymphoma Society; Medac
   GmbH; Medical College of Wisconsin; Merck Co, Inc.Merck & Company;
   Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi
   Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum
   Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America
   Pharmaceutical, Inc.Otsuka Pharmaceutical; Perkin Elmer, Inc.; Remedy
   Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals;
   Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord
   Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan
   Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience, Inc.;
   THERAKOS, Inc.; University of MinnesotaUniversity of Minnesota System;
   University of Utah; Wellpoint, Inc.
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
   Agreement U24-CA076518 from the National Cancer Institute (NCI), the
   National Heart, Lung and Blood Institute (NHLBI) and the National
   Institute of Allergy and Infectious Diseases (NIAID); a
   Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract
   HHSH250201200016C with Health Resources and Services Administration
   (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the
   Office of Naval Research; and grants from *Actinium Pharmaceuticals;
   Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the
   Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue
   Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.;
   Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America,
   Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;*Gentium
   SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell
   Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff
   Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma
   Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.;
   Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi
   Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum
   Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America
   Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi
   US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St.
   Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.;
   Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix
   Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.;
   University of Minnesota; University of Utah; and *Wellpoint, Inc. The
   views expressed in this article do not reflect the official policy or
   position of the National Institute of Health, the Department of the
   Navy, the Department of Defense, Health Resources and Services
   Administration (HRSA) or any other agency of the US Government.
CR Ahmed S, 2019, BIOL BLOOD MARROW TR, V25, P1859, DOI 10.1016/j.bbmt.2019.05.025
   Armand P, 2014, BLOOD, V123, P3664, DOI 10.1182/blood-2014-01-552984
   Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004
   Bashey A, 2017, J CLIN ONCOL, V35, P3002, DOI 10.1200/JCO.2017.72.8428
   Ciurea SO, 2015, BLOOD, V126, P1033, DOI 10.1182/blood-2015-04-639831
   Dietrich S, 2016, LEUKEMIA, V30, P2086, DOI 10.1038/leu.2016.125
   Dreger P, 2019, BLOOD ADV, V3, P360, DOI 10.1182/bloodadvances.2018027748
   ECKARDT JR, 1993, BONE MARROW TRANSPL, V11, P125
   Florek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145763
   Frey NV, 2006, BONE MARROW TRANSPL, V38, P399, DOI 10.1038/sj.bmt.1705462
   Ghosh N, 2016, J CLIN ONCOL, V34, P3141, DOI 10.1200/JCO.2015.66.3476
   Guan WJ, 2020, NEW ENGL J MED, DOI [10.1056/NEJ-Moa2002032, DOI 10.1056/NEJ-MOA2002032]
   Kanate AS, 2016, BLOOD, V127, P938, DOI 10.1182/blood-2015-09-671834
   Kim DH, 2007, BIOL BLOOD MARROW TR, V13, P1233, DOI 10.1016/j.bbmt.2007.07.003
   LASKY LC, 1989, TRANSFUSION, V29, P182, DOI 10.1046/j.1537-2995.1989.29289146840.x
   Li XJ, 2009, CRYOBIOLOGY, V59, P322, DOI 10.1016/j.cryobiol.2009.09.004
   Luznik L, 2008, BIOL BLOOD MARROW TR, V14, P641, DOI 10.1016/j.bbmt.2008.03.005
   McCurdy SR, 2018, BLOOD ADV, V2, P299, DOI 10.1182/bloodadvances.2017014829
   Medd P, 2013, BONE MARROW TRANSPL, V48, P243, DOI 10.1038/bmt.2012.118
   PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
   Rashidi A, 2019, BLOOD ADV, V3, P1826, DOI 10.1182/bloodadvances.2019000050
   Shinkoda Y, 2004, CLIN TRANSPLANT, V18, P743, DOI 10.1111/j.1399-0012.2004.00273.x
   SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0
   Stockschlader M, 1997, BRIT J HAEMATOL, V96, P382, DOI 10.1046/j.1365-2141.1997.d01-2032.x
   Zhang X, 2007, COMPUT METH PROG BIO, V88, P95, DOI 10.1016/j.cmpb.2007.07.010
   Zhang X, 2011, COMPUT METH PROG BIO, V101, P87, DOI 10.1016/j.cmpb.2010.07.005
NR 26
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUL
PY 2020
VL 26
IS 7
BP 1312
EP 1317
DI 10.1016/j.bbmt.2020.04.001
PG 6
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA LY6SD
UT WOS:000540658100015
PM 32283185
OA Green Accepted, Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Eapen, M
   Zhang, MJ
   Tang, XY
   Lee, SJ
   Fei, MW
   Wang, HL
   Hebert, KM
   Arora, M
   Chhabra, S
   Devine, SM
   Hamadani, M
   D'Souza, A
   Pasquini, MC
   Phelan, R
   Rizzo, JD
   Saber, W
   Shaw, BE
   Weisdorf, DJ
   Horowitz, MM
AF Eapen, Mary
   Zhang, Mei-Jie
   Tang, Xiao-Ying
   Lee, Stephanie J.
   Fei, Ming-Wei
   Wang, Hai-lin
   Hebert, Kyle M.
   Arora, Mukta
   Chhabra, Saurabh
   Devine, Steven M.
   Hamadani, Mehdi
   D'Souza, Anita
   Pasquini, Marcelo C.
   Phelan, Rachel
   Rizzo, J. Douglas
   Saber, Wael
   Shaw, Bronwen E.
   Weisdorf, Daniel J.
   Horowitz, Mary M.
TI Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe
   Aplastic Anemia
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Cryopreserved graft; Severe aplastic anemia
ID BONE-MARROW-TRANSPLANTATION; OUTCOMES; ENGRAFTMENT; DIAGNOSIS;
   CONSENSUS; IMPACT; GVHD
AB With the COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplantation conditioning. The effect on transplantation outcomes in nonmalignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the United States during 2013 to 2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received noncryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (hazard ratio [HR], 2.26; 95% confidence interval, 1.17 to 4.35; P =.01) and of 1-year overall mortality (HR, 3.13; 95% CI, 1.60 to 6.11; P =.0008) after transplantation of cryopreserved compared with noncryopreserved grafts, with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match. The incidence of acute and chronic graft-versus-host disease did not differ between the 2 groups. Adjusted probabilities of 1-year survival were 73% (95% CI, 60% to 84%) in the cryopreserved graft group and 91% (95% CI, 86% to 94%) in the noncryopreserved graft group. These data support the use of noncryopreserved grafts whenever possible in patients with severe aplastic anemia. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
C1 [Eapen, Mary; Zhang, Mei-Jie; Tang, Xiao-Ying; Fei, Ming-Wei; Wang, Hai-lin; Hebert, Kyle M.; Chhabra, Saurabh; Hamadani, Mehdi; D'Souza, Anita; Pasquini, Marcelo C.; Phelan, Rachel; Rizzo, J. Douglas; Saber, Wael; Shaw, Bronwen E.; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, 9200 West Wisconsin Ave,Suite C5, Milwaukee, WI 53226 USA.
   [Eapen, Mary; Chhabra, Saurabh; Hamadani, Mehdi; D'Souza, Anita; Pasquini, Marcelo C.; Rizzo, J. Douglas; Saber, Wael; Shaw, Bronwen E.; Horowitz, Mary M.] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA.
   [Zhang, Mei-Jie] Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA.
   [Lee, Stephanie J.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
   [Arora, Mukta; Weisdorf, Daniel J.] Univ Minnesota, Div Hematol Oncol, Minneapolis, MN USA.
   [Devine, Steven M.] Natl Marrow Donor Program Be Match, Minneapolis, MN USA.
   [Phelan, Rachel] Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol, Milwaukee, WI 53226 USA.
RP Eapen, M (corresponding author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, 9200 West Wisconsin Ave,Suite C5, Milwaukee, WI 53226 USA.
EM meapen@mcw.edu
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [5U24-CA076518]; National Heart, Lung and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI); National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); Health Resources and Services
   Administration (HRSA)United States Department of Health & Human
   ServicesUnited States Health Resources & Service Administration (HRSA)
   [HHSH250201200016C]; Office of Naval ResearchOffice of Naval Research
   [N00014-15-1-0848, N00014-16-1-2020]
FX The Center for International Blood and Marrow Transplant Research is
   supported primarily by Public Health Service Grant/Cooperative Agreement
   5U24-CA076518 from the National Cancer Institute, the National Heart,
   Lung and Blood Institute, and the National Institute of Allergy and
   Infectious Diseases; Contract HHSH250201200016C with the Health
   Resources and Services Administration (HRSA); and Grants
   N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research.
   The views expressed in this article do not reflect the official policy
   or position of the National Institutes of Health, Department of the
   Navy, Department of Defense, HRSA, or any other agency of the US
   Government.
CR American Society for Transplantation and Cellular Therapy, ASTCT RES COVID 19
   ATKINSON K, 1989, BONE MARROW TRANSPL, V4, P247
   Bacigalupo A, 2017, BLOOD, V129, P1428, DOI 10.1182/blood-2016-08-693481
   Bejanyan N, 2019, BLOOD ADV, V3, P3123, DOI 10.1182/bloodadvances.2019000722
   Collins NH, 2010, BIOL BLOOD MARROW TR, V16, P253, DOI 10.1016/j.bbmt.2009.10.004
   COX DR, 1972, J R STAT SOC B, V34, P187
   Eapen M, 2011, BLOOD, V118, P2618, DOI 10.1182/blood-2011-05-354001
   Frey NV, 2006, BONE MARROW TRANSPL, V38, P399, DOI 10.1038/sj.bmt.1705462
   Gupta V, 2010, HAEMATOL-HEMATOL J, V95, P2119, DOI 10.3324/haematol.2010.026682
   Hamadani M, 2000, BIOL BLOOD MARROW TR, V26, P1312
   Horan J, 2012, BLOOD, V120, P2918, DOI 10.1182/blood-2012-03-417758
   Islam MS, 2010, BONE MARROW TRANSPL, V45, P886, DOI 10.1038/bmt.2009.267
   Kim DH, 2007, BIOL BLOOD MARROW TR, V13, P1233, DOI 10.1016/j.bbmt.2007.07.003
   Lioznov M, 2008, BONE MARROW TRANSPL, V42, P121, DOI 10.1038/bmt.2008.93
   Marsh JCW, 2009, BRIT J HAEMATOL, V147, P43, DOI 10.1111/j.1365-2141.2009.07842.x
   Medd P, 2013, BONE MARROW TRANSPL, V48, P243, DOI 10.1038/bmt.2012.118
   Olsson R, 2013, BONE MARROW TRANSPL, V48, P537, DOI 10.1038/bmt.2012.239
   PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
   Schrezenmeier H, 2007, BLOOD, V110, P1397, DOI 10.1182/blood-2007-03-081596
   Stockschlader M, 1997, BRIT J HAEMATOL, V96, P382, DOI 10.1046/j.1365-2141.1997.d01-2032.x
   Young NS, 2018, NEW ENGL J MED, V379, P1643, DOI 10.1056/NEJMra1413485
   Zhang X, 2007, COMPUT METH PROG BIO, V88, P95, DOI 10.1016/j.cmpb.2007.07.010
   Zhang X, 2011, COMPUT METH PROG BIO, V101, P87, DOI 10.1016/j.cmpb.2010.07.005
NR 23
TC 6
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUL
PY 2020
VL 26
IS 7
BP E161
EP E166
DI 10.1016/j.bbmt.2020.04.027
PG 6
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA LY6SD
UT WOS:000540658100003
PM 32389803
OA Bronze, Green Accepted, Green Published
DA 2021-01-01
ER

EF